	0	1	2	3
0	281	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2022_00024384', 'CSN': None, 'TRF': 'ORD_1488563_01', 'MRN': '48284577', 'PhysicianId': '109266', 'NPI': 'International'}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1217532', 'clinicalId': '1218902', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1488563_01', 'SampleName': 'US1425102.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1488563_01', 'SampleId': 'US1425102.01', 'BlockId': 'S111_09619A (PF22121)', 'TRFNumber': 'ORD_1488563_01', 'TestType': 'FoundationOne CDX', 'SpecFormat': 'Slide Deck', 'ReceivedDate': '2022_10_27', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}]}}, 'PMI': {'ReportId': 'ORD_1488563_01', 'MRN': '48284577', 'FullName': 'Fan, Kuang Hua', 'FirstName': 'Kuang Hua', 'LastName': 'Fan', 'SubmittedDiagnosis': 'Brain glioblastoma (GBM)', 'Gender': 'Male', 'DOB': '1963_08_11', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Brain', 'CollDate': '2022_03_09', 'ReceivedDate': '2022_10_27', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': {'PertinentNegative': [{'Gene': 'EGFR'}, {'Gene': 'IDH1'}]}, 'Summaries': {'alterationCount': '26', 'clinicalTrialCount': '23', 'resistiveCount': '0', 'sensitizingCount': '4'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'D1179E'}, {'geneName': 'FGFR4', 'isVUS': 'true', 'variantName': 'R234H'}, {'geneName': 'FOXL2', 'isVUS': 'true', 'variantName': 'R349G'}, {'geneName': 'GSK3B', 'isVUS': 'true', 'variantName': 'T403A'}, {'geneName': 'KDM5A', 'isVUS': 'true', 'variantName': 'T269N'}, {'geneName': 'MLL2', 'isVUS': 'true', 'variantName': 'S2215T'}, {'geneName': 'PDGFRA', 'isVUS': 'true', 'variantName': 'C290Y,S348_E358del,S348_I363del'}, {'geneName': 'PIK3C2G', 'isVUS': 'true', 'variantName': 'S1238L'}, {'geneName': 'RAD52', 'isVUS': 'true', 'variantName': 'G125C'}, {'geneName': 'ROS1', 'isVUS': 'true', 'variantName': 'Y1783H'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'KIT', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'KIT (also called c_KIT) encodes a cell surface tyrosine kinase receptor that, upon ligand binding and dimerization, activates the PI3K_AKT and RAS_MAPK signaling pathways (Linnekin, 1999; 10582339). KIT aberrations, including point mutations, translocations, amplification, and overexpression, have been associated with various malignancies, and KIT is considered an oncoprotein (Fletcher, 2004; 15175998). KIT has been reported to be amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). In the TCGA datasets, KIT amplification has been reported in 2.5% of lower grade gliomas (grades 2 and 3)(Cancer Genome Atlas Research Network., 2015; 26061751) and 9.2% of glioblastomas (Grade 4 astrocytoma)(cBio_Brennan et al., 2013; 24120142). KIT amplification has been variously reported in 4_47% of glioblastomas in the scientific literature (Nobusawa et al., 2011; 21382095, Joensuu et al., 2005; 16021678, Burford et al., 2013; 23990986). Amplification of KIT has been strongly correlated with the presence of KDR and/or PDGFRA amplification in glioblastoma (Joensuu et al., 2005; 16021678, Holtkamp et al., 2007; 17504929, Puputti et al., 2006; 17189383). One study found no correlation between KIT amplification and overall survival in patients with glioblastoma, while a separate study reported that overexpression of KIT was associated with tumor grade and shorter survival in patients with malignant glioma (Nobusawa et al., 2011; 21382095, Skardelly et al., 2009; 19701495). On the basis of clinical evidence, primarily in gastrointestinal stromal tumor (GIST), melanoma, AML, and systemic mastocytosis, KIT activating alterations are associated with sensitivity to TKIs including imatinib, sunitinib, sorafenib, dasatinib, nilotinib, pazopanib, regorafenib, ponatinib, midostaurin, apatinib, avapritinib, and ripretinib (Heinrich et al., 2014; ASCO Abstract 10506, Heinrich et al., 2017; ASCO Abstract 11011, DeAngelo et al., 2017; ASH Abstract 2, Evans et al., 2017; 29093181, Abbaspour Babaei et al., 2016; 27536065, Ramaswamy et al., 2016; 27563456, Demetri et al., 2013; 23177515, Gotlib et al., 2016; 27355533, Jawhar et al., 2017; 28424161, Xu et al., 2014; 25031773, Gotlib et al., 2005; 15972446, George et al., 2018; ASCO Abstract 11511, Luo et al., 2017; 29066909). The use of mTOR inhibitors as an alternative therapeutic strategy has demonstrated limited success in KIT_mutated, imatinib_resistant melanoma, with 1 PR and 3 SD observed for 4 patients treated with everolimus (Si et al., 2012; ASCO Abstract 8562, Si et al., 2012; 22162580). However, no responses were observed for 10 patients with mastocytosis following everolimus monotherapy, with 8/10 patients harboring the KIT D816V mutation (Parikh et al., 2010; 20038218). The role of KIT amplification as a biomarker for response to mTOR inhibitors has not been investigated (PubMed, Mar 2022). Clinical benefit has been observed for patients with KIT amplified or overexpressing tumors following treatment with imatinib (Wei et al., 2019; 30075827, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685, Guo et al., 2011; 21690468, Debiec_Rychter et al., 2005; 15685537, DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Hotte et al., 2005; 15659505, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Reardon et al., 2009; 19904263), nilotinib (Lee et al., 2015; 26424760), sorafenib (Llovet et al., 2012; 22374331, Zhang et al., 2013; 23058498, Seino et al., 2014; 25450081, Li et al., 2009; 18846437), and sunitinib (Minor et al., 2012; 22261812, Mahipal et al., 2012; 23114504), suggesting that KIT amplification may be sensitive to these inhibitors. However, evidence demonstrating clinical benefit for regorafenib, dasatinib, pazopanib, or ponatinib in the context of KIT amplified or overexpressing tumors is limited.', 'Include': 'true', 'ClinicalTrialNote': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Sorafenib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Quintás_Cardama et al., 2008; 18936790, Bisagni et al., 2009; 19461405, Handolias et al., 2010; 20372153, Disel et al., 2011; 20970876, Park et al., 2012; 22270258, Catania et al., 2014; 24855380, Guo et al., 2007; 17699867, Hu et al., 2008; 18483300) or KIT_expressing tumors (Llovet et al., 2012; 22374331, Zhang et al., 2013; 23058498, Seino et al., 2014; 25450081, Li et al., 2009; 18846437), KIT activating alterations may predict sensitivity to sorafenib. On the basis of clinical responses in patients with GIST, PDGFRA activating mutations may predict sensitivity to sorafenib (Fumagalli et al., 2012; ESMO Abstract 1491P)(Roubaud et al., 2012; 22294526). </p> <p><b>Supporting Data:</b> Phase 2 studies of sorafenib plus temozolomide report limited activity in patients with relapsed glioblastoma multiforme (GBM) (Zustovich et al., 2013; 23898124; Reardon et al., 2011; 20443129). A Phase 1/2 trial of temsirolimus in combination with sorafenib in patients with glioblastoma was terminated at the Phase 2 interim analysis after patients failed to meet the primary endpoint of 6 month progression_free survival (Lee et al., 2012; 23099651). A Phase 2 trial of sorafenib and erlotinib in glioblastoma also did not meet its primary endpoint, and erlotinib clearance was increased by the addition of sorafenib (Peereboom et al., 2013; 23328813). In a Phase 1 trial in patients with high_grade glioma, the combination of sorafenib with radiation therapy (RT) and temozolomide (TMZ) resulted in increased toxicity and did not result in significant improvement in clinical efficacy compared with RT and TMZ alone (Hottinger et al., 2014; 24786603). In a clinical study of sorafenib in pediatric patients with low_grade astrocytoma, one patient achieved a partial response (PR), one had stable disease (SD), and 9 patients had progressive disease; this study was terminated early due to unexpectedly high disease progression rates (Karajannis et al., 2014; 24803676). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Nilotinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Nilotinib targets tyrosine kinases such as ABL (including BCR_ABL), PDGFRs, KIT, CSF1R, DDR1, and DDR2. It is FDA approved to treat newly diagnosed pediatric or adult patients with Philadelphia chromosome_positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with Ph+ CML in chronic or accelerated phase with resistance or intolerance to prior therapy including imatinib, and pediatric patients with Ph+ CML in chronic phase with resistance or intolerance to prior tyrosine_kinase inhibitor therapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Lee et al., 2015; 26424760, Carvajal et al., 2015; 25695690, Hochhaus et al., 2015; 26002753, Blay et al., 2015; 25882987, Kaijimoto et al., 2015; 26722383), KIT_amplified (Lee et al., 2015; 26424760), or KIT_expressing tumors (Sako et al., 2014; 25221952), KIT activating alterations may confer sensitivity to nilotinib. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of nilotinib for the treatment of CNS tumors are limited (PubMed, Jul 2022). Nilotinib has been primarily investigated as a therapeutic option for the treatment of CML or gastrointestinal stromal tumors (GIST). In the context of CML, a Phase 3 clinical trial of Ph+ patients treated with imatinib or nilotinib (300 mg or 400 mg) reported progression_free survival (PFS) rates of 93% and 97_98% and overall survival (OS) rates of 93% and 94_97%, respectively, at 4 years (Hughes et al., 2014; 24335106). For imatinib_resistant Japanese patients with CML, a Phase 2 trial reported a 47.8% major medical response rate to treatment with nilotinib at 12 months (Takahashi et al., 2014; 24650752). A Phase 3 clinical trial of single_agent nilotinib in 240 patients with advanced GIST who failed prior treatment with imatinib or sunitinib reported no significant difference in progression_free survival between nilotinib and the best supportive care, but did report increased overall survival for nilotinib_treated patients (Reichardt et al., 2012; 22357255). A Phase 2 trial has shown that nilotinib was well tolerated and suggested it may be particularly useful for treating patients with GIST harboring mutations in KIT exon 17 (Cauchi et al., 2012; 22119758). Preclinical, cell_based assays have reported efficacy for nilotinib alone and in combination with additional therapies in the context of leiomyosarcoma and synovial sarcoma (Villar et al., 2012; 22662203). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Imatinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Imatinib targets the BCR_ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT_positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence, PDGFRA activating mutations (Cassier et al., 2012; 22718859, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Heinrich et al., 2003; 14645423, Yoo et al., 2016; 26130666), fusions (Baccarani et al., 2007; 17666373, Curtis et al., 2007; 17555450, Griffin et al., 2003; 12808148, Helbig et al., 2009; 19120352, Klion et al., 2004; 14504092, Qu et al., 2016; 27120808, Metzgeroth et al., 2007; 17377585, Metzgeroth et al., 2008; 18950453, Ogbogu et al., 2009; 19910029, Sugimoto et al., 2015; 26319757), and expression (Frenard et al., 2016; 27051816) may predict sensitivity to imatinib. On the basis of clinical and preclinical data in KIT_mutated (Carvajal et al., 2011; 21642685, Debiec_Rychter et al., 2006; 16624552, Heinrich et al., 2003; 14645423, Hodi et al., 2013; 23775962), KIT_amplified (Wei et al., 2019; 30075827, Guo et al., 2011; 21690468, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685), or KIT_expressing tumors (DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Hotte et al., 2005; 15659505, Reardon et al., 2009; 19904263, Kamenz et al., 2006; 16570351, Wang et al., 2005; 15650049), KIT activating alterations may confer sensitivity to imatinib. PDGFRA amplification may predict sensitivity to tyrosine kinase inhibitors such as imatinib; a patient with Merkel cell carcinoma expressing PDGFRA achieved a complete response to imatinib (Frenard et al., 2016; 27051816). </p> <p><b>Supporting Data:</b> In a clinical study where patients with recurrent glioblastoma were given imatinib, 2/24 patients achieved a PR, 10 patients reported SD, and median OS and PFS was observed to be 6.2 and 3 months, respectively (Hassler et al., 2014; 25674429). However, other Phase 2 clinical trials of imatinib have reported no anti_tumor activity, with a study of 231 patients with glioblastoma reporting a radiographic response rate of only 3.4% (Razis et al., 2009; 19789313, Reardon et al., 2009; 19904263). In another Phase 2 study, imatinib plus hydroxyurea was shown to be well tolerated among patients with recurrent/progressive low_grade glioma, but had negligible antitumor activity (Reardon et al., 2012; 22371319). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Sunitinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Sunitinib is a small_molecule tyrosine kinase inhibitor that targets PDGFRs, VEGFRs, KIT, FLT3, CSF_1R, and RET. It is FDA approved for the treatment of advanced or metastatic pancreatic neuroendocrine tumors, gastrointestinal stromal tumors (GISTs) in patients who have progressed on or are intolerant to imatinib, and advanced renal cell carcinoma (RCC) as well as for the adjuvant treatment of patients at high risk of recurrent RCC after nephrectomy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Minor et al., 2012; 22261812, Heinrich et al., 2008; 18955458, Buchbinder et al., 2015; 26264378, Reichardt et al., 2016; 26772734, Hirai et al., 2016; 27073655, Goemans et al., 2010; 20435347) or KIT_expressing tumors (Mahipal et al., 2012; 23114504, Minor et al., 2012; 22261812), KIT activating alterations may predict sensitivity to sunitinib. </p> <p><b>Supporting Data:</b> Phase 2 clinical trials of sunitinib in glioblastoma have reported no significant improvement in clinical outcome (Pan et al., 2012; 22832897, Kreisl et al., 2013; 23086433). A Phase 2 trial that examined sunitinib treatment followed by radiation therapy in patients with glioblastoma reported a median progression_free survival (PFS) of 7.7 weeks, and a median overall survival (OS) of 12.8 weeks; 83.3% (10/12) of patients experienced neurological deterioration prior to radiation therapy (Balaña et al., 2014; 24424564). Another Phase 2 study that examined daily sunitinib treatment in patients with glioblastoma reported no objective response in any of the 40 patients, with a median PFS of 2.2 months and a median OS of 9.2 months; five patients in the study had stable disease for more than six months (Hutterer et al., 2014; 24311637). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT05024214', 'Include': 'true'}, {'nctId': 'NCT05098847', 'Include': 'true'}, {'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT04977453', 'Include': 'true'}, {'nctId': 'NCT03564691', 'Include': 'true'}, {'nctId': 'NCT04008797', 'Include': 'true'}, {'nctId': 'NCT03025893', 'Include': 'true'}, {'nctId': 'NCT04729348', 'Include': 'true'}, {'nctId': 'NCT02379416', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'MDM4', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'MDM4 acts as a negative regulator of p53, but a fraction of MDM4 localized to the mitochondria acts in concert with p53 to promote apoptosis (Mancini et al., 2009; 19521340). MDM4 has been reported to be amplified in cancer and therapies targeting MDM4 or MDM2 have been shown to increase levels of the tumor suppressor p53 in cancer cells (Wade et al., 2013; 23303139, Gao et al., 2013; 23550210, Danovi et al., 2004; 15199139, Beging et al., 2014; 24739573). In the TCGA dataset, amplification of MDM4 was observed in 8.5% of glioblastoma cases (cBio_Brennan et al., 2013; 24120142). MDM4 amplification or amplification of the 1q32.1 chromosomal locus, which encompasses MDM4 and PIK3C2B, has been frequently reported, particularly in Grade 3 and 4 astrocytoma or glioblastoma multiforme (GBM) cases; one study reported MDM4 amplification in 27% (23/86) of astrocytoma samples (Arjona et al., 2005; 16319692, Schiffman et al., 2010; 20068183, Nobusawa et al., 2010; 20406234, Rao et al., 2010; 19609742, Jin et al., 2010; 20472715, Riemenschneider et al., 1999; 10626796). A study also reported MDM4 amplification in 4% (4/106) of GBMs and in 4% (1/27) of anaplastic oligodendrogliomas; MDM4 amplification was not detected in any of the 56 low_grade (Grade 1 or 2) gliomas investigated (Riemenschneider et al., 1999; 10626796). The association of MDM4 amplification with tumor grade in astrocytomas is unclear (Arjona et al., 2005; 16319692, Schiffman et al., 2010; 20068183). Small molecules targeting MDM4 or the MDM2_MDM4 complex, such as idasanutlin, have reported clinical benefit for patients with polycythemia vera (Mascarenhas et al., 2022; 34933330, Mascarenhas et al., 2019; 31167802) and AML (Reis et al 2016; 26869629) and have shown anti_tumor activity in preclinical assays (Chen et al., 2019; 30536898). Additional nutlins have been in preclinical and clinical development (Vaseva et al., 2011; 21562588, Wang and Yan, 2011; 21750655, Wang et al., 2011; 21075910, Reed et al., 2010; 20080970, Smalley et al., 2007; 17210701, Vogel et al., 2012; 23035244, Mandke et al., 2012; 22870278) and have been shown to be effective against cancer cells in the presence of a wildtype p53 allele (Hirose et al., 2014; 25621298, Chang et al., 2013; 23946421, Bernal et al., 2010; 21075307, Wade et al., 2013; 23303139). Additional therapeutic mechanisms that target MDM4 are also in preclinical development (Vogel et al., 2012; 23035244, Mandke et al., 2012; 22870278).', 'Include': 'true', 'ClinicalTrialNote': 'Tumors with MDM4 amplification or overexpression and wild_type p53 may be sensitive to inhibitors of MDM_p53 interactions.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': {'nctId': 'NCT03725436', 'Include': 'true'}}}}, 'ReferenceLinks': None}, {'Name': 'PDGFRA', 'Include': 'true', 'Alterations': {'Alteration': [{'Name': 'deletion exons 8_9', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'deletion exons 8_9'}}, 'Interpretation': 'PDGFRA encodes platelet_derived growth factor receptor alpha (PDGFR_alpha), a tyrosine kinase receptor that, upon binding of cognate ligands (PDGFA or PDGFB), activates several signaling pathways, including PI3K and MAPK (Andrae et al., 2008; 18483217). PDGFR aberrations, including point mutations, translocations, amplification, and/or overexpression, have been associated with various malignancies (Fletcher, 2004; 15175998). Amplification of PDGFRA, frequently occurring with amplification of the genes KDR and KIT, has been associated with increased PDGFRA expression (Burford et al., 2013; 23990986, Flavahan et al., 2016; 26700815, Roszik et al., 2016; 26787600, Verhaak et al., 2010; 20129251) and poor prognosis (Burford et al., 2013; 23990986, Koschmann et al., 2016; 27582545, Phillips et al., 2013; 23438035, Puget et al., 2012; 22389665) in some subtypes of glioma. The PDGFRA rearrangement in this tumor results in deletion of exons 8_9. The PDGFRA exon 8_9 deletion mutant was demonstrated to be active in the absence of ligand and has been characterized as transforming (Clarke et al., 2003; 12569364, Ozawa et al., 2010; 20889717). This mutant was sensitive to imatinib and the kinase inhibitor vatalanib (Ozawa et al., 2010; 20889717). Although alterations such as E229K and R841K seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. PDGFRA amplification has been suggested to be more common in higher grade astrocytomas than in lower grade astrocytomas; studies have reported PDGFRA amplification in 16.3% (27/166) of Grade 2 astrocytomas and in 23.6% (91/386) of Grade 3 and 4 astrocytomas analyzed (Holtkamp et al., 2007; 17504929, Phillips et al., 2013; 23438035, Motomura et al., 2013; 23242283). PDGFRA amplification has been reported in 5.2_33% of glioblastoma cases (cBio_Brennan et al., 2013; 24120142, Phillips et al., 2013; 23438035, Sottoriva et al., 2013; 23412337, Nobusawa et al., 2011; 21382095, Joensuu et al., 2005; 16021678, Alentorn et al., 2012; 23074200). PDGFRA mutation has been identified in 5.6% of Grade 3 and 5.4% of Grade 4 astrocytomas, 2.4% of Grade 3 oligodendrogliomas, and 12% (3/25) of gliosarcomas analyzed in COSMIC (Feb 2022)(Tate et al., 2019; 30371878). PDGFRA mutations have been reported in 0_5% of lower grade glioma and glioblastoma samples (cBio_Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2008; 18772890, cBio_Hoadley et al., 2018; 29625048, cBio_Ellrott et al., 2018; 29596782, cBio_Taylor et al., 2018; 29622463, cBio_Gao et al., 2018; 29617662, cBio_Liu et al., 2018; 29625055, cBio_Sanchez_Vega et al., 2018; 29625050), Ceccarelli et al., 2016; 26824661, Cancer Genome Atlas Research Network., 2015; 26061751, cBio_Johnson et al., 2014; 24336570, cBio_Thomas et al., 2017; 28472509, cBio_Jones et al., 2013; 23817572). A retrospective analysis of TCGA glioma samples reported elevated expression of ERBB3 correlated with PDGFRA expression and co_expression of these genes was an indicator of poor prognosis in a GBM patient cohort (Song et al., 2018; 29888103). Amplification of PDGFRA has been associated with tumor grade and poor progression_free and overall survival in patients with glioblastoma (Alentorn et al., 2012; 23074200, Sottoriva et al., 2013; 23412337, Phillips et al., 2013; 23438035). In addition, PDGFRA amplification has been reported to occur in conjunction with IDH1 mutation in glioblastoma, and both alterations in the same tumor have been associated with poor patient prognosis (Phillips et al., 2013; 23438035). Amplification of PDGFRA has also been strongly correlated with the presence of KDR and/or KIT amplification in glioblastomas, as well as with EGFR amplification (Joensuu et al., 2005; 16021678, Holtkamp et al., 2007; 17504929, Puputti et al., 2006; 17189383, Szerlip et al., 2012; 22323597). On the basis of extensive clinical evidence in solid tumors and hematologic cancers, PDGFRA activating alterations are associated with sensitivity to imatinib (Arefi et al., 2012; 22806436, Baccarani et al., 2007; 17666373, Cassier et al., 2012; 22718859, Chalmers et al., 2015; 25658984, Cools et al., 2003; 12660384, Curtis et al., 2007; 17555450, Debiec_Rychter et al., 2016; 15010069, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Florian et al., 2006; 16406018, Frenard et al., 2016; 27051816, Griffin et al., 2003; 12808148, Heinrich et al., 2003; 14645423, Helbig et al., 2009; 19120352, Helbig et al., 2014; 24009127, Hus et al., 2011; 21093052, Ikezoe et al., 2010; 20303172, Intermesoli et al., 2009; 19735261, Jain et al., 2009; 19013640, Jovanovic et al., 2007; 17299092, Kang et al., 2012; 22150077, Klion et al., 2004; 14504092, Kobayashi et al., 2009; 19192229, Kocáková et al., 2014; 24635438, Metzgeroth et al., 2008; 18950453, Murayama et al., 2012; 22645636, Ogbogu et al., 2009; 19910029, Ohnishi et al., 2006; 16856885, Pardanani et al., 2003; 12842979, Pardanani et al., 2004; 15284118, Qu et al., 2016; 27120808, Score et al., 2006; 16498388, Shah et al., 2011; 24669761, Sugimoto et al., 2015; 26319757, Volz et al., 2011; 20609486, von Bubnoff et al., 2005; 15618966, Walz et al., 2006; 16845659, Yoo et al., 2016; 26130666). Sorafenib has shown clinical and preclinical activity against the FIP1L1_PDGFRA fusion in chronic eosinophilic leukemia (CEL) and mutations associated with clinical resistance to imatinib and sunitinib in both CEL and gastrointestinal stromal tumor (GIST)(Fumagalli et al., 2012; ESMO Abstract 1491P, Al_Riyami et al., 2013; 23157309, Lierman et al., 2006; 16645167, Lierman et al., 2009; 19212337, Metzgeroth et al., 2012; 21818111, Roubaud et al., 2012; 22294526, Von Bubnoff et al., 2011; 20972453). Complete responses to nilotinib have been reported in patients with CEL or hypereosinophilic syndrome with FIP1L1_PDGFRA or activating mutations (Hochhaus et al., 2013; 24057647, Ikezoe et al., 2010; 20303172, Tabouret et al., 2011; 20832858); preclinical evidence has reported efficacy of nilotinib in the context of PDGFRA mutations associated with GIST (Dewaele et al., 2008; 18794084, Weisberg et al., 2006; 17087936). Patients with GIST harboring PDGFRA activating mutations have been reported to derive clinical benefit from treatment with sunitinib (Heinrich et al., 2006; ASCO Abstract 9502, Brohl et al., 2015; 26396737) or regorafenib (Grellety et al., 2015; 28031906, Kollar et al., 2014; 25905001). Preclinical studies have reported sensitivity of activating PDGFRA mutations and FIP1L1_PDGFRA fusion to dasatinib (Dewaele et al., 2008; 18794084, Lierman et al., 2009; 19212337). PDGFRA D842 mutations were reported to be sensitive to avapritinib in clinical (Heinrich et al., 2017; ASCO Abstract 11011, Evans et al., 2017; 29093181) and preclinical (Evans et al., 2017; 29093181) studies of GIST, and demonstrated sensitivity to ripretinib for 1 patient (Jaku et al., 2017; ASCO Abstract 2515).', 'Include': 'true', 'ClinicalTrialNote': 'PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies. PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Sorafenib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Quintás_Cardama et al., 2008; 18936790, Bisagni et al., 2009; 19461405, Handolias et al., 2010; 20372153, Disel et al., 2011; 20970876, Park et al., 2012; 22270258, Catania et al., 2014; 24855380, Guo et al., 2007; 17699867, Hu et al., 2008; 18483300) or KIT_expressing tumors (Llovet et al., 2012; 22374331, Zhang et al., 2013; 23058498, Seino et al., 2014; 25450081, Li et al., 2009; 18846437), KIT activating alterations may predict sensitivity to sorafenib. On the basis of clinical responses in patients with GIST, PDGFRA activating mutations may predict sensitivity to sorafenib (Fumagalli et al., 2012; ESMO Abstract 1491P)(Roubaud et al., 2012; 22294526). </p> <p><b>Supporting Data:</b> Phase 2 studies of sorafenib plus temozolomide report limited activity in patients with relapsed glioblastoma multiforme (GBM) (Zustovich et al., 2013; 23898124; Reardon et al., 2011; 20443129). A Phase 1/2 trial of temsirolimus in combination with sorafenib in patients with glioblastoma was terminated at the Phase 2 interim analysis after patients failed to meet the primary endpoint of 6 month progression_free survival (Lee et al., 2012; 23099651). A Phase 2 trial of sorafenib and erlotinib in glioblastoma also did not meet its primary endpoint, and erlotinib clearance was increased by the addition of sorafenib (Peereboom et al., 2013; 23328813). In a Phase 1 trial in patients with high_grade glioma, the combination of sorafenib with radiation therapy (RT) and temozolomide (TMZ) resulted in increased toxicity and did not result in significant improvement in clinical efficacy compared with RT and TMZ alone (Hottinger et al., 2014; 24786603). In a clinical study of sorafenib in pediatric patients with low_grade astrocytoma, one patient achieved a partial response (PR), one had stable disease (SD), and 9 patients had progressive disease; this study was terminated early due to unexpectedly high disease progression rates (Karajannis et al., 2014; 24803676). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Imatinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Imatinib targets the BCR_ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT_positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence, PDGFRA activating mutations (Cassier et al., 2012; 22718859, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Heinrich et al., 2003; 14645423, Yoo et al., 2016; 26130666), fusions (Baccarani et al., 2007; 17666373, Curtis et al., 2007; 17555450, Griffin et al., 2003; 12808148, Helbig et al., 2009; 19120352, Klion et al., 2004; 14504092, Qu et al., 2016; 27120808, Metzgeroth et al., 2007; 17377585, Metzgeroth et al., 2008; 18950453, Ogbogu et al., 2009; 19910029, Sugimoto et al., 2015; 26319757), and expression (Frenard et al., 2016; 27051816) may predict sensitivity to imatinib. On the basis of clinical and preclinical data in KIT_mutated (Carvajal et al., 2011; 21642685, Debiec_Rychter et al., 2006; 16624552, Heinrich et al., 2003; 14645423, Hodi et al., 2013; 23775962), KIT_amplified (Wei et al., 2019; 30075827, Guo et al., 2011; 21690468, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685), or KIT_expressing tumors (DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Hotte et al., 2005; 15659505, Reardon et al., 2009; 19904263, Kamenz et al., 2006; 16570351, Wang et al., 2005; 15650049), KIT activating alterations may confer sensitivity to imatinib. PDGFRA amplification may predict sensitivity to tyrosine kinase inhibitors such as imatinib; a patient with Merkel cell carcinoma expressing PDGFRA achieved a complete response to imatinib (Frenard et al., 2016; 27051816). </p> <p><b>Supporting Data:</b> In a clinical study where patients with recurrent glioblastoma were given imatinib, 2/24 patients achieved a PR, 10 patients reported SD, and median OS and PFS was observed to be 6.2 and 3 months, respectively (Hassler et al., 2014; 25674429). However, other Phase 2 clinical trials of imatinib have reported no anti_tumor activity, with a study of 231 patients with glioblastoma reporting a radiographic response rate of only 3.4% (Razis et al., 2009; 19789313, Reardon et al., 2009; 19904263). In another Phase 2 study, imatinib plus hydroxyurea was shown to be well tolerated among patients with recurrent/progressive low_grade glioma, but had negligible antitumor activity (Reardon et al., 2012; 22371319). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT03970447', 'Include': 'true'}, {'nctId': 'NCT03025893', 'Include': 'true'}, {'nctId': 'NCT05159245', 'Include': 'true'}, {'nctId': 'NCT02379416', 'Include': 'true'}, {'nctId': 'NCT04771520', 'Include': 'true'}, {'nctId': 'NCT01738139', 'Include': 'true'}]}}, {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'PDGFRA encodes platelet_derived growth factor receptor alpha (PDGFR_alpha), a tyrosine kinase receptor that, upon binding of cognate ligands (PDGFA or PDGFB), activates several signaling pathways, including PI3K and MAPK (Andrae et al., 2008; 18483217). PDGFR aberrations, including point mutations, translocations, amplification, and/or overexpression, have been associated with various malignancies (Fletcher, 2004; 15175998). Amplification of PDGFRA, frequently occurring with amplification of the genes KDR and KIT, has been associated with increased PDGFRA expression (Burford et al., 2013; 23990986, Flavahan et al., 2016; 26700815, Roszik et al., 2016; 26787600, Verhaak et al., 2010; 20129251) and poor prognosis (Burford et al., 2013; 23990986, Koschmann et al., 2016; 27582545, Phillips et al., 2013; 23438035, Puget et al., 2012; 22389665) in some subtypes of glioma. The PDGFRA rearrangement in this tumor results in deletion of exons 8_9. The PDGFRA exon 8_9 deletion mutant was demonstrated to be active in the absence of ligand and has been characterized as transforming (Clarke et al., 2003; 12569364, Ozawa et al., 2010; 20889717). This mutant was sensitive to imatinib and the kinase inhibitor vatalanib (Ozawa et al., 2010; 20889717). Although alterations such as E229K and R841K seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. PDGFRA amplification has been suggested to be more common in higher grade astrocytomas than in lower grade astrocytomas; studies have reported PDGFRA amplification in 16.3% (27/166) of Grade 2 astrocytomas and in 23.6% (91/386) of Grade 3 and 4 astrocytomas analyzed (Holtkamp et al., 2007; 17504929, Phillips et al., 2013; 23438035, Motomura et al., 2013; 23242283). PDGFRA amplification has been reported in 5.2_33% of glioblastoma cases (cBio_Brennan et al., 2013; 24120142, Phillips et al., 2013; 23438035, Sottoriva et al., 2013; 23412337, Nobusawa et al., 2011; 21382095, Joensuu et al., 2005; 16021678, Alentorn et al., 2012; 23074200). PDGFRA mutation has been identified in 5.6% of Grade 3 and 5.4% of Grade 4 astrocytomas, 2.4% of Grade 3 oligodendrogliomas, and 12% (3/25) of gliosarcomas analyzed in COSMIC (Feb 2022)(Tate et al., 2019; 30371878). PDGFRA mutations have been reported in 0_5% of lower grade glioma and glioblastoma samples (cBio_Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2008; 18772890, cBio_Hoadley et al., 2018; 29625048, cBio_Ellrott et al., 2018; 29596782, cBio_Taylor et al., 2018; 29622463, cBio_Gao et al., 2018; 29617662, cBio_Liu et al., 2018; 29625055, cBio_Sanchez_Vega et al., 2018; 29625050), Ceccarelli et al., 2016; 26824661, Cancer Genome Atlas Research Network., 2015; 26061751, cBio_Johnson et al., 2014; 24336570, cBio_Thomas et al., 2017; 28472509, cBio_Jones et al., 2013; 23817572). A retrospective analysis of TCGA glioma samples reported elevated expression of ERBB3 correlated with PDGFRA expression and co_expression of these genes was an indicator of poor prognosis in a GBM patient cohort (Song et al., 2018; 29888103). Amplification of PDGFRA has been associated with tumor grade and poor progression_free and overall survival in patients with glioblastoma (Alentorn et al., 2012; 23074200, Sottoriva et al., 2013; 23412337, Phillips et al., 2013; 23438035). In addition, PDGFRA amplification has been reported to occur in conjunction with IDH1 mutation in glioblastoma, and both alterations in the same tumor have been associated with poor patient prognosis (Phillips et al., 2013; 23438035). Amplification of PDGFRA has also been strongly correlated with the presence of KDR and/or KIT amplification in glioblastomas, as well as with EGFR amplification (Joensuu et al., 2005; 16021678, Holtkamp et al., 2007; 17504929, Puputti et al., 2006; 17189383, Szerlip et al., 2012; 22323597). On the basis of extensive clinical evidence in solid tumors and hematologic cancers, PDGFRA activating alterations are associated with sensitivity to imatinib (Arefi et al., 2012; 22806436, Baccarani et al., 2007; 17666373, Cassier et al., 2012; 22718859, Chalmers et al., 2015; 25658984, Cools et al., 2003; 12660384, Curtis et al., 2007; 17555450, Debiec_Rychter et al., 2016; 15010069, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Florian et al., 2006; 16406018, Frenard et al., 2016; 27051816, Griffin et al., 2003; 12808148, Heinrich et al., 2003; 14645423, Helbig et al., 2009; 19120352, Helbig et al., 2014; 24009127, Hus et al., 2011; 21093052, Ikezoe et al., 2010; 20303172, Intermesoli et al., 2009; 19735261, Jain et al., 2009; 19013640, Jovanovic et al., 2007; 17299092, Kang et al., 2012; 22150077, Klion et al., 2004; 14504092, Kobayashi et al., 2009; 19192229, Kocáková et al., 2014; 24635438, Metzgeroth et al., 2008; 18950453, Murayama et al., 2012; 22645636, Ogbogu et al., 2009; 19910029, Ohnishi et al., 2006; 16856885, Pardanani et al., 2003; 12842979, Pardanani et al., 2004; 15284118, Qu et al., 2016; 27120808, Score et al., 2006; 16498388, Shah et al., 2011; 24669761, Sugimoto et al., 2015; 26319757, Volz et al., 2011; 20609486, von Bubnoff et al., 2005; 15618966, Walz et al., 2006; 16845659, Yoo et al., 2016; 26130666). Sorafenib has shown clinical and preclinical activity against the FIP1L1_PDGFRA fusion in chronic eosinophilic leukemia (CEL) and mutations associated with clinical resistance to imatinib and sunitinib in both CEL and gastrointestinal stromal tumor (GIST)(Fumagalli et al., 2012; ESMO Abstract 1491P, Al_Riyami et al., 2013; 23157309, Lierman et al., 2006; 16645167, Lierman et al., 2009; 19212337, Metzgeroth et al., 2012; 21818111, Roubaud et al., 2012; 22294526, Von Bubnoff et al., 2011; 20972453). Complete responses to nilotinib have been reported in patients with CEL or hypereosinophilic syndrome with FIP1L1_PDGFRA or activating mutations (Hochhaus et al., 2013; 24057647, Ikezoe et al., 2010; 20303172, Tabouret et al., 2011; 20832858); preclinical evidence has reported efficacy of nilotinib in the context of PDGFRA mutations associated with GIST (Dewaele et al., 2008; 18794084, Weisberg et al., 2006; 17087936). Patients with GIST harboring PDGFRA activating mutations have been reported to derive clinical benefit from treatment with sunitinib (Heinrich et al., 2006; ASCO Abstract 9502, Brohl et al., 2015; 26396737) or regorafenib (Grellety et al., 2015; 28031906, Kollar et al., 2014; 25905001). Preclinical studies have reported sensitivity of activating PDGFRA mutations and FIP1L1_PDGFRA fusion to dasatinib (Dewaele et al., 2008; 18794084, Lierman et al., 2009; 19212337). PDGFRA D842 mutations were reported to be sensitive to avapritinib in clinical (Heinrich et al., 2017; ASCO Abstract 11011, Evans et al., 2017; 29093181) and preclinical (Evans et al., 2017; 29093181) studies of GIST, and demonstrated sensitivity to ripretinib for 1 patient (Jaku et al., 2017; ASCO Abstract 2515).', 'Include': 'true', 'ClinicalTrialNote': 'PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies. PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Sorafenib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Quintás_Cardama et al., 2008; 18936790, Bisagni et al., 2009; 19461405, Handolias et al., 2010; 20372153, Disel et al., 2011; 20970876, Park et al., 2012; 22270258, Catania et al., 2014; 24855380, Guo et al., 2007; 17699867, Hu et al., 2008; 18483300) or KIT_expressing tumors (Llovet et al., 2012; 22374331, Zhang et al., 2013; 23058498, Seino et al., 2014; 25450081, Li et al., 2009; 18846437), KIT activating alterations may predict sensitivity to sorafenib. On the basis of clinical responses in patients with GIST, PDGFRA activating mutations may predict sensitivity to sorafenib (Fumagalli et al., 2012; ESMO Abstract 1491P)(Roubaud et al., 2012; 22294526). </p> <p><b>Supporting Data:</b> Phase 2 studies of sorafenib plus temozolomide report limited activity in patients with relapsed glioblastoma multiforme (GBM) (Zustovich et al., 2013; 23898124; Reardon et al., 2011; 20443129). A Phase 1/2 trial of temsirolimus in combination with sorafenib in patients with glioblastoma was terminated at the Phase 2 interim analysis after patients failed to meet the primary endpoint of 6 month progression_free survival (Lee et al., 2012; 23099651). A Phase 2 trial of sorafenib and erlotinib in glioblastoma also did not meet its primary endpoint, and erlotinib clearance was increased by the addition of sorafenib (Peereboom et al., 2013; 23328813). In a Phase 1 trial in patients with high_grade glioma, the combination of sorafenib with radiation therapy (RT) and temozolomide (TMZ) resulted in increased toxicity and did not result in significant improvement in clinical efficacy compared with RT and TMZ alone (Hottinger et al., 2014; 24786603). In a clinical study of sorafenib in pediatric patients with low_grade astrocytoma, one patient achieved a partial response (PR), one had stable disease (SD), and 9 patients had progressive disease; this study was terminated early due to unexpectedly high disease progression rates (Karajannis et al., 2014; 24803676). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Imatinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Imatinib targets the BCR_ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT_positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence, PDGFRA activating mutations (Cassier et al., 2012; 22718859, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Heinrich et al., 2003; 14645423, Yoo et al., 2016; 26130666), fusions (Baccarani et al., 2007; 17666373, Curtis et al., 2007; 17555450, Griffin et al., 2003; 12808148, Helbig et al., 2009; 19120352, Klion et al., 2004; 14504092, Qu et al., 2016; 27120808, Metzgeroth et al., 2007; 17377585, Metzgeroth et al., 2008; 18950453, Ogbogu et al., 2009; 19910029, Sugimoto et al., 2015; 26319757), and expression (Frenard et al., 2016; 27051816) may predict sensitivity to imatinib. On the basis of clinical and preclinical data in KIT_mutated (Carvajal et al., 2011; 21642685, Debiec_Rychter et al., 2006; 16624552, Heinrich et al., 2003; 14645423, Hodi et al., 2013; 23775962), KIT_amplified (Wei et al., 2019; 30075827, Guo et al., 2011; 21690468, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685), or KIT_expressing tumors (DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Hotte et al., 2005; 15659505, Reardon et al., 2009; 19904263, Kamenz et al., 2006; 16570351, Wang et al., 2005; 15650049), KIT activating alterations may confer sensitivity to imatinib. PDGFRA amplification may predict sensitivity to tyrosine kinase inhibitors such as imatinib; a patient with Merkel cell carcinoma expressing PDGFRA achieved a complete response to imatinib (Frenard et al., 2016; 27051816). </p> <p><b>Supporting Data:</b> In a clinical study where patients with recurrent glioblastoma were given imatinib, 2/24 patients achieved a PR, 10 patients reported SD, and median OS and PFS was observed to be 6.2 and 3 months, respectively (Hassler et al., 2014; 25674429). However, other Phase 2 clinical trials of imatinib have reported no anti_tumor activity, with a study of 231 patients with glioblastoma reporting a radiographic response rate of only 3.4% (Razis et al., 2009; 19789313, Reardon et al., 2009; 19904263). In another Phase 2 study, imatinib plus hydroxyurea was shown to be well tolerated among patients with recurrent/progressive low_grade glioma, but had negligible antitumor activity (Reardon et al., 2012; 22371319). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT03970447', 'Include': 'true'}, {'nctId': 'NCT03025893', 'Include': 'true'}, {'nctId': 'NCT05159245', 'Include': 'true'}, {'nctId': 'NCT02379416', 'Include': 'true'}, {'nctId': 'NCT04771520', 'Include': 'true'}, {'nctId': 'NCT01738139', 'Include': 'true'}]}}, {'Name': 'E229K, R841K', 'AlterationProperties': {'AlterationProperty': [{'isEquivocal': 'false', 'name': 'E229K'}, {'isEquivocal': 'false', 'name': 'R841K'}]}, 'Interpretation': 'PDGFRA encodes platelet_derived growth factor receptor alpha (PDGFR_alpha), a tyrosine kinase receptor that, upon binding of cognate ligands (PDGFA or PDGFB), activates several signaling pathways, including PI3K and MAPK (Andrae et al., 2008; 18483217). PDGFR aberrations, including point mutations, translocations, amplification, and/or overexpression, have been associated with various malignancies (Fletcher, 2004; 15175998). Amplification of PDGFRA, frequently occurring with amplification of the genes KDR and KIT, has been associated with increased PDGFRA expression (Burford et al., 2013; 23990986, Flavahan et al., 2016; 26700815, Roszik et al., 2016; 26787600, Verhaak et al., 2010; 20129251) and poor prognosis (Burford et al., 2013; 23990986, Koschmann et al., 2016; 27582545, Phillips et al., 2013; 23438035, Puget et al., 2012; 22389665) in some subtypes of glioma. The PDGFRA rearrangement in this tumor results in deletion of exons 8_9. The PDGFRA exon 8_9 deletion mutant was demonstrated to be active in the absence of ligand and has been characterized as transforming (Clarke et al., 2003; 12569364, Ozawa et al., 2010; 20889717). This mutant was sensitive to imatinib and the kinase inhibitor vatalanib (Ozawa et al., 2010; 20889717). Although alterations such as E229K and R841K seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. PDGFRA amplification has been suggested to be more common in higher grade astrocytomas than in lower grade astrocytomas; studies have reported PDGFRA amplification in 16.3% (27/166) of Grade 2 astrocytomas and in 23.6% (91/386) of Grade 3 and 4 astrocytomas analyzed (Holtkamp et al., 2007; 17504929, Phillips et al., 2013; 23438035, Motomura et al., 2013; 23242283). PDGFRA amplification has been reported in 5.2_33% of glioblastoma cases (cBio_Brennan et al., 2013; 24120142, Phillips et al., 2013; 23438035, Sottoriva et al., 2013; 23412337, Nobusawa et al., 2011; 21382095, Joensuu et al., 2005; 16021678, Alentorn et al., 2012; 23074200). PDGFRA mutation has been identified in 5.6% of Grade 3 and 5.4% of Grade 4 astrocytomas, 2.4% of Grade 3 oligodendrogliomas, and 12% (3/25) of gliosarcomas analyzed in COSMIC (Feb 2022)(Tate et al., 2019; 30371878). PDGFRA mutations have been reported in 0_5% of lower grade glioma and glioblastoma samples (cBio_Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2008; 18772890, cBio_Hoadley et al., 2018; 29625048, cBio_Ellrott et al., 2018; 29596782, cBio_Taylor et al., 2018; 29622463, cBio_Gao et al., 2018; 29617662, cBio_Liu et al., 2018; 29625055, cBio_Sanchez_Vega et al., 2018; 29625050), Ceccarelli et al., 2016; 26824661, Cancer Genome Atlas Research Network., 2015; 26061751, cBio_Johnson et al., 2014; 24336570, cBio_Thomas et al., 2017; 28472509, cBio_Jones et al., 2013; 23817572). A retrospective analysis of TCGA glioma samples reported elevated expression of ERBB3 correlated with PDGFRA expression and co_expression of these genes was an indicator of poor prognosis in a GBM patient cohort (Song et al., 2018; 29888103). Amplification of PDGFRA has been associated with tumor grade and poor progression_free and overall survival in patients with glioblastoma (Alentorn et al., 2012; 23074200, Sottoriva et al., 2013; 23412337, Phillips et al., 2013; 23438035). In addition, PDGFRA amplification has been reported to occur in conjunction with IDH1 mutation in glioblastoma, and both alterations in the same tumor have been associated with poor patient prognosis (Phillips et al., 2013; 23438035). Amplification of PDGFRA has also been strongly correlated with the presence of KDR and/or KIT amplification in glioblastomas, as well as with EGFR amplification (Joensuu et al., 2005; 16021678, Holtkamp et al., 2007; 17504929, Puputti et al., 2006; 17189383, Szerlip et al., 2012; 22323597). On the basis of extensive clinical evidence in solid tumors and hematologic cancers, PDGFRA activating alterations are associated with sensitivity to imatinib (Arefi et al., 2012; 22806436, Baccarani et al., 2007; 17666373, Cassier et al., 2012; 22718859, Chalmers et al., 2015; 25658984, Cools et al., 2003; 12660384, Curtis et al., 2007; 17555450, Debiec_Rychter et al., 2016; 15010069, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Florian et al., 2006; 16406018, Frenard et al., 2016; 27051816, Griffin et al., 2003; 12808148, Heinrich et al., 2003; 14645423, Helbig et al., 2009; 19120352, Helbig et al., 2014; 24009127, Hus et al., 2011; 21093052, Ikezoe et al., 2010; 20303172, Intermesoli et al., 2009; 19735261, Jain et al., 2009; 19013640, Jovanovic et al., 2007; 17299092, Kang et al., 2012; 22150077, Klion et al., 2004; 14504092, Kobayashi et al., 2009; 19192229, Kocáková et al., 2014; 24635438, Metzgeroth et al., 2008; 18950453, Murayama et al., 2012; 22645636, Ogbogu et al., 2009; 19910029, Ohnishi et al., 2006; 16856885, Pardanani et al., 2003; 12842979, Pardanani et al., 2004; 15284118, Qu et al., 2016; 27120808, Score et al., 2006; 16498388, Shah et al., 2011; 24669761, Sugimoto et al., 2015; 26319757, Volz et al., 2011; 20609486, von Bubnoff et al., 2005; 15618966, Walz et al., 2006; 16845659, Yoo et al., 2016; 26130666). Sorafenib has shown clinical and preclinical activity against the FIP1L1_PDGFRA fusion in chronic eosinophilic leukemia (CEL) and mutations associated with clinical resistance to imatinib and sunitinib in both CEL and gastrointestinal stromal tumor (GIST)(Fumagalli et al., 2012; ESMO Abstract 1491P, Al_Riyami et al., 2013; 23157309, Lierman et al., 2006; 16645167, Lierman et al., 2009; 19212337, Metzgeroth et al., 2012; 21818111, Roubaud et al., 2012; 22294526, Von Bubnoff et al., 2011; 20972453). Complete responses to nilotinib have been reported in patients with CEL or hypereosinophilic syndrome with FIP1L1_PDGFRA or activating mutations (Hochhaus et al., 2013; 24057647, Ikezoe et al., 2010; 20303172, Tabouret et al., 2011; 20832858); preclinical evidence has reported efficacy of nilotinib in the context of PDGFRA mutations associated with GIST (Dewaele et al., 2008; 18794084, Weisberg et al., 2006; 17087936). Patients with GIST harboring PDGFRA activating mutations have been reported to derive clinical benefit from treatment with sunitinib (Heinrich et al., 2006; ASCO Abstract 9502, Brohl et al., 2015; 26396737) or regorafenib (Grellety et al., 2015; 28031906, Kollar et al., 2014; 25905001). Preclinical studies have reported sensitivity of activating PDGFRA mutations and FIP1L1_PDGFRA fusion to dasatinib (Dewaele et al., 2008; 18794084, Lierman et al., 2009; 19212337). PDGFRA D842 mutations were reported to be sensitive to avapritinib in clinical (Heinrich et al., 2017; ASCO Abstract 11011, Evans et al., 2017; 29093181) and preclinical (Evans et al., 2017; 29093181) studies of GIST, and demonstrated sensitivity to ripretinib for 1 patient (Jaku et al., 2017; ASCO Abstract 2515).', 'Include': 'true', 'ClinicalTrialNote': 'PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies. PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Sorafenib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Quintás_Cardama et al., 2008; 18936790, Bisagni et al., 2009; 19461405, Handolias et al., 2010; 20372153, Disel et al., 2011; 20970876, Park et al., 2012; 22270258, Catania et al., 2014; 24855380, Guo et al., 2007; 17699867, Hu et al., 2008; 18483300) or KIT_expressing tumors (Llovet et al., 2012; 22374331, Zhang et al., 2013; 23058498, Seino et al., 2014; 25450081, Li et al., 2009; 18846437), KIT activating alterations may predict sensitivity to sorafenib. On the basis of clinical responses in patients with GIST, PDGFRA activating mutations may predict sensitivity to sorafenib (Fumagalli et al., 2012; ESMO Abstract 1491P)(Roubaud et al., 2012; 22294526). </p> <p><b>Supporting Data:</b> Phase 2 studies of sorafenib plus temozolomide report limited activity in patients with relapsed glioblastoma multiforme (GBM) (Zustovich et al., 2013; 23898124; Reardon et al., 2011; 20443129). A Phase 1/2 trial of temsirolimus in combination with sorafenib in patients with glioblastoma was terminated at the Phase 2 interim analysis after patients failed to meet the primary endpoint of 6 month progression_free survival (Lee et al., 2012; 23099651). A Phase 2 trial of sorafenib and erlotinib in glioblastoma also did not meet its primary endpoint, and erlotinib clearance was increased by the addition of sorafenib (Peereboom et al., 2013; 23328813). In a Phase 1 trial in patients with high_grade glioma, the combination of sorafenib with radiation therapy (RT) and temozolomide (TMZ) resulted in increased toxicity and did not result in significant improvement in clinical efficacy compared with RT and TMZ alone (Hottinger et al., 2014; 24786603). In a clinical study of sorafenib in pediatric patients with low_grade astrocytoma, one patient achieved a partial response (PR), one had stable disease (SD), and 9 patients had progressive disease; this study was terminated early due to unexpectedly high disease progression rates (Karajannis et al., 2014; 24803676). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Imatinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Imatinib targets the BCR_ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT_positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence, PDGFRA activating mutations (Cassier et al., 2012; 22718859, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Heinrich et al., 2003; 14645423, Yoo et al., 2016; 26130666), fusions (Baccarani et al., 2007; 17666373, Curtis et al., 2007; 17555450, Griffin et al., 2003; 12808148, Helbig et al., 2009; 19120352, Klion et al., 2004; 14504092, Qu et al., 2016; 27120808, Metzgeroth et al., 2007; 17377585, Metzgeroth et al., 2008; 18950453, Ogbogu et al., 2009; 19910029, Sugimoto et al., 2015; 26319757), and expression (Frenard et al., 2016; 27051816) may predict sensitivity to imatinib. On the basis of clinical and preclinical data in KIT_mutated (Carvajal et al., 2011; 21642685, Debiec_Rychter et al., 2006; 16624552, Heinrich et al., 2003; 14645423, Hodi et al., 2013; 23775962), KIT_amplified (Wei et al., 2019; 30075827, Guo et al., 2011; 21690468, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685), or KIT_expressing tumors (DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Hotte et al., 2005; 15659505, Reardon et al., 2009; 19904263, Kamenz et al., 2006; 16570351, Wang et al., 2005; 15650049), KIT activating alterations may confer sensitivity to imatinib. PDGFRA amplification may predict sensitivity to tyrosine kinase inhibitors such as imatinib; a patient with Merkel cell carcinoma expressing PDGFRA achieved a complete response to imatinib (Frenard et al., 2016; 27051816). </p> <p><b>Supporting Data:</b> In a clinical study where patients with recurrent glioblastoma were given imatinib, 2/24 patients achieved a PR, 10 patients reported SD, and median OS and PFS was observed to be 6.2 and 3 months, respectively (Hassler et al., 2014; 25674429). However, other Phase 2 clinical trials of imatinib have reported no anti_tumor activity, with a study of 231 patients with glioblastoma reporting a radiographic response rate of only 3.4% (Razis et al., 2009; 19789313, Reardon et al., 2009; 19904263). In another Phase 2 study, imatinib plus hydroxyurea was shown to be well tolerated among patients with recurrent/progressive low_grade glioma, but had negligible antitumor activity (Reardon et al., 2012; 22371319). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT03970447', 'Include': 'true'}, {'nctId': 'NCT03025893', 'Include': 'true'}, {'nctId': 'NCT05159245', 'Include': 'true'}, {'nctId': 'NCT02379416', 'Include': 'true'}, {'nctId': 'NCT04771520', 'Include': 'true'}, {'nctId': 'NCT01738139', 'Include': 'true'}]}}]}, 'ReferenceLinks': None}, {'Name': 'PIK3CA', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'E545K', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'E545K'}}, 'Interpretation': 'PIK3CA encodes p110_alpha, which is the catalytic subunit of phosphatidylinositol 3_kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival (Samuels et al., 2005; 15950905, Engelman, 2009; 19629070). PIK3CA alterations that have been characterized as activating, such as observed here, are predicted to be oncogenic (Kang et al., 2005; 15647370, Ikenoue et al., 2005; 15930273, Gymnopoulos et al., 2007; 17376864, Horn et al., 2008; 18317450, Rudd et al., 2011; 21266528, Hon et al., 2012; 22120714, Burke et al., 2012; 22949682, Wu et al., 2009; 19915146, Dbouk et al., 2010; 2103068, Dan et al., 2010; 20530683, Oda et al., 2008; 18829572, Zhao and Vogt, 2008; 18794883, Lui et al., 2013; 23619167, Ross et al., 2013; 22430209, Riviere et al., 2012; 22729224, Shibata et al., 2009; 19394761, Droguluk et al., 2015; 26627007, Croessmann et al., 2018; 29284706, Ng et al., 2018; 29533785, Spangle et al., 2020; 32929011, Chen et al., 2018; 29636477, Jin et al., 2021; 34779417). PIK3CA mutations have been reported in 9% of glioblastoma (GBM) samples analyzed in the TCGA dataset (cBio_Brennan et al., 2013; 24120142), and other studies report the incidence of PIK3CA mutations in primary GBMs as 5_18% (Gallia et al., 2006; 17050665, Broderick et al., 2004; 15289301, El_Habr et al., 2010; 20569675). One study detected PIK3CA mutation in 16% (36/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). PIK3CA mutations have been reported in 5_23% of high_grade gliomas (including glioblastomas, anaplastic astrocytomas, and anaplastic oligodendrogliomas) (El_Habr et al., 2010; 20569675, Gallia et al., 2006; 17050665, Broderick et al., 2004; 15289301, Derakhshandeh_Peykar et al., 2011; 22026810, Cancer Genome Atlas Research Network., 2008; 18772890). While another study did not observe PIK3CA mutations in low_grade astrocytomas or in anaplastic astrocytomas, it did report high ERK and AKT activity (El_Habr et al., 2010; 20569675). One study found that PIK3CA mutation in glioblastoma (GBM) was associated with shorter median PFS in both a discovery cohort (6.9 vs. 12.4 months, HR=2.89, p=0.01) and in the TCGA cohort (6.1 vs. 9 months, p=0.008), but was not consistently associated with median OS (Tanaka et al., 2019; 31036078). In a study of IDH_wildtype GBM, patients with alterations in PI3K class I genes (PIK3CA, PIK3R1, PIK3CG, and PIK3R2) had significantly longer OS (20.0 months altered vs. 16.9 months wildtype, HR=0.62, p=0.002) and PFS (11.0 months altered vs. 7.4 months wildtype, p=0.0043); patients with PIK3CA alterations experienced an improved OS but this association was not highly significant (20.0 months altered vs. 18.1 months wildtype, p=0.0407)(Yan et al. 2020; DOI:10.1200/PO.19.00385). Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K (Fritsch et al., 2014; 24608574, Juric et al., 2018; 29401002, Gallant et al., 2019; 30793038, Canaud et al., 2021; ESMO Abstract LBA23, Delestre et al., 2021; 34613809, Morschhauser et al., 2020; 31619463, Patnaik et al., 2016; 27672108, Santin et al., 2020; 31934607, Damodaran et al., 2022; 35133871), AKT (Andre et al., 2019; 31091374, Smyth et al., 2021; 33863913), or mTOR (Varnier et al., 2019; 31351267, Basse et al., 2018; 32914004, Sultova et al., 2021; 33277683, Mackay et al., 2014; 24166148, Myers et al., 2016; 27016228, Dhami et al., 2018; 29588307, Harris et al., 2019; 30863722, Hanna et al., 2018; 29301825). The Phase 2 NCI_MATCH study of copanlisib for patients with refractory solid tumors harboring PIK3CA mutations with or without PTEN loss met its primary endpoint with an ORR of 16% (4/25 PRs); responses (PR or SD >6 months) were seen in patients with ameloblastoma, liposarcoma, and carcinomas of the endometrium, ovary, esophagus, lung, and prostate (Damodaran et al., 2022; 35133871). However, the Phase 2 study of copanlisib for patients with endometrial carcinoma harboring PIK3CA hotspot mutations failed to report any objective responses (n=11)(Santin et al., 2020; 31934607). Two other studies of copanlisib for patients with genomically unselected tumors reported 1 CR and 2 PRs (1 unconfirmed) among 16 total patients with PIK3CA_mutated solid tumors with or without PTEN alterations (Morschhauser et al., 2020; 31619463, Patnaik et al., 2016; 27672108). In the Phase 2 MATCH trial for patients with PIK3CA_mutated solid tumors, 28% (18/65) of patients experienced PFS lasting at least 6 months after treatment with taselisib; however, no ORs were observed in this study (Krop et al., 2018; ASCO Abstract 101). A separate Phase 1b study of taselisib in combination with the CDK4/6 inhibitor palbociclib for patients with PIK3CA_mutated solid tumors reported an ORR of 0% (n=12) and a DCR of 17% (2/12) (Pascual et al., 2021; 32958578). In a Phase 1 trial of the dual PI3K/mTOR kinase inhibitor apitolisib, 79% (11/14) of patients with PIK3CA_mutated advanced solid tumors experienced disease control (3 PRs, 8 SDs) (Dolly et al., 2016; 26787751). The PI3K inhibitor alpelisib is approved as a single agent for the treatment of patients with PIK3CA_related overgrowth spectrum (PROS) (Canaud et al., 2021; ESMO Abstract LBA23), but has shown limited activity as monotherapy for PIK3CA_mutated solid tumors with a Phase 1a study reporting an ORR of 6.0% (8/134) and a DCR of 58% (78/134) (Juric et al., 2018; 2941002).', 'Include': 'true', 'ClinicalTrialNote': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04589845', 'Include': 'true'}, {'nctId': 'NCT04341259', 'Include': 'true'}, {'nctId': 'NCT03239015', 'Include': 'true'}, {'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT04526470', 'Include': 'true'}, {'nctId': 'NCT05125523', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT04317105', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'CDKN2A/B', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'p16INK4a loss and p14ARF loss exons 2_3', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'p16INK4a loss and p14ARF loss exons 2_3'}}, 'Interpretation': 'CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas (cBio_Ceccarelli et al., 2016; 26824661) and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)(cBio_Brennan et al., 2013; 24120142) than in those with lower grade gliomas (6%) (Jonsson et al., 2019; 31263031). In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM) (Verhaak et al., 2010; 20129251, Sottoriva et al., 2013; 23412337, Weber et al., 2007; 16909113). A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF_encoding locus alone (Nakamura et al., 2001; 11303791). One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples (Chakravarti et al., 2001; 11489817). Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression (Feng et al., 2012; 21713760, Sottoriva et al., 2013; 23412337). In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas (Raabe et al., 2011; 21636552, Liu et al., 2011; 21843312). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'CDKN2C', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'L24fs*5', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'L24fs*5'}}, 'Interpretation': 'CDKN2C encodes p18, also known as INK4c, a member of a family of cyclin_dependent kinase 4 (CDK4) inhibitors. INK4 family members are commonly deleted in cancer, which results in unrestrained CDK4/6 activity and dysregulated cell cycle entry (Ortega et al., 2002; 11960696). CDKN2C alterations that result in loss or disruption of the ankyrin repeats (amino acids 4_132), are predicted to be inactivating (Venkataramani et al., 1998; 9437433, Li et al., 1999; 10074345), although some alterations seen in the context of cancer have not been directly functionally characterized. Although CDKN2C missense mutations are rare in the context of cancer, loss of p18INK4c expression, genomic loss, deletion, and promoter methylation have been frequently reported in Merkel cell carcinoma (Leonard et al., 2000; 11198276, Vortmeyer et al., 1998; 9576574), anaplastic meningioma (Leuraud et al., 2000; 11263500, Bostrom et al., 2001; 11485924, Santarius et al., 2000; 10736068), uterine leiomyomata (Christacos et al., 2006; 16320247), leiomyosarcoma (Williams et al., 2020; 33015533), pituitary adenoma (Hossain et al., 2010; 19401813, Kirsch et al., 2009; 18973139), Hodgkin lymphoma (Sanchez_Aguilera et al., 2004; 14645011), multiple myeloma (Leone et al., 2008; 18829482, Boyd et al., 2011; 21994415, Walker et al., 2010; 20616218), hepatocellular carcinoma (HCC) (Morishita et al., 2004; 15349907), adenoid cystic carcinoma of the salivary gland (Daa et al., 2008; 18254776), secondary angiosarcoma (Styring et al., 2014; 24983371), pancreatic carcinoma (Lindberg et al., 2008; 17803708, Liang et al., 2014; 25502777), gastroenteropancreatic neuroendocrine tumors (Kim et al., 2014; 25036575), glioblastoma (Solomon et al., 2008; 18381405, Wiedemeyer et al., 2008; 18394558, Brennan et al., 2013; 24120142), Wilms tumors (Arcellana_Panlilio et al., 2000; 10918395), and mantle cell lymphoma (MCL) (Hartman et al., 2010; 20421449, Flordal Thelander et al., 2007; 17161458, Bea et al., 2009; 18984860). CDKN2C alterations, including missense mutations, have also been reported in parathyroid adenomas (Tahara et al., 1997; 9286748, Costa_Guda et al., 2013; 23715670, Gluick et al., 2013; 24127162) and thyroid carcinomas (TCs) (van Veelen et al., 2009; 18942719, Pita et al., 2014; 24423316, Kunstman et al., 2015; 25576899); single nucleotide polymorphisms within the region encoding CDKN2C have been associated with increased risk of papillary TC (Neta et al., 2011; 21642358) and with increased tumor size in sporadic medullary TC (Barbieri et al., 2014; 25565272). CDKN2C alterations or loss of p18INK4c expression are negative prognostic factors in multiple myeloma (Leone et al., 2008; 18829482, Boyd et al., 2011; 21994415, Walker et al., 2010; 20616218), HCC (Morishita et al., 2004; 15349907), MCL (Hartman et al., 2010; 20421449), and acute myeloid leukemia (AML) (Hattori et al., 2006; 16651240). However, p18INK4c has been reported to be overexpressed in mesothelioma (Romagnoli et al., 2009; 19218339), and nuclear p18INK4c expression has been reported to be a poor prognostic factor in oligodendroglioma (Korshunov and Golanov, 2002; 11800646). On the basis of preclinical studies, CDKN2C inactivation may promote sensitivity to CDK4/6 inhibitors (Cen et al., 2012; 22711607, Wiedemeyer et al., 2010; 20534551, Eguchi et al., 2009; 19509251, Jalili et al., 2012; 22997239), although this has not been demonstrated clinically.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'HGF', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'E199K', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'E199K'}}, 'Interpretation': 'HGF encodes hepatocyte growth factor, also known as scatter factor, an activating ligand of the receptor tyrosine kinase MET. Certain splice isoforms of HGF may also act as MET antagonists (Stamos et al., 2004; 15167892, Tolbert et al., 2010; 20624990). HGF plays an important role in normal development, acting as a growth factor in a number of different tissues (Stamos et al., 2004; 15167892, Tolbert et al., 2010; 20624990). HGF and its receptor, MET, have been implicated in growth, invasion, and metastasis of many solid tumors (Tolbert et al., 2010; 20624990). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. Characterized HGF mutations have rarely been reported in solid tumors (cBio_Zehir et al., 2017; 28481359, Nguyen et al., 2022; 35120664). HGF expression within tumor glioma cells is associated with high_grade glioma and increased microvessels, and tumor_derived HGF expression has been shown to correlate with reduced survival time (Guo et al., 2012; 22741575). Elevated expression of HGF and MET mRNA have been reported in GBM (Garnett et al., 2013; 23359207, Kunkel et al., 2001; 11296484), and HGF expression in GBM models has been shown to be associated with responsiveness to MET inhibition (Zhang et al., 2013; 23386689). On the basis of several preclinical studies in different cancer types, high HGF gene expression may associate with sensitivity to MET_targeted therapies, such as the approved multikinase inhibitors crizotinib and cabozantinib (Zhang et al., 2013; 23386689, Xie et al., 2012; 22203985, Kentsis et al., 2012; 22683780, Qian et al., 2013; 24167653, Wanjala et al., 2015; 25381262). However, this hypothesis has not been extensively tested in clinical studies. Whereas patients with glioblastoma and high tumor HGF gene expression experienced longer survival and a higher objective response rate (5/14 vs. 0/16) on the MET_targeting antibody onartuzumab combined with the anti_VEGF antibody bevacizumab than with placebo plus bevacizumab (Cloughesy et al., 2015; ASCO Abstract 2015), tumor HGF gene expression did not predict significant benefit from onartuzumab added to the EGFR_inhibitor erlotinib for patients with non_small cell lung cancer (Koeppen et al., 2014; 24687921). Anti_HGF antibodies, such as ficlatuzumab, are also under clinical investigation (Patnaik et al., 2014; 24901237, Iveson et al., 2014; 24965569). It is unclear if missense mutations in HGF may lead to increased expression or activation, and therefore it is unknown whether these therapeutic approaches would be relevant.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'MS_Stable', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'MS_Stable'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). Low_level MSI has been reported in 5_9% of glioblastoma (GBM) samples (Martinez et al., 2004; 15331927, Martinez et al., 2005; 15672285, Martinez et al., 2007; 17498554). A large_scale study did not find high_level microsatellite instability (MSI_H) in any of 129 GBM samples (Martinez et al., 2004; 15331927), although a small_scale study reported MSI_H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs (Szybka et al., 2003; 12908754). The frequency of MSI has been reported to be increased in relapsed compared to primary GBM (Martinez et al., 2004; 15331927), in GBMs with a previous lower grade astrocytoma (Martinez et al., 2005; 15672285), and in giant cell GBM compared to classic GBM (Martinez et al., 2007; 17498554). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'PIK3C2B', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'PI3K signaling is implicated in the regulation of metabolic control, immunity, angiogenesis and cardiovascular homeostasis, and is one of the most frequently dysregulated pathways in cancer. In contrast to class I PI3Ks, including p110_alpha and p110_beta, the functional roles of class II PI3Ks, encoded by PIK3C2A, PIK3C2B, and PIK3C2G, are not well understood (Biswas et al., 2013; 23192342). Although PIK3C2B mutation has not been reported for many tumor types, microarray analysis of glioblastoma cell lines revealed that increased gene expression of PIK3C2B significantly correlated with insensitivity to erlotinib (Low et al., 2008; 19189657). In addition, 8% of 465 glioblastoma multiforme (GBM) tumor samples analyzed in one study demonstrated copy number amplification of PIK3C2B (Rao et al., 2010; 19609742). Although elevated expression of PIK3C2B has been observed in GBM, it is unclear if this plays any role in oncogenesis. There are no therapies known to effectively target mutations in PIK3C2B.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TERT', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'promoter _146C>T', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'promoter _146C>T'}}, 'Interpretation': 'Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length (Shay et al., 2011; 22015685). Activation of TERT is a hallmark of cancer, being detected in up to 80_90% of malignancies and absent in quiescent cells (Shay et al., 1997; 9282118, Kim et al., 1994; 7605428, Hanahan and Weinberg, 2000; 10647931). Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at _124 bp and _146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)(Horn et al., 2013; 23348503, Huang et al., 2014; 23348506, Vinagre et al., 2013; 23887589), as well as tandem mutations at positions –124/–125 bp and –138/–139 bp (Horn et al., 2013; 23348503). TERT promoter mutations have been reported in 51_59% of gliomas (Killela et al., 2013; 23530248, Killela et al., 2014; 24722048), most frequently in glioblastoma (GBM, 54_84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25_31%) but less frequently in lower grade astrocytomas (10_18%) and in only 1% of ependymomas (Nonoguchi et al., 2013; 23955565, Liu et al., 2013; 23603989, Koelsche et al., 2013; 24154961, Killela et al., 2013; 23530248, Killela et al., 2014; 24722048). In patients with glioblastoma (GBM), the prevalence of TERT promoter mutation is lower in pediatric primary GBM (11%) and adult secondary GBM (28%) compared with adult primary GBM (58_83%) (Nonoguchi et al., 2013; 23955565, Killela et al., 2013; 23530248). One study detected TERT promoter mutations in 78% (181/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM (Arita et al., 2013; 23764841). TERT promoter mutations significantly associate with poor prognosis in patients with GBM, although this correlation may be due to the association with primary GBM as opposed to IDH_positive secondary GBM (Killela et al., 2013; 23530248, Nonoguchi et al., 2013; 23955565, Reitman et al., 2013; 24217890, Arita et al., 2013; 23764841). In the context of IDH_wildtype glioma, TERT mutations are associated with reduced OS (NCCN CNS Cancers Guidelines, v1.2022). Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor_associated antigen and antisense oligonucleotide_ or peptide_based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials (Zanetti et al., 2017; 27245281); however, in one preclinical study, the combination of a TERT peptide vaccine and anti_CTLA_4 therapy suppressed tumor growth (Duperret at al., 2018; 29249395). A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non_small cell lung cancer reported no improvement in PFS or OS (Chiappori et al., 2015; 25467017). TERT mutations are associated with 1p/19q co_deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX_wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v1.2022)(Weller et al., 2020; 33293629). The presence of EGFR gene amplification or TERT promoter mutations are indicative of diffuse astrocytic glioma with molecular features of glioblastoma, WHO grade 4 in IDH1/2_wildtype tumors (NCCN CNS Cancers Guidelines, v1.2022) (Louis et al., 2021; 34185076).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Tumor Mutation Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '08', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '08'}}, 'Interpretation': 'Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Touat et al., 2020; 32322066, Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556, Lukas et al., 2018; 30073642). Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 4.2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). For pediatric patients, high TMB has been reported in a subset of high_grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB (Patel et al., 2020; 32386112, Johnson et al., 2017; 28912153). Increased TMB has been reported to correlate with higher tumor grade in glioma (Draaisma et al., 2015; 26699864) and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD) (Bouffet et al., 2016; 27001570), as well as with shorter OS of patients with diffuse glioma (Wang et al., 2020; 32164609). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported (Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Touat et al., 2020; 32322066). However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti_PD_1 (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556) or anti_PD_L1 (Lukas et al., 2018; 30073642) therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD_1 or PD_L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_L1, FGFRs, RET, PDGFRA, VEGFRs, KIT, FLT3, CSF1R', 'Locations': 'Hangzhou (China), Shanghai (China), Dongguan (China), Guangzhou (China), Zhuhai (China), Benbu (China), Zhengzhou (China), Jinan (China), Dalian (China), Tianjin (China)', 'NCTID': 'NCT05024214', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT05098847', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'GI_101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1, CTLA_4', 'Locations': 'Daejeon (Korea, Republic of), Suwon_si (Korea, Republic of), Seoul (Korea, Republic of)', 'NCTID': 'NCT04977453', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Study of MK_4830 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_4830_001)', 'StudyPhase': 'PHASE 1', 'Target': 'ITL4, FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1', 'Locations': 'Seoul (Korea, Republic of), Liverpool (Australia), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Haifa (Israel), Warszawa (Poland), Gdansk (Poland), Thessaloniki (Greece), Heraklion (Greece)', 'NCTID': 'NCT03564691', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor', 'StudyPhase': 'PHASE 1', 'Target': 'CBP, Beta_catenin, FGFRs, RET, PDGFRA, VEGFRs, KIT', 'Locations': 'Osakasayama (Japan), Chuo_Ku (Japan), Chiba (Japan), Kashiwa (Japan)', 'NCTID': 'NCT04008797', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'A Phase II/III Study of High_dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme', 'StudyPhase': 'PHASE 2/3', 'Target': 'FLT3, VEGFRs, CSF1R, KIT, RET', 'Locations': 'Groningen (Netherlands), Nijmegen (Netherlands), Amsterdam (Netherlands)', 'NCTID': 'NCT03025893', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Pembrolizumab And Lenvatinib In Leptomeningeal Metastases', 'StudyPhase': 'PHASE 2', 'Target': 'PD_1, KIT, VEGFRs, FGFRs, PDGFRA, RET', 'Locations': 'Massachusetts', 'NCTID': 'NCT04729348', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'ABL, KIT', 'Locations': 'Maryland', 'NCTID': 'NCT02379416', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'MDM4', 'Alteration': 'amplification', 'Title': 'ALRN_6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'MDM2, MDM4', 'Locations': 'Texas', 'NCTID': 'NCT03725436', 'Note': 'Tumors with MDM4 amplification or overexpression and wild_type p53 may be sensitive to inhibitors of MDM_p53 interactions.', 'Include': 'true'}, {'Gene': 'PDGFRA', 'Alteration': 'deletion exons 8_9amplificationE229K, R841K', 'Title': 'A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma', 'StudyPhase': 'PHASE 2/3', 'Target': 'BRAF, VEGFRs, RET, KIT', 'Locations': 'Utah, Michigan, New York, Alabama', 'NCTID': 'NCT03970447', 'Note': 'PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies. PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.', 'Include': 'true'}, {'Gene': 'PDGFRA', 'Alteration': 'deletion exons 8_9amplificationE229K, R841K', 'Title': 'A Phase II/III Study of High_dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme', 'StudyPhase': 'PHASE 2/3', 'Target': 'FLT3, VEGFRs, CSF1R, KIT, RET', 'Locations': 'Groningen (Netherlands), Nijmegen (Netherlands), Amsterdam (Netherlands)', 'NCTID': 'NCT03025893', 'Note': 'PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies. PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.', 'Include': 'true'}, {'Gene': 'PDGFRA', 'Alteration': 'deletion exons 8_9amplificationE229K, R841K', 'Title': 'The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs', 'StudyPhase': 'PHASE 2', 'Target': 'BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6', 'Locations': 'Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)', 'NCTID': 'NCT05159245', 'Note': 'PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies. PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.', 'Include': 'true'}, {'Gene': 'PDGFRA', 'Alteration': 'deletion exons 8_9amplificationE229K, R841K', 'Title': 'Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'ABL, KIT', 'Locations': 'Maryland', 'NCTID': 'NCT02379416', 'Note': 'PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies. PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.', 'Include': 'true'}, {'Gene': 'PDGFRA', 'Alteration': 'deletion exons 8_9amplificationE229K, R841K', 'Title': 'Avapritinib for the Treatment of CKIT or PDGFRA Mutation_Positive Locally Advanced or Metastatic Malignant Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'KIT, PDGFRA', 'Locations': 'Texas', 'NCTID': 'NCT04771520', 'Note': 'PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies. PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.', 'Include': 'true'}, {'Gene': 'PDGFRA', 'Alteration': 'deletion exons 8_9amplificationE229K, R841K', 'Title': 'Ipilimumab and Imatinib Mesylate in Advanced Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'KIT, ABL, CTLA_4', 'Locations': 'Texas', 'NCTID': 'NCT01738139', 'Note': 'PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies. PDGFRA activating mutations may predict sensitivity to certain PDGFRA_targeted therapies.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'E545K', 'Title': 'Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study', 'StudyPhase': 'PHASE 2', 'Target': 'TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha, RAFs, NRAS', 'Locations': 'Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Shanghai City (China), Shanghai (China), Shatin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi an (China), Tianjin (China)', 'NCTID': 'NCT04589845', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'E545K', 'Title': 'A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.', 'StudyPhase': 'PHASE 1', 'Target': 'AKTs', 'Locations': 'Shanghai City (China)', 'NCTID': 'NCT04341259', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'E545K', 'Title': 'Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event', 'StudyPhase': 'PHASE 2', 'Target': 'EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT03239015', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'E545K', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'E545K', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'E545K', 'Title': 'Alpelisib and Paclitaxel in PIK3CA_altered Gastric Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'PI3K_alpha', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of)', 'NCTID': 'NCT04526470', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'E545K', 'Title': 'A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'mTOR', 'Locations': 'Tianjin (China)', 'NCTID': 'NCT05125523', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'E545K', 'Title': 'Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, AKTs, PD_L1', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT03772561', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'E545K', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'E545K', 'Title': 'Testing the Addition of an Anti_cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1, CTLA_4, PI3K', 'Locations': 'Toronto (Canada), Texas, Virginia', 'NCTID': 'NCT04317105', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '18483217', 'FullCitation': 'Andrae J, et al. Genes Dev. (2008) pmid: 18483217', 'Include': 'true'}, {'number': '1', 'ReferenceId': '15175998', 'FullCitation': 'Semin. Oncol. (2004) pmid: 15175998', 'Include': 'true'}, {'number': '2', 'ReferenceId': '23990986', 'FullCitation': 'Burford A, et al. PLoS ONE (2013) pmid: 23990986', 'Include': 'true'}, {'number': '3', 'ReferenceId': '26700815', 'FullCitation': 'Flavahan WA, et al. Nature (2016) pmid: 26700815', 'Include': 'true'}, {'number': '4', 'ReferenceId': '26787600', 'FullCitation': 'Roszik J, et al. Sci Rep (2016) pmid: 26787600', 'Include': 'true'}, {'number': '5', 'ReferenceId': '20129251', 'FullCitation': 'Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251', 'Include': 'true'}, {'number': '6', 'ReferenceId': '27582545', 'FullCitation': 'Koschmann C, et al. Oncotarget (2016) pmid: 27582545', 'Include': 'true'}, {'number': '7', 'ReferenceId': '23438035', 'FullCitation': 'Phillips JJ, et al. Brain Pathol. (2013) pmid: 23438035', 'Include': 'true'}, {'number': '8', 'ReferenceId': '22389665', 'FullCitation': 'Puget S, et al. PLoS ONE (2012) pmid: 22389665', 'Include': 'true'}, {'number': '9', 'ReferenceId': '12569364', 'FullCitation': 'Clarke ID, et al. Oncogene (2003) pmid: 12569364', 'Include': 'true'}, {'number': '10', 'ReferenceId': '20889717', 'FullCitation': 'Ozawa T, et al. Genes Dev. (2010) pmid: 20889717', 'Include': 'true'}, {'number': '11', 'ReferenceId': '17504929', 'FullCitation': 'Holtkamp N, et al. Neuro_oncology (2007) pmid: 17504929', 'Include': 'true'}, {'number': '12', 'ReferenceId': '23242283', 'FullCitation': 'Motomura K, et al. J. Neuropathol. Exp. Neurol. (2013) pmid: 23242283', 'Include': 'true'}, {'number': '13', 'ReferenceId': '24120142', 'FullCitation': 'Brennan CW, et al. Cell (2013) pmid: 24120142', 'Include': 'true'}, {'number': '14', 'ReferenceId': '23412337', 'FullCitation': 'Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23412337', 'Include': 'true'}, {'number': '15', 'ReferenceId': '21382095', 'FullCitation': 'Nobusawa S, et al. Neuropathology (2011) pmid: 21382095', 'Include': 'true'}, {'number': '16', 'ReferenceId': '16021678', 'FullCitation': 'Joensuu H, et al. J. Pathol. (2005) pmid: 16021678', 'Include': 'true'}, {'number': '17', 'ReferenceId': '23074200', 'FullCitation': 'Alentorn A, et al. Neuro_oncology (2012) pmid: 23074200', 'Include': 'true'}, {'number': '18', 'ReferenceId': '30371878', 'FullCitation': 'Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878', 'Include': 'true'}, {'number': '19', 'ReferenceId': '18772890', 'FullCitation': 'Nature (2008) pmid: 18772890', 'Include': 'true'}, {'number': '20', 'ReferenceId': '29625048', 'FullCitation': 'Hoadley KA, et al. Cell (2018) pmid: 29625048', 'Include': 'true'}, {'number': '21', 'ReferenceId': '29596782', 'FullCitation': 'Ellrott K, et al. Cell Syst (2018) pmid: 29596782', 'Include': 'true'}, {'number': '22', 'ReferenceId': '29622463', 'FullCitation': 'Taylor AM, et al. Cancer Cell (2018) pmid: 29622463', 'Include': 'true'}, {'number': '23', 'ReferenceId': '29617662', 'FullCitation': 'Gao Q, et al. Cell Rep (2018) pmid: 29617662', 'Include': 'true'}, {'number': '24', 'ReferenceId': '29625055', 'FullCitation': 'Liu J, et al. Cell (2018) pmid: 29625055', 'Include': 'true'}, {'number': '25', 'ReferenceId': '29625050', 'FullCitation': 'Sanchez_Vega F, et al. Cell (2018) pmid: 29625050', 'Include': 'true'}, {'number': '26', 'ReferenceId': '29888103', 'FullCitation': 'Song K, et al. Am J Cancer Res (2018) pmid: 29888103', 'Include': 'true'}, {'number': '27', 'ReferenceId': '17189383', 'FullCitation': 'Puputti M, et al. Mol. Cancer Res. (2006) pmid: 17189383', 'Include': 'true'}, {'number': '28', 'ReferenceId': '22323597', 'FullCitation': 'Szerlip NJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22323597', 'Include': 'true'}, {'number': '29', 'ReferenceId': '22806436', 'FullCitation': 'Arefi M, et al. Int. J. Hematol. (2012) pmid: 22806436', 'Include': 'true'}, {'number': '30', 'ReferenceId': '17666373', 'FullCitation': 'Baccarani M, et al. Haematologica (2007) pmid: 17666373', 'Include': 'true'}, {'number': '31', 'ReferenceId': '22718859', 'FullCitation': 'Cassier PA, et al. Clin. Cancer Res. (2012) pmid: 22718859', 'Include': 'true'}, {'number': '32', 'ReferenceId': '25658984', 'FullCitation': 'Chalmers ZR, et al. Blood Cancer J (2015) pmid: 25658984', 'Include': 'true'}, {'number': '33', 'ReferenceId': '12660384', 'FullCitation': 'Cools J, et al. N. Engl. J. Med. (2003) pmid: 12660384', 'Include': 'true'}, {'number': '34', 'ReferenceId': '17555450', 'FullCitation': 'Curtis CE, et al. Br. J. Haematol. (2007) pmid: 17555450', 'Include': 'true'}, {'number': '35', 'ReferenceId': '15010069', 'FullCitation': 'Debiec_Rychter M, et al. Eur. J. Cancer (2004) pmid: 15010069', 'Include': 'true'}, {'number': '36', 'ReferenceId': '20473908', 'FullCitation': 'Dileo P, et al. Int. J. Cancer (2011) pmid: 20473908', 'Include': 'true'}, {'number': '37', 'ReferenceId': '24638008', 'FullCitation': 'Fanta PT, et al. J. Clin. Oncol. (2015) pmid: 24638008', 'Include': 'true'}, {'number': '38', 'ReferenceId': '16406018', 'FullCitation': 'Florian S, et al. Leuk. Res. (2006) pmid: 16406018', 'Include': 'true'}, {'number': '39', 'ReferenceId': '27051816', 'FullCitation': 'Frenard C, et al. JAAD Case Rep (2016) pmid: 27051816', 'Include': 'true'}, {'number': '40', 'ReferenceId': '12808148', 'FullCitation': 'Griffin JH, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808148', 'Include': 'true'}, {'number': '41', 'ReferenceId': '14645423', 'FullCitation': 'Heinrich MC, et al. J. Clin. Oncol. (2003) pmid: 14645423', 'Include': 'true'}, {'number': '42', 'ReferenceId': '19120352', 'FullCitation': 'Helbig G, et al. Br. J. Haematol. (2009) pmid: 19120352', 'Include': 'true'}, {'number': '43', 'ReferenceId': '24009127', 'FullCitation': 'Helbig G, et al. Am. J. Hematol. (2014) pmid: 24009127', 'Include': 'true'}, {'number': '44', 'ReferenceId': '21093052', 'FullCitation': 'Hus M, et al. Leuk. Res. (2011) pmid: 21093052', 'Include': 'true'}, {'number': '45', 'ReferenceId': '20303172', 'FullCitation': 'Ikezoe T, et al. Leuk. Res. (2010) pmid: 20303172', 'Include': 'true'}, {'number': '46', 'ReferenceId': '19735261', 'FullCitation': 'Intermesoli T, et al. Br. J. Haematol. (2009) pmid: 19735261', 'Include': 'true'}, {'number': '47', 'ReferenceId': '19013640', 'FullCitation': 'Jain N, et al. Leuk. Res. (2009) pmid: 19013640', 'Include': 'true'}, {'number': '48', 'ReferenceId': '17299092', 'FullCitation': 'Jovanovic JV, et al. Blood (2007) pmid: 17299092', 'Include': 'true'}, {'number': '49', 'ReferenceId': '22150077', 'FullCitation': 'Kang HJ, et al. Acta Oncol (2012) pmid: 22150077', 'Include': 'true'}, {'number': '50', 'ReferenceId': '14504092', 'FullCitation': 'Klion AD, et al. Blood (2004) pmid: 14504092', 'Include': 'true'}, {'number': '51', 'ReferenceId': '19192229', 'FullCitation': 'Kobayashi M, et al. Respirology (2009) pmid: 19192229', 'Include': 'true'}, {'number': '52', 'ReferenceId': '24635438', 'FullCitation': 'Kocáková I, et al. Klin Onkol (2014) pmid: 24635438', 'Include': 'true'}, {'number': '53', 'ReferenceId': '18950453', 'FullCitation': 'Metzgeroth G, et al. Br. J. Haematol. (2008) pmid: 18950453', 'Include': 'true'}, {'number': '54', 'ReferenceId': '22645636', 'FullCitation': 'Murayama Y, et al. World J Gastrointest Oncol (2012) pmid: 22645636', 'Include': 'true'}, {'number': '55', 'ReferenceId': '19910029', 'FullCitation': 'Ogbogu PU, et al. J. Allergy Clin. Immunol. (2009) pmid: 19910029', 'Include': 'true'}, {'number': '56', 'ReferenceId': '16856885', 'FullCitation': 'Ohnishi H, et al. Br. J. Haematol. (2006) pmid: 16856885', 'Include': 'true'}, {'number': '57', 'ReferenceId': '12842979', 'FullCitation': 'Pardanani A, et al. Blood (2003) pmid: 12842979', 'Include': 'true'}, {'number': '58', 'ReferenceId': '15284118', 'FullCitation': 'Pardanani A, et al. Blood (2004) pmid: 15284118', 'Include': 'true'}, {'number': '59', 'ReferenceId': '27120808', 'FullCitation': 'Qu SQ, et al. Oncotarget (2016) pmid: 27120808', 'Include': 'true'}, {'number': '60', 'ReferenceId': '16498388', 'FullCitation': 'Score J, et al. Leukemia (2006) pmid: 16498388', 'Include': 'true'}, {'number': '61', 'ReferenceId': '24669761', 'FullCitation': 'Shah S, et al. J Hematol Oncol (2014) pmid: 24669761', 'Include': 'true'}, {'number': '62', 'ReferenceId': '26319757', 'FullCitation': 'Sugimoto Y, et al. Cancer Genet (2015) pmid: 26319757', 'Include': 'true'}, {'number': '63', 'ReferenceId': '20609486', 'FullCitation': 'Volz HC, et al. Int. J. Cardiol. (2011) pmid: 20609486', 'Include': 'true'}, {'number': '64', 'ReferenceId': '15618966', 'FullCitation': 'von Bubnoff N, et al. Leukemia (2005) pmid: 15618966', 'Include': 'true'}, {'number': '65', 'ReferenceId': '16845659', 'FullCitation': 'Walz C, et al. Genes Chromosomes Cancer (2006) pmid: 16845659', 'Include': 'true'}, {'number': '66', 'ReferenceId': '26130666', 'FullCitation': 'Yoo C, et al. Cancer Res Treat (2016) pmid: 26130666', 'Include': 'true'}, {'number': '67', 'ReferenceId': '23157309', 'FullCitation': 'Al_Riyami AZ, et al. Leuk. Lymphoma (2013) pmid: 23157309', 'Include': 'true'}, {'number': '68', 'ReferenceId': '16645167', 'FullCitation': 'Lierman E, et al. Blood (2006) pmid: 16645167', 'Include': 'true'}, {'number': '69', 'ReferenceId': '19212337', 'FullCitation': 'Lierman E, et al. Leukemia (2009) pmid: 19212337', 'Include': 'true'}, {'number': '70', 'ReferenceId': '21818111', 'FullCitation': 'Metzgeroth G, et al. Leukemia (2012) pmid: 21818111', 'Include': 'true'}, {'number': '71', 'ReferenceId': '22294526', 'FullCitation': 'Roubaud G, et al. Ann. Oncol. (2012) pmid: 22294526', 'Include': 'true'}, {'number': '72', 'ReferenceId': '20972453', 'FullCitation': 'von Bubnoff N, et al. Oncogene (2011) pmid: 20972453', 'Include': 'true'}, {'number': '73', 'ReferenceId': '24057647', 'FullCitation': 'Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2013) pmid: 24057647', 'Include': 'true'}, {'number': '74', 'ReferenceId': '20832858', 'FullCitation': 'Tabouret E, et al. Leuk. Res. (2011) pmid: 20832858', 'Include': 'true'}, {'number': '75', 'ReferenceId': '18794084', 'FullCitation': 'Dewaele B, et al. Clin. Cancer Res. (2008) pmid: 18794084', 'Include': 'true'}, {'number': '76', 'ReferenceId': '17087936', 'FullCitation': 'Weisberg E, et al. Gastroenterology (2006) pmid: 17087936', 'Include': 'true'}, {'number': '77', 'ReferenceId': '26396737', 'FullCitation': 'Brohl AS, et al. Clin Sarcoma Res (2015) pmid: 26396737', 'Include': 'true'}, {'number': '78', 'ReferenceId': '28031906', 'FullCitation': 'Grellety T, et al. Future Sci OA (2015) pmid: 28031906', 'Include': 'true'}, {'number': '79', 'ReferenceId': '25905001', 'FullCitation': 'Kollàr A, et al. Clin Sarcoma Res (2014) pmid: 25905001', 'Include': 'true'}, {'number': '80', 'ReferenceId': '29093181', 'FullCitation': 'Evans EK, et al. Sci Transl Med (2017) pmid: 29093181', 'Include': 'true'}, {'number': '81', 'ReferenceId': '10582339', 'FullCitation': 'Int. J. Biochem. Cell Biol. (1999) pmid: 10582339', 'Include': 'true'}, {'number': '82', 'ReferenceId': '23550210', 'FullCitation': 'Gao J, et al. Sci Signal (2013) pmid: 23550210', 'Include': 'true'}, {'number': '83', 'ReferenceId': '24071852', 'FullCitation': 'Zack TI, et al. Nat. Genet. (2013) pmid: 24071852', 'Include': 'true'}, {'number': '84', 'ReferenceId': '20164920', 'FullCitation': 'Beroukhim R, et al. Nature (2010) pmid: 20164920', 'Include': 'true'}, {'number': '85', 'ReferenceId': '26061751', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751', 'Include': 'true'}, {'number': '86', 'ReferenceId': '19701495', 'FullCitation': 'Skardelly M, et al. Transl Oncol (2009) pmid: 19701495', 'Include': 'true'}, {'number': '87', 'ReferenceId': '27536065', 'FullCitation': 'Abbaspour Babaei M, et al. Drug Des Devel Ther (2016) pmid: 27536065', 'Include': 'true'}, {'number': '88', 'ReferenceId': '27563456', 'FullCitation': 'Ramaswamy A, et al. J Gastrointest Oncol (2016) pmid: 27563456', 'Include': 'true'}, {'number': '89', 'ReferenceId': '23177515', 'FullCitation': 'Demetri GD, et al. Lancet (2013) pmid: 23177515', 'Include': 'true'}, {'number': '90', 'ReferenceId': '27355533', 'FullCitation': 'Gotlib J, et al. N. Engl. J. Med. (2016) pmid: 27355533', 'Include': 'true'}, {'number': '91', 'ReferenceId': '28424161', 'FullCitation': 'Jawhar M, et al. Blood (2017) pmid: 28424161', 'Include': 'true'}, {'number': '92', 'ReferenceId': '25031773', 'FullCitation': 'Xu X, et al. Int J Clin Exp Pathol (2014) pmid: 25031773', 'Include': 'true'}, {'number': '93', 'ReferenceId': '15972446', 'FullCitation': 'Gotlib J, et al. Blood (2005) pmid: 15972446', 'Include': 'true'}, {'number': '94', 'ReferenceId': '29066909', 'FullCitation': 'Luo C, et al. Onco Targets Ther (2017) pmid: 29066909', 'Include': 'true'}, {'number': '95', 'ReferenceId': '22162580', 'FullCitation': 'Si L, et al. J. Clin. Oncol. (2012) pmid: 22162580', 'Include': 'true'}, {'number': '96', 'ReferenceId': '20038218', 'FullCitation': 'Parikh SA, et al. Leuk Lymphoma (2010) pmid: 20038218', 'Include': 'true'}, {'number': '97', 'ReferenceId': '30075827', 'FullCitation': 'Wei X, et al. Oncol. Res. (2019) pmid: 30075827', 'Include': 'true'}, {'number': '98', 'ReferenceId': '23775962', 'FullCitation': 'Hodi FS, et al. J. Clin. Oncol. (2013) pmid: 23775962', 'Include': 'true'}, {'number': '99', 'ReferenceId': '21642685', 'FullCitation': 'Carvajal RD, et al. JAMA (2011) pmid: 21642685', 'Include': 'true'}, {'number': '100', 'ReferenceId': '21690468', 'FullCitation': 'Guo J, et al. J. Clin. Oncol. (2011) pmid: 21690468', 'Include': 'true'}, {'number': '101', 'ReferenceId': '15685537', 'FullCitation': 'Debiec_Rychter M, et al. Gastroenterology (2005) pmid: 15685537', 'Include': 'true'}, {'number': '102', 'ReferenceId': '19303137', 'FullCitation': 'Dematteo RP, et al. Lancet (2009) pmid: 19303137', 'Include': 'true'}, {'number': '103', 'ReferenceId': '16135502', 'FullCitation': 'Faivre S, et al. J. Clin. Oncol. (2005) pmid: 16135502', 'Include': 'true'}, {'number': '104', 'ReferenceId': '15659505', 'FullCitation': 'Hotte SJ, et al. J. Clin. Oncol. (2005) pmid: 15659505', 'Include': 'true'}, {'number': '105', 'ReferenceId': '15350030', 'FullCitation': 'Alcedo JC, et al. Head Neck (2004) pmid: 15350030', 'Include': 'true'}, {'number': '106', 'ReferenceId': '21403650', 'FullCitation': 'Brandwein JM, et al. Leukemia (2011) pmid: 21403650', 'Include': 'true'}, {'number': '107', 'ReferenceId': '19904263', 'FullCitation': 'Reardon DA, et al. Br. J. Cancer (2009) pmid: 19904263', 'Include': 'true'}, {'number': '108', 'ReferenceId': '26424760', 'FullCitation': 'Lee SJ, et al. Oncologist (2015) pmid: 26424760', 'Include': 'true'}, {'number': '109', 'ReferenceId': '22374331', 'FullCitation': 'Llovet JM, et al. Clin. Cancer Res. (2012) pmid: 22374331', 'Include': 'true'}, {'number': '110', 'ReferenceId': '23058498', 'FullCitation': 'Zhang HL, et al. Clin Genitourin Cancer (2013) pmid: 23058498', 'Include': 'true'}, {'number': '111', 'ReferenceId': '25450081', 'FullCitation': 'Seino S, et al. Gastroenterology (2014) pmid: 25450081', 'Include': 'true'}, {'number': '112', 'ReferenceId': '18846437', 'FullCitation': 'Li XF, et al. Med. Oncol. (2009) pmid: 18846437', 'Include': 'true'}, {'number': '113', 'ReferenceId': '22261812', 'FullCitation': 'Minor DR, et al. Clin. Cancer Res. (2012) pmid: 22261812', 'Include': 'true'}, {'number': '114', 'ReferenceId': '23114504', 'FullCitation': 'Mahipal A, et al. Melanoma Res. (2012) pmid: 23114504', 'Include': 'true'}, {'number': '115', 'ReferenceId': '15950905', 'FullCitation': 'Samuels Y, et al. Cancer Cell (2005) pmid: 15950905', 'Include': 'true'}, {'number': '116', 'ReferenceId': '19629070', 'FullCitation': 'Nat. Rev. Cancer (2009) pmid: 19629070', 'Include': 'true'}, {'number': '117', 'ReferenceId': '15647370', 'FullCitation': 'Kang S, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15647370', 'Include': 'true'}, {'number': '118', 'ReferenceId': '15930273', 'FullCitation': 'Ikenoue T, et al. Cancer Res. (2005) pmid: 15930273', 'Include': 'true'}, {'number': '119', 'ReferenceId': '17376864', 'FullCitation': 'Gymnopoulos M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17376864', 'Include': 'true'}, {'number': '120', 'ReferenceId': '18317450', 'FullCitation': 'Horn S, et al. Oncogene (2008) pmid: 18317450', 'Include': 'true'}, {'number': '121', 'ReferenceId': '21266528', 'FullCitation': 'Rudd ML, et al. Clin. Cancer Res. (2011) pmid: 21266528', 'Include': 'true'}, {'number': '122', 'ReferenceId': '22120714', 'FullCitation': 'Hon WC, et al. Oncogene (2012) pmid: 22120714', 'Include': 'true'}, {'number': '123', 'ReferenceId': '22949682', 'FullCitation': 'Burke JE, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22949682', 'Include': 'true'}, {'number': '124', 'ReferenceId': '19915146', 'FullCitation': 'Wu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19915146', 'Include': 'true'}, {'number': '125', 'ReferenceId': '2103068', 'FullCitation': 'Laurenti R, et al. Rev Saude Publica (1990) pmid: 2103068', 'Include': 'true'}, {'number': '126', 'ReferenceId': '20530683', 'FullCitation': 'Dan S, et al. Cancer Res. (2010) pmid: 20530683', 'Include': 'true'}, {'number': '127', 'ReferenceId': '18829572', 'FullCitation': 'Oda K, et al. Cancer Res. (2008) pmid: 18829572', 'Include': 'true'}, {'number': '128', 'ReferenceId': '18794883', 'FullCitation': 'Zhao L, et al. Oncogene (2008) pmid: 18794883', 'Include': 'true'}, {'number': '129', 'ReferenceId': '23619167', 'FullCitation': 'Lui VW, et al. Cancer Discov (2013) pmid: 23619167', 'Include': 'true'}, {'number': '130', 'ReferenceId': '22430209', 'FullCitation': 'Ross RL, et al. Oncogene (2013) pmid: 22430209', 'Include': 'true'}, {'number': '131', 'ReferenceId': '22729224', 'FullCitation': 'Rivière JB, et al. Nat. Genet. (2012) pmid: 22729224', 'Include': 'true'}, {'number': '132', 'ReferenceId': '19394761', 'FullCitation': 'Shibata T, et al. Cancer Lett. (2009) pmid: 19394761', 'Include': 'true'}, {'number': '133', 'ReferenceId': '26627007', 'FullCitation': 'Dogruluk T, et al. Cancer Res. (2015) pmid: 26627007', 'Include': 'true'}, {'number': '134', 'ReferenceId': '29284706', 'FullCitation': 'Croessmann S, et al. Clin. Cancer Res. (2018) pmid: 29284706', 'Include': 'true'}, {'number': '135', 'ReferenceId': '29533785', 'FullCitation': 'Ng PK, et al. Cancer Cell (2018) pmid: 29533785', 'Include': 'true'}, {'number': '136', 'ReferenceId': '32929011', 'FullCitation': 'Spangle JM, et al. (2020) pmid: 32929011', 'Include': 'true'}, {'number': '137', 'ReferenceId': '29636477', 'FullCitation': 'Chen L, et al. Nat Commun (2018) pmid: 29636477', 'Include': 'true'}, {'number': '138', 'ReferenceId': '34779417', 'FullCitation': 'Jin N, et al. J Clin Invest (2021) pmid: 34779417', 'Include': 'true'}, {'number': '139', 'ReferenceId': '17050665', 'FullCitation': 'Gallia GL, et al. Mol. Cancer Res. (2006) pmid: 17050665', 'Include': 'true'}, {'number': '140', 'ReferenceId': '15289301', 'FullCitation': 'Broderick DK, et al. Cancer Res. (2004) pmid: 15289301', 'Include': 'true'}, {'number': '141', 'ReferenceId': '20569675', 'FullCitation': 'El_Habr EA, et al. Clin. Neuropathol. () pmid: 20569675', 'Include': 'true'}, {'number': '142', 'ReferenceId': '22026810', 'FullCitation': 'Derakhshandeh_Peykar P, et al. J. Neurogenet. (2011) pmid: 22026810', 'Include': 'true'}, {'number': '143', 'ReferenceId': '31036078', 'FullCitation': 'Tanaka S, et al. Acta Neuropathol Commun (2019) pmid: 31036078', 'Include': 'true'}, {'number': '144', 'ReferenceId': '24608574', 'FullCitation': 'Fritsch C, et al. Mol. Cancer Ther. (2014) pmid: 24608574', 'Include': 'true'}, {'number': '145', 'ReferenceId': '29401002', 'FullCitation': 'Juric D, et al. J. Clin. Oncol. (2018) pmid: 29401002', 'Include': 'true'}, {'number': '146', 'ReferenceId': '30793038', 'FullCitation': 'Gallant JN, et al. NPJ Precis Oncol (2019) pmid: 30793038', 'Include': 'true'}, {'number': '147', 'ReferenceId': '34613809', 'FullCitation': 'Delestre F, et al. Sci Transl Med (2021) pmid: 34613809', 'Include': 'true'}, {'number': '148', 'ReferenceId': '31619463', 'FullCitation': 'Morschhauser F, et al. Mol Cancer Ther (2020) pmid: 31619463', 'Include': 'true'}, {'number': '149', 'ReferenceId': '27672108', 'FullCitation': 'Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108', 'Include': 'true'}, {'number': '150', 'ReferenceId': '31934607', 'FullCitation': 'Santin AD, et al. Gynecol Oncol Rep (2020) pmid: 31934607', 'Include': 'true'}, {'number': '151', 'ReferenceId': '35133871', 'FullCitation': 'Damodaran S, et al. J Clin Oncol (2022) pmid: 35133871', 'Include': 'true'}, {'number': '152', 'ReferenceId': '31091374', 'FullCitation': 'André F, et al. N. Engl. J. Med. (2019) pmid: 31091374', 'Include': 'true'}, {'number': '153', 'ReferenceId': '33863913', 'FullCitation': 'Smyth LM, et al. NPJ Breast Cancer (2021) pmid: 33863913', 'Include': 'true'}, {'number': '154', 'ReferenceId': '31351267', 'FullCitation': 'Varnier R, et al. Eur J Cancer (2019) pmid: 31351267', 'Include': 'true'}, {'number': '155', 'ReferenceId': '32914004', 'FullCitation': 'Basse C, et al. JCO Precis Oncol (2018) pmid: 32914004', 'Include': 'true'}, {'number': '156', 'ReferenceId': '33277683', 'FullCitation': 'Sultova E, et al. Arch Gynecol Obstet (2021) pmid: 33277683', 'Include': 'true'}, {'number': '157', 'ReferenceId': '24166148', 'FullCitation': 'Mackay HJ, et al. Cancer (2014) pmid: 24166148', 'Include': 'true'}, {'number': '158', 'ReferenceId': '27016228', 'FullCitation': 'Myers AP, et al. Gynecol. Oncol. (2016) pmid: 27016228', 'Include': 'true'}, {'number': '159', 'ReferenceId': '29588307', 'FullCitation': 'Dhami J, et al. Cold Spring Harb Mol Case Stud (2018) pmid: 29588307', 'Include': 'true'}, {'number': '160', 'ReferenceId': '30863722', 'FullCitation': 'Harris EJ, et al. Front Oncol (2019) pmid: 30863722', 'Include': 'true'}, {'number': '161', 'ReferenceId': '29301825', 'FullCitation': 'Hanna GJ, et al. Clin Cancer Res (2018) pmid: 29301825', 'Include': 'true'}, {'number': '162', 'ReferenceId': '32958578', 'FullCitation': 'Pascual J, et al. Cancer Discov (2021) pmid: 32958578', 'Include': 'true'}, {'number': '163', 'ReferenceId': '26787751', 'FullCitation': 'Dolly SO, et al. Clin. Cancer Res. (2016) pmid: 26787751', 'Include': 'true'}, {'number': '164', 'ReferenceId': '2941002', 'FullCitation': 'Aust Fam Physician (1986) pmid: 2941002', 'Include': 'true'}, {'number': '165', 'ReferenceId': '19521340', 'FullCitation': 'Mancini F, et al. EMBO J. (2009) pmid: 19521340', 'Include': 'true'}, {'number': '166', 'ReferenceId': '23303139', 'FullCitation': 'Wade M, et al. Nat. Rev. Cancer (2013) pmid: 23303139', 'Include': 'true'}, {'number': '167', 'ReferenceId': '15199139', 'FullCitation': 'Danovi D, et al. Mol. Cell. Biol. (2004) pmid: 15199139', 'Include': 'true'}, {'number': '168', 'ReferenceId': '24739573', 'FullCitation': 'Bieging KT, et al. Nat. Rev. Cancer (2014) pmid: 24739573', 'Include': 'true'}, {'number': '169', 'ReferenceId': '16319692', 'FullCitation': 'Arjona D, et al. Diagn. Mol. Pathol. (2005) pmid: 16319692', 'Include': 'true'}, {'number': '170', 'ReferenceId': '20068183', 'FullCitation': 'Schiffman JD, et al. Cancer Res. (2010) pmid: 20068183', 'Include': 'true'}, {'number': '171', 'ReferenceId': '20406234', 'FullCitation': 'Nobusawa S, et al. Brain Pathol. (2010) pmid: 20406234', 'Include': 'true'}, {'number': '172', 'ReferenceId': '19609742', 'FullCitation': 'Rao SK, et al. J. Neurooncol. (2010) pmid: 19609742', 'Include': 'true'}, {'number': '173', 'ReferenceId': '20472715', 'FullCitation': 'Jin G, et al. Neuro_oncology (2010) pmid: 20472715', 'Include': 'true'}, {'number': '174', 'ReferenceId': '10626796', 'FullCitation': 'Riemenschneider MJ, et al. Cancer Res. (1999) pmid: 10626796', 'Include': 'true'}, {'number': '175', 'ReferenceId': '34933330', 'FullCitation': 'Mascarenhas J, et al. Blood Adv (2022) pmid: 34933330', 'Include': 'true'}, {'number': '176', 'ReferenceId': '31167802', 'FullCitation': 'Mascarenhas J, et al. Blood (2019) pmid: 31167802', 'Include': 'true'}, {'number': '177', 'ReferenceId': '30536898', 'FullCitation': 'Chen L, et al. Int J Cancer (2019) pmid: 30536898', 'Include': 'true'}, {'number': '178', 'ReferenceId': '21562588', 'FullCitation': 'Vaseva AV, et al. Cell Death Dis (2011) pmid: 21562588', 'Include': 'true'}, {'number': '179', 'ReferenceId': '21750655', 'FullCitation': 'Wang H, et al. Neoplasia (2011) pmid: 21750655', 'Include': 'true'}, {'number': '180', 'ReferenceId': '21075910', 'FullCitation': 'Wang H, et al. Mol. Cancer Ther. (2011) pmid: 21075910', 'Include': 'true'}, {'number': '181', 'ReferenceId': '20080970', 'FullCitation': 'Reed D, et al. J. Biol. Chem. (2010) pmid: 20080970', 'Include': 'true'}, {'number': '182', 'ReferenceId': '17210701', 'FullCitation': 'Smalley KS, et al. Cancer Res. (2007) pmid: 17210701', 'Include': 'true'}, {'number': '183', 'ReferenceId': '23035244', 'FullCitation': 'Vogel SM, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 23035244', 'Include': 'true'}, {'number': '184', 'ReferenceId': '22870278', 'FullCitation': 'Mandke P, et al. PLoS ONE (2012) pmid: 22870278', 'Include': 'true'}, {'number': '185', 'ReferenceId': '25621298', 'FullCitation': 'Hirose M, et al. Oncoscience (2014) pmid: 25621298', 'Include': 'true'}, {'number': '186', 'ReferenceId': '23946421', 'FullCitation': 'Chang YS, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23946421', 'Include': 'true'}, {'number': '187', 'ReferenceId': '21075307', 'FullCitation': 'Bernal F, et al. Cancer Cell (2010) pmid: 21075307', 'Include': 'true'}, {'number': '188', 'ReferenceId': '22015685', 'FullCitation': 'Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685', 'Include': 'true'}, {'number': '189', 'ReferenceId': '9282118', 'FullCitation': 'Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118', 'Include': 'true'}, {'number': '190', 'ReferenceId': '7605428', 'FullCitation': 'Kim NW, et al. Science (1994) pmid: 7605428', 'Include': 'true'}, {'number': '191', 'ReferenceId': '10647931', 'FullCitation': 'Hanahan D, et al. Cell (2000) pmid: 10647931', 'Include': 'true'}, {'number': '192', 'ReferenceId': '23348503', 'FullCitation': 'Horn S, et al. Science (2013) pmid: 23348503', 'Include': 'true'}, {'number': '193', 'ReferenceId': '23348506', 'FullCitation': 'Huang FW, et al. Science (2013) pmid: 23348506', 'Include': 'true'}, {'number': '194', 'ReferenceId': '23887589', 'FullCitation': 'Vinagre J, et al. Nat Commun (2013) pmid: 23887589', 'Include': 'true'}, {'number': '195', 'ReferenceId': '23530248', 'FullCitation': 'Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248', 'Include': 'true'}, {'number': '196', 'ReferenceId': '24722048', 'FullCitation': 'Killela PJ, et al. Oncotarget (2014) pmid: 24722048', 'Include': 'true'}, {'number': '197', 'ReferenceId': '23955565', 'FullCitation': 'Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565', 'Include': 'true'}, {'number': '198', 'ReferenceId': '23603989', 'FullCitation': 'Liu X, et al. Cell Cycle (2013) pmid: 23603989', 'Include': 'true'}, {'number': '199', 'ReferenceId': '24154961', 'FullCitation': 'Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961', 'Include': 'true'}, {'number': '200', 'ReferenceId': '23764841', 'FullCitation': 'Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841', 'Include': 'true'}, {'number': '201', 'ReferenceId': '24217890', 'FullCitation': 'Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890', 'Include': 'true'}, {'number': '202', 'ReferenceId': '27245281', 'FullCitation': 'Nat Rev Clin Oncol (2017) pmid: 27245281', 'Include': 'true'}, {'number': '203', 'ReferenceId': '29249395', 'FullCitation': 'Duperret EK, et al. Mol Ther (2018) pmid: 29249395', 'Include': 'true'}, {'number': '204', 'ReferenceId': '25467017', 'FullCitation': 'Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017', 'Include': 'true'}, {'number': '205', 'ReferenceId': '33293629', 'FullCitation': 'Weller M, et al. Nat Rev Clin Oncol (2021) pmid: 33293629', 'Include': 'true'}, {'number': '206', 'ReferenceId': '34185076', 'FullCitation': 'Louis DN, et al. Neuro Oncol (2021) pmid: 34185076', 'Include': 'true'}, {'number': '207', 'ReferenceId': '23192342', 'FullCitation': 'Biswas K, et al. J. Biol. Chem. (2013) pmid: 23192342', 'Include': 'true'}, {'number': '208', 'ReferenceId': '19189657', 'FullCitation': 'Löw S, et al. Anticancer Res. () pmid: 19189657', 'Include': 'true'}, {'number': '209', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '210', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '211', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '212', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '213', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '214', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '215', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '216', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '217', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '218', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '219', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '220', 'ReferenceId': '32322066', 'FullCitation': 'Touat M, et al. Nature (2020) pmid: 32322066', 'Include': 'true'}, {'number': '221', 'ReferenceId': '30742119', 'FullCitation': 'Zhao J, et al. Nat. Med. (2019) pmid: 30742119', 'Include': 'true'}, {'number': '222', 'ReferenceId': '30643254', 'FullCitation': 'Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254', 'Include': 'true'}, {'number': '223', 'ReferenceId': '27001570', 'FullCitation': 'Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570', 'Include': 'true'}, {'number': '224', 'ReferenceId': '27683556', 'FullCitation': 'Johanns TM, et al. Cancer Discov (2016) pmid: 27683556', 'Include': 'true'}, {'number': '225', 'ReferenceId': '30073642', 'FullCitation': 'Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642', 'Include': 'true'}, {'number': '226', 'ReferenceId': '28420421', 'FullCitation': 'Chalmers ZR, et al. Genome Med (2017) pmid: 28420421', 'Include': 'true'}, {'number': '227', 'ReferenceId': '32386112', 'FullCitation': 'Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112', 'Include': 'true'}, {'number': '228', 'ReferenceId': '28912153', 'FullCitation': 'Johnson A, et al. Oncologist (2017) pmid: 28912153', 'Include': 'true'}, {'number': '229', 'ReferenceId': '26699864', 'FullCitation': 'Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864', 'Include': 'true'}, {'number': '230', 'ReferenceId': '32164609', 'FullCitation': 'Wang L, et al. BMC Cancer (2020) pmid: 32164609', 'Include': 'true'}, {'number': '231', 'ReferenceId': '28835386', 'FullCitation': 'Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386', 'Include': 'true'}, {'number': '232', 'ReferenceId': '31405947', 'FullCitation': 'Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947', 'Include': 'true'}, {'number': '233', 'ReferenceId': '30309915', 'FullCitation': 'Cristescu R, et al. Science (2018) pmid: 30309915', 'Include': 'true'}, {'number': '234', 'ReferenceId': '30785829', 'FullCitation': 'Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829', 'Include': 'true'}, {'number': '235', 'ReferenceId': '29658845', 'FullCitation': 'Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845', 'Include': 'true'}, {'number': '236', 'ReferenceId': '29657128', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128', 'Include': 'true'}, {'number': '237', 'ReferenceId': '29731394', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394', 'Include': 'true'}, {'number': '238', 'ReferenceId': '33558721', 'FullCitation': 'Rozeman EA, et al. Nat Med (2021) pmid: 33558721', 'Include': 'true'}, {'number': '239', 'ReferenceId': '32916128', 'FullCitation': 'Sharma P, et al. Cancer Cell (2020) pmid: 32916128', 'Include': 'true'}, {'number': '240', 'ReferenceId': '11960696', 'FullCitation': 'Ortega S, et al. Biochim. Biophys. Acta (2002) pmid: 11960696', 'Include': 'true'}, {'number': '241', 'ReferenceId': '9437433', 'FullCitation': 'Venkataramani R, et al. Nat. Struct. Biol. (1998) pmid: 9437433', 'Include': 'true'}, {'number': '242', 'ReferenceId': '10074345', 'FullCitation': 'Li J, et al. Biochemistry (1999) pmid: 10074345', 'Include': 'true'}, {'number': '243', 'ReferenceId': '11198276', 'FullCitation': 'Leonard JH, et al. Cancer Detect. Prev. (2000) pmid: 11198276', 'Include': 'true'}, {'number': '244', 'ReferenceId': '9576574', 'FullCitation': 'Vortmeyer AO, et al. Am. J. Clin. Pathol. (1998) pmid: 9576574', 'Include': 'true'}, {'number': '245', 'ReferenceId': '11263500', 'FullCitation': 'Leuraud P, et al. J. Neurooncol. (2000) pmid: 11263500', 'Include': 'true'}, {'number': '246', 'ReferenceId': '11485924', 'FullCitation': 'Boström J, et al. Am. J. Pathol. (2001) pmid: 11485924', 'Include': 'true'}, {'number': '247', 'ReferenceId': '10736068', 'FullCitation': 'Santarius T, et al. Neuropathol. Appl. Neurobiol. (2000) pmid: 10736068', 'Include': 'true'}, {'number': '248', 'ReferenceId': '16320247', 'FullCitation': 'Christacos NC, et al. Genes Chromosomes Cancer (2006) pmid: 16320247', 'Include': 'true'}, {'number': '249', 'ReferenceId': '33015533', 'FullCitation': 'Williams EA, et al. JCO Precis Oncol (2020) pmid: 33015533', 'Include': 'true'}, {'number': '250', 'ReferenceId': '19401813', 'FullCitation': 'Hossain MG, et al. Endocr. Pathol. (2009) pmid: 19401813', 'Include': 'true'}, {'number': '251', 'ReferenceId': '18973139', 'FullCitation': 'Kirsch M, et al. Genes Chromosomes Cancer (2009) pmid: 18973139', 'Include': 'true'}, {'number': '252', 'ReferenceId': '14645011', 'FullCitation': 'Sánchez_Aguilera A, et al. Blood (2004) pmid: 14645011', 'Include': 'true'}, {'number': '253', 'ReferenceId': '18829482', 'FullCitation': 'Leone PE, et al. Clin. Cancer Res. (2008) pmid: 18829482', 'Include': 'true'}, {'number': '254', 'ReferenceId': '21994415', 'FullCitation': 'Boyd KD, et al. Clin. Cancer Res. (2011) pmid: 21994415', 'Include': 'true'}, {'number': '255', 'ReferenceId': '20616218', 'FullCitation': 'Walker BA, et al. Blood (2010) pmid: 20616218', 'Include': 'true'}, {'number': '256', 'ReferenceId': '15349907', 'FullCitation': 'Morishita A, et al. Hepatology (2004) pmid: 15349907', 'Include': 'true'}, {'number': '257', 'ReferenceId': '18254776', 'FullCitation': 'Daa T, et al. APMIS (2008) pmid: 18254776', 'Include': 'true'}, {'number': '258', 'ReferenceId': '24983371', 'FullCitation': 'Styring E, et al. Br. J. Cancer (2014) pmid: 24983371', 'Include': 'true'}, {'number': '259', 'ReferenceId': '17803708', 'FullCitation': 'Lindberg D, et al. Clin. Endocrinol. (Oxf) (2008) pmid: 17803708', 'Include': 'true'}, {'number': '260', 'ReferenceId': '25502777', 'FullCitation': 'Liang JW, et al. PLoS ONE (2014) pmid: 25502777', 'Include': 'true'}, {'number': '261', 'ReferenceId': '25036575', 'FullCitation': 'Kim HS, et al. Cancer Res Treat (2014) pmid: 25036575', 'Include': 'true'}, {'number': '262', 'ReferenceId': '18381405', 'FullCitation': 'Solomon DA, et al. Cancer Res. (2008) pmid: 18381405', 'Include': 'true'}, {'number': '263', 'ReferenceId': '18394558', 'FullCitation': 'Wiedemeyer R, et al. Cancer Cell (2008) pmid: 18394558', 'Include': 'true'}, {'number': '264', 'ReferenceId': '10918395', 'FullCitation': 'Arcellana_Panlilio MY, et al. Genes Chromosomes Cancer (2000) pmid: 10918395', 'Include': 'true'}, {'number': '265', 'ReferenceId': '20421449', 'FullCitation': 'Hartmann EM, et al. Blood (2010) pmid: 20421449', 'Include': 'true'}, {'number': '266', 'ReferenceId': '17161458', 'FullCitation': 'Flordal Thelander E, et al. Leuk. Res. (2007) pmid: 17161458', 'Include': 'true'}, {'number': '267', 'ReferenceId': '18984860', 'FullCitation': 'Beà S, et al. Blood (2009) pmid: 18984860', 'Include': 'true'}, {'number': '268', 'ReferenceId': '9286748', 'FullCitation': 'Tahara H, et al. J. Bone Miner. Res. (1997) pmid: 9286748', 'Include': 'true'}, {'number': '269', 'ReferenceId': '23715670', 'FullCitation': 'Costa_Guda J, et al. Horm Cancer (2013) pmid: 23715670', 'Include': 'true'}, {'number': '270', 'ReferenceId': '24127162', 'FullCitation': 'Gluick T, et al. Endocr. Relat. Cancer (2013) pmid: 24127162', 'Include': 'true'}, {'number': '271', 'ReferenceId': '18942719', 'FullCitation': 'van Veelen W, et al. Int. J. Cancer (2009) pmid: 18942719', 'Include': 'true'}, {'number': '272', 'ReferenceId': '24423316', 'FullCitation': 'Pita JM, et al. J. Clin. Endocrinol. Metab. (2014) pmid: 24423316', 'Include': 'true'}, {'number': '273', 'ReferenceId': '25576899', 'FullCitation': 'Kunstman JW, et al. Hum. Mol. Genet. (2015) pmid: 25576899', 'Include': 'true'}, {'number': '274', 'ReferenceId': '21642358', 'FullCitation': 'Neta G, et al. Carcinogenesis (2011) pmid: 21642358', 'Include': 'true'}, {'number': '275', 'ReferenceId': '25565272', 'FullCitation': 'Barbieri RB, et al. Eur. J. Endocrinol. (2014) pmid: 25565272', 'Include': 'true'}, {'number': '276', 'ReferenceId': '16651240', 'FullCitation': 'Hattori H, et al. Pediatr Hematol Oncol (2006) pmid: 16651240', 'Include': 'true'}, {'number': '277', 'ReferenceId': '19218339', 'FullCitation': 'Romagnoli S, et al. Am. J. Pathol. (2009) pmid: 19218339', 'Include': 'true'}, {'number': '278', 'ReferenceId': '11800646', 'FullCitation': 'Korshunov A, et al. Arch. Pathol. Lab. Med. (2002) pmid: 11800646', 'Include': 'true'}, {'number': '279', 'ReferenceId': '22711607', 'FullCitation': 'Cen L, et al. Neuro_oncology (2012) pmid: 22711607', 'Include': 'true'}, {'number': '280', 'ReferenceId': '20534551', 'FullCitation': 'Wiedemeyer WR, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20534551', 'Include': 'true'}, {'number': '281', 'ReferenceId': '19509251', 'FullCitation': 'Eguchi T, et al. Mol. Cancer Ther. (2009) pmid: 19509251', 'Include': 'true'}, {'number': '282', 'ReferenceId': '22997239', 'FullCitation': 'Jalili A, et al. J. Natl. Cancer Inst. (2012) pmid: 22997239', 'Include': 'true'}, {'number': '283', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '284', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '285', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '286', 'ReferenceId': '9823339', 'FullCitation': 'Boland CR, et al. Cancer Res. (1998) pmid: 9823339', 'Include': 'true'}, {'number': '287', 'ReferenceId': '15528785', 'FullCitation': 'Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785', 'Include': 'true'}, {'number': '288', 'ReferenceId': '20420947', 'FullCitation': 'Boland CR, et al. Gastroenterology (2010) pmid: 20420947', 'Include': 'true'}, {'number': '289', 'ReferenceId': '15331927', 'FullCitation': 'Martinez R, et al. Oncology (2004) pmid: 15331927', 'Include': 'true'}, {'number': '290', 'ReferenceId': '15672285', 'FullCitation': 'Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285', 'Include': 'true'}, {'number': '291', 'ReferenceId': '17498554', 'FullCitation': 'Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554', 'Include': 'true'}, {'number': '292', 'ReferenceId': '12908754', 'FullCitation': 'Szybka M, et al. Clin. Neuropathol. () pmid: 12908754', 'Include': 'true'}, {'number': '293', 'ReferenceId': '25392179', 'FullCitation': 'Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179', 'Include': 'true'}, {'number': '294', 'ReferenceId': '26140250', 'FullCitation': 'Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250', 'Include': 'true'}, {'number': '295', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '296', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '297', 'ReferenceId': '8521522', 'FullCitation': 'Quelle DE, et al. Cell (1995) pmid: 8521522', 'Include': 'true'}, {'number': '298', 'ReferenceId': '15878778', 'FullCitation': 'Mutat. Res. (2005) pmid: 15878778', 'Include': 'true'}, {'number': '299', 'ReferenceId': '9484839', 'FullCitation': 'Gazzeri S, et al. Oncogene (1998) pmid: 9484839', 'Include': 'true'}, {'number': '300', 'ReferenceId': '10498883', 'FullCitation': 'Oncogene (1999) pmid: 10498883', 'Include': 'true'}, {'number': '301', 'ReferenceId': '16869746', 'FullCitation': 'Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746', 'Include': 'true'}, {'number': '302', 'ReferenceId': '20549699', 'FullCitation': 'Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699', 'Include': 'true'}, {'number': '303', 'ReferenceId': '10498896', 'FullCitation': 'Ruas M, et al. Oncogene (1999) pmid: 10498896', 'Include': 'true'}, {'number': '304', 'ReferenceId': '17909018', 'FullCitation': 'Jones R, et al. Cancer Res. (2007) pmid: 17909018', 'Include': 'true'}, {'number': '305', 'ReferenceId': '18843795', 'FullCitation': 'Haferkamp S, et al. Aging Cell (2008) pmid: 18843795', 'Include': 'true'}, {'number': '306', 'ReferenceId': '12417717', 'FullCitation': 'Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717', 'Include': 'true'}, {'number': '307', 'ReferenceId': '11518711', 'FullCitation': 'Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711', 'Include': 'true'}, {'number': '308', 'ReferenceId': '9324288', 'FullCitation': 'Gombart AF, et al. Leukemia (1997) pmid: 9324288', 'Include': 'true'}, {'number': '309', 'ReferenceId': '7780957', 'FullCitation': 'Yang R, et al. Cancer Res. (1995) pmid: 7780957', 'Include': 'true'}, {'number': '310', 'ReferenceId': '8668202', 'FullCitation': 'Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202', 'Include': 'true'}, {'number': '311', 'ReferenceId': '12606942', 'FullCitation': 'Greenblatt MS, et al. Oncogene (2003) pmid: 12606942', 'Include': 'true'}, {'number': '312', 'ReferenceId': '10491434', 'FullCitation': 'Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434', 'Include': 'true'}, {'number': '313', 'ReferenceId': '11255261', 'FullCitation': 'Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261', 'Include': 'true'}, {'number': '314', 'ReferenceId': '9660926', 'FullCitation': 'Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926', 'Include': 'true'}, {'number': '315', 'ReferenceId': '19260062', 'FullCitation': 'Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062', 'Include': 'true'}, {'number': '316', 'ReferenceId': '10719365', 'FullCitation': 'Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365', 'Include': 'true'}, {'number': '317', 'ReferenceId': '7777061', 'FullCitation': 'Koh J, et al. Nature (1995) pmid: 7777061', 'Include': 'true'}, {'number': '318', 'ReferenceId': '20340136', 'FullCitation': 'McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136', 'Include': 'true'}, {'number': '319', 'ReferenceId': '21462282', 'FullCitation': 'Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282', 'Include': 'true'}, {'number': '320', 'ReferenceId': '905385', 'FullCitation': 'Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385', 'Include': 'true'}, {'number': '321', 'ReferenceId': '24659262', 'FullCitation': 'Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262', 'Include': 'true'}, {'number': '322', 'ReferenceId': '23190892', 'FullCitation': 'Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892', 'Include': 'true'}, {'number': '323', 'ReferenceId': '10389768', 'FullCitation': 'Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768', 'Include': 'true'}, {'number': '324', 'ReferenceId': '12853981', 'FullCitation': 'Rutter JL, et al. Oncogene (2003) pmid: 12853981', 'Include': 'true'}, {'number': '325', 'ReferenceId': '18538737', 'FullCitation': 'Itahana K, et al. Cancer Cell (2008) pmid: 18538737', 'Include': 'true'}, {'number': '326', 'ReferenceId': '10360174', 'FullCitation': 'Zhang Y, et al. Mol. Cell (1999) pmid: 10360174', 'Include': 'true'}, {'number': '327', 'ReferenceId': '9529249', 'FullCitation': 'Zhang Y, et al. Cell (1998) pmid: 9529249', 'Include': 'true'}, {'number': '328', 'ReferenceId': '26824661', 'FullCitation': 'Ceccarelli M, et al. Cell (2016) pmid: 26824661', 'Include': 'true'}, {'number': '329', 'ReferenceId': '31263031', 'FullCitation': 'Jonsson P, et al. Clin. Cancer Res. (2019) pmid: 31263031', 'Include': 'true'}, {'number': '330', 'ReferenceId': '16909113', 'FullCitation': 'Weber RG, et al. Oncogene (2007) pmid: 16909113', 'Include': 'true'}, {'number': '331', 'ReferenceId': '11303791', 'FullCitation': 'Nakamura M, et al. Brain Pathol. (2001) pmid: 11303791', 'Include': 'true'}, {'number': '332', 'ReferenceId': '11489817', 'FullCitation': 'Chakravarti A, et al. Clin. Cancer Res. (2001) pmid: 11489817', 'Include': 'true'}, {'number': '333', 'ReferenceId': '21713760', 'FullCitation': 'Feng J, et al. Cancer (2012) pmid: 21713760', 'Include': 'true'}, {'number': '334', 'ReferenceId': '21636552', 'FullCitation': 'Raabe EH, et al. Clin. Cancer Res. (2011) pmid: 21636552', 'Include': 'true'}, {'number': '335', 'ReferenceId': '21843312', 'FullCitation': 'Liu W, et al. J. Exp. Clin. Cancer Res. (2011) pmid: 21843312', 'Include': 'true'}, {'number': '336', 'ReferenceId': '21278246', 'FullCitation': 'Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246', 'Include': 'true'}, {'number': '337', 'ReferenceId': '21871868', 'FullCitation': 'Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868', 'Include': 'true'}, {'number': '338', 'ReferenceId': '23898052', 'FullCitation': 'Logan JE, et al. Anticancer Res. (2013) pmid: 23898052', 'Include': 'true'}, {'number': '339', 'ReferenceId': '35157829', 'FullCitation': 'Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829', 'Include': 'true'}, {'number': '340', 'ReferenceId': '28283584', 'FullCitation': 'Elvin JA, et al. Oncologist (2017) pmid: 28283584', 'Include': 'true'}, {'number': '341', 'ReferenceId': '26715889', 'FullCitation': 'Gao J, et al. Curr Oncol (2015) pmid: 26715889', 'Include': 'true'}, {'number': '342', 'ReferenceId': '25501126', 'FullCitation': 'DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126', 'Include': 'true'}, {'number': '343', 'ReferenceId': '25524798', 'FullCitation': 'Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798', 'Include': 'true'}, {'number': '344', 'ReferenceId': '27542767', 'FullCitation': 'Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767', 'Include': 'true'}, {'number': '345', 'ReferenceId': '24797823', 'FullCitation': 'Johnson DB, et al. Oncologist (2014) pmid: 24797823', 'Include': 'true'}, {'number': '346', 'ReferenceId': '21460101', 'FullCitation': 'Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101', 'Include': 'true'}, {'number': '347', 'ReferenceId': '21725357', 'FullCitation': 'Gamble LD, et al. Oncogene (2012) pmid: 21725357', 'Include': 'true'}, {'number': '348', 'ReferenceId': '7666917', 'FullCitation': 'Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917', 'Include': 'true'}, {'number': '349', 'ReferenceId': '20687502', 'FullCitation': 'Adv Exp Med Biol (2010) pmid: 20687502', 'Include': 'true'}, {'number': '350', 'ReferenceId': '9479083', 'FullCitation': 'Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083', 'Include': 'true'}, {'number': '351', 'ReferenceId': '29543703', 'FullCitation': 'De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703', 'Include': 'true'}, {'number': '352', 'ReferenceId': '26892650', 'FullCitation': 'Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650', 'Include': 'true'}, {'number': '353', 'ReferenceId': '29405243', 'FullCitation': 'Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243', 'Include': 'true'}, {'number': '354', 'ReferenceId': '8414022', 'FullCitation': 'Kaufman DK, et al. Neurology (1993) pmid: 8414022', 'Include': 'true'}, {'number': '355', 'ReferenceId': '9622062', 'FullCitation': 'Bahuau M, et al. Cancer Res (1998) pmid: 9622062', 'Include': 'true'}, {'number': '356', 'ReferenceId': '28699883', 'FullCitation': 'Chan AK, et al. Clin Neuropathol () pmid: 28699883', 'Include': 'true'}, {'number': '357', 'ReferenceId': '15167892', 'FullCitation': 'Stamos J, et al. EMBO J. (2004) pmid: 15167892', 'Include': 'true'}, {'number': '358', 'ReferenceId': '20624990', 'FullCitation': 'Tolbert WD, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20624990', 'Include': 'true'}, {'number': '359', 'ReferenceId': '28481359', 'FullCitation': 'Zehir A, et al. Nat. Med. (2017) pmid: 28481359', 'Include': 'true'}, {'number': '360', 'ReferenceId': '35120664', 'FullCitation': 'Nguyen B, et al. Cell (2022) pmid: 35120664', 'Include': 'true'}, {'number': '361', 'ReferenceId': '22741575', 'FullCitation': 'Guo YF, et al. World J Surg Oncol (2012) pmid: 22741575', 'Include': 'true'}, {'number': '362', 'ReferenceId': '23359207', 'FullCitation': 'Garnett J, et al. Neoplasia (2013) pmid: 23359207', 'Include': 'true'}, {'number': '363', 'ReferenceId': '11296484', 'FullCitation': 'Kunkel P, et al. Neuro_oncology (2001) pmid: 11296484', 'Include': 'true'}, {'number': '364', 'ReferenceId': '23386689', 'FullCitation': 'Zhang Y, et al. Clin. Cancer Res. (2013) pmid: 23386689', 'Include': 'true'}, {'number': '365', 'ReferenceId': '22203985', 'FullCitation': 'Xie Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22203985', 'Include': 'true'}, {'number': '366', 'ReferenceId': '22683780', 'FullCitation': 'Kentsis A, et al. Nat. Med. (2012) pmid: 22683780', 'Include': 'true'}, {'number': '367', 'ReferenceId': '24167653', 'FullCitation': 'Xie Q, et al. Genes Cancer (2013) pmid: 24167653', 'Include': 'true'}, {'number': '368', 'ReferenceId': '25381262', 'FullCitation': 'Wanjala J, et al. Mol. Cancer Ther. (2015) pmid: 25381262', 'Include': 'true'}, {'number': '369', 'ReferenceId': '24687921', 'FullCitation': 'Koeppen H, et al. Clin. Cancer Res. (2014) pmid: 24687921', 'Include': 'true'}, {'number': '370', 'ReferenceId': '24901237', 'FullCitation': 'Patnaik A, et al. Br. J. Cancer (2014) pmid: 24901237', 'Include': 'true'}, {'number': '371', 'ReferenceId': '24965569', 'FullCitation': 'Iveson T, et al. Lancet Oncol. (2014) pmid: 24965569', 'Include': 'true'}, {'number': '372', 'ReferenceId': '22832897', 'FullCitation': 'Pan E, et al. J. Neurooncol. (2012) pmid: 22832897', 'Include': 'true'}, {'number': '373', 'ReferenceId': '23086433', 'FullCitation': 'Kreisl TN, et al. J. Neurooncol. (2013) pmid: 23086433', 'Include': 'true'}, {'number': '374', 'ReferenceId': '24424564', 'FullCitation': 'Balaña C, et al. Target Oncol (2014) pmid: 24424564', 'Include': 'true'}, {'number': '375', 'ReferenceId': '24311637', 'FullCitation': 'Hutterer M, et al. Neuro_oncology (2014) pmid: 24311637', 'Include': 'true'}, {'number': '376', 'ReferenceId': '18955458', 'FullCitation': 'Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955458', 'Include': 'true'}, {'number': '377', 'ReferenceId': '26264378', 'FullCitation': 'Buchbinder EI, et al. Cancer (2015) pmid: 26264378', 'Include': 'true'}, {'number': '378', 'ReferenceId': '26772734', 'FullCitation': 'Reichardt P, et al. BMC Cancer (2016) pmid: 26772734', 'Include': 'true'}, {'number': '379', 'ReferenceId': '27073655', 'FullCitation': 'Hirai F, et al. Mol Clin Oncol (2016) pmid: 27073655', 'Include': 'true'}, {'number': '380', 'ReferenceId': '20435347', 'FullCitation': 'Goemans BF, et al. Leuk. Res. (2010) pmid: 20435347', 'Include': 'true'}, {'number': '381', 'ReferenceId': '24335106', 'FullCitation': 'Hughes TP, et al. Blood (2014) pmid: 24335106', 'Include': 'true'}, {'number': '382', 'ReferenceId': '24650752', 'FullCitation': 'Takahashi N, et al. Biomark Res (2014) pmid: 24650752', 'Include': 'true'}, {'number': '383', 'ReferenceId': '22357255', 'FullCitation': 'Reichardt P, et al. Ann. Oncol. (2012) pmid: 22357255', 'Include': 'true'}, {'number': '384', 'ReferenceId': '22119758', 'FullCitation': 'Cauchi C, et al. Cancer Chemother. Pharmacol. (2012) pmid: 22119758', 'Include': 'true'}, {'number': '385', 'ReferenceId': '22662203', 'FullCitation': 'Villar VH, et al. PLoS ONE (2012) pmid: 22662203', 'Include': 'true'}, {'number': '386', 'ReferenceId': '25695690', 'FullCitation': 'Carvajal RD, et al. Clin. Cancer Res. (2015) pmid: 25695690', 'Include': 'true'}, {'number': '387', 'ReferenceId': '26002753', 'FullCitation': 'Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2015) pmid: 26002753', 'Include': 'true'}, {'number': '388', 'ReferenceId': '25882987', 'FullCitation': 'Blay JY, et al. Lancet Oncol. (2015) pmid: 25882987', 'Include': 'true'}, {'number': '389', 'ReferenceId': '26722383', 'FullCitation': 'Kajimoto N, et al. Int J Clin Exp Pathol (2015) pmid: 26722383', 'Include': 'true'}, {'number': '390', 'ReferenceId': '25221952', 'FullCitation': 'Sako H, et al. PLoS ONE (2014) pmid: 25221952', 'Include': 'true'}, {'number': '391', 'ReferenceId': '25674429', 'FullCitation': 'Hassler MR, et al. Springerplus (2014) pmid: 25674429', 'Include': 'true'}, {'number': '392', 'ReferenceId': '19789313', 'FullCitation': 'Razis E, et al. Clin. Cancer Res. (2009) pmid: 19789313', 'Include': 'true'}, {'number': '393', 'ReferenceId': '22371319', 'FullCitation': 'Reardon DA, et al. Cancer (2012) pmid: 22371319', 'Include': 'true'}, {'number': '394', 'ReferenceId': '16624552', 'FullCitation': 'Debiec_Rychter M, et al. Eur. J. Cancer (2006) pmid: 16624552', 'Include': 'true'}, {'number': '395', 'ReferenceId': '16570351', 'FullCitation': 'Kamenz T, et al. World J. Gastroenterol. (2006) pmid: 16570351', 'Include': 'true'}, {'number': '396', 'ReferenceId': '15650049', 'FullCitation': 'Wang YY, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15650049', 'Include': 'true'}, {'number': '397', 'ReferenceId': '17377585', 'FullCitation': 'Metzgeroth G, et al. Leukemia (2007) pmid: 17377585', 'Include': 'true'}, {'number': '398', 'ReferenceId': '23898124', 'FullCitation': 'Zustovich F, et al. Anticancer Res. (2013) pmid: 23898124', 'Include': 'true'}, {'number': '399', 'ReferenceId': '20443129', 'FullCitation': 'Reardon DA, et al. J. Neurooncol. (2011) pmid: 20443129', 'Include': 'true'}, {'number': '400', 'ReferenceId': '23099651', 'FullCitation': 'Lee EQ, et al. Neuro_oncology (2012) pmid: 23099651', 'Include': 'true'}, {'number': '401', 'ReferenceId': '23328813', 'FullCitation': 'Peereboom DM, et al. Neuro_oncology (2013) pmid: 23328813', 'Include': 'true'}, {'number': '402', 'ReferenceId': '24786603', 'FullCitation': 'Hottinger AF, et al. Br. J. Cancer (2014) pmid: 24786603', 'Include': 'true'}, {'number': '403', 'ReferenceId': '24803676', 'FullCitation': 'Karajannis MA, et al. Neuro_oncology (2014) pmid: 24803676', 'Include': 'true'}, {'number': '404', 'ReferenceId': '18936790', 'FullCitation': 'Quintás_Cardama A, et al. Nat Clin Pract Oncol (2008) pmid: 18936790', 'Include': 'true'}, {'number': '405', 'ReferenceId': '19461405', 'FullCitation': 'Bisagni G, et al. J Thorac Oncol (2009) pmid: 19461405', 'Include': 'true'}, {'number': '406', 'ReferenceId': '20372153', 'FullCitation': 'Handolias D, et al. Br. J. Cancer (2010) pmid: 20372153', 'Include': 'true'}, {'number': '407', 'ReferenceId': '20970876', 'FullCitation': 'Dişel U, et al. Lung Cancer (2011) pmid: 20970876', 'Include': 'true'}, {'number': '408', 'ReferenceId': '22270258', 'FullCitation': 'Park SH, et al. Invest New Drugs (2012) pmid: 22270258', 'Include': 'true'}, {'number': '409', 'ReferenceId': '24855380', 'FullCitation': 'Catania C, et al. Onco Targets Ther (2014) pmid: 24855380', 'Include': 'true'}, {'number': '410', 'ReferenceId': '17699867', 'FullCitation': 'Guo T, et al. Clin. Cancer Res. (2007) pmid: 17699867', 'Include': 'true'}, {'number': '411', 'ReferenceId': '18483300', 'FullCitation': 'Hu S, et al. Mol. Cancer Ther. (2008) pmid: 18483300', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2022_11_07 20:00:27', 'OpName': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': '734x'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': '8 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': 'Units Not Reported'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'BRAIN', 'disease_ontology': 'Brain glioblastoma (GBM)', 'flowcell_analysis': '2000024356', 'gender': 'male', 'pathology_diagnosis': 'Glioblastoma', 'percent_tumor_nuclei': '50', 'pipeline_version': 'v3.15.0', 'purity_assessment': '70.0', 'specimen': 'ORD_1488563_01*US1425102.01', 'study': 'CLINICAL_F1CDx v2', 'test_request': 'ORD_1488563_01', 'test_type': 'FoundationOneDx', 'tissue_of_origin': 'Brain', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'DX2', 'mean_exon_depth': '830.35', 'name': 'SQ_US1425102.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.4794', 'cds_effect': '806C>A', 'depth': '632', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KDM5A', 'percent_reads': '47.94', 'position': 'chr12:464388', 'protein_effect': 'T269N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001042603', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.4857', 'cds_effect': '701_702GC>AT', 'depth': '630', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGFR4', 'percent_reads': '48.57', 'position': 'chr5:176518783', 'protein_effect': 'R234H', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_213647', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.0958', 'cds_effect': '1041_1088del48', 'depth': '16123', 'equivocal': 'false', 'functional_effect': 'nonframeshift', 'gene': 'PDGFRA', 'percent_reads': '9.58', 'position': 'chr4:55133827', 'protein_effect': 'S348_I363del', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006206', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.3435', 'cds_effect': '3713C>T', 'depth': '655', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PIK3C2G', 'percent_reads': '34.35', 'position': 'chr12:18716366', 'protein_effect': 'S1238L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_004570', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.4915', 'cds_effect': '5347T>C', 'depth': '706', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ROS1', 'percent_reads': '49.15', 'position': 'chr6:117650511', 'protein_effect': 'Y1783H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002944', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.064', 'cds_effect': '869G>A', 'depth': '9331', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PDGFRA', 'percent_reads': '6.4', 'position': 'chr4:55133565', 'protein_effect': 'C290Y', 'status': 'unknown', 'strand': '+', 'subclonal': 'true', 'transcript': 'NM_006206', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.4558', 'cds_effect': '71_74delTGTT', 'depth': '441', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'CDKN2C', 'percent_reads': '45.58', 'position': 'chr1:51436110', 'protein_effect': 'L24fs*5', 'status': 'likely', 'strand': '+', 'transcript': 'NM_001262', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.856', 'cds_effect': '1045C>G', 'depth': '368', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FOXL2', 'percent_reads': '85.6', 'position': 'chr3:138664520', 'protein_effect': 'R349G', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_023067', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.0058', 'cds_effect': '685G>A', 'depth': '8947', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PDGFRA', 'percent_reads': '0.58', 'position': 'chr4:55131142', 'protein_effect': 'E229K', 'status': 'known', 'strand': '+', 'subclonal': 'true', 'transcript': 'NM_006206', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.1302', 'cds_effect': '1207A>G', 'depth': '668', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GSK3B', 'percent_reads': '13.02', 'position': 'chr3:119562129', 'protein_effect': 'T403A', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002093', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.0128', 'cds_effect': '2522G>A', 'depth': '10439', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PDGFRA', 'percent_reads': '1.28', 'position': 'chr4:55152090', 'protein_effect': 'R841K', 'status': 'known', 'strand': '+', 'subclonal': 'true', 'transcript': 'NM_006206', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.3213', 'cds_effect': '595G>A', 'depth': '747', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'HGF', 'percent_reads': '32.13', 'position': 'chr7:81381466', 'protein_effect': 'E199K', 'status': 'known', 'strand': '_', 'transcript': 'NM_000601', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.3405', 'cds_effect': '1633G>A', 'depth': '881', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PIK3CA', 'percent_reads': '34.05', 'position': 'chr3:178936091', 'protein_effect': 'E545K', 'status': 'known', 'strand': '+', 'transcript': 'NM_006218', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.3438', 'cds_effect': '_146C>T', 'depth': '160', 'equivocal': 'false', 'functional_effect': 'promoter', 'gene': 'TERT', 'percent_reads': '34.38', 'position': 'chr5:1295250', 'protein_effect': 'promoter _146C>T', 'status': 'known', 'strand': '_', 'transcript': 'NM_198253', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.0545', 'cds_effect': '1042_1074del33', 'depth': '13935', 'equivocal': 'false', 'functional_effect': 'nonframeshift', 'gene': 'PDGFRA', 'percent_reads': '5.45', 'position': 'chr4:55133828', 'protein_effect': 'S348_E358del', 'status': 'unknown', 'strand': '+', 'subclonal': 'true', 'transcript': 'NM_006206', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.5082', 'cds_effect': '6643T>A', 'depth': '669', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MLL2', 'percent_reads': '50.82', 'position': 'chr12:49434910', 'protein_effect': 'S2215T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003482', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.4586', 'cds_effect': '3537C>A', 'depth': '798', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '45.86', 'position': 'chr2:212248730', 'protein_effect': 'D1179E', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'allele_fraction': '0.508', 'cds_effect': '373G>T', 'depth': '626', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RAD52', 'percent_reads': '50.8', 'position': 'chr12:1036405', 'protein_effect': 'G125C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_134424', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}]}, 'copy_number_alterations': {'copy_number_alteration': [{'copy_number': '43', 'equivocal': 'false', 'gene': 'KIT', 'number_of_exons': '21 of 21', 'position': 'chr4:55475828_55631891', 'ratio': '16.45', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'copy_number': '58', 'equivocal': 'false', 'gene': 'PDGFRA', 'number_of_exons': '22 of 22', 'position': 'chr4:55079414_55202195', 'ratio': '21.86', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'copy_number': '34', 'equivocal': 'false', 'gene': 'MDM4', 'number_of_exons': '10 of 10', 'position': 'chr1:204494620_204518810', 'ratio': '12.91', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'copy_number': '37', 'equivocal': 'false', 'gene': 'PIK3C2B', 'number_of_exons': '32 of 32', 'position': 'chr1:204393979_204438930', 'ratio': '14.22', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}, {'copy_number': '0', 'equivocal': 'false', 'gene': 'CDKN2A', 'number_of_exons': '4 of 5', 'position': 'chr9:21954944_21974826', 'ratio': '0.35', 'status': 'known', 'type': 'loss', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}]}, 'rearrangements': {'rearrangement': {'description': 'PDGFRA(NM_006206) deletion intron 7 _ intron 9', 'equivocal': 'false', 'in_frame': 'Yes', 'other_gene': 'PDGFRA', 'pos1': 'chr4:55134246_55134486', 'pos2': 'chr4:55138890_55139066', 'status': 'known', 'supporting_read_pairs': '48', 'targeted_gene': 'PDGFRA', 'type': 'deletion', 'dna_evidence': {'sample': 'SQ_US1425102.01_1'}}}, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '8.45', 'status': 'intermediate', 'unit': 'mutations_per_megabase'}}, 'non_human_content': None}}}}	M111-10001          	PF22121             
1	293	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2022_00025077', 'CSN': None, 'TRF': 'ORD_1512963_01', 'MRN': '48830359', 'PhysicianId': '109266', 'NPI': 'International'}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1230375', 'clinicalId': '1231745', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1512963_01', 'SampleName': 'US1447467.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1512963_01', 'SampleId': 'US1447467.01', 'BlockId': 'J_HL 1/4/1941', 'TRFNumber': 'ORD_1512963_01', 'TestType': 'FoundationOneLiquidDx', 'SpecFormat': 'Tube Set', 'ReceivedDate': '2022_11_28', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}]}}, 'PMI': {'ReportId': 'ORD_1512963_01', 'MRN': '48830359', 'FullName': 'Lin, Jui_Hui', 'FirstName': 'Jui_Hui', 'LastName': 'Lin', 'SubmittedDiagnosis': 'Pancreas ductal adenocarcinoma', 'Gender': 'Female', 'DOB': '1941_01_04', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Blood', 'CollDate': '2022_11_23', 'ReceivedDate': '2022_11_28', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': None, 'Summaries': {'alterationCount': '17', 'clinicalTrialCount': '6', 'resistiveCount': '0', 'sensitizingCount': '0'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'ARAF', 'isVUS': 'true', 'variantName': 'W384L'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'G1076V'}, {'geneName': 'FANCA', 'isVUS': 'true', 'variantName': 'P1222L'}, {'geneName': 'HSD3B1', 'isVUS': 'true', 'variantName': 'G178S'}, {'geneName': 'KDM6A', 'isVUS': 'true', 'variantName': 'A1278V'}, {'geneName': 'MERTK', 'isVUS': 'true', 'variantName': 'V272M'}, {'geneName': 'REL', 'isVUS': 'true', 'variantName': 'N551S'}, {'geneName': 'SETD2', 'isVUS': 'true', 'variantName': 'R2077Q,Y1293C'}, {'geneName': 'ZNF217', 'isVUS': 'true', 'variantName': 'S3L'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'EGFR', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'T354M', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'T354M'}}, 'Interpretation': 'EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide (Ciardiello and Tortora, 2008; 18337605). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. EGFR mutations are rare in pancreatic carcinomas, having been observed in <1% (1/109) of samples (cBio_Witkiewicz et al., 2015; 25855536, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). For patients with pancreatic carcinomas, EGFR overexpression has been correlated with lymph node metastasis and shorter median OS (Lozano_Leon et al., 2011; 21573507, Oh et al., 2012; 21404106, Valsecchi et al., 2012; 22086503). For patients with non_small cell lung cancer (NSCLC), EGFR activating mutations may predict sensitivity to EGFR–TKIs, including erlotinib (Rosell et al., 2011; 22285168), gefitinib (Douillard et al., 2014; 24263064, Hayashi et al., 2020; 32673682, Cao et al., 2018; 29780256, Yang et al., 2011; 21422421), afatinib (Sequist et al., 2013; 23816960, Bao_Dong Qin et al., 2018; 30127622, Frega et al., 2016; 27131295, Long et al., 2020; 33116645), dacomitinib (Mok et al., 2018; 29864379), and osimertinib (Janne et al., 2015; 25923549, Bao_Dong Qin et al., 2018; 30127622); however, the data for patients with other tumor types are limited (Hong et al., 2020; 32749686, Kim et al., 2015; 26462025, Kim et al., 2015; 25424851, Mondal et al., 2020; 32303840, Cavalieri et al., 2018; 29734047, Chi et al., 2020; 32923886, Audet et al., 2013; ASCO Abstract 6041). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true', 'ClinicalTrialNote': 'EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT03783403', 'Include': 'true'}, {'nctId': 'NCT04946968', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}, {'nctId': 'NCT04720976', 'Include': 'true'}, {'nctId': 'NCT04670679', 'Include': 'true'}, {'nctId': 'NCT04616196', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'Blood Tumor Mutational Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '03', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '03'}}, 'Interpretation': 'Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2022). Published data investigating the prognostic implications of bTMB levels in pancreatic carcinoma are limited (PubMed, Jul 2022). A study of patients with pancreatic ductal adenocarcinoma harboring mismatch repair gene mutations reported improved prognosis for patients with high TMB measured in tissue samples (defined as >50 mutations; survival 69_314 months) compared to those with lower TMB (average of 5.7 mutations; 10_42 months) (Hu et al., 2017; ASCO Abstract e15791). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti_PD_L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi_solid_tumor trial showed that bTMB ≥16 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB ≥28 Muts/Mb (approximate equivalency ≥14 Muts/Mb as measured by this assay) was associated with improved OS from a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'DNMT3A', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'C541fs*110', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'C541fs*110'}}, 'Interpretation': 'The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation (Trowbridge and Orkin, 2012; 22200773, Chédin, 2011; 21507354). The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor (Yang et al., 2011; 21887466, Vallböhmer et al., 2006; 16870044, Daskalos et al., 2011; 21351083, Fabbri et al., 2007; 17890317, Gao et al., 2011; 22011581, Kim et al., 2013; 23031157). Alterations such as seen here may disrupt DNMT3A function or expression (Chen et al., 2005; 15861382, Guo et al., 2015; 25383530, Sandoval et al., 2019; 30705090, Zhang et al., 2018; 29414941). DNMT3A alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Feb 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2022). There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Cannot Be Determined', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Cannot Be Determined'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI is rare in pancreatic carcinoma, reported in less than 1% of samples (n=>1,000)(Hu et al., 2018; 29367431, Campbell et al., 2017; 29056344, Pihlak et al., 2018; 29329208, Salem et al., 2018; 29523759, Lahgi et al., 2012; 23029359). The prognostic significance of MSI in pancreatic cancer is unknown (PubMed, Aug 2022). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TET2', 'Include': 'true', 'Alterations': {'Alteration': [{'Name': 'L1081*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'L1081*'}}, 'Interpretation': 'TET2 encodes a tumor suppressor involved in reversing DNA methylation marks, a process critical for proper gene regulation (Ito et al., 2010; 20639862, Guo et al., 2011; 21496894). Alterations such as seen here may disrupt TET2 function or expression (Iyer et al., 2009; 19411852, Ko et al., 2010; 21057493, Yang et al., 2013; 22391558, Hu et al., 2013; 24315485, Wang et al., 2015; 25601757). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. TET2 alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Jan 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of TET2 alterations in solid tumors are limited (PubMed, Jan 2022). There are no targeted therapies available to address genomic alterations in TET2 in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}, {'Name': 'H1219R', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'H1219R'}}, 'Interpretation': 'TET2 encodes a tumor suppressor involved in reversing DNA methylation marks, a process critical for proper gene regulation (Ito et al., 2010; 20639862, Guo et al., 2011; 21496894). Alterations such as seen here may disrupt TET2 function or expression (Iyer et al., 2009; 19411852, Ko et al., 2010; 21057493, Yang et al., 2013; 22391558, Hu et al., 2013; 24315485, Wang et al., 2015; 25601757). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. TET2 alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Jan 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of TET2 alterations in solid tumors are limited (PubMed, Jan 2022). There are no targeted therapies available to address genomic alterations in TET2 in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}]}, 'ReferenceLinks': None}, {'Name': 'Tumor Fraction', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Elevated Tumor Fraction Not Detected', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Elevated Tumor Fraction Not Detected'}}, 'Interpretation': 'Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'EGFR', 'Alteration': 'T354M', 'Title': 'A Study of CC_95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers', 'StudyPhase': 'PHASE 1', 'Target': 'CD20, EGFR, SIRP_alpha', 'Locations': 'Seoul (Korea, Republic of), Heidelberg (Australia), Melbourne (Australia), Manchester (United Kingdom), Edmonton (Canada), Rouen (France), Oregon, Marseille (France), Creteil (France), Nantes Cedex 01 (France)', 'NCTID': 'NCT03783403', 'Note': 'EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'EGFR', 'Alteration': 'T354M', 'Title': 'Phase_2 Dacomitinib Study on Patients With EGFR_Driven Advanced Solid Tumours With Low EGFR_AS1 IncRNA Expr or Other Novel Emerging Biomarkers', 'StudyPhase': 'PHASE 2', 'Target': 'ERBB4, EGFR, ERBB2', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT04946968', 'Note': 'EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'EGFR', 'Alteration': 'T354M', 'Title': 'Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO', 'Locations': 'Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)', 'NCTID': 'NCT03297606', 'Note': 'EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'EGFR', 'Alteration': 'T354M', 'Title': 'JAB_3312 Activity in Adult Patients With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'MEK, SHP2, PD_1, EGFR, KRAS', 'Locations': 'Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut', 'NCTID': 'NCT04720976', 'Note': 'EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'EGFR', 'Alteration': 'T354M', 'Title': 'A Dose Escalation/Expansion Study of ERAS_601 in Patients With Advanced or Metastatic Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'SHP2, EGFR', 'Locations': 'Perth (Australia), Melbourne (Australia), Nevada, California, Texas, Massachusetts, New York, Tennessee, Florida', 'NCTID': 'NCT04670679', 'Note': 'EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'EGFR', 'Alteration': 'T354M', 'Title': 'Study of NKTR 255 in Combination With Cetuximab in Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'EGFR', 'Locations': 'California, Montana, Arizona, Minnesota, Illinois, Michigan, Texas, New York', 'NCTID': 'NCT04616196', 'Note': 'EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR_targeted therapies. Strategies to overcome resistance to current agents include next_generation EGFR inhibitors and combination therapies. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '18337605', 'FullCitation': 'Ciardiello F, et al. N. Engl. J. Med. (2008) pmid: 18337605', 'Include': 'true'}, {'number': '1', 'ReferenceId': '25855536', 'FullCitation': 'Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536', 'Include': 'true'}, {'number': '2', 'ReferenceId': '22588877', 'FullCitation': 'Cerami E, et al. Cancer Discov (2012) pmid: 22588877', 'Include': 'true'}, {'number': '3', 'ReferenceId': '23550210', 'FullCitation': 'Gao J, et al. Sci Signal (2013) pmid: 23550210', 'Include': 'true'}, {'number': '4', 'ReferenceId': '21573507', 'FullCitation': 'Lozano_Leon A, et al. Oncol. Rep. (2011) pmid: 21573507', 'Include': 'true'}, {'number': '5', 'ReferenceId': '21404106', 'FullCitation': 'Oh DY, et al. Invest New Drugs (2012) pmid: 21404106', 'Include': 'true'}, {'number': '6', 'ReferenceId': '22086503', 'FullCitation': 'Valsecchi ME, et al. Cancer (2012) pmid: 22086503', 'Include': 'true'}, {'number': '7', 'ReferenceId': '22285168', 'FullCitation': 'Rosell R, et al. Lancet Oncol. (2012) pmid: 22285168', 'Include': 'true'}, {'number': '8', 'ReferenceId': '24263064', 'FullCitation': 'Douillard JY, et al. Br. J. Cancer (2014) pmid: 24263064', 'Include': 'true'}, {'number': '9', 'ReferenceId': '32673682', 'FullCitation': 'Hayashi T, et al. Hum Pathol (2020) pmid: 32673682', 'Include': 'true'}, {'number': '10', 'ReferenceId': '29780256', 'FullCitation': 'Cao L, et al. Onco Targets Ther (2018) pmid: 29780256', 'Include': 'true'}, {'number': '11', 'ReferenceId': '21422421', 'FullCitation': 'Yang TY, et al. J. Clin. Oncol. (2011) pmid: 21422421', 'Include': 'true'}, {'number': '12', 'ReferenceId': '23816960', 'FullCitation': 'Sequist LV, et al. J. Clin. Oncol. (2013) pmid: 23816960', 'Include': 'true'}, {'number': '13', 'ReferenceId': '30127622', 'FullCitation': 'Qin BD, et al. Onco Targets Ther (2018) pmid: 30127622', 'Include': 'true'}, {'number': '14', 'ReferenceId': '27131295', 'FullCitation': 'Frega S, et al. J Thorac Oncol (2016) pmid: 27131295', 'Include': 'true'}, {'number': '15', 'ReferenceId': '33116645', 'FullCitation': 'Long X, et al. Onco Targets Ther (2020) pmid: 33116645', 'Include': 'true'}, {'number': '16', 'ReferenceId': '29864379', 'FullCitation': 'Mok TS, et al. J. Clin. Oncol. (2018) pmid: 29864379', 'Include': 'true'}, {'number': '17', 'ReferenceId': '25923549', 'FullCitation': 'Jänne PA, et al. N. Engl. J. Med. (2015) pmid: 25923549', 'Include': 'true'}, {'number': '18', 'ReferenceId': '32749686', 'FullCitation': 'Hong MH, et al. Cancer (2020) pmid: 32749686', 'Include': 'true'}, {'number': '19', 'ReferenceId': '26462025', 'FullCitation': 'Kim HS, et al. Oncotarget (2015) pmid: 26462025', 'Include': 'true'}, {'number': '20', 'ReferenceId': '25424851', 'FullCitation': 'Kim HS, et al. Clin. Cancer Res. (2015) pmid: 25424851', 'Include': 'true'}, {'number': '21', 'ReferenceId': '32303840', 'FullCitation': 'Mondal G, et al. Acta Neuropathol (2020) pmid: 32303840', 'Include': 'true'}, {'number': '22', 'ReferenceId': '29734047', 'FullCitation': 'Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047', 'Include': 'true'}, {'number': '23', 'ReferenceId': '32923886', 'FullCitation': 'Chi AS, et al. JCO Precis Oncol (2020) pmid: 32923886', 'Include': 'true'}, {'number': '24', 'ReferenceId': '22200773', 'FullCitation': 'Trowbridge JJ, et al. Nat. Genet. (2011) pmid: 22200773', 'Include': 'true'}, {'number': '25', 'ReferenceId': '21507354', 'FullCitation': 'Prog Mol Biol Transl Sci (2011) pmid: 21507354', 'Include': 'true'}, {'number': '26', 'ReferenceId': '21887466', 'FullCitation': 'Yang J, et al. Mol Med Rep () pmid: 21887466', 'Include': 'true'}, {'number': '27', 'ReferenceId': '16870044', 'FullCitation': 'Vallböhmer D, et al. Clin Lung Cancer (2006) pmid: 16870044', 'Include': 'true'}, {'number': '28', 'ReferenceId': '21351083', 'FullCitation': 'Daskalos A, et al. Cancer (2011) pmid: 21351083', 'Include': 'true'}, {'number': '29', 'ReferenceId': '17890317', 'FullCitation': 'Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17890317', 'Include': 'true'}, {'number': '30', 'ReferenceId': '22011581', 'FullCitation': 'Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 22011581', 'Include': 'true'}, {'number': '31', 'ReferenceId': '23031157', 'FullCitation': 'Kim MS, et al. APMIS (2013) pmid: 23031157', 'Include': 'true'}, {'number': '32', 'ReferenceId': '15861382', 'FullCitation': 'Chen ZX, et al. J. Cell. Biochem. (2005) pmid: 15861382', 'Include': 'true'}, {'number': '33', 'ReferenceId': '25383530', 'FullCitation': 'Guo X, et al. Nature (2015) pmid: 25383530', 'Include': 'true'}, {'number': '34', 'ReferenceId': '30705090', 'FullCitation': 'Sandoval JE, et al. J. Biol. Chem. (2019) pmid: 30705090', 'Include': 'true'}, {'number': '35', 'ReferenceId': '29414941', 'FullCitation': 'Zhang ZM, et al. Nature (2018) pmid: 29414941', 'Include': 'true'}, {'number': '36', 'ReferenceId': '25426837', 'FullCitation': 'Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837', 'Include': 'true'}, {'number': '37', 'ReferenceId': '25426838', 'FullCitation': 'Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838', 'Include': 'true'}, {'number': '38', 'ReferenceId': '25326804', 'FullCitation': 'Xie M, et al. Nat. Med. (2014) pmid: 25326804', 'Include': 'true'}, {'number': '39', 'ReferenceId': '28669404', 'FullCitation': 'Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404', 'Include': 'true'}, {'number': '40', 'ReferenceId': '29678827', 'FullCitation': 'Severson EA, et al. Blood (2018) pmid: 29678827', 'Include': 'true'}, {'number': '41', 'ReferenceId': '29420212', 'FullCitation': 'Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212', 'Include': 'true'}, {'number': '42', 'ReferenceId': '30504320', 'FullCitation': 'Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320', 'Include': 'true'}, {'number': '43', 'ReferenceId': '32269342', 'FullCitation': 'Chabon JJ, et al. Nature (2020) pmid: 32269342', 'Include': 'true'}, {'number': '44', 'ReferenceId': '31768066', 'FullCitation': 'Razavi P, et al. Nat. Med. (2019) pmid: 31768066', 'Include': 'true'}, {'number': '45', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '46', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '47', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '48', 'ReferenceId': '29367431', 'FullCitation': 'Hu ZI, et al. Clin. Cancer Res. (2018) pmid: 29367431', 'Include': 'true'}, {'number': '49', 'ReferenceId': '29056344', 'FullCitation': 'Campbell BB, et al. Cell (2017) pmid: 29056344', 'Include': 'true'}, {'number': '50', 'ReferenceId': '29329208', 'FullCitation': 'Pihlak R, et al. Cancers (Basel) (2018) pmid: 29329208', 'Include': 'true'}, {'number': '51', 'ReferenceId': '29523759', 'FullCitation': 'Salem ME, et al. Mol. Cancer Res. (2018) pmid: 29523759', 'Include': 'true'}, {'number': '52', 'ReferenceId': '23029359', 'FullCitation': 'Laghi L, et al. PLoS ONE (2012) pmid: 23029359', 'Include': 'true'}, {'number': '53', 'ReferenceId': '17204026', 'FullCitation': 'Histopathology (2007) pmid: 17204026', 'Include': 'true'}, {'number': '54', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '55', 'ReferenceId': '28734759', 'FullCitation': 'Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759', 'Include': 'true'}, {'number': '56', 'ReferenceId': '29355075', 'FullCitation': 'Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075', 'Include': 'true'}, {'number': '57', 'ReferenceId': '35322232', 'FullCitation': 'Shitara K, et al. Nature (2022) pmid: 35322232', 'Include': 'true'}, {'number': '58', 'ReferenceId': '23169436', 'FullCitation': 'Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436', 'Include': 'true'}, {'number': '59', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '60', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '61', 'ReferenceId': '33001143', 'FullCitation': 'Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143', 'Include': 'true'}, {'number': '62', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '63', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '64', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '65', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '66', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '67', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '68', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '69', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '70', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '71', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '72', 'ReferenceId': '30082870', 'FullCitation': 'Gandara DR, et al. Nat. Med. (2018) pmid: 30082870', 'Include': 'true'}, {'number': '73', 'ReferenceId': '30816954', 'FullCitation': 'Wang Z, et al. JAMA Oncol (2019) pmid: 30816954', 'Include': 'true'}, {'number': '74', 'ReferenceId': '32102950', 'FullCitation': 'Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950', 'Include': 'true'}, {'number': '75', 'ReferenceId': '35274716', 'FullCitation': 'Sturgill EG, et al. Oncologist (2022) pmid: 35274716', 'Include': 'true'}, {'number': '76', 'ReferenceId': '32379280', 'FullCitation': 'Chen EX, et al. JAMA Oncol (2020) pmid: 32379280', 'Include': 'true'}, {'number': '77', 'ReferenceId': '32271377', 'FullCitation': 'Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377', 'Include': 'true'}, {'number': '78', 'ReferenceId': '33355200', 'FullCitation': 'Si H, et al. Clin Cancer Res (2021) pmid: 33355200', 'Include': 'true'}, {'number': '79', 'ReferenceId': '34800700', 'FullCitation': 'Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700', 'Include': 'true'}, {'number': '80', 'ReferenceId': '20639862', 'FullCitation': 'Ito S, et al. Nature (2010) pmid: 20639862', 'Include': 'true'}, {'number': '81', 'ReferenceId': '21496894', 'FullCitation': 'Guo JU, et al. Cell (2011) pmid: 21496894', 'Include': 'true'}, {'number': '82', 'ReferenceId': '19411852', 'FullCitation': 'Iyer LM, et al. Cell Cycle (2009) pmid: 19411852', 'Include': 'true'}, {'number': '83', 'ReferenceId': '21057493', 'FullCitation': 'Ko M, et al. Nature (2010) pmid: 21057493', 'Include': 'true'}, {'number': '84', 'ReferenceId': '22391558', 'FullCitation': 'Yang H, et al. Oncogene (2013) pmid: 22391558', 'Include': 'true'}, {'number': '85', 'ReferenceId': '24315485', 'FullCitation': 'Hu L, et al. Cell (2013) pmid: 24315485', 'Include': 'true'}, {'number': '86', 'ReferenceId': '25601757', 'FullCitation': 'Wang Y, et al. Mol. Cell (2015) pmid: 25601757', 'Include': 'true'}, {'number': '87', 'ReferenceId': '31602320', 'FullCitation': 'Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320', 'Include': 'true'}, {'number': '88', 'ReferenceId': '32757294', 'FullCitation': 'Zhang EW, et al. Cancer (2020) pmid: 32757294', 'Include': 'true'}, {'number': '89', 'ReferenceId': '30833418', 'FullCitation': 'Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418', 'Include': 'true'}, {'number': '90', 'ReferenceId': '24553385', 'FullCitation': 'Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385', 'Include': 'true'}, {'number': '91', 'ReferenceId': '30400802', 'FullCitation': 'Lapin M, et al. J Transl Med (2018) pmid: 30400802', 'Include': 'true'}, {'number': '92', 'ReferenceId': '30131550', 'FullCitation': 'Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550', 'Include': 'true'}, {'number': '93', 'ReferenceId': '30385733', 'FullCitation': 'Choudhury AD, et al. JCI Insight (2018) pmid: 30385733', 'Include': 'true'}, {'number': '94', 'ReferenceId': '29298117', 'FullCitation': 'Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117', 'Include': 'true'}, {'number': '95', 'ReferenceId': '30793095', 'FullCitation': 'Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095', 'Include': 'true'}, {'number': '96', 'ReferenceId': '31059681', 'FullCitation': 'Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681', 'Include': 'true'}, {'number': '97', 'ReferenceId': '28187169', 'FullCitation': 'Fan G, et al. PLoS ONE (2017) pmid: 28187169', 'Include': 'true'}, {'number': '98', 'ReferenceId': '30923679', 'FullCitation': 'Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679', 'Include': 'true'}, {'number': '99', 'ReferenceId': '30093454', 'FullCitation': 'Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454', 'Include': 'true'}, {'number': '100', 'ReferenceId': '30860573', 'FullCitation': 'Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573', 'Include': 'true'}, {'number': '101', 'ReferenceId': '28450425', 'FullCitation': 'Goodall J, et al. Cancer Discov (2017) pmid: 28450425', 'Include': 'true'}, {'number': '102', 'ReferenceId': '29330207', 'FullCitation': 'Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2022_12_05 19:37:56', 'OpName': 'Julie Tse, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Julie Tse, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': 'N/A'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': '3 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': '0%'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'PANCREAS', 'disease_ontology': 'Pancreas ductal adenocarcinoma', 'flowcell_analysis': '2000025358', 'gender': 'female', 'pathology_diagnosis': 'pancreas adenocarcinoma', 'pipeline_version': 'v3.15.0', 'purity_assessment': '12.0', 'specimen': 'ORD_1512963_01*US1447467.01', 'study': 'CLINICAL_F1LCDx', 'test_request': 'ORD_1512963_01', 'test_type': 'FoundationOneLiquidDx', 'tissue_of_origin': 'Blood', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'AB1', 'name': 'SQ_US1447467.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.0013', 'cds_effect': '6230G>A', 'depth': '4792', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SETD2', 'percent_reads': '0.13', 'position': 'chr3:47103716', 'protein_effect': 'R2077Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_014159', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'allele_fraction': '0.002', 'cds_effect': '3833C>T', 'depth': '3553', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KDM6A', 'percent_reads': '0.2', 'position': 'chrX:44950064', 'protein_effect': 'A1278V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_021140', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'allele_fraction': '0.0063', 'cds_effect': '3878A>G', 'depth': '2538', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SETD2', 'percent_reads': '0.63', 'position': 'chr3:47162248', 'protein_effect': 'Y1293C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_014159', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'allele_fraction': '0.0011', 'cds_effect': '1061C>T', 'depth': '5349', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EGFR', 'percent_reads': '0.11', 'position': 'chr7:55224280', 'protein_effect': 'T354M', 'status': 'known', 'strand': '+', 'transcript': 'NM_005228', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'allele_fraction': '0.4816', 'cds_effect': '532G>A', 'depth': '2340', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'HSD3B1', 'percent_reads': '48.16', 'position': 'chr1:120056678', 'protein_effect': 'G178S', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000862', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'allele_fraction': '0.0141', 'cds_effect': '1623delT', 'depth': '1918', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'DNMT3A', 'percent_reads': '1.41', 'position': 'chr2:25467452', 'protein_effect': 'C541fs*110', 'status': 'likely', 'strand': '_', 'transcript': 'NM_022552', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'allele_fraction': '0.486', 'cds_effect': '814G>A', 'depth': '2183', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MERTK', 'percent_reads': '48.6', 'position': 'chr2:112722824', 'protein_effect': 'V272M', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006343', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'allele_fraction': '0.5', 'cds_effect': '3665C>T', 'depth': '1146', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FANCA', 'percent_reads': '50.0', 'position': 'chr16:89809308', 'protein_effect': 'P1222L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000135', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'allele_fraction': '0.0201', 'cds_effect': '3656A>G', 'depth': '1491', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TET2', 'percent_reads': '2.01', 'position': 'chr4:106164788', 'protein_effect': 'H1219R', 'status': 'known', 'strand': '+', 'transcript': 'NM_001127208', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'allele_fraction': '0.4797', 'cds_effect': '1652A>G', 'depth': '1649', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'REL', 'percent_reads': '47.97', 'position': 'chr2:61149462', 'protein_effect': 'N551S', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002908', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'allele_fraction': '8.0E_4', 'cds_effect': '1151G>T', 'depth': '8897', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ARAF', 'percent_reads': '0.08', 'position': 'chrX:47428191', 'protein_effect': 'W384L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001654', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'allele_fraction': '0.0409', 'cds_effect': '8C>T', 'depth': '538', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ZNF217', 'percent_reads': '4.09', 'position': 'chr20:52199358', 'protein_effect': 'S3L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006526', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'allele_fraction': '0.0302', 'cds_effect': '3242T>A', 'depth': '1094', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'TET2', 'percent_reads': '3.02', 'position': 'chr4:106158341', 'protein_effect': 'L1081*', 'status': 'likely', 'strand': '+', 'transcript': 'NM_001127208', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'allele_fraction': '0.0138', 'cds_effect': '3227G>T', 'depth': '1596', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '1.38', 'position': 'chr2:212251832', 'protein_effect': 'G1076V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}]}, 'copy_number_alterations': None, 'rearrangements': None, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '2.53', 'status': 'low', 'unit': 'mutations_per_megabase'}}, 'non_human_content': {'non_human': [{'organism': 'HPV_16', 'reads_per_million': '23', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'organism': 'HHV_8', 'reads_per_million': '12', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}, {'organism': 'HHV_4', 'reads_per_million': '34', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1447467.01_1'}}]}}}}}	M111-10027          	PF22132             
2	323	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2023_00027170', 'CSN': None, 'TRF': 'ORD_1570859_01', 'MRN': '38460321', 'PhysicianId': '109266', 'NPI': None}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1280565', 'clinicalId': '1281915', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1570859_01', 'SampleName': 'US1501620.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1570859_01', 'SampleId': 'US1501620.01', 'BlockId': 'S112_02810 A (PF23015)', 'TRFNumber': 'ORD_1570859_01', 'TestType': 'FoundationOne CDX', 'SpecFormat': 'Slide Deck', 'ReceivedDate': '2023_02_20', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}]}}, 'PMI': {'ReportId': 'ORD_1570859_01', 'MRN': '38460321', 'FullName': 'Huang, Chien Chang', 'FirstName': 'Chien Chang', 'LastName': 'Huang', 'SubmittedDiagnosis': 'Bladder carcinoma (NOS)', 'Gender': 'Male', 'DOB': '1961_08_20', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Bone', 'CollDate': '2023_01_30', 'ReceivedDate': '2023_02_20', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': {'PertinentNegative': [{'Gene': 'FGFR2'}, {'Gene': 'FGFR3'}]}, 'Summaries': {'alterationCount': '38', 'clinicalTrialCount': '26', 'resistiveCount': '0', 'sensitizingCount': '8'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'ARID1A', 'isVUS': 'true', 'variantName': 'S334L'}, {'geneName': 'ATR', 'isVUS': 'true', 'variantName': 'D2331V'}, {'geneName': 'BCL6', 'isVUS': 'true', 'variantName': 'K534N'}, {'geneName': 'BRD4', 'isVUS': 'true', 'variantName': 'V228I'}, {'geneName': 'CCND1', 'isVUS': 'true', 'variantName': 'E66K'}, {'geneName': 'CCNE1', 'isVUS': 'true', 'variantName': 'G21S'}, {'geneName': 'CD79A', 'isVUS': 'true', 'variantName': 'W66C'}, {'geneName': 'EPHB1', 'isVUS': 'true', 'variantName': 'Y471N'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'R95H'}, {'geneName': 'FGFR3', 'isVUS': 'true', 'variantName': 'V553M'}, {'geneName': 'GATA6', 'isVUS': 'true', 'variantName': 'Y569C'}, {'geneName': 'JAK2', 'isVUS': 'true', 'variantName': 'E173K'}, {'geneName': 'JAK3', 'isVUS': 'true', 'variantName': 'R214W'}, {'geneName': 'KEL', 'isVUS': 'true', 'variantName': 'G480A'}, {'geneName': 'LTK', 'isVUS': 'true', 'variantName': 'E187K'}, {'geneName': 'MERTK', 'isVUS': 'true', 'variantName': 'H424Q'}, {'geneName': 'MSH6', 'isVUS': 'true', 'variantName': 'K1358fs*2,T118K,T1225M'}, {'geneName': 'MST1R', 'isVUS': 'true', 'variantName': 'V199M'}, {'geneName': 'NTRK1', 'isVUS': 'true', 'variantName': 'E275A'}, {'geneName': 'RET', 'isVUS': 'true', 'variantName': 'R749T'}, {'geneName': 'RICTOR', 'isVUS': 'true', 'variantName': 'S1042L'}, {'geneName': 'SMO', 'isVUS': 'true', 'variantName': 'G720L'}, {'geneName': 'SNCAIP', 'isVUS': 'true', 'variantName': 'E831G'}, {'geneName': 'TEK', 'isVUS': 'true', 'variantName': 'S123F'}, {'geneName': 'TP53', 'isVUS': 'true', 'variantName': 'rearrangement'}, {'geneName': 'ZNF703', 'isVUS': 'true', 'variantName': 'S229F'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'FANCA', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'A778fs*45', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '14.69', 'isEquivocal': 'false', 'name': 'A778fs*45'}}, 'Interpretation': 'FANCA encodes a key component of the multi_protein Fanconi anemia (FA) complex, a nuclear E3 ubiquitin ligase that is essential for preventing chromosome breakage caused by DNA damage (D Andrea, 2010; 20484397, Moldovan and D’Andrea., 2009; 19686080). Germline mutations or deletions affecting FANCA have been reported in 26_65% of patients with Fanconi anemia (FA), a rare autosomal recessive disorder characterized by congenital abnormalities, bone marrow failure, hypersensitivity to DNA crosslinking agents, and predisposition to a subset of cancers, including acute myeloid leukemia, myelodysplastic syndrome, gynecological malignancies, and head and neck tumors (Alter, 2014; 25455269, Kee and D Andrea, 2012; 23114602, Rosenberg et al., 2008; 18322251, Khincha and Savage, 2013; 24246701, Chandrasekharappa et al., 2013; 23613520, Selenti et al., 2013; 23898106, Park et al., 2013; 23067021, Chen et al., 2007; 17221219). Frequency estimates suggest an incidence of 3:1,000,000 individuals in Europe and the US, and a heterozygote carrier frequency of 1:181 to 1:300 in the US and Europe, respectively, with slightly higher rates for some populations, such as the Ashkenazi Jewish population (1:89) (Tischkowitz and Hodgson, 2003; 12525534, Khincha and Savage, 2013; 24246701). Alterations such as seen here may disrupt FANCA function or expression (Li et al., 2018; 29702541, Castella et al., 2011; 21273304, Qian et al., 2013; 24349332, Benitez et al., 2014; 24170812, Kruyt et al., 1999; 10567393, Folias et al., 2002; 12354784, Lightfoot et al., 1999; 10332032, Ali et al., 2012; 22343915, Yan et al., 2012; 22705371, Leung et al., 2012; 22396592, Matsuoka et al., 2007; 17525332, Collins et al., 2009; 19109555, Shukla et al., 2013; 23370339, Otsuki et al., 2001; 11726552). FANCA mutations and deletion have been reported at low frequencies (<2.5%) across solid tumors (Zehir et al., 2017; 28481359, Nguyen et al., 2022; 35120664). In some patient populations, germline polymorphisms specifically in FANCA have been linked to an increased risk of esophageal, breast, cervical, and bladder cancer (Akbari et al., 2011; 21279724, Haiman et al., 2008; 18056155, Michiels et al., 2009; 19237606, Wang et al., 2009; 19012493). A single nucleotide polymorphism (SNP) in FANCA has been correlated with inferior PFS and OS for patients with melanoma (Yin et al., 2015; 25243787), whereas methylation of FANCA correlated with inferior prognosis in high_grade serous ovarian carcinoma (Dai et al., 2013; 23965899). However, the link between FANCA expression and function has either not been explored, or not correlated with outcome, in these studies and other studies have failed to link FANCA polymorphisms with the risk of breast or cervical cancer (Barroso et al., 2009; 19536649, Juko_Pecirep et al., 2011; 21543111). Low expression of FANCA has been correlated with inferior prognosis in univariate but not multivariate analysis in breast cancer (Ribeiro et al., 2013; 23825533). FANCA has been reported to be downregulated in higher versus lower grade ovarian cancer, but FANCA expression did not impact OS or PFS (Ganzinellie et al., 2011; 21216588). Gain of 16q, associated with increased copy number of FANCA, correlated with decreased PFS (Bauer et al., 2008; 18810378). Inactivation of the FA/BRCA pathway sensitizes cells to mitomycin C and cisplatin (Villarroel et al., 2011; 21135251, Pennington et al., 2014; 24240112, Wang and Gautier, 2010; 20807115, Ghosh et al., 2014; 24200853) and results in increased sensitivity of glioma cells to alkylating agents such as temozolomide (Chen et al., 2007; 17221219). There are no therapies that directly target defects in the FA complex. Clinical evidence in prostate (Mateo et al., 2020; 31806540, Abida et al., 2020; 3208634, Mateo et al., 2015; 26510020, Smith et al., 2019; ESMO Abstract LBA50), breast (Gruber et al., 2019; ASCO Abstract 3006), and ovarian cancers (Swisher et al., 2017; 27908594), including multiple patient responses, indicates that FANCA inactivation may confer sensitivity to PARP inhibitors. Inactivation of the FA/BRCA pathway sensitizes cells to mitomycin C and cisplatin (Villarroel et al., 2011; 21135251, Pennington et al., 2014; 24240112, Wang and Gautier, 2010; 20807115, Ghosh et al., 2014; 24200853) and results in increased sensitivity of glioma cells to alkylating agents such as temozolomide (Chen et al., 2007; 17221219).', 'Include': 'true', 'ClinicalTrialNote': 'FANCA alterations may predict sensitivity to PARP inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT03869190', 'Include': 'true'}, {'nctId': 'NCT04123366', 'Include': 'true'}, {'nctId': 'NCT03742895', 'Include': 'true'}, {'nctId': 'NCT02264678', 'Include': 'true'}, {'nctId': 'NCT05035745', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT04497116', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}, {'nctId': 'NCT04991480', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'FBXW7', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'E471G', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '37.57', 'isEquivocal': 'false', 'name': 'E471G'}}, 'Interpretation': 'FBXW7 encodes the F_box protein subunit of the SCF ubiquitin ligase complex, which targets proteins for degradation (Welcker and Clurman, 2008; 18094723). FBXW7 inactivation is associated with chromosomal instability and with stabilization of proto_oncogenes, such as mTOR, MYC, cyclin E, NOTCH, and JUN; FBXW7 is therefore considered a tumor suppressor (Akhoondi et al., 2007; 17909001, Welcker and Clurman, 2008; 18094723). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. In the bladder urothelial carcinoma TCGA dataset, FBXW7 mutations were detected in 8.7% of cases (Cancer Genome Atlas Research Network, 2014; 24476821). Another study identified FBXW7 mutation in 4.3% (2/47) of bladder urothelial carcinomas and in 13% (2/16) of non_bladder urothelial carcinomas (Millis et al., 2015; 25178641). Published data investigating the prognostic implications of FBXW7 alterations in urothelial carcinoma are limited (PubMed, Jul 2022). Reduced FBXW7 expression has been associated with poor prognosis in some cancers such as colorectal cancer, gastric cancer, esophageal SCC, cervical SCC, melanoma, and non_small cell lung carcinoma (Tu et al., 2012; 22548670, Iwatsuki et al., 2010; 19739118, Yokobori et al., 2012; 22576686, Yokobori et al., 2009; 19366810, Yokobori et al., 2014; 24165483, Rajagopalan et al., 2004; 14999283, Cheng et al., 2013; 23381582, Xu et al., 2016; 26954701). FBXW7 inactivating alterations may indicate sensitivity to mTOR inhibitors (Mao et al., 2008; 18787170, Yang et al., 2015; 25749036). Case series reported objective responses for 2 patients with FBXW7_mutated cervical squamous cell carcinoma treated with everolimus (Kulkarni et al., 2020; SGO Abstract 356). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true', 'ClinicalTrialNote': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT03239015', 'Include': 'true'}, {'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT05125523', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}, {'nctId': 'NCT03203525', 'Include': 'true'}, {'nctId': 'NCT05036226', 'Include': 'true'}, {'nctId': 'NCT01582191', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'Tumor Mutation Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '28', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '28'}}, 'Interpretation': 'Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level that may be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors in urothelial carcinoma (Galsky et al., 2017; ESMO Abstract 848PD, Necchi et al., 2018; AACR Abstract CT003, Rosenberg et al., 2016; 26952546, Balar et al., 2017; 27939400, Powles et al., 2018; 29268948, Mariathasan et al., 2018; 29443960, Miao et al., 2018; 30150660, Samstein et al., 2019; 30643254, Sarid et al., 2019; ESMO Abstract 938, Marabelle et al., 2020; 32919526). In the Bladder Urothelial Carcinoma TCGA dataset, the median somatic mutation burden was 5.5 mutations per megabase (muts/Mb)(Cancer Genome Atlas Research Network, 2014; 24476821). One study reported that the number of somatic mutations positively correlates with increased tumor stage and grade of bladder cancers (Cazier et al., 2016; 24777035). For patients with metastatic urothelial carcinoma receiving atezolizumab, however, higher median mutation load has been reported to be significantly associated with improved PFS and OS (Rosenberg et al., 2016; ASCO Abstract 104, Rosenberg et al., 2016; 26952546, Balar et al., 2017; 27939400). Another study for patients with urothelial bladder carcinoma showed that high tumor mutational burden (TMB) was associated with superior OS and disease_specific survival compared with low TMB; the OS benefit of high TMB was driven by the cohort with Stage 3 disease, whereas OS was similar between low and high TMB for patients with Stage 2 or Stage 4 disease (Voutsadakis, 2022; 35323317). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple studies of immune checkpoint inhibitors in urothelial carcinoma, higher TMB has corresponded with clinical benefit from treatment with anti_PD_L1 (Rosenberg et al., 2016; 26952546, Balar et al., 2017; 27939400, Powles et al., 2018; 29268948, Mariathasan et al., 2018; 29443960, Samstein et al., 2019; 30643254, Miao et al., 2018; 30150660) and anti_PD_1 immunotherapeutic agents (Galsky et al., 2017; ESMO Abstract 848PD, Necchi et al., 2018; AACR Abstract CT003). For patients with metastatic urothelial carcinoma treated with the PD_L1 inhibitor atezolizumab, those with a significantly increased mutational load (9.7 Muts/Mb or greater by this assay or others) were associated with response and longer OS compared with those with lower TMB (Rosenberg et al., 2016; 26952546, Powles et al., 2018; 29268948, Balar et al., 2017; 27939400, Samstein et al., 2019; 30643254). Similarly, in a study of pembrolizumab in muscle invasive bladder cancer, the median TMB in responders was 12.3 Muts/Mb, versus 7.0 Muts/Mb in nonresponding patients (Necchi et al., 2018; AACR Abstract CT003). The PD_1 inhibitor nivolumab led to increased ORR, PFS, and OS for patients with a TMB of 167 missense mutations/tumor or higher (~ equivalency = 9 Muts/Mb or higher as measured by this assay) compared with those harboring lower TMB in a study of metastatic urothelial cancer (Galsky et al., 2017; ESMO Abstract 848PD).', 'Include': 'true', 'ClinicalTrialNote': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Cemiplimab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Cemiplimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC), cutaneous squamous cell carcinoma, or basal cell carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of cemiplimab for the treatment of urothelial carcinoma are limited (PubMed, Sep 2022). Cemiplimab has been studied primarily in advanced cutaneous squamous cell carcinoma (CSCC), where it elicited a combined ORR of 48% (41/85) in Phase 1 and 2 studies (Migden et al., 2018; 29863979). A Phase 2 trial of cemiplimab in patients with basal cell carcinoma (BCC) reported ORRs of 31% (5 CRs and 21 PRs) in patients with locally advanced BCC and 21% (6 PRs) in patients with metastatic BCC (Stratigos et al., 2020; EMSO Abstract LBA47, Lewis et al. 2020; doi: 10.1136/jitc_2020_SITC2020.0428). The Phase 3 EMPOWER_Lung 1 trial for advanced non_small cell lung cancer (NSCLC) with PD_L1 expression ≥50% reported that cemiplimab is associated with improved PFS (8.2 vs. 5.7 months), OS (not reached vs. 14.2 months), and ORR (37% vs. 21%) compared with chemotherapy (Sezer et al., 2020; ESMO Abstract LBA52). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Durvalumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Durvalumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and biliary tract cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In the first_line setting for locally advanced or metastatic urothelial carcinoma, the randomized controlled Phase 3 DANUBE study showed that durvalumab monotherapy did not significantly improve median OS (mOS) for patients with PD_L1_high tumor status compared with chemotherapy (14.4 vs. 12.1 months, HR=0.89, p=0.30) (Powles et al., 2020; 32971005, Powles et al., 2020; ESMO Abstract 697O). For chemotherapy_pretreated patients with advanced urinary tract carcinoma, the Phase 3b STRONG study of durvalumab reported an ORR of 18% and mOS of 7.0 months, with longer mOS observed for patients with high PD_L1 expression (9.3 vs. 6.5 months) (Sonpavde et al., 2021; ASCO GI Abstract 429). The Phase 2 DUART study of concurrent durvalumab and radiation therapy followed by adjuvant durvalumab for patients with locally advanced bladder urothelial carcinoma reported a 65% (13/20) ORR and a 70% (14/20) DCR; median PFS was 18.5 months and mOS was not reached, but 1_ and 2_year OS probabilities were 84% and 77%, respectively (Joshi et al., 2021; ASCO GU Abstract 398). Interim results from the Phase 2 ARCADIA study evaluating the combination of durvalumab and cabozantinib to treat patients with advanced urothelial carcinoma following progression on platinum chemotherapy reported an ORR of 38% (6/16, 2 CRs) (Marandino et al., 2021; 34006499). Combining durvalumab with matched targeted therapies (FGFR, PARP, or mTOR inhibitors) did not improve PFS or OS for patients with platinum_refractory advanced urothelial cancer in the Phase 2 BISCAY study (Powles et al., 2021; 33941921). In the neoadjuvant setting, a Phase 2 study of durvalumab and olaparib yielded an ORR of 14% (4/29) for patients with muscle_invasive bladder carcinoma (Rodriguez_Moreno et al., 2020; ESMO Abstract 761P). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Pembrolizumab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Pembrolizumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved for patients with tumor mutational burden (TMB)_high (≥10 Muts/Mb), microsatellite instability_high (MSI_H), or mismatch repair_deficient (dMMR) solid tumors; as monotherapy for PD_L1_positive head and neck squamous cell cancer (HNSCC), cervical cancer, or esophageal cancer; and in combination with chemotherapy for PD_L1_positive triple_negative breast cancer (TNBC) or cervical cancer. It is also approved in various treatment settings as monotherapy for patients with non_small cell lung cancer (NSCLC), melanoma, HNSCC, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma, endometrial carcinoma that is MSI_H or dMMR, classical Hodgkin lymphoma, or primary mediastinal large B_cell lymphoma; and in combination with chemotherapy or targeted therapy for NSCLC, HNSCC, esophageal or gastroesophageal junction cancer, renal cell carcinoma, TNBC, or endometrial carcinoma that is not MSI_H or dMMR. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In the Phase 2 PURE_01 study of neoadjuvant pembrolizumab for muscle_invasive bladder urothelial carcinoma, TMB was significantly associated with the probability of pathologic CR (pCR) but was not an independent marker of pCR probability (Bandini et al., 2020; 32516377). For TMB ≤11 Muts/Mb, the probability of pCR was not dependent on the PD_L1 combined positive score (CPS); however, increased CPS was associated with increased pCR probability for TMB >11 Muts/Mb (Bandini et al., 2020; 32516377). The Phase 3 KEYNOTE_045 trial for patients with advanced urothelial carcinoma (UC) found second_line pembrolizumab superior to chemotherapy for median OS (mOS) (10.3 vs. 7.4 months, HR=0.74) (Bellmunt et al., 2017; 28212060) and 4_year PFS (9.5% vs. 2.7%) and OS (17% vs. 10%) rates (Balar et al., 2022; 36494006). First_line pembrolizumab therapy for cisplatin_ineligible patients with advanced UC achieved a confirmed ORR of 29%, median duration of response (mDOR) of 33.4 months, and mOS of 11.3 months after 5 years of follow_up in a Phase 2 trial; improved clinical benefit was observed for patients with a PD_L1 combined positive score (CPS) ≥10 compared with patients with PD_L1 CPS <10 (mOS 18.5 vs. 9.7 months, ORR 47% vs. 21%) (Balar et al., 2022; 36494006). However, the Phase 3 KEYNOTE_361 study investigating pembrolizumab in first_line settings for advanced UC reported similar mOS for patients treated with single_agent pembrolizumab versus chemotherapy (15.6 vs. 14.3 months, HR=0.92) irrespective of PD_L1 CPS ≥10 (16.1 vs. 15.2 months, HR=1.01) and found that the addition of pembrolizumab to chemotherapy was not superior to chemotherapy (mOS 17.0 vs. 14.3 months, HR=0.86) (Powles et al., 2021; 34051178). A post_hoc analysis of pembrolizumab monotherapy efficacy in KEYNOTE_361 and KEYNOTE_052 reported that patients with a CR or PR response at 9 weeks of pembrolizumab therapy achieved better mOS outcomes (50.7 months) than patients with SD (17.5 months) or PD (5.3 months) as best response (Powles et al., 2022; ASCO Abstract 519). The Phase 3 LEAP_011 trial for advanced UC reported that the addition of lenvatinib to first_line pembrolizumab was similar to pembrolizumab monotherapy, with a median PFS of 4.2 versus 4.0 months (HR=0.91), an mOS of 11.2 versus 13.8 months (HR=1.25), and an ORR of 31.2% versus 26.5% (Loriot et al., 2022; ASCO Abstract 432). A Phase 2 study investigated neoadjuvant pembrolizumab followed by radical cystectomy in muscle_invasive urothelial bladder carcinoma (MIBC) and reported pathologic CRs for 42% (21/50) of patients; 54% (19/35) of patients experiencing CR had a PD_L1 CPS ≥10 (Necchi et al., 2018; 30343614). For patients with high_risk non_MIBC carcinoma in situ unresponsive to the Bacillus Calmette_Guerin vaccine, follow_up analysis from a Phase 2 trial reported a 3_month CR rate of 40% for patients treated with pembrolizumab, 75% and 53% of whom experienced a CR duration of at least 6 months and 12 months, respectively (De Wit et al., 2019; ASCO Abstract 4530). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Nivolumab + Ipilimumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response, and ipilimumab is a cytotoxic T_lymphocyte antigen 4 (CTLA_4)_blocking antibody. The combination is FDA approved in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), pleural mesothelioma, and esophageal squamous cell carcinoma (ESCC). Furthermore, nivolumab is approved in combination with ipilimumab to treat patients with mismatch repair_deficient (dMMR) or microsatellite instability_high (MSI_H) colorectal cancer (CRC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hodi et al., 2019; AACR abstract CT037), a TMB score of ≥10 Muts/Mb (as measured by this assay) may predict sensitivity to combination nivolumab and ipilimumab treatment. </p> <p><b>Supporting Data:</b> A Phase 2 study of ipilimumab and nivolumab for patients with platinum_refractory metastatic UC who progressed on nivolumab monotherapy observed PRs for 23% (5/22) of patients (Keegan et al., 2019; ASCO GU Abstract 481). The Phase 1/2 CheckMate 032 reported a 38% ORR, a 4.9 month median PFS, and a 15.3 month median OS for patients with locally advanced or metastatic UC treated with nivolumab and ipilimumab; a 58% ORR was observed for patients with ≥1% tumor PD_L1 expression (Sharma et al., 2019; 31100038). A Phase 2 study of nivolumab in combination with ipilimumab for patients with advanced bladder cancers reported 1 CR in a patient with plasmacytoid carcinoma and 2 PRs in patients with small cell carcinoma (McGregor et al., 2019; ASCO Abstract 4518). A Phase 1 trial of nivolumab plus ipilimumab and cabozantinib in patients with refractory metastatic UC and other genitourinary cancers reported a 42% ORR among patients with metastatic UC and bladder squamous cell carcinoma (Apolo et al., 2017; ASCO Abstract 4562). In the Phase 1 NABUCCO study of neoadjuvant ipilimumab plus nivolumab for patients with advanced urothelial cancer, 93% (23/24) of patients underwent resection within 12 weeks and 46% (11/24) had a pathological CR (Dijk et al., 2020; 33046870). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Dostarlimab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Dostarlimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer or solid tumors. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of dostarlimab for the treatment of urothelial carcinoma are limited (PubMed, Sep 2022). Dostarlimab has been studied primarily in recurrent and advanced mismatch repair_deficient (dMMR) endometrial and non_endometrial cancers (Andre et al., 2021; ASCO GI Abstract 9, Oaknin et al., 2020; 33001143, Berton et al., 2021; ASCO Abstract 2564). In the Phase 1 GARNET trial, single_agent dostarlimab elicited an ORR of 39% (41/106) and an immune_related ORR of 46% (50/110) for patients with non_endometrial dMMR solid tumors (Andre et al., 2021; ASCO GI Abstract 9, Andre et al., 2021; ESMO GI Abstract SO_9). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Nivolumab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response. It is FDA approved as a monotherapy in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, colorectal cancer (CRC), classical Hodgkin lymphoma (cHL), gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma or squamous cell carcinoma (ESCC). It is also approved in combination with chemotherapy to treat ESCC, in combination with cabozantinib to treat RCC, and in combination with relatlimab to treat melanoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> The Phase 2 CheckMate 275 and Phase 1/2 CheckMate 032 studies evaluating nivolumab for patients with platinum_refractory metastatic urothelial carcinoma (UC) reported ORRs of 20% (6.3% CR) and 26% (10.3% CR), PFS of 1.9 and 2.8 months, and OS of 8.6 and 9.9 months, respectively (Sharma et al., 2019; 31100038, Sharma et al., 2017; 28131785, Sharma et al., 2018; AACR Abstract CT178). CheckMate 032 additionally reported a 38% ORR, 4.9 month median PFS (mPFS), and 15.3 month median OS for patients treated with nivolumab and ipilimumab; a 58% ORR was observed for patients with ≥1% tumor PD_L1 expression (Sharma et al., 2019; 31100038). In a Phase 3 trial of neoadjuvant nivolumab and ipilimumab for patients with high_risk advanced UC, 60% (9/15) of patients with a combined positive PD_L1 score ≥10 experienced a pathologic CR compared with 22% (2/9) of patients with lower PD_L1 expression (van der Heijden et al., 2019; ESMO Abstract 904PD). A Phase 2 study of ipilimumab and nivolumab for patients with platinum_refractory metastatic UC who progressed on nivolumab monotherapy observed PRs for 23% (5/22) of patients (Keegan et al., 2019; ASCO GU Abstract 481). The Phase 3 CheckMate_274 study of adjuvant nivolumab versus placebo following radical surgery for patients with high_risk muscle_invasive UC reported an improved median disease_free survival (20.8 vs. 10.8 months) with 75% of patients treated with nivolumab alive and disease_free at 6 months versus 60% with placebo (HR=0.70); the percentages were 75% and 56%, respectively, for patients with PD_L1 expression ≥1% (HR=0.55); in an exploratory subgroup analysis, the DFS HR was 0.82 for patients with PD_L1_negative tumors (Bajorin et al., 2021; 34077643). A Phase 2 study of nivolumab plus chemotherapy for patients with muscle_invasive bladder cancer reported a complete clinical response (cCR) rate of 48% (31/64)(Galsky et al., 2021; ASCO Abstract 4503). An exploratory biomarker analysis of this study found an association between cCR and TMB ≥ 10 Muts/Mb (p=0.02) or ERCC2 mutation (p=0.02)(Galsky et al., 2021; ASCO Abstract 4503). Combining the multikinase inhibitor cabozantinib with nivolumab or with nivolumab plus ipilimumab demonstrated activity for immunotherapy_naive patients with chemotherapy_refractory metastatic UC (ORR of 50% [6/12] and 22% [2/9], respectively; mPFS of 24 and 10 months, respectively); cabozantinib combined with nivolumab also benefited immunotherapy_refractory patients (ORR of 29% [2/7])(Nadal et al., 2018; ASCO Abstract 4528) and responses to these combination treatments were observed for patients with bladder squamous cell carcinoma or bladder adenocarcinoma (Nadal et al., 2018; ASCO GU Abstract 515). Addition of the IDO1 inhibitor BMS986205 to nivolumab in previously treated advanced UC elicited ORRs for 37% (3/27 CRs, 7/27 PRs) of immunotherapy_naive patients but no responses for 3 patients who had prior immunotherapy (Luke et al., 2019; ASCO GU Abstract 358). As first_line therapy for advanced UC, nivolumab combined with the immunostimulatory therapy bempegaldesleukin achieved an ORR of 48% (13/27; 5/27 CRs), with 50% (6/12) of PD_L1_positive and 45% (5/11) of PD_L1_negative patients responding (Siefker_Radtke et al., 2019; ASCO GU Abstract 388). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Atezolizumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Atezolizumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC) as well as adult and pediatric patients 2 years and older with alveolar soft part sarcoma, depending on treatment setting. Atezolizumab is also approved in combination with other therapies to treat patients with non_squamous NSCLC lacking EGFR or ALK alterations, small cell lung cancer, hepatocellular carcinoma, and BRAF V600_positive melanoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In the IMvigor130 study, patients with metastatic urothelial carcinoma harboring TMB_high (>10 muts/Mb) and PD_L1 expression >5% experienced improved OS with atezolizumab monotherapy compared to platinum_based chemotherapy (HR=0.22)(Galsky et al., 2020; ASCO Abstract 5011). As second_line therapy for advanced urothelial carcinoma in the Phase 3 IMvigor211 study, atezolizumab compared with chemotherapy did not significantly improve median OS (mOS) (11.1 vs. 10.6 months, HR=0.87) for patients with PD_L1 expression on 5% or more of tumor_infiltrating immune cells (Powles et al., 2018; 29268948). The ORRs (23% vs. 22%) and median PFSs (mPFS) (HR=1.01) were similar between the treatment arms, but atezolizumab was associated with a numerically longer median duration of response (15.9 vs. 8.3 months) (Powles et al., 2018; 29268948). The 2_year OS rate was 23% with atezolizumab versus 13% with chemotherapy in an exploratory analysis of the overall trial population irrespective of PD_L1 status (van der Heijden et al., 2021; 33902955). The Phase 3 IMvigor130 study for patients with treatment_naive metastatic urothelial carcinoma found that the addition of atezolizumab to platinum_based chemotherapy improved mPFS (8.2 vs. 6.3 months, HR=0.82) and numerically improved mOS (16.0 vs. 13.4 months, HR=0.83) compared with placebo, with similar ORRs (47% vs. 44%) (Galsky et al., 2020; 32416780). A second interim analysis of mOS in the IMvigor130 trial showed a favorable trend for atezolizumab monotherapy compared with platinum_based chemotherapy (15.2 vs. 13.1 months, OS HR=0.99 ) but did not reach statistical significance, and exploratory analysis observed the greatest benefit for patients who were cisplatin_ineligible with tumor portion score (TPS) of ≥5% (OS HR=0.60) (Davis et al., 2021; AACR Abstract CT040). In a Phase 2 study, patients with metastatic urothelial carcinoma treated with atezolizumab as first_line therapy experienced an ORR of 23%, a CR rate of 8.9%, and a clinical benefit rate of 30% (Balar et al., 2017; 27939400). Multiple studies have reported superior ORR and OS outcomes with atezolizumab monotherapy for patients with higher tumor mutational burden (TMB) or PD_L1 expression compared with those with lower TMB or PD_L1 expression (Balar et al., 2017; 27939400, Powles et al., 2018; 29268948, Rosenberg et al., 2016; 26952546, Galsky et al., 2020; ASCO Abstract 5011). A neoadjuvant trial for patients with muscle_invasive bladder cancer added atezolizumab to gemcitabine plus cisplatin and met its primary endpoint (non_muscle_invasive downstaging rate of 27/39) (Funt et al., 2022; 35089812). In the COSMIC_021 trial, patients with urothelial carcinoma (UC) post_platinum chemotherapy treated with the combination of atezolizumab with cabozantinib experienced an ORR of 27%, a DCR of 64%, and a median PFS (mPFS) of 5.4 months (n=30) (Pal et al., 2020; ASCO Abstract 5013). The trial also reported benefit for patients with locally advanced or metastatic UC (mUC) receiving the combination in the first line, whether cisplatin_eligible (ORR: 30% [9/30]) or ineligible (ORR: 20% [6/30]) (Pal et al., 2022; ASCO Abstract 4504). For patients who had previously received an immune_checkpoint inhibitor (ICI), the ORR was 10% (3/31) (Pal et al., 2022; ASCO Abstract 4504). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Avelumab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Avelumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 in order to enhance antitumor immune responses. It is FDA approved to treat patients 12 years and older with Merkel cell carcinoma, or for urothelial carcinoma in various treatment settings. The combination of avelumab and axitinib is FDA approved for patients with renal cell carcinoma (RCC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> The Phase 3 JAVELIN Bladder 100 trial of maintenance avelumab for patients with advanced or metastatic urothelial cancer reported longer median OS (mOS; 21.4 vs. 14.3 months, HR=0.69) for avelumab plus best supportive care (BSC) compared with BSC in the randomized population (Powles et al., 2020; 32945632). Biomarker analysis of JAVELIN Bladder 100 showed further survival benefit with the addition of avelumab to BSC for patients with elevated TMB (HR=0.48) relative to those with TMB at or below the median (HR=0.88) and for patients with high PD_L1 expression (HR=0.35) relative to those with low PD_L1 expression (HR=0.79) (Powles et al., 2021; 34893775). A Phase 2 trial of first_line avelumab for patients with metastatic or advanced urothelial cancer with PD_L1_positive disease and who were ineligible for cisplatin treatment reported an ORR of 23% (16/71), median PFS of 2 months, and mOS of 10 months (Iacovelli et al., 2022; ASCO GU Abstract 439). In a Phase 2 study, avelumab plus axitinib yielded an ORR of 10% (2/20) and mPFS of 2.3 months for patients with treatment_naive, cisplatin_ineligible urothelial carcinoma (Galffy et al., 2020; SITC Abstract 281). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04237649', 'Include': 'true'}, {'nctId': 'NCT03682068', 'Include': 'true'}, {'nctId': 'NCT04960709', 'Include': 'true'}, {'nctId': 'NCT04241185', 'Include': 'true'}, {'nctId': 'NCT04700124', 'Include': 'true'}, {'nctId': 'NCT03869190', 'Include': 'true'}, {'nctId': 'NCT04589845', 'Include': 'true'}, {'nctId': 'NCT03674567', 'Include': 'true'}, {'nctId': 'NCT04047862', 'Include': 'true'}, {'nctId': 'NCT05166577', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'CREBBP', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Q104*', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '36.7', 'isEquivocal': 'false', 'name': 'Q104*'}}, 'Interpretation': 'CREBBP encodes a ubiquitously expressed transcriptional coregulatory protein that interacts with multiple transcription factors and can couple control of gene expression to chromatin remodeling via its histone acetyltransferase activity. Inherited microdeletions and truncating point mutations in CREBBP are reported to be causal in approximately 20% of cases of Rubinstein_Taybi syndrome (Pertij et al., 2000; 10699051). The chromosomal rearrangement t(8;16)(p11;p13) is characteristic of the M4/M5 subtype of acute myeloid leukemia (AML) and results in a chimeric gene fusing MYST3/MOZ (a gene essential for the development of the hematopoietic system and maintenance of hematopoietic stem cells) to CREBBP (Borrow et al., 1996; 8782817). CREBBP_BCORL1 fusion has been reported in patients with ossifying fibromyxoid tumors (Kao et al., 2017; 27537276, Hofvander et al., 2020; 31932680). CREBBP mutations have been observed at high frequency in follicular lymphoma (FL, 26%) and diffuse large B_cell lymphoma (DLBCL, 16%), and at lower frequency in acute lymphoblastic leukemia (ALL, 7%), and tumors of the urinary tract (15%), skin (12%), liver (8.7%), endometrium (8.5%), and stomach (8.2%)(COSMIC, 2023)(Tate et al., 2019; 30371878). These mutations include missense substitutions clustered in the CREBBP histone acetyltransferase domain and truncating mutations throughout the gene sequence, suggesting a role for CREBBP inactivation in these diseases. CREBBP mutations have been reported to occur in the transition from prostate acinar carcinoma to squamous cell carcinoma (SCC) (Grasso et al., 2015; 25735316), which may indicate significance for CREBBP in SCC. In two cases of relapsed pediatric B_cell ALL, CREBBP mutation conferred resistance to glucocorticoid therapy (Ma et al., 2015; 25790293). Reports have found CREBBP mutation in 62_68% of patients with FL (Green et al., 2015; 25713363, Loeffler et al., 2015; 25027518), which was associated with immune evasion (Green et al., 2015; 25713363). AML with MYST3/CREBBP fusion was reported to occur in 60_80% of cases 9_72 months after adjuvant chemotherapy for breast cancer and was associated with a poor prognosis (Gervais et al., 2008; 18528428, Haferlach et al., 2009; 19194466). There are no targeted therapies available to address genomic alterations in CREBBP. The use of histone deacetylase (HDAC) inhibitors are being investigated in clinical trials that are recruiting patients with either lymphoma or urothelial carcinoma harboring CREBBP alterations. However, it has been reported that there is no correlation between CREBBP mutation status and response to HDAC inhibitors in DLBCL (Mensah et al., 2015; 25671298).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'KDM6A', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'A516fs*17', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '11.64', 'isEquivocal': 'false', 'name': 'A516fs*17'}}, 'Interpretation': 'KDM6A encodes a histone H3 lysine 27 demethylase UTX, which functions as a transcriptional regulator (van Haaften et al., 2009; 19330029). A significant number of inactivating KDM6A mutations have been found across multiple tumor types, suggesting a role as a tumor suppressor (van Haaften et al., 2009; 19330029). KDM6A mutations have been reported in 3.9% of samples analyzed, with the highest incidence in tumors of the urinary tract (31%), liver (7.3%), endometrium (6.7%), salivary gland (6.0%), and pancreas (5.1%) (COSMIC, Jan 2023)(Tate et al., 2019; 30371878). KDM6A mutations or copy number alterations have also been identified in medulloblastoma (8.9%)(Robinson et al., 2012; 22722829), adenoid cystic carcinoma (6.7%) (Ho et al., 2013; 23685749), and metastatic prostate cancer (10%) (Grasso et al., 2012; 22722839). KDM6A inactivation has been found as a recurrent tumorigenic event in male T_cell acute lymphoblastic leukemia (T_ALL), and loss of KDM6A increased the sensitivity of T_ALL cells to therapies targeting histone H3 lysine 27 methylation in preclinical assays (Van der Meulen et al., 2014; 25320243). However, KDM6A overexpression has been noted in breast cancer and renal cell carcinoma, and correlated with inferior prognosis in patients with breast cancer (Wang et al., 2013; 23792809, Kim et al., 2014; 24491801, Shen et al., 2012; 23057811). There are no therapies available to address KDM6A alterations in cancer.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'MS_Stable', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'MS_Stable'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI has been detected in 26_49% of urothelial carcinomas (Mylona et al., 2008; 18254781, Amira et al., 2003; 14501713); MSI_H has also been reported in multiple case studies of upper urinary tract urothelial carcinoma (Bai et al., 2013; 23690119). Microsatellite instability (MSI), as determined through loss of MSH2 or MSH6 protein expression, correlated with noninvasive well_differentiated bladder tumors and favorable OS (Mylona et al., 2008; 18254781). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'RB1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'S576*', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '20.73', 'isEquivocal': 'false', 'name': 'S576*'}}, 'Interpretation': 'RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (Burkhart and Sage, 2008; 18650841, Knudsen and Knudsen, 2008; 19143056). Alterations such as seen here may disrupt RB1 function or expression (Berge et al., 2010; 20594292, Giacinti et al., 2006; 16936740, Otterson et al., 1997; 9342358, Otterson et al., 1999; 10486322, Qin et al., 1992; 1534305, Rubin et al., 2005; 16360038, Sun et al., 2006; 16449662). RB1 mutations have been reported in 80% (49/61) of bladder small cell carcinomas (Chang et al., 2018; 29180607). RB1 mutations have been detected in 10_20% of bladder urothelial carcinomas, including transitional cell carcinomas (Cancer Genome Atlas Research Network, 2014; 24476821, cBio_Guo et al., 2013; 24121792, cBio_Kim et al., 2014; 25092538) and in up to 5.4% (2/37) of upper tract urothelial carcinomas (cBio_Robinson et al., 2019; 31278255, cBio_Su et al., 2021; 33397444, cBio_Sfakianos et al., 2015; 26278805). Recurrent focal genomic deletion of RB1 has been reported in urothelial carcinomas (Lindgren et al., 2012; 22685613). Expression of Rb has been reported in 47_52% of bladder urothelial carcinomas in one study, and was found to correlate with RB1 alteration (Diaz_Cano et al., 2000; 10744064). Published data investigating the prognostic implications of RB1 alterations in bladder neuroendocrine carcinomas are limited (PubMed, Nov 2022). Loss of Rb expression has been suggested to play a role in the progression of urothelial cancers, and has been associated with advanced tumor stage and poor patient survival (Ishikawa et al., 1991; 1913692, Logothetis et al., 1992; 1640485, Cordon_Cardo et al., 1992; 1640484). On the basis of limited clinical data (Owonikoko et al., 2016; ESMO Abstract 14230) and strong preclinical data (Hook et al., 2012; 22222631, Gong et al., 2019; 30373917, Oser et al., 2019; 30373918, Yang et al., 2022; 34741392), RB1 inactivation may be associated with sensitivity to inhibitors of Aurora kinase A, particularly in small cell lung cancer (SCLC). A clinical study evaluating the Aurora kinase A inhibitor alisertib for patients with prostate cancer did not find an association between RB1 deletion and clinical benefit (Beltran et al., 2019; 30232224). Other approaches to target RB1 inactivation under investigation in preclinical studies include inhibitors of BCL_2 family members (Allaman_Pillet et al., 2013; 21955141) and activation of the NOTCH pathway (Viatour et al., 2011; 21875955). Loss of Rb function has been associated with increased sensitivity to cytotoxic agents and chemotherapeutics in both preclinical studies and in patients with bladder or breast cancer (Derenzini et al., 2008; 18381962, Knudsen and Knudsen, 2008; 19143056). Mutations in RB1 underlie the development of retinoblastoma (RB), a rare tumor that arises at a rate of approximately 1:20,000 live births, with nearly 5,000 new cases worldwide per year (Chen et al., 2014; 24282159). Germline mutations in RB1 account for approximately 40% of RB tumors (Yun et al., 2011; 22553621) and are associated with an increased risk of developing secondary malignancies that include soft tissue and bone sarcoma and malignant melanoma (Houston et al., 2011; 21139478, Ng et al., 2010; 19959033). In the appropriate clinical context, germline testing of RB1 is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'STAG2', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'M1I', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '29.17', 'isEquivocal': 'false', 'name': 'M1I'}}, 'Interpretation': 'STAG2 encodes a subunit of the cohesin complex, which maintains sister chromatid cohesion. The cohesin complex includes four subunits: SMC1A, SMC3, RAD21, and either STAG1 or STAG2 (Solomon et al., 2014; 24856830). Cohesin is also involved in transcriptional regulation, DNA replication and DNA repair (Solomon et al., 2014; 24856830). STAG2 mutations, which are mostly truncating, or loss of STAG2 protein expression have been reported in multiple cancer types (Kandoth et al., 2013; 24132290, Solomon et al., 2014; 24856830). STAG2 deletion has been shown to promote tumorigenesis in preclinical studies (Evers et al., 2014; 24484537), and STAG2 inactivation has been proposed to promote tumorigenesis via a mechanism that involves increased aneuploidy (Guo et al., 2013; 24121792, Solomon et al., 2013; 24121789, Solomon et al., 2011; 21852505) or altered transcriptional regulation (Thota et al., 2014; 25006131, Balbás_Martínez et al., 2013; 24121791, Kon et al., 2013; 23955599, Taylor et al., 2014; 24270882). STAG2 mutations have been observed most frequently in urothelial bladder carcinoma (16_35%) (Solomon et al., 2013; 24121789, Balbas_Martinez et al., 2013; 24121791, Guo et al., 2013; 24121792, Taylor et al., 2014; 24270882, Cancer Genome Atlas Research Network, 2014; 24476821), Ewing sarcoma (13_22%) (Tirode et al., 2014; 25223734, Brohl et al., 2014; 25010205), upper urinary tract urothelial carcinoma (11%) (Hoang et al., 2013; 23926200), myeloid malignancies (6%) (Thota et al., 2014; 25006131, Kon et al., 2013; 23955599), and glioblastoma (6%) (Solomon et al., 2011; 21852505). STAG2 truncation mutations are associated with loss of protein expression (Solomon et al., 2013; 24121789, Balbas_Martinez et al., 2013; 24121791, Taylor et al., 2014; 24270882, Brohl et al., 2014; 25010205). In patients with Ewing sarcoma, STAG2 and TP53 mutations often co_occur and are associated with decreased OS, although mutation of either STAG2 or TP53 alone was not demonstrated to affect survival (Tirode et al., 2014; 25223734, Brohl et al., 2014; 25010205). STAG2 mutation in patients with myelodysplastic syndrome is associated with decreased OS and has also been associated with increased response to treatment with azacitidine or decitabine in patients with myeloid malignancies (Thota et al., 2014; 25006131). The data on the prognostic significance of STAG2 mutation or loss of STAG2 protein expression in the context of urothelial bladder carcinoma are conflicting (Solomon et al., 2013; 24121789, Balbas_Martinez et al., 2013; 24121791, Guo et al., 2013; 24121792, Taylor et al., 2014; 24270882). In patients with pancreatic ductal adenocarcinoma, loss of STAG2 staining was significantly associated with decreased OS but was also associated with survival benefit from adjuvant chemotherapy (Evers et al., 2014; 24484537). An inactivating STAG2 mutation was identified in a patient with melanoma that acquired resistance to vemurafenib and preclinical evidence suggests that loss of STAG2 expression decreases the sensitivity of BRAF V600E_positive melanoma cells to vemurafenib, dabrafenib, and trametinib (Shen et al., 2016; 27500726). There are no therapies that directly target STAG2. However, in preclinical studies, STAG2 inactivation by mutation or knockdown resulted in increased sensitivity to PARP inhibitors (Bailey et al., 2014; 24356817) or oxaliplatin (Evers et al., 2014; 24484537).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TERT', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'promoter _124C>T', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '47.64', 'isEquivocal': 'false', 'name': 'promoter _124C>T'}}, 'Interpretation': 'Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length (Shay et al., 2011; 22015685). Activation of TERT is a hallmark of cancer, being detected in up to 80_90% of malignancies and absent in quiescent cells (Shay et al., 1997; 9282118, Kim et al., 1994; 7605428, Hanahan and Weinberg, 2000; 10647931). Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at _124 bp and _146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)(Horn et al., 2013; 23348503, Huang et al., 2014; 23348506, Vinagre et al., 2013; 23887589), as well as tandem mutations at positions –124/–125 bp and –138/–139 bp (Horn et al., 2013; 23348503). In 1 study, TERT promoter mutations were reported in all 11 urinary bladder small cell cancers analyzed (Zheng et al., 2014; 25042800). One study reported TERT promoter mutations in 67% (14/21) of high_grade and in 56% (34/61) of low_grade bladder carcinomas (Vinagre et al., 2013; 23887589). Another study reported that 85% (44/52) of all bladder cancer samples harbored a TERT promoter mutation (Liu et al., 2013; 23603989). For patients with bladder urothelial carcinoma, both TERT promoter mutations and increased TERT expression associate with poor prognosis, although carrying an additional germline alteration at _245 (rs2853669) may confer a better prognosis (Kinde et al., 2013; 24121487, Rachakonda et al., 2013; 24101484, Borah et al., 2015; 25722414). In urothelial cancer, the prognostic significance of TERT promoter mutation in clinical benefit from immune checkpoint inhibitors (ICI) is unclear; 1 study reported an association between TERT promoter mutations and improved median OS from ICIs (n=78) (Kouchkovsky et al., 2021; 33980590), but another study observed no such relationship (n=166)(Chawla et al., 2022; ASCO Abstract 561). Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor_associated antigen and antisense oligonucleotide_ or peptide_based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials (Zanetti et al., 2017; 27245281); however, in one preclinical study, the combination of a TERT peptide vaccine and anti_CTLA_4 therapy suppressed tumor growth (Duperret at al., 2018; 29249395). A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non_small cell lung cancer reported no improvement in PFS or OS (Chiappori et al., 2015; 25467017).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TP53', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'loss exons 8_9', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'loss exons 8_9'}}, 'Interpretation': 'Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutation was detected in 90% (55/61) of small cell carcinoma of the bladder in a study (Chang et al., 2018; 29180607). Similarly, in one genomic analysis of 132 bladder cancer specimens that harbored a small cell component, TP53 mutations were identified in 92% of samples (Hoffman_Censits et al., 2021; 32061548). TP53 mutation has been reported in 49–54% of bladder urothelial carcinoma (UC) (Ross et al., 2013; 23887298, Cancer Genome Atlas Research Network, 2014; 24476821), 33% of renal pelvis UC (Bringuier et al., 1998; 9761125), and 25% (22/71) of ureter UC samples (Furihata et al., 2000; 10675480). Expression of p53 has been correlated with TP53 mutation, and reported in 52–84% of bladder cancers (Esrig et al., 1993; 7901994, Cordon_Cardo et al., 1994; 7906253, Diaz_Cano et al., 2000; 10744064, Kapur et al., 2011; 21571954, Lotan et al., 2013; 23571005, Kim et al., 2014; 25092538), 48% (24/50) bladder SCCs (El_Kenawy et al., 2003; 14756544), 36–53% of upper urinary tract UCs (UTUC) (Joung et al., 2008; 18931548, Jinza et al., 1998; 9644783, Kamijima et al., 2005; 16351648), and in 4/4 urethral clear cell carcinomas (Alexiev et al., 2013; 23307189). TP53 mutations in both bladder and renal pelvis urothelial carcinoma (UC) are more common in invasive tumors (Bringuier et al., 1998; 9761125, Goebell and Knowles, 2010; 20610279, Lindgren et al., 2012; 22685613, Kim et al., 2014; 25092538), and have been associated with inferior survival in patients with renal pelvis UC (Bringuier et al., 1998; 9761125) or upper tract UC (UTUC) (Feng et al., 2014; 24500328). Alterations to the p53 pathway are correlated with aggressive disease and poor prognosis in bladder cancer (Eissa et al., 2010; 20012564, Mitra et al., 2007; 17710407, Lambrou et al., 2013; 23624844), and p53 overexpression has been linked to poor progression_free survival in UTUC (Lee et al., 2013; 23482786, Feng et al., 2014; 24500328), disease progression in UC of the renal pelvis and ureter (Hashimoto et al., 2000; 11168685), and higher tumor grade in bladder squamous cell carcinoma (Osman et al., 1997; 9815716, Helal et al., 2006; 16998598, Jalali et al., 2011; 22126554). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'FANCA', 'Alteration': 'A778fs*45', 'Title': 'A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy_based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum_Containing Chemotherapy', 'StudyPhase': 'PHASE 1/2', 'Target': 'CD38, PARP, CD47, PD_L1, Nectin_4, IL_6R', 'Locations': 'Taipei City (Taiwan), Huwei Township (Taiwan), Tainan (Taiwan), Kaohsiung City (Taiwan), Seoul (Korea, Republic of), Athens (Greece), London (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Caen (France)', 'NCTID': 'NCT03869190', 'Note': 'FANCA alterations may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCA', 'Alteration': 'A778fs*45', 'Title': 'Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP, PD_1', 'Locations': 'Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)', 'NCTID': 'NCT04123366', 'Note': 'FANCA alterations may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCA', 'Alteration': 'A778fs*45', 'Title': 'Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Darlinghurst (Australia), Adana (Turkey), Jerusalem (Israel), Konya (Turkey), Ramat Gan (Israel), Istanbul (Turkey), Antalya (Turkey), Brasov (Romania)', 'NCTID': 'NCT03742895', 'Note': 'FANCA alterations may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCA', 'Alteration': 'A778fs*45', 'Title': 'Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP, PD_L1', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)', 'NCTID': 'NCT02264678', 'Note': 'FANCA alterations may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCA', 'Alteration': 'A778fs*45', 'Title': 'Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)', 'StudyPhase': 'PHASE 1/2', 'Target': 'XPO1, PARP', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT05035745', 'Note': 'FANCA alterations may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCA', 'Alteration': 'A778fs*45', 'Title': 'Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, AKTs, PD_L1', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT03772561', 'Note': 'FANCA alterations may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCA', 'Alteration': 'A778fs*45', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'FANCA alterations may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCA', 'Alteration': 'A778fs*45', 'Title': 'Study of RP_3500 in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP', 'Locations': 'Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Illinois, Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee', 'NCTID': 'NCT04497116', 'Note': 'FANCA alterations may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCA', 'Alteration': 'A778fs*45', 'Title': 'Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO', 'Locations': 'Vancouver (Canada), Kelowna (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)', 'NCTID': 'NCT03297606', 'Note': 'FANCA alterations may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCA', 'Alteration': 'A778fs*45', 'Title': 'A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'PARP, Pol theta', 'Locations': 'London (United Kingdom), Oklahoma, Connecticut, New York, Pennsylvania, Tennessee, Texas, Florida', 'NCTID': 'NCT04991480', 'Note': 'FANCA alterations may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'E471G', 'Title': 'Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event', 'StudyPhase': 'PHASE 2', 'Target': 'EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT03239015', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'E471G', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'E471G', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'E471G', 'Title': 'A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'mTOR', 'Locations': 'Tianjin (China)', 'NCTID': 'NCT05125523', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'E471G', 'Title': 'Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO', 'Locations': 'Vancouver (Canada), Kelowna (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)', 'NCTID': 'NCT03297606', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'E471G', 'Title': 'Combination Chemotherapy and Bevacizumab With the NovoTTF_100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'VEGFA, mTOR', 'Locations': 'Texas', 'NCTID': 'NCT03203525', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'E471G', 'Title': 'COAST Therapy in Advanced Solid Tumors and Prostate Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'DDR2, ABL, SRC, KIT, mTOR', 'Locations': 'South Carolina', 'NCTID': 'NCT05036226', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'E471G', 'Title': 'A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'mTOR, EGFR, SRC, RET, VEGFRs', 'Locations': 'Texas', 'NCTID': 'NCT01582191', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '28', 'Title': 'KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'ADORA2A, CD73, PD_1', 'Locations': 'Taipei (Taiwan), Shatin, New Territories (Hong Kong), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Toronto (Canada), Missouri', 'NCTID': 'NCT04237649', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '28', 'Title': 'Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer', 'StudyPhase': 'PHASE 3', 'Target': 'PD_L1, CTLA_4', 'Locations': 'Taipei (Taiwan), Taoyuan (Taiwan), Xiamen (China), Hangzhou (China), Shanghai (China), Nanchang (China), Suzhou (China), Nanjing (China), Guangzhou (China), Beijing (China)', 'NCTID': 'NCT03682068', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '28', 'Title': 'Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin', 'StudyPhase': 'PHASE 3', 'Target': 'PD_L1, Nectin_4, CTLA_4', 'Locations': 'Taipei (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Busan (Korea, Republic of), Shatin (Hong Kong), Miyazaki_shi (Japan), Kumamoto_shi (Japan), Fukuoka_shi (Japan), Matsuyama_shi (Japan), Incheon (Korea, Republic of)', 'NCTID': 'NCT04960709', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '28', 'Title': 'Efficacy and Safety of Pembrolizumab (MK_3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle_invasive Bladder Cancer (MIBC) (MK_3475_992/KEYNOTE_992)', 'StudyPhase': 'PHASE 3', 'Target': 'PD_1', 'Locations': 'Taipei (Taiwan), Taichung (Taiwan), Tainan City (Taiwan), Nagasaki (Japan), Daejeon (Korea, Republic of), Seongnam_si (Korea, Republic of), Songpagu (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Takatsuki (Japan)', 'NCTID': 'NCT04241185', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '28', 'Title': 'Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK_3475) Versus Neoadjuvant Chemotherapy for Cisplatin_eligible Muscle Invasive Bladder Cancer (MIBC) (MK_3475_B15/ KEYNOTE_B15 / EV_304)', 'StudyPhase': 'PHASE 3', 'Target': 'PD_1, Nectin_4', 'Locations': 'Taipei (Taiwan), Taichung (Taiwan), Shanghai (China), Nantong (China), Nanjing (China), Guangzhou (China), Changsha (China), Nagasaki (Japan), Jeollanam_do (Korea, Republic of), Seoul (Korea, Republic of)', 'NCTID': 'NCT04700124', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '28', 'Title': 'A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy_based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum_Containing Chemotherapy', 'StudyPhase': 'PHASE 1/2', 'Target': 'CD38, PARP, CD47, PD_L1, Nectin_4, IL_6R', 'Locations': 'Taipei City (Taiwan), Huwei Township (Taiwan), Tainan (Taiwan), Kaohsiung City (Taiwan), Seoul (Korea, Republic of), Athens (Greece), London (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Caen (France)', 'NCTID': 'NCT03869190', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '28', 'Title': 'Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study', 'StudyPhase': 'PHASE 2', 'Target': 'TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha, RAFs, NRAS', 'Locations': 'Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Shanghai City (China), Shanghai (China), Shatin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi an (China), Tianjin (China)', 'NCTID': 'NCT04589845', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '28', 'Title': 'Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1, CCR4', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Busan (Korea, Republic of), Shatin (Hong Kong), High West (Hong Kong), Chungbuk (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Bangkok (Thailand), Nedlands (Australia)', 'NCTID': 'NCT03674567', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '28', 'Title': 'Study of BGB_A1217 in Combination With Tislelizumab in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, TIGIT', 'Locations': 'Taipei (Taiwan), Taoyuan (Taiwan), Hualien City (Taiwan), Taichung (Taiwan), Fujian (China), Hangzhou (China), Shanghai (China), Hefei (China), Guangdong (China), Changsha (China)', 'NCTID': 'NCT04047862', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '28', 'Title': 'Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM_NPC', 'StudyPhase': 'PHASE 1/2', 'Target': 'HDAC, PD_1', 'Locations': 'Taipei City (Taiwan), Taipei (Taiwan), Taoyuan City (Taiwan), Sha Tin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Kuching (Malaysia), Kuala Lumpur (Malaysia), Singapore (Singapore), Blacktown (Australia)', 'NCTID': 'NCT05166577', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '18094723', 'FullCitation': 'Welcker M, et al. Nat. Rev. Cancer (2008) pmid: 18094723', 'Include': 'true'}, {'number': '1', 'ReferenceId': '17909001', 'FullCitation': 'Akhoondi S, et al. Cancer Res. (2007) pmid: 17909001', 'Include': 'true'}, {'number': '2', 'ReferenceId': '24476821', 'FullCitation': 'Nature (2014) pmid: 24476821', 'Include': 'true'}, {'number': '3', 'ReferenceId': '25178641', 'FullCitation': 'Millis SZ, et al. Clin Genitourin Cancer (2015) pmid: 25178641', 'Include': 'true'}, {'number': '4', 'ReferenceId': '22548670', 'FullCitation': 'Tu K, et al. Hepatol. Res. (2012) pmid: 22548670', 'Include': 'true'}, {'number': '5', 'ReferenceId': '19739118', 'FullCitation': 'Iwatsuki M, et al. Int. J. Cancer (2010) pmid: 19739118', 'Include': 'true'}, {'number': '6', 'ReferenceId': '22576686', 'FullCitation': 'Yokobori T, et al. Int. J. Oncol. (2012) pmid: 22576686', 'Include': 'true'}, {'number': '7', 'ReferenceId': '19366810', 'FullCitation': 'Yokobori T, et al. Cancer Res. (2009) pmid: 19366810', 'Include': 'true'}, {'number': '8', 'ReferenceId': '24165483', 'FullCitation': 'Yokobori T, et al. Mol. Cancer Res. (2014) pmid: 24165483', 'Include': 'true'}, {'number': '9', 'ReferenceId': '14999283', 'FullCitation': 'Rajagopalan H, et al. Nature (2004) pmid: 14999283', 'Include': 'true'}, {'number': '10', 'ReferenceId': '23381582', 'FullCitation': 'Cheng Y, et al. J. Invest. Dermatol. (2013) pmid: 23381582', 'Include': 'true'}, {'number': '11', 'ReferenceId': '26954701', 'FullCitation': 'Xu Y, et al. Biomarkers (2016) pmid: 26954701', 'Include': 'true'}, {'number': '12', 'ReferenceId': '18787170', 'FullCitation': 'Mao JH, et al. Science (2008) pmid: 18787170', 'Include': 'true'}, {'number': '13', 'ReferenceId': '25749036', 'FullCitation': 'Yang H, et al. Oncotarget (2015) pmid: 25749036', 'Include': 'true'}, {'number': '14', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '15', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '16', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '17', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '18', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '19', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '20', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '21', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '22', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '23', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '24', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '25', 'ReferenceId': '26952546', 'FullCitation': 'Rosenberg JE, et al. Lancet (2016) pmid: 26952546', 'Include': 'true'}, {'number': '26', 'ReferenceId': '27939400', 'FullCitation': 'Balar AV, et al. Lancet (2017) pmid: 27939400', 'Include': 'true'}, {'number': '27', 'ReferenceId': '29268948', 'FullCitation': 'Powles T, et al. Lancet (2018) pmid: 29268948', 'Include': 'true'}, {'number': '28', 'ReferenceId': '29443960', 'FullCitation': 'Mariathasan S, et al. Nature (2018) pmid: 29443960', 'Include': 'true'}, {'number': '29', 'ReferenceId': '30150660', 'FullCitation': 'Miao D, et al. Nat. Genet. (2018) pmid: 30150660', 'Include': 'true'}, {'number': '30', 'ReferenceId': '30643254', 'FullCitation': 'Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254', 'Include': 'true'}, {'number': '31', 'ReferenceId': '32919526', 'FullCitation': 'Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526', 'Include': 'true'}, {'number': '32', 'ReferenceId': '24777035', 'FullCitation': 'Cazier JB, et al. Nat Commun (2014) pmid: 24777035', 'Include': 'true'}, {'number': '33', 'ReferenceId': '35323317', 'FullCitation': 'Curr Oncol (2022) pmid: 35323317', 'Include': 'true'}, {'number': '34', 'ReferenceId': '28835386', 'FullCitation': 'Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386', 'Include': 'true'}, {'number': '35', 'ReferenceId': '31405947', 'FullCitation': 'Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947', 'Include': 'true'}, {'number': '36', 'ReferenceId': '30309915', 'FullCitation': 'Cristescu R, et al. Science (2018) pmid: 30309915', 'Include': 'true'}, {'number': '37', 'ReferenceId': '30785829', 'FullCitation': 'Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829', 'Include': 'true'}, {'number': '38', 'ReferenceId': '29658845', 'FullCitation': 'Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845', 'Include': 'true'}, {'number': '39', 'ReferenceId': '29657128', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128', 'Include': 'true'}, {'number': '40', 'ReferenceId': '29731394', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394', 'Include': 'true'}, {'number': '41', 'ReferenceId': '33558721', 'FullCitation': 'Rozeman EA, et al. Nat Med (2021) pmid: 33558721', 'Include': 'true'}, {'number': '42', 'ReferenceId': '32916128', 'FullCitation': 'Sharma P, et al. Cancer Cell (2020) pmid: 32916128', 'Include': 'true'}, {'number': '43', 'ReferenceId': '20484397', 'FullCitation': 'N. Engl. J. Med. (2010) pmid: 20484397', 'Include': 'true'}, {'number': '44', 'ReferenceId': '19686080', 'FullCitation': 'Moldovan GL, et al. Annu. Rev. Genet. (2009) pmid: 19686080', 'Include': 'true'}, {'number': '45', 'ReferenceId': '25455269', 'FullCitation': 'Best Pract Res Clin Haematol () pmid: 25455269', 'Include': 'true'}, {'number': '46', 'ReferenceId': '23114602', 'FullCitation': 'Kee Y, et al. J. Clin. Invest. (2012) pmid: 23114602', 'Include': 'true'}, {'number': '47', 'ReferenceId': '18322251', 'FullCitation': 'Rosenberg PS, et al. Haematologica (2008) pmid: 18322251', 'Include': 'true'}, {'number': '48', 'ReferenceId': '24246701', 'FullCitation': 'Khincha PP, et al. Semin. Hematol. (2013) pmid: 24246701', 'Include': 'true'}, {'number': '49', 'ReferenceId': '23613520', 'FullCitation': 'Chandrasekharappa SC, et al. Blood (2013) pmid: 23613520', 'Include': 'true'}, {'number': '50', 'ReferenceId': '23898106', 'FullCitation': 'Selenti N, et al. Anticancer Res. (2013) pmid: 23898106', 'Include': 'true'}, {'number': '51', 'ReferenceId': '23067021', 'FullCitation': 'Park J, et al. Clin. Genet. (2013) pmid: 23067021', 'Include': 'true'}, {'number': '52', 'ReferenceId': '17221219', 'FullCitation': 'Chen CC, et al. J. Mol. Med. (2007) pmid: 17221219', 'Include': 'true'}, {'number': '53', 'ReferenceId': '12525534', 'FullCitation': 'Tischkowitz MD, et al. J. Med. Genet. (2003) pmid: 12525534', 'Include': 'true'}, {'number': '54', 'ReferenceId': '29702541', 'FullCitation': 'Li N, et al. J. Pediatr. Hematol. Oncol. (2018) pmid: 29702541', 'Include': 'true'}, {'number': '55', 'ReferenceId': '21273304', 'FullCitation': 'Castella M, et al. Blood (2011) pmid: 21273304', 'Include': 'true'}, {'number': '56', 'ReferenceId': '24349332', 'FullCitation': 'Qian L, et al. PLoS ONE (2013) pmid: 24349332', 'Include': 'true'}, {'number': '57', 'ReferenceId': '24170812', 'FullCitation': 'Benitez A, et al. Nucleic Acids Res. (2014) pmid: 24170812', 'Include': 'true'}, {'number': '58', 'ReferenceId': '10567393', 'FullCitation': 'Kruyt FA, et al. J. Biol. Chem. (1999) pmid: 10567393', 'Include': 'true'}, {'number': '59', 'ReferenceId': '12354784', 'FullCitation': 'Folias A, et al. Hum. Mol. Genet. (2002) pmid: 12354784', 'Include': 'true'}, {'number': '60', 'ReferenceId': '10332032', 'FullCitation': 'Lightfoot J, et al. Hum. Mol. Genet. (1999) pmid: 10332032', 'Include': 'true'}, {'number': '61', 'ReferenceId': '22343915', 'FullCitation': 'Ali AM, et al. Blood (2012) pmid: 22343915', 'Include': 'true'}, {'number': '62', 'ReferenceId': '22705371', 'FullCitation': 'Yan Z, et al. Mol. Cell (2012) pmid: 22705371', 'Include': 'true'}, {'number': '63', 'ReferenceId': '22396592', 'FullCitation': 'Leung JW, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22396592', 'Include': 'true'}, {'number': '64', 'ReferenceId': '17525332', 'FullCitation': 'Matsuoka S, et al. Science (2007) pmid: 17525332', 'Include': 'true'}, {'number': '65', 'ReferenceId': '19109555', 'FullCitation': 'Collins NB, et al. Blood (2009) pmid: 19109555', 'Include': 'true'}, {'number': '66', 'ReferenceId': '23370339', 'FullCitation': 'Shukla P, et al. Gene (2013) pmid: 23370339', 'Include': 'true'}, {'number': '67', 'ReferenceId': '11726552', 'FullCitation': 'Otsuki T, et al. Hum. Mol. Genet. (2001) pmid: 11726552', 'Include': 'true'}, {'number': '68', 'ReferenceId': '28481359', 'FullCitation': 'Zehir A, et al. Nat. Med. (2017) pmid: 28481359', 'Include': 'true'}, {'number': '69', 'ReferenceId': '35120664', 'FullCitation': 'Nguyen B, et al. Cell (2022) pmid: 35120664', 'Include': 'true'}, {'number': '70', 'ReferenceId': '21279724', 'FullCitation': 'Akbari MR, et al. Hum. Genet. (2011) pmid: 21279724', 'Include': 'true'}, {'number': '71', 'ReferenceId': '18056155', 'FullCitation': 'Haiman CA, et al. Hum. Mol. Genet. (2008) pmid: 18056155', 'Include': 'true'}, {'number': '72', 'ReferenceId': '19237606', 'FullCitation': 'Michiels S, et al. Carcinogenesis (2009) pmid: 19237606', 'Include': 'true'}, {'number': '73', 'ReferenceId': '19012493', 'FullCitation': 'Wang SS, et al. J. Infect. Dis. (2009) pmid: 19012493', 'Include': 'true'}, {'number': '74', 'ReferenceId': '25243787', 'FullCitation': 'Yin J, et al. J. Invest. Dermatol. (2015) pmid: 25243787', 'Include': 'true'}, {'number': '75', 'ReferenceId': '23965899', 'FullCitation': 'Dai W, et al. Clin. Cancer Res. (2013) pmid: 23965899', 'Include': 'true'}, {'number': '76', 'ReferenceId': '19536649', 'FullCitation': 'Barroso E, et al. Breast Cancer Res. Treat. (2009) pmid: 19536649', 'Include': 'true'}, {'number': '77', 'ReferenceId': '21543111', 'FullCitation': 'Juko_Pecirep I, et al. Gynecol. Oncol. (2011) pmid: 21543111', 'Include': 'true'}, {'number': '78', 'ReferenceId': '23825533', 'FullCitation': 'Ribeiro E, et al. PLoS ONE (2013) pmid: 23825533', 'Include': 'true'}, {'number': '79', 'ReferenceId': '21216588', 'FullCitation': 'Ganzinelli M, et al. Eur. J. Cancer (2011) pmid: 21216588', 'Include': 'true'}, {'number': '80', 'ReferenceId': '18810378', 'FullCitation': 'Bauer VL, et al. J. Mol. Med. (2008) pmid: 18810378', 'Include': 'true'}, {'number': '81', 'ReferenceId': '21135251', 'FullCitation': 'Villarroel MC, et al. Mol. Cancer Ther. (2011) pmid: 21135251', 'Include': 'true'}, {'number': '82', 'ReferenceId': '24240112', 'FullCitation': 'Pennington KP, et al. Clin. Cancer Res. (2014) pmid: 24240112', 'Include': 'true'}, {'number': '83', 'ReferenceId': '20807115', 'FullCitation': 'Wang LC, et al. Crit. Rev. Biochem. Mol. Biol. (2010) pmid: 20807115', 'Include': 'true'}, {'number': '84', 'ReferenceId': '24200853', 'FullCitation': 'Ghosh S, et al. Am. J. Pathol. (2014) pmid: 24200853', 'Include': 'true'}, {'number': '85', 'ReferenceId': '31806540', 'FullCitation': 'Mateo J, et al. Lancet Oncol. (2019) pmid: 31806540', 'Include': 'true'}, {'number': '86', 'ReferenceId': '3208634', 'FullCitation': 'Anderson BJ, et al. Diabetes Educ () pmid: 3208634', 'Include': 'true'}, {'number': '87', 'ReferenceId': '26510020', 'FullCitation': 'Mateo J, et al. N. Engl. J. Med. (2015) pmid: 26510020', 'Include': 'true'}, {'number': '88', 'ReferenceId': '27908594', 'FullCitation': 'Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594', 'Include': 'true'}, {'number': '89', 'ReferenceId': '19935675', 'FullCitation': 'Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675', 'Include': 'true'}, {'number': '90', 'ReferenceId': '18410249', 'FullCitation': 'Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249', 'Include': 'true'}, {'number': '91', 'ReferenceId': '12826609', 'FullCitation': 'Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609', 'Include': 'true'}, {'number': '92', 'ReferenceId': '20978130', 'FullCitation': 'Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130', 'Include': 'true'}, {'number': '93', 'ReferenceId': '28472496', 'FullCitation': 'Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496', 'Include': 'true'}, {'number': '94', 'ReferenceId': '17690113', 'FullCitation': 'Yamada H, et al. Carcinogenesis (2007) pmid: 17690113', 'Include': 'true'}, {'number': '95', 'ReferenceId': '29180607', 'FullCitation': 'Chang MT, et al. Clin Cancer Res (2018) pmid: 29180607', 'Include': 'true'}, {'number': '96', 'ReferenceId': '32061548', 'FullCitation': 'Hoffman_Censits J, et al. (2020) pmid: 32061548', 'Include': 'true'}, {'number': '97', 'ReferenceId': '23887298', 'FullCitation': 'Ross JS, et al. Mod. Pathol. (2014) pmid: 23887298', 'Include': 'true'}, {'number': '98', 'ReferenceId': '9761125', 'FullCitation': 'Bringuier PP, et al. Int. J. Cancer (1998) pmid: 9761125', 'Include': 'true'}, {'number': '99', 'ReferenceId': '10675480', 'FullCitation': 'Furihata M, et al. Int. J. Oncol. (2000) pmid: 10675480', 'Include': 'true'}, {'number': '100', 'ReferenceId': '7901994', 'FullCitation': 'Esrig D, et al. Am. J. Pathol. (1993) pmid: 7901994', 'Include': 'true'}, {'number': '101', 'ReferenceId': '7906253', 'FullCitation': 'Cordon_Cardo C, et al. Int. J. Cancer (1994) pmid: 7906253', 'Include': 'true'}, {'number': '102', 'ReferenceId': '10744064', 'FullCitation': 'Diaz_Cano SJ, et al. Lab. Invest. (2000) pmid: 10744064', 'Include': 'true'}, {'number': '103', 'ReferenceId': '21571954', 'FullCitation': 'Kapur P, et al. Am. J. Clin. Pathol. (2011) pmid: 21571954', 'Include': 'true'}, {'number': '104', 'ReferenceId': '23571005', 'FullCitation': 'Lotan Y, et al. Eur. Urol. (2013) pmid: 23571005', 'Include': 'true'}, {'number': '105', 'ReferenceId': '25092538', 'FullCitation': 'Kim PH, et al. Eur. Urol. (2015) pmid: 25092538', 'Include': 'true'}, {'number': '106', 'ReferenceId': '14756544', 'FullCitation': 'El_Kenawy Ael_M, et al. Int. J. Biol. Markers () pmid: 14756544', 'Include': 'true'}, {'number': '107', 'ReferenceId': '18931548', 'FullCitation': 'Joung JY, et al. Urol. Int. (2008) pmid: 18931548', 'Include': 'true'}, {'number': '108', 'ReferenceId': '9644783', 'FullCitation': 'Jinza S, et al. Urol. Int. (1998) pmid: 9644783', 'Include': 'true'}, {'number': '109', 'ReferenceId': '16351648', 'FullCitation': 'Kamijima S, et al. Int. J. Urol. (2005) pmid: 16351648', 'Include': 'true'}, {'number': '110', 'ReferenceId': '23307189', 'FullCitation': 'Alexiev BA, et al. Virchows Arch. (2013) pmid: 23307189', 'Include': 'true'}, {'number': '111', 'ReferenceId': '20610279', 'FullCitation': 'Goebell PJ, et al. Urol. Oncol. () pmid: 20610279', 'Include': 'true'}, {'number': '112', 'ReferenceId': '22685613', 'FullCitation': 'Lindgren D, et al. PLoS ONE (2012) pmid: 22685613', 'Include': 'true'}, {'number': '113', 'ReferenceId': '24500328', 'FullCitation': 'Feng C, et al. Sci Rep (2014) pmid: 24500328', 'Include': 'true'}, {'number': '114', 'ReferenceId': '20012564', 'FullCitation': 'Eissa S, et al. Med. Oncol. (2010) pmid: 20012564', 'Include': 'true'}, {'number': '115', 'ReferenceId': '17710407', 'FullCitation': 'Mitra AP, et al. World J Urol (2007) pmid: 17710407', 'Include': 'true'}, {'number': '116', 'ReferenceId': '23624844', 'FullCitation': 'Lambrou GI, et al. Cell Cycle (2013) pmid: 23624844', 'Include': 'true'}, {'number': '117', 'ReferenceId': '23482786', 'FullCitation': 'Lee YC, et al. Anticancer Res. (2013) pmid: 23482786', 'Include': 'true'}, {'number': '118', 'ReferenceId': '11168685', 'FullCitation': 'Hashimoto H, et al. Int. J. Urol. (2000) pmid: 11168685', 'Include': 'true'}, {'number': '119', 'ReferenceId': '9815716', 'FullCitation': 'Osman I, et al. Clin. Cancer Res. (1997) pmid: 9815716', 'Include': 'true'}, {'number': '120', 'ReferenceId': '16998598', 'FullCitation': 'Helal Tel A, et al. Pathol. Oncol. Res. (2006) pmid: 16998598', 'Include': 'true'}, {'number': '121', 'ReferenceId': '22126554', 'FullCitation': 'Jalali MM, et al. Asian Pac. J. Cancer Prev. (2011) pmid: 22126554', 'Include': 'true'}, {'number': '122', 'ReferenceId': '20107315', 'FullCitation': 'Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315', 'Include': 'true'}, {'number': '123', 'ReferenceId': '21799033', 'FullCitation': 'Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033', 'Include': 'true'}, {'number': '124', 'ReferenceId': '21389100', 'FullCitation': 'Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100', 'Include': 'true'}, {'number': '125', 'ReferenceId': '25504633', 'FullCitation': 'Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633', 'Include': 'true'}, {'number': '126', 'ReferenceId': '12489850', 'FullCitation': 'Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850', 'Include': 'true'}, {'number': '127', 'ReferenceId': '11713371', 'FullCitation': 'Xu L, et al. Mol. Med. (2001) pmid: 11713371', 'Include': 'true'}, {'number': '128', 'ReferenceId': '23470564', 'FullCitation': 'Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564', 'Include': 'true'}, {'number': '129', 'ReferenceId': '25240597', 'FullCitation': 'Kim SS, et al. Nanomedicine (2015) pmid: 25240597', 'Include': 'true'}, {'number': '130', 'ReferenceId': '27357628', 'FullCitation': 'Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628', 'Include': 'true'}, {'number': '131', 'ReferenceId': '27601554', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554', 'Include': 'true'}, {'number': '132', 'ReferenceId': '27998224', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224', 'Include': 'true'}, {'number': '133', 'ReferenceId': '31315834', 'FullCitation': 'Lee J, et al. Cancer Discov (2019) pmid: 31315834', 'Include': 'true'}, {'number': '134', 'ReferenceId': '29535125', 'FullCitation': 'Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125', 'Include': 'true'}, {'number': '135', 'ReferenceId': '34538072', 'FullCitation': 'Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072', 'Include': 'true'}, {'number': '136', 'ReferenceId': '26014290', 'FullCitation': 'Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290', 'Include': 'true'}, {'number': '137', 'ReferenceId': '23355100', 'FullCitation': 'Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100', 'Include': 'true'}, {'number': '138', 'ReferenceId': '11219776', 'FullCitation': 'Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776', 'Include': 'true'}, {'number': '139', 'ReferenceId': '9006316', 'FullCitation': 'Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316', 'Include': 'true'}, {'number': '140', 'ReferenceId': '19204208', 'FullCitation': 'Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208', 'Include': 'true'}, {'number': '141', 'ReferenceId': '12672316', 'FullCitation': 'Lalloo F, et al. Lancet (2003) pmid: 12672316', 'Include': 'true'}, {'number': '142', 'ReferenceId': '31050713', 'FullCitation': 'Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713', 'Include': 'true'}, {'number': '143', 'ReferenceId': '10699051', 'FullCitation': 'Petrij F, et al. J. Med. Genet. (2000) pmid: 10699051', 'Include': 'true'}, {'number': '144', 'ReferenceId': '8782817', 'FullCitation': 'Borrow J, et al. Nat. Genet. (1996) pmid: 8782817', 'Include': 'true'}, {'number': '145', 'ReferenceId': '27537276', 'FullCitation': 'Kao YC, et al. Genes Chromosomes Cancer (2017) pmid: 27537276', 'Include': 'true'}, {'number': '146', 'ReferenceId': '31932680', 'FullCitation': 'Hofvander J, et al. Mod. Pathol. (2020) pmid: 31932680', 'Include': 'true'}, {'number': '147', 'ReferenceId': '30371878', 'FullCitation': 'Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878', 'Include': 'true'}, {'number': '148', 'ReferenceId': '25735316', 'FullCitation': 'Grasso CS, et al. Ann. Oncol. (2015) pmid: 25735316', 'Include': 'true'}, {'number': '149', 'ReferenceId': '25790293', 'FullCitation': 'Ma X, et al. Nat Commun (2015) pmid: 25790293', 'Include': 'true'}, {'number': '150', 'ReferenceId': '25713363', 'FullCitation': 'Green MR, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25713363', 'Include': 'true'}, {'number': '151', 'ReferenceId': '25027518', 'FullCitation': 'Loeffler M, et al. Leukemia (2015) pmid: 25027518', 'Include': 'true'}, {'number': '152', 'ReferenceId': '18528428', 'FullCitation': 'Gervais C, et al. Leukemia (2008) pmid: 18528428', 'Include': 'true'}, {'number': '153', 'ReferenceId': '19194466', 'FullCitation': 'Haferlach T, et al. Leukemia (2009) pmid: 19194466', 'Include': 'true'}, {'number': '154', 'ReferenceId': '25671298', 'FullCitation': 'Mensah AA, et al. Oncotarget (2015) pmid: 25671298', 'Include': 'true'}, {'number': '155', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '156', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '157', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '158', 'ReferenceId': '9823339', 'FullCitation': 'Boland CR, et al. Cancer Res. (1998) pmid: 9823339', 'Include': 'true'}, {'number': '159', 'ReferenceId': '15528785', 'FullCitation': 'Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785', 'Include': 'true'}, {'number': '160', 'ReferenceId': '20420947', 'FullCitation': 'Boland CR, et al. Gastroenterology (2010) pmid: 20420947', 'Include': 'true'}, {'number': '161', 'ReferenceId': '18254781', 'FullCitation': 'Mylona E, et al. APMIS (2008) pmid: 18254781', 'Include': 'true'}, {'number': '162', 'ReferenceId': '14501713', 'FullCitation': 'Amira N, et al. J. Urol. (2003) pmid: 14501713', 'Include': 'true'}, {'number': '163', 'ReferenceId': '23690119', 'FullCitation': 'Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119', 'Include': 'true'}, {'number': '164', 'ReferenceId': '25392179', 'FullCitation': 'Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179', 'Include': 'true'}, {'number': '165', 'ReferenceId': '26140250', 'FullCitation': 'Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250', 'Include': 'true'}, {'number': '166', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '167', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '168', 'ReferenceId': '24856830', 'FullCitation': 'Solomon DA, et al. BMB Rep (2014) pmid: 24856830', 'Include': 'true'}, {'number': '169', 'ReferenceId': '24132290', 'FullCitation': 'Kandoth C, et al. Nature (2013) pmid: 24132290', 'Include': 'true'}, {'number': '170', 'ReferenceId': '24484537', 'FullCitation': 'Evers L, et al. Genome Med (2014) pmid: 24484537', 'Include': 'true'}, {'number': '171', 'ReferenceId': '24121792', 'FullCitation': 'Guo G, et al. Nat. Genet. (2013) pmid: 24121792', 'Include': 'true'}, {'number': '172', 'ReferenceId': '24121789', 'FullCitation': 'Solomon DA, et al. Nat. Genet. (2013) pmid: 24121789', 'Include': 'true'}, {'number': '173', 'ReferenceId': '21852505', 'FullCitation': 'Solomon DA, et al. Science (2011) pmid: 21852505', 'Include': 'true'}, {'number': '174', 'ReferenceId': '25006131', 'FullCitation': 'Thota S, et al. Blood (2014) pmid: 25006131', 'Include': 'true'}, {'number': '175', 'ReferenceId': '24121791', 'FullCitation': 'Balbás_Martínez C, et al. Nat. Genet. (2013) pmid: 24121791', 'Include': 'true'}, {'number': '176', 'ReferenceId': '23955599', 'FullCitation': 'Kon A, et al. Nat. Genet. (2013) pmid: 23955599', 'Include': 'true'}, {'number': '177', 'ReferenceId': '24270882', 'FullCitation': 'Taylor CF, et al. Hum. Mol. Genet. (2014) pmid: 24270882', 'Include': 'true'}, {'number': '178', 'ReferenceId': '25223734', 'FullCitation': 'Tirode F, et al. Cancer Discov (2014) pmid: 25223734', 'Include': 'true'}, {'number': '179', 'ReferenceId': '25010205', 'FullCitation': 'Brohl AS, et al. PLoS Genet. (2014) pmid: 25010205', 'Include': 'true'}, {'number': '180', 'ReferenceId': '23926200', 'FullCitation': 'Hoang ML, et al. Sci Transl Med (2013) pmid: 23926200', 'Include': 'true'}, {'number': '181', 'ReferenceId': '27500726', 'FullCitation': 'Shen CH, et al. Nat. Med. (2016) pmid: 27500726', 'Include': 'true'}, {'number': '182', 'ReferenceId': '24356817', 'FullCitation': 'Bailey ML, et al. Mol. Cancer Ther. (2014) pmid: 24356817', 'Include': 'true'}, {'number': '183', 'ReferenceId': '19330029', 'FullCitation': 'van Haaften G, et al. Nat. Genet. (2009) pmid: 19330029', 'Include': 'true'}, {'number': '184', 'ReferenceId': '22722829', 'FullCitation': 'Robinson G, et al. Nature (2012) pmid: 22722829', 'Include': 'true'}, {'number': '185', 'ReferenceId': '23685749', 'FullCitation': 'Ho AS, et al. Nat. Genet. (2013) pmid: 23685749', 'Include': 'true'}, {'number': '186', 'ReferenceId': '22722839', 'FullCitation': 'Grasso CS, et al. Nature (2012) pmid: 22722839', 'Include': 'true'}, {'number': '187', 'ReferenceId': '25320243', 'FullCitation': 'Van der Meulen J, et al. Blood (2015) pmid: 25320243', 'Include': 'true'}, {'number': '188', 'ReferenceId': '23792809', 'FullCitation': 'Wang L, et al. Nat Commun (2013) pmid: 23792809', 'Include': 'true'}, {'number': '189', 'ReferenceId': '24491801', 'FullCitation': 'Kim JH, et al. Cancer Res. (2014) pmid: 24491801', 'Include': 'true'}, {'number': '190', 'ReferenceId': '23057811', 'FullCitation': 'Shen Y, et al. BMC Cancer (2012) pmid: 23057811', 'Include': 'true'}, {'number': '191', 'ReferenceId': '22015685', 'FullCitation': 'Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685', 'Include': 'true'}, {'number': '192', 'ReferenceId': '9282118', 'FullCitation': 'Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118', 'Include': 'true'}, {'number': '193', 'ReferenceId': '7605428', 'FullCitation': 'Kim NW, et al. Science (1994) pmid: 7605428', 'Include': 'true'}, {'number': '194', 'ReferenceId': '10647931', 'FullCitation': 'Hanahan D, et al. Cell (2000) pmid: 10647931', 'Include': 'true'}, {'number': '195', 'ReferenceId': '23348503', 'FullCitation': 'Horn S, et al. Science (2013) pmid: 23348503', 'Include': 'true'}, {'number': '196', 'ReferenceId': '23348506', 'FullCitation': 'Huang FW, et al. Science (2013) pmid: 23348506', 'Include': 'true'}, {'number': '197', 'ReferenceId': '23887589', 'FullCitation': 'Vinagre J, et al. Nat Commun (2013) pmid: 23887589', 'Include': 'true'}, {'number': '198', 'ReferenceId': '25042800', 'FullCitation': 'Zheng X, et al. J Hematol Oncol (2014) pmid: 25042800', 'Include': 'true'}, {'number': '199', 'ReferenceId': '23603989', 'FullCitation': 'Liu X, et al. Cell Cycle (2013) pmid: 23603989', 'Include': 'true'}, {'number': '200', 'ReferenceId': '24121487', 'FullCitation': 'Kinde I, et al. Cancer Res. (2013) pmid: 24121487', 'Include': 'true'}, {'number': '201', 'ReferenceId': '24101484', 'FullCitation': 'Rachakonda PS, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 24101484', 'Include': 'true'}, {'number': '202', 'ReferenceId': '25722414', 'FullCitation': 'Borah S, et al. Science (2015) pmid: 25722414', 'Include': 'true'}, {'number': '203', 'ReferenceId': '33980590', 'FullCitation': 'de Kouchkovsky I, et al. J Immunother Cancer (2021) pmid: 33980590', 'Include': 'true'}, {'number': '204', 'ReferenceId': '27245281', 'FullCitation': 'Nat Rev Clin Oncol (2017) pmid: 27245281', 'Include': 'true'}, {'number': '205', 'ReferenceId': '29249395', 'FullCitation': 'Duperret EK, et al. Mol Ther (2018) pmid: 29249395', 'Include': 'true'}, {'number': '206', 'ReferenceId': '25467017', 'FullCitation': 'Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017', 'Include': 'true'}, {'number': '207', 'ReferenceId': '18650841', 'FullCitation': 'Burkhart DL, et al. Nat. Rev. Cancer (2008) pmid: 18650841', 'Include': 'true'}, {'number': '208', 'ReferenceId': '19143056', 'FullCitation': 'Knudsen ES, et al. Nat. Rev. Cancer (2008) pmid: 19143056', 'Include': 'true'}, {'number': '209', 'ReferenceId': '20594292', 'FullCitation': 'Berge EO, et al. Mol. Cancer (2010) pmid: 20594292', 'Include': 'true'}, {'number': '210', 'ReferenceId': '16936740', 'FullCitation': 'Giacinti C, et al. Oncogene (2006) pmid: 16936740', 'Include': 'true'}, {'number': '211', 'ReferenceId': '9342358', 'FullCitation': 'Otterson GA, et al. Proc. Natl. Acad. Sci. U.S.A. (1997) pmid: 9342358', 'Include': 'true'}, {'number': '212', 'ReferenceId': '10486322', 'FullCitation': 'Otterson GA, et al. Am. J. Hum. Genet. (1999) pmid: 10486322', 'Include': 'true'}, {'number': '213', 'ReferenceId': '1534305', 'FullCitation': 'Qin XQ, et al. Genes Dev. (1992) pmid: 1534305', 'Include': 'true'}, {'number': '214', 'ReferenceId': '16360038', 'FullCitation': 'Rubin SM, et al. Cell (2005) pmid: 16360038', 'Include': 'true'}, {'number': '215', 'ReferenceId': '16449662', 'FullCitation': 'Sun H, et al. Mol. Cell. Biol. (2006) pmid: 16449662', 'Include': 'true'}, {'number': '216', 'ReferenceId': '31278255', 'FullCitation': 'Robinson BD, et al. Nat Commun (2019) pmid: 31278255', 'Include': 'true'}, {'number': '217', 'ReferenceId': '33397444', 'FullCitation': 'Su X, et al. Genome Biol (2021) pmid: 33397444', 'Include': 'true'}, {'number': '218', 'ReferenceId': '26278805', 'FullCitation': 'Sfakianos JP, et al. Eur. Urol. (2015) pmid: 26278805', 'Include': 'true'}, {'number': '219', 'ReferenceId': '1913692', 'FullCitation': 'Ishikawa J, et al. Cancer Res. (1991) pmid: 1913692', 'Include': 'true'}, {'number': '220', 'ReferenceId': '1640485', 'FullCitation': 'Logothetis CJ, et al. J. Natl. Cancer Inst. (1992) pmid: 1640485', 'Include': 'true'}, {'number': '221', 'ReferenceId': '1640484', 'FullCitation': 'Cordon_Cardo C, et al. J. Natl. Cancer Inst. (1992) pmid: 1640484', 'Include': 'true'}, {'number': '222', 'ReferenceId': '22222631', 'FullCitation': 'Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631', 'Include': 'true'}, {'number': '223', 'ReferenceId': '30373917', 'FullCitation': 'Gong X, et al. Cancer Discov (2019) pmid: 30373917', 'Include': 'true'}, {'number': '224', 'ReferenceId': '30373918', 'FullCitation': 'Oser MG, et al. Cancer Discov (2019) pmid: 30373918', 'Include': 'true'}, {'number': '225', 'ReferenceId': '34741392', 'FullCitation': 'Yang W, et al. Kaohsiung J Med Sci (2022) pmid: 34741392', 'Include': 'true'}, {'number': '226', 'ReferenceId': '30232224', 'FullCitation': 'Beltran H, et al. Clin. Cancer Res. (2019) pmid: 30232224', 'Include': 'true'}, {'number': '227', 'ReferenceId': '21955141', 'FullCitation': 'Allaman_Pillet N, et al. Ophthalmic Genet. () pmid: 21955141', 'Include': 'true'}, {'number': '228', 'ReferenceId': '21875955', 'FullCitation': 'Viatour P, et al. J. Exp. Med. (2011) pmid: 21875955', 'Include': 'true'}, {'number': '229', 'ReferenceId': '18381962', 'FullCitation': 'Derenzini M, et al. Clin. Cancer Res. (2008) pmid: 18381962', 'Include': 'true'}, {'number': '230', 'ReferenceId': '24282159', 'FullCitation': 'Chen Z, et al. Hum. Mutat. (2014) pmid: 24282159', 'Include': 'true'}, {'number': '231', 'ReferenceId': '22553621', 'FullCitation': 'Yun J, et al. Int J Ophthalmol (2011) pmid: 22553621', 'Include': 'true'}, {'number': '232', 'ReferenceId': '21139478', 'FullCitation': 'Houston SK, et al. Int Ophthalmol Clin (2011) pmid: 21139478', 'Include': 'true'}, {'number': '233', 'ReferenceId': '19959033', 'FullCitation': 'Ng AK, et al. Semin Radiat Oncol (2010) pmid: 19959033', 'Include': 'true'}, {'number': '234', 'ReferenceId': '29863979', 'FullCitation': 'Migden MR, et al. N. Engl. J. Med. (2018) pmid: 29863979', 'Include': 'true'}, {'number': '235', 'ReferenceId': '32945632', 'FullCitation': 'Powles T, et al. N Engl J Med (2020) pmid: 32945632', 'Include': 'true'}, {'number': '236', 'ReferenceId': '34893775', 'FullCitation': 'Powles T, et al. Nat Med (2021) pmid: 34893775', 'Include': 'true'}, {'number': '237', 'ReferenceId': '33001143', 'FullCitation': 'Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143', 'Include': 'true'}, {'number': '238', 'ReferenceId': '31100038', 'FullCitation': 'Sharma P, et al. J. Clin. Oncol. (2019) pmid: 31100038', 'Include': 'true'}, {'number': '239', 'ReferenceId': '28131785', 'FullCitation': 'Sharma P, et al. Lancet Oncol. (2017) pmid: 28131785', 'Include': 'true'}, {'number': '240', 'ReferenceId': '34077643', 'FullCitation': 'Bajorin DF, et al. N Engl J Med (2021) pmid: 34077643', 'Include': 'true'}, {'number': '241', 'ReferenceId': '28212060', 'FullCitation': 'Bellmunt J, et al. N. Engl. J. Med. (2017) pmid: 28212060', 'Include': 'true'}, {'number': '242', 'ReferenceId': '36494006', 'FullCitation': 'Balar AV, et al. Ann Oncol (2022) pmid: 36494006', 'Include': 'true'}, {'number': '243', 'ReferenceId': '34051178', 'FullCitation': 'Powles T, et al. Lancet Oncol (2021) pmid: 34051178', 'Include': 'true'}, {'number': '244', 'ReferenceId': '30343614', 'FullCitation': 'Necchi A, et al. J Clin Oncol (2018) pmid: 30343614', 'Include': 'true'}, {'number': '245', 'ReferenceId': '32516377', 'FullCitation': 'Bandini M, et al. J. Natl. Cancer Inst. (2020) pmid: 32516377', 'Include': 'true'}, {'number': '246', 'ReferenceId': '33902955', 'FullCitation': 'van der Heijden MS, et al. Eur Urol (2021) pmid: 33902955', 'Include': 'true'}, {'number': '247', 'ReferenceId': '32416780', 'FullCitation': 'Galsky MD, et al. Lancet (2020) pmid: 32416780', 'Include': 'true'}, {'number': '248', 'ReferenceId': '35089812', 'FullCitation': 'Funt SA, et al. J Clin Oncol (2022) pmid: 35089812', 'Include': 'true'}, {'number': '249', 'ReferenceId': '33046870', 'FullCitation': 'van Dijk N, et al. Nat Med (2020) pmid: 33046870', 'Include': 'true'}, {'number': '250', 'ReferenceId': '32971005', 'FullCitation': 'Powles T, et al. Lancet Oncol (2020) pmid: 32971005', 'Include': 'true'}, {'number': '251', 'ReferenceId': '34006499', 'FullCitation': 'Marandino L, et al. Clin Genitourin Cancer (2021) pmid: 34006499', 'Include': 'true'}, {'number': '252', 'ReferenceId': '33941921', 'FullCitation': 'Powles T, et al. Nat Med (2021) pmid: 33941921', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2023_02_27 23:05:26', 'OpName': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': '924x'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': '28 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': 'Units Not Reported'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'BLADDER', 'disease_ontology': 'Bladder carcinoma (NOS)', 'flowcell_analysis': '2000027767', 'gender': 'male', 'pathology_diagnosis': 'Urinary Bladder Cancer, C67', 'percent_tumor_nuclei': '20', 'pipeline_version': 'v3.19.0', 'purity_assessment': '59.0', 'specimen': 'ORD_1570859_01*US1501620.01', 'study': 'CLINICAL_F1CDx v2', 'test_request': 'ORD_1570859_01', 'test_type': 'FoundationOneDx', 'tissue_of_origin': 'Bone', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'DX2', 'mean_exon_depth': '945.75', 'name': 'SQ_US1501620.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Qualified'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.2206', 'cds_effect': '198G>T', 'depth': '843', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CD79A', 'percent_reads': '22.06', 'position': 'chr19:42383178', 'protein_effect': 'W66C', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001783', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.1811', 'cds_effect': '559G>A', 'depth': '486', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'LTK', 'percent_reads': '18.11', 'position': 'chr15:41804113', 'protein_effect': 'E187K', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002344', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.2073', 'cds_effect': '1727C>G', 'depth': '791', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'RB1', 'percent_reads': '20.73', 'position': 'chr13:49027160', 'protein_effect': 'S576*', 'status': 'likely', 'strand': '+', 'transcript': 'NM_000321', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.1227', 'cds_effect': '595G>A', 'depth': '921', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MST1R', 'percent_reads': '12.27', 'position': 'chr3:49940448', 'protein_effect': 'V199M', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002447', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.3339', 'cds_effect': '3125C>T', 'depth': '1198', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RICTOR', 'percent_reads': '33.39', 'position': 'chr5:38952300', 'protein_effect': 'S1042L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_152756', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.3721', 'cds_effect': '4071_4072insGATT', 'depth': '516', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'MSH6', 'percent_reads': '37.21', 'position': 'chr2:48033987', 'protein_effect': 'K1358fs*2', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000179', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.2248', 'cds_effect': '517G>A', 'depth': '1130', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'JAK2', 'percent_reads': '22.48', 'position': 'chr9:5050734', 'protein_effect': 'E173K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_004972', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.1469', 'cds_effect': '2332delG', 'depth': '565', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'FANCA', 'percent_reads': '14.69', 'position': 'chr16:89836416', 'protein_effect': 'A778fs*45', 'status': 'likely', 'strand': '_', 'transcript': 'NM_000135', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.6063', 'cds_effect': '1272C>G', 'depth': '762', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MERTK', 'percent_reads': '60.63', 'position': 'chr2:112740546', 'protein_effect': 'H424Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006343', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.1122', 'cds_effect': '6992A>T', 'depth': '624', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATR', 'percent_reads': '11.22', 'position': 'chr3:142183988', 'protein_effect': 'D2331V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001184', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.0966', 'cds_effect': '2158_2159GG>TT', 'depth': '735', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SMO', 'percent_reads': '9.66', 'position': 'chr7:128852086', 'protein_effect': 'G720L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005631', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.3819', 'cds_effect': '3674C>T', 'depth': '796', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MSH6', 'percent_reads': '38.19', 'position': 'chr2:48033370', 'protein_effect': 'T1225M', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000179', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.0512', 'cds_effect': '196G>A', 'depth': '684', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CCND1', 'percent_reads': '5.12', 'position': 'chr11:69456277', 'protein_effect': 'E66K', 'status': 'unknown', 'strand': '+', 'subclonal': 'false', 'transcript': 'NM_053056', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.0597', 'cds_effect': '640C>T', 'depth': '519', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'JAK3', 'percent_reads': '5.97', 'position': 'chr19:17953346', 'protein_effect': 'R214W', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000215', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.5766', 'cds_effect': '284G>A', 'depth': '888', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '57.66', 'position': 'chr2:212812292', 'protein_effect': 'R95H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.4764', 'cds_effect': '_124C>T', 'depth': '296', 'equivocal': 'false', 'functional_effect': 'promoter', 'gene': 'TERT', 'percent_reads': '47.64', 'position': 'chr5:1295228', 'protein_effect': 'promoter _124C>T', 'status': 'known', 'strand': '_', 'transcript': 'NM_198253', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.2917', 'cds_effect': '3G>A', 'depth': '360', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'STAG2', 'percent_reads': '29.17', 'position': 'chrX:123156480', 'protein_effect': 'M1I', 'status': 'likely', 'strand': '+', 'transcript': 'NM_006603', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.1328', 'cds_effect': '368C>T', 'depth': '851', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TEK', 'percent_reads': '13.28', 'position': 'chr9:27168496', 'protein_effect': 'S123F', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000459', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.3757', 'cds_effect': '1412A>G', 'depth': '889', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FBXW7', 'percent_reads': '37.57', 'position': 'chr4:153249366', 'protein_effect': 'E471G', 'status': 'known', 'strand': '_', 'transcript': 'NM_033632', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.1164', 'cds_effect': '1547_1592del46', 'depth': '627', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'KDM6A', 'percent_reads': '11.64', 'position': 'chrX:44922685', 'protein_effect': 'A516fs*17', 'status': 'likely', 'strand': '+', 'transcript': 'NM_021140', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.5088', 'cds_effect': '682G>A', 'depth': '627', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRD4', 'percent_reads': '50.88', 'position': 'chr19:15376332', 'protein_effect': 'V228I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_014299', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.4612', 'cds_effect': '2246G>C', 'depth': '889', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RET', 'percent_reads': '46.12', 'position': 'chr10:43612141', 'protein_effect': 'R749T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_020975', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.2447', 'cds_effect': '2492A>G', 'depth': '1185', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SNCAIP', 'percent_reads': '24.47', 'position': 'chr5:121787034', 'protein_effect': 'E831G', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005460', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.367', 'cds_effect': '310C>T', 'depth': '989', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'CREBBP', 'percent_reads': '36.7', 'position': 'chr16:3900786', 'protein_effect': 'Q104*', 'status': 'known', 'strand': '_', 'transcript': 'NM_004380', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.5253', 'cds_effect': '824A>C', 'depth': '809', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NTRK1', 'percent_reads': '52.53', 'position': 'chr1:156841521', 'protein_effect': 'E275A', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002529', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.1039', 'cds_effect': '1411T>A', 'depth': '635', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EPHB1', 'percent_reads': '10.39', 'position': 'chr3:134873107', 'protein_effect': 'Y471N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_004441', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.6153', 'cds_effect': '353C>A', 'depth': '850', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MSH6', 'percent_reads': '61.53', 'position': 'chr2:48018158', 'protein_effect': 'T118K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000179', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.2562', 'cds_effect': '686C>T', 'depth': '687', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ZNF703', 'percent_reads': '25.62', 'position': 'chr8:37555105', 'protein_effect': 'S229F', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_025069', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.072', 'cds_effect': '61G>A', 'depth': '653', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CCNE1', 'percent_reads': '7.2', 'position': 'chr19:30303633', 'protein_effect': 'G21S', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001238', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.2163', 'cds_effect': '1001C>T', 'depth': '786', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ARID1A', 'percent_reads': '21.63', 'position': 'chr1:27023895', 'protein_effect': 'S334L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006015', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.3144', 'cds_effect': '1706A>G', 'depth': '846', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GATA6', 'percent_reads': '31.44', 'position': 'chr18:19780704', 'protein_effect': 'Y569C', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005257', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.5341', 'cds_effect': '1657G>A', 'depth': '1056', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGFR3', 'percent_reads': '53.41', 'position': 'chr4:1807488', 'protein_effect': 'V553M', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000142', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.4899', 'cds_effect': '1602G>C', 'depth': '843', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BCL6', 'percent_reads': '48.99', 'position': 'chr3:187444625', 'protein_effect': 'K534N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001706', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}, {'allele_fraction': '0.0541', 'cds_effect': '1439G>C', 'depth': '555', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KEL', 'percent_reads': '5.41', 'position': 'chr7:142641462', 'protein_effect': 'G480A', 'status': 'unknown', 'strand': '_', 'subclonal': 'false', 'transcript': 'NM_000420', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}]}, 'copy_number_alterations': {'copy_number_alteration': {'copy_number': '0', 'equivocal': 'false', 'gene': 'TP53', 'number_of_exons': '3 of 14', 'position': 'chr17:7576495_7577155', 'ratio': '0.59', 'status': 'known', 'type': 'loss', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}}, 'rearrangements': {'rearrangement': {'description': 'TP53(NM_000546) deletion intron 7 _ intron 9', 'equivocal': 'false', 'in_frame': 'No', 'other_gene': 'TP53', 'pos1': 'chr17:7577156_7577298', 'pos2': 'chr17:7574173_7574424', 'status': 'unknown', 'supporting_read_pairs': '111', 'targeted_gene': 'TP53', 'type': 'rearrangement', 'dna_evidence': {'sample': 'SQ_US1501620.01_1'}}}, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '27.76', 'status': 'high', 'unit': 'mutations_per_megabase'}}, 'non_human_content': None}}}}	M112-10048          	PF23015             
3	330	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2023_00027697', 'CSN': None, 'TRF': 'ORD_1585457_01', 'MRN': '33214436', 'PhysicianId': '109266', 'NPI': None}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1292132', 'clinicalId': '1293482', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1585457_01', 'SampleName': 'US1515644.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1585457_01', 'SampleId': 'US1515644.01', 'BlockId': 'S111_44872B (PF23024)', 'TRFNumber': 'ORD_1585457_01', 'TestType': 'FoundationOne CDX', 'SpecFormat': 'Slide Deck', 'ReceivedDate': '2023_03_13', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}]}}, 'PMI': {'ReportId': 'ORD_1585457_01', 'MRN': '33214436', 'FullName': 'Tsai, Hsiu Hsiung', 'FirstName': 'Hsiu Hsiung', 'LastName': 'Tsai', 'SubmittedDiagnosis': 'Skin melanoma', 'Gender': 'Male', 'DOB': '1941_04_06', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Lung', 'CollDate': '2022_11_02', 'ReceivedDate': '2023_03_13', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': {'PertinentNegative': [{'Gene': 'BRAF'}, {'Gene': 'KIT'}, {'Gene': 'NRAS'}]}, 'Summaries': {'alterationCount': '33', 'clinicalTrialCount': '13', 'resistiveCount': '0', 'sensitizingCount': '0'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'ASXL1', 'isVUS': 'true', 'variantName': 'R625Q'}, {'geneName': 'BCOR', 'isVUS': 'true', 'variantName': 'P152L'}, {'geneName': 'CCND2', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'CDK6', 'isVUS': 'true', 'variantName': 'R305S'}, {'geneName': 'CDKN1B', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'EP300', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'E276G'}, {'geneName': 'FGF23', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'FGF6', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'FGFR2', 'isVUS': 'true', 'variantName': 'V463D'}, {'geneName': 'GNAS', 'isVUS': 'true', 'variantName': 'A280T'}, {'geneName': 'KDM5A', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'KRAS', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'MKNK1', 'isVUS': 'true', 'variantName': 'R35Q'}, {'geneName': 'MST1R', 'isVUS': 'true', 'variantName': 'K881N'}, {'geneName': 'NF1', 'isVUS': 'true', 'variantName': 'M1162V'}, {'geneName': 'PARP2', 'isVUS': 'true', 'variantName': 'A522V'}, {'geneName': 'PIK3C2G', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'POLE', 'isVUS': 'true', 'variantName': 'A2142T'}, {'geneName': 'PTPRO', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'RAD52', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'RET', 'isVUS': 'true', 'variantName': 'Q681E'}, {'geneName': 'TEK', 'isVUS': 'true', 'variantName': 'loss'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'KRAS', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Q61R', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '72.44', 'isEquivocal': 'false', 'name': 'Q61R'}}, 'Interpretation': 'KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, E63K, R68S, and K117N have been characterized as activating and oncogenic (Akagi et al., 2007; 17150185, Bollag et al., 1996; 8955068, Buhrman et al., 2010; 20194776, Colicelli, 2004; 15367757, Edkins et al., 2006; 16969076, Feig and Cooper, 1988; 3043178, Gremer et al., 2011; 20949621, Janakiraman et al., 2010; 20570890, Kim et al., 2016; 27147599, Lukman et al., 2010; 20838576, Naguib et al., 2011; 21371307, Prior et al., 2012; 22589270, Privé et al., 1992; 1565661, Pylayeva_Gupta et al., 2011; 21993244, Scheffzek et al., 1997; 9219684, Scholl et al., 2009; 19490892, Smith et al., 2010; 20147967, Tyner et al., 2009; 19075190, Valencia et al., 1991; 2029511, White et al., 2016; 26854029, Wiest et al., 1994; 8058307, Kim et al., 2016; 27147599, Angeles et al., 2019; 31289513, Tong et al., 2014; 24642870, Loree et al., 2021; 34117033). KRAS mutations have been reported in up to 2% of cutaneous melanoma samples, but have not been found in uveal melanoma cases (cBioPortal, COSMIC, Feb 2023)(Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). One study reported KRAS mutations in 4/71 (6%) mucosal melanoma samples (Cosgarea et al., 2017; 28380455). The RAS pathway is a significant driver in melanoma tumorigenesis, although mutations in BRAF and NRAS are more frequently observed than KRAS mutations (Reifenberger et al., 2004; 14961576). In melanoma, high KRAS expression has been reported to be associated with metastasis and with reduced median OS compared with low KRAS expression (Dietrich et al., 2017; 29059159). Mutations in KRAS have also been associated with worse median OS for patients with melanoma brain metastases (Rabbie et al., 2021; 33024263). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). While clinical responses have been reported for patients with KRAS_mutated ovarian (Monk et al., 2020; 32822286, Farley et al., 2013; 23261356, Pejovic et al., 2015; Am J Clin Exp Obstet Gynecol 2:140_143, Slosberg et al., 2018; 29765547, Han et al., 2018; 29946554), cervical small cell neuroendocrine (Lyons et al., 2014; 26075998), or uterine cancer (Slosberg et al., 2018; 29765547) treated with MEK inhibitor monotherapy, multiple clinical trials have not demonstrated increased response rates for patients with KRAS_altered tumors including KRAS_mutated CRC (Tsimberidou et al., 2013; ASCO Abstract e22086, Infante et al., 2012; 22805291, Zimmer et al., 2014; 24947927, Bennouna et al., 2011; 20127139, Weekes et al., 2013; 23434733), pancreatic cancer (Van Laethem et al., 2017; 27975152, Infante et al., 2014; 24915778, Van Cutsem et al., 2018; 29756206), and NSCLC (Blumenschein et al., 2015; 25722381, Leijen et al., 2012; 22767668, Zimmer et al., 2014; 24947927). A Phase 2 study of trametinib and uprosertib for patients with recurrent cervical cancer reported no responses for patients with KRAS_mutated (2/2 SDs) or KRAS_amplified (1/1 SD) cancer (Lui et al., 2019; 31118140). Clinical responses have been reported for combination treatment strategies including MEK inhibitors with PI3K or AKT inhibitors for patients with KRAS_mutated ovarian cancer (Spreafico et al., 2014; ASCO Abstract 5506, Juric et al., 2014; ASCO Abstract 9051, Banerji et al., 2014; ASCO Abstract e13559) and KRAS_mutated endometrioid adenocarcinoma (Shapiro et al., 2019; 31020608). In a Phase 1 study evaluating the MEK_pan_RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non_small cell lung cancer (NCSLC), 1 with low_grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma (Guo et al., 2020; 33128873). Combination of CH5126766 with the FAK inhibitor defactinib elicited PR rates of 50% (4/8) for patients with KRAS_mutated low_grade serous ovarian cancer and 12% (2/17) for patients with KRAS_mutated non_small cell lung cancer (NSCLC) in a Phase 1 study (Krebs et al., 2021; AACR Abstract CT019, Shinde et al., 2020; AACR Abstract CT143). Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors (Lu et al., 2019; 31068384, Mainardi et al., 2018; 29808006, Koczywas et al., 2021; AACR Abstract LB001, Brana et al., 2021; ASCO Abstract 3005, Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). A Phase 1 study of RMC_4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations (Koczywas et al., 2021; AACR Abstract LB001). Interim results from a Phase 1/2 study of RMC_4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS_mutated colorectal cancer (Bendell et al., 2020; EORTC_NCI_AACR Abstract 5). Preclinical data suggest that KRAS mutation may confer sensitivity to SOS1 inhibitors (Hillig et al., 2019; 30683722, Hofmann et al., 2021; 32816843, Gerlach et al., 2020; AACR Abstract 1091). Phase 1 studies of the SOS1 inhibitor BI 1701963 alone or in combination with MEK inhibitors, KRAS G12C inhibitors, or irinotecan are recruiting for patients with solid tumors harboring KRAS mutations (Hofmann et al., 2021; AACR Abstract CT210, Gort et al., 2020; ASCO Abstract TPS3651).', 'Include': 'true', 'ClinicalTrialNote': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT04985604', 'Include': 'true'}, {'nctId': 'NCT03284502', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT03175432', 'Include': 'true'}, {'nctId': 'NCT03905148', 'Include': 'true'}, {'nctId': 'NCT02645149', 'Include': 'true'}, {'nctId': 'NCT05159245', 'Include': 'true'}, {'nctId': 'NCT04817956', 'Include': 'true'}, {'nctId': 'NCT04551521', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'MTAP', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'loss', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'loss'}}, 'Interpretation': 'MTAP encodes S_methyl_5 _thioadenosine (MTA) phosphorylase, a tumor suppressor involved in polyamine metabolism and methionine synthesis, although its enzymatic function is dispensable for its tumor suppressor activity (Limm et al., 2016; 27479139, Tang et al., 2014; 25387827). Decreased expression of MTAP leads to MTA accumulation within tumor cells and their microenvironment (Kirovski et al., 2011; 21356366, Limm et al., 2013; 23265702, Stevens et al., 2009; 19097084), thereby reducing intracellular arginine methylation (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360) and altering cell signaling (Limm et al., 2014; 25087184, Stevens et al., 2009; 19097084). MTAP is located at 9p21, adjacent to CDKN2A and CDKN2B, with which it is frequently co_deleted in various cancers. Other alterations in MTAP are rare and have not been extensively characterized. MTAP loss/homozygous deletion as well as loss of expression has been reported in a wide variety of solid tumors and hematologic cancers (Wei et al., 2016; 27929028, Zhao and Zhao, 2016; 27556634); such events have been correlated with poor prognosis in a variety of cancer types, including hepatocellular carcinoma (Kirovski et al., 2011; 21356366), gastrointestinal stromal tumors (Huang et al., 2009; 19887491), mantle cell lymphoma (MCL)(Marce et al., 2006; 16778103), melanoma (Meyer et al., 2010; 20500769, Wild et al., 2006; 16618867), gastric cancer (Kim et al., 2011; 21412930), myxofibrosarcoma (Li et al., 2014; 25426549), nasopharyngeal carcinoma (He et al., 2015; 26656376), ovarian carcinoma (Wei et al., 2016; 27929028) and non_small cell lung cancer (Su et al., 2014; 24969958). MTAP loss was not prognostic in pediatric B_cell acute lymphocytic leukemia (Mirebeau et al., 2006; 16818274) or in astrocytoma (Becker et al., 2015; 26088413). However, MTAP has also been reported to be overexpressed in colorectal cancer (CRC) samples (Snezhkina et al., 2016; 27433286), and MTAP retention is thought to be important for prostate cancer growth due to continuous supply of SAM (Bistulfi et al., 2016; 26910893). Germline SNPs in MTAP have been correlated with the development of cutaneous melanoma (Antonopoulou et al., 2015; 25407435, Mccioni et al., 2013; 23816148), esophageal cancer (Hyland et al., 2016; 26635288, Lin et al., 2017; 27960044), osteosarcoma (Zhi et al., 2016; 27994653), and CRC (Gu et al., 2013; 23361049). MTAP inactivation produces specific metabolic vulnerabilities that may be sensitive to MAT2A (Kalev et al., 2021; 33450196, Heist et al., 2019; AACR_NCI_EORTC Abstract B116, Marjon et al., 2016; 27068473) or PRMT5 inhibition (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360). A Phase 1 trial of MAT2A inhibitor AG_270 reported 1 PR and 2 SDs lasting longer than 6 months for patients with advanced solid tumors displaying MTAP loss (Heist et al., 2019; AACR_NCI_EORTC Abstract B116). Preclinical data suggest that MTAP loss sensitizes cells to S_adenosyl_L_methionine (SAM)_competitive PRMT5 inhibitors (Guccione and Richard, 2019; 31350521), dual PRMT1 and PRMT5 inhibitors (Fedoriw et al., 2019; 31257072, Srour et al., 2019; 31287990, Gao et al., 2019; 30916320), and PRMT5 inhibitors that selectively bind the PRMT5 when complexed with S_methyl_5 _thioadenosine (MTA), such as MRTX1719, TNG908, and AMG193 (Smith et al., 2022; 35041419, Briggs et al., 2022; AACR Abstract 3941). In preclinical models, MTAP inactivation showed increased sensitivity to inhibitors of purine synthesis or purine analogs, especially upon addition of exogenous MTA (Hansen et al., 2019; 31040154, Tang et al., 2018; 29844120, Munshi et al., 2014; 24928612, de Oliveira et al., 2016; 26751376, Lubin and Lubin, 2009; 19478948, Tang et al., 2012; 22825330, Collins et al., 2012; 22252602, Bertino et al., 2011; 21301207, Coulthard et al., 2011; 21282358, Miyazaki et al., 2007; 17912432, Efferth et al., 2002; 11987241). A Phase 2 study of L_alanosine, an inhibitor of adenine synthesis, as a monotherapy for 65 patients with MTAP_deficient cancers reported no responses and SD for 24% (13/55) of patients (Kindler et al., 2009; 18618081). Preclinical and limited clinical evidence suggest MTAP deficiency may confer sensitivity to pemetrexed (Alhalabi et al., 2022; 35379845).', 'Include': 'true', 'ClinicalTrialNote': 'MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT05094336', 'Include': 'true'}, {'nctId': 'NCT05275478', 'Include': 'true'}, {'nctId': 'NCT05245500', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'CCND3', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'true', 'name': 'amplification'}}, 'Interpretation': 'CCND3 encodes cyclin D3, a G1/S_specific cell cycle regulator. Cyclin D3 interacts with and regulates the cyclin_dependent kinases CDK4 and CDK6, resulting in the phosphorylation and inactivation of Rb and the progression of the cell cycle (Sridhar et al., 2006; 16584130). CCND3 amplification has been associated with increased cyclin D3 expression (Kusugai et al., 2005; 16322284). In the TCGA datasets, CCND3 amplification has been reported in 4% of cutaneous melanoma and 6.3% (5/80) of uveal melanoma cases (cBioPortal, Oct 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). A study reported cyclin D3 expression has been reported in 96% of primary melanomas, 97% of metastatic melanomas, and 20% of superficial tumors, and association between high cyclin D3 expression and early relapse and decreased overall survival in patients with superficial melanoma tumors (Flørenes et al., 2000; 10999753). On the basis of preclinical studies, amplification or activation of CCND3 may predict sensitivity to CDK4/6 inhibitors, such as abemaciclib (Gong et al. 2017; 29232554, Tanaka et al., 2020; 31849147) and palbociclib (Schmitz et al., 2012; 22885699, Choi et al., 2012; 23079655, Sawai et al., 2012; 23079656); however, 1 preclinical study implicated CCND3 overexpression as a potential mechanism of resistance to palbociclib (Ketzer et al., 2022; 35013097).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'CDKN2A/B', 'Include': 'true', 'Alterations': {'Alteration': [{'Name': 'CDKN2B loss', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'CDKN2B loss'}}, 'Interpretation': 'CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Concomitant loss of p16INK4a and p14ARF in melanoma is common, although loss of activity of either may also occur as a result of transcript_specific mutations or hypermethylation (Gallagher et al., 2008; 18953432, Freedberg et al., 2008; 18505964, Bachmann et al., 2004; 15547691, van der Velden et al., 2001; 11431374, Fauri et al., 2011; 22942654, Jonsson et al., 2010; 20703244, Hsieh et al., 2009; 20415670). Homozygous deletion of CDKN2A and/or CDKN2B has been reported in 14_29% of melanoma cases (cBioPortal, Oct 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Jönsson et al., 2010; 20460471, Busch et al., 2010; 20505745, Flores et al., 1996; 8895759). Various correlations between CDKN2A alterations and tumor histology or patient prognosis in melanoma have been reported in the literature, with some studies reporting CDKN2A deletion to be associated with adverse prognosis and other studies reporting no association between CDKN2A deletion and prognosis (Grafström et al., 2005; 15837753, Jönsson et al., 2010; 20460471, Puig et al., 2000; 10890376, Busch et al., 2010; 20505745). Studies suggest that deletion of CDKN2A is an early event in melanoma tumorigenesis, and loss of p16INK4a has been associated with increased DNA damage in human benign melanocytic tumors and has been suggested to contribute to tumorigenesis by promoting the proliferation of cells with genetic damage (Fung et al., 2012; 23279822, Matsumura et al., 1998; 9617435). CDKN2A alterations affecting p16INK4a, p14ARF, or both have been strongly associated (up to a 76% risk) with familial melanoma (Aspinwall et al., 2013; 23382133, Bandarchi et al., 2010; 20936153, Binni et al., 2010; 20132244, Garcia_Casado et al., 2009; 19741424, Gruis et al., 1995; 7640518, Harland et al., 2001; 11726555, Liu et al., 1995; 7624155, Puntervoll et al., 2013; 23384855, Ranade et al., 1995; 7647780, Randerson_Moor et al., 2001; 11136714, Veinalde et al., 2013; 23546221). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. The p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, and although concomitant loss of CDKN2A and CDKN2B may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500, Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126), direct supporting data for CDKN2B alteration as a predictive biomarker for these therapies are limited (Su et al., 2019; 31700061, Tramontana et al., 2020; 32923894). Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}, {'Name': 'CDKN2A loss', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'CDKN2A loss'}}, 'Interpretation': 'CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Concomitant loss of p16INK4a and p14ARF in melanoma is common, although loss of activity of either may also occur as a result of transcript_specific mutations or hypermethylation (Gallagher et al., 2008; 18953432, Freedberg et al., 2008; 18505964, Bachmann et al., 2004; 15547691, van der Velden et al., 2001; 11431374, Fauri et al., 2011; 22942654, Jonsson et al., 2010; 20703244, Hsieh et al., 2009; 20415670). Homozygous deletion of CDKN2A and/or CDKN2B has been reported in 14_29% of melanoma cases (cBioPortal, Oct 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Jönsson et al., 2010; 20460471, Busch et al., 2010; 20505745, Flores et al., 1996; 8895759). Various correlations between CDKN2A alterations and tumor histology or patient prognosis in melanoma have been reported in the literature, with some studies reporting CDKN2A deletion to be associated with adverse prognosis and other studies reporting no association between CDKN2A deletion and prognosis (Grafström et al., 2005; 15837753, Jönsson et al., 2010; 20460471, Puig et al., 2000; 10890376, Busch et al., 2010; 20505745). Studies suggest that deletion of CDKN2A is an early event in melanoma tumorigenesis, and loss of p16INK4a has been associated with increased DNA damage in human benign melanocytic tumors and has been suggested to contribute to tumorigenesis by promoting the proliferation of cells with genetic damage (Fung et al., 2012; 23279822, Matsumura et al., 1998; 9617435). CDKN2A alterations affecting p16INK4a, p14ARF, or both have been strongly associated (up to a 76% risk) with familial melanoma (Aspinwall et al., 2013; 23382133, Bandarchi et al., 2010; 20936153, Binni et al., 2010; 20132244, Garcia_Casado et al., 2009; 19741424, Gruis et al., 1995; 7640518, Harland et al., 2001; 11726555, Liu et al., 1995; 7624155, Puntervoll et al., 2013; 23384855, Ranade et al., 1995; 7647780, Randerson_Moor et al., 2001; 11136714, Veinalde et al., 2013; 23546221). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. The p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, and although concomitant loss of CDKN2A and CDKN2B may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500, Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126), direct supporting data for CDKN2B alteration as a predictive biomarker for these therapies are limited (Su et al., 2019; 31700061, Tramontana et al., 2020; 32923894). Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}]}, 'ReferenceLinks': None}, {'Name': 'CRKL', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'CRKL encodes an adaptor protein that has been shown to mediate growth, motility, and adhesion in solid tumor cells (Yanagi et al., 2012; 22244889). Studies in non_small cell lung cancer (NSCLC) and pancreatic cancer cells have linked CRKL amplification and overexpression with increased cell proliferation and with tumorigenesis (Wang et al., 2012; 22753141, Cheung et al., 2011; 22586683, Kim et al., 2010; 19966867; Fu et al., 2015; 25318601). CRKL amplification has been identified in various solid tumor types, including uterine carcinosarcoma (7%), pancreatic ductal adenocarcinoma (5.5%)(cBio_Witkiewicz et al., 2015; 25855536), lung squamous cell carcinoma (4.5%)(Cancer Genome Atlas Research Network., 2012; 22960745), sarcoma (4%), ovarian serous cystadenocarcinoma (3%), bladder urothelial carcinoma (3%)(Cancer Genome Atlas Research Network., 2014; 24476821), and melanoma (2%)(cBioPortal, 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Increased CRKL expression has been reported in many tumor types, including lung (Kim et al., 2010; 19966867, Wang et al., 2012; 22753141), breast (Zhao et al., 2013; 23686806, Singer et al., 2006; 16391854), ovarian (Wang et al., 2011; 21319228, Singer et al., 2006; 16391854), pancreatic (Fu et al., 2015; 25318601), skin (Singer et al., 2006; 16391854), colon (Singer et al., 2006; 16391854, Lan et al., 2014; 24389200), hepatocellular (Liu et al., 2013; 23397142), and gastric cancers (Natsume et al., 2012; 22591714). CRKL overexpression has been shown to significantly correlate with reduced OS for patients with NSCLC or hepatocellular carcinoma (Wang et al., 2012; 22753141, Liu et al., 2013; 23397142) and with tumor size and metastasis for patients with breast cancer (Zhao et al., 2013; 23686806). There are no approved therapies that directly target CRKL (Natsume et al., 2012; 22591714, Cheung et al., 2011; 22586683). Preclinical studies report that some cancer cell lines with CRKL amplification are sensitive to tyrosine kinase inhibitor (TKI) dasatinib (Natsume et al., 2012; 22591714, Lin et al., 2012; 22787428, Cheung et al., 2011; 22586683). However, a patient with CRKL_amplified pancreatic cancer did not respond to dasatinib (Garrido_Laguna et al., 2015; 25897431). CRKL amplification has been shown to be a mechanism of acquired resistance to EGFR TKIs (Suda et al., 2012; 22736441, Cheung et al., 2011; 22586683).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'MAPK1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'true', 'name': 'amplification'}}, 'Interpretation': 'MAPK1, also known as ERK2, encodes a mitogen_activated protein kinase family member that is involved in the transduction of proliferation and differentiation signals. MAPK1 amplification is associated with increased MAPK1 gene expression (Ercan et al., 2012; 22961667). MAPK1 amplification was detected in one patient with non_small cell lung cancer who exhibited resistance to erlotinib (Ercan et al., 2012; 22961667). Preclinical evidence suggests that amplification of MAPK1 may reduce sensitivity to the third_generation EGFR inhibitor WZ4002 as well as to cytotoxic chemotherapy (Ercan et al., 2012; 22961667). MAPK1 amplification has been reported with the highest incidence in sarcoma (4%), lung squamous cell carcinoma (3%), ovarian serous cystadenocarcinoma (2%), bladder urothelial carcinoma (2%), esophageal squamous cell carcinoma (2%), and testicular germ cell cancer (2%); MAPK1 amplification has been reported in fewer than 1% of hematologic malignancies (cBioPortal, 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In the scientific literature, MAPK1 amplification has been observed in 7% (5/68) of Type 2 ovarian carcinomas (Rahman et al., 2013; 23820584), 18% (4/22) of laryngeal squamous cell carcinomas (Kostrzewska_Poczekaj et al., 2011; 21896986), and 9% (3/34) of angiosarcoma (Murali et al., 2015; 26440310). MAPK1 amplification is associated with significantly shorter PFS in patients with ovarian cancer (Rahman et al., 2013; 23820584). Further, higher levels of ERK2 or phosphorylated ERK2 expression is a predictor of poor prognosis of acute myelogenous leukemia (Kornblau et al., 2006; 16763210) or angioimmunoblastic T_cell lymphoma (Manso et al., 2017; 26915336). There are no approved drugs that directly target ERK2, although ERK1/2 inhibitors are in clinical trials. In preclinical studies, ERK1/2 inhibitors have been shown to inhibit the activities of ERK2 mutations (Chakraborty et al., 2017; 28512266, Brenan et al., 2016; 27760319, Goetz et al., 2014; 25320010) or restore sensitivity to the EGFR inhibitor WZ4002 in a WZ4002_resistant cell line harboring MAPK1 amplification (Ercan et al., 2012; 22961667).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'MS_Stable', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'MS_Stable'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI has been detected in 16_32% of cutaneous melanomas in several small datasets, with the majority exhibiting MSI_low (Kubecek et al., 2016; 27623135). A higher frequency of MSI (low and high) has been reported in metastatic tumors (20_77%) compared to primary tumors (2_30%) (Kubecek et al., 2016; 27372860). No association between MSI status and clinicopathological features of patients with melanoma was reported in one study (Peris et al., 1995; 7561170). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Tumor Mutation Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '04', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '04'}}, 'Interpretation': 'Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Johnson et al., 2016; 27671167, Goodman et al., 2017; 28835386, Eroglu et al, 2018; 29320474, Shin et al., 2017; 27903500, Riaz et al., 2017; 29033130, Cristescu et al., 2018; 30309915, Samstein et al., 2019; 30643254, Ribas et al., 2019; AACR abstract 4217, Hodi et al., 2019; AACR abstract CT037, Marabelle et al., 2020; 32919529). A large_scale genomic analysis found that various melanoma subtypes harbored median TMBs between 6.3 and 14.4 Muts/Mb, and 25% to 40% of cases had elevated TMBs of greater than 20 Muts/Mb (FMI_Chalmers et al., 2017; 28420421). Malignant melanoma has been reported to have a high prevalence of somatic mutations compared with other tumor types (Alexandrov et al., 2013; 23945592), with desmoplastic melanoma ranking among the highest of melanoma subtypes (median TMB of 62 Muts/Mb)(Shain et al., 2015; 26343386). Higher mutational load has been reported in NF1_mutant melanoma samples compared with BRAF_mutant, NRAS_mutant, or BRAF/NRAS/NF1 wild_type samples (Johnson et al., 2016; 27671167). In 1 study, elevated TMB correlated with PD_L1 positive status and increased OS in tissue specimens from patients with Stage 3 melanoma (Madore et al., 2016; 26960397). In another study, elevated tissue TMB (>20 Muts/Mb) was associated with longer PFS and OS in patients treated with anti_PD_1 or anti_PD_L1 immunotherapy as compared with patients with lower TMB (Johnson et al., 2016; 27671167). Increased TMB has also been associated with histologic stage and cumulative sun exposure (Shain et al., 2015; 26559571). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple studies of immune checkpoint inhibitors in melanoma, higher TMB has corresponded with clinical benefit from treatment with anti_PD_1 or anti_PD_L1 treatments (Hodi et al., 2019; AACR Abstract CT037, Ribas et al., 2019; AACR Abstract 4217, Cristescu et al., 2018; 30309915, Johnson et al., 2016; 27671167, Ning et al., 2022; 35355708). Increased TMB has been associated with longer PFS and OS for patients with melanoma treated with nivolumab, with studies reporting increased benefit for patients with a mutational load above 162 missense mutations per tumor (~equivalency >8 Muts/Mb as measured by this assay) (Hodi et al., 2019; AACR abstract CT037). Increased TMB (~equivalency >10.8 Muts/Mb as measured by this assay) has also been associated with longer PFS and OS for patients with melanoma treated with combination nivolumab and ipilumumab (Hodi et al., 2019; AACR abstract CT037). Improved PFS and OS of patients with melanoma treated with ipilumumab has been observed across all TMB levels (Ribas et al., 2019; AACR abstract 4217, Liu et al., 2019; 31515453).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'VEGFA', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'true', 'name': 'amplification'}}, 'Interpretation': 'VEGFA (vascular endothelial growth factor A) encodes a ligand that promotes angiogenesis through the receptor tyrosine kinases VEGFR1 and VEGFR2 (Goel and Mercurio., 2013; 24263190). VEGFA promotes tumor growth by activating both autocrine VEGFR signaling in tumor cells and paracrine signaling to fibroblasts and immune cells in the tumor microenvironment (Goel and Mercurio., 2013; 24263190). VEGFA has been reported to be amplified in cancer (Gao et al., 2013; 23550210), and is associated with response to sorafenib (Horwitz et al., 2014; 24687604). In the TCGA dataset, VEGFA amplification and mutation were observed in 3% and 2% of cutaneous melanoma cases, respectively (cBio_Van Allen et al., 2015; 26359337). VEGFA concentration has been reported as elevated in melanoma (Bauer et al., 2015; 25977583) and uveal melanoma cases (Sahin et al., 2007; 17926107, Missotten et al., 2006; 17030710) and has been correlated with increased tumor size and metastasis (Koch et al., 2014; 24677103, Sahin et al., 2007; 17926107, Missotten et al., 2006; 17030710). The approved VEGFA_targeted agents bevacizumab and ziv_aflibercept have demonstrated efficacy in multiple tumor types; however, expression or amplification of VEGFA has not been established as a reliable biomarker of response to these therapies (Van Cutsem et al., 2012; 22565005, Miles et al., 2013; 23422754, Gianni et al., 2013; 23569311, Cameron et al., 2013; 23932548, Hegde et al., 2013; 23169435, Schneider et al., 2012; 23340303, Baumgarten et al., 2016; 26627848, Sathornsumetee et al., 2008; 18182667, Olafson et al., 2019; 31582283, Nishikawa et al., 2013; ASCO Abstract 2023, Wick et al., 2013; WCN Abstract 1207, Duda et al., 2010; 20484123, Stremitzer et al., 2016; 27535973, Weickhardt et al., 2015; 26125443, Kopetz et al., 2009; 20008624, Fountzilas et al., 2011; 21868552, Sánchez_Rovira et al., 2013; 23397155, Mok et al., 2014; 24807156, An et al., 2014; 24577128, Bais et al., 2017; 29059426, Van Cutsem et al., 2011; EMCC Abstract 803, Xu et al., 2009; 19826039, Hasselbalch et al., 2010; 20666740, Marisi et al., 2017; 28465540, Jubb et al., 2005; 16365183, Goede et al., 2010; 20924372, Bruhn et al., 2013; 24374727, Escudier et al., 2007; 18156031, Yang et al., 2003; 12890841, Burstein et al., 2008; 19047116, Jubb et al., 2011; 21224365, Miles et al., 2017; 27817944, Dowlati et al., 2008; 18316562, Horn et al., 2009; 19826110, Blakeley et al., 2016; 26976425). Preclinical hepatocellular carcinoma (HCC) models with VEGFA amplification showed increased sensitivity to sorafenib, and a small retrospective study reported significantly increased OS for 7 patients with VEGFA_amplified HCC treated with sorafenib (Horwitz et al., 2014; 24687604). However, a prospective biomarker study showed that VEGFA amplification detected by circulating cell_free DNA was not significantly associated with DCR, time to progression, or median OS for patients with HCC treated with first_line sorafenib (Oh et al., 2019; 30935424). It is currently not known if VEGFA amplification predicts response to other inhibitors targeting VEGFRs.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'KRAS', 'Alteration': 'Q61R', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'Q61R', 'Title': 'DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'BRAF, MEK', 'Locations': 'Busan (Korea, Republic of), Seoul (Korea, Republic of), Clayton (Australia), Edegem (Belgium), Oregon, Barcelona (Spain), Madrid (Spain), California, Colorado', 'NCTID': 'NCT04985604', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'Q61R', 'Title': 'Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'MEK, RAFs, NRAS', 'Locations': 'Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of)', 'NCTID': 'NCT03284502', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'Q61R', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'Q61R', 'Title': 'Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFA, PD_L1, MEK', 'Locations': 'Texas', 'NCTID': 'NCT03175432', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'Q61R', 'Title': 'Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'RAFs, EGFR, MEK', 'Locations': 'Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), California, Texas', 'NCTID': 'NCT03905148', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'Q61R', 'Title': 'Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma', 'StudyPhase': 'PHASE 2', 'Target': 'ROS1, ALK, MEK, CDK6, CDK4', 'Locations': 'Wollstonecraft (Australia)', 'NCTID': 'NCT02645149', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'Q61R', 'Title': 'The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs', 'StudyPhase': 'PHASE 2', 'Target': 'BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6', 'Locations': 'Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)', 'NCTID': 'NCT05159245', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'Q61R', 'Title': 'Improving Public Cancer Care by Implementing Precision Medicine in Norway', 'StudyPhase': 'PHASE 2', 'Target': 'PD_L1, VEGFA, ERBB2, ALK, RET, PARP, SMO, TRKB, TRKC, ROS1, TRKA, MEK, BRAF, PI3K_alpha, FGFR1, FGFR2, FGFR3, MET, KIT, ABL', 'Locations': 'Tromsø (Norway), Bodø (Norway), Hamar (Norway), Oslo (Norway), Fredrikstad (Norway), Drammen (Norway), Trondheim (Norway), Skien (Norway), Førde (Norway), Bergen (Norway)', 'NCTID': 'NCT04817956', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'Q61R', 'Title': 'CRAFT: The NCT_PMO_1602 Phase II Trial', 'StudyPhase': 'PHASE 2', 'Target': 'PD_L1, AKTs, MEK, BRAF, ALK, RET, ERBB2', 'Locations': 'Würzburg (Germany), Mainz (Germany), Heidelberg (Germany), Tübingen (Germany)', 'NCTID': 'NCT04551521', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.', 'Include': 'true'}, {'Gene': 'MTAP', 'Alteration': 'loss', 'Title': 'AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)_Null Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'PRMT5_MTA', 'Locations': 'Tainan (Taiwan), Hong Kong (Hong Kong), Nagoya_shi (Japan), Chuo_ku (Japan), Kashiwa_shi (Japan), Camperdown (Australia), Halle (Saale) (Germany), Salzburg (Austria), Wuerzburg (Germany), Ulm (Germany)', 'NCTID': 'NCT05094336', 'Note': 'MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.', 'Include': 'true'}, {'Gene': 'MTAP', 'Alteration': 'loss', 'Title': 'Safety and Tolerability of TNG908 in Patients With MTAP_deleted Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'PRMT5_MTA', 'Locations': 'Lyon (France), Villejuif (France), Missouri, Massachusetts, Tennessee, Texas, Virginia', 'NCTID': 'NCT05275478', 'Note': 'MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.', 'Include': 'true'}, {'Gene': 'MTAP', 'Alteration': 'loss', 'Title': 'Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion', 'StudyPhase': 'PHASE 1/2', 'Target': 'PRMT5_MTA', 'Locations': 'Colorado, Arizona, Minnesota, Massachusetts, New York, Tennessee, Texas, Florida', 'NCTID': 'NCT05245500', 'Note': 'MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '27479139', 'FullCitation': 'Limm K, et al. PLoS ONE (2016) pmid: 27479139', 'Include': 'true'}, {'number': '1', 'ReferenceId': '25387827', 'FullCitation': 'Tang B, et al. G3 (Bethesda) (2014) pmid: 25387827', 'Include': 'true'}, {'number': '2', 'ReferenceId': '21356366', 'FullCitation': 'Kirovski G, et al. Am. J. Pathol. (2011) pmid: 21356366', 'Include': 'true'}, {'number': '3', 'ReferenceId': '23265702', 'FullCitation': 'Limm K, et al. Eur. J. Cancer (2013) pmid: 23265702', 'Include': 'true'}, {'number': '4', 'ReferenceId': '19097084', 'FullCitation': 'Stevens AP, et al. J. Cell. Biochem. (2009) pmid: 19097084', 'Include': 'true'}, {'number': '5', 'ReferenceId': '27068473', 'FullCitation': 'Marjon K, et al. Cell Rep (2016) pmid: 27068473', 'Include': 'true'}, {'number': '6', 'ReferenceId': '26912361', 'FullCitation': 'Mavrakis KJ, et al. Science (2016) pmid: 26912361', 'Include': 'true'}, {'number': '7', 'ReferenceId': '26912360', 'FullCitation': 'Kryukov GV, et al. Science (2016) pmid: 26912360', 'Include': 'true'}, {'number': '8', 'ReferenceId': '25087184', 'FullCitation': 'Limm K, et al. Eur. J. Cancer (2014) pmid: 25087184', 'Include': 'true'}, {'number': '9', 'ReferenceId': '27929028', 'FullCitation': 'Wei R, et al. Sci Rep (2016) pmid: 27929028', 'Include': 'true'}, {'number': '10', 'ReferenceId': '27556634', 'FullCitation': 'Zhao M, et al. BMC Genomics (2016) pmid: 27556634', 'Include': 'true'}, {'number': '11', 'ReferenceId': '19887491', 'FullCitation': 'Huang HY, et al. Clin. Cancer Res. (2009) pmid: 19887491', 'Include': 'true'}, {'number': '12', 'ReferenceId': '16778103', 'FullCitation': 'Marcé S, et al. Clin. Cancer Res. (2006) pmid: 16778103', 'Include': 'true'}, {'number': '13', 'ReferenceId': '20500769', 'FullCitation': 'Meyer S, et al. Exp. Dermatol. (2010) pmid: 20500769', 'Include': 'true'}, {'number': '14', 'ReferenceId': '16618867', 'FullCitation': 'Wild PJ, et al. Arch Dermatol (2006) pmid: 16618867', 'Include': 'true'}, {'number': '15', 'ReferenceId': '21412930', 'FullCitation': 'Kim J, et al. Genes Chromosomes Cancer (2011) pmid: 21412930', 'Include': 'true'}, {'number': '16', 'ReferenceId': '25426549', 'FullCitation': 'Li CF, et al. Oncotarget (2014) pmid: 25426549', 'Include': 'true'}, {'number': '17', 'ReferenceId': '26656376', 'FullCitation': 'He HL, et al. Medicine (Baltimore) (2015) pmid: 26656376', 'Include': 'true'}, {'number': '18', 'ReferenceId': '24969958', 'FullCitation': 'Su CY, et al. Eur J Surg Oncol (2014) pmid: 24969958', 'Include': 'true'}, {'number': '19', 'ReferenceId': '16818274', 'FullCitation': 'Mirebeau D, et al. Haematologica (2006) pmid: 16818274', 'Include': 'true'}, {'number': '20', 'ReferenceId': '26088413', 'FullCitation': 'Becker AP, et al. Pathobiology (2015) pmid: 26088413', 'Include': 'true'}, {'number': '21', 'ReferenceId': '27433286', 'FullCitation': 'Snezhkina AV, et al. Oxid Med Cell Longev (2016) pmid: 27433286', 'Include': 'true'}, {'number': '22', 'ReferenceId': '26910893', 'FullCitation': 'Bistulfi G, et al. Oncotarget (2016) pmid: 26910893', 'Include': 'true'}, {'number': '23', 'ReferenceId': '25407435', 'FullCitation': 'Antonopoulou K, et al. J. Invest. Dermatol. (2015) pmid: 25407435', 'Include': 'true'}, {'number': '24', 'ReferenceId': '23816148', 'FullCitation': 'Maccioni L, et al. BMC Cancer (2013) pmid: 23816148', 'Include': 'true'}, {'number': '25', 'ReferenceId': '26635288', 'FullCitation': 'Hyland PL, et al. Int J Epidemiol (2016) pmid: 26635288', 'Include': 'true'}, {'number': '26', 'ReferenceId': '27960044', 'FullCitation': 'Lin X, et al. Cancer Sci. (2017) pmid: 27960044', 'Include': 'true'}, {'number': '27', 'ReferenceId': '27994653', 'FullCitation': 'Zhi L, et al. J Cancer (2016) pmid: 27994653', 'Include': 'true'}, {'number': '28', 'ReferenceId': '23361049', 'FullCitation': 'Gu F, et al. Br. J. Cancer (2013) pmid: 23361049', 'Include': 'true'}, {'number': '29', 'ReferenceId': '33450196', 'FullCitation': 'Kalev P, et al. Cancer Cell (2021) pmid: 33450196', 'Include': 'true'}, {'number': '30', 'ReferenceId': '31350521', 'FullCitation': 'Guccione E, et al. Nat. Rev. Mol. Cell Biol. (2019) pmid: 31350521', 'Include': 'true'}, {'number': '31', 'ReferenceId': '31257072', 'FullCitation': 'Fedoriw A, et al. Cancer Cell (2019) pmid: 31257072', 'Include': 'true'}, {'number': '32', 'ReferenceId': '31287990', 'FullCitation': 'Srour N, et al. Cancer Cell (2019) pmid: 31287990', 'Include': 'true'}, {'number': '33', 'ReferenceId': '30916320', 'FullCitation': 'Gao G, et al. Nucleic Acids Res. (2019) pmid: 30916320', 'Include': 'true'}, {'number': '34', 'ReferenceId': '35041419', 'FullCitation': 'Smith CR, et al. J Med Chem (2022) pmid: 35041419', 'Include': 'true'}, {'number': '35', 'ReferenceId': '31040154', 'FullCitation': 'Hansen LJ, et al. Cancer Res. (2019) pmid: 31040154', 'Include': 'true'}, {'number': '36', 'ReferenceId': '29844120', 'FullCitation': 'Tang B, et al. Cancer Res. (2018) pmid: 29844120', 'Include': 'true'}, {'number': '37', 'ReferenceId': '24928612', 'FullCitation': 'Munshi PN, et al. Oncologist (2014) pmid: 24928612', 'Include': 'true'}, {'number': '38', 'ReferenceId': '26751376', 'FullCitation': 'de Oliveira SF, et al. PLoS ONE (2016) pmid: 26751376', 'Include': 'true'}, {'number': '39', 'ReferenceId': '19478948', 'FullCitation': 'Lubin M, et al. PLoS ONE (2009) pmid: 19478948', 'Include': 'true'}, {'number': '40', 'ReferenceId': '22825330', 'FullCitation': 'Tang B, et al. Cancer Biol. Ther. (2012) pmid: 22825330', 'Include': 'true'}, {'number': '41', 'ReferenceId': '22252602', 'FullCitation': 'Collins CC, et al. Mol. Cancer Ther. (2012) pmid: 22252602', 'Include': 'true'}, {'number': '42', 'ReferenceId': '21301207', 'FullCitation': 'Bertino JR, et al. Cancer Biol. Ther. (2011) pmid: 21301207', 'Include': 'true'}, {'number': '43', 'ReferenceId': '21282358', 'FullCitation': 'Coulthard SA, et al. Mol. Cancer Ther. (2011) pmid: 21282358', 'Include': 'true'}, {'number': '44', 'ReferenceId': '17912432', 'FullCitation': 'Miyazaki S, et al. Int. J. Oncol. (2007) pmid: 17912432', 'Include': 'true'}, {'number': '45', 'ReferenceId': '11987241', 'FullCitation': 'Efferth T, et al. Blood Cells Mol. Dis. () pmid: 11987241', 'Include': 'true'}, {'number': '46', 'ReferenceId': '18618081', 'FullCitation': 'Kindler HL, et al. Invest New Drugs (2009) pmid: 18618081', 'Include': 'true'}, {'number': '47', 'ReferenceId': '35379845', 'FullCitation': 'Alhalabi O, et al. Nat Commun (2022) pmid: 35379845', 'Include': 'true'}, {'number': '48', 'ReferenceId': '21993244', 'FullCitation': 'Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244', 'Include': 'true'}, {'number': '49', 'ReferenceId': '3310850', 'FullCitation': 'Kahn S, et al. Anticancer Res. () pmid: 3310850', 'Include': 'true'}, {'number': '50', 'ReferenceId': '17150185', 'FullCitation': 'Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185', 'Include': 'true'}, {'number': '51', 'ReferenceId': '8955068', 'FullCitation': 'Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068', 'Include': 'true'}, {'number': '52', 'ReferenceId': '20194776', 'FullCitation': 'Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776', 'Include': 'true'}, {'number': '53', 'ReferenceId': '15367757', 'FullCitation': 'Sci. STKE (2004) pmid: 15367757', 'Include': 'true'}, {'number': '54', 'ReferenceId': '16969076', 'FullCitation': 'Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076', 'Include': 'true'}, {'number': '55', 'ReferenceId': '3043178', 'FullCitation': 'Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178', 'Include': 'true'}, {'number': '56', 'ReferenceId': '20949621', 'FullCitation': 'Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621', 'Include': 'true'}, {'number': '57', 'ReferenceId': '20570890', 'FullCitation': 'Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890', 'Include': 'true'}, {'number': '58', 'ReferenceId': '27147599', 'FullCitation': 'Kim E, et al. Cancer Discov (2016) pmid: 27147599', 'Include': 'true'}, {'number': '59', 'ReferenceId': '20838576', 'FullCitation': 'Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576', 'Include': 'true'}, {'number': '60', 'ReferenceId': '21371307', 'FullCitation': 'Naguib A, et al. J Mol Signal (2011) pmid: 21371307', 'Include': 'true'}, {'number': '61', 'ReferenceId': '22589270', 'FullCitation': 'Prior IA, et al. Cancer Res. (2012) pmid: 22589270', 'Include': 'true'}, {'number': '62', 'ReferenceId': '1565661', 'FullCitation': 'Privé GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661', 'Include': 'true'}, {'number': '63', 'ReferenceId': '9219684', 'FullCitation': 'Scheffzek K, et al. Science (1997) pmid: 9219684', 'Include': 'true'}, {'number': '64', 'ReferenceId': '19490892', 'FullCitation': 'Scholl C, et al. Cell (2009) pmid: 19490892', 'Include': 'true'}, {'number': '65', 'ReferenceId': '20147967', 'FullCitation': 'Smith G, et al. Br. J. Cancer (2010) pmid: 20147967', 'Include': 'true'}, {'number': '66', 'ReferenceId': '19075190', 'FullCitation': 'Tyner JW, et al. Blood (2009) pmid: 19075190', 'Include': 'true'}, {'number': '67', 'ReferenceId': '2029511', 'FullCitation': 'Valencia A, et al. Biochemistry (1991) pmid: 2029511', 'Include': 'true'}, {'number': '68', 'ReferenceId': '26854029', 'FullCitation': 'White Y, et al. Nat Commun (2016) pmid: 26854029', 'Include': 'true'}, {'number': '69', 'ReferenceId': '8058307', 'FullCitation': 'Wiest JS, et al. Oncogene (1994) pmid: 8058307', 'Include': 'true'}, {'number': '70', 'ReferenceId': '31289513', 'FullCitation': 'Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513', 'Include': 'true'}, {'number': '71', 'ReferenceId': '24642870', 'FullCitation': 'Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870', 'Include': 'true'}, {'number': '72', 'ReferenceId': '34117033', 'FullCitation': 'Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033', 'Include': 'true'}, {'number': '73', 'ReferenceId': '30371878', 'FullCitation': 'Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878', 'Include': 'true'}, {'number': '74', 'ReferenceId': '22588877', 'FullCitation': 'Cerami E, et al. Cancer Discov (2012) pmid: 22588877', 'Include': 'true'}, {'number': '75', 'ReferenceId': '23550210', 'FullCitation': 'Gao J, et al. Sci Signal (2013) pmid: 23550210', 'Include': 'true'}, {'number': '76', 'ReferenceId': '28380455', 'FullCitation': 'Cosgarea I, et al. Oncotarget (2017) pmid: 28380455', 'Include': 'true'}, {'number': '77', 'ReferenceId': '14961576', 'FullCitation': 'Reifenberger J, et al. Int. J. Cancer (2004) pmid: 14961576', 'Include': 'true'}, {'number': '78', 'ReferenceId': '29059159', 'FullCitation': 'Dietrich P, et al. Oncogene (2018) pmid: 29059159', 'Include': 'true'}, {'number': '79', 'ReferenceId': '33024263', 'FullCitation': 'Rabbie R, et al. Br J Cancer (2021) pmid: 33024263', 'Include': 'true'}, {'number': '80', 'ReferenceId': '6320174', 'FullCitation': 'Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174', 'Include': 'true'}, {'number': '81', 'ReferenceId': '21523318', 'FullCitation': 'Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318', 'Include': 'true'}, {'number': '82', 'ReferenceId': '23438367', 'FullCitation': 'Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367', 'Include': 'true'}, {'number': '83', 'ReferenceId': '21245089', 'FullCitation': 'Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089', 'Include': 'true'}, {'number': '84', 'ReferenceId': '19372556', 'FullCitation': 'Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556', 'Include': 'true'}, {'number': '85', 'ReferenceId': '32822286', 'FullCitation': 'Monk BJ, et al. J Clin Oncol (2020) pmid: 32822286', 'Include': 'true'}, {'number': '86', 'ReferenceId': '23261356', 'FullCitation': 'Farley J, et al. Lancet Oncol. (2013) pmid: 23261356', 'Include': 'true'}, {'number': '87', 'ReferenceId': '29765547', 'FullCitation': 'Slosberg ED, et al. Oncotarget (2018) pmid: 29765547', 'Include': 'true'}, {'number': '88', 'ReferenceId': '29946554', 'FullCitation': 'Han C, et al. Gynecol Oncol Rep (2018) pmid: 29946554', 'Include': 'true'}, {'number': '89', 'ReferenceId': '26075998', 'FullCitation': 'Lyons YA, et al. Gynecol Oncol Rep (2014) pmid: 26075998', 'Include': 'true'}, {'number': '90', 'ReferenceId': '22805291', 'FullCitation': 'Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291', 'Include': 'true'}, {'number': '91', 'ReferenceId': '24947927', 'FullCitation': 'Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927', 'Include': 'true'}, {'number': '92', 'ReferenceId': '20127139', 'FullCitation': 'Bennouna J, et al. Invest New Drugs (2011) pmid: 20127139', 'Include': 'true'}, {'number': '93', 'ReferenceId': '23434733', 'FullCitation': 'Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733', 'Include': 'true'}, {'number': '94', 'ReferenceId': '27975152', 'FullCitation': 'Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152', 'Include': 'true'}, {'number': '95', 'ReferenceId': '24915778', 'FullCitation': 'Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778', 'Include': 'true'}, {'number': '96', 'ReferenceId': '29756206', 'FullCitation': 'Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206', 'Include': 'true'}, {'number': '97', 'ReferenceId': '25722381', 'FullCitation': 'Blumenschein GR, et al. Ann. Oncol. (2015) pmid: 25722381', 'Include': 'true'}, {'number': '98', 'ReferenceId': '22767668', 'FullCitation': 'Leijen S, et al. Clin. Cancer Res. (2012) pmid: 22767668', 'Include': 'true'}, {'number': '99', 'ReferenceId': '31118140', 'FullCitation': 'Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31118140', 'Include': 'true'}, {'number': '100', 'ReferenceId': '31020608', 'FullCitation': 'Shapiro GI, et al. Invest New Drugs (2019) pmid: 31020608', 'Include': 'true'}, {'number': '101', 'ReferenceId': '33128873', 'FullCitation': 'Guo C, et al. Lancet Oncol (2020) pmid: 33128873', 'Include': 'true'}, {'number': '102', 'ReferenceId': '31068384', 'FullCitation': 'Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384', 'Include': 'true'}, {'number': '103', 'ReferenceId': '29808006', 'FullCitation': 'Mainardi S, et al. Nat Med (2018) pmid: 29808006', 'Include': 'true'}, {'number': '104', 'ReferenceId': '30683722', 'FullCitation': 'Hillig RC, et al. Proc Natl Acad Sci U S A (2019) pmid: 30683722', 'Include': 'true'}, {'number': '105', 'ReferenceId': '32816843', 'FullCitation': 'Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843', 'Include': 'true'}, {'number': '106', 'ReferenceId': '8521522', 'FullCitation': 'Quelle DE, et al. Cell (1995) pmid: 8521522', 'Include': 'true'}, {'number': '107', 'ReferenceId': '15878778', 'FullCitation': 'Mutat. Res. (2005) pmid: 15878778', 'Include': 'true'}, {'number': '108', 'ReferenceId': '9484839', 'FullCitation': 'Gazzeri S, et al. Oncogene (1998) pmid: 9484839', 'Include': 'true'}, {'number': '109', 'ReferenceId': '10498883', 'FullCitation': 'Oncogene (1999) pmid: 10498883', 'Include': 'true'}, {'number': '110', 'ReferenceId': '16869746', 'FullCitation': 'Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746', 'Include': 'true'}, {'number': '111', 'ReferenceId': '20549699', 'FullCitation': 'Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699', 'Include': 'true'}, {'number': '112', 'ReferenceId': '10498896', 'FullCitation': 'Ruas M, et al. Oncogene (1999) pmid: 10498896', 'Include': 'true'}, {'number': '113', 'ReferenceId': '17909018', 'FullCitation': 'Jones R, et al. Cancer Res. (2007) pmid: 17909018', 'Include': 'true'}, {'number': '114', 'ReferenceId': '18843795', 'FullCitation': 'Haferkamp S, et al. Aging Cell (2008) pmid: 18843795', 'Include': 'true'}, {'number': '115', 'ReferenceId': '12417717', 'FullCitation': 'Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717', 'Include': 'true'}, {'number': '116', 'ReferenceId': '11518711', 'FullCitation': 'Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711', 'Include': 'true'}, {'number': '117', 'ReferenceId': '9324288', 'FullCitation': 'Gombart AF, et al. Leukemia (1997) pmid: 9324288', 'Include': 'true'}, {'number': '118', 'ReferenceId': '7780957', 'FullCitation': 'Yang R, et al. Cancer Res. (1995) pmid: 7780957', 'Include': 'true'}, {'number': '119', 'ReferenceId': '8668202', 'FullCitation': 'Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202', 'Include': 'true'}, {'number': '120', 'ReferenceId': '12606942', 'FullCitation': 'Greenblatt MS, et al. Oncogene (2003) pmid: 12606942', 'Include': 'true'}, {'number': '121', 'ReferenceId': '10491434', 'FullCitation': 'Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434', 'Include': 'true'}, {'number': '122', 'ReferenceId': '11255261', 'FullCitation': 'Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261', 'Include': 'true'}, {'number': '123', 'ReferenceId': '9660926', 'FullCitation': 'Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926', 'Include': 'true'}, {'number': '124', 'ReferenceId': '19260062', 'FullCitation': 'Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062', 'Include': 'true'}, {'number': '125', 'ReferenceId': '10719365', 'FullCitation': 'Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365', 'Include': 'true'}, {'number': '126', 'ReferenceId': '7777061', 'FullCitation': 'Koh J, et al. Nature (1995) pmid: 7777061', 'Include': 'true'}, {'number': '127', 'ReferenceId': '20340136', 'FullCitation': 'McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136', 'Include': 'true'}, {'number': '128', 'ReferenceId': '21462282', 'FullCitation': 'Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282', 'Include': 'true'}, {'number': '129', 'ReferenceId': '905385', 'FullCitation': 'Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385', 'Include': 'true'}, {'number': '130', 'ReferenceId': '24659262', 'FullCitation': 'Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262', 'Include': 'true'}, {'number': '131', 'ReferenceId': '23190892', 'FullCitation': 'Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892', 'Include': 'true'}, {'number': '132', 'ReferenceId': '10389768', 'FullCitation': 'Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768', 'Include': 'true'}, {'number': '133', 'ReferenceId': '12853981', 'FullCitation': 'Rutter JL, et al. Oncogene (2003) pmid: 12853981', 'Include': 'true'}, {'number': '134', 'ReferenceId': '18538737', 'FullCitation': 'Itahana K, et al. Cancer Cell (2008) pmid: 18538737', 'Include': 'true'}, {'number': '135', 'ReferenceId': '10360174', 'FullCitation': 'Zhang Y, et al. Mol. Cell (1999) pmid: 10360174', 'Include': 'true'}, {'number': '136', 'ReferenceId': '9529249', 'FullCitation': 'Zhang Y, et al. Cell (1998) pmid: 9529249', 'Include': 'true'}, {'number': '137', 'ReferenceId': '25873077', 'FullCitation': 'Jafri M, et al. Cancer Discov (2015) pmid: 25873077', 'Include': 'true'}, {'number': '138', 'ReferenceId': '18953432', 'FullCitation': 'Gallagher SJ, et al. Neoplasia (2008) pmid: 18953432', 'Include': 'true'}, {'number': '139', 'ReferenceId': '18505964', 'FullCitation': 'Freedberg DE, et al. J. Natl. Cancer Inst. (2008) pmid: 18505964', 'Include': 'true'}, {'number': '140', 'ReferenceId': '15547691', 'FullCitation': 'Bachmann IM, et al. Int. J. Oncol. (2004) pmid: 15547691', 'Include': 'true'}, {'number': '141', 'ReferenceId': '11431374', 'FullCitation': 'van der Velden PA, et al. Cancer Res. (2001) pmid: 11431374', 'Include': 'true'}, {'number': '142', 'ReferenceId': '22942654', 'FullCitation': 'Fauri J, et al. Can J Plast Surg (2011) pmid: 22942654', 'Include': 'true'}, {'number': '143', 'ReferenceId': '20703244', 'FullCitation': 'Jonsson A, et al. J. Invest. Dermatol. (2010) pmid: 20703244', 'Include': 'true'}, {'number': '144', 'ReferenceId': '20415670', 'FullCitation': 'Hsieh R, et al. Int. J. Dermatol. (2009) pmid: 20415670', 'Include': 'true'}, {'number': '145', 'ReferenceId': '20460471', 'FullCitation': 'Jönsson G, et al. Clin. Cancer Res. (2010) pmid: 20460471', 'Include': 'true'}, {'number': '146', 'ReferenceId': '20505745', 'FullCitation': 'Busch C, et al. J. Invest. Dermatol. (2010) pmid: 20505745', 'Include': 'true'}, {'number': '147', 'ReferenceId': '8895759', 'FullCitation': 'Flores JF, et al. Cancer Res. (1996) pmid: 8895759', 'Include': 'true'}, {'number': '148', 'ReferenceId': '15837753', 'FullCitation': 'Grafström E, et al. Clin. Cancer Res. (2005) pmid: 15837753', 'Include': 'true'}, {'number': '149', 'ReferenceId': '10890376', 'FullCitation': 'Puig S, et al. Melanoma Res. (2000) pmid: 10890376', 'Include': 'true'}, {'number': '150', 'ReferenceId': '23279822', 'FullCitation': 'Fung C, et al. Pigment Cell Melanoma Res (2013) pmid: 23279822', 'Include': 'true'}, {'number': '151', 'ReferenceId': '9617435', 'FullCitation': 'Matsumura Y, et al. Arch. Dermatol. Res. (1998) pmid: 9617435', 'Include': 'true'}, {'number': '152', 'ReferenceId': '23382133', 'FullCitation': 'Aspinwall LG, et al. Psychooncology (2013) pmid: 23382133', 'Include': 'true'}, {'number': '153', 'ReferenceId': '20936153', 'FullCitation': 'Bandarchi B, et al. Dermatol Res Pract (2010) pmid: 20936153', 'Include': 'true'}, {'number': '154', 'ReferenceId': '20132244', 'FullCitation': 'Binni F, et al. Clin. Genet. (2010) pmid: 20132244', 'Include': 'true'}, {'number': '155', 'ReferenceId': '19741424', 'FullCitation': 'Garcia_Casado Z, et al. Melanoma Res. (2009) pmid: 19741424', 'Include': 'true'}, {'number': '156', 'ReferenceId': '7640518', 'FullCitation': 'Gruis NA, et al. Melanoma Res. (1995) pmid: 7640518', 'Include': 'true'}, {'number': '157', 'ReferenceId': '11726555', 'FullCitation': 'Harland M, et al. Hum. Mol. Genet. (2001) pmid: 11726555', 'Include': 'true'}, {'number': '158', 'ReferenceId': '7624155', 'FullCitation': 'Liu L, et al. Oncogene (1995) pmid: 7624155', 'Include': 'true'}, {'number': '159', 'ReferenceId': '23384855', 'FullCitation': 'Puntervoll HE, et al. J. Med. Genet. (2013) pmid: 23384855', 'Include': 'true'}, {'number': '160', 'ReferenceId': '7647780', 'FullCitation': 'Ranade K, et al. Nat. Genet. (1995) pmid: 7647780', 'Include': 'true'}, {'number': '161', 'ReferenceId': '11136714', 'FullCitation': 'Randerson_Moor JA, et al. Hum. Mol. Genet. (2001) pmid: 11136714', 'Include': 'true'}, {'number': '162', 'ReferenceId': '23546221', 'FullCitation': 'Veinalde R, et al. Melanoma Res. (2013) pmid: 23546221', 'Include': 'true'}, {'number': '163', 'ReferenceId': '21278246', 'FullCitation': 'Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246', 'Include': 'true'}, {'number': '164', 'ReferenceId': '21871868', 'FullCitation': 'Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868', 'Include': 'true'}, {'number': '165', 'ReferenceId': '22711607', 'FullCitation': 'Cen L, et al. Neuro_oncology (2012) pmid: 22711607', 'Include': 'true'}, {'number': '166', 'ReferenceId': '23898052', 'FullCitation': 'Logan JE, et al. Anticancer Res. (2013) pmid: 23898052', 'Include': 'true'}, {'number': '167', 'ReferenceId': '35157829', 'FullCitation': 'Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829', 'Include': 'true'}, {'number': '168', 'ReferenceId': '28283584', 'FullCitation': 'Elvin JA, et al. Oncologist (2017) pmid: 28283584', 'Include': 'true'}, {'number': '169', 'ReferenceId': '26715889', 'FullCitation': 'Gao J, et al. Curr Oncol (2015) pmid: 26715889', 'Include': 'true'}, {'number': '170', 'ReferenceId': '25501126', 'FullCitation': 'DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126', 'Include': 'true'}, {'number': '171', 'ReferenceId': '25524798', 'FullCitation': 'Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798', 'Include': 'true'}, {'number': '172', 'ReferenceId': '27542767', 'FullCitation': 'Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767', 'Include': 'true'}, {'number': '173', 'ReferenceId': '24797823', 'FullCitation': 'Johnson DB, et al. Oncologist (2014) pmid: 24797823', 'Include': 'true'}, {'number': '174', 'ReferenceId': '22090362', 'FullCitation': 'Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362', 'Include': 'true'}, {'number': '175', 'ReferenceId': '23569312', 'FullCitation': 'Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312', 'Include': 'true'}, {'number': '176', 'ReferenceId': '31700061', 'FullCitation': 'Su D, et al. Nat Commun (2019) pmid: 31700061', 'Include': 'true'}, {'number': '177', 'ReferenceId': '32923894', 'FullCitation': 'Tramontana TF, et al. JCO Precis Oncol (2020) pmid: 32923894', 'Include': 'true'}, {'number': '178', 'ReferenceId': '21460101', 'FullCitation': 'Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101', 'Include': 'true'}, {'number': '179', 'ReferenceId': '21725357', 'FullCitation': 'Gamble LD, et al. Oncogene (2012) pmid: 21725357', 'Include': 'true'}, {'number': '180', 'ReferenceId': '7666917', 'FullCitation': 'Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917', 'Include': 'true'}, {'number': '181', 'ReferenceId': '20687502', 'FullCitation': 'Adv Exp Med Biol (2010) pmid: 20687502', 'Include': 'true'}, {'number': '182', 'ReferenceId': '9479083', 'FullCitation': 'Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083', 'Include': 'true'}, {'number': '183', 'ReferenceId': '29543703', 'FullCitation': 'De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703', 'Include': 'true'}, {'number': '184', 'ReferenceId': '26892650', 'FullCitation': 'Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650', 'Include': 'true'}, {'number': '185', 'ReferenceId': '29405243', 'FullCitation': 'Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243', 'Include': 'true'}, {'number': '186', 'ReferenceId': '8414022', 'FullCitation': 'Kaufman DK, et al. Neurology (1993) pmid: 8414022', 'Include': 'true'}, {'number': '187', 'ReferenceId': '9622062', 'FullCitation': 'Bahuau M, et al. Cancer Res (1998) pmid: 9622062', 'Include': 'true'}, {'number': '188', 'ReferenceId': '28699883', 'FullCitation': 'Chan AK, et al. Clin Neuropathol () pmid: 28699883', 'Include': 'true'}, {'number': '189', 'ReferenceId': '16584130', 'FullCitation': 'Sridhar J, et al. AAPS J (2006) pmid: 16584130', 'Include': 'true'}, {'number': '190', 'ReferenceId': '16322284', 'FullCitation': 'Kasugai Y, et al. Clin. Cancer Res. (2005) pmid: 16322284', 'Include': 'true'}, {'number': '191', 'ReferenceId': '10999753', 'FullCitation': 'Flørenes VA, et al. Clin. Cancer Res. (2000) pmid: 10999753', 'Include': 'true'}, {'number': '192', 'ReferenceId': '31849147', 'FullCitation': 'Tanaka Y, et al. Cancer Sci (2020) pmid: 31849147', 'Include': 'true'}, {'number': '193', 'ReferenceId': '22885699', 'FullCitation': 'Schmitz R, et al. Nature (2012) pmid: 22885699', 'Include': 'true'}, {'number': '194', 'ReferenceId': '23079655', 'FullCitation': 'Choi YJ, et al. Cancer Cell (2012) pmid: 23079655', 'Include': 'true'}, {'number': '195', 'ReferenceId': '23079656', 'FullCitation': 'Sawai CM, et al. Cancer Cell (2012) pmid: 23079656', 'Include': 'true'}, {'number': '196', 'ReferenceId': '35013097', 'FullCitation': 'Ketzer F, et al. Oncogenesis (2022) pmid: 35013097', 'Include': 'true'}, {'number': '197', 'ReferenceId': '22244889', 'FullCitation': 'Yanagi H, et al. Biochem. Biophys. Res. Commun. (2012) pmid: 22244889', 'Include': 'true'}, {'number': '198', 'ReferenceId': '22753141', 'FullCitation': 'Wang Y, et al. Mol. Carcinog. (2013) pmid: 22753141', 'Include': 'true'}, {'number': '199', 'ReferenceId': '22586683', 'FullCitation': 'Cheung HW, et al. Cancer Discov (2011) pmid: 22586683', 'Include': 'true'}, {'number': '200', 'ReferenceId': '19966867', 'FullCitation': 'Kim YH, et al. Oncogene (2010) pmid: 19966867', 'Include': 'true'}, {'number': '201', 'ReferenceId': '25318601', 'FullCitation': 'Fu L, et al. Tumour Biol. (2015) pmid: 25318601', 'Include': 'true'}, {'number': '202', 'ReferenceId': '25855536', 'FullCitation': 'Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536', 'Include': 'true'}, {'number': '203', 'ReferenceId': '22960745', 'FullCitation': 'Nature (2012) pmid: 22960745', 'Include': 'true'}, {'number': '204', 'ReferenceId': '24476821', 'FullCitation': 'Nature (2014) pmid: 24476821', 'Include': 'true'}, {'number': '205', 'ReferenceId': '23686806', 'FullCitation': 'Zhao T, et al. Tumour Biol. (2013) pmid: 23686806', 'Include': 'true'}, {'number': '206', 'ReferenceId': '16391854', 'FullCitation': 'Singer CF, et al. Oncol. Rep. (2006) pmid: 16391854', 'Include': 'true'}, {'number': '207', 'ReferenceId': '21319228', 'FullCitation': 'Wang J, et al. Mol. Carcinog. (2011) pmid: 21319228', 'Include': 'true'}, {'number': '208', 'ReferenceId': '24389200', 'FullCitation': 'Lan B, et al. Front Biosci (Landmark Ed) (2014) pmid: 24389200', 'Include': 'true'}, {'number': '209', 'ReferenceId': '23397142', 'FullCitation': 'Liu CH, et al. Mol. Cell Proteomics (2013) pmid: 23397142', 'Include': 'true'}, {'number': '210', 'ReferenceId': '22591714', 'FullCitation': 'Natsume H, et al. J Transl Med (2012) pmid: 22591714', 'Include': 'true'}, {'number': '211', 'ReferenceId': '22787428', 'FullCitation': 'Lin YC, et al. Neoplasia (2012) pmid: 22787428', 'Include': 'true'}, {'number': '212', 'ReferenceId': '25897431', 'FullCitation': 'Garrido_Laguna I, et al. Oncoscience (2015) pmid: 25897431', 'Include': 'true'}, {'number': '213', 'ReferenceId': '22736441', 'FullCitation': 'Suda K, et al. Cancer Metastasis Rev. (2012) pmid: 22736441', 'Include': 'true'}, {'number': '214', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '215', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '216', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '217', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '218', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '219', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '220', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '221', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '222', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '223', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '224', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '225', 'ReferenceId': '27671167', 'FullCitation': 'Johnson DB, et al. Cancer Immunol Res (2016) pmid: 27671167', 'Include': 'true'}, {'number': '226', 'ReferenceId': '28835386', 'FullCitation': 'Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386', 'Include': 'true'}, {'number': '227', 'ReferenceId': '29320474', 'FullCitation': 'Eroglu Z, et al. Nature (2018) pmid: 29320474', 'Include': 'true'}, {'number': '228', 'ReferenceId': '27903500', 'FullCitation': 'Shin DS, et al. Cancer Discov (2017) pmid: 27903500', 'Include': 'true'}, {'number': '229', 'ReferenceId': '29033130', 'FullCitation': 'Riaz N, et al. Cell (2017) pmid: 29033130', 'Include': 'true'}, {'number': '230', 'ReferenceId': '30309915', 'FullCitation': 'Cristescu R, et al. Science (2018) pmid: 30309915', 'Include': 'true'}, {'number': '231', 'ReferenceId': '30643254', 'FullCitation': 'Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254', 'Include': 'true'}, {'number': '232', 'ReferenceId': '32919529', 'FullCitation': 'Lancet Oncol. (2020) pmid: 32919529', 'Include': 'true'}, {'number': '233', 'ReferenceId': '28420421', 'FullCitation': 'Chalmers ZR, et al. Genome Med (2017) pmid: 28420421', 'Include': 'true'}, {'number': '234', 'ReferenceId': '23945592', 'FullCitation': 'Alexandrov LB, et al. Nature (2013) pmid: 23945592', 'Include': 'true'}, {'number': '235', 'ReferenceId': '26343386', 'FullCitation': 'Shain AH, et al. Nat. Genet. (2015) pmid: 26343386', 'Include': 'true'}, {'number': '236', 'ReferenceId': '26960397', 'FullCitation': 'Madore J, et al. Clin. Cancer Res. (2016) pmid: 26960397', 'Include': 'true'}, {'number': '237', 'ReferenceId': '26559571', 'FullCitation': 'Shain AH, et al. N. Engl. J. Med. (2015) pmid: 26559571', 'Include': 'true'}, {'number': '238', 'ReferenceId': '31405947', 'FullCitation': 'Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947', 'Include': 'true'}, {'number': '239', 'ReferenceId': '30785829', 'FullCitation': 'Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829', 'Include': 'true'}, {'number': '240', 'ReferenceId': '29658845', 'FullCitation': 'Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845', 'Include': 'true'}, {'number': '241', 'ReferenceId': '29657128', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128', 'Include': 'true'}, {'number': '242', 'ReferenceId': '29731394', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394', 'Include': 'true'}, {'number': '243', 'ReferenceId': '33558721', 'FullCitation': 'Rozeman EA, et al. Nat Med (2021) pmid: 33558721', 'Include': 'true'}, {'number': '244', 'ReferenceId': '32916128', 'FullCitation': 'Sharma P, et al. Cancer Cell (2020) pmid: 32916128', 'Include': 'true'}, {'number': '245', 'ReferenceId': '35355708', 'FullCitation': 'Ning B, et al. Front Pharmacol (2022) pmid: 35355708', 'Include': 'true'}, {'number': '246', 'ReferenceId': '31515453', 'FullCitation': 'Liu L, et al. Clin. Cancer Res. (2019) pmid: 31515453', 'Include': 'true'}, {'number': '247', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '248', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '249', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '250', 'ReferenceId': '9823339', 'FullCitation': 'Boland CR, et al. Cancer Res. (1998) pmid: 9823339', 'Include': 'true'}, {'number': '251', 'ReferenceId': '15528785', 'FullCitation': 'Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785', 'Include': 'true'}, {'number': '252', 'ReferenceId': '20420947', 'FullCitation': 'Boland CR, et al. Gastroenterology (2010) pmid: 20420947', 'Include': 'true'}, {'number': '253', 'ReferenceId': '27623135', 'FullCitation': 'Kubeček O, et al. Melanoma Res. (2016) pmid: 27623135', 'Include': 'true'}, {'number': '254', 'ReferenceId': '27372860', 'FullCitation': 'Kubecek O, et al. Med. Hypotheses (2016) pmid: 27372860', 'Include': 'true'}, {'number': '255', 'ReferenceId': '7561170', 'FullCitation': 'Peris K, et al. J. Invest. Dermatol. (1995) pmid: 7561170', 'Include': 'true'}, {'number': '256', 'ReferenceId': '25392179', 'FullCitation': 'Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179', 'Include': 'true'}, {'number': '257', 'ReferenceId': '26140250', 'FullCitation': 'Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250', 'Include': 'true'}, {'number': '258', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '259', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '260', 'ReferenceId': '22961667', 'FullCitation': 'Ercan D, et al. Cancer Discov (2012) pmid: 22961667', 'Include': 'true'}, {'number': '261', 'ReferenceId': '23820584', 'FullCitation': 'Rahman MT, et al. Int J Mol Sci (2013) pmid: 23820584', 'Include': 'true'}, {'number': '262', 'ReferenceId': '21896986', 'FullCitation': 'Kostrzewska_Poczekaj M, et al. Cancer Biomark () pmid: 21896986', 'Include': 'true'}, {'number': '263', 'ReferenceId': '26440310', 'FullCitation': 'Murali R, et al. Oncotarget (2015) pmid: 26440310', 'Include': 'true'}, {'number': '264', 'ReferenceId': '16763210', 'FullCitation': 'Kornblau SM, et al. Blood (2006) pmid: 16763210', 'Include': 'true'}, {'number': '265', 'ReferenceId': '26915336', 'FullCitation': 'Manso R, et al. Br. J. Haematol. (2017) pmid: 26915336', 'Include': 'true'}, {'number': '266', 'ReferenceId': '28512266', 'FullCitation': 'Chakraborty R, et al. Oncotarget (2017) pmid: 28512266', 'Include': 'true'}, {'number': '267', 'ReferenceId': '27760319', 'FullCitation': 'Brenan L, et al. Cell Rep (2016) pmid: 27760319', 'Include': 'true'}, {'number': '268', 'ReferenceId': '25320010', 'FullCitation': 'Goetz EM, et al. Cancer Res. (2014) pmid: 25320010', 'Include': 'true'}, {'number': '269', 'ReferenceId': '24263190', 'FullCitation': 'Goel HL, et al. Nat. Rev. Cancer (2013) pmid: 24263190', 'Include': 'true'}, {'number': '270', 'ReferenceId': '24687604', 'FullCitation': 'Horwitz E, et al. Cancer Discov (2014) pmid: 24687604', 'Include': 'true'}, {'number': '271', 'ReferenceId': '26359337', 'FullCitation': 'Van Allen EM, et al. Science (2015) pmid: 26359337', 'Include': 'true'}, {'number': '272', 'ReferenceId': '25977583', 'FullCitation': 'Bauer AT, et al. Blood (2015) pmid: 25977583', 'Include': 'true'}, {'number': '273', 'ReferenceId': '17926107', 'FullCitation': 'Sahin A, et al. Jpn. J. Ophthalmol. () pmid: 17926107', 'Include': 'true'}, {'number': '274', 'ReferenceId': '17030710', 'FullCitation': 'Missotten GS, et al. Arch. Ophthalmol. (2006) pmid: 17030710', 'Include': 'true'}, {'number': '275', 'ReferenceId': '24677103', 'FullCitation': 'Koch KR, et al. Invest. Ophthalmol. Vis. Sci. (2014) pmid: 24677103', 'Include': 'true'}, {'number': '276', 'ReferenceId': '22565005', 'FullCitation': 'Van Cutsem E, et al. J. Clin. Oncol. (2012) pmid: 22565005', 'Include': 'true'}, {'number': '277', 'ReferenceId': '23422754', 'FullCitation': 'Miles DW, et al. Br. J. Cancer (2013) pmid: 23422754', 'Include': 'true'}, {'number': '278', 'ReferenceId': '23569311', 'FullCitation': 'Gianni L, et al. J. Clin. Oncol. (2013) pmid: 23569311', 'Include': 'true'}, {'number': '279', 'ReferenceId': '23932548', 'FullCitation': 'Cameron D, et al. Lancet Oncol. (2013) pmid: 23932548', 'Include': 'true'}, {'number': '280', 'ReferenceId': '23169435', 'FullCitation': 'Hegde PS, et al. Clin. Cancer Res. (2013) pmid: 23169435', 'Include': 'true'}, {'number': '281', 'ReferenceId': '23340303', 'FullCitation': 'Schneider BP, et al. Clin. Cancer Res. (2013) pmid: 23340303', 'Include': 'true'}, {'number': '282', 'ReferenceId': '26627848', 'FullCitation': 'Baumgarten P, et al. Neuro_oncology (2016) pmid: 26627848', 'Include': 'true'}, {'number': '283', 'ReferenceId': '18182667', 'FullCitation': 'Sathornsumetee S, et al. J. Clin. Oncol. (2008) pmid: 18182667', 'Include': 'true'}, {'number': '284', 'ReferenceId': '31582283', 'FullCitation': 'Olafson LR, et al. J Clin Neurosci (2019) pmid: 31582283', 'Include': 'true'}, {'number': '285', 'ReferenceId': '20484123', 'FullCitation': 'Duda DG, et al. Oncologist (2010) pmid: 20484123', 'Include': 'true'}, {'number': '286', 'ReferenceId': '27535973', 'FullCitation': 'Stremitzer S, et al. Mol. Cancer Ther. (2016) pmid: 27535973', 'Include': 'true'}, {'number': '287', 'ReferenceId': '26125443', 'FullCitation': 'Weickhardt AJ, et al. Br. J. Cancer (2015) pmid: 26125443', 'Include': 'true'}, {'number': '288', 'ReferenceId': '20008624', 'FullCitation': 'Kopetz S, et al. J. Clin. Oncol. (2010) pmid: 20008624', 'Include': 'true'}, {'number': '289', 'ReferenceId': '21868552', 'FullCitation': 'Fountzilas G, et al. Anticancer Res. (2011) pmid: 21868552', 'Include': 'true'}, {'number': '290', 'ReferenceId': '23397155', 'FullCitation': 'Sánchez_Rovira P, et al. Clin Transl Oncol (2013) pmid: 23397155', 'Include': 'true'}, {'number': '291', 'ReferenceId': '24807156', 'FullCitation': 'Mok T, et al. J Thorac Oncol (2014) pmid: 24807156', 'Include': 'true'}, {'number': '292', 'ReferenceId': '24577128', 'FullCitation': 'An SJ, et al. Cancer Gene Ther. (2014) pmid: 24577128', 'Include': 'true'}, {'number': '293', 'ReferenceId': '29059426', 'FullCitation': 'Bais C, et al. J. Natl. Cancer Inst. (2017) pmid: 29059426', 'Include': 'true'}, {'number': '294', 'ReferenceId': '19826039', 'FullCitation': 'Xu L, et al. Cancer Res. (2009) pmid: 19826039', 'Include': 'true'}, {'number': '295', 'ReferenceId': '20666740', 'FullCitation': 'Hasselbalch B, et al. APMIS (2010) pmid: 20666740', 'Include': 'true'}, {'number': '296', 'ReferenceId': '28465540', 'FullCitation': 'Marisi G, et al. Sci Rep (2017) pmid: 28465540', 'Include': 'true'}, {'number': '297', 'ReferenceId': '16365183', 'FullCitation': 'Jubb AM, et al. J. Clin. Oncol. (2006) pmid: 16365183', 'Include': 'true'}, {'number': '298', 'ReferenceId': '20924372', 'FullCitation': 'Goede V, et al. Br. J. Cancer (2010) pmid: 20924372', 'Include': 'true'}, {'number': '299', 'ReferenceId': '24374727', 'FullCitation': 'Bruhn MA, et al. Int. J. Cancer (2014) pmid: 24374727', 'Include': 'true'}, {'number': '300', 'ReferenceId': '18156031', 'FullCitation': 'Escudier B, et al. Lancet (2007) pmid: 18156031', 'Include': 'true'}, {'number': '301', 'ReferenceId': '12890841', 'FullCitation': 'Yang JC, et al. N. Engl. J. Med. (2003) pmid: 12890841', 'Include': 'true'}, {'number': '302', 'ReferenceId': '19047116', 'FullCitation': 'Burstein HJ, et al. Clin. Cancer Res. (2008) pmid: 19047116', 'Include': 'true'}, {'number': '303', 'ReferenceId': '21224365', 'FullCitation': 'Jubb AM, et al. Clin. Cancer Res. (2011) pmid: 21224365', 'Include': 'true'}, {'number': '304', 'ReferenceId': '27817944', 'FullCitation': 'Miles D, et al. Eur. J. Cancer (2017) pmid: 27817944', 'Include': 'true'}, {'number': '305', 'ReferenceId': '18316562', 'FullCitation': 'Dowlati A, et al. Clin. Cancer Res. (2008) pmid: 18316562', 'Include': 'true'}, {'number': '306', 'ReferenceId': '19826110', 'FullCitation': 'Horn L, et al. J. Clin. Oncol. (2009) pmid: 19826110', 'Include': 'true'}, {'number': '307', 'ReferenceId': '26976425', 'FullCitation': 'Blakeley JO, et al. J. Clin. Oncol. (2016) pmid: 26976425', 'Include': 'true'}, {'number': '308', 'ReferenceId': '30935424', 'FullCitation': 'Oh CR, et al. BMC Cancer (2019) pmid: 30935424', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2023_03_22 03:15:55', 'OpName': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': '813x'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': '4 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': 'Units Not Reported'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'SKIN', 'disease_ontology': 'Skin melanoma', 'flowcell_analysis': '2000028219', 'gender': 'male', 'pathology_diagnosis': 'C43, Melanoma', 'percent_tumor_nuclei': '50', 'pipeline_version': 'v3.20.0', 'purity_assessment': '72.0', 'specimen': 'ORD_1585457_01*US1515644.01', 'study': 'CLINICAL_F1CDx v2', 'test_request': 'ORD_1585457_01', 'test_type': 'FoundationOneDx', 'tissue_of_origin': 'Lung', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'DX2', 'mean_exon_depth': '833.53', 'name': 'SQ_US1515644.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.9953', 'cds_effect': '455C>T', 'depth': '428', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BCOR', 'percent_reads': '99.53', 'position': 'chrX:39934144', 'protein_effect': 'P152L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_017745', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'allele_fraction': '0.5', 'cds_effect': '827A>G', 'depth': '734', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '50.0', 'position': 'chr2:212587174', 'protein_effect': 'E276G', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'allele_fraction': '0.4626', 'cds_effect': '1565C>T', 'depth': '748', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PARP2', 'percent_reads': '46.26', 'position': 'chr14:20825652', 'protein_effect': 'A522V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005484', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'allele_fraction': '0.3893', 'cds_effect': '6424G>A', 'depth': '637', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'POLE', 'percent_reads': '38.93', 'position': 'chr12:133202810', 'protein_effect': 'A2142T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006231', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'allele_fraction': '0.4629', 'cds_effect': '838G>A', 'depth': '728', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GNAS', 'percent_reads': '46.29', 'position': 'chr20:57429158', 'protein_effect': 'A280T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_080425', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'allele_fraction': '0.4003', 'cds_effect': '2041C>G', 'depth': '652', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RET', 'percent_reads': '40.03', 'position': 'chr10:43610089', 'protein_effect': 'Q681E', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_020975', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'allele_fraction': '0.4883', 'cds_effect': '1874G>A', 'depth': '940', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ASXL1', 'percent_reads': '48.83', 'position': 'chr20:31022389', 'protein_effect': 'R625Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_015338', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'allele_fraction': '0.4927', 'cds_effect': '2643G>T', 'depth': '822', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MST1R', 'percent_reads': '49.27', 'position': 'chr3:49933634', 'protein_effect': 'K881N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002447', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'allele_fraction': '0.4316', 'cds_effect': '104G>A', 'depth': '526', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MKNK1', 'percent_reads': '43.16', 'position': 'chr1:47048932', 'protein_effect': 'R35Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003684', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'allele_fraction': '0.5126', 'cds_effect': '915G>T', 'depth': '677', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CDK6', 'percent_reads': '51.26', 'position': 'chr7:92244520', 'protein_effect': 'R305S', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001259', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'allele_fraction': '0.7244', 'cds_effect': '182A>G', 'depth': '1357', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KRAS', 'percent_reads': '72.44', 'position': 'chr12:25380276', 'protein_effect': 'Q61R', 'status': 'known', 'strand': '_', 'transcript': 'NM_004985', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'allele_fraction': '0.5913', 'cds_effect': '3484A>G', 'depth': '756', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NF1', 'percent_reads': '59.13', 'position': 'chr17:29559887', 'protein_effect': 'M1162V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001042492', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'allele_fraction': '0.4838', 'cds_effect': '1388T>A', 'depth': '618', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGFR2', 'percent_reads': '48.38', 'position': 'chr10:123263355', 'protein_effect': 'V463D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000141', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}]}, 'copy_number_alterations': {'copy_number_alteration': [{'copy_number': '9', 'equivocal': 'true', 'gene': 'RAD52', 'number_of_exons': '11 of 11', 'position': 'chr12:1022522_1042247', 'ratio': '1.94', 'status': 'ambiguous', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '9', 'equivocal': 'true', 'gene': 'PTPRO', 'number_of_exons': '27 of 27', 'position': 'chr12:15475633_15747987', 'ratio': '1.93', 'status': 'ambiguous', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '9', 'equivocal': 'true', 'gene': 'PIK3C2G', 'number_of_exons': '31 of 31', 'position': 'chr12:18435015_18800962', 'ratio': '1.89', 'status': 'ambiguous', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '9', 'equivocal': 'true', 'gene': 'FGF23', 'number_of_exons': '3 of 3', 'position': 'chr12:4479508_4488748', 'ratio': '1.97', 'status': 'ambiguous', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '0', 'equivocal': 'false', 'gene': 'TEK', 'number_of_exons': '23 of 23', 'position': 'chr9:27109549_27229257', 'ratio': '0.26', 'status': 'unknown', 'type': 'loss', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '9', 'equivocal': 'true', 'gene': 'FGF6', 'number_of_exons': '3 of 3', 'position': 'chr12:4543380_4554736', 'ratio': '1.91', 'status': 'ambiguous', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '0', 'equivocal': 'false', 'gene': 'CDKN2B', 'number_of_exons': '5 of 5', 'position': 'chr9:22002170_22010784', 'ratio': '0.28', 'status': 'known', 'type': 'loss', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '9', 'equivocal': 'true', 'gene': 'CCND2', 'number_of_exons': '5 of 5', 'position': 'chr12:4383206_4409175', 'ratio': '1.87', 'status': 'ambiguous', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '21', 'equivocal': 'false', 'gene': 'CRKL', 'number_of_exons': '5 of 5', 'position': 'chr22:21272222_21304133', 'ratio': '4.15', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '9', 'equivocal': 'true', 'gene': 'KDM5A', 'number_of_exons': '28 of 28', 'position': 'chr12:394621_498257', 'ratio': '1.95', 'status': 'ambiguous', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '13', 'equivocal': 'true', 'gene': 'VEGFA', 'number_of_exons': '8 of 8', 'position': 'chr6:43738443_43752419', 'ratio': '2.55', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '9', 'equivocal': 'true', 'gene': 'KRAS', 'number_of_exons': '5 of 5', 'position': 'chr12:25362722_25398327', 'ratio': '1.91', 'status': 'ambiguous', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '10', 'equivocal': 'true', 'gene': 'EP300', 'number_of_exons': '31 of 31', 'position': 'chr22:41488990_41574960', 'ratio': '2.04', 'status': 'unknown', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '9', 'equivocal': 'true', 'gene': 'CDKN1B', 'number_of_exons': '3 of 3', 'position': 'chr12:12870773_12874150', 'ratio': '1.89', 'status': 'ambiguous', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '0', 'equivocal': 'false', 'gene': 'MTAP', 'number_of_exons': '8 of 8', 'position': 'chr9:21802699_21862058', 'ratio': '0.26', 'status': 'known', 'type': 'loss', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '13', 'equivocal': 'true', 'gene': 'CCND3', 'number_of_exons': '5 of 5', 'position': 'chr6:41903677_41909387', 'ratio': '2.56', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '0', 'equivocal': 'false', 'gene': 'CDKN2A', 'number_of_exons': '5 of 5', 'position': 'chr9:21968169_21994453', 'ratio': '0.27', 'status': 'known', 'type': 'loss', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}, {'copy_number': '10', 'equivocal': 'true', 'gene': 'MAPK1', 'number_of_exons': '8 of 8', 'position': 'chr22:22123486_22221735', 'ratio': '2.11', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1515644.01_1'}}]}, 'rearrangements': None, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '3.62', 'status': 'low', 'unit': 'mutations_per_megabase'}}, 'non_human_content': None}}}}	M112-10067          	PF23024             
4	341	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2023_00028536', 'CSN': None, 'TRF': 'ORD_1606878_01', 'MRN': '46204846', 'PhysicianId': '109266', 'NPI': None}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1304636', 'clinicalId': '1305986', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1606878_01', 'SampleName': 'US1533679.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1606878_01', 'SampleId': 'US1533679.01', 'BlockId': 'S110_34021 D (PF23035)', 'TRFNumber': 'ORD_1606878_01', 'TestType': 'FoundationOne CDX', 'SpecFormat': 'Slide Deck', 'ReceivedDate': '2023_04_10', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}]}}, 'PMI': {'ReportId': 'ORD_1606878_01', 'MRN': '46204846', 'FullName': 'Yang, Shih Chang', 'FirstName': 'Shih Chang', 'LastName': 'Yang', 'SubmittedDiagnosis': 'Colon adenocarcinoma (CRC)', 'Gender': 'Male', 'DOB': '1969_10_24', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Colon', 'CollDate': '2021_11_09', 'ReceivedDate': '2023_04_10', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': {'PertinentNegative': [{'Gene': 'BRAF'}, {'Gene': 'KRAS'}, {'Gene': 'NRAS'}]}, 'Summaries': {'alterationCount': '22', 'clinicalTrialCount': '28', 'resistiveCount': '0', 'sensitizingCount': '5'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'ALK', 'isVUS': 'true', 'variantName': 'R510W'}, {'geneName': 'BRD4', 'isVUS': 'true', 'variantName': 'V228I'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'R979Q'}, {'geneName': 'FANCC', 'isVUS': 'true', 'variantName': 'A325T'}, {'geneName': 'MTOR', 'isVUS': 'true', 'variantName': 'G279E'}, {'geneName': 'POLE', 'isVUS': 'true', 'variantName': 'G1535S,R1679C'}, {'geneName': 'RAD52', 'isVUS': 'true', 'variantName': 'amplification'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'APC', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R232*', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '56.74', 'isEquivocal': 'false', 'name': 'R232*'}}, 'Interpretation': 'APC (adenomatous polyposis coli) encodes a tumor suppressor with critical roles in regulating cell division and adhesion. APC interacts with beta_catenin and controls signaling in the WNT pathway, which regulates embryonic development and cell differentiation (Logan and Nusse, 2004; 15473860). Alterations such as seen here may disrupt APC function or expression (Eklof et al., 2001; 11707392, Liu et al., 2006; 16753179, Dikovskaya et al., 2010; 20144988, Murphy et al., 2007; 17410430, Aretz et al., 2004; 15459959). APC mutations have been found in 73% of tumors in the colorectal adenocarcinoma TCGA dataset (Cancer Genome Atlas Network, 2012; 22810696). In 1 study, loss of heterozygosity (LOH) of APC was observed in 32% of colorectal cancer (CRC) samples (Christie et al., 2013; 23085758). The prognostic significance of APC mutations in sporadic CRC remains unclear (Quyn et al., 2008; 19110823). Solid tumors with WNT/beta_catenin pathway alterations, as seen here, were observed to have significantly less T_cell inflammation in one study (Luke et al., 2019; 30635339). There are no approved drugs targeting APC inactivation in cancer. Loss of APC function leads to accumulation of beta_catenin and upregulation of WNT pathway transcription programs (Zhan et al., 2017; 27617575), and potential therapeutic approaches to target this pathway include CBP/beta_catenin antagonists, which interfere with the ability of beta_catenin to interact with transcriptional co_activator CBP (Jung et al., 2020; 32037398, Krishnamurthy and Kurzrock, 2018; 29169144). In a Phase 1 trial of the CBP/beta_catenin antagonist E7386, 1 patient with APC_mutated small bowel adenocarcinoma achieved a PR with tumor shrinkage of _69% and response duration of 165 days (Kawazoe et al., 2021; ESMO Abstract 473P); preclinical data support sensitivity of APC_deficient gastric or colorectal cancer models to E7386 (Yamada et al., 2021; 33408116, Kanda et al., 2022; 34837838). One or more of the APC variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with familial adenomatous polyposis (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in APC are found in more than 90% of patients with familial adenomatous polyposis (FAP) (Kerr et al., 2013; 23159591, Fearon, 2011; 21090969, Kastritis et al., 2009; 18844223). The prevalence for FAP in the general population is estimated to be 1:8,300 from birth (Half et al., 2009; 19822006), and in the appropriate clinical context germline testing of APC is recommended.', 'Include': 'true', 'ClinicalTrialNote': 'Based on preclinical and limited clinical data, APC inactivation may be associated with sensitivity to CBP/beta_catenin interaction inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT05091346', 'Include': 'true'}, {'nctId': 'NCT04008797', 'Include': 'true'}, {'nctId': 'NCT03264664', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'CCND2', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'CCND2 encodes the protein cyclin D2, which binds and regulates the cyclin_dependent kinases that control cell cycle progression, and is a downstream target of cancer signaling pathways including hedgehog and PI3K (Katoh and Katoh, 2009; 19860666, White et al., 2006; 16301994). CCND2 has been reported to be amplified in cancer (Gao et al., 2013; 23550210), and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). In the Colorectal Adenocarcinoma TCGA dataset, putative high_level amplification of CCND2 has been found in 1.4% of cases (Cancer Genome Atlas Network., 2012; 22810696). Cyclin D2 has also reportedly been overexpressed in 53% of colorectal adenocarcinomas (Mermelshtein et al., 2005; 16012517). Overexpression of CCND2 mRNA in CRC has been correlated with poor patient prognosis (Liu et al., 2010; 21052002). In addition, the expression of cyclin D2 at the invasive margin has been associated with liver metastasis in colorectal cancer, and in patients with Stage 1 and 2 tumors, cyclin D2 expression has also been associated with reduced patient survival (Sarkar et al., 2010; 19508551). Although preclinical studies suggest that cyclin D2 activates CDK4/6 (Busk et al., 2005; 15707582, Busk, 2003; 12695654), it is unknown whether CCND2 amplification or activating mutation predicts response to CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib. Clinical studies of CDK4/6 inhibitors have shown the most promise for estrogen receptor_positive breast cancer (Finn et al., 2014; 25524798, DeMichele et al., 2014; 25501126).', 'Include': 'true', 'ClinicalTrialNote': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04282031', 'Include': 'true'}, {'nctId': 'NCT05480280', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT03994796', 'Include': 'true'}, {'nctId': 'NCT05252416', 'Include': 'true'}, {'nctId': 'NCT02896335', 'Include': 'true'}, {'nctId': 'NCT04616183', 'Include': 'true'}, {'nctId': 'NCT05159245', 'Include': 'true'}, {'nctId': 'NCT03310879', 'Include': 'true'}, {'nctId': 'NCT03454035', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'ERBB2', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'T798I', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '39.22', 'isEquivocal': 'false', 'name': 'T798I'}}, 'Interpretation': 'ERBB2 (also known as HER2) encodes a receptor tyrosine kinase which is in the same family as EGFR. The ERBB2 gatekeeper mutation T798I has been found to lack transforming ability (Trowe et al., 2008; 18413839, Hanker et al., 2017; 28274957), but was reported to be an emergent mutation associated with acquired resistance to neratinib (Hanker et al., 2017; 28274957). Preclinical studies have reported that this mutation also confers reduced sensitivity to lapatinib (Trowe et al., 2008; 18413839, Li et al., 2014; 25238247). ERBB2 T798I retains sensitivity to other irreversible pan_HER inhibitors such as afatinib (Hanker et al., 2017; 28274957) and PD168393 (Li et al., 2014; 25238247). ERBB2 mutation or amplification was observed in 4% and 2_6% of colorectal adenocarcinoma cases, respectively (Cancer Genome Atlas Network, 2012; 22810696, Ross et al., 2018; 29338072, Heppner et al., 2014; 25211663, Seo et al., 2014; 24879338). For patients with colorectal cancer, multiple studies have shown that ERBB2 overexpression does not correlate with survival (Wu et al., 2015; 26276145, Seo et al., 2014; 24879338, Sclafani et al., 2013; 24146218) and is not considered prognostic (NCCN Colon Cancer Guidelines, v3.2022, NCCN Rectal Guidelines, v4.2022); however, studies have shown an association of ERBB2 amplification with reduced response and/or shorter survival for patients treated with anti_EGFR antibodies (Martin et al., 2013; 23348520, Sartore_Bianchi et al., 2019; 30952821, Raghav et al., 2019; DOI: 10.1200/PO.18.00226). On the basis of extensive clinical evidence, ERBB2 amplification or activating mutation may predict sensitivity to therapies targeting HER2, including antibodies such as trastuzumab (Slamon et al., 2001; 11248153, Bang et al., 2010; 20728210, Chumsri et al., 2015; 26358791, Cappuzzo et al., 2006; 16775247, Falchook et al., 2013; 23328556, Mazieres et al., 2013; 23610105), pertuzumab in combination with trastuzumab (Baselga et al., 2012; 22149875, Swain et al., 2015; 25693012, Chumsri et al., 2015; 26358791, Meric_Bernstam et al., 2019; 30857956), and zanidatamab (ZW25) (Meric_Bernstam et al., 2022; 36400106), as well as antibody_directed conjugates such as ado_trastuzumab emtansine (T_DM1) (Verma et al., 2012; 23020162) and fam_trastuzumab deruxtecan (T_DXd) (Modi et al., 2020; 31825192, Shitara et al., 2020; 32469182, Li et al., 2022; 34534430, Smit et al., 2021; ESMO Abstract 1361TiP), HER2 kinase inhibitors such as tucatinib (Murthy et al., 2020; 31825569, Borges et al., 2018; 29955792, Murthy et al., 2018; 29804905, Moulder et al., 2017; 28053022, Strickler et al., 2022; ESMO GI Abstract LBA_2), and dual EGFR/HER2 kinase inhibitors such as lapatinib (Fan et al., 2020; 32478891, Cameron et al., 2010; 20736298, Geyer et al., 2006; 17192538, Serra et al., 2013; 23950206, Ali et al., 2014; 24516025, Grellety et al., 2015; 26487584, Vornicova et al., 2014; 25085898, Ronellenfitsch et al., 2020; 32017710, Hou et al., 2020; 32405522), afatinib (Lin et al., 2012; 22418700, Schwab et al., 2014; 25268372, De Greve et al., 2015; 25682316, De Greve et al., 2012; 22325357, Li et al., 2015; 26559459, Mazieres et al., 2013; 23610105, Bedard et al., 2019; AACR Abstract CT139, Dziadziuszko et al., 2019; 30825613, Lai et al., 2019; 30685684, Liu et al., 2018; 30425522, Fang et al., 2019; 31748336, Yuan et al., 2020; 32477948), neratinib (Ben_Baruch et al., 2015; 26358790, Ma et al., 2017; 28679771, Hyman et al., 2018; 29420467, Smyth et al., 2020; 31806627, Li et al., 2020; WCLC Abstract FP14.15), dacomitinib (Kris et al., 2015; 25899785), and pyrotinib (Jiang et al., 2019; ASCO Abstract 1001, Xu et al., 2020; ASCO Abstract 1003). The Phase 1 trial of HER2_selective TKI BI_1810631 for patients with HER2_aberration_positive metastatic solid tumors reported a 3.7% ORR (7/19) and an 84% DCR; for patients with NSCLC, a 45% ORR (5/11) and a 91% DCR were reported (Opdam et al., 2022; ENA Abstract 1LBA). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. Tyrosine kinase inhibitors such as afatinib and lapatinib have yielded limited clinical efficacy as monotherapies in CRC, suggesting antibody therapeutics or combination therapies may be more beneficial in this tumor type (Johnsson et al., 2013; 23788755, Ma et al., 2013; 24114668, Frank et al., 2012; 22811876, Bouche et al., 2011; 21737652). Limited clinical and preclinical data indicate that ERBB2 T798I may confer resistance to lapatinib (Trowe et al., 2008; 18413839, Li et al., 2014; 25238247) and neratinib (Hanker et al., 2017; 2827495) and remain sensitive to afatinib (Hanker et al., 2017; 28274957) and PD168393 (Li et al., 2014; 25238247).', 'Include': 'true', 'ClinicalTrialNote': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors. Based on limited clinical and preclinical evidence, ERBB2 T798I may confer reduced sensitivity to lapatinib and neratinib. Tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib, and lapatinib have yielded limited clinical efficacy as monotherapies in CRC, suggesting that antibody therapeutics or combination therapies may be more beneficial in this tumor type. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04589845', 'Include': 'true'}, {'nctId': 'NCT04579380', 'Include': 'true'}, {'nctId': 'NCT04999761', 'Include': 'true'}, {'nctId': 'NCT02693535', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}, {'nctId': 'NCT05159245', 'Include': 'true'}, {'nctId': 'NCT04817956', 'Include': 'true'}, {'nctId': 'NCT04294628', 'Include': 'true'}, {'nctId': 'NCT05395052', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'NF1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'loss exons 37_58', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'loss exons 37_58'}}, 'Interpretation': 'NF1 encodes neurofibromin, a GTPase_activating protein (GAP) that is a key negative regulator of the RAS signaling pathway (Hattori et al., 1991; 1904223). Neurofibromin acts as a tumor suppressor by repressing RAS signaling (Morcos et al., 1996; 8628317). Alterations such as seen here may disrupt NF1 function or expression (Ballester et al., 1990; 2121371, Xu et al., 1990; 2116237, Martin et al., 1990; 2121370, Thomas et al., 2012; 22807134, Skuse and Cappione, 1997; 9300663, Morcos et al., 1996; 8628317, Messiaen et al., 1999; 11258625, Ars et al., 2000; 10607834, Messiaen and Wimmer, 2005; 15863657, Poullet et al., 1994; 8264648). In the Colorectal Adenocarcinoma TCGA dataset, NF1 mutations have been found in 1.4% of sequenced tumors (cBio_Cancer Genome Atlas Network, 2012; 22810696). For patients with colorectal cancer (CRC), NF1 mutations have been reported to be associated with significantly worse OS following treatment with cetuximab or bevacizumab (p=0.04 and 0.007, HR=2.62 and 2.05); low NF1 expression was associated with significantly worse OS (p=0.003, HR=1.49) and PFS (p=0.02, HR=1.36) when compared with high NF1 expression (Arai et al., 2022; 34728807). On the basis of clinical evidence in neurofibromatosis Type 1_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma or glioblastoma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors such as cobimetinib, trametinib, binimetinib, and selumetinib. On the basis of limited clinical data (Lim et al., 2016; 26859683 , Weiss et al., 2015; 25314964, Janku et al., 2014; 24931142) and preclinical data (Johannessen et al., 2008; 18164202, Johannessen et al., 2005; 15937108), loss or inactivation of NF1 may predict sensitivity to mTOR inhibitors, including everolimus and temsirolimus. A preclinical study suggests that combined mTOR and MEK inhibition is effective in a model of NF1_deficient malignant peripheral nerve sheath tumors (MPNST) (Malone et al., 2014; 24913553). Multiple clinical studies report that inhibitors of the PI3K_AKT_mTOR pathway have not produced significant clinical benefit as monotherapies to treat CRC, even for tumors that harbor alterations in PIK3CA or PTEN; data are more limited for alterations in other genes in this pathway (Ng et al., 2013; 23743569, Ganesan et al., 2013; 24092809, Janku et al., 2014; 24440717). Germline mutations in NF1 cause the autosomal dominant disorder neurofibromatosis type 1, which is characterized in part by increased risk of developing various tumors, including sarcoma, glioma, breast carcinoma, and neuroendocrine and hematological neoplasms (Jett and Friedman, 2010; 20027112, Patil and Chamberlain, 2012; 22240541, Evans et al., 2012; 23036231). Estimates for the prevalence of the disorder in the general population range from 1:2,500 to 1:3,000 (Upadhyaya et al., 1995; 8544190, Williams et al., 2009; 19117870), and in the appropriate clinical context, germline testing of NF1 is recommended.', 'Include': 'true', 'ClinicalTrialNote': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors. Several clinical studies have shown that inhibitors of the PI3K_AKT_mTOR pathway have not produced significant clinical benefit when used as a monotherapy in patients with colorectal cancer; combination therapies may be required to overcome this lack of response.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Selumetinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients with neurofibromatosis type 1 (NF1)_associated plexiform neurofibromas (PNs). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in neurofibromatosis type 1 (NF1)_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> In Phase 2 studies for chemotherapy_refractory metastatic colorectal cancer (CRC), single_agent selumetinib demonstrated similar outcomes compared with capecitabine in genomically unselected patients (ORR, 0% [0/34] vs. 2.8% [1/35]; median PFS [mPFS], 81 vs. 88 days) (Bennouna et al., 2011; 20127139), and combination of selumetinib with irinotecan elicited an ORR of 9.7% (3/31 PRs), mPFS of 105 days, and median OS of 267 days in patients with KRAS mutation (Hochster et al., 2015; 25322874). Phase 1 and 2 studies have evaluated selumetinib in combination with the AKT inhibitor MK_2206 (Do et al., 2015; 25637165, Tolcher et al., 2015; 25516890), the EGFR_targeting monoclonal antibody cetuximab (Deming et al., 2016; 26666244), the EGFR_targeting TKI afatinib (van Brummelen et al., 2021; 33296125), or Cyclosporin A (Krishnamurthy et al., 2018; 30042150), but have reported limited activity and no confirmed objective responses for patients with CRC. </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Trametinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in neurofibromatosis type 1 (NF1)_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> Trametinib has shown limited activity as a single agent in advanced or metastatic colorectal cancer (CRC), with no objective responses in 28 patients (including 13 with KRAS and 3 with BRAF mutation) included in a Phase 1 study (Infante et al., 2012; 22805291) nor in 7 patients with non_V600 BRAF mutation included in the Phase 2 NCI_MATCH trial (Johnson et al., 2020; 31924734). In Phase 1/2 studies for metastatic CRC (mCRC), combination of trametinib with the EGFR_targeting antibody panitumumab demonstrated modest activity for BRAF/KRAS/NRAS_wildtype patients, with 38% (5/13) confirmed ORR, 92% (12/13) DCR, and 4.4 months median PFS (Alshammari et al., 2021; 34417144), but limited activity for patients with BRAF V600 mutation, with 0% (0/31) ORR, 55% (17/31) DCR, 2.6 months mPFS, and 8.2 months median OS (Corcoran et al., 2018; 29431699). Combination of trametinib with the PD_1_targeting antibody pembrolizumab did not elicit any objective responses in 15 patients with genomically unselected CRC in the Phase 1/2 KEYNOTE_022 study (Maio et al., 2022; 34801354), and trametinib plus the PD_L1_targeting antibody durvalumab showed limited activity in microsatellite stable mCRC with 3.4% (1/29) ORR and 41% (12/29) DCR (Johnson et al., 2020; ASCO GI Abstract 152). Early phase studies examining combination of trametinib with agents targeting the PI3K_AKT_mTOR pathway (Tolcher et al., 2015; 25344362, Tolcher et al., 2014; 25417902, Grilley_Olson et al., 2016; 27450049, Bedard et al., 2015; 25500057), CDK4/6 inhibitors palbociclib or ribociclib (LoRusso et al., 2020; ESMO Abstract 561P, Sullivan et al., 2015; AACR_NCI_EORTC Abstract PR06), the multi_TKI pazopanib (Kurzrock et al., 2019; 31186313), or the BCL_2 inhibitor navitoclax (Corcoran et al., 2019; ESMO Abstract 447PD) have shown minimal anti_tumor activity for included patients with CRC. Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Cobimetinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Cobimetinib is a MEK inhibitor that is FDA approved to treat patients with histiocytic neoplasms. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in neurofibromatosis type 1 (NF1)_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> The Phase 3 IMblaze370 study of cobimetinib plus atezolizumab for patients with chemotherapy_refractory metastatic colorectal cancer (CRC) reported similar median OS (8.9 vs. 7.1 vs. 8.5 months, HR=1.0–1.2), median PFS (1.9 vs. 1.9 vs. 2.0 months), and ORR (2.7% vs. 2.2% vs. 2.2%) to atezolizumab monotherapy or regorafenib, respectively (Eng et al., 2019; 31003911). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT04985604', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT03905148', 'Include': 'true'}, {'nctId': 'NCT04965818', 'Include': 'true'}, {'nctId': 'NCT05159245', 'Include': 'true'}, {'nctId': 'NCT04817956', 'Include': 'true'}, {'nctId': 'NCT04551521', 'Include': 'true'}, {'nctId': 'NCT04720976', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'FGF23', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'FGF23 encodes a member of the fibroblast growth factor protein family that plays a central role in phosphate homeostasis (Jonsson et al., 2003; 12711740). Overexpression of FGF23 by tumor cells can cause hypophosphatemia through excessive renal phosphate clearance (Shimada et al., 2001; 11344269), while germline gain_of_function (protein stabilizing) mutations in FGF23 cause autosomal dominant hypophosphatemic rickets (Xu and White, 2005; 15863037). FGF23 alterations have been reported with highest incidence in uterine carcinosarcoma (7.0%), ovarian carcinoma (6.5%), testicular germ cell cancer (5.4%), cutaneous melanoma (5.0%), low_grade glioma (4.9%), lung squamous cell carcinoma (4.5%), sarcoma (4.3%), colorectal adenocarcinoma (4.2%), lung adenocarcinoma (3.7%), and head and neck squamous cell carcinoma (3.4%) (cBioPortal, 2023) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). There are no targeted therapies that directly address genomic alterations in FGF23. Inhibitors of FGF receptors, however, are undergoing clinical trials in a number of different cancers. Limited data suggest that pan_FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan_FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR (Dumbrava et al., 2018; doi/full/10.1200/PO.18.00100).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'FGF6', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'FGF6 (also known as HST_2) encodes a member of the fibroblast growth factor protein family and is hypothesized to play a role in muscle tissue regeneration (Neuhaus et al., 2003; 12917328) by signaling through FGFR4, and to a lesser extent FGFR1 and FGFR2 (Ornitz et al., 1996; 8663044). FGF6 expression has been observed in several cancers (Iida et al., 1992; 1549352, Ropiquet et al., 2000; 10945637, Niini et al., 2002; 12399964) and was shown to be oncogenic in preclinical models (Marics et al., 1989; 2649847, Iida et al., 1992; 1549352). FGF6 has been reported as amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). Somatic alterations affecting FGF6 are infrequently documented, with the highest rates reported in penile cancer (4%), cutaneous melanoma (1_3%), stomach carcinoma (1_3%) and colorectal cancer (1%) (cBioPortal, COSMIC, 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Amplification of FGF6 has been frequently observed in testicular germ cell cancer (5%) and ovarian serous cystadenocarcinoma (5%), and in 2_6% of lower_grade gliomas, glioblastomas, sarcomas, breast invasive carcinomas, uterine carcinosarcomas, lung squamous cell carcinomas (SCC), head and neck SCC, pancreatic adenocarcinomas, and esophageal carcinomas (cBioPortal, 2023) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). FGF6 is co_localized with FGF23 and CCND2 at chromosomal locus 12p13 and has been reported to be co_amplified with these genes in 1.3% of patients with breast cancer (Parish et al., 2015; 25950492). FGF6 expression has been reported in 54% (14/26) of prostate cancer samples, which also frequently express FGFR4 (Ropiquet et al., 2000; 10945637). FGF6 expression has also been observed in 71% (12/17) of patients with childhood acute lymphoblastic leukemia (Niini et al., 2002; 12399964). There are no targeted therapies that directly address genomic alterations in FGF6. Inhibitors of FGF receptors, however, are undergoing clinical trials in a number of different cancers. Limited data suggest that pan_FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan_FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR (Dumbrava et al., 2018; doi/full/10.1200/PO.18.00100).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'KDM5A', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'KDM5A encodes a lysine_specific histone demethylase that potentiates the expression of genes involved in cellular proliferation, senescence, angiogenesis, and migration (Zeng et al., 2010; 19850045, Chicas et al., 2012; 22615382, Teng et al., 2013; 23722541, Li et al., 2014; 24716659, Lin et al., 2014; 25537453). KDM5A overexpression alters the transcriptional regulation of cell cycle genes, including CCND1, and a variety of cyclin_dependent kinase inhibitors (CDKIs), including CDKN1A, CDKN1B, and CDKN2A, and results in cell cycle progression (Zeng et al., 2010; 19850045, Teng et al., 2013; 23722541, Liang et al., 2013; 23922798, Jiping et al., 2013; 23794145, Vieira et al., 2014; 24200674, Li et al., 2014; 24716659). Additionally, elevated KDM5A expression and associated chromatin remodeling has been implicated in resistance to various tyrosine kinase inhibitors in vitro, including erlotinib and gefitinib (Sharma et al., 2010; 20371346, Dannenberg et al., 2010; 20371339, Hou et al., 2012; 22937203). KDM5A amplification has been reported with the highest incidence in TCGA datasets in ovarian serous cystadenocarcinoma (7.2%), testicular germ cell cancer (5.8%), pancreatic adenocarcinoma (4.3%), and lung squamous cell carcinoma (3.9%) (cBioPortal, Jan 2023)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Elevated levels of KDM5A expression have also been reported in a range of solid tumor types (Hou et al., 2012; 22937203, Liang et al., 2013; 23922798, Teng et al., 2013; 23722541, Paolicchi et al., 2013; 23266085, Vieira et al., 2014; 24200674, Li et al., 2014; 24716659), and fusion of KDM5A to NUP98 has been documented in acute myeloid leukemia (van Zutven et al., 2006; 16419055, Wang et al., 2009; 19430464). KDM5A expression is significantly correlated with HIF_1alpha and VEGF expression, as well as tumor size, angiogenesis, and poor patient prognosis in lung cancer (Qi et al., 2014; 25162518). There are no targeted therapies available to directly address genomic alterations in KDM5A. However, multiple preclinical studies have identified potential targets in KDM5A amplified or activated cells that may respond to therapy. KDM5A_mediated chromatin remodeling induces CCND1 expression and represses CDKI expression (Zeng et al., 2010; 19850045, Teng et al., 2013; 23722541, Liang et al., 2013; 23922798, Jiping et al., 2013; 23794145, Vieira et al., 2014; 24200674); therefore, KDM5A activation or amplification may sensitize cells to CDK4/CDK6 inhibitors. Drug_resistant cell populations, characterized by elevated KDM5A expression, responded to histone deacetylase (HDAC) inhibition (Sharma et al., 2010; 20371346), suggesting that HDAC inhibitors may be a potential therapeutic option. KDM5A also induces expression of VEGF and promotes angiogenesis, oncogenic transformation, and tumorigenesis, which can be inhibited by KDM5A knockdown (Li et al., 2014; 24716659, Qi et al., 2014; 25162518), suggesting that tumors harboring KDM5A amplification may be sensitive to angiogenesis inhibitors, including kinase inhibitors that target the VEGF receptors, such as sunitinib, sorafenib, vandetanib, ponatinib, cabozantinib, regorafenib, pazopanib, and axitinib. However, these inhibitors have yet to be extensively tested in the context of KDM5A amplification or activation; therefore, it is not known if these therapeutic strategies are relevant.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'KRAS', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'wildtype', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'wildtype'}}, 'Interpretation': 'KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). No alterations in KRAS were identified in this case. Approximately 50_65% of colorectal cancers (CRCs) have been reported to lack KRAS mutations (Lievre et al., 2006; 16618717, De Roock et al., 2011; 21163703, Chen et al., 2014; 25367198, Li et al., 2015; 25929517, Hu et al., 2016; 27977612, Zekri et al., 2017; 28218784, Staudacher et al., 2017; 29048416, Wang et al., 2018; 29705968, Guo et al., 2018; 29666387). Numerous studies have reported that KRAS wild_type status is associated with decreased metastasis, better clinicopathological features, and longer survival of patients with CRC (Chen et al., 2014; 25367198, Li et al., 2015; 25929517, Hu et al., 2016; 27977612, Mármol et al., 2017; 28106826, Zekri et al., 2017; 28218784, Kwak et al., 2017; 28858102). Lack of mutations in KRAS or NRAS is associated with clinical benefit of treatment with EGFR_targeting antibodies cetuximab (Van Cutsem et al., 2011; 21502544, Bokemeyer et al., 2011; 21228335, Karapetis et al., 2008; 18946061, De Roock et al., 2008; 17998284) or panitumumab (Douillard et al., 2014; 24718886, Douillard et al., 2012; 24024839, Amado et al., 2008; 18316791) for patients with CRC. Therefore, these agents are indicated to treat patients with CRC lacking such mutations (NCCN Colon Cancer Guidelines, v3.2022, Rectal Cancer Guidelines, v4.2022).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Cetuximab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Cetuximab is a monoclonal antibody that targets EGFR. It is FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and KRAS_wild_type, EGFR_expressing metastatic colorectal cancer (CRC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Therapies targeting EGFR, including cetuximab, have been shown to have significant clinical activity for patients with CRC (Bokemeyer et al., 2011; 21228335, Cunningham et al., 2004; 15269313, De Roock et al., 2008; 17998284, Jonker et al., 2007; 18003960, Karapetis et al., 2008; 18946061, Van Cutsem et al., 2011; 21502544); wild_type KRAS and NRAS are predictive biomarkers for the efficacy of cetuximab in metastatic CRC (NCCN Colon Cancer Guidelines, v3.2022, NCCN Rectal Cancer Guidelines, v4.2022). </p> <p><b>Supporting Data:</b> Cetuximab has been shown to improve OS, PFS, and response rate for patients with KRAS_wildtype colorectal cancer (CRC), both in combination with FOLFIRI, FOLFOX4, or irinotecan (Van Cutsem et al., 2011; 21502544, Bokemeyer et al., 2011; 21228335, Jonker et al., 2007; 18003960, Cunningham et al., 2004; 15269313, Papamichael et al., 2022; 35033994) and as monotherapy for chemotherapy_refractory patients (De Roock et al., 2008; 17998284, Karapetis et al., 2014; 24218517). The Phase 3 study STRATEGIC_1 reported a similar duration of disease control (DDC) for patients with unresectable metastatic CRC (mCRC) and KRAS_, NRAS_, and BRAF_wildtype status treated with mFOLFOX_bevacizumab alternated with a cetuximab regimen in first or second line, respectively (overall DDC 22.5 vs. 23.5 months); in addition, the study reported similar OS (37.8 vs. 34.4 months) and higher numerical ORR for patients treated with cetuximab in the first line followed by mFOLFOX_bevacizumab compared with those receiving EGFR_directed antibodies in the second or third line (Chibaudel et al., 2022; ASCO Abstract 3504). A prospective study of cetuximab monotherapy for patients with KRAS_, NRAS_, and BRAF_wildtype mCRC reported 11% (2/19) PRs and 58% (11/19) SDs (Moiseyenko et al., 2018; 29470838). The Phase 2 AVETUX trial of cetuximab combined with avelumab and mFOLFOX6 for patients with RAS_ and BRAF_wildtype mCRC resulted in an ORR of 81% (4 CR and 27 PRs, n=37) and a DCR of 89% (Stein et al., 2021; 34315821). In the Phase 3 ASPECCT study, panitumumab was found to be non_inferior to cetuximab with respect to median OS (10.4 vs. 10.0 months, HR=0.97) for patients with previously treated KRAS exon 2 wildtype metastatic colorectal cancer; median PFS was also similar between the two treatment groups (4.4 vs. 4.1 months, HR=1.00)(Price et al., 2014; 24739896). In a similar patient population, a Phase 2 study of combination panitumumab and irinotecan versus combination cetuximab and irinotecan also demonstrated non_inferiority with respect to median PFS (5.4 vs. 4.3 months, HR = 0.64) and median OS (14.9 vs. 11.5 months, HR=0.66)(Sakai et al., 2020; 32526634). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Panitumumab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Panitumumab is a monoclonal antibody that targets EGFR. It is FDA approved to treat KRAS wild_type and NRAS wild_type metastatic colorectal cancer (CRC) combined with chemotherapy or as monotherapy for patients who have progressed on prior chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Therapies targeting EGFR, including panitumumab, have been shown to have significant clinical activity for patients with CRC (Douillard et al., 2014; 24718886, Price et al., 2014; 24739896, Van Cutsem et al., 2007; 17470858); wild_type KRAS and NRAS are predictive biomarkers for the efficacy of panitumumab in metastatic CRC (NCCN Colon Cancer Guidelines v3.2022)(NCCN Rectal Cancers Guidelines, v4.2022). </p> <p><b>Supporting Data:</b> Panitumumab has been shown to improve OS, PFS, and ORR for patients with KRAS_wildtype colorectal cancer (CRC), both in combination with FOLFOX4, FOLFIRI, irinotecan, or best supportive care (Douillard et al., 2014; 24718886, Peeters et al., 2015; 26341920, Watanabe et al., 2022; 35723084, Kim et al., 2018; 29703606, Shitara et al., 2016; 27712015), and as monotherapy for chemotherapy_refractory patients (Price et al., 2014; 24739896, Van Cutsem et al., 2007; 17470858, Peeters et al., 2013; 23325582). The Phase 3 PARADIGM trial comparing panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first_line treatment for patients with RAS_wildtype left_sided metastatic CRC demonstrated that treatment with panitumumab significantly improved median OS (mOS; 36.2 months vs. 31.3 months) compared with bevacizumab (Yoshino et al., 2022; ASCO Abstract LBA1). A Phase 2 trial reported that, for patients with unresectable RAS_wildtype colorectal adenocarcinoma treated with panitumumab plus FOLFOX4, maintenance with a combination of panitumumab plus fluorouracil and leucovorin was superior to panitumumab monotherapy (10_month PFS OF 59% vs. 49%)(Pietrantonio et al., 2019; 31268481). In the Phase 3 ASPECCT study, panitumumab was found to be non_inferior to cetuximab with respect to median OS (10.4 vs. 10.0 months, HR=0.97) for patients with previously treated KRAS exon 2 wildtype metastatic colorectal cancer; median PFS was also similar between the two treatment groups (4.4 vs. 4.1 months, HR=1.00)(Price et al., 2014; 24739896). In a similar patient population, a Phase 2 study of combination panitumumab and irinotecan versus combination cetuximab and irinotecan also demonstrated non_inferiority with respect to median PFS (5.4 vs. 4.3 months, HR = 0.64) and median OS (14.9 vs. 11.5 months, HR=0.66)(Sakai et al., 2020; 32526634). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'MS_Stable', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'MS_Stable'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS colorectal cancers (CRCs) make up 70_85% of CRC cases (Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Jass, 2007; 17204026, Lal et al., 2015; 25949894). MSS colorectal cancers are molecularly heterogeneous, driven by diverse mechanisms such as extensive DNA methylation, oncogenic mutations in KRAS or BRAF, or chromosomal instability (Jass, 2007; 17204026). Multiple studies have shown that MSS CRCs have a worse prognosis than MSI_high tumors (Samowitz et al., 2001; 11535541, Elsaleh and Iacopetta, 2001; 12445368, Brueckl et al., 2003; 12820457, Guidoboni et al., 2001; 11438476, Gryfe et al., 2000; 10631274, Sinicrope et al., 2006; 16952542, Guastadisegni et al., 2010; 20627535, Laghi and Malesci, 2012; 22722556). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60). For patients with chemotherapy_refractory microsatellite_stable (MSS) metastatic colorectal cancer (CRC), a Phase 3 trial reported no OS advantage from the combination of the PD_L1 inhibitor atezolizumab plus cobimetinib relative to regorafenib (8.9 vs. 8.5 months, HR=1.00); atezolizumab monotherapy similarly did not prolong OS (7.1 vs. 8.5 months, HR=1.19) (Ciardiello et al., 2018; ESMO Abstract LBA_004). For patients with MSS CRC, a Phase 2 study combining ipilimumab and nivolumab reported an overall DCR of 25% (10/40) (Parikh et al., 2021; DOI: 10.1038/s43018_021_00269_7). Two Phase 1 studies for patients with MSS CRC treated with regorafenib and nivolumab reported PFSs of 7.9 months (Fukuoka et al., 2020; 32343640) and 5.7 months (Kim et al., 2020; DOI: 10.1016/j.annonc.2020.04.073), and a patient with MSS CRC refractory to chemotherapy treated with the PD_1 inhibitor sintilimab and regorafenib reported a CR (Zhang et al., 2021; 34688262). MSI has not been found to be a predictive biomarker for combination chemotherapy regimens, including FOLFOX (Sinicrope et al., 2013; 24019539, Gavin et al., 2012; 23045248) and FOLFIRI (Bertagnolli et al., 2009; 19273709, Van Cutsem et al., 2009; 19451425). Patients with MSS CRC are more likely to benefit from postsurgical fluorouracil (FU)_based adjuvant therapy (Ribic et al., 2003; 12867608, Sargent et al., 2010; 20498393) but less likely to benefit from irinotecan chemotherapy (Fallik et al., 2003; 14522894).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'NOTCH3', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'splice site 119_156_197+54>GGGGG', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '11.18', 'isEquivocal': 'false', 'name': 'splice site 119_156_197+54>GGGGG'}}, 'Interpretation': 'NOTCH3 encodes a member of the NOTCH family of receptors, which are involved in cell fate determination and various developmental processes. Upon binding of membrane_bound ligands, NOTCH signaling involves cleavage of the NOTCH intracellular domain (NICD), which subsequently forms part of a transcription factor complex that regulates downstream target genes (Penton et al., 2012; 22306179, Kopan and Ilagan, 2009; 19379690). Alterations that disrupt or remove the transmembrane domain (amino acids 1644_1664), RAM domain (amino acids 1665_1837), and/or ANK repeats region (amino acids 1838_2000), which are necessary for the transcriptional activity of NOTCH family proteins, as well as internal deletions that remove EGF repeats (7_10 and 21_22), have been shown in vitro to negatively affect ligand binding and reduce NOTCH3 transcriptional activity and are predicted to be inactivating (Kopan and Ilagan, 2009; 19379690, Deregowski et al., 2006; 16869730, Beà et al., 2013; 24145436, McDaniell et al., 2006; 16773578, Lin et al., 2010; 20068176). NOTCH3 mutations have been reported in 6% of colorectal adenocarcinomas (CRC), whereas NOTCH3 amplification was reported in 1% of cases (Cancer Genome Atlas Network., 2012; 22810696). NOTCH3 rearrangements were reported in <0.1% of colorectal cancers (Nguyen et al., 2022; 35120664). NOTCH3 activation has been reported to be frequent in CRC, with mRNA and/or protein overexpression reported in 19.7_38% of samples (Serafin et al., 2011; 21598247, Ozawa et al., 2014; 24728738, Furukawa et al., 2011; 24244701). NOTCH3 expression is more frequent in aggressive colorectal micropapillary carcinoma (35/51, 69%) than in microsatellite_stable CRC (42/97, 43%) cases (P=0.005)(Lee et al., 2013; 23060121). Nuclear (activated) NOTCH3 expression has been associated with advanced disease and tumor recurrence in patients with Stage 2 and 3 colorectal cancer (Ozawa et al., 2014; 24728738). Several approaches for inhibiting NOTCH3 signaling are being developed, including neutralizing NOTCH antibodies such as tarextumab (OMP_59R5) (Yen et al., 2015; 25934888), which targets NOTCH2 and NOTCH3, and pan_NOTCH inhibitors, such as gamma_secretase inhibitors (GSI) (Hu et al., 2014; 24743243, Konishi et al., 2007; 17804716, Xiao et al., 2011; 20838375). In a Phase 2 study, the GSI AL101 (BMS_906024) elicited PR in 15% (6/39) and SD in 54% (21/39) of patients with metastatic adenoid cystic carcinoma harboring NOTCH activating alterations (Ferrarotto et al., 2020; ESMO Abstract 919MO). Phase 2 studies have evaluated the efficacy of tarextumab in combination with chemotherapy in metastatic pancreatic cancer or extensive_stage small cell lung cancer, though NOTCH3 expression was not found to be a predictor of OS or PFS in either study (Hu et al., 2019; 31347292; O’Reilly et al., 2015; Gastrointestinal Cancers Symposium Abstract 278, Daniel et al., 2017; ESMO Abstract 1530PD). These approaches would not be relevant in the context of inactivating alterations, as seen here.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'NRAS', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'wildtype', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'wildtype'}}, 'Interpretation': 'NRAS encodes a member of the RAS family of small GTPases that mediate transduction of growth signals. Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF_MAPK_ERK, PI3K, and other pathways (Pylayeva_Gupta et al., 2011; 21993244). No alterations in NRAS were identified in this case. The majority of colorectal cancers (CRCs) (91_98%) have been reported to lack NRAS mutations (Pentheroudakis et al., 2013; 23374602, Vaughn et al., 2011; 21305640, Janku et al., 2013; 23400451, De Roock et al., 2010; 20619739, Irahara et al., 2010; 20736745, Cancer Genome Atlas Network., 2012; 22810696, Schirripa et al., 2015; 24806288, Guo et al., 2018; 29666387). NRAS wild_type status has been reported to be associated with decreased frequency of metastasis (Guo et al., 2018; 29666387) and longer survival (Schirripa et al., 2015; 24806288, Cercek et al., 2017; 28446505) of patients with CRC. Lack of mutations in KRAS or NRAS is associated with clinical benefit of treatment with EGFR_targeting antibodies cetuximab (Van Cutsem et al., 2011; 21502544, Bokemeyer et al., 2011; 21228335, Karapetis et al., 2008; 18946061, De Roock et al., 2008; 17998284) or panitumumab (Douillard et al., 2014; 24718886, Douillard et al., 2012; 24024839, Amado et al., 2008; 18316791) for patients with CRC. Therefore, these agents are indicated to treat patients with CRC lacking such mutations (NCCN Colon Cancer Guidelines, v3.2022, Rectal Cancer Guidelines, v4.2022).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Cetuximab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Cetuximab is a monoclonal antibody that targets EGFR. It is FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and KRAS_wild_type, EGFR_expressing metastatic colorectal cancer (CRC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Therapies targeting EGFR, including cetuximab, have been shown to have significant clinical activity for patients with CRC (Bokemeyer et al., 2011; 21228335, Cunningham et al., 2004; 15269313, De Roock et al., 2008; 17998284, Jonker et al., 2007; 18003960, Karapetis et al., 2008; 18946061, Van Cutsem et al., 2011; 21502544); wild_type KRAS and NRAS are predictive biomarkers for the efficacy of cetuximab in metastatic CRC (NCCN Colon Cancer Guidelines, v3.2022, NCCN Rectal Cancer Guidelines, v4.2022). </p> <p><b>Supporting Data:</b> Cetuximab has been shown to improve OS, PFS, and response rate for patients with KRAS_wildtype colorectal cancer (CRC), both in combination with FOLFIRI, FOLFOX4, or irinotecan (Van Cutsem et al., 2011; 21502544, Bokemeyer et al., 2011; 21228335, Jonker et al., 2007; 18003960, Cunningham et al., 2004; 15269313, Papamichael et al., 2022; 35033994) and as monotherapy for chemotherapy_refractory patients (De Roock et al., 2008; 17998284, Karapetis et al., 2014; 24218517). The Phase 3 study STRATEGIC_1 reported a similar duration of disease control (DDC) for patients with unresectable metastatic CRC (mCRC) and KRAS_, NRAS_, and BRAF_wildtype status treated with mFOLFOX_bevacizumab alternated with a cetuximab regimen in first or second line, respectively (overall DDC 22.5 vs. 23.5 months); in addition, the study reported similar OS (37.8 vs. 34.4 months) and higher numerical ORR for patients treated with cetuximab in the first line followed by mFOLFOX_bevacizumab compared with those receiving EGFR_directed antibodies in the second or third line (Chibaudel et al., 2022; ASCO Abstract 3504). A prospective study of cetuximab monotherapy for patients with KRAS_, NRAS_, and BRAF_wildtype mCRC reported 11% (2/19) PRs and 58% (11/19) SDs (Moiseyenko et al., 2018; 29470838). The Phase 2 AVETUX trial of cetuximab combined with avelumab and mFOLFOX6 for patients with RAS_ and BRAF_wildtype mCRC resulted in an ORR of 81% (4 CR and 27 PRs, n=37) and a DCR of 89% (Stein et al., 2021; 34315821). In the Phase 3 ASPECCT study, panitumumab was found to be non_inferior to cetuximab with respect to median OS (10.4 vs. 10.0 months, HR=0.97) for patients with previously treated KRAS exon 2 wildtype metastatic colorectal cancer; median PFS was also similar between the two treatment groups (4.4 vs. 4.1 months, HR=1.00)(Price et al., 2014; 24739896). In a similar patient population, a Phase 2 study of combination panitumumab and irinotecan versus combination cetuximab and irinotecan also demonstrated non_inferiority with respect to median PFS (5.4 vs. 4.3 months, HR = 0.64) and median OS (14.9 vs. 11.5 months, HR=0.66)(Sakai et al., 2020; 32526634). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Panitumumab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Panitumumab is a monoclonal antibody that targets EGFR. It is FDA approved to treat KRAS wild_type and NRAS wild_type metastatic colorectal cancer (CRC) combined with chemotherapy or as monotherapy for patients who have progressed on prior chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Therapies targeting EGFR, including panitumumab, have been shown to have significant clinical activity for patients with CRC (Douillard et al., 2014; 24718886, Price et al., 2014; 24739896, Van Cutsem et al., 2007; 17470858); wild_type KRAS and NRAS are predictive biomarkers for the efficacy of panitumumab in metastatic CRC (NCCN Colon Cancer Guidelines v3.2022)(NCCN Rectal Cancers Guidelines, v4.2022). </p> <p><b>Supporting Data:</b> Panitumumab has been shown to improve OS, PFS, and ORR for patients with KRAS_wildtype colorectal cancer (CRC), both in combination with FOLFOX4, FOLFIRI, irinotecan, or best supportive care (Douillard et al., 2014; 24718886, Peeters et al., 2015; 26341920, Watanabe et al., 2022; 35723084, Kim et al., 2018; 29703606, Shitara et al., 2016; 27712015), and as monotherapy for chemotherapy_refractory patients (Price et al., 2014; 24739896, Van Cutsem et al., 2007; 17470858, Peeters et al., 2013; 23325582). The Phase 3 PARADIGM trial comparing panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 as first_line treatment for patients with RAS_wildtype left_sided metastatic CRC demonstrated that treatment with panitumumab significantly improved median OS (mOS; 36.2 months vs. 31.3 months) compared with bevacizumab (Yoshino et al., 2022; ASCO Abstract LBA1). A Phase 2 trial reported that, for patients with unresectable RAS_wildtype colorectal adenocarcinoma treated with panitumumab plus FOLFOX4, maintenance with a combination of panitumumab plus fluorouracil and leucovorin was superior to panitumumab monotherapy (10_month PFS OF 59% vs. 49%)(Pietrantonio et al., 2019; 31268481). In the Phase 3 ASPECCT study, panitumumab was found to be non_inferior to cetuximab with respect to median OS (10.4 vs. 10.0 months, HR=0.97) for patients with previously treated KRAS exon 2 wildtype metastatic colorectal cancer; median PFS was also similar between the two treatment groups (4.4 vs. 4.1 months, HR=1.00)(Price et al., 2014; 24739896). In a similar patient population, a Phase 2 study of combination panitumumab and irinotecan versus combination cetuximab and irinotecan also demonstrated non_inferiority with respect to median PFS (5.4 vs. 4.3 months, HR = 0.64) and median OS (14.9 vs. 11.5 months, HR=0.66)(Sakai et al., 2020; 32526634). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'SMAD4', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'loss', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'loss'}}, 'Interpretation': 'SMAD4, also known as DPC4, encodes a tumor suppressor that regulates transcriptional activity downstream of TGF_beta receptor signaling (Massague et al., 2012; 22992590, Massague et al., 2008; 18662538). SMAD4 alterations that result in loss or disruption of the MH1 domain (aa 18_142), MH2 domain (aa 323_552), or SAD domain (aa 275_320) are predicted to be inactivating (Massague et al., 2005; 16322555, Morén et al., 2000; 10980615, Xu and Attisano, 2000; 10781087, Luo et al., 1999; 10485843, Jones and Kern, 2000; 10871368, Fink et al., 2001; 11196171, De Bosscher et al., 2004; 14715079, Shi et al., 1997; 9214508, Miyaki et al., 1999; 10340381, Prokova et al., 2007; 17994767, Wu et al., 2001; 11274206, Ding et al., 2009; 19139564, Kuang et al., 2004; 14647410, Watanabe et al., 2000; 11265759, Bosscher et al., 2004; 14715079). SMAD4 mutation or homozygous deletion is most frequently observed in pancreatic adenocarcinoma (43%)(cBio_Witkiewicz et al., 2015; 25855536), pancreatic acinar cell carcinoma (26%)(Jiao et al., 2014; 24293293), cholangiocarcinoma (25%)(Churi et al., 2014; 25536104), small intestine cancer (20%) (Takeda et al., 2022; ASCO GI Abstract 642), appendiceal adenocarcinoma (14_20% mutation; 57% deletion)(Liu et al., 2014; 24821835, Maru et al., 2004; 14647445), colorectal adenocarcinoma (CRC; 14%)(Cancer Genome Atlas Network., 2012; 22810696), esophageal adenocarcinoma (14%)(Wang et al., 2015; 26336083), and stomach adenocarcinoma (13%)(Cancer Genome Atlas Research Network., 2014; 25079317). In preclinical studies, SMAD4 loss of function has been implicated in the development of mucinous neoplasms of the pancreas, including mucinous cystic neoplasms (MCN)(Izeradjene et al., 2007; 17349581) and intraductal papillary mucinous neoplasms (IPMN)(Bardeesy et al., 2006; 17114584); in clinical samples, SMAD4 homozygous deletion has been observed in 10% of IPMNs and 8% of MCNs, and mutation was also observed in 5% of IPMNs (Springer et al., 2015; 26253305). SMAD4 gene alterations have been associated with reduced OS for patients with pancreatic adenocarcinoma (Blackford et al., 2009; 19584151). Reduced SMAD4 expression has been associated with worse prognosis in various cancer types, including CRC (Yan et al., 2016; 26861460, Kozak et al., 2015; 25681512, Roth et al., 2012; 23104212), appendiceal mucinous neoplasm (Davison et al., 2014; 24618609), gastric adenocarcinoma (Kim et al., 2004; 15033661, Xiangming et al., 2001; 11234879), esophageal adenocarcinoma (Singhi et al., 2015; 25634752), esophageal squamous cell carcinoma (Natsugoe et al., 2002; 12060625), breast cancer (de Kruijf et al., 2013; 23022998), and prostate cancer (Shipitsin et al., 2014; 25032733). There are no targeted therapies available to address genomic alterations in SMAD4. Preclinical studies in colorectal cancer have reported associations of SMAD4 inactivation or loss with sensitivity to inhibitors of Aurora kinase A (Shi et al., 2022; 35393542) and the Wnt/beta_catenin pathway (Park et al., 2022; 35274815). Clinical studies have reported associations of SMAD4 loss or low SMAD4 expression with improved responses to chemotherapeutic agents in patients with pancreatic cancer (Ormanns et al., 2017; 28534865, Fei et al., 2021; 34002944, Bachet et al., 2012; 22377565) and non_small cell lung cancer (NSCLC) (Ziemke et al., 2017; 28577946). Other clinical studies in pancreatic cancer have reported an association of high SMAD4 expression with better responses to neoadjuvant chemotherapy (Kassardjian and Wang, 2020; 32897998) and adjuvant chemoradiotherapy (Pen et al., 2021; 33667587). Germline SMAD4 mutations, including those at the R361 hotspot, have been observed in patients with juvenile polyposis syndrome (Houlston et al., 1998; 9811934, Woodford_Richens et al., 2000; 10764709, Howe et al., 2004; 15235019, Howe et al., 2004; 15235019, Howe et al., 2004; 15235019), which is associated with an increased risk of gastrointestinal cancers (Brosens et al., 2011; 22171123). The penetrance of deleterious SMAD4 mutations in patients with colon cancer is estimated at 20% by age 35 and 70% by age 65 (Kalia et al., 2017; 27854360). In the appropriate clinical context, germline testing of SMAD4 is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TP53', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'P151R', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '67.35', 'isEquivocal': 'false', 'name': 'P151R'}}, 'Interpretation': 'Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations have been reported in up to 75% of colorectal cancer cases (Cancer Genome Atlas Network., 2012; 22810696, Goh et al., 1995; 7585578, Berg et al., 2010; 21103049, Han et al., 2013; 23700467, Peeters et al., 2013; 23325582, Malhotra et al., 2013; 23526092, Di Bartolomeo et al., 2013; 23821376, Fong et al., 2022; ASCO GI Abstract 57). A study reported p53 expression in 49% of analyzed colorectal cancer cases (Wangefjord et al., 2013; 23337059). TP53 mutation has not been consistently demonstrated to be a significant independent prognostic marker in the context of CRC (Russo et al., 2005; 16172461, Fong et al., 2022; ASCO GI Abstract 57). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Tumor Mutation Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '01', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '01'}}, 'Interpretation': 'Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Samstein et al., 2019; 30643254, Fabrizio et al., 2018; 30151257, Marabelle et al., 2020; 32919526). Elevated tumor mutational burden (TMB) has been reported in 8_25% of colorectal cancer (CRC) samples (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117, Shao et al., 2020; 33119110). Multiple studies have reported that up to 90% of hypermutated CRC cases exhibit high levels of microsatellite instability (MSI_H) and mismatch repair deficiency (MMR_D) (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117). Increased TMB is significantly associated with MSI_H and MMR_D, with studies reporting that 100% of MSI_H CRCs harbor elevated TMB and conversely that 100% of tumors with low TMB harbor intact MMR (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Stadler et al., 2016; 27022117). A subset of CRCs that harbor increased TMB but not MSI_H are driven by mutations in POLE, which leads to an “ultramutated” phenotype with especially high TMB (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117). Tumors with increased TMB harbor BRAF V600E mutations more frequently than those with low TMB (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117), whereas TMB_low tumors more frequently harbor mutations in TP53 and APC (Cancer Genome Atlas Network, 2012; 22810696). The prognostic value of tumor mutational burden (TMB) in colorectal cancer (CRC) is context_ and therapy_dependent. A study of tissue TMB (tTMB) in 145 CRC samples showed longer OS in TMB_high samples compared with TMB_low ones (Schwartz et al., 2018; ASCO Abstract 572). Similarly, for patients with metastatic CRC treated with first_line chemotherapy combined with bevacizumab or cetuximab, high tissue TMB (tTMB_H) was associated with longer OS (Innocenti et al., 2019; 30865548). For patients treated with adjuvant chemotherapy, tTMB_H was associated with better 5_year relapse_free survival (Lee et al., 2019; 31285374). However, for patients with EGFR/BRAF_inhibitor_treated, BRAF_mutated microsatellite stable (MSS) metastatic CRC, intermediate tTMB was associated with significantly poorer PFS and OS compared with TMB_low status; patients with primary resistance to EGFR/BRAF blockage had higher TMB than those sensitive to these therapies (Randon et al., 2022; 34933155). In a study for 61 patients with metastatic, MSS CRC treated with best standard of care, plasma TMB scores ≥28 Muts/Mb (approximately 14 Muts/Mb as measured by this assay) were associated with reduced OS compared with plasma TMB scores <28 Muts/Mb (3.0 vs. 5.3 months, HR=0.76, p=0.007), whereas tTMB was not found to be prognostic in this population (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB ≥10 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores ≥ 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB ≥ 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB ≥ 16 Muts/Mb than those with TMB ≥ 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). In CRC specifically, a retrospective analysis of immune checkpoint inhibitor efficacy reported significantly improved OS for patients with tumors harboring TMB ≥9.8 Muts/MB compared with those with tumors with TMB <9.8 Muts/Mb (~ equivalency <12 Muts/Mb as measured by this assay) (Samstein et al., 2019; 30643254). Another retrospective study reported that a TMB ≥12 Muts/Mb cutoff identifies >99% of MSI_High CRC cases but only 3% of MSS cases, indicating the utility of this cutoff for identification of patients with CRC likely to benefit from treatment with immune checkpoint inhibitors (Fabrizio et al., 2018; 30151257).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'APC', 'Alteration': 'R232*', 'Title': 'A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'CBP, Beta_catenin, PD_1', 'Locations': 'Fukuoka (Japan), Osaka (Japan), Shizouka (Japan), Tokyo (Japan), Chiba_shi (Japan), Kashiwa (Japan), Sapporo shi (Japan), Glasgow (United Kingdom), Manchester (United Kingdom), London (United Kingdom)', 'NCTID': 'NCT05091346', 'Note': 'Based on preclinical and limited clinical data, APC inactivation may be associated with sensitivity to CBP/beta_catenin interaction inhibitors.', 'Include': 'true'}, {'Gene': 'APC', 'Alteration': 'R232*', 'Title': 'A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor', 'StudyPhase': 'PHASE 1', 'Target': 'CBP, Beta_catenin, FGFRs, RET, PDGFRA, VEGFRs, KIT', 'Locations': 'Kurume (Japan), Matsuyama (Japan), Seodaemun (Korea, Republic of), Osakasayama (Japan), Nagoya (Japan), Kawasaki (Japan), Chuo_Ku (Japan), Koto_ku (Japan), Chiba (Japan), Kashiwa (Japan)', 'NCTID': 'NCT04008797', 'Note': 'Based on preclinical and limited clinical data, APC inactivation may be associated with sensitivity to CBP/beta_catenin interaction inhibitors.', 'Include': 'true'}, {'Gene': 'APC', 'Alteration': 'R232*', 'Title': 'Study of E7386 in Participants With Selected Advanced Neoplasms', 'StudyPhase': 'PHASE 1', 'Target': 'CBP, Beta_catenin', 'Locations': 'Glasgow (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Sutton (United Kingdom)', 'NCTID': 'NCT03264664', 'Note': 'Based on preclinical and limited clinical data, APC inactivation may be associated with sensitivity to CBP/beta_catenin interaction inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'A Study of BPI_1178 in Patients With Advanced Solid Tumor and HR+/HER2_ Breast Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'CDK6, CDK4, ER, Aromatase', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT04282031', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'CDK6, CDK4', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT05480280', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'Genetic Testing in Guiding Treatment for Patients With Brain Metastases', 'StudyPhase': 'PHASE 2', 'Target': 'TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR', 'Locations': 'Washington, Oregon, Idaho, Montana', 'NCTID': 'NCT03994796', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': '(VELA) Study of BLU_222 in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'ER, CDK4, CDK6, CDK2', 'Locations': 'Illinois, Massachusetts, Arkansas, New York, Virginia, Texas, Florida', 'NCTID': 'NCT05252416', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'Palbociclib In Progressive Brain Metastases', 'StudyPhase': 'PHASE 2', 'Target': 'CDK4, CDK6', 'Locations': 'Massachusetts', 'NCTID': 'NCT02896335', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'ERK1, ERK2, EGFR, CDK4, CDK6', 'Locations': 'Texas', 'NCTID': 'NCT04616183', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs', 'StudyPhase': 'PHASE 2', 'Target': 'BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6', 'Locations': 'Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)', 'NCTID': 'NCT05159245', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D_type Cyclins or Amplification of CDK4 or CDK6', 'StudyPhase': 'PHASE 2', 'Target': 'CDK4, CDK6', 'Locations': 'Massachusetts', 'NCTID': 'NCT03310879', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'MAPK3, MAPK1, CDK4, CDK6', 'Locations': 'North Carolina', 'NCTID': 'NCT03454035', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'T798I', 'Title': 'Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study', 'StudyPhase': 'PHASE 2', 'Target': 'TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha, RAFs, NRAS', 'Locations': 'Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Shanghai City (China), Shanghai (China), Shatin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi an (China), Tianjin (China)', 'NCTID': 'NCT04589845', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors. Based on limited clinical and preclinical evidence, ERBB2 T798I may confer reduced sensitivity to lapatinib and neratinib. Tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib, and lapatinib have yielded limited clinical efficacy as monotherapies in CRC, suggesting that antibody therapeutics or combination therapies may be more beneficial in this tumor type. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'T798I', 'Title': 'Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations', 'StudyPhase': 'PHASE 2', 'Target': 'ERBB2, ER', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Osakasayama (Japan), Nagoya_shi (Japan), Kawasaki_shi (Japan), Chuo_Ku (Japan), Tokyo (Japan), Kashiwa_shi (Japan), Poznan (Poland), Berlin (Germany)', 'NCTID': 'NCT04579380', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors. Based on limited clinical and preclinical evidence, ERBB2 T798I may confer reduced sensitivity to lapatinib and neratinib. Tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib, and lapatinib have yielded limited clinical efficacy as monotherapies in CRC, suggesting that antibody therapeutics or combination therapies may be more beneficial in this tumor type. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'T798I', 'Title': 'AB122 Platform Study', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, HSP90, FGFRs', 'Locations': 'Ehime (Japan), Wakayama (Japan), Osaka (Japan), Aichi (Japan), Shizuoka (Japan), Kanagawa (Japan), Tokyo (Japan), Chiba (Japan), Hokkaido (Japan)', 'NCTID': 'NCT04999761', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors. Based on limited clinical and preclinical evidence, ERBB2 T798I may confer reduced sensitivity to lapatinib and neratinib. Tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib, and lapatinib have yielded limited clinical efficacy as monotherapies in CRC, suggesting that antibody therapeutics or combination therapies may be more beneficial in this tumor type. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'T798I', 'Title': 'TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'CDK4, CDK6, FLT3, VEGFRs, CSF1R, KIT, RET, mTOR, ERBB2, MEK, BRAF, PARP, PD_1, CTLA_4, PD_L1, TRKB, ALK, TRKC, ROS1, TRKA, FGFRs', 'Locations': 'Hawaii, Washington, Oregon, California', 'NCTID': 'NCT02693535', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors. Based on limited clinical and preclinical evidence, ERBB2 T798I may confer reduced sensitivity to lapatinib and neratinib. Tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib, and lapatinib have yielded limited clinical efficacy as monotherapies in CRC, suggesting that antibody therapeutics or combination therapies may be more beneficial in this tumor type. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'T798I', 'Title': 'Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO', 'Locations': 'Vancouver (Canada), Kelowna (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)', 'NCTID': 'NCT03297606', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors. Based on limited clinical and preclinical evidence, ERBB2 T798I may confer reduced sensitivity to lapatinib and neratinib. Tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib, and lapatinib have yielded limited clinical efficacy as monotherapies in CRC, suggesting that antibody therapeutics or combination therapies may be more beneficial in this tumor type. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'T798I', 'Title': 'The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs', 'StudyPhase': 'PHASE 2', 'Target': 'BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6', 'Locations': 'Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)', 'NCTID': 'NCT05159245', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors. Based on limited clinical and preclinical evidence, ERBB2 T798I may confer reduced sensitivity to lapatinib and neratinib. Tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib, and lapatinib have yielded limited clinical efficacy as monotherapies in CRC, suggesting that antibody therapeutics or combination therapies may be more beneficial in this tumor type. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'T798I', 'Title': 'Improving Public Cancer Care by Implementing Precision Medicine in Norway', 'StudyPhase': 'PHASE 2', 'Target': 'PD_L1, VEGFA, ERBB2, ALK, RET, PARP, SMO, TRKB, TRKC, ROS1, TRKA, MEK, BRAF, PI3K_alpha, FGFR1, FGFR2, FGFR3, MET, KIT, ABL', 'Locations': 'Tromsø (Norway), Bodø (Norway), Hamar (Norway), Oslo (Norway), Fredrikstad (Norway), Drammen (Norway), Trondheim (Norway), Skien (Norway), Førde (Norway), Bergen (Norway)', 'NCTID': 'NCT04817956', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors. Based on limited clinical and preclinical evidence, ERBB2 T798I may confer reduced sensitivity to lapatinib and neratinib. Tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib, and lapatinib have yielded limited clinical efficacy as monotherapies in CRC, suggesting that antibody therapeutics or combination therapies may be more beneficial in this tumor type. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'T798I', 'Title': 'Testing the Biological Effects of DS_8201a on Patients With Advanced Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'ERBB2', 'Locations': 'Ohio, Pennsylvania, Massachusetts, New York, Maryland', 'NCTID': 'NCT04294628', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors. Based on limited clinical and preclinical evidence, ERBB2 T798I may confer reduced sensitivity to lapatinib and neratinib. Tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib, and lapatinib have yielded limited clinical efficacy as monotherapies in CRC, suggesting that antibody therapeutics or combination therapies may be more beneficial in this tumor type. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'T798I', 'Title': 'FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'MET, EGFR, PD_1, PD_L1, ERBB2', 'Locations': 'California, Arizona, New Jersey, Texas, North Carolina', 'NCTID': 'NCT05395052', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors. Based on limited clinical and preclinical evidence, ERBB2 T798I may confer reduced sensitivity to lapatinib and neratinib. Tyrosine kinase inhibitors such as erlotinib, gefitinib, afatinib, and lapatinib have yielded limited clinical efficacy as monotherapies in CRC, suggesting that antibody therapeutics or combination therapies may be more beneficial in this tumor type. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'loss exons 37_58', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors. Several clinical studies have shown that inhibitors of the PI3K_AKT_mTOR pathway have not produced significant clinical benefit when used as a monotherapy in patients with colorectal cancer; combination therapies may be required to overcome this lack of response.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'loss exons 37_58', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors. Several clinical studies have shown that inhibitors of the PI3K_AKT_mTOR pathway have not produced significant clinical benefit when used as a monotherapy in patients with colorectal cancer; combination therapies may be required to overcome this lack of response.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'loss exons 37_58', 'Title': 'DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'BRAF, MEK', 'Locations': 'Busan (Korea, Republic of), Seoul (Korea, Republic of), Clayton (Australia), Edegem (Belgium), Oregon, Barcelona (Spain), Madrid (Spain), California, Colorado', 'NCTID': 'NCT04985604', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors. Several clinical studies have shown that inhibitors of the PI3K_AKT_mTOR pathway have not produced significant clinical benefit when used as a monotherapy in patients with colorectal cancer; combination therapies may be required to overcome this lack of response.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'loss exons 37_58', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors. Several clinical studies have shown that inhibitors of the PI3K_AKT_mTOR pathway have not produced significant clinical benefit when used as a monotherapy in patients with colorectal cancer; combination therapies may be required to overcome this lack of response.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'loss exons 37_58', 'Title': 'Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'RAFs, EGFR, MEK', 'Locations': 'Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), California, Texas', 'NCTID': 'NCT03905148', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors. Several clinical studies have shown that inhibitors of the PI3K_AKT_mTOR pathway have not produced significant clinical benefit when used as a monotherapy in patients with colorectal cancer; combination therapies may be required to overcome this lack of response.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'loss exons 37_58', 'Title': 'Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'MEK, FGFRs', 'Locations': 'California, Indiana, Texas', 'NCTID': 'NCT04965818', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors. Several clinical studies have shown that inhibitors of the PI3K_AKT_mTOR pathway have not produced significant clinical benefit when used as a monotherapy in patients with colorectal cancer; combination therapies may be required to overcome this lack of response.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'loss exons 37_58', 'Title': 'The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs', 'StudyPhase': 'PHASE 2', 'Target': 'BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6', 'Locations': 'Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)', 'NCTID': 'NCT05159245', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors. Several clinical studies have shown that inhibitors of the PI3K_AKT_mTOR pathway have not produced significant clinical benefit when used as a monotherapy in patients with colorectal cancer; combination therapies may be required to overcome this lack of response.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'loss exons 37_58', 'Title': 'Improving Public Cancer Care by Implementing Precision Medicine in Norway', 'StudyPhase': 'PHASE 2', 'Target': 'PD_L1, VEGFA, ERBB2, ALK, RET, PARP, SMO, TRKB, TRKC, ROS1, TRKA, MEK, BRAF, PI3K_alpha, FGFR1, FGFR2, FGFR3, MET, KIT, ABL', 'Locations': 'Tromsø (Norway), Bodø (Norway), Hamar (Norway), Oslo (Norway), Fredrikstad (Norway), Drammen (Norway), Trondheim (Norway), Skien (Norway), Førde (Norway), Bergen (Norway)', 'NCTID': 'NCT04817956', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors. Several clinical studies have shown that inhibitors of the PI3K_AKT_mTOR pathway have not produced significant clinical benefit when used as a monotherapy in patients with colorectal cancer; combination therapies may be required to overcome this lack of response.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'loss exons 37_58', 'Title': 'CRAFT: The NCT_PMO_1602 Phase II Trial', 'StudyPhase': 'PHASE 2', 'Target': 'PD_L1, AKTs, MEK, BRAF, ALK, RET, ERBB2', 'Locations': 'Würzburg (Germany), Mainz (Germany), Heidelberg (Germany), Tübingen (Germany)', 'NCTID': 'NCT04551521', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors. Several clinical studies have shown that inhibitors of the PI3K_AKT_mTOR pathway have not produced significant clinical benefit when used as a monotherapy in patients with colorectal cancer; combination therapies may be required to overcome this lack of response.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'loss exons 37_58', 'Title': 'JAB_3312 Activity in Adult Patients With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'MEK, SHP2, PD_1, EGFR, KRAS', 'Locations': 'Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut', 'NCTID': 'NCT04720976', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors. Several clinical studies have shown that inhibitors of the PI3K_AKT_mTOR pathway have not produced significant clinical benefit when used as a monotherapy in patients with colorectal cancer; combination therapies may be required to overcome this lack of response.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '19860666', 'FullCitation': 'Katoh Y, et al. Curr. Mol. Med. (2009) pmid: 19860666', 'Include': 'true'}, {'number': '1', 'ReferenceId': '16301994', 'FullCitation': 'White PC, et al. Oncogene (2006) pmid: 16301994', 'Include': 'true'}, {'number': '2', 'ReferenceId': '23550210', 'FullCitation': 'Gao J, et al. Sci Signal (2013) pmid: 23550210', 'Include': 'true'}, {'number': '3', 'ReferenceId': '24071852', 'FullCitation': 'Zack TI, et al. Nat. Genet. (2013) pmid: 24071852', 'Include': 'true'}, {'number': '4', 'ReferenceId': '20164920', 'FullCitation': 'Beroukhim R, et al. Nature (2010) pmid: 20164920', 'Include': 'true'}, {'number': '5', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '6', 'ReferenceId': '16012517', 'FullCitation': 'Mermelshtein A, et al. Br. J. Cancer (2005) pmid: 16012517', 'Include': 'true'}, {'number': '7', 'ReferenceId': '21052002', 'FullCitation': 'Liu Y, et al. Diagn. Mol. Pathol. (2010) pmid: 21052002', 'Include': 'true'}, {'number': '8', 'ReferenceId': '19508551', 'FullCitation': 'Sarkar R, et al. Colorectal Dis (2010) pmid: 19508551', 'Include': 'true'}, {'number': '9', 'ReferenceId': '15707582', 'FullCitation': 'Busk PK, et al. Exp. Cell Res. (2005) pmid: 15707582', 'Include': 'true'}, {'number': '10', 'ReferenceId': '12695654', 'FullCitation': 'Busk PK, et al. Cell Cycle () pmid: 12695654', 'Include': 'true'}, {'number': '11', 'ReferenceId': '25524798', 'FullCitation': 'Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798', 'Include': 'true'}, {'number': '12', 'ReferenceId': '25501126', 'FullCitation': 'DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126', 'Include': 'true'}, {'number': '13', 'ReferenceId': '18413839', 'FullCitation': 'Trowe T, et al. Clin. Cancer Res. (2008) pmid: 18413839', 'Include': 'true'}, {'number': '14', 'ReferenceId': '28274957', 'FullCitation': 'Hanker AB, et al. Cancer Discov (2017) pmid: 28274957', 'Include': 'true'}, {'number': '15', 'ReferenceId': '25238247', 'FullCitation': 'Li G, et al. PLoS ONE (2014) pmid: 25238247', 'Include': 'true'}, {'number': '16', 'ReferenceId': '29338072', 'FullCitation': 'Ross JS, et al. Cancer (2018) pmid: 29338072', 'Include': 'true'}, {'number': '17', 'ReferenceId': '25211663', 'FullCitation': 'Ingold Heppner B, et al. Br. J. Cancer (2014) pmid: 25211663', 'Include': 'true'}, {'number': '18', 'ReferenceId': '24879338', 'FullCitation': 'Seo AN, et al. PLoS ONE (2014) pmid: 24879338', 'Include': 'true'}, {'number': '19', 'ReferenceId': '26276145', 'FullCitation': 'Wu SW, et al. Diagn Pathol (2015) pmid: 26276145', 'Include': 'true'}, {'number': '20', 'ReferenceId': '24146218', 'FullCitation': 'Sclafani F, et al. Ann. Oncol. (2013) pmid: 24146218', 'Include': 'true'}, {'number': '21', 'ReferenceId': '23348520', 'FullCitation': 'Martin V, et al. Br. J. Cancer (2013) pmid: 23348520', 'Include': 'true'}, {'number': '22', 'ReferenceId': '30952821', 'FullCitation': 'Sartore_Bianchi A, et al. Oncologist (2019) pmid: 30952821', 'Include': 'true'}, {'number': '23', 'ReferenceId': '11248153', 'FullCitation': 'Slamon DJ, et al. N. Engl. J. Med. (2001) pmid: 11248153', 'Include': 'true'}, {'number': '24', 'ReferenceId': '20728210', 'FullCitation': 'Bang YJ, et al. Lancet (2010) pmid: 20728210', 'Include': 'true'}, {'number': '25', 'ReferenceId': '26358791', 'FullCitation': 'Chumsri S, et al. J Natl Compr Canc Netw (2015) pmid: 26358791', 'Include': 'true'}, {'number': '26', 'ReferenceId': '16775247', 'FullCitation': 'Cappuzzo F, et al. N. Engl. J. Med. (2006) pmid: 16775247', 'Include': 'true'}, {'number': '27', 'ReferenceId': '23328556', 'FullCitation': 'Falchook GS, et al. J Thorac Oncol (2013) pmid: 23328556', 'Include': 'true'}, {'number': '28', 'ReferenceId': '23610105', 'FullCitation': 'Mazières J, et al. J. Clin. Oncol. (2013) pmid: 23610105', 'Include': 'true'}, {'number': '29', 'ReferenceId': '22149875', 'FullCitation': 'Baselga J, et al. N. Engl. J. Med. (2012) pmid: 22149875', 'Include': 'true'}, {'number': '30', 'ReferenceId': '25693012', 'FullCitation': 'Swain SM, et al. N. Engl. J. Med. (2015) pmid: 25693012', 'Include': 'true'}, {'number': '31', 'ReferenceId': '30857956', 'FullCitation': 'Meric_Bernstam F, et al. Lancet Oncol. (2019) pmid: 30857956', 'Include': 'true'}, {'number': '32', 'ReferenceId': '36400106', 'FullCitation': 'Meric_Bernstam F, et al. Lancet Oncol (2022) pmid: 36400106', 'Include': 'true'}, {'number': '33', 'ReferenceId': '23020162', 'FullCitation': 'Verma S, et al. N. Engl. J. Med. (2012) pmid: 23020162', 'Include': 'true'}, {'number': '34', 'ReferenceId': '31825192', 'FullCitation': 'Modi S, et al. N. Engl. J. Med. (2019) pmid: 31825192', 'Include': 'true'}, {'number': '35', 'ReferenceId': '32469182', 'FullCitation': 'Shitara K, et al. N. Engl. J. Med. (2020) pmid: 32469182', 'Include': 'true'}, {'number': '36', 'ReferenceId': '34534430', 'FullCitation': 'Li BT, et al. N Engl J Med (2021) pmid: 34534430', 'Include': 'true'}, {'number': '37', 'ReferenceId': '31825569', 'FullCitation': 'Murthy RK, et al. N. Engl. J. Med. (2020) pmid: 31825569', 'Include': 'true'}, {'number': '38', 'ReferenceId': '29955792', 'FullCitation': 'Borges VF, et al. JAMA Oncol (2018) pmid: 29955792', 'Include': 'true'}, {'number': '39', 'ReferenceId': '29804905', 'FullCitation': 'Murthy R, et al. Lancet Oncol. (2018) pmid: 29804905', 'Include': 'true'}, {'number': '40', 'ReferenceId': '28053022', 'FullCitation': 'Moulder SL, et al. Clin. Cancer Res. (2017) pmid: 28053022', 'Include': 'true'}, {'number': '41', 'ReferenceId': '32478891', 'FullCitation': 'Fan Y, et al. Mol Oncol (2020) pmid: 32478891', 'Include': 'true'}, {'number': '42', 'ReferenceId': '20736298', 'FullCitation': 'Cameron D, et al. Oncologist (2010) pmid: 20736298', 'Include': 'true'}, {'number': '43', 'ReferenceId': '17192538', 'FullCitation': 'Geyer CE, et al. N. Engl. J. Med. (2006) pmid: 17192538', 'Include': 'true'}, {'number': '44', 'ReferenceId': '23950206', 'FullCitation': 'Serra V, et al. Cancer Discov (2013) pmid: 23950206', 'Include': 'true'}, {'number': '45', 'ReferenceId': '24516025', 'FullCitation': 'Ali SM, et al. J. Clin. Oncol. (2014) pmid: 24516025', 'Include': 'true'}, {'number': '46', 'ReferenceId': '26487584', 'FullCitation': 'Grellety T, et al. Ann. Oncol. (2016) pmid: 26487584', 'Include': 'true'}, {'number': '47', 'ReferenceId': '25085898', 'FullCitation': 'Vornicova O, et al. Oncologist (2014) pmid: 25085898', 'Include': 'true'}, {'number': '48', 'ReferenceId': '32017710', 'FullCitation': 'Ronellenfitsch MW, et al. J Clin Invest (2020) pmid: 32017710', 'Include': 'true'}, {'number': '49', 'ReferenceId': '32405522', 'FullCitation': 'Hou JY, et al. Gynecol Oncol Rep (2020) pmid: 32405522', 'Include': 'true'}, {'number': '50', 'ReferenceId': '22418700', 'FullCitation': 'Lin NU, et al. Breast Cancer Res. Treat. (2012) pmid: 22418700', 'Include': 'true'}, {'number': '51', 'ReferenceId': '25268372', 'FullCitation': 'Schwab CL, et al. Br. J. Cancer (2014) pmid: 25268372', 'Include': 'true'}, {'number': '52', 'ReferenceId': '25682316', 'FullCitation': 'De Grève J, et al. Lung Cancer (2015) pmid: 25682316', 'Include': 'true'}, {'number': '53', 'ReferenceId': '22325357', 'FullCitation': 'De Grève J, et al. Lung Cancer (2012) pmid: 22325357', 'Include': 'true'}, {'number': '54', 'ReferenceId': '26559459', 'FullCitation': 'Li BT, et al. Lung Cancer (2015) pmid: 26559459', 'Include': 'true'}, {'number': '55', 'ReferenceId': '30825613', 'FullCitation': 'Dziadziuszko R, et al. J Thorac Oncol (2019) pmid: 30825613', 'Include': 'true'}, {'number': '56', 'ReferenceId': '30685684', 'FullCitation': 'Lai WV, et al. Eur. J. Cancer (2019) pmid: 30685684', 'Include': 'true'}, {'number': '57', 'ReferenceId': '30425522', 'FullCitation': 'Liu Z, et al. Onco Targets Ther (2018) pmid: 30425522', 'Include': 'true'}, {'number': '58', 'ReferenceId': '31748336', 'FullCitation': 'Fang W, et al. Oncologist (2019) pmid: 31748336', 'Include': 'true'}, {'number': '59', 'ReferenceId': '32477948', 'FullCitation': 'Yuan B, et al. Front Oncol (2020) pmid: 32477948', 'Include': 'true'}, {'number': '60', 'ReferenceId': '26358790', 'FullCitation': 'Ben_Baruch NE, et al. J Natl Compr Canc Netw (2015) pmid: 26358790', 'Include': 'true'}, {'number': '61', 'ReferenceId': '28679771', 'FullCitation': 'Ma CX, et al. Clin. Cancer Res. (2017) pmid: 28679771', 'Include': 'true'}, {'number': '62', 'ReferenceId': '29420467', 'FullCitation': 'Hyman DM, et al. Nature (2018) pmid: 29420467', 'Include': 'true'}, {'number': '63', 'ReferenceId': '31806627', 'FullCitation': 'Smyth LM, et al. Cancer Discov (2019) pmid: 31806627', 'Include': 'true'}, {'number': '64', 'ReferenceId': '25899785', 'FullCitation': 'Kris MG, et al. Ann. Oncol. (2015) pmid: 25899785', 'Include': 'true'}, {'number': '65', 'ReferenceId': '23788755', 'FullCitation': 'Johnsson A, et al. Ann. Oncol. (2013) pmid: 23788755', 'Include': 'true'}, {'number': '66', 'ReferenceId': '24114668', 'FullCitation': 'Ma BB, et al. Cancer (2013) pmid: 24114668', 'Include': 'true'}, {'number': '67', 'ReferenceId': '22811876', 'FullCitation': 'Frank D, et al. J Gastrointest Oncol (2012) pmid: 22811876', 'Include': 'true'}, {'number': '68', 'ReferenceId': '21737652', 'FullCitation': 'Bouche O, et al. Anticancer Res. (2011) pmid: 21737652', 'Include': 'true'}, {'number': '69', 'ReferenceId': '2827495', 'FullCitation': 'Yamashiroya HM, et al. Am. J. Pathol. (1988) pmid: 2827495', 'Include': 'true'}, {'number': '70', 'ReferenceId': '1904223', 'FullCitation': 'Hattori S, et al. Biochem. Biophys. Res. Commun. (1991) pmid: 1904223', 'Include': 'true'}, {'number': '71', 'ReferenceId': '8628317', 'FullCitation': 'Morcos P, et al. Mol. Cell. Biol. (1996) pmid: 8628317', 'Include': 'true'}, {'number': '72', 'ReferenceId': '2121371', 'FullCitation': 'Ballester R, et al. Cell (1990) pmid: 2121371', 'Include': 'true'}, {'number': '73', 'ReferenceId': '2116237', 'FullCitation': 'Xu GF, et al. Cell (1990) pmid: 2116237', 'Include': 'true'}, {'number': '74', 'ReferenceId': '2121370', 'FullCitation': 'Martin GA, et al. Cell (1990) pmid: 2121370', 'Include': 'true'}, {'number': '75', 'ReferenceId': '22807134', 'FullCitation': 'Thomas L, et al. Hum. Mutat. (2012) pmid: 22807134', 'Include': 'true'}, {'number': '76', 'ReferenceId': '9300663', 'FullCitation': 'Skuse GR, et al. Hum. Mol. Genet. (1997) pmid: 9300663', 'Include': 'true'}, {'number': '77', 'ReferenceId': '11258625', 'FullCitation': 'Messiaen LM, et al. Genet. Med. () pmid: 11258625', 'Include': 'true'}, {'number': '78', 'ReferenceId': '10607834', 'FullCitation': 'Ars E, et al. Hum. Mol. Genet. (2000) pmid: 10607834', 'Include': 'true'}, {'number': '79', 'ReferenceId': '15863657', 'FullCitation': 'Messiaen LM, et al. J. Med. Genet. (2005) pmid: 15863657', 'Include': 'true'}, {'number': '80', 'ReferenceId': '8264648', 'FullCitation': 'Poullet P, et al. Mol. Cell. Biol. (1994) pmid: 8264648', 'Include': 'true'}, {'number': '81', 'ReferenceId': '34728807', 'FullCitation': 'Arai H, et al. Oncogene (2022) pmid: 34728807', 'Include': 'true'}, {'number': '82', 'ReferenceId': '28029918', 'FullCitation': 'Dombi E, et al. N. Engl. J. Med. (2016) pmid: 28029918', 'Include': 'true'}, {'number': '83', 'ReferenceId': '33903938', 'FullCitation': 'Schalkwijk S, et al. Cancer Chemother Pharmacol (2021) pmid: 33903938', 'Include': 'true'}, {'number': '84', 'ReferenceId': '33751171', 'FullCitation': 'Toledano H, et al. Childs Nerv Syst (2021) pmid: 33751171', 'Include': 'true'}, {'number': '85', 'ReferenceId': '33939292', 'FullCitation': 'Ronsley R, et al. Cancer Med (2021) pmid: 33939292', 'Include': 'true'}, {'number': '86', 'ReferenceId': '31151904', 'FullCitation': 'Fangusaro J, et al. Lancet Oncol. (2019) pmid: 31151904', 'Include': 'true'}, {'number': '87', 'ReferenceId': '32780261', 'FullCitation': 'Manoharan N, et al. J Neurooncol (2020) pmid: 32780261', 'Include': 'true'}, {'number': '88', 'ReferenceId': '30097824', 'FullCitation': 'Kondyli M, et al. J Neurooncol (2018) pmid: 30097824', 'Include': 'true'}, {'number': '89', 'ReferenceId': '33082744', 'FullCitation': 'Awada G, et al. Case Rep Oncol () pmid: 33082744', 'Include': 'true'}, {'number': '90', 'ReferenceId': '32669708', 'FullCitation': 'Middleton G, et al. Nature (2020) pmid: 32669708', 'Include': 'true'}, {'number': '91', 'ReferenceId': '26859683', 'FullCitation': 'Lim SM, et al. Oncotarget (2016) pmid: 26859683', 'Include': 'true'}, {'number': '92', 'ReferenceId': '25314964', 'FullCitation': 'Weiss B, et al. Neuro_oncology (2015) pmid: 25314964', 'Include': 'true'}, {'number': '93', 'ReferenceId': '24931142', 'FullCitation': 'Janku F, et al. Oncotarget (2014) pmid: 24931142', 'Include': 'true'}, {'number': '94', 'ReferenceId': '18164202', 'FullCitation': 'Johannessen CM, et al. Curr. Biol. (2008) pmid: 18164202', 'Include': 'true'}, {'number': '95', 'ReferenceId': '15937108', 'FullCitation': 'Johannessen CM, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15937108', 'Include': 'true'}, {'number': '96', 'ReferenceId': '24913553', 'FullCitation': 'Malone CF, et al. Cancer Discov (2014) pmid: 24913553', 'Include': 'true'}, {'number': '97', 'ReferenceId': '23743569', 'FullCitation': 'Ng K, et al. Clin. Cancer Res. (2013) pmid: 23743569', 'Include': 'true'}, {'number': '98', 'ReferenceId': '24092809', 'FullCitation': 'Ganesan P, et al. Mol. Cancer Ther. (2013) pmid: 24092809', 'Include': 'true'}, {'number': '99', 'ReferenceId': '24440717', 'FullCitation': 'Janku F, et al. Cell Rep (2014) pmid: 24440717', 'Include': 'true'}, {'number': '100', 'ReferenceId': '20027112', 'FullCitation': 'Jett K, et al. Genet. Med. (2010) pmid: 20027112', 'Include': 'true'}, {'number': '101', 'ReferenceId': '22240541', 'FullCitation': 'Patil S, et al. Oncologist (2012) pmid: 22240541', 'Include': 'true'}, {'number': '102', 'ReferenceId': '23036231', 'FullCitation': 'Evans DG, et al. Clin Sarcoma Res (2012) pmid: 23036231', 'Include': 'true'}, {'number': '103', 'ReferenceId': '8544190', 'FullCitation': 'Upadhyaya M, et al. J. Med. Genet. (1995) pmid: 8544190', 'Include': 'true'}, {'number': '104', 'ReferenceId': '19117870', 'FullCitation': 'Williams VC, et al. Pediatrics (2009) pmid: 19117870', 'Include': 'true'}, {'number': '105', 'ReferenceId': '15473860', 'FullCitation': 'Logan CY, et al. Annu. Rev. Cell Dev. Biol. (2004) pmid: 15473860', 'Include': 'true'}, {'number': '106', 'ReferenceId': '11707392', 'FullCitation': 'Eklof Spink K, et al. EMBO J. (2001) pmid: 11707392', 'Include': 'true'}, {'number': '107', 'ReferenceId': '16753179', 'FullCitation': 'Liu J, et al. J. Mol. Biol. (2006) pmid: 16753179', 'Include': 'true'}, {'number': '108', 'ReferenceId': '20144988', 'FullCitation': 'Dikovskaya D, et al. J. Cell. Sci. (2010) pmid: 20144988', 'Include': 'true'}, {'number': '109', 'ReferenceId': '17410430', 'FullCitation': 'Murphy SJ, et al. Dig. Dis. Sci. (2007) pmid: 17410430', 'Include': 'true'}, {'number': '110', 'ReferenceId': '15459959', 'FullCitation': 'Aretz S, et al. Hum. Mutat. (2004) pmid: 15459959', 'Include': 'true'}, {'number': '111', 'ReferenceId': '23085758', 'FullCitation': 'Christie M, et al. Oncogene (2013) pmid: 23085758', 'Include': 'true'}, {'number': '112', 'ReferenceId': '19110823', 'FullCitation': 'Quyn AJ, et al. Surgeon (2008) pmid: 19110823', 'Include': 'true'}, {'number': '113', 'ReferenceId': '30635339', 'FullCitation': 'Luke JJ, et al. Clin Cancer Res (2019) pmid: 30635339', 'Include': 'true'}, {'number': '114', 'ReferenceId': '27617575', 'FullCitation': 'Zhan T, et al. Oncogene (2017) pmid: 27617575', 'Include': 'true'}, {'number': '115', 'ReferenceId': '32037398', 'FullCitation': 'Jung YS, et al. Exp Mol Med (2020) pmid: 32037398', 'Include': 'true'}, {'number': '116', 'ReferenceId': '29169144', 'FullCitation': 'Krishnamurthy N, et al. Cancer Treat Rev (2018) pmid: 29169144', 'Include': 'true'}, {'number': '117', 'ReferenceId': '33408116', 'FullCitation': 'Yamada K, et al. Cancer Res (2021) pmid: 33408116', 'Include': 'true'}, {'number': '118', 'ReferenceId': '34837838', 'FullCitation': 'Kanda Y, et al. Biochem Biophys Res Commun (2022) pmid: 34837838', 'Include': 'true'}, {'number': '119', 'ReferenceId': '29165669', 'FullCitation': 'Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669', 'Include': 'true'}, {'number': '120', 'ReferenceId': '23159591', 'FullCitation': 'Kerr SE, et al. J Mol Diagn (2013) pmid: 23159591', 'Include': 'true'}, {'number': '121', 'ReferenceId': '21090969', 'FullCitation': 'Annu Rev Pathol (2011) pmid: 21090969', 'Include': 'true'}, {'number': '122', 'ReferenceId': '18844223', 'FullCitation': 'Kastritis E, et al. Int. J. Cancer (2009) pmid: 18844223', 'Include': 'true'}, {'number': '123', 'ReferenceId': '19822006', 'FullCitation': 'Half E, et al. Orphanet J Rare Dis (2009) pmid: 19822006', 'Include': 'true'}, {'number': '124', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '125', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '126', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '127', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '128', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '129', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '130', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '131', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '132', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '133', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '134', 'ReferenceId': '30643254', 'FullCitation': 'Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254', 'Include': 'true'}, {'number': '135', 'ReferenceId': '30151257', 'FullCitation': 'Fabrizio DA, et al. J Gastrointest Oncol (2018) pmid: 30151257', 'Include': 'true'}, {'number': '136', 'ReferenceId': '32919526', 'FullCitation': 'Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526', 'Include': 'true'}, {'number': '137', 'ReferenceId': '27022117', 'FullCitation': 'Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117', 'Include': 'true'}, {'number': '138', 'ReferenceId': '33119110', 'FullCitation': 'Shao C, et al. JAMA Netw Open (2020) pmid: 33119110', 'Include': 'true'}, {'number': '139', 'ReferenceId': '30865548', 'FullCitation': 'Innocenti F, et al. J Clin Oncol (2019) pmid: 30865548', 'Include': 'true'}, {'number': '140', 'ReferenceId': '31285374', 'FullCitation': 'Lee DW, et al. Clin Cancer Res (2019) pmid: 31285374', 'Include': 'true'}, {'number': '141', 'ReferenceId': '34933155', 'FullCitation': 'Randon G, et al. Eur J Cancer (2022) pmid: 34933155', 'Include': 'true'}, {'number': '142', 'ReferenceId': '32379280', 'FullCitation': 'Chen EX, et al. JAMA Oncol (2020) pmid: 32379280', 'Include': 'true'}, {'number': '143', 'ReferenceId': '28835386', 'FullCitation': 'Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386', 'Include': 'true'}, {'number': '144', 'ReferenceId': '31405947', 'FullCitation': 'Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947', 'Include': 'true'}, {'number': '145', 'ReferenceId': '30309915', 'FullCitation': 'Cristescu R, et al. Science (2018) pmid: 30309915', 'Include': 'true'}, {'number': '146', 'ReferenceId': '30785829', 'FullCitation': 'Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829', 'Include': 'true'}, {'number': '147', 'ReferenceId': '29658845', 'FullCitation': 'Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845', 'Include': 'true'}, {'number': '148', 'ReferenceId': '29657128', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128', 'Include': 'true'}, {'number': '149', 'ReferenceId': '29731394', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394', 'Include': 'true'}, {'number': '150', 'ReferenceId': '33558721', 'FullCitation': 'Rozeman EA, et al. Nat Med (2021) pmid: 33558721', 'Include': 'true'}, {'number': '151', 'ReferenceId': '32916128', 'FullCitation': 'Sharma P, et al. Cancer Cell (2020) pmid: 32916128', 'Include': 'true'}, {'number': '152', 'ReferenceId': '30557521', 'FullCitation': 'Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521', 'Include': 'true'}, {'number': '153', 'ReferenceId': '35101941', 'FullCitation': 'Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941', 'Include': 'true'}, {'number': '154', 'ReferenceId': '34876409', 'FullCitation': 'Friedman CF, et al. Cancer Discov (2022) pmid: 34876409', 'Include': 'true'}, {'number': '155', 'ReferenceId': '35274716', 'FullCitation': 'Sturgill EG, et al. Oncologist (2022) pmid: 35274716', 'Include': 'true'}, {'number': '156', 'ReferenceId': '12917328', 'FullCitation': 'Neuhaus P, et al. Mol. Cell. Biol. (2003) pmid: 12917328', 'Include': 'true'}, {'number': '157', 'ReferenceId': '8663044', 'FullCitation': 'Ornitz DM, et al. J. Biol. Chem. (1996) pmid: 8663044', 'Include': 'true'}, {'number': '158', 'ReferenceId': '1549352', 'FullCitation': 'Iida S, et al. Oncogene (1992) pmid: 1549352', 'Include': 'true'}, {'number': '159', 'ReferenceId': '10945637', 'FullCitation': 'Ropiquet F, et al. Cancer Res. (2000) pmid: 10945637', 'Include': 'true'}, {'number': '160', 'ReferenceId': '12399964', 'FullCitation': 'Niini T, et al. Leukemia (2002) pmid: 12399964', 'Include': 'true'}, {'number': '161', 'ReferenceId': '2649847', 'FullCitation': 'Marics I, et al. Oncogene (1989) pmid: 2649847', 'Include': 'true'}, {'number': '162', 'ReferenceId': '22588877', 'FullCitation': 'Cerami E, et al. Cancer Discov (2012) pmid: 22588877', 'Include': 'true'}, {'number': '163', 'ReferenceId': '30371878', 'FullCitation': 'Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878', 'Include': 'true'}, {'number': '164', 'ReferenceId': '25950492', 'FullCitation': 'Parish A, et al. Cell Cycle (2015) pmid: 25950492', 'Include': 'true'}, {'number': '165', 'ReferenceId': '19850045', 'FullCitation': 'Zeng J, et al. Gastroenterology (2010) pmid: 19850045', 'Include': 'true'}, {'number': '166', 'ReferenceId': '22615382', 'FullCitation': 'Chicas A, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22615382', 'Include': 'true'}, {'number': '167', 'ReferenceId': '23722541', 'FullCitation': 'Teng YC, et al. Cancer Res. (2013) pmid: 23722541', 'Include': 'true'}, {'number': '168', 'ReferenceId': '24716659', 'FullCitation': 'Li L, et al. Mol. Cancer (2014) pmid: 24716659', 'Include': 'true'}, {'number': '169', 'ReferenceId': '25537453', 'FullCitation': 'Lin W, et al. Mol. Cancer Res. (2015) pmid: 25537453', 'Include': 'true'}, {'number': '170', 'ReferenceId': '23922798', 'FullCitation': 'Liang X, et al. PLoS ONE (2013) pmid: 23922798', 'Include': 'true'}, {'number': '171', 'ReferenceId': '23794145', 'FullCitation': 'Jiping Z, et al. J. Cell. Biochem. (2013) pmid: 23794145', 'Include': 'true'}, {'number': '172', 'ReferenceId': '24200674', 'FullCitation': 'Vieira FQ, et al. Endocr. Relat. Cancer (2014) pmid: 24200674', 'Include': 'true'}, {'number': '173', 'ReferenceId': '20371346', 'FullCitation': 'Sharma SV, et al. Cell (2010) pmid: 20371346', 'Include': 'true'}, {'number': '174', 'ReferenceId': '20371339', 'FullCitation': 'Dannenberg JH, et al. Cell (2010) pmid: 20371339', 'Include': 'true'}, {'number': '175', 'ReferenceId': '22937203', 'FullCitation': 'Hou J, et al. Am J Transl Res (2012) pmid: 22937203', 'Include': 'true'}, {'number': '176', 'ReferenceId': '23266085', 'FullCitation': 'Paolicchi E, et al. Crit. Rev. Oncol. Hematol. (2013) pmid: 23266085', 'Include': 'true'}, {'number': '177', 'ReferenceId': '16419055', 'FullCitation': 'van Zutven LJ, et al. Genes Chromosomes Cancer (2006) pmid: 16419055', 'Include': 'true'}, {'number': '178', 'ReferenceId': '19430464', 'FullCitation': 'Wang GG, et al. Nature (2009) pmid: 19430464', 'Include': 'true'}, {'number': '179', 'ReferenceId': '25162518', 'FullCitation': 'Qi L, et al. PLoS ONE (2014) pmid: 25162518', 'Include': 'true'}, {'number': '180', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '181', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '182', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '183', 'ReferenceId': '9823339', 'FullCitation': 'Boland CR, et al. Cancer Res. (1998) pmid: 9823339', 'Include': 'true'}, {'number': '184', 'ReferenceId': '15528785', 'FullCitation': 'Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785', 'Include': 'true'}, {'number': '185', 'ReferenceId': '20420947', 'FullCitation': 'Boland CR, et al. Gastroenterology (2010) pmid: 20420947', 'Include': 'true'}, {'number': '186', 'ReferenceId': '20627535', 'FullCitation': 'Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535', 'Include': 'true'}, {'number': '187', 'ReferenceId': '17204026', 'FullCitation': 'Histopathology (2007) pmid: 17204026', 'Include': 'true'}, {'number': '188', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '189', 'ReferenceId': '11535541', 'FullCitation': 'Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541', 'Include': 'true'}, {'number': '190', 'ReferenceId': '12445368', 'FullCitation': 'Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368', 'Include': 'true'}, {'number': '191', 'ReferenceId': '12820457', 'FullCitation': 'Brueckl WM, et al. Anticancer Res. () pmid: 12820457', 'Include': 'true'}, {'number': '192', 'ReferenceId': '11438476', 'FullCitation': 'Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476', 'Include': 'true'}, {'number': '193', 'ReferenceId': '10631274', 'FullCitation': 'Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274', 'Include': 'true'}, {'number': '194', 'ReferenceId': '16952542', 'FullCitation': 'Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542', 'Include': 'true'}, {'number': '195', 'ReferenceId': '22722556', 'FullCitation': 'Laghi L, et al. Dig Dis (2012) pmid: 22722556', 'Include': 'true'}, {'number': '196', 'ReferenceId': '25392179', 'FullCitation': 'Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179', 'Include': 'true'}, {'number': '197', 'ReferenceId': '26140250', 'FullCitation': 'Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250', 'Include': 'true'}, {'number': '198', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '199', 'ReferenceId': '32343640', 'FullCitation': 'Fukuoka S, et al. J. Clin. Oncol. (2020) pmid: 32343640', 'Include': 'true'}, {'number': '200', 'ReferenceId': '34688262', 'FullCitation': 'Zhang Y, et al. BMC Gastroenterol (2021) pmid: 34688262', 'Include': 'true'}, {'number': '201', 'ReferenceId': '24019539', 'FullCitation': 'Sinicrope FA, et al. J. Clin. Oncol. (2013) pmid: 24019539', 'Include': 'true'}, {'number': '202', 'ReferenceId': '23045248', 'FullCitation': 'Gavin PG, et al. Clin. Cancer Res. (2012) pmid: 23045248', 'Include': 'true'}, {'number': '203', 'ReferenceId': '19273709', 'FullCitation': 'Bertagnolli MM, et al. J. Clin. Oncol. (2009) pmid: 19273709', 'Include': 'true'}, {'number': '204', 'ReferenceId': '19451425', 'FullCitation': 'Van Cutsem E, et al. J. Clin. Oncol. (2009) pmid: 19451425', 'Include': 'true'}, {'number': '205', 'ReferenceId': '12867608', 'FullCitation': 'Ribic CM, et al. N. Engl. J. Med. (2003) pmid: 12867608', 'Include': 'true'}, {'number': '206', 'ReferenceId': '20498393', 'FullCitation': 'Sargent DJ, et al. J. Clin. Oncol. (2010) pmid: 20498393', 'Include': 'true'}, {'number': '207', 'ReferenceId': '14522894', 'FullCitation': 'Fallik D, et al. Cancer Res. (2003) pmid: 14522894', 'Include': 'true'}, {'number': '208', 'ReferenceId': '22992590', 'FullCitation': 'Nat. Rev. Mol. Cell Biol. (2012) pmid: 22992590', 'Include': 'true'}, {'number': '209', 'ReferenceId': '18662538', 'FullCitation': 'Cell (2008) pmid: 18662538', 'Include': 'true'}, {'number': '210', 'ReferenceId': '16322555', 'FullCitation': 'Massagué J, et al. Genes Dev. (2005) pmid: 16322555', 'Include': 'true'}, {'number': '211', 'ReferenceId': '10980615', 'FullCitation': 'Morén A, et al. Oncogene (2000) pmid: 10980615', 'Include': 'true'}, {'number': '212', 'ReferenceId': '10781087', 'FullCitation': 'Xu J, et al. Proc. Natl. Acad. Sci. U.S.A. (2000) pmid: 10781087', 'Include': 'true'}, {'number': '213', 'ReferenceId': '10485843', 'FullCitation': 'Luo K, et al. Genes Dev. (1999) pmid: 10485843', 'Include': 'true'}, {'number': '214', 'ReferenceId': '10871368', 'FullCitation': 'Jones JB, et al. Nucleic Acids Res. (2000) pmid: 10871368', 'Include': 'true'}, {'number': '215', 'ReferenceId': '11196171', 'FullCitation': 'Fink SP, et al. Cancer Res. (2001) pmid: 11196171', 'Include': 'true'}, {'number': '216', 'ReferenceId': '14715079', 'FullCitation': 'De Bosscher K, et al. Biochem. J. (2004) pmid: 14715079', 'Include': 'true'}, {'number': '217', 'ReferenceId': '9214508', 'FullCitation': 'Shi Y, et al. Nature (1997) pmid: 9214508', 'Include': 'true'}, {'number': '218', 'ReferenceId': '10340381', 'FullCitation': 'Miyaki M, et al. Oncogene (1999) pmid: 10340381', 'Include': 'true'}, {'number': '219', 'ReferenceId': '17994767', 'FullCitation': 'Prokova V, et al. Biochemistry (2007) pmid: 17994767', 'Include': 'true'}, {'number': '220', 'ReferenceId': '11274206', 'FullCitation': 'Wu JW, et al. J. Biol. Chem. (2001) pmid: 11274206', 'Include': 'true'}, {'number': '221', 'ReferenceId': '19139564', 'FullCitation': 'Ding L, et al. J. Clin. Invest. (2009) pmid: 19139564', 'Include': 'true'}, {'number': '222', 'ReferenceId': '14647410', 'FullCitation': 'Kuang C, et al. Oncogene (2004) pmid: 14647410', 'Include': 'true'}, {'number': '223', 'ReferenceId': '11265759', 'FullCitation': 'Watanabe M, et al. EMBO Rep. (2000) pmid: 11265759', 'Include': 'true'}, {'number': '224', 'ReferenceId': '25855536', 'FullCitation': 'Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536', 'Include': 'true'}, {'number': '225', 'ReferenceId': '24293293', 'FullCitation': 'Jiao Y, et al. J. Pathol. (2014) pmid: 24293293', 'Include': 'true'}, {'number': '226', 'ReferenceId': '25536104', 'FullCitation': 'Churi CR, et al. PLoS ONE (2014) pmid: 25536104', 'Include': 'true'}, {'number': '227', 'ReferenceId': '24821835', 'FullCitation': 'Liu X, et al. Clin. Chem. (2014) pmid: 24821835', 'Include': 'true'}, {'number': '228', 'ReferenceId': '14647445', 'FullCitation': 'Maru D, et al. Oncogene (2004) pmid: 14647445', 'Include': 'true'}, {'number': '229', 'ReferenceId': '26336083', 'FullCitation': 'Wang K, et al. Oncologist (2015) pmid: 26336083', 'Include': 'true'}, {'number': '230', 'ReferenceId': '25079317', 'FullCitation': 'Nature (2014) pmid: 25079317', 'Include': 'true'}, {'number': '231', 'ReferenceId': '17349581', 'FullCitation': 'Izeradjene K, et al. Cancer Cell (2007) pmid: 17349581', 'Include': 'true'}, {'number': '232', 'ReferenceId': '17114584', 'FullCitation': 'Bardeesy N, et al. Genes Dev. (2006) pmid: 17114584', 'Include': 'true'}, {'number': '233', 'ReferenceId': '26253305', 'FullCitation': 'Springer S, et al. Gastroenterology (2015) pmid: 26253305', 'Include': 'true'}, {'number': '234', 'ReferenceId': '19584151', 'FullCitation': 'Blackford A, et al. Clin. Cancer Res. (2009) pmid: 19584151', 'Include': 'true'}, {'number': '235', 'ReferenceId': '26861460', 'FullCitation': 'Yan P, et al. Clin. Cancer Res. (2016) pmid: 26861460', 'Include': 'true'}, {'number': '236', 'ReferenceId': '25681512', 'FullCitation': 'Kozak MM, et al. J. Clin. Pathol. (2015) pmid: 25681512', 'Include': 'true'}, {'number': '237', 'ReferenceId': '23104212', 'FullCitation': 'Roth AD, et al. J. Natl. Cancer Inst. (2012) pmid: 23104212', 'Include': 'true'}, {'number': '238', 'ReferenceId': '24618609', 'FullCitation': 'Davison JM, et al. Am. J. Surg. Pathol. (2014) pmid: 24618609', 'Include': 'true'}, {'number': '239', 'ReferenceId': '15033661', 'FullCitation': 'Kim YH, et al. Ann. Oncol. (2004) pmid: 15033661', 'Include': 'true'}, {'number': '240', 'ReferenceId': '11234879', 'FullCitation': 'Xiangming C, et al. Clin. Cancer Res. (2001) pmid: 11234879', 'Include': 'true'}, {'number': '241', 'ReferenceId': '25634752', 'FullCitation': 'Singhi AD, et al. Am. J. Surg. Pathol. (2015) pmid: 25634752', 'Include': 'true'}, {'number': '242', 'ReferenceId': '12060625', 'FullCitation': 'Natsugoe S, et al. Clin. Cancer Res. (2002) pmid: 12060625', 'Include': 'true'}, {'number': '243', 'ReferenceId': '23022998', 'FullCitation': 'de Kruijf EM, et al. Ann. Oncol. (2013) pmid: 23022998', 'Include': 'true'}, {'number': '244', 'ReferenceId': '25032733', 'FullCitation': 'Shipitsin M, et al. Br. J. Cancer (2014) pmid: 25032733', 'Include': 'true'}, {'number': '245', 'ReferenceId': '35393542', 'FullCitation': 'Shi C, et al. Oncogene (2022) pmid: 35393542', 'Include': 'true'}, {'number': '246', 'ReferenceId': '35274815', 'FullCitation': 'Park JW, et al. Cancer Med (2022) pmid: 35274815', 'Include': 'true'}, {'number': '247', 'ReferenceId': '28534865', 'FullCitation': 'Ormanns S, et al. Int J Mol Sci (2017) pmid: 28534865', 'Include': 'true'}, {'number': '248', 'ReferenceId': '34002944', 'FullCitation': 'Fei N, et al. Clin Transl Sci (2021) pmid: 34002944', 'Include': 'true'}, {'number': '249', 'ReferenceId': '22377565', 'FullCitation': 'Bachet JB, et al. Ann. Oncol. (2012) pmid: 22377565', 'Include': 'true'}, {'number': '250', 'ReferenceId': '28577946', 'FullCitation': 'Ziemke M, et al. Lung Cancer (2017) pmid: 28577946', 'Include': 'true'}, {'number': '251', 'ReferenceId': '32897998', 'FullCitation': 'Kassardjian A, et al. Pancreas (2020) pmid: 32897998', 'Include': 'true'}, {'number': '252', 'ReferenceId': '33667587', 'FullCitation': 'Pen SL, et al. Radiother Oncol (2021) pmid: 33667587', 'Include': 'true'}, {'number': '253', 'ReferenceId': '9811934', 'FullCitation': 'Houlston R, et al. Hum. Mol. Genet. (1998) pmid: 9811934', 'Include': 'true'}, {'number': '254', 'ReferenceId': '10764709', 'FullCitation': 'Woodford_Richens K, et al. Gut (2000) pmid: 10764709', 'Include': 'true'}, {'number': '255', 'ReferenceId': '15235019', 'FullCitation': 'Howe JR, et al. J. Med. Genet. (2004) pmid: 15235019', 'Include': 'true'}, {'number': '256', 'ReferenceId': '22171123', 'FullCitation': 'Brosens LA, et al. World J. Gastroenterol. (2011) pmid: 22171123', 'Include': 'true'}, {'number': '257', 'ReferenceId': '27854360', 'FullCitation': 'Kalia SS, et al. Genet. Med. (2017) pmid: 27854360', 'Include': 'true'}, {'number': '258', 'ReferenceId': '19935675', 'FullCitation': 'Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675', 'Include': 'true'}, {'number': '259', 'ReferenceId': '18410249', 'FullCitation': 'Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249', 'Include': 'true'}, {'number': '260', 'ReferenceId': '12826609', 'FullCitation': 'Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609', 'Include': 'true'}, {'number': '261', 'ReferenceId': '20978130', 'FullCitation': 'Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130', 'Include': 'true'}, {'number': '262', 'ReferenceId': '28472496', 'FullCitation': 'Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496', 'Include': 'true'}, {'number': '263', 'ReferenceId': '17690113', 'FullCitation': 'Yamada H, et al. Carcinogenesis (2007) pmid: 17690113', 'Include': 'true'}, {'number': '264', 'ReferenceId': '7585578', 'FullCitation': 'Goh HS, et al. Cancer Res. (1995) pmid: 7585578', 'Include': 'true'}, {'number': '265', 'ReferenceId': '21103049', 'FullCitation': 'Berg M, et al. PLoS ONE (2010) pmid: 21103049', 'Include': 'true'}, {'number': '266', 'ReferenceId': '23700467', 'FullCitation': 'Han SW, et al. PLoS ONE (2013) pmid: 23700467', 'Include': 'true'}, {'number': '267', 'ReferenceId': '23325582', 'FullCitation': 'Peeters M, et al. Clin. Cancer Res. (2013) pmid: 23325582', 'Include': 'true'}, {'number': '268', 'ReferenceId': '23526092', 'FullCitation': 'Malhotra P, et al. Tumour Biol. (2013) pmid: 23526092', 'Include': 'true'}, {'number': '269', 'ReferenceId': '23821376', 'FullCitation': 'Di Bartolomeo M, et al. Target Oncol (2014) pmid: 23821376', 'Include': 'true'}, {'number': '270', 'ReferenceId': '23337059', 'FullCitation': 'Wangefjord S, et al. Diagn Pathol (2013) pmid: 23337059', 'Include': 'true'}, {'number': '271', 'ReferenceId': '16172461', 'FullCitation': 'Russo A, et al. J. Clin. Oncol. (2005) pmid: 16172461', 'Include': 'true'}, {'number': '272', 'ReferenceId': '20107315', 'FullCitation': 'Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315', 'Include': 'true'}, {'number': '273', 'ReferenceId': '21799033', 'FullCitation': 'Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033', 'Include': 'true'}, {'number': '274', 'ReferenceId': '21389100', 'FullCitation': 'Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100', 'Include': 'true'}, {'number': '275', 'ReferenceId': '25504633', 'FullCitation': 'Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633', 'Include': 'true'}, {'number': '276', 'ReferenceId': '12489850', 'FullCitation': 'Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850', 'Include': 'true'}, {'number': '277', 'ReferenceId': '11713371', 'FullCitation': 'Xu L, et al. Mol. Med. (2001) pmid: 11713371', 'Include': 'true'}, {'number': '278', 'ReferenceId': '23470564', 'FullCitation': 'Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564', 'Include': 'true'}, {'number': '279', 'ReferenceId': '25240597', 'FullCitation': 'Kim SS, et al. Nanomedicine (2015) pmid: 25240597', 'Include': 'true'}, {'number': '280', 'ReferenceId': '27357628', 'FullCitation': 'Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628', 'Include': 'true'}, {'number': '281', 'ReferenceId': '27601554', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554', 'Include': 'true'}, {'number': '282', 'ReferenceId': '27998224', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224', 'Include': 'true'}, {'number': '283', 'ReferenceId': '31315834', 'FullCitation': 'Lee J, et al. Cancer Discov (2019) pmid: 31315834', 'Include': 'true'}, {'number': '284', 'ReferenceId': '29535125', 'FullCitation': 'Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125', 'Include': 'true'}, {'number': '285', 'ReferenceId': '34538072', 'FullCitation': 'Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072', 'Include': 'true'}, {'number': '286', 'ReferenceId': '36084396', 'FullCitation': 'Park H, et al. ESMO Open (2022) pmid: 36084396', 'Include': 'true'}, {'number': '287', 'ReferenceId': '26014290', 'FullCitation': 'Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290', 'Include': 'true'}, {'number': '288', 'ReferenceId': '23355100', 'FullCitation': 'Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100', 'Include': 'true'}, {'number': '289', 'ReferenceId': '11219776', 'FullCitation': 'Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776', 'Include': 'true'}, {'number': '290', 'ReferenceId': '9006316', 'FullCitation': 'Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316', 'Include': 'true'}, {'number': '291', 'ReferenceId': '19204208', 'FullCitation': 'Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208', 'Include': 'true'}, {'number': '292', 'ReferenceId': '12672316', 'FullCitation': 'Lalloo F, et al. Lancet (2003) pmid: 12672316', 'Include': 'true'}, {'number': '293', 'ReferenceId': '31050713', 'FullCitation': 'Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713', 'Include': 'true'}, {'number': '294', 'ReferenceId': '25426837', 'FullCitation': 'Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837', 'Include': 'true'}, {'number': '295', 'ReferenceId': '25426838', 'FullCitation': 'Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838', 'Include': 'true'}, {'number': '296', 'ReferenceId': '25326804', 'FullCitation': 'Xie M, et al. Nat. Med. (2014) pmid: 25326804', 'Include': 'true'}, {'number': '297', 'ReferenceId': '28669404', 'FullCitation': 'Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404', 'Include': 'true'}, {'number': '298', 'ReferenceId': '29678827', 'FullCitation': 'Severson EA, et al. Blood (2018) pmid: 29678827', 'Include': 'true'}, {'number': '299', 'ReferenceId': '29420212', 'FullCitation': 'Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212', 'Include': 'true'}, {'number': '300', 'ReferenceId': '30504320', 'FullCitation': 'Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320', 'Include': 'true'}, {'number': '301', 'ReferenceId': '32269342', 'FullCitation': 'Chabon JJ, et al. Nature (2020) pmid: 32269342', 'Include': 'true'}, {'number': '302', 'ReferenceId': '31768066', 'FullCitation': 'Razavi P, et al. Nat. Med. (2019) pmid: 31768066', 'Include': 'true'}, {'number': '303', 'ReferenceId': '21993244', 'FullCitation': 'Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244', 'Include': 'true'}, {'number': '304', 'ReferenceId': '3310850', 'FullCitation': 'Kahn S, et al. Anticancer Res. () pmid: 3310850', 'Include': 'true'}, {'number': '305', 'ReferenceId': '16618717', 'FullCitation': 'Lièvre A, et al. Cancer Res. (2006) pmid: 16618717', 'Include': 'true'}, {'number': '306', 'ReferenceId': '21163703', 'FullCitation': 'De Roock W, et al. Lancet Oncol. (2011) pmid: 21163703', 'Include': 'true'}, {'number': '307', 'ReferenceId': '25367198', 'FullCitation': 'Chen J, et al. BMC Cancer (2014) pmid: 25367198', 'Include': 'true'}, {'number': '308', 'ReferenceId': '25929517', 'FullCitation': 'Li W, et al. BMC Cancer (2015) pmid: 25929517', 'Include': 'true'}, {'number': '309', 'ReferenceId': '27977612', 'FullCitation': 'Hu J, et al. Medicine (Baltimore) (2016) pmid: 27977612', 'Include': 'true'}, {'number': '310', 'ReferenceId': '28218784', 'FullCitation': 'Zekri J, et al. Genet. Mol. Res. (2017) pmid: 28218784', 'Include': 'true'}, {'number': '311', 'ReferenceId': '29048416', 'FullCitation': 'Staudacher JJ, et al. Clin Transl Gastroenterol (2017) pmid: 29048416', 'Include': 'true'}, {'number': '312', 'ReferenceId': '29705968', 'FullCitation': 'Wang Y, et al. Virchows Arch. (2018) pmid: 29705968', 'Include': 'true'}, {'number': '313', 'ReferenceId': '29666387', 'FullCitation': 'Guo F, et al. Sci Rep (2018) pmid: 29666387', 'Include': 'true'}, {'number': '314', 'ReferenceId': '28106826', 'FullCitation': 'Mármol I, et al. Int J Mol Sci (2017) pmid: 28106826', 'Include': 'true'}, {'number': '315', 'ReferenceId': '28858102', 'FullCitation': 'Kwak MS, et al. Medicine (Baltimore) (2017) pmid: 28858102', 'Include': 'true'}, {'number': '316', 'ReferenceId': '21502544', 'FullCitation': 'Van Cutsem E, et al. J. Clin. Oncol. (2011) pmid: 21502544', 'Include': 'true'}, {'number': '317', 'ReferenceId': '21228335', 'FullCitation': 'Bokemeyer C, et al. Ann. Oncol. (2011) pmid: 21228335', 'Include': 'true'}, {'number': '318', 'ReferenceId': '18946061', 'FullCitation': 'Karapetis CS, et al. N. Engl. J. Med. (2008) pmid: 18946061', 'Include': 'true'}, {'number': '319', 'ReferenceId': '17998284', 'FullCitation': 'De Roock W, et al. Ann. Oncol. (2008) pmid: 17998284', 'Include': 'true'}, {'number': '320', 'ReferenceId': '24718886', 'FullCitation': 'Douillard JY, et al. Ann. Oncol. (2014) pmid: 24718886', 'Include': 'true'}, {'number': '321', 'ReferenceId': '24024839', 'FullCitation': 'Douillard JY, et al. N. Engl. J. Med. (2013) pmid: 24024839', 'Include': 'true'}, {'number': '322', 'ReferenceId': '18316791', 'FullCitation': 'Amado RG, et al. J. Clin. Oncol. (2008) pmid: 18316791', 'Include': 'true'}, {'number': '323', 'ReferenceId': '22306179', 'FullCitation': 'Penton AL, et al. Semin. Cell Dev. Biol. (2012) pmid: 22306179', 'Include': 'true'}, {'number': '324', 'ReferenceId': '19379690', 'FullCitation': 'Kopan R, et al. Cell (2009) pmid: 19379690', 'Include': 'true'}, {'number': '325', 'ReferenceId': '16869730', 'FullCitation': 'Deregowski V, et al. J. Bone Miner. Res. (2006) pmid: 16869730', 'Include': 'true'}, {'number': '326', 'ReferenceId': '24145436', 'FullCitation': 'Beà S, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 24145436', 'Include': 'true'}, {'number': '327', 'ReferenceId': '16773578', 'FullCitation': 'McDaniell R, et al. Am. J. Hum. Genet. (2006) pmid: 16773578', 'Include': 'true'}, {'number': '328', 'ReferenceId': '20068176', 'FullCitation': 'Lin L, et al. Cancer Res. (2010) pmid: 20068176', 'Include': 'true'}, {'number': '329', 'ReferenceId': '35120664', 'FullCitation': 'Nguyen B, et al. Cell (2022) pmid: 35120664', 'Include': 'true'}, {'number': '330', 'ReferenceId': '21598247', 'FullCitation': 'Serafin V, et al. J. Pathol. (2011) pmid: 21598247', 'Include': 'true'}, {'number': '331', 'ReferenceId': '24728738', 'FullCitation': 'Ozawa T, et al. Ann. Surg. Oncol. (2014) pmid: 24728738', 'Include': 'true'}, {'number': '332', 'ReferenceId': '24244701', 'FullCitation': 'Furukawa S, et al. PLoS ONE (2013) pmid: 24244701', 'Include': 'true'}, {'number': '333', 'ReferenceId': '23060121', 'FullCitation': 'Lee HJ, et al. Mod. Pathol. (2013) pmid: 23060121', 'Include': 'true'}, {'number': '334', 'ReferenceId': '25934888', 'FullCitation': 'Yen WC, et al. Clin. Cancer Res. (2015) pmid: 25934888', 'Include': 'true'}, {'number': '335', 'ReferenceId': '24743243', 'FullCitation': 'Hu W, et al. Cancer Res. (2014) pmid: 24743243', 'Include': 'true'}, {'number': '336', 'ReferenceId': '17804716', 'FullCitation': 'Konishi J, et al. Cancer Res. (2007) pmid: 17804716', 'Include': 'true'}, {'number': '337', 'ReferenceId': '20838375', 'FullCitation': 'Xiao Y, et al. Oncogene (2011) pmid: 20838375', 'Include': 'true'}, {'number': '338', 'ReferenceId': '31347292', 'FullCitation': 'Hu ZI, et al. Cancer Med (2019) pmid: 31347292', 'Include': 'true'}, {'number': '339', 'ReferenceId': '12711740', 'FullCitation': 'Jonsson KB, et al. N. Engl. J. Med. (2003) pmid: 12711740', 'Include': 'true'}, {'number': '340', 'ReferenceId': '11344269', 'FullCitation': 'Shimada T, et al. Proc. Natl. Acad. Sci. U.S.A. (2001) pmid: 11344269', 'Include': 'true'}, {'number': '341', 'ReferenceId': '15863037', 'FullCitation': 'Yu X, et al. Cytokine Growth Factor Rev. (2005) pmid: 15863037', 'Include': 'true'}, {'number': '342', 'ReferenceId': '23374602', 'FullCitation': 'Pentheroudakis G, et al. BMC Cancer (2013) pmid: 23374602', 'Include': 'true'}, {'number': '343', 'ReferenceId': '21305640', 'FullCitation': 'Vaughn CP, et al. Genes Chromosomes Cancer (2011) pmid: 21305640', 'Include': 'true'}, {'number': '344', 'ReferenceId': '23400451', 'FullCitation': 'Janku F, et al. Target Oncol (2013) pmid: 23400451', 'Include': 'true'}, {'number': '345', 'ReferenceId': '20619739', 'FullCitation': 'De Roock W, et al. Lancet Oncol. (2010) pmid: 20619739', 'Include': 'true'}, {'number': '346', 'ReferenceId': '20736745', 'FullCitation': 'Irahara N, et al. Diagn. Mol. Pathol. (2010) pmid: 20736745', 'Include': 'true'}, {'number': '347', 'ReferenceId': '24806288', 'FullCitation': 'Schirripa M, et al. Int. J. Cancer (2015) pmid: 24806288', 'Include': 'true'}, {'number': '348', 'ReferenceId': '28446505', 'FullCitation': 'Cercek A, et al. Clin. Cancer Res. (2017) pmid: 28446505', 'Include': 'true'}, {'number': '349', 'ReferenceId': '24739896', 'FullCitation': 'Price TJ, et al. Lancet Oncol. (2014) pmid: 24739896', 'Include': 'true'}, {'number': '350', 'ReferenceId': '32526634', 'FullCitation': 'Sakai D, et al. Eur J Cancer (2020) pmid: 32526634', 'Include': 'true'}, {'number': '351', 'ReferenceId': '18003960', 'FullCitation': 'Jonker DJ, et al. N. Engl. J. Med. (2007) pmid: 18003960', 'Include': 'true'}, {'number': '352', 'ReferenceId': '15269313', 'FullCitation': 'Cunningham D, et al. N. Engl. J. Med. (2004) pmid: 15269313', 'Include': 'true'}, {'number': '353', 'ReferenceId': '35033994', 'FullCitation': 'Papamichael D, et al. Eur J Cancer (2022) pmid: 35033994', 'Include': 'true'}, {'number': '354', 'ReferenceId': '24218517', 'FullCitation': 'Karapetis CS, et al. Clin. Cancer Res. (2014) pmid: 24218517', 'Include': 'true'}, {'number': '355', 'ReferenceId': '29470838', 'FullCitation': 'Moiseyenko VM, et al. Clin Drug Investig (2018) pmid: 29470838', 'Include': 'true'}, {'number': '356', 'ReferenceId': '34315821', 'FullCitation': 'Stein A, et al. J Immunother Cancer (2021) pmid: 34315821', 'Include': 'true'}, {'number': '357', 'ReferenceId': '31003911', 'FullCitation': 'Eng C, et al. Lancet Oncol. (2019) pmid: 31003911', 'Include': 'true'}, {'number': '358', 'ReferenceId': '26341920', 'FullCitation': 'Peeters M, et al. Clin. Cancer Res. (2015) pmid: 26341920', 'Include': 'true'}, {'number': '359', 'ReferenceId': '35723084', 'FullCitation': 'Watanabe J, et al. Int J Cancer (2022) pmid: 35723084', 'Include': 'true'}, {'number': '360', 'ReferenceId': '29703606', 'FullCitation': 'Kim TW, et al. Clin Colorectal Cancer (2018) pmid: 29703606', 'Include': 'true'}, {'number': '361', 'ReferenceId': '27712015', 'FullCitation': 'Shitara K, et al. Cancer Sci (2016) pmid: 27712015', 'Include': 'true'}, {'number': '362', 'ReferenceId': '17470858', 'FullCitation': 'Van Cutsem E, et al. J. Clin. Oncol. (2007) pmid: 17470858', 'Include': 'true'}, {'number': '363', 'ReferenceId': '31268481', 'FullCitation': 'Pietrantonio F, et al. JAMA Oncol (2019) pmid: 31268481', 'Include': 'true'}, {'number': '364', 'ReferenceId': '20127139', 'FullCitation': 'Bennouna J, et al. Invest New Drugs (2011) pmid: 20127139', 'Include': 'true'}, {'number': '365', 'ReferenceId': '25322874', 'FullCitation': 'Hochster HS, et al. Cancer Chemother. Pharmacol. (2015) pmid: 25322874', 'Include': 'true'}, {'number': '366', 'ReferenceId': '25637165', 'FullCitation': 'Do K, et al. Invest New Drugs (2015) pmid: 25637165', 'Include': 'true'}, {'number': '367', 'ReferenceId': '25516890', 'FullCitation': 'Tolcher AW, et al. Clin. Cancer Res. (2015) pmid: 25516890', 'Include': 'true'}, {'number': '368', 'ReferenceId': '26666244', 'FullCitation': 'Deming DA, et al. Invest New Drugs (2016) pmid: 26666244', 'Include': 'true'}, {'number': '369', 'ReferenceId': '33296125', 'FullCitation': 'van Brummelen EMJ, et al. Oncologist (2021) pmid: 33296125', 'Include': 'true'}, {'number': '370', 'ReferenceId': '30042150', 'FullCitation': 'Krishnamurthy A, et al. Cancer Res. (2018) pmid: 30042150', 'Include': 'true'}, {'number': '371', 'ReferenceId': '25344362', 'FullCitation': 'Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362', 'Include': 'true'}, {'number': '372', 'ReferenceId': '22805291', 'FullCitation': 'Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291', 'Include': 'true'}, {'number': '373', 'ReferenceId': '31924734', 'FullCitation': 'Johnson DB, et al. Clin Cancer Res (2020) pmid: 31924734', 'Include': 'true'}, {'number': '374', 'ReferenceId': '34417144', 'FullCitation': 'Alshammari K, et al. Clin Colorectal Cancer (2021) pmid: 34417144', 'Include': 'true'}, {'number': '375', 'ReferenceId': '29431699', 'FullCitation': 'Corcoran RB, et al. Cancer Discov (2018) pmid: 29431699', 'Include': 'true'}, {'number': '376', 'ReferenceId': '34801354', 'FullCitation': 'Maio M, et al. Eur J Cancer (2022) pmid: 34801354', 'Include': 'true'}, {'number': '377', 'ReferenceId': '25417902', 'FullCitation': 'Tolcher AW, et al. Cancer Chemother Pharmacol (2015) pmid: 25417902', 'Include': 'true'}, {'number': '378', 'ReferenceId': '27450049', 'FullCitation': 'Grilley_Olson JE, et al. Invest New Drugs (2016) pmid: 27450049', 'Include': 'true'}, {'number': '379', 'ReferenceId': '25500057', 'FullCitation': 'Bedard PL, et al. Clin. Cancer Res. (2015) pmid: 25500057', 'Include': 'true'}, {'number': '380', 'ReferenceId': '31186313', 'FullCitation': 'Kurzrock R, et al. Clin Cancer Res (2019) pmid: 31186313', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2023_04_17 21:34:52', 'OpName': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': '946x'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': '1 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': 'Units Not Reported'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'COLON', 'disease_ontology': 'Colon adenocarcinoma (CRC)', 'flowcell_analysis': '2000028633', 'gender': 'male', 'pathology_diagnosis': 'Adenocarcinoma', 'percent_tumor_nuclei': '40', 'pipeline_version': 'v3.21.1', 'purity_assessment': '76.21', 'specimen': 'ORD_1606878_01*US1533679.01', 'study': 'CLINICAL_F1CDx v2', 'test_request': 'ORD_1606878_01', 'test_type': 'FoundationOneDx', 'tissue_of_origin': 'Colon', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'DX2', 'mean_exon_depth': '963.95', 'name': 'SQ_US1533679.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.4879', 'cds_effect': '973G>A', 'depth': '951', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FANCC', 'percent_reads': '48.79', 'position': 'chr9:97887391', 'protein_effect': 'A325T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000136', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'allele_fraction': '0.4896', 'cds_effect': '5035C>T', 'depth': '815', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'POLE', 'percent_reads': '48.96', 'position': 'chr12:133218901', 'protein_effect': 'R1679C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006231', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'allele_fraction': '0.4763', 'cds_effect': '682G>A', 'depth': '886', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRD4', 'percent_reads': '47.63', 'position': 'chr19:15376332', 'protein_effect': 'V228I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_014299', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'allele_fraction': '0.3922', 'cds_effect': '2393C>T', 'depth': '974', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB2', 'percent_reads': '39.22', 'position': 'chr17:37881064', 'protein_effect': 'T798I', 'status': 'known', 'strand': '+', 'transcript': 'NM_004448', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'allele_fraction': '0.495', 'cds_effect': '2936G>A', 'depth': '798', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '49.5', 'position': 'chr2:212286760', 'protein_effect': 'R979Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'allele_fraction': '0.3772', 'cds_effect': '836G>A', 'depth': '578', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MTOR', 'percent_reads': '37.72', 'position': 'chr1:11313900', 'protein_effect': 'G279E', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004958', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'allele_fraction': '0.6735', 'cds_effect': '452C>G', 'depth': '680', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TP53', 'percent_reads': '67.35', 'position': 'chr17:7578478', 'protein_effect': 'P151R', 'status': 'known', 'strand': '_', 'transcript': 'NM_000546', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'allele_fraction': '0.5674', 'cds_effect': '694C>T', 'depth': '571', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'APC', 'percent_reads': '56.74', 'position': 'chr5:112128191', 'protein_effect': 'R232*', 'status': 'known', 'strand': '+', 'transcript': 'NM_000038', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'allele_fraction': '0.4903', 'cds_effect': '4603G>A', 'depth': '667', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'POLE', 'percent_reads': '49.03', 'position': 'chr12:133219531', 'protein_effect': 'G1535S', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006231', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'allele_fraction': '0.1118', 'cds_effect': '119_156_197+54>GGGGG', 'depth': '313', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'NOTCH3', 'percent_reads': '11.18', 'position': 'chr19:15308257', 'protein_effect': 'splice site 119_156_197+54>GGGGG', 'status': 'likely', 'strand': '_', 'transcript': 'NM_000435', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'allele_fraction': '0.5125', 'cds_effect': '1528C>T', 'depth': '601', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ALK', 'percent_reads': '51.25', 'position': 'chr2:29543635', 'protein_effect': 'R510W', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004304', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}]}, 'copy_number_alterations': {'copy_number_alteration': [{'copy_number': '9', 'equivocal': 'false', 'gene': 'RAD52', 'number_of_exons': '11 of 11', 'position': 'chr12:1022522_1042247', 'ratio': '3.56', 'status': 'unknown', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'copy_number': '0', 'equivocal': 'false', 'gene': 'SMAD4', 'number_of_exons': '11 of 11', 'position': 'chr18:48573416_48604837', 'ratio': '0.22', 'status': 'known', 'type': 'loss', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'copy_number': '9', 'equivocal': 'false', 'gene': 'FGF6', 'number_of_exons': '3 of 3', 'position': 'chr12:4543380_4554736', 'ratio': '3.4', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'copy_number': '11', 'equivocal': 'false', 'gene': 'KDM5A', 'number_of_exons': '28 of 28', 'position': 'chr12:394621_498257', 'ratio': '4.3', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'copy_number': '9', 'equivocal': 'false', 'gene': 'CCND2', 'number_of_exons': '5 of 5', 'position': 'chr12:4383206_4409175', 'ratio': '3.88', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'copy_number': '9', 'equivocal': 'false', 'gene': 'FGF23', 'number_of_exons': '3 of 3', 'position': 'chr12:4479508_4488748', 'ratio': '3.59', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}, {'copy_number': '0', 'equivocal': 'false', 'gene': 'NF1', 'number_of_exons': '23 of 59', 'position': 'chr17:29652837_29701173', 'ratio': '0.25', 'status': 'known', 'type': 'loss', 'dna_evidence': {'sample': 'SQ_US1533679.01_1'}}]}, 'rearrangements': None, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '1.21', 'status': 'low', 'unit': 'mutations_per_megabase'}}, 'non_human_content': None}}}}	M112-10086          	PF23035             
5	348	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2023_00029047', 'CSN': None, 'TRF': 'ORD_1619484_01', 'MRN': '24127524', 'PhysicianId': '109266', 'NPI': None}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1313963', 'clinicalId': '1315310', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1619484_01', 'SampleName': 'US1545611.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1619484_01', 'SampleId': 'US1545611.01', 'BlockId': 'S111_70820 A (PF23042', 'TRFNumber': 'ORD_1619484_01', 'TestType': 'FoundationOne CDX', 'SpecFormat': 'Slide Deck', 'ReceivedDate': '2023_04_28', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}]}}, 'PMI': {'ReportId': 'ORD_1619484_01', 'MRN': '24127524', 'FullName': 'Kao, Jui Yu', 'FirstName': 'Jui Yu', 'LastName': 'Kao', 'SubmittedDiagnosis': 'Liver angiosarcoma', 'Gender': 'Male', 'DOB': '1987_11_27', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Liver', 'CollDate': '2022_06_07', 'ReceivedDate': '2023_04_28', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': None, 'Summaries': {'alterationCount': '10', 'clinicalTrialCount': '0', 'resistiveCount': '0', 'sensitizingCount': '0'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'ALK', 'isVUS': 'true', 'variantName': 'W1320R'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'rearrangement'}, {'geneName': 'MAP3K1', 'isVUS': 'true', 'variantName': 'G51D'}, {'geneName': 'MSH3', 'isVUS': 'true', 'variantName': 'A58V'}, {'geneName': 'ROS1', 'isVUS': 'true', 'variantName': 'I537K'}, {'geneName': 'SPEN', 'isVUS': 'true', 'variantName': 'S2306del'}, {'geneName': 'TSC1', 'isVUS': 'true', 'variantName': 'Q654E'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Cannot Be Determined', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Cannot Be Determined'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. In a computational analysis of paired tumor and normal sarcomas in the TCGA dataset, of which 25% were liposarcomas, only 0.8% (2/255) of samples were MSI_high (MSI_H) (Bonneville et al., 2017; 29850653). However, reports of MSI in sarcomas in the literature are conflicting and varied due to substantial heterogeneity, lack of consensus on the markers and methods used for MSI assessment, and small sample size in most studies (Monument et al., 2012; 23401795). In these smaller studies of soft tissue sarcoma, reports of MSI at any level have been rare, with the highest incidences between 11% (2/18) to 25% (10/40) of cases (Wooster al., 1994; 8162069, Kawaguchi et al., 2005; 15643505, Saito et al., 2003; 14562278, Suwa et al., 1999; 10370164, Garcia et al., 2006; 16619000, Aue et al., 1998; 9689926). In one study, MSI was reported to occur more frequently in high_grade soft tissue sarcomas compared with lower grade (Rucińska et al., 2005; 15668629). However, published data investigating the prognostic implications of MSI in sarcoma are limited (PubMed, Jan 2023). On the basis of clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), retifanlimab, and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143, Berton et al., 2021; SITC Abstract 956), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (alone or in combination with tremelimumab) (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92, Pietrantonio et al., 2023; ASCO GI Abstract 358, Lee et al., 2023; ASCO GI abstract 401, Rubinstein et al., 2022; 36512912, Marie et al., 2021; 33811152). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TP53', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'rearrangement intron 7', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'rearrangement intron 7'}}, 'Interpretation': 'Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutation has been cited at various incidences in studies of angiosarcoma, which may reflect small sample sizes or differences in tumor site examined (Naka et al., 1997; 9185695, Santi et al., 2011; 21323968, Italiano et al., 2012; 22648906, Zietz et al., 1998; 9811333, Soini et al., 1995; 7586214, Painter et al., 2020; 32042194). Expression of p53, which is typically associated with non_functional p53, has been reported in 49%_100% of patients with angiosarcoma, and has been correlated with poor prognosis (Italiano et al., 2012; 22648906, Chen et al., 2008; 18700251). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Tumor Mutation Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Cannot Be Determined', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Cannot Be Determined'}}, 'Interpretation': 'Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). Elevated TMB has been reported to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors in multiple solid tumor types (Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915). However, the TMB level in this sample could not be determined with confidence. Angiosarcomas of the head, neck, face, or scalp were associated with a high TMB (median of 20.7 Muts/Mb, >10 Muts/Mb in 9/12 samples) and a dominant ultraviolet light exposure mutational signature in one study (Painter et al., 2020; 32042194). In contrast, angiosarcomas of other sites, including cutaneous radiation_associated or breast angiosarcomas (median TMB of 3.7 and 1.7 Muts/Mb, respectively) had lower TMB (Painter et al., 2020; 32042194). Soft tissue sarcomas harbor a median tumor mutational burden (TMB) of 2.4_2.5 mutations per megabase (muts/Mb), with angiosarcoma (up to 15%) and malignant peripheral nerve sheath tumor (up to 11%) having the highest percentage of cases with high TMB (Gounder et al., 2022; 35705558, FMI_Chalmers et al., 2017; 28420421). In a study, 3.9% of soft tissue sarcoma samples analyzed harbor TMB ≥10 muts/Mb (Gounder et al., 2022; 35705558); in addition, increased mutational burden has been reported in undifferentiated pleomorphic sarcomas as compared with Ewing sarcomas or rhabdomyosarcomas (Lim et al., 2015; 26330427, Brohl et al., 2014; 25010205, Chen et al., 2013; 24332040). Published data investigating the prognostic implications of tissue TMB in sarcoma are conflicting (PubMed, Feb 2023). High tissue TMB was associated with improved PFS and metastasis_free survival in a study of undifferentiated sarcomas (Steele et al., 2019; 30889380), but with reduced survival in a study of patients with rhabdomyosarcoma (Casey et al., 2020; 31699828). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB ≥10 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores ≥ 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB ≥ 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB ≥ 16 Muts/Mb than those with TMB ≥ 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). As the TMB status of this tumor cannot be determined with confidence, the benefit of these therapeutic approaches is unclear.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': None, 'References': {'Reference': [{'number': '0', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '1', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '2', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '3', 'ReferenceId': '29850653', 'FullCitation': 'Bonneville R, et al. JCO Precis Oncol (2017) pmid: 29850653', 'Include': 'true'}, {'number': '4', 'ReferenceId': '23401795', 'FullCitation': 'Monument MJ, et al. ISRN Oncol (2012) pmid: 23401795', 'Include': 'true'}, {'number': '5', 'ReferenceId': '8162069', 'FullCitation': 'Wooster R, et al. Nat. Genet. (1994) pmid: 8162069', 'Include': 'true'}, {'number': '6', 'ReferenceId': '15643505', 'FullCitation': 'Kawaguchi K, et al. Oncol. Rep. (2005) pmid: 15643505', 'Include': 'true'}, {'number': '7', 'ReferenceId': '14562278', 'FullCitation': 'Saito T, et al. Hum. Pathol. (2003) pmid: 14562278', 'Include': 'true'}, {'number': '8', 'ReferenceId': '10370164', 'FullCitation': 'Suwa K, et al. J Orthop Sci (1999) pmid: 10370164', 'Include': 'true'}, {'number': '9', 'ReferenceId': '16619000', 'FullCitation': 'Garcia JJ, et al. Mod. Pathol. (2006) pmid: 16619000', 'Include': 'true'}, {'number': '10', 'ReferenceId': '9689926', 'FullCitation': 'Aue G, et al. Cancer Genet. Cytogenet. (1998) pmid: 9689926', 'Include': 'true'}, {'number': '11', 'ReferenceId': '15668629', 'FullCitation': 'Rucińska M, et al. Med. Sci. Monit. (2005) pmid: 15668629', 'Include': 'true'}, {'number': '12', 'ReferenceId': '17204026', 'FullCitation': 'Histopathology (2007) pmid: 17204026', 'Include': 'true'}, {'number': '13', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '14', 'ReferenceId': '28734759', 'FullCitation': 'Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759', 'Include': 'true'}, {'number': '15', 'ReferenceId': '29355075', 'FullCitation': 'Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075', 'Include': 'true'}, {'number': '16', 'ReferenceId': '35322232', 'FullCitation': 'Shitara K, et al. Nature (2022) pmid: 35322232', 'Include': 'true'}, {'number': '17', 'ReferenceId': '23169436', 'FullCitation': 'Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436', 'Include': 'true'}, {'number': '18', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '19', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '20', 'ReferenceId': '33001143', 'FullCitation': 'Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143', 'Include': 'true'}, {'number': '21', 'ReferenceId': '36512912', 'FullCitation': 'Rubinstein MM, et al. Gynecol Oncol (2022) pmid: 36512912', 'Include': 'true'}, {'number': '22', 'ReferenceId': '33811152', 'FullCitation': 'Kanikarla Marie P, et al. Clin Cancer Res (2021) pmid: 33811152', 'Include': 'true'}, {'number': '23', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '24', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '25', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '26', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '27', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '28', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '29', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '30', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '31', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '32', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '33', 'ReferenceId': '32919526', 'FullCitation': 'Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526', 'Include': 'true'}, {'number': '34', 'ReferenceId': '31405947', 'FullCitation': 'Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947', 'Include': 'true'}, {'number': '35', 'ReferenceId': '28835386', 'FullCitation': 'Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386', 'Include': 'true'}, {'number': '36', 'ReferenceId': '30309915', 'FullCitation': 'Cristescu R, et al. Science (2018) pmid: 30309915', 'Include': 'true'}, {'number': '37', 'ReferenceId': '32042194', 'FullCitation': 'Painter CA, et al. Nat. Med. (2020) pmid: 32042194', 'Include': 'true'}, {'number': '38', 'ReferenceId': '35705558', 'FullCitation': 'Gounder MM, et al. Nat Commun (2022) pmid: 35705558', 'Include': 'true'}, {'number': '39', 'ReferenceId': '28420421', 'FullCitation': 'Chalmers ZR, et al. Genome Med (2017) pmid: 28420421', 'Include': 'true'}, {'number': '40', 'ReferenceId': '26330427', 'FullCitation': 'Lim J, et al. Clin. Cancer Res. (2015) pmid: 26330427', 'Include': 'true'}, {'number': '41', 'ReferenceId': '25010205', 'FullCitation': 'Brohl AS, et al. PLoS Genet. (2014) pmid: 25010205', 'Include': 'true'}, {'number': '42', 'ReferenceId': '24332040', 'FullCitation': 'Chen X, et al. Cancer Cell (2013) pmid: 24332040', 'Include': 'true'}, {'number': '43', 'ReferenceId': '30889380', 'FullCitation': 'Steele CD, et al. Cancer Cell (2019) pmid: 30889380', 'Include': 'true'}, {'number': '44', 'ReferenceId': '31699828', 'FullCitation': 'Casey DL, et al. Clin Cancer Res (2020) pmid: 31699828', 'Include': 'true'}, {'number': '45', 'ReferenceId': '30643254', 'FullCitation': 'Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254', 'Include': 'true'}, {'number': '46', 'ReferenceId': '30785829', 'FullCitation': 'Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829', 'Include': 'true'}, {'number': '47', 'ReferenceId': '29658845', 'FullCitation': 'Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845', 'Include': 'true'}, {'number': '48', 'ReferenceId': '29657128', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128', 'Include': 'true'}, {'number': '49', 'ReferenceId': '29731394', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394', 'Include': 'true'}, {'number': '50', 'ReferenceId': '33558721', 'FullCitation': 'Rozeman EA, et al. Nat Med (2021) pmid: 33558721', 'Include': 'true'}, {'number': '51', 'ReferenceId': '32916128', 'FullCitation': 'Sharma P, et al. Cancer Cell (2020) pmid: 32916128', 'Include': 'true'}, {'number': '52', 'ReferenceId': '30557521', 'FullCitation': 'Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521', 'Include': 'true'}, {'number': '53', 'ReferenceId': '35101941', 'FullCitation': 'Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941', 'Include': 'true'}, {'number': '54', 'ReferenceId': '34876409', 'FullCitation': 'Friedman CF, et al. Cancer Discov (2022) pmid: 34876409', 'Include': 'true'}, {'number': '55', 'ReferenceId': '35274716', 'FullCitation': 'Sturgill EG, et al. Oncologist (2022) pmid: 35274716', 'Include': 'true'}, {'number': '56', 'ReferenceId': '19935675', 'FullCitation': 'Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675', 'Include': 'true'}, {'number': '57', 'ReferenceId': '18410249', 'FullCitation': 'Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249', 'Include': 'true'}, {'number': '58', 'ReferenceId': '12826609', 'FullCitation': 'Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609', 'Include': 'true'}, {'number': '59', 'ReferenceId': '20978130', 'FullCitation': 'Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130', 'Include': 'true'}, {'number': '60', 'ReferenceId': '28472496', 'FullCitation': 'Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496', 'Include': 'true'}, {'number': '61', 'ReferenceId': '17690113', 'FullCitation': 'Yamada H, et al. Carcinogenesis (2007) pmid: 17690113', 'Include': 'true'}, {'number': '62', 'ReferenceId': '9185695', 'FullCitation': 'Naka N, et al. Int. J. Cancer (1997) pmid: 9185695', 'Include': 'true'}, {'number': '63', 'ReferenceId': '21323968', 'FullCitation': 'Santi R, et al. Histopathology (2011) pmid: 21323968', 'Include': 'true'}, {'number': '64', 'ReferenceId': '22648906', 'FullCitation': 'Italiano A, et al. Cancer (2012) pmid: 22648906', 'Include': 'true'}, {'number': '65', 'ReferenceId': '9811333', 'FullCitation': 'Zietz C, et al. Am J Pathol (1998) pmid: 9811333', 'Include': 'true'}, {'number': '66', 'ReferenceId': '7586214', 'FullCitation': 'Soini Y, et al. Carcinogenesis (1995) pmid: 7586214', 'Include': 'true'}, {'number': '67', 'ReferenceId': '18700251', 'FullCitation': 'Chen SY, et al. J. Cutan. Pathol. (2008) pmid: 18700251', 'Include': 'true'}, {'number': '68', 'ReferenceId': '20107315', 'FullCitation': 'Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315', 'Include': 'true'}, {'number': '69', 'ReferenceId': '21799033', 'FullCitation': 'Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033', 'Include': 'true'}, {'number': '70', 'ReferenceId': '21389100', 'FullCitation': 'Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100', 'Include': 'true'}, {'number': '71', 'ReferenceId': '25504633', 'FullCitation': 'Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633', 'Include': 'true'}, {'number': '72', 'ReferenceId': '12489850', 'FullCitation': 'Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850', 'Include': 'true'}, {'number': '73', 'ReferenceId': '11713371', 'FullCitation': 'Xu L, et al. Mol. Med. (2001) pmid: 11713371', 'Include': 'true'}, {'number': '74', 'ReferenceId': '23470564', 'FullCitation': 'Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564', 'Include': 'true'}, {'number': '75', 'ReferenceId': '25240597', 'FullCitation': 'Kim SS, et al. Nanomedicine (2015) pmid: 25240597', 'Include': 'true'}, {'number': '76', 'ReferenceId': '27357628', 'FullCitation': 'Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628', 'Include': 'true'}, {'number': '77', 'ReferenceId': '27601554', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554', 'Include': 'true'}, {'number': '78', 'ReferenceId': '27998224', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224', 'Include': 'true'}, {'number': '79', 'ReferenceId': '31315834', 'FullCitation': 'Lee J, et al. Cancer Discov (2019) pmid: 31315834', 'Include': 'true'}, {'number': '80', 'ReferenceId': '29535125', 'FullCitation': 'Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125', 'Include': 'true'}, {'number': '81', 'ReferenceId': '34538072', 'FullCitation': 'Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072', 'Include': 'true'}, {'number': '82', 'ReferenceId': '26014290', 'FullCitation': 'Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290', 'Include': 'true'}, {'number': '83', 'ReferenceId': '23355100', 'FullCitation': 'Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100', 'Include': 'true'}, {'number': '84', 'ReferenceId': '11219776', 'FullCitation': 'Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776', 'Include': 'true'}, {'number': '85', 'ReferenceId': '9006316', 'FullCitation': 'Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316', 'Include': 'true'}, {'number': '86', 'ReferenceId': '19204208', 'FullCitation': 'Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208', 'Include': 'true'}, {'number': '87', 'ReferenceId': '12672316', 'FullCitation': 'Lalloo F, et al. Lancet (2003) pmid: 12672316', 'Include': 'true'}, {'number': '88', 'ReferenceId': '31050713', 'FullCitation': 'Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2023_05_07 15:31:44', 'OpName': 'Douglas A. Mata, MD, MPH | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Douglas A. Mata, MD, MPH | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': '424x'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': '1 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': 'Units Not Reported'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'LIVER', 'disease_ontology': 'Liver angiosarcoma', 'flowcell_analysis': '2000028929', 'gender': 'male', 'pathology_diagnosis': 'Angiosarcoma', 'percent_tumor_nuclei': '30', 'pipeline_version': 'v3.22.0', 'purity_assessment': '19.07', 'specimen': 'ORD_1619484_01*US1545611.01', 'study': 'CLINICAL_F1CDx v2', 'test_request': 'ORD_1619484_01', 'test_type': 'FoundationOneDx', 'tissue_of_origin': 'Liver', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'DX2', 'mean_exon_depth': '424.68', 'name': 'SQ_US1545611.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Qualified'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.4504', 'cds_effect': '6915_6917delCAG', 'depth': '353', 'equivocal': 'false', 'functional_effect': 'nonframeshift', 'gene': 'SPEN', 'percent_reads': '45.04', 'position': 'chr1:16259649', 'protein_effect': 'S2306del', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_015001', 'dna_evidence': {'sample': 'SQ_US1545611.01_1'}}, {'allele_fraction': '0.51', 'cds_effect': '173C>T', 'depth': '200', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MSH3', 'percent_reads': '51.0', 'position': 'chr5:79950719', 'protein_effect': 'A58V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002439', 'dna_evidence': {'sample': 'SQ_US1545611.01_1'}}, {'allele_fraction': '0.1746', 'cds_effect': '1610T>A', 'depth': '544', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ROS1', 'percent_reads': '17.46', 'position': 'chr6:117710662', 'protein_effect': 'I537K', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002944', 'dna_evidence': {'sample': 'SQ_US1545611.01_1'}}, {'allele_fraction': '0.0972', 'cds_effect': '3958T>C', 'depth': '463', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ALK', 'percent_reads': '9.72', 'position': 'chr2:29420523', 'protein_effect': 'W1320R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004304', 'dna_evidence': {'sample': 'SQ_US1545611.01_1'}}, {'allele_fraction': '0.5556', 'cds_effect': '152G>A', 'depth': '171', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MAP3K1', 'percent_reads': '55.56', 'position': 'chr5:56111552', 'protein_effect': 'G51D', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005921', 'dna_evidence': {'sample': 'SQ_US1545611.01_1'}}, {'allele_fraction': '0.5394', 'cds_effect': '1960C>G', 'depth': '406', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TSC1', 'percent_reads': '53.94', 'position': 'chr9:135781005', 'protein_effect': 'Q654E', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000368', 'dna_evidence': {'sample': 'SQ_US1545611.01_1'}}]}, 'copy_number_alterations': None, 'rearrangements': {'rearrangement': [{'allele_fraction': '0.0717', 'description': 'ERBB4(NM_005235) rearrangement intron 22', 'equivocal': 'false', 'in_frame': 'unknown', 'other_gene': 'SCIN', 'percent_reads': '7.17', 'pos1': 'chr2:212293049', 'pos2': 'chr7:12665886', 'status': 'unknown', 'supporting_read_pairs': '39', 'targeted_gene': 'ERBB4', 'type': 'rearrangement', 'dna_evidence': {'sample': 'SQ_US1545611.01_1'}}, {'allele_fraction': '0.0596', 'description': 'TP53(NM_000546) rearrangement intron 7', 'equivocal': 'false', 'in_frame': 'unknown', 'other_gene': 'AP3B1', 'percent_reads': '5.96', 'pos1': 'chr17:7577284', 'pos2': 'chr5:77361467', 'status': 'likely', 'supporting_read_pairs': '24', 'targeted_gene': 'TP53', 'type': 'truncation', 'dna_evidence': {'sample': 'SQ_US1545611.01_1'}}]}, 'biomarkers': {'microsatellite_instability': {'status': 'unknown'}, 'tumor_mutation_burden': {'score': '1.21', 'status': 'unknown', 'unit': 'mutations_per_megabase'}}, 'non_human_content': None}}}}	M112-10097          	PF23042             
6	362	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2023_00029578', 'CSN': None, 'TRF': 'ORD_1632719_01', 'MRN': '26689974', 'PhysicianId': '109266', 'NPI': None}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1323179', 'clinicalId': '1324526', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1632719_01', 'SampleName': 'US1557183.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1632719_01', 'SampleId': 'US1557183.01', 'BlockId': 'SHL 02/25/1955', 'TRFNumber': 'ORD_1632719_01', 'TestType': 'FoundationOneLiquidDx', 'SpecFormat': 'Tube Set', 'ReceivedDate': '2023_05_18', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}]}}, 'PMI': {'ReportId': 'ORD_1632719_01', 'MRN': '26689974', 'FullName': 'Lo, Shun_Hsing', 'FirstName': 'Shun_Hsing', 'LastName': 'Lo', 'SubmittedDiagnosis': 'Stomach adenocarcinoma (NOS)', 'Gender': 'Male', 'DOB': '1955_02_25', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Blood', 'CollDate': '2023_05_16', 'ReceivedDate': '2023_05_18', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': None, 'Summaries': {'alterationCount': '28', 'clinicalTrialCount': '24', 'resistiveCount': '0', 'sensitizingCount': '0'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'APC', 'isVUS': 'true', 'variantName': 'S89L'}, {'geneName': 'ATM', 'isVUS': 'true', 'variantName': 'G2063R'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'W1243L'}, {'geneName': 'FBXW7', 'isVUS': 'true', 'variantName': 'H155Y'}, {'geneName': 'GABRA6', 'isVUS': 'true', 'variantName': 'S268T'}, {'geneName': 'GNAS', 'isVUS': 'true', 'variantName': 'E355Q'}, {'geneName': 'IRF2', 'isVUS': 'true', 'variantName': 'R325Q'}, {'geneName': 'LYN', 'isVUS': 'true', 'variantName': 'F84L'}, {'geneName': 'MAP3K1', 'isVUS': 'true', 'variantName': 'P1236S,R179H'}, {'geneName': 'MSH2', 'isVUS': 'true', 'variantName': 'E809K'}, {'geneName': 'NOTCH3', 'isVUS': 'true', 'variantName': 'R421C'}, {'geneName': 'NTRK1', 'isVUS': 'true', 'variantName': 'H151Q'}, {'geneName': 'REL', 'isVUS': 'true', 'variantName': 'L436V'}, {'geneName': 'RET', 'isVUS': 'true', 'variantName': 'R844P'}, {'geneName': 'RICTOR', 'isVUS': 'true', 'variantName': 'T733R'}, {'geneName': 'SMAD4', 'isVUS': 'true', 'variantName': 'I61T'}, {'geneName': 'SNCAIP', 'isVUS': 'true', 'variantName': 'E756K'}, {'geneName': 'SRC', 'isVUS': 'true', 'variantName': 'rearrangement'}, {'geneName': 'TENT5C (FAM46C)', 'isVUS': 'true', 'variantName': 'L71M'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'Blood Tumor Mutational Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '14', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '14'}}, 'Interpretation': 'Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a bTMB level that may be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2023). For patients with gastric cancer, increased TMB is reported to be associated with prolonged OS (Cai et al., 2020; 32141230, Zhao et al., 2021; 33510848, Wei et al., 2021; 33613701). One study observed that the OS and disease_free survival (DFS) benefits of postoperative chemotherapy were more pronounced in patients with TMB_low gastric cancer (stage Ib/II) compared to those with TMB_high; however, patients with stage III gastric cancer benefitted regardless of TMB level (Wang et al., 2021; 33687617). In esophageal cancer, patients with TMB_high who had not received radiotherapy had significantly reduced OS (p=0.038) compared to those with TMB_low (Yuan et al., 2019; 32165590). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti_PD_L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi_solid_tumor trial showed that bTMB ≥16 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB ≥28 Muts/Mb (approximate equivalency ≥14 Muts/Mb as measured by this assay) was associated with improved OS from a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).', 'Include': 'true', 'ClinicalTrialNote': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04237649', 'Include': 'true'}, {'nctId': 'NCT03281369', 'Include': 'true'}, {'nctId': 'NCT03829501', 'Include': 'true'}, {'nctId': 'NCT05007106', 'Include': 'true'}, {'nctId': 'NCT03674567', 'Include': 'true'}, {'nctId': 'NCT04047862', 'Include': 'true'}, {'nctId': 'NCT05166577', 'Include': 'true'}, {'nctId': 'NCT05489211', 'Include': 'true'}, {'nctId': 'NCT03530397', 'Include': 'true'}, {'nctId': 'NCT04879368', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'CTNNB1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'D32N', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '72.43', 'isEquivocal': 'false', 'name': 'D32N'}}, 'Interpretation': 'CTNNB1 encodes beta_catenin, a key downstream component of the WNT signaling pathway. Beta_catenin interacts with cadherin to regulate cell_cell adhesion; as a component of the WNT pathway, it also plays a role in development, cell proliferation, and cell differentiation (Kikuchi, 2000; 10679188). CTNNB1 exon 3 mutations are activating in that they lead to increased beta_catenin protein stability and activation of the WNT pathway (Anastas and Moon, 2013; 23258168, Fukuchi et al., 1998; 9721853, Kikuchi et al., 2003; 12824913, Takahashi et al., 2006; 16523258, Tanaka et al., 2001; 11731417, Abraham et al., 2002; 11943721, Austinat et al., 2008; 18282277, Wu et al., 2003; 12820959, Provost et al., 2005; 15829978, Polakis, 1999; 10072352, Segditsas and Tomlinson, 2006; 17143297, Barth et al., 1997; 9024698, Harada et al., 1999; 10545105, Hsu et al., 1998; 9671490, Breuhahn et al., 2008; 18491352, Soon et al., 2008; 18515740, Tacon et al., 2011; 21212436, Simon and Hammer, 2012; 22266195, Hirotsu et al., 2016; 26850916). One or more of the CTNNB1 exon 3 mutations seen here are expected to be activating. CTNNB1 mutations have been identified in 1.3_2.5% of esophageal cancers (Busch et al., 2017; 29156750, Maeng et al., 2012; 22870241), 1.7_8.0% of gastric cancers (Busch et al., 2017; 29156750, Ge et al., 2017; 28744403, Li_Chang et al., 2015; 25656989), and 0.0_2.2% of gastroesophageal cancers (Borger et al., 2017; 22180306, Li_Chang et al., 2015; 25656989). Expression of beta_catenin has been reported in 69_78% of gastric carcinoma cases (Ayed_Guerfali et al., 2013; 24197976, Sun et al., 2012; 23359759). Activated, nuclear beta_catenin has been reported in high_grade dysplasia, but not in Barrett metaplasia, which is a precursor to esophageal adenocarcinoma; the authors suggest that activation of WNT signaling may be involved in the progression but not in the initiation of Barrett esophagus (Moyes et al., 2012; 22653845, Krishnan et al., 2012; 21948356). One study reported that expression of beta_catenin correlated with longer overall survival in gastric cancer patients, and dual loss of E_cadherin and beta_catenin has been correlated with lymph node metastasis (Ayed_Guerfali et al., 2013; 24197976, Yoshii et al., 2013; 23748820). Solid tumors with WNT/beta_catenin pathway alterations, as seen here, were observed to have significantly less T_cell inflammation in one study (Luke et al., 2019; 30635339). Mutation or activation of CTNNB1 signaling has been shown to increase mTOR signaling, promote tumorigenesis, and respond to mTOR inhibition in preclinical studies (Tanwar et al., 2009; 19403928, Tanwar et al., 2011; 21695255, Fujishita et al., 2008; 18768809). Small studies have reported clinical benefit following treatment of everolimus combined with other targeted agents for patients with CTNNB1_mutated hepatocellular carcinoma (Bhoori et al., 2010; 20347502, Janku et al., 2014; 24931142) or endometrial carcinoma (Slomovitz et al., 2015; 25624430). In preclinical studies, CTNNB1 activating mutations have been shown to increase expression of WNT pathway member DKK1, which may promote tumor cell proliferation and immune evasion (Niida et al., 2004; 15378020, Chamorro et al., 2005; 15592430, Kagey and He, 2017; 28574171). A Phase 1 trial of DKK1_targeting antibody DKN_01 in combination with paclitaxel in esophageal cancer reported a 50% (2/4) PR rate and 25% (1/4) SD rate in patients with CTNNB1 activating mutations, compared with 24% (10/41) PR and 37% (15/41) SD in unselected patients (Kagey et al., 2017; AACR Abstract 369). Multiple preclinical studies in cancer models harboring CTNNB1 mutation or beta_catenin pathway activation have reported activation of the NOTCH pathway and sensitivity to pharmacologic inhibition of NOTCH signaling by gamma_secretase inhibitors (Kwon et al., 2011; 21841793, Arcaroli et al., 2013; 23868008, Shang et al., 2015; 26349011, Kode et al., 2014; 24429522). Clinical trials of gamma_secretase inhibitor nirogacestat have shown high response rates in patients with desmoid tumors, which are driven by activating CTNNB1 mutations in the majority of cases (Kasper et al., 2022; ESMO Abstract LBA2, Kummar et al., 2015; ASCO Abstract 10563, Messersmith et al., 2015; 25231399), suggesting CTNNB1_mutated tumors may be sensitive to gamma_secretase inhibitors. Although WNT pathway inhibitors have been explored preclinically in CTNNB1_mutated cells, clinical data supporting this therapeutic approach are lacking (Zhu et al., 2012; 22964660, Tanwar et al., 2011; 21695255, Kogan et al., 2012; 22356261, Lachenmayer et al., 2012; 22811581).', 'Include': 'true', 'ClinicalTrialNote': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT05036226', 'Include': 'true'}, {'nctId': 'NCT01582191', 'Include': 'true'}, {'nctId': 'NCT03203525', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'KEAP1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'P322L', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '0.79', 'isEquivocal': 'false', 'name': 'P322L'}}, 'Interpretation': 'KEAP1 encodes a substrate adaptor protein that regulates the cellular response to oxidative stress by providing substrate specificity for a CUL3_dependent ubiquitin ligase (Lo and Hannink, 2006; 17046835). KEAP1 exerts anti_tumor effects through negative regulation of NRF2, a transcription factor encoded by NFE2L2 (Wakabayashi et al., 2003; 14517554, Kansanen et al., 2013; 24024136, Hast et al., 2013; 23382044); KEAP1 inactivation promotes cancer progression through NRF2_mediated chemoresistance and cell growth (Kansanen et al., 2013; 24024136, Hast et al., 2013; 23382044). Somatic mutation of KEAP1 occurs in a range of solid tumors, including gastric, hepatocellular, colorectal, and lung cancers (Yoo et al., 2012; 22348534). KEAP1 mutations are rare in hematological malignancies, occurring in fewer than 1% of samples analyzed (COSMIC, 2023)(Tate et al., 2019; 30371878). In a retrospective analysis of the pan_solid MSKCC dataset, KEAP1 mutation correlated with reduced OS (13.28 vs. 26.53 months) (Xu et al., 2020; 32272498). A study of patients with localized non_small cell lung cancer (NSCLC) identified pathogenic KEAP1 and NFE2L2 mutations as predictors of local recurrence following radiotherapy but not surgery; limited preclinical data also showed that treatment with a glutaminase inhibitor sensitized KEAP1_mutated NSCLC cells to radiation (Binkley et al., 2020; 33071215). In other preclinical studies, treatment with AKT inhibitors sensitized lung cancer cells harboring KEAP1 or NFE2L2 mutations to both chemotherapy and radiation therapy (Chowdhry et al., 2013; 22964642, Abazeed et al., 2013; 23980093). Mixed clinical data have been reported for the association between KEAP1 mutations and the response to immunotherapy. A pan_cancer study of immunotherapy showed that patients with KEAP1 mutations had shorter OS (10 vs. 20 months) than those without (Chen et al., 2020; 32175433). However, another study across solid tumors showed that KEAP1 mutations were associated with higher tumor mutational burden (TMB) and PD_L1 expression, as well as improved survival outcomes with immunotherapy compared with other treatments (20.0 vs. 11.5 months) (Xu et al., 2020; 32272498). For patients with non_small cell lung cancer (NSCLC), a study of PD_L1 inhibitors showed that patients with concurrent mutations of STK11 and KEAP1 (n=39) experienced significantly shorter PFS (1.6 vs. 2.5 months, HR=1.5) and OS (4 vs. 11 months, HR=1.9) compared with patients with STK11_ and KEAP1_wildtype tumors (n=210) despite significantly higher TMB in the group harboring STK11 and KEAP1 mutations (median 9.4 vs. 6.1 Muts/Mb) (Arbour et al., 2018; IASLC WCLC Abstract MA19.09). Retrospective analyses of patients with NSCLC who received immunotherapy reported reduced OS (p=0.040) for patients harboring KEAP1_ or NFE2L2_mutated tumors (Zhang et al., 2020; 32471565) or STK11_ or KEAP1_mutated tumors (p <0.001) (Shang et al., 2020; WCLC Abstract P75.02) compared with those without. Studies of immune checkpoint inhibitors for patients with lung adenocarcinoma showed that coexisting mutations between KEAP1, PBRM1, SMARCA4, STK11, and KRAS were associated with worse OS (Marinelli et al., 2020; 32866624, Ricciuti et al., 2020; WCLC Abstract P14.26). An exploratory analysis of a subset of patients with PD_L1_positive NSCLC treated in the first_line setting with pembrolizumab showed similar ORR, PFS, and OS when comparing patients with STK11 or KEAP1 mutations and those without (Cho et al., 2020; AACR Abstract CT084). In addition, preclinical data suggest that KEAP1 inactivation increases tumor demand for glutamine and increases tumor sensitivity to glutaminase inhibitors like telaglenastat (Gwinn et al., 2018; 29316436, Sayin et al., 2017; 28967864, Romero et al., 2017; 28967920). Limited clinical data suggest that KEAP1 mutations may predict improved clinical benefit from combinations of glutaminase inhibitors and anti_PD_1 inhibitors (Skoulidis et al., 2021; ASCO Abstract TPS9627); a Phase 1/2 study of the glutaminase inhibitor telaglenastat (CB_839) plus nivolumab to treat advanced NSCLC reported better clinical benefit rates and median PFS for patients with KEAP1 mutations (75% [3/4] vs. 15% [2/13], 6.4 vs. 3.7 months), KRAS mutations (38% [3/8] vs. 20% [2/10], 4.5 vs. 3.7 months), or KEAP1 and KRAS concurrent mutations (100% [2/2] vs. 13% [1/8], 7.2 vs. 3.7 months) compared with patients without these mutations (Skoulidis et al., 2021; ASCO Abstract TPS9627). The KEAP1 mutation has also been identified as a potential biomarker for sensitivity to combined AKT and TXNRD1 inhibition in lung cancer (Dai et al., 2013; 23824739).', 'Include': 'true', 'ClinicalTrialNote': 'KEAP1 inactivation may predict sensitivity to glutaminase inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': {'nctId': 'NCT05039801', 'Include': 'true'}}}}, 'ReferenceLinks': None}, {'Name': 'RET', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'T636M', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '34.6', 'isEquivocal': 'false', 'name': 'T636M'}}, 'Interpretation': 'RET (Rearranged during transfection) encodes a receptor tyrosine kinase primarily expressed in cells of the nervous system. It has been identified as a proto_oncogene that results in transformation of cells upon recombination with a partner gene (Takahashi et al., 1985; 2992805). The RET alteration observed here has been characterized as activating and is predicted to be oncogenic (Asai et al., 1999; 10049754, Cordella et al., 2006; 16954442, Muzza et al., 2010; 20103606, Silva et al., 2015; 25725622, Krampitz et al., 2014; 24699901, Fazioli et al., 2008; 18631007). RET mutations have been observed in 1.6_4.0% of gastric, esophageal, and gastroesophageal carcinoma samples (cBioPortal, COSMIC, Oct 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878, cBio_Lin et al., 2014; 24686850, cBio_Dulak et al., 2013; 23525077, Cancer Genome Atlas Research Network., 2017; 28052061, cBio_Janjigian et al., 2018; 29122777). Published data investigating the prognostic implications of RET alterations in gastric, esophageal, or gastroesophageal adenocarcinoma are limited (PubMed, Oct 2022). On the basis of clinical evidence, RET activating alterations may predict response to selective RET inhibitors such as pralsetinib (Gainor et al., 2020; ASCO Abstract 9515, Subbiah et al., 2020; ASCO Abstract 109, Hu et al., 2020; ESMO Abstract 1913O), selpercatinib (Drilon et al., 2019; WCLC Abstract PL02.08, Wirth et al., 2019; ESMO Abstract LBA93), and BOS172738 (Schoffski et al., 2021; Abstract 3008), as well as the multikinase inhibitors cabozantinib (Chen et al., 2021; 33869783, Drilon et al., 2016; 27825636, Drilon et al., 2013; 23533264, Gautschi et al., 2017; 28447912, Mukhopadhyay et al., 2014; 25436805, Nokihara et al., 2019; 30718102, Zhang et al., 2021; WCLC Abstract P87.03, Xu et al., 2020; ESMO Abstract 415P, Fei et al., 2018; IASLC Abstract P081, Xing et al., 2020; doi: 10.21037/tcr_20_754, Overbeck and Schildhaus, 2017; IASLC Abstract P3.02c_017, Wang et al., 2019; 30653139, Sarfaty et al., 2017; 28082048, Zheng et al., 2020; 32718536, Nokihara et al., 2013; JSMO Abstract O2_026, Chae et al., 2019; 32914006, Abbar et al., 2019; 31668323, Drilon et al., 2015; 25567908, Wang et al., 2016; 27334835, Ross et al., 2017; 28961851, Elisei et al., 2013; 24002501, Michels et al., 2016; 26762747, Sherman et al., 2016; 27525386), lenvatinib (Li et al., 2019; ATA Abstract 291, Gautschi et al., 2017; 28447912, Hida et al., 2019; 31710864, Yao et al., 2019; ASCO Abstract e20634, Chu et al., 2020; 32737449, Velcheti et al., 2016; ESMO Abstract 1204PD, Schlumberger et al., 2016; 26311725), sorafenib (Jones et al., 2010; 20696054, Gautschi et al., 2017; 28447912, Horiike et al., 2016; 26898613, Chen et al., 2011; 21186953, Ballerini et al., 2012; 22513837), sunitinib (Wu et al., 2015; 26291023, Gautschi et al., 2017; 28447912, Lee et al., 2015; AACR Abstract 2416), and vandetanib (Moore et al., 2020; 31762146, Gautschi et al., 2017; 28447912, Yoh et al., 2021; 33725547, Lee et al., 2020; 32083304, Lee et al., 2017; 27803005, Platt et al., 2015; 25881079, Gautschi et al., 2013; 23584301, Drilon et al., 2018; 30017832, Dagogo_Jack et al., 2018; 30368414, Loh et al., 2019; 31808254, Falchook et al., 2016; 25366691, Varella_Garcia et al., 2013; ASCO Abstract 8024, Davis et al., 2020; 31994201, Cohen, 2015; 26693082, Subbiah et al., 2015; 25982012, Wells et al., 2012; 22025146, Yoh et al., 2017; 27825616). In the context of RET mutation, these therapies have primarily been investigated for the treatment of patients with medullary thyroid carcinoma (MTC) where pralsetinib (Hu et al., 2020; ESMO Abstract 1913O, Taylor et al., 2019; ASCO Abstract 6018), selpercatinib (Sherman et al., 2021; ASCO Abstract 6073), cabozantinib (Elisei et al., 2013; 24002501, Schlumberger et al., 2017; 29045520, Sherman et al., 2016; 27525386, Koehler et al., 2021; 32781914), lenvatinib (Schlumberger et al., 2012; ASCO Abstract 5591, Sato et al., 2020; 32219805), sorafenib (Lam et al., 2010; 20368568), sunitinib (De Souza et al., 2010; ASCO Abstract 5504), and vandetanib (Wells et al., 2012; 22025146, Koehler et al., 2021; 32781914) were reported to achieve clinical benefit. However, small studies of lenvatinib showed no significant difference in efficacy between patients with RET_mutated and RET_wildtype MTC (Schlumberger et al., 2012; ASCO Abstract 5591, Schlumberger et al., 2016; 26311725) or melanoma (Sachdev et al., 2013; ASCO Abstract 9058). A Phase 1 study of the selective RET inhibitor BOS172738 reported an ORR of 44% (7/16) across all dose levels for patients with RET_mutated advanced MTC (Schoffski et al., 2021; Abstract 3008). In a Phase 1/1b study of RXDX_105 for advanced solid tumors, a patient with MTC harboring RET M918T experienced an ongoing PR (Drilon et al., 2016; EORTC_NCI_AACR Abstract 437). Preclinical studies have shown that RET mutation may confer sensitivity to ponatinib (Dabir et al., 2014; 25122427, De Falco et al., 2013, Mologni et al., 2013; 23811235). Activating heterozygous germline mutations in RET may be associated with multiple endocrine neoplasia type 2 (MEN2), an uncommon autosomal dominant disorder with an estimated prevalence of 1:30,000_1:200,000 (ATA Task Force et al., 2009; 19469690, Romei et al., 2012; 23209466, Taieb et al., 2014; 24889858, Moline et al., 2014; 21552134). MEN2 is comprised of 3 subtypes, MEN2A, MEN2B and familial medullary thyroid carcinoma (FMTC). Additionally, inactivating germline mutations of RET have been associated with Hirschsprung disease, which has an estimated prevalence of 1:5,000_1:10,000 (Best et al., 2014; 25066220, Goldberg et al., 1984; 6240474). Subtypes of MEN2 and Hirschsprung disease may result in medullary thyroid cancer (MTC), pheochromocytomas, neuroganglionomas, and other tumors (Salehian and Samoa, 2013; 23455356). Therefore, in the appropriate clinical context, germline testing of RET is recommended.', 'Include': 'true', 'ClinicalTrialNote': 'RET activating mutations, or activating fusions may confer sensitivity to kinase inhibitors targeting RET.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04008797', 'Include': 'true'}, {'nctId': 'NCT05024214', 'Include': 'true'}, {'nctId': 'NCT05098847', 'Include': 'true'}, {'nctId': 'NCT03239015', 'Include': 'true'}, {'nctId': 'NCT05171530', 'Include': 'true'}, {'nctId': 'NCT04977453', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT03564691', 'Include': 'true'}, {'nctId': 'NCT05740215', 'Include': 'true'}, {'nctId': 'NCT05221775', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Cannot Be Determined', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Cannot Be Determined'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI_H tumors reportedly make up 12_35% of sporadic gastric cancers (Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086, Cancer Genome Atlas Research Network, 2017; 28052061). In the context of diffuse_type gastric cancer, a higher frequency of MSI_H tumors has been reported in familial (28%, 7/25) versus sporadic (7%, 7/107) tumors; no difference in frequency of MSI_H tumors was observed for intestinal_type gastric cancer (Fang et al., 2013; 23555086). MSI_H tumors have been frequently associated with hypermethylation and loss of MLH1 expression in cancers of the upper gastrointestinal tract, including esophageal, gastroesophageal junction, and gastric adenocarcinomas (Fang et al., 2013; 23555086, Gu et al., 2009; 19621725, Sasaki et al., 2011; 22866067, Fleisher et al., 1999; 10070967, Vasavi et al., 2010; 21045259, Zhang et al., 2013; 24035280). MSI_H gastric cancers are associated with certain clinicopathological and molecular features, including intestinal type differentiation, antral location, advanced age, reduced lymph node metastasis, and better prognosis (Zhu et al., 2015; 26137290, Leung et al., 1999; 9892201, dos Santos et al., 1996; 8536886, Wu et al., 1998; 9537253, Seo et al., 2015; 26078567, Cancer Genome Atlas Research Network., 2014; 25079317). A retrospective meta_analysis of the prognostic role of MSI in gastric cancers reported an increased DFS and OS in patients with MSI_H versus MSS/MSI_Low (Pietrantonio et al., 2019; 31513484). Conversely, in the same study, MSI_H was a negative predictor of response and MSS/MSI_Low correlated with increased benefit for patients treated with chemotherapy plus surgery as opposed to surgery alone (Pietrantonio et al., 2019; 31513484). In gastroesophageal cancer, MSI_H status was associated with shorter PFS compared to MSS patients for patients treated with chemotherapy (mPFS 4.8 months vs 6.9 months, HR=0.4) (Janjigian et al., 2018; 29122777). On the basis of clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), retifanlimab, and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143, Berton et al., 2021; SITC Abstract 956), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (alone or in combination with tremelimumab) (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92, Pietrantonio et al., 2023; ASCO GI Abstract 358, Lee et al., 2023; ASCO GI abstract 401, Rubinstein et al., 2022; 36512912, Marie et al., 2021; 33811152). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'PBRM1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'I404fs*1', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '0.89', 'isEquivocal': 'false', 'name': 'I404fs*1'}}, 'Interpretation': 'PBRM1 (Polybromo_1), also known as BAF180, encodes a subunit of ATP_dependent chromatin_remodeling complexes and a required cofactor for ligand_dependent transactivation by nuclear hormone receptors (Lemon et al., 2001; 11780067). Mutation, loss, or inactivation of PBRM1 has been reported in several cancers, suggesting PBRM1 is a tumor suppressor (Varela et al., 2011; 21248752, Jiao et al., 2013; 24185509, Xia et al., 2008; 18339845). Alterations such as seen here may disrupt PBRM1 function or expression (Hopson and Thompson, 2017; 28921948, Porter et al., 2017; 28053089, Niimi et al., 2015; 26117423, Brownlee et al., 2014; 24613357, Kakarougkas et al., 2014; 25066234, Gao et al., 2017; 28082722). Somatic mutations in PBRM1 are prevalent in clear cell renal cell carcinomas (ccRCC) (41%) (Varela et al., 2011; 21248752), intrahepatic cholangiocarcinomas (9_13%) (Fujimoto et al., 2015; 25636086, Jiao et al., 2013; 24185509, Churi et al., 2014; 25536104, Simbolo et al., 2014; 24867389), and bladder urothelial carcinomas (6_14%) (cBio_Cancer Genome Atlas Research Network, 2014; 24476821, cBio_Robertson et al., 2017; 28988769, cBio_Pietzak et al., 2017; 28583311). PBRM1 mutations are detected in other tumor types, including in 37% (11/30) of papillary meningiomas and 4% (2/54) of thymic carcinomas (Williams et al., 2020; 32405805, Petrini et al., 2014; 24974848) and in tumors of the skin (7.2%), stomach (5.7%), large intestine (4.8%), lung (2.7%), and soft tissue (2.4%) (COSMIC, Jan 2023)(Tate et al., 2019; 30371878). Preclinical studies have shown that PBRM1 loss increases the proliferation of clear cell renal cell carcinoma (ccRCC) cell lines (Varela et al., 2011; 21248752). PBRM1 protein loss or mutations are correlated with late tumor stage, low differentiation grade, and/or poor patient prognosis in ccRCC (da Costa et al., 2014; 24053427, Pawłowski et al., 2013; 22949125, Hakimi et al., 2013; 23036577), extrahepatic cholangiocarcinoma (Churi et al., 2014; 25536104), and pancreatic cancer (Numata et al., 2013; 23229642). However, 1 ccRCC study reported no correlation between PBRM1 mutations and cancer_specific survival (Hakimi et al., 2013; 23620406). In ccRCC, PBRM1 alterations are generally observed to be mutually exclusive with BAP1 alterations (Varela et al., 2011; 21248752, Pena_Llopis et al., 2012; 22683710); a retrospective analysis of 145 primary ccRCCs found a decreased median OS for patients with mutations in both BAP1 and PBRM1 compared with patients having either mutated gene alone (Kapur et al., 2013; 23333114). A trend toward worse survival was also seen for patients with intrahepatic cholangiocarcinoma harboring mutations in chromatin modifiers, including BAP1, ARID1A, or PBRM1 (Jiao et al., 2013; 24185509). On the basis of significant clinical data from prospective studies, PBRM1 inactivation may predict benefit from PD_1_targeting immune checkpoint inhibitors, such as nivolumab, pembrolizumab, cemiplimab, or dostarlimab, for patients with clear cell renal cell carcinoma and prior anti_angiogenic therapy (Braun et al., 2019; 31486842, Braun et al., 2020; 32472114, Vano et al., 2020; ASCO GU Abstract 618, Miao et al., 2018; 29301960). However, multiple retrospective analyses report that PBRM1 mutation status is not associated with clinical benefit from various immune checkpoint inhibitors in other solid tumor types, including non_small cell lung cancer, urothelial carcinoma, melanoma, or esophagogastric cancer, suggesting that the impact of PBRM1 loss of function may depend on tumor type (Abou Alaiwi et al., 2020; 32321774, Hakimi et al., 2020; 32820162, Miao et al., 2018; 30150660, Yang et al., 2021; 33850862).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TP53', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R282W', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '75.93', 'isEquivocal': 'false', 'name': 'R282W'}}, 'Interpretation': 'Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 is frequently mutated in cancers of the gastrointestinal tract, with alterations reported in 34–72% of esophageal, gastroesophageal junction, and gastric adenocarcinomas (Dulak et al., 2013; 23525077, Cancer Genome Atlas Research Network., 2014; 25079317, Sengpiel et al., 2009; 19160092, Pühringer_Oppermann et al., 2006; 16538517). Overexpression of p53 protein, which may occur as a result of mutation, has been reported in approximately 36% of gastric cancers, with p53 expression reported to be more frequent in intestinal_type compared with diffuse_type gastric cancer (Lee et al., 2014; 23969480, Sezer et al., 2013; 23613399, Victorzon et al., 1996; 8664030, Gonçalves et al., 2011; 21116760). While some studies have reported no association between TP53 mutation status and prognosis in patients with esophageal carcinoma or gastroesophageal junction adenocarcinoma (Sengpiel et al., 2009; 19160092, Pühringer_Oppermann et al., 2006; 16538517) others have associated TP53 mutation and elevated p53 expression with poor prognosis for patients with esophageal squamous cell carcinoma (Han et al., 2007; 17760650, Yamasaki et al., 2010; 19941080) or stomach cancer (Liu et al., 2012; 23285001, Wiksten et al., 2008; 18751407, Migliavacca et al., 2004; 15254976). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Apr 2023)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Tumor Fraction', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Elevated Tumor Fraction', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Elevated Tumor Fraction'}}, 'Interpretation': 'Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction have high circulating_tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '14', 'Title': 'KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'ADORA2A, CD73, PD_1', 'Locations': 'Taipei (Taiwan), Shatin, New Territories (Hong Kong), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Toronto (Canada), Missouri', 'NCTID': 'NCT04237649', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '14', 'Title': 'A Study of Multiple Immunotherapy_Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus_Gastric Cancer)', 'StudyPhase': 'PHASE 1/2', 'Target': 'MEK, CXCR4, VEGFRs, PD_L1', 'Locations': 'Taipei City (Taiwan), Zhongzheng Dist. (Taiwan), Tainan (Taiwan), Suwon_si (Korea, Republic of), Seodaemun_Gu (Korea, Republic of), Seoul (Korea, Republic of), Blacktown (Australia), Melbourne (Australia), Clayton (Australia), Haifa (Israel)', 'NCTID': 'NCT03281369', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '14', 'Title': 'Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'ICOS, PD_L1', 'Locations': 'Taipei (Taiwan), Changhua City (Taiwan), Siedlce (Poland), Nyíregyháza (Hungary), Budapest (Hungary), Meldola (Italy), Roma (Italy), Milano (Italy), Manchester (United Kingdom), London (United Kingdom)', 'NCTID': 'NCT03829501', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '14', 'Title': 'MK_7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK_7684A_005)', 'StudyPhase': 'PHASE 2', 'Target': 'PD_1, KIT, VEGFRs, FGFRs, PDGFRA, RET, TIGIT', 'Locations': 'Taoyuan (Taiwan), Taipei (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Osaka (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Alaska, Adana (Turkey)', 'NCTID': 'NCT05007106', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '14', 'Title': 'Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1, CCR4', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Busan (Korea, Republic of), Shatin (Hong Kong), High West (Hong Kong), Chungbuk (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Bangkok (Thailand), Nedlands (Australia)', 'NCTID': 'NCT03674567', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '14', 'Title': 'Study of BGB_A1217 in Combination With Tislelizumab in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, TIGIT', 'Locations': 'Taipei (Taiwan), Taoyuan (Taiwan), Hualien City (Taiwan), Taichung (Taiwan), Fujian (China), Hangzhou (China), Shanghai (China), Hefei (China), Guangdong (China), Changsha (China)', 'NCTID': 'NCT04047862', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '14', 'Title': 'Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM_NPC', 'StudyPhase': 'PHASE 1/2', 'Target': 'HDAC, PD_1', 'Locations': 'Taipei City (Taiwan), Taipei (Taiwan), Taoyuan City (Taiwan), Sha Tin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Kuching (Malaysia), Kuala Lumpur (Malaysia), Singapore (Singapore), Blacktown (Australia)', 'NCTID': 'NCT05166577', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '14', 'Title': 'Study of Dato_Dxd as Monotherapy and in Combination With Anti_cancer Agents in Patients With Advanced Solid Tumours (TROPION_PanTumor03)', 'StudyPhase': 'PHASE 2', 'Target': 'TROP2, PD_L1, PARP1, PD_1', 'Locations': 'Taipei (Taiwan), Taoyuan (Taiwan), Liou Ying Township (Taiwan), Shanghai (China), Seoul (Korea, Republic of), Seodaemun_gu (Korea, Republic of), Suita_shi (Japan), Chuo_ku (Japan), Koto_ku (Japan), Kashiwa (Japan)', 'NCTID': 'NCT05489211', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '14', 'Title': 'A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_L1, PD_1, CTLA_4', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Cheongju_si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Melbourne (Australia), Amsterdam (Netherlands), Ravenna (Italy), Meldola (Italy)', 'NCTID': 'NCT03530397', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '14', 'Title': 'RegoNivo vs Standard of Care Chemotherapy in AGOC', 'StudyPhase': 'PHASE 3', 'Target': 'PD_1, BRAF, VEGFRs, RET, KIT', 'Locations': 'Kaohsiung (Taiwan), Jinju (Korea, Republic of), Busan (Korea, Republic of), Anyang (Korea, Republic of), Seoul (Korea, Republic of), Sapporo (Japan), Tiwi (Australia), Douglas (Australia), Subiaco (Australia), Nedlands (Australia)', 'NCTID': 'NCT04879368', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'D32N', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'D32N', 'Title': 'COAST Therapy in Advanced Solid Tumors and Prostate Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'DDR2, ABL, SRC, KIT, mTOR', 'Locations': 'South Carolina', 'NCTID': 'NCT05036226', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'D32N', 'Title': 'A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'mTOR, EGFR, SRC, RET, VEGFRs', 'Locations': 'Texas', 'NCTID': 'NCT01582191', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'D32N', 'Title': 'Combination Chemotherapy and Bevacizumab With the NovoTTF_100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'VEGFA, mTOR', 'Locations': 'Texas', 'NCTID': 'NCT03203525', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'KEAP1', 'Alteration': 'P322L', 'Title': 'IACS_6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'GLS, PD_1', 'Locations': 'Texas', 'NCTID': 'NCT05039801', 'Note': 'KEAP1 inactivation may predict sensitivity to glutaminase inhibitors.', 'Include': 'true'}, {'Gene': 'RET', 'Alteration': 'T636M', 'Title': 'A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor', 'StudyPhase': 'PHASE 1', 'Target': 'CBP, Beta_catenin, FGFRs, RET, PDGFRA, VEGFRs, KIT', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Kurume (Japan), Matsuyama (Japan), Seongnamsi Bundang (Korea, Republic of), Songpa_gu (Korea, Republic of), Seodaemun (Korea, Republic of), Seoul (Korea, Republic of), Jongno_gu (Korea, Republic of), Osakasayama (Japan)', 'NCTID': 'NCT04008797', 'Note': 'RET activating mutations, or activating fusions may confer sensitivity to kinase inhibitors targeting RET.', 'Include': 'true'}, {'Gene': 'RET', 'Alteration': 'T636M', 'Title': 'Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_L1, FGFRs, RET, PDGFRA, VEGFRs, KIT, FLT3, CSF1R', 'Locations': 'Hangzhou (China), Shanghai (China), Dongguan (China), Guangzhou (China), Zhuhai (China), Benbu (China), Zhengzhou (China), Jinan (China), Dalian (China), Tianjin (China)', 'NCTID': 'NCT05024214', 'Note': 'RET activating mutations, or activating fusions may confer sensitivity to kinase inhibitors targeting RET.', 'Include': 'true'}, {'Gene': 'RET', 'Alteration': 'T636M', 'Title': 'Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT05098847', 'Note': 'RET activating mutations, or activating fusions may confer sensitivity to kinase inhibitors targeting RET.', 'Include': 'true'}, {'Gene': 'RET', 'Alteration': 'T636M', 'Title': 'Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event', 'StudyPhase': 'PHASE 2', 'Target': 'EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT03239015', 'Note': 'RET activating mutations, or activating fusions may confer sensitivity to kinase inhibitors targeting RET.', 'Include': 'true'}, {'Gene': 'RET', 'Alteration': 'T636M', 'Title': 'Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'FGFRs, RET, PDGFRA, VEGFRs, KIT', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT05171530', 'Note': 'RET activating mutations, or activating fusions may confer sensitivity to kinase inhibitors targeting RET.', 'Include': 'true'}, {'Gene': 'RET', 'Alteration': 'T636M', 'Title': 'GI_101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1, CTLA_4', 'Locations': 'Daejeon (Korea, Republic of), Suwon_si (Korea, Republic of), Seoul (Korea, Republic of), North Carolina', 'NCTID': 'NCT04977453', 'Note': 'RET activating mutations, or activating fusions may confer sensitivity to kinase inhibitors targeting RET.', 'Include': 'true'}, {'Gene': 'RET', 'Alteration': 'T636M', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'RET activating mutations, or activating fusions may confer sensitivity to kinase inhibitors targeting RET.', 'Include': 'true'}, {'Gene': 'RET', 'Alteration': 'T636M', 'Title': 'Study of MK_4830 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_4830_001)', 'StudyPhase': 'PHASE 1', 'Target': 'ITL4, FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1', 'Locations': 'Seoul (Korea, Republic of), Chengdu (China), Brisbane (Australia), Liverpool (Australia), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Haifa (Israel), Warszawa (Poland), Gdansk (Poland)', 'NCTID': 'NCT03564691', 'Note': 'RET activating mutations, or activating fusions may confer sensitivity to kinase inhibitors targeting RET.', 'Include': 'true'}, {'Gene': 'RET', 'Alteration': 'T636M', 'Title': 'Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1, FGFRs, RET, PDGFRA, VEGFRs, KIT', 'Locations': 'Chongqing (China)', 'NCTID': 'NCT05740215', 'Note': 'RET activating mutations, or activating fusions may confer sensitivity to kinase inhibitors targeting RET.', 'Include': 'true'}, {'Gene': 'RET', 'Alteration': 'T636M', 'Title': 'Safety of XELOX Combined With GLS_010 and Lenvatinib in Advanced AFP_positive Gastric Cancer Patients', 'StudyPhase': 'PHASE 1', 'Target': 'FGFRs, RET, PDGFRA, VEGFRs, KIT', 'Locations': 'Tianjin (China)', 'NCTID': 'NCT05221775', 'Note': 'RET activating mutations, or activating fusions may confer sensitivity to kinase inhibitors targeting RET.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '10679188', 'FullCitation': 'Biochem. Biophys. Res. Commun. (2000) pmid: 10679188', 'Include': 'true'}, {'number': '1', 'ReferenceId': '23258168', 'FullCitation': 'Anastas JN, et al. Nat. Rev. Cancer (2013) pmid: 23258168', 'Include': 'true'}, {'number': '2', 'ReferenceId': '9721853', 'FullCitation': 'Fukuchi T, et al. Cancer Res. (1998) pmid: 9721853', 'Include': 'true'}, {'number': '3', 'ReferenceId': '12824913', 'FullCitation': 'Cancer Sci. (2003) pmid: 12824913', 'Include': 'true'}, {'number': '4', 'ReferenceId': '16523258', 'FullCitation': 'Takahashi Y, et al. Virchows Arch. (2006) pmid: 16523258', 'Include': 'true'}, {'number': '5', 'ReferenceId': '11731417', 'FullCitation': 'Tanaka Y, et al. Cancer Res. (2001) pmid: 11731417', 'Include': 'true'}, {'number': '6', 'ReferenceId': '11943721', 'FullCitation': 'Abraham SC, et al. Am. J. Pathol. (2002) pmid: 11943721', 'Include': 'true'}, {'number': '7', 'ReferenceId': '18282277', 'FullCitation': 'Austinat M, et al. Mol. Cancer (2008) pmid: 18282277', 'Include': 'true'}, {'number': '8', 'ReferenceId': '12820959', 'FullCitation': 'Wu G, et al. Mol. Cell (2003) pmid: 12820959', 'Include': 'true'}, {'number': '9', 'ReferenceId': '15829978', 'FullCitation': 'Provost E, et al. Oncogene (2005) pmid: 15829978', 'Include': 'true'}, {'number': '10', 'ReferenceId': '10072352', 'FullCitation': 'Curr. Opin. Genet. Dev. (1999) pmid: 10072352', 'Include': 'true'}, {'number': '11', 'ReferenceId': '17143297', 'FullCitation': 'Segditsas S, et al. Oncogene (2006) pmid: 17143297', 'Include': 'true'}, {'number': '12', 'ReferenceId': '9024698', 'FullCitation': 'Barth AI, et al. J. Cell Biol. (1997) pmid: 9024698', 'Include': 'true'}, {'number': '13', 'ReferenceId': '10545105', 'FullCitation': 'Harada N, et al. EMBO J. (1999) pmid: 10545105', 'Include': 'true'}, {'number': '14', 'ReferenceId': '9671490', 'FullCitation': 'Hsu SC, et al. Mol. Cell. Biol. (1998) pmid: 9671490', 'Include': 'true'}, {'number': '15', 'ReferenceId': '18491352', 'FullCitation': 'Breuhahn K, et al. J. Pathol. (2008) pmid: 18491352', 'Include': 'true'}, {'number': '16', 'ReferenceId': '18515740', 'FullCitation': 'Soon PS, et al. Oncologist (2008) pmid: 18515740', 'Include': 'true'}, {'number': '17', 'ReferenceId': '21212436', 'FullCitation': 'Tacon LJ, et al. Oncologist (2011) pmid: 21212436', 'Include': 'true'}, {'number': '18', 'ReferenceId': '22266195', 'FullCitation': 'Simon DP, et al. Mol. Cell. Endocrinol. (2012) pmid: 22266195', 'Include': 'true'}, {'number': '19', 'ReferenceId': '26850916', 'FullCitation': 'Hirotsu Y, et al. Hepatol. Res. (2016) pmid: 26850916', 'Include': 'true'}, {'number': '20', 'ReferenceId': '29156750', 'FullCitation': 'Busch EL, et al. Oncotarget (2017) pmid: 29156750', 'Include': 'true'}, {'number': '21', 'ReferenceId': '22870241', 'FullCitation': 'Maeng CH, et al. PLoS ONE (2012) pmid: 22870241', 'Include': 'true'}, {'number': '22', 'ReferenceId': '28744403', 'FullCitation': 'Ge S, et al. Am J Cancer Res (2017) pmid: 28744403', 'Include': 'true'}, {'number': '23', 'ReferenceId': '25656989', 'FullCitation': 'Li_Chang HH, et al. BMC Cancer (2015) pmid: 25656989', 'Include': 'true'}, {'number': '24', 'ReferenceId': '22180306', 'FullCitation': 'Borger DR, et al. Oncologist (2012) pmid: 22180306', 'Include': 'true'}, {'number': '25', 'ReferenceId': '24197976', 'FullCitation': 'Ayed_Guerfali DB, et al. Tumour Biol. (2014) pmid: 24197976', 'Include': 'true'}, {'number': '26', 'ReferenceId': '23359759', 'FullCitation': 'Sun GY, et al. Chin. J. Cancer Res. (2012) pmid: 23359759', 'Include': 'true'}, {'number': '27', 'ReferenceId': '22653845', 'FullCitation': 'Moyes LH, et al. J. Pathol. (2012) pmid: 22653845', 'Include': 'true'}, {'number': '28', 'ReferenceId': '21948356', 'FullCitation': 'Krishnan K, et al. Dig. Dis. Sci. (2012) pmid: 21948356', 'Include': 'true'}, {'number': '29', 'ReferenceId': '23748820', 'FullCitation': 'Yoshii T, et al. Tumori () pmid: 23748820', 'Include': 'true'}, {'number': '30', 'ReferenceId': '30635339', 'FullCitation': 'Luke JJ, et al. Clin Cancer Res (2019) pmid: 30635339', 'Include': 'true'}, {'number': '31', 'ReferenceId': '19403928', 'FullCitation': 'Tanwar PS, et al. Biol. Reprod. (2009) pmid: 19403928', 'Include': 'true'}, {'number': '32', 'ReferenceId': '21695255', 'FullCitation': 'Tanwar PS, et al. PLoS ONE (2011) pmid: 21695255', 'Include': 'true'}, {'number': '33', 'ReferenceId': '18768809', 'FullCitation': 'Fujishita T, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18768809', 'Include': 'true'}, {'number': '34', 'ReferenceId': '20347502', 'FullCitation': 'Bhoori S, et al. J. Hepatol. (2010) pmid: 20347502', 'Include': 'true'}, {'number': '35', 'ReferenceId': '24931142', 'FullCitation': 'Janku F, et al. Oncotarget (2014) pmid: 24931142', 'Include': 'true'}, {'number': '36', 'ReferenceId': '25624430', 'FullCitation': 'Slomovitz BM, et al. J. Clin. Oncol. (2015) pmid: 25624430', 'Include': 'true'}, {'number': '37', 'ReferenceId': '15378020', 'FullCitation': 'Niida A, et al. Oncogene (2004) pmid: 15378020', 'Include': 'true'}, {'number': '38', 'ReferenceId': '15592430', 'FullCitation': 'Chamorro MN, et al. EMBO J. (2005) pmid: 15592430', 'Include': 'true'}, {'number': '39', 'ReferenceId': '28574171', 'FullCitation': 'Kagey MH, et al. Br. J. Pharmacol. (2017) pmid: 28574171', 'Include': 'true'}, {'number': '40', 'ReferenceId': '21841793', 'FullCitation': 'Kwon C, et al. Nat. Cell Biol. (2011) pmid: 21841793', 'Include': 'true'}, {'number': '41', 'ReferenceId': '23868008', 'FullCitation': 'Arcaroli JJ, et al. Br. J. Cancer (2013) pmid: 23868008', 'Include': 'true'}, {'number': '42', 'ReferenceId': '26349011', 'FullCitation': 'Shang H, et al. Cancer (2015) pmid: 26349011', 'Include': 'true'}, {'number': '43', 'ReferenceId': '24429522', 'FullCitation': 'Kode A, et al. Nature (2014) pmid: 24429522', 'Include': 'true'}, {'number': '44', 'ReferenceId': '25231399', 'FullCitation': 'Messersmith WA, et al. Clin. Cancer Res. (2015) pmid: 25231399', 'Include': 'true'}, {'number': '45', 'ReferenceId': '22964660', 'FullCitation': 'Zhu J, et al. Carcinogenesis (2012) pmid: 22964660', 'Include': 'true'}, {'number': '46', 'ReferenceId': '22356261', 'FullCitation': 'Kogan Y, et al. Biochem. J. (2012) pmid: 22356261', 'Include': 'true'}, {'number': '47', 'ReferenceId': '22811581', 'FullCitation': 'Lachenmayer A, et al. Clin. Cancer Res. (2012) pmid: 22811581', 'Include': 'true'}, {'number': '48', 'ReferenceId': '17046835', 'FullCitation': 'Lo SC, et al. J. Biol. Chem. (2006) pmid: 17046835', 'Include': 'true'}, {'number': '49', 'ReferenceId': '14517554', 'FullCitation': 'Wakabayashi N, et al. Nat. Genet. (2003) pmid: 14517554', 'Include': 'true'}, {'number': '50', 'ReferenceId': '24024136', 'FullCitation': 'Kansanen E, et al. Redox Biol (2013) pmid: 24024136', 'Include': 'true'}, {'number': '51', 'ReferenceId': '23382044', 'FullCitation': 'Hast BE, et al. Cancer Res. (2013) pmid: 23382044', 'Include': 'true'}, {'number': '52', 'ReferenceId': '22348534', 'FullCitation': 'Yoo NJ, et al. Histopathology (2012) pmid: 22348534', 'Include': 'true'}, {'number': '53', 'ReferenceId': '30371878', 'FullCitation': 'Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878', 'Include': 'true'}, {'number': '54', 'ReferenceId': '32272498', 'FullCitation': 'Xu X, et al. Oncologist (2020) pmid: 32272498', 'Include': 'true'}, {'number': '55', 'ReferenceId': '33071215', 'FullCitation': 'Binkley MS, et al. Cancer Discov (2020) pmid: 33071215', 'Include': 'true'}, {'number': '56', 'ReferenceId': '22964642', 'FullCitation': 'Chowdhry S, et al. Oncogene (2013) pmid: 22964642', 'Include': 'true'}, {'number': '57', 'ReferenceId': '23980093', 'FullCitation': 'Abazeed ME, et al. Cancer Res. (2013) pmid: 23980093', 'Include': 'true'}, {'number': '58', 'ReferenceId': '32175433', 'FullCitation': 'Chen X, et al. Ann Transl Med (2020) pmid: 32175433', 'Include': 'true'}, {'number': '59', 'ReferenceId': '32471565', 'FullCitation': 'Zhang C, et al. J Thorac Oncol (2020) pmid: 32471565', 'Include': 'true'}, {'number': '60', 'ReferenceId': '32866624', 'FullCitation': 'Marinelli D, et al. Ann Oncol (2020) pmid: 32866624', 'Include': 'true'}, {'number': '61', 'ReferenceId': '29316436', 'FullCitation': 'Gwinn DM, et al. Cancer Cell (2018) pmid: 29316436', 'Include': 'true'}, {'number': '62', 'ReferenceId': '28967864', 'FullCitation': 'Sayin VI, et al. Elife (2017) pmid: 28967864', 'Include': 'true'}, {'number': '63', 'ReferenceId': '28967920', 'FullCitation': 'Romero R, et al. Nat. Med. (2017) pmid: 28967920', 'Include': 'true'}, {'number': '64', 'ReferenceId': '23824739', 'FullCitation': 'Dai B, et al. Cancer Res. (2013) pmid: 23824739', 'Include': 'true'}, {'number': '65', 'ReferenceId': '2992805', 'FullCitation': 'Takahashi M, et al. Cell (1985) pmid: 2992805', 'Include': 'true'}, {'number': '66', 'ReferenceId': '10049754', 'FullCitation': 'Asai N, et al. Biochem. Biophys. Res. Commun. (1999) pmid: 10049754', 'Include': 'true'}, {'number': '67', 'ReferenceId': '16954442', 'FullCitation': 'Cordella D, et al. Endocr Relat Cancer (2006) pmid: 16954442', 'Include': 'true'}, {'number': '68', 'ReferenceId': '20103606', 'FullCitation': 'Muzza M, et al. Eur. J. Endocrinol. (2010) pmid: 20103606', 'Include': 'true'}, {'number': '69', 'ReferenceId': '25725622', 'FullCitation': 'Silva AL, et al. Endocrine (2015) pmid: 25725622', 'Include': 'true'}, {'number': '70', 'ReferenceId': '24699901', 'FullCitation': 'Krampitz GW, et al. Cancer (2014) pmid: 24699901', 'Include': 'true'}, {'number': '71', 'ReferenceId': '18631007', 'FullCitation': 'Fazioli F, et al. Thyroid (2008) pmid: 18631007', 'Include': 'true'}, {'number': '72', 'ReferenceId': '22588877', 'FullCitation': 'Cerami E, et al. Cancer Discov (2012) pmid: 22588877', 'Include': 'true'}, {'number': '73', 'ReferenceId': '23550210', 'FullCitation': 'Gao J, et al. Sci Signal (2013) pmid: 23550210', 'Include': 'true'}, {'number': '74', 'ReferenceId': '24686850', 'FullCitation': 'Lin DC, et al. Nat. Genet. (2014) pmid: 24686850', 'Include': 'true'}, {'number': '75', 'ReferenceId': '23525077', 'FullCitation': 'Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077', 'Include': 'true'}, {'number': '76', 'ReferenceId': '28052061', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2017) pmid: 28052061', 'Include': 'true'}, {'number': '77', 'ReferenceId': '29122777', 'FullCitation': 'Janjigian YY, et al. Cancer Discov (2018) pmid: 29122777', 'Include': 'true'}, {'number': '78', 'ReferenceId': '33869783', 'FullCitation': 'Chen L, et al. Open Med (Wars) (2021) pmid: 33869783', 'Include': 'true'}, {'number': '79', 'ReferenceId': '27825636', 'FullCitation': 'Drilon A, et al. Lancet Oncol. (2016) pmid: 27825636', 'Include': 'true'}, {'number': '80', 'ReferenceId': '23533264', 'FullCitation': 'Drilon A, et al. Cancer Discov (2013) pmid: 23533264', 'Include': 'true'}, {'number': '81', 'ReferenceId': '28447912', 'FullCitation': 'Gautschi O, et al. J. Clin. Oncol. (2017) pmid: 28447912', 'Include': 'true'}, {'number': '82', 'ReferenceId': '25436805', 'FullCitation': 'Mukhopadhyay S, et al. J Thorac Oncol (2014) pmid: 25436805', 'Include': 'true'}, {'number': '83', 'ReferenceId': '30718102', 'FullCitation': 'Nokihara H, et al. Clin Lung Cancer (2019) pmid: 30718102', 'Include': 'true'}, {'number': '84', 'ReferenceId': '30653139', 'FullCitation': 'Wang Y, et al. Medicine (Baltimore) (2019) pmid: 30653139', 'Include': 'true'}, {'number': '85', 'ReferenceId': '28082048', 'FullCitation': 'Sarfaty M, et al. Clin Lung Cancer (2017) pmid: 28082048', 'Include': 'true'}, {'number': '86', 'ReferenceId': '32718536', 'FullCitation': 'Zheng Q, et al. J Thorac Oncol (2020) pmid: 32718536', 'Include': 'true'}, {'number': '87', 'ReferenceId': '32914006', 'FullCitation': 'Chae YK, et al. JCO Precis Oncol (2019) pmid: 32914006', 'Include': 'true'}, {'number': '88', 'ReferenceId': '31668323', 'FullCitation': 'Abbar B, et al. J Thorac Oncol (2019) pmid: 31668323', 'Include': 'true'}, {'number': '89', 'ReferenceId': '25567908', 'FullCitation': 'Drilon A, et al. Clin. Cancer Res. (2015) pmid: 25567908', 'Include': 'true'}, {'number': '90', 'ReferenceId': '27334835', 'FullCitation': 'Wang K, et al. Clin. Cancer Res. (2016) pmid: 27334835', 'Include': 'true'}, {'number': '91', 'ReferenceId': '28961851', 'FullCitation': 'Ross JS, et al. Ann. Oncol. (2017) pmid: 28961851', 'Include': 'true'}, {'number': '92', 'ReferenceId': '24002501', 'FullCitation': 'Elisei R, et al. J. Clin. Oncol. (2013) pmid: 24002501', 'Include': 'true'}, {'number': '93', 'ReferenceId': '26762747', 'FullCitation': 'Michels S, et al. J Thorac Oncol (2016) pmid: 26762747', 'Include': 'true'}, {'number': '94', 'ReferenceId': '27525386', 'FullCitation': 'Sherman SI, et al. Cancer (2016) pmid: 27525386', 'Include': 'true'}, {'number': '95', 'ReferenceId': '31710864', 'FullCitation': 'Hida T, et al. Lung Cancer (2019) pmid: 31710864', 'Include': 'true'}, {'number': '96', 'ReferenceId': '32737449', 'FullCitation': 'Chu YH, et al. Mod Pathol (2020) pmid: 32737449', 'Include': 'true'}, {'number': '97', 'ReferenceId': '26311725', 'FullCitation': 'Schlumberger M, et al. Clin. Cancer Res. (2016) pmid: 26311725', 'Include': 'true'}, {'number': '98', 'ReferenceId': '20696054', 'FullCitation': 'Jones SJ, et al. Genome Biol. (2010) pmid: 20696054', 'Include': 'true'}, {'number': '99', 'ReferenceId': '26898613', 'FullCitation': 'Horiike A, et al. Lung Cancer (2016) pmid: 26898613', 'Include': 'true'}, {'number': '100', 'ReferenceId': '21186953', 'FullCitation': 'Chen L, et al. Thyroid (2011) pmid: 21186953', 'Include': 'true'}, {'number': '101', 'ReferenceId': '22513837', 'FullCitation': 'Ballerini P, et al. Leukemia (2012) pmid: 22513837', 'Include': 'true'}, {'number': '102', 'ReferenceId': '26291023', 'FullCitation': 'Wu H, et al. J Thorac Oncol (2015) pmid: 26291023', 'Include': 'true'}, {'number': '103', 'ReferenceId': '31762146', 'FullCitation': 'Moore A, et al. Head Neck (2020) pmid: 31762146', 'Include': 'true'}, {'number': '104', 'ReferenceId': '33725547', 'FullCitation': 'Yoh K, et al. Lung Cancer (2021) pmid: 33725547', 'Include': 'true'}, {'number': '105', 'ReferenceId': '32083304', 'FullCitation': 'Lee J, et al. Jpn J Clin Oncol (2020) pmid: 32083304', 'Include': 'true'}, {'number': '106', 'ReferenceId': '27803005', 'FullCitation': 'Lee SH, et al. Ann. Oncol. (2017) pmid: 27803005', 'Include': 'true'}, {'number': '107', 'ReferenceId': '25881079', 'FullCitation': 'Platt A, et al. BMC Cancer (2015) pmid: 25881079', 'Include': 'true'}, {'number': '108', 'ReferenceId': '23584301', 'FullCitation': 'Gautschi O, et al. J Thorac Oncol (2013) pmid: 23584301', 'Include': 'true'}, {'number': '109', 'ReferenceId': '30017832', 'FullCitation': 'Drilon A, et al. J Thorac Oncol (2018) pmid: 30017832', 'Include': 'true'}, {'number': '110', 'ReferenceId': '30368414', 'FullCitation': 'Dagogo_Jack I, et al. J Thorac Oncol (2018) pmid: 30368414', 'Include': 'true'}, {'number': '111', 'ReferenceId': '31808254', 'FullCitation': 'Loh Z, et al. Intern Med J (2019) pmid: 31808254', 'Include': 'true'}, {'number': '112', 'ReferenceId': '25366691', 'FullCitation': 'Falchook GS, et al. J. Clin. Oncol. (2016) pmid: 25366691', 'Include': 'true'}, {'number': '113', 'ReferenceId': '31994201', 'FullCitation': 'Davis JL, et al. Histopathology (2020) pmid: 31994201', 'Include': 'true'}, {'number': '114', 'ReferenceId': '26693082', 'FullCitation': 'Dermatol Pract Concept (2015) pmid: 26693082', 'Include': 'true'}, {'number': '115', 'ReferenceId': '25982012', 'FullCitation': 'Subbiah V, et al. Lung Cancer (2015) pmid: 25982012', 'Include': 'true'}, {'number': '116', 'ReferenceId': '22025146', 'FullCitation': 'Wells SA, et al. J. Clin. Oncol. (2012) pmid: 22025146', 'Include': 'true'}, {'number': '117', 'ReferenceId': '27825616', 'FullCitation': 'Yoh K, et al. Lancet Respir Med (2017) pmid: 27825616', 'Include': 'true'}, {'number': '118', 'ReferenceId': '29045520', 'FullCitation': 'Schlumberger M, et al. Ann. Oncol. (2017) pmid: 29045520', 'Include': 'true'}, {'number': '119', 'ReferenceId': '32781914', 'FullCitation': 'Koehler VF, et al. Thyroid (2021) pmid: 32781914', 'Include': 'true'}, {'number': '120', 'ReferenceId': '32219805', 'FullCitation': 'Sato H, et al. Tokai J Exp Clin Med (2020) pmid: 32219805', 'Include': 'true'}, {'number': '121', 'ReferenceId': '20368568', 'FullCitation': 'Lam ET, et al. J. Clin. Oncol. (2010) pmid: 20368568', 'Include': 'true'}, {'number': '122', 'ReferenceId': '25122427', 'FullCitation': 'Dabir S, et al. J Thorac Oncol (2014) pmid: 25122427', 'Include': 'true'}, {'number': '123', 'ReferenceId': '23811235', 'FullCitation': 'Mologni L, et al. Mol. Cell. Endocrinol. (2013) pmid: 23811235', 'Include': 'true'}, {'number': '124', 'ReferenceId': '19469690', 'FullCitation': 'American Thyroid Association Guidelines Task Force, et al. Thyroid (2009) pmid: 19469690', 'Include': 'true'}, {'number': '125', 'ReferenceId': '23209466', 'FullCitation': 'Romei C, et al. J Oncol (2012) pmid: 23209466', 'Include': 'true'}, {'number': '126', 'ReferenceId': '24889858', 'FullCitation': 'Taïeb D, et al. Clin. Endocrinol. (Oxf) (2014) pmid: 24889858', 'Include': 'true'}, {'number': '127', 'ReferenceId': '21552134', 'FullCitation': 'Moline J, et al. Genet. Med. (2011) pmid: 21552134', 'Include': 'true'}, {'number': '128', 'ReferenceId': '25066220', 'FullCitation': 'Best KE, et al. Birth Defects Res. Part A Clin. Mol. Teratol. (2014) pmid: 25066220', 'Include': 'true'}, {'number': '129', 'ReferenceId': '6240474', 'FullCitation': 'Int J Epidemiol (1984) pmid: 6240474', 'Include': 'true'}, {'number': '130', 'ReferenceId': '23455356', 'FullCitation': 'Salehian B, et al. J Clin Res Pediatr Endocrinol (2013) pmid: 23455356', 'Include': 'true'}, {'number': '131', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '132', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '133', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '134', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '135', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '136', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '137', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '138', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '139', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '140', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '141', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '142', 'ReferenceId': '30082870', 'FullCitation': 'Gandara DR, et al. Nat. Med. (2018) pmid: 30082870', 'Include': 'true'}, {'number': '143', 'ReferenceId': '30816954', 'FullCitation': 'Wang Z, et al. JAMA Oncol (2019) pmid: 30816954', 'Include': 'true'}, {'number': '144', 'ReferenceId': '32102950', 'FullCitation': 'Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950', 'Include': 'true'}, {'number': '145', 'ReferenceId': '32141230', 'FullCitation': 'Cai L, et al. Cancer Commun (Lond) (2020) pmid: 32141230', 'Include': 'true'}, {'number': '146', 'ReferenceId': '33510848', 'FullCitation': 'Zhao DY, et al. World J Gastrointest Oncol (2021) pmid: 33510848', 'Include': 'true'}, {'number': '147', 'ReferenceId': '33613701', 'FullCitation': 'Wei XL, et al. Ther Adv Med Oncol (2021) pmid: 33613701', 'Include': 'true'}, {'number': '148', 'ReferenceId': '33687617', 'FullCitation': 'Wang D, et al. Gastric Cancer (2021) pmid: 33687617', 'Include': 'true'}, {'number': '149', 'ReferenceId': '32165590', 'FullCitation': 'Yuan C, et al. Aging (Albany NY) (2020) pmid: 32165590', 'Include': 'true'}, {'number': '150', 'ReferenceId': '35274716', 'FullCitation': 'Sturgill EG, et al. Oncologist (2022) pmid: 35274716', 'Include': 'true'}, {'number': '151', 'ReferenceId': '32379280', 'FullCitation': 'Chen EX, et al. JAMA Oncol (2020) pmid: 32379280', 'Include': 'true'}, {'number': '152', 'ReferenceId': '32271377', 'FullCitation': 'Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377', 'Include': 'true'}, {'number': '153', 'ReferenceId': '33355200', 'FullCitation': 'Si H, et al. Clin Cancer Res (2021) pmid: 33355200', 'Include': 'true'}, {'number': '154', 'ReferenceId': '34800700', 'FullCitation': 'Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700', 'Include': 'true'}, {'number': '155', 'ReferenceId': '31602320', 'FullCitation': 'Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320', 'Include': 'true'}, {'number': '156', 'ReferenceId': '32757294', 'FullCitation': 'Zhang EW, et al. Cancer (2020) pmid: 32757294', 'Include': 'true'}, {'number': '157', 'ReferenceId': '30833418', 'FullCitation': 'Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418', 'Include': 'true'}, {'number': '158', 'ReferenceId': '24553385', 'FullCitation': 'Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385', 'Include': 'true'}, {'number': '159', 'ReferenceId': '30400802', 'FullCitation': 'Lapin M, et al. J Transl Med (2018) pmid: 30400802', 'Include': 'true'}, {'number': '160', 'ReferenceId': '30131550', 'FullCitation': 'Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550', 'Include': 'true'}, {'number': '161', 'ReferenceId': '30385733', 'FullCitation': 'Choudhury AD, et al. JCI Insight (2018) pmid: 30385733', 'Include': 'true'}, {'number': '162', 'ReferenceId': '29298117', 'FullCitation': 'Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117', 'Include': 'true'}, {'number': '163', 'ReferenceId': '30793095', 'FullCitation': 'Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095', 'Include': 'true'}, {'number': '164', 'ReferenceId': '31059681', 'FullCitation': 'Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681', 'Include': 'true'}, {'number': '165', 'ReferenceId': '28187169', 'FullCitation': 'Fan G, et al. PLoS ONE (2017) pmid: 28187169', 'Include': 'true'}, {'number': '166', 'ReferenceId': '30923679', 'FullCitation': 'Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679', 'Include': 'true'}, {'number': '167', 'ReferenceId': '30093454', 'FullCitation': 'Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454', 'Include': 'true'}, {'number': '168', 'ReferenceId': '30860573', 'FullCitation': 'Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573', 'Include': 'true'}, {'number': '169', 'ReferenceId': '28450425', 'FullCitation': 'Goodall J, et al. Cancer Discov (2017) pmid: 28450425', 'Include': 'true'}, {'number': '170', 'ReferenceId': '29330207', 'FullCitation': 'Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207', 'Include': 'true'}, {'number': '171', 'ReferenceId': '19935675', 'FullCitation': 'Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675', 'Include': 'true'}, {'number': '172', 'ReferenceId': '18410249', 'FullCitation': 'Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249', 'Include': 'true'}, {'number': '173', 'ReferenceId': '12826609', 'FullCitation': 'Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609', 'Include': 'true'}, {'number': '174', 'ReferenceId': '20978130', 'FullCitation': 'Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130', 'Include': 'true'}, {'number': '175', 'ReferenceId': '28472496', 'FullCitation': 'Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496', 'Include': 'true'}, {'number': '176', 'ReferenceId': '17690113', 'FullCitation': 'Yamada H, et al. Carcinogenesis (2007) pmid: 17690113', 'Include': 'true'}, {'number': '177', 'ReferenceId': '25079317', 'FullCitation': 'Nature (2014) pmid: 25079317', 'Include': 'true'}, {'number': '178', 'ReferenceId': '19160092', 'FullCitation': 'Sengpiel C, et al. Cancer Invest. (2009) pmid: 19160092', 'Include': 'true'}, {'number': '179', 'ReferenceId': '16538517', 'FullCitation': 'Pühringer_Oppermann F, et al. J. Cancer Res. Clin. Oncol. (2006) pmid: 16538517', 'Include': 'true'}, {'number': '180', 'ReferenceId': '23969480', 'FullCitation': 'Lee HE, et al. Pathobiology (2014) pmid: 23969480', 'Include': 'true'}, {'number': '181', 'ReferenceId': '23613399', 'FullCitation': 'Sezer C, et al. J BUON () pmid: 23613399', 'Include': 'true'}, {'number': '182', 'ReferenceId': '8664030', 'FullCitation': 'Victorzon M, et al. Eur. J. Cancer (1996) pmid: 8664030', 'Include': 'true'}, {'number': '183', 'ReferenceId': '21116760', 'FullCitation': 'Gonçalves AR, et al. Pathol. Oncol. Res. (2011) pmid: 21116760', 'Include': 'true'}, {'number': '184', 'ReferenceId': '17760650', 'FullCitation': 'Han U, et al. Dis. Esophagus (2007) pmid: 17760650', 'Include': 'true'}, {'number': '185', 'ReferenceId': '19941080', 'FullCitation': 'Yamasaki M, et al. Ann. Surg. Oncol. (2010) pmid: 19941080', 'Include': 'true'}, {'number': '186', 'ReferenceId': '23285001', 'FullCitation': 'Liu X, et al. PLoS ONE (2012) pmid: 23285001', 'Include': 'true'}, {'number': '187', 'ReferenceId': '18751407', 'FullCitation': 'Wiksten JP, et al. Anticancer Res. () pmid: 18751407', 'Include': 'true'}, {'number': '188', 'ReferenceId': '15254976', 'FullCitation': 'Migliavacca M, et al. J. Cell. Physiol. (2004) pmid: 15254976', 'Include': 'true'}, {'number': '189', 'ReferenceId': '20107315', 'FullCitation': 'Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315', 'Include': 'true'}, {'number': '190', 'ReferenceId': '21799033', 'FullCitation': 'Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033', 'Include': 'true'}, {'number': '191', 'ReferenceId': '21389100', 'FullCitation': 'Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100', 'Include': 'true'}, {'number': '192', 'ReferenceId': '25504633', 'FullCitation': 'Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633', 'Include': 'true'}, {'number': '193', 'ReferenceId': '12489850', 'FullCitation': 'Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850', 'Include': 'true'}, {'number': '194', 'ReferenceId': '11713371', 'FullCitation': 'Xu L, et al. Mol. Med. (2001) pmid: 11713371', 'Include': 'true'}, {'number': '195', 'ReferenceId': '23470564', 'FullCitation': 'Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564', 'Include': 'true'}, {'number': '196', 'ReferenceId': '25240597', 'FullCitation': 'Kim SS, et al. Nanomedicine (2015) pmid: 25240597', 'Include': 'true'}, {'number': '197', 'ReferenceId': '27357628', 'FullCitation': 'Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628', 'Include': 'true'}, {'number': '198', 'ReferenceId': '27601554', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554', 'Include': 'true'}, {'number': '199', 'ReferenceId': '27998224', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224', 'Include': 'true'}, {'number': '200', 'ReferenceId': '31315834', 'FullCitation': 'Lee J, et al. Cancer Discov (2019) pmid: 31315834', 'Include': 'true'}, {'number': '201', 'ReferenceId': '29535125', 'FullCitation': 'Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125', 'Include': 'true'}, {'number': '202', 'ReferenceId': '34538072', 'FullCitation': 'Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072', 'Include': 'true'}, {'number': '203', 'ReferenceId': '36084396', 'FullCitation': 'Park H, et al. ESMO Open (2022) pmid: 36084396', 'Include': 'true'}, {'number': '204', 'ReferenceId': '29165669', 'FullCitation': 'Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669', 'Include': 'true'}, {'number': '205', 'ReferenceId': '26014290', 'FullCitation': 'Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290', 'Include': 'true'}, {'number': '206', 'ReferenceId': '23355100', 'FullCitation': 'Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100', 'Include': 'true'}, {'number': '207', 'ReferenceId': '11219776', 'FullCitation': 'Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776', 'Include': 'true'}, {'number': '208', 'ReferenceId': '9006316', 'FullCitation': 'Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316', 'Include': 'true'}, {'number': '209', 'ReferenceId': '19204208', 'FullCitation': 'Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208', 'Include': 'true'}, {'number': '210', 'ReferenceId': '12672316', 'FullCitation': 'Lalloo F, et al. Lancet (2003) pmid: 12672316', 'Include': 'true'}, {'number': '211', 'ReferenceId': '31050713', 'FullCitation': 'Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713', 'Include': 'true'}, {'number': '212', 'ReferenceId': '25426837', 'FullCitation': 'Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837', 'Include': 'true'}, {'number': '213', 'ReferenceId': '25426838', 'FullCitation': 'Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838', 'Include': 'true'}, {'number': '214', 'ReferenceId': '25326804', 'FullCitation': 'Xie M, et al. Nat. Med. (2014) pmid: 25326804', 'Include': 'true'}, {'number': '215', 'ReferenceId': '28669404', 'FullCitation': 'Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404', 'Include': 'true'}, {'number': '216', 'ReferenceId': '29678827', 'FullCitation': 'Severson EA, et al. Blood (2018) pmid: 29678827', 'Include': 'true'}, {'number': '217', 'ReferenceId': '29420212', 'FullCitation': 'Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212', 'Include': 'true'}, {'number': '218', 'ReferenceId': '30504320', 'FullCitation': 'Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320', 'Include': 'true'}, {'number': '219', 'ReferenceId': '32269342', 'FullCitation': 'Chabon JJ, et al. Nature (2020) pmid: 32269342', 'Include': 'true'}, {'number': '220', 'ReferenceId': '31768066', 'FullCitation': 'Razavi P, et al. Nat. Med. (2019) pmid: 31768066', 'Include': 'true'}, {'number': '221', 'ReferenceId': '11780067', 'FullCitation': 'Lemon B, et al. Nature () pmid: 11780067', 'Include': 'true'}, {'number': '222', 'ReferenceId': '21248752', 'FullCitation': 'Varela I, et al. Nature (2011) pmid: 21248752', 'Include': 'true'}, {'number': '223', 'ReferenceId': '24185509', 'FullCitation': 'Jiao Y, et al. Nat. Genet. (2013) pmid: 24185509', 'Include': 'true'}, {'number': '224', 'ReferenceId': '18339845', 'FullCitation': 'Xia W, et al. Cancer Res. (2008) pmid: 18339845', 'Include': 'true'}, {'number': '225', 'ReferenceId': '28921948', 'FullCitation': 'Hopson S, et al. ACS Chem. Biol. (2017) pmid: 28921948', 'Include': 'true'}, {'number': '226', 'ReferenceId': '28053089', 'FullCitation': 'Porter EG, et al. J. Biol. Chem. (2017) pmid: 28053089', 'Include': 'true'}, {'number': '227', 'ReferenceId': '26117423', 'FullCitation': 'Niimi A, et al. Mutat. Res. (2015) pmid: 26117423', 'Include': 'true'}, {'number': '228', 'ReferenceId': '24613357', 'FullCitation': 'Brownlee PM, et al. Cell Rep (2014) pmid: 24613357', 'Include': 'true'}, {'number': '229', 'ReferenceId': '25066234', 'FullCitation': 'Kakarougkas A, et al. Mol. Cell (2014) pmid: 25066234', 'Include': 'true'}, {'number': '230', 'ReferenceId': '28082722', 'FullCitation': 'Gao W, et al. Proc. Natl. Acad. Sci. U.S.A. (2017) pmid: 28082722', 'Include': 'true'}, {'number': '231', 'ReferenceId': '25636086', 'FullCitation': 'Fujimoto A, et al. Nat Commun (2015) pmid: 25636086', 'Include': 'true'}, {'number': '232', 'ReferenceId': '25536104', 'FullCitation': 'Churi CR, et al. PLoS ONE (2014) pmid: 25536104', 'Include': 'true'}, {'number': '233', 'ReferenceId': '24867389', 'FullCitation': 'Simbolo M, et al. Oncotarget (2014) pmid: 24867389', 'Include': 'true'}, {'number': '234', 'ReferenceId': '24476821', 'FullCitation': 'Nature (2014) pmid: 24476821', 'Include': 'true'}, {'number': '235', 'ReferenceId': '28988769', 'FullCitation': 'Robertson AG, et al. Cell (2017) pmid: 28988769', 'Include': 'true'}, {'number': '236', 'ReferenceId': '28583311', 'FullCitation': 'Pietzak EJ, et al. Eur. Urol. (2017) pmid: 28583311', 'Include': 'true'}, {'number': '237', 'ReferenceId': '32405805', 'FullCitation': 'Williams EA, et al. Acta Neuropathol. (2020) pmid: 32405805', 'Include': 'true'}, {'number': '238', 'ReferenceId': '24974848', 'FullCitation': 'Petrini I, et al. Nat. Genet. (2014) pmid: 24974848', 'Include': 'true'}, {'number': '239', 'ReferenceId': '24053427', 'FullCitation': 'da Costa WH, et al. BJU Int. (2014) pmid: 24053427', 'Include': 'true'}, {'number': '240', 'ReferenceId': '22949125', 'FullCitation': 'Pawłowski R, et al. Int. J. Cancer (2013) pmid: 22949125', 'Include': 'true'}, {'number': '241', 'ReferenceId': '23036577', 'FullCitation': 'Hakimi AA, et al. Eur. Urol. (2013) pmid: 23036577', 'Include': 'true'}, {'number': '242', 'ReferenceId': '23229642', 'FullCitation': 'Numata M, et al. Int. J. Oncol. (2013) pmid: 23229642', 'Include': 'true'}, {'number': '243', 'ReferenceId': '23620406', 'FullCitation': 'Hakimi AA, et al. Clin. Cancer Res. (2013) pmid: 23620406', 'Include': 'true'}, {'number': '244', 'ReferenceId': '22683710', 'FullCitation': 'Peña_Llopis S, et al. Nat. Genet. (2012) pmid: 22683710', 'Include': 'true'}, {'number': '245', 'ReferenceId': '23333114', 'FullCitation': 'Kapur P, et al. Lancet Oncol. (2013) pmid: 23333114', 'Include': 'true'}, {'number': '246', 'ReferenceId': '31486842', 'FullCitation': 'Braun DA, et al. JAMA Oncol (2019) pmid: 31486842', 'Include': 'true'}, {'number': '247', 'ReferenceId': '32472114', 'FullCitation': 'Braun DA, et al. Nat Med (2020) pmid: 32472114', 'Include': 'true'}, {'number': '248', 'ReferenceId': '29301960', 'FullCitation': 'Miao D, et al. Science (2018) pmid: 29301960', 'Include': 'true'}, {'number': '249', 'ReferenceId': '32321774', 'FullCitation': 'Abou Alaiwi S, et al. Cancer Immunol Res (2020) pmid: 32321774', 'Include': 'true'}, {'number': '250', 'ReferenceId': '32820162', 'FullCitation': 'Hakimi AA, et al. Nat Commun (2020) pmid: 32820162', 'Include': 'true'}, {'number': '251', 'ReferenceId': '30150660', 'FullCitation': 'Miao D, et al. Nat. Genet. (2018) pmid: 30150660', 'Include': 'true'}, {'number': '252', 'ReferenceId': '33850862', 'FullCitation': 'Yang Q, et al. Ann Transl Med (2021) pmid: 33850862', 'Include': 'true'}, {'number': '253', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '254', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '255', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '256', 'ReferenceId': '15209621', 'FullCitation': 'Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621', 'Include': 'true'}, {'number': '257', 'ReferenceId': '9537253', 'FullCitation': 'Wu MS, et al. Cancer Res. (1998) pmid: 9537253', 'Include': 'true'}, {'number': '258', 'ReferenceId': '8536886', 'FullCitation': 'dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886', 'Include': 'true'}, {'number': '259', 'ReferenceId': '23555086', 'FullCitation': 'Fang WL, et al. Biomed Res Int (2013) pmid: 23555086', 'Include': 'true'}, {'number': '260', 'ReferenceId': '19621725', 'FullCitation': 'Gu M, et al. Hepatogastroenterology () pmid: 19621725', 'Include': 'true'}, {'number': '261', 'ReferenceId': '22866067', 'FullCitation': 'Sasaki S, et al. Oncol Lett (2011) pmid: 22866067', 'Include': 'true'}, {'number': '262', 'ReferenceId': '10070967', 'FullCitation': 'Fleisher AS, et al. Cancer Res. (1999) pmid: 10070967', 'Include': 'true'}, {'number': '263', 'ReferenceId': '21045259', 'FullCitation': 'Vasavi M, et al. Cancer Biomark (2010) pmid: 21045259', 'Include': 'true'}, {'number': '264', 'ReferenceId': '24035280', 'FullCitation': 'Zhang LH, et al. Pathol. Res. Pract. (2013) pmid: 24035280', 'Include': 'true'}, {'number': '265', 'ReferenceId': '26137290', 'FullCitation': 'Zhu L, et al. Mol Clin Oncol (2015) pmid: 26137290', 'Include': 'true'}, {'number': '266', 'ReferenceId': '9892201', 'FullCitation': 'Leung SY, et al. Cancer Res. (1999) pmid: 9892201', 'Include': 'true'}, {'number': '267', 'ReferenceId': '26078567', 'FullCitation': 'Seo JY, et al. World J. Gastroenterol. (2015) pmid: 26078567', 'Include': 'true'}, {'number': '268', 'ReferenceId': '31513484', 'FullCitation': 'Pietrantonio F, et al. J. Clin. Oncol. (2019) pmid: 31513484', 'Include': 'true'}, {'number': '269', 'ReferenceId': '17204026', 'FullCitation': 'Histopathology (2007) pmid: 17204026', 'Include': 'true'}, {'number': '270', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '271', 'ReferenceId': '28734759', 'FullCitation': 'Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759', 'Include': 'true'}, {'number': '272', 'ReferenceId': '29355075', 'FullCitation': 'Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075', 'Include': 'true'}, {'number': '273', 'ReferenceId': '35322232', 'FullCitation': 'Shitara K, et al. Nature (2022) pmid: 35322232', 'Include': 'true'}, {'number': '274', 'ReferenceId': '23169436', 'FullCitation': 'Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436', 'Include': 'true'}, {'number': '275', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '276', 'ReferenceId': '33001143', 'FullCitation': 'Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143', 'Include': 'true'}, {'number': '277', 'ReferenceId': '36512912', 'FullCitation': 'Rubinstein MM, et al. Gynecol Oncol (2022) pmid: 36512912', 'Include': 'true'}, {'number': '278', 'ReferenceId': '33811152', 'FullCitation': 'Kanikarla Marie P, et al. Clin Cancer Res (2021) pmid: 33811152', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2023_05_25 19:42:14', 'OpName': 'J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': 'N/A'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': '14 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': '69%'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'STOMACH', 'disease_ontology': 'Stomach adenocarcinoma (NOS)', 'flowcell_analysis': '2000029221', 'gender': 'male', 'pathology_diagnosis': 'Stomach cancer.', 'pipeline_version': 'v3.22.0', 'purity_assessment': '82.16', 'specimen': 'ORD_1632719_01*US1557183.01', 'study': 'CLINICAL_F1LCDx', 'test_request': 'ORD_1632719_01', 'test_type': 'FoundationOneLiquidDx', 'tissue_of_origin': 'Blood', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'AB1', 'name': 'SQ_US1557183.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.5671', 'cds_effect': '2531G>C', 'depth': '4957', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RET', 'percent_reads': '56.71', 'position': 'chr10:43615117', 'protein_effect': 'R844P', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_020975', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.0044', 'cds_effect': '252C>A', 'depth': '1575', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'LYN', 'percent_reads': '0.44', 'position': 'chr8:56860250', 'protein_effect': 'F84L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002350', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.6984', 'cds_effect': '182T>C', 'depth': '756', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SMAD4', 'percent_reads': '69.84', 'position': 'chr18:48573598', 'protein_effect': 'I61T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005359', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.0059', 'cds_effect': '463C>T', 'depth': '1018', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FBXW7', 'percent_reads': '0.59', 'position': 'chr4:153332493', 'protein_effect': 'H155Y', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_033632', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.0054', 'cds_effect': '1063G>C', 'depth': '7999', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GNAS', 'percent_reads': '0.54', 'position': 'chr20:57429383', 'protein_effect': 'E355Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_080425', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.1364', 'cds_effect': '1261C>T', 'depth': '711', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NOTCH3', 'percent_reads': '13.64', 'position': 'chr19:15299917', 'protein_effect': 'R421C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000435', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.4657', 'cds_effect': '453C>G', 'depth': '1675', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NTRK1', 'percent_reads': '46.57', 'position': 'chr1:156837920', 'protein_effect': 'H151Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002529', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.0059', 'cds_effect': '802T>A', 'depth': '1352', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GABRA6', 'percent_reads': '0.59', 'position': 'chr5:161117335', 'protein_effect': 'S268T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000811', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.4986', 'cds_effect': '3706C>T', 'depth': '1093', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MAP3K1', 'percent_reads': '49.86', 'position': 'chr5:56179393', 'protein_effect': 'P1236S', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005921', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.346', 'cds_effect': '1907C>T', 'depth': '6223', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RET', 'percent_reads': '34.6', 'position': 'chr10:43609955', 'protein_effect': 'T636M', 'status': 'known', 'strand': '+', 'transcript': 'NM_020975', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.0028', 'cds_effect': '211C>A', 'depth': '1774', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FAM46C', 'percent_reads': '0.28', 'position': 'chr1:118165701', 'protein_effect': 'L71M', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_017709', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.0079', 'cds_effect': '965C>T', 'depth': '889', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KEAP1', 'percent_reads': '0.79', 'position': 'chr19:10602613', 'protein_effect': 'P322L', 'status': 'known', 'strand': '_', 'transcript': 'NM_012289', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.0011', 'cds_effect': '6187G>A', 'depth': '6628', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATM', 'percent_reads': '0.11', 'position': 'chr11:108186829', 'protein_effect': 'G2063R', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000051', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.4222', 'cds_effect': '2266G>A', 'depth': '2589', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SNCAIP', 'percent_reads': '42.22', 'position': 'chr5:121786808', 'protein_effect': 'E756K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005460', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.7243', 'cds_effect': '94G>A', 'depth': '2630', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CTNNB1', 'percent_reads': '72.43', 'position': 'chr3:41266097', 'protein_effect': 'D32N', 'status': 'known', 'strand': '+', 'transcript': 'NM_001904', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.0089', 'cds_effect': '1209_1213delAATAG', 'depth': '674', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'PBRM1', 'percent_reads': '0.89', 'position': 'chr3:52668705', 'protein_effect': 'I404fs*1', 'status': 'likely', 'strand': '_', 'transcript': 'NM_018313', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.4529', 'cds_effect': '1306C>G', 'depth': '2091', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'REL', 'percent_reads': '45.29', 'position': 'chr2:61149116', 'protein_effect': 'L436V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002908', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.0093', 'cds_effect': '3727_3728TG>CT', 'depth': '3125', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '0.93', 'position': 'chr2:212248539', 'protein_effect': 'W1243L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.7593', 'cds_effect': '844C>T', 'depth': '3643', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TP53', 'percent_reads': '75.93', 'position': 'chr17:7577094', 'protein_effect': 'R282W', 'status': 'known', 'strand': '_', 'transcript': 'NM_000546', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.0044', 'cds_effect': '2198C>G', 'depth': '908', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RICTOR', 'percent_reads': '0.44', 'position': 'chr5:38958914', 'protein_effect': 'T733R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_152756', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.4865', 'cds_effect': '974G>A', 'depth': '1295', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IRF2', 'percent_reads': '48.65', 'position': 'chr4:185309988', 'protein_effect': 'R325Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002199', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.0057', 'cds_effect': '536G>A', 'depth': '1226', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MAP3K1', 'percent_reads': '0.57', 'position': 'chr5:56152480', 'protein_effect': 'R179H', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005921', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.5291', 'cds_effect': '2425G>A', 'depth': '1652', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MSH2', 'percent_reads': '52.91', 'position': 'chr2:47705625', 'protein_effect': 'E809K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000251', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'allele_fraction': '0.4215', 'cds_effect': '266C>T', 'depth': '4849', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'APC', 'percent_reads': '42.15', 'position': 'chr5:112102931', 'protein_effect': 'S89L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000038', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}]}, 'copy_number_alterations': None, 'rearrangements': {'rearrangement': {'allele_fraction': '0.0028', 'description': 'SRC(NM_005417) inversion exon 5 _ intron 13', 'equivocal': 'false', 'in_frame': 'unknown', 'other_gene': 'SRC', 'percent_reads': '0.28', 'pos1': 'chr20:36014511', 'pos2': 'chr20:36031300', 'status': 'unknown', 'supporting_read_pairs': '5', 'targeted_gene': 'SRC', 'type': 'rearrangement', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}}, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '13.91', 'status': 'intermediate', 'unit': 'mutations_per_megabase'}}, 'non_human_content': {'non_human': [{'organism': 'HHV_8', 'reads_per_million': '85', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'organism': 'HPV_18', 'reads_per_million': '42', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'organism': 'HHV_4', 'reads_per_million': '2170', 'status': 'likely', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'organism': 'HPV_6', 'reads_per_million': '30', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}, {'organism': 'HPV_16', 'reads_per_million': '263', 'status': 'likely', 'dna_evidence': {'sample': 'SQ_US1557183.01_1'}}]}}}}}	M112-10120          	PF23058             
7	363	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2023_00029501', 'CSN': None, 'TRF': 'ORD_1631801_01', 'MRN': '49487516', 'PhysicianId': '109266', 'NPI': None}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1322190', 'clinicalId': '1323537', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1631801_01', 'SampleName': 'US1556823.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1631801_01', 'SampleId': 'US1556823.01', 'BlockId': 'S112_20568 A (PF23056)', 'TRFNumber': 'ORD_1631801_01', 'TestType': 'FoundationOne CDX', 'SpecFormat': 'Slide Deck', 'ReceivedDate': '2023_05_17', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}]}}, 'PMI': {'ReportId': 'ORD_1631801_01', 'MRN': '49487516', 'FullName': 'Chen, Hsiao Ting', 'FirstName': 'Hsiao Ting', 'LastName': 'Chen', 'SubmittedDiagnosis': 'Kidney urothelial carcinoma', 'Gender': 'Female', 'DOB': '1981_01_20', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Kidney', 'CollDate': '2023_05_08', 'ReceivedDate': '2023_05_17', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': {'PertinentNegative': [{'Gene': 'FGFR2'}, {'Gene': 'FGFR3'}]}, 'Summaries': {'alterationCount': '21', 'clinicalTrialCount': '20', 'resistiveCount': '0', 'sensitizingCount': '9'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'AR', 'isVUS': 'true', 'variantName': 'S176R'}, {'geneName': 'AXIN1', 'isVUS': 'true', 'variantName': 'V849I'}, {'geneName': 'CHEK2', 'isVUS': 'true', 'variantName': 'V463F'}, {'geneName': 'CSF3R', 'isVUS': 'true', 'variantName': 'E206Q'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'splice site 1717_2A>T'}, {'geneName': 'FGFR4', 'isVUS': 'true', 'variantName': 'D709G'}, {'geneName': 'JAK1', 'isVUS': 'true', 'variantName': 'R69C'}, {'geneName': 'KLHL6', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'KMT2D (MLL2)', 'isVUS': 'true', 'variantName': 'P4916L'}, {'geneName': 'MST1R', 'isVUS': 'true', 'variantName': 'rearrangement'}, {'geneName': 'PDGFRA', 'isVUS': 'true', 'variantName': 'L875Q'}, {'geneName': 'ROS1', 'isVUS': 'true', 'variantName': 'W1361R'}, {'geneName': 'SRC', 'isVUS': 'true', 'variantName': 'A79V'}, {'geneName': 'TENT5C (FAM46C)', 'isVUS': 'true', 'variantName': 'M215L'}, {'geneName': 'ZNF703', 'isVUS': 'true', 'variantName': 'S395C'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'ARID1A', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'E966*', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '82.99', 'isEquivocal': 'false', 'name': 'E966*'}}, 'Interpretation': 'ARID1A encodes the AT_rich interactive domain_containing protein 1A, also known as Baf250a, a member of the SWI/SNF chromatin remodeling complex. Mutation, loss, or inactivation of ARID1A has been reported in many cancers, and the gene is considered a tumor suppressor (Guan et al., 2011; 21900401, Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Yan et al., 2014; 24293408, Wang et al., 2012; 22808142, Huang et al., 2012; 22922871, Chan_On et al., 2013; 24185513, Mamo et al., 2012; 21892209). ARID1A mutations, which are mostly truncating, have been identified along the entire gene and often correlate with ARID1A protein loss (Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Zang et al., 2012; 22484628, Wang et al., 2011; 22037554), whereas ARID1A missense mutations are mostly uncharacterized. ARID1A alterations are particularly prevalent in ovarian clear cell carcinoma (46_50%), ovarian and uterine endometrioid carcinomas (24_44%), and cholangiocarcinoma (27%); they are also reported in up to 27% of gastric carcinoma, esophageal adenocarcinoma, Waldenstrom macroglobulinemia, pediatric Burkitt lymphoma, hepatocellular carcinoma, colorectal carcinoma, and urothelial carcinoma samples analyzed (COSMIC, cBioPortal, 2023) (Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Wu et al., 2014; 24618703, Jones et al., 2012; 22009941, Dulak et al., 2013; 23525077, Streppel et al., 2013; 23318448, Jiao et al., 2014; 24293293, Ross et al., 2014; 24563076). ARID1A loss is associated with microsatellite instability in ovarian and endometrial endometrioid adenocarcinomas (Huang et al., 2014; 25195947, Hussein et al., 2014; 25394778, Bosse et al., 2013; 23702729, Allo et al., 2014; 23887303, Okamura et al., 2020; 32111729), CRC (Chou et al., 2014; 24925223, Ye et al., 2014; 25311944, Wei et al., 2014; 25561809, Okamura et al., 2020; 32111729), and gastric cancer (Chen et al., 2015; 25583476, Wang et al., 2011; 22037554, Abe et al., 2012; 22915242, Wang et al., 2012; 22808142, Wiegand et al., 2014; 24767857, Okamura et al., 2020; 32111729). In the context of urothelial carcinomas, one study reported no association between ARID1A mutation and tumor grade (Gui et al., 2011; 21822268), whereas others have reported contradictory associations between ARID1A protein loss and prognosis (Balbás_Martínez et al., 2013; 23650517, Faraj et al., 2014; 25175170). There are no therapies approved to address the mutation or loss of ARID1A in cancer. However, on the basis of limited clinical and preclinical evidence, ARID1A inactivating mutations may lead to sensitivity to ATR inhibitors such as M6620 and ceralasertib (Williamson et al., 2016; 27958275). In a Phase 2 study of ceralasertib in solid tumors, 2 patients with endometrial carcinoma in the cohort with loss of ARID1A expression achieved CRs on ceralasertib monotherapy; at least 1 of these 2 patients carried an inactivating ARID1A mutation. In contrast, no responses were observed for patients with normal ARID1A expression treated with ceralasertib combined with olaparib (Aggarwal et al., 2021; ESMO Abstract 512O). One patient with small cell lung cancer harboring an ARID1A mutation experienced a PR when treated with M6620 combined with topotecan (Thomas et al., 2018; 29252124). In a Phase 1 trial, a patient with metastatic colorectal cancer (CRC) harboring both an ARID1A mutation and ATM loss treated with single_agent M6620 achieved a CR that was ongoing at 29 months (Yap et al., 2020; 32568634). On the basis of limited clinical and preclinical evidence, ARID1A inactivation may predict sensitivity to EZH2 inhibitors (Papadopoulos et al., 2022; ENA Abstract 188, Bitler et al., 2015; 25686104, Kim et al., 2015; 26552009). A Phase 1 study of EZH2 inhibitor CPI_0209 reported 1 PR for a patient with ARID1A_mutated endometrial cancer (Papadopoulos et al., 2022; ENA Abstract 188). Other studies have reported that the loss of ARID1A may activate the PI3K_AKT pathway and be linked with sensitivity to inhibitors of this pathway (Wiegand et al., 2014; 24559118, Huang et al., 2014; 24336158, Samartzis et al., 2014; 24979463). Patients with ARID1A alterations in advanced or metastatic solid tumors may derive benefit from treatment with anti_PD_1 or anti_PD_L1 immunotherapy (Okamura et al., 2020; 32111729). Loss of ARID1A expression has been associated with chemoresistance to platinum_based therapy for patients with ovarian clear cell carcinoma (Yokoyama et al., 2014; 24459582, Katagiri et al., 2012; 22101352) and to 5_fluorouracil in CRC cell lines (Xie et al., 2014; 24833095). Limited clinical evidence indicates that ARID1A_altered urothelial cancer may be sensitive to pan_HDAC inhibitors; a retrospective analysis reported a CR to belinostat and a PR to panobinostat in patients with ARID1A alterations (Gupta et al., 2019; 30301863).', 'Include': 'true', 'ClinicalTrialNote': 'ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT05166577', 'Include': 'true'}, {'nctId': 'NCT02264678', 'Include': 'true'}, {'nctId': 'NCT05320640', 'Include': 'true'}, {'nctId': 'NCT04802174', 'Include': 'true'}, {'nctId': 'NCT04657068', 'Include': 'true'}, {'nctId': 'NCT04514497', 'Include': 'true'}, {'nctId': 'NCT05053971', 'Include': 'true'}, {'nctId': 'NCT03669601', 'Include': 'true'}, {'nctId': 'NCT01543763', 'Include': 'true'}, {'nctId': 'NCT04491942', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'TP53', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Y220C', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '82', 'isEquivocal': 'false', 'name': 'Y220C'}}, 'Interpretation': 'Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 Y220C is targetable by mutation_specific inhibitors such as PC14586 (Dumbrava et al., 2022; ASCO Abstract 3003). TP53 mutation has been reported in 49–54% of bladder urothelial carcinoma (UC) (Ross et al., 2013; 23887298, Cancer Genome Atlas Research Network, 2014; 24476821), 33% of renal pelvis UC (Bringuier et al., 1998; 9761125), and 25% (22/71) of ureter UC samples (Furihata et al., 2000; 10675480). Expression of p53 has been correlated with TP53 mutation, and reported in 52–84% of bladder cancers (Esrig et al., 1993; 7901994, Cordon_Cardo et al., 1994; 7906253, Diaz_Cano et al., 2000; 10744064, Kapur et al., 2011; 21571954, Lotan et al., 2013; 23571005, Kim et al., 2014; 25092538), 48% (24/50) bladder SCCs (El_Kenawy et al., 2003; 14756544), 36–53% of upper urinary tract UCs (UTUC) (Joung et al., 2008; 18931548, Jinza et al., 1998; 9644783, Kamijima et al., 2005; 16351648), and in 4/4 urethral clear cell carcinomas (Alexiev et al., 2013; 23307189). TP53 mutations in both bladder and renal pelvis urothelial carcinoma (UC) are more common in invasive tumors (Bringuier et al., 1998; 9761125, Goebell and Knowles, 2010; 20610279, Lindgren et al., 2012; 22685613, Kim et al., 2014; 25092538), and have been associated with inferior survival in patients with renal pelvis UC (Bringuier et al., 1998; 9761125) or upper tract UC (UTUC) (Feng et al., 2014; 24500328). Alterations to the p53 pathway are correlated with aggressive disease and poor prognosis in bladder cancer (Eissa et al., 2010; 20012564, Mitra et al., 2007; 17710407, Lambrou et al., 2013; 23624844), and p53 overexpression has been linked to poor progression_free survival in UTUC (Lee et al., 2013; 23482786, Feng et al., 2014; 24500328), disease progression in UC of the renal pelvis and ureter (Hashimoto et al., 2000; 11168685), and higher tumor grade in bladder squamous cell carcinoma (Osman et al., 1997; 9815716, Helal et al., 2006; 16998598, Jalali et al., 2011; 22126554). For patients with TP53 Y220C_mutated disease, a Phase 1 study of the Y220C_specific reactivator PC14586 reported an ORR of 32% (8/25) and DCR of 88% (22/25) at higher doses across a variety of solid tumor types (Dumbrava et al., 2022; ASCO Abstract 3003). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Apr 2023)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': 'Clinical evidence suggests patients with TP53 Y220C mutations may benefit from Y220C_specific reactivators of TP53.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': {'nctId': 'NCT04585750', 'Include': 'true'}}}}, 'ReferenceLinks': None}, {'Name': 'Tumor Mutation Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '12', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '12'}}, 'Interpretation': 'Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level that may be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors in urothelial carcinoma (Galsky et al., 2017; ESMO Abstract 848PD, Necchi et al., 2018; AACR Abstract CT003, Rosenberg et al., 2016; 26952546, Balar et al., 2017; 27939400, Powles et al., 2018; 29268948, Mariathasan et al., 2018; 29443960, Miao et al., 2018; 30150660, Samstein et al., 2019; 30643254, Sarid et al., 2019; ESMO Abstract 938, Marabelle et al., 2020; 32919526). In the Bladder Urothelial Carcinoma TCGA dataset, the median somatic mutation burden was 5.5 mutations per megabase (muts/Mb)(Cancer Genome Atlas Research Network, 2014; 24476821). One study reported that the number of somatic mutations positively correlates with increased tumor stage and grade of bladder cancers (Cazier et al., 2016; 24777035). For patients with metastatic urothelial carcinoma receiving atezolizumab, however, higher median mutation load has been reported to be significantly associated with improved PFS and OS (Rosenberg et al., 2016; ASCO Abstract 104, Rosenberg et al., 2016; 26952546, Balar et al., 2017; 27939400). Another study for patients with urothelial bladder carcinoma showed that high tumor mutational burden (TMB) was associated with superior OS and disease_specific survival compared with low TMB; the OS benefit of high TMB was driven by the cohort with Stage 3 disease, whereas OS was similar between low and high TMB for patients with Stage 2 or Stage 4 disease (Voutsadakis, 2022; 35323317). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple studies of immune checkpoint inhibitors in urothelial carcinoma, higher TMB has corresponded with clinical benefit from treatment with anti_PD_L1 (Rosenberg et al., 2016; 26952546, Balar et al., 2017; 27939400, Powles et al., 2018; 29268948, Mariathasan et al., 2018; 29443960, Samstein et al., 2019; 30643254, Miao et al., 2018; 30150660) and anti_PD_1 immunotherapeutic agents (Galsky et al., 2017; ESMO Abstract 848PD, Necchi et al., 2018; AACR Abstract CT003). For patients with metastatic urothelial carcinoma treated with the PD_L1 inhibitor atezolizumab, those with a significantly increased mutational load (9.7 Muts/Mb or greater by this assay or others) were associated with response and longer OS compared with those with lower TMB (Rosenberg et al., 2016; 26952546, Powles et al., 2018; 29268948, Balar et al., 2017; 27939400, Samstein et al., 2019; 30643254). Similarly, in a study of pembrolizumab in muscle invasive bladder cancer, the median TMB in responders was 12.3 Muts/Mb, versus 7.0 Muts/Mb in nonresponding patients (Necchi et al., 2018; AACR Abstract CT003). The PD_1 inhibitor nivolumab led to increased ORR, PFS, and OS for patients with a TMB of 167 missense mutations/tumor or higher (~ equivalency = 9 Muts/Mb or higher as measured by this assay) compared with those harboring lower TMB in a study of metastatic urothelial cancer (Galsky et al., 2017; ESMO Abstract 848PD).', 'Include': 'true', 'ClinicalTrialNote': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Pembrolizumab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Pembrolizumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved for patients with tumor mutational burden_high (≥10 Muts/Mb), microsatellite instability_high (MSI_H), or MMR_deficient (dMMR) solid tumors; as monotherapy for PD_L1_positive head and neck squamous cell cancer (HNSCC), cervical cancer, or esophageal cancer; and in combination with chemotherapy for PD_L1_positive triple_negative breast cancer (TNBC) or cervical cancer. It is also approved in various treatment settings as monotherapy for patients with non_small cell lung cancer (NSCLC), melanoma, HNSCC, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma, MSI_H or dMMR endometrial carcinoma, classical Hodgkin lymphoma, or primary mediastinal large B_cell lymphoma; and in combination with chemotherapy or targeted therapy for NSCLC, HNSCC, esophageal or gastroesophageal junction cancer, renal cell carcinoma, TNBC, urothelial carcinoma, or endometrial carcinoma that is not MSI_H or dMMR. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In the Phase 2 PURE_01 study of neoadjuvant pembrolizumab for muscle_invasive bladder urothelial carcinoma, TMB was significantly associated with the probability of pathologic CR (pCR) but was not an independent marker of pCR probability (Bandini et al., 2020; 32516377). For TMB ≤11 Muts/Mb, the probability of pCR was not dependent on the PD_L1 combined positive score (CPS); however, increased CPS was associated with increased pCR probability for TMB >11 Muts/Mb (Bandini et al., 2020; 32516377). The Phase 3 KEYNOTE_045 trial for patients with platinum_refractory advanced urothelial carcinoma (UC) found second_line pembrolizumab superior to chemotherapy (median OS [mOS] 10.1 vs. 7.2 months, HR=0.71; 4_year OS rate 17% vs. 10%) (Balar et al., 2022; 36494006, Bellmunt et al., 2017; 28212060). For cisplatin_ineligible patients with advanced UC, first_line pembrolizumab monotherapy achieved an ORR of 29% and mOS of 11.3 months, with improved clinical benefit observed for patients with a PD_L1 combined positive score (CPS) ≥10 compared with patients with PD_L1 CPS <10 (mOS 18.5 vs. 9.7 months, ORR 47% vs. 21%) (Balar et al., 2022; 36494006); pembrolizumab combined with the Nectin 4_directed antibody drug conjugate enfortumab vedotin has benefited patients in this setting irrespective of PD_L1 expression (ORR 65_73%, mOS 26.1 months) (O Donnell et al., 2023; ASCO GU Abstract 499, Hoimes et al., 2023; 36041086). The EV_103/KEYNOTE_869 trial reported an ORR of 65% (49/76) for cisplatin_ineligible patients, including 61% (27/44) for patients with PD_L1 expression of CPS <10 (O Donnell et al., 2023; ASCO GU Abstract 499). The Phase 3 KEYNOTE_361 study investigating first_line pembrolizumab for advanced UC reported similar mOS for patients treated with single_agent pembrolizumab versus platinum_containing chemotherapy (15.6 vs. 14.3 months, HR=0.92) irrespective of PD_L1 CPS ≥10 (16.1 vs. 15.2 months, HR=1.01) and found that the addition of pembrolizumab to chemotherapy was not superior to chemotherapy (mOS 17.0 vs. 14.3 months, HR=0.86) (Powles et al., 2021; 34051178). A post_hoc analysis of first_line pembrolizumab monotherapy efficacy reported that patients with a CR or PR at 9 weeks of pembrolizumab therapy achieved better mOS outcomes (50.7 months) than patients with SD (17.5 months) or PD (5.3 months) as best response (Powles et al., 2022; ASCO Abstract 519). A Phase 2 study investigated neoadjuvant pembrolizumab followed by radical cystectomy in muscle_invasive urothelial bladder carcinoma (MIBC) and reported pathologic CRs for 42% (21/50) of patients (Necchi et al., 2018; 30343614). Three_year event_free survival rates of 60%, 77%, and 90% were reported for cohorts with PD_L1 low, medium, and high CPS, respectively (Basile et al., 2022; 36190522). The Phase 2 KEYNOTE_057 trial evaluating pembrolizumab for patients with high_risk non_MIBC unresponsive to the Bacillus Calmette_Guerin vaccine reported clinical benefit for patients with carcinoma in situ (CIS) with and without papillary tumors (cohort A) (Balar et al., 2021; 34051177) and non_CIS papillary tumors (cohort B) (Necchi et al., 2023; ASCO GU Abstract LBA442). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Nivolumab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response. It is FDA approved as a monotherapy in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, colorectal cancer (CRC), classical Hodgkin lymphoma (cHL), gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma or squamous cell carcinoma (ESCC). It is also approved in combination with chemotherapy to treat ESCC, in combination with cabozantinib to treat RCC, and in combination with relatlimab to treat melanoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Exploratory analysis of the CheckMate_274 trial suggests that adjuvant nivolumab may provide less benefit for patients with upper tract high_risk muscle_invasive urothelial carcinoma (estimated disease_free survival HR of 1.23 and 1.56 for patients with renal pelvis and ureteral primary tumors, respectively)(Bajorin et al., 2021; 34077643). Phase 1/2 and Phase 2 studies evaluating nivolumab for patients with platinum_refractory metastatic urothelial carcinoma (UC) reported ORRs of 21_26%, PFS of 1.9_2.8 months, and OS of 8.6_9.9 months (Galsky et al., 2020; 32532789, Sharma et al., 2019; 31100038, Sharma et al., 2017; 28131785, Siefker_Radtke et al., 2019; ASCO Abstract 4524). The Phase 3 CheckMate_274 study of adjuvant nivolumab versus placebo following radical surgery for patients with high_risk muscle_invasive UC reported an improved median disease_free survival (mDFS) for the intent_to_treat population (22.0 vs. 10.9 months, HR=0.71) as well as for patients with PD_L1+ tumors (tumor cell score ≥1%: 52.6 vs. 8.4 months, HR=0.52; combined positive score ≥1%: 24.6 vs. 9.4 months, HR=0.62) (Galsky et al., 2023; 36868932, Galsky et al., 2023; ASCO GU Abstract LBA443, Bajorin et al., 2021; 34077643). A Phase 2 study of nivolumab plus chemotherapy for patients with muscle_invasive bladder cancer reported a complete clinical response (cCR) rate of 43% (33/76); an exploratory biomarker analysis of this study found an association between cCR and tumor mutational burden ≥10 Muts/Mb (Galsky et al., 2023; ASCO GU Abstract 447). Combining the multikinase inhibitor cabozantinib with nivolumab or with nivolumab plus ipilimumab demonstrated activity for patients with chemotherapy_refractory metastatic UC who were immunotherapy_naive (ORR of 50% [6/12] and 22% [2/9], respectively; median PFS of 24 and 10 months, respectively); cabozantinib combined with nivolumab also benefited patients who were immunotherapy_refractory (ORR of 29% [2/7]) (Nadal et al., 2018; ASCO Abstract 4528), and responses to these combination treatments were observed for patients with bladder squamous cell carcinoma (SCC) or bladder adenocarcinoma (Nadal et al., 2018; ASCO GU Abstract 515). Addition of the IDO1 inhibitor BMS986205 to nivolumab in previously treated advanced UC elicited ORRs for 37% (3/27 CRs, 7/27 PRs) of patients who were immunotherapy_naive but no responses for 3 patients who had prior immunotherapy (Luke et al., 2019; ASCO GU Abstract 358). As first_line therapy for advanced UC, nivolumab combined with the immunostimulatory therapy bempegaldesleukin achieved an ORR of 48% (13/27, 5/27 CRs), with 50% (6/12) of patients who were PD_L1+ and 45% (5/11) of patients who were PD_L1_ responding (Siefker_Radtke et al., 2019; ASCO GU Abstract 388). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Cemiplimab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Cemiplimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC), cutaneous squamous cell carcinoma, or basal cell carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of cemiplimab for the treatment of urothelial carcinoma are limited (PubMed, Feb 2023). Cemiplimab has been studied primarily in advanced cutaneous squamous cell carcinoma (CSCC), where it elicited a combined ORR of 48% (41/85) in Phase 1 and 2 studies (Migden et al., 2018; 29863979). A Phase 2 trial of cemiplimab in patients with basal cell carcinoma (BCC) reported ORRs of 31% (5 CRs and 21 PRs) in patients with locally advanced BCC and 21% (6 PRs) in patients with metastatic BCC (Stratigos et al., 2020; EMSO Abstract LBA47, Lewis et al. 2020; doi: 10.1136/jitc_2020_SITC2020.0428). The Phase 3 EMPOWER_Lung 1 trial for advanced non_small cell lung cancer (NSCLC) with PD_L1 expression ≥50% reported that cemiplimab is associated with improved PFS (8.2 vs. 5.7 months), OS (not reached vs. 14.2 months), and ORR (37% vs. 21%) compared with chemotherapy (Sezer et al., 2020; ESMO Abstract LBA52). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Nivolumab + Ipilimumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response, and ipilimumab is a cytotoxic T_lymphocyte antigen 4 (CTLA_4)_blocking antibody. The combination is FDA approved in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), pleural mesothelioma, and esophageal squamous cell carcinoma (ESCC). Furthermore, nivolumab is approved in combination with ipilimumab to treat patients with mismatch repair_deficient (dMMR) or microsatellite instability_high (MSI_H) colorectal cancer (CRC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hodi et al., 2019; AACR abstract CT037), a TMB score of ≥10 Muts/Mb (as measured by this assay) may predict sensitivity to combination nivolumab and ipilimumab treatment. </p> <p><b>Supporting Data:</b> In a Phase 3 trial of neoadjuvant nivolumab and ipilimumab for patients with high_risk advanced urothelial carcinoma (UC), 60% (9/15) of patients with a combined positive PD_L1 score ≥10 experienced a pathologic CR compared with 22% (2/9) of patients with lower PD_L1 expression (van der Heijden et al., 2019; ESMO Abstract 904PD). A Phase 2 study of ipilimumab and nivolumab for patients with platinum_refractory metastatic UC who progressed on nivolumab monotherapy observed PRs for 23% (5/22) of patients (Keegan et al., 2019; ASCO GU Abstract 481). The Phase 1/2 CheckMate 032 trial reported a 38% ORR, a 4.9_month median PFS, and a 15.3_month median OS for patients with locally advanced or metastatic UC treated with nivolumab and ipilimumab; a 58% ORR was observed for patients with ≥1% tumor PD_L1 expression (Sharma et al., 2019; 31100038). A Phase 2 study of nivolumab in combination with ipilimumab for patients with advanced bladder cancers reported 1 CR for a patient with plasmacytoid carcinoma and 2 PRs for patients with small cell carcinoma (McGregor et al., 2019; ASCO Abstract 4518). A Phase 1 trial of nivolumab plus ipilimumab and cabozantinib for patients with refractory metastatic UC and other genitourinary cancers reported a 42% ORR among patients with metastatic UC and bladder squamous cell carcinoma (SCC) (Apolo et al., 2017; ASCO Abstract 4562). In the Phase 1 NABUCCO study of neoadjuvant ipilimumab plus nivolumab for patients with advanced urothelial cancer, 96% (23/24) of patients underwent resection within 12 weeks and 46% (11/24) had a pathological CR (Dijk et al., 2020; 33046870). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Retifanlimab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Retifanlimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with Merkel cell carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> The Phase 2 POD1UM_203 trial of retifanlimab for patients with cisplatin_ineligible locally advanced or metastatic urothelial carcinoma with PD_L1 expression (combined positive score ≥10%) reported an ORR of 38% (11/29; 1 CR, 10 PRs), median PFS of 5.7 months, and median OS of 15.2 months (Maio et al., 2021; ASCO Abstract 2571). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Dostarlimab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Dostarlimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer or solid tumors. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of dostarlimab for the treatment of urothelial carcinoma are limited (PubMed, Feb 2023). Dostarlimab has been studied primarily in recurrent and advanced mismatch repair_deficient (dMMR) endometrial and non_endometrial cancers (Andre et al., 2021; ASCO GI Abstract 9, Oaknin et al., 2020; 33001143, Berton et al., 2021; ASCO Abstract 2564). In the Phase 1 GARNET trial, single_agent dostarlimab elicited an ORR of 39% (41/106) and an immune_related ORR of 46% (50/110) for patients with non_endometrial dMMR solid tumors (Andre et al., 2021; ASCO GI Abstract 9, Andre et al., 2021; ESMO GI Abstract SO_9). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Durvalumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Durvalumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and biliary tract cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In the neoadjuvant setting, a Phase 2 study of durvalumab and olaparib yielded an ORR of 14% (4/29) for patients with muscle_invasive bladder carcinoma (Rodriguez_Moreno et al., 2020; ESMO Abstract 761P). In the first_line setting for locally advanced or metastatic urothelial carcinoma, the randomized controlled Phase 3 DANUBE study showed that durvalumab monotherapy did not significantly improve median OS (mOS) for patients with PD_L1_high tumor status compared with chemotherapy (14.4 vs. 12.1 months, HR=0.89, p=0.30) (Powles et al., 2020; 32971005, Powles et al., 2020; ESMO Abstract 697O). For chemotherapy_pretreated patients with advanced urinary tract carcinoma, the Phase 3b STRONG study of durvalumab reported an ORR of 18% and mOS of 7.0 months, with longer mOS observed for patients with high PD_L1 expression (9.3 vs. 6.5 months) (Sonpavde et al., 2021; ASCO GI Abstract 429). The Phase 2 DUART study of concurrent durvalumab and radiation therapy followed by adjuvant durvalumab for patients with locally advanced bladder urothelial carcinoma reported a 65% (13/20) ORR and a 70% (14/20) DCR; median PFS was 18.5 months and mOS was not reached, but 1_ and 2_year OS probabilities were 84% and 77%, respectively (Joshi et al., 2021; ASCO GU Abstract 398). Interim results from the Phase 2 ARCADIA study evaluating the combination of durvalumab and cabozantinib to treat patients with advanced urothelial carcinoma following progression on platinum chemotherapy reported an ORR of 38% (6/16, 2 CRs) (Marandino et al., 2021; 34006499). Combining durvalumab with matched targeted therapies (FGFR, PARP, or mTOR inhibitors) did not improve PFS or OS for patients with platinum_refractory advanced urothelial cancer in the Phase 2 BISCAY study (Powles et al., 2021; 33941921). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Avelumab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Avelumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 in order to enhance antitumor immune responses. It is FDA approved to treat patients 12 years and older with Merkel cell carcinoma, or for urothelial carcinoma in various treatment settings. The combination of avelumab and axitinib is FDA approved for patients with renal cell carcinoma (RCC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In the dose expansion phase of the Phase 1b/2 JAVELIN PARP Medley combining talazoparib with avelumab for solid tumors, patients with genomically unselected urothelial carcinoma experienced an ORR of 15% (6/40, 1 CR), and of those with DNA damage repair alterations (n=15), an ORR of 13% (Yap et al., 2022; 36394849). The Phase 3 JAVELIN Bladder 100 trial of maintenance avelumab for patients with advanced or metastatic urothelial cancer reported longer median OS (mOS) for avelumab plus best supportive care (BSC) compared with BSC in the randomized population (29.7 vs. 20.5 months, HR=0.69) (Powles et al., 2020; 32945632, Shridar et al., 2023; ASCO GU Abstract 508). Biomarker analysis of JAVELIN Bladder 100 showed further survival benefit with the addition of avelumab to BSC for patients with elevated TMB (HR=0.48) relative to those with TMB at or below the median (HR=0.88) and for patients with high PD_L1 expression (HR=0.35) relative to those with low PD_L1 expression (HR=0.79) (Powles et al., 2021; 34893775). A Phase 2 trial of first_line avelumab for patients with metastatic or advanced urothelial cancer with PD_L1_positive disease who were ineligible for cisplatin treatment reported an ORR of 23% (16/71), a median PFS (mPFS) of 2 months, and mOS of 10 months (Iacovelli et al., 2022; ASCO GU Abstract 439). In a Phase 2 study, avelumab plus axitinib yielded an ORR of 10% (2/20) and mPFS of 2.3 months for patients with treatment_naive, cisplatin_ineligible urothelial carcinoma (Galffy et al., 2020; SITC Abstract 281). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Atezolizumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Atezolizumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC) as well as adult and pediatric patients 2 years and older with alveolar soft part sarcoma, depending on treatment setting. Atezolizumab is also approved in combination with other therapies to treat patients with non_squamous NSCLC lacking EGFR or ALK alterations, small cell lung cancer, hepatocellular carcinoma, and BRAF V600_positive melanoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In the IMvigor130 study, patients with metastatic urothelial carcinoma harboring TMB_high (>10 muts/Mb) and PD_L1 expression >5% experienced improved OS with atezolizumab monotherapy compared to platinum_based chemotherapy (HR=0.22)(Galsky et al., 2020; ASCO Abstract 5011). As second_line therapy for advanced urothelial carcinoma in the Phase 3 IMvigor211 study, atezolizumab did not significantly improve median OS (mOS) compared with chemotherapy (11.1 vs. 10.6 months, HR=0.87) but was associated with a numerically longer median duration of response (15.9 vs. 8.3 months) for patients with PD_L1 expression on 5% or more of tumor_infiltrating immune cells (Powles et al., 2018; 29268948) and improved 2_year OS rate (23% vs. 13%, HR=0.82) irrespective of PD_L1 status (van der Heijden et al., 2021; 33902955). The Phase 3 IMvigor130 study for patients with treatment_naive metastatic urothelial carcinoma found that the addition of atezolizumab to platinum_based chemotherapy improved median PFS (8.2 vs. 6.3 months, HR=0.82) and mOS (16.1 vs. 13.4 months, HR=0.85) (Galsky et al., 2020; 32416780, Galsky et al., 2023; ASCO GU Abstract LBA440), while atezolizumab monotherapy compared with chemotherapy did not significantly improve mOS (15.2 vs. 13.3 months, HR=0.98) (Bamias et al., 2023; ASCO GU Abstract LBA441). In a Phase 2 study, patients with metastatic urothelial carcinoma treated with atezolizumab as first_line therapy experienced an ORR of 23%, a CR rate of 8.9%, and a clinical benefit rate of 30% (Balar et al., 2017; 27939400). Multiple studies have reported superior ORR and OS outcomes with atezolizumab monotherapy for patients with higher tumor mutational burden (TMB) or PD_L1 expression compared with those with lower TMB or PD_L1 expression (Balar et al., 2017; 27939400, Powles et al., 2018; 29268948, Rosenberg et al., 2016; 26952546, Galsky et al., 2020; ASCO Abstract 5011, Bamias et al., 2023; ASCO GU Abstract LBA441). A neoadjuvant trial for patients with muscle_invasive bladder cancer added atezolizumab to gemcitabine plus cisplatin and met its primary endpoint (non_muscle_invasive downstaging rate of 27/39) (Funt et al., 2022; 35089812). In the COSMIC_021 trial, patients with urothelial carcinoma (UC) post_platinum chemotherapy treated with the combination of atezolizumab with cabozantinib experienced an ORR of 27%, a DCR of 64%, and a median PFS (mPFS) of 5.4 months (n=30) (Pal et al., 2020; ASCO Abstract 5013). The trial also reported benefit for patients with locally advanced or metastatic UC (mUC) receiving the combination in the first line, whether cisplatin_eligible (ORR: 30% [9/30]) or ineligible (ORR: 20% [6/30]) (Pal et al., 2022; ASCO Abstract 4504). For patients who had previously received an immune_checkpoint inhibitor (ICI), the ORR was 10% (3/31) (Pal et al., 2022; ASCO Abstract 4504). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04237649', 'Include': 'true'}, {'nctId': 'NCT03682068', 'Include': 'true'}, {'nctId': 'NCT03869190', 'Include': 'true'}, {'nctId': 'NCT04589845', 'Include': 'true'}, {'nctId': 'NCT03674567', 'Include': 'true'}, {'nctId': 'NCT04047862', 'Include': 'true'}, {'nctId': 'NCT05166577', 'Include': 'true'}, {'nctId': 'NCT03530397', 'Include': 'true'}, {'nctId': 'NCT03967977', 'Include': 'true'}, {'nctId': 'NCT03821935', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'EMSY (C11orf30)', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'EMSY, also known as C11orf30, encodes a BRCA2_interacting protein with roles in transcriptional regulation (Varier et al., 2016; 26841866, Hughes_Davies et al., 2003; 14651845). Preclinical studies have suggested that EMSY binds to and suppresses the function of BRCA2, and EMSY overexpression may therefore mimic BRCA2 inactivation (Cousineau and Belmaaza, 2011; 21409565, Hughes_Davies et al., 2003; 14651845). Amplification of the EMSY gene correlates with increased mRNA expression (Wilkerson et al., 2011; 21735447, van Hattem et al., 2008; 18787609), although conflicting data have been reported (Shih et al., 2005; 16172393). The functional consequences of other EMSY alterations have not been extensively studied (PubMed, Jan 2023). In the TCGA datasets, EMSY amplification has been most frequently observed in ovarian carcinoma (8%)(Cancer Genome Atlas Research Network., 2011; 21720365), breast invasive carcinoma (6%)(Cancer Genome Atlas Network., 2012; 23000897), esophageal carcinoma (5%)(cBioPortal, 2023), and head and neck squamous cell carcinoma (3.5%)(HNSCC_Cancer Genome Atlas Network., 2015; 25631445, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). EMSY overexpression has been primarily reported in breast and high_grade ovarian cancers, where it is implicated in BRCA2 inactivation and correlates with poor prognosis or advanced disease (Wilkerson et al., 2011; 21735447, Brown et al., 2008; 18314909, Brown et al., 2010; 19636701, Altinisik et al., 2011; 20349280, Madjd et al., 2014; 24641409, Bane et al., 2011; 21327470, Rodriguez et al., 2004; 15355907, Hughes_Davies et al., 2003; 14651845). The consequences of EMSY alterations in other solid tumors or hematologic malignancies have not been studied in detail in the scientific literature (PubMed, Jan 2023). EMSY overexpression in breast cancer cell lines has been reported to mimic the effects of inactivating BRCA2 mutations (Cousineau and Belmaaza, 2011; 21409565). Unlike BRCA2 inactivation, which predicts sensitivity to DNA_repair_associated inhibitors, such as the PARP inhibitor olaparib (Dedes et al., 2011; 21487248, Ihnen et al., 2013; 23729402), EMSY amplification in breast cancer lines was not associated with enhanced sensitivity to this drug in 1 preclinical study (Wilkerson et al., 2011; 21735447). In a preclinical study of KEAP1_mutated lung cancer, loss of KEAP1 induced EMSY accumulation and sensitization to PARP inhibitors and stimulator of interferon genes protein agonists (Marzio et al., 2022; 34963055). In clinical studies of high_grade serous ovarian cancer, high EMSY expression was associated with greater rates of response to platinum_based chemotherapy and improved clinical outcomes (Hollis et al., 2022; 35696721, Hollis et al., 2019; 31154673, Weberpals et al., 2021; 33811746), although EMSY copy number was found to be a poor predictor of EMSY overexpression (Hollis et al., 2022; 35696721). There are no therapies that target EMSY alterations.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'KMT2D (MLL2)', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'K3630*', 'AlterationProperties': {'AlterationProperty': {'dnaFraction': '46.12', 'isEquivocal': 'false', 'name': 'K3630*'}}, 'Interpretation': 'MLL2 encodes an H3K4_specific histone methyltransferase that is involved in the transcriptional response to progesterone signaling (Vicent et al., 2011; 21447625). Germline de novo mutations of MLL2 are responsible for the majority of cases of Kabuki syndrome, a complex and phenotypically distinctive developmental disorder (Hannibal et al., 2011; 21671394). A significant number of inactivating MLL2 alterations have been observed in multiple tumor types, suggesting a tumor suppressor role (Fagan et al.,2019; 31128216). MLL2 alterations are observed in a number of solid tumor contexts (cBio_Zehir et al., 2017; 28481359), and are especially prevalent in lung squamous cell carcinoma (SCC) (Cancer Genome Atlas Research Network et al., 2012; 22960745) and small cell lung carcinoma (SCLC) (Augert et al., 2017; 28007623). MLL2 mutation was found to be an independent prognostic factor of poor PFS and OS in non_small cell lung cancer, but not in SCLC (Ardeshir_Larijani et al., 2018; 29627316). One study reported that MLL2 truncating mutations were more common in recurrent ovary granulosa cell tumors (GCT) compared with primary GCTs (24% [10/42] vs. 3.0% [1/32])(Hillman et al., 2018; 29950560). In a study of esophageal SCC, high MLL2 expression positively correlated with tumor stage, differentiation, and size, and negatively correlated with OS (Abudureheman et al., 2018; 29532228). There are no targeted therapies available to address genomic alterations in MLL2. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). Comprehensive genomic profiling of solid tumors may detect nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'MS_Stable', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'MS_Stable'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI has been detected in 26_49% of urothelial carcinomas (Mylona et al., 2008; 18254781, Amira et al., 2003; 14501713); MSI_H has also been reported in multiple case studies of upper urinary tract urothelial carcinoma (Bai et al., 2013; 23690119). Microsatellite instability (MSI), as determined through loss of MSH2 or MSH6 protein expression, correlated with noninvasive well_differentiated bladder tumors and favorable OS (Mylona et al., 2008; 18254781). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'ARID1A', 'Alteration': 'E966*', 'Title': 'Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM_NPC', 'StudyPhase': 'PHASE 1/2', 'Target': 'HDAC, PD_1', 'Locations': 'Taipei City (Taiwan), Taipei (Taiwan), Taoyuan City (Taiwan), Sha Tin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Kuching (Malaysia), Kuala Lumpur (Malaysia), Singapore (Singapore), Blacktown (Australia)', 'NCTID': 'NCT05166577', 'Note': 'ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.', 'Include': 'true'}, {'Gene': 'ARID1A', 'Alteration': 'E966*', 'Title': 'Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP, PD_L1', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)', 'NCTID': 'NCT02264678', 'Note': 'ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.', 'Include': 'true'}, {'Gene': 'ARID1A', 'Alteration': 'E966*', 'Title': 'Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_L1, CTLA_4, DNMT, HDAC, PD_1', 'Locations': 'Beijing (China)', 'NCTID': 'NCT05320640', 'Note': 'ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.', 'Include': 'true'}, {'Gene': 'ARID1A', 'Alteration': 'E966*', 'Title': 'Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High_Grade Neuroendocrine Cancers', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR', 'Locations': 'Maryland', 'NCTID': 'NCT04802174', 'Note': 'ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.', 'Include': 'true'}, {'Gene': 'ARID1A', 'Alteration': 'E966*', 'Title': 'A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR', 'Locations': 'London (United Kingdom), Colorado, Oklahoma, Texas, Pennsylvania, Tennessee, Florida', 'NCTID': 'NCT04657068', 'Note': 'ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.', 'Include': 'true'}, {'Gene': 'ARID1A', 'Alteration': 'E966*', 'Title': 'Testing the Addition of an Anti_cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'TOP1, ATR', 'Locations': 'California, Arizona, Minnesota, Oklahoma, Missouri, Pennsylvania, Connecticut, New York', 'NCTID': 'NCT04514497', 'Note': 'ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.', 'Include': 'true'}, {'Gene': 'ARID1A', 'Alteration': 'E966*', 'Title': 'Testing A New Anti_cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas', 'StudyPhase': 'PHASE 1/2', 'Target': 'BRD3, BRD4, BRD2, BRDT, HDAC', 'Locations': 'Oklahoma, Connecticut, Florida', 'NCTID': 'NCT05053971', 'Note': 'ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.', 'Include': 'true'}, {'Gene': 'ARID1A', 'Alteration': 'E966*', 'Title': 'AZD6738 & Gemcitabine as Combination Therapy', 'StudyPhase': 'PHASE 1', 'Target': 'ATR', 'Locations': 'Cambridge (United Kingdom)', 'NCTID': 'NCT03669601', 'Note': 'ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.', 'Include': 'true'}, {'Gene': 'ARID1A', 'Alteration': 'E966*', 'Title': 'Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI_24781 in Patients With Metastatic Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'HDAC, FGFR3, KIT, FGFR1, VEGFRs, FGFR2', 'Locations': 'California', 'NCTID': 'NCT01543763', 'Note': 'ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.', 'Include': 'true'}, {'Gene': 'ARID1A', 'Alteration': 'E966*', 'Title': 'Testing the Addition of an Anti_cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'ATR', 'Locations': 'California, Wisconsin, Toronto (Canada), Ohio, Pennsylvania, Maryland', 'NCTID': 'NCT04491942', 'Note': 'ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.', 'Include': 'true'}, {'Gene': 'TP53', 'Alteration': 'Y220C', 'Title': 'The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation', 'StudyPhase': 'PHASE 1/2', 'Target': 'TP53', 'Locations': 'Washington, Oregon, California, Ohio, Massachusetts, Connecticut, New York, Texas, Tennessee', 'NCTID': 'NCT04585750', 'Note': 'Clinical evidence suggests patients with TP53 Y220C mutations may benefit from Y220C_specific reactivators of TP53.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '12', 'Title': 'KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'ADORA2A, CD73, PD_1', 'Locations': 'Taipei (Taiwan), Shatin, New Territories (Hong Kong), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Toronto (Canada), Missouri', 'NCTID': 'NCT04237649', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '12', 'Title': 'Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer', 'StudyPhase': 'PHASE 3', 'Target': 'PD_L1, CTLA_4', 'Locations': 'Taipei (Taiwan), Taoyuan (Taiwan), Xiamen (China), Hangzhou (China), Shanghai (China), Nanchang (China), Suzhou (China), Nanjing (China), Guangzhou (China), Beijing (China)', 'NCTID': 'NCT03682068', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '12', 'Title': 'A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy_based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum_Containing Chemotherapy', 'StudyPhase': 'PHASE 1/2', 'Target': 'CD38, PARP, CD47, PD_L1, Nectin_4, IL_6R', 'Locations': 'Taipei City (Taiwan), Huwei Township (Taiwan), Tainan (Taiwan), Kaohsiung City (Taiwan), Seoul (Korea, Republic of), Athens (Greece), London (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Caen (France)', 'NCTID': 'NCT03869190', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '12', 'Title': 'Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study', 'StudyPhase': 'PHASE 2', 'Target': 'TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha, RAFs, NRAS', 'Locations': 'Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Shanghai City (China), Shanghai (China), Shatin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Seongnam_si (Korea, Republic of), Xi an (China)', 'NCTID': 'NCT04589845', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '12', 'Title': 'Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1, CCR4', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Busan (Korea, Republic of), Shatin (Hong Kong), High West (Hong Kong), Chungbuk (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Bangkok (Thailand), Nedlands (Australia)', 'NCTID': 'NCT03674567', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '12', 'Title': 'Study of BGB_A1217 in Combination With Tislelizumab in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, TIGIT', 'Locations': 'Taipei (Taiwan), Taoyuan (Taiwan), Hualien City (Taiwan), Taichung (Taiwan), Fujian (China), Hangzhou (China), Shanghai (China), Hefei (China), Guangdong (China), Changsha (China)', 'NCTID': 'NCT04047862', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '12', 'Title': 'Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM_NPC', 'StudyPhase': 'PHASE 1/2', 'Target': 'HDAC, PD_1', 'Locations': 'Taipei City (Taiwan), Taipei (Taiwan), Taoyuan City (Taiwan), Sha Tin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Kuching (Malaysia), Kuala Lumpur (Malaysia), Singapore (Singapore), Blacktown (Australia)', 'NCTID': 'NCT05166577', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '12', 'Title': 'A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_L1, PD_1, CTLA_4', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Cheongju_si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Melbourne (Australia), Amsterdam (Netherlands), Ravenna (Italy), Meldola (Italy)', 'NCTID': 'NCT03530397', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '12', 'Title': 'Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma', 'StudyPhase': 'PHASE 3', 'Target': 'PD_1', 'Locations': 'Fuzhou (China), Quanzhou (China), Wenzhou (China), Xiamen (China), Ningbo (China), Hangzhou (China), Shanghai (China), Nanchang (China), Nanjing (China), Hefei (China)', 'NCTID': 'NCT03967977', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '12', 'Title': 'Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV_151 as a Single Agent and in Combination With ABBV_181 in Participants With Locally Advanced or Metastatic Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, GARP', 'Locations': 'Taichung City (Taiwan), Taipei City (Taiwan), Seoul (Korea, Republic of), Chuo_ku (Japan), Kashiwa_shi (Japan), South Brisbane (Australia), Camperdown (Australia), Ramat Gan (Israel), Tel Aviv_Yafo (Israel), Haifa (Israel)', 'NCTID': 'NCT03821935', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '21900401', 'FullCitation': 'Guan B, et al. Cancer Res. (2011) pmid: 21900401', 'Include': 'true'}, {'number': '1', 'ReferenceId': '22009941', 'FullCitation': 'Jones S, et al. Hum. Mutat. (2012) pmid: 22009941', 'Include': 'true'}, {'number': '2', 'ReferenceId': '20942669', 'FullCitation': 'Wiegand KC, et al. N. Engl. J. Med. (2010) pmid: 20942669', 'Include': 'true'}, {'number': '3', 'ReferenceId': '20826764', 'FullCitation': 'Jones S, et al. Science (2010) pmid: 20826764', 'Include': 'true'}, {'number': '4', 'ReferenceId': '24293408', 'FullCitation': 'Yan HB, et al. Carcinogenesis (2014) pmid: 24293408', 'Include': 'true'}, {'number': '5', 'ReferenceId': '22808142', 'FullCitation': 'Wang DD, et al. PLoS ONE (2012) pmid: 22808142', 'Include': 'true'}, {'number': '6', 'ReferenceId': '22922871', 'FullCitation': 'Huang J, et al. Nat. Genet. (2012) pmid: 22922871', 'Include': 'true'}, {'number': '7', 'ReferenceId': '24185513', 'FullCitation': 'Chan_On W, et al. Nat. Genet. (2013) pmid: 24185513', 'Include': 'true'}, {'number': '8', 'ReferenceId': '21892209', 'FullCitation': 'Mamo A, et al. Oncogene (2012) pmid: 21892209', 'Include': 'true'}, {'number': '9', 'ReferenceId': '22484628', 'FullCitation': 'Zang ZJ, et al. Nat. Genet. (2012) pmid: 22484628', 'Include': 'true'}, {'number': '10', 'ReferenceId': '22037554', 'FullCitation': 'Wang K, et al. Nat. Genet. (2011) pmid: 22037554', 'Include': 'true'}, {'number': '11', 'ReferenceId': '30371878', 'FullCitation': 'Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878', 'Include': 'true'}, {'number': '12', 'ReferenceId': '22588877', 'FullCitation': 'Cerami E, et al. Cancer Discov (2012) pmid: 22588877', 'Include': 'true'}, {'number': '13', 'ReferenceId': '23550210', 'FullCitation': 'Gao J, et al. Sci Signal (2013) pmid: 23550210', 'Include': 'true'}, {'number': '14', 'ReferenceId': '24618703', 'FullCitation': 'Wu RC, et al. Cancer Biol. Ther. (2014) pmid: 24618703', 'Include': 'true'}, {'number': '15', 'ReferenceId': '23525077', 'FullCitation': 'Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077', 'Include': 'true'}, {'number': '16', 'ReferenceId': '23318448', 'FullCitation': 'Streppel MM, et al. Oncogene (2014) pmid: 23318448', 'Include': 'true'}, {'number': '17', 'ReferenceId': '24293293', 'FullCitation': 'Jiao Y, et al. J. Pathol. (2014) pmid: 24293293', 'Include': 'true'}, {'number': '18', 'ReferenceId': '24563076', 'FullCitation': 'Ross JS, et al. Oncologist (2014) pmid: 24563076', 'Include': 'true'}, {'number': '19', 'ReferenceId': '25195947', 'FullCitation': 'Huang HN, et al. Histopathology (2015) pmid: 25195947', 'Include': 'true'}, {'number': '20', 'ReferenceId': '25394778', 'FullCitation': 'Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778', 'Include': 'true'}, {'number': '21', 'ReferenceId': '23702729', 'FullCitation': 'Bosse T, et al. Mod. Pathol. (2013) pmid: 23702729', 'Include': 'true'}, {'number': '22', 'ReferenceId': '23887303', 'FullCitation': 'Allo G, et al. Mod. Pathol. (2014) pmid: 23887303', 'Include': 'true'}, {'number': '23', 'ReferenceId': '32111729', 'FullCitation': 'Okamura R, et al. J Immunother Cancer (2020) pmid: 32111729', 'Include': 'true'}, {'number': '24', 'ReferenceId': '24925223', 'FullCitation': 'Chou A, et al. Hum. Pathol. (2014) pmid: 24925223', 'Include': 'true'}, {'number': '25', 'ReferenceId': '25311944', 'FullCitation': 'Ye J, et al. Hum. Pathol. (2014) pmid: 25311944', 'Include': 'true'}, {'number': '26', 'ReferenceId': '25561809', 'FullCitation': 'Wei XL, et al. World J. Gastroenterol. (2014) pmid: 25561809', 'Include': 'true'}, {'number': '27', 'ReferenceId': '25583476', 'FullCitation': 'Chen K, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25583476', 'Include': 'true'}, {'number': '28', 'ReferenceId': '22915242', 'FullCitation': 'Abe H, et al. Virchows Arch. (2012) pmid: 22915242', 'Include': 'true'}, {'number': '29', 'ReferenceId': '24767857', 'FullCitation': 'Wiegand KC, et al. Hum. Pathol. (2014) pmid: 24767857', 'Include': 'true'}, {'number': '30', 'ReferenceId': '21822268', 'FullCitation': 'Gui Y, et al. Nat. Genet. (2011) pmid: 21822268', 'Include': 'true'}, {'number': '31', 'ReferenceId': '23650517', 'FullCitation': 'Balbás_Martínez C, et al. PLoS ONE (2013) pmid: 23650517', 'Include': 'true'}, {'number': '32', 'ReferenceId': '25175170', 'FullCitation': 'Faraj SF, et al. Hum. Pathol. (2014) pmid: 25175170', 'Include': 'true'}, {'number': '33', 'ReferenceId': '27958275', 'FullCitation': 'Williamson CT, et al. Nat Commun (2016) pmid: 27958275', 'Include': 'true'}, {'number': '34', 'ReferenceId': '29252124', 'FullCitation': 'Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124', 'Include': 'true'}, {'number': '35', 'ReferenceId': '32568634', 'FullCitation': 'Yap TA, et al. J Clin Oncol (2020) pmid: 32568634', 'Include': 'true'}, {'number': '36', 'ReferenceId': '25686104', 'FullCitation': 'Bitler BG, et al. Nat. Med. (2015) pmid: 25686104', 'Include': 'true'}, {'number': '37', 'ReferenceId': '26552009', 'FullCitation': 'Kim KH, et al. Nat. Med. (2015) pmid: 26552009', 'Include': 'true'}, {'number': '38', 'ReferenceId': '24559118', 'FullCitation': 'Wiegand KC, et al. BMC Cancer (2014) pmid: 24559118', 'Include': 'true'}, {'number': '39', 'ReferenceId': '24336158', 'FullCitation': 'Huang HN, et al. Mod. Pathol. (2014) pmid: 24336158', 'Include': 'true'}, {'number': '40', 'ReferenceId': '24979463', 'FullCitation': 'Samartzis EP, et al. Oncotarget (2014) pmid: 24979463', 'Include': 'true'}, {'number': '41', 'ReferenceId': '24459582', 'FullCitation': 'Yokoyama Y, et al. J Gynecol Oncol (2014) pmid: 24459582', 'Include': 'true'}, {'number': '42', 'ReferenceId': '22101352', 'FullCitation': 'Katagiri A, et al. Mod. Pathol. (2012) pmid: 22101352', 'Include': 'true'}, {'number': '43', 'ReferenceId': '24833095', 'FullCitation': 'Xie C, et al. Tumour Biol. (2014) pmid: 24833095', 'Include': 'true'}, {'number': '44', 'ReferenceId': '30301863', 'FullCitation': 'Gupta S, et al. Mol. Cancer Ther. (2019) pmid: 30301863', 'Include': 'true'}, {'number': '45', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '46', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '47', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '48', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '49', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '50', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '51', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '52', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '53', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '54', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '55', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '56', 'ReferenceId': '26952546', 'FullCitation': 'Rosenberg JE, et al. Lancet (2016) pmid: 26952546', 'Include': 'true'}, {'number': '57', 'ReferenceId': '27939400', 'FullCitation': 'Balar AV, et al. Lancet (2017) pmid: 27939400', 'Include': 'true'}, {'number': '58', 'ReferenceId': '29268948', 'FullCitation': 'Powles T, et al. Lancet (2018) pmid: 29268948', 'Include': 'true'}, {'number': '59', 'ReferenceId': '29443960', 'FullCitation': 'Mariathasan S, et al. Nature (2018) pmid: 29443960', 'Include': 'true'}, {'number': '60', 'ReferenceId': '30150660', 'FullCitation': 'Miao D, et al. Nat. Genet. (2018) pmid: 30150660', 'Include': 'true'}, {'number': '61', 'ReferenceId': '30643254', 'FullCitation': 'Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254', 'Include': 'true'}, {'number': '62', 'ReferenceId': '32919526', 'FullCitation': 'Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526', 'Include': 'true'}, {'number': '63', 'ReferenceId': '24476821', 'FullCitation': 'Nature (2014) pmid: 24476821', 'Include': 'true'}, {'number': '64', 'ReferenceId': '24777035', 'FullCitation': 'Cazier JB, et al. Nat Commun (2014) pmid: 24777035', 'Include': 'true'}, {'number': '65', 'ReferenceId': '35323317', 'FullCitation': 'Curr Oncol (2022) pmid: 35323317', 'Include': 'true'}, {'number': '66', 'ReferenceId': '28835386', 'FullCitation': 'Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386', 'Include': 'true'}, {'number': '67', 'ReferenceId': '31405947', 'FullCitation': 'Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947', 'Include': 'true'}, {'number': '68', 'ReferenceId': '30309915', 'FullCitation': 'Cristescu R, et al. Science (2018) pmid: 30309915', 'Include': 'true'}, {'number': '69', 'ReferenceId': '30785829', 'FullCitation': 'Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829', 'Include': 'true'}, {'number': '70', 'ReferenceId': '29658845', 'FullCitation': 'Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845', 'Include': 'true'}, {'number': '71', 'ReferenceId': '29657128', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128', 'Include': 'true'}, {'number': '72', 'ReferenceId': '29731394', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394', 'Include': 'true'}, {'number': '73', 'ReferenceId': '33558721', 'FullCitation': 'Rozeman EA, et al. Nat Med (2021) pmid: 33558721', 'Include': 'true'}, {'number': '74', 'ReferenceId': '32916128', 'FullCitation': 'Sharma P, et al. Cancer Cell (2020) pmid: 32916128', 'Include': 'true'}, {'number': '75', 'ReferenceId': '19935675', 'FullCitation': 'Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675', 'Include': 'true'}, {'number': '76', 'ReferenceId': '18410249', 'FullCitation': 'Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249', 'Include': 'true'}, {'number': '77', 'ReferenceId': '12826609', 'FullCitation': 'Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609', 'Include': 'true'}, {'number': '78', 'ReferenceId': '20978130', 'FullCitation': 'Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130', 'Include': 'true'}, {'number': '79', 'ReferenceId': '28472496', 'FullCitation': 'Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496', 'Include': 'true'}, {'number': '80', 'ReferenceId': '17690113', 'FullCitation': 'Yamada H, et al. Carcinogenesis (2007) pmid: 17690113', 'Include': 'true'}, {'number': '81', 'ReferenceId': '23887298', 'FullCitation': 'Ross JS, et al. Mod. Pathol. (2014) pmid: 23887298', 'Include': 'true'}, {'number': '82', 'ReferenceId': '9761125', 'FullCitation': 'Bringuier PP, et al. Int. J. Cancer (1998) pmid: 9761125', 'Include': 'true'}, {'number': '83', 'ReferenceId': '10675480', 'FullCitation': 'Furihata M, et al. Int. J. Oncol. (2000) pmid: 10675480', 'Include': 'true'}, {'number': '84', 'ReferenceId': '7901994', 'FullCitation': 'Esrig D, et al. Am. J. Pathol. (1993) pmid: 7901994', 'Include': 'true'}, {'number': '85', 'ReferenceId': '7906253', 'FullCitation': 'Cordon_Cardo C, et al. Int. J. Cancer (1994) pmid: 7906253', 'Include': 'true'}, {'number': '86', 'ReferenceId': '10744064', 'FullCitation': 'Diaz_Cano SJ, et al. Lab. Invest. (2000) pmid: 10744064', 'Include': 'true'}, {'number': '87', 'ReferenceId': '21571954', 'FullCitation': 'Kapur P, et al. Am. J. Clin. Pathol. (2011) pmid: 21571954', 'Include': 'true'}, {'number': '88', 'ReferenceId': '23571005', 'FullCitation': 'Lotan Y, et al. Eur. Urol. (2013) pmid: 23571005', 'Include': 'true'}, {'number': '89', 'ReferenceId': '25092538', 'FullCitation': 'Kim PH, et al. Eur. Urol. (2015) pmid: 25092538', 'Include': 'true'}, {'number': '90', 'ReferenceId': '14756544', 'FullCitation': 'El_Kenawy Ael_M, et al. Int. J. Biol. Markers () pmid: 14756544', 'Include': 'true'}, {'number': '91', 'ReferenceId': '18931548', 'FullCitation': 'Joung JY, et al. Urol. Int. (2008) pmid: 18931548', 'Include': 'true'}, {'number': '92', 'ReferenceId': '9644783', 'FullCitation': 'Jinza S, et al. Urol. Int. (1998) pmid: 9644783', 'Include': 'true'}, {'number': '93', 'ReferenceId': '16351648', 'FullCitation': 'Kamijima S, et al. Int. J. Urol. (2005) pmid: 16351648', 'Include': 'true'}, {'number': '94', 'ReferenceId': '23307189', 'FullCitation': 'Alexiev BA, et al. Virchows Arch. (2013) pmid: 23307189', 'Include': 'true'}, {'number': '95', 'ReferenceId': '20610279', 'FullCitation': 'Goebell PJ, et al. Urol. Oncol. () pmid: 20610279', 'Include': 'true'}, {'number': '96', 'ReferenceId': '22685613', 'FullCitation': 'Lindgren D, et al. PLoS ONE (2012) pmid: 22685613', 'Include': 'true'}, {'number': '97', 'ReferenceId': '24500328', 'FullCitation': 'Feng C, et al. Sci Rep (2014) pmid: 24500328', 'Include': 'true'}, {'number': '98', 'ReferenceId': '20012564', 'FullCitation': 'Eissa S, et al. Med. Oncol. (2010) pmid: 20012564', 'Include': 'true'}, {'number': '99', 'ReferenceId': '17710407', 'FullCitation': 'Mitra AP, et al. World J Urol (2007) pmid: 17710407', 'Include': 'true'}, {'number': '100', 'ReferenceId': '23624844', 'FullCitation': 'Lambrou GI, et al. Cell Cycle (2013) pmid: 23624844', 'Include': 'true'}, {'number': '101', 'ReferenceId': '23482786', 'FullCitation': 'Lee YC, et al. Anticancer Res. (2013) pmid: 23482786', 'Include': 'true'}, {'number': '102', 'ReferenceId': '11168685', 'FullCitation': 'Hashimoto H, et al. Int. J. Urol. (2000) pmid: 11168685', 'Include': 'true'}, {'number': '103', 'ReferenceId': '9815716', 'FullCitation': 'Osman I, et al. Clin. Cancer Res. (1997) pmid: 9815716', 'Include': 'true'}, {'number': '104', 'ReferenceId': '16998598', 'FullCitation': 'Helal Tel A, et al. Pathol. Oncol. Res. (2006) pmid: 16998598', 'Include': 'true'}, {'number': '105', 'ReferenceId': '22126554', 'FullCitation': 'Jalali MM, et al. Asian Pac. J. Cancer Prev. (2011) pmid: 22126554', 'Include': 'true'}, {'number': '106', 'ReferenceId': '20107315', 'FullCitation': 'Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315', 'Include': 'true'}, {'number': '107', 'ReferenceId': '21799033', 'FullCitation': 'Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033', 'Include': 'true'}, {'number': '108', 'ReferenceId': '21389100', 'FullCitation': 'Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100', 'Include': 'true'}, {'number': '109', 'ReferenceId': '25504633', 'FullCitation': 'Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633', 'Include': 'true'}, {'number': '110', 'ReferenceId': '12489850', 'FullCitation': 'Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850', 'Include': 'true'}, {'number': '111', 'ReferenceId': '11713371', 'FullCitation': 'Xu L, et al. Mol. Med. (2001) pmid: 11713371', 'Include': 'true'}, {'number': '112', 'ReferenceId': '23470564', 'FullCitation': 'Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564', 'Include': 'true'}, {'number': '113', 'ReferenceId': '25240597', 'FullCitation': 'Kim SS, et al. Nanomedicine (2015) pmid: 25240597', 'Include': 'true'}, {'number': '114', 'ReferenceId': '27357628', 'FullCitation': 'Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628', 'Include': 'true'}, {'number': '115', 'ReferenceId': '27601554', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554', 'Include': 'true'}, {'number': '116', 'ReferenceId': '27998224', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224', 'Include': 'true'}, {'number': '117', 'ReferenceId': '31315834', 'FullCitation': 'Lee J, et al. Cancer Discov (2019) pmid: 31315834', 'Include': 'true'}, {'number': '118', 'ReferenceId': '29535125', 'FullCitation': 'Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125', 'Include': 'true'}, {'number': '119', 'ReferenceId': '34538072', 'FullCitation': 'Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072', 'Include': 'true'}, {'number': '120', 'ReferenceId': '36084396', 'FullCitation': 'Park H, et al. ESMO Open (2022) pmid: 36084396', 'Include': 'true'}, {'number': '121', 'ReferenceId': '29165669', 'FullCitation': 'Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669', 'Include': 'true'}, {'number': '122', 'ReferenceId': '26014290', 'FullCitation': 'Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290', 'Include': 'true'}, {'number': '123', 'ReferenceId': '23355100', 'FullCitation': 'Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100', 'Include': 'true'}, {'number': '124', 'ReferenceId': '11219776', 'FullCitation': 'Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776', 'Include': 'true'}, {'number': '125', 'ReferenceId': '9006316', 'FullCitation': 'Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316', 'Include': 'true'}, {'number': '126', 'ReferenceId': '19204208', 'FullCitation': 'Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208', 'Include': 'true'}, {'number': '127', 'ReferenceId': '12672316', 'FullCitation': 'Lalloo F, et al. Lancet (2003) pmid: 12672316', 'Include': 'true'}, {'number': '128', 'ReferenceId': '31050713', 'FullCitation': 'Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713', 'Include': 'true'}, {'number': '129', 'ReferenceId': '25426837', 'FullCitation': 'Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837', 'Include': 'true'}, {'number': '130', 'ReferenceId': '25426838', 'FullCitation': 'Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838', 'Include': 'true'}, {'number': '131', 'ReferenceId': '25326804', 'FullCitation': 'Xie M, et al. Nat. Med. (2014) pmid: 25326804', 'Include': 'true'}, {'number': '132', 'ReferenceId': '28669404', 'FullCitation': 'Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404', 'Include': 'true'}, {'number': '133', 'ReferenceId': '29678827', 'FullCitation': 'Severson EA, et al. Blood (2018) pmid: 29678827', 'Include': 'true'}, {'number': '134', 'ReferenceId': '29420212', 'FullCitation': 'Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212', 'Include': 'true'}, {'number': '135', 'ReferenceId': '30504320', 'FullCitation': 'Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320', 'Include': 'true'}, {'number': '136', 'ReferenceId': '32269342', 'FullCitation': 'Chabon JJ, et al. Nature (2020) pmid: 32269342', 'Include': 'true'}, {'number': '137', 'ReferenceId': '31768066', 'FullCitation': 'Razavi P, et al. Nat. Med. (2019) pmid: 31768066', 'Include': 'true'}, {'number': '138', 'ReferenceId': '21447625', 'FullCitation': 'Vicent GP, et al. Genes Dev. (2011) pmid: 21447625', 'Include': 'true'}, {'number': '139', 'ReferenceId': '21671394', 'FullCitation': 'Hannibal MC, et al. Am. J. Med. Genet. A (2011) pmid: 21671394', 'Include': 'true'}, {'number': '140', 'ReferenceId': '31128216', 'FullCitation': 'Fagan RJ, et al. Cancer Lett. (2019) pmid: 31128216', 'Include': 'true'}, {'number': '141', 'ReferenceId': '28481359', 'FullCitation': 'Zehir A, et al. Nat. Med. (2017) pmid: 28481359', 'Include': 'true'}, {'number': '142', 'ReferenceId': '22960745', 'FullCitation': 'Nature (2012) pmid: 22960745', 'Include': 'true'}, {'number': '143', 'ReferenceId': '28007623', 'FullCitation': 'Augert A, et al. J Thorac Oncol (2017) pmid: 28007623', 'Include': 'true'}, {'number': '144', 'ReferenceId': '29627316', 'FullCitation': 'Ardeshir_Larijani F, et al. Clin Lung Cancer (2018) pmid: 29627316', 'Include': 'true'}, {'number': '145', 'ReferenceId': '29950560', 'FullCitation': 'Hillman RT, et al. Nat Commun (2018) pmid: 29950560', 'Include': 'true'}, {'number': '146', 'ReferenceId': '29532228', 'FullCitation': 'Abudureheman A, et al. J. Cancer Res. Clin. Oncol. (2018) pmid: 29532228', 'Include': 'true'}, {'number': '147', 'ReferenceId': '26841866', 'FullCitation': 'Varier RA, et al. J. Biol. Chem. (2016) pmid: 26841866', 'Include': 'true'}, {'number': '148', 'ReferenceId': '14651845', 'FullCitation': 'Hughes_Davies L, et al. Cell (2003) pmid: 14651845', 'Include': 'true'}, {'number': '149', 'ReferenceId': '21409565', 'FullCitation': 'Cousineau I, et al. Mol. Genet. Genomics (2011) pmid: 21409565', 'Include': 'true'}, {'number': '150', 'ReferenceId': '21735447', 'FullCitation': 'Wilkerson PM, et al. J. Pathol. (2011) pmid: 21735447', 'Include': 'true'}, {'number': '151', 'ReferenceId': '18787609', 'FullCitation': 'van Hattem WA, et al. Int J Clin Exp Pathol (2008) pmid: 18787609', 'Include': 'true'}, {'number': '152', 'ReferenceId': '16172393', 'FullCitation': 'Shih IeM, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 16172393', 'Include': 'true'}, {'number': '153', 'ReferenceId': '21720365', 'FullCitation': 'Nature (2011) pmid: 21720365', 'Include': 'true'}, {'number': '154', 'ReferenceId': '23000897', 'FullCitation': 'Nature (2012) pmid: 23000897', 'Include': 'true'}, {'number': '155', 'ReferenceId': '25631445', 'FullCitation': 'Nature (2015) pmid: 25631445', 'Include': 'true'}, {'number': '156', 'ReferenceId': '18314909', 'FullCitation': 'Brown LA, et al. Genes Chromosomes Cancer (2008) pmid: 18314909', 'Include': 'true'}, {'number': '157', 'ReferenceId': '19636701', 'FullCitation': 'Brown LA, et al. Breast Cancer Res. Treat. (2010) pmid: 19636701', 'Include': 'true'}, {'number': '158', 'ReferenceId': '20349280', 'FullCitation': 'Altinisik J, et al. Mol. Biol. Rep. (2011) pmid: 20349280', 'Include': 'true'}, {'number': '159', 'ReferenceId': '24641409', 'FullCitation': 'Madjd Z, et al. Asian Pac. J. Cancer Prev. (2014) pmid: 24641409', 'Include': 'true'}, {'number': '160', 'ReferenceId': '21327470', 'FullCitation': 'Bane AL, et al. Breast Cancer Res. Treat. (2011) pmid: 21327470', 'Include': 'true'}, {'number': '161', 'ReferenceId': '15355907', 'FullCitation': 'Rodriguez C, et al. Clin. Cancer Res. (2004) pmid: 15355907', 'Include': 'true'}, {'number': '162', 'ReferenceId': '21487248', 'FullCitation': 'Dedes KJ, et al. Cell Cycle (2011) pmid: 21487248', 'Include': 'true'}, {'number': '163', 'ReferenceId': '23729402', 'FullCitation': 'Ihnen M, et al. Mol. Cancer Ther. (2013) pmid: 23729402', 'Include': 'true'}, {'number': '164', 'ReferenceId': '34963055', 'FullCitation': 'Marzio A, et al. Cell (2022) pmid: 34963055', 'Include': 'true'}, {'number': '165', 'ReferenceId': '35696721', 'FullCitation': 'Hollis RL, et al. Clin Cancer Res (2022) pmid: 35696721', 'Include': 'true'}, {'number': '166', 'ReferenceId': '31154673', 'FullCitation': 'Hollis RL, et al. Cancer (2019) pmid: 31154673', 'Include': 'true'}, {'number': '167', 'ReferenceId': '33811746', 'FullCitation': 'Weberpals JI, et al. Cancer Med (2021) pmid: 33811746', 'Include': 'true'}, {'number': '168', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '169', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '170', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '171', 'ReferenceId': '9823339', 'FullCitation': 'Boland CR, et al. Cancer Res. (1998) pmid: 9823339', 'Include': 'true'}, {'number': '172', 'ReferenceId': '15528785', 'FullCitation': 'Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785', 'Include': 'true'}, {'number': '173', 'ReferenceId': '20420947', 'FullCitation': 'Boland CR, et al. Gastroenterology (2010) pmid: 20420947', 'Include': 'true'}, {'number': '174', 'ReferenceId': '18254781', 'FullCitation': 'Mylona E, et al. APMIS (2008) pmid: 18254781', 'Include': 'true'}, {'number': '175', 'ReferenceId': '14501713', 'FullCitation': 'Amira N, et al. J. Urol. (2003) pmid: 14501713', 'Include': 'true'}, {'number': '176', 'ReferenceId': '23690119', 'FullCitation': 'Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119', 'Include': 'true'}, {'number': '177', 'ReferenceId': '25392179', 'FullCitation': 'Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179', 'Include': 'true'}, {'number': '178', 'ReferenceId': '26140250', 'FullCitation': 'Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250', 'Include': 'true'}, {'number': '179', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '180', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '181', 'ReferenceId': '36494006', 'FullCitation': 'Balar AV, et al. Ann Oncol (2022) pmid: 36494006', 'Include': 'true'}, {'number': '182', 'ReferenceId': '28212060', 'FullCitation': 'Bellmunt J, et al. N. Engl. J. Med. (2017) pmid: 28212060', 'Include': 'true'}, {'number': '183', 'ReferenceId': '36041086', 'FullCitation': 'Hoimes CJ, et al. J Clin Oncol (2023) pmid: 36041086', 'Include': 'true'}, {'number': '184', 'ReferenceId': '34051178', 'FullCitation': 'Powles T, et al. Lancet Oncol (2021) pmid: 34051178', 'Include': 'true'}, {'number': '185', 'ReferenceId': '30343614', 'FullCitation': 'Necchi A, et al. J Clin Oncol (2018) pmid: 30343614', 'Include': 'true'}, {'number': '186', 'ReferenceId': '36190522', 'FullCitation': 'Basile G, et al. Clin Cancer Res (2022) pmid: 36190522', 'Include': 'true'}, {'number': '187', 'ReferenceId': '34051177', 'FullCitation': 'Balar AV, et al. Lancet Oncol (2021) pmid: 34051177', 'Include': 'true'}, {'number': '188', 'ReferenceId': '32516377', 'FullCitation': 'Bandini M, et al. J. Natl. Cancer Inst. (2020) pmid: 32516377', 'Include': 'true'}, {'number': '189', 'ReferenceId': '32532789', 'FullCitation': 'Galsky MD, et al. Clin Cancer Res (2020) pmid: 32532789', 'Include': 'true'}, {'number': '190', 'ReferenceId': '31100038', 'FullCitation': 'Sharma P, et al. J. Clin. Oncol. (2019) pmid: 31100038', 'Include': 'true'}, {'number': '191', 'ReferenceId': '28131785', 'FullCitation': 'Sharma P, et al. Lancet Oncol. (2017) pmid: 28131785', 'Include': 'true'}, {'number': '192', 'ReferenceId': '36868932', 'FullCitation': 'Galsky MD, et al. Eur Urol (2023) pmid: 36868932', 'Include': 'true'}, {'number': '193', 'ReferenceId': '34077643', 'FullCitation': 'Bajorin DF, et al. N Engl J Med (2021) pmid: 34077643', 'Include': 'true'}, {'number': '194', 'ReferenceId': '33001143', 'FullCitation': 'Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143', 'Include': 'true'}, {'number': '195', 'ReferenceId': '32945632', 'FullCitation': 'Powles T, et al. N Engl J Med (2020) pmid: 32945632', 'Include': 'true'}, {'number': '196', 'ReferenceId': '34893775', 'FullCitation': 'Powles T, et al. Nat Med (2021) pmid: 34893775', 'Include': 'true'}, {'number': '197', 'ReferenceId': '36394849', 'FullCitation': 'Yap TA, et al. JAMA Oncol (2022) pmid: 36394849', 'Include': 'true'}, {'number': '198', 'ReferenceId': '33902955', 'FullCitation': 'van der Heijden MS, et al. Eur Urol (2021) pmid: 33902955', 'Include': 'true'}, {'number': '199', 'ReferenceId': '32416780', 'FullCitation': 'Galsky MD, et al. Lancet (2020) pmid: 32416780', 'Include': 'true'}, {'number': '200', 'ReferenceId': '35089812', 'FullCitation': 'Funt SA, et al. J Clin Oncol (2022) pmid: 35089812', 'Include': 'true'}, {'number': '201', 'ReferenceId': '29863979', 'FullCitation': 'Migden MR, et al. N. Engl. J. Med. (2018) pmid: 29863979', 'Include': 'true'}, {'number': '202', 'ReferenceId': '33046870', 'FullCitation': 'van Dijk N, et al. Nat Med (2020) pmid: 33046870', 'Include': 'true'}, {'number': '203', 'ReferenceId': '32971005', 'FullCitation': 'Powles T, et al. Lancet Oncol (2020) pmid: 32971005', 'Include': 'true'}, {'number': '204', 'ReferenceId': '34006499', 'FullCitation': 'Marandino L, et al. Clin Genitourin Cancer (2021) pmid: 34006499', 'Include': 'true'}, {'number': '205', 'ReferenceId': '33941921', 'FullCitation': 'Powles T, et al. Nat Med (2021) pmid: 33941921', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2023_05_25 17:45:07', 'OpName': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': '470x'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': '12 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': 'Units Not Reported'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'KIDNEY', 'disease_ontology': 'Kidney urothelial carcinoma', 'flowcell_analysis': '2000029197', 'gender': 'female', 'pathology_diagnosis': 'Urothelial carcinoma', 'percent_tumor_nuclei': '50', 'pipeline_version': 'v3.22.0', 'purity_assessment': '82.98', 'specimen': 'ORD_1631801_01*US1556823.01', 'study': 'CLINICAL_F1CDx v2', 'test_request': 'ORD_1631801_01', 'test_type': 'FoundationOneDx', 'tissue_of_origin': 'Kidney', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'DX2', 'mean_exon_depth': '516.34', 'name': 'SQ_US1556823.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.8299', 'cds_effect': '2896G>T', 'depth': '341', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'ARID1A', 'percent_reads': '82.99', 'position': 'chr1:27092965', 'protein_effect': 'E966*', 'status': 'likely', 'strand': '+', 'transcript': 'NM_006015', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.7895', 'cds_effect': '643A>T', 'depth': '418', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FAM46C', 'percent_reads': '78.95', 'position': 'chr1:118166133', 'protein_effect': 'M215L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_017709', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.82', 'cds_effect': '659A>G', 'depth': '300', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TP53', 'percent_reads': '82.0', 'position': 'chr17:7578190', 'protein_effect': 'Y220C', 'status': 'known', 'strand': '_', 'transcript': 'NM_000546', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.8198', 'cds_effect': '616G>C', 'depth': '333', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CSF3R', 'percent_reads': '81.98', 'position': 'chr1:36939093', 'protein_effect': 'E206Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_156039', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.5448', 'cds_effect': '236C>T', 'depth': '290', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SRC', 'percent_reads': '54.48', 'position': 'chr20:36012792', 'protein_effect': 'A79V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005417', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.0873', 'cds_effect': '2126A>G', 'depth': '229', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGFR4', 'percent_reads': '8.73', 'position': 'chr5:176523715', 'protein_effect': 'D709G', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_213647', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.4612', 'cds_effect': '10888A>T', 'depth': '399', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'MLL2', 'percent_reads': '46.12', 'position': 'chr12:49427600', 'protein_effect': 'K3630*', 'status': 'likely', 'strand': '_', 'transcript': 'NM_003482', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.5236', 'cds_effect': '205C>T', 'depth': '296', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'JAK1', 'percent_reads': '52.36', 'position': 'chr1:65348960', 'protein_effect': 'R69C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002227', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.2457', 'cds_effect': '1717_2A>T', 'depth': '407', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'ERBB4', 'percent_reads': '24.57', 'position': 'chr2:212530204', 'protein_effect': 'splice site 1717_2A>T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.3378', 'cds_effect': '4081T>A', 'depth': '521', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ROS1', 'percent_reads': '33.78', 'position': 'chr6:117677852', 'protein_effect': 'W1361R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002944', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.609', 'cds_effect': '528C>A', 'depth': '335', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'AR', 'percent_reads': '60.9', 'position': 'chrX:66765516', 'protein_effect': 'S176R', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000044', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.5057', 'cds_effect': '2624T>A', 'depth': '439', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PDGFRA', 'percent_reads': '50.57', 'position': 'chr4:55153658', 'protein_effect': 'L875Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006206', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.3478', 'cds_effect': '1183A>T', 'depth': '460', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ZNF703', 'percent_reads': '34.78', 'position': 'chr8:37555602', 'protein_effect': 'S395C', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_025069', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.5818', 'cds_effect': '2545G>A', 'depth': '330', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'AXIN1', 'percent_reads': '58.18', 'position': 'chr16:338166', 'protein_effect': 'V849I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003502', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.2077', 'cds_effect': '1387G>T', 'depth': '284', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CHEK2', 'percent_reads': '20.77', 'position': 'chr22:29090094', 'protein_effect': 'V463F', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_007194', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'allele_fraction': '0.5224', 'cds_effect': '14747C>T', 'depth': '268', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MLL2', 'percent_reads': '52.24', 'position': 'chr12:49421002', 'protein_effect': 'P4916L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003482', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}]}, 'copy_number_alterations': {'copy_number_alteration': [{'copy_number': '11', 'equivocal': 'false', 'gene': 'EMSY', 'number_of_exons': '20 of 20', 'position': 'chr11:76157953_76261190', 'ratio': '2.9', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}, {'copy_number': '32', 'equivocal': 'false', 'gene': 'KLHL6', 'number_of_exons': '7 of 7', 'position': 'chr3:183209714_183273441', 'ratio': '8.78', 'status': 'unknown', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}]}, 'rearrangements': {'rearrangement': {'allele_fraction': '0.1522', 'description': 'MST1R(NM_002447) rearrangement exon 15', 'equivocal': 'false', 'in_frame': 'unknown', 'other_gene': 'N/A', 'percent_reads': '15.22', 'pos1': 'chr3:49929263', 'pos2': 'chr3:49970007', 'status': 'unknown', 'supporting_read_pairs': '202', 'targeted_gene': 'MST1R', 'type': 'rearrangement', 'dna_evidence': {'sample': 'SQ_US1556823.01_1'}}}, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '12.07', 'status': 'intermediate', 'unit': 'mutations_per_megabase'}}, 'non_human_content': None}}}}	M112-10132          	PF23056             
8	365	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2021_00017105', 'CSN': None, 'TRF': 'ORD_1223719_01', 'MRN': '26693243', 'PhysicianId': '16468', 'NPI': 'International'}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '917803', 'clinicalId': '919199', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1223719_01', 'SampleName': 'US1179091.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1223719_01', 'SampleId': 'US1179091.01', 'BlockId': 'CCC 7/1/1940', 'TRFNumber': 'ORD_1223719_01', 'TestType': 'FoundationOneLiquidDx', 'SpecFormat': 'Tube Set', 'ReceivedDate': '2021_10_26', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}]}}, 'PMI': {'ReportId': 'ORD_1223719_01', 'MRN': '26693243', 'FullName': 'Chang, Chi_Chun', 'FirstName': 'Chi_Chun', 'LastName': 'Chang', 'SubmittedDiagnosis': 'Stomach adenocarcinoma (NOS)', 'Gender': 'Female', 'DOB': '1940_07_01', 'OrderingMD': 'Chen, Ming_Huang', 'OrderingMDId': '16468', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Blood', 'CollDate': '2021_10_22', 'ReceivedDate': '2021_10_26', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': None, 'Summaries': {'alterationCount': '43', 'clinicalTrialCount': '33', 'resistiveCount': '0', 'sensitizingCount': '2'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'AKT1', 'isVUS': 'true', 'variantName': 'K377T'}, {'geneName': 'ATM', 'isVUS': 'true', 'variantName': 'S2141T'}, {'geneName': 'AXL', 'isVUS': 'true', 'variantName': 'N814I'}, {'geneName': 'BRCA1', 'isVUS': 'true', 'variantName': 'K1207T'}, {'geneName': 'BRCA2', 'isVUS': 'true', 'variantName': 'S662A'}, {'geneName': 'BRD4', 'isVUS': 'true', 'variantName': 'A1301P'}, {'geneName': 'CCNE1', 'isVUS': 'true', 'variantName': 'P396L'}, {'geneName': 'CD22', 'isVUS': 'true', 'variantName': 'K707T'}, {'geneName': 'CREBBP', 'isVUS': 'true', 'variantName': 'E43A'}, {'geneName': 'DNMT3A', 'isVUS': 'true', 'variantName': 'V897G,W409L'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'K191T'}, {'geneName': 'FANCA', 'isVUS': 'true', 'variantName': 'Q376E'}, {'geneName': 'FGFR2', 'isVUS': 'true', 'variantName': 'K196T,L647R,S299C,rearrangement'}, {'geneName': 'GABRA6', 'isVUS': 'true', 'variantName': 'V32I'}, {'geneName': 'GATA4', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'HNF1A', 'isVUS': 'true', 'variantName': 'D80E'}, {'geneName': 'IDH2', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'MAP3K13', 'isVUS': 'true', 'variantName': 'L606V'}, {'geneName': 'MET', 'isVUS': 'true', 'variantName': 'K80T'}, {'geneName': 'NOTCH2', 'isVUS': 'true', 'variantName': 'N570T'}, {'geneName': 'NTRK2', 'isVUS': 'true', 'variantName': 'L584V'}, {'geneName': 'NTRK3', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'PALB2', 'isVUS': 'true', 'variantName': 'A900V'}, {'geneName': 'PTCH1', 'isVUS': 'true', 'variantName': 'R1319C'}, {'geneName': 'RAD21', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'TSC1', 'isVUS': 'true', 'variantName': 'E1101V'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'Blood Tumor Mutational Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '20', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '20'}}, 'Interpretation': 'Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a bTMB level that may be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). For patients with gastric cancer, increased TMB is reported to be associated with prolonged OS (Cai et al., 2020; 32141230, Zhao et al., 2021; 33510848, Wei et al., 2021; 33613701). One study observed that the OS and disease_free survival (DFS) benefits of postoperative chemotherapy were more pronounced in patients with TMB_low gastric cancer (stage Ib/II) compared to those with TMB_high; however, patients with stage III gastric cancer benefitted regardless of TMB level (Wang et al., 2021; 33687617). In esophageal cancer, patients with TMB_high who had not received radiotherapy had significantly reduced OS (p=0.038) compared to those with TMB_low (Yuan et al., 2019; 32165590). On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511) and anti_PD_1 (Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074) therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). In HNSCC, a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511).', 'Include': 'true', 'ClinicalTrialNote': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04237649', 'Include': 'true'}, {'nctId': 'NCT04592913', 'Include': 'true'}, {'nctId': 'NCT03281369', 'Include': 'true'}, {'nctId': 'NCT03674567', 'Include': 'true'}, {'nctId': 'NCT04181788', 'Include': 'true'}, {'nctId': 'NCT02829723', 'Include': 'true'}, {'nctId': 'NCT03797326', 'Include': 'true'}, {'nctId': 'NCT03829501', 'Include': 'true'}, {'nctId': 'NCT03530397', 'Include': 'true'}, {'nctId': 'NCT03192345', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'CDK6', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'true', 'name': 'amplification'}}, 'Interpretation': 'CDK6 encodes cyclin_dependent kinase 6, which regulates the cell cycle, differentiation, senescence, and apoptosis (Meyerson et al., 1994; 8114739, Grossel and Hinds, 2006; 16294322, Choi et al., 2014; 23644662). CDK6 and its functional homolog CDK4 are activated by D_type cyclins and promote cell cycle progression by inactivating the tumor suppressor Rb (Weinberg et al., 1995; 7736585, Musgrove et al., 2011; 21734724). Amplification of the chromosomal region that includes CDK6 has been reported in multiple cancer types, and has been associated with overexpression of CDK6 protein (Ismail et al., 2011; 21593195, van Dekken et al., 2009; 19167610). In the TCGA dataset, amplification of CDK6 was found in 8% of stomach adenocarcinoma cases (Cancer Genome Atlas Research Network., 2014; 25079317). High_level amplification or copy number gain of CDK6 has been observed in 35.5% (11/31) of gastric cancer cell lines and was associated with increased CDK6 mRNA levels (Takada et al., 2005; 15723654). CDK6 overexpression has also been reported in patients with gastric cancer, and was found to be significantly associated with metastasis, poor differentiation, and poor survival (Feng et al., 2012; 21264532). Tumors with CDK6 activation may be sensitive to CDK4/6 inhibitors, such as abemaciclib, palbociclib, and ribociclib (Infante et al., 2014; ASCO Abstract 2528, Flaherty et al., 2012; 22090362, Finn et al., 2014; 25524798, Turner et al., 2015; 26030518, Patnaik et al., 2016; 27217383). Clinical benefit has been reported for patients with CDK6_amplified or mutated solid tumors in response to treatment with ribociclib (Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557).', 'Include': 'true', 'ClinicalTrialNote': 'Tumors with CDK6 amplification may be sensitive to CDK4/6 inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04594005', 'Include': 'true'}, {'nctId': 'NCT03099174', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT03994796', 'Include': 'true'}, {'nctId': 'NCT02693535', 'Include': 'true'}, {'nctId': 'NCT02896335', 'Include': 'true'}, {'nctId': 'NCT03310879', 'Include': 'true'}, {'nctId': 'NCT03065062', 'Include': 'true'}, {'nctId': 'NCT03454035', 'Include': 'true'}, {'nctId': 'NCT02897375', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'FGFR2', 'Include': 'true', 'Alterations': {'Alteration': [{'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'FGFR2 encodes a tyrosine kinase cell surface receptor, which plays an important role in cell differentiation, growth, and angiogenesis (Powers et al., 2000; 11021964, Turner and Grose, 2010; 20094046). FGFR2 amplification has been reported in a variety of cancer types (Gao et al., 2013; 23550210) and has been shown to correlate with increased mRNA and protein expression (Pearson et al., 2016; 27179038, Tokunaga et al., 2016; 26933914). Higher level, clonal FGFR2 amplification has been reported to correlate with higher response rates to FGFR inhibitors (Pearson et al., 2016; 27179038, André et al., 2013; 23658459). FGFR2 fusions retaining the kinase domain encoded by exons 11_17 have been reported to be activating, oncogenic, and sensitive to FGFR inhibitors (Singh et al., 2012; 22837387, Lorenzi et al., 1996; 8799135, Wu et al., 2013; 23558953, Arai et al., 2013; 24122810, Wu et al., 2013; 23558953). Furthermore, FGFR2 variants lacking a portion of the cytoplasmic domain encoded by exon 18 have been reported to be oncogenic in vitro (Lorenzi et al., 1997; 9266968, Lorenzi et al., 1996; 8799135, Ueda et al., 1999; 10626794, Wu et al., 2013; 23558953, Cha et al., 2009; 19103595). FGFR2 variants truncated after exon 17, as observed here, have been reported to be oncogenic, efficiently transforming cultured cells and driving xenograft growth in mice with higher potency than full_length FGFR2 (Lorenzi et al., 1997; 9266968, Itoh et al., 1994; 8205545, Cha et al., 2009; 19103595, Ueda et al., 1999; 10626794). FGFR2 mutations have been reported in 0_4% of gastric adenocarcinoma cases (Cancer Genome Atlas Research Network., 2014; 25079317, cBio_Wang et al., 2014; 24816253, cBio_Kakiuchi et al., 2014; 24816255, cBio_Wang et al., 2011; 22037554). In the Stomach Adenocarcinoma TCGA dataset, putative high_level amplification of FGFR2 has been reported in 5% of cases (Cancer Genome Atlas Research Network., 2014; 25079317). Studies have reported FGFR2 amplification in 2_9% of gastric cancer samples analyzed (Jung et al., 2012; 22440694, Matsumoto et al., 2012; 22240789, Deng et al., 2012; 22315472, Betts et al., 2013; 24306956). FGFR2 protein expression and pathway alteration has been associated with diffuse_type gastric cancer and not with the intestinal type (Toyokawa et al., 2009; 19287982, Hattori et al., 1996; 9816310, Yamashita et al., 2011; 21191688). However, one study did report FGFR2 protein overexpression in intestinal_type gastric cancer (Guo et al., 2012; 22533479). High FGFR2 protein expression or FGFR2 gene amplification in patients with gastric carcinoma has been correlated with worse prognosis, tumor infiltration, and a more advanced disease state (Toyokawa et al., 2009; 19287982, Hattori et al., 1996; 9816310, Matsumoto et al., 2012; 22240789, Jung et al., 2012; 22440694, Deng et al., 2012; 22315472, Betts et al., 2013; 24306956). FGFR2 activating mutations, amplifications, or fusions may confer sensitivity to selective FGFR inhibitors such as erdafitinib (Tabernero et al., 2015; 26324363, Siefker_Radtke et al., 2018; ASCO Abstract 4503, Soria et al., 2017; ASCO Abstract 4074, Park et al., 2019; ASCO Abstract 4117), pemigatinib (Hollebecque et al., 2019; ESMO Abstract 720P, Krook et al., 2019; 31371345, Abou_Alfa et al., 2020; 32203698, Kuboki et al., 2019; JSMO Abstract P1_156), infigratinib (Nogova et al., 2016; 27870574, Javle et al., 2021; ASCO GI Abstract 265), E7090 (Morizane et al., 2020; ASCO GI Abstract 538), AZD4547 (Pearson et al., 2016; 27179038, Van Cutsem et al., 2017; 29177434, Aggarwal et al., 2019; 31195180, Chae et al., 2018; ASCO Abstract 2503), Debio 1347 (Voss et al., 2019; 30745300, Clearly et al., 2021; 33926920), rogaratinib (Schuler et al., 2019; 31405822), futibatinib (Bahleda et al., 2018; AACR Abstract CT121, Goyal et al., 2019; 31109923, Tran et al., 2018; ESMO Abstract 155O), and derazantinib (Mazzaferro et al., 2019; 30420614) as well as to the multikinase inhibitors pazopanib (Borad et al., 2014; 24550739, Liao et al., 2013; 23786770) and ponatinib (Gozgit et al., 2012; 22238366). In a Phase 2 study of the FGFR inhibitor AZD4547, responses were reported in 33% (3/9) of patients with FGFR2_amplified gastroesophageal cancer; in this study, higher_level amplification correlated with higher likelihood of response to FGFR inhibitors (Pearson et al., 2016; 27179038). However, a randomized Phase 2 study of AZD4547 compared with paclitaxel for the treatment of patients with advanced stomach adenocarcinoma harboring FGFR2 amplification or polysomy reported no significant increase in median PFS, median OS, or ORR (Van Cutsem et al., 2017; 29177434). Bemarituzumab, a monoclonal antibody against the FGFR2 splice variant FGFR2b, has been evaluated to treat patients with gastroesophageal junction (GEJ) adenocarcinoma expressing FGFR2b (Catenacci et al., 2020; 32167861, Wainberg et al., 2021; ASCO Abstract 160). In a Phase 1 study of single_agent bemarituzumab, the ORR was higher for patients with GEJ adenocarcinoma and high FGFR2b expression (all FGFR2_amplified) than for those with low FGFR2b expression (none FGFR2_amplified) (18% [5/28] vs. 8% [1/12]) (Catenacci et al., 2020; 32167861). The addition of bemarituzumab to modified FOLFOX6 as first_line treatment in a Phase 2 study for patients with FGFR2b_positive, HER2_negative gastric or GEJ adenocarcinoma improved median OS (19.2 vs. 13.5 months, HR=0.60) with 12.5 months of follow_up, median PFS (9.5 vs. 7.4 months, HR=0.68, p=0.0727), and ORR (47% vs. 33%) (Catenacci et al., 2021; ASCO Abstract 4010, Wainberg et al., 2021; ASCO Abstract 160). In the context of FGFR2 rearrangement, FGFR inhibitors have primarily been investigated for patients with previously treated intrahepatic cholangiocarcinoma (ICC), with the Phase 2 FIGHT_202 trial for pemigatinib (Abou_Alfa et al., 2020; 32203698) and a Phase 2 trial for infigratinib (Javle et al., 2021; ASCO GI Abstract 265) respectively reporting ORRs of 36% (38/107) and 23% (25/108). Responses to erdafitinib have been reported in patients with FGFR2 fusion_positive urothelial carcinoma (Siefker_Radtke et al., 2018; ASCO Abstract 4503) and endometrial carcinoma (Tabernero et al., 2015; 26324363).', 'Include': 'true', 'ClinicalTrialNote': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Pazopanib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Pazopanib is a tyrosine kinase inhibitor that targets VEGFRs, PDGFRs, FGFRs, KIT, ITK, LCK, and c_FMS. It is FDA approved for the treatment of advanced renal cell carcinoma and soft tissue sarcomas that have progressed after prior chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Analysis of a single_arm Phase 2 study in advanced gastric cancer suggests that patients with FGFR2 protein overexpression may benefit from the addition of pazopanib to chemotherapy (Kim et al., 2016; 26983912). Based on a PR in a patient with FGFR2_rearranged cholangiocarcinoma (Borad et al., 2014; 24550739), FGFR2 fusions may predict sensitivity to pazopanib. </p> <p><b>Supporting Data:</b> In a Phase 2 study of pazopanib plus capecitabine and oxaliplatin for the treatment of patients with advanced gastric cancer, 85.7% (6/7) of the patients with FGFR2 protein expression exhibited a PR, and PFS was significantly improved for patients with FGFR2 expression compared to those without (8.5 vs. 5.6 months, p=0.050) (Kim et al., 2016; 26983912). In a Phase 2 study comparing pazopanib in combination with fluorouracil, leukovorin, and oxaliplatin (FLO) to treatment with FLO alone in 87 patients with HER2_negative gastric or gastroesophageal junction cancer, pazopanib showed marginal efficacy, and both the pazopanib and control cohorts experienced inferior PFS compared to previous studies (Thuss_Patience et al., 2015; ASCO Abstract 4033). A Phase 1 study of pazopanib in combination with paclitaxel and carboplatin for patients with advanced solid tumors (n=34) reported CRs for 2 of 4 patients with esophageal cancer and a PR for 1 of 2 patients with gastroesophageal junction cancer (Burris et al., 2012; 22679111). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Erdafitinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Erdafitinib is a pan_fibroblast growth factor receptor (FGFR) inhibitor. It is FDA approved for the treatment of patients with advanced or metastatic urothelial carcinoma who have FGFR2 or FGFR3 alterations and have progressed after prior chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence for FGFR2 fusions (Tabernero et al., 2015; 26324363, Siefker_Radtke et al., 2018; ASCO Abstract 4503, Park et al., 2019; ASCO Abstract 4117), limited evidence for FGFR2 mutations (Soria et al., 2017; ASCO Abstract 4074, Park et al., 2019; ASCO Abstract 4117) and limited evidence for FGFR2 amplification (Bahleda et al., 2019; 31088831), and preclinical data (Perera et al., 2017; 28341788, Karkera et al., 2017; 28416604), FGFR2 activating alterations may confer sensitivity to erdafitinib. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of erdafitinib for the treatment of gastric or esophageal carcinomas are limited (PubMed, Oct 2021). Erdafitinib has been primarily studied for the treatment of FGFR_altered urothelial carcinoma. A Phase 2 study evaluating erdafitinib for the treatment of patients with metastatic or unresectable urothelial carcinoma (mUC) previously treated with chemotherapy and harboring FGFR2/3 fusions or FGFR3 activating mutations reported an ORR of 40% (40/99, 3 CR), and a DCR of 80% (79/99) (Loriot et al., 2019; 31340094). A Phase 1 trial of erdafitinib reported clinical responses in for patients with various FGFR2_ or FGFR3_altered solid tumors (Qin et al., 2019; 30267839, Soria et al., 2016; ASCO Abstract 4074, Tabernero et al., 2015; 26324363, Di Stefano et al., 2015; 25609060), including cholangiocarcinoma (27% ORR, 3/11), NSCLC (5% ORR, 1/21), breast (9% ORR, 3/34), and ovarian (9% ORR, 1/11), while other cancers including endometrial carcinoma and glioblastoma showed a low ORR (2%, 1/58)(Bahleda et al., 2019; 31088831). Following progression on multiple other lines of therapy, a patient with metastatic FGFR2_fusion_positive NSCLC treated with erdafitinib exhibited an 11_month PR (Qin et al., 2019; 30267839). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04083976', 'Include': 'true'}, {'nctId': 'NCT03797326', 'Include': 'true'}, {'nctId': 'NCT02450136', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT04189445', 'Include': 'true'}, {'nctId': 'NCT03564691', 'Include': 'true'}, {'nctId': 'NCT04008797', 'Include': 'true'}, {'nctId': 'NCT03547037', 'Include': 'true'}, {'nctId': 'NCT04042116', 'Include': 'true'}, {'nctId': 'NCT04565275', 'Include': 'true'}]}}, {'Name': 'rearrangement intron 17', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'rearrangement intron 17'}}, 'Interpretation': 'FGFR2 encodes a tyrosine kinase cell surface receptor, which plays an important role in cell differentiation, growth, and angiogenesis (Powers et al., 2000; 11021964, Turner and Grose, 2010; 20094046). FGFR2 amplification has been reported in a variety of cancer types (Gao et al., 2013; 23550210) and has been shown to correlate with increased mRNA and protein expression (Pearson et al., 2016; 27179038, Tokunaga et al., 2016; 26933914). Higher level, clonal FGFR2 amplification has been reported to correlate with higher response rates to FGFR inhibitors (Pearson et al., 2016; 27179038, André et al., 2013; 23658459). FGFR2 fusions retaining the kinase domain encoded by exons 11_17 have been reported to be activating, oncogenic, and sensitive to FGFR inhibitors (Singh et al., 2012; 22837387, Lorenzi et al., 1996; 8799135, Wu et al., 2013; 23558953, Arai et al., 2013; 24122810, Wu et al., 2013; 23558953). Furthermore, FGFR2 variants lacking a portion of the cytoplasmic domain encoded by exon 18 have been reported to be oncogenic in vitro (Lorenzi et al., 1997; 9266968, Lorenzi et al., 1996; 8799135, Ueda et al., 1999; 10626794, Wu et al., 2013; 23558953, Cha et al., 2009; 19103595). FGFR2 variants truncated after exon 17, as observed here, have been reported to be oncogenic, efficiently transforming cultured cells and driving xenograft growth in mice with higher potency than full_length FGFR2 (Lorenzi et al., 1997; 9266968, Itoh et al., 1994; 8205545, Cha et al., 2009; 19103595, Ueda et al., 1999; 10626794). FGFR2 mutations have been reported in 0_4% of gastric adenocarcinoma cases (Cancer Genome Atlas Research Network., 2014; 25079317, cBio_Wang et al., 2014; 24816253, cBio_Kakiuchi et al., 2014; 24816255, cBio_Wang et al., 2011; 22037554). In the Stomach Adenocarcinoma TCGA dataset, putative high_level amplification of FGFR2 has been reported in 5% of cases (Cancer Genome Atlas Research Network., 2014; 25079317). Studies have reported FGFR2 amplification in 2_9% of gastric cancer samples analyzed (Jung et al., 2012; 22440694, Matsumoto et al., 2012; 22240789, Deng et al., 2012; 22315472, Betts et al., 2013; 24306956). FGFR2 protein expression and pathway alteration has been associated with diffuse_type gastric cancer and not with the intestinal type (Toyokawa et al., 2009; 19287982, Hattori et al., 1996; 9816310, Yamashita et al., 2011; 21191688). However, one study did report FGFR2 protein overexpression in intestinal_type gastric cancer (Guo et al., 2012; 22533479). High FGFR2 protein expression or FGFR2 gene amplification in patients with gastric carcinoma has been correlated with worse prognosis, tumor infiltration, and a more advanced disease state (Toyokawa et al., 2009; 19287982, Hattori et al., 1996; 9816310, Matsumoto et al., 2012; 22240789, Jung et al., 2012; 22440694, Deng et al., 2012; 22315472, Betts et al., 2013; 24306956). FGFR2 activating mutations, amplifications, or fusions may confer sensitivity to selective FGFR inhibitors such as erdafitinib (Tabernero et al., 2015; 26324363, Siefker_Radtke et al., 2018; ASCO Abstract 4503, Soria et al., 2017; ASCO Abstract 4074, Park et al., 2019; ASCO Abstract 4117), pemigatinib (Hollebecque et al., 2019; ESMO Abstract 720P, Krook et al., 2019; 31371345, Abou_Alfa et al., 2020; 32203698, Kuboki et al., 2019; JSMO Abstract P1_156), infigratinib (Nogova et al., 2016; 27870574, Javle et al., 2021; ASCO GI Abstract 265), E7090 (Morizane et al., 2020; ASCO GI Abstract 538), AZD4547 (Pearson et al., 2016; 27179038, Van Cutsem et al., 2017; 29177434, Aggarwal et al., 2019; 31195180, Chae et al., 2018; ASCO Abstract 2503), Debio 1347 (Voss et al., 2019; 30745300, Clearly et al., 2021; 33926920), rogaratinib (Schuler et al., 2019; 31405822), futibatinib (Bahleda et al., 2018; AACR Abstract CT121, Goyal et al., 2019; 31109923, Tran et al., 2018; ESMO Abstract 155O), and derazantinib (Mazzaferro et al., 2019; 30420614) as well as to the multikinase inhibitors pazopanib (Borad et al., 2014; 24550739, Liao et al., 2013; 23786770) and ponatinib (Gozgit et al., 2012; 22238366). In a Phase 2 study of the FGFR inhibitor AZD4547, responses were reported in 33% (3/9) of patients with FGFR2_amplified gastroesophageal cancer; in this study, higher_level amplification correlated with higher likelihood of response to FGFR inhibitors (Pearson et al., 2016; 27179038). However, a randomized Phase 2 study of AZD4547 compared with paclitaxel for the treatment of patients with advanced stomach adenocarcinoma harboring FGFR2 amplification or polysomy reported no significant increase in median PFS, median OS, or ORR (Van Cutsem et al., 2017; 29177434). Bemarituzumab, a monoclonal antibody against the FGFR2 splice variant FGFR2b, has been evaluated to treat patients with gastroesophageal junction (GEJ) adenocarcinoma expressing FGFR2b (Catenacci et al., 2020; 32167861, Wainberg et al., 2021; ASCO Abstract 160). In a Phase 1 study of single_agent bemarituzumab, the ORR was higher for patients with GEJ adenocarcinoma and high FGFR2b expression (all FGFR2_amplified) than for those with low FGFR2b expression (none FGFR2_amplified) (18% [5/28] vs. 8% [1/12]) (Catenacci et al., 2020; 32167861). The addition of bemarituzumab to modified FOLFOX6 as first_line treatment in a Phase 2 study for patients with FGFR2b_positive, HER2_negative gastric or GEJ adenocarcinoma improved median OS (19.2 vs. 13.5 months, HR=0.60) with 12.5 months of follow_up, median PFS (9.5 vs. 7.4 months, HR=0.68, p=0.0727), and ORR (47% vs. 33%) (Catenacci et al., 2021; ASCO Abstract 4010, Wainberg et al., 2021; ASCO Abstract 160). In the context of FGFR2 rearrangement, FGFR inhibitors have primarily been investigated for patients with previously treated intrahepatic cholangiocarcinoma (ICC), with the Phase 2 FIGHT_202 trial for pemigatinib (Abou_Alfa et al., 2020; 32203698) and a Phase 2 trial for infigratinib (Javle et al., 2021; ASCO GI Abstract 265) respectively reporting ORRs of 36% (38/107) and 23% (25/108). Responses to erdafitinib have been reported in patients with FGFR2 fusion_positive urothelial carcinoma (Siefker_Radtke et al., 2018; ASCO Abstract 4503) and endometrial carcinoma (Tabernero et al., 2015; 26324363).', 'Include': 'true', 'ClinicalTrialNote': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Pazopanib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Pazopanib is a tyrosine kinase inhibitor that targets VEGFRs, PDGFRs, FGFRs, KIT, ITK, LCK, and c_FMS. It is FDA approved for the treatment of advanced renal cell carcinoma and soft tissue sarcomas that have progressed after prior chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Analysis of a single_arm Phase 2 study in advanced gastric cancer suggests that patients with FGFR2 protein overexpression may benefit from the addition of pazopanib to chemotherapy (Kim et al., 2016; 26983912). Based on a PR in a patient with FGFR2_rearranged cholangiocarcinoma (Borad et al., 2014; 24550739), FGFR2 fusions may predict sensitivity to pazopanib. </p> <p><b>Supporting Data:</b> In a Phase 2 study of pazopanib plus capecitabine and oxaliplatin for the treatment of patients with advanced gastric cancer, 85.7% (6/7) of the patients with FGFR2 protein expression exhibited a PR, and PFS was significantly improved for patients with FGFR2 expression compared to those without (8.5 vs. 5.6 months, p=0.050) (Kim et al., 2016; 26983912). In a Phase 2 study comparing pazopanib in combination with fluorouracil, leukovorin, and oxaliplatin (FLO) to treatment with FLO alone in 87 patients with HER2_negative gastric or gastroesophageal junction cancer, pazopanib showed marginal efficacy, and both the pazopanib and control cohorts experienced inferior PFS compared to previous studies (Thuss_Patience et al., 2015; ASCO Abstract 4033). A Phase 1 study of pazopanib in combination with paclitaxel and carboplatin for patients with advanced solid tumors (n=34) reported CRs for 2 of 4 patients with esophageal cancer and a PR for 1 of 2 patients with gastroesophageal junction cancer (Burris et al., 2012; 22679111). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Erdafitinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Erdafitinib is a pan_fibroblast growth factor receptor (FGFR) inhibitor. It is FDA approved for the treatment of patients with advanced or metastatic urothelial carcinoma who have FGFR2 or FGFR3 alterations and have progressed after prior chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence for FGFR2 fusions (Tabernero et al., 2015; 26324363, Siefker_Radtke et al., 2018; ASCO Abstract 4503, Park et al., 2019; ASCO Abstract 4117), limited evidence for FGFR2 mutations (Soria et al., 2017; ASCO Abstract 4074, Park et al., 2019; ASCO Abstract 4117) and limited evidence for FGFR2 amplification (Bahleda et al., 2019; 31088831), and preclinical data (Perera et al., 2017; 28341788, Karkera et al., 2017; 28416604), FGFR2 activating alterations may confer sensitivity to erdafitinib. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of erdafitinib for the treatment of gastric or esophageal carcinomas are limited (PubMed, Oct 2021). Erdafitinib has been primarily studied for the treatment of FGFR_altered urothelial carcinoma. A Phase 2 study evaluating erdafitinib for the treatment of patients with metastatic or unresectable urothelial carcinoma (mUC) previously treated with chemotherapy and harboring FGFR2/3 fusions or FGFR3 activating mutations reported an ORR of 40% (40/99, 3 CR), and a DCR of 80% (79/99) (Loriot et al., 2019; 31340094). A Phase 1 trial of erdafitinib reported clinical responses in for patients with various FGFR2_ or FGFR3_altered solid tumors (Qin et al., 2019; 30267839, Soria et al., 2016; ASCO Abstract 4074, Tabernero et al., 2015; 26324363, Di Stefano et al., 2015; 25609060), including cholangiocarcinoma (27% ORR, 3/11), NSCLC (5% ORR, 1/21), breast (9% ORR, 3/34), and ovarian (9% ORR, 1/11), while other cancers including endometrial carcinoma and glioblastoma showed a low ORR (2%, 1/58)(Bahleda et al., 2019; 31088831). Following progression on multiple other lines of therapy, a patient with metastatic FGFR2_fusion_positive NSCLC treated with erdafitinib exhibited an 11_month PR (Qin et al., 2019; 30267839). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04083976', 'Include': 'true'}, {'nctId': 'NCT03797326', 'Include': 'true'}, {'nctId': 'NCT02450136', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT04189445', 'Include': 'true'}, {'nctId': 'NCT03564691', 'Include': 'true'}, {'nctId': 'NCT04008797', 'Include': 'true'}, {'nctId': 'NCT03547037', 'Include': 'true'}, {'nctId': 'NCT04042116', 'Include': 'true'}, {'nctId': 'NCT04565275', 'Include': 'true'}]}}]}, 'ReferenceLinks': None}, {'Name': 'MYC', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'MYC (c_MYC) encodes a transcription factor that regulates many genes related to cell cycle regulation and cell growth. It is an oncogene and may be activated in as many as 20% of cancers (Dang et al., 2006; 16904903). MYC dysregulation (amplification, overexpression, translocation) has been identified in a number of different cancer types (Nesbit et al., 1999; 10378696). MYC amplification has been significantly linked with increased mRNA and protein levels and results in the dysregulation of a large number of target genes (Blancato et al., 2004; 15083194, Dang et al., 2006; 16904903, Fromont et al., 2013; 23574779). MYC amplification has been reported in 9_51% of gastric adenocarcinomas, although gains of chromosome 8q, where the MYC gene resides, have been identified in up to 78% of gastric adenocarcinomas (Mitsui et al., 2007; 17431415, Hara et al., 1998; 9759658, Buffart et al., 2009; 19697059, Calcagno et al., 2013; 24053468, Cancer Genome Atlas Research Network., 2014; 25079317). MYC dysregulation, especially MYC amplification, has been suggested to play a role in gastric carcinogenesis (Calcagno et al., 2008; 18932273). Overexpression of MYC protein and mRNA has been associated with tumor metastasis, particularly in intestinal type gastric adenocarcinoma, and high MYC expression has been observed in gastric cancer samples from patients with poor disease_free survival (Kozma et al., 2001; 11299830, Burbano et al., 2006; 16886612, Han et al., 1999; 10576148, de Souza et al., 2013; 23717612, Radetsky, 1990; 2405346). There are no available therapies that directly target MYC. However, preclinical data indicate that MYC overexpression may predict sensitivity to investigational agents targeting CDK1 (Horiuchi et al., 2012; 22430491, Goga et al., 2007; 17589519), CDK2 (Molenaar et al., 2009; 19525400), Aurora kinase A (Dammert et al., 2019; 31375684, Mollaoglu et al., 2017; 28089889, Robert et al., 2017; 29088717, Wang et al., 2017; 28417568, Takahashi et al., 2015; 25632068, Li et al., 2018; 30226440, Kong et al., 2017; DOI: 10.21037/tcr.2017.06.41, Mahadeva et al.,2014; 24893165, Park et al., 2019; 31429028), Aurora kinase B (Helfrich et al., 2016; 27496133, Hook et al., 2012; 22222631, Yang et al., 2010; 20643922, He et al., 2019; 30540594), glutaminase (Shroff et al., 2015; 25964345, Effenberger et al., 2017; 29156762, Shen et al., 2018; 30103944, Xiang et al., 2015; 25915584), or BET bromodomain_containing proteins (Delmore et al., 2011; 21889194, Bandopadhayay et al., 2013; 24297863, Loven et al., 2013; 23582323, Otto et al., 2019; 31734632), as well as agents targeting both HDAC and PI3K (Dong et al., 2013; 23866964, Pei et al., 2016; 26977882; Fu et al., 2019; 30224636). A Phase 2 study reported a PFS benefit associated with a combination of the Aurora A kinase inhibitor alisertib and paclitaxel as second_line therapy for patients with MYC_overexpressed small cell lung cancer but not for patients without MYC overexpression (Simmons et al., 2020; 31655296). A patient with MYC_amplified invasive ductal breast carcinoma experienced a PR to an Aurora kinase inhibitor (Ganesan et al., 2014; 25253784). The glutaminase inhibitor CB_839, in combination with either everolimus or cabozantinib, has demonstrated encouraging efficacy in Phase 1 and 2 studies enrolling patients with pretreated advanced renal cell carcinoma (Tannir et al., 2018; ASCO GU Abstract 603, Motzer et al., 2019; ESMO Abstract LBA54). MYC amplification has also been suggested to predict response to chemotherapy in patients with breast cancer in some studies (Pereira et al., 2013; 23555992, Yasojima et al., 2011; 21741827). Preclinical evidence suggests that colon cancer cells with MYC amplification may be more sensitive to 5_fluorouracil and paclitaxel (Arango et al., 2001; 11406570, Bottone et al., 2003; 14516787).', 'Include': 'true', 'ClinicalTrialNote': 'MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT03220347', 'Include': 'true'}, {'nctId': 'NCT03297424', 'Include': 'true'}, {'nctId': 'NCT04555837', 'Include': 'true'}, {'nctId': 'NCT01434316', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'DNMT3A', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'F732fs*8', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'F732fs*8'}}, 'Interpretation': 'The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation (Trowbridge and Orkin, 2012; 22200773, Chédin, 2011; 21507354). The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor (Yang et al., 2011; 21887466, Vallböhmer et al., 2006; 16870044, Daskalos et al., 2011; 21351083, Fabbri et al., 2007; 17890317, Gao et al., 2011; 22011581, Kim et al., 2013; 23031157). Alterations such as seen here may disrupt DNMT3A function or expression (Chen et al., 2005; 15861382, Guo et al., 2015; 25383530, Sandoval et al., 2019; 30705090, Zhang et al., 2018; 29414941). DNMT3A alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Feb 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2021). There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'EPHB4', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'EPHB4 encodes a member of the EPH family of receptor tyrosine kinases (Noren et al., 2007; 17483308). Ephrin signaling has been implicated in multiple processes, including cell adhesion, cytoskeletal organization, and cell migration (Pasquale, 2008; 18394988), and signaling between EPHB4 and its ligand EphrinB2 is particularly important for angiogenesis (Salvucci and Tosato, 2012; 22588055, Pitulescu and Adams, 2010; 21078817). EPHB receptors, including EPHB4, have been shown to undergo dysregulation (amplification, mutation, under_ or overexpression) in a number of different cancer types (Pasquale, 2010; 20179713). EPHB4 amplification has been reported in several solid tumor types (Hasina et al., 2013; 23100466, Boberg et al., 2013; 23063927, Masood et al., 2006; 16615113, Sinha et al., 2006; 17043250, Cromer et al., 2004; 14676830) and was associated with advanced disease stage in head and neck squamous cell carcinoma (HNSCC) (Sinha et al., 2006; 17043250). Activating missense mutations in or near the tyrosine kinase domain, including G723S, A742V, and P881S, have also been identified in lung cancer (Ferguson et al., 2015; 26073592). Increased EPHB4 mRNA and/or protein expression has been reported in a variety of cancer types, including head and neck squamous cell carcinoma (HNSCC) (Sinha et al., 2006; 17043250, Masood et al., 2006; 16615113, Ferguson et al., 2014; 25391996, Yavrouian et al., 2008; 18794445), gastric and esophageal (Liersch_Löhn et al., 2016; 26414866, Hu et al., 2014; 24771266, Hasina et al., 2013; 23100466, Li et al., 2011; 20686847, Yin et al., 2017; 28739744), colorectal carcinoma (CRC) (Stephenson et al., 2001; 11801186, Liu et al., 2002; 11920461, McCall et al., 2016; 27273865, Stremitzer et al., 2016; 27535973, Lv et al., 2016; 27072105, Guijarro_Muñoz et al., 2013; 23579861, Kumar et al., 2009; 19366806), breast (Wu et al., 2004; 15029258, Berclaz et al., 2002; 12168060, Brantley_Sieders et al., 2011; 21935409, Huang et al., 2015; 26191333, Pradeep et al., 2015; 26481148), ovarian (Pradeep et al., 2015; 26481148, Alam et al., 2008; 18231102, Kumar et al., 2007; 17353927), endometrial (Takai et al., 2001; 11295082, Dong et al., 2017; 28454369, Berclaz et al., 2003; 12562648), thyroid (Sharma et al., 2015; 24634162, Giaginis et al., 2016; 26220827, Xuqing et al., 2012; 22528941), lung (Ferguson et al., 2013; 23844053, Zheng et al., 2012; 22684742), glioma (Chen et al., 2013; 23138393, Tu et al., 2012; 22374425), and other solid tumors (Li and Zhao, 2013; 23079712, Xia et al., 2005; 15930280, Alam et al., 2009; 19356789, Ozgür et al., 2011; 19272799, Li et al., 2014; 25148033, Pierscianek et al., 2017; 27388534, Pierscianek et al., 2016; 26951238, Becerikli et al., 2015; 25274141, Xia et al., 2005; 15958611). In several of these studies, increased EPHB4 expression has been associated with clinicopathologic features, including disease stage (Sinha et al., 2006; 17043250, Li and Zhao, 2013; 23079712, Wu et al., 2004; 15029258, Alam et al., 2008; 18231102, Kumar et al., 2007; 17353927, Alam et al., 2009; 19356789, Zheng et al., 2012; 22684742, Li et al., 2014; 25148033), histological grade (Hasina et al., 2013; 23100466, Wu et al., 2004; 15029258, Takai et al., 2001; 11295082, Tu et al., 2012; 22374425), and hormone receptor status (Huang et al., 2015; 26191333, Dong et al., 2017; 28454369). High EPHB4 expression has been associated with inferior survival in multivariate analyses for patients with CRC treated with bevacizumab [hazard ratio (HR) = 5.95] (Guijarro_Muñoz et al., 2013; 23579861), HNSCC (HR = 2.95) (Yavrouian et al., 2008; 18794445), epithelial ovarian cancer (HR = 4.53) (Pradeep et al., 2015; 26481148), or glioma (HR = 3.21) (Tu et al., 2012; 22374425). There are no approved therapies available to target EPHB4 alterations in cancer. sEPHB4 is a soluble monomeric extracellular domain of EPHB4 that functions as an antagonist of EphrinB2_EPHB4 interaction (Kertesz et al., 2006; 16322467), and fusion of sEPHB4 with human serum albumin (HSA) increases its stability (Shi et al., 2012; 22411527). Recombinant sEPHB4_HSA is under investigation in clinical trials. Preclinical studies have demonstrated that sEPHB4_HSA inhibits cell proliferation and xenograft tumor growth, including for cells expressing cancer_associated EPHB4 mutants or overexpressing wild_type EPHB4 (Kertesz et al., 2006; 16322467, Li et al., 2014; 25148033, Liu et al., 2013; 23721559, Bhatia et al., 2016; 27941840, Scehnet et al., 2009; 18836096, Ferguson et al., 2015; 26073592). In addition, small_molecule inhibitors targeting multiple tyrosine kinases including EPHB4, such as JI_101 and XL647, have been under preclinical and clinical investigation (Werner et al., 2015; 26365907, Pietanza et al., 2012; 22011666, Pietanza et al., 2012; 22722787).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'GATA6', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'true', 'name': 'amplification'}}, 'Interpretation': 'GATA6 encodes a zinc finger transcription factor, which is involved in the development of several tissues and is expressed in proliferating cells throughout the intestinal tract (Zheng et al., 2010; 21779441). GATA6 has been described as both a tumor suppressor and an oncogene, which may be dependent on the tumor type. GATA6 was identified as a tumor suppressor in a preclinical model of astrocytoma and verified in human samples; GATA6 mutations, loss of GATA6 expression, or loss of heterozygosity were discovered in glioblastomas, but not in lower grade astrocytomas, and restoration of GATA6 inhibited glioblastoma cell line growth (Kamnasaran et al., 2007; 17463088). However, overexpression of GATA6 has been detected in pancreatic and bile duct carcinoma and is associated with increased proliferation, cell cycle progression, and colony formation, which have been shown to be inhibited by GATA6 siRNA knockdown in pancreatic carcinoma cell lines (Fu et al., 2008; 18769116, Kwei et al., 2008; 18535672). GATA6 overexpression in colorectal carcinoma is also associated with poor prognosis and metastasis (Shen et al., 2013; 23784465). There are no targeted therapies available to address genomic alterations in GATA6.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'GNAS', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Q227E', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Q227E'}}, 'Interpretation': 'GNAS encodes the alpha subunit of the stimulatory G protein (Gs_alpha) (Hayward et al., 1998; 9860993). Gs_alpha is a guanine_nucleotide binding protein (G protein) that is involved in hormonal regulation of adenylate cyclase (Hayward et al., 1998; 9860993). GNAS has been reported to be amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). GNAS alterations that have been shown to result in constitutive activation of adenylyl cyclase and an increase in cellular cAMP concentration (Masters et al., 1989; 2549064, Graziano and Gilman, 1989; 2549065, Jang and Juhnn, 2001; 11322485, Landis et al., 1989; 2549426, Tobar_Rubin et al., 2013; 23288949, Mariot et al., 2011; 20887824) are predicted to be activating. Mutations at R201 specifically are commonly associated with McCune_Albright syndrome, a disease that can co_occur with various cancers in patients with GNAS activating mutations (Weinstein et al., 1991; 1944469, Collins et al., 2003; 12970318, Nault et al., 2012; 21835143). The highest incidences of GNAS mutations have been reported in intraductal papillary mucinous neoplasms (40_66%)(Furukawa et al., 2011; 22355676, Wu et al., 2011; 21775669) and appendiceal mucinous neoplasms (50_72%)(Nishikawa et al., 2013; 23403822, Singhi et al., 2014; 24925222) as well as in tumors affecting the peritoneum (22%), pituitary gland (20%), bone (15%), pancreas (12%), and small intestine (12%)(COSMIC, 2021)(Tate et al., 2019; 30371878). Amplification of GNAS has been reported in ovarian epithelial carcinomas (12_30%)(Cancer Genome Atlas Research Network., 2011; 21720365, Kan et al., 2010; 20668451, Tominaga et al., 2010; 20537689), colorectal adenocarcinoma (9%)(Cancer Genome Atlas Network., 2012; 22810696), stomach adenocarcinoma (7%)(Cancer Genome Atlas Research Network., 2014; 25079317), lung adenocarcinoma (6.5%)(Cancer Genome Atlas Research Network., 2014; 25079552), breast invasive carcinoma (6.5%)(Cancer Genome Atlas Network., 2012; 23000897), pancreatic adenocarcinoma (6%)(Bio_Witkiewicz et al., 2015; 25855536), and sarcomas (5.8%)(cBio_Barretina et al., 2010; 20601955). GNAS mutations are rare in hematological malignancies generally (COSMIC, 2021)(Tate et al., 2019; 30371878, cBio_Lohr et al., 2014; 24434212, Chapman et al., 2011; 21430775). Activating GNAS mutations have been identified in gastrointestinal polyps in 75% (3/4) of patients with McCune_Albright syndrome (Zacharin et al., 2011; 21357941). Amplification of GNAS has been associated with shorter progression_free survival in patients with ovarian cancer (Kan et al., 2010; 20668451, Tominaga et al., 2010; 20537689), while activating GNAS mutations have been correlated with tumor progression and poor prognosis in patients with gastric cancer (Alakus et al., 2009; 20027678). There are no therapies targeted to GNAS mutation in cancer. However, there is limited data indicating that a patient with appendiceal adenocarcinoma and a GNAS mutation (R201H) benefited from trametinib for 4 months (Ang et al., 2017; 28868010). Additionally, a patient with GNAS_mutated Erdheim_Chester disease exhibited a PR following treatment with single_agent trametinib (Saunders et al., 2019; 31740567).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Cannot Be Determined', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Cannot Be Determined'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. In the context of diffuse_type gastric cancer, a higher frequency of MSI_H tumors has been reported in familial (28%, 7/25) versus sporadic (7%, 7/107) tumors; no difference in frequency of MSI_H tumors was observed for intestinal_type gastric cancer (Fang et al., 2013; 23555086). MSI_H tumors have been frequently associated with hypermethylation and loss of MLH1 expression in cancers of the upper gastrointestinal tract, including esophageal, gastroesophageal junction, and gastric adenocarcinomas (Fang et al., 2013; 23555086, Gu et al., 2009; 19621725, Sasaki et al., 2011; 22866067, Fleisher et al., 1999; 10070967, Vasavi et al., 2010; 21045259, Zhang et al., 2013; 24035280). MSI_H gastric cancers are associated with certain clinicopathological and molecular features, including intestinal type differentiation, antral location, advanced age, reduced lymph node metastasis, and better prognosis (Zhu et al., 2015; 26137290, Leung et al., 1999; 9892201, dos Santos et al., 1996; 8536886, Wu et al., 1998; 9537253, Seo et al., 2015; 26078567, Cancer Genome Atlas Research Network., 2014; 25079317). A retrospective meta_analysis of the prognostic role of MSI in gastric cancers reported an increased DFS and OS in patients with MSI_H versus MSS/MSI_Low (Pietrantonio et al., 2019; 31513484). Conversely, in the same study, MSI_H was a negative predictor of response and MSS/MSI_Low correlated with increased benefit for patients treated with chemotherapy plus surgery as opposed to surgery alone (Pietrantonio et al., 2019; 31513484). In gastroesophageal cancer, MSI_H status was associated with shorter PFS compared to MSS patients for patients treated with chemotherapy (mPFS 4.8 months vs 6.9 months, HR=0.4) (Janjigian et al., 2018; 29122777). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143) and PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear. While approximately 80% of MSI_H tumors arise due to somatic inactivation of an MMR pathway protein, about 20% arise due to germline mutations in one of the MMR genes (Kocarnik et al., 2015; 26337942), which are associated with a condition known as Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC) (Lynch et al., 2009; 19659756). Lynch syndrome leads to an increased risk of colorectal, endometrial, gastric, and other cancers (Lynch et al., 2009; 19659756, Pande et al., 2012; 22714864, Kastrinos and Syngal, 2007; 17920897) and has an estimated prevalence in the general population ranging from 1:600 to 1:2000 (Silva et al., 2009; 19466295, Sehgal et al., 2014; 24978665, de la Chapelle et al., 2005; 16136383). Therefore, in the appropriate clinical context, germline testing of MLH1, MSH2, MSH6, and PMS2 is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TP53', 'Include': 'true', 'Alterations': {'Alteration': [{'Name': 'H214R', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'H214R'}}, 'Interpretation': 'Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 is frequently mutated in cancers of the gastrointestinal tract, with alterations reported in 34–72% of esophageal, gastroesophageal junction, and gastric adenocarcinomas (Dulak et al., 2013; 23525077, Cancer Genome Atlas Research Network., 2014; 25079317, Sengpiel et al., 2009; 19160092, Pühringer_Oppermann et al., 2006; 16538517). Overexpression of p53 protein, which may occur as a result of mutation, has been reported in approximately 36% of gastric cancers, with p53 expression reported to be more frequent in intestinal_type compared with diffuse_type gastric cancer (Lee et al., 2014; 23969480, Sezer et al., 2013; 23613399, Victorzon et al., 1996; 8664030, Gonçalves et al., 2011; 21116760). While some studies have reported no association between TP53 mutation status and prognosis in patients with esophageal carcinoma or gastroesophageal junction adenocarcinoma (Sengpiel et al., 2009; 19160092, Pühringer_Oppermann et al., 2006; 16538517) others have associated TP53 mutation and elevated p53 expression with poor prognosis for patients with esophageal squamous cell carcinoma (Han et al., 2007; 17760650, Yamasaki et al., 2010; 19941080) or stomach cancer (Liu et al., 2012; 23285001, Wiksten et al., 2008; 18751407, Migliavacca et al., 2004; 15254976). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) for patients with TP53 mutations versus 12.1% (4/33) for patients who were TP53 wild_type (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53_mutated, but not TP53_wild_type, breast cancer xenotransplant mouse model (Ma et al., 2012; 22446188). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Sep 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}, {'Name': 'L206fs*3', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'L206fs*3'}}, 'Interpretation': 'Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 is frequently mutated in cancers of the gastrointestinal tract, with alterations reported in 34–72% of esophageal, gastroesophageal junction, and gastric adenocarcinomas (Dulak et al., 2013; 23525077, Cancer Genome Atlas Research Network., 2014; 25079317, Sengpiel et al., 2009; 19160092, Pühringer_Oppermann et al., 2006; 16538517). Overexpression of p53 protein, which may occur as a result of mutation, has been reported in approximately 36% of gastric cancers, with p53 expression reported to be more frequent in intestinal_type compared with diffuse_type gastric cancer (Lee et al., 2014; 23969480, Sezer et al., 2013; 23613399, Victorzon et al., 1996; 8664030, Gonçalves et al., 2011; 21116760). While some studies have reported no association between TP53 mutation status and prognosis in patients with esophageal carcinoma or gastroesophageal junction adenocarcinoma (Sengpiel et al., 2009; 19160092, Pühringer_Oppermann et al., 2006; 16538517) others have associated TP53 mutation and elevated p53 expression with poor prognosis for patients with esophageal squamous cell carcinoma (Han et al., 2007; 17760650, Yamasaki et al., 2010; 19941080) or stomach cancer (Liu et al., 2012; 23285001, Wiksten et al., 2008; 18751407, Migliavacca et al., 2004; 15254976). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) for patients with TP53 mutations versus 12.1% (4/33) for patients who were TP53 wild_type (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53_mutated, but not TP53_wild_type, breast cancer xenotransplant mouse model (Ma et al., 2012; 22446188). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Sep 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}]}, 'ReferenceLinks': None}, {'Name': 'Tumor Fraction', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '50', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '50'}}, 'Interpretation': 'Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with high tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus higher sensitivity for identifying genomic alterations. Such specimens are at a lower risk of false negative results (Li et al., 2021; AACR Abstract 2231). However, if tumor fraction is not detected as high, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '20', 'Title': 'KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'ADORA2A, CD73, PD_1', 'Locations': 'Taipei (Taiwan), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Missouri, Connecticut, Texas', 'NCTID': 'NCT04237649', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '20', 'Title': 'Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer', 'StudyPhase': 'PHASE 3', 'Target': 'PD_L1', 'Locations': 'Taipei (Taiwan), Taoyuan City (Taiwan), Taichung (Taiwan), Tainan City (Taiwan), Kaohsiung (Taiwan), Hwasun_gun (Korea, Republic of), Anyang_si (Korea, Republic of), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Suita_shi (Japan)', 'NCTID': 'NCT04592913', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '20', 'Title': 'A Study of Multiple Immunotherapy_Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus_Gastric Cancer)', 'StudyPhase': 'PHASE 1/2', 'Target': 'MEK, CXCR4, VEGFRs, PD_L1', 'Locations': 'Taipei City (Taiwan), Zhongzheng Dist. (Taiwan), Tainan (Taiwan), Suwon_si, (Korea, Republic of), Seodaemun_Gu (Korea, Republic of), Seoul (Korea, Republic of), Songpa_gu (Korea, Republic of), Blacktown (Australia), Melbourne (Australia), Clayton (Australia)', 'NCTID': 'NCT03281369', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '20', 'Title': 'Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1, CCR4', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Shatin (Hong Kong), High West (Hong Kong), Ulsan (Korea, Republic of), Chungbuk (Korea, Republic of), Seoul (Korea, Republic of), Bangkok (Thailand), Nedlands (Australia), Heidelberg (Australia)', 'NCTID': 'NCT03674567', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '20', 'Title': 'Sasanlimab (PF_06801591, PD_1 Inhibitor) in Participants With Advanced Malignancies', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1', 'Locations': 'Taipei (Taiwan), Kaohsiung (Taiwan), Shanghai (China), Nanjing (China), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Chongqing (China), Beijing (China), Chuo_ku (Japan), Kopeysk (Russian Federation)', 'NCTID': 'NCT04181788', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '20', 'Title': 'Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1, CSF1R', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Nagoya (Japan), Koto ku (Japan), Singapore (Singapore), Tel Aviv (Israel), Zurich (Switzerland), Rozzano (Italy), Barcelona (Spain), Hospitalet de LLobregat (Spain)', 'NCTID': 'NCT02829723', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '20', 'Title': 'Efficacy and Safety of Pembrolizumab (MK_3475) Plus Lenvatinib (E7080/MK_7902) in Previously Treated Participants With Select Solid Tumors (MK_7902_005/E7080_G000_224/LEAP_005)', 'StudyPhase': 'PHASE 2', 'Target': 'PD_1, FGFRs, KIT, PDGFRA, RET, VEGFRs', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Songpagu (Korea, Republic of), Bangkok (Thailand), Nedlands (Australia), Kazan (Russian Federation), Herston (Australia), Arkhangelsk (Russian Federation), Moscow (Russian Federation)', 'NCTID': 'NCT03797326', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '20', 'Title': 'Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'ICOS, PD_L1', 'Locations': 'Taipei (Taiwan), Napoli (Italy), Milano (Italy), Manchester (United Kingdom), Sutton (United Kingdom), Connecticut, Tennessee, Texas, Florida', 'NCTID': 'NCT03829501', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '20', 'Title': 'A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_L1, PD_1, CTLA_4', 'Locations': 'Taipei (Taiwan), Cheongju_si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Amsterdam (Netherlands), Napoli (Italy), Roma (Italy), Villejuif Cedex (France), Barcelona (Spain)', 'NCTID': 'NCT03530397', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '20', 'Title': 'A First_in_human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti_tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, TGF_beta', 'Locations': 'Taipei 100 (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Seoul (Korea, Republic of), Heidelberg West (Australia), Melbourne (Australia), Tallinn (Estonia), Hannover (Germany), Essen (Germany), Utrecht (Netherlands)', 'NCTID': 'NCT03192345', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'CDK6', 'Alteration': 'amplification', 'Title': 'CDK4/6 Tumor, Abemaciclib, Paclitaxel', 'StudyPhase': 'PHASE 1/2', 'Target': 'CDK4, CDK6', 'Locations': 'Seoul (Korea, Republic of)', 'NCTID': 'NCT04594005', 'Note': 'Tumors with CDK6 amplification may be sensitive to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CDK6', 'Alteration': 'amplification', 'Title': 'This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.', 'StudyPhase': 'PHASE 1', 'Target': 'CDK4, CDK6, IGF_1, IGF_2, Aromatase, ER', 'Locations': 'Seoul (Korea, Republic of), Goyang (Korea, Republic of), Aichi, Nagoya (Japan), Kanagawa, Isehara (Japan), Tokyo, Chuo_ku (Japan), Tokyo, Koto_ku (Japan), Chiba, Kashiwa (Japan), Helsinki (Finland), Tampere (Finland), Turku (Finland)', 'NCTID': 'NCT03099174', 'Note': 'Tumors with CDK6 amplification may be sensitive to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CDK6', 'Alteration': 'amplification', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'Tumors with CDK6 amplification may be sensitive to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CDK6', 'Alteration': 'amplification', 'Title': 'Genetic Testing in Guiding Treatment for Patients With Brain Metastases', 'StudyPhase': 'PHASE 2', 'Target': 'ALK, ROS1, TRKA, TRKB, TRKC, CDK4, CDK6, PI3K, mTOR', 'Locations': 'Alaska, Washington', 'NCTID': 'NCT03994796', 'Note': 'Tumors with CDK6 amplification may be sensitive to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CDK6', 'Alteration': 'amplification', 'Title': 'TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, CDK4, CDK6, CSF1R, FLT3, KIT, RET, mTOR, EGFR, ERBB2, ERBB3, MEK, BRAF, SMO, DDR2, PARP, PD_1, CTLA_4, ERBB4', 'Locations': 'Hawaii, Washington, Oregon, California', 'NCTID': 'NCT02693535', 'Note': 'Tumors with CDK6 amplification may be sensitive to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CDK6', 'Alteration': 'amplification', 'Title': 'Palbociclib In Progressive Brain Metastases', 'StudyPhase': 'PHASE 2', 'Target': 'CDK4, CDK6', 'Locations': 'Massachusetts', 'NCTID': 'NCT02896335', 'Note': 'Tumors with CDK6 amplification may be sensitive to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CDK6', 'Alteration': 'amplification', 'Title': 'Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D_type Cyclins or Amplification of CDK4 or CDK6', 'StudyPhase': 'PHASE 2', 'Target': 'CDK4, CDK6', 'Locations': 'Massachusetts', 'NCTID': 'NCT03310879', 'Note': 'Tumors with CDK6 amplification may be sensitive to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CDK6', 'Alteration': 'amplification', 'Title': 'Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6', 'Locations': 'Massachusetts', 'NCTID': 'NCT03065062', 'Note': 'Tumors with CDK6 amplification may be sensitive to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CDK6', 'Alteration': 'amplification', 'Title': 'Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'MAPK3, MAPK1, CDK4, CDK6', 'Locations': 'North Carolina', 'NCTID': 'NCT03454035', 'Note': 'Tumors with CDK6 amplification may be sensitive to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CDK6', 'Alteration': 'amplification', 'Title': 'Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'CDK4, CDK6', 'Locations': 'Georgia', 'NCTID': 'NCT02897375', 'Note': 'Tumors with CDK6 amplification may be sensitive to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'amplificationrearrangement intron 17', 'Title': 'A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations', 'StudyPhase': 'PHASE 2', 'Target': 'FGFRs', 'Locations': 'Taipei (Taiwan), Taoyuan City (Taiwan), Taichung (Taiwan), Changhua (Taiwan), Tainan (Taiwan), Kaohsiung City (Taiwan), Kaohsiung (Taiwan), Hangzhou (China), Shanghai (China), Nanjing (China)', 'NCTID': 'NCT04083976', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'amplificationrearrangement intron 17', 'Title': 'Efficacy and Safety of Pembrolizumab (MK_3475) Plus Lenvatinib (E7080/MK_7902) in Previously Treated Participants With Select Solid Tumors (MK_7902_005/E7080_G000_224/LEAP_005)', 'StudyPhase': 'PHASE 2', 'Target': 'PD_1, FGFRs, KIT, PDGFRA, RET, VEGFRs', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Songpagu (Korea, Republic of), Bangkok (Thailand), Nedlands (Australia), Kazan (Russian Federation), Herston (Australia), Arkhangelsk (Russian Federation), Moscow (Russian Federation)', 'NCTID': 'NCT03797326', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'amplificationrearrangement intron 17', 'Title': 'Single_arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'FGFR1, FGFR2, FGFR3, KIT, VEGFRs', 'Locations': 'Seoul (Korea, Republic of)', 'NCTID': 'NCT02450136', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'amplificationrearrangement intron 17', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'amplificationrearrangement intron 17', 'Title': 'Futibatinib in Patients With Specific FGFR Aberrations', 'StudyPhase': 'PHASE 2', 'Target': 'FGFRs', 'Locations': 'Seul (Korea, Republic of), Sapporo_shi (Japan), London (United Kingdom), California, Arizona, Wisconsin, Texas', 'NCTID': 'NCT04189445', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'amplificationrearrangement intron 17', 'Title': 'Study of MK_4830 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_4830_001)', 'StudyPhase': 'PHASE 1', 'Target': 'ITL4, FGFRs, KIT, PDGFRA, RET, VEGFRs, PD_1', 'Locations': 'Seoul (Korea, Republic of), Tokyo (Japan), Haifa (Israel), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Warszawa (Poland), Gdansk (Poland), Heraklion (Greece), Washington', 'NCTID': 'NCT03564691', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'amplificationrearrangement intron 17', 'Title': 'A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor', 'StudyPhase': 'PHASE 1', 'Target': 'CBP, Beta_catenin, FGFRs, KIT, PDGFRA, RET, VEGFRs', 'Locations': 'Osakasayama (Japan), Chuo_Ku (Japan), Kashiwa (Japan)', 'NCTID': 'NCT04008797', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'amplificationrearrangement intron 17', 'Title': 'A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ_63723283, an Anti_Programmed Cell Death (PD)_1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, FGFRs', 'Locations': 'Chuo_Ku (Japan), Kashiwa (Japan)', 'NCTID': 'NCT03547037', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'amplificationrearrangement intron 17', 'Title': 'A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor', 'StudyPhase': 'PHASE 1/2', 'Target': 'FGFRs, VEGFRs, PD_1', 'Locations': 'Innsbruck (Austria), Essen (Germany), Bologna (Italy), Naples (Italy), Leuven (Belgium), Brussels (Belgium), Ghent (Belgium), Washington, Barcelona (Spain), Madrid (Spain)', 'NCTID': 'NCT04042116', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'amplificationrearrangement intron 17', 'Title': 'A Study of ICP_192 in Patients With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'FGFR1, FGFR2, FGFR3, FGFR4', 'Locations': 'Colorado, Minnesota, Arizona, Florida', 'NCTID': 'NCT04565275', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'MYC', 'Alteration': 'amplification', 'Title': 'A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC_90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non_Hodgkin s Lymphomas', 'StudyPhase': 'PHASE 1', 'Target': 'BRD2, BRD3, BRD4, BRDT', 'Locations': 'Kashiwa (Japan), Meldola (Italy), Napoli, Campania (Italy), Rozzano (MI) (Italy), Villejuif (France), Bordeaux (France), Barcelona (Spain), Madrid (Spain)', 'NCTID': 'NCT03220347', 'Note': 'MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.', 'Include': 'true'}, {'Gene': 'MYC', 'Alteration': 'amplification', 'Title': 'A Study of PLX2853 in Advanced Malignancies.', 'StudyPhase': 'PHASE 1/2', 'Target': 'BRD4', 'Locations': 'Arizona, New York, Texas, Virginia, Florida', 'NCTID': 'NCT03297424', 'Note': 'MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.', 'Include': 'true'}, {'Gene': 'MYC', 'Alteration': 'amplification', 'Title': 'Alisertib and Pembrolizumab for the Treatment of Patients With Rb_deficient Head and Neck Squamous Cell Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'Aurora kinase A, PD_1', 'Locations': 'Texas', 'NCTID': 'NCT04555837', 'Note': 'MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.', 'Include': 'true'}, {'Gene': 'MYC', 'Alteration': 'amplification', 'Title': 'Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, CDK1, CDK2, CDK5, CDK9', 'Locations': 'Massachusetts', 'NCTID': 'NCT01434316', 'Note': 'MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '11021964', 'FullCitation': 'Powers CJ, et al. Endocr. Relat. Cancer (2000) pmid: 11021964', 'Include': 'true'}, {'number': '1', 'ReferenceId': '20094046', 'FullCitation': 'Turner N, et al. Nat. Rev. Cancer (2010) pmid: 20094046', 'Include': 'true'}, {'number': '2', 'ReferenceId': '23550210', 'FullCitation': 'Gao J, et al. Sci Signal (2013) pmid: 23550210', 'Include': 'true'}, {'number': '3', 'ReferenceId': '27179038', 'FullCitation': 'Pearson A, et al. Cancer Discov (2016) pmid: 27179038', 'Include': 'true'}, {'number': '4', 'ReferenceId': '26933914', 'FullCitation': 'Tokunaga R, et al. Oncotarget (2016) pmid: 26933914', 'Include': 'true'}, {'number': '5', 'ReferenceId': '23658459', 'FullCitation': 'André F, et al. Clin. Cancer Res. (2013) pmid: 23658459', 'Include': 'true'}, {'number': '6', 'ReferenceId': '22837387', 'FullCitation': 'Singh D, et al. Science (2012) pmid: 22837387', 'Include': 'true'}, {'number': '7', 'ReferenceId': '8799135', 'FullCitation': 'Lorenzi MV, et al. Proc. Natl. Acad. Sci. U.S.A. (1996) pmid: 8799135', 'Include': 'true'}, {'number': '8', 'ReferenceId': '23558953', 'FullCitation': 'Wu YM, et al. Cancer Discov (2013) pmid: 23558953', 'Include': 'true'}, {'number': '9', 'ReferenceId': '24122810', 'FullCitation': 'Arai Y, et al. Hepatology (2014) pmid: 24122810', 'Include': 'true'}, {'number': '10', 'ReferenceId': '9266968', 'FullCitation': 'Lorenzi MV, et al. Oncogene (1997) pmid: 9266968', 'Include': 'true'}, {'number': '11', 'ReferenceId': '10626794', 'FullCitation': 'Ueda T, et al. Cancer Res. (1999) pmid: 10626794', 'Include': 'true'}, {'number': '12', 'ReferenceId': '19103595', 'FullCitation': 'Cha JY, et al. J. Biol. Chem. (2009) pmid: 19103595', 'Include': 'true'}, {'number': '13', 'ReferenceId': '8205545', 'FullCitation': 'Itoh H, et al. Cancer Res. (1994) pmid: 8205545', 'Include': 'true'}, {'number': '14', 'ReferenceId': '25079317', 'FullCitation': 'Nature (2014) pmid: 25079317', 'Include': 'true'}, {'number': '15', 'ReferenceId': '24816253', 'FullCitation': 'Wang K, et al. Nat. Genet. (2014) pmid: 24816253', 'Include': 'true'}, {'number': '16', 'ReferenceId': '24816255', 'FullCitation': 'Kakiuchi M, et al. Nat. Genet. (2014) pmid: 24816255', 'Include': 'true'}, {'number': '17', 'ReferenceId': '22037554', 'FullCitation': 'Wang K, et al. Nat. Genet. (2011) pmid: 22037554', 'Include': 'true'}, {'number': '18', 'ReferenceId': '22440694', 'FullCitation': 'Jung EJ, et al. Hum. Pathol. (2012) pmid: 22440694', 'Include': 'true'}, {'number': '19', 'ReferenceId': '22240789', 'FullCitation': 'Matsumoto K, et al. Br. J. Cancer (2012) pmid: 22240789', 'Include': 'true'}, {'number': '20', 'ReferenceId': '22315472', 'FullCitation': 'Deng N, et al. Gut (2012) pmid: 22315472', 'Include': 'true'}, {'number': '21', 'ReferenceId': '24306956', 'FullCitation': 'Betts G, et al. Virchows Arch. (2014) pmid: 24306956', 'Include': 'true'}, {'number': '22', 'ReferenceId': '19287982', 'FullCitation': 'Toyokawa T, et al. Oncol. Rep. (2009) pmid: 19287982', 'Include': 'true'}, {'number': '23', 'ReferenceId': '9816310', 'FullCitation': 'Hattori Y, et al. Clin. Cancer Res. (1996) pmid: 9816310', 'Include': 'true'}, {'number': '24', 'ReferenceId': '21191688', 'FullCitation': 'Yamashita K, et al. Surg. Today (2011) pmid: 21191688', 'Include': 'true'}, {'number': '25', 'ReferenceId': '22533479', 'FullCitation': 'Guo T, et al. J. Proteome Res. (2012) pmid: 22533479', 'Include': 'true'}, {'number': '26', 'ReferenceId': '26324363', 'FullCitation': 'Tabernero J, et al. J. Clin. Oncol. (2015) pmid: 26324363', 'Include': 'true'}, {'number': '27', 'ReferenceId': '31371345', 'FullCitation': 'Krook MA, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 31371345', 'Include': 'true'}, {'number': '28', 'ReferenceId': '32203698', 'FullCitation': 'Abou_Alfa GK, et al. Lancet Oncol. (2020) pmid: 32203698', 'Include': 'true'}, {'number': '29', 'ReferenceId': '27870574', 'FullCitation': 'Nogova L, et al. J. Clin. Oncol. (2017) pmid: 27870574', 'Include': 'true'}, {'number': '30', 'ReferenceId': '29177434', 'FullCitation': 'Van Cutsem E, et al. Ann. Oncol. (2017) pmid: 29177434', 'Include': 'true'}, {'number': '31', 'ReferenceId': '31195180', 'FullCitation': 'Aggarwal C, et al. J Thorac Oncol (2019) pmid: 31195180', 'Include': 'true'}, {'number': '32', 'ReferenceId': '30745300', 'FullCitation': 'Voss MH, et al. Clin. Cancer Res. (2019) pmid: 30745300', 'Include': 'true'}, {'number': '33', 'ReferenceId': '33926920', 'FullCitation': 'Cleary JM, et al. Cancer Discov (2021) pmid: 33926920', 'Include': 'true'}, {'number': '34', 'ReferenceId': '31405822', 'FullCitation': 'Schuler M, et al. Lancet Oncol. (2019) pmid: 31405822', 'Include': 'true'}, {'number': '35', 'ReferenceId': '31109923', 'FullCitation': 'Goyal L, et al. Cancer Discov (2019) pmid: 31109923', 'Include': 'true'}, {'number': '36', 'ReferenceId': '30420614', 'FullCitation': 'Mazzaferro V, et al. Br. J. Cancer (2019) pmid: 30420614', 'Include': 'true'}, {'number': '37', 'ReferenceId': '24550739', 'FullCitation': 'Borad MJ, et al. PLoS Genet. (2014) pmid: 24550739', 'Include': 'true'}, {'number': '38', 'ReferenceId': '23786770', 'FullCitation': 'Liao RG, et al. Cancer Res. (2013) pmid: 23786770', 'Include': 'true'}, {'number': '39', 'ReferenceId': '22238366', 'FullCitation': 'Gozgit JM, et al. Mol. Cancer Ther. (2012) pmid: 22238366', 'Include': 'true'}, {'number': '40', 'ReferenceId': '32167861', 'FullCitation': 'Catenacci DVT, et al. J Clin Oncol (2020) pmid: 32167861', 'Include': 'true'}, {'number': '41', 'ReferenceId': '8114739', 'FullCitation': 'Meyerson M, et al. Mol. Cell. Biol. (1994) pmid: 8114739', 'Include': 'true'}, {'number': '42', 'ReferenceId': '16294322', 'FullCitation': 'Grossel MJ, et al. J. Cell. Biochem. (2006) pmid: 16294322', 'Include': 'true'}, {'number': '43', 'ReferenceId': '23644662', 'FullCitation': 'Choi YJ, et al. Oncogene (2014) pmid: 23644662', 'Include': 'true'}, {'number': '44', 'ReferenceId': '7736585', 'FullCitation': 'Cell (1995) pmid: 7736585', 'Include': 'true'}, {'number': '45', 'ReferenceId': '21734724', 'FullCitation': 'Musgrove EA, et al. Nat. Rev. Cancer (2011) pmid: 21734724', 'Include': 'true'}, {'number': '46', 'ReferenceId': '21593195', 'FullCitation': 'Ismail A, et al. Clin. Cancer Res. (2011) pmid: 21593195', 'Include': 'true'}, {'number': '47', 'ReferenceId': '19167610', 'FullCitation': 'van Dekken H, et al. Cancer Genet. Cytogenet. (2009) pmid: 19167610', 'Include': 'true'}, {'number': '48', 'ReferenceId': '15723654', 'FullCitation': 'Takada H, et al. Cancer Sci. (2005) pmid: 15723654', 'Include': 'true'}, {'number': '49', 'ReferenceId': '21264532', 'FullCitation': 'Feng L, et al. Med. Oncol. (2012) pmid: 21264532', 'Include': 'true'}, {'number': '50', 'ReferenceId': '22090362', 'FullCitation': 'Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362', 'Include': 'true'}, {'number': '51', 'ReferenceId': '25524798', 'FullCitation': 'Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798', 'Include': 'true'}, {'number': '52', 'ReferenceId': '26030518', 'FullCitation': 'Turner NC, et al. N. Engl. J. Med. (2015) pmid: 26030518', 'Include': 'true'}, {'number': '53', 'ReferenceId': '27217383', 'FullCitation': 'Patnaik A, et al. Cancer Discov (2016) pmid: 27217383', 'Include': 'true'}, {'number': '54', 'ReferenceId': '16904903', 'FullCitation': 'Dang CV, et al. Semin. Cancer Biol. (2006) pmid: 16904903', 'Include': 'true'}, {'number': '55', 'ReferenceId': '10378696', 'FullCitation': 'Nesbit CE, et al. Oncogene (1999) pmid: 10378696', 'Include': 'true'}, {'number': '56', 'ReferenceId': '15083194', 'FullCitation': 'Blancato J, et al. Br. J. Cancer (2004) pmid: 15083194', 'Include': 'true'}, {'number': '57', 'ReferenceId': '23574779', 'FullCitation': 'Fromont G, et al. Hum. Pathol. (2013) pmid: 23574779', 'Include': 'true'}, {'number': '58', 'ReferenceId': '17431415', 'FullCitation': 'Mitsui F, et al. Mod. Pathol. (2007) pmid: 17431415', 'Include': 'true'}, {'number': '59', 'ReferenceId': '9759658', 'FullCitation': 'Hara T, et al. Lab. Invest. (1998) pmid: 9759658', 'Include': 'true'}, {'number': '60', 'ReferenceId': '19697059', 'FullCitation': 'Buffart TE, et al. Virchows Arch. (2009) pmid: 19697059', 'Include': 'true'}, {'number': '61', 'ReferenceId': '24053468', 'FullCitation': 'Calcagno DQ, et al. BMC Gastroenterol (2013) pmid: 24053468', 'Include': 'true'}, {'number': '62', 'ReferenceId': '18932273', 'FullCitation': 'Calcagno DQ, et al. World J. Gastroenterol. (2008) pmid: 18932273', 'Include': 'true'}, {'number': '63', 'ReferenceId': '11299830', 'FullCitation': 'Kozma L, et al. Anticancer Res. () pmid: 11299830', 'Include': 'true'}, {'number': '64', 'ReferenceId': '16886612', 'FullCitation': 'Burbano RR, et al. Anticancer Res. () pmid: 16886612', 'Include': 'true'}, {'number': '65', 'ReferenceId': '10576148', 'FullCitation': 'Han S, et al. J. Korean Med. Sci. (1999) pmid: 10576148', 'Include': 'true'}, {'number': '66', 'ReferenceId': '23717612', 'FullCitation': 'de Souza CR, et al. PLoS ONE (2013) pmid: 23717612', 'Include': 'true'}, {'number': '67', 'ReferenceId': '2405346', 'FullCitation': 'Pediatr. Infect. Dis. J. (1990) pmid: 2405346', 'Include': 'true'}, {'number': '68', 'ReferenceId': '22430491', 'FullCitation': 'Horiuchi D, et al. J. Exp. Med. (2012) pmid: 22430491', 'Include': 'true'}, {'number': '69', 'ReferenceId': '17589519', 'FullCitation': 'Goga A, et al. Nat. Med. (2007) pmid: 17589519', 'Include': 'true'}, {'number': '70', 'ReferenceId': '19525400', 'FullCitation': 'Molenaar JJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19525400', 'Include': 'true'}, {'number': '71', 'ReferenceId': '31375684', 'FullCitation': 'Dammert MA, et al. Nat Commun (2019) pmid: 31375684', 'Include': 'true'}, {'number': '72', 'ReferenceId': '28089889', 'FullCitation': 'Mollaoglu G, et al. Cancer Cell (2017) pmid: 28089889', 'Include': 'true'}, {'number': '73', 'ReferenceId': '29088717', 'FullCitation': 'Cardnell RJ, et al. Oncotarget (2017) pmid: 29088717', 'Include': 'true'}, {'number': '74', 'ReferenceId': '28417568', 'FullCitation': 'Wang L, et al. Mol Oncol (2017) pmid: 28417568', 'Include': 'true'}, {'number': '75', 'ReferenceId': '25632068', 'FullCitation': 'Takahashi Y, et al. Ann. Oncol. (2015) pmid: 25632068', 'Include': 'true'}, {'number': '76', 'ReferenceId': '30226440', 'FullCitation': 'Li Y, et al. Thyroid (2018) pmid: 30226440', 'Include': 'true'}, {'number': '77', 'ReferenceId': '24893165', 'FullCitation': 'Mahadevan D, et al. PLoS ONE (2014) pmid: 24893165', 'Include': 'true'}, {'number': '78', 'ReferenceId': '31429028', 'FullCitation': 'Park SI, et al. Target Oncol (2019) pmid: 31429028', 'Include': 'true'}, {'number': '79', 'ReferenceId': '27496133', 'FullCitation': 'Helfrich BA, et al. Mol. Cancer Ther. (2016) pmid: 27496133', 'Include': 'true'}, {'number': '80', 'ReferenceId': '22222631', 'FullCitation': 'Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631', 'Include': 'true'}, {'number': '81', 'ReferenceId': '20643922', 'FullCitation': 'Yang D, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20643922', 'Include': 'true'}, {'number': '82', 'ReferenceId': '30540594', 'FullCitation': 'He J, et al. Anticancer Drugs (2019) pmid: 30540594', 'Include': 'true'}, {'number': '83', 'ReferenceId': '25964345', 'FullCitation': 'Shroff EH, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25964345', 'Include': 'true'}, {'number': '84', 'ReferenceId': '29156762', 'FullCitation': 'Effenberger M, et al. Oncotarget (2017) pmid: 29156762', 'Include': 'true'}, {'number': '85', 'ReferenceId': '30103944', 'FullCitation': 'Qu X, et al. Biochem. Biophys. Res. Commun. (2018) pmid: 30103944', 'Include': 'true'}, {'number': '86', 'ReferenceId': '25915584', 'FullCitation': 'Xiang Y, et al. J. Clin. Invest. (2015) pmid: 25915584', 'Include': 'true'}, {'number': '87', 'ReferenceId': '21889194', 'FullCitation': 'Delmore JE, et al. Cell (2011) pmid: 21889194', 'Include': 'true'}, {'number': '88', 'ReferenceId': '24297863', 'FullCitation': 'Bandopadhayay P, et al. Clin. Cancer Res. (2014) pmid: 24297863', 'Include': 'true'}, {'number': '89', 'ReferenceId': '23582323', 'FullCitation': 'Lovén J, et al. Cell (2013) pmid: 23582323', 'Include': 'true'}, {'number': '90', 'ReferenceId': '31734632', 'FullCitation': 'Otto C, et al. Neoplasia (2019) pmid: 31734632', 'Include': 'true'}, {'number': '91', 'ReferenceId': '23866964', 'FullCitation': 'Dong LH, et al. J Hematol Oncol (2013) pmid: 23866964', 'Include': 'true'}, {'number': '92', 'ReferenceId': '26977882', 'FullCitation': 'Pei Y, et al. Cancer Cell (2016) pmid: 26977882', 'Include': 'true'}, {'number': '93', 'ReferenceId': '30224636', 'FullCitation': 'Fu XH, et al. Acta Pharmacol. Sin. (2019) pmid: 30224636', 'Include': 'true'}, {'number': '94', 'ReferenceId': '31655296', 'FullCitation': 'Owonikoko TK, et al. J Thorac Oncol (2020) pmid: 31655296', 'Include': 'true'}, {'number': '95', 'ReferenceId': '25253784', 'FullCitation': 'Ganesan P, et al. Mol. Cancer Ther. (2014) pmid: 25253784', 'Include': 'true'}, {'number': '96', 'ReferenceId': '23555992', 'FullCitation': 'Pereira CB, et al. PLoS ONE (2013) pmid: 23555992', 'Include': 'true'}, {'number': '97', 'ReferenceId': '21741827', 'FullCitation': 'Yasojima H, et al. Eur. J. Cancer (2011) pmid: 21741827', 'Include': 'true'}, {'number': '98', 'ReferenceId': '11406570', 'FullCitation': 'Arango D, et al. Cancer Res. (2001) pmid: 11406570', 'Include': 'true'}, {'number': '99', 'ReferenceId': '14516787', 'FullCitation': 'Bottone MG, et al. Exp. Cell Res. (2003) pmid: 14516787', 'Include': 'true'}, {'number': '100', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '101', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '102', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '103', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '104', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '105', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '106', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '107', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '108', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '109', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '110', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '111', 'ReferenceId': '30082870', 'FullCitation': 'Gandara DR, et al. Nat. Med. (2018) pmid: 30082870', 'Include': 'true'}, {'number': '112', 'ReferenceId': '30816954', 'FullCitation': 'Wang Z, et al. JAMA Oncol (2019) pmid: 30816954', 'Include': 'true'}, {'number': '113', 'ReferenceId': '32102950', 'FullCitation': 'Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950', 'Include': 'true'}, {'number': '114', 'ReferenceId': '22588877', 'FullCitation': 'Cerami E, et al. Cancer Discov (2012) pmid: 22588877', 'Include': 'true'}, {'number': '115', 'ReferenceId': '30371878', 'FullCitation': 'Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878', 'Include': 'true'}, {'number': '116', 'ReferenceId': '32141230', 'FullCitation': 'Cai L, et al. Cancer Commun (Lond) (2020) pmid: 32141230', 'Include': 'true'}, {'number': '117', 'ReferenceId': '33510848', 'FullCitation': 'Zhao DY, et al. World J Gastrointest Oncol (2021) pmid: 33510848', 'Include': 'true'}, {'number': '118', 'ReferenceId': '33613701', 'FullCitation': 'Wei XL, et al. Ther Adv Med Oncol (2021) pmid: 33613701', 'Include': 'true'}, {'number': '119', 'ReferenceId': '33687617', 'FullCitation': 'Wang D, et al. Gastric Cancer (2021) pmid: 33687617', 'Include': 'true'}, {'number': '120', 'ReferenceId': '32165590', 'FullCitation': 'Yuan C, et al. Aging (Albany NY) (2020) pmid: 32165590', 'Include': 'true'}, {'number': '121', 'ReferenceId': '9860993', 'FullCitation': 'Hayward BE, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9860993', 'Include': 'true'}, {'number': '122', 'ReferenceId': '24071852', 'FullCitation': 'Zack TI, et al. Nat. Genet. (2013) pmid: 24071852', 'Include': 'true'}, {'number': '123', 'ReferenceId': '20164920', 'FullCitation': 'Beroukhim R, et al. Nature (2010) pmid: 20164920', 'Include': 'true'}, {'number': '124', 'ReferenceId': '2549064', 'FullCitation': 'Masters SB, et al. J. Biol. Chem. (1989) pmid: 2549064', 'Include': 'true'}, {'number': '125', 'ReferenceId': '2549065', 'FullCitation': 'Graziano MP, et al. J. Biol. Chem. (1989) pmid: 2549065', 'Include': 'true'}, {'number': '126', 'ReferenceId': '11322485', 'FullCitation': 'Jang IS, et al. Exp. Mol. Med. (2001) pmid: 11322485', 'Include': 'true'}, {'number': '127', 'ReferenceId': '2549426', 'FullCitation': 'Landis CA, et al. Nature (1989) pmid: 2549426', 'Include': 'true'}, {'number': '128', 'ReferenceId': '23288949', 'FullCitation': 'Tobar_Rubin R, et al. J. Mol. Endocrinol. (2013) pmid: 23288949', 'Include': 'true'}, {'number': '129', 'ReferenceId': '20887824', 'FullCitation': 'Mariot V, et al. Bone (2011) pmid: 20887824', 'Include': 'true'}, {'number': '130', 'ReferenceId': '1944469', 'FullCitation': 'Weinstein LS, et al. N. Engl. J. Med. (1991) pmid: 1944469', 'Include': 'true'}, {'number': '131', 'ReferenceId': '12970318', 'FullCitation': 'Collins MT, et al. J. Clin. Endocrinol. Metab. (2003) pmid: 12970318', 'Include': 'true'}, {'number': '132', 'ReferenceId': '21835143', 'FullCitation': 'Nault JC, et al. J. Hepatol. (2012) pmid: 21835143', 'Include': 'true'}, {'number': '133', 'ReferenceId': '22355676', 'FullCitation': 'Furukawa T, et al. Sci Rep (2011) pmid: 22355676', 'Include': 'true'}, {'number': '134', 'ReferenceId': '21775669', 'FullCitation': 'Wu J, et al. Sci Transl Med (2011) pmid: 21775669', 'Include': 'true'}, {'number': '135', 'ReferenceId': '23403822', 'FullCitation': 'Nishikawa G, et al. Br. J. Cancer (2013) pmid: 23403822', 'Include': 'true'}, {'number': '136', 'ReferenceId': '24925222', 'FullCitation': 'Singhi AD, et al. Hum. Pathol. (2014) pmid: 24925222', 'Include': 'true'}, {'number': '137', 'ReferenceId': '21720365', 'FullCitation': 'Nature (2011) pmid: 21720365', 'Include': 'true'}, {'number': '138', 'ReferenceId': '20668451', 'FullCitation': 'Kan Z, et al. Nature (2010) pmid: 20668451', 'Include': 'true'}, {'number': '139', 'ReferenceId': '20537689', 'FullCitation': 'Tominaga E, et al. Gynecol. Oncol. (2010) pmid: 20537689', 'Include': 'true'}, {'number': '140', 'ReferenceId': '25079552', 'FullCitation': 'Nature (2014) pmid: 25079552', 'Include': 'true'}, {'number': '141', 'ReferenceId': '23000897', 'FullCitation': 'Nature (2012) pmid: 23000897', 'Include': 'true'}, {'number': '142', 'ReferenceId': '25855536', 'FullCitation': 'Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536', 'Include': 'true'}, {'number': '143', 'ReferenceId': '20601955', 'FullCitation': 'Barretina J, et al. Nat. Genet. (2010) pmid: 20601955', 'Include': 'true'}, {'number': '144', 'ReferenceId': '24434212', 'FullCitation': 'Lohr JG, et al. Cancer Cell (2014) pmid: 24434212', 'Include': 'true'}, {'number': '145', 'ReferenceId': '21430775', 'FullCitation': 'Chapman MA, et al. Nature (2011) pmid: 21430775', 'Include': 'true'}, {'number': '146', 'ReferenceId': '21357941', 'FullCitation': 'Zacharin M, et al. J. Med. Genet. (2011) pmid: 21357941', 'Include': 'true'}, {'number': '147', 'ReferenceId': '20027678', 'FullCitation': 'Alakus H, et al. World J. Gastroenterol. (2009) pmid: 20027678', 'Include': 'true'}, {'number': '148', 'ReferenceId': '28868010', 'FullCitation': 'Ang C, et al. Case Rep Oncol () pmid: 28868010', 'Include': 'true'}, {'number': '149', 'ReferenceId': '31740567', 'FullCitation': 'Saunders IM, et al. Oncologist (2019) pmid: 31740567', 'Include': 'true'}, {'number': '150', 'ReferenceId': '19935675', 'FullCitation': 'Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675', 'Include': 'true'}, {'number': '151', 'ReferenceId': '18410249', 'FullCitation': 'Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249', 'Include': 'true'}, {'number': '152', 'ReferenceId': '12826609', 'FullCitation': 'Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609', 'Include': 'true'}, {'number': '153', 'ReferenceId': '20978130', 'FullCitation': 'Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130', 'Include': 'true'}, {'number': '154', 'ReferenceId': '28472496', 'FullCitation': 'Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496', 'Include': 'true'}, {'number': '155', 'ReferenceId': '17690113', 'FullCitation': 'Yamada H, et al. Carcinogenesis (2007) pmid: 17690113', 'Include': 'true'}, {'number': '156', 'ReferenceId': '23525077', 'FullCitation': 'Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077', 'Include': 'true'}, {'number': '157', 'ReferenceId': '19160092', 'FullCitation': 'Sengpiel C, et al. Cancer Invest. (2009) pmid: 19160092', 'Include': 'true'}, {'number': '158', 'ReferenceId': '16538517', 'FullCitation': 'Pühringer_Oppermann F, et al. J. Cancer Res. Clin. Oncol. (2006) pmid: 16538517', 'Include': 'true'}, {'number': '159', 'ReferenceId': '23969480', 'FullCitation': 'Lee HE, et al. Pathobiology (2014) pmid: 23969480', 'Include': 'true'}, {'number': '160', 'ReferenceId': '23613399', 'FullCitation': 'Sezer C, et al. J BUON () pmid: 23613399', 'Include': 'true'}, {'number': '161', 'ReferenceId': '8664030', 'FullCitation': 'Victorzon M, et al. Eur. J. Cancer (1996) pmid: 8664030', 'Include': 'true'}, {'number': '162', 'ReferenceId': '21116760', 'FullCitation': 'Gonçalves AR, et al. Pathol. Oncol. Res. (2011) pmid: 21116760', 'Include': 'true'}, {'number': '163', 'ReferenceId': '17760650', 'FullCitation': 'Han U, et al. Dis. Esophagus (2007) pmid: 17760650', 'Include': 'true'}, {'number': '164', 'ReferenceId': '19941080', 'FullCitation': 'Yamasaki M, et al. Ann. Surg. Oncol. (2010) pmid: 19941080', 'Include': 'true'}, {'number': '165', 'ReferenceId': '23285001', 'FullCitation': 'Liu X, et al. PLoS ONE (2012) pmid: 23285001', 'Include': 'true'}, {'number': '166', 'ReferenceId': '18751407', 'FullCitation': 'Wiksten JP, et al. Anticancer Res. () pmid: 18751407', 'Include': 'true'}, {'number': '167', 'ReferenceId': '15254976', 'FullCitation': 'Migliavacca M, et al. J. Cell. Physiol. (2004) pmid: 15254976', 'Include': 'true'}, {'number': '168', 'ReferenceId': '20107315', 'FullCitation': 'Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315', 'Include': 'true'}, {'number': '169', 'ReferenceId': '21799033', 'FullCitation': 'Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033', 'Include': 'true'}, {'number': '170', 'ReferenceId': '21389100', 'FullCitation': 'Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100', 'Include': 'true'}, {'number': '171', 'ReferenceId': '25504633', 'FullCitation': 'Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633', 'Include': 'true'}, {'number': '172', 'ReferenceId': '12489850', 'FullCitation': 'Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850', 'Include': 'true'}, {'number': '173', 'ReferenceId': '11713371', 'FullCitation': 'Xu L, et al. Mol. Med. (2001) pmid: 11713371', 'Include': 'true'}, {'number': '174', 'ReferenceId': '23470564', 'FullCitation': 'Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564', 'Include': 'true'}, {'number': '175', 'ReferenceId': '25240597', 'FullCitation': 'Kim SS, et al. Nanomedicine (2015) pmid: 25240597', 'Include': 'true'}, {'number': '176', 'ReferenceId': '27357628', 'FullCitation': 'Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628', 'Include': 'true'}, {'number': '177', 'ReferenceId': '27601554', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554', 'Include': 'true'}, {'number': '178', 'ReferenceId': '27998224', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224', 'Include': 'true'}, {'number': '179', 'ReferenceId': '31315834', 'FullCitation': 'Lee J, et al. Cancer Discov (2019) pmid: 31315834', 'Include': 'true'}, {'number': '180', 'ReferenceId': '29535125', 'FullCitation': 'Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125', 'Include': 'true'}, {'number': '181', 'ReferenceId': '22446188', 'FullCitation': 'Ma CX, et al. J. Clin. Invest. (2012) pmid: 22446188', 'Include': 'true'}, {'number': '182', 'ReferenceId': '22965953', 'FullCitation': 'Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953', 'Include': 'true'}, {'number': '183', 'ReferenceId': '26086967', 'FullCitation': 'Mohell N, et al. Cell Death Dis (2015) pmid: 26086967', 'Include': 'true'}, {'number': '184', 'ReferenceId': '27179933', 'FullCitation': 'Fransson Å, et al. J Ovarian Res (2016) pmid: 27179933', 'Include': 'true'}, {'number': '185', 'ReferenceId': '26563132', 'FullCitation': 'Kwok M, et al. Blood (2016) pmid: 26563132', 'Include': 'true'}, {'number': '186', 'ReferenceId': '30975914', 'FullCitation': 'Boudny M, et al. Haematologica (2019) pmid: 30975914', 'Include': 'true'}, {'number': '187', 'ReferenceId': '28062704', 'FullCitation': 'Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704', 'Include': 'true'}, {'number': '188', 'ReferenceId': '30127241', 'FullCitation': 'Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241', 'Include': 'true'}, {'number': '189', 'ReferenceId': '29165669', 'FullCitation': 'Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669', 'Include': 'true'}, {'number': '190', 'ReferenceId': '26014290', 'FullCitation': 'Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290', 'Include': 'true'}, {'number': '191', 'ReferenceId': '23355100', 'FullCitation': 'Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100', 'Include': 'true'}, {'number': '192', 'ReferenceId': '11219776', 'FullCitation': 'Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776', 'Include': 'true'}, {'number': '193', 'ReferenceId': '9006316', 'FullCitation': 'Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316', 'Include': 'true'}, {'number': '194', 'ReferenceId': '19204208', 'FullCitation': 'Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208', 'Include': 'true'}, {'number': '195', 'ReferenceId': '12672316', 'FullCitation': 'Lalloo F, et al. Lancet (2003) pmid: 12672316', 'Include': 'true'}, {'number': '196', 'ReferenceId': '31050713', 'FullCitation': 'Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713', 'Include': 'true'}, {'number': '197', 'ReferenceId': '25426837', 'FullCitation': 'Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837', 'Include': 'true'}, {'number': '198', 'ReferenceId': '25426838', 'FullCitation': 'Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838', 'Include': 'true'}, {'number': '199', 'ReferenceId': '25326804', 'FullCitation': 'Xie M, et al. Nat. Med. (2014) pmid: 25326804', 'Include': 'true'}, {'number': '200', 'ReferenceId': '28669404', 'FullCitation': 'Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404', 'Include': 'true'}, {'number': '201', 'ReferenceId': '29678827', 'FullCitation': 'Severson EA, et al. Blood (2018) pmid: 29678827', 'Include': 'true'}, {'number': '202', 'ReferenceId': '29420212', 'FullCitation': 'Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212', 'Include': 'true'}, {'number': '203', 'ReferenceId': '30504320', 'FullCitation': 'Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320', 'Include': 'true'}, {'number': '204', 'ReferenceId': '32269342', 'FullCitation': 'Chabon JJ, et al. Nature (2020) pmid: 32269342', 'Include': 'true'}, {'number': '205', 'ReferenceId': '31768066', 'FullCitation': 'Razavi P, et al. Nat. Med. (2019) pmid: 31768066', 'Include': 'true'}, {'number': '206', 'ReferenceId': '31602320', 'FullCitation': 'Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320', 'Include': 'true'}, {'number': '207', 'ReferenceId': '32757294', 'FullCitation': 'Zhang EW, et al. Cancer (2020) pmid: 32757294', 'Include': 'true'}, {'number': '208', 'ReferenceId': '30833418', 'FullCitation': 'Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418', 'Include': 'true'}, {'number': '209', 'ReferenceId': '24553385', 'FullCitation': 'Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385', 'Include': 'true'}, {'number': '210', 'ReferenceId': '30400802', 'FullCitation': 'Lapin M, et al. J Transl Med (2018) pmid: 30400802', 'Include': 'true'}, {'number': '211', 'ReferenceId': '30131550', 'FullCitation': 'Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550', 'Include': 'true'}, {'number': '212', 'ReferenceId': '30385733', 'FullCitation': 'Choudhury AD, et al. JCI Insight (2018) pmid: 30385733', 'Include': 'true'}, {'number': '213', 'ReferenceId': '29298117', 'FullCitation': 'Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117', 'Include': 'true'}, {'number': '214', 'ReferenceId': '30793095', 'FullCitation': 'Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095', 'Include': 'true'}, {'number': '215', 'ReferenceId': '31059681', 'FullCitation': 'Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681', 'Include': 'true'}, {'number': '216', 'ReferenceId': '28187169', 'FullCitation': 'Fan G, et al. PLoS ONE (2017) pmid: 28187169', 'Include': 'true'}, {'number': '217', 'ReferenceId': '30923679', 'FullCitation': 'Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679', 'Include': 'true'}, {'number': '218', 'ReferenceId': '30093454', 'FullCitation': 'Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454', 'Include': 'true'}, {'number': '219', 'ReferenceId': '30860573', 'FullCitation': 'Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573', 'Include': 'true'}, {'number': '220', 'ReferenceId': '28450425', 'FullCitation': 'Goodall J, et al. Cancer Discov (2017) pmid: 28450425', 'Include': 'true'}, {'number': '221', 'ReferenceId': '29330207', 'FullCitation': 'Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207', 'Include': 'true'}, {'number': '222', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '223', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '224', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '225', 'ReferenceId': '23555086', 'FullCitation': 'Fang WL, et al. Biomed Res Int (2013) pmid: 23555086', 'Include': 'true'}, {'number': '226', 'ReferenceId': '19621725', 'FullCitation': 'Gu M, et al. Hepatogastroenterology () pmid: 19621725', 'Include': 'true'}, {'number': '227', 'ReferenceId': '22866067', 'FullCitation': 'Sasaki S, et al. Oncol Lett (2011) pmid: 22866067', 'Include': 'true'}, {'number': '228', 'ReferenceId': '10070967', 'FullCitation': 'Fleisher AS, et al. Cancer Res. (1999) pmid: 10070967', 'Include': 'true'}, {'number': '229', 'ReferenceId': '21045259', 'FullCitation': 'Vasavi M, et al. Cancer Biomark (2010) pmid: 21045259', 'Include': 'true'}, {'number': '230', 'ReferenceId': '24035280', 'FullCitation': 'Zhang LH, et al. Pathol. Res. Pract. (2013) pmid: 24035280', 'Include': 'true'}, {'number': '231', 'ReferenceId': '26137290', 'FullCitation': 'Zhu L, et al. Mol Clin Oncol (2015) pmid: 26137290', 'Include': 'true'}, {'number': '232', 'ReferenceId': '9892201', 'FullCitation': 'Leung SY, et al. Cancer Res. (1999) pmid: 9892201', 'Include': 'true'}, {'number': '233', 'ReferenceId': '8536886', 'FullCitation': 'dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886', 'Include': 'true'}, {'number': '234', 'ReferenceId': '9537253', 'FullCitation': 'Wu MS, et al. Cancer Res. (1998) pmid: 9537253', 'Include': 'true'}, {'number': '235', 'ReferenceId': '26078567', 'FullCitation': 'Seo JY, et al. World J. Gastroenterol. (2015) pmid: 26078567', 'Include': 'true'}, {'number': '236', 'ReferenceId': '31513484', 'FullCitation': 'Pietrantonio F, et al. J. Clin. Oncol. (2019) pmid: 31513484', 'Include': 'true'}, {'number': '237', 'ReferenceId': '29122777', 'FullCitation': 'Janjigian YY, et al. Cancer Discov (2018) pmid: 29122777', 'Include': 'true'}, {'number': '238', 'ReferenceId': '17204026', 'FullCitation': 'Histopathology (2007) pmid: 17204026', 'Include': 'true'}, {'number': '239', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '240', 'ReferenceId': '28734759', 'FullCitation': 'Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759', 'Include': 'true'}, {'number': '241', 'ReferenceId': '29355075', 'FullCitation': 'Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075', 'Include': 'true'}, {'number': '242', 'ReferenceId': '23169436', 'FullCitation': 'Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436', 'Include': 'true'}, {'number': '243', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '244', 'ReferenceId': '33001143', 'FullCitation': 'Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143', 'Include': 'true'}, {'number': '245', 'ReferenceId': '19659756', 'FullCitation': 'Lynch HT, et al. Clin. Genet. (2009) pmid: 19659756', 'Include': 'true'}, {'number': '246', 'ReferenceId': '22714864', 'FullCitation': 'Pande M, et al. Fam. Cancer (2012) pmid: 22714864', 'Include': 'true'}, {'number': '247', 'ReferenceId': '17920897', 'FullCitation': 'Kastrinos F, et al. Semin. Oncol. (2007) pmid: 17920897', 'Include': 'true'}, {'number': '248', 'ReferenceId': '19466295', 'FullCitation': 'Silva FC, et al. Sao Paulo Med J (2009) pmid: 19466295', 'Include': 'true'}, {'number': '249', 'ReferenceId': '24978665', 'FullCitation': 'Sehgal R, et al. Genes (Basel) (2014) pmid: 24978665', 'Include': 'true'}, {'number': '250', 'ReferenceId': '16136383', 'FullCitation': 'Fam. Cancer (2005) pmid: 16136383', 'Include': 'true'}, {'number': '251', 'ReferenceId': '21779441', 'FullCitation': 'Zheng R, et al. Genes Cancer (2010) pmid: 21779441', 'Include': 'true'}, {'number': '252', 'ReferenceId': '17463088', 'FullCitation': 'Kamnasaran D, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17463088', 'Include': 'true'}, {'number': '253', 'ReferenceId': '18769116', 'FullCitation': 'Fu B, et al. Cancer Biol. Ther. (2008) pmid: 18769116', 'Include': 'true'}, {'number': '254', 'ReferenceId': '18535672', 'FullCitation': 'Kwei KA, et al. PLoS Genet. (2008) pmid: 18535672', 'Include': 'true'}, {'number': '255', 'ReferenceId': '23784465', 'FullCitation': 'Shen F, et al. Oncol. Rep. (2013) pmid: 23784465', 'Include': 'true'}, {'number': '256', 'ReferenceId': '22200773', 'FullCitation': 'Trowbridge JJ, et al. Nat. Genet. (2011) pmid: 22200773', 'Include': 'true'}, {'number': '257', 'ReferenceId': '21507354', 'FullCitation': 'Prog Mol Biol Transl Sci (2011) pmid: 21507354', 'Include': 'true'}, {'number': '258', 'ReferenceId': '21887466', 'FullCitation': 'Yang J, et al. Mol Med Rep () pmid: 21887466', 'Include': 'true'}, {'number': '259', 'ReferenceId': '16870044', 'FullCitation': 'Vallböhmer D, et al. Clin Lung Cancer (2006) pmid: 16870044', 'Include': 'true'}, {'number': '260', 'ReferenceId': '21351083', 'FullCitation': 'Daskalos A, et al. Cancer (2011) pmid: 21351083', 'Include': 'true'}, {'number': '261', 'ReferenceId': '17890317', 'FullCitation': 'Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17890317', 'Include': 'true'}, {'number': '262', 'ReferenceId': '22011581', 'FullCitation': 'Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 22011581', 'Include': 'true'}, {'number': '263', 'ReferenceId': '23031157', 'FullCitation': 'Kim MS, et al. APMIS (2013) pmid: 23031157', 'Include': 'true'}, {'number': '264', 'ReferenceId': '15861382', 'FullCitation': 'Chen ZX, et al. J. Cell. Biochem. (2005) pmid: 15861382', 'Include': 'true'}, {'number': '265', 'ReferenceId': '25383530', 'FullCitation': 'Guo X, et al. Nature (2015) pmid: 25383530', 'Include': 'true'}, {'number': '266', 'ReferenceId': '30705090', 'FullCitation': 'Sandoval JE, et al. J. Biol. Chem. (2019) pmid: 30705090', 'Include': 'true'}, {'number': '267', 'ReferenceId': '29414941', 'FullCitation': 'Zhang ZM, et al. Nature (2018) pmid: 29414941', 'Include': 'true'}, {'number': '268', 'ReferenceId': '17483308', 'FullCitation': 'Noren NK, et al. Cancer Res. (2007) pmid: 17483308', 'Include': 'true'}, {'number': '269', 'ReferenceId': '18394988', 'FullCitation': 'Cell (2008) pmid: 18394988', 'Include': 'true'}, {'number': '270', 'ReferenceId': '22588055', 'FullCitation': 'Salvucci O, et al. Adv. Cancer Res. (2012) pmid: 22588055', 'Include': 'true'}, {'number': '271', 'ReferenceId': '21078817', 'FullCitation': 'Pitulescu ME, et al. Genes Dev. (2010) pmid: 21078817', 'Include': 'true'}, {'number': '272', 'ReferenceId': '20179713', 'FullCitation': 'Nat. Rev. Cancer (2010) pmid: 20179713', 'Include': 'true'}, {'number': '273', 'ReferenceId': '23100466', 'FullCitation': 'Hasina R, et al. Cancer Res. (2013) pmid: 23100466', 'Include': 'true'}, {'number': '274', 'ReferenceId': '23063927', 'FullCitation': 'Boberg DR, et al. Chem. Biol. Interact. (2013) pmid: 23063927', 'Include': 'true'}, {'number': '275', 'ReferenceId': '16615113', 'FullCitation': 'Masood R, et al. Int. J. Cancer (2006) pmid: 16615113', 'Include': 'true'}, {'number': '276', 'ReferenceId': '17043250', 'FullCitation': 'Sinha UK, et al. Arch. Otolaryngol. Head Neck Surg. (2006) pmid: 17043250', 'Include': 'true'}, {'number': '277', 'ReferenceId': '14676830', 'FullCitation': 'Cromer A, et al. Oncogene (2004) pmid: 14676830', 'Include': 'true'}, {'number': '278', 'ReferenceId': '26073592', 'FullCitation': 'Ferguson BD, et al. Sci Rep (2015) pmid: 26073592', 'Include': 'true'}, {'number': '279', 'ReferenceId': '25391996', 'FullCitation': 'Ferguson BD, et al. Growth Factors (2014) pmid: 25391996', 'Include': 'true'}, {'number': '280', 'ReferenceId': '18794445', 'FullCitation': 'Yavrouian EJ, et al. Arch. Otolaryngol. Head Neck Surg. (2008) pmid: 18794445', 'Include': 'true'}, {'number': '281', 'ReferenceId': '26414866', 'FullCitation': 'Liersch_Löhn B, et al. Int. J. Cancer (2016) pmid: 26414866', 'Include': 'true'}, {'number': '282', 'ReferenceId': '24771266', 'FullCitation': 'Hu F, et al. Tumour Biol. (2014) pmid: 24771266', 'Include': 'true'}, {'number': '283', 'ReferenceId': '20686847', 'FullCitation': 'Li M, et al. Dig. Dis. Sci. (2011) pmid: 20686847', 'Include': 'true'}, {'number': '284', 'ReferenceId': '28739744', 'FullCitation': 'Yin J, et al. Anticancer Res. (2017) pmid: 28739744', 'Include': 'true'}, {'number': '285', 'ReferenceId': '11801186', 'FullCitation': 'Stephenson SA, et al. BMC Mol. Biol. (2001) pmid: 11801186', 'Include': 'true'}, {'number': '286', 'ReferenceId': '11920461', 'FullCitation': 'Liu W, et al. Cancer (2002) pmid: 11920461', 'Include': 'true'}, {'number': '287', 'ReferenceId': '27273865', 'FullCitation': 'McCall JL, et al. Mol. Cell. Biol. (2016) pmid: 27273865', 'Include': 'true'}, {'number': '288', 'ReferenceId': '27535973', 'FullCitation': 'Stremitzer S, et al. Mol. Cancer Ther. (2016) pmid: 27535973', 'Include': 'true'}, {'number': '289', 'ReferenceId': '27072105', 'FullCitation': 'Lv J, et al. Exp. Mol. Pathol. (2016) pmid: 27072105', 'Include': 'true'}, {'number': '290', 'ReferenceId': '23579861', 'FullCitation': 'Guijarro_Muñoz I, et al. Med. Oncol. (2013) pmid: 23579861', 'Include': 'true'}, {'number': '291', 'ReferenceId': '19366806', 'FullCitation': 'Kumar SR, et al. Cancer Res. (2009) pmid: 19366806', 'Include': 'true'}, {'number': '292', 'ReferenceId': '15029258', 'FullCitation': 'Wu Q, et al. Pathol. Oncol. Res. (2004) pmid: 15029258', 'Include': 'true'}, {'number': '293', 'ReferenceId': '12168060', 'FullCitation': 'Berclaz G, et al. Oncol. Rep. () pmid: 12168060', 'Include': 'true'}, {'number': '294', 'ReferenceId': '21935409', 'FullCitation': 'Brantley_Sieders DM, et al. PLoS ONE (2011) pmid: 21935409', 'Include': 'true'}, {'number': '295', 'ReferenceId': '26191333', 'FullCitation': 'Huang G, et al. Int J Clin Exp Pathol (2015) pmid: 26191333', 'Include': 'true'}, {'number': '296', 'ReferenceId': '26481148', 'FullCitation': 'Pradeep S, et al. Cancer Cell (2015) pmid: 26481148', 'Include': 'true'}, {'number': '297', 'ReferenceId': '18231102', 'FullCitation': 'Alam SM, et al. Br. J. Cancer (2008) pmid: 18231102', 'Include': 'true'}, {'number': '298', 'ReferenceId': '17353927', 'FullCitation': 'Kumar SR, et al. Br. J. Cancer (2007) pmid: 17353927', 'Include': 'true'}, {'number': '299', 'ReferenceId': '11295082', 'FullCitation': 'Takai N, et al. Oncol. Rep. () pmid: 11295082', 'Include': 'true'}, {'number': '300', 'ReferenceId': '28454369', 'FullCitation': 'Dong LD, et al. Oncol Lett (2017) pmid: 28454369', 'Include': 'true'}, {'number': '301', 'ReferenceId': '12562648', 'FullCitation': 'Berclaz G, et al. Ann. Oncol. (2003) pmid: 12562648', 'Include': 'true'}, {'number': '302', 'ReferenceId': '24634162', 'FullCitation': 'Sharma GK, et al. Head Neck (2015) pmid: 24634162', 'Include': 'true'}, {'number': '303', 'ReferenceId': '26220827', 'FullCitation': 'Giaginis C, et al. Pathol. Oncol. Res. (2016) pmid: 26220827', 'Include': 'true'}, {'number': '304', 'ReferenceId': '22528941', 'FullCitation': 'Xuqing W, et al. Tumour Biol. (2012) pmid: 22528941', 'Include': 'true'}, {'number': '305', 'ReferenceId': '23844053', 'FullCitation': 'Ferguson BD, et al. PLoS ONE (2013) pmid: 23844053', 'Include': 'true'}, {'number': '306', 'ReferenceId': '22684742', 'FullCitation': 'Zheng MF, et al. Mol Med Rep (2012) pmid: 22684742', 'Include': 'true'}, {'number': '307', 'ReferenceId': '23138393', 'FullCitation': 'Chen T, et al. Tumour Biol. (2013) pmid: 23138393', 'Include': 'true'}, {'number': '308', 'ReferenceId': '22374425', 'FullCitation': 'Tu Y, et al. Clin Transl Oncol (2012) pmid: 22374425', 'Include': 'true'}, {'number': '309', 'ReferenceId': '23079712', 'FullCitation': 'Li M, et al. Mol. Biol. Rep. (2013) pmid: 23079712', 'Include': 'true'}, {'number': '310', 'ReferenceId': '15930280', 'FullCitation': 'Xia G, et al. Cancer Res. (2005) pmid: 15930280', 'Include': 'true'}, {'number': '311', 'ReferenceId': '19356789', 'FullCitation': 'Alam SM, et al. Gynecol. Oncol. (2009) pmid: 19356789', 'Include': 'true'}, {'number': '312', 'ReferenceId': '19272799', 'FullCitation': 'Ozgür E, et al. Urol. Oncol. () pmid: 19272799', 'Include': 'true'}, {'number': '313', 'ReferenceId': '25148033', 'FullCitation': 'Li X, et al. PLoS ONE (2014) pmid: 25148033', 'Include': 'true'}, {'number': '314', 'ReferenceId': '27388534', 'FullCitation': 'Pierscianek D, et al. Neuropathology (2017) pmid: 27388534', 'Include': 'true'}, {'number': '315', 'ReferenceId': '26951238', 'FullCitation': 'Pierscianek D, et al. Brain Tumor Pathol (2016) pmid: 26951238', 'Include': 'true'}, {'number': '316', 'ReferenceId': '25274141', 'FullCitation': 'Becerikli M, et al. Int. J. Cancer (2015) pmid: 25274141', 'Include': 'true'}, {'number': '317', 'ReferenceId': '15958611', 'FullCitation': 'Xia G, et al. Clin. Cancer Res. (2005) pmid: 15958611', 'Include': 'true'}, {'number': '318', 'ReferenceId': '16322467', 'FullCitation': 'Kertesz N, et al. Blood (2006) pmid: 16322467', 'Include': 'true'}, {'number': '319', 'ReferenceId': '22411527', 'FullCitation': 'Shi S, et al. J Pharm Sci (2012) pmid: 22411527', 'Include': 'true'}, {'number': '320', 'ReferenceId': '23721559', 'FullCitation': 'Liu R, et al. BMC Cancer (2013) pmid: 23721559', 'Include': 'true'}, {'number': '321', 'ReferenceId': '27941840', 'FullCitation': 'Bhatia S, et al. Sci Rep (2016) pmid: 27941840', 'Include': 'true'}, {'number': '322', 'ReferenceId': '18836096', 'FullCitation': 'Scehnet JS, et al. Blood (2009) pmid: 18836096', 'Include': 'true'}, {'number': '323', 'ReferenceId': '26365907', 'FullCitation': 'Werner TL, et al. Invest New Drugs (2015) pmid: 26365907', 'Include': 'true'}, {'number': '324', 'ReferenceId': '22011666', 'FullCitation': 'Pietanza MC, et al. J Thorac Oncol (2012) pmid: 22011666', 'Include': 'true'}, {'number': '325', 'ReferenceId': '22722787', 'FullCitation': 'Pietanza MC, et al. J Thorac Oncol (2012) pmid: 22722787', 'Include': 'true'}, {'number': '326', 'ReferenceId': '31340094', 'FullCitation': 'Loriot Y, et al. N. Engl. J. Med. (2019) pmid: 31340094', 'Include': 'true'}, {'number': '327', 'ReferenceId': '30267839', 'FullCitation': 'Qin A, et al. J Thorac Oncol (2019) pmid: 30267839', 'Include': 'true'}, {'number': '328', 'ReferenceId': '25609060', 'FullCitation': 'Di Stefano AL, et al. Clin. Cancer Res. (2015) pmid: 25609060', 'Include': 'true'}, {'number': '329', 'ReferenceId': '31088831', 'FullCitation': 'Bahleda R, et al. Clin. Cancer Res. (2019) pmid: 31088831', 'Include': 'true'}, {'number': '330', 'ReferenceId': '28341788', 'FullCitation': 'Perera TPS, et al. Mol. Cancer Ther. (2017) pmid: 28341788', 'Include': 'true'}, {'number': '331', 'ReferenceId': '28416604', 'FullCitation': 'Karkera JD, et al. Mol. Cancer Ther. (2017) pmid: 28416604', 'Include': 'true'}, {'number': '332', 'ReferenceId': '26983912', 'FullCitation': 'Kim ST, et al. J. Cancer Res. Clin. Oncol. (2016) pmid: 26983912', 'Include': 'true'}, {'number': '333', 'ReferenceId': '22679111', 'FullCitation': 'Burris HA, et al. Mol. Cancer Ther. (2012) pmid: 22679111', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2021_11_04 14:53:37', 'OpName': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': 'N/A'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': '20 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': '50%'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'STOMACH', 'disease_ontology': 'Stomach adenocarcinoma (NOS)', 'flowcell_analysis': '2000018381', 'gender': 'female', 'pathology_diagnosis': 'Gastric adenocarcinoma', 'pipeline_version': 'v3.8.2', 'purity_assessment': '40.0', 'specimen': 'ORD_1223719_01*US1179091.01', 'study': 'CLINICAL_F1LCDx', 'test_request': 'ORD_1223719_01', 'test_type': 'FoundationOneLiquidDx', 'tissue_of_origin': 'Blood', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'AB1', 'name': 'SQ_US1179091.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.0025', 'cds_effect': '1816T>G', 'depth': '2010', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MAP3K13', 'percent_reads': '0.25', 'position': 'chr3:185190935', 'protein_effect': 'L606V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_004721', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0073', 'cds_effect': '2120A>C', 'depth': '2481', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CD22', 'percent_reads': '0.73', 'position': 'chr19:35835816', 'protein_effect': 'K707T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001771', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.036', 'cds_effect': '1750T>G', 'depth': '778', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NTRK2', 'percent_reads': '3.6', 'position': 'chr9:87549193', 'protein_effect': 'L584V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006180', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.1348', 'cds_effect': '572A>C', 'depth': '1291', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '13.48', 'position': 'chr2:212615414', 'protein_effect': 'K191T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.2185', 'cds_effect': '1126C>G', 'depth': '842', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FANCA', 'percent_reads': '21.85', 'position': 'chr16:89858434', 'protein_effect': 'Q376E', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000135', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0068', 'cds_effect': '128A>C', 'depth': '1028', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CREBBP', 'percent_reads': '0.68', 'position': 'chr16:3900968', 'protein_effect': 'E43A', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004380', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0031', 'cds_effect': '1984T>G', 'depth': '7789', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRCA2', 'percent_reads': '0.31', 'position': 'chr13:32910476', 'protein_effect': 'S662A', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000059', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.001', 'cds_effect': '895A>T', 'depth': '123565', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGFR2', 'percent_reads': '0.1', 'position': 'chr10:123279537', 'protein_effect': 'S299C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000141', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0187', 'cds_effect': '1187C>T', 'depth': '1122', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CCNE1', 'percent_reads': '1.87', 'position': 'chr19:30314638', 'protein_effect': 'P396L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001238', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.4716', 'cds_effect': '94G>A', 'depth': '899', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GABRA6', 'percent_reads': '47.16', 'position': 'chr5:161113291', 'protein_effect': 'V32I', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000811', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0075', 'cds_effect': '3302A>T', 'depth': '2385', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TSC1', 'percent_reads': '0.75', 'position': 'chr9:135771815', 'protein_effect': 'E1101V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000368', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0075', 'cds_effect': '617_618insT', 'depth': '5166', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'TP53', 'percent_reads': '0.75', 'position': 'chr17:7578231', 'protein_effect': 'L206fs*3', 'status': 'likely', 'strand': '_', 'transcript': 'NM_000546', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0066', 'cds_effect': '1709A>C', 'depth': '1066', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NOTCH2', 'percent_reads': '0.66', 'position': 'chr1:120506403', 'protein_effect': 'N570T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_024408', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0103', 'cds_effect': '587A>C', 'depth': '83922', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGFR2', 'percent_reads': '1.03', 'position': 'chr10:123310841', 'protein_effect': 'K196T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000141', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.3615', 'cds_effect': '240C>A', 'depth': '2238', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'HNF1A', 'percent_reads': '36.15', 'position': 'chr12:121416811', 'protein_effect': 'D80E', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000545', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.7051', 'cds_effect': '3955C>T', 'depth': '1007', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PTCH1', 'percent_reads': '70.51', 'position': 'chr9:98209583', 'protein_effect': 'R1319C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000264', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0048', 'cds_effect': '3901G>C', 'depth': '1471', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRD4', 'percent_reads': '0.48', 'position': 'chr19:15349673', 'protein_effect': 'A1301P', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_058243', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0045', 'cds_effect': '6421T>A', 'depth': '7714', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATM', 'percent_reads': '0.45', 'position': 'chr11:108190754', 'protein_effect': 'S2141T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000051', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.003', 'cds_effect': '679C>G', 'depth': '7416', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GNAS', 'percent_reads': '0.3', 'position': 'chr20:57484595', 'protein_effect': 'Q227E', 'status': 'known', 'strand': '+', 'transcript': 'NM_000516', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0013', 'cds_effect': '3620A>C', 'depth': '13930', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRCA1', 'percent_reads': '0.13', 'position': 'chr17:41243928', 'protein_effect': 'K1207T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_007294', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0128', 'cds_effect': '2699C>T', 'depth': '6854', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PALB2', 'percent_reads': '1.28', 'position': 'chr16:23637606', 'protein_effect': 'A900V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_024675', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.4918', 'cds_effect': '641A>G', 'depth': '4667', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TP53', 'percent_reads': '49.18', 'position': 'chr17:7578208', 'protein_effect': 'H214R', 'status': 'known', 'strand': '_', 'transcript': 'NM_000546', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0084', 'cds_effect': '1130A>C', 'depth': '3206', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'AKT1', 'percent_reads': '0.84', 'position': 'chr14:105239257', 'protein_effect': 'K377T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001014431', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0285', 'cds_effect': '2196_2197delTG', 'depth': '1826', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'DNMT3A', 'percent_reads': '2.85', 'position': 'chr2:25463295', 'protein_effect': 'F732fs*8', 'status': 'likely', 'strand': '_', 'transcript': 'NM_022552', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '7.0E_4', 'cds_effect': '1940T>G', 'depth': '151947', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGFR2', 'percent_reads': '0.07', 'position': 'chr10:123247551', 'protein_effect': 'L647R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000141', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0016', 'cds_effect': '239A>C', 'depth': '7401', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MET', 'percent_reads': '0.16', 'position': 'chr7:116339377', 'protein_effect': 'K80T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000245', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0035', 'cds_effect': '2441A>T', 'depth': '3178', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'AXL', 'percent_reads': '0.35', 'position': 'chr19:41765592', 'protein_effect': 'N814I', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001699', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0038', 'cds_effect': '1226G>T', 'depth': '1839', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'DNMT3A', 'percent_reads': '0.38', 'position': 'chr2:25469542', 'protein_effect': 'W409L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_022552', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.0109', 'cds_effect': '2690T>G', 'depth': '1656', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'DNMT3A', 'percent_reads': '1.09', 'position': 'chr2:25457197', 'protein_effect': 'V897G', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_022552', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}]}, 'copy_number_alterations': {'copy_number_alteration': [{'copy_number': '9', 'equivocal': 'false', 'gene': 'GATA4', 'number_of_exons': '6 of 6', 'position': 'chr8:11565821_11615984', 'ratio': '2.36', 'status': 'unknown', 'type': 'amplification'}, {'copy_number': '10', 'equivocal': 'false', 'gene': 'NTRK3', 'number_of_exons': '20 of 20', 'position': 'chr15:88420165_88799384', 'ratio': '2.39', 'status': 'unknown', 'type': 'amplification'}, {'copy_number': '149', 'equivocal': 'false', 'gene': 'FGFR2', 'number_of_exons': '19 of 19', 'position': 'chr10:123197644_123402122', 'ratio': '21.56', 'status': 'known', 'type': 'amplification'}, {'copy_number': '14', 'equivocal': 'false', 'gene': 'EPHB4', 'number_of_exons': '17 of 17', 'position': 'chr7:100401082_100424691', 'ratio': '3.18', 'status': 'known', 'type': 'amplification'}, {'copy_number': '7', 'equivocal': 'true', 'gene': 'GATA6', 'number_of_exons': '6 of 6', 'position': 'chr18:19751105_19780786', 'ratio': '2.16', 'status': 'known', 'type': 'amplification'}, {'copy_number': '8', 'equivocal': 'false', 'gene': 'RAD21', 'number_of_exons': '13 of 13', 'position': 'chr8:117859738_117878968', 'ratio': '1.78', 'status': 'ambiguous', 'type': 'amplification'}, {'copy_number': '7', 'equivocal': 'true', 'gene': 'CDK6', 'number_of_exons': '6 of 7', 'position': 'chr7:92205279_92404145', 'ratio': '1.77', 'status': 'known', 'type': 'amplification'}, {'copy_number': '16', 'equivocal': 'false', 'gene': 'IDH2', 'number_of_exons': '11 of 11', 'position': 'chr15:90627476_90645629', 'ratio': '3.76', 'status': 'unknown', 'type': 'amplification'}, {'copy_number': '8', 'equivocal': 'false', 'gene': 'MYC', 'number_of_exons': '5 of 5', 'position': 'chr8:128706589_128801451', 'ratio': '1.75', 'status': 'known', 'type': 'amplification'}]}, 'rearrangements': {'rearrangement': [{'allele_fraction': '0.038', 'description': 'FGFR2(NM_000141) inversion intron 2 _ intron 17', 'equivocal': 'false', 'in_frame': 'unknown', 'other_gene': 'FGFR2', 'percent_reads': '3.8', 'pos1': 'chr10:123242127', 'pos2': 'chr10:123334692', 'status': 'unknown', 'supporting_read_pairs': '3891', 'targeted_gene': 'FGFR2', 'type': 'rearrangement', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}, {'allele_fraction': '0.1696', 'description': 'FGFR2(NM_000141) rearrangement intron 17', 'equivocal': 'false', 'in_frame': 'unknown', 'other_gene': 'ATE1', 'percent_reads': '16.96', 'pos1': 'chr10:123241267', 'pos2': 'chr10:123640486', 'status': 'likely', 'supporting_read_pairs': '7065', 'targeted_gene': 'FGFR2', 'type': 'rearrangement', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}]}, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '20.23', 'status': 'high', 'unit': 'mutations_per_megabase'}}, 'non_human_content': {'non_human': {'organism': 'HHV_4', 'reads_per_million': '22', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1179091.01_1'}}}}}}}	S110-89473          	PF21032             
9	417	"{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2021_00016520', 'CSN': None, 'TRF': 'ORD_1194331_01', 'MRN': '47551224', 'PhysicianId': '86631', 'NPI': 'International'}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '889790', 'clinicalId': '891195', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1194331_01', 'SampleName': 'US1153674.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1194331_01', 'SampleId': 'US1153674.01', 'BlockId': 'S110_67168 R (PF21018)', 'TRFNumber': 'ORD_1194331_01', 'TestType': 'FoundationOne CDX', 'SpecFormat': 'Slide Deck', 'ReceivedDate': '2021_09_21', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}]}}, 'PMI': {'ReportId': 'ORD_1194331_01', 'MRN': '47551224', 'FullName': 'Li, Meng_Ju', 'FirstName': 'Meng_Ju', 'LastName': 'Li', 'SubmittedDiagnosis': 'Uterus endometrial adenocarcinoma endometrioid', 'Gender': 'Female', 'DOB': '1974_12_12', 'OrderingMD': 'Chen, Yi_Jen', 'OrderingMDId': '86631', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Uterus', 'CollDate': '2021_08_18', 'ReceivedDate': '2021_09_21', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': None, 'Summaries': {'alterationCount': '318', 'clinicalTrialCount': '56', 'resistiveCount': '0', 'sensitizingCount': '16'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'ABL1', 'isVUS': 'true', 'variantName': 'V43fs*4'}, {'geneName': 'AKT3', 'isVUS': 'true', 'variantName': 'L277R,R241W,V419A,splice site 697_2A>C'}, {'geneName': 'ALK', 'isVUS': 'true', 'variantName': 'N285Y'}, {'geneName': 'APC', 'isVUS': 'true', 'variantName': 'L2136I,L23F,L2574I'}, {'geneName': 'AR', 'isVUS': 'true', 'variantName': 'A871V,D551E,Y364D'}, {'geneName': 'ARID1A', 'isVUS': 'true', 'variantName': 'G851D'}, {'geneName': 'ASXL1', 'isVUS': 'true', 'variantName': 'E824D,G1401E,R394H'}, {'geneName': 'ATM', 'isVUS': 'true', 'variantName': 'E2052K,R493C'}, {'geneName': 'ATR', 'isVUS': 'true', 'variantName': 'E254D,L108P,R1300C,R635Q,S1701Y'}, {'geneName': 'ATRX', 'isVUS': 'true', 'variantName': 'D1875Y,K467Q,R701H,T480R'}, {'geneName': 'BAP1', 'isVUS': 'true', 'variantName': 'D608N'}, {'geneName': 'BCOR', 'isVUS': 'true', 'variantName': 'E27K,L1334V,V293I'}, {'geneName': 'BCORL1', 'isVUS': 'true', 'variantName': 'R1226H,S244L,S663Y'}, {'geneName': 'BRAF', 'isVUS': 'true', 'variantName': 'R389C'}, {'geneName': 'BRCA1', 'isVUS': 'true', 'variantName': 'D749Y'}, {'geneName': 'BRCA2', 'isVUS': 'true', 'variantName': 'E1455_E1456>DK,E2020K,L3317R,N1316H,T3414A'}, {'geneName': 'BRD4', 'isVUS': 'true', 'variantName': 'S499L'}, {'geneName': 'BRIP1', 'isVUS': 'true', 'variantName': 'L892I,R356Q'}, {'geneName': 'BTK', 'isVUS': 'true', 'variantName': 'L23I,R13*,R288W,T33I'}, {'geneName': 'C11orf30 (EMSY)', 'isVUS': 'true', 'variantName': 'E924K,S335N'}, {'geneName': 'CARD11', 'isVUS': 'true', 'variantName': 'E420D,P567L'}, {'geneName': 'CASP8', 'isVUS': 'true', 'variantName': 'E311D'}, {'geneName': 'CBFB', 'isVUS': 'true', 'variantName': 'A99T'}, {'geneName': 'CBL', 'isVUS': 'true', 'variantName': 'E394G,R462Q'}, {'geneName': 'CCND2', 'isVUS': 'true', 'variantName': 'K71T'}, {'geneName': 'CDK12', 'isVUS': 'true', 'variantName': 'K726T'}, {'geneName': 'CDK6', 'isVUS': 'true', 'variantName': 'R214C'}, {'geneName': 'CDK8', 'isVUS': 'true', 'variantName': 'N372S,V78I,splice site 1110+1G>T,splice site 205_1G>A'}, {'geneName': 'CHEK1', 'isVUS': 'true', 'variantName': 'F70L'}, {'geneName': 'CREBBP', 'isVUS': 'true', 'variantName': 'G211E,T872M'}, {'geneName': 'CRKL', 'isVUS': 'true', 'variantName': 'A208T,F134V'}, {'geneName': 'CTCF', 'isVUS': 'true', 'variantName': 'K208N'}, {'geneName': 'CTNNA1', 'isVUS': 'true', 'variantName': 'K867T'}, {'geneName': 'CUL3', 'isVUS': 'true', 'variantName': 'F224C,F377C'}, {'geneName': 'DAXX', 'isVUS': 'true', 'variantName': 'K662N,Q469H'}, {'geneName': 'DIS3', 'isVUS': 'true', 'variantName': 'E117D,R108H'}, {'geneName': 'DNMT3A', 'isVUS': 'true', 'variantName': 'D702N'}, {'geneName': 'DOT1L', 'isVUS': 'true', 'variantName': 'S631L'}, {'geneName': 'EED', 'isVUS': 'true', 'variantName': 'L425F'}, {'geneName': 'EP300', 'isVUS': 'true', 'variantName': 'E1531G,L68I,M205R'}, {'geneName': 'EPHA3', 'isVUS': 'true', 'variantName': 'E647*,V626A'}, {'geneName': 'EPHB1', 'isVUS': 'true', 'variantName': 'E116D,R663W,V234A'}, {'geneName': 'ERBB2', 'isVUS': 'true', 'variantName': 'R1161Q'}, {'geneName': 'ERBB3', 'isVUS': 'true', 'variantName': 'H578N'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'A1219T'}, {'geneName': 'ERG', 'isVUS': 'true', 'variantName': 'F430C'}, {'geneName': 'ESR1', 'isVUS': 'true', 'variantName': 'D218N'}, {'geneName': 'FAM123B', 'isVUS': 'true', 'variantName': 'K170Q,S286N'}, {'geneName': 'FANCG', 'isVUS': 'true', 'variantName': 'V64A,Y268H'}, {'geneName': 'FAS', 'isVUS': 'true', 'variantName': 'R279C'}, {'geneName': 'FGF12', 'isVUS': 'true', 'variantName': 'R224M,Y155D'}, {'geneName': 'FGF23', 'isVUS': 'true', 'variantName': 'A213V'}, {'geneName': 'FGF3', 'isVUS': 'true', 'variantName': 'R151I,S108L'}, {'geneName': 'FGF4', 'isVUS': 'true', 'variantName': 'G37D'}, {'geneName': 'FGFR4', 'isVUS': 'true', 'variantName': 'L113F'}, {'geneName': 'FH', 'isVUS': 'true', 'variantName': 'P461T'}, {'geneName': 'FLT1', 'isVUS': 'true', 'variantName': 'F333Y,M945fs*15'}, {'geneName': 'FLT3', 'isVUS': 'true', 'variantName': 'F710V'}, {'geneName': 'GABRA6', 'isVUS': 'true', 'variantName': 'L424I,Y233C'}, {'geneName': 'GATA6', 'isVUS': 'true', 'variantName': 'E460K,N510D'}, {'geneName': 'GNAS', 'isVUS': 'true', 'variantName': 'A475V,F315C,L132M'}, {'geneName': 'GSK3B', 'isVUS': 'true', 'variantName': 'A22T,R92I'}, {'geneName': 'HGF', 'isVUS': 'true', 'variantName': 'L565I,P299H'}, {'geneName': 'HSD3B1', 'isVUS': 'true', 'variantName': 'L167M'}, {'geneName': 'IDH1', 'isVUS': 'true', 'variantName': 'R222C'}, {'geneName': 'IDH2', 'isVUS': 'true', 'variantName': 'D200Y'}, {'geneName': 'IGF1R', 'isVUS': 'true', 'variantName': 'E83K'}, {'geneName': 'IKBKE', 'isVUS': 'true', 'variantName': 'E705K'}, {'geneName': 'IKZF1', 'isVUS': 'true', 'variantName': 'K275N,S105P,S364L'}, {'geneName': 'INPP4B', 'isVUS': 'true', 'variantName': 'E807D,L277V,L344R'}, {'geneName': 'IRS2', 'isVUS': 'true', 'variantName': 'D276N,E1199K,P813S,S1174L'}, {'geneName': 'JAK1', 'isVUS': 'true', 'variantName': 'R93C'}, {'geneName': 'JAK2', 'isVUS': 'true', 'variantName': 'R803Q'}, {'geneName': 'KDM5A', 'isVUS': 'true', 'variantName': 'E1098*,R893Q,R902W'}, {'geneName': 'KDM5C', 'isVUS': 'true', 'variantName': 'K101N'}, {'geneName': 'KDM6A', 'isVUS': 'true', 'variantName': 'R519G'}, {'geneName': 'KDR', 'isVUS': 'true', 'variantName': 'E685K,G335D,R652I,V1251fs*5'}, {'geneName': 'KEAP1', 'isVUS': 'true', 'variantName': 'R614Q'}, {'geneName': 'KEL', 'isVUS': 'true', 'variantName': 'A311T,D497N,E352D,Y714H'}, {'geneName': 'KIT', 'isVUS': 'true', 'variantName': 'R956W'}, {'geneName': 'KLHL6', 'isVUS': 'true', 'variantName': 'N200H'}, {'geneName': 'KMT2A (MLL)', 'isVUS': 'true', 'variantName': 'I3660V,L950I,S941Y,T3574M'}, {'geneName': 'LTK', 'isVUS': 'true', 'variantName': 'K827T,S830N'}, {'geneName': 'MAF', 'isVUS': 'true', 'variantName': 'N365K'}, {'geneName': 'MAP2K4', 'isVUS': 'true', 'variantName': 'R304Q'}, {'geneName': 'MAP3K1', 'isVUS': 'true', 'variantName': 'R532Q'}, {'geneName': 'MED12', 'isVUS': 'true', 'variantName': 'L1300M,R422W,R438C,R470H'}, {'geneName': 'MERTK', 'isVUS': 'true', 'variantName': 'D579Y,P81S'}, {'geneName': 'MET', 'isVUS': 'true', 'variantName': 'R1166*'}, {'geneName': 'MITF', 'isVUS': 'true', 'variantName': 'splice site 760_2A>C'}, {'geneName': 'MLH1', 'isVUS': 'true', 'variantName': 'D63Y'}, {'geneName': 'MLL2', 'isVUS': 'true', 'variantName': 'A781T,E1588K,L3776R'}, {'geneName': 'MSH6', 'isVUS': 'true', 'variantName': 'A780T,E995K,K431T,R1242H'}, {'geneName': 'MST1R', 'isVUS': 'true', 'variantName': 'F574L,G356D'}, {'geneName': 'MTOR', 'isVUS': 'true', 'variantName': 'Q2223R'}, {'geneName': 'NBN', 'isVUS': 'true', 'variantName': 'E474D'}, {'geneName': 'NF1', 'isVUS': 'true', 'variantName': 'K63N,L2639I,W837L'}, {'geneName': 'NF2', 'isVUS': 'true', 'variantName': 'R187I,R418C'}, {'geneName': 'NKX2_1', 'isVUS': 'true', 'variantName': 'D356G'}, {'geneName': 'NOTCH1', 'isVUS': 'true', 'variantName': 'A105T,D464N,G2333D'}, {'geneName': 'NRAS', 'isVUS': 'true', 'variantName': 'Y4C'}, {'geneName': 'NSD3 (WHSC1L1)', 'isVUS': 'true', 'variantName': 'G748V'}, {'geneName': 'NT5C2', 'isVUS': 'true', 'variantName': 'K244E,K45N'}, {'geneName': 'NTRK1', 'isVUS': 'true', 'variantName': 'M566T'}, {'geneName': 'NTRK2', 'isVUS': 'true', 'variantName': 'E70K,R124*'}, {'geneName': 'NTRK3', 'isVUS': 'true', 'variantName': 'E559G,P725H,R721C'}, {'geneName': 'P2RY8', 'isVUS': 'true', 'variantName': 'S58L'}, {'geneName': 'PALB2', 'isVUS': 'true', 'variantName': 'K279N'}, {'geneName': 'PARP1', 'isVUS': 'true', 'variantName': 'A194V'}, {'geneName': 'PARP2', 'isVUS': 'true', 'variantName': 'E222Q'}, {'geneName': 'PBRM1', 'isVUS': 'true', 'variantName': 'R876C'}, {'geneName': 'PDCD1 (PD_1)', 'isVUS': 'true', 'variantName': 'A50T'}, {'geneName': 'PDGFRA', 'isVUS': 'true', 'variantName': 'E556*,M1073V,R346S,splice site 1122_1G>T'}, {'geneName': 'PDK1', 'isVUS': 'true', 'variantName': 'K73N,R341I'}, {'geneName': 'PIK3CA', 'isVUS': 'true', 'variantName': 'L285V,R230*,splice site 352+1G>A'}, {'geneName': 'PIK3CB', 'isVUS': 'true', 'variantName': 'A655V,E225*,N377H,R955*'}, {'geneName': 'POLD1', 'isVUS': 'true', 'variantName': 'R177C'}, {'geneName': 'POLE', 'isVUS': 'true', 'variantName': 'L1235I'}, {'geneName': 'PPP2R2A', 'isVUS': 'true', 'variantName': 'E338A'}, {'geneName': 'PTCH1', 'isVUS': 'true', 'variantName': 'L223I'}, {'geneName': 'PTEN', 'isVUS': 'true', 'variantName': 'E157D,I5T'}, {'geneName': 'PTPN11', 'isVUS': 'true', 'variantName': 'K590T'}, {'geneName': 'PTPRO', 'isVUS': 'true', 'variantName': 'L832R'}, {'geneName': 'RAD51', 'isVUS': 'true', 'variantName': 'L274I'}, {'geneName': 'RAD51B', 'isVUS': 'true', 'variantName': 'L321R'}, {'geneName': 'RAD51C', 'isVUS': 'true', 'variantName': 'S163R'}, {'geneName': 'RAD52', 'isVUS': 'true', 'variantName': 'R55H'}, {'geneName': 'RAF1', 'isVUS': 'true', 'variantName': 'E104K'}, {'geneName': 'RBM10', 'isVUS': 'true', 'variantName': 'E705D'}, {'geneName': 'REL', 'isVUS': 'true', 'variantName': 'R45Q'}, {'geneName': 'RET', 'isVUS': 'true', 'variantName': 'R474W'}, {'geneName': 'RICTOR', 'isVUS': 'true', 'variantName': 'H1453R,K1155T,L612R,L804I,R1110C,R222Q'}, {'geneName': 'ROS1', 'isVUS': 'true', 'variantName': 'E402D,E908*,I883L,K1533N,N399H,R1212C,R922I,V785M'}, {'geneName': 'SETD2', 'isVUS': 'true', 'variantName': 'P190L'}, {'geneName': 'SF3B1', 'isVUS': 'true', 'variantName': 'E809*,R451Q'}, {'geneName': 'SGK1', 'isVUS': 'true', 'variantName': 'L363I'}, {'geneName': 'SMAD2', 'isVUS': 'true', 'variantName': 'S276L,S464A'}, {'geneName': 'SPEN', 'isVUS': 'true', 'variantName': 'R535Q'}, {'geneName': 'SPOP', 'isVUS': 'true', 'variantName': 'R284C'}, {'geneName': 'STAG2', 'isVUS': 'true', 'variantName': 'D153N,F1214L'}, {'geneName': 'STAT3', 'isVUS': 'true', 'variantName': 'T494fs*55'}, {'geneName': 'TBX3', 'isVUS': 'true', 'variantName': 'A418T,E720K,R304W,S363L'}, {'geneName': 'TEK', 'isVUS': 'true', 'variantName': 'splice site 3063_1G>A'}, {'geneName': 'TET2', 'isVUS': 'true', 'variantName': 'A241V,Y1935H'}, {'geneName': 'TNFAIP3', 'isVUS': 'true', 'variantName': 'H289Q'}, {'geneName': 'TSC1', 'isVUS': 'true', 'variantName': 'K475Q,L930P,R228Q'}, {'geneName': 'TSC2', 'isVUS': 'true', 'variantName': 'D8Y,K69N'}, {'geneName': 'U2AF1', 'isVUS': 'true', 'variantName': 'R234C'}, {'geneName': 'VEGFA', 'isVUS': 'true', 'variantName': 'P363S,S186Y'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'ATM', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R250*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R250*'}}, 'Interpretation': 'ATM encodes the protein ataxia telangiectasia mutated, which is a serine/threonine protein kinase that plays a key role in the DNA damage response (Shiloh and Ziv, 2013; 23847781). Loss of functional ATM promotes tumorigenesis (Cremona and Behrens, 2014; 23851492). Alterations such as seen here may disrupt ATM function or expression (Jiang et al., 2006; 16603769, Fernandes et al., 2005; 15713674, Scott et al., 2002; 11805335). ATM mutation and homozygous deletion have been observed in 11_12% and up to 1.8% (5/761) samples of endometrial carcinoma, respectively (cBioPortal, COSMIC, Mar 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Altered expression of ATM has been reported in 4.5% (1/22) of endometrial hyperplasia samples and in 3.3% (2/61) of endometrioid_type endometrial cancer samples analyzed in one study (Tsuda et al., 2003; 12931023). Hypermethylation of ATM has been reported in 11% of endometrial carcinomas (Suehiro et al., 2008; 18519763). Conflicting findings have been reported regarding the prognostic implications of ATM expression in endometrial carcinomas, with one study reporting a negative correlation between ATM expression and pathological grade (Shan et al., 2015; 25608836) and another a positive correlation between increased ATM expression and unfavorable clinicopathologic features, including increased tumor grade and reduced 5_year recurrence free survival (Mhawech_Fauceglia et al., 2014; 24508840). Loss of functional ATM results in a defective DNA damage response and homologous recombination_mediated DNA repair and may predict sensitivity to PARP inhibitors (Michels et al., 2014; 24037533). Clinical data in prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), gastric cancer (Bang et al., 2015; 26282658), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), papillary renal cell carcinoma (Olson et al., 2016; 27079472), and cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096) indicate that loss or inactivation of ATM may confer sensitivity to PARP inhibitors (Weston et al., 2010; 20739657, Williamson et al., 2010; 20124459, Gilardini et al., 2013; 24252502, Bryant and Helleday, 2006; 16556909, Ihnen et al., 2013; 23729402, Williamson et al., 2012; 22416035, Kubota et al., 2014; 24841718, Huehls et al., 2012; 22833573). In Phase 1 trials of ATR inhibitors, a heavily pretreated patient with colorectal cancer who achieved a CR to berzosertib (O Carrigan et al., 2016; ASCO Abstract 2504) and 4 out of 4 patients with diverse solid tumors who achieved PRs to BAY1895344 (Yap et al., 2020; 32988960) harbored ATM inactivation or protein loss; studies showing reduced cell viability and increased DNA damage in preclinical models of solid tumors (Menezes et al., 2015; 25232030, Vendetti et al., 2015; 26517239, Min et al., 2017; 28138034) and hematologic malignancies (Menezes et al., 2015; 25232030, Kwok et al., 2016; 26563132) also support the increased sensitivity of ATM_deficient cells to ATR inhibitors. Preclinical experiments also indicate that loss of ATM causes dependency on DNA_PKcs in cancer cells; DNA_PKcs inhibitors promoted apoptosis in ATM_deficient cells and were active in a lymphoma mouse model lacking ATM activity (Riabinska et al., 2013; 23761041). One or more of the ATM variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with ataxia_telangiectasia syndrome (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. ATM mutation carriers have increased cancer risk, with female carriers displaying a 38% lifetime risk of breast cancer (van Os et al., 2016; 26662178). Biallelic mutations in ATM underlie the rare autosomal_recessive inherited disorder ataxia_telangiectasia (A_T), also referred to as genome instability or DNA damage response syndrome (Rothblum_Oviatt et al., 2016; 27884168). This disease is characterized by genomic instability, sensitivity to DNA_damaging agents, and increased risk of developing cancer (Shiloh and Ziv, 2013; 23847781, Rothblum_Oviatt et al., 2016; 27884168). The prevalence of A_T is estimated at 1:40,000 to 1:100,000 worldwide (Rothblum_Oviatt et al., 2016; 27884168). In the appropriate clinical context, germline testing of ATM is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). Comprehensive genomic profiling of solid tumors may detect nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': 'Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Talazoparib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> The PARP inhibitor talazoparib is FDA approved to treat HER2_negative locally advanced or metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of strong clinical data in breast cancer (Turner et al., 2017; ASCO Abstract 1007)(Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753) and additional clinical evidence in ovarian, pancreatic, and prostate cancer (Meehan et al., 2017; AACR Abstract 4687)(de Bono et al., 2017; 28242752, Lu et al., 2018; 30099369, De Bono et al., 2020; ASCO Abstract 5566), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to talazoparib. </p> <p><b>Supporting Data:</b> A Phase 1 study reported a PR for a patient with uterine carcinoma and a BRCA2 germline mutation treated with talazoparib plus carboplatin and paclitaxel followed by talazoparib monotherapy (Turk et al., 2018; ASCO Abstract 2548). Talazoparib has been studied primarily in the context of BRCA_mutated, HER2_negative breast cancer, where patients achieved significantly longer median PFS (8.6 vs. 5.6 months, HR=0.54), a higher ORR (62.6% vs. 27.2%), and improved quality of life on talazoparib compared with standard chemotherapy in a Phase 3 study (Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753). In a Phase 2 study of talazoparib for BRCA1/2_wildtype patients with homologous recombination pathway alterations, the best outcome in non_breast tumors was SD ≥ 6 months for 2/7 patients who had colon cancer with germline ATM alteration or testicular cancer with germline CHEK2 and somatic ATM alteration (Gruber et al., 2019; ASCO Abstract 3006). Clinical activity of single_agent talazoparib has been observed in numerous other solid tumors, including responses in BRCA_mutated ovarian, pancreatic, prostate, and ampulla of Vater cancers; PALB2_mutated pancreatic and bladder cancers; ATM_mutated cholangiocarcinoma; and small cell lung cancer (deBono et al., 2017; 28242752, Lu et al., 2018; 30099369)(Piha_Paul et al., 2017; EORTC_NCI_AACR Abstract A096, Meehan et al., 2017; AACR Abstract 4687). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Rucaparib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> The PARP inhibitor rucaparib is FDA approved to treat patients with metastatic castration_resistant prostate cancer (mCRPC) or epithelial ovarian, Fallopian tube, or primary peritoneal cancer and deleterious somatic or germline BRCA mutations. Rucaparib is also approved as a maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of strong clinical evidence in ovarian cancer (Shapira_Frommer et al., 2015; ASCO Abstract 5513)(Swisher et al., 2016; 27908594, Drew et al., 2016; 27002934), as well as clinical data in other cancer types (Kristeleit et al., 2014; ASCO Abstract 2573, Domcheck et al., 2016; ASCO Abstract 4110)(Drew et al., 2016; 27002934), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to rucaparib. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of rucaparib for the treatment of endometrial cancers are limited (PubMed, May 2021). Rucaparib has primarily been evaluated in the context of ovarian carcinoma, breast carcinoma, pancreatic carcinoma, and melanoma. In a Phase 2 study of rucaparib for recurrent, platinum_sensitive ovarian, peritoneal, or fallopian tube carcinoma, median PFS was significantly longer in patients with BRCA1/2 mutations (12.8 months) or high loss of heterozygosity (LOH; 5.7 months) compared to patients with low LOH (5.2 months). Objective responses were observed for 80% (32/40) of patients with BRCA1/2 mutations, for 29% (24/82) with high LOH, and for 10% (7/10) with low LOH (Swisher et al., 2016; 27908594). In heavily pretreated patients with a germline BRCA1/2 mutation who had received 2_4 prior chemotherapy treatments and had a progression free interval of greater than 6 months, 65% (17/26) of patients achieved an objective response with rucaparib treatment (Shapira_Frommer et al., 2015; ASCO Abstract 5513). In a Phase 2 study evaluating rucaparib for patients with advanced breast or ovarian cancer and germline BRCA1/2 mutations, disease control was observed in 92% (12/13) of patients with ovarian cancer treated with oral rucaparib dosed continuously, but no objective responses were reported in breast cancer patients (n=23). However, 39% (9/23) of evaluable patients with breast cancer achieved SD lasting 12 weeks or more (Drew et al., 2016; 27002934). In a Phase 1 study of rucaparib treatment in patients with solid tumors, 3/4 patients with ovarian cancer and 1/1 patient with breast cancer given the recommended Phase 2 dose reported objective responses; all responders harbored BRCA1/2 mutations (Kristeleit et al., 2014; ASCO Abstract 2573). A Phase 2 study of rucaparib treatment for patients with relapsed pancreatic cancer reported 1/19 CR, 2/19 PR (one unconfirmed) and 4/19 SD. Of the 19 patients treated in the study, 15 (79%) had a BRCA2 mutation (Domcheck et al., 2016; ASCO Abstract 4110). In a Phase 2 study of intravenous rucaparib in combination with temozolomide for patients with metastatic melanoma, 8/46 patients achieved a PR and 8/46 had SD (Plummer et al., 2013; 23423489); a Phase 1 study reported 1 CR, 1 PR, and 4 SD lasting six months or longer in patients with metastatic melanoma (Plummer et al., 2008; 19047122). A Phase 1 study of intravenous and oral rucaparib in combination with chemotherapy for the treatment of advanced solid tumors reported a disease control rate of 68.8% (53/77), including 1 CR and 9 PRs (Wilson et al., 2017; 28222073). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Olaparib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> The PARP inhibitor olaparib is FDA approved to treat patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer, patients with deleterious or suspected deleterious gBRCA_mutated pancreatic adenocarcinoma or HER2_negative breast cancer, and patients with prostate cancer and mutations in homologous recombination repair genes. Olaparib is also approved in combination with bevacizumab to treat patients with ovarian, Fallopian tube, or primary peritoneal cancer with deleterious or suspected deleterious somatic or gBRCA mutation and/or genomic instability. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of extensive clinical evidence in ovarian cancer (Fong et al., 2009; 19553641, Audeh et al., 2010; 20609468, Fong et al., 2010; 20406929, Gelmon et al., 2011; 21862407, Kaye et al., 2012; 22203755) as well as strong clinical evidence in multiple other cancer types (Fong et al., 2009; 19553641, Tutt et al., 2010; 20609467, Gelmon et al., 2011; 21862407, Del Conte et al., 2014; 25025963, Kaufman et al., 2015; 25366685, Mateo et al., 2015; 26510020, Golan et al., 2019; 31157963), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to olaparib. </p> <p><b>Supporting Data:</b> A heavily pretreated patient with low_grade endometrioid endometrial adenocarcinoma and germline and somatic BRCA2 mutations experienced ongoing SD for 15 months from single_agent olaparib (Gockley et al., 2018; 29937315). A patient with high_grade serous endometrial cancer harboring a somatic BRIP1 frameshift alteration experienced a CR following olaparib monotherapy (Nakamura et al., 2020; DOI: 10.1200/PO.19.00368). A patient with endometrial adenocarcinoma and PTEN loss experienced clinical benefit for 8 months following olaparib therapy. Although BRCA alterations were not detected, only a subset of common BRCA mutations were assessed, and the authors could not exclude the possibility of other BRCA alterations contributing to the response (Forster et al., 2011; 21468130). Olaparib has been studied primarily for the treatment of ovarian cancer, with response rates often significantly higher for patients with BRCA mutations than for those without (Fong et al., 2009; 19553641, Gelmon et al., 2011; 21862407); higher response rates have also been observed for patients with platinum_sensitive versus platinum_resistant cancer (Domchek et al., 2016; 26723501, Matulonis et al., 2016; 26961146, Gelmon et al., 2011; 21862407, Fong et al., 2010; 20406929). As maintenance therapy for patients with newly diagnosed or platinum_sensitive relapsed ovarian cancer, olaparib has demonstrated significantly improved median PFS and median OS compared with placebo in the Phase 3 SOLO_1 study (Moore et al., 2018; 30345884) and in multiple later_phase studies (Pujade_Lauraine et al., 2017; 28754483, Ledermann et al., 2016; 27617661, Ledermann et al., 2012; 22452356, Ledermann et al., 2014; 24882434). Phase 3 studies of olaparib for patients with BRCA_mutated metastatic breast (Robson et al., 2017; 28578601) or pancreatic cancer (Golan et al., 2019; 31157963) or for patients with metastatic castration_resistant prostate cancer and BRCA or ATM alterations (de Bono et al., 2020; 32343890) have also reported significantly longer median PFS compared with chemotherapy, placebo, or hormone therapy. Additionally, olaparib has demonstrated clinical activity for patients with other solid tumors harboring BRCA mutations, including leiomyosarcoma (Seligson et al., 2019; 30541756), cholangiocarcinoma (Lin et al., 2019; 31068370), and bladder cancer (Necchi et al., 2018; 29680362) in smaller studies. Olaparib in combination with the AKT inhibitor capivasertib has demonstrated clinical benefit for patients with solid tumors; a Phase 1 trial reported a 45% (25/56) DCR, including 14 PRs and 11 SDs, and 14 of those experiencing clinical benefit had germline BRCA1/2 mutated_solid tumors (Yap et al., 2020; 3253274). In a Phase 2 study of olaparib plus pembrolizumab for patients with advanced solid tumors, those with BRCA1 or BRCA2 mutations and those with homologous recombination deficient tumors reported the highest ORRs of 29% (6/21) and 21% (16/76), respectively. Patients with homologous recombination repair deficient tumors, including and excluding patients with BRCA1/2 mutations, reported lower ORRs of 15% (8/53) and 6.3% (2/32), respectively (Maio et al., 2021; AACR abstract CT178). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Niraparib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> The PARP inhibitor niraparib is FDA approved to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, with or without homologous recombination deficiency (HRD)_positive status. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of clinical evidence in ovarian and breast cancers (Konstantinopolous et al., 2018; ASCO Abstract 106, Mirza et al., 2016; 27717299, Sandhu et al., 2013; 23810788), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors such as niraparib. </p> <p><b>Supporting Data:</b> In a Phase 2 study of niraparib for patients with endometrial cancer, patients experienced an ORR of 4.0% (1/23) and a DCR of 20%, while patients treated with niraparib and dostarlimab experienced an ORR of 14% (3/22) and a DCR of 32% (Madariaga et al., 2021; ASCO Abstract 5574). Niraparib has been primarily evaluated in the context of ovarian cancer. In a Phase 3 study of patients with platinum_sensitive, recurrent ovarian cancer, niraparib significantly increased median PFS, as compared to placebo, in patients with germline BRCA mutations (21 vs. 5.5 months) and in patients without germline BRCA mutations (9.3 vs. 3.9 months) as well as in a subgroup of the patients without germline BRCA mutations with homologous recombination_deficient tumors (12.9 vs. 3.8 months)(Mirza et al., 2016; 27717299). In a Phase 1 study of niraparib treatment for patients with solid tumors, 40% (8/20) of patients with ovarian cancer and BRCA mutations and 50% (2/4) of patients with breast cancer and BRCA mutations experienced a PR, and 43% (9/21) of patients with castration_resistant prostate cancer and 100% (2/2) of patients with non_small cell lung cancer achieved SD (Sandhu et al., 2013; 23810788). A Phase 1 study of the combination of niraparib and bevacizumab in patients with platinum_sensitive, high_grade ovarian cancer reported a DCR of 91% (10/11), with a response rate of 45% (5/11)(Mirza et al., 2016; ASCO Abstract 5555). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04269200', 'Include': 'true'}, {'nctId': 'NCT04123366', 'Include': 'true'}, {'nctId': 'NCT03742895', 'Include': 'true'}, {'nctId': 'NCT04716686', 'Include': 'true'}, {'nctId': 'NCT02264678', 'Include': 'true'}, {'nctId': 'NCT02630199', 'Include': 'true'}, {'nctId': 'NCT04635631', 'Include': 'true'}, {'nctId': 'NCT03188965', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'BRCA2', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'E1879D', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'E1879D'}}, 'Interpretation': 'The BRCA2 tumor suppressor gene encodes a protein that regulates the response to DNA damage (Yang et al., 2002; 12228710). Inactivating mutations in BRCA2 can lead to the inability to repair DNA damage and loss of cell cycle checkpoints, which can lead to tumorigenesis (Holloman, 2011; 21731065). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. BRCA2 mutation has been reported in 10% of uterine corpus endometrial and endometrioid carcinoma cases analyzed in the TCGA dataset (Cancer Genome Atlas Research Network., 2013; 23636398). LOH of the wild type BRCA1/2 allele in patients with endometrial carcinoma harboring germline BRCA1/2 mutations has been associated with higher FIGO grade, nonendometrioid histology, and frequent co_occurrence of TP53 mutation (de Jonge et al., 2019; 31492746). Studies have reported that BRCA2 germline mutations do not increase the lifetime risk of endometrial cancer (Levine et al., 2001; 11263938, Segev et al., 2013; 23562522). Alterations that inactivate BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors (Kaufman et al., 2015; 25366685, Mateo et al., 2015; 26510020, Tutt et al., 2010; 20609467, Robson et al., 2017; 28578601, Mirza et al., 2016; 27717299, Sandhu et al., 2013; 23810788, Swisher et al., 2016; 27908594, Drew et al., 2016; 27002934, Pujade_Lauraine et al., 2017; 28754483, Ledermann et al., 2016; 27617661, Fong et al., 2009; 19553641, Audeh et al., 2010; 20609468, Fong et al., 2010; 20406929, Gelmon et al., 2011; 21862407, Kaye et al., 2012; 22203755, Domchek et al., 2016; 26723501, Moore et al., 2018; 30345884, Golan et al., 2019; 31157963) or ATR inhibitors (Yap et al., 2020; 32988960, Thomas et al., 2018; 29252124, O Carrigan et al., 2016; ASCO Abstract 2504, Yap et al., 2016; AACR_NCI_EORTC Abstract 1LBA, Saito et al., 2018; 31299005). Clinical responses to PARP inhibitors have been reported for patients with either germline or somatic BRCA1/2 mutations (Mateo et al., 2015; 26510020, Swisher et al., 2016; 27908594, Ledermann et al., 2016; 27617661, Moore et al., 2018; 30345884, Golan et al., 2019; 31157963) and for patients with platinum_resistant or _refractory disease (Fong et al., 2010; 20406929, Kaufman et al., 2015; 25366685, Sandhu et al., 2013; 23810788, Domchek et al., 2016; 26723501). In a case study, a patient with therapy_induced neuroendocrine prostate cancer and an inactivating BRCA2 rearrangement experienced a CR ongoing for 20 months to the ATR inhibitor berzosertib (Saito et al., 2018; 31299005). Preclinical studies of BRCA1/2 inactivation in T_cell acute lymphoblastic leukemia (T_ALL) (Pouliot et al., 2019; 31721781), ovarian carcinoma (Kim et al., 2017; 27993965), and triple_negative breast cancer (TNBC) (Jin et al., 2018; 29605721) showing reduced cell viability and increased DNA damage during ATR treatment further support the sensitivity of BRCA2_deficient cells to ATR inhibitors. The WEE1 inhibitor adavosertib has been evaluated as a monotherapy and in combination with PARP_inhibitor, olaparib. In a Phase 2 study for patients with PARP_resistant ovarian cancer, the combination of olaparib and adavosertib elicited improved clinical benefit (ORR: 29%; DCR: 89%) compared to adavosertib alone (ORR: 23%; DCR: 63%); however, in the BRCA_mutated cohort, no significant difference in clinical benefit was observed between the combination (ORR: 19%) and monotherapy (ORR: 20%) treatments (Westin et al., 2021; ASCO Abstract 5505). In a Phase 1 monotherapy trial of adavosertib that included 9 patients with BRCA1/2_mutated solid tumors, 2 patients with BRCA1_mutated cancers (1 with ovarian serous carcinoma and 1 with oral squamous cell carcinoma) achieved PRs, and a third patient with ovarian serous carcinoma harboring mutations in BRCA1 and TP53 experienced 14% tumor shrinkage prior to disease progression (Do et al., 2015; 25964244). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. Inactivation of BRCA2 may also predict sensitivity to DNA_damaging drugs such as trabectedin, lurbinectedin, and the platinum chemotherapies cisplatin and carboplatin (Isakoff et al., 2015; 25847936, Dann et al., 2012; 22406760, Evers et al., 2008; 18559613, Soares et al., 2007; 17656556, Miolo et al., 2016; 27561088, Ghouadni et al., 2017; 28467918, Tedesco et al., 2011; ASCO Abstract 1125, Perez et al., 2017; 28626402, Monk et al., 2020; 31924332, Harnicek et al., 2016; 26933761, Cruz et al., 2018; 30240327, Awada et al., 2018; ASCO Abstract 1072, Poveda et al., 2017; 28368437). Inactivating germline mutations in BRCA1 or BRCA2 are associated with autosomal dominant hereditary breast and ovarian cancer (Miki et al., 1994; 7545954, Wooster et al., 1995; 8524414), and the lifetime risk of breast and ovarian cancer in BRCA2 mutation carriers has been estimated to be as high as >80% and 23%, respectively (King et al., 2003; 14576434). Elevated risk for other cancer types, including gastric, pancreatic, prostate, and colorectal, has also been identified, with an increase in risk ranging from 20 to 60% (Friedenson, 2005; 16369438). The estimated prevalence of deleterious germline BRCA1/2 mutations in the general population is between 1:400 and 1:800, with an approximately 10_fold higher prevalence in the Ashkenazi Jewish population (Ford et al., 1994; 7907678, Whittemore et al., 1997; 9042908, Claus et al., 1996; 8635102, Struewing et al., 1997; 9145676, Oddoux et al., 1996; 8841192, King et al., 2003; 14576434, Hall et al., 2009; 19241424). In the appropriate clinical context, germline testing of BRCA2 is recommended.', 'Include': 'true', 'ClinicalTrialNote': 'BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Talazoparib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> The PARP inhibitor talazoparib is FDA approved to treat HER2_negative locally advanced or metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of strong clinical data in breast cancer (Turner et al., 2017; ASCO Abstract 1007)(Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753) and additional clinical evidence in ovarian, pancreatic, and prostate cancer (Meehan et al., 2017; AACR Abstract 4687)(de Bono et al., 2017; 28242752, Lu et al., 2018; 30099369, De Bono et al., 2020; ASCO Abstract 5566), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to talazoparib. </p> <p><b>Supporting Data:</b> A Phase 1 study reported a PR for a patient with uterine carcinoma and a BRCA2 germline mutation treated with talazoparib plus carboplatin and paclitaxel followed by talazoparib monotherapy (Turk et al., 2018; ASCO Abstract 2548). Talazoparib has been studied primarily in the context of BRCA_mutated, HER2_negative breast cancer, where patients achieved significantly longer median PFS (8.6 vs. 5.6 months, HR=0.54), a higher ORR (62.6% vs. 27.2%), and improved quality of life on talazoparib compared with standard chemotherapy in a Phase 3 study (Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753). In a Phase 2 study of talazoparib for BRCA1/2_wildtype patients with homologous recombination pathway alterations, the best outcome in non_breast tumors was SD ≥ 6 months for 2/7 patients who had colon cancer with germline ATM alteration or testicular cancer with germline CHEK2 and somatic ATM alteration (Gruber et al., 2019; ASCO Abstract 3006). Clinical activity of single_agent talazoparib has been observed in numerous other solid tumors, including responses in BRCA_mutated ovarian, pancreatic, prostate, and ampulla of Vater cancers; PALB2_mutated pancreatic and bladder cancers; ATM_mutated cholangiocarcinoma; and small cell lung cancer (deBono et al., 2017; 28242752, Lu et al., 2018; 30099369)(Piha_Paul et al., 2017; EORTC_NCI_AACR Abstract A096, Meehan et al., 2017; AACR Abstract 4687). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Rucaparib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> The PARP inhibitor rucaparib is FDA approved to treat patients with metastatic castration_resistant prostate cancer (mCRPC) or epithelial ovarian, Fallopian tube, or primary peritoneal cancer and deleterious somatic or germline BRCA mutations. Rucaparib is also approved as a maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of strong clinical evidence in ovarian cancer (Shapira_Frommer et al., 2015; ASCO Abstract 5513)(Swisher et al., 2016; 27908594, Drew et al., 2016; 27002934), as well as clinical data in other cancer types (Kristeleit et al., 2014; ASCO Abstract 2573, Domcheck et al., 2016; ASCO Abstract 4110)(Drew et al., 2016; 27002934), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to rucaparib. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of rucaparib for the treatment of endometrial cancers are limited (PubMed, May 2021). Rucaparib has primarily been evaluated in the context of ovarian carcinoma, breast carcinoma, pancreatic carcinoma, and melanoma. In a Phase 2 study of rucaparib for recurrent, platinum_sensitive ovarian, peritoneal, or fallopian tube carcinoma, median PFS was significantly longer in patients with BRCA1/2 mutations (12.8 months) or high loss of heterozygosity (LOH; 5.7 months) compared to patients with low LOH (5.2 months). Objective responses were observed for 80% (32/40) of patients with BRCA1/2 mutations, for 29% (24/82) with high LOH, and for 10% (7/10) with low LOH (Swisher et al., 2016; 27908594). In heavily pretreated patients with a germline BRCA1/2 mutation who had received 2_4 prior chemotherapy treatments and had a progression free interval of greater than 6 months, 65% (17/26) of patients achieved an objective response with rucaparib treatment (Shapira_Frommer et al., 2015; ASCO Abstract 5513). In a Phase 2 study evaluating rucaparib for patients with advanced breast or ovarian cancer and germline BRCA1/2 mutations, disease control was observed in 92% (12/13) of patients with ovarian cancer treated with oral rucaparib dosed continuously, but no objective responses were reported in breast cancer patients (n=23). However, 39% (9/23) of evaluable patients with breast cancer achieved SD lasting 12 weeks or more (Drew et al., 2016; 27002934). In a Phase 1 study of rucaparib treatment in patients with solid tumors, 3/4 patients with ovarian cancer and 1/1 patient with breast cancer given the recommended Phase 2 dose reported objective responses; all responders harbored BRCA1/2 mutations (Kristeleit et al., 2014; ASCO Abstract 2573). A Phase 2 study of rucaparib treatment for patients with relapsed pancreatic cancer reported 1/19 CR, 2/19 PR (one unconfirmed) and 4/19 SD. Of the 19 patients treated in the study, 15 (79%) had a BRCA2 mutation (Domcheck et al., 2016; ASCO Abstract 4110). In a Phase 2 study of intravenous rucaparib in combination with temozolomide for patients with metastatic melanoma, 8/46 patients achieved a PR and 8/46 had SD (Plummer et al., 2013; 23423489); a Phase 1 study reported 1 CR, 1 PR, and 4 SD lasting six months or longer in patients with metastatic melanoma (Plummer et al., 2008; 19047122). A Phase 1 study of intravenous and oral rucaparib in combination with chemotherapy for the treatment of advanced solid tumors reported a disease control rate of 68.8% (53/77), including 1 CR and 9 PRs (Wilson et al., 2017; 28222073). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Olaparib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> The PARP inhibitor olaparib is FDA approved to treat patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer, patients with deleterious or suspected deleterious gBRCA_mutated pancreatic adenocarcinoma or HER2_negative breast cancer, and patients with prostate cancer and mutations in homologous recombination repair genes. Olaparib is also approved in combination with bevacizumab to treat patients with ovarian, Fallopian tube, or primary peritoneal cancer with deleterious or suspected deleterious somatic or gBRCA mutation and/or genomic instability. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of extensive clinical evidence in ovarian cancer (Fong et al., 2009; 19553641, Audeh et al., 2010; 20609468, Fong et al., 2010; 20406929, Gelmon et al., 2011; 21862407, Kaye et al., 2012; 22203755) as well as strong clinical evidence in multiple other cancer types (Fong et al., 2009; 19553641, Tutt et al., 2010; 20609467, Gelmon et al., 2011; 21862407, Del Conte et al., 2014; 25025963, Kaufman et al., 2015; 25366685, Mateo et al., 2015; 26510020, Golan et al., 2019; 31157963), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to olaparib. </p> <p><b>Supporting Data:</b> A heavily pretreated patient with low_grade endometrioid endometrial adenocarcinoma and germline and somatic BRCA2 mutations experienced ongoing SD for 15 months from single_agent olaparib (Gockley et al., 2018; 29937315). A patient with high_grade serous endometrial cancer harboring a somatic BRIP1 frameshift alteration experienced a CR following olaparib monotherapy (Nakamura et al., 2020; DOI: 10.1200/PO.19.00368). A patient with endometrial adenocarcinoma and PTEN loss experienced clinical benefit for 8 months following olaparib therapy. Although BRCA alterations were not detected, only a subset of common BRCA mutations were assessed, and the authors could not exclude the possibility of other BRCA alterations contributing to the response (Forster et al., 2011; 21468130). Olaparib has been studied primarily for the treatment of ovarian cancer, with response rates often significantly higher for patients with BRCA mutations than for those without (Fong et al., 2009; 19553641, Gelmon et al., 2011; 21862407); higher response rates have also been observed for patients with platinum_sensitive versus platinum_resistant cancer (Domchek et al., 2016; 26723501, Matulonis et al., 2016; 26961146, Gelmon et al., 2011; 21862407, Fong et al., 2010; 20406929). As maintenance therapy for patients with newly diagnosed or platinum_sensitive relapsed ovarian cancer, olaparib has demonstrated significantly improved median PFS and median OS compared with placebo in the Phase 3 SOLO_1 study (Moore et al., 2018; 30345884) and in multiple later_phase studies (Pujade_Lauraine et al., 2017; 28754483, Ledermann et al., 2016; 27617661, Ledermann et al., 2012; 22452356, Ledermann et al., 2014; 24882434). Phase 3 studies of olaparib for patients with BRCA_mutated metastatic breast (Robson et al., 2017; 28578601) or pancreatic cancer (Golan et al., 2019; 31157963) or for patients with metastatic castration_resistant prostate cancer and BRCA or ATM alterations (de Bono et al., 2020; 32343890) have also reported significantly longer median PFS compared with chemotherapy, placebo, or hormone therapy. Additionally, olaparib has demonstrated clinical activity for patients with other solid tumors harboring BRCA mutations, including leiomyosarcoma (Seligson et al., 2019; 30541756), cholangiocarcinoma (Lin et al., 2019; 31068370), and bladder cancer (Necchi et al., 2018; 29680362) in smaller studies. Olaparib in combination with the AKT inhibitor capivasertib has demonstrated clinical benefit for patients with solid tumors; a Phase 1 trial reported a 45% (25/56) DCR, including 14 PRs and 11 SDs, and 14 of those experiencing clinical benefit had germline BRCA1/2 mutated_solid tumors (Yap et al., 2020; 3253274). In a Phase 2 study of olaparib plus pembrolizumab for patients with advanced solid tumors, those with BRCA1 or BRCA2 mutations and those with homologous recombination deficient tumors reported the highest ORRs of 29% (6/21) and 21% (16/76), respectively. Patients with homologous recombination repair deficient tumors, including and excluding patients with BRCA1/2 mutations, reported lower ORRs of 15% (8/53) and 6.3% (2/32), respectively (Maio et al., 2021; AACR abstract CT178). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Niraparib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> The PARP inhibitor niraparib is FDA approved to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, with or without homologous recombination deficiency (HRD)_positive status. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ATM inactivation may predict sensitivity to PARP inhibitors. ATM alterations have been associated with clinical benefit from PARP inhibitors in solid tumors, including prostate cancer (Mateo et al., 2015; 26510020, Mateo et al., 2020; 31806540, de Bono et al., 2020; ASCO GU Abstract 119, Abida et al., 2020; 32086346), colorectal cancer (Gruber et al., 2019; ASCO Abstract 3006), breast cancer (Gruber et al., 2019; ASCO Abstract 3006), gastric cancer (Bang et al., 2015; 26282658), cholangiocarcinoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096), and papillary renal cell carcinoma (Olson et al., 2016; 27079472). On the basis of clinical evidence in ovarian and breast cancers (Konstantinopolous et al., 2018; ASCO Abstract 106, Mirza et al., 2016; 27717299, Sandhu et al., 2013; 23810788), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors such as niraparib. </p> <p><b>Supporting Data:</b> In a Phase 2 study of niraparib for patients with endometrial cancer, patients experienced an ORR of 4.0% (1/23) and a DCR of 20%, while patients treated with niraparib and dostarlimab experienced an ORR of 14% (3/22) and a DCR of 32% (Madariaga et al., 2021; ASCO Abstract 5574). Niraparib has been primarily evaluated in the context of ovarian cancer. In a Phase 3 study of patients with platinum_sensitive, recurrent ovarian cancer, niraparib significantly increased median PFS, as compared to placebo, in patients with germline BRCA mutations (21 vs. 5.5 months) and in patients without germline BRCA mutations (9.3 vs. 3.9 months) as well as in a subgroup of the patients without germline BRCA mutations with homologous recombination_deficient tumors (12.9 vs. 3.8 months)(Mirza et al., 2016; 27717299). In a Phase 1 study of niraparib treatment for patients with solid tumors, 40% (8/20) of patients with ovarian cancer and BRCA mutations and 50% (2/4) of patients with breast cancer and BRCA mutations experienced a PR, and 43% (9/21) of patients with castration_resistant prostate cancer and 100% (2/2) of patients with non_small cell lung cancer achieved SD (Sandhu et al., 2013; 23810788). A Phase 1 study of the combination of niraparib and bevacizumab in patients with platinum_sensitive, high_grade ovarian cancer reported a DCR of 91% (10/11), with a response rate of 45% (5/11)(Mirza et al., 2016; ASCO Abstract 5555). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04269200', 'Include': 'true'}, {'nctId': 'NCT03239015', 'Include': 'true'}, {'nctId': 'NCT04123366', 'Include': 'true'}, {'nctId': 'NCT03742895', 'Include': 'true'}, {'nctId': 'NCT04716686', 'Include': 'true'}, {'nctId': 'NCT02264678', 'Include': 'true'}, {'nctId': 'NCT02630199', 'Include': 'true'}, {'nctId': 'NCT04635631', 'Include': 'true'}, {'nctId': 'NCT03188965', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'CTNNB1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'K335T', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'K335T'}}, 'Interpretation': 'CTNNB1 encodes beta_catenin, a key downstream component of the WNT signaling pathway. Beta_catenin interacts with cadherin to regulate cell_cell adhesion; as a component of the WNT pathway, it also plays a role in development, cell proliferation, and cell differentiation (Kikuchi, 2000; 10679188). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. CTNNB1 mutations have been reported in 7_45% of endometrial carcinomas (ECs) (Cancer Genome Atlas Research Network., 2013; 23636398, Dellinger et al., 2012; 22149432, Saegusa et al., 2001; 11161379, McConechy et al., 2014; 23765252, Huang et al., 2013; 23760948). CTNNB1 mutations are more common in Type 1 EC than Type 2 (Yeramian et al., 2012; 22430211, Machin et al., 2002; 11957146). In addition, one study found that CTNNB1 mutations were identified more frequently in sporadic ECs (31%, 18/58), than in Lynch syndrome (LS)_associated ECs (6.9%, 2/29) (Huang et al., 2013; 23760948). Nuclear beta_catenin protein expression has been observed in 14.7_27.6% (33/224_55/199) of ECs, with a significantly higher incidence in Type 1 tumors (Peiró et al., 2013; 22955108, Saegusa et al., 2001; 11161379). Multiple studies have reported that CTNNB1 mutation characterizes an aggressive subset of EC (Kurnit et al., 2017; 28281553, Stelloo et al., 2016; 27006490, Liu et al., 2014; 25214561). One study found that that TP53 or CTNNB1 mutation was an independent marker of poor recurrence_free survival (HR=4.69) for patients with low grade, early stage EC (Kurnit et al., 2017; 28281553). Low membrane expression of beta_catenin has been linked with poor prognosis in EC and ovarian endometrioid carcinomas (Rosen et al., 2010; 19820688, Athanassiadou et al., 2007; 17504383). Mutation or activation of CTNNB1 signaling has been shown to increase mTOR signaling, promote tumorigenesis, and respond to mTOR inhibition in preclinical studies (Tanwar et al., 2009; 19403928, Tanwar et al., 2011; 21695255, Fujishita et al., 2008; 18768809). Small studies have reported clinical benefit following treatment of everolimus combined with other targeted agents for patients with CTNNB1_mutated hepatocellular carcinoma (Bhoori et al., 2010; 20347502, Janku et al., 2014; 24931142) or endometrial carcinoma (Slomovitz et al., 2015; 25624430). In preclinical studies, CTNNB1 activating mutations have been shown to increase expression of WNT pathway member DKK1, which may promote tumor cell proliferation and immune evasion (Niida et al., 2004; 15378020, Chamorro et al., 2005; 15592430, Kagey and He, 2017; 28574171). A Phase 1 trial of DKK1_targeting antibody DKN_01 in combination with paclitaxel in esophageal cancer reported a PR rate in 2 out of 4 patients and SD rate of in 1 out of 4 patients with CTNNB1 activating mutations, compared with 24% (10/41) PR and 37% (15/41) SD in unselected patients (Kagey et al., 2017; AACR Abstract 369). Multiple preclinical studies in cancer models harboring CTNNB1 mutation or beta_catenin pathway activation have reported activation of the NOTCH pathway and sensitivity to pharmacologic inhibition of NOTCH signaling by gamma_secretase inhibitors (Kwon et al., 2011; 21841793, Arcaroli et al., 2013; 23868008, Shang et al., 2015; 26349011, Kode et al., 2014; 24429522). Phase 1 and 2 clinical trials of gamma_secretase inhibitor PF_03084014 have shown high response rates in patients with desmoid tumors, which are driven by activating CTNNB1 mutations in the majority of cases (Kummar et al., 2015; ASCO Abstract 10563)(Messersmith et al., 2015; 25231399), suggesting CTNNB1_mutated tumors may be sensitive to gamma_secretase inhibitors. Although WNT pathway inhibitors have been explored preclinically in CTNNB1_mutated cells, clinical data supporting this therapeutic approach are lacking (Zhu et al., 2012; 22964660, Tanwar et al., 2011; 21695255, Kogan et al., 2012; 22356261, Lachenmayer et al., 2012; 22811581). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true', 'ClinicalTrialNote': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT03008408', 'Include': 'true'}, {'nctId': 'NCT03065062', 'Include': 'true'}, {'nctId': 'NCT01582191', 'Include': 'true'}, {'nctId': 'NCT02159989', 'Include': 'true'}, {'nctId': 'NCT02321501', 'Include': 'true'}, {'nctId': 'NCT03017833', 'Include': 'true'}, {'nctId': 'NCT03430882', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'FANCL', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'splice site 904_2A>C', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'splice site 904_2A>C'}}, 'Interpretation': 'FANCL encodes a member of the Fanconi anemia nuclear complex, a multiprotein structure also including the products of FANCA, FANCC, FANCF and FANCG. The activity of this complex is essential to prevention of chromosome breakage caused by DNA damage (Pace et al., 2002; 12093742). Germline mutations in FANCL cause Fanconi anemia, a clinically heterogeneous disorder involving various developmental abnormalities as well as predisposition to cancer; underlying these phenotypes are defects in DNA repair (Deakyne and Mazin, 2011; 21568838). Alterations such as seen here may disrupt FANCL function or expression (Alpi et al., 2007; 17938197, Alpi et al., 2008; 19111657, Meetei et al., 2003; 12973351, Machida et al., 2006; 16916645, Hodson et al., 2011; 21775430, Hodson et al., 2013; 24389026, Hodson et al., 2014; 24389026, Seki et al., 2007; 17352736, Ali et al., 2008; 19405097). Germline mutations in FANCL, such as T367fs*13, have been associated with Fanconi anemia, breast cancer, and ovarian cancer and with an increased risk of esophageal cancer and prostate cancer (Fostira et al., 2018; 29335925, Akbari et al., 21279724, Hart et al., 2016; 27084275, Del Valle et al., 2020; 32235514, Chandrasekharappa, et al., 2013; 23613520, Dicks et al., 2017; 28881617). FANCL mutations are most frequently observed in tumors of the prostate (5.9%), liver (4.1%), biliary tract (3.4%), endometrium (3.2%), pancreas (2.7%), large intestine (2.4%), and stomach (2.4%) (COSMIC, May 2021)(Tate et al., 2019; 30371878). Published data investigating the prognostic implications of FANCL alterations in solid tumors and hematologic malignancies are limited (PubMed, May 2021). In a prospective study of 255 patients with follicular lymphoma, 2p gain, which includes VRK2, FANCL, and LINC01122, was associated with worse PFS and OS in multivariate analysis (Qu et al., 2019; 30446494). There are no targeted therapies that directly address genomic alterations in FANCL. Clinical evidence in ovarian cancer indicates that FANCL inactivation may confer sensitivity to PARP inhibitors (O Malley et al., 2017; AACR_NCI_EORTC Abstract LB_A12, Dougherty et al., 2014; ASCO Abstract 5536).', 'Include': 'true', 'ClinicalTrialNote': 'On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04269200', 'Include': 'true'}, {'nctId': 'NCT04123366', 'Include': 'true'}, {'nctId': 'NCT03742895', 'Include': 'true'}, {'nctId': 'NCT04716686', 'Include': 'true'}, {'nctId': 'NCT02264678', 'Include': 'true'}, {'nctId': 'NCT04635631', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT04497116', 'Include': 'true'}, {'nctId': 'NCT04159155', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'FBXW7', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R441W', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R441W'}}, 'Interpretation': 'FBXW7 encodes the F_box protein subunit of the SCF ubiquitin ligase complex, which targets proteins for degradation (Welcker and Clurman, 2008; 18094723). FBXW7 inactivation is associated with chromosomal instability and with stabilization of proto_oncogenes, such as mTOR, MYC, cyclin E, NOTCH, and JUN; FBXW7 is therefore considered a tumor suppressor (Akhoondi et al., 2007; 17909001, Welcker and Clurman, 2008; 18094723). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. FBXW7 mutations have been reported in 14.2% of endometrial carcinomas (COSMIC, Feb 2021) (Tate et al., 2019; 30371878). Studies have variously reported FBXW7 mutation in 18_29% of uterine serous carcinoma, 16% of endometrial cancer, and 2% of endometrioid endometrial cancer cases (Zhao et al., 2013; 23359684, Le et al., 2012; 23104009, Kuhn et al., 2012; 22923510, Spruck et al., 2002; 12183400, Cassia et al., 2003; 14648662). In primary endometrial carcinomas, FBXW7 mutations correlated with lymph node involvement (Garcia_Dios et al., 2013; 23219661). Reduced FBXW7 expression has been associated with poor prognosis in some cancers such as colorectal cancer, gastric cancer, esophageal SCC, cervical SCC, melanoma, and non_small cell lung carcinoma (Tu et al., 2012; 22548670, Iwatsuki et al., 2010; 19739118, Yokobori et al., 2012; 22576686, Yokobori et al., 2009; 19366810, Yokobori et al., 2014; 24165483, Rajagopalan et al., 2004; 14999283, Cheng et al., 2013; 23381582, Xu et al., 2016; 26954701). FBXW7 inactivating alterations may indicate sensitivity to mTOR inhibitors (Mao et al., 2008; 18787170, Yang et al., 2015; 25749036). Several case studies reported clinical benefit for patients with FBXW7_mutated cancers, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; https://doi.org/10.1016/j.ygyno.2020.05.244). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. FBXW7 inactivation may also result in resistance to anti_tubulin chemotherapies based on results from preclinical studies (Wertz et al., 2011; 21368834).', 'Include': 'true', 'ClinicalTrialNote': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Everolimus', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Everolimus is an orally available mTOR inhibitor that is FDA approved to treat renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors; and well_differentiated non_functional neuroendocrine tumors of the lung or gastrointestinal tract. Everolimus is also approved to treat either renal angiomyolipoma or subependymal giant cell astrocytoma in association with tuberous sclerosis complex (TSC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> Clinical benefit has been reported for several patients with PIK3CA_mutated endometrial cancer treated with everolimus as a single agent (Varnier et al., 2019; 31351267, Tredan et al., 2012; 23238879, Myers et al., 2016; 27016228) or combined with hormone therapy (Myers et al., 2016; 27016228, Slomovitz et al., 2015; 25624430). In a Phase 2 clinical trial of recurrent endometrial cancer, 43% (12/28) of patients reported SD at 8 weeks and 21% (6/28) of patients achieved clinical benefit at 20 weeks upon administration of everolimus monotherapy (Slomovitz et al., 2010; 20681032). Combination with the aromatase inhibitor letrozole for the same disease population achieved an ORR of 31% (11/35), with 9 CRs (Slomovitz et al., 2015; 25624430). Further addition of metformin to this regimen led to a clinical benefit rate (CR+PR+SD) of 67% (32/48), including PR in 29% (14/48) of cases; no significant difference was observed between cases with and without KRAS mutation (Soliman et al., 2016; ASCO Abstract 5506). Everolimus achieved PR or SD in 35% of patients with recurrent endometrial carcinoma; KRAS mutation was associated with reduced median PFS (3.1 vs. 1.0 months) and median OS (9.3 vs. 2.3 months) (Tredan et al., 2012; 23238879). Another study investigating estrogen and/or progesterone receptor_positive gynecologic or breast malignancies featuring mutation or loss of genes in the PI3K_AKT_mTOR pathway, including PIK3CA, AKT1, or PTEN, observed SD in 17% (1/6) of patients with endometrial cancer following combined treatment with everolimus and anastrozole (Wheler et al., 2014; 24912489). No response was seen in a patient with endometrial stromal sarcoma and Peutz_Jeghers Syndrome associated with a germline STK11 mutation treated with a combination of everolimus and anastrozole (Noriega_Iriondo et al., 2015; 25649062). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Temsirolimus', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Temsirolimus is an intravenous mTOR inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> In a pooled analysis, 14% (3/21) of patients with PIK3CA_mutated endometrial cancer treated with temsirolimus or ridaforolimus achieved objective response and 29% (6/21) experienced disease progression (Mackay et al., 2014; 24166148). A case report described a patient with heavily pretreated PIK3CA_mutated endometrial cancer who had SD for 17 months with temsirolimus alone followed by combination with letrozole (Dhami et al., 2018; 29588307). A Phase 2 clinical trial of temsirolimus in recurrent or metastatic endometrial cancer reported PR in 4/29 (14%) chemotherapy_naïve patients and 4% (1/25) of chemotherapy_treated patients, with SD reported in 69% (20/29) of chemotherapy_naïve patients and 48% (12/25) of chemotherapy_treated patients; however, response in this study was found to be independent of molecular markers of PI3K_AKT_mTOR pathway activation (Oza et al., 2011; 21788564). Another Phase 2 study of temsirolimus in patients with endometrial cancer reported PFS of >15 months in 6 patients and associated clinical benefit and longer PFS with mutation of AKT1 or CTNNB1, respectively (Myers et al., 2015; ASCO Annual Meeting Abstract 5592). Temsirolimus combined with carboplatin and paclitaxel achieved objective partial responses in 82% (9/11) of patients with endometrial cancer (Kollmannsberger et al., 2012; 21447615). A Phase 2 trial of temsirolimus in combination with bevacizumab in patients with endometrial carcinoma reported clinical response in 25% of patients (Alvarez et. al, 2013; 23262204). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT03239015', 'Include': 'true'}, {'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}, {'nctId': 'NCT02397083', 'Include': 'true'}, {'nctId': 'NCT03008408', 'Include': 'true'}, {'nctId': 'NCT03217669', 'Include': 'true'}, {'nctId': 'NCT03065062', 'Include': 'true'}, {'nctId': 'NCT01582191', 'Include': 'true'}, {'nctId': 'NCT02159989', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'FGFR2', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'N549D', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'N549D'}}, 'Interpretation': 'FGFR2 encodes a tyrosine kinase cell surface receptor, which plays an important role in cell differentiation, growth, and angiogenesis (Powers et al., 2000; 11021964, Turner and Grose, 2010; 20094046). FGFR2 mutations that have been characterized as activating, such as observed here, are predicted to be oncogenic (Reintjes et al., 2013; 23527311, Dutt et al., 2008; 18552176, Byron et al., 2012; 22383975, Ratisoontorn et al., 2003; 12952211, Mohammadi et al., 2005; 15863029, Ibrahimi et al., 2004; 15282208, Pollock et al., 2007; 17525745, Kapeli and Hurlin, 2011; 21908617, Eathiraij et al., 2011; 21454610, Tanizaki et al., 2015; 26048680, Lorenzi et al., 1997; 9266968, Itoh et al., 1994; 8205545, Chen et al., 2007; 17803937). FGFR2 activating alterations that affect amino acid E565 and mutations such as S252W, P253R, W290C, S372C, Y375C, N549K, and K659E have been reported in patients with Apert, Pfeiffer, Beare_Stevenson, and Crouzon syndromes and syndromic craniosynostosis (Park et al., 1995; 7668257, Wilke et al., 1995; 7719344, Lajeunie et al., 2008; 16418739, Chen et al., 2013; 24411056, Slavotinek et al., 2009; 19610084, Dutt et al., 2008; 18552176, Gozgit et al., 2013; 23468082, Chen et al., 2007; 17803937, Przylepa et al., 1996; 8696350, Kan et al., 2002; 11781872). FGFR2 mutations have been reported in 12.5% of cases in the Uterine Corpus Endometrioid Carcinoma TCGA dataset (Cancer Genome Atlas Research Network., 2013; 23636398). In the scientific literature, mutation of FGFR2 has been identified in 10.3% (48/466) of endometrial carcinoma (EC) tumors in one study, and at similar frequencies in others (Krakstad et al., 2012; 23300780, Dutt et al., 2008; 18552176, Byron et al., 2012; 22383975). FGFR2 expression has been identified in 71.9% (23/32) of EC specimens in one study; however, levels of FGFR2 protein or FGFR2 mRNA have not been consistently demonstrated to be higher in tumor specimens compared to normal endometrial tissues (Gatius et al., 2011; 21725289, Ishikawa et al., 2008; 18292933, Siegfried et al., 1997; 9070494). FGFR2 mutations in endometrioid endometrial tumors have been correlated with decreased disease_free survival in one study (Byron et al., 2012; 22383975). FGFR2 activating mutations, amplifications, or fusions may confer sensitivity to selective FGFR inhibitors such as erdafitinib (Tabernero et al., 2015; 26324363, Siefker_Radtke et al., 2018; ASCO Abstract 4503, Soria et al., 2017; ASCO Abstract 4074, Park et al., 2019; ASCO Abstract 4117), pemigatinib (Hollebecque et al., 2019; ESMO Abstract 720P, Krook et al., 2019; 31371345, Abou_Alfa et al., 2020; 32203698, Kuboki et al., 2019; JSMO Abstract P1_156), infigratinib (Nogova et al., 2016; 27870574, Javle et al., 2021; ASCO GI Abstract 265), E7090 (Morizane et al., 2020; ASCO GI Abstract 538), AZD4547 (Pearson et al., 2016; 27179038, Van Cutsem et al., 2017; 29177434, Aggarwal et al., 2019; 31195180, Chae et al., 2018; ASCO Abstract 2503), Debio 1347 (Voss et al., 2019; 30745300, Clearly et al., 2021; 33926920), rogaratinib (Schuler et al., 2019; 31405822), futibatinib (Bahleda et al., 2018; AACR Abstract CT121, Goyal et al., 2019; 31109923, Tran et al., 2018; ESMO Abstract 155O), and derazantinib (Mazzaferro et al., 2019; 30420614) as well as to the multikinase inhibitors pazopanib (Borad et al., 2014; 24550739, Liao et al., 2013; 23786770) and ponatinib (Gozgit et al., 2012; 22238366). Cases of clinical response to selective FGFR inhibitors have been reported for patients with various FGFR2_mutated tumors, including PRs for patients with FGFR2_mutated cholangiocarcinoma treated with AZD4547 (Chae et al., 2018; ASCO Abstract 2503) or erdafitinib (Soria et al., 2017; ASCO Abstract 4074) and a PR for a patient with FGFR2_mutated lung squamous cell carcinoma treated with infigratinib (Slosberg et al., 2018; 29765547). A patient with endometrioid adenocarcinoma and cervical cancer and both an FGFR2 amplification and mutation experienced a PR following treatment with Debio_1347 (Voss et al., 2019; 30745300). Additional clinical responses associated with FGFR2 mutation have been reported for a patient with HNSCC (Liao et al., 2013; 23786770), and in a patient with solitary fibrous tumor treated with pazopanib (Yue et al., 2016; AMP Abstract S06).', 'Include': 'true', 'ClinicalTrialNote': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04865289', 'Include': 'true'}, {'nctId': 'NCT02450136', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT03564691', 'Include': 'true'}, {'nctId': 'NCT04042116', 'Include': 'true'}, {'nctId': 'NCT04565275', 'Include': 'true'}, {'nctId': 'NCT02272998', 'Include': 'true'}, {'nctId': 'NCT02856425', 'Include': 'true'}, {'nctId': 'NCT01543763', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'NF1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R1362*, R2450*', 'AlterationProperties': {'AlterationProperty': [{'isEquivocal': 'false', 'name': 'R1362*'}, {'isEquivocal': 'false', 'name': 'R2450*'}]}, 'Interpretation': 'NF1 encodes neurofibromin, a GTPase_activating protein (GAP) that is a key negative regulator of the RAS signaling pathway (Hattori et al., 1991; 1904223). Neurofibromin acts as a tumor suppressor by repressing RAS signaling (Morcos et al., 1996; 8628317). Alterations such as seen here may disrupt NF1 function or expression (Ballester et al., 1990; 2121371, Xu et al., 1990; 2116237, Martin et al., 1990; 2121370, Thomas et al., 2012; 22807134, Skuse and Cappione, 1997; 9300663, Morcos et al., 1996; 8628317, Messiaen et al., 1999; 11258625, Ars et al., 2000; 10607834, Messiaen and Wimmer, 2005; 15863657, Poullet et al., 1994; 8264648). NF1 alterations have been reported in 5_9% of endometrial carcinomas (Myers et al., 2016; 27016228, cBio_Soumerai et al., 2018; 30068706, Cancer Genome Atlas Research Network., 2013; 23636398). Loss of NF1 has been reported in 13% (4/31) of endometrial carcinomas (Murayama_Hosokawa et al., 2010; 20062086). Published data investigating the prognostic implications of NF1 mutation in endometrial carcinomas are limited (PubMed, Feb 2021). On the basis of clinical evidence in neurofibromatosis Type 1_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma or glioblastoma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors such as cobimetinib, trametinib, binimetinib, and selumetinib. Loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors, including the approved agents everolimus and temsirolimus, based on limited clinical data (Lim et al., 2016; 26859683, Weiss et al., 2015; 25314964, Janku et al., 2014; 24931142) and strong preclinical data in models of malignant peripheral nerve sheath tumor (MPNST)(Johannessen et al., 2008; 18164202, Johannessen et al., 2005; 15937108). A preclinical study suggests that combined mTOR and MEK inhibition is effective in a model of NF1_deficient MPNST (Malone et al., 2014; 24913553). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). One or more of the NF1 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with neurofibromatosis type 1 (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in NF1 cause the autosomal dominant disorder neurofibromatosis type 1, which is characterized in part by increased risk of developing various tumors, including sarcoma, glioma, breast carcinoma, and neuroendocrine and hematological neoplasms (Jett and Friedman, 2010; 20027112, Patil and Chamberlain, 2012; 22240541, Evans et al., 2012; 23036231). Estimates for the prevalence of the disorder in the general population range from 1:2,500 to 1:3,000 (Upadhyaya et al., 1995; 8544190, Williams et al., 2009; 19117870), and in the appropriate clinical context, germline testing of NF1 is recommended.', 'Include': 'true', 'ClinicalTrialNote': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Trametinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in neurofibromatosis type 1 (NF1)_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> Although very little clinical data has been reported on the use of MEK inhibitors in endometrial or uterine cancer, a Phase 1 trial of trametinib in combination with an AKT inhibitor (GSK2141795), reported 3/3 objective responses in uterine/endometrial tumors, with 2 patients achieving stable disease (SD) and 1 partial response (PR) occurring in a patient with mutant KRAS and PTEN loss (Kurzrock et al., 2011; ASCO abstract 3085). In other solid tumor types, a Phase 1 trial of trametinib in 206 patients with solid tumors reported 21 (10%) objective responses (Infante et al., 2012; 22805291). Phase 1 monotherapy trials of RO4987655, another MEK inhibitor, have shown significant response rates in patients with melanoma, including those with BRAF and NRAS mutations, but very low response rates in patients with other solid tumors, including those with KRAS mutations (Leijen et al., 2012; 22767668, Zimmer et al., 2014; 24947927). A Phase 1b trial of trametinib in combination with gemcitabine in patients with solid tumors showed a complete response in a patient with breast cancer, as well as partial responses in patients with pancreatic or salivary gland cancer (Infante et al., 2013; 23583440). A Phase 1b trial of combination treatment with the MEK inhibitor MEK162 and the PI3K_alpha inhibitor BYL719 reported disease control (partial responses or stable disease) in 47% (21/45) of patients, including partial responses in 2 of 3 patients with KRAS_mutant ovarian cancer and 1 of 3 patients with NRAS_mutant melanoma; a 43% rate of stable disease was observed in patients with KRAS_mutant colorectal cancer, with responses independent of PIK3CA mutation status (Juric et al., 2014; ASCO Abstract 9051). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Selumetinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PNs). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in neurofibromatosis type 1 (NF1)_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> A Phase 2 study evaluating selumetinib in patients with recurrent endometrial cancer who had received prior treatment with 1_2 therapies did not reach its primary endpoints of efficacy and 6_month event_free survival, reporting mPFS of 2.3 months and mOS of 8.5 months with 1 CR and 2 PR observed in 52 patients (Coleman et al., 2015; 25887099). Selumetinib has demonstrated efficacy in NF1_associated neurofibroma in Phase 2 studies (Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612) and a Phase 1 study (Dombi et al., 2016; 28029918). Phase 2 studies reported clinical responses in low_grade glioma (Fangusaro et al., 2019; 31151904, Banerjee et al., 2017; 28339824), melanoma (Gupta et al., 2014; 24567366, Robert et al., 2013; 23735514, Kirkwood et al., 2012; 22048237, Banerji et al., 2010; 20179232, Boers_Sonderen et al., 2012; 22293660), and in lung (Lopez_Chavez et al., 2015; 25667274, Hainsworth et al., 2010; 20802351, Middleton et al., 2020; 32669708) and endometrial cancer (Coleman et al., 2015; 25887099). A Phase 2 study of selumetinib for patients with activating alterations in the MAPK pathway reported a DCR of 15% (3/20), with no objective responses observed (Allen et al., 2021; ASCO Abstract 10008). Phase 1 studies of selumetinib to treat patients with solid tumors reported 1/15 PR for a patient with colorectal cancer (CRC) and 5/15 SDs for patients with tonsil squamous cell carcinoma (SCC), non_small cell lung cancer (NSCLC), and CRC (Deming et al., 2016; 26666244); 2/39 PRs (for patients with CRC) and 18/39 SDs were achieved when selumetinib was administered in combination with cyclosporin A (Krishnamurthy et al., 2018; 30042150). Multiple Phase 1 studies combining selumetinib with erlotinib or temsirolimus (Infante et al., 2017; 28424891), docetaxel or dacarbazine (LoRusso et al., 2017; 28264648), AKT inhibitors (Tolcher et al., 2015; 25516890), or cixutumumab (an anti_IGF_1R antibody)(Wilky et al., 2015; 25268371) reported clinical responses for patients with advanced solid tumors including NSCLC, thyroid carcinoma, tongue SCC, and ovarian cancer. </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT03239015', 'Include': 'true'}, {'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT03989115', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT03905148', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}, {'nctId': 'NCT04800822', 'Include': 'true'}, {'nctId': 'NCT02397083', 'Include': 'true'}, {'nctId': 'NCT02070549', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'PIK3CA', 'Include': 'true', 'Alterations': {'Alteration': [{'Name': 'R88Q', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R88Q'}}, 'Interpretation': 'PIK3CA encodes p110_alpha, which is the catalytic subunit of phosphatidylinositol 3_kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival (Samuels et al., 2005; 15950905, Engelman, 2009; 19629070). PIK3CA alterations that have been characterized as activating, such as R88Q observed here, are predicted to be oncogenic (Kang et al., 2005; 15647370, Ikenoue et al., 2005; 15930273, Gymnopoulos et al., 2007; 17376864, Horn et al., 2008; 18317450, Rudd et al., 2011; 21266528, Hon et al., 2012; 22120714, Burke et al., 2012; 22949682, Wu et al., 2009; 19915146, Dbouk et al., 2010; 2103068, Dan et al., 2010; 20530683, Oda et al., 2008; 18829572, Zhao and Vogt, 2008; 18794883, Lui et al., 2013; 23619167, Ross et al., 2013; 22430209, Riviere et al., 2012; 22729224, Shibata et al., 2009; 19394761, Droguluk et al., 2015; 26627007,Croessmann et al., 2018; 29284706, Ng et al., 2018; 29533785, Spangle et al., 2020; 32929011, Chen et al., 2018; 29636477). Although alterations such as T1025A seen here have not been fully characterized, they have been associated with sensitivity to targeted therapies or have shown cancer association, which may indicate biological relevance (Tate et al., 2019; 30371878, Rivière et al., 2012; 22729224, Akgumus et al., 2017; 28502730, Slomovitz et al., 2015; 25624430, Al_Rohil et al., 2016; 26479420, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In the scientific literature, PIK3CA mutations have been reported in 16_54% of endometrial carcinomas (Garcia_Dios et al., 2013; 23219661, Rudd et al., 2011; 21266528, Kandoth et al., 2013; 23636398). In endometrial cancers, PIK3CA mutations often co_occur with other mutations that activate the PI3K_AKT_mTOR signaling axis, such as PTEN and KRAS alterations (Oda et al., 2005; 16322209, Oda et al., 2008; 18829572). Overexpression of p110_alpha has been reported in 72% of endometrial carcinomas (Akiyama_Abe et al., 2013; 23949151). One study reported PIK3CA exon 9 or 20 mutations in 20% (20/99) of high_grade endometrial carcinomas; these mutations were associated with shorter patient survival within Grade 3 endometrioid carcinoma, but not within endometrial serous carcinoma (McIntyre et al., 2013; 24262879). Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K (Fritsch et al., 2014; 24608574, Juric et al., 2018; 29401002, Gallant et al., 2019; 30793038), AKT (Andre et al., 2019; 31091374, Smyth et al., 2021; 33863913), or mTOR (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452). Results from the Phase 2 MATCH trial for patients with PIK3CA_altered solid tumors found that 27% (18/65) of patients experienced PFS lasting at least 6 months after treatment with taselisib; however, no ORs were observed in this study (Krop et al., 2018; ASCO Abstract 101). In a Phase 1 trial of the dual PI3K/mTOR kinase inhibitor apitolisib, 79% (11/14) of patients with PIK3CA_mutated advanced solid tumors experienced disease control (3 PRs, 8 SDs) (Dolly et al., 2016; 26787751). The PI3K inhibitor alpelisib demonstrated an ORR of 6.0% (8/134) and a DCR of 58% (78/134) in a study of PIK3CA_mutated solid tumors (Juric et al., 2018; 2941002). However, the PI3K inhibitor copanlisib exhibited limited efficacy in PIK3CA_altered tumors (Santin et al., 2020; 31934607, Patnaik et al., 2016; 27672108). Activating mutations in PIK3CA may confer resistance to HER2_targeted therapies; combined inhibition of HER2 and the PI3K pathway may be required in HER2_positive tumors with PIK3CA mutation (Esteva et al., 2010; 20813970, Baselga et al., 2014; 25332247, Chakrabarty et al., 2010; 20581867, Cizkova et al., 2010; San Antonio Breast Cancer Symposium Abstract P2_09_30, Kataoka et al., 2010; 19633047, Wang et al., 2011; 21676217).', 'Include': 'true', 'ClinicalTrialNote': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Everolimus', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Everolimus is an orally available mTOR inhibitor that is FDA approved to treat renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors; and well_differentiated non_functional neuroendocrine tumors of the lung or gastrointestinal tract. Everolimus is also approved to treat either renal angiomyolipoma or subependymal giant cell astrocytoma in association with tuberous sclerosis complex (TSC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> Clinical benefit has been reported for several patients with PIK3CA_mutated endometrial cancer treated with everolimus as a single agent (Varnier et al., 2019; 31351267, Tredan et al., 2012; 23238879, Myers et al., 2016; 27016228) or combined with hormone therapy (Myers et al., 2016; 27016228, Slomovitz et al., 2015; 25624430). In a Phase 2 clinical trial of recurrent endometrial cancer, 43% (12/28) of patients reported SD at 8 weeks and 21% (6/28) of patients achieved clinical benefit at 20 weeks upon administration of everolimus monotherapy (Slomovitz et al., 2010; 20681032). Combination with the aromatase inhibitor letrozole for the same disease population achieved an ORR of 31% (11/35), with 9 CRs (Slomovitz et al., 2015; 25624430). Further addition of metformin to this regimen led to a clinical benefit rate (CR+PR+SD) of 67% (32/48), including PR in 29% (14/48) of cases; no significant difference was observed between cases with and without KRAS mutation (Soliman et al., 2016; ASCO Abstract 5506). Everolimus achieved PR or SD in 35% of patients with recurrent endometrial carcinoma; KRAS mutation was associated with reduced median PFS (3.1 vs. 1.0 months) and median OS (9.3 vs. 2.3 months) (Tredan et al., 2012; 23238879). Another study investigating estrogen and/or progesterone receptor_positive gynecologic or breast malignancies featuring mutation or loss of genes in the PI3K_AKT_mTOR pathway, including PIK3CA, AKT1, or PTEN, observed SD in 17% (1/6) of patients with endometrial cancer following combined treatment with everolimus and anastrozole (Wheler et al., 2014; 24912489). No response was seen in a patient with endometrial stromal sarcoma and Peutz_Jeghers Syndrome associated with a germline STK11 mutation treated with a combination of everolimus and anastrozole (Noriega_Iriondo et al., 2015; 25649062). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Temsirolimus', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Temsirolimus is an intravenous mTOR inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> In a pooled analysis, 14% (3/21) of patients with PIK3CA_mutated endometrial cancer treated with temsirolimus or ridaforolimus achieved objective response and 29% (6/21) experienced disease progression (Mackay et al., 2014; 24166148). A case report described a patient with heavily pretreated PIK3CA_mutated endometrial cancer who had SD for 17 months with temsirolimus alone followed by combination with letrozole (Dhami et al., 2018; 29588307). A Phase 2 clinical trial of temsirolimus in recurrent or metastatic endometrial cancer reported PR in 4/29 (14%) chemotherapy_naïve patients and 4% (1/25) of chemotherapy_treated patients, with SD reported in 69% (20/29) of chemotherapy_naïve patients and 48% (12/25) of chemotherapy_treated patients; however, response in this study was found to be independent of molecular markers of PI3K_AKT_mTOR pathway activation (Oza et al., 2011; 21788564). Another Phase 2 study of temsirolimus in patients with endometrial cancer reported PFS of >15 months in 6 patients and associated clinical benefit and longer PFS with mutation of AKT1 or CTNNB1, respectively (Myers et al., 2015; ASCO Annual Meeting Abstract 5592). Temsirolimus combined with carboplatin and paclitaxel achieved objective partial responses in 82% (9/11) of patients with endometrial cancer (Kollmannsberger et al., 2012; 21447615). A Phase 2 trial of temsirolimus in combination with bevacizumab in patients with endometrial carcinoma reported clinical response in 25% of patients (Alvarez et. al, 2013; 23262204). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04589845', 'Include': 'true'}, {'nctId': 'NCT03239015', 'Include': 'true'}, {'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT02688881', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT04632992', 'Include': 'true'}, {'nctId': 'NCT03994796', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}]}}, {'Name': 'T1025A', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'T1025A'}}, 'Interpretation': 'PIK3CA encodes p110_alpha, which is the catalytic subunit of phosphatidylinositol 3_kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival (Samuels et al., 2005; 15950905, Engelman, 2009; 19629070). PIK3CA alterations that have been characterized as activating, such as R88Q observed here, are predicted to be oncogenic (Kang et al., 2005; 15647370, Ikenoue et al., 2005; 15930273, Gymnopoulos et al., 2007; 17376864, Horn et al., 2008; 18317450, Rudd et al., 2011; 21266528, Hon et al., 2012; 22120714, Burke et al., 2012; 22949682, Wu et al., 2009; 19915146, Dbouk et al., 2010; 2103068, Dan et al., 2010; 20530683, Oda et al., 2008; 18829572, Zhao and Vogt, 2008; 18794883, Lui et al., 2013; 23619167, Ross et al., 2013; 22430209, Riviere et al., 2012; 22729224, Shibata et al., 2009; 19394761, Droguluk et al., 2015; 26627007,Croessmann et al., 2018; 29284706, Ng et al., 2018; 29533785, Spangle et al., 2020; 32929011, Chen et al., 2018; 29636477). Although alterations such as T1025A seen here have not been fully characterized, they have been associated with sensitivity to targeted therapies or have shown cancer association, which may indicate biological relevance (Tate et al., 2019; 30371878, Rivière et al., 2012; 22729224, Akgumus et al., 2017; 28502730, Slomovitz et al., 2015; 25624430, Al_Rohil et al., 2016; 26479420, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In the scientific literature, PIK3CA mutations have been reported in 16_54% of endometrial carcinomas (Garcia_Dios et al., 2013; 23219661, Rudd et al., 2011; 21266528, Kandoth et al., 2013; 23636398). In endometrial cancers, PIK3CA mutations often co_occur with other mutations that activate the PI3K_AKT_mTOR signaling axis, such as PTEN and KRAS alterations (Oda et al., 2005; 16322209, Oda et al., 2008; 18829572). Overexpression of p110_alpha has been reported in 72% of endometrial carcinomas (Akiyama_Abe et al., 2013; 23949151). One study reported PIK3CA exon 9 or 20 mutations in 20% (20/99) of high_grade endometrial carcinomas; these mutations were associated with shorter patient survival within Grade 3 endometrioid carcinoma, but not within endometrial serous carcinoma (McIntyre et al., 2013; 24262879). Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K (Fritsch et al., 2014; 24608574, Juric et al., 2018; 29401002, Gallant et al., 2019; 30793038), AKT (Andre et al., 2019; 31091374, Smyth et al., 2021; 33863913), or mTOR (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452). Results from the Phase 2 MATCH trial for patients with PIK3CA_altered solid tumors found that 27% (18/65) of patients experienced PFS lasting at least 6 months after treatment with taselisib; however, no ORs were observed in this study (Krop et al., 2018; ASCO Abstract 101). In a Phase 1 trial of the dual PI3K/mTOR kinase inhibitor apitolisib, 79% (11/14) of patients with PIK3CA_mutated advanced solid tumors experienced disease control (3 PRs, 8 SDs) (Dolly et al., 2016; 26787751). The PI3K inhibitor alpelisib demonstrated an ORR of 6.0% (8/134) and a DCR of 58% (78/134) in a study of PIK3CA_mutated solid tumors (Juric et al., 2018; 2941002). However, the PI3K inhibitor copanlisib exhibited limited efficacy in PIK3CA_altered tumors (Santin et al., 2020; 31934607, Patnaik et al., 2016; 27672108). Activating mutations in PIK3CA may confer resistance to HER2_targeted therapies; combined inhibition of HER2 and the PI3K pathway may be required in HER2_positive tumors with PIK3CA mutation (Esteva et al., 2010; 20813970, Baselga et al., 2014; 25332247, Chakrabarty et al., 2010; 20581867, Cizkova et al., 2010; San Antonio Breast Cancer Symposium Abstract P2_09_30, Kataoka et al., 2010; 19633047, Wang et al., 2011; 21676217).', 'Include': 'true', 'ClinicalTrialNote': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Everolimus', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Everolimus is an orally available mTOR inhibitor that is FDA approved to treat renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors; and well_differentiated non_functional neuroendocrine tumors of the lung or gastrointestinal tract. Everolimus is also approved to treat either renal angiomyolipoma or subependymal giant cell astrocytoma in association with tuberous sclerosis complex (TSC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> Clinical benefit has been reported for several patients with PIK3CA_mutated endometrial cancer treated with everolimus as a single agent (Varnier et al., 2019; 31351267, Tredan et al., 2012; 23238879, Myers et al., 2016; 27016228) or combined with hormone therapy (Myers et al., 2016; 27016228, Slomovitz et al., 2015; 25624430). In a Phase 2 clinical trial of recurrent endometrial cancer, 43% (12/28) of patients reported SD at 8 weeks and 21% (6/28) of patients achieved clinical benefit at 20 weeks upon administration of everolimus monotherapy (Slomovitz et al., 2010; 20681032). Combination with the aromatase inhibitor letrozole for the same disease population achieved an ORR of 31% (11/35), with 9 CRs (Slomovitz et al., 2015; 25624430). Further addition of metformin to this regimen led to a clinical benefit rate (CR+PR+SD) of 67% (32/48), including PR in 29% (14/48) of cases; no significant difference was observed between cases with and without KRAS mutation (Soliman et al., 2016; ASCO Abstract 5506). Everolimus achieved PR or SD in 35% of patients with recurrent endometrial carcinoma; KRAS mutation was associated with reduced median PFS (3.1 vs. 1.0 months) and median OS (9.3 vs. 2.3 months) (Tredan et al., 2012; 23238879). Another study investigating estrogen and/or progesterone receptor_positive gynecologic or breast malignancies featuring mutation or loss of genes in the PI3K_AKT_mTOR pathway, including PIK3CA, AKT1, or PTEN, observed SD in 17% (1/6) of patients with endometrial cancer following combined treatment with everolimus and anastrozole (Wheler et al., 2014; 24912489). No response was seen in a patient with endometrial stromal sarcoma and Peutz_Jeghers Syndrome associated with a germline STK11 mutation treated with a combination of everolimus and anastrozole (Noriega_Iriondo et al., 2015; 25649062). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Temsirolimus', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Temsirolimus is an intravenous mTOR inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of several case reports describing clinical benefit for patients with FBXW7_mutated cancers treated with mTOR inhibitors, including lung adenocarcinoma (Villaruz and Socinski, 2014; 24360397), renal cell carcinoma (Olson et al., 2016; 27079472), and cervical squamous cell carcinoma (Kulkarni et al., 2020; DOI: 10.1016/j.ygyno.2020.05.244), FBXW7 loss or inactivation may predict sensitivity to everolimus or temsirolimus. On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> In a pooled analysis, 14% (3/21) of patients with PIK3CA_mutated endometrial cancer treated with temsirolimus or ridaforolimus achieved objective response and 29% (6/21) experienced disease progression (Mackay et al., 2014; 24166148). A case report described a patient with heavily pretreated PIK3CA_mutated endometrial cancer who had SD for 17 months with temsirolimus alone followed by combination with letrozole (Dhami et al., 2018; 29588307). A Phase 2 clinical trial of temsirolimus in recurrent or metastatic endometrial cancer reported PR in 4/29 (14%) chemotherapy_naïve patients and 4% (1/25) of chemotherapy_treated patients, with SD reported in 69% (20/29) of chemotherapy_naïve patients and 48% (12/25) of chemotherapy_treated patients; however, response in this study was found to be independent of molecular markers of PI3K_AKT_mTOR pathway activation (Oza et al., 2011; 21788564). Another Phase 2 study of temsirolimus in patients with endometrial cancer reported PFS of >15 months in 6 patients and associated clinical benefit and longer PFS with mutation of AKT1 or CTNNB1, respectively (Myers et al., 2015; ASCO Annual Meeting Abstract 5592). Temsirolimus combined with carboplatin and paclitaxel achieved objective partial responses in 82% (9/11) of patients with endometrial cancer (Kollmannsberger et al., 2012; 21447615). A Phase 2 trial of temsirolimus in combination with bevacizumab in patients with endometrial carcinoma reported clinical response in 25% of patients (Alvarez et. al, 2013; 23262204). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04589845', 'Include': 'true'}, {'nctId': 'NCT03239015', 'Include': 'true'}, {'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT02688881', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT04632992', 'Include': 'true'}, {'nctId': 'NCT03994796', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}]}}]}, 'ReferenceLinks': None}, {'Name': 'PIK3CB', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R321Q', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R321Q'}}, 'Interpretation': 'PIK3CB (PI3K_beta, p110_beta) encodes a member of the class IA phosphoinositide 3_kinases (PIK3CA, PIK3CB, PIK3CD, and PIK3CG), which are essential regulators of cellular proliferation, survival, metabolism, and motility. Dysregulation of the PI3K signaling pathway is observed in many human cancers and occurs most frequently through loss of the tumor suppressor PTEN or activating mutations in PIK3CA (p110_alpha). Contrary to PIK3CA, which is frequently mutated within hot spots causing increased kinase activity, mutation of PIK3CB is quite rare (Phillips et al., 2006; 16380997, Dbouk et al., 2013; 23734178, Pazarentzos et al., 2015; 25982275). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. In the Uterine Corpus Endometrial Carcinoma TCGA dataset, PIK3CB mutations and amplification have been observed in 5.4% and 2.1% of cases, respectively (Cancer Genome Atlas Research Network., 2013; 23636398). Published data investigating the prognostic implications of PIK3CB alterations in endometrial carcinoma are limited (PubMed, Oct 2020). However, a preclinical study reported that elevated PIK3CB mRNA levels contributed to early endometrial tumorigenesis and increased cellular proliferation of primary tumors (Karlsson et al., 2017; 28002804). Preclinical evidence indicates that PTEN_deficient tumors depend on PI3K_beta (Wee et al., 2008; 18755892, Jia et al., 2008; 18594509, Schmit et al., 2014; 24737887), and inhibitors selective for PI3K_beta, including GSK2636771 and AZD8186, are in clinical trials for PTEN_deficient tumors (Arkenau et al., 2014; ASCO Abstract 2514, Siu et al., 2015; AACR Abstract CT329). PIK3CB activating alterations may further refine the use of PI3K_beta_selective inhibitors (Pazarentzos et al., 2015; 25982275). Two patients with PTEN_deficient prostate tumors and concurrent PIK3CB L1049R mutation or PIK3CB amplification derived significant clinical benefit from treatment with GSK2636771 (de Bono et al., 2015; AACR Abstract CT328). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true', 'ClinicalTrialNote': 'Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT03239015', 'Include': 'true'}, {'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT04001569', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}, {'nctId': 'NCT03994796', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}, {'nctId': 'NCT03673787', 'Include': 'true'}, {'nctId': 'NCT02397083', 'Include': 'true'}, {'nctId': 'NCT03711058', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'PIK3R1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'E476*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'E476*'}}, 'Interpretation': 'PIK3R1 encodes the p85_alpha regulatory subunit of phosphatidylinositol 3_kinase (PI3K)(Huang et al., 2008; 18418043). Loss of PIK3R1 has been shown to result in increased PI3K signaling (Taniguchi et al., 2010; 20530665, Luo et al., 2006; 16679293, Ueki et al., 2003; 14504291, Mauvais_Jarvis et al., 2002; 11781359), promote tumorigenesis (Taniguchi et al., 2010; 20530665, Thorpe et al., 2017; 28630349, Li et al., 2019; 30755611), and promote hyperplasia in the context of PTEN_deficiency (Luo et al., 2005; 16006513). Alterations such as seen here may disrupt PIK3R1 function or expression (Jaiswal et al., 2009; 19962665, Cheung et al., 2011; 21984976, Ko et al., 2014; 24651434, Quayle et al., 2012; 23166678, Sun et al., 2010; 20713702, Wu et al., 2009; 19915146, Urick et al., 2011; 21478295, Huang et al., 2007; 18079394, Bousquet et al., 2006; 16917505, Oliver et al., 2017; 28143957, Philp et al., 2001; 11606375, Lucas et al., 2014; 25488983, Chen et al., 2018; 29636477, Cheung et al., 2014; 25284480). In the TCGA datasets, PIK3R1 mutation is most frequently observed in endometrial carcinoma (33%)(Cancer Genome Atlas Research Network., 2013; 23636398), glioblastoma (GBM; 11%)(cBio_Brennan et al., 2013; 24120142), uterine carcinosarcoma (11%)(cBioPortal, 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210), and lower grade glioma (5%)(Cancer Genome Atlas Research Network., 2015; 26061751). PIK3R1 is often inactivated by in_frame insertions or deletions (indels), and the majority of this class of mutation (80%) was observed in endometrial carcinoma (Ye et al., 2016; 26657142, Cheung et al., 2011; 21984976, Urick et al., 2011; 21478295), although PIK3R1 indels have been reported in other cancer types such as GBM, cervical squamous cell carcinoma, and urothelial bladder carcinoma (Ye et al., 2016; 26657142). On the basis of limited clinical data, reduced PIK3R1 expression has been associated with reduced disease_free survival in prostate cancer (Munkley et al., 2015; 26501081) and metastasis_free survival in breast cancer (Cizkova et al., 2013; 24229379). PIK3R1 expression is not associated with overall survival in neuroendocrine tumors (Qian et al., 2013; 23980085). On the basis of clinical (Matulonis et al., 2015; 25528496, Piha_Paul et al., 2015; ASCO Abstract 2516, Pitz et al., 2015; 25605819, Juric et al., 2016; SABCS Abstract P3_14_01) and preclinical (Thorpe et al., 2017; 28630349, Sun et al., 2010; 20713702) data, PIK3R1 alteration may predict sensitivity to pan_PI3K or PI3K_alpha_selective inhibitors. In patients with PIK3R1 mutation and no other alterations in the PI3K_AKT_mTOR pathway, 2 CRs have been achieved by patients with endometrial cancer treated with the pan_PI3K inhibitor pilaralisib (Matulonis et al., 2015; 25528496), and 1 PR has been achieved by a patient with breast cancer treated with the PI3K_alpha inhibitor alpelisib in combination with ribociclib and letrozole (Juric et al., 2016; SABCS Abstract P3_14_01). Limited clinical and preclinical data suggest that PIK3R1 alterations may also be sensitive to inhibitors of mTOR (Groisberg et al., ASCO 2017; Abstract 2582, Basho et al., 2015; European Cancer Congress Abstract 1871, Basho et al., 2017; 27893038, Myers et al., 2016; 27016228, Day et al., 2019; 30420444, Sun et al., 2010; 20713702, Ou et al., 2014; 25193464) or AKT (Groisberg et al., ASCO 2017; Abstract 2582, Li et al., 2019; 30755611, Quayle et al., 2012; 23166678). One preclinical study reported that PIK3R1 truncation mutations in the 299–370 range confer sensitivity to MEK inhibitors (Cheung et al., 2014; 25284480).', 'Include': 'true', 'ClinicalTrialNote': 'On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan_PI3K or PI3K_alpha_selective inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT03711058', 'Include': 'true'}, {'nctId': 'NCT03502733', 'Include': 'true'}, {'nctId': 'NCT03586661', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'PTEN', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R130Q, R173H', 'AlterationProperties': {'AlterationProperty': [{'isEquivocal': 'false', 'name': 'R130Q'}, {'isEquivocal': 'false', 'name': 'R173H'}]}, 'Interpretation': 'PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K_AKT_mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodríguez_Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andrés_Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454). PTEN mutation has been observed in 55_65% of endometrial cancers and in 70% of primary endometrioid endometrial cancers, whereas PTEN loss has been reported in 5% of endometrial carcinoma cases (Cancer Genome Atlas Research Network., 2013; 23636398, Byron et al., 2008; 18757403, Peterson et al., 2012; 22498935). PTEN mutation or loss has been suggested to play a role in endometrial cancer progression; high PTEN expression has been observed in Grade 1 and 2 tumors but not in Grade 3 tumors (Daniilidou et al., 2013; 23613406, van der Zee et al., 2013; 23288720, Joshi et al., 2012; 22503752, Akiyama_Abe et al., 2013; 23949151). Loss of PTEN protein expression has been correlated with increased survival of patients with Stage 3 or 4 endometrial carcinoma, but not Stage 1 or 2 (Akiyama_Abe et al., 2013; 23949151). PTEN loss or mutation leads to activation of the PI3K_AKT_mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). Clinical studies in endometrial cancer have not observed an association between PTEN deficiency and response to the mTOR inhibitors everolimus or temsirolimus (Meyer et al., 2014; 24651628, Oza et al., 2011; 21788564, Mackay et al., 2014; 24166148, Fleming et al., 2014; 24456823, Tsoref et al., 2014; 25173583, Myers et al., 2016; 27016228, Tredan et al., 2013; 23238879, Slomovitz et al., 2010; 20681032). Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes_Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN_altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha_Paul et al., 2018; AACR Abstract A096). In a Phase 1 study of patients treated with PARP and AKT inhibitors olaparib and capivasertib, two patients with PTEN_mutated ovarian cancer and a patient with PTEN_mutated endometrial cancer achieved clinical benefit (CR, PR, or SD >4 months) (Yap et al, 2020; 32532747). One or more of the PTEN variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hamartoma tumor syndrome (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte_Duclos disease (LD), Bannayan_Riley_Ruvalcaba syndrome (BRRS), PTEN_related Proteus syndrome (PS), and Proteus_like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.', 'Include': 'true', 'ClinicalTrialNote': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04269200', 'Include': 'true'}, {'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT04716686', 'Include': 'true'}, {'nctId': 'NCT04001569', 'Include': 'true'}, {'nctId': 'NCT02264678', 'Include': 'true'}, {'nctId': 'NCT04635631', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT04632992', 'Include': 'true'}, {'nctId': 'NCT04497116', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'RAD51D', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R253Q', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R253Q'}}, 'Interpretation': 'RAD51D, also known as RAD51L3, is involved in homologous recombination_mediated DNA repair and telomere maintenance (Tarsounas et al., 2004; 15109494, Suwaki et al., 2011; 21821141, Sasaki et al., 2004; 15162012, Smiraldo et al., 2005; 15781618). Germline mutations in RAD51D have been associated with hereditary breast and ovarian cancer (Baker et al. 2015; 25445424, Graffeo et al., 2016; 27734215, Osher et al., 2012; 22415235, Peltarri et al., 2012; 22652533, Gutierrez et al., 2014; 24130102, Loveday et al., 2011; 21822267), and RAD51D mutation carriers have an increased lifetime risk of ovarian cancer, estimated to be 10_12% (Loveday et al., 2011; 21822267, Song et al., 2015; 26261251). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. RAD51D mutation has been observed in 3.1% of endometrioid carcinomas, but not in any samples of other endometrial histologies analyzed in the COSMIC database (Sep 2021)(Tate et al., 2019; 30371878). Published data investigating the prognostic implications of RAD51D alteration in endometrial carcinomas are limited (PubMed, Sep 2021). Limited preclinical data (Rivera et al., 2017; 28646019, Loveday et al., 2011; 21822267) and clinical evidence in ovarian cancer (Swisher et al., 2017; 27908594, Kondrashova et al., 2017; 28588062, Chandran et al., 2018; DOI: 10.1200/PO.18.00253, O Malley et al., 2017; AACR_NCI_EORTC Abstract LB_A12) indicate that loss or inactivation of RAD51D may confer sensitivity to PARP inhibitors. Loss of functional RAD51D may also predict sensitivity to DNA_damaging drugs such as mitomycin C and cisplatin (Hinz et al., 2006; 16522646, Wiese et al., 2006; 16717288, Rivera et al., 2017; 28646019, Wickramanayake et al., 2012; 22986143). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. Inactivating germline mutations in RAD51D are associated with hereditary breast and ovarian cancer (HBOC) syndrome, an autosomal dominant disorder that predisposes patients to breast and ovarian malignancies (Janatova et al., 2015; 26057125, Stafford et al., 2017; 28591191). The risk of ovarian cancer in RAD51D mutation carriers has been estimated to be 10 to 12% (Loveday et al., 2011; 21822267, Song et al., 2015; 26261251). Germline RAD51D mutation has been reported at frequencies of up to 1% in breast and ovarian familial cancer populations without BRCA1/2 mutation (Gutiérrez_Enríquez et al., 2014; 24130102, Konstanta, et al., 2018; 30111881, Chen et al., 2018; 30165555). In the appropriate clinical context, germline testing of RAD51D is recommended.', 'Include': 'true', 'ClinicalTrialNote': 'Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04269200', 'Include': 'true'}, {'nctId': 'NCT04123366', 'Include': 'true'}, {'nctId': 'NCT03742895', 'Include': 'true'}, {'nctId': 'NCT04716686', 'Include': 'true'}, {'nctId': 'NCT02264678', 'Include': 'true'}, {'nctId': 'NCT04635631', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT04497116', 'Include': 'true'}, {'nctId': 'NCT04159155', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'TSC1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Q739*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Q739*'}}, 'Interpretation': 'TSC1 encodes the protein Hamartin, which interacts with Tuberin, the gene product of TSC2, to inhibit and regulate mTOR activity (Tee et al., 2003; 12906785, Inoki et al., 2003; 12869586). Alterations such as seen here may disrupt TSC1 function or expression (Miloloza et al., 2000; 10915759, Hoogeveen_Westerveld et al., 2010; 20547222, Hodges et al., 2001; 11741833). TSC1 mutations have been reported in 5.2% of endometrial carcinomas analyzed in COSMIC (Sep 2021)(Tate et al., 2019; 30371878). Published data investigating the prognostic implications of TSC1 alterations in endometrial cancer are limited (PubMed, Oct 2020). Loss or inactivation of TSC1 can activate mTOR signaling (Tee et al., 2003; 12906785, Mallela et al., 2021; 33575875); however, response rates for patients with TSC1_mutated solid tumors treated with MTOR inhibitors such as everolimus and temsirolimus have been low (Adib et al., 2021; 33727259, Nassar et al., 2020; 31653662, Voss et al., 2019; 30327302). In the prospective NCI_MATCH study, the ORR for patients with various TSC1_mutated solid tumors treated with everolimus was 7.7% (1/13); the single response was reported for a patient with urothelial cancer (Adib et al., 2021; 33727259). In TSC1_mutated renal cell carcinoma (RCC), responses to MTOR inhibitors have been described in multiple case series and reports (Ali et al., 2015; 25796537, Lim et al., 2016; 26859683, Kwiatkowski et al., 2016; 26831717, Hamieh et al., 2018; 30256787, Roldan_Romero et al., 2020; 31335987), but retrospective analysis of a broader cohort showed no responses in TSC1_mutated RCC (0/7)(Nassar et al., 2020; 31653662). Retrospective analyses of the RECORD_3, GRANITE_1, and EVOLVE_1 studies of everolimus to treat patients with RCC, gastric cancer, or hepatocellular carcinoma, respectively, showed no significant association between alterations in MTOR, TSC1, or TSC2 and median PFS (Voss et al., 2019; 30327302). Inactivating germline mutations in TSC1 are associated with the autosomal dominant disorder tuberous sclerosis complex, which results in the development of hamartomas in multiple organ systems and an increased risk of developing renal cell carcinoma (Gomez, 1991; 2039135, van Slegtenhorst et al., 1997; 9242607). TSC1 mutations account for approximately 10 to 30% of reported sporadic cases (Crino et al., 2006; 17005952). Prevalence for this disorder in the general population is estimated to be 1/6,000 from birth and 1/12,000 to 1/14,000 in children under 10 years of age (Curatolo et al., 2008; 18722871). In the appropriate clinical context, germline testing of TSC1 is recommended.', 'Include': 'true', 'ClinicalTrialNote': 'Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT03239015', 'Include': 'true'}, {'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT02693535', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}, {'nctId': 'NCT02397083', 'Include': 'true'}, {'nctId': 'NCT03008408', 'Include': 'true'}, {'nctId': 'NCT03217669', 'Include': 'true'}, {'nctId': 'NCT03065062', 'Include': 'true'}, {'nctId': 'NCT01582191', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'Tumor Mutation Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '372', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '372'}}, 'Interpretation': 'Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level that may be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors in multiple solid tumor types (Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915). A large_scale genomic analysis found that endometrial adenocarcinomas harbored a median TMB of 4.5 Muts/Mb, and 15% of cases had an elevated TMB of greater than 20 Muts/Mb (FMI_Chalmers et al., 2017; 28420421). Another study evaluating TMB in endometrial adenocarcinoma reported that 24% of tumors had a mutational burden of greater than 10.4 Muts/Mb (Santin et al., 2016; ASCO Abstract 5591). Increased tumor mutational burden (TMB) in endometrial carcinoma has been correlated with POLE mutation and advanced high_grade endometrioid subtypes (Mehnert et al., 2016; 27159395, Cancer Genome Atlas Research Network, 2013; 23636398, Hussein et al., 2015; 25394778, Church et al., 2013; 23528559). Ultramutated endometrial tumors (elevated TMB with POLE mutations) have also been associated with improved PFS (Cancer Genome Atlas Research Network, 2013; 23636398). The same study associated lower mutational burden, independent of PD_L1 status, in endometrial carcinomas with poorer prognosis (Cancer Genome Atlas Research Network, 2013; 23636398). For patients with advanced microsatellite_stable endometrial carcinoma not treated with immunotherapy, OS did not significantly differ between patients with TMB_high (≥10 Muts/Mb) and TMB_low (11.4 vs. 13.5 months, adjusted HR=1.15) in 1 study (Shao et al., 2020; 33119110). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB ≥10 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB ≥10 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors.', 'Include': 'true', 'ClinicalTrialNote': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Dostarlimab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Dostarlimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer or solid tumors. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Single_agent dostarlimab has been approved to treat patients with mismatch repair deficient (dMMR) endometrial cancer based on results observed in the Phase 1 GARNET study. In the study, dostarlimab elicited an ORR of 42% (30/71; 9 CRs, 21 PRs) for patients with endometrial cancer; median PFS, median OS, and median duration of response (DOR) have not been reached (Oaknin et al., 2020; 33001143). In a Phase 2 study of combination niraparib and dostarlimab for patients with endometrial cancer, patients experienced an ORR of 14% (3/22) and a DCR of 32%, while patients treated with niraparib experienced an ORR of 4.0% (1/23) and a DCR of 20% (Madariaga et al., 2021; ASCO Abstract 5574). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Atezolizumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Atezolizumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC) and urothelial carcinoma, depending on treatment setting. Atezolizumab is also approved in combination with other therapies to treat patients with non_squamous NSCLC lacking EGFR or ALK alterations, small cell lung cancer, triple_negative breast cancer, hepatocellular carcinoma, and BRAF V600_positive melanoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In a Phase 1 study of single_agent atezolizumab, patients with advanced or recurrent uterine cancer achieved an ORR of 13.3% (2/15), a median PFS of 1.4 months, and a median OS of 9.6 months; both objective responses occurred in PD_L1_positive patients (≥ 5% of immune cells), and one of these patients was also MSI_High (Liu et al., 2019; 31204078). In a retrospective analysis of patients with 17 solid tumor types (comprised of 47% NSCLC, 40% urothelial carcinoma, and 13% encompassing 15 other solid tumors), TMB of 16 Muts/Mb or greater was reported to be associated with an improved ORR to atezolizumab compared to chemotherapy (30% vs. 14%)(Legrand et al., 2018; ASCO Abstract 12000). Atezolizumab has been studied primarily for the treatment of non_small cell lung cancer (NSCLC) (Smith et al., 2016; ASCO Abstract 9028, Mazieres et al., 2016; ASCO Abstract 9032, Besse et al., 2015; ECC Abstract 16LBA, Spigel et al., 2015; ASCO Abstract 8028, Fehrenbacher et al., 2016; 26970723, Herbst et al., 2014; 25428504) and urothelial carcinoma (Balar et al., 2016; ASCO Abstract LBA4500, Dreicer et al., 2016; ASCO Abstract 4515)(Rosenberg et al., 2016; 26952546, Powles et al., 2014; 25428503). A study of atezolizumab as monotherapy for patients with advanced solid tumors reported a median PFS of 18 weeks and an ORR of 21%, including confirmed responses in 25.6% (11/43) of melanomas, 12.5% (7/56) of renal cell carcinomas (RCC) and 16.7% (1/6) of colorectal cancers (CRCs)(Herbst et al., 2014; 25428504). As single_agent therapy in genomically unselected young patients (<30 years old) with relapsed or refractory cancers, atezolizumab elicited an ORR of 1.5% (1/67) for patients with solid tumors, with similar safety and pharmacokinetics as seen in adults (Geoerger et al., 2020; 31780255). A Phase 1a study of atezolizumab reported an ORR of 14.5% (9/62), a median PFS of 5.6 months, and a median OS of 28.9 months for patients with clear cell RCC (McDermott et al., 2016; 26755520). A Phase 1b study evaluated atezolizumab combined with nab_paclitaxel for patients with previously treated metastatic triple_negative breast cancer (mTNBC) and reported confirmed objective responses for 41.7% (10/24) of patients; no dose_limiting toxicities were observed (Adams et al., 2016; ASCO Abstract 1009). A Phase 1b study that evaluated atezolizumab in combination with the MEK inhibitor cobimetinib for advanced solid tumors reported an ORR of 8.3% (7/84) in patients with CRC, 40.9% (9/22) in patients with melanoma, 17.9% (5/28) in patients with NSCLC, and 18.8% (3/16) in patients with other tumors (ovarian cancer, clear_cell sarcoma, and RCC); there was no association between BRAF or KRAS mutation status and response rate in any disease setting, and no dose_limiting toxicities were encountered (Hellmann et al., 2019; 30918950, Bendell et al., 2016; ASCO Abstract 3502). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Nivolumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response. It is FDA approved in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, classical Hodgkin lymphoma (cHL), gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma or squamous cell carcinoma (ESCC). Furthermore, nivolumab is approved to treat patients with mismatch repair_deficient (dMMR) or microsatellite instability_high (MSI_H) metastatic colorectal cancer (CRC) that has progressed on fluoropyrimidine, oxaliplatin, and irinotecan. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> A Phase 2 study of cabozantinib combined with nivolumab reported improved median PFS (5.3 vs. 1.9 months) and ORR (25% [9/36] vs. 16.7% [3/18]) compared with nivolumab monotherapy for patients with endometrial cancer; OS was also improved with combination therapy (13.0 vs. 7.9 months), although the data have not matured yet (Lheureux et al., 2020; ASCO Abstract 6010). A retrospective analysis of patients with recurrent and refractory endometrial cancer treated with nivolumab alone or in combination with other agents reported a CR of >20 months for a patient treated with nivolumab and everolimus and an overall clinical benefit rate of 75% (9/12), including 8 SDs of >3 months (Takano et al., 2019; ASCO Abstract e17124). A case study reported 2 PRs to nivolumab for patients with endometrial carcinoma harboring high tumor mutation burden; response was ongoing at 7_9 months (Santin et al., 2016; 27486176). Nivolumab monotherapy has been reported to elicit clinical benefit for patients with multiple types of solid tumors, including melanoma (27–31% ORR) (Postow et al., 2015; 25891304, Larkin et al., 2015; 26027431, Robert et al., 2014; 25399552, Topalian et al., 2014; 24590637, Weber et al., 2015; 25795410), non_small cell lung carcinoma (NSCLC; 17–20% ORR and 9–10 months mOS in unselected patients) (Brahmer et al., 2014; ASCO Abstract 8112, Gettinger et al., 2014; ASCO Abstract 8024, Antonia et al., 2014; ASCO Abstract 8023, Rizvi et al., 2014; ASCO Abstract 8022, Antonia et al., 2014; ASCO Abstract 8113, Brahmer et al., 2015; 26028407, Borghaei et al., 2015; 26412456), urothelial carcinoma (20–26% ORR in unselected patients) (Sharma et al., 2019; 31100038, Sharma et al., 2017; 28131785), renal cell carcinoma (RCC; 26% ORR) (Amin et al., 2014; ASCO Abstract 5010, McDermott et al., 2016, ASCO Abstract 4507)(Motzer et al., 2014; 25452452, Topalian et al., 2012; 22658127, Brahmer et al., 2010; 20516446, Motzer et al., 2015; 26406148), MSI_High colorectal cancer (CRC; 58% ORR) (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO GI Abstract 481), head and neck squamous cell carcinoma (11–17% ORR) (Gillison et al., 2016; AACR Abstract CT099, Ferris et al., 2016; ASCO Abstract 6009, Ferris et al. 2019; 31239321), ovarian cancer (6–15% ORR) (Brahmer et al., 2012; 22658128, Hamanishi et al., 2015; 26351349, Normann et al., 2019; 31074244), small cell lung cancer (SCLC; 10–12% ORR) (Calvo et al., 2015; ECC Abstract 3098, Hellmann et al., 2017; ASCO Abstract 8503, Antonia et al., 2016; 27269741), gastroesophageal carcinoma (12–18% ORR) (Le et al., 2016; ASCO GI Cancers Abstract 06, Kojima et al., 2016; ASCO GI Cancers Abstract TPS175, Janjigian et al., 2018; 30110194), and cancer of unknown primary (CUP; 10% ORR in unselected, previously treated patients) (Tanizaki et al., 2020; ASCO Abstract 106), as well as with Hodgkin lymphoma (66–87% ORR) (Ansell et al., 2015; ASH Abstract 583, Ansell et al., 2015; 25482239, Younes et al., 2016; 27451390). Combination treatment with nivolumab plus the CTLA_4 inhibitor ipilimumab has achieved further efficacy in melanoma (up to 61% ORR; mOS > 60 months for the combination vs. 37 months for nivolumab monotherapy) (Hodi et al., 2018; 30361170, Postow et al., 2015; 25891304, Hodi et al., 2016; 27622997, Larkin et al., 2019; 31562797), NSCLC (17 months mOS) (Hellmann et al., 2019; 31562796), MSI_High CRC (64% ORR) (Lenz et al., 2020; ASCO GI Abstract 11), RCC (42% ORR) (Motzer et al., 2019; 31427204, Motzer et al., 2018; 29562145), SCLC (19–25% ORR) (Hellmann et al., 2017; ASCO Abstract 8503, Antonia et al., 2016; 27269741), urothelial carcinoma (38% ORR in unselected patients; 58% ORR in patients with ≥1% tumor PD_L1 expression) (Sharma et al., 2019; 31100038), and other solid tumors. Combinations of nivolumab with various targeted therapies, such as pazopanib (1a PR in a patient with epithelioid sarcoma) (Paoluzzi et al., 2016; ASCO Abstract 11047), sunitinib (9% ORR in unselected patients with sarcoma) (Broto et al., 2019; ESMO Abstract 1669O), cabozantinib (29% ORR in patients with immunotherapy_refractory urothelial carcinoma) (Nadal et al., 2018; ASCO Abstract 4528), or vemurafenib (1a durable PR in a patient with BRAF V600E_mutated and PD_L1 positive anaplastic thyroid cancer) (Kollipara et al., 2017; 28778959), have also shown evidence of efficacy and continue to undergo clinical investigation. </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Avelumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Avelumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 in order to enhance antitumor immune responses. It is FDA approved to treat patients 12 years and older with Merkel cell carcinoma, or for urothelial carcinoma in various treatment settings. The combination of avelumab and axitinib is FDA approved for patients with renal cell carcinoma (RCC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In a Phase 2 trial of avelumab in recurrent endometrial cancer, patients with MMR deficiency or POLE mutation achieved an ORR of 26.7% (4/15) and a median PFS of 4.4 months; for patients with MMR_proficient tumors, the ORR was 6.2% (1/16) and the median PFS was 1.9 months (Konstantinopoulos et al., 2019; 31461377). The JAVELIN Phase 1b study has demonstrated clinical benefit from single_agent avelumab in a variety of solid tumor types, including non_small cell lung carcinoma (NSCLC)(Verschraegen et al., 2016; ASCO Abstract 9036), gastric carcinoma and gastroesophageal junction (GEJ) adenocarcinoma (Chung et al., 2016; ASCO Abstract 4009), urothelial carcinoma (Patel et al., 2016; ESMO Abstract 777PD), mesothelioma (Hassan et al., 2016; ASCO Abstract 8503), ovarian carcinoma (Disis et al., 2016; ASCO Abstract 5533), and breast cancer (Dirix et al., 2016; SABCS Abstract S1_04), and from avelumab combined with axitinib in renal cell carcinoma (Larkin et al., 2016; ESMO Abstract 775PD). Emerging clinical data show a positive trend toward the association of tumor cell PD_L1 expression and improved objective response rate, progression_free survival, or overall survival in NSCLC in the first_line setting and in ovarian and breast cancer (Disis et al., 2016; ASCO Abstract 5533, Dirix et al., 2016; SABCS Abstract S1_04, Verschraegen et al., 2016; ASCO Abstract 9036). Limited clinical data indicate activity of avelumab in adrenocortical carcinoma, metastatic castration_resistant prostate cancer, and thymic cancer (Le Tourneau et al., 2016; ASCO Abstract 4516, Fakhrejahani et al., 2017; ASCO GU Abstract 159, Rajan et al., 2016; ASCO Abstract e20106). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Durvalumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Durvalumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> The PHAEDRA Phase 2 trial of durvalumab in advanced endometrial cancer reported an ORR of 43% and a DCR of 66% (5 CRs, 10 PRs, 8 SDs in 35 patients) for the MMR_deficient cohort, and an ORR of 3% and a DCR of 29% (1 PR, 9 SDs in 35 patients) for the MMR_proficient cohort using iRECIST criteria (Antill et al., 2019; ASCO Abstract 5501). A Phase 2 study for patients with endometrial carcinoma and carcinosarcoma evaluated durvalumab with or without tremelimumab and reported ORR of 14.8% (4/27 with 1 CR and 3 PRs) versus 11.1% (3/27 with 2 CRs and 1 PR), median PFS of 7.6 weeks versus 8.1 weeks, and median duration of response of 16 weeks versus 8 weeks (Rubinstein et al., 2019; ASCO Abstract 5582). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Pembrolizumab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Pembrolizumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved for patients with tumor mutational burden_high (TMB_High; ≥10 Muts/Mb), microsatellite instability_high (MSI_High), or mismatch repair deficient (dMMR) solid tumors, or PD_L1_positive non_small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), classical Hodgkin lymphoma, cervical cancer, gastric cancer, esophageal cancer, or gastroesophageal junction (GEJ) carcinoma. It is also approved in various treatment settings for patients with melanoma, NSCLC, small cell lung cancer, HNSCC, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, or cutaneous squamous cell carcinoma (CSCC). Combination treatments with pembrolizumab are approved for patients with NSCLC, renal cell carcinoma, endometrial carcinoma that is not MSI_High or dMMR, or triple_negative breast cancer (TNBC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In the Phase 3 KEYNOTE_775 study, combination pembrolizumab and lenvatinib treatment improved median PFS (mPFS, 7.2 vs. 3.8 months, HR=0.56) and median OS (mOS, 18.3 vs. 11.4 months, HR=0.62) for patients with advanced endometrial cancer and prior platinum chemotherapy, compared with physician’s choice of chemotherapy; benefit was observed in both mismatch repair deficient (dMMR, mPFS HR=0.36, mOS HR=0.37) and proficient (pMMR, mPFS HR=0.60, mOS HR=0.68) subgroups (Makker et al., 2021; SGO Abstract 11512). Similar results for pembrolizumab with lenvatinib were reported in the Phase 1b/2 KEYNOTE_146 study, with a trend toward an improved ORR for patients who were dMMR compared with pMMR (64% vs. 37%) but a similar ORR for patients who were PD_L1 positive (CPS ≥1.0%) compared with PD_L1 negative (36% vs. 40%)(Makker et al., 2020; 32167863). Single_agent pembrolizumab elicited clinical benefit for 26% (3/23 PRs and 3/23 SDs) of patients with advanced PD_L1_positive (CPS ≥1.0%) endometrial cancer included in the Phase 1b KEYNOTE_028 study, with a mPFS of 1.8 months (Ott et al., 2017; 28489510). In the Phase 2 KEYNOTE 158 multi_solid tumor trial, treatment with the PD_1 inhibitor pembrolizumab led to improved ORR for patients with TMB of 10 Muts/Mb or higher compared those with TMB <10 Muts/Mb (28.3% [34/120] vs. 6.5% [41/635])(Marabelle et al., 2020; 32919526). In the KEYNOTE 028/012 pan_solid tumor trials, a similar improvement in ORR was reported for patients with >103 non_synonymous mutations/exome (~ equivalency >8 Muts/Mb as measured by this assay) compared to those with <103 non_synonymous mutations/exome (30.6% [11/36] vs. 6.5% [5/77])(Cristescu et al., 2018; 30309915). A patient with PD_L1_positive, ultramutated endometrial adenocarcinoma harboring POLE mutation experienced a PR to pembrolizumab for more than 14 months (Mehnert et al., 2016; 27159395). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Nivolumab + Ipilimumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response, and ipilimumab is a cytotoxic T_lymphocyte antigen 4 (CTLA_4)_blocking antibody. The combination is FDA approved in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and pleural mesothelioma. Furthermore, nivolumab is approved in combination with ipilimumab to treat patients with mismatch repair_deficient (dMMR) or microsatellite instability_high (MSI_H) metastatic colorectal cancer (CRC) that has progressed on fluoropyrimidine, oxaliplatin, and irinotecan. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hodi et al., 2019; AACR abstract CT037), a TMB score of ≥10 Muts/Mb (as measured by this assay) may predict sensitivity to combination nivolumab and ipilimumab treatment. </p> <p><b>Supporting Data:</b> A Phase 2 trial treating patients with rare gynecological malignancies with combination nivolumab and ipilimumab reported objective responses in 27% (11/41) of patients, including those with vaginal SCC, ovarian and uterine carcinosarcoma, uterine serous cancer, uterine clear cell carcinoma, and uterine leiomyosarcoma (Klein et al., 2020; ASCO Abstract 6091). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Cemiplimab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Cemiplimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved to treat patients with NSCLC with high PD_L1 expression (TPS ≥ 50%), cutaneous squamous cell carcinoma (CSCC), or basal cell carcinoma (BCC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of cemiplimab for the treatment of endometrial cancer are limited (PubMed, May 2021). Cemiplimab has been studied primarily in advanced cutaneous squamous cell carcinoma (CSCC), where it elicited a combined ORR of 48% (41/85) in Phase 1 and 2 studies (Migden et al., 2018; 29863979). A Phase 2 trial of cemiplimab in patients with basal cell carcinoma (BCC) reported ORRs of 31% (5 CRs and 21 PRs) in patients with locally advanced BCC and 21% (6 PRs) in patients with metastatic BCC (Stratigos et al., 2020; EMSO Abstract LBA47, Lewis et al. 2020; doi: 10.1136/jitc_2020_SITC2020.0428). The Phase 3 EMPOWER_Lung 1 trial for advanced non_small cell lung cancer (NSCLC) with PD_L1 expression ≥50% reported that cemiplimab is associated with improved PFS (8.2 vs. 5.7 months), OS (not reached vs. 14.2 months), and ORR (37% vs. 21%) compared with chemotherapy (Sezer et al., 2020; ESMO Abstract LBA52). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04237649', 'Include': 'true'}, {'nctId': 'NCT04589845', 'Include': 'true'}, {'nctId': 'NCT04181788', 'Include': 'true'}, {'nctId': 'NCT02829723', 'Include': 'true'}, {'nctId': 'NCT03530397', 'Include': 'true'}, {'nctId': 'NCT02628067', 'Include': 'true'}, {'nctId': 'NCT03192345', 'Include': 'true'}, {'nctId': 'NCT04261439', 'Include': 'true'}, {'nctId': 'NCT03565445', 'Include': 'true'}, {'nctId': 'NCT03799003', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'APC', 'Include': 'true', 'Alterations': {'Alteration': [{'Name': 'S2307L', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'S2307L'}}, 'Interpretation': 'APC (adenomatous polyposis coli) encodes a tumor suppressor with critical roles in regulating cell division and adhesion. APC interacts with beta_catenin and controls signaling in the WNT pathway, which regulates embryonic development and cell differentiation (Logan and Nusse, 2004; 15473860). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. In the Uterine Corpus Endometrial Carcinoma TCGA dataset, APC mutations are reported in 12% of cases (Cancer Genome Atlas Research Network., 2013; 23636398). Studies have reported APC mutations at varying frequencies in endometrial carcinoma, from no mutations being detected in 128 samples to 43% (12/28) of analyzed endometrial carcinomas having APC mutations (Pijnenborg et al., 2004; 15361208, Moreno_Bueno et al., 2002; 12439748). APC methylation has been detected at a higher frequency in endometrial adenocarcinomas with microsatellite instability (MSI) (43%, 17/40), than in cases without MSI (16%, 12/74) (Zysman et al., 2002; 12097272, Moreno_Bueno et al., 2002; 12439748). Two studies of endometrial carcinomas have reported the absence of APC protein expression in 8% (2/24) and 71% (30/42) of cases (Pijnenborg et al., 2004; 15361208, Singh et al., 2011; 21813170). A preclinical study using a mouse model demonstrated that loss of APC could induce endometrial cancer (Tanwar et al., 2011; 21363919). The prognostic significance of APC mutations in endometrial cancer remains unclear (PubMed, Jul 2021). Solid tumors with WNT/beta_catenin pathway alterations, as seen here, were observed to have significantly less T_cell inflammation in one study (Luke et al., 2019; 30635339). There are no approved drugs targeted to APC defects or WNT upregulation in solid tumors. Preclinical studies have reported that APC inactivation or beta_catenin activation confer synthetic lethality when TRAIL receptors are upregulated and the TRAIL death receptor program is activated (Zhang et al., 2010; 20348907). In addition, the COX_2 inhibitor celecoxib was shown to reduce WNT signaling in cancer cell lines (Lu et al., 2009; 19026633, Tuynman et al., 2008; 18281498). A preclinical study has found that a small_molecule tankyrase inhibitor shows some activity in APC_mutant CRC models (Lau et al., 2013; 23539443). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. One or more of the APC variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with familial adenomatous polyposis (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in APC are found in more than 90% of patients with familial adenomatous polyposis (FAP) (Kerr et al., 2013; 23159591, Fearon, 2011; 21090969, Kastritis et al., 2009; 18844223). The prevalence for FAP in the general population is estimated to be 1:8,300 from birth (Half et al., 2009; 19822006), and in the appropriate clinical context germline testing of APC is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}, {'Name': 'R2204*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R2204*'}}, 'Interpretation': 'APC (adenomatous polyposis coli) encodes a tumor suppressor with critical roles in regulating cell division and adhesion. APC interacts with beta_catenin and controls signaling in the WNT pathway, which regulates embryonic development and cell differentiation (Logan and Nusse, 2004; 15473860). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. In the Uterine Corpus Endometrial Carcinoma TCGA dataset, APC mutations are reported in 12% of cases (Cancer Genome Atlas Research Network., 2013; 23636398). Studies have reported APC mutations at varying frequencies in endometrial carcinoma, from no mutations being detected in 128 samples to 43% (12/28) of analyzed endometrial carcinomas having APC mutations (Pijnenborg et al., 2004; 15361208, Moreno_Bueno et al., 2002; 12439748). APC methylation has been detected at a higher frequency in endometrial adenocarcinomas with microsatellite instability (MSI) (43%, 17/40), than in cases without MSI (16%, 12/74) (Zysman et al., 2002; 12097272, Moreno_Bueno et al., 2002; 12439748). Two studies of endometrial carcinomas have reported the absence of APC protein expression in 8% (2/24) and 71% (30/42) of cases (Pijnenborg et al., 2004; 15361208, Singh et al., 2011; 21813170). A preclinical study using a mouse model demonstrated that loss of APC could induce endometrial cancer (Tanwar et al., 2011; 21363919). The prognostic significance of APC mutations in endometrial cancer remains unclear (PubMed, Jul 2021). Solid tumors with WNT/beta_catenin pathway alterations, as seen here, were observed to have significantly less T_cell inflammation in one study (Luke et al., 2019; 30635339). There are no approved drugs targeted to APC defects or WNT upregulation in solid tumors. Preclinical studies have reported that APC inactivation or beta_catenin activation confer synthetic lethality when TRAIL receptors are upregulated and the TRAIL death receptor program is activated (Zhang et al., 2010; 20348907). In addition, the COX_2 inhibitor celecoxib was shown to reduce WNT signaling in cancer cell lines (Lu et al., 2009; 19026633, Tuynman et al., 2008; 18281498). A preclinical study has found that a small_molecule tankyrase inhibitor shows some activity in APC_mutant CRC models (Lau et al., 2013; 23539443). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. One or more of the APC variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with familial adenomatous polyposis (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in APC are found in more than 90% of patients with familial adenomatous polyposis (FAP) (Kerr et al., 2013; 23159591, Fearon, 2011; 21090969, Kastritis et al., 2009; 18844223). The prevalence for FAP in the general population is estimated to be 1:8,300 from birth (Half et al., 2009; 19822006), and in the appropriate clinical context germline testing of APC is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}]}, 'ReferenceLinks': None}, {'Name': 'ATRX', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R907*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R907*'}}, 'Interpretation': 'ATRX encodes a SWI/SNF chromatin remodeling protein implicated in histone variant H3.3 deposition, transcriptional regulation, and telomere maintenance (Clynes et al., 2013; 23916100, Ratnakumar and Bernstein, 2013; 23249563). ATRX inactivation or loss of expression is associated with alternative lengthening of telomeres (ALT)(Lovejoy et al., 2012; 22829774, Bower et al, 2012; 23185534; Heaphy et al., 2011; 21719641, Liau et al., 2015; 25229770). Alterations that disrupt the ADD domain (aa 167_270) or helicase domain (aa 2010_2280) of ATRX are predicted to result in loss of ATRX function (Nan et al., 2007; 17296936, Garrick et al., 2004; 14729260, Eustermann et al., 2011; 21666677); however, the loss of ATRX function is not sufficient to induce ALT, which requires other undetermined factors (Clynes et al., 2013; 23916100, Flynn et al., 2015; 25593184). Germline mutations in ATRX give rise to alpha_thalassemia X_linked intellectual disability syndrome (ATR_X syndrome)(Gibbons et al., 1995; 7697714). Somatic mutation of ATRX has been reported in a number of solid tumor types, often associated with ALT (Heaphy et al., 2011; 21719641). ATRX mutation correlating with ALT has been reported in 10_20% of pancreatic neuroendocrine tumors (PNETs)(Singhi et al., 2015; USCAP Abstract 1797)(Jiao et al., 2011; 21252315, Heaphy et al., 2011; 21719641), 12.6% of pheochromocytomas and paragangliomas (Fishbein et al., 2015; 25608029), and 48% of adolescent and young adult (AYA) patients with glioblastoma (GBM) or neuroblastoma (Morosini et al., 2014; ASCO Abstract 11008)(Cheung et al., 2012; 22416102, Molenaar et al., 2012; 22367537, Pugh et al., 2013; 23334666, Cheung and Dyer, 2013; 23702928). ATRX loss in PNET (Singhi et al., 2015; USCAP Abstract 1797)(Marinoni et al., 2014; 24148618) and melanoma (Qadeer et al., 2014; 24468746) and mutation in other neuroendocrine tumors (Fishbein et al., 2015; 25608029) is associated with poor prognosis. Pediatric patients with high_grade glioma and ATRX mutation were shown to have more aggressive disease but are more responsive to treatment with double_strand break therapy (Koschmann et al., 2016; 26936505). ATRX mutation or loss of expression is more frequent in Grade 2/3 astrocytoma and secondary GBM than primary GBM, oligodendroglioma, and oligoastrocytoma (Kannan et al., 2012; 23104868, Haberler and Wöhrer, 2014; 24559763, Reuss et al., 2014; 25427834, Sahm et al., 2014; 25143301) and has been proposed as a distinguishing biomarker (Haberler and Wöhrer, 2014; 24559763, Reuss et al., 2014; 25427834, Sahm et al., 2014; 25143301). ATRX mutation has not been detected in concurrence with MYCN amplification in glioma and neuroblastoma (Cheung et al., 2012; 22416102, Molenaar et al., 2012; 22367537, Pugh et al., 2013; 23334666, Cheung and Dyer, 2013; 23702928). Low_grade gliomas with both IDH1/2 mutation and ATRX mutation are associated with worse prognosis than those with IDH1/2 mutation but no ATRX mutation (Haberler and Wöhrer, 2014; 24559763). Loss of ATRX protein expression has been reported in 33_39% of incidences of leiomyosarcoma (LMS) associating with ALT, a poor prognostic factor across all LMS subtypes, and with poor prognosis in extrauterine LMS but not in uterine LMS (Singhi et al., 2015; USCAP Abstract 93)(Liau et al., 2015; 25229770). No targeted therapies are available to directly address ATRX inactivation. Based on preclinical (Liang et al., 2020; 31551363, Garbarino et al., 2021; 34118569) and limited clinical data (Cole et al., 2021; AACR Abstract CT059), ATRX alterations may confer sensitivity to combination strategies involving WEE1 inhibition. In a Phase 2 study evaluating the WEE1 inhibitor adavosertib plus irinotecan for the treatment of pediatric patients with neuroblastoma, prolonged SD was reported for 44% (4/9) of patients with ATRX_deficient tumors and responses were seen in two tumors that had evidence of ALT (Cole et al., 2021; AACR Abstract CT059). Preclinical evidence also suggests that ATRX deficiency may impart sensitivity to synthetic lethal approaches involving PARP inhibition and irinotecan (George et al., 2020; 32846370), combined PARP and ATR inhibition (Garbarino et al., 2021; 34118569), or double_strand break_induction with agents such as doxorubicin, irinotecan, and topotecan (Koschmann et al., 2016; 26936505); however, these approaches have not been demonstrated clinically.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'CARD11', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R271W', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R271W'}}, 'Interpretation': 'CARD11 (also known as CARMA1) is a scaffold protein critical for B_ and T_cell receptor_mediated NF_kappaB (NF_kB) activation (Weil et al., 2004; 15134788, Paul et al., 2013; 23474202, Juilland et al., 2016; 27135977). Activating CARD11 mutations, often occurring within the CARD (aa 18_110) or coiled_coil (aa 130_499) domains, can facilitate constitutive NF_kB signaling, proliferation, and cell survival in lymphomas (Juilland et al., 2016; 27135977, Bognar et al., 2016; 26776161, Chan et al., 2013; 23149938, Brohl et al., 2014; 25352053, Jeelall et al., 2012; 23027925, Lenz et al., 2008; 18323416, Lamason et al., 2010; 20799731, Dong et al., 2011; 21266526, Compagno et al., 2009; 19412164, da Silva Almeida et al., 2015; 26551667, Vallois et al., 2016; 27369867). Preclinical evidence suggests that activating CARD11 mutations may reduce sensitivity to ibrutinib, lenalidomide, and sotrastaurin in lymphoma (Wu et al., 2016; 27224912, Nagel et al., 2015; 26540570, Naylor et al., 2011; 21324920). Some germline CARD11 mutations have been found to underlie B_cell expansion with NF_kB and T_cell anergy (BENTA), a disorder characterized by congenital B_cell lymphocytosis (Snow et al., 2012; 23129749, Brohl et al., 2015; 25352053, Juilland et al., 2016; 27135977). CARD11 alterations have been most frequently reported in B_cell lymphomas, including diffuse large B_cell lymphoma (DLBCL; 11_23%)(Bu et al., 2012; 22397314, Lenz et al., 2008; 18323416, Morin et al., 2013; 23699601), follicular lymphoma (21_25%)(Morin et al., 2011; 21796119), primary central nervous system lymphoma (16_30%)(Montesinos_Rongen et al., 2010; 20544211, Braggio et al., 2015; 25991819), splenic marginal zone lymphoma (7_9%)(Rossi et al., 2012; 22891273; Yan et al., 2012; 22102703), and mantle cell lymphoma (6%)(Wu et al., 2016; 27224912). CARD11 mutations have also been detected in T_cell lymphomas, specifically in angioimmunoblastic T_cell lymphomas (AITLs), peripheral T_cell lymphomas (PTCLs), and cases of Sezary syndrome (Vallois et al., 2016; 27369867, Wang et al., 2015; 26551670, da Silva Almeida et al., 2015; 26551667). Copy number gains and consequent CARD11 overexpression have been reported in 71% (12/17) of patients with aggressive AITL and in 41% (30/73) of patients with PTCL (Oshiro et al., 2006; 16484591, Fujiwara et al., 2008; 18633432). Increased CARD11 expression has also been observed in T_ALL (Ma et al., 2014; 25384343). CARD11 amplification in DLBCL and increased CARD11 protein expression in AITL or PTCL is associated with reduced overall survival (Bu et al., 2012; 22397314, Fujiwara et al., 2008; 18633432). Although CARD11 mutations have been detected in a variety of solid tumors (cBio_Krauthammer et al., 2012; 22842228, cBio_Hodis et al., 2012; 22817889, cBio_Witkiewicz et al., 2015; 25855536, Cancer Genome Atlas Research Network., 2014; 25079317, Cancer Genome Atlas Research Network., 2014; 25079552, Cancer Genome Atlas Research Network., 2014; 24476821), the prognostic implications of CARD11 alterations in non_hematological malignancies are unclear. Although there are no therapies targeting CARD11 alterations, a number of drugs that block NF_kB activation are under investigation (Thome et al., 2010; 20685844, Lim et al., 2012; 22435566, Milhollen et al., 2010; 20525923). Preclinical evidence from models of mantle cell lymphoma suggests that tumors with CARD11 mutations may exhibit reduced sensitivity to inhibitors of BCR/NF_kB signaling including ibrutinib and lenalidomide (Wu et al., 2016; 27224912, Nagel et al., 2015; 26540570). CARD11 mutations have also been correlated with reduced sensitivity to sotrastaurin (protein kinase C inhibitor) in preclinical models of DLBCL (Naylor et al., 2011; 21324920).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'CREBBP', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'E50*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'E50*'}}, 'Interpretation': 'CREBBP encodes a ubiquitously expressed transcriptional coregulatory protein that interacts with multiple transcription factors and can couple control of gene expression to chromatin remodeling via its histone acetyltransferase activity. Inherited microdeletions and truncating point mutations in CREBBP are reported to be causal in approximately 20% of cases of Rubinstein_Taybi syndrome (Pertij et al., 2000; 10699051). The chromosomal rearrangement t(8;16)(p11;p13) is characteristic of the M4/M5 subtype of acute myeloid leukemia (AML) and results in a chimeric gene fusing MYST3/MOZ (a gene essential for the development of the hematopoietic system and maintenance of hematopoietic stem cells) to CREBBP (Borrow et al., 1996; 8782817). CREBBP_BCORL1 fusion has been reported in patients with ossifying fibromyxoid tumors (Kao et al., 2017; 27537276, Hofvander et al., 2020; 31932680). CREBBP mutations have been observed at high frequency in follicular lymphoma (FL, 39%) and diffuse large B_cell lymphoma (DLBCL, 17%), and at lower frequency in acute lymphoblastic leukemia (ALL, 6%), and tumors of the urinary tract (15%), skin (11%), endometrium (9%), liver (9%), and stomach (9%) (COSMIC, 2021)(Tate et al., 2019; 30371878). These mutations include missense substitutions clustered in the CREBBP histone acetyltransferase domain and truncating mutations throughout the gene sequence, suggesting a role for CREBBP inactivation in these diseases. CREBBP mutations have been reported to occur in the transition from prostate acinar carcinoma to squamous cell carcinoma (SCC) (Grasso et al., 2015; 25735316), which may indicate significance for CREBBP in SCC. In two cases of relapsed pediatric B_cell ALL, CREBBP mutation conferred resistance to glucocorticoid therapy (Ma et al., 2015; 25790293). Reports have found CREBBP mutation in 62_68% of patients with FL (Green et al., 2015; 25713363, Loeffler et al., 2015; 25027518), which was associated with immune evasion (Green et al., 2015; 25713363). AML with MYST3/CREBBP fusion was reported to occur in 60_80% of cases 9_72 months after adjuvant chemotherapy for breast cancer and was associated with a poor prognosis (Gervais et al., 2008; 18528428, Haferlach et al., 2009; 19194466). There are no targeted therapies available to address genomic alterations in CREBBP. The use of histone deacetylase (HDAC) inhibitors are being investigated in clinical trials that are recruiting patients with either lymphoma or urothelial carcinoma harboring CREBBP alterations. However, it has been reported that there is no correlation between CREBBP mutation status and response to HDAC inhibitors in DLBCL (Mensah et al., 2015; 25671298).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'CTCF', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R129*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R129*'}}, 'Interpretation': 'CTCF encodes an 11_zinc_finger protein that is implicated in a number of regulatory roles, including gene activation and repression, imprinting, insulation, methylation, and X chromosome inactivation (Phillips and Corces, 2009; 19563753). CTCF plays a role in transcriptional regulation of a number of key cancer_associated genes, including the oncogene MYC (Gombert and Krumm, 2009; 19568426) and tumor suppressor TP53 (Soto_Reyes and Recillas_Targa, 2010; 20101205), via maintenance of local DNA methylation status. The decreased expression levels of CTCF and/or BORIS, another 11_zinc_finger transcriptional regulator, were reported to be closely associated with global DNA methylation variability and decreased overall survival in epithelial ovarian cancer (Woloszynska_Read et al., 2011; 21296871, Kemp et al., 2014; 24794443). Somatic mutations in CTCF are infrequently reported in most cancers, but have been observed more commonly (24%) in uterine corpus endometrial carcinoma (cBioPortal, 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210); nearly half of the observed mutations were truncating, suggesting a tumor suppressor role for CTCF in this disease. In addition, CTCF has been found to act as a tumor suppressor in breast cancer cell line studies (Méndez_Catalá et al., 2013; 23908591, Tiffen et al., 2013; 23553099). There are no targeted therapies available to address genomic alterations in CTCF.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'CTNNA1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R451*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R451*'}}, 'Interpretation': 'CTNNA1 encodes alpha_catenin, a member of the cadherin family that functions in cell adhesion. Alpha_catenin acts as a tumor suppressor, through mechanisms that can vary by tissue (Kobielak and Fuchs, 2004; 15366705, Bajpai et al., 2009; 19458087). Alpha_catenin is one of three catenin proteins that are in complex with E_cadherin to help mediate cell_cell adhesion in epithelial tumor suppression (Kobielak and Fuchs, 2004; 15366705, Bajpai et al., 2009; 19458087); loss of cell adhesion may contribute to cancer cell invasiveness and formation of metastases. In epidermal cells, alpha_catenin acts as a tumor suppressor by inducing YAP1 phosphorylation and cytoplasmic localization (Silvis et al., 2011; 21610251, Piao et al., 2014; 24509793). Alpha_catenin also acts as a tumor suppressor by interacting with IKBalpha to influence the NF_KB pathway in E_cadherin_negative basal_like breast cancer cells (Piao et al., 2014; 24509793). Loss of alpha_catenin expression is also hypothesized to alter the balance between the cytoplasmic (cell adhesion) and nuclear (cell proliferation) functions of beta_catenin, further contributing to oncogenesis (Inge et al., 2008; 18566211). CTNNA1 mutations have been observed with highest incidence in endometrial carcinoma (6.8%)(Cancer Genome Atlas Research Network., 2018; 29625048), cutaneous melanoma (6.4%)(Van Allen., 2014; 24265153), colorectal adenocarcinoma (4.4%)(Cancer Genome Atlas Research Network., 2018; 29625048), and stomach adenocarcinoma (4.0%) TCGA datasets (cBioPortal, 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). CTNNA1 mutations have been observed in patients with hereditary diffuse gastric carcinoma without CDH1 mutations (Hansford et al., 2015; 26182300, Majewski et al., 2013; 23208944). Reduced CTNNA1 expression in patients with breast cancer has been correlated with a poor clinical outcome and breast cancer brain metastasis (Ding et al., 2010; 20393555, Piao et al., 2014; 24509793). Deletion and hypermethylation of CTNNA1 has been observed in up to 22% (18/83) of myelodysplastic syndrome (MDS) cases and associated with poor clinicopathological features (Qian et al., 2014; 25153418, Ye et al., 2009; 19826047, Liu et al., 2007; 17159988, Ye et al., 2009; 19826047) and a trend for inferior survival (Qian et al., 2014; 25153418). Loss of CTNNA1 expression via 5q deletion or hypermethylation has been reported as a frequent event in acute myeloid leukemia and associated with shorter relapse_free survival in one study (Liu et al., 2007; 17159988, Chen et al., 2014; 24685333, Li et al., 2016; 27129146). There are no available targeted therapies to address genomic alterations in CTNNA1.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'CUL3', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'L602*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'L602*'}}, 'Interpretation': 'CUL3 encodes the RING ubiquitin ligase cullin 3, which has been shown to form complexes regulating diverse cellular processes, including development and stress responses. Mutations affecting CUL3_KEAP1 complex formation and regulation of the stress_regulated transcription factor NRF2 have been found in 4/5 cases of sporadic papillary renal cell carcinoma (Ooi et al., 2013; 23365135). Mutations affecting the CUL3_KEAP1 complex have also been reported in lung cancer, and linked to increased NF_kB signaling through upregulation of IkkB protein expression (Genschik et al., 2013; 23912815). Decreased CUL3 expression has been linked to an aggressive phenotype in bladder cancer models (Grau et al., 2013; 23308193) and to formation of hepatocellular carcinomas through regulation of cyclin E expression (Kossatz et al., 2013; 20978349). There are no therapies available to directly address genomic alterations in CUL3.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'ESR1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R256Q', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R256Q'}}, 'Interpretation': 'ESR1 encodes estrogen receptor alpha (ER_alpha), one of the major estrogen receptor isoforms in humans. Along with co_activator proteins, the ER complex promotes transcription of genes involved in cell cycle progression and survival (Pearce and Jordan, 2004; 15094156). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. ESR1 mutation has been reported in 2.5_7.1% of endometrial carcinomas analyzed (COSMIC, cBioPortal, Nov 2020)(Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Lower levels of ER_alpha protein and/or ESR1 mRNA expression have been associated with a reduced survival in endometrial carcinoma (Wik et al., 2013; 23319822, Rahman et al., 2013; 24023309). Therapies that directly target ER_alpha, such as selective ER modulators (SERMs) and the selective ER degrader (SERD) fulvestrant, as well as aromatase inhibitors (AIs) that inhibit estrogen production, are approved to treat ER_positive (ER+) and/or hormone receptor_positive (HR+) breast cancer (NCCN Guidelines v6.2020). AI treatment has also been reported to provide clinical benefit in a subset of HR+ gynecologic malignancies (Straubhar et al., 2017; 28560298, Thangavelu et al., 2013; 24076063, Gershenson et al., 2017; 28221866, Eshfani et al., 2014; 24925537, Ramirez et al., 2008; 18457865). Combinations of fulvestrant and CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib, have also demonstrated efficacy for patients with ESR1_mutated breast cancer (Tolaney et al., 2019; Abstract 4458, Neven et al., 2018; SABCS Abstract PD2_05, Turner et al., 2016; ASCO Abstract 512, Turner et al., 2018; 30345905, Martin et al., 2019; SABCS Abstract GS2_07). Clinical data suggest that ESR1 mutations may confer sensitivity to the first_generation SERD fulvestrant in breast cancer (Fribbens et al., 2016; 27269946, Spoerke et al., 2016; 27174596). A retrospective analysis of ESR1 mutations in gynecologic malignancies reported clinical benefit for patients with ESR1 mutations and fulvestrant treatment as a monotherapy or in combination, including 1 patient with peritoneal serous carcinoma and an ESR1 Y537N mutation who experienced prolonged clinical benefit (48+ months) from fulvestrant monotherapy (Galliard et al., 2019; 30987772). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. Extensive clinical evidence indicates that ESR1 mutations arise primarily during treatment with AIs, especially relative to other ER_targeting therapies, and ESR1 ligand_independent activating alterations may predict lack of benefit from subsequent AI treatment in breast carcinoma (Turner et al., 2016; ASCO Abstract 512, Schiavon et al., 2015; 26560360, Fribbens et al., 2016; 27269946, Chandarlapaty et al., 2016; 27532364). In gynecologic malignancies, activating ESR1 Y537S and D538G mutations have been reported to confer resistance to AI treatment, particularly for patients who have already received AI treatment (Galliard et al., 2019; 30987772, Stover et al., 2018; 30828692, Morel et al., 2019; DOI: 10.1200/PO.18.00398 JCO Precision Oncology).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'FAM123B', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'E387*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'E387*'}}, 'Interpretation': 'FAM123B, also known as AMER1, encodes the protein WTX, which binds to beta_catenin, enhancing its proteasomal degradation and thereby exerting a repressive effect on WNT pathway signaling (Major et al., 2007; 17510365). Germline mutation or deletion of FAM123B causes osteopathia striata with cranial sclerosis (Jenkins et al., 2009; 19079258, Perdu et al., 2010; 20209645). Somatic mutation of FAM123B is rare in most cancers (COSMIC, 2021)(Tate et al., 2019; 30371878), but is observed at rates ranging from 5_30% in Wilms tumor (Perotti et al., 2008; 18391980, Ruteshouser et al., 2008; 18311776, Rivera et al., 2007; 17204608). No association between FAM123B alteration and clinical features or outcomes of Wilms tumor has been documented. There are no targeted therapies available to address genomic alterations in FAM123B.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'KEL', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'E494*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'E494*'}}, 'Interpretation': 'KEL encodes a transmembrane glycoprotein with similarities to zinc_dependent metalloproteases; this glycoprotein is highly polymorphic and forms the Kell blood group antigen (Claperon et al., 2005; 15769748). KEL mutations have been reported in tumors of the skin, lung, endometrium, stomach, large intestine, soft tissue, and liver at rates of 1.9_8.4%; up to 1.2% of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic lymphocytic leukemia_small lymphocytic lymphoma (CLL/SLL) samples (COSMIC, 2021)(Tate et al., 2019; 30371878). However, the mechanism by which KEL mutations contribute to tumor formation is not known. There are no therapies available to target genomic alterations in KEL.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'KLHL6', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'D104N', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'D104N'}}, 'Interpretation': 'KLHL6 encodes a protein that exhibits homology to the Drosophila Kelch gene and is hypothesized to play a role in germinal center B_cell differentiation (Gupta_Rossi et al., 2003; 12617994). Whole genome sequencing identified somatic alteration of KLHL6 in a small number of chronic lymphocytic leukemias (Puente et al., 2011; 21642962), whereas an exome_sequencing effort identified similar alterations in a follicular lymphoma case (Weigert et al., 2012; 22585168). KLHL6 lies in a segment of chromosome 3q that has been observed to exhibit significant amplification in both squamous cell lung (Cancer Genome Atlas Research Network, 2012; 22960745) and ovarian (Cancer Genome Atlas Research Network, 2012; 21720365) carcinoma. No targeted therapies are available to address genomic alterations in KLHL6.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'MAP3K1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'G914*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'G914*'}}, 'Interpretation': 'MAP3K1 encodes a multifunctional protein kinase and E3 ubiquitin ligase involved in several signal transduction pathways central to cancer cell biology (Xia et al., 1998; 9808624). Different MAP3K1 protein isoforms have been suggested to exert both pro_ and anti_apoptotic influences (Lu et al., 2002; 12049732, Schlesinger et al., 2002; 11782455). Germline polymorphism in MAP3K1 has been hypothesized to associate with risk for at least some subtypes of breast carcinoma (Garcia_Closas et al., 2008; 18437204), but the extent of effect is small and experimental results have been inconsistently replicated (Slattery et al., 2011; 21475998). Somatic alterations of MAP3K1, including missense mutations, truncating alterations, and loss of heterozygosity, have been observed most frequently in breast and uterine carcinomas (cBioPortal, COSMIC, 2021)(Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). There are no targeted therapies available to address genomic alterations in MAP3K1.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'MLL2', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R5214C', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R5214C'}}, 'Interpretation': 'MLL2 encodes an H3K4_specific histone methyltransferase that is involved in the transcriptional response to progesterone signaling (Vicent et al., 2011; 21447625). Germline de novo mutations of MLL2 are responsible for the majority of cases of Kabuki syndrome, a complex and phenotypically distinctive developmental disorder (Hannibal et al., 2011; 21671394). A significant number of inactivating MLL2 alterations have been observed in multiple tumor types, suggesting a tumor suppressor role (Fagan et al.,2019; 31128216). MLL2 alterations are observed in a number of solid tumor contexts (COSMIC, 2021)(Tate et al., 2019; 30371878), and are especially prevalent in lung squamous cell carcinoma (SCC) (Cancer Genome Atlas Research Network et al., 2012; 22960745) and small cell lung carcinoma (SCLC) (Augert et al., 2017; 28007623). MLL2 mutation was found to be an independent prognostic factor of poor PFS and OS in non_small cell lung cancer, but not in SCLC (Ardeshir_Larijani et al., 2018; 29627316). One study reported that MLL2 truncating mutations were more common in recurrent ovary granulosa cell tumors (GCT) compared with primary GCTs (24% [10/42] vs. 3.0% [1/32])(Hillman et al., 2018; 29950560). In a study of esophageal SCC, high MLL2 expression positively correlated with tumor stage, differentiation, and size, and negatively correlated with OS (Abudureheman et al., 2018; 29532228). There are no targeted therapies available to address genomic alterations in MLL2. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). Comprehensive genomic profiling of solid tumors may detect nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'MSH6', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'E641*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'E641*'}}, 'Interpretation': 'MSH6 encodes MutS homolog 6 protein, a member of the mismatch repair (MMR) gene family. Defective MMR occurring as a result of mutation(s) in the MMR family (MLH1, MSH2, MSH6, or PMS2) can result in microsatellite instability (MSI), common in colon, endometrium, and stomach cancers (You et al., 2010; 21081928). Alterations such as seen here may disrupt MSH6 function or expression (Li et al., 2013; 23622243, Wu et al., 2011; 21720545, Edelbrock et al., 2013; 23391514, Berends et al., 2002; 11709755, Warren et al., 2007; 17531815, Geng et al., 2012; 22277660). MSH6 mutations have been reported in 17% of endometrioid carcinomas (Cancer Genome Atlas Research Network., 2013; 23636398). Multiple studies have cited an increased risk (16_44%) of endometrial cancer for female carriers of germline MSH6 mutations (Bonadona et al., 2011; 21642682, Baglietto et al., 2010; 20028993, Lu and Daniels, 2013; 23765559). Endometrial tumors harboring MMR protein alterations have been associated with worse overall and progression_free survival (Shih et al., 2011; 21742371). Numerous studies in various cancer types have shown that MSH6 loss or inactivation is associated with MSI and increased mutation burden (Cancer Genome Atlas Network., 2012; 22810696, You et al., 2010; 21081928, Joly et al., 2015; 25504677, Pritchard et al., 2014; 25255306, Rosty et al., 2014; 25117503, McConechy et al., 2015; 25636458). Clinical studies have shown that MSI is associated with patient responses to anti_programmed death 1 (PD_1) immune checkpoint inhibitors pembrolizumab (Le et al., 2015; ASCO Abstract LBA100)(Le et al., 2015; 26028255) and nivolumab (Lipson et al., 2013; 23169436). Higher mutation burden was also reported to be associated with response to pembrolizumab (Rizvi et al., 2015; 25765070). Furthermore, MSI status correlates with higher PD_1 and PD_L1 expression (Gatalica et al., 2014; 25392179), potential biomarkers of response to PD_1 targeted immunotherapies. Therefore, inactivation of MSH6 may confer sensitivity to anti_PD_1 immune checkpoint inhibitors. One or more of the MSH6 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hereditary cancer_predisposing syndrome (ClinVar, Mar 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in MSH6 are associated with both ""typical"" and ""atypical"" forms of autosomal dominant Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC), which accounts for 1_7% of all colorectal cancers (Silva et al., 2009; 19466295). Approximately 10% of all Lynch syndrome_associated mutations have been attributed to alterations in MSH6 (Peltomaki, 2005; 16083711). Carriers of mutations in MSH6 have a 60_80% risk of colorectal cancer (Kastrinos and Syngal, 2007; 17920897). Lynch syndrome has an estimated prevalence in the general population ranging from 1:600 to 1:2000 (Silva et al., 2009; 19466295, Sehgal et al., 2014; 24978665, de la Chapelle et al., 2005; 16136383). Biallelic germline mutation of MSH6 has been shown to account for 20% of cases of the very rare syndrome Constitutional Mismatch Repair Deficiency (CMMRD), which is characterized by a 95% incidence rate of childhood onset lymphoma, leukemia and brain tumors, followed by early_onset colorectal cancer (reviewed in Wimmer et al., 2008; 18709565, Wimmer et al., 2014; 24737826, Scott et al., 2007; 17259933, Ripperger et al., 2010; 20015892, Baris et al., 2016; 26544533). Given the association between MSH6 and these inherited syndromes, in the appropriate clinical context, germline testing of MSH6 is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'MS_Stable', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'MS_Stable'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS has been reported in 73_89% of endometrial cancers (Cancer Genome Research Atlas., 2013; 23636398, Black et al., 2006; 16549821, Mackay et al., 2010; 20304627, Kanopiene et al., 2014; 25458958, Hampel et al., 2006; 16885385, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452, Church et al., 2013; 23528559). Data regarding the role of MSI status on prognosis and survival in endometrial cancer are conflicting, with most studies finding no relationship between MSI_H endometrial cancers and survival (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao_Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958), and one study predicting improved disease_free and disease_specific survival (Black et al., 2006; 16549821). However, these studies often evaluated endometrial cancers of all FIGO stages together. Studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI_H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI_H predicts for poor prognosis in this subset of endometrial tumors. On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'POLE', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'V411L', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'V411L'}}, 'Interpretation': 'POLE encodes the catalytic subunit A of DNA polymerase epsilon, which plays roles in DNA replication and repair (Popanda and Thielmann., 1992; 1730053). Deleterious mutations in POLE, mainly located within the exonuclease domain (amino acids 268–471) and reported at hotspot residues F104, D275, P286, S297, N363, D368, V411, L424, P436, R446, A456, Y458, S459, and S461, are predicted to disrupt the proofreading function of the enzyme, resulting in a high mutation rate and contributing to the development of ""ultramutated,"" microsatellite_stable cancers (Palles et al., 2013; 23263490, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Valle et al., 2014; 24501277, Church et al., 2013; 23528559, Cancer Genome Atlas Network, 2012; 22810696, Cancer Genome Atlas Research Network, 2013; 23636398, Rayner et al., 2016; 26822575, Spier et al., 2015; 25529843, Shinbrot et al., 2014; 25228659, Bouffet et al., 2016; 27001570, Schlien et al., 2015; 25642631, Rohlin et al., 2014; 24788313, Abdus Sattar et al., 1996; 8987997, Murphy et al., 2006; 16699561). POLE alterations have been reported in 6_15% of endometrial carcinomas (COSMIC, Feb 2021)(Tate et al., 2019; 30371878, Billingsley et al., 2016; 26937754, Church et al., 2013; 23528559, McConechy et al., 2016; 26763250). In the context of endometrial carcinoma, POLE mutations are associated with high tumor grade (Church et al., 2013; 23528559) and correlate with better prognosis, with the most favorable prognosis seen for high_grade tumors (NCCN Uterine Neoplasms Guidelines, v2.2021)(Billingsley et al., 2016; 26937754, Church et al., 2014; 25505230, McConechy et al., 2016; 26763250, Meng et al., 2014; 24844595, Murali et al., 2014; 24872110, Cancer Genome Atlas Research Network et al., 2013; 23636398). There are no targeted therapies that directly address POLE mutations. However, increased mutation load, such as may occur in ""ultramutated"" cancers harboring deleterious mutations in POLE, has been reported to be associated with response to the anti_programmed death 1 (PD_1) immune checkpoint inhibitors pembrolizumab (Mehnert et al., 2016; 27159395, Rizvi et al., 2015; 25765070) and nivolumab (Bouffet et al., 2016; 27001570, Schlien et al., 2015; 25642631). In particular, a patient with non_small cell lung cancer harboring a deleterious POLE mutation achieved durable clinical benefit on pembrolizumab (Rizvi et al., 2015; 25765070); two patients with POLE_mutated endometrial cancer responded to pembrolizumab (Mehnert et al., 2016; 27159395) or nivolumab (Santin et al., 2016; 27486176); two patients with POLE_mutated, TMB_high, MSS colorectal cancer responded to pembrolizumab (Gong et al., 2017; 28188185, Silberman et al., 2019; DOI: 10.1200/PO.18.00214); and two patients with biallelic mismatch repair deficiency (bMMRD)_associated glioblastoma harboring POLE mutations experienced clinically and radiologically significant responses to nivolumab (Bouffet et al., 2016; 27001570). Furthermore, POLE_mutated endometrial cancers have been shown to have higher predicted neoantigen load, increased numbers of tumor_infiltrated lymphocytes (TILs), and higher expression of PD_1 and PD_L1 in the TILs (Howitt et al., 2015; 26181000), which are potential biomarkers of response to anti_PD_1 immunotherapies. Germline mutations in POLE underlie polymerase proofreading_associated polyposis (PPAP), a highly penetrant, autosomal_dominant disorder characterized by the development of adenomatous polyps and an increased risk of intestinal, colorectal, and endometrial cancers (Palles et al., 2013; 23263490, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Valle et al., 2014; 24501277, Church et al., 2014; 24509466, Spier et al., 2015; 25529843). PPAP underlies 0.1% to 0.4% of familial cancers (Mur et al., 2020; 32792570). The lifetime risk of colorectal cancer for a POLE mutation carrier is estimated to be 21% to 28% (Buchanan et al., 2018; 29120461). In the appropriate clinical context, germline testing of POLE is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'SETD2', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'splice site 5278_1G>T', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'splice site 5278_1G>T'}}, 'Interpretation': 'SETD2 encodes a histone lysine_36 methyltransferase (Sun et al., 2005; 16118227) that preferentially interacts with the expanded N_terminal polyglutamine tracts present in mutant huntingtin, implicating it in the pathogenesis of Huntington disease (Faber et al., 1998; 9700202). SETD2 mRNA expression has been observed to be consistently reduced in breast tumors relative to adjacent non_tumor tissue, suggesting a potential tumor suppressor role (Al Sarakbi et al., 2009; 19698110). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. Somatic inactivating alterations of SETD2 are documented to occur at low frequency in a number of solid tumors, most commonly in renal carcinoma (Varela et al., 2011; 21248752). SETD2 has been associated with favorable prognosis in gastric cancer (Chen et al., 2018; 29522714). SETD2 has also been associated with poor prognosis in RCC and MDS (Chen et al., 2020; 32202636, Liu et al.,; 2015; 26559293), while data in other tumor types is limited (PubMed, Jun 2021). There are no targeted therapies available to address genomic alterations in SETD2.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'SPEN', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'A2727V', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'A2727V'}}, 'Interpretation': 'SPEN (also known as MINT or SHARP) encodes a transcriptional regulator that interacts with HDAC1 and the SMRT/NcoR corepressors (Shi et al., 2001; 11331609, Ariyoshi and Schwabe, 2003; 12897056). SPEN represses the transcriptional activity of the NOTCH signaling pathway (Kuroda et al., 2003; 12594956, Oswald et al., 2002; 12374742). Activation of NOTCH signaling results in binding of the transcription factor RBPJ to the NOTCH intracellular domain and consequent activation of the NOTCH transcriptional program (Kopan and Ilagan., 2009; 19379690). SPEN binding to RBPJ has been shown to repress NOTCH_mediated transcription (Kuroda et al., 2003; 12594956, Oswald et al., 2002; 12374742). SPEN alterations that result in loss of the RBPJ_interaction domain (aa 2804_2816)(Kuroda et al., 2003; 12594956, Oswald et al., 2002; 12374742) or the SPOC domain (aa 3498_3664)(Ariyoshi and Schwabe, 2003; 12897056) are predicted to disrupt binding of SPEN to RBPJ or corepressors and are likely to be inactivating. SPEN truncating mutations have been reported in adenoid cystic carcinoma (ACC) (21%) (Stephens et al., 2013; 23778141) and splenic marginal zone lymphoma (SMZL) (5%) (Rossi et al., 2012; 22891273); NOTCH pathway gene mutations were frequent in both ACC and SMZL and observed in approximately 30% of cases (Stephens et al., 2013; 23778141, Rossi et al., 2012; 22891273). There are no targeted therapies available to address SPEN inactivating mutations. Although gamma_secretase inhibitors are in clinical development to target NOTCH activation, it is not known if these therapies would be beneficial in the context of SPEN mutation.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'STAG2', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'splice site 463_1G>T', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'splice site 463_1G>T'}}, 'Interpretation': 'STAG2 encodes a subunit of the cohesin complex, which maintains sister chromatid cohesion. The cohesin complex includes four subunits: SMC1A, SMC3, RAD21, and either STAG1 or STAG2 (Solomon et al., 2014; 24856830). Cohesin is also involved in transcriptional regulation, DNA replication and DNA repair (Solomon et al., 2014; 24856830). STAG2 mutations, which are mostly truncating, or loss of STAG2 protein expression have been reported in multiple cancer types (Kandoth et al., 2013; 24132290, Solomon et al., 2014; 24856830). STAG2 deletion has been shown to promote tumorigenesis in preclinical studies (Evers et al., 2014; 24484537), and STAG2 inactivation has been proposed to promote tumorigenesis via a mechanism that involves increased aneuploidy (Guo et al., 2013; 24121792, Solomon et al., 2013; 24121789, Solomon et al., 2011; 21852505) or altered transcriptional regulation (Thota et al., 2014; 25006131, Balbás_Martínez et al., 2013; 24121791, Kon et al., 2013; 23955599, Taylor et al., 2014; 24270882). STAG2 mutations have been observed most frequently in urothelial bladder carcinoma (16_35%) (Solomon et al., 2013; 24121789, Balbás_Martínez et al., 2013; 24121791, Guo et al., 2013; 24121792, Taylor et al., 2014; 24270882, Cancer Genome Atlas Research Network., 2014; 24476821), Ewing sarcoma (13_22%) (Tirode et al., 2014; 25223734, Brohl et al., 2014; 25010205), upper urinary tract urothelial carcinoma (11%) (Hoang et al., 2013; 23926200), myeloid malignancies (6%) (Thota et al., 2014; 25006131, Kon et al., 2013; 23955599), and glioblastoma (6%) (Solomon et al., 2011; 21852505). STAG2 truncation mutations are associated with loss of protein expression (Solomon et al., 2013; 24121789, Balbás_Martínez et al., 2013; 24121791, Taylor et al., 2014; 24270882, Brohl et al., 2014; 25010205). In patients with Ewing sarcoma, STAG2 and TP53 mutations often co_occur and are associated with decreased overall survival, although mutation of either STAG2 or TP53 alone was not demonstrated to affect survival (Tirode et al., 2014; 25223734, Brohl et al., 2014; 25010205). STAG2 mutation in patients with myelodysplastic syndrome is associated with decreased overall survival and has also been associated with increased response to treatment with azacitidine or decitabine in patients with myeloid malignancies (Thota et al., 2014; 25006131). The data on the prognostic significance of STAG2 mutation or loss of STAG2 protein expression in the context of urothelial bladder carcinoma are conflicting (Solomon et al., 2013; 24121789, Balbás_Martínez et al., 2013; 24121791, Guo et al., 2013; 24121792, Taylor et al., 2014; 24270882). In patients with pancreatic ductal adenocarcinoma, loss of STAG2 staining was significantly associated with decreased overall survival, but was also associated with survival benefit from adjuvant chemotherapy (Evers et al., 2014; 24484537). An inactivating STAG2 mutation was identified in a patient with melanoma that acquired resistance to vemurafenib and preclinical evidence suggests that loss of STAG2 expression decreases the sensitivity of BRAF V600E_positive melanoma cells to vemurafenib, dabrafenib, and trametinib (Shen et al., 2016; 27500726). There are no therapies that directly target STAG2. However, in preclinical studies, STAG2 inactivation by mutation or knockdown resulted in increased sensitivity to PARP inhibitors (Bailey et al., 2014; 24356817) or oxaliplatin (Evers et al., 2014; 24484537).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TNFAIP3', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R87*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R87*'}}, 'Interpretation': 'TNFAIP3 encodes tumor necrosis factor alpha_induced protein 3, also known as A20, a regulator of NF_kB signaling and apoptosis (Harhaj and Dixit, 2011; 21119682) that has both ubiquitin ligase and deubiquitinase activities (Wertz et al., 2004; 15258597, Wertz et al., 2015; 26649818) and whose loss or inactivation may be tumorigenic (Honma et al., 2009; 19608751). TNFAIP3 is frequently deleted or mutated in lymphoma, where it functions as a tumor suppressor (Honma et al., 2009; 19608751), but its expression and function are context dependent in solid tumors (Wang et al., 2016; 26909601, Couch et al., 2016; 27072986, Wang et al., 2015; 26485275, Harhaj and Dixit, 2011; 21119682, Salim et al., 2013; 23929716), leukemia (Saitoh et al., 2016; 26437781, Johansson et al., 2016; 26199174, Chen et al., 2015; 26159495), and multiple myeloma (Broyl et al., 2010; 20574050, Troppan et al., 2015; 25856582). TNFAIP3 mutations that disrupt the A20p37 chain (amino acids 371–790), which mediates ubiquitin ligase activity and interaction with the cIAP1/TRAF2 complex (Wertz et al., 2004; 15258597, Yamaguchi et al., 2013; 24008839), are predicted to be inactivating. In T_cells, cleavage of A20 codon R439 by MALT1 has been shown to upregulate NFkB signaling; R439A has been shown to block MALT1_mediated NF_kB activation (Coornaert et al., 2008; 18223652); however, the function of R439 mutations outside of the context of T_cell lymphoma has not been reported. In the COSMIC dataset, TNFAIP3 mutations have been reported in 3.5% of prostate, 3.1% of endometrial, 2.8% of skin, 2.7% of gastric, and 2.4% of large intestine cancers (Jan 2021)(Tate et al., 2019; 30371878). Overexpression of TNFAIP3 has been associated with aggressive high_grade ER_/PR_negative breast tumors (Vendrell et al., 2007; 17297453), resistance to TNF_alpha and TRAIL_induced apoptosis in glioblastoma (Hjelmeland et al., 2010; 20186265, Bellail et al., 2012; 22585859) and to chemotherapy in acute lymphoblastic leukemia (Chen et al., 2015; 26159495), and poor prognosis in adrenocortical carcinoma (Hantel et al., 2016; 26768118). Loss of heterozygosity in the genomic region including TNFAIP3 has been found in 16.8% (25/149) of colorectal adenocarcinomas, and significantly decreased TNFAIP3 mRNA expression has been observed in colorectal cancer (CRC) tumors compared with adjacent non_neoplastic mucosa (Ungerbäck et al., 2012; 22843550). Reduced A20 expression has been suggested as a marker of poor prognosis in CRC (Bavi et al., 2011; 22704353). There are no therapies that address the loss of TNFAIP3. A20 has multiple functions and is subject to a wide range of genomic lesions, thereby making it challenging to develop a unified therapeutic approach. Potential avenues targeting dysregulation of ubiquitination pathways include anti_CD20 therapies, such as rituximab, and proteasome inhibitors, such as bortezomib (Hymowitz and Wertz, 2010; 20383180). RNAi_mediated downregulation of TNFAIP3 has been reported to sensitize multiple myeloma cells to bortezomib (Zhu et al., 2011; 21289309).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TP53', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'F113V, T211A', 'AlterationProperties': {'AlterationProperty': [{'isEquivocal': 'false', 'name': 'F113V'}, {'isEquivocal': 'false', 'name': 'T211A'}]}, 'Interpretation': 'Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutations have been reported in 29% of endometrial carcinomas analyzed in COSMIC, including 60% of serous carcinomas, 36% of clear cell carcinomas, and 23% of endometrioid carcinomas (Feb 2021)(Tate et al., 2019; 30371878). In one large study, high (pathologic) expression of p53 was found in 24% of endometrial carcinoma samples and was associated with non_endometrioid histology, high grade (Grade 3 vs. Grade 1_2), and advanced FIGO stage, as well as with lymph node metastasis and poor disease_specific survival, but was not an independent factor for poor prognosis in multivariate analysis (Trovik et al., 2013; 23932335). In other studies, p53 alterations (defined as TP53 mutation or p53 nuclear expression) have been found to be associated with poor prognosis in patients with endometrial cancer (Wild et al., 2012; 22678923, Lee et al., 2010; 20006376). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% (17/176) and SDs in 53.4% (94/176) of patients with solid tumors; the response rate was 21.1% (4/19) in patients with TP53 mutations versus 12.1% (4/33) in patients who were TP53 wild_type (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 31.9% (30/94, 3 CR) ORR and a 73.4% (69/94) DCR in patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 42.9% (9/21, 1 CR) ORR and a 76.2% (16/21) DCR in patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin in patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24.0% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71.4% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel in patients with solid tumors, 75.0% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Additionally, the combination of a CHK1 inhibitor and irinotecan reportedly reduced tumor growth and prolonged survival in a TP53_mutated, but not TP53_wild_type, breast cancer xenotransplant mouse model (Ma et al., 2012; 22446188). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'XPO1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R749Q', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R749Q'}}, 'Interpretation': 'XPO1 encodes exportin_1, also known as CRM1, a nuclear pore protein that controls nuclear export and localization of multiple cell cycle_ and proliferation_associated proteins (Kırlı et al., 2015; 26673895). Exportin_1 may also be required for efficient centrosome maintenance by BRCA1 (Brodie and Henderson, 2012; 22262852). XPO1 residue E571 is a mutational hotspot in chronic lymphocytic leukemia (CLL) and other tumor types (Puente et al., 2011; 21642962, Luthra et al., 2014; 24142997, Jeromin et al., 2014; 24113472, Vollbrecht et al., 2015; 26053404, Herling et al., 2016; 27226433, Jardin et al., 2016; 27312795), although mutations at this site have not been functionally characterized. XPO1 D624G has been reported in the context of esophageal squamous cell carcinoma (ESCC) and has been suggested to lead to gain of function (Lin et al., 2014; 24686850). XPO1 mutations have been reported at highest frequency in chronic lymphocytic leukemia (2_15%) and endometrial tumors (3_5%) and at lower incidences in other tumor types (COSMIC, 2021) (Puente et al., 2011; 21642962, Cancer Genome Atlas Research Network., 2013; 23636398, Vollbrecht et al., 2015; 26053404, Guièze et al., 2015; 26316624, Herling et al., 2016; 27226433, Tate et al., 2019; 30371878). One study reported XPO1 mutation at high frequency in cases of Hodgkin lymphoma (26%, 5/19) and primary mediastinal B_cell lymphoma (24%, 28/117) (Jardin et al., 2016; 27312795). In CLL, XPO1 correlates with unmutated IGHV status, presence of NOTCH1 mutations, increased white blood cell count, and decreased progression_free survival after certain chemoimmunotherapy regimens (Puente et al., 2011; 21642962, Jeromin et al., 2014; 24113472, Vollbrecht et al., 2015; 26053404, Herling et al., 2016; 27226433). Increased levels of nuclear exportin_1 have been reported to correlate with clinical stage in human cholangiocarcinoma samples, and reduced exportin_1 expression suppressed tumor growth in a xenograft model of the disease (Luo et al., 2016; 27279267). XPO1 activation may predict sensitivity to XPO1 inhibitors (Neggers et al., 2015; 25579209), such as the selective inhibitors of nuclear export (SINEs) (Ranganathan et al., 2012; 22677130) KPT_330 (Etchin et al., 2013; 23373539) and KPT_8602 (Hing et al., 2016; 27323910, Etchin et al., 2016; 27211268), which are in clinical trials in solid tumors and hematological cancers. In a Phase 1 trial of KPT_330 for unselected advanced solid tumors, one of 157 evaluable patients achieved a complete response, six achieved partial responses (4%), and 67 (43%) achieved stable disease (SD), which was durable for ≥4 months for 27 patients (17%) (Abdul Razak et al., 2016; 26926685). A patient with accelerated_phase chronic myelogenous leukemia (CML) refractory to available tyrosine kinase inhibitors demonstrated short_term anti_leukemic activity from KPT_330 (Walker et al., 2013; 23970380). Inhibitors of XPO1 have shown efficacy in mouse models and cultured cells of CML, T_cell acute lymphoblastic leukemia, acute myeloid leukemia, mantle cell lymphoma, multiple myeloma, and CLL (Etchin et al., 2016; 27211268, Etchin et al., 2016; 26202935, Ranganathan et al., 2016; 27358488, Walker et al., 2013; 23970380, Etchin et al., 2013; 23373539, Zhang et al., 2013; 22986101, Schmidt et al., 2013; 23752175, Lapalombella et al., 2012; 23034282), as well as in GIST, a subset of sarcomas (Nakayama et al., 2016; 26918731), and ESCCs (Lin et al., 2014; 24686850).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'ZNF217', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'D326N', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'D326N'}}, 'Interpretation': 'ZNF217 encodes a candidate oncogene that has likely roles in histone modification and transcriptional repression (Huang et al., 2005; 16203743, Banck et al., 2009; 19242095). ZNF217 amplification has been correlated with protein overexpression in breast carcinoma tumors and cell lines (Collins et al., 1998; 9671742). The role of ZNF217 in promoting tumorigenesis was established in preclinical studies demonstrating that expression of ZNF217 results in the immortalization of both human mammary epithelial cells and ovarian surface epithelial cells in culture (Nonet et al., 2001; 11245413, Li et al., 2007; 17266044). Amplification and/or overexpression of ZNF217 has been reported in breast (Vendrell et al., 2012; 22593193), ovarian (Li et al., 2014; 25031722, Rahman et al., 2012; 22843878), gastric (Yang et al., 2005; 15701848, Shida et al., 2014; 25202062), colon (Rooney et al., 2004; 15476264), prostate (Szczyrba et al., 2012; 22815235), esophageal (Geppert et al., 2014; 24853183), and urothelial carcinomas (Toncheva et al., 2005; 15897688), glioblastoma (Mao et al., 2011; 21483406), and ovarian carcinosarcomas (Schipf et al., 2008; 18193277). Overexpression in these tumors has generally been linked with aggressive tumor behavior and poor clinical prognosis. High levels of ZNF217 expression result in dysregulation of a broad range of genes that may contribute to tumorigenesis (Quinlan et al., 2007; 17572303, Krig et al., 2007; 17259635, Cowger et al., 2007; 17130829), and increased expression or activation of ERBB3 (Krig et al., 2010; 20661224, Vendrell et al., 2012; 22593193), FAK (Vendrell et al., 2012; 22593193), Aurora kinase A (Thollet et al., 2010; 21059223), AKT (Huang et al., 2005; 16203743), and TGF_beta/SMAD signaling (Vendrell et al., 2012; 22593193) has been demonstrated in ZNF217_expressing tumors or cells. There are no available targeted therapies to address genomic alterations in ZNF217. Expression of ZNF217 may predict relapse of estrogen receptor (ER)_positive breast cancer under hormone therapy through its direct interaction with ER_alpha (Nguyen et al., 2014; 24973012, Frietze et al., 2014; 24962896). ZNF217 overexpression has also been associated with resistance to paclitaxel (Thollet et al., 2010; 21059223) and doxorubicin (Huang et al., 2005; 16203743) in breast cancer cell lines. ZNF217 has been suggested as a potential biomarker for treatment with the DNA synthesis inhibitor and AKT inhibitor triciribine in breast cancer based on preclinical findings in cultured cells and xenografts expressing high levels of ZNF217; triciribine treatment also restored sensitivity to doxorubicin in these cells (Littlepage et al., 2012; 22728437).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'ATM', 'Alteration': 'R250*', 'Title': 'Durvalumab With or Without Olaparib as Maintenance Therapy After First_Line Treatment of Advanced and Recurrent Endometrial Cancer', 'StudyPhase': 'PHASE 3', 'Target': 'PD_L1, PARP', 'Locations': 'Nakagami_gun (Japan), Shanghai (China), Guangdong (China), Hong Kong (Hong Kong), HKG (Hong Kong), Changchun (China), Wuhan (China), Kurume_shi (Japan), Gyeongsangnam_do (Korea, Republic of), Suwon (Korea, Republic of)', 'NCTID': 'NCT04269200', 'Note': 'Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.', 'Include': 'true'}, {'Gene': 'ATM', 'Alteration': 'R250*', 'Title': 'Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP, PD_1', 'Locations': 'Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)', 'NCTID': 'NCT04123366', 'Note': 'Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.', 'Include': 'true'}, {'Gene': 'ATM', 'Alteration': 'R250*', 'Title': 'Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Nedlands (Australia), Kazan (Russian Federation), Arkhangelsk (Russian Federation), Port Macquarie (Australia), Ryazan (Russian Federation), Darlinghurst (Australia), Moscow (Russian Federation)', 'NCTID': 'NCT03742895', 'Note': 'Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.', 'Include': 'true'}, {'Gene': 'ATM', 'Alteration': 'R250*', 'Title': 'Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma', 'StudyPhase': 'PHASE 2', 'Target': 'PARP', 'Locations': 'Jinan (China)', 'NCTID': 'NCT04716686', 'Note': 'Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.', 'Include': 'true'}, {'Gene': 'ATM', 'Alteration': 'R250*', 'Title': 'Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP, PD_L1', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California', 'NCTID': 'NCT02264678', 'Note': 'Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.', 'Include': 'true'}, {'Gene': 'ATM', 'Alteration': 'R250*', 'Title': 'Study of AZD6738, DNA Damage Repair/Novel Anti_cancer Agent, in Combination With Paclitaxel, in Refractory Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'ATR', 'Locations': 'Seoul (Korea, Republic of)', 'NCTID': 'NCT02630199', 'Note': 'Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.', 'Include': 'true'}, {'Gene': 'ATM', 'Alteration': 'R250*', 'Title': 'STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS', 'StudyPhase': 'PHASE 1', 'Target': 'PARP', 'Locations': 'Beijing (China), Changchun (China)', 'NCTID': 'NCT04635631', 'Note': 'Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.', 'Include': 'true'}, {'Gene': 'ATM', 'Alteration': 'R250*', 'Title': 'First_in_human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas', 'StudyPhase': 'PHASE 1', 'Target': 'ATR', 'Locations': 'Sunto (Japan), Chuo_ku (Japan), Kashiwa (Japan), Singapore (Singapore), St. Gallen (Switzerland), Bellinzona (Switzerland), Newcastle Upon Tyne (United Kingdom), Genève (Switzerland), Sutton (United Kingdom), Edmonton (Canada)', 'NCTID': 'NCT03188965', 'Note': 'Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.', 'Include': 'true'}, {'Gene': 'ATM', 'Alteration': 'R250*', 'Title': 'Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, AKTs, PD_L1', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT03772561', 'Note': 'Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.', 'Include': 'true'}, {'Gene': 'ATM', 'Alteration': 'R250*', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'Loss or inactivation of ATM may increase sensitivity to PARP inhibitors, ATR inhibitors, or DNA_PKcs inhibitors.', 'Include': 'true'}, {'Gene': 'BRCA2', 'Alteration': 'E1879D', 'Title': 'Durvalumab With or Without Olaparib as Maintenance Therapy After First_Line Treatment of Advanced and Recurrent Endometrial Cancer', 'StudyPhase': 'PHASE 3', 'Target': 'PD_L1, PARP', 'Locations': 'Nakagami_gun (Japan), Shanghai (China), Guangdong (China), Hong Kong (Hong Kong), HKG (Hong Kong), Changchun (China), Wuhan (China), Kurume_shi (Japan), Gyeongsangnam_do (Korea, Republic of), Suwon (Korea, Republic of)', 'NCTID': 'NCT04269200', 'Note': 'BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'BRCA2', 'Alteration': 'E1879D', 'Title': 'Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event', 'StudyPhase': 'PHASE 2', 'Target': 'EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT03239015', 'Note': 'BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'BRCA2', 'Alteration': 'E1879D', 'Title': 'Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP, PD_1', 'Locations': 'Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)', 'NCTID': 'NCT04123366', 'Note': 'BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'BRCA2', 'Alteration': 'E1879D', 'Title': 'Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Nedlands (Australia), Kazan (Russian Federation), Arkhangelsk (Russian Federation), Port Macquarie (Australia), Ryazan (Russian Federation), Darlinghurst (Australia), Moscow (Russian Federation)', 'NCTID': 'NCT03742895', 'Note': 'BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'BRCA2', 'Alteration': 'E1879D', 'Title': 'Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma', 'StudyPhase': 'PHASE 2', 'Target': 'PARP', 'Locations': 'Jinan (China)', 'NCTID': 'NCT04716686', 'Note': 'BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'BRCA2', 'Alteration': 'E1879D', 'Title': 'Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP, PD_L1', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California', 'NCTID': 'NCT02264678', 'Note': 'BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'BRCA2', 'Alteration': 'E1879D', 'Title': 'Study of AZD6738, DNA Damage Repair/Novel Anti_cancer Agent, in Combination With Paclitaxel, in Refractory Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'ATR', 'Locations': 'Seoul (Korea, Republic of)', 'NCTID': 'NCT02630199', 'Note': 'BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'BRCA2', 'Alteration': 'E1879D', 'Title': 'STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS', 'StudyPhase': 'PHASE 1', 'Target': 'PARP', 'Locations': 'Beijing (China), Changchun (China)', 'NCTID': 'NCT04635631', 'Note': 'BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'BRCA2', 'Alteration': 'E1879D', 'Title': 'First_in_human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas', 'StudyPhase': 'PHASE 1', 'Target': 'ATR', 'Locations': 'Sunto (Japan), Chuo_ku (Japan), Kashiwa (Japan), Singapore (Singapore), St. Gallen (Switzerland), Bellinzona (Switzerland), Newcastle Upon Tyne (United Kingdom), Genève (Switzerland), Sutton (United Kingdom), Edmonton (Canada)', 'NCTID': 'NCT03188965', 'Note': 'BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'BRCA2', 'Alteration': 'E1879D', 'Title': 'Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, AKTs, PD_L1', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT03772561', 'Note': 'BRCA2 loss or inactivating alterations may predict sensitivity to PARP inhibitors or to ATR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'K335T', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'K335T', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'K335T', 'Title': 'Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'Aromatase, mTOR, CDK4, CDK6', 'Locations': 'Texas', 'NCTID': 'NCT03008408', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'K335T', 'Title': 'Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6', 'Locations': 'Massachusetts', 'NCTID': 'NCT03065062', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'K335T', 'Title': 'A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'mTOR, EGFR, RET, SRC, VEGFRs', 'Locations': 'Texas', 'NCTID': 'NCT01582191', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'K335T', 'Title': 'Sapanisertib and Ziv_Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery', 'StudyPhase': 'PHASE 1', 'Target': 'PIGF, VEGFA, VEGFB, mTORC1, mTORC2', 'Locations': 'Texas', 'NCTID': 'NCT02159989', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'K335T', 'Title': 'Phase I/Ib Dose Escalation & Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non_Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression', 'StudyPhase': 'PHASE 1', 'Target': 'ROS1, ALK, mTOR', 'Locations': 'Texas', 'NCTID': 'NCT02321501', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'K335T', 'Title': 'Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers', 'StudyPhase': 'PHASE 1', 'Target': 'mTORC1, mTORC2', 'Locations': 'Texas', 'NCTID': 'NCT03017833', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'K335T', 'Title': 'Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'mTORC1, mTORC2', 'Locations': 'Texas', 'NCTID': 'NCT03430882', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FANCL', 'Alteration': 'splice site 904_2A>C', 'Title': 'Durvalumab With or Without Olaparib as Maintenance Therapy After First_Line Treatment of Advanced and Recurrent Endometrial Cancer', 'StudyPhase': 'PHASE 3', 'Target': 'PD_L1, PARP', 'Locations': 'Nakagami_gun (Japan), Shanghai (China), Guangdong (China), Hong Kong (Hong Kong), HKG (Hong Kong), Changchun (China), Wuhan (China), Kurume_shi (Japan), Gyeongsangnam_do (Korea, Republic of), Suwon (Korea, Republic of)', 'NCTID': 'NCT04269200', 'Note': 'On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCL', 'Alteration': 'splice site 904_2A>C', 'Title': 'Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP, PD_1', 'Locations': 'Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)', 'NCTID': 'NCT04123366', 'Note': 'On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCL', 'Alteration': 'splice site 904_2A>C', 'Title': 'Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Nedlands (Australia), Kazan (Russian Federation), Arkhangelsk (Russian Federation), Port Macquarie (Australia), Ryazan (Russian Federation), Darlinghurst (Australia), Moscow (Russian Federation)', 'NCTID': 'NCT03742895', 'Note': 'On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCL', 'Alteration': 'splice site 904_2A>C', 'Title': 'Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma', 'StudyPhase': 'PHASE 2', 'Target': 'PARP', 'Locations': 'Jinan (China)', 'NCTID': 'NCT04716686', 'Note': 'On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCL', 'Alteration': 'splice site 904_2A>C', 'Title': 'Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP, PD_L1', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California', 'NCTID': 'NCT02264678', 'Note': 'On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCL', 'Alteration': 'splice site 904_2A>C', 'Title': 'STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS', 'StudyPhase': 'PHASE 1', 'Target': 'PARP', 'Locations': 'Beijing (China), Changchun (China)', 'NCTID': 'NCT04635631', 'Note': 'On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCL', 'Alteration': 'splice site 904_2A>C', 'Title': 'Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, AKTs, PD_L1', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT03772561', 'Note': 'On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCL', 'Alteration': 'splice site 904_2A>C', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCL', 'Alteration': 'splice site 904_2A>C', 'Title': 'Study of RP_3500 in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP', 'Locations': 'Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas', 'NCTID': 'NCT04497116', 'Note': 'On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FANCL', 'Alteration': 'splice site 904_2A>C', 'Title': 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'StudyPhase': 'PHASE 2/3', 'Target': 'PARP', 'Locations': 'Toronto (Canada)', 'NCTID': 'NCT04159155', 'Note': 'On the basis of clinical evidence in ovarian cancer, FANCL loss or inactivation may confer sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'R441W', 'Title': 'Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event', 'StudyPhase': 'PHASE 2', 'Target': 'EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT03239015', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'R441W', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'R441W', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'R441W', 'Title': 'Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO', 'Locations': 'Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)', 'NCTID': 'NCT03297606', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'R441W', 'Title': 'Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR', 'Locations': 'Colorado, Michigan, Virginia, Texas', 'NCTID': 'NCT02397083', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'R441W', 'Title': 'Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'Aromatase, mTOR, CDK4, CDK6', 'Locations': 'Texas', 'NCTID': 'NCT03008408', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'R441W', 'Title': 'Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy', 'StudyPhase': 'PHASE 1', 'Target': 'IDO1, mTOR', 'Locations': 'Kansas', 'NCTID': 'NCT03217669', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'R441W', 'Title': 'Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6', 'Locations': 'Massachusetts', 'NCTID': 'NCT03065062', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'R441W', 'Title': 'A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'mTOR, EGFR, RET, SRC, VEGFRs', 'Locations': 'Texas', 'NCTID': 'NCT01582191', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FBXW7', 'Alteration': 'R441W', 'Title': 'Sapanisertib and Ziv_Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery', 'StudyPhase': 'PHASE 1', 'Target': 'PIGF, VEGFA, VEGFB, mTORC1, mTORC2', 'Locations': 'Texas', 'NCTID': 'NCT02159989', 'Note': 'Loss or inactivation of FBXW7 may lead to increased mTOR activation and may predict sensitivity to mTOR inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'N549D', 'Title': 'Pembrolizumab (MK_3475) Plus Lenvatinib (E7080/MK_7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT_en9 / MK_7902_001) _China Extension Study', 'StudyPhase': 'PHASE 3', 'Target': 'FGFRs, KIT, PD_1, PDGFRA, RET, VEGFRs', 'Locations': 'Hangzhou (China), Shanghai (China), Nanchang (China), Nanjing (China), Hefei (China), Guangzhou (China), Changsha (China), Wuhan (China), Nanning (China), Chongqing (China)', 'NCTID': 'NCT04865289', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'N549D', 'Title': 'Single_arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'FGFR1, FGFR2, FGFR3, KIT, VEGFRs', 'Locations': 'Seoul (Korea, Republic of)', 'NCTID': 'NCT02450136', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'N549D', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'N549D', 'Title': 'Study of MK_4830 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_4830_001)', 'StudyPhase': 'PHASE 1', 'Target': 'ITL4, FGFRs, KIT, PDGFRA, RET, VEGFRs, PD_1', 'Locations': 'Seoul (Korea, Republic of), Tokyo (Japan), Haifa (Israel), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Warszawa (Poland), Gdansk (Poland), Heraklion (Greece), Washington', 'NCTID': 'NCT03564691', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'N549D', 'Title': 'A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor', 'StudyPhase': 'PHASE 1/2', 'Target': 'FGFRs, VEGFRs, PD_1', 'Locations': 'Innsbruck (Austria), Essen (Germany), Bologna (Italy), Naples (Italy), Leuven (Belgium), Brussels (Belgium), Ghent (Belgium), Washington, Barcelona (Spain), Madrid (Spain)', 'NCTID': 'NCT04042116', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'N549D', 'Title': 'A Study of ICP_192 in Patients With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'FGFR1, FGFR2, FGFR3, FGFR4', 'Locations': 'Colorado, Minnesota, Arizona, Florida', 'NCTID': 'NCT04565275', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'N549D', 'Title': 'Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.', 'StudyPhase': 'PHASE 2', 'Target': 'ABL, FGFRs, FLT3, KIT, RET, VEGFRs', 'Locations': 'Ohio', 'NCTID': 'NCT02272998', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'N549D', 'Title': 'Trial Of Pembrolizumab And Nintedanib', 'StudyPhase': 'PHASE 1', 'Target': 'FGFR1, FGFR2, FGFR3, FLT3, LCK, LYN, SRC, VEGFRs, PD_1', 'Locations': 'Villejuif (France)', 'NCTID': 'NCT02856425', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'FGFR2', 'Alteration': 'N549D', 'Title': 'Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI_24781 in Patients With Metastatic Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'HDAC, FGFR1, FGFR2, FGFR3, KIT, VEGFRs', 'Locations': 'California', 'NCTID': 'NCT01543763', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'R1362*, R2450*', 'Title': 'Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event', 'StudyPhase': 'PHASE 2', 'Target': 'EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT03239015', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'R1362*, R2450*', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'R1362*, R2450*', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'R1362*, R2450*', 'Title': 'Dose_Escalation and Dose_Expansion of RMC_4630 and Cobimetinib in Relapsed/Refractory Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'SHP2, MEK', 'Locations': 'Seoul (Korea, Republic of), Oregon, California, Colorado, Arizona, Wisconsin, Illinois', 'NCTID': 'NCT03989115', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'R1362*, R2450*', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'R1362*, R2450*', 'Title': 'Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'RAFs, EGFR, MEK', 'Locations': 'Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), Texas', 'NCTID': 'NCT03905148', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'R1362*, R2450*', 'Title': 'Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO', 'Locations': 'Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)', 'NCTID': 'NCT03297606', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'R1362*, R2450*', 'Title': 'PF_07284892 in Participants With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'SHP2, ROS1, ALK, BRAF, EGFR, MEK', 'Locations': 'California, Michigan, New York, Tennessee, Texas', 'NCTID': 'NCT04800822', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'R1362*, R2450*', 'Title': 'Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR', 'Locations': 'Colorado, Michigan, Virginia, Texas', 'NCTID': 'NCT02397083', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'NF1', 'Alteration': 'R1362*, R2450*', 'Title': 'Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction', 'StudyPhase': 'PHASE 1', 'Target': 'MEK', 'Locations': 'Toronto (Canada)', 'NCTID': 'NCT02070549', 'Note': 'On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'R88QT1025A', 'Title': 'Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study', 'StudyPhase': 'PHASE 2', 'Target': 'ALK, ROS1, TRKA, TRKB, TRKC, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha', 'Locations': 'Zhongzheng Dist. (Taiwan), Taipei City (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Beijing (China), Woolloongabba (Australia), Darlinghurst (Australia), Randwick (Australia), Melbourne (Australia), Haifa (Israel)', 'NCTID': 'NCT04589845', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'R88QT1025A', 'Title': 'Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event', 'StudyPhase': 'PHASE 2', 'Target': 'EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT03239015', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'R88QT1025A', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'R88QT1025A', 'Title': 'Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors', 'StudyPhase': 'PHASE 4', 'Target': 'mTOR', 'Locations': 'Seoul (Korea, Republic of)', 'NCTID': 'NCT02688881', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'R88QT1025A', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'R88QT1025A', 'Title': 'Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, AKTs, PD_L1', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT03772561', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'R88QT1025A', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'R88QT1025A', 'Title': 'A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response', 'StudyPhase': 'PHASE 2', 'Target': 'ALK, ROS1, TRKA, TRKB, TRKC, PD_L1, ERBB2, ERBB3, PI3K_alpha, RET, AKTs', 'Locations': 'Alaska, Washington, Oregon, California, Montana', 'NCTID': 'NCT04632992', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'R88QT1025A', 'Title': 'Genetic Testing in Guiding Treatment for Patients With Brain Metastases', 'StudyPhase': 'PHASE 2', 'Target': 'ALK, ROS1, TRKA, TRKB, TRKC, CDK4, CDK6, PI3K, mTOR', 'Locations': 'Alaska, Washington', 'NCTID': 'NCT03994796', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CA', 'Alteration': 'R88QT1025A', 'Title': 'Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO', 'Locations': 'Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)', 'NCTID': 'NCT03297606', 'Note': 'PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.', 'Include': 'true'}, {'Gene': 'PIK3CB', 'Alteration': 'R321Q', 'Title': 'Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event', 'StudyPhase': 'PHASE 2', 'Target': 'EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT03239015', 'Note': 'Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'PIK3CB', 'Alteration': 'R321Q', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'PIK3CB', 'Alteration': 'R321Q', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'PIK3CB', 'Alteration': 'R321Q', 'Title': 'AZD8186 and Paclitaxel in Advanced Gastric Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'PI3K_beta', 'Locations': 'Seongnam_si (Korea, Republic of)', 'NCTID': 'NCT04001569', 'Note': 'Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'PIK3CB', 'Alteration': 'R321Q', 'Title': 'Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, AKTs, PD_L1', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT03772561', 'Note': 'Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'PIK3CB', 'Alteration': 'R321Q', 'Title': 'Genetic Testing in Guiding Treatment for Patients With Brain Metastases', 'StudyPhase': 'PHASE 2', 'Target': 'ALK, ROS1, TRKA, TRKB, TRKC, CDK4, CDK6, PI3K, mTOR', 'Locations': 'Alaska, Washington', 'NCTID': 'NCT03994796', 'Note': 'Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'PIK3CB', 'Alteration': 'R321Q', 'Title': 'Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO', 'Locations': 'Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)', 'NCTID': 'NCT03297606', 'Note': 'Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'PIK3CB', 'Alteration': 'R321Q', 'Title': 'A Trial of Ipatasertib in Combination With Atezolizumab', 'StudyPhase': 'PHASE 1/2', 'Target': 'AKTs, PD_L1', 'Locations': 'Sutton (United Kingdom)', 'NCTID': 'NCT03673787', 'Note': 'Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'PIK3CB', 'Alteration': 'R321Q', 'Title': 'Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR', 'Locations': 'Colorado, Michigan, Virginia, Texas', 'NCTID': 'NCT02397083', 'Note': 'Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'PIK3CB', 'Alteration': 'R321Q', 'Title': 'Study of PI3Kinase Inhibition (Copanlisib) and Anti_PD_1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch_repair Proficient (MSS) Colorectal Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1, PI3K', 'Locations': 'Maryland', 'NCTID': 'NCT03711058', 'Note': 'Preclinical evidence suggests that overexpression of PIK3CB promotes cellular transformation, and that PTEN_deficient cancers may be dependent on PIK3CB for growth. Therefore, inhibitors of PIK3CB or downstream pathway components including AKT may be beneficial in tumors harboring PIK3CB alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'PIK3R1', 'Alteration': 'E476*', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan_PI3K or PI3K_alpha_selective inhibitors.', 'Include': 'true'}, {'Gene': 'PIK3R1', 'Alteration': 'E476*', 'Title': 'Study of PI3Kinase Inhibition (Copanlisib) and Anti_PD_1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch_repair Proficient (MSS) Colorectal Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1, PI3K', 'Locations': 'Maryland', 'NCTID': 'NCT03711058', 'Note': 'On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan_PI3K or PI3K_alpha_selective inhibitors.', 'Include': 'true'}, {'Gene': 'PIK3R1', 'Alteration': 'E476*', 'Title': 'Copanlisib and Nivolumab in Treating Patients With Metastatic Solid Tumors or Lymphoma', 'StudyPhase': 'PHASE 1', 'Target': 'PI3K, PD_1', 'Locations': 'Maryland, Texas', 'NCTID': 'NCT03502733', 'Note': 'On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan_PI3K or PI3K_alpha_selective inhibitors.', 'Include': 'true'}, {'Gene': 'PIK3R1', 'Alteration': 'E476*', 'Title': 'Niraparib and Copanlisib in Treating Participants With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'PI3K, PARP', 'Locations': 'Texas', 'NCTID': 'NCT03586661', 'Note': 'On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan_PI3K or PI3K_alpha_selective inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'R130Q, R173H', 'Title': 'Durvalumab With or Without Olaparib as Maintenance Therapy After First_Line Treatment of Advanced and Recurrent Endometrial Cancer', 'StudyPhase': 'PHASE 3', 'Target': 'PD_L1, PARP', 'Locations': 'Nakagami_gun (Japan), Shanghai (China), Guangdong (China), Hong Kong (Hong Kong), HKG (Hong Kong), Changchun (China), Wuhan (China), Kurume_shi (Japan), Gyeongsangnam_do (Korea, Republic of), Suwon (Korea, Republic of)', 'NCTID': 'NCT04269200', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'R130Q, R173H', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'R130Q, R173H', 'Title': 'Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma', 'StudyPhase': 'PHASE 2', 'Target': 'PARP', 'Locations': 'Jinan (China)', 'NCTID': 'NCT04716686', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'R130Q, R173H', 'Title': 'AZD8186 and Paclitaxel in Advanced Gastric Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'PI3K_beta', 'Locations': 'Seongnam_si (Korea, Republic of)', 'NCTID': 'NCT04001569', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'R130Q, R173H', 'Title': 'Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP, PD_L1', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California', 'NCTID': 'NCT02264678', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'R130Q, R173H', 'Title': 'STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS', 'StudyPhase': 'PHASE 1', 'Target': 'PARP', 'Locations': 'Beijing (China), Changchun (China)', 'NCTID': 'NCT04635631', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'R130Q, R173H', 'Title': 'Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, AKTs, PD_L1', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT03772561', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'R130Q, R173H', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'R130Q, R173H', 'Title': 'A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response', 'StudyPhase': 'PHASE 2', 'Target': 'ALK, ROS1, TRKA, TRKB, TRKC, PD_L1, ERBB2, ERBB3, PI3K_alpha, RET, AKTs', 'Locations': 'Alaska, Washington, Oregon, California, Montana', 'NCTID': 'NCT04632992', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'R130Q, R173H', 'Title': 'Study of RP_3500 in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP', 'Locations': 'Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas', 'NCTID': 'NCT04497116', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'RAD51D', 'Alteration': 'R253Q', 'Title': 'Durvalumab With or Without Olaparib as Maintenance Therapy After First_Line Treatment of Advanced and Recurrent Endometrial Cancer', 'StudyPhase': 'PHASE 3', 'Target': 'PD_L1, PARP', 'Locations': 'Nakagami_gun (Japan), Shanghai (China), Guangdong (China), Hong Kong (Hong Kong), HKG (Hong Kong), Changchun (China), Wuhan (China), Kurume_shi (Japan), Gyeongsangnam_do (Korea, Republic of), Suwon (Korea, Republic of)', 'NCTID': 'NCT04269200', 'Note': 'Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'RAD51D', 'Alteration': 'R253Q', 'Title': 'Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP, PD_1', 'Locations': 'Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)', 'NCTID': 'NCT04123366', 'Note': 'Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'RAD51D', 'Alteration': 'R253Q', 'Title': 'Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Chelyabinsk (Russian Federation), Nedlands (Australia), Kazan (Russian Federation), Arkhangelsk (Russian Federation), Port Macquarie (Australia), Ryazan (Russian Federation), Darlinghurst (Australia), Moscow (Russian Federation)', 'NCTID': 'NCT03742895', 'Note': 'Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'RAD51D', 'Alteration': 'R253Q', 'Title': 'Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma', 'StudyPhase': 'PHASE 2', 'Target': 'PARP', 'Locations': 'Jinan (China)', 'NCTID': 'NCT04716686', 'Note': 'Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'RAD51D', 'Alteration': 'R253Q', 'Title': 'Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP, PD_L1', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), London (United Kingdom), Sutton (United Kingdom), Villejuif (France), Saint Herblain (France), California', 'NCTID': 'NCT02264678', 'Note': 'Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'RAD51D', 'Alteration': 'R253Q', 'Title': 'STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS', 'StudyPhase': 'PHASE 1', 'Target': 'PARP', 'Locations': 'Beijing (China), Changchun (China)', 'NCTID': 'NCT04635631', 'Note': 'Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'RAD51D', 'Alteration': 'R253Q', 'Title': 'Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, AKTs, PD_L1', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT03772561', 'Note': 'Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'RAD51D', 'Alteration': 'R253Q', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'RAD51D', 'Alteration': 'R253Q', 'Title': 'Study of RP_3500 in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP', 'Locations': 'Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee, Texas', 'NCTID': 'NCT04497116', 'Note': 'Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'RAD51D', 'Alteration': 'R253Q', 'Title': 'A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer', 'StudyPhase': 'PHASE 2/3', 'Target': 'PARP', 'Locations': 'Toronto (Canada)', 'NCTID': 'NCT04159155', 'Note': 'Inactivation of RAD51D may predict sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'TSC1', 'Alteration': 'Q739*', 'Title': 'Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event', 'StudyPhase': 'PHASE 2', 'Target': 'EGFR, ERBB2, ERBB4, PARP, mTOR, MET, RET, ROS1, VEGFRs, BRAF, CDK4, CDK6', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT03239015', 'Note': 'Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'TSC1', 'Alteration': 'Q739*', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'TSC1', 'Alteration': 'Q739*', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, KIT, PDGFRA, RET, VEGFRs, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'TSC1', 'Alteration': 'Q739*', 'Title': 'TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, CDK4, CDK6, CSF1R, FLT3, KIT, RET, mTOR, EGFR, ERBB2, ERBB3, MEK, BRAF, SMO, DDR2, PARP, PD_1, CTLA_4, ERBB4', 'Locations': 'Hawaii, Washington, Oregon, California', 'NCTID': 'NCT02693535', 'Note': 'Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'TSC1', 'Alteration': 'Q739*', 'Title': 'Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, AXL, MET, ROS1, TRKA, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, CSF1R, FLT3, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO', 'Locations': 'Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)', 'NCTID': 'NCT03297606', 'Note': 'Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'TSC1', 'Alteration': 'Q739*', 'Title': 'Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR', 'Locations': 'Colorado, Michigan, Virginia, Texas', 'NCTID': 'NCT02397083', 'Note': 'Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'TSC1', 'Alteration': 'Q739*', 'Title': 'Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'Aromatase, mTOR, CDK4, CDK6', 'Locations': 'Texas', 'NCTID': 'NCT03008408', 'Note': 'Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'TSC1', 'Alteration': 'Q739*', 'Title': 'Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy', 'StudyPhase': 'PHASE 1', 'Target': 'IDO1, mTOR', 'Locations': 'Kansas', 'NCTID': 'NCT03217669', 'Note': 'Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'TSC1', 'Alteration': 'Q739*', 'Title': 'Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6', 'Locations': 'Massachusetts', 'NCTID': 'NCT03065062', 'Note': 'Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'TSC1', 'Alteration': 'Q739*', 'Title': 'A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'mTOR, EGFR, RET, SRC, VEGFRs', 'Locations': 'Texas', 'NCTID': 'NCT01582191', 'Note': 'Inactivating TSC1 alterations may lead to increased mTOR activation and predict sensitivity to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '372', 'Title': 'KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'ADORA2A, CD73, PD_1', 'Locations': 'Taipei (Taiwan), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Missouri, Connecticut, Texas', 'NCTID': 'NCT04237649', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '372', 'Title': 'Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study', 'StudyPhase': 'PHASE 2', 'Target': 'ALK, ROS1, TRKA, TRKB, TRKC, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha', 'Locations': 'Zhongzheng Dist. (Taiwan), Taipei City (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Beijing (China), Woolloongabba (Australia), Darlinghurst (Australia), Randwick (Australia), Melbourne (Australia), Haifa (Israel)', 'NCTID': 'NCT04589845', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '372', 'Title': 'Sasanlimab (PF_06801591, PD_1 Inhibitor) in Participants With Advanced Malignancies', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1', 'Locations': 'Taipei (Taiwan), Kaohsiung (Taiwan), Shanghai (China), Nanjing (China), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Chongqing (China), Beijing (China), Chuo_ku (Japan), Kopeysk (Russian Federation)', 'NCTID': 'NCT04181788', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '372', 'Title': 'Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1, CSF1R', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Nagoya (Japan), Koto ku (Japan), Singapore (Singapore), Tel Aviv (Israel), Zurich (Switzerland), Rozzano (Italy), Barcelona (Spain), Hospitalet de LLobregat (Spain)', 'NCTID': 'NCT02829723', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '372', 'Title': 'A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_L1, PD_1, CTLA_4', 'Locations': 'Taipei (Taiwan), Cheongju_si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Amsterdam (Netherlands), Napoli (Italy), Roma (Italy), Villejuif Cedex (France), Barcelona (Spain)', 'NCTID': 'NCT03530397', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '372', 'Title': 'Study of Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_3475_158/KEYNOTE_158)', 'StudyPhase': 'PHASE 2', 'Target': 'PD_1', 'Locations': 'Taipei (Taiwan), Makati (Philippines), Seoul (Korea, Republic of), Beijing (China), Chiyoda_Ku, Tokyo (Japan), North Ryde (Australia), Moscow (Russian Federation), Hod Hasharon (Israel), Drammen (Norway), Glostrup (Denmark)', 'NCTID': 'NCT02628067', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '372', 'Title': 'A First_in_human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti_tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, TGF_beta', 'Locations': 'Taipei 100 (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Seoul (Korea, Republic of), Heidelberg West (Australia), Melbourne (Australia), Tallinn (Estonia), Hannover (Germany), Essen (Germany), Utrecht (Netherlands)', 'NCTID': 'NCT03192345', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '372', 'Title': 'A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1', 'Locations': 'Taipei (Taiwan), Chuo ku (Japan), Essen (Germany), Napoli (Italy), Leuven (Belgium), Barcelona (Spain), California, Texas', 'NCTID': 'NCT04261439', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '372', 'Title': 'A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, NRP1', 'Locations': 'Taipei (Taiwan), Seoul (Korea, Republic of), Tokyo (Japan), Chiba (Japan), Meldola (Italy), Modena (Italy), Newcastle upon Tyne (United Kingdom), Monza (Italy), Milano (Italy), Glasgow (United Kingdom)', 'NCTID': 'NCT03565445', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '372', 'Title': 'A Study of ASP1951 in Subjects With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, TNFRSF18', 'Locations': 'Taipei (Taiwan), Taichung (Taiwan), Daegu (Korea, Republic of), Chungcheongbukdo (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Washington, California, Nevada', 'NCTID': 'NCT03799003', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '1730053', 'FullCitation': 'Popanda O, et al. Biochim. Biophys. Acta (1992) pmid: 1730053', 'Include': 'true'}, {'number': '1', 'ReferenceId': '23263490', 'FullCitation': 'Palles C, et al. Nat. Genet. (2013) pmid: 23263490', 'Include': 'true'}, {'number': '2', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '3', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '4', 'ReferenceId': '24501277', 'FullCitation': 'Valle L, et al. Hum. Mol. Genet. (2014) pmid: 24501277', 'Include': 'true'}, {'number': '5', 'ReferenceId': '23528559', 'FullCitation': 'Church DN, et al. Hum. Mol. Genet. (2013) pmid: 23528559', 'Include': 'true'}, {'number': '6', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '7', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '8', 'ReferenceId': '26822575', 'FullCitation': 'Rayner E, et al. Nat. Rev. Cancer (2016) pmid: 26822575', 'Include': 'true'}, {'number': '9', 'ReferenceId': '25529843', 'FullCitation': 'Spier I, et al. Int. J. Cancer (2015) pmid: 25529843', 'Include': 'true'}, {'number': '10', 'ReferenceId': '25228659', 'FullCitation': 'Shinbrot E, et al. Genome Res. (2014) pmid: 25228659', 'Include': 'true'}, {'number': '11', 'ReferenceId': '27001570', 'FullCitation': 'Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570', 'Include': 'true'}, {'number': '12', 'ReferenceId': '25642631', 'FullCitation': 'Shlien A, et al. Nat. Genet. (2015) pmid: 25642631', 'Include': 'true'}, {'number': '13', 'ReferenceId': '24788313', 'FullCitation': 'Rohlin A, et al. Int. J. Oncol. (2014) pmid: 24788313', 'Include': 'true'}, {'number': '14', 'ReferenceId': '8987997', 'FullCitation': 'Abdus Sattar AK, et al. Biochemistry (1996) pmid: 8987997', 'Include': 'true'}, {'number': '15', 'ReferenceId': '16699561', 'FullCitation': 'Murphy K, et al. Genome (2006) pmid: 16699561', 'Include': 'true'}, {'number': '16', 'ReferenceId': '30371878', 'FullCitation': 'Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878', 'Include': 'true'}, {'number': '17', 'ReferenceId': '26937754', 'FullCitation': 'Billingsley CC, et al. Int. J. Gynecol. Cancer (2016) pmid: 26937754', 'Include': 'true'}, {'number': '18', 'ReferenceId': '26763250', 'FullCitation': 'McConechy MK, et al. Clin. Cancer Res. (2016) pmid: 26763250', 'Include': 'true'}, {'number': '19', 'ReferenceId': '25505230', 'FullCitation': 'Church DN, et al. J. Natl. Cancer Inst. (2015) pmid: 25505230', 'Include': 'true'}, {'number': '20', 'ReferenceId': '24844595', 'FullCitation': 'Meng B, et al. Gynecol. Oncol. (2014) pmid: 24844595', 'Include': 'true'}, {'number': '21', 'ReferenceId': '24872110', 'FullCitation': 'Murali R, et al. Lancet Oncol. (2014) pmid: 24872110', 'Include': 'true'}, {'number': '22', 'ReferenceId': '27159395', 'FullCitation': 'Mehnert JM, et al. J. Clin. Invest. (2016) pmid: 27159395', 'Include': 'true'}, {'number': '23', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '24', 'ReferenceId': '27486176', 'FullCitation': 'Santin AD, et al. Clin. Cancer Res. (2016) pmid: 27486176', 'Include': 'true'}, {'number': '25', 'ReferenceId': '28188185', 'FullCitation': 'Gong J, et al. J Natl Compr Canc Netw (2017) pmid: 28188185', 'Include': 'true'}, {'number': '26', 'ReferenceId': '26181000', 'FullCitation': 'Howitt BE, et al. JAMA Oncol (2015) pmid: 26181000', 'Include': 'true'}, {'number': '27', 'ReferenceId': '24509466', 'FullCitation': 'Dis. Colon Rectum (2014) pmid: 24509466', 'Include': 'true'}, {'number': '28', 'ReferenceId': '32792570', 'FullCitation': 'Mur P, et al. Genet Med (2020) pmid: 32792570', 'Include': 'true'}, {'number': '29', 'ReferenceId': '29120461', 'FullCitation': 'Buchanan DD, et al. Genet Med (2018) pmid: 29120461', 'Include': 'true'}, {'number': '30', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '31', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '32', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '33', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '34', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '35', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '36', 'ReferenceId': '32919526', 'FullCitation': 'Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526', 'Include': 'true'}, {'number': '37', 'ReferenceId': '31405947', 'FullCitation': 'Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947', 'Include': 'true'}, {'number': '38', 'ReferenceId': '28835386', 'FullCitation': 'Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386', 'Include': 'true'}, {'number': '39', 'ReferenceId': '30309915', 'FullCitation': 'Cristescu R, et al. Science (2018) pmid: 30309915', 'Include': 'true'}, {'number': '40', 'ReferenceId': '28420421', 'FullCitation': 'Chalmers ZR, et al. Genome Med (2017) pmid: 28420421', 'Include': 'true'}, {'number': '41', 'ReferenceId': '25394778', 'FullCitation': 'Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778', 'Include': 'true'}, {'number': '42', 'ReferenceId': '33119110', 'FullCitation': 'Shao C, et al. JAMA Netw Open (2020) pmid: 33119110', 'Include': 'true'}, {'number': '43', 'ReferenceId': '30643254', 'FullCitation': 'Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254', 'Include': 'true'}, {'number': '44', 'ReferenceId': '30785829', 'FullCitation': 'Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829', 'Include': 'true'}, {'number': '45', 'ReferenceId': '29658845', 'FullCitation': 'Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845', 'Include': 'true'}, {'number': '46', 'ReferenceId': '29657128', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128', 'Include': 'true'}, {'number': '47', 'ReferenceId': '29731394', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394', 'Include': 'true'}, {'number': '48', 'ReferenceId': '33558721', 'FullCitation': 'Rozeman EA, et al. Nat Med (2021) pmid: 33558721', 'Include': 'true'}, {'number': '49', 'ReferenceId': '32916128', 'FullCitation': 'Sharma P, et al. Cancer Cell (2020) pmid: 32916128', 'Include': 'true'}, {'number': '50', 'ReferenceId': '26673895', 'FullCitation': 'Kırlı K, et al. Elife (2015) pmid: 26673895', 'Include': 'true'}, {'number': '51', 'ReferenceId': '22262852', 'FullCitation': 'Brodie KM, et al. J. Biol. Chem. (2012) pmid: 22262852', 'Include': 'true'}, {'number': '52', 'ReferenceId': '21642962', 'FullCitation': 'Puente XS, et al. Nature (2011) pmid: 21642962', 'Include': 'true'}, {'number': '53', 'ReferenceId': '24142997', 'FullCitation': 'Luthra R, et al. Haematologica (2014) pmid: 24142997', 'Include': 'true'}, {'number': '54', 'ReferenceId': '24113472', 'FullCitation': 'Jeromin S, et al. Leukemia (2014) pmid: 24113472', 'Include': 'true'}, {'number': '55', 'ReferenceId': '26053404', 'FullCitation': 'Vollbrecht C, et al. PLoS ONE (2015) pmid: 26053404', 'Include': 'true'}, {'number': '56', 'ReferenceId': '27226433', 'FullCitation': 'Herling CD, et al. Blood (2016) pmid: 27226433', 'Include': 'true'}, {'number': '57', 'ReferenceId': '27312795', 'FullCitation': 'Jardin F, et al. Am. J. Hematol. (2016) pmid: 27312795', 'Include': 'true'}, {'number': '58', 'ReferenceId': '24686850', 'FullCitation': 'Lin DC, et al. Nat. Genet. (2014) pmid: 24686850', 'Include': 'true'}, {'number': '59', 'ReferenceId': '26316624', 'FullCitation': 'Guièze R, et al. Blood (2015) pmid: 26316624', 'Include': 'true'}, {'number': '60', 'ReferenceId': '27279267', 'FullCitation': 'Luo J, et al. Int. J. Mol. Med. (2016) pmid: 27279267', 'Include': 'true'}, {'number': '61', 'ReferenceId': '25579209', 'FullCitation': 'Neggers JE, et al. Chem. Biol. (2015) pmid: 25579209', 'Include': 'true'}, {'number': '62', 'ReferenceId': '22677130', 'FullCitation': 'Ranganathan P, et al. Blood (2012) pmid: 22677130', 'Include': 'true'}, {'number': '63', 'ReferenceId': '23373539', 'FullCitation': 'Etchin J, et al. Br. J. Haematol. (2013) pmid: 23373539', 'Include': 'true'}, {'number': '64', 'ReferenceId': '27323910', 'FullCitation': 'Hing ZA, et al. Leukemia (2016) pmid: 27323910', 'Include': 'true'}, {'number': '65', 'ReferenceId': '27211268', 'FullCitation': 'Etchin J, et al. Leukemia (2017) pmid: 27211268', 'Include': 'true'}, {'number': '66', 'ReferenceId': '26926685', 'FullCitation': 'Abdul Razak AR, et al. J. Clin. Oncol. (2016) pmid: 26926685', 'Include': 'true'}, {'number': '67', 'ReferenceId': '23970380', 'FullCitation': 'Walker CJ, et al. Blood (2013) pmid: 23970380', 'Include': 'true'}, {'number': '68', 'ReferenceId': '26202935', 'FullCitation': 'Etchin J, et al. Leukemia (2016) pmid: 26202935', 'Include': 'true'}, {'number': '69', 'ReferenceId': '27358488', 'FullCitation': 'Ranganathan P, et al. Clin. Cancer Res. (2016) pmid: 27358488', 'Include': 'true'}, {'number': '70', 'ReferenceId': '22986101', 'FullCitation': 'Zhang K, et al. Exp. Hematol. (2013) pmid: 22986101', 'Include': 'true'}, {'number': '71', 'ReferenceId': '23752175', 'FullCitation': 'Schmidt J, et al. Leukemia (2013) pmid: 23752175', 'Include': 'true'}, {'number': '72', 'ReferenceId': '23034282', 'FullCitation': 'Lapalombella R, et al. Blood (2012) pmid: 23034282', 'Include': 'true'}, {'number': '73', 'ReferenceId': '26918731', 'FullCitation': 'Nakayama R, et al. Oncotarget (2016) pmid: 26918731', 'Include': 'true'}, {'number': '74', 'ReferenceId': '23847781', 'FullCitation': 'Shiloh Y, et al. Nat. Rev. Mol. Cell Biol. (2013) pmid: 23847781', 'Include': 'true'}, {'number': '75', 'ReferenceId': '23851492', 'FullCitation': 'Cremona CA, et al. Oncogene (2014) pmid: 23851492', 'Include': 'true'}, {'number': '76', 'ReferenceId': '16603769', 'FullCitation': 'Jiang X, et al. J. Biol. Chem. (2006) pmid: 16603769', 'Include': 'true'}, {'number': '77', 'ReferenceId': '15713674', 'FullCitation': 'Fernandes N, et al. J. Biol. Chem. (2005) pmid: 15713674', 'Include': 'true'}, {'number': '78', 'ReferenceId': '11805335', 'FullCitation': 'Scott SP, et al. Proc. Natl. Acad. Sci. U.S.A. (2002) pmid: 11805335', 'Include': 'true'}, {'number': '79', 'ReferenceId': '22588877', 'FullCitation': 'Cerami E, et al. Cancer Discov (2012) pmid: 22588877', 'Include': 'true'}, {'number': '80', 'ReferenceId': '23550210', 'FullCitation': 'Gao J, et al. Sci Signal (2013) pmid: 23550210', 'Include': 'true'}, {'number': '81', 'ReferenceId': '12931023', 'FullCitation': 'Tsuda H, et al. Oncology (2003) pmid: 12931023', 'Include': 'true'}, {'number': '82', 'ReferenceId': '18519763', 'FullCitation': 'Suehiro Y, et al. Clin. Cancer Res. (2008) pmid: 18519763', 'Include': 'true'}, {'number': '83', 'ReferenceId': '25608836', 'FullCitation': 'Shan W, et al. Tumour Biol. (2015) pmid: 25608836', 'Include': 'true'}, {'number': '84', 'ReferenceId': '24508840', 'FullCitation': 'Mhawech_Fauceglia P, et al. Gynecol. Oncol. (2014) pmid: 24508840', 'Include': 'true'}, {'number': '85', 'ReferenceId': '24037533', 'FullCitation': 'Michels J, et al. Oncogene (2014) pmid: 24037533', 'Include': 'true'}, {'number': '86', 'ReferenceId': '26510020', 'FullCitation': 'Mateo J, et al. N. Engl. J. Med. (2015) pmid: 26510020', 'Include': 'true'}, {'number': '87', 'ReferenceId': '31806540', 'FullCitation': 'Mateo J, et al. Lancet Oncol. (2019) pmid: 31806540', 'Include': 'true'}, {'number': '88', 'ReferenceId': '32086346', 'FullCitation': 'Abida W, et al. Clin. Cancer Res. (2020) pmid: 32086346', 'Include': 'true'}, {'number': '89', 'ReferenceId': '26282658', 'FullCitation': 'Bang YJ, et al. J. Clin. Oncol. (2015) pmid: 26282658', 'Include': 'true'}, {'number': '90', 'ReferenceId': '27079472', 'FullCitation': 'Olson D, et al. Clin Genitourin Cancer (2016) pmid: 27079472', 'Include': 'true'}, {'number': '91', 'ReferenceId': '20739657', 'FullCitation': 'Weston VJ, et al. Blood (2010) pmid: 20739657', 'Include': 'true'}, {'number': '92', 'ReferenceId': '20124459', 'FullCitation': 'Williamson CT, et al. Mol. Cancer Ther. (2010) pmid: 20124459', 'Include': 'true'}, {'number': '93', 'ReferenceId': '24252502', 'FullCitation': 'Gilardini Montani MS, et al. J. Exp. Clin. Cancer Res. (2013) pmid: 24252502', 'Include': 'true'}, {'number': '94', 'ReferenceId': '16556909', 'FullCitation': 'Bryant HE, et al. Nucleic Acids Res. (2006) pmid: 16556909', 'Include': 'true'}, {'number': '95', 'ReferenceId': '23729402', 'FullCitation': 'Ihnen M, et al. Mol. Cancer Ther. (2013) pmid: 23729402', 'Include': 'true'}, {'number': '96', 'ReferenceId': '22416035', 'FullCitation': 'Williamson CT, et al. EMBO Mol Med (2012) pmid: 22416035', 'Include': 'true'}, {'number': '97', 'ReferenceId': '24841718', 'FullCitation': 'Kubota E, et al. Cell Cycle (2014) pmid: 24841718', 'Include': 'true'}, {'number': '98', 'ReferenceId': '22833573', 'FullCitation': 'Huehls AM, et al. Mol. Pharmacol. (2012) pmid: 22833573', 'Include': 'true'}, {'number': '99', 'ReferenceId': '32988960', 'FullCitation': 'Yap TA, et al. Cancer Discov (2021) pmid: 32988960', 'Include': 'true'}, {'number': '100', 'ReferenceId': '25232030', 'FullCitation': 'Menezes DL, et al. Mol. Cancer Res. (2015) pmid: 25232030', 'Include': 'true'}, {'number': '101', 'ReferenceId': '26517239', 'FullCitation': 'Vendetti FP, et al. Oncotarget (2015) pmid: 26517239', 'Include': 'true'}, {'number': '102', 'ReferenceId': '28138034', 'FullCitation': 'Min A, et al. Mol. Cancer Ther. (2017) pmid: 28138034', 'Include': 'true'}, {'number': '103', 'ReferenceId': '26563132', 'FullCitation': 'Kwok M, et al. Blood (2016) pmid: 26563132', 'Include': 'true'}, {'number': '104', 'ReferenceId': '23761041', 'FullCitation': 'Riabinska A, et al. Sci Transl Med (2013) pmid: 23761041', 'Include': 'true'}, {'number': '105', 'ReferenceId': '29165669', 'FullCitation': 'Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669', 'Include': 'true'}, {'number': '106', 'ReferenceId': '26662178', 'FullCitation': 'van Os NJ, et al. Clin Genet (2016) pmid: 26662178', 'Include': 'true'}, {'number': '107', 'ReferenceId': '27884168', 'FullCitation': 'Rothblum_Oviatt C, et al. Orphanet J Rare Dis (2016) pmid: 27884168', 'Include': 'true'}, {'number': '108', 'ReferenceId': '25426837', 'FullCitation': 'Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837', 'Include': 'true'}, {'number': '109', 'ReferenceId': '25426838', 'FullCitation': 'Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838', 'Include': 'true'}, {'number': '110', 'ReferenceId': '25326804', 'FullCitation': 'Xie M, et al. Nat. Med. (2014) pmid: 25326804', 'Include': 'true'}, {'number': '111', 'ReferenceId': '28669404', 'FullCitation': 'Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404', 'Include': 'true'}, {'number': '112', 'ReferenceId': '29678827', 'FullCitation': 'Severson EA, et al. Blood (2018) pmid: 29678827', 'Include': 'true'}, {'number': '113', 'ReferenceId': '29420212', 'FullCitation': 'Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212', 'Include': 'true'}, {'number': '114', 'ReferenceId': '32269342', 'FullCitation': 'Chabon JJ, et al. Nature (2020) pmid: 32269342', 'Include': 'true'}, {'number': '115', 'ReferenceId': '31768066', 'FullCitation': 'Razavi P, et al. Nat. Med. (2019) pmid: 31768066', 'Include': 'true'}, {'number': '116', 'ReferenceId': '9808624', 'FullCitation': 'Xia Y, et al. Genes Dev. (1998) pmid: 9808624', 'Include': 'true'}, {'number': '117', 'ReferenceId': '12049732', 'FullCitation': 'Lu Z, et al. Mol. Cell (2002) pmid: 12049732', 'Include': 'true'}, {'number': '118', 'ReferenceId': '11782455', 'FullCitation': 'Schlesinger TK, et al. J. Biol. Chem. (2002) pmid: 11782455', 'Include': 'true'}, {'number': '119', 'ReferenceId': '18437204', 'FullCitation': 'Garcia_Closas M, et al. PLoS Genet. (2008) pmid: 18437204', 'Include': 'true'}, {'number': '120', 'ReferenceId': '21475998', 'FullCitation': 'Slattery ML, et al. Breast Cancer Res. Treat. (2011) pmid: 21475998', 'Include': 'true'}, {'number': '121', 'ReferenceId': '12228710', 'FullCitation': 'Yang H, et al. Science (2002) pmid: 12228710', 'Include': 'true'}, {'number': '122', 'ReferenceId': '21731065', 'FullCitation': 'Nat. Struct. Mol. Biol. (2011) pmid: 21731065', 'Include': 'true'}, {'number': '123', 'ReferenceId': '31492746', 'FullCitation': 'de Jonge MM, et al. Clin. Cancer Res. (2019) pmid: 31492746', 'Include': 'true'}, {'number': '124', 'ReferenceId': '11263938', 'FullCitation': 'Levine DA, et al. Gynecol. Oncol. (2001) pmid: 11263938', 'Include': 'true'}, {'number': '125', 'ReferenceId': '23562522', 'FullCitation': 'Segev Y, et al. Gynecol. Oncol. (2013) pmid: 23562522', 'Include': 'true'}, {'number': '126', 'ReferenceId': '25366685', 'FullCitation': 'Kaufman B, et al. J. Clin. Oncol. (2015) pmid: 25366685', 'Include': 'true'}, {'number': '127', 'ReferenceId': '20609467', 'FullCitation': 'Tutt A, et al. Lancet (2010) pmid: 20609467', 'Include': 'true'}, {'number': '128', 'ReferenceId': '28578601', 'FullCitation': 'Robson M, et al. N. Engl. J. Med. (2017) pmid: 28578601', 'Include': 'true'}, {'number': '129', 'ReferenceId': '27717299', 'FullCitation': 'Mirza MR, et al. N. Engl. J. Med. (2016) pmid: 27717299', 'Include': 'true'}, {'number': '130', 'ReferenceId': '23810788', 'FullCitation': 'Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788', 'Include': 'true'}, {'number': '131', 'ReferenceId': '27908594', 'FullCitation': 'Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594', 'Include': 'true'}, {'number': '132', 'ReferenceId': '27002934', 'FullCitation': 'Drew Y, et al. Br. J. Cancer (2016) pmid: 27002934', 'Include': 'true'}, {'number': '133', 'ReferenceId': '28754483', 'FullCitation': 'Pujade_Lauraine E, et al. Lancet Oncol. (2017) pmid: 28754483', 'Include': 'true'}, {'number': '134', 'ReferenceId': '27617661', 'FullCitation': 'Ledermann JA, et al. Lancet Oncol. (2016) pmid: 27617661', 'Include': 'true'}, {'number': '135', 'ReferenceId': '19553641', 'FullCitation': 'Fong PC, et al. N. Engl. J. Med. (2009) pmid: 19553641', 'Include': 'true'}, {'number': '136', 'ReferenceId': '20609468', 'FullCitation': 'Audeh MW, et al. Lancet (2010) pmid: 20609468', 'Include': 'true'}, {'number': '137', 'ReferenceId': '20406929', 'FullCitation': 'Fong PC, et al. J. Clin. Oncol. (2010) pmid: 20406929', 'Include': 'true'}, {'number': '138', 'ReferenceId': '21862407', 'FullCitation': 'Gelmon KA, et al. Lancet Oncol. (2011) pmid: 21862407', 'Include': 'true'}, {'number': '139', 'ReferenceId': '22203755', 'FullCitation': 'Kaye SB, et al. J. Clin. Oncol. (2012) pmid: 22203755', 'Include': 'true'}, {'number': '140', 'ReferenceId': '26723501', 'FullCitation': 'Domchek SM, et al. Gynecol. Oncol. (2016) pmid: 26723501', 'Include': 'true'}, {'number': '141', 'ReferenceId': '30345884', 'FullCitation': 'Moore K, et al. N. Engl. J. Med. (2018) pmid: 30345884', 'Include': 'true'}, {'number': '142', 'ReferenceId': '31157963', 'FullCitation': 'Golan T, et al. N. Engl. J. Med. (2019) pmid: 31157963', 'Include': 'true'}, {'number': '143', 'ReferenceId': '29252124', 'FullCitation': 'Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124', 'Include': 'true'}, {'number': '144', 'ReferenceId': '31299005', 'FullCitation': 'Saito YD, et al. Cancer Treat Res Commun (2018) pmid: 31299005', 'Include': 'true'}, {'number': '145', 'ReferenceId': '31721781', 'FullCitation': 'Pouliot GP, et al. PLoS ONE (2019) pmid: 31721781', 'Include': 'true'}, {'number': '146', 'ReferenceId': '27993965', 'FullCitation': 'Kim H, et al. Clin. Cancer Res. (2017) pmid: 27993965', 'Include': 'true'}, {'number': '147', 'ReferenceId': '29605721', 'FullCitation': 'Jin J, et al. Neoplasia (2018) pmid: 29605721', 'Include': 'true'}, {'number': '148', 'ReferenceId': '25964244', 'FullCitation': 'Do K, et al. J. Clin. Oncol. (2015) pmid: 25964244', 'Include': 'true'}, {'number': '149', 'ReferenceId': '25847936', 'FullCitation': 'Isakoff SJ, et al. J. Clin. Oncol. (2015) pmid: 25847936', 'Include': 'true'}, {'number': '150', 'ReferenceId': '22406760', 'FullCitation': 'Dann RB, et al. Gynecol. Oncol. (2012) pmid: 22406760', 'Include': 'true'}, {'number': '151', 'ReferenceId': '18559613', 'FullCitation': 'Evers B, et al. Clin. Cancer Res. (2008) pmid: 18559613', 'Include': 'true'}, {'number': '152', 'ReferenceId': '17656556', 'FullCitation': 'Soares DG, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17656556', 'Include': 'true'}, {'number': '153', 'ReferenceId': '27561088', 'FullCitation': 'Miolo G, et al. Cancer Biol. Ther. (2016) pmid: 27561088', 'Include': 'true'}, {'number': '154', 'ReferenceId': '28467918', 'FullCitation': 'Ghouadni A, et al. Breast (2017) pmid: 28467918', 'Include': 'true'}, {'number': '155', 'ReferenceId': '28626402', 'FullCitation': 'Case Rep Oncol () pmid: 28626402', 'Include': 'true'}, {'number': '156', 'ReferenceId': '31924332', 'FullCitation': 'Monk BJ, et al. Gynecol. Oncol. (2020) pmid: 31924332', 'Include': 'true'}, {'number': '157', 'ReferenceId': '26933761', 'FullCitation': 'Harnicek D, et al. Int. J. Cancer (2016) pmid: 26933761', 'Include': 'true'}, {'number': '158', 'ReferenceId': '30240327', 'FullCitation': 'Cruz C, et al. J. Clin. Oncol. (2018) pmid: 30240327', 'Include': 'true'}, {'number': '159', 'ReferenceId': '28368437', 'FullCitation': 'Poveda A, et al. Ann. Oncol. (2017) pmid: 28368437', 'Include': 'true'}, {'number': '160', 'ReferenceId': '7545954', 'FullCitation': 'Miki Y, et al. Science (1994) pmid: 7545954', 'Include': 'true'}, {'number': '161', 'ReferenceId': '8524414', 'FullCitation': 'Wooster R, et al. Nature () pmid: 8524414', 'Include': 'true'}, {'number': '162', 'ReferenceId': '14576434', 'FullCitation': 'King MC, et al. Science (2003) pmid: 14576434', 'Include': 'true'}, {'number': '163', 'ReferenceId': '16369438', 'FullCitation': 'MedGenMed (2005) pmid: 16369438', 'Include': 'true'}, {'number': '164', 'ReferenceId': '7907678', 'FullCitation': 'Ford D, et al. Lancet (1994) pmid: 7907678', 'Include': 'true'}, {'number': '165', 'ReferenceId': '9042908', 'FullCitation': 'Whittemore AS, et al. Am. J. Hum. Genet. (1997) pmid: 9042908', 'Include': 'true'}, {'number': '166', 'ReferenceId': '8635102', 'FullCitation': 'Claus EB, et al. Cancer (1996) pmid: 8635102', 'Include': 'true'}, {'number': '167', 'ReferenceId': '9145676', 'FullCitation': 'Struewing JP, et al. N. Engl. J. Med. (1997) pmid: 9145676', 'Include': 'true'}, {'number': '168', 'ReferenceId': '8841192', 'FullCitation': 'Oddoux C, et al. Nat. Genet. (1996) pmid: 8841192', 'Include': 'true'}, {'number': '169', 'ReferenceId': '19241424', 'FullCitation': 'Hall MJ, et al. Cancer (2009) pmid: 19241424', 'Include': 'true'}, {'number': '170', 'ReferenceId': '16203743', 'FullCitation': 'Huang G, et al. Hum. Mol. Genet. (2005) pmid: 16203743', 'Include': 'true'}, {'number': '171', 'ReferenceId': '19242095', 'FullCitation': 'Banck MS, et al. Epigenetics (2009) pmid: 19242095', 'Include': 'true'}, {'number': '172', 'ReferenceId': '9671742', 'FullCitation': 'Collins C, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9671742', 'Include': 'true'}, {'number': '173', 'ReferenceId': '11245413', 'FullCitation': 'Nonet GH, et al. Cancer Res. (2001) pmid: 11245413', 'Include': 'true'}, {'number': '174', 'ReferenceId': '17266044', 'FullCitation': 'Li P, et al. Int. J. Cancer (2007) pmid: 17266044', 'Include': 'true'}, {'number': '175', 'ReferenceId': '22593193', 'FullCitation': 'Vendrell JA, et al. Cancer Res. (2012) pmid: 22593193', 'Include': 'true'}, {'number': '176', 'ReferenceId': '25031722', 'FullCitation': 'Li J, et al. Int J Clin Exp Pathol (2014) pmid: 25031722', 'Include': 'true'}, {'number': '177', 'ReferenceId': '22843878', 'FullCitation': 'Rahman MT, et al. Anticancer Res. (2012) pmid: 22843878', 'Include': 'true'}, {'number': '178', 'ReferenceId': '15701848', 'FullCitation': 'Yang SH, et al. Clin. Cancer Res. (2005) pmid: 15701848', 'Include': 'true'}, {'number': '179', 'ReferenceId': '25202062', 'FullCitation': 'Shida A, et al. Anticancer Res. (2014) pmid: 25202062', 'Include': 'true'}, {'number': '180', 'ReferenceId': '15476264', 'FullCitation': 'Rooney PH, et al. J. Pathol. (2004) pmid: 15476264', 'Include': 'true'}, {'number': '181', 'ReferenceId': '22815235', 'FullCitation': 'Szczyrba J, et al. Int. J. Cancer (2013) pmid: 22815235', 'Include': 'true'}, {'number': '182', 'ReferenceId': '24853183', 'FullCitation': 'Geppert CI, et al. Br. J. Cancer (2014) pmid: 24853183', 'Include': 'true'}, {'number': '183', 'ReferenceId': '15897688', 'FullCitation': 'Toncheva D, et al. Tumour Biol. () pmid: 15897688', 'Include': 'true'}, {'number': '184', 'ReferenceId': '21483406', 'FullCitation': 'Mao XG, et al. Lab. Invest. (2011) pmid: 21483406', 'Include': 'true'}, {'number': '185', 'ReferenceId': '18193277', 'FullCitation': 'Schipf A, et al. Virchows Arch. (2008) pmid: 18193277', 'Include': 'true'}, {'number': '186', 'ReferenceId': '17572303', 'FullCitation': 'Quinlan KG, et al. Biochim. Biophys. Acta (2007) pmid: 17572303', 'Include': 'true'}, {'number': '187', 'ReferenceId': '17259635', 'FullCitation': 'Krig SR, et al. J. Biol. Chem. (2007) pmid: 17259635', 'Include': 'true'}, {'number': '188', 'ReferenceId': '17130829', 'FullCitation': 'Cowger JJ, et al. Oncogene (2007) pmid: 17130829', 'Include': 'true'}, {'number': '189', 'ReferenceId': '20661224', 'FullCitation': 'Krig SR, et al. Oncogene (2010) pmid: 20661224', 'Include': 'true'}, {'number': '190', 'ReferenceId': '21059223', 'FullCitation': 'Thollet A, et al. Mol. Cancer (2010) pmid: 21059223', 'Include': 'true'}, {'number': '191', 'ReferenceId': '24973012', 'FullCitation': 'Nguyen NT, et al. Mol Oncol (2014) pmid: 24973012', 'Include': 'true'}, {'number': '192', 'ReferenceId': '24962896', 'FullCitation': 'Frietze S, et al. BMC Genomics (2014) pmid: 24962896', 'Include': 'true'}, {'number': '193', 'ReferenceId': '22728437', 'FullCitation': 'Littlepage LE, et al. Cancer Discov (2012) pmid: 22728437', 'Include': 'true'}, {'number': '194', 'ReferenceId': '15769748', 'FullCitation': 'Clapéron A, et al. J. Biol. Chem. (2005) pmid: 15769748', 'Include': 'true'}, {'number': '195', 'ReferenceId': '19563753', 'FullCitation': 'Phillips JE, et al. Cell (2009) pmid: 19563753', 'Include': 'true'}, {'number': '196', 'ReferenceId': '19568426', 'FullCitation': 'Gombert WM, et al. PLoS ONE (2009) pmid: 19568426', 'Include': 'true'}, {'number': '197', 'ReferenceId': '20101205', 'FullCitation': 'Soto_Reyes E, et al. Oncogene (2010) pmid: 20101205', 'Include': 'true'}, {'number': '198', 'ReferenceId': '21296871', 'FullCitation': 'Woloszynska_Read A, et al. Clin. Cancer Res. (2011) pmid: 21296871', 'Include': 'true'}, {'number': '199', 'ReferenceId': '24794443', 'FullCitation': 'Kemp CJ, et al. Cell Rep (2014) pmid: 24794443', 'Include': 'true'}, {'number': '200', 'ReferenceId': '23908591', 'FullCitation': 'Méndez_Catalá CF, et al. Neoplasia (2013) pmid: 23908591', 'Include': 'true'}, {'number': '201', 'ReferenceId': '23553099', 'FullCitation': 'Tiffen JC, et al. Int. J. Cancer (2013) pmid: 23553099', 'Include': 'true'}, {'number': '202', 'ReferenceId': '10699051', 'FullCitation': 'Petrij F, et al. J. Med. Genet. (2000) pmid: 10699051', 'Include': 'true'}, {'number': '203', 'ReferenceId': '8782817', 'FullCitation': 'Borrow J, et al. Nat. Genet. (1996) pmid: 8782817', 'Include': 'true'}, {'number': '204', 'ReferenceId': '27537276', 'FullCitation': 'Kao YC, et al. Genes Chromosomes Cancer (2017) pmid: 27537276', 'Include': 'true'}, {'number': '205', 'ReferenceId': '31932680', 'FullCitation': 'Hofvander J, et al. Mod. Pathol. (2020) pmid: 31932680', 'Include': 'true'}, {'number': '206', 'ReferenceId': '25735316', 'FullCitation': 'Grasso CS, et al. Ann. Oncol. (2015) pmid: 25735316', 'Include': 'true'}, {'number': '207', 'ReferenceId': '25790293', 'FullCitation': 'Ma X, et al. Nat Commun (2015) pmid: 25790293', 'Include': 'true'}, {'number': '208', 'ReferenceId': '25713363', 'FullCitation': 'Green MR, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25713363', 'Include': 'true'}, {'number': '209', 'ReferenceId': '25027518', 'FullCitation': 'Loeffler M, et al. Leukemia (2015) pmid: 25027518', 'Include': 'true'}, {'number': '210', 'ReferenceId': '18528428', 'FullCitation': 'Gervais C, et al. Leukemia (2008) pmid: 18528428', 'Include': 'true'}, {'number': '211', 'ReferenceId': '19194466', 'FullCitation': 'Haferlach T, et al. Leukemia (2009) pmid: 19194466', 'Include': 'true'}, {'number': '212', 'ReferenceId': '25671298', 'FullCitation': 'Mensah AA, et al. Oncotarget (2015) pmid: 25671298', 'Include': 'true'}, {'number': '213', 'ReferenceId': '16118227', 'FullCitation': 'Sun XJ, et al. J. Biol. Chem. (2005) pmid: 16118227', 'Include': 'true'}, {'number': '214', 'ReferenceId': '9700202', 'FullCitation': 'Faber PW, et al. Hum. Mol. Genet. (1998) pmid: 9700202', 'Include': 'true'}, {'number': '215', 'ReferenceId': '19698110', 'FullCitation': 'Al Sarakbi W, et al. BMC Cancer (2009) pmid: 19698110', 'Include': 'true'}, {'number': '216', 'ReferenceId': '21248752', 'FullCitation': 'Varela I, et al. Nature (2011) pmid: 21248752', 'Include': 'true'}, {'number': '217', 'ReferenceId': '29522714', 'FullCitation': 'Chen Z, et al. Biochem Biophys Res Commun (2018) pmid: 29522714', 'Include': 'true'}, {'number': '218', 'ReferenceId': '32202636', 'FullCitation': 'Chen BY, et al. Blood (2020) pmid: 32202636', 'Include': 'true'}, {'number': '219', 'ReferenceId': '19935675', 'FullCitation': 'Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675', 'Include': 'true'}, {'number': '220', 'ReferenceId': '18410249', 'FullCitation': 'Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249', 'Include': 'true'}, {'number': '221', 'ReferenceId': '12826609', 'FullCitation': 'Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609', 'Include': 'true'}, {'number': '222', 'ReferenceId': '20978130', 'FullCitation': 'Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130', 'Include': 'true'}, {'number': '223', 'ReferenceId': '28472496', 'FullCitation': 'Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496', 'Include': 'true'}, {'number': '224', 'ReferenceId': '17690113', 'FullCitation': 'Yamada H, et al. Carcinogenesis (2007) pmid: 17690113', 'Include': 'true'}, {'number': '225', 'ReferenceId': '23932335', 'FullCitation': 'Trovik J, et al. Eur. J. Cancer (2013) pmid: 23932335', 'Include': 'true'}, {'number': '226', 'ReferenceId': '22678923', 'FullCitation': 'Wild PJ, et al. EMBO Mol Med (2012) pmid: 22678923', 'Include': 'true'}, {'number': '227', 'ReferenceId': '20006376', 'FullCitation': 'Lee EJ, et al. Gynecol. Oncol. (2010) pmid: 20006376', 'Include': 'true'}, {'number': '228', 'ReferenceId': '20107315', 'FullCitation': 'Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315', 'Include': 'true'}, {'number': '229', 'ReferenceId': '21799033', 'FullCitation': 'Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033', 'Include': 'true'}, {'number': '230', 'ReferenceId': '21389100', 'FullCitation': 'Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100', 'Include': 'true'}, {'number': '231', 'ReferenceId': '25504633', 'FullCitation': 'Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633', 'Include': 'true'}, {'number': '232', 'ReferenceId': '12489850', 'FullCitation': 'Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850', 'Include': 'true'}, {'number': '233', 'ReferenceId': '11713371', 'FullCitation': 'Xu L, et al. Mol. Med. (2001) pmid: 11713371', 'Include': 'true'}, {'number': '234', 'ReferenceId': '23470564', 'FullCitation': 'Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564', 'Include': 'true'}, {'number': '235', 'ReferenceId': '25240597', 'FullCitation': 'Kim SS, et al. Nanomedicine (2015) pmid: 25240597', 'Include': 'true'}, {'number': '236', 'ReferenceId': '27357628', 'FullCitation': 'Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628', 'Include': 'true'}, {'number': '237', 'ReferenceId': '27601554', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554', 'Include': 'true'}, {'number': '238', 'ReferenceId': '27998224', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224', 'Include': 'true'}, {'number': '239', 'ReferenceId': '31315834', 'FullCitation': 'Lee J, et al. Cancer Discov (2019) pmid: 31315834', 'Include': 'true'}, {'number': '240', 'ReferenceId': '29535125', 'FullCitation': 'Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125', 'Include': 'true'}, {'number': '241', 'ReferenceId': '22446188', 'FullCitation': 'Ma CX, et al. J. Clin. Invest. (2012) pmid: 22446188', 'Include': 'true'}, {'number': '242', 'ReferenceId': '22965953', 'FullCitation': 'Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953', 'Include': 'true'}, {'number': '243', 'ReferenceId': '26086967', 'FullCitation': 'Mohell N, et al. Cell Death Dis (2015) pmid: 26086967', 'Include': 'true'}, {'number': '244', 'ReferenceId': '27179933', 'FullCitation': 'Fransson Å, et al. J Ovarian Res (2016) pmid: 27179933', 'Include': 'true'}, {'number': '245', 'ReferenceId': '30975914', 'FullCitation': 'Boudny M, et al. Haematologica (2019) pmid: 30975914', 'Include': 'true'}, {'number': '246', 'ReferenceId': '28062704', 'FullCitation': 'Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704', 'Include': 'true'}, {'number': '247', 'ReferenceId': '30127241', 'FullCitation': 'Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241', 'Include': 'true'}, {'number': '248', 'ReferenceId': '26014290', 'FullCitation': 'Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290', 'Include': 'true'}, {'number': '249', 'ReferenceId': '23355100', 'FullCitation': 'Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100', 'Include': 'true'}, {'number': '250', 'ReferenceId': '11219776', 'FullCitation': 'Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776', 'Include': 'true'}, {'number': '251', 'ReferenceId': '9006316', 'FullCitation': 'Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316', 'Include': 'true'}, {'number': '252', 'ReferenceId': '19204208', 'FullCitation': 'Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208', 'Include': 'true'}, {'number': '253', 'ReferenceId': '12672316', 'FullCitation': 'Lalloo F, et al. Lancet (2003) pmid: 12672316', 'Include': 'true'}, {'number': '254', 'ReferenceId': '31050713', 'FullCitation': 'Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713', 'Include': 'true'}, {'number': '255', 'ReferenceId': '30504320', 'FullCitation': 'Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320', 'Include': 'true'}, {'number': '256', 'ReferenceId': '15094156', 'FullCitation': 'Pearce ST, et al. Crit. Rev. Oncol. Hematol. (2004) pmid: 15094156', 'Include': 'true'}, {'number': '257', 'ReferenceId': '23319822', 'FullCitation': 'Wik E, et al. Clin. Cancer Res. (2013) pmid: 23319822', 'Include': 'true'}, {'number': '258', 'ReferenceId': '24023309', 'FullCitation': 'Rahman MT, et al. Anticancer Res. (2013) pmid: 24023309', 'Include': 'true'}, {'number': '259', 'ReferenceId': '28560298', 'FullCitation': 'Straubhar A, et al. Gynecol Oncol Rep (2017) pmid: 28560298', 'Include': 'true'}, {'number': '260', 'ReferenceId': '24076063', 'FullCitation': 'Thangavelu A, et al. Gynecol. Oncol. (2013) pmid: 24076063', 'Include': 'true'}, {'number': '261', 'ReferenceId': '28221866', 'FullCitation': 'Gershenson DM, et al. J. Clin. Oncol. (2017) pmid: 28221866', 'Include': 'true'}, {'number': '262', 'ReferenceId': '24925537', 'FullCitation': 'Esfahani K, et al. BMJ Case Rep (2014) pmid: 24925537', 'Include': 'true'}, {'number': '263', 'ReferenceId': '18457865', 'FullCitation': 'Ramirez PT, et al. Gynecol. Oncol. (2008) pmid: 18457865', 'Include': 'true'}, {'number': '264', 'ReferenceId': '30345905', 'FullCitation': 'Turner NC, et al. N. Engl. J. Med. (2018) pmid: 30345905', 'Include': 'true'}, {'number': '265', 'ReferenceId': '27269946', 'FullCitation': 'Fribbens C, et al. J. Clin. Oncol. (2016) pmid: 27269946', 'Include': 'true'}, {'number': '266', 'ReferenceId': '27174596', 'FullCitation': 'Spoerke JM, et al. Nat Commun (2016) pmid: 27174596', 'Include': 'true'}, {'number': '267', 'ReferenceId': '30987772', 'FullCitation': 'Gaillard SL, et al. Gynecol. Oncol. (2019) pmid: 30987772', 'Include': 'true'}, {'number': '268', 'ReferenceId': '26560360', 'FullCitation': 'Schiavon G, et al. Sci Transl Med (2015) pmid: 26560360', 'Include': 'true'}, {'number': '269', 'ReferenceId': '27532364', 'FullCitation': 'Chandarlapaty S, et al. JAMA Oncol (2016) pmid: 27532364', 'Include': 'true'}, {'number': '270', 'ReferenceId': '30828692', 'FullCitation': 'Stover EH, et al. JCO Precis Oncol (2018) pmid: 30828692', 'Include': 'true'}, {'number': '271', 'ReferenceId': '12906785', 'FullCitation': 'Tee AR, et al. Curr. Biol. (2003) pmid: 12906785', 'Include': 'true'}, {'number': '272', 'ReferenceId': '12869586', 'FullCitation': 'Inoki K, et al. Genes Dev. (2003) pmid: 12869586', 'Include': 'true'}, {'number': '273', 'ReferenceId': '10915759', 'FullCitation': 'Miloloza A, et al. Hum. Mol. Genet. (2000) pmid: 10915759', 'Include': 'true'}, {'number': '274', 'ReferenceId': '20547222', 'FullCitation': 'Hoogeveen_Westerveld M, et al. Biochim. Biophys. Acta (2010) pmid: 20547222', 'Include': 'true'}, {'number': '275', 'ReferenceId': '11741833', 'FullCitation': 'Hodges AK, et al. Hum. Mol. Genet. (2001) pmid: 11741833', 'Include': 'true'}, {'number': '276', 'ReferenceId': '33575875', 'FullCitation': 'Mallela K, et al. Mol Cell Biochem (2021) pmid: 33575875', 'Include': 'true'}, {'number': '277', 'ReferenceId': '33727259', 'FullCitation': 'Adib E, et al. Clin Cancer Res (2021) pmid: 33727259', 'Include': 'true'}, {'number': '278', 'ReferenceId': '31653662', 'FullCitation': 'Nassar AH, et al. Mol Cancer Ther (2020) pmid: 31653662', 'Include': 'true'}, {'number': '279', 'ReferenceId': '30327302', 'FullCitation': 'Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302', 'Include': 'true'}, {'number': '280', 'ReferenceId': '25796537', 'FullCitation': 'Ali SM, et al. Eur. Urol. (2015) pmid: 25796537', 'Include': 'true'}, {'number': '281', 'ReferenceId': '26859683', 'FullCitation': 'Lim SM, et al. Oncotarget (2016) pmid: 26859683', 'Include': 'true'}, {'number': '282', 'ReferenceId': '26831717', 'FullCitation': 'Kwiatkowski DJ, et al. Clin. Cancer Res. (2016) pmid: 26831717', 'Include': 'true'}, {'number': '283', 'ReferenceId': '30256787', 'FullCitation': 'Hamieh L, et al. PLoS Genet (2018) pmid: 30256787', 'Include': 'true'}, {'number': '284', 'ReferenceId': '31335987', 'FullCitation': 'Roldan_Romero JM, et al. Int J Cancer (2020) pmid: 31335987', 'Include': 'true'}, {'number': '285', 'ReferenceId': '2039135', 'FullCitation': 'Ann. N. Y. Acad. Sci. (1991) pmid: 2039135', 'Include': 'true'}, {'number': '286', 'ReferenceId': '9242607', 'FullCitation': 'van Slegtenhorst M, et al. Science (1997) pmid: 9242607', 'Include': 'true'}, {'number': '287', 'ReferenceId': '17005952', 'FullCitation': 'Crino PB, et al. N. Engl. J. Med. (2006) pmid: 17005952', 'Include': 'true'}, {'number': '288', 'ReferenceId': '18722871', 'FullCitation': 'Curatolo P, et al. Lancet (2008) pmid: 18722871', 'Include': 'true'}, {'number': '289', 'ReferenceId': '15109494', 'FullCitation': 'Tarsounas M, et al. Cell (2004) pmid: 15109494', 'Include': 'true'}, {'number': '290', 'ReferenceId': '21821141', 'FullCitation': 'Suwaki N, et al. Semin. Cell Dev. Biol. (2011) pmid: 21821141', 'Include': 'true'}, {'number': '291', 'ReferenceId': '15162012', 'FullCitation': 'Sasaki MS, et al. Cytogenet. Genome Res. (2004) pmid: 15162012', 'Include': 'true'}, {'number': '292', 'ReferenceId': '15781618', 'FullCitation': 'Smiraldo PG, et al. Cancer Res. (2005) pmid: 15781618', 'Include': 'true'}, {'number': '293', 'ReferenceId': '27734215', 'FullCitation': 'Graffeo R, et al. Breast Cancer Res. Treat. (2016) pmid: 27734215', 'Include': 'true'}, {'number': '294', 'ReferenceId': '22415235', 'FullCitation': 'Osher DJ, et al. Br. J. Cancer (2012) pmid: 22415235', 'Include': 'true'}, {'number': '295', 'ReferenceId': '22652533', 'FullCitation': 'Pelttari LM, et al. J. Med. Genet. (2012) pmid: 22652533', 'Include': 'true'}, {'number': '296', 'ReferenceId': '24130102', 'FullCitation': 'Gutiérrez_Enríquez S, et al. Int. J. Cancer (2014) pmid: 24130102', 'Include': 'true'}, {'number': '297', 'ReferenceId': '21822267', 'FullCitation': 'Loveday C, et al. Nat. Genet. (2011) pmid: 21822267', 'Include': 'true'}, {'number': '298', 'ReferenceId': '26261251', 'FullCitation': 'Song H, et al. J. Clin. Oncol. (2015) pmid: 26261251', 'Include': 'true'}, {'number': '299', 'ReferenceId': '28646019', 'FullCitation': 'Rivera B, et al. Cancer Res. (2017) pmid: 28646019', 'Include': 'true'}, {'number': '300', 'ReferenceId': '28588062', 'FullCitation': 'Kondrashova O, et al. Cancer Discov (2017) pmid: 28588062', 'Include': 'true'}, {'number': '301', 'ReferenceId': '16522646', 'FullCitation': 'Hinz JM, et al. Nucleic Acids Res. (2006) pmid: 16522646', 'Include': 'true'}, {'number': '302', 'ReferenceId': '16717288', 'FullCitation': 'Wiese C, et al. Nucleic Acids Res. (2006) pmid: 16717288', 'Include': 'true'}, {'number': '303', 'ReferenceId': '22986143', 'FullCitation': 'Wickramanayake A, et al. Gynecol. Oncol. (2012) pmid: 22986143', 'Include': 'true'}, {'number': '304', 'ReferenceId': '26057125', 'FullCitation': 'Janatova M, et al. PLoS ONE (2015) pmid: 26057125', 'Include': 'true'}, {'number': '305', 'ReferenceId': '28591191', 'FullCitation': 'Stafford JL, et al. PLoS ONE (2017) pmid: 28591191', 'Include': 'true'}, {'number': '306', 'ReferenceId': '30111881', 'FullCitation': 'Konstanta I, et al. J. Hum. Genet. (2018) pmid: 30111881', 'Include': 'true'}, {'number': '307', 'ReferenceId': '30165555', 'FullCitation': 'Chen X, et al. Ann. Oncol. (2018) pmid: 30165555', 'Include': 'true'}, {'number': '308', 'ReferenceId': '17510365', 'FullCitation': 'Major MB, et al. Science (2007) pmid: 17510365', 'Include': 'true'}, {'number': '309', 'ReferenceId': '19079258', 'FullCitation': 'Jenkins ZA, et al. Nat. Genet. (2009) pmid: 19079258', 'Include': 'true'}, {'number': '310', 'ReferenceId': '20209645', 'FullCitation': 'Perdu B, et al. J. Bone Miner. Res. (2010) pmid: 20209645', 'Include': 'true'}, {'number': '311', 'ReferenceId': '18391980', 'FullCitation': 'Perotti D, et al. Oncogene (2008) pmid: 18391980', 'Include': 'true'}, {'number': '312', 'ReferenceId': '18311776', 'FullCitation': 'Ruteshouser EC, et al. Genes Chromosomes Cancer (2008) pmid: 18311776', 'Include': 'true'}, {'number': '313', 'ReferenceId': '17204608', 'FullCitation': 'Rivera MN, et al. Science (2007) pmid: 17204608', 'Include': 'true'}, {'number': '314', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '315', 'ReferenceId': '23622243', 'FullCitation': 'Li F, et al. Cell (2013) pmid: 23622243', 'Include': 'true'}, {'number': '316', 'ReferenceId': '21720545', 'FullCitation': 'Wu H, et al. PLoS ONE (2011) pmid: 21720545', 'Include': 'true'}, {'number': '317', 'ReferenceId': '23391514', 'FullCitation': 'Edelbrock MA, et al. Mutat. Res. () pmid: 23391514', 'Include': 'true'}, {'number': '318', 'ReferenceId': '11709755', 'FullCitation': 'Berends MJ, et al. Am. J. Hum. Genet. (2002) pmid: 11709755', 'Include': 'true'}, {'number': '319', 'ReferenceId': '17531815', 'FullCitation': 'Warren JJ, et al. Mol. Cell (2007) pmid: 17531815', 'Include': 'true'}, {'number': '320', 'ReferenceId': '22277660', 'FullCitation': 'Geng H, et al. J. Biol. Chem. (2012) pmid: 22277660', 'Include': 'true'}, {'number': '321', 'ReferenceId': '21642682', 'FullCitation': 'Bonadona V, et al. JAMA (2011) pmid: 21642682', 'Include': 'true'}, {'number': '322', 'ReferenceId': '20028993', 'FullCitation': 'Baglietto L, et al. J. Natl. Cancer Inst. (2010) pmid: 20028993', 'Include': 'true'}, {'number': '323', 'ReferenceId': '23765559', 'FullCitation': 'Lu KH, et al. Fam. Cancer (2013) pmid: 23765559', 'Include': 'true'}, {'number': '324', 'ReferenceId': '21742371', 'FullCitation': 'Shih KK, et al. Gynecol. Oncol. (2011) pmid: 21742371', 'Include': 'true'}, {'number': '325', 'ReferenceId': '25504677', 'FullCitation': 'Joly MO, et al. Hum. Mutat. (2015) pmid: 25504677', 'Include': 'true'}, {'number': '326', 'ReferenceId': '25255306', 'FullCitation': 'Pritchard CC, et al. Nat Commun (2014) pmid: 25255306', 'Include': 'true'}, {'number': '327', 'ReferenceId': '25117503', 'FullCitation': 'Rosty C, et al. Fam. Cancer (2014) pmid: 25117503', 'Include': 'true'}, {'number': '328', 'ReferenceId': '25636458', 'FullCitation': 'McConechy MK, et al. Gynecol. Oncol. (2015) pmid: 25636458', 'Include': 'true'}, {'number': '329', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '330', 'ReferenceId': '23169436', 'FullCitation': 'Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436', 'Include': 'true'}, {'number': '331', 'ReferenceId': '25392179', 'FullCitation': 'Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179', 'Include': 'true'}, {'number': '332', 'ReferenceId': '19466295', 'FullCitation': 'Silva FC, et al. Sao Paulo Med J (2009) pmid: 19466295', 'Include': 'true'}, {'number': '333', 'ReferenceId': '16083711', 'FullCitation': 'Raevaara TE, et al. Gastroenterology (2005) pmid: 16083711', 'Include': 'true'}, {'number': '334', 'ReferenceId': '17920897', 'FullCitation': 'Kastrinos F, et al. Semin. Oncol. (2007) pmid: 17920897', 'Include': 'true'}, {'number': '335', 'ReferenceId': '24978665', 'FullCitation': 'Sehgal R, et al. Genes (Basel) (2014) pmid: 24978665', 'Include': 'true'}, {'number': '336', 'ReferenceId': '16136383', 'FullCitation': 'Fam. Cancer (2005) pmid: 16136383', 'Include': 'true'}, {'number': '337', 'ReferenceId': '18709565', 'FullCitation': 'Wimmer K, et al. Hum. Genet. (2008) pmid: 18709565', 'Include': 'true'}, {'number': '338', 'ReferenceId': '24737826', 'FullCitation': 'Wimmer K, et al. J. Med. Genet. (2014) pmid: 24737826', 'Include': 'true'}, {'number': '339', 'ReferenceId': '17259933', 'FullCitation': 'Scott RH, et al. Nat Clin Pract Oncol (2007) pmid: 17259933', 'Include': 'true'}, {'number': '340', 'ReferenceId': '20015892', 'FullCitation': 'Ripperger T, et al. Haematologica (2010) pmid: 20015892', 'Include': 'true'}, {'number': '341', 'ReferenceId': '26544533', 'FullCitation': 'Baris HN, et al. Pediatr Blood Cancer (2016) pmid: 26544533', 'Include': 'true'}, {'number': '342', 'ReferenceId': '23365135', 'FullCitation': 'Ooi A, et al. Cancer Res. (2013) pmid: 23365135', 'Include': 'true'}, {'number': '343', 'ReferenceId': '23912815', 'FullCitation': 'Genschik P, et al. EMBO J. (2013) pmid: 23912815', 'Include': 'true'}, {'number': '344', 'ReferenceId': '23308193', 'FullCitation': 'Grau L, et al. PLoS ONE (2013) pmid: 23308193', 'Include': 'true'}, {'number': '345', 'ReferenceId': '20978349', 'FullCitation': 'Kossatz U, et al. J. Clin. Invest. (2010) pmid: 20978349', 'Include': 'true'}, {'number': '346', 'ReferenceId': '18418043', 'FullCitation': 'Huang CH, et al. Cell Cycle (2008) pmid: 18418043', 'Include': 'true'}, {'number': '347', 'ReferenceId': '20530665', 'FullCitation': 'Taniguchi CM, et al. Cancer Res. (2010) pmid: 20530665', 'Include': 'true'}, {'number': '348', 'ReferenceId': '16679293', 'FullCitation': 'Luo J, et al. Cell Metab. (2006) pmid: 16679293', 'Include': 'true'}, {'number': '349', 'ReferenceId': '14504291', 'FullCitation': 'Ueki K, et al. J. Biol. Chem. (2003) pmid: 14504291', 'Include': 'true'}, {'number': '350', 'ReferenceId': '11781359', 'FullCitation': 'Mauvais_Jarvis F, et al. J. Clin. Invest. (2002) pmid: 11781359', 'Include': 'true'}, {'number': '351', 'ReferenceId': '28630349', 'FullCitation': 'Thorpe LM, et al. Proc. Natl. Acad. Sci. U.S.A. (2017) pmid: 28630349', 'Include': 'true'}, {'number': '352', 'ReferenceId': '30755611', 'FullCitation': 'Li X, et al. Nat Commun (2019) pmid: 30755611', 'Include': 'true'}, {'number': '353', 'ReferenceId': '16006513', 'FullCitation': 'Luo J, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 16006513', 'Include': 'true'}, {'number': '354', 'ReferenceId': '19962665', 'FullCitation': 'Jaiswal BS, et al. Cancer Cell (2009) pmid: 19962665', 'Include': 'true'}, {'number': '355', 'ReferenceId': '21984976', 'FullCitation': 'Cheung LW, et al. Cancer Discov (2011) pmid: 21984976', 'Include': 'true'}, {'number': '356', 'ReferenceId': '24651434', 'FullCitation': 'Ko HR, et al. Cell Death Dis (2014) pmid: 24651434', 'Include': 'true'}, {'number': '357', 'ReferenceId': '23166678', 'FullCitation': 'Quayle SN, et al. PLoS ONE (2012) pmid: 23166678', 'Include': 'true'}, {'number': '358', 'ReferenceId': '20713702', 'FullCitation': 'Sun M, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20713702', 'Include': 'true'}, {'number': '359', 'ReferenceId': '19915146', 'FullCitation': 'Wu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19915146', 'Include': 'true'}, {'number': '360', 'ReferenceId': '21478295', 'FullCitation': 'Urick ME, et al. Cancer Res. (2011) pmid: 21478295', 'Include': 'true'}, {'number': '361', 'ReferenceId': '18079394', 'FullCitation': 'Huang CH, et al. Science (2007) pmid: 18079394', 'Include': 'true'}, {'number': '362', 'ReferenceId': '16917505', 'FullCitation': 'Bousquet C, et al. EMBO J. (2006) pmid: 16917505', 'Include': 'true'}, {'number': '363', 'ReferenceId': '28143957', 'FullCitation': 'Oliver MD, et al. Biosci. Rep. (2017) pmid: 28143957', 'Include': 'true'}, {'number': '364', 'ReferenceId': '11606375', 'FullCitation': 'Philp AJ, et al. Cancer Res. (2001) pmid: 11606375', 'Include': 'true'}, {'number': '365', 'ReferenceId': '25488983', 'FullCitation': 'Lucas CL, et al. J. Exp. Med. (2014) pmid: 25488983', 'Include': 'true'}, {'number': '366', 'ReferenceId': '29636477', 'FullCitation': 'Chen L, et al. Nat Commun (2018) pmid: 29636477', 'Include': 'true'}, {'number': '367', 'ReferenceId': '25284480', 'FullCitation': 'Cheung LW, et al. Cancer Cell (2014) pmid: 25284480', 'Include': 'true'}, {'number': '368', 'ReferenceId': '24120142', 'FullCitation': 'Brennan CW, et al. Cell (2013) pmid: 24120142', 'Include': 'true'}, {'number': '369', 'ReferenceId': '26061751', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751', 'Include': 'true'}, {'number': '370', 'ReferenceId': '26657142', 'FullCitation': 'Ye K, et al. Nat. Med. (2016) pmid: 26657142', 'Include': 'true'}, {'number': '371', 'ReferenceId': '26501081', 'FullCitation': 'Munkley J, et al. Oncoscience (2015) pmid: 26501081', 'Include': 'true'}, {'number': '372', 'ReferenceId': '24229379', 'FullCitation': 'Cizkova M, et al. BMC Cancer (2013) pmid: 24229379', 'Include': 'true'}, {'number': '373', 'ReferenceId': '23980085', 'FullCitation': 'Qian ZR, et al. J. Clin. Oncol. (2013) pmid: 23980085', 'Include': 'true'}, {'number': '374', 'ReferenceId': '25528496', 'FullCitation': 'Matulonis U, et al. Gynecol. Oncol. (2015) pmid: 25528496', 'Include': 'true'}, {'number': '375', 'ReferenceId': '25605819', 'FullCitation': 'Pitz MW, et al. Neuro_oncology (2015) pmid: 25605819', 'Include': 'true'}, {'number': '376', 'ReferenceId': '27893038', 'FullCitation': 'Basho RK, et al. JAMA Oncol (2017) pmid: 27893038', 'Include': 'true'}, {'number': '377', 'ReferenceId': '27016228', 'FullCitation': 'Myers AP, et al. Gynecol. Oncol. (2016) pmid: 27016228', 'Include': 'true'}, {'number': '378', 'ReferenceId': '30420444', 'FullCitation': 'Day TA, et al. Clin. Cancer Res. (2019) pmid: 30420444', 'Include': 'true'}, {'number': '379', 'ReferenceId': '25193464', 'FullCitation': 'Ou O, et al. Cancer Lett. (2014) pmid: 25193464', 'Include': 'true'}, {'number': '380', 'ReferenceId': '15366705', 'FullCitation': 'Kobielak A, et al. Nat. Rev. Mol. Cell Biol. (2004) pmid: 15366705', 'Include': 'true'}, {'number': '381', 'ReferenceId': '19458087', 'FullCitation': 'Bajpai S, et al. J. Biol. Chem. (2009) pmid: 19458087', 'Include': 'true'}, {'number': '382', 'ReferenceId': '21610251', 'FullCitation': 'Silvis MR, et al. Sci Signal (2011) pmid: 21610251', 'Include': 'true'}, {'number': '383', 'ReferenceId': '24509793', 'FullCitation': 'Piao HL, et al. Nat. Cell Biol. (2014) pmid: 24509793', 'Include': 'true'}, {'number': '384', 'ReferenceId': '18566211', 'FullCitation': 'Inge LJ, et al. Mol. Cancer Ther. (2008) pmid: 18566211', 'Include': 'true'}, {'number': '385', 'ReferenceId': '29625048', 'FullCitation': 'Hoadley KA, et al. Cell (2018) pmid: 29625048', 'Include': 'true'}, {'number': '386', 'ReferenceId': '24265153', 'FullCitation': 'Van Allen EM, et al. Cancer Discov (2014) pmid: 24265153', 'Include': 'true'}, {'number': '387', 'ReferenceId': '26182300', 'FullCitation': 'Hansford S, et al. JAMA Oncol (2015) pmid: 26182300', 'Include': 'true'}, {'number': '388', 'ReferenceId': '23208944', 'FullCitation': 'Majewski IJ, et al. J. Pathol. (2013) pmid: 23208944', 'Include': 'true'}, {'number': '389', 'ReferenceId': '20393555', 'FullCitation': 'Ding L, et al. Nature (2010) pmid: 20393555', 'Include': 'true'}, {'number': '390', 'ReferenceId': '25153418', 'FullCitation': 'Qian J, et al. Clin. Chem. Lab. Med. (2014) pmid: 25153418', 'Include': 'true'}, {'number': '391', 'ReferenceId': '19826047', 'FullCitation': 'Ye Y, et al. Cancer Res. (2009) pmid: 19826047', 'Include': 'true'}, {'number': '392', 'ReferenceId': '17159988', 'FullCitation': 'Liu TX, et al. Nat. Med. (2007) pmid: 17159988', 'Include': 'true'}, {'number': '393', 'ReferenceId': '24685333', 'FullCitation': 'Chen XX, et al. Leuk. Res. (2014) pmid: 24685333', 'Include': 'true'}, {'number': '394', 'ReferenceId': '27129146', 'FullCitation': 'Li M, et al. Oncotarget (2016) pmid: 27129146', 'Include': 'true'}, {'number': '395', 'ReferenceId': '21119682', 'FullCitation': 'Harhaj EW, et al. Cell Res. (2011) pmid: 21119682', 'Include': 'true'}, {'number': '396', 'ReferenceId': '15258597', 'FullCitation': 'Wertz IE, et al. Nature (2004) pmid: 15258597', 'Include': 'true'}, {'number': '397', 'ReferenceId': '26649818', 'FullCitation': 'Wertz IE, et al. Nature (2015) pmid: 26649818', 'Include': 'true'}, {'number': '398', 'ReferenceId': '19608751', 'FullCitation': 'Honma K, et al. Blood (2009) pmid: 19608751', 'Include': 'true'}, {'number': '399', 'ReferenceId': '26909601', 'FullCitation': 'Wang X, et al. Oncotarget (2016) pmid: 26909601', 'Include': 'true'}, {'number': '400', 'ReferenceId': '27072986', 'FullCitation': 'Couch G, et al. Cancer Prev Res (Phila) (2016) pmid: 27072986', 'Include': 'true'}, {'number': '401', 'ReferenceId': '26485275', 'FullCitation': 'Wang Y, et al. PLoS ONE (2015) pmid: 26485275', 'Include': 'true'}, {'number': '402', 'ReferenceId': '23929716', 'FullCitation': 'Salim H, et al. Genes Chromosomes Cancer (2013) pmid: 23929716', 'Include': 'true'}, {'number': '403', 'ReferenceId': '26437781', 'FullCitation': 'Saitoh Y, et al. Leukemia (2016) pmid: 26437781', 'Include': 'true'}, {'number': '404', 'ReferenceId': '26199174', 'FullCitation': 'Johansson P, et al. Int. J. Cancer (2016) pmid: 26199174', 'Include': 'true'}, {'number': '405', 'ReferenceId': '26159495', 'FullCitation': 'Chen S, et al. Leuk. Res. (2015) pmid: 26159495', 'Include': 'true'}, {'number': '406', 'ReferenceId': '20574050', 'FullCitation': 'Broyl A, et al. Blood (2010) pmid: 20574050', 'Include': 'true'}, {'number': '407', 'ReferenceId': '25856582', 'FullCitation': 'Troppan K, et al. PLoS ONE (2015) pmid: 25856582', 'Include': 'true'}, {'number': '408', 'ReferenceId': '24008839', 'FullCitation': 'Yamaguchi N, et al. Sci Rep (2013) pmid: 24008839', 'Include': 'true'}, {'number': '409', 'ReferenceId': '18223652', 'FullCitation': 'Coornaert B, et al. Nat. Immunol. (2008) pmid: 18223652', 'Include': 'true'}, {'number': '410', 'ReferenceId': '17297453', 'FullCitation': 'Vendrell JA, et al. Oncogene (2007) pmid: 17297453', 'Include': 'true'}, {'number': '411', 'ReferenceId': '20186265', 'FullCitation': 'Hjelmeland AB, et al. PLoS Biol. (2010) pmid: 20186265', 'Include': 'true'}, {'number': '412', 'ReferenceId': '22585859', 'FullCitation': 'Bellail AC, et al. Cancer Discov (2012) pmid: 22585859', 'Include': 'true'}, {'number': '413', 'ReferenceId': '26768118', 'FullCitation': 'Hantel C, et al. Mol. Cell. Endocrinol. (2016) pmid: 26768118', 'Include': 'true'}, {'number': '414', 'ReferenceId': '22843550', 'FullCitation': 'Ungerbäck J, et al. Carcinogenesis (2012) pmid: 22843550', 'Include': 'true'}, {'number': '415', 'ReferenceId': '22704353', 'FullCitation': 'Bavi P, et al. Clin Epigenetics (2011) pmid: 22704353', 'Include': 'true'}, {'number': '416', 'ReferenceId': '20383180', 'FullCitation': 'Hymowitz SG, et al. Nat. Rev. Cancer (2010) pmid: 20383180', 'Include': 'true'}, {'number': '417', 'ReferenceId': '21289309', 'FullCitation': 'Zhu YX, et al. Blood (2011) pmid: 21289309', 'Include': 'true'}, {'number': '418', 'ReferenceId': '15134788', 'FullCitation': 'Weil R, et al. Curr. Opin. Immunol. (2004) pmid: 15134788', 'Include': 'true'}, {'number': '419', 'ReferenceId': '23474202', 'FullCitation': 'Paul S, et al. Trends Immunol. (2013) pmid: 23474202', 'Include': 'true'}, {'number': '420', 'ReferenceId': '27135977', 'FullCitation': 'Juilland M, et al. Curr. Opin. Hematol. (2016) pmid: 27135977', 'Include': 'true'}, {'number': '421', 'ReferenceId': '26776161', 'FullCitation': 'Bognar MK, et al. Oncogene (2016) pmid: 26776161', 'Include': 'true'}, {'number': '422', 'ReferenceId': '23149938', 'FullCitation': 'Chan W, et al. Mol. Cell. Biol. (2013) pmid: 23149938', 'Include': 'true'}, {'number': '423', 'ReferenceId': '25352053', 'FullCitation': 'Brohl AS, et al. J. Clin. Immunol. (2015) pmid: 25352053', 'Include': 'true'}, {'number': '424', 'ReferenceId': '23027925', 'FullCitation': 'Jeelall YS, et al. J. Exp. Med. (2012) pmid: 23027925', 'Include': 'true'}, {'number': '425', 'ReferenceId': '18323416', 'FullCitation': 'Lenz G, et al. Science (2008) pmid: 18323416', 'Include': 'true'}, {'number': '426', 'ReferenceId': '20799731', 'FullCitation': 'Lamason RL, et al. Biochemistry (2010) pmid: 20799731', 'Include': 'true'}, {'number': '427', 'ReferenceId': '21266526', 'FullCitation': 'Dong G, et al. Clin. Cancer Res. (2011) pmid: 21266526', 'Include': 'true'}, {'number': '428', 'ReferenceId': '19412164', 'FullCitation': 'Compagno M, et al. Nature (2009) pmid: 19412164', 'Include': 'true'}, {'number': '429', 'ReferenceId': '26551667', 'FullCitation': 'da Silva Almeida AC, et al. Nat. Genet. (2015) pmid: 26551667', 'Include': 'true'}, {'number': '430', 'ReferenceId': '27369867', 'FullCitation': 'Vallois D, et al. Blood (2016) pmid: 27369867', 'Include': 'true'}, {'number': '431', 'ReferenceId': '27224912', 'FullCitation': 'Wu C, et al. Oncotarget (2016) pmid: 27224912', 'Include': 'true'}, {'number': '432', 'ReferenceId': '26540570', 'FullCitation': 'Nagel D, et al. Oncotarget (2015) pmid: 26540570', 'Include': 'true'}, {'number': '433', 'ReferenceId': '21324920', 'FullCitation': 'Naylor TL, et al. Cancer Res. (2011) pmid: 21324920', 'Include': 'true'}, {'number': '434', 'ReferenceId': '23129749', 'FullCitation': 'Snow AL, et al. J. Exp. Med. (2012) pmid: 23129749', 'Include': 'true'}, {'number': '435', 'ReferenceId': '22397314', 'FullCitation': 'Bu R, et al. Leuk. Lymphoma (2012) pmid: 22397314', 'Include': 'true'}, {'number': '436', 'ReferenceId': '23699601', 'FullCitation': 'Morin RD, et al. Blood (2013) pmid: 23699601', 'Include': 'true'}, {'number': '437', 'ReferenceId': '21796119', 'FullCitation': 'Morin RD, et al. Nature (2011) pmid: 21796119', 'Include': 'true'}, {'number': '438', 'ReferenceId': '20544211', 'FullCitation': 'Montesinos_Rongen M, et al. Acta Neuropathol. (2010) pmid: 20544211', 'Include': 'true'}, {'number': '439', 'ReferenceId': '25991819', 'FullCitation': 'Braggio E, et al. Clin. Cancer Res. (2015) pmid: 25991819', 'Include': 'true'}, {'number': '440', 'ReferenceId': '22891273', 'FullCitation': 'Rossi D, et al. J. Exp. Med. (2012) pmid: 22891273', 'Include': 'true'}, {'number': '441', 'ReferenceId': '22102703', 'FullCitation': 'Yan Q, et al. Haematologica (2012) pmid: 22102703', 'Include': 'true'}, {'number': '442', 'ReferenceId': '26551670', 'FullCitation': 'Wang L, et al. Nat. Genet. (2015) pmid: 26551670', 'Include': 'true'}, {'number': '443', 'ReferenceId': '16484591', 'FullCitation': 'Oshiro A, et al. Blood (2006) pmid: 16484591', 'Include': 'true'}, {'number': '444', 'ReferenceId': '18633432', 'FullCitation': 'Fujiwara SI, et al. Leukemia (2008) pmid: 18633432', 'Include': 'true'}, {'number': '445', 'ReferenceId': '25384343', 'FullCitation': 'Ma Y, et al. Eur. J. Med. Res. (2014) pmid: 25384343', 'Include': 'true'}, {'number': '446', 'ReferenceId': '22842228', 'FullCitation': 'Krauthammer M, et al. Nat. Genet. (2012) pmid: 22842228', 'Include': 'true'}, {'number': '447', 'ReferenceId': '22817889', 'FullCitation': 'Hodis E, et al. Cell (2012) pmid: 22817889', 'Include': 'true'}, {'number': '448', 'ReferenceId': '25855536', 'FullCitation': 'Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536', 'Include': 'true'}, {'number': '449', 'ReferenceId': '25079317', 'FullCitation': 'Nature (2014) pmid: 25079317', 'Include': 'true'}, {'number': '450', 'ReferenceId': '25079552', 'FullCitation': 'Nature (2014) pmid: 25079552', 'Include': 'true'}, {'number': '451', 'ReferenceId': '24476821', 'FullCitation': 'Nature (2014) pmid: 24476821', 'Include': 'true'}, {'number': '452', 'ReferenceId': '20685844', 'FullCitation': 'Thome M, et al. Cold Spring Harb Perspect Biol (2010) pmid: 20685844', 'Include': 'true'}, {'number': '453', 'ReferenceId': '22435566', 'FullCitation': 'Lim KH, et al. Immunol. Rev. (2012) pmid: 22435566', 'Include': 'true'}, {'number': '454', 'ReferenceId': '20525923', 'FullCitation': 'Milhollen MA, et al. Blood (2010) pmid: 20525923', 'Include': 'true'}, {'number': '455', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '456', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '457', 'ReferenceId': '9823339', 'FullCitation': 'Boland CR, et al. Cancer Res. (1998) pmid: 9823339', 'Include': 'true'}, {'number': '458', 'ReferenceId': '15528785', 'FullCitation': 'Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785', 'Include': 'true'}, {'number': '459', 'ReferenceId': '20420947', 'FullCitation': 'Boland CR, et al. Gastroenterology (2010) pmid: 20420947', 'Include': 'true'}, {'number': '460', 'ReferenceId': '16549821', 'FullCitation': 'Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821', 'Include': 'true'}, {'number': '461', 'ReferenceId': '20304627', 'FullCitation': 'Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627', 'Include': 'true'}, {'number': '462', 'ReferenceId': '25458958', 'FullCitation': 'Kanopienė D, et al. Medicina (Kaunas) (2014) pmid: 25458958', 'Include': 'true'}, {'number': '463', 'ReferenceId': '16885385', 'FullCitation': 'Hampel H, et al. Cancer Res. (2006) pmid: 16885385', 'Include': 'true'}, {'number': '464', 'ReferenceId': '21547578', 'FullCitation': 'Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578', 'Include': 'true'}, {'number': '465', 'ReferenceId': '20005452', 'FullCitation': 'Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452', 'Include': 'true'}, {'number': '466', 'ReferenceId': '17513808', 'FullCitation': 'Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808', 'Include': 'true'}, {'number': '467', 'ReferenceId': '25026289', 'FullCitation': 'Bilbao_Sieyro C, et al. Oncotarget (2014) pmid: 25026289', 'Include': 'true'}, {'number': '468', 'ReferenceId': '19275958', 'FullCitation': 'Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958', 'Include': 'true'}, {'number': '469', 'ReferenceId': '27006490', 'FullCitation': 'Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490', 'Include': 'true'}, {'number': '470', 'ReferenceId': '22609107', 'FullCitation': 'Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107', 'Include': 'true'}, {'number': '471', 'ReferenceId': '26140250', 'FullCitation': 'Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250', 'Include': 'true'}, {'number': '472', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '473', 'ReferenceId': '15473860', 'FullCitation': 'Logan CY, et al. Annu. Rev. Cell Dev. Biol. (2004) pmid: 15473860', 'Include': 'true'}, {'number': '474', 'ReferenceId': '15361208', 'FullCitation': 'Pijnenborg JM, et al. Int. J. Gynecol. Cancer () pmid: 15361208', 'Include': 'true'}, {'number': '475', 'ReferenceId': '12439748', 'FullCitation': 'Moreno_Bueno G, et al. Oncogene (2002) pmid: 12439748', 'Include': 'true'}, {'number': '476', 'ReferenceId': '12097272', 'FullCitation': 'Zysman M, et al. Cancer Res. (2002) pmid: 12097272', 'Include': 'true'}, {'number': '477', 'ReferenceId': '21813170', 'FullCitation': 'Singh M, et al. Gynecol. Oncol. (2011) pmid: 21813170', 'Include': 'true'}, {'number': '478', 'ReferenceId': '21363919', 'FullCitation': 'Tanwar PS, et al. Cancer Res. (2011) pmid: 21363919', 'Include': 'true'}, {'number': '479', 'ReferenceId': '30635339', 'FullCitation': 'Luke JJ, et al. Clin Cancer Res (2019) pmid: 30635339', 'Include': 'true'}, {'number': '480', 'ReferenceId': '20348907', 'FullCitation': 'Zhang L, et al. Nature (2010) pmid: 20348907', 'Include': 'true'}, {'number': '481', 'ReferenceId': '19026633', 'FullCitation': 'Lu W, et al. Eur. J. Pharmacol. (2009) pmid: 19026633', 'Include': 'true'}, {'number': '482', 'ReferenceId': '18281498', 'FullCitation': 'Tuynman JB, et al. Cancer Res. (2008) pmid: 18281498', 'Include': 'true'}, {'number': '483', 'ReferenceId': '23539443', 'FullCitation': 'Lau T, et al. Cancer Res. (2013) pmid: 23539443', 'Include': 'true'}, {'number': '484', 'ReferenceId': '23159591', 'FullCitation': 'Kerr SE, et al. J Mol Diagn (2013) pmid: 23159591', 'Include': 'true'}, {'number': '485', 'ReferenceId': '21090969', 'FullCitation': 'Annu Rev Pathol (2011) pmid: 21090969', 'Include': 'true'}, {'number': '486', 'ReferenceId': '18844223', 'FullCitation': 'Kastritis E, et al. Int. J. Cancer (2009) pmid: 18844223', 'Include': 'true'}, {'number': '487', 'ReferenceId': '19822006', 'FullCitation': 'Half E, et al. Orphanet J Rare Dis (2009) pmid: 19822006', 'Include': 'true'}, {'number': '488', 'ReferenceId': '15950905', 'FullCitation': 'Samuels Y, et al. Cancer Cell (2005) pmid: 15950905', 'Include': 'true'}, {'number': '489', 'ReferenceId': '19629070', 'FullCitation': 'Nat. Rev. Cancer (2009) pmid: 19629070', 'Include': 'true'}, {'number': '490', 'ReferenceId': '15647370', 'FullCitation': 'Kang S, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15647370', 'Include': 'true'}, {'number': '491', 'ReferenceId': '15930273', 'FullCitation': 'Ikenoue T, et al. Cancer Res. (2005) pmid: 15930273', 'Include': 'true'}, {'number': '492', 'ReferenceId': '17376864', 'FullCitation': 'Gymnopoulos M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17376864', 'Include': 'true'}, {'number': '493', 'ReferenceId': '18317450', 'FullCitation': 'Horn S, et al. Oncogene (2008) pmid: 18317450', 'Include': 'true'}, {'number': '494', 'ReferenceId': '21266528', 'FullCitation': 'Rudd ML, et al. Clin. Cancer Res. (2011) pmid: 21266528', 'Include': 'true'}, {'number': '495', 'ReferenceId': '22120714', 'FullCitation': 'Hon WC, et al. Oncogene (2012) pmid: 22120714', 'Include': 'true'}, {'number': '496', 'ReferenceId': '22949682', 'FullCitation': 'Burke JE, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22949682', 'Include': 'true'}, {'number': '497', 'ReferenceId': '2103068', 'FullCitation': 'Laurenti R, et al. Rev Saude Publica (1990) pmid: 2103068', 'Include': 'true'}, {'number': '498', 'ReferenceId': '20530683', 'FullCitation': 'Dan S, et al. Cancer Res. (2010) pmid: 20530683', 'Include': 'true'}, {'number': '499', 'ReferenceId': '18829572', 'FullCitation': 'Oda K, et al. Cancer Res. (2008) pmid: 18829572', 'Include': 'true'}, {'number': '500', 'ReferenceId': '18794883', 'FullCitation': 'Zhao L, et al. Oncogene (2008) pmid: 18794883', 'Include': 'true'}, {'number': '501', 'ReferenceId': '23619167', 'FullCitation': 'Lui VW, et al. Cancer Discov (2013) pmid: 23619167', 'Include': 'true'}, {'number': '502', 'ReferenceId': '22430209', 'FullCitation': 'Ross RL, et al. Oncogene (2013) pmid: 22430209', 'Include': 'true'}, {'number': '503', 'ReferenceId': '22729224', 'FullCitation': 'Rivière JB, et al. Nat. Genet. (2012) pmid: 22729224', 'Include': 'true'}, {'number': '504', 'ReferenceId': '19394761', 'FullCitation': 'Shibata T, et al. Cancer Lett. (2009) pmid: 19394761', 'Include': 'true'}, {'number': '505', 'ReferenceId': '26627007', 'FullCitation': 'Dogruluk T, et al. Cancer Res. (2015) pmid: 26627007', 'Include': 'true'}, {'number': '506', 'ReferenceId': '29284706', 'FullCitation': 'Croessmann S, et al. Clin. Cancer Res. (2018) pmid: 29284706', 'Include': 'true'}, {'number': '507', 'ReferenceId': '29533785', 'FullCitation': 'Ng PK, et al. Cancer Cell (2018) pmid: 29533785', 'Include': 'true'}, {'number': '508', 'ReferenceId': '32929011', 'FullCitation': 'Spangle JM, et al. (2020) pmid: 32929011', 'Include': 'true'}, {'number': '509', 'ReferenceId': '28502730', 'FullCitation': 'Akgumus G, et al. J Mol Diagn (2017) pmid: 28502730', 'Include': 'true'}, {'number': '510', 'ReferenceId': '25624430', 'FullCitation': 'Slomovitz BM, et al. J. Clin. Oncol. (2015) pmid: 25624430', 'Include': 'true'}, {'number': '511', 'ReferenceId': '26479420', 'FullCitation': 'Al_Rohil RN, et al. Cancer (2016) pmid: 26479420', 'Include': 'true'}, {'number': '512', 'ReferenceId': '23219661', 'FullCitation': 'Garcia_Dios DA, et al. Gynecol. Oncol. (2013) pmid: 23219661', 'Include': 'true'}, {'number': '513', 'ReferenceId': '16322209', 'FullCitation': 'Oda K, et al. Cancer Res. (2005) pmid: 16322209', 'Include': 'true'}, {'number': '514', 'ReferenceId': '23949151', 'FullCitation': 'Akiyama_Abe A, et al. Br. J. Cancer (2013) pmid: 23949151', 'Include': 'true'}, {'number': '515', 'ReferenceId': '24262879', 'FullCitation': 'McIntyre JB, et al. Gynecol. Oncol. (2014) pmid: 24262879', 'Include': 'true'}, {'number': '516', 'ReferenceId': '24608574', 'FullCitation': 'Fritsch C, et al. Mol. Cancer Ther. (2014) pmid: 24608574', 'Include': 'true'}, {'number': '517', 'ReferenceId': '29401002', 'FullCitation': 'Juric D, et al. J. Clin. Oncol. (2018) pmid: 29401002', 'Include': 'true'}, {'number': '518', 'ReferenceId': '30793038', 'FullCitation': 'Gallant JN, et al. NPJ Precis Oncol (2019) pmid: 30793038', 'Include': 'true'}, {'number': '519', 'ReferenceId': '31091374', 'FullCitation': 'André F, et al. N. Engl. J. Med. (2019) pmid: 31091374', 'Include': 'true'}, {'number': '520', 'ReferenceId': '33863913', 'FullCitation': 'Smyth LM, et al. NPJ Breast Cancer (2021) pmid: 33863913', 'Include': 'true'}, {'number': '521', 'ReferenceId': '27105424', 'FullCitation': 'Park HS, et al. PLoS ONE (2016) pmid: 27105424', 'Include': 'true'}, {'number': '522', 'ReferenceId': '25426553', 'FullCitation': 'Hou MM, et al. Oncotarget (2014) pmid: 25426553', 'Include': 'true'}, {'number': '523', 'ReferenceId': '31351267', 'FullCitation': 'Varnier R, et al. Eur J Cancer (2019) pmid: 31351267', 'Include': 'true'}, {'number': '524', 'ReferenceId': '24440717', 'FullCitation': 'Janku F, et al. Cell Rep (2014) pmid: 24440717', 'Include': 'true'}, {'number': '525', 'ReferenceId': '22927482', 'FullCitation': 'Moroney J, et al. Clin. Cancer Res. (2012) pmid: 22927482', 'Include': 'true'}, {'number': '526', 'ReferenceId': '21890452', 'FullCitation': 'Moroney JW, et al. Clin. Cancer Res. (2011) pmid: 21890452', 'Include': 'true'}, {'number': '527', 'ReferenceId': '26787751', 'FullCitation': 'Dolly SO, et al. Clin. Cancer Res. (2016) pmid: 26787751', 'Include': 'true'}, {'number': '528', 'ReferenceId': '2941002', 'FullCitation': 'Aust Fam Physician (1986) pmid: 2941002', 'Include': 'true'}, {'number': '529', 'ReferenceId': '31934607', 'FullCitation': 'Santin AD, et al. Gynecol Oncol Rep (2020) pmid: 31934607', 'Include': 'true'}, {'number': '530', 'ReferenceId': '27672108', 'FullCitation': 'Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108', 'Include': 'true'}, {'number': '531', 'ReferenceId': '20813970', 'FullCitation': 'Esteva FJ, et al. Am. J. Pathol. (2010) pmid: 20813970', 'Include': 'true'}, {'number': '532', 'ReferenceId': '25332247', 'FullCitation': 'Baselga J, et al. J. Clin. Oncol. (2014) pmid: 25332247', 'Include': 'true'}, {'number': '533', 'ReferenceId': '20581867', 'FullCitation': 'Chakrabarty A, et al. Oncogene (2010) pmid: 20581867', 'Include': 'true'}, {'number': '534', 'ReferenceId': '19633047', 'FullCitation': 'Kataoka Y, et al. Ann. Oncol. (2010) pmid: 19633047', 'Include': 'true'}, {'number': '535', 'ReferenceId': '21676217', 'FullCitation': 'Wang L, et al. BMC Cancer (2011) pmid: 21676217', 'Include': 'true'}, {'number': '536', 'ReferenceId': '10679188', 'FullCitation': 'Biochem. Biophys. Res. Commun. (2000) pmid: 10679188', 'Include': 'true'}, {'number': '537', 'ReferenceId': '22149432', 'FullCitation': 'Dellinger TH, et al. Expert Rev Anticancer Ther (2012) pmid: 22149432', 'Include': 'true'}, {'number': '538', 'ReferenceId': '11161379', 'FullCitation': 'Saegusa M, et al. Br. J. Cancer (2001) pmid: 11161379', 'Include': 'true'}, {'number': '539', 'ReferenceId': '23765252', 'FullCitation': 'McConechy MK, et al. Mod. Pathol. (2014) pmid: 23765252', 'Include': 'true'}, {'number': '540', 'ReferenceId': '23760948', 'FullCitation': 'Huang M, et al. Cancer (2013) pmid: 23760948', 'Include': 'true'}, {'number': '541', 'ReferenceId': '22430211', 'FullCitation': 'Yeramian A, et al. Oncogene (2013) pmid: 22430211', 'Include': 'true'}, {'number': '542', 'ReferenceId': '11957146', 'FullCitation': 'Machin P, et al. Hum. Pathol. (2002) pmid: 11957146', 'Include': 'true'}, {'number': '543', 'ReferenceId': '22955108', 'FullCitation': 'Peiró G, et al. Hum. Pathol. (2013) pmid: 22955108', 'Include': 'true'}, {'number': '544', 'ReferenceId': '28281553', 'FullCitation': 'Kurnit KC, et al. Mod. Pathol. (2017) pmid: 28281553', 'Include': 'true'}, {'number': '545', 'ReferenceId': '25214561', 'FullCitation': 'Liu Y, et al. J. Natl. Cancer Inst. (2014) pmid: 25214561', 'Include': 'true'}, {'number': '546', 'ReferenceId': '19820688', 'FullCitation': 'Rosen DG, et al. Mod. Pathol. (2010) pmid: 19820688', 'Include': 'true'}, {'number': '547', 'ReferenceId': '17504383', 'FullCitation': 'Athanassiadou P, et al. Int. J. Gynecol. Cancer () pmid: 17504383', 'Include': 'true'}, {'number': '548', 'ReferenceId': '19403928', 'FullCitation': 'Tanwar PS, et al. Biol. Reprod. (2009) pmid: 19403928', 'Include': 'true'}, {'number': '549', 'ReferenceId': '21695255', 'FullCitation': 'Tanwar PS, et al. PLoS ONE (2011) pmid: 21695255', 'Include': 'true'}, {'number': '550', 'ReferenceId': '18768809', 'FullCitation': 'Fujishita T, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18768809', 'Include': 'true'}, {'number': '551', 'ReferenceId': '20347502', 'FullCitation': 'Bhoori S, et al. J. Hepatol. (2010) pmid: 20347502', 'Include': 'true'}, {'number': '552', 'ReferenceId': '24931142', 'FullCitation': 'Janku F, et al. Oncotarget (2014) pmid: 24931142', 'Include': 'true'}, {'number': '553', 'ReferenceId': '15378020', 'FullCitation': 'Niida A, et al. Oncogene (2004) pmid: 15378020', 'Include': 'true'}, {'number': '554', 'ReferenceId': '15592430', 'FullCitation': 'Chamorro MN, et al. EMBO J. (2005) pmid: 15592430', 'Include': 'true'}, {'number': '555', 'ReferenceId': '28574171', 'FullCitation': 'Kagey MH, et al. Br. J. Pharmacol. (2017) pmid: 28574171', 'Include': 'true'}, {'number': '556', 'ReferenceId': '21841793', 'FullCitation': 'Kwon C, et al. Nat. Cell Biol. (2011) pmid: 21841793', 'Include': 'true'}, {'number': '557', 'ReferenceId': '23868008', 'FullCitation': 'Arcaroli JJ, et al. Br. J. Cancer (2013) pmid: 23868008', 'Include': 'true'}, {'number': '558', 'ReferenceId': '26349011', 'FullCitation': 'Shang H, et al. Cancer (2015) pmid: 26349011', 'Include': 'true'}, {'number': '559', 'ReferenceId': '24429522', 'FullCitation': 'Kode A, et al. Nature (2014) pmid: 24429522', 'Include': 'true'}, {'number': '560', 'ReferenceId': '25231399', 'FullCitation': 'Messersmith WA, et al. Clin. Cancer Res. (2015) pmid: 25231399', 'Include': 'true'}, {'number': '561', 'ReferenceId': '22964660', 'FullCitation': 'Zhu J, et al. Carcinogenesis (2012) pmid: 22964660', 'Include': 'true'}, {'number': '562', 'ReferenceId': '22356261', 'FullCitation': 'Kogan Y, et al. Biochem. J. (2012) pmid: 22356261', 'Include': 'true'}, {'number': '563', 'ReferenceId': '22811581', 'FullCitation': 'Lachenmayer A, et al. Clin. Cancer Res. (2012) pmid: 22811581', 'Include': 'true'}, {'number': '564', 'ReferenceId': '18094723', 'FullCitation': 'Welcker M, et al. Nat. Rev. Cancer (2008) pmid: 18094723', 'Include': 'true'}, {'number': '565', 'ReferenceId': '17909001', 'FullCitation': 'Akhoondi S, et al. Cancer Res. (2007) pmid: 17909001', 'Include': 'true'}, {'number': '566', 'ReferenceId': '23359684', 'FullCitation': 'Zhao S, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23359684', 'Include': 'true'}, {'number': '567', 'ReferenceId': '23104009', 'FullCitation': 'Le Gallo M, et al. Nat. Genet. (2012) pmid: 23104009', 'Include': 'true'}, {'number': '568', 'ReferenceId': '22923510', 'FullCitation': 'Kuhn E, et al. J. Natl. Cancer Inst. (2012) pmid: 22923510', 'Include': 'true'}, {'number': '569', 'ReferenceId': '12183400', 'FullCitation': 'Spruck CH, et al. Cancer Res. (2002) pmid: 12183400', 'Include': 'true'}, {'number': '570', 'ReferenceId': '14648662', 'FullCitation': 'Cassia R, et al. J. Pathol. (2003) pmid: 14648662', 'Include': 'true'}, {'number': '571', 'ReferenceId': '22548670', 'FullCitation': 'Tu K, et al. Hepatol. Res. (2012) pmid: 22548670', 'Include': 'true'}, {'number': '572', 'ReferenceId': '19739118', 'FullCitation': 'Iwatsuki M, et al. Int. J. Cancer (2010) pmid: 19739118', 'Include': 'true'}, {'number': '573', 'ReferenceId': '22576686', 'FullCitation': 'Yokobori T, et al. Int. J. Oncol. (2012) pmid: 22576686', 'Include': 'true'}, {'number': '574', 'ReferenceId': '19366810', 'FullCitation': 'Yokobori T, et al. Cancer Res. (2009) pmid: 19366810', 'Include': 'true'}, {'number': '575', 'ReferenceId': '24165483', 'FullCitation': 'Yokobori T, et al. Mol. Cancer Res. (2014) pmid: 24165483', 'Include': 'true'}, {'number': '576', 'ReferenceId': '14999283', 'FullCitation': 'Rajagopalan H, et al. Nature (2004) pmid: 14999283', 'Include': 'true'}, {'number': '577', 'ReferenceId': '23381582', 'FullCitation': 'Cheng Y, et al. J. Invest. Dermatol. (2013) pmid: 23381582', 'Include': 'true'}, {'number': '578', 'ReferenceId': '26954701', 'FullCitation': 'Xu Y, et al. Biomarkers (2016) pmid: 26954701', 'Include': 'true'}, {'number': '579', 'ReferenceId': '18787170', 'FullCitation': 'Mao JH, et al. Science (2008) pmid: 18787170', 'Include': 'true'}, {'number': '580', 'ReferenceId': '25749036', 'FullCitation': 'Yang H, et al. Oncotarget (2015) pmid: 25749036', 'Include': 'true'}, {'number': '581', 'ReferenceId': '24360397', 'FullCitation': 'Villaruz LC, et al. Lung Cancer (2014) pmid: 24360397', 'Include': 'true'}, {'number': '582', 'ReferenceId': '21368834', 'FullCitation': 'Wertz IE, et al. Nature (2011) pmid: 21368834', 'Include': 'true'}, {'number': '583', 'ReferenceId': '11237521', 'FullCitation': 'Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521', 'Include': 'true'}, {'number': '584', 'ReferenceId': '12857747', 'FullCitation': 'Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747', 'Include': 'true'}, {'number': '585', 'ReferenceId': '21828076', 'FullCitation': 'Rodríguez_Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076', 'Include': 'true'}, {'number': '586', 'ReferenceId': '23475934', 'FullCitation': 'He X, et al. Cancer Res. (2013) pmid: 23475934', 'Include': 'true'}, {'number': '587', 'ReferenceId': '10866302', 'FullCitation': 'Han SY, et al. Cancer Res. (2000) pmid: 10866302', 'Include': 'true'}, {'number': '588', 'ReferenceId': '9811831', 'FullCitation': 'Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831', 'Include': 'true'}, {'number': '589', 'ReferenceId': '24498881', 'FullCitation': 'Pradella LM, et al. BMC Cancer (2014) pmid: 24498881', 'Include': 'true'}, {'number': '590', 'ReferenceId': '21536651', 'FullCitation': 'Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651', 'Include': 'true'}, {'number': '591', 'ReferenceId': '17213812', 'FullCitation': 'Denning G, et al. Oncogene (2007) pmid: 17213812', 'Include': 'true'}, {'number': '592', 'ReferenceId': '16619501', 'FullCitation': 'Hlobilkova A, et al. Anticancer Res. () pmid: 16619501', 'Include': 'true'}, {'number': '593', 'ReferenceId': '20718038', 'FullCitation': 'Redfern RE, et al. Protein Sci. (2010) pmid: 20718038', 'Include': 'true'}, {'number': '594', 'ReferenceId': '22505997', 'FullCitation': 'Shenoy S, et al. PLoS ONE (2012) pmid: 22505997', 'Include': 'true'}, {'number': '595', 'ReferenceId': '19329485', 'FullCitation': 'Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485', 'Include': 'true'}, {'number': '596', 'ReferenceId': '16829519', 'FullCitation': 'Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519', 'Include': 'true'}, {'number': '597', 'ReferenceId': '10555148', 'FullCitation': 'Lee JO, et al. Cell (1999) pmid: 10555148', 'Include': 'true'}, {'number': '598', 'ReferenceId': '9635567', 'FullCitation': 'Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567', 'Include': 'true'}, {'number': '599', 'ReferenceId': '9865913', 'FullCitation': 'Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913', 'Include': 'true'}, {'number': '600', 'ReferenceId': '11051241', 'FullCitation': 'Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241', 'Include': 'true'}, {'number': '601', 'ReferenceId': '22891331', 'FullCitation': 'Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331', 'Include': 'true'}, {'number': '602', 'ReferenceId': '23066114', 'FullCitation': 'Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114', 'Include': 'true'}, {'number': '603', 'ReferenceId': '19457929', 'FullCitation': 'Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929', 'Include': 'true'}, {'number': '604', 'ReferenceId': '23995781', 'FullCitation': 'Liu J, et al. Oncogene (2014) pmid: 23995781', 'Include': 'true'}, {'number': '605', 'ReferenceId': '11395408', 'FullCitation': 'Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408', 'Include': 'true'}, {'number': '606', 'ReferenceId': '10807691', 'FullCitation': 'De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691', 'Include': 'true'}, {'number': '607', 'ReferenceId': '10051603', 'FullCitation': 'Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603', 'Include': 'true'}, {'number': '608', 'ReferenceId': '15988030', 'FullCitation': 'Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030', 'Include': 'true'}, {'number': '609', 'ReferenceId': '15026806', 'FullCitation': 'Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806', 'Include': 'true'}, {'number': '610', 'ReferenceId': '25875300', 'FullCitation': 'Gil A, et al. PLoS ONE (2015) pmid: 25875300', 'Include': 'true'}, {'number': '611', 'ReferenceId': '9823298', 'FullCitation': 'Furnari FB, et al. Cancer Res. (1998) pmid: 9823298', 'Include': 'true'}, {'number': '612', 'ReferenceId': '25527629', 'FullCitation': 'Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629', 'Include': 'true'}, {'number': '613', 'ReferenceId': '29706633', 'FullCitation': 'Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633', 'Include': 'true'}, {'number': '614', 'ReferenceId': '20538496', 'FullCitation': 'Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496', 'Include': 'true'}, {'number': '615', 'ReferenceId': '17942903', 'FullCitation': 'Andrés_Pons A, et al. Cancer Res. (2007) pmid: 17942903', 'Include': 'true'}, {'number': '616', 'ReferenceId': '15805158', 'FullCitation': 'Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158', 'Include': 'true'}, {'number': '617', 'ReferenceId': '10468583', 'FullCitation': 'Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583', 'Include': 'true'}, {'number': '618', 'ReferenceId': '12085208', 'FullCitation': 'Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208', 'Include': 'true'}, {'number': '619', 'ReferenceId': '24292679', 'FullCitation': 'Nguyen HN, et al. Oncogene (2014) pmid: 24292679', 'Include': 'true'}, {'number': '620', 'ReferenceId': '19114656', 'FullCitation': 'Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656', 'Include': 'true'}, {'number': '621', 'ReferenceId': '12808147', 'FullCitation': 'Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147', 'Include': 'true'}, {'number': '622', 'ReferenceId': '18498243', 'FullCitation': 'Wang X, et al. Biochem. J. (2008) pmid: 18498243', 'Include': 'true'}, {'number': '623', 'ReferenceId': '15951562', 'FullCitation': 'Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562', 'Include': 'true'}, {'number': '624', 'ReferenceId': '25263454', 'FullCitation': 'Nguyen HN, et al. Oncogene (2015) pmid: 25263454', 'Include': 'true'}, {'number': '625', 'ReferenceId': '18757403', 'FullCitation': 'Byron SA, et al. Cancer Res. (2008) pmid: 18757403', 'Include': 'true'}, {'number': '626', 'ReferenceId': '22498935', 'FullCitation': 'Peterson LM, et al. Int. J. Gynecol. Pathol. (2012) pmid: 22498935', 'Include': 'true'}, {'number': '627', 'ReferenceId': '23613406', 'FullCitation': 'Daniilidou K, et al. J BUON () pmid: 23613406', 'Include': 'true'}, {'number': '628', 'ReferenceId': '23288720', 'FullCitation': 'van der Zee M, et al. J. Pathol. (2013) pmid: 23288720', 'Include': 'true'}, {'number': '629', 'ReferenceId': '22503752', 'FullCitation': 'Joshi A, et al. Am. J. Pathol. (2012) pmid: 22503752', 'Include': 'true'}, {'number': '630', 'ReferenceId': '20085938', 'FullCitation': 'Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938', 'Include': 'true'}, {'number': '631', 'ReferenceId': '28220839', 'FullCitation': 'Milella M, et al. Sci Rep (2017) pmid: 28220839', 'Include': 'true'}, {'number': '632', 'ReferenceId': '24651628', 'FullCitation': 'Meyer LA, et al. Int J Gynecol Cancer (2014) pmid: 24651628', 'Include': 'true'}, {'number': '633', 'ReferenceId': '21788564', 'FullCitation': 'Oza AM, et al. J. Clin. Oncol. (2011) pmid: 21788564', 'Include': 'true'}, {'number': '634', 'ReferenceId': '24166148', 'FullCitation': 'Mackay HJ, et al. Cancer (2014) pmid: 24166148', 'Include': 'true'}, {'number': '635', 'ReferenceId': '24456823', 'FullCitation': 'Fleming GF, et al. Gynecol. Oncol. (2014) pmid: 24456823', 'Include': 'true'}, {'number': '636', 'ReferenceId': '25173583', 'FullCitation': 'Tsoref D, et al. Gynecol. Oncol. (2014) pmid: 25173583', 'Include': 'true'}, {'number': '637', 'ReferenceId': '23238879', 'FullCitation': 'Trédan O, et al. Target Oncol (2013) pmid: 23238879', 'Include': 'true'}, {'number': '638', 'ReferenceId': '20681032', 'FullCitation': 'Slomovitz BM, et al. Cancer (2010) pmid: 20681032', 'Include': 'true'}, {'number': '639', 'ReferenceId': '20049735', 'FullCitation': 'Mendes_Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735', 'Include': 'true'}, {'number': '640', 'ReferenceId': '23881923', 'FullCitation': 'Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923', 'Include': 'true'}, {'number': '641', 'ReferenceId': '23565244', 'FullCitation': 'Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244', 'Include': 'true'}, {'number': '642', 'ReferenceId': '26905328', 'FullCitation': 'McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328', 'Include': 'true'}, {'number': '643', 'ReferenceId': '21468130', 'FullCitation': 'Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130', 'Include': 'true'}, {'number': '644', 'ReferenceId': '33242536', 'FullCitation': 'Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536', 'Include': 'true'}, {'number': '645', 'ReferenceId': '33970096', 'FullCitation': 'Pan M, et al. Perm J (2021) pmid: 33970096', 'Include': 'true'}, {'number': '646', 'ReferenceId': '32988624', 'FullCitation': 'Romero I, et al. Gynecol Oncol (2020) pmid: 32988624', 'Include': 'true'}, {'number': '647', 'ReferenceId': '32532747', 'FullCitation': 'Yap TA, et al. Cancer Discov (2020) pmid: 32532747', 'Include': 'true'}, {'number': '648', 'ReferenceId': '18781191', 'FullCitation': 'Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191', 'Include': 'true'}, {'number': '649', 'ReferenceId': '18794875', 'FullCitation': 'Orloff MS, et al. Oncogene (2008) pmid: 18794875', 'Include': 'true'}, {'number': '650', 'ReferenceId': '17167516', 'FullCitation': 'Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516', 'Include': 'true'}, {'number': '651', 'ReferenceId': '12093742', 'FullCitation': 'Pace P, et al. EMBO J. (2002) pmid: 12093742', 'Include': 'true'}, {'number': '652', 'ReferenceId': '21568838', 'FullCitation': 'Deakyne JS, et al. Biochemistry Mosc. (2011) pmid: 21568838', 'Include': 'true'}, {'number': '653', 'ReferenceId': '17938197', 'FullCitation': 'Alpi A, et al. Mol. Cell. Biol. (2007) pmid: 17938197', 'Include': 'true'}, {'number': '654', 'ReferenceId': '19111657', 'FullCitation': 'Alpi AF, et al. Mol. Cell (2008) pmid: 19111657', 'Include': 'true'}, {'number': '655', 'ReferenceId': '12973351', 'FullCitation': 'Meetei AR, et al. Nat. Genet. (2003) pmid: 12973351', 'Include': 'true'}, {'number': '656', 'ReferenceId': '16916645', 'FullCitation': 'Machida YJ, et al. Mol. Cell (2006) pmid: 16916645', 'Include': 'true'}, {'number': '657', 'ReferenceId': '21775430', 'FullCitation': 'Hodson C, et al. J. Biol. Chem. (2011) pmid: 21775430', 'Include': 'true'}, {'number': '658', 'ReferenceId': '24389026', 'FullCitation': 'Hodson C, et al. Structure (2014) pmid: 24389026', 'Include': 'true'}, {'number': '659', 'ReferenceId': '17352736', 'FullCitation': 'Seki S, et al. Genes Cells (2007) pmid: 17352736', 'Include': 'true'}, {'number': '660', 'ReferenceId': '19405097', 'FullCitation': 'Ali AM, et al. Hum. Mutat. (2009) pmid: 19405097', 'Include': 'true'}, {'number': '661', 'ReferenceId': '29335925', 'FullCitation': 'Fostira F, et al. Breast Cancer Res. Treat. (2018) pmid: 29335925', 'Include': 'true'}, {'number': '662', 'ReferenceId': '27084275', 'FullCitation': 'Hart SN, et al. BMJ Open (2016) pmid: 27084275', 'Include': 'true'}, {'number': '663', 'ReferenceId': '32235514', 'FullCitation': 'Del Valle J, et al. Cancers (Basel) (2020) pmid: 32235514', 'Include': 'true'}, {'number': '664', 'ReferenceId': '23613520', 'FullCitation': 'Chandrasekharappa SC, et al. Blood (2013) pmid: 23613520', 'Include': 'true'}, {'number': '665', 'ReferenceId': '28881617', 'FullCitation': 'Dicks E, et al. Oncotarget (2017) pmid: 28881617', 'Include': 'true'}, {'number': '666', 'ReferenceId': '30446494', 'FullCitation': 'Qu X, et al. Blood (2019) pmid: 30446494', 'Include': 'true'}, {'number': '667', 'ReferenceId': '1904223', 'FullCitation': 'Hattori S, et al. Biochem. Biophys. Res. Commun. (1991) pmid: 1904223', 'Include': 'true'}, {'number': '668', 'ReferenceId': '8628317', 'FullCitation': 'Morcos P, et al. Mol. Cell. Biol. (1996) pmid: 8628317', 'Include': 'true'}, {'number': '669', 'ReferenceId': '2121371', 'FullCitation': 'Ballester R, et al. Cell (1990) pmid: 2121371', 'Include': 'true'}, {'number': '670', 'ReferenceId': '2116237', 'FullCitation': 'Xu GF, et al. Cell (1990) pmid: 2116237', 'Include': 'true'}, {'number': '671', 'ReferenceId': '2121370', 'FullCitation': 'Martin GA, et al. Cell (1990) pmid: 2121370', 'Include': 'true'}, {'number': '672', 'ReferenceId': '22807134', 'FullCitation': 'Thomas L, et al. Hum. Mutat. (2012) pmid: 22807134', 'Include': 'true'}, {'number': '673', 'ReferenceId': '9300663', 'FullCitation': 'Skuse GR, et al. Hum. Mol. Genet. (1997) pmid: 9300663', 'Include': 'true'}, {'number': '674', 'ReferenceId': '11258625', 'FullCitation': 'Messiaen LM, et al. Genet. Med. () pmid: 11258625', 'Include': 'true'}, {'number': '675', 'ReferenceId': '10607834', 'FullCitation': 'Ars E, et al. Hum. Mol. Genet. (2000) pmid: 10607834', 'Include': 'true'}, {'number': '676', 'ReferenceId': '15863657', 'FullCitation': 'Messiaen LM, et al. J. Med. Genet. (2005) pmid: 15863657', 'Include': 'true'}, {'number': '677', 'ReferenceId': '8264648', 'FullCitation': 'Poullet P, et al. Mol. Cell. Biol. (1994) pmid: 8264648', 'Include': 'true'}, {'number': '678', 'ReferenceId': '30068706', 'FullCitation': 'Soumerai TE, et al. Clin. Cancer Res. (2018) pmid: 30068706', 'Include': 'true'}, {'number': '679', 'ReferenceId': '20062086', 'FullCitation': 'Murayama_Hosokawa S, et al. Oncogene (2010) pmid: 20062086', 'Include': 'true'}, {'number': '680', 'ReferenceId': '28029918', 'FullCitation': 'Dombi E, et al. N. Engl. J. Med. (2016) pmid: 28029918', 'Include': 'true'}, {'number': '681', 'ReferenceId': '33903938', 'FullCitation': 'Schalkwijk S, et al. Cancer Chemother Pharmacol (2021) pmid: 33903938', 'Include': 'true'}, {'number': '682', 'ReferenceId': '33751171', 'FullCitation': 'Toledano H, et al. Childs Nerv Syst (2021) pmid: 33751171', 'Include': 'true'}, {'number': '683', 'ReferenceId': '33939292', 'FullCitation': 'Ronsley R, et al. Cancer Med (2021) pmid: 33939292', 'Include': 'true'}, {'number': '684', 'ReferenceId': '31151904', 'FullCitation': 'Fangusaro J, et al. Lancet Oncol. (2019) pmid: 31151904', 'Include': 'true'}, {'number': '685', 'ReferenceId': '32780261', 'FullCitation': 'Manoharan N, et al. J Neurooncol (2020) pmid: 32780261', 'Include': 'true'}, {'number': '686', 'ReferenceId': '30097824', 'FullCitation': 'Kondyli M, et al. J Neurooncol (2018) pmid: 30097824', 'Include': 'true'}, {'number': '687', 'ReferenceId': '33082744', 'FullCitation': 'Awada G, et al. Case Rep Oncol () pmid: 33082744', 'Include': 'true'}, {'number': '688', 'ReferenceId': '32669708', 'FullCitation': 'Middleton G, et al. Nature (2020) pmid: 32669708', 'Include': 'true'}, {'number': '689', 'ReferenceId': '25314964', 'FullCitation': 'Weiss B, et al. Neuro_oncology (2015) pmid: 25314964', 'Include': 'true'}, {'number': '690', 'ReferenceId': '18164202', 'FullCitation': 'Johannessen CM, et al. Curr. Biol. (2008) pmid: 18164202', 'Include': 'true'}, {'number': '691', 'ReferenceId': '15937108', 'FullCitation': 'Johannessen CM, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15937108', 'Include': 'true'}, {'number': '692', 'ReferenceId': '24913553', 'FullCitation': 'Malone CF, et al. Cancer Discov (2014) pmid: 24913553', 'Include': 'true'}, {'number': '693', 'ReferenceId': '25344362', 'FullCitation': 'Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362', 'Include': 'true'}, {'number': '694', 'ReferenceId': '20027112', 'FullCitation': 'Jett K, et al. Genet. Med. (2010) pmid: 20027112', 'Include': 'true'}, {'number': '695', 'ReferenceId': '22240541', 'FullCitation': 'Patil S, et al. Oncologist (2012) pmid: 22240541', 'Include': 'true'}, {'number': '696', 'ReferenceId': '23036231', 'FullCitation': 'Evans DG, et al. Clin Sarcoma Res (2012) pmid: 23036231', 'Include': 'true'}, {'number': '697', 'ReferenceId': '8544190', 'FullCitation': 'Upadhyaya M, et al. J. Med. Genet. (1995) pmid: 8544190', 'Include': 'true'}, {'number': '698', 'ReferenceId': '19117870', 'FullCitation': 'Williams VC, et al. Pediatrics (2009) pmid: 19117870', 'Include': 'true'}, {'number': '699', 'ReferenceId': '16380997', 'FullCitation': 'Phillips WA, et al. Int. J. Cancer (2006) pmid: 16380997', 'Include': 'true'}, {'number': '700', 'ReferenceId': '23734178', 'FullCitation': 'Dbouk HA, et al. PLoS ONE (2013) pmid: 23734178', 'Include': 'true'}, {'number': '701', 'ReferenceId': '25982275', 'FullCitation': 'Pazarentzos E, et al. Oncogene (2016) pmid: 25982275', 'Include': 'true'}, {'number': '702', 'ReferenceId': '28002804', 'FullCitation': 'Karlsson T, et al. Oncotarget (2017) pmid: 28002804', 'Include': 'true'}, {'number': '703', 'ReferenceId': '18755892', 'FullCitation': 'Wee S, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18755892', 'Include': 'true'}, {'number': '704', 'ReferenceId': '18594509', 'FullCitation': 'Jia S, et al. Nature (2008) pmid: 18594509', 'Include': 'true'}, {'number': '705', 'ReferenceId': '24737887', 'FullCitation': 'Schmit F, et al. Proc. Natl. Acad. Sci. U.S.A. (2014) pmid: 24737887', 'Include': 'true'}, {'number': '706', 'ReferenceId': '11021964', 'FullCitation': 'Powers CJ, et al. Endocr. Relat. Cancer (2000) pmid: 11021964', 'Include': 'true'}, {'number': '707', 'ReferenceId': '20094046', 'FullCitation': 'Turner N, et al. Nat. Rev. Cancer (2010) pmid: 20094046', 'Include': 'true'}, {'number': '708', 'ReferenceId': '23527311', 'FullCitation': 'Reintjes N, et al. PLoS ONE (2013) pmid: 23527311', 'Include': 'true'}, {'number': '709', 'ReferenceId': '18552176', 'FullCitation': 'Dutt A, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18552176', 'Include': 'true'}, {'number': '710', 'ReferenceId': '22383975', 'FullCitation': 'Byron SA, et al. PLoS ONE (2012) pmid: 22383975', 'Include': 'true'}, {'number': '711', 'ReferenceId': '12952211', 'FullCitation': 'Ratisoontorn C, et al. Connect. Tissue Res. (2003) pmid: 12952211', 'Include': 'true'}, {'number': '712', 'ReferenceId': '15863029', 'FullCitation': 'Mohammadi M, et al. Cytokine Growth Factor Rev. (2005) pmid: 15863029', 'Include': 'true'}, {'number': '713', 'ReferenceId': '15282208', 'FullCitation': 'Ibrahimi OA, et al. Hum. Mol. Genet. (2004) pmid: 15282208', 'Include': 'true'}, {'number': '714', 'ReferenceId': '17525745', 'FullCitation': 'Pollock PM, et al. Oncogene (2007) pmid: 17525745', 'Include': 'true'}, {'number': '715', 'ReferenceId': '21908617', 'FullCitation': 'Kapeli K, et al. J. Biol. Chem. (2011) pmid: 21908617', 'Include': 'true'}, {'number': '716', 'ReferenceId': '21454610', 'FullCitation': 'Eathiraj S, et al. J. Biol. Chem. (2011) pmid: 21454610', 'Include': 'true'}, {'number': '717', 'ReferenceId': '26048680', 'FullCitation': 'Tanizaki J, et al. Cancer Res. (2015) pmid: 26048680', 'Include': 'true'}, {'number': '718', 'ReferenceId': '9266968', 'FullCitation': 'Lorenzi MV, et al. Oncogene (1997) pmid: 9266968', 'Include': 'true'}, {'number': '719', 'ReferenceId': '8205545', 'FullCitation': 'Itoh H, et al. Cancer Res. (1994) pmid: 8205545', 'Include': 'true'}, {'number': '720', 'ReferenceId': '17803937', 'FullCitation': 'Chen H, et al. Mol. Cell (2007) pmid: 17803937', 'Include': 'true'}, {'number': '721', 'ReferenceId': '7668257', 'FullCitation': 'Park WJ, et al. Am. J. Hum. Genet. (1995) pmid: 7668257', 'Include': 'true'}, {'number': '722', 'ReferenceId': '7719344', 'FullCitation': 'Wilkie AO, et al. Nat. Genet. (1995) pmid: 7719344', 'Include': 'true'}, {'number': '723', 'ReferenceId': '16418739', 'FullCitation': 'Lajeunie E, et al. Eur. J. Hum. Genet. (2006) pmid: 16418739', 'Include': 'true'}, {'number': '724', 'ReferenceId': '24411056', 'FullCitation': 'Chen CP, et al. Taiwan J Obstet Gynecol (2013) pmid: 24411056', 'Include': 'true'}, {'number': '725', 'ReferenceId': '19610084', 'FullCitation': 'Slavotinek A, et al. Am. J. Med. Genet. A (2009) pmid: 19610084', 'Include': 'true'}, {'number': '726', 'ReferenceId': '23468082', 'FullCitation': 'Gozgit JM, et al. Cancer Chemother. Pharmacol. (2013) pmid: 23468082', 'Include': 'true'}, {'number': '727', 'ReferenceId': '8696350', 'FullCitation': 'Przylepa KA, et al. Nat. Genet. (1996) pmid: 8696350', 'Include': 'true'}, {'number': '728', 'ReferenceId': '11781872', 'FullCitation': 'Kan SH, et al. Am. J. Hum. Genet. (2002) pmid: 11781872', 'Include': 'true'}, {'number': '729', 'ReferenceId': '23300780', 'FullCitation': 'Krakstad C, et al. PLoS ONE (2012) pmid: 23300780', 'Include': 'true'}, {'number': '730', 'ReferenceId': '21725289', 'FullCitation': 'Gatius S, et al. Mod. Pathol. (2011) pmid: 21725289', 'Include': 'true'}, {'number': '731', 'ReferenceId': '18292933', 'FullCitation': 'Ishikawa A, et al. Int. J. Oncol. (2008) pmid: 18292933', 'Include': 'true'}, {'number': '732', 'ReferenceId': '9070494', 'FullCitation': 'Siegfried S, et al. Cancer (1997) pmid: 9070494', 'Include': 'true'}, {'number': '733', 'ReferenceId': '26324363', 'FullCitation': 'Tabernero J, et al. J. Clin. Oncol. (2015) pmid: 26324363', 'Include': 'true'}, {'number': '734', 'ReferenceId': '31371345', 'FullCitation': 'Krook MA, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 31371345', 'Include': 'true'}, {'number': '735', 'ReferenceId': '32203698', 'FullCitation': 'Abou_Alfa GK, et al. Lancet Oncol. (2020) pmid: 32203698', 'Include': 'true'}, {'number': '736', 'ReferenceId': '27870574', 'FullCitation': 'Nogova L, et al. J. Clin. Oncol. (2017) pmid: 27870574', 'Include': 'true'}, {'number': '737', 'ReferenceId': '27179038', 'FullCitation': 'Pearson A, et al. Cancer Discov (2016) pmid: 27179038', 'Include': 'true'}, {'number': '738', 'ReferenceId': '29177434', 'FullCitation': 'Van Cutsem E, et al. Ann. Oncol. (2017) pmid: 29177434', 'Include': 'true'}, {'number': '739', 'ReferenceId': '31195180', 'FullCitation': 'Aggarwal C, et al. J Thorac Oncol (2019) pmid: 31195180', 'Include': 'true'}, {'number': '740', 'ReferenceId': '30745300', 'FullCitation': 'Voss MH, et al. Clin. Cancer Res. (2019) pmid: 30745300', 'Include': 'true'}, {'number': '741', 'ReferenceId': '33926920', 'FullCitation': 'Cleary JM, et al. Cancer Discov (2021) pmid: 33926920', 'Include': 'true'}, {'number': '742', 'ReferenceId': '31405822', 'FullCitation': 'Schuler M, et al. Lancet Oncol. (2019) pmid: 31405822', 'Include': 'true'}, {'number': '743', 'ReferenceId': '31109923', 'FullCitation': 'Goyal L, et al. Cancer Discov (2019) pmid: 31109923', 'Include': 'true'}, {'number': '744', 'ReferenceId': '30420614', 'FullCitation': 'Mazzaferro V, et al. Br. J. Cancer (2019) pmid: 30420614', 'Include': 'true'}, {'number': '745', 'ReferenceId': '24550739', 'FullCitation': 'Borad MJ, et al. PLoS Genet. (2014) pmid: 24550739', 'Include': 'true'}, {'number': '746', 'ReferenceId': '23786770', 'FullCitation': 'Liao RG, et al. Cancer Res. (2013) pmid: 23786770', 'Include': 'true'}, {'number': '747', 'ReferenceId': '22238366', 'FullCitation': 'Gozgit JM, et al. Mol. Cancer Ther. (2012) pmid: 22238366', 'Include': 'true'}, {'number': '748', 'ReferenceId': '29765547', 'FullCitation': 'Slosberg ED, et al. Oncotarget (2018) pmid: 29765547', 'Include': 'true'}, {'number': '749', 'ReferenceId': '24856830', 'FullCitation': 'Solomon DA, et al. BMB Rep (2014) pmid: 24856830', 'Include': 'true'}, {'number': '750', 'ReferenceId': '24132290', 'FullCitation': 'Kandoth C, et al. Nature (2013) pmid: 24132290', 'Include': 'true'}, {'number': '751', 'ReferenceId': '24484537', 'FullCitation': 'Evers L, et al. Genome Med (2014) pmid: 24484537', 'Include': 'true'}, {'number': '752', 'ReferenceId': '24121792', 'FullCitation': 'Guo G, et al. Nat. Genet. (2013) pmid: 24121792', 'Include': 'true'}, {'number': '753', 'ReferenceId': '24121789', 'FullCitation': 'Solomon DA, et al. Nat. Genet. (2013) pmid: 24121789', 'Include': 'true'}, {'number': '754', 'ReferenceId': '21852505', 'FullCitation': 'Solomon DA, et al. Science (2011) pmid: 21852505', 'Include': 'true'}, {'number': '755', 'ReferenceId': '25006131', 'FullCitation': 'Thota S, et al. Blood (2014) pmid: 25006131', 'Include': 'true'}, {'number': '756', 'ReferenceId': '24121791', 'FullCitation': 'Balbás_Martínez C, et al. Nat. Genet. (2013) pmid: 24121791', 'Include': 'true'}, {'number': '757', 'ReferenceId': '23955599', 'FullCitation': 'Kon A, et al. Nat. Genet. (2013) pmid: 23955599', 'Include': 'true'}, {'number': '758', 'ReferenceId': '24270882', 'FullCitation': 'Taylor CF, et al. Hum. Mol. Genet. (2014) pmid: 24270882', 'Include': 'true'}, {'number': '759', 'ReferenceId': '25223734', 'FullCitation': 'Tirode F, et al. Cancer Discov (2014) pmid: 25223734', 'Include': 'true'}, {'number': '760', 'ReferenceId': '25010205', 'FullCitation': 'Brohl AS, et al. PLoS Genet. (2014) pmid: 25010205', 'Include': 'true'}, {'number': '761', 'ReferenceId': '23926200', 'FullCitation': 'Hoang ML, et al. Sci Transl Med (2013) pmid: 23926200', 'Include': 'true'}, {'number': '762', 'ReferenceId': '27500726', 'FullCitation': 'Shen CH, et al. Nat. Med. (2016) pmid: 27500726', 'Include': 'true'}, {'number': '763', 'ReferenceId': '24356817', 'FullCitation': 'Bailey ML, et al. Mol. Cancer Ther. (2014) pmid: 24356817', 'Include': 'true'}, {'number': '764', 'ReferenceId': '12617994', 'FullCitation': 'Gupta_Rossi N, et al. Mol. Immunol. (2003) pmid: 12617994', 'Include': 'true'}, {'number': '765', 'ReferenceId': '22585168', 'FullCitation': 'Weigert O, et al. Cancer Discov (2012) pmid: 22585168', 'Include': 'true'}, {'number': '766', 'ReferenceId': '22960745', 'FullCitation': 'Nature (2012) pmid: 22960745', 'Include': 'true'}, {'number': '767', 'ReferenceId': '21720365', 'FullCitation': 'Nature (2011) pmid: 21720365', 'Include': 'true'}, {'number': '768', 'ReferenceId': '21447625', 'FullCitation': 'Vicent GP, et al. Genes Dev. (2011) pmid: 21447625', 'Include': 'true'}, {'number': '769', 'ReferenceId': '21671394', 'FullCitation': 'Hannibal MC, et al. Am. J. Med. Genet. A (2011) pmid: 21671394', 'Include': 'true'}, {'number': '770', 'ReferenceId': '31128216', 'FullCitation': 'Fagan RJ, et al. Cancer Lett. (2019) pmid: 31128216', 'Include': 'true'}, {'number': '771', 'ReferenceId': '28007623', 'FullCitation': 'Augert A, et al. J Thorac Oncol (2017) pmid: 28007623', 'Include': 'true'}, {'number': '772', 'ReferenceId': '29627316', 'FullCitation': 'Ardeshir_Larijani F, et al. Clin Lung Cancer (2018) pmid: 29627316', 'Include': 'true'}, {'number': '773', 'ReferenceId': '29950560', 'FullCitation': 'Hillman RT, et al. Nat Commun (2018) pmid: 29950560', 'Include': 'true'}, {'number': '774', 'ReferenceId': '29532228', 'FullCitation': 'Abudureheman A, et al. J. Cancer Res. Clin. Oncol. (2018) pmid: 29532228', 'Include': 'true'}, {'number': '775', 'ReferenceId': '23916100', 'FullCitation': 'Clynes D, et al. Trends Biochem. Sci. (2013) pmid: 23916100', 'Include': 'true'}, {'number': '776', 'ReferenceId': '23249563', 'FullCitation': 'Ratnakumar K, et al. Epigenetics (2013) pmid: 23249563', 'Include': 'true'}, {'number': '777', 'ReferenceId': '22829774', 'FullCitation': 'Lovejoy CA, et al. PLoS Genet. (2012) pmid: 22829774', 'Include': 'true'}, {'number': '778', 'ReferenceId': '23185534', 'FullCitation': 'Bower K, et al. PLoS ONE (2012) pmid: 23185534', 'Include': 'true'}, {'number': '779', 'ReferenceId': '21719641', 'FullCitation': 'Heaphy CM, et al. Science (2011) pmid: 21719641', 'Include': 'true'}, {'number': '780', 'ReferenceId': '25229770', 'FullCitation': 'Liau JY, et al. Am. J. Surg. Pathol. (2015) pmid: 25229770', 'Include': 'true'}, {'number': '781', 'ReferenceId': '17296936', 'FullCitation': 'Nan X, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17296936', 'Include': 'true'}, {'number': '782', 'ReferenceId': '14729260', 'FullCitation': 'Garrick D, et al. Gene (2004) pmid: 14729260', 'Include': 'true'}, {'number': '783', 'ReferenceId': '21666677', 'FullCitation': 'Eustermann S, et al. Nat. Struct. Mol. Biol. (2011) pmid: 21666677', 'Include': 'true'}, {'number': '784', 'ReferenceId': '25593184', 'FullCitation': 'Flynn RL, et al. Science (2015) pmid: 25593184', 'Include': 'true'}, {'number': '785', 'ReferenceId': '7697714', 'FullCitation': 'Gibbons RJ, et al. Cell (1995) pmid: 7697714', 'Include': 'true'}, {'number': '786', 'ReferenceId': '21252315', 'FullCitation': 'Jiao Y, et al. Science (2011) pmid: 21252315', 'Include': 'true'}, {'number': '787', 'ReferenceId': '25608029', 'FullCitation': 'Fishbein L, et al. Nat Commun (2015) pmid: 25608029', 'Include': 'true'}, {'number': '788', 'ReferenceId': '22416102', 'FullCitation': 'Cheung NK, et al. JAMA (2012) pmid: 22416102', 'Include': 'true'}, {'number': '789', 'ReferenceId': '22367537', 'FullCitation': 'Molenaar JJ, et al. Nature (2012) pmid: 22367537', 'Include': 'true'}, {'number': '790', 'ReferenceId': '23334666', 'FullCitation': 'Pugh TJ, et al. Nat. Genet. (2013) pmid: 23334666', 'Include': 'true'}, {'number': '791', 'ReferenceId': '23702928', 'FullCitation': 'Cheung NK, et al. Nat. Rev. Cancer (2013) pmid: 23702928', 'Include': 'true'}, {'number': '792', 'ReferenceId': '24148618', 'FullCitation': 'Marinoni I, et al. Gastroenterology (2014) pmid: 24148618', 'Include': 'true'}, {'number': '793', 'ReferenceId': '24468746', 'FullCitation': 'Qadeer ZA, et al. J. Invest. Dermatol. (2014) pmid: 24468746', 'Include': 'true'}, {'number': '794', 'ReferenceId': '26936505', 'FullCitation': 'Koschmann C, et al. Sci Transl Med (2016) pmid: 26936505', 'Include': 'true'}, {'number': '795', 'ReferenceId': '23104868', 'FullCitation': 'Kannan K, et al. Oncotarget (2012) pmid: 23104868', 'Include': 'true'}, {'number': '796', 'ReferenceId': '24559763', 'FullCitation': 'Haberler C, et al. Clin. Neuropathol. () pmid: 24559763', 'Include': 'true'}, {'number': '797', 'ReferenceId': '25427834', 'FullCitation': 'Reuss DE, et al. Acta Neuropathol. (2015) pmid: 25427834', 'Include': 'true'}, {'number': '798', 'ReferenceId': '25143301', 'FullCitation': 'Sahm F, et al. Acta Neuropathol. (2014) pmid: 25143301', 'Include': 'true'}, {'number': '799', 'ReferenceId': '31551363', 'FullCitation': 'Liang J, et al. Cancer Res (2020) pmid: 31551363', 'Include': 'true'}, {'number': '800', 'ReferenceId': '34118569', 'FullCitation': 'Garbarino J, et al. Transl Oncol (2021) pmid: 34118569', 'Include': 'true'}, {'number': '801', 'ReferenceId': '32846370', 'FullCitation': 'George SL, et al. EBioMedicine (2020) pmid: 32846370', 'Include': 'true'}, {'number': '802', 'ReferenceId': '11331609', 'FullCitation': 'Shi Y, et al. Genes Dev. (2001) pmid: 11331609', 'Include': 'true'}, {'number': '803', 'ReferenceId': '12897056', 'FullCitation': 'Ariyoshi M, et al. Genes Dev. (2003) pmid: 12897056', 'Include': 'true'}, {'number': '804', 'ReferenceId': '12594956', 'FullCitation': 'Kuroda K, et al. Immunity (2003) pmid: 12594956', 'Include': 'true'}, {'number': '805', 'ReferenceId': '12374742', 'FullCitation': 'Oswald F, et al. EMBO J. (2002) pmid: 12374742', 'Include': 'true'}, {'number': '806', 'ReferenceId': '19379690', 'FullCitation': 'Kopan R, et al. Cell (2009) pmid: 19379690', 'Include': 'true'}, {'number': '807', 'ReferenceId': '23778141', 'FullCitation': 'Stephens PJ, et al. J. Clin. Invest. (2013) pmid: 23778141', 'Include': 'true'}, {'number': '808', 'ReferenceId': '32167863', 'FullCitation': 'Makker V, et al. J. Clin. Oncol. (2020) pmid: 32167863', 'Include': 'true'}, {'number': '809', 'ReferenceId': '28489510', 'FullCitation': 'Ott PA, et al. J Clin Oncol (2017) pmid: 28489510', 'Include': 'true'}, {'number': '810', 'ReferenceId': '26970723', 'FullCitation': 'Fehrenbacher L, et al. Lancet (2016) pmid: 26970723', 'Include': 'true'}, {'number': '811', 'ReferenceId': '25428504', 'FullCitation': 'Herbst RS, et al. Nature (2014) pmid: 25428504', 'Include': 'true'}, {'number': '812', 'ReferenceId': '26952546', 'FullCitation': 'Rosenberg JE, et al. Lancet (2016) pmid: 26952546', 'Include': 'true'}, {'number': '813', 'ReferenceId': '25428503', 'FullCitation': 'Powles T, et al. Nature (2014) pmid: 25428503', 'Include': 'true'}, {'number': '814', 'ReferenceId': '31780255', 'FullCitation': 'Geoerger B, et al. Lancet Oncol. (2020) pmid: 31780255', 'Include': 'true'}, {'number': '815', 'ReferenceId': '26755520', 'FullCitation': 'McDermott DF, et al. J. Clin. Oncol. (2016) pmid: 26755520', 'Include': 'true'}, {'number': '816', 'ReferenceId': '30918950', 'FullCitation': 'Hellmann MD, et al. Ann. Oncol. (2019) pmid: 30918950', 'Include': 'true'}, {'number': '817', 'ReferenceId': '31204078', 'FullCitation': 'Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31204078', 'Include': 'true'}, {'number': '818', 'ReferenceId': '24912489', 'FullCitation': 'Wheler JJ, et al. Oncotarget (2014) pmid: 24912489', 'Include': 'true'}, {'number': '819', 'ReferenceId': '25649062', 'FullCitation': 'Noriega_Iriondo MF, et al. Hered Cancer Clin Pract (2015) pmid: 25649062', 'Include': 'true'}, {'number': '820', 'ReferenceId': '23066039', 'FullCitation': 'Janku F, et al. Cancer Res. (2013) pmid: 23066039', 'Include': 'true'}, {'number': '821', 'ReferenceId': '22271473', 'FullCitation': 'Janku F, et al. J. Clin. Oncol. (2012) pmid: 22271473', 'Include': 'true'}, {'number': '822', 'ReferenceId': '21216929', 'FullCitation': 'Janku F, et al. Mol. Cancer Ther. (2011) pmid: 21216929', 'Include': 'true'}, {'number': '823', 'ReferenceId': '25878190', 'FullCitation': 'Moulder S, et al. Ann. Oncol. (2015) pmid: 25878190', 'Include': 'true'}, {'number': '824', 'ReferenceId': '29863979', 'FullCitation': 'Migden MR, et al. N. Engl. J. Med. (2018) pmid: 29863979', 'Include': 'true'}, {'number': '825', 'ReferenceId': '33001143', 'FullCitation': 'Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143', 'Include': 'true'}, {'number': '826', 'ReferenceId': '23423489', 'FullCitation': 'Plummer R, et al. Cancer Chemother. Pharmacol. (2013) pmid: 23423489', 'Include': 'true'}, {'number': '827', 'ReferenceId': '19047122', 'FullCitation': 'Plummer R, et al. Clin. Cancer Res. (2008) pmid: 19047122', 'Include': 'true'}, {'number': '828', 'ReferenceId': '28222073', 'FullCitation': 'Wilson RH, et al. Br. J. Cancer (2017) pmid: 28222073', 'Include': 'true'}, {'number': '829', 'ReferenceId': '26961146', 'FullCitation': 'Matulonis UA, et al. Ann. Oncol. (2016) pmid: 26961146', 'Include': 'true'}, {'number': '830', 'ReferenceId': '22452356', 'FullCitation': 'Ledermann J, et al. N. Engl. J. Med. (2012) pmid: 22452356', 'Include': 'true'}, {'number': '831', 'ReferenceId': '24882434', 'FullCitation': 'Ledermann J, et al. Lancet Oncol. (2014) pmid: 24882434', 'Include': 'true'}, {'number': '832', 'ReferenceId': '32343890', 'FullCitation': 'de Bono J, et al. N. Engl. J. Med. (2020) pmid: 32343890', 'Include': 'true'}, {'number': '833', 'ReferenceId': '30541756', 'FullCitation': 'Seligson ND, et al. Oncologist (2019) pmid: 30541756', 'Include': 'true'}, {'number': '834', 'ReferenceId': '31068370', 'FullCitation': 'Lin J, et al. Clin. Cancer Res. (2019) pmid: 31068370', 'Include': 'true'}, {'number': '835', 'ReferenceId': '29680362', 'FullCitation': 'Necchi A, et al. Eur. J. Cancer (2018) pmid: 29680362', 'Include': 'true'}, {'number': '836', 'ReferenceId': '3253274', 'FullCitation': 'Vinitski S, et al. Heart Vessels (1988) pmid: 3253274', 'Include': 'true'}, {'number': '837', 'ReferenceId': '29937315', 'FullCitation': 'Gockley AA, et al. Gynecol. Oncol. (2018) pmid: 29937315', 'Include': 'true'}, {'number': '838', 'ReferenceId': '25025963', 'FullCitation': 'Del Conte G, et al. Br. J. Cancer (2014) pmid: 25025963', 'Include': 'true'}, {'number': '839', 'ReferenceId': '21447615', 'FullCitation': 'Kollmannsberger C, et al. Ann. Oncol. (2012) pmid: 21447615', 'Include': 'true'}, {'number': '840', 'ReferenceId': '23262204', 'FullCitation': 'Alvarez EA, et al. Gynecol. Oncol. (2013) pmid: 23262204', 'Include': 'true'}, {'number': '841', 'ReferenceId': '29588307', 'FullCitation': 'Dhami J, et al. Cold Spring Harb Mol Case Stud (2018) pmid: 29588307', 'Include': 'true'}, {'number': '842', 'ReferenceId': '31461377', 'FullCitation': 'Konstantinopoulos PA, et al. J. Clin. Oncol. (2019) pmid: 31461377', 'Include': 'true'}, {'number': '843', 'ReferenceId': '25891304', 'FullCitation': 'Postow MA, et al. N. Engl. J. Med. (2015) pmid: 25891304', 'Include': 'true'}, {'number': '844', 'ReferenceId': '26027431', 'FullCitation': 'Larkin J, et al. N. Engl. J. Med. (2015) pmid: 26027431', 'Include': 'true'}, {'number': '845', 'ReferenceId': '25399552', 'FullCitation': 'Robert C, et al. N. Engl. J. Med. (2015) pmid: 25399552', 'Include': 'true'}, {'number': '846', 'ReferenceId': '24590637', 'FullCitation': 'Topalian SL, et al. J. Clin. Oncol. (2014) pmid: 24590637', 'Include': 'true'}, {'number': '847', 'ReferenceId': '25795410', 'FullCitation': 'Weber JS, et al. Lancet Oncol. (2015) pmid: 25795410', 'Include': 'true'}, {'number': '848', 'ReferenceId': '26028407', 'FullCitation': 'Brahmer J, et al. N. Engl. J. Med. (2015) pmid: 26028407', 'Include': 'true'}, {'number': '849', 'ReferenceId': '26412456', 'FullCitation': 'Borghaei H, et al. N. Engl. J. Med. (2015) pmid: 26412456', 'Include': 'true'}, {'number': '850', 'ReferenceId': '31100038', 'FullCitation': 'Sharma P, et al. J. Clin. Oncol. (2019) pmid: 31100038', 'Include': 'true'}, {'number': '851', 'ReferenceId': '28131785', 'FullCitation': 'Sharma P, et al. Lancet Oncol. (2017) pmid: 28131785', 'Include': 'true'}, {'number': '852', 'ReferenceId': '25452452', 'FullCitation': 'Motzer RJ, et al. J. Clin. Oncol. (2015) pmid: 25452452', 'Include': 'true'}, {'number': '853', 'ReferenceId': '22658127', 'FullCitation': 'Topalian SL, et al. N. Engl. J. Med. (2012) pmid: 22658127', 'Include': 'true'}, {'number': '854', 'ReferenceId': '20516446', 'FullCitation': 'Brahmer JR, et al. J. Clin. Oncol. (2010) pmid: 20516446', 'Include': 'true'}, {'number': '855', 'ReferenceId': '26406148', 'FullCitation': 'Motzer RJ, et al. N. Engl. J. Med. (2015) pmid: 26406148', 'Include': 'true'}, {'number': '856', 'ReferenceId': '28734759', 'FullCitation': 'Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759', 'Include': 'true'}, {'number': '857', 'ReferenceId': '29355075', 'FullCitation': 'Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075', 'Include': 'true'}, {'number': '858', 'ReferenceId': '22658128', 'FullCitation': 'Brahmer JR, et al. N. Engl. J. Med. (2012) pmid: 22658128', 'Include': 'true'}, {'number': '859', 'ReferenceId': '26351349', 'FullCitation': 'Hamanishi J, et al. J. Clin. Oncol. (2015) pmid: 26351349', 'Include': 'true'}, {'number': '860', 'ReferenceId': '31074244', 'FullCitation': 'Normann MC, et al. J Gynecol Oncol (2019) pmid: 31074244', 'Include': 'true'}, {'number': '861', 'ReferenceId': '27269741', 'FullCitation': 'Antonia SJ, et al. Lancet Oncol. (2016) pmid: 27269741', 'Include': 'true'}, {'number': '862', 'ReferenceId': '30110194', 'FullCitation': 'Janjigian YY, et al. J. Clin. Oncol. (2018) pmid: 30110194', 'Include': 'true'}, {'number': '863', 'ReferenceId': '25482239', 'FullCitation': 'Ansell SM, et al. N. Engl. J. Med. (2015) pmid: 25482239', 'Include': 'true'}, {'number': '864', 'ReferenceId': '27451390', 'FullCitation': 'Younes A, et al. Lancet Oncol. (2016) pmid: 27451390', 'Include': 'true'}, {'number': '865', 'ReferenceId': '30361170', 'FullCitation': 'Hodi FS, et al. Lancet Oncol. (2018) pmid: 30361170', 'Include': 'true'}, {'number': '866', 'ReferenceId': '27622997', 'FullCitation': 'Hodi FS, et al. Lancet Oncol. (2016) pmid: 27622997', 'Include': 'true'}, {'number': '867', 'ReferenceId': '31562797', 'FullCitation': 'Larkin J, et al. N. Engl. J. Med. (2019) pmid: 31562797', 'Include': 'true'}, {'number': '868', 'ReferenceId': '31562796', 'FullCitation': 'Hellmann MD, et al. N. Engl. J. Med. (2019) pmid: 31562796', 'Include': 'true'}, {'number': '869', 'ReferenceId': '31427204', 'FullCitation': 'Motzer RJ, et al. Lancet Oncol. (2019) pmid: 31427204', 'Include': 'true'}, {'number': '870', 'ReferenceId': '29562145', 'FullCitation': 'Motzer RJ, et al. N. Engl. J. Med. (2018) pmid: 29562145', 'Include': 'true'}, {'number': '871', 'ReferenceId': '28778959', 'FullCitation': 'Kollipara R, et al. Oncologist (2017) pmid: 28778959', 'Include': 'true'}, {'number': '872', 'ReferenceId': '22805291', 'FullCitation': 'Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291', 'Include': 'true'}, {'number': '873', 'ReferenceId': '22767668', 'FullCitation': 'Leijen S, et al. Clin. Cancer Res. (2012) pmid: 22767668', 'Include': 'true'}, {'number': '874', 'ReferenceId': '24947927', 'FullCitation': 'Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927', 'Include': 'true'}, {'number': '875', 'ReferenceId': '23583440', 'FullCitation': 'Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440', 'Include': 'true'}, {'number': '876', 'ReferenceId': '30110579', 'FullCitation': 'Litton JK, et al. N. Engl. J. Med. (2018) pmid: 30110579', 'Include': 'true'}, {'number': '877', 'ReferenceId': '30124753', 'FullCitation': 'Ettl J, et al. Ann. Oncol. (2018) pmid: 30124753', 'Include': 'true'}, {'number': '878', 'ReferenceId': '28242752', 'FullCitation': 'de Bono J, et al. Cancer Discov (2017) pmid: 28242752', 'Include': 'true'}, {'number': '879', 'ReferenceId': '30099369', 'FullCitation': 'Lu E, et al. J Natl Compr Canc Netw (2018) pmid: 30099369', 'Include': 'true'}, {'number': '880', 'ReferenceId': '28339824', 'FullCitation': 'Banerjee A, et al. Neuro_oncology (2017) pmid: 28339824', 'Include': 'true'}, {'number': '881', 'ReferenceId': '24567366', 'FullCitation': 'Gupta A, et al. Ann. Oncol. (2014) pmid: 24567366', 'Include': 'true'}, {'number': '882', 'ReferenceId': '23735514', 'FullCitation': 'Robert C, et al. Lancet Oncol. (2013) pmid: 23735514', 'Include': 'true'}, {'number': '883', 'ReferenceId': '22048237', 'FullCitation': 'Kirkwood JM, et al. Clin. Cancer Res. (2012) pmid: 22048237', 'Include': 'true'}, {'number': '884', 'ReferenceId': '20179232', 'FullCitation': 'Banerji U, et al. Clin. Cancer Res. (2010) pmid: 20179232', 'Include': 'true'}, {'number': '885', 'ReferenceId': '22293660', 'FullCitation': 'Boers_Sonderen MJ, et al. Anticancer Drugs (2012) pmid: 22293660', 'Include': 'true'}, {'number': '886', 'ReferenceId': '25667274', 'FullCitation': 'Lopez_Chavez A, et al. J. Clin. Oncol. (2015) pmid: 25667274', 'Include': 'true'}, {'number': '887', 'ReferenceId': '20802351', 'FullCitation': 'Hainsworth JD, et al. J Thorac Oncol (2010) pmid: 20802351', 'Include': 'true'}, {'number': '888', 'ReferenceId': '25887099', 'FullCitation': 'Coleman RL, et al. Gynecol. Oncol. (2015) pmid: 25887099', 'Include': 'true'}, {'number': '889', 'ReferenceId': '26666244', 'FullCitation': 'Deming DA, et al. Invest New Drugs (2016) pmid: 26666244', 'Include': 'true'}, {'number': '890', 'ReferenceId': '30042150', 'FullCitation': 'Krishnamurthy A, et al. Cancer Res. (2018) pmid: 30042150', 'Include': 'true'}, {'number': '891', 'ReferenceId': '28424891', 'FullCitation': 'Infante JR, et al. Invest New Drugs (2017) pmid: 28424891', 'Include': 'true'}, {'number': '892', 'ReferenceId': '28264648', 'FullCitation': 'LoRusso PM, et al. BMC Cancer (2017) pmid: 28264648', 'Include': 'true'}, {'number': '893', 'ReferenceId': '25516890', 'FullCitation': 'Tolcher AW, et al. Clin. Cancer Res. (2015) pmid: 25516890', 'Include': 'true'}, {'number': '894', 'ReferenceId': '25268371', 'FullCitation': 'Wilky BA, et al. Br. J. Cancer (2015) pmid: 25268371', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2021_09_28 20:19:44', 'OpName': 'Douglas Lin, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Douglas Lin, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': '994x'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': '372 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '_3 pca_score'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': 'Units Not Reported'}]}, 'comments': {'comment': {'commentedBy': 'Douglas Lin, M.D.', 'commentedDts': '2021_09_28T20:18:20.000Z', 'text': 'The genomic profile is compatible with a POLE_ultramutated endometrial carcinoma.'}}, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'UTERUS', 'disease_ontology': 'Uterus endometrial adenocarcinoma endometrioid', 'flowcell_analysis': '2000017789', 'gender': 'female', 'pathology_diagnosis': 'Endometrioid Carcinoma', 'percent_tumor_nuclei': '30', 'pipeline_version': 'v3.7.0', 'purity_assessment': '8.7', 'specimen': 'ORD_1194331_01*US1153674.01', 'study': 'CLINICAL_F1CDx', 'test_request': 'ORD_1194331_01', 'test_type': 'FoundationOneDx', 'tissue_of_origin': 'Uterus', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'DX1', 'mean_exon_depth': '1008.49', 'name': 'SQ_US1153674.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.3107', 'cds_effect': '1095C>A', 'depth': '811', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MAF', 'percent_reads': '31.07', 'position': 'chr16:79632705', 'protein_effect': 'N365K', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005360', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3472', 'cds_effect': '1231G>C', 'depth': '720', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'POLE', 'percent_reads': '34.72', 'position': 'chr12:133250289', 'protein_effect': 'V411L', 'status': 'known', 'strand': '_', 'transcript': 'NM_006231', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3223', 'cds_effect': '1735G>T', 'depth': '636', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MERTK', 'percent_reads': '32.23', 'position': 'chr2:112760713', 'protein_effect': 'D579Y', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006343', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3432', 'cds_effect': '1422A>C', 'depth': '641', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NBN', 'percent_reads': '34.32', 'position': 'chr8:90965895', 'protein_effect': 'E474D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002485', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3775', 'cds_effect': '5102C>A', 'depth': '845', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATR', 'percent_reads': '37.75', 'position': 'chr3:142224075', 'protein_effect': 'S1701Y', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001184', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.35', 'cds_effect': '2177A>C', 'depth': '680', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CDK12', 'percent_reads': '35.0', 'position': 'chr17:37649072', 'protein_effect': 'K726T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_016507', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3172', 'cds_effect': '2353G>A', 'depth': '908', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ROS1', 'percent_reads': '31.72', 'position': 'chr6:117704623', 'protein_effect': 'V785M', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002944', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.328', 'cds_effect': '2115G>T', 'depth': '991', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RBM10', 'percent_reads': '32.8', 'position': 'chrX:47044715', 'protein_effect': 'E705D', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005676', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3599', 'cds_effect': '6998G>A', 'depth': '978', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NOTCH1', 'percent_reads': '35.99', 'position': 'chr9:139391193', 'protein_effect': 'G2333D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_017617', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2846', 'cds_effect': '2765G>T', 'depth': '889', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ROS1', 'percent_reads': '28.46', 'position': 'chr6:117687286', 'protein_effect': 'R922I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002944', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.1101', 'cds_effect': '1732C>A', 'depth': '899', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB3', 'percent_reads': '11.01', 'position': 'chr12:56488213', 'protein_effect': 'H578N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001982', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3232', 'cds_effect': '7720C>A', 'depth': '1086', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'APC', 'percent_reads': '32.32', 'position': 'chr5:112179011', 'protein_effect': 'L2574I', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000038', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.353', 'cds_effect': '2552G>A', 'depth': '966', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ARID1A', 'percent_reads': '35.3', 'position': 'chr1:27089596', 'protein_effect': 'G851D', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006015', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3059', 'cds_effect': '67C>A', 'depth': '765', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BTK', 'percent_reads': '30.59', 'position': 'chrX:100630206', 'protein_effect': 'L23I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000061', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3717', 'cds_effect': '652G>A', 'depth': '748', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ESR1', 'percent_reads': '37.17', 'position': 'chr6:152201798', 'protein_effect': 'D218N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000125', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3464', 'cds_effect': '896C>A', 'depth': '791', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'HGF', 'percent_reads': '34.64', 'position': 'chr7:81359065', 'protein_effect': 'P299H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000601', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.7148', 'cds_effect': '7348C>T', 'depth': '845', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'NF1', 'percent_reads': '71.48', 'position': 'chr17:29677227', 'protein_effect': 'R2450*', 'status': 'known', 'strand': '+', 'transcript': 'NM_001042492', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3722', 'cds_effect': '1038G>T', 'depth': '1080', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PDGFRA', 'percent_reads': '37.22', 'position': 'chr4:55133825', 'protein_effect': 'R346S', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006206', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3354', 'cds_effect': '351G>T', 'depth': '790', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'DIS3', 'percent_reads': '33.54', 'position': 'chr13:73355019', 'protein_effect': 'E117D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_014953', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.341', 'cds_effect': '2410C>A', 'depth': '698', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RICTOR', 'percent_reads': '34.1', 'position': 'chr5:38958555', 'protein_effect': 'L804I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_152756', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3557', 'cds_effect': '1489G>A', 'depth': '776', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KEL', 'percent_reads': '35.57', 'position': 'chr7:142641412', 'protein_effect': 'D497N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000420', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3669', 'cds_effect': '700C>T', 'depth': '586', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'U2AF1', 'percent_reads': '36.69', 'position': 'chr21:44513235', 'protein_effect': 'R234C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006758', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3502', 'cds_effect': '2822C>A', 'depth': '931', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MLL', 'percent_reads': '35.02', 'position': 'chr11:118344696', 'protein_effect': 'S941Y', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005933', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.338', 'cds_effect': '1407G>T', 'depth': '938', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'DAXX', 'percent_reads': '33.8', 'position': 'chr6:33287846', 'protein_effect': 'Q469H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001350', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3574', 'cds_effect': '400T>G', 'depth': '747', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CRKL', 'percent_reads': '35.74', 'position': 'chr22:21288155', 'protein_effect': 'F134V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005207', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.322', 'cds_effect': '189G>T', 'depth': '736', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NF1', 'percent_reads': '32.2', 'position': 'chr17:29483129', 'protein_effect': 'K63N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001042492', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3632', 'cds_effect': '1087C>T', 'depth': '782', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'VEGFA', 'percent_reads': '36.32', 'position': 'chr6:43749694', 'protein_effect': 'P363S', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001025366', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.4659', 'cds_effect': '2489G>A', 'depth': '983', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'LTK', 'percent_reads': '46.59', 'position': 'chr15:41796300', 'protein_effect': 'S830N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002344', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3627', 'cds_effect': '721C>T', 'depth': '579', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'AKT3', 'percent_reads': '36.27', 'position': 'chr1:243736326', 'protein_effect': 'R241W', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005465', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3507', 'cds_effect': '2848C>A', 'depth': '921', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MLL', 'percent_reads': '35.07', 'position': 'chr11:118344722', 'protein_effect': 'L950I', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005933', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3399', 'cds_effect': '1165C>T', 'depth': '965', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRAF', 'percent_reads': '33.99', 'position': 'chr7:140487360', 'protein_effect': 'R389C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004333', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3836', 'cds_effect': '2421A>C', 'depth': '782', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'INPP4B', 'percent_reads': '38.36', 'position': 'chr4:143007363', 'protein_effect': 'E807D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003866', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3208', 'cds_effect': '2158G>A', 'depth': '907', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TBX3', 'percent_reads': '32.08', 'position': 'chr12:115109720', 'protein_effect': 'E720K', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_016569', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.4726', 'cds_effect': '164G>A', 'depth': '749', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RAD52', 'percent_reads': '47.26', 'position': 'chr12:1040408', 'protein_effect': 'R55H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_134424', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3441', 'cds_effect': '1676A>G', 'depth': '715', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NTRK3', 'percent_reads': '34.41', 'position': 'chr15:88524501', 'protein_effect': 'E559G', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001007156', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.355', 'cds_effect': '598A>C', 'depth': '1217', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KLHL6', 'percent_reads': '35.5', 'position': 'chr3:183226158', 'protein_effect': 'N200H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_130446', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.4525', 'cds_effect': '1653C>G', 'depth': '926', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'AR', 'percent_reads': '45.25', 'position': 'chrX:66863134', 'protein_effect': 'D551E', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000044', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3261', 'cds_effect': '1480G>T', 'depth': '742', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'KEL', 'percent_reads': '32.61', 'position': 'chr7:142641421', 'protein_effect': 'E494*', 'status': 'likely', 'strand': '_', 'transcript': 'NM_000420', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3645', 'cds_effect': '6610C>T', 'depth': '963', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'APC', 'percent_reads': '36.45', 'position': 'chr5:112177901', 'protein_effect': 'R2204*', 'status': 'likely', 'strand': '+', 'transcript': 'NM_000038', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3168', 'cds_effect': '1110+1G>T', 'depth': '865', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'CDK8', 'percent_reads': '31.68', 'position': 'chr13:26975485', 'protein_effect': 'splice site 1110+1G>T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001260', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3697', 'cds_effect': '4202G>A', 'depth': '1155', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ASXL1', 'percent_reads': '36.97', 'position': 'chr20:31024717', 'protein_effect': 'G1401E', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_015338', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.329', 'cds_effect': '22G>T', 'depth': '772', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TSC2', 'percent_reads': '32.9', 'position': 'chr16:2098638', 'protein_effect': 'D8Y', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000548', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.4019', 'cds_effect': '64G>A', 'depth': '821', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GSK3B', 'percent_reads': '40.19', 'position': 'chr3:119812218', 'protein_effect': 'A22T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002093', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3393', 'cds_effect': '2704C>T', 'depth': '1123', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KDM5A', 'percent_reads': '33.93', 'position': 'chr12:427465', 'protein_effect': 'R902W', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001042603', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.323', 'cds_effect': '665G>A', 'depth': '712', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RICTOR', 'percent_reads': '32.3', 'position': 'chr5:38982057', 'protein_effect': 'R222Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_152756', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3324', 'cds_effect': '598G>T', 'depth': '1092', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IDH2', 'percent_reads': '33.24', 'position': 'chr15:90631671', 'protein_effect': 'D200Y', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002168', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3217', 'cds_effect': '352+1G>A', 'depth': '858', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'PIK3CA', 'percent_reads': '32.17', 'position': 'chr3:178916966', 'protein_effect': 'splice site 352+1G>A', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006218', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3499', 'cds_effect': '825G>T', 'depth': '723', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IKZF1', 'percent_reads': '34.99', 'position': 'chr7:50459536', 'protein_effect': 'K275N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006060', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3464', 'cds_effect': '2863C>T', 'depth': '638', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'PIK3CB', 'percent_reads': '34.64', 'position': 'chr3:138376611', 'protein_effect': 'R955*', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006219', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3106', 'cds_effect': '911G>A', 'depth': '718', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MAP2K4', 'percent_reads': '31.06', 'position': 'chr17:12032475', 'protein_effect': 'R304Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_003010', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3645', 'cds_effect': '1987C>T', 'depth': '1196', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EPHB1', 'percent_reads': '36.45', 'position': 'chr3:134911522', 'protein_effect': 'R663W', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_004441', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3074', 'cds_effect': '2719C>T', 'depth': '1106', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'ATRX', 'percent_reads': '30.74', 'position': 'chrX:76938029', 'protein_effect': 'R907*', 'status': 'known', 'strand': '_', 'transcript': 'NM_000489', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.01', 'cds_effect': '758G>A', 'depth': '800', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RAD51D', 'percent_reads': '1.0', 'position': 'chr17:33428365', 'protein_effect': 'R253Q', 'status': 'known', 'strand': '_', 'transcript': 'NM_002878', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0225', 'cds_effect': '811C>T', 'depth': '843', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CARD11', 'percent_reads': '2.25', 'position': 'chr7:2979436', 'protein_effect': 'R271W', 'status': 'known', 'strand': '_', 'transcript': 'NM_032415', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3476', 'cds_effect': '1129A>C', 'depth': '820', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PIK3CB', 'percent_reads': '34.76', 'position': 'chr3:138433483', 'protein_effect': 'N377H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006219', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3792', 'cds_effect': '4762G>A', 'depth': '886', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MLL2', 'percent_reads': '37.92', 'position': 'chr12:49438728', 'protein_effect': 'E1588K', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003482', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0502', 'cds_effect': '1004G>A', 'depth': '737', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KDR', 'percent_reads': '5.02', 'position': 'chr4:55976908', 'protein_effect': 'G335D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002253', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3002', 'cds_effect': '1260G>T', 'depth': '846', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CARD11', 'percent_reads': '30.02', 'position': 'chr7:2976752', 'protein_effect': 'E420D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_032415', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.1925', 'cds_effect': '1769A>C', 'depth': '748', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PTPN11', 'percent_reads': '19.25', 'position': 'chr12:112942555', 'protein_effect': 'K590T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002834', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3251', 'cds_effect': '463_1G>T', 'depth': '646', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'STAG2', 'percent_reads': '32.51', 'position': 'chrX:123179013', 'protein_effect': 'splice site 463_1G>T', 'status': 'likely', 'strand': '+', 'transcript': 'NM_006603', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2624', 'cds_effect': '508A>C', 'depth': '1071', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FAM123B', 'percent_reads': '26.24', 'position': 'chrX:63412659', 'protein_effect': 'K170Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_152424', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3615', 'cds_effect': '2425G>T', 'depth': '758', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'SF3B1', 'percent_reads': '36.15', 'position': 'chr2:198266195', 'protein_effect': 'E809*', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_012433', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3117', 'cds_effect': '701T>C', 'depth': '969', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EPHB1', 'percent_reads': '31.17', 'position': 'chr3:134670790', 'protein_effect': 'V234A', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_004441', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3764', 'cds_effect': '826G>A', 'depth': '829', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IRS2', 'percent_reads': '37.64', 'position': 'chr13:110437575', 'protein_effect': 'D276N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003749', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3526', 'cds_effect': '640C>T', 'depth': '760', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CDK6', 'percent_reads': '35.26', 'position': 'chr7:92300747', 'protein_effect': 'R214C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001259', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3496', 'cds_effect': '1390G>A', 'depth': '801', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NOTCH1', 'percent_reads': '34.96', 'position': 'chr9:139412255', 'protein_effect': 'D464N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_017617', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3113', 'cds_effect': '212A>C', 'depth': '697', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CCND2', 'percent_reads': '31.13', 'position': 'chr12:4385187', 'protein_effect': 'K71T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001759', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3289', 'cds_effect': '560G>T', 'depth': '757', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NF2', 'percent_reads': '32.89', 'position': 'chr22:30051626', 'protein_effect': 'R187I', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000268', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.367', 'cds_effect': '295G>A', 'depth': '793', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CBFB', 'percent_reads': '36.7', 'position': 'chr16:67100597', 'protein_effect': 'A99T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_022845', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.376', 'cds_effect': '6406C>A', 'depth': '976', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'APC', 'percent_reads': '37.6', 'position': 'chr5:112177697', 'protein_effect': 'L2136I', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000038', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0077', 'cds_effect': '337T>G', 'depth': '909', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TP53', 'percent_reads': '0.77', 'position': 'chr17:7579350', 'protein_effect': 'F113V', 'status': 'known', 'strand': '_', 'subclonal': 'true', 'transcript': 'NM_000546', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3537', 'cds_effect': '2600A>C', 'depth': '950', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CTNNA1', 'percent_reads': '35.37', 'position': 'chr5:138269657', 'protein_effect': 'K867T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001903', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0746', 'cds_effect': '2495T>G', 'depth': '764', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PTPRO', 'percent_reads': '7.46', 'position': 'chr12:15704542', 'protein_effect': 'L832R', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_030667', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.336', 'cds_effect': '853T>G', 'depth': '997', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PIK3CA', 'percent_reads': '33.6', 'position': 'chr3:178921371', 'protein_effect': 'L285V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006218', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3983', 'cds_effect': '3677G>A', 'depth': '831', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BCORL1', 'percent_reads': '39.83', 'position': 'chrX:129156941', 'protein_effect': 'R1226H', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_021946', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3257', 'cds_effect': '614T>G', 'depth': '1142', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EP300', 'percent_reads': '32.57', 'position': 'chr22:41513710', 'protein_effect': 'M205R', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001429', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3774', 'cds_effect': '1381C>A', 'depth': '681', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FH', 'percent_reads': '37.74', 'position': 'chr1:241663746', 'protein_effect': 'P461T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000143', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3475', 'cds_effect': '208G>A', 'depth': '846', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NTRK2', 'percent_reads': '34.75', 'position': 'chr9:87285871', 'protein_effect': 'E70K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006180', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2728', 'cds_effect': '471A>C', 'depth': '799', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PTEN', 'percent_reads': '27.28', 'position': 'chr10:89692987', 'protein_effect': 'E157D', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000314', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3631', 'cds_effect': '867C>A', 'depth': '785', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TNFAIP3', 'percent_reads': '36.31', 'position': 'chr6:138198274', 'protein_effect': 'H289Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006290', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3634', 'cds_effect': '313T>C', 'depth': '919', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IKZF1', 'percent_reads': '36.34', 'position': 'chr7:50444383', 'protein_effect': 'S105P', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006060', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3456', 'cds_effect': '2245G>T', 'depth': '1007', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRCA1', 'percent_reads': '34.56', 'position': 'chr17:41245303', 'protein_effect': 'D749Y', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_007294', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.329', 'cds_effect': '3703C>A', 'depth': '924', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'POLE', 'percent_reads': '32.9', 'position': 'chr12:133226355', 'protein_effect': 'L1235I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006231', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3402', 'cds_effect': '1986G>T', 'depth': '926', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'DAXX', 'percent_reads': '34.02', 'position': 'chr6:33286951', 'protein_effect': 'K662N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001350', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3477', 'cds_effect': '1256T>C', 'depth': '719', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'AKT3', 'percent_reads': '34.77', 'position': 'chr1:243675724', 'protein_effect': 'V419A', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005465', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3462', 'cds_effect': '3725G>A', 'depth': '751', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MSH6', 'percent_reads': '34.62', 'position': 'chr2:48033421', 'protein_effect': 'R1242H', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000179', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3604', 'cds_effect': '1289T>G', 'depth': '1218', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERG', 'percent_reads': '36.04', 'position': 'chr21:39755476', 'protein_effect': 'F430C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_182918', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.056', 'cds_effect': '3482G>A', 'depth': '982', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB2', 'percent_reads': '5.6', 'position': 'chr17:37884011', 'protein_effect': 'R1161Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_004448', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3572', 'cds_effect': '1130T>G', 'depth': '683', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CUL3', 'percent_reads': '35.72', 'position': 'chr2:225370749', 'protein_effect': 'F377C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003590', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0575', 'cds_effect': '4358A>G', 'depth': '731', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RICTOR', 'percent_reads': '5.75', 'position': 'chr5:38946611', 'protein_effect': 'H1453R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_152756', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3496', 'cds_effect': '389G>A', 'depth': '941', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PTEN', 'percent_reads': '34.96', 'position': 'chr10:89692905', 'protein_effect': 'R130Q', 'status': 'known', 'strand': '+', 'transcript': 'NM_000314', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2718', 'cds_effect': '2480A>C', 'depth': '1008', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'LTK', 'percent_reads': '27.18', 'position': 'chr15:41796309', 'protein_effect': 'K827T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002344', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.332', 'cds_effect': '1939G>T', 'depth': '1015', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'EPHA3', 'percent_reads': '33.2', 'position': 'chr3:89468405', 'protein_effect': 'E647*', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005233', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3384', 'cds_effect': '910C>T', 'depth': '721', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TBX3', 'percent_reads': '33.84', 'position': 'chr12:115115416', 'protein_effect': 'R304W', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_016569', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3456', 'cds_effect': '1390T>G', 'depth': '897', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SMAD2', 'percent_reads': '34.56', 'position': 'chr18:45368212', 'protein_effect': 'S464A', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005901', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3584', 'cds_effect': '1067G>A', 'depth': '971', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRIP1', 'percent_reads': '35.84', 'position': 'chr17:59878687', 'protein_effect': 'R356Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_032043', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3506', 'cds_effect': '1835T>G', 'depth': '790', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RICTOR', 'percent_reads': '35.06', 'position': 'chr5:38960516', 'protein_effect': 'L612R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_152756', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.083', 'cds_effect': '1091C>T', 'depth': '843', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IKZF1', 'percent_reads': '8.3', 'position': 'chr7:50467856', 'protein_effect': 'S364L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006060', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3502', 'cds_effect': '1604G>A', 'depth': '871', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SPEN', 'percent_reads': '35.02', 'position': 'chr1:16245981', 'protein_effect': 'R535Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_015001', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.009', 'cds_effect': '2246G>A', 'depth': '777', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'XPO1', 'percent_reads': '0.9', 'position': 'chr2:61715367', 'protein_effect': 'R749Q', 'status': 'known', 'strand': '_', 'transcript': 'NM_003400', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3896', 'cds_effect': '67C>T', 'depth': '670', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'APC', 'percent_reads': '38.96', 'position': 'chr5:112090654', 'protein_effect': 'L23F', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000038', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3541', 'cds_effect': '7915C>A', 'depth': '884', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NF1', 'percent_reads': '35.41', 'position': 'chr17:29684332', 'protein_effect': 'L2639I', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001042492', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3456', 'cds_effect': '2833_2834insA', 'depth': '489', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'FLT1', 'percent_reads': '34.56', 'position': 'chr13:28897046', 'protein_effect': 'M945fs*15', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002019', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3285', 'cds_effect': '241C>T', 'depth': '1096', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MERTK', 'percent_reads': '32.85', 'position': 'chr2:112686876', 'protein_effect': 'P81S', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006343', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3497', 'cds_effect': '6668A>G', 'depth': '755', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MTOR', 'percent_reads': '34.97', 'position': 'chr1:11182178', 'protein_effect': 'Q2223R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004958', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3453', 'cds_effect': '1700C>T', 'depth': '698', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CARD11', 'percent_reads': '34.53', 'position': 'chr7:2968286', 'protein_effect': 'P567L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_032415', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3514', 'cds_effect': '1273C>T', 'depth': '814', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EED', 'percent_reads': '35.14', 'position': 'chr11:85989514', 'protein_effect': 'L425F', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_003797', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3589', 'cds_effect': '202C>A', 'depth': '1081', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EP300', 'percent_reads': '35.89', 'position': 'chr22:41513298', 'protein_effect': 'L68I', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001429', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3292', 'cds_effect': '3328C>T', 'depth': '1215', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RICTOR', 'percent_reads': '32.92', 'position': 'chr5:38950622', 'protein_effect': 'R1110C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_152756', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3605', 'cds_effect': '631A>G', 'depth': '896', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TP53', 'percent_reads': '36.05', 'position': 'chr17:7578218', 'protein_effect': 'T211A', 'status': 'known', 'strand': '_', 'transcript': 'NM_000546', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.333', 'cds_effect': '499C>A', 'depth': '1123', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'HSD3B1', 'percent_reads': '33.3', 'position': 'chr1:120056645', 'protein_effect': 'L167M', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000862', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3477', 'cds_effect': '2612C>T', 'depth': '837', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'AR', 'percent_reads': '34.77', 'position': 'chrX:66943532', 'protein_effect': 'A871V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000044', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3593', 'cds_effect': '6154G>A', 'depth': '977', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATM', 'percent_reads': '35.93', 'position': 'chr11:108186796', 'protein_effect': 'E2052K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000051', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3692', 'cds_effect': '10240A>G', 'depth': '826', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRCA2', 'percent_reads': '36.92', 'position': 'chr13:32972890', 'protein_effect': 'T3414A', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000059', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3695', 'cds_effect': '1022G>T', 'depth': '912', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PDK1', 'percent_reads': '36.95', 'position': 'chr2:173451082', 'protein_effect': 'R341I', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002610', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.4326', 'cds_effect': '2408G>A', 'depth': '705', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'JAK2', 'percent_reads': '43.26', 'position': 'chr9:5080657', 'protein_effect': 'R803Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_004972', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3336', 'cds_effect': '6058G>A', 'depth': '1103', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRCA2', 'percent_reads': '33.36', 'position': 'chr13:32914550', 'protein_effect': 'E2020K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000059', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.067', 'cds_effect': '762A>C', 'depth': '1223', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATR', 'percent_reads': '6.7', 'position': 'chr3:142281482', 'protein_effect': 'E254D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001184', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3566', 'cds_effect': '323C>T', 'depth': '659', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGF3', 'percent_reads': '35.66', 'position': 'chr11:69631089', 'protein_effect': 'S108L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005247', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3165', 'cds_effect': '1206A>C', 'depth': '714', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ROS1', 'percent_reads': '31.65', 'position': 'chr6:117714443', 'protein_effect': 'E402D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002944', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3486', 'cds_effect': '232G>A', 'depth': '958', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CDK8', 'percent_reads': '34.86', 'position': 'chr13:26923236', 'protein_effect': 'V78I', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001260', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3255', 'cds_effect': '2472G>T', 'depth': '1023', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ASXL1', 'percent_reads': '32.55', 'position': 'chr20:31022987', 'protein_effect': 'E824D', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_015338', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3436', 'cds_effect': '4365_4366AG>CA', 'depth': '1010', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRCA2', 'percent_reads': '34.36', 'position': 'chr13:32912857', 'protein_effect': 'E1455_E1456>DK', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000059', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2842', 'cds_effect': '1666G>T', 'depth': '1010', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'PDGFRA', 'percent_reads': '28.42', 'position': 'chr4:55141020', 'protein_effect': 'E556*', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006206', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3644', 'cds_effect': '135G>T', 'depth': '752', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NT5C2', 'percent_reads': '36.44', 'position': 'chr10:104899203', 'protein_effect': 'K45N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001134373', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3491', 'cds_effect': '1321C>T', 'depth': '951', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FBXW7', 'percent_reads': '34.91', 'position': 'chr4:153249457', 'protein_effect': 'R441W', 'status': 'known', 'strand': '_', 'transcript': 'NM_033632', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.343', 'cds_effect': '976G>A', 'depth': '1338', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ZNF217', 'percent_reads': '34.3', 'position': 'chr20:52198390', 'protein_effect': 'D326N', 'status': 'known', 'strand': '_', 'transcript': 'NM_006526', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.368', 'cds_effect': '837A>C', 'depth': '1174', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PALB2', 'percent_reads': '36.8', 'position': 'chr16:23647030', 'protein_effect': 'K279N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_024675', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3414', 'cds_effect': '205_1G>A', 'depth': '873', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'CDK8', 'percent_reads': '34.14', 'position': 'chr13:26923208', 'protein_effect': 'splice site 205_1G>A', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001260', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3678', 'cds_effect': '110G>A', 'depth': '522', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGF4', 'percent_reads': '36.78', 'position': 'chr11:69589743', 'protein_effect': 'G37D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002007', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3196', 'cds_effect': '2770G>A', 'depth': '1042', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EMSY', 'percent_reads': '31.96', 'position': 'chr11:76255363', 'protein_effect': 'E924K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_020193', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3558', 'cds_effect': '6920C>T', 'depth': '1113', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'APC', 'percent_reads': '35.58', 'position': 'chr5:112178211', 'protein_effect': 'S2307L', 'status': 'known', 'strand': '+', 'transcript': 'NM_000038', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3577', 'cds_effect': '667C>A', 'depth': '875', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PTCH1', 'percent_reads': '35.77', 'position': 'chr9:98244310', 'protein_effect': 'L223I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000264', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3443', 'cds_effect': '857G>A', 'depth': '1092', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FAM123B', 'percent_reads': '34.43', 'position': 'chrX:63412310', 'protein_effect': 'S286N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_152424', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.5059', 'cds_effect': '1697T>C', 'depth': '939', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NTRK1', 'percent_reads': '50.59', 'position': 'chr1:156846256', 'protein_effect': 'M566T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002529', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3575', 'cds_effect': '5278_1G>T', 'depth': '870', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'SETD2', 'percent_reads': '35.75', 'position': 'chr3:47127805', 'protein_effect': 'splice site 5278_1G>T', 'status': 'likely', 'strand': '_', 'transcript': 'NM_014159', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3339', 'cds_effect': '697_2A>C', 'depth': '611', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'AKT3', 'percent_reads': '33.39', 'position': 'chr1:243736352', 'protein_effect': 'splice site 697_2A>C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005465', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3793', 'cds_effect': '1292A>C', 'depth': '1102', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MSH6', 'percent_reads': '37.93', 'position': 'chr2:48026414', 'protein_effect': 'K431T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000179', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3485', 'cds_effect': '5803T>C', 'depth': '964', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TET2', 'percent_reads': '34.85', 'position': 'chr4:106197470', 'protein_effect': 'Y1935H', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001127208', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3483', 'cds_effect': '1805T>G', 'depth': '689', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'CUL3', 'percent_reads': '34.83', 'position': 'chr2:225360586', 'protein_effect': 'L602*', 'status': 'likely', 'strand': '_', 'transcript': 'NM_003590', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3603', 'cds_effect': '2128T>G', 'depth': '877', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FLT3', 'percent_reads': '36.03', 'position': 'chr13:28601304', 'protein_effect': 'F710V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004119', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3325', 'cds_effect': '134G>A', 'depth': '770', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'REL', 'percent_reads': '33.25', 'position': 'chr2:61118941', 'protein_effect': 'R45Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002908', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3484', 'cds_effect': '1426G>T', 'depth': '732', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'PIK3R1', 'percent_reads': '34.84', 'position': 'chr5:67590364', 'protein_effect': 'E476*', 'status': 'likely', 'strand': '+', 'transcript': 'NM_181523', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.101', 'cds_effect': '5637G>T', 'depth': '1050', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRCA2', 'percent_reads': '10.1', 'position': 'chr13:32914129', 'protein_effect': 'E1879D', 'status': 'known', 'strand': '+', 'transcript': 'NM_000059', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3559', 'cds_effect': '2215C>T', 'depth': '885', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'TSC1', 'percent_reads': '35.59', 'position': 'chr9:135778168', 'protein_effect': 'Q739*', 'status': 'likely', 'strand': '_', 'transcript': 'NM_000368', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3651', 'cds_effect': '664C>T', 'depth': '734', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IDH1', 'percent_reads': '36.51', 'position': 'chr2:209108185', 'protein_effect': 'R222C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005896', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3836', 'cds_effect': '148G>T', 'depth': '829', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'CREBBP', 'percent_reads': '38.36', 'position': 'chr16:3900948', 'protein_effect': 'E50*', 'status': 'likely', 'strand': '_', 'transcript': 'NM_004380', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3311', 'cds_effect': '731C>T', 'depth': '1063', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BCORL1', 'percent_reads': '33.11', 'position': 'chrX:129147479', 'protein_effect': 'S244L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_021946', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3263', 'cds_effect': '904_2A>C', 'depth': '754', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'FANCL', 'percent_reads': '32.63', 'position': 'chr2:58388775', 'protein_effect': 'splice site 904_2A>C', 'status': 'likely', 'strand': '_', 'transcript': 'NM_018062', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3666', 'cds_effect': '393_394CC>TA', 'depth': '1023', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GNAS', 'percent_reads': '36.66', 'position': 'chr20:57478807', 'protein_effect': 'L132M', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000516', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3627', 'cds_effect': '820C>A', 'depth': '714', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RAD51', 'percent_reads': '36.27', 'position': 'chr15:41023298', 'protein_effect': 'L274I', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001164270', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3231', 'cds_effect': '632G>A', 'depth': '1176', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CREBBP', 'percent_reads': '32.31', 'position': 'chr16:3900464', 'protein_effect': 'G211E', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004380', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2086', 'cds_effect': '1181G>A', 'depth': '1146', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ASXL1', 'percent_reads': '20.86', 'position': 'chr20:31021182', 'protein_effect': 'R394H', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_015338', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3275', 'cds_effect': '1090T>G', 'depth': '1081', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'AR', 'percent_reads': '32.75', 'position': 'chrX:66766078', 'protein_effect': 'Y364D', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000044', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3546', 'cds_effect': '730A>G', 'depth': '784', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NT5C2', 'percent_reads': '35.46', 'position': 'chr10:104857089', 'protein_effect': 'K244E', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001134373', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3071', 'cds_effect': '1195A>C', 'depth': '775', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ROS1', 'percent_reads': '30.71', 'position': 'chr6:117714454', 'protein_effect': 'N399H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002944', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3237', 'cds_effect': '518G>A', 'depth': '973', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PTEN', 'percent_reads': '32.37', 'position': 'chr10:89711900', 'protein_effect': 'R173H', 'status': 'known', 'strand': '+', 'transcript': 'NM_000314', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3672', 'cds_effect': '11327T>G', 'depth': '956', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MLL2', 'percent_reads': '36.72', 'position': 'chr12:49427161', 'protein_effect': 'L3776R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003482', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3078', 'cds_effect': '931G>A', 'depth': '835', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KEL', 'percent_reads': '30.78', 'position': 'chr7:142651037', 'protein_effect': 'A311T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000420', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3055', 'cds_effect': '1409G>A', 'depth': '874', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MED12', 'percent_reads': '30.55', 'position': 'chrX:70342648', 'protein_effect': 'R470H', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005120', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0638', 'cds_effect': '1420C>T', 'depth': '1144', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RET', 'percent_reads': '6.38', 'position': 'chr10:43606811', 'protein_effect': 'R474W', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_020975', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3165', 'cds_effect': '1115A>G', 'depth': '1011', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CDK8', 'percent_reads': '31.65', 'position': 'chr13:26975607', 'protein_effect': 'N372S', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001260', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3474', 'cds_effect': '1423A>C', 'depth': '662', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TSC1', 'percent_reads': '34.74', 'position': 'chr9:135782133', 'protein_effect': 'K475Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000368', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3255', 'cds_effect': '1181A>G', 'depth': '719', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CBL', 'percent_reads': '32.55', 'position': 'chr11:119148961', 'protein_effect': 'E394G', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005188', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3687', 'cds_effect': '98C>T', 'depth': '830', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BTK', 'percent_reads': '36.87', 'position': 'chrX:100630175', 'protein_effect': 'T33I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000061', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.32', 'cds_effect': '4000T>G', 'depth': '903', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BCOR', 'percent_reads': '32.0', 'position': 'chrX:39922070', 'protein_effect': 'L1334V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_017745', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0535', 'cds_effect': '2678G>A', 'depth': '1084', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KDM5A', 'percent_reads': '5.35', 'position': 'chr12:427491', 'protein_effect': 'R893Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001042603', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3496', 'cds_effect': '4592A>G', 'depth': '798', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EP300', 'percent_reads': '34.96', 'position': 'chr22:41568642', 'protein_effect': 'E1531G', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001429', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3659', 'cds_effect': '760_2A>C', 'depth': '973', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'MITF', 'percent_reads': '36.59', 'position': 'chr3:69998200', 'protein_effect': 'splice site 760_2A>C', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006722', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3531', 'cds_effect': '2140T>C', 'depth': '909', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KEL', 'percent_reads': '35.31', 'position': 'chr7:142638398', 'protein_effect': 'Y714H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000420', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3512', 'cds_effect': '210C>A', 'depth': '820', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CHEK1', 'percent_reads': '35.12', 'position': 'chr11:125497646', 'protein_effect': 'F70L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001274', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3547', 'cds_effect': '1159G>T', 'depth': '1015', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'FAM123B', 'percent_reads': '35.47', 'position': 'chrX:63412008', 'protein_effect': 'E387*', 'status': 'likely', 'strand': '_', 'transcript': 'NM_152424', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3564', 'cds_effect': '2722G>T', 'depth': '1010', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'ROS1', 'percent_reads': '35.64', 'position': 'chr6:117687329', 'protein_effect': 'E908*', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002944', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3394', 'cds_effect': '944T>G', 'depth': '993', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GNAS', 'percent_reads': '33.94', 'position': 'chr20:57485110', 'protein_effect': 'F315C', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000516', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3468', 'cds_effect': '802T>C', 'depth': '1018', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FANCG', 'percent_reads': '34.68', 'position': 'chr9:35076843', 'protein_effect': 'Y268H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004629', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.369', 'cds_effect': '337C>T', 'depth': '1103', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGFR4', 'percent_reads': '36.9', 'position': 'chr5:176517636', 'protein_effect': 'L113F', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_213647', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3815', 'cds_effect': '557C>A', 'depth': '852', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'VEGFA', 'percent_reads': '38.15', 'position': 'chr6:43752346', 'protein_effect': 'S186Y', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001171629', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3489', 'cds_effect': '2647A>C', 'depth': '940', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ROS1', 'percent_reads': '34.89', 'position': 'chr6:117687404', 'protein_effect': 'I883L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002944', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3371', 'cds_effect': '1693C>A', 'depth': '703', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'HGF', 'percent_reads': '33.71', 'position': 'chr7:81335667', 'protein_effect': 'L565I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000601', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2669', 'cds_effect': '998T>A', 'depth': '622', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FLT1', 'percent_reads': '26.69', 'position': 'chr13:29004295', 'protein_effect': 'F333Y', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002019', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3792', 'cds_effect': '1904G>A', 'depth': '807', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATR', 'percent_reads': '37.92', 'position': 'chr3:142275399', 'protein_effect': 'R635Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001184', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3668', 'cds_effect': '187G>T', 'depth': '946', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MLH1', 'percent_reads': '36.68', 'position': 'chr3:37038180', 'protein_effect': 'D63Y', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000249', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3455', 'cds_effect': '671G>T', 'depth': '851', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGF12', 'percent_reads': '34.55', 'position': 'chr3:191861859', 'protein_effect': 'R224M', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_021032', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3286', 'cds_effect': '1477C>T', 'depth': '1047', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATM', 'percent_reads': '32.86', 'position': 'chr11:108121669', 'protein_effect': 'R493C', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000051', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3571', 'cds_effect': '2053G>A', 'depth': '1190', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KDR', 'percent_reads': '35.71', 'position': 'chr4:55968610', 'protein_effect': 'E685K', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002253', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3836', 'cds_effect': '1004A>C', 'depth': '670', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CTNNB1', 'percent_reads': '38.36', 'position': 'chr3:41268766', 'protein_effect': 'K335T', 'status': 'known', 'strand': '+', 'transcript': 'NM_001904', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.344', 'cds_effect': '722C>T', 'depth': '965', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TET2', 'percent_reads': '34.4', 'position': 'chr4:106155821', 'protein_effect': 'A241V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001127208', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3719', 'cds_effect': '1722C>A', 'depth': '761', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MST1R', 'percent_reads': '37.19', 'position': 'chr3:49935642', 'protein_effect': 'F574L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002447', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3762', 'cds_effect': '1528A>G', 'depth': '848', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GATA6', 'percent_reads': '37.62', 'position': 'chr18:19762912', 'protein_effect': 'N510D', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005257', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3402', 'cds_effect': '2104G>A', 'depth': '873', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'DNMT3A', 'percent_reads': '34.02', 'position': 'chr2:25463578', 'protein_effect': 'D702N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_022552', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3408', 'cds_effect': '489T>G', 'depth': '845', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RAD51C', 'percent_reads': '34.08', 'position': 'chr17:56774138', 'protein_effect': 'S163R', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_058216', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3348', 'cds_effect': '862C>T', 'depth': '938', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BTK', 'percent_reads': '33.48', 'position': 'chrX:100614313', 'protein_effect': 'R288W', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000061', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3753', 'cds_effect': '14T>C', 'depth': '1207', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PTEN', 'percent_reads': '37.53', 'position': 'chr10:89624240', 'protein_effect': 'I5T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000314', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3581', 'cds_effect': '259C>T', 'depth': '916', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'TNFAIP3', 'percent_reads': '35.81', 'position': 'chr6:138192623', 'protein_effect': 'R87*', 'status': 'likely', 'strand': '+', 'transcript': 'NM_006290', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3354', 'cds_effect': '1841G>A', 'depth': '811', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KEAP1', 'percent_reads': '33.54', 'position': 'chr19:10597362', 'protein_effect': 'R614Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_012289', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3433', 'cds_effect': '638C>T', 'depth': '999', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGF23', 'percent_reads': '34.33', 'position': 'chr12:4479627', 'protein_effect': 'A213V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_020638', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0793', 'cds_effect': '2866C>T', 'depth': '1009', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KIT', 'percent_reads': '7.93', 'position': 'chr4:55604658', 'protein_effect': 'R956W', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000222', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.33', 'cds_effect': '624A>C', 'depth': '994', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CTCF', 'percent_reads': '33.0', 'position': 'chr16:67645359', 'protein_effect': 'K208N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006565', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3518', 'cds_effect': '10721C>T', 'depth': '847', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MLL', 'percent_reads': '35.18', 'position': 'chr11:118377337', 'protein_effect': 'T3574M', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005933', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3626', 'cds_effect': '385C>T', 'depth': '626', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'CTCF', 'percent_reads': '36.26', 'position': 'chr16:67660469', 'protein_effect': 'R129*', 'status': 'known', 'strand': '+', 'transcript': 'NM_001191022', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3446', 'cds_effect': '827C>T', 'depth': '830', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SMAD2', 'percent_reads': '34.46', 'position': 'chr18:45375016', 'protein_effect': 'S276L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005901', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3815', 'cds_effect': '10978A>G', 'depth': '810', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MLL', 'percent_reads': '38.15', 'position': 'chr11:118380749', 'protein_effect': 'I3660V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005933', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3393', 'cds_effect': '126_127insT', 'depth': '731', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'ABL1', 'percent_reads': '33.93', 'position': 'chr9:133589832', 'protein_effect': 'V43fs*4', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_007313', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3626', 'cds_effect': '1004G>A', 'depth': '1150', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EMSY', 'percent_reads': '36.26', 'position': 'chr11:76183780', 'protein_effect': 'S335N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_020193', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3401', 'cds_effect': '1595G>A', 'depth': '991', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MAP3K1', 'percent_reads': '34.01', 'position': 'chr5:56168741', 'protein_effect': 'R532Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005921', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.369', 'cds_effect': '2615C>T', 'depth': '1111', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CREBBP', 'percent_reads': '36.9', 'position': 'chr16:3820836', 'protein_effect': 'T872M', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004380', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3483', 'cds_effect': '1645A>G', 'depth': '1091', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGFR2', 'percent_reads': '34.83', 'position': 'chr10:123258036', 'protein_effect': 'N549D', 'status': 'known', 'strand': '_', 'transcript': 'NM_000141', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3024', 'cds_effect': '1270C>A', 'depth': '969', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GABRA6', 'percent_reads': '30.24', 'position': 'chr5:161128687', 'protein_effect': 'L424I', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000811', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0117', 'cds_effect': '15640C>T', 'depth': '937', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MLL2', 'percent_reads': '1.17', 'position': 'chr12:49420109', 'protein_effect': 'R5214C', 'status': 'known', 'strand': '_', 'transcript': 'NM_003482', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3604', 'cds_effect': '1352G>A', 'depth': '985', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SF3B1', 'percent_reads': '36.04', 'position': 'chr2:198270084', 'protein_effect': 'R451Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_012433', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2805', 'cds_effect': '3898C>A', 'depth': '884', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MED12', 'percent_reads': '28.05', 'position': 'chrX:70349915', 'protein_effect': 'L1300M', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005120', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0533', 'cds_effect': '463T>G', 'depth': '694', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGF12', 'percent_reads': '5.33', 'position': 'chr3:191888397', 'protein_effect': 'Y155D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_021032', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3643', 'cds_effect': '1312C>T', 'depth': '851', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MED12', 'percent_reads': '36.43', 'position': 'chrX:70342421', 'protein_effect': 'R438C', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005120', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3065', 'cds_effect': '962T>G', 'depth': '868', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RAD51B', 'percent_reads': '30.65', 'position': 'chr14:68934893', 'protein_effect': 'L321R', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_133509', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3576', 'cds_effect': '452G>T', 'depth': '990', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGF3', 'percent_reads': '35.76', 'position': 'chr11:69625341', 'protein_effect': 'R151I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005247', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3593', 'cds_effect': '2983G>A', 'depth': '974', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MSH6', 'percent_reads': '35.93', 'position': 'chr2:48028105', 'protein_effect': 'E995K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000179', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3503', 'cds_effect': '3946A>C', 'depth': '862', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRCA2', 'percent_reads': '35.03', 'position': 'chr13:32912438', 'protein_effect': 'N1316H', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000059', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2629', 'cds_effect': '1252C>T', 'depth': '1088', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NF2', 'percent_reads': '26.29', 'position': 'chr22:30069387', 'protein_effect': 'R418C', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000268', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3235', 'cds_effect': '1351C>T', 'depth': '680', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'CTNNA1', 'percent_reads': '32.35', 'position': 'chr5:138240092', 'protein_effect': 'R451*', 'status': 'known', 'strand': '+', 'transcript': 'NM_001903', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3412', 'cds_effect': '748C>T', 'depth': '929', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'ATM', 'percent_reads': '34.12', 'position': 'chr11:108115600', 'protein_effect': 'R250*', 'status': 'known', 'strand': '+', 'transcript': 'NM_000051', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3418', 'cds_effect': '1424C>T', 'depth': '790', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GNAS', 'percent_reads': '34.18', 'position': 'chr20:57429744', 'protein_effect': 'A475V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_080425', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.351', 'cds_effect': '850C>T', 'depth': '772', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SPOP', 'percent_reads': '35.1', 'position': 'chr17:47679357', 'protein_effect': 'R284C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003563', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0509', 'cds_effect': '2510G>T', 'depth': '1022', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NF1', 'percent_reads': '5.09', 'position': 'chr17:29556143', 'protein_effect': 'W837L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001042492', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2987', 'cds_effect': '877G>A', 'depth': '1175', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BCOR', 'percent_reads': '29.87', 'position': 'chrX:39933722', 'protein_effect': 'V293I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_017745', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3626', 'cds_effect': '1385G>A', 'depth': '946', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CBL', 'percent_reads': '36.26', 'position': 'chr11:119149377', 'protein_effect': 'R462Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005188', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0577', 'cds_effect': '1087C>A', 'depth': '659', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SGK1', 'percent_reads': '5.77', 'position': 'chr6:134492005', 'protein_effect': 'L363I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005627', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3447', 'cds_effect': '277C>T', 'depth': '760', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'JAK1', 'percent_reads': '34.47', 'position': 'chr1:65344760', 'protein_effect': 'R93C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002227', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3311', 'cds_effect': '683G>A', 'depth': '900', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TSC1', 'percent_reads': '33.11', 'position': 'chr9:135796804', 'protein_effect': 'R228Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000368', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3602', 'cds_effect': '688C>T', 'depth': '1044', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'PIK3CA', 'percent_reads': '36.02', 'position': 'chr3:178919203', 'protein_effect': 'R230*', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006218', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3419', 'cds_effect': '1921G>T', 'depth': '968', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'MSH6', 'percent_reads': '34.19', 'position': 'chr2:48027043', 'protein_effect': 'E641*', 'status': 'likely', 'strand': '+', 'transcript': 'NM_000179', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.361', 'cds_effect': '962G>A', 'depth': '698', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PIK3CB', 'percent_reads': '36.1', 'position': 'chr3:138453486', 'protein_effect': 'R321Q', 'status': 'known', 'strand': '_', 'transcript': 'NM_006219', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3403', 'cds_effect': '1555C>G', 'depth': '670', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KDM6A', 'percent_reads': '34.03', 'position': 'chrX:44922694', 'protein_effect': 'R519G', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_021140', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3835', 'cds_effect': '933G>T', 'depth': '1017', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CASP8', 'percent_reads': '38.35', 'position': 'chr2:202149618', 'protein_effect': 'E311D', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001228', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.4969', 'cds_effect': '1067G>A', 'depth': '1119', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MST1R', 'percent_reads': '49.69', 'position': 'chr3:49939976', 'protein_effect': 'G356D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002447', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3316', 'cds_effect': '830T>G', 'depth': '760', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'AKT3', 'percent_reads': '33.16', 'position': 'chr1:243727140', 'protein_effect': 'L277R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005465', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.343', 'cds_effect': '1877T>C', 'depth': '962', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EPHA3', 'percent_reads': '34.3', 'position': 'chr3:89462405', 'protein_effect': 'V626A', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005233', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0948', 'cds_effect': '529C>T', 'depth': '949', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'POLD1', 'percent_reads': '9.48', 'position': 'chr19:50905321', 'protein_effect': 'R177C', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002691', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3504', 'cds_effect': '148G>A', 'depth': '939', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PDCD1', 'percent_reads': '35.04', 'position': 'chr2:242795061', 'protein_effect': 'A50T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005018', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3723', 'cds_effect': '581C>T', 'depth': '873', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PARP1', 'percent_reads': '37.23', 'position': 'chr1:226578147', 'protein_effect': 'A194V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001618', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3586', 'cds_effect': '2674C>A', 'depth': '912', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRIP1', 'percent_reads': '35.86', 'position': 'chr17:59763428', 'protein_effect': 'L892I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_032043', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.012', 'cds_effect': '310G>A', 'depth': '830', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KLHL6', 'percent_reads': '1.2', 'position': 'chr3:183245782', 'protein_effect': 'D104N', 'status': 'known', 'strand': '_', 'transcript': 'NM_130446', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3509', 'cds_effect': '275G>T', 'depth': '761', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GSK3B', 'percent_reads': '35.09', 'position': 'chr3:119720900', 'protein_effect': 'R92I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002093', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3549', 'cds_effect': '348G>T', 'depth': '1037', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EPHB1', 'percent_reads': '35.49', 'position': 'chr3:134670437', 'protein_effect': 'E116D', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_004441', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.1784', 'cds_effect': '1122_1G>T', 'depth': '863', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'PDGFRA', 'percent_reads': '17.84', 'position': 'chr4:55136799', 'protein_effect': 'splice site 1122_1G>T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006206', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.4511', 'cds_effect': '664G>C', 'depth': '747', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PARP2', 'percent_reads': '45.11', 'position': 'chr14:20822268', 'protein_effect': 'E222Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005484', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0599', 'cds_effect': '9950T>G', 'depth': '1019', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRCA2', 'percent_reads': '5.99', 'position': 'chr13:32972600', 'protein_effect': 'L3317R', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000059', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3406', 'cds_effect': '3496C>T', 'depth': '869', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'MET', 'percent_reads': '34.06', 'position': 'chr7:116418985', 'protein_effect': 'R1166*', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000245', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2947', 'cds_effect': '829T>G', 'depth': '543', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'INPP4B', 'percent_reads': '29.47', 'position': 'chr4:143159024', 'protein_effect': 'L277V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003866', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3246', 'cds_effect': '1439C>G', 'depth': '1254', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATRX', 'percent_reads': '32.46', 'position': 'chrX:76939309', 'protein_effect': 'T480R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000489', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3399', 'cds_effect': '79G>A', 'depth': '818', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BCOR', 'percent_reads': '33.99', 'position': 'chrX:39937104', 'protein_effect': 'E27K', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_017745', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3155', 'cds_effect': '303G>T', 'depth': '843', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KDM5C', 'percent_reads': '31.55', 'position': 'chrX:53247506', 'protein_effect': 'K101N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004187', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3496', 'cds_effect': '698A>G', 'depth': '801', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GABRA6', 'percent_reads': '34.96', 'position': 'chr5:161117231', 'protein_effect': 'Y233C', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000811', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3308', 'cds_effect': '2113G>A', 'depth': '928', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IKBKE', 'percent_reads': '33.08', 'position': 'chr1:206667320', 'protein_effect': 'E705K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_014002', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.337', 'cds_effect': '312_313TG>CA', 'depth': '825', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NOTCH1', 'percent_reads': '33.7', 'position': 'chr9:139418259', 'protein_effect': 'A105T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_017617', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3804', 'cds_effect': '671T>G', 'depth': '652', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CUL3', 'percent_reads': '38.04', 'position': 'chr2:225376283', 'protein_effect': 'F224C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003590', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3455', 'cds_effect': '4084C>T', 'depth': '738', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'NF1', 'percent_reads': '34.55', 'position': 'chr17:29576111', 'protein_effect': 'R1362*', 'status': 'known', 'strand': '+', 'transcript': 'NM_001042492', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3234', 'cds_effect': '3063_1G>A', 'depth': '1002', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'TEK', 'percent_reads': '32.34', 'position': 'chr9:27218774', 'protein_effect': 'splice site 3063_1G>A', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000459', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3515', 'cds_effect': '622G>A', 'depth': '990', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CRKL', 'percent_reads': '35.15', 'position': 'chr22:21288377', 'protein_effect': 'A208T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005207', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3606', 'cds_effect': '673G>T', 'depth': '649', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'PIK3CB', 'percent_reads': '36.06', 'position': 'chr3:138456677', 'protein_effect': 'E225*', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006219', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3626', 'cds_effect': '2789T>C', 'depth': '888', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TSC1', 'percent_reads': '36.26', 'position': 'chr9:135772834', 'protein_effect': 'L930P', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000368', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3615', 'cds_effect': '310G>A', 'depth': '758', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RAF1', 'percent_reads': '36.15', 'position': 'chr3:12653459', 'protein_effect': 'E104K', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002880', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3623', 'cds_effect': '1088C>T', 'depth': '701', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TBX3', 'percent_reads': '36.23', 'position': 'chr12:115114129', 'protein_effect': 'S363L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_016569', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3605', 'cds_effect': '1264C>T', 'depth': '993', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MED12', 'percent_reads': '36.05', 'position': 'chrX:70342373', 'protein_effect': 'R422W', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005120', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3608', 'cds_effect': '1892C>T', 'depth': '607', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'DOT1L', 'percent_reads': '36.08', 'position': 'chr19:2214564', 'protein_effect': 'S631L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_032482', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3625', 'cds_effect': '1955G>T', 'depth': '960', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KDR', 'percent_reads': '36.25', 'position': 'chr4:55970842', 'protein_effect': 'R652I', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002253', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2317', 'cds_effect': '1399A>C', 'depth': '1273', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATRX', 'percent_reads': '23.17', 'position': 'chrX:76939349', 'protein_effect': 'K467Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000489', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3733', 'cds_effect': '3521C>T', 'depth': '1125', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IRS2', 'percent_reads': '37.33', 'position': 'chr13:110434880', 'protein_effect': 'S1174L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003749', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3579', 'cds_effect': '1496C>T', 'depth': '827', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRD4', 'percent_reads': '35.79', 'position': 'chr19:15367830', 'protein_effect': 'S499L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_014299', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3504', 'cds_effect': '11A>G', 'depth': '842', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NRAS', 'percent_reads': '35.04', 'position': 'chr1:115258771', 'protein_effect': 'Y4C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002524', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.1769', 'cds_effect': '3642C>A', 'depth': '752', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'STAG2', 'percent_reads': '17.69', 'position': 'chrX:123229269', 'protein_effect': 'F1214L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006603', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3207', 'cds_effect': '1056G>T', 'depth': '920', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KEL', 'percent_reads': '32.07', 'position': 'chr7:142650912', 'protein_effect': 'E352D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000420', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3599', 'cds_effect': '3750_3751insA', 'depth': '942', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'KDR', 'percent_reads': '35.99', 'position': 'chr4:55948714', 'protein_effect': 'V1251fs*5', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002253', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3467', 'cds_effect': '3464A>C', 'depth': '1122', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RICTOR', 'percent_reads': '34.67', 'position': 'chr5:38950486', 'protein_effect': 'K1155T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_152756', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3151', 'cds_effect': '2102G>A', 'depth': '1171', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATRX', 'percent_reads': '31.51', 'position': 'chrX:76938646', 'protein_effect': 'R701H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000489', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.363', 'cds_effect': '263G>A', 'depth': '1000', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PIK3CA', 'percent_reads': '36.3', 'position': 'chr3:178916876', 'protein_effect': 'R88Q', 'status': 'known', 'strand': '+', 'transcript': 'NM_006218', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.37', 'cds_effect': '3073A>G', 'depth': '1135', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PIK3CA', 'percent_reads': '37.0', 'position': 'chr3:178952018', 'protein_effect': 'T1025A', 'status': 'known', 'strand': '+', 'transcript': 'NM_006218', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3453', 'cds_effect': '457G>A', 'depth': '695', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'STAG2', 'percent_reads': '34.53', 'position': 'chrX:123176490', 'protein_effect': 'D153N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006603', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.4798', 'cds_effect': '569C>T', 'depth': '1313', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SETD2', 'percent_reads': '47.98', 'position': 'chr3:47165557', 'protein_effect': 'P190L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_014159', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.36', 'cds_effect': '2626C>T', 'depth': '850', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PBRM1', 'percent_reads': '36.0', 'position': 'chr3:52637690', 'protein_effect': 'R876C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_018313', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0533', 'cds_effect': '1031T>G', 'depth': '751', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'INPP4B', 'percent_reads': '5.33', 'position': 'chr4:143129619', 'protein_effect': 'L344R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003866', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3611', 'cds_effect': '3217A>G', 'depth': '911', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PDGFRA', 'percent_reads': '36.11', 'position': 'chr4:55161386', 'protein_effect': 'M1073V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006206', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3553', 'cds_effect': '247G>A', 'depth': '1213', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IGF1R', 'percent_reads': '35.53', 'position': 'chr15:99250943', 'protein_effect': 'E83K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000875', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3331', 'cds_effect': '2740G>T', 'depth': '1267', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'MAP3K1', 'percent_reads': '33.31', 'position': 'chr5:56177767', 'protein_effect': 'G914*', 'status': 'likely', 'strand': '+', 'transcript': 'NM_005921', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3591', 'cds_effect': '8180C>T', 'depth': '1153', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SPEN', 'percent_reads': '35.91', 'position': 'chr1:16260915', 'protein_effect': 'A2727V', 'status': 'known', 'strand': '+', 'transcript': 'NM_015001', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3373', 'cds_effect': '2174C>A', 'depth': '1186', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NTRK3', 'percent_reads': '33.73', 'position': 'chr15:88423619', 'protein_effect': 'P725H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002530', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0558', 'cds_effect': '2161C>T', 'depth': '1201', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NTRK3', 'percent_reads': '5.58', 'position': 'chr15:88423632', 'protein_effect': 'R721C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002530', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.358', 'cds_effect': '2338G>A', 'depth': '891', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MSH6', 'percent_reads': '35.8', 'position': 'chr2:48027460', 'protein_effect': 'A780T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000179', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3456', 'cds_effect': '370C>T', 'depth': '735', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'NTRK2', 'percent_reads': '34.56', 'position': 'chr9:87322769', 'protein_effect': 'R124*', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006180', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3211', 'cds_effect': '1378G>A', 'depth': '710', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GATA6', 'percent_reads': '32.11', 'position': 'chr18:19761489', 'protein_effect': 'E460K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005257', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3793', 'cds_effect': '5623G>T', 'depth': '754', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATRX', 'percent_reads': '37.93', 'position': 'chrX:76855977', 'protein_effect': 'D1875Y', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000489', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0823', 'cds_effect': '1252G>A', 'depth': '1057', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TBX3', 'percent_reads': '8.23', 'position': 'chr12:115112488', 'protein_effect': 'A418T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_016569', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.4891', 'cds_effect': '2437C>T', 'depth': '1196', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IRS2', 'percent_reads': '48.91', 'position': 'chr13:110435964', 'protein_effect': 'P813S', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003749', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.355', 'cds_effect': '2243G>T', 'depth': '862', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'WHSC1L1', 'percent_reads': '35.5', 'position': 'chr8:38162963', 'protein_effect': 'G748V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_023034', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3612', 'cds_effect': '3292G>T', 'depth': '645', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'KDM5A', 'percent_reads': '36.12', 'position': 'chr12:419055', 'protein_effect': 'E1098*', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001042603', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3307', 'cds_effect': '323G>A', 'depth': '756', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'DIS3', 'percent_reads': '33.07', 'position': 'chr13:73355047', 'protein_effect': 'R108H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_014953', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3279', 'cds_effect': '835C>T', 'depth': '1101', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FAS', 'percent_reads': '32.79', 'position': 'chr10:90774034', 'protein_effect': 'R279C', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000043', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2987', 'cds_effect': '1988C>A', 'depth': '1058', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BCORL1', 'percent_reads': '29.87', 'position': 'chrX:129148736', 'protein_effect': 'S663Y', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_021946', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3431', 'cds_effect': '853A>T', 'depth': '816', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ALK', 'percent_reads': '34.31', 'position': 'chr2:29917815', 'protein_effect': 'N285Y', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004304', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.0516', 'cds_effect': '4599A>C', 'depth': '717', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ROS1', 'percent_reads': '5.16', 'position': 'chr6:117663633', 'protein_effect': 'K1533N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002944', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3683', 'cds_effect': '2341G>A', 'depth': '1029', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MLL2', 'percent_reads': '36.83', 'position': 'chr12:49445125', 'protein_effect': 'A781T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003482', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3458', 'cds_effect': '3634C>T', 'depth': '723', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ROS1', 'percent_reads': '34.58', 'position': 'chr6:117680986', 'protein_effect': 'R1212C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002944', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.2837', 'cds_effect': '207A>C', 'depth': '571', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TSC2', 'percent_reads': '28.37', 'position': 'chr16:2100469', 'protein_effect': 'K69N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000548', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3555', 'cds_effect': '173C>T', 'depth': '948', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'P2RY8', 'percent_reads': '35.55', 'position': 'chrX:1585279', 'protein_effect': 'S58L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_178129', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.333', 'cds_effect': '219G>T', 'depth': '898', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PDK1', 'percent_reads': '33.3', 'position': 'chr2:173423458', 'protein_effect': 'K73N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002610', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3226', 'cds_effect': '1067A>G', 'depth': '902', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NKX2_1', 'percent_reads': '32.26', 'position': 'chr14:36986532', 'protein_effect': 'D356G', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003317', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3299', 'cds_effect': '323T>C', 'depth': '788', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATR', 'percent_reads': '32.99', 'position': 'chr3:142281921', 'protein_effect': 'L108P', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001184', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3698', 'cds_effect': '1479_1480insT', 'depth': '849', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'STAT3', 'percent_reads': '36.98', 'position': 'chr17:40476849', 'protein_effect': 'T494fs*55', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_139276', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3663', 'cds_effect': '767G>A', 'depth': '808', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ESR1', 'percent_reads': '36.63', 'position': 'chr6:152265314', 'protein_effect': 'R256Q', 'status': 'known', 'strand': '+', 'transcript': 'NM_000125', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3278', 'cds_effect': '3898C>T', 'depth': '784', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATR', 'percent_reads': '32.78', 'position': 'chr3:142253969', 'protein_effect': 'R1300C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001184', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3598', 'cds_effect': '3595G>A', 'depth': '792', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IRS2', 'percent_reads': '35.98', 'position': 'chr13:110434806', 'protein_effect': 'E1199K', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003749', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3317', 'cds_effect': '1822G>A', 'depth': '841', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BAP1', 'percent_reads': '33.17', 'position': 'chr3:52437222', 'protein_effect': 'D608N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004656', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3178', 'cds_effect': '37C>T', 'depth': '837', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'BTK', 'percent_reads': '31.78', 'position': 'chrX:100630236', 'protein_effect': 'R13*', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000061', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3304', 'cds_effect': '3655G>A', 'depth': '1244', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '33.04', 'position': 'chr2:212248612', 'protein_effect': 'A1219T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3618', 'cds_effect': '1013A>C', 'depth': '738', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PPP2R2A', 'percent_reads': '36.18', 'position': 'chr8:26223871', 'protein_effect': 'E338A', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002717', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3375', 'cds_effect': '191T>C', 'depth': '809', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FANCG', 'percent_reads': '33.75', 'position': 'chr9:35078718', 'protein_effect': 'V64A', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004629', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}, {'allele_fraction': '0.3458', 'cds_effect': '1964C>T', 'depth': '697', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PIK3CB', 'percent_reads': '34.58', 'position': 'chr3:138409914', 'protein_effect': 'A655V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006219', 'dna_evidence': {'sample': 'SQ_US1153674.01_1'}}]}, 'copy_number_alterations': None, 'rearrangements': None, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '371.95', 'status': 'high', 'unit': 'mutations_per_megabase'}}, 'non_human_content': None}}}}"	S110-99654          	PF21018             
10	447	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2022_00023114', 'CSN': None, 'TRF': 'ORD_1450681_01', 'MRN': '48800722', 'PhysicianId': '109266', 'NPI': 'International'}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1191858', 'clinicalId': '1193228', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1450681_01', 'SampleName': 'US1390521.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1450681_01', 'SampleId': 'US1390521.01', 'BlockId': 'S111_30912A (PF22102)', 'TRFNumber': 'ORD_1450681_01', 'TestType': 'FoundationOne CDX', 'SpecFormat': 'Slide Deck', 'ReceivedDate': '2022_09_07', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}]}}, 'PMI': {'ReportId': 'ORD_1450681_01', 'MRN': '48800722', 'FullName': 'Chao, Ching', 'FirstName': 'Ching', 'LastName': 'Chao', 'SubmittedDiagnosis': 'Unknown primary adenocarcinoma', 'Gender': 'Female', 'DOB': '1985_03_04', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Brain', 'CollDate': '2022_08_11', 'ReceivedDate': '2022_09_07', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': None, 'Summaries': {'alterationCount': '19', 'clinicalTrialCount': '14', 'resistiveCount': '0', 'sensitizingCount': '9'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'ATM', 'isVUS': 'true', 'variantName': 'H42R'}, {'geneName': 'BAP1', 'isVUS': 'true', 'variantName': 'A321T'}, {'geneName': 'CDK12', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'M322K'}, {'geneName': 'FANCC', 'isVUS': 'true', 'variantName': 'I80T'}, {'geneName': 'LYN', 'isVUS': 'true', 'variantName': 'rearrangement'}, {'geneName': 'RNF43', 'isVUS': 'true', 'variantName': 'R145Q'}, {'geneName': 'STAG2', 'isVUS': 'true', 'variantName': 'R760C'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'CTNNB1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'S45P', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'S45P'}}, 'Interpretation': 'CTNNB1 encodes beta_catenin, a key downstream component of the WNT signaling pathway. Beta_catenin interacts with cadherin to regulate cell_cell adhesion; as a component of the WNT pathway, it also plays a role in development, cell proliferation, and cell differentiation (Kikuchi, 2000; 10679188). CTNNB1 exon 3 mutations, such as observed here, lead to increased beta_catenin protein stability and activation of the WNT pathway, and are considered to be activating (Anastas and Moon, 2013; 23258168, Fukuchi et al., 1998; 9721853, Kikuchi et al., 2003; 12824913, Takahashi et al., 2006; 16523258, Tanaka et al., 2001; 11731417, Abraham et al., 2002; 11943721, Austinat et al., 2008; 18282277, Wu et al., 2003; 12820959, Provost et al., 2005; 15829978, Polakis, 1999; 10072352, Segditsas and Tomlinson, 2006; 17143297, Barth et al., 1997; 9024698, Harada et al., 1999; 10545105, Hsu et al., 1998; 9671490, Breuhahn et al., 2008; 18491352, Soon et al., 2008; 18515740, Tacon et al., 2011; 21212436, Simon and Hammer, 2012; 22266195, Hirotsu et al., 2016; 26850916). CTNNB1 mutations are common in various solid tumors and are often seen in endometrial (14%), hepatobiliary (11%), melanoma (4.7%), prostate (3.4%), and non_small cell lung (2.9%) cancer (NSCLC) (cBio_Zehir et al., 2017; 28481359). Aberrant beta_catenin expression has been associated with poor prognosis in lung adenocarcinoma and other non_small cell lung carcinomas (Nozawa et al., 2006; 16843618, Chiu et al., 2012; 22402266, Kim et al., 2013; 23483484). Low membrane expression of beta_catenin has been associated with poor prognosis in ovarian endometrioid and endometrial carcinomas (Rosen et al., 2010; 19820688, Athanassiadou et al., 2007; 17504383). Solid tumors with WNT/beta_catenin pathway alterations, as seen here, were observed to have significantly less T_cell inflammation in one study (Luke et al., 2019; 30635339). Mutation or activation of CTNNB1 signaling has been shown to increase mTOR signaling, promote tumorigenesis, and respond to mTOR inhibition in preclinical studies (Tanwar et al., 2009; 19403928, Tanwar et al., 2011; 21695255, Fujishita et al., 2008; 18768809). Small studies have reported clinical benefit following treatment of everolimus combined with other targeted agents for patients with CTNNB1_mutated hepatocellular carcinoma (Bhoori et al., 2010; 20347502, Janku et al., 2014; 24931142) or endometrial carcinoma (Slomovitz et al., 2015; 25624430). In preclinical studies, CTNNB1 activating mutations have been shown to increase expression of WNT pathway member DKK1, which may promote tumor cell proliferation and immune evasion (Niida et al., 2004; 15378020, Chamorro et al., 2005; 15592430, Kagey and He, 2017; 28574171). A Phase 1 trial of DKK1_targeting antibody DKN_01 in combination with paclitaxel in esophageal cancer reported a PR rate in 2 out of 4 patients and SD rate of in 1 out of 4 patients with CTNNB1 activating mutations, compared with 24% (10/41) PR and 37% (15/41) SD in unselected patients (Kagey et al., 2017; AACR Abstract 369). Multiple preclinical studies in cancer models harboring CTNNB1 mutation or beta_catenin pathway activation have reported activation of the NOTCH pathway and sensitivity to pharmacologic inhibition of NOTCH signaling by gamma_secretase inhibitors (Kwon et al., 2011; 21841793, Arcaroli et al., 2013; 23868008, Shang et al., 2015; 26349011, Kode et al., 2014; 24429522). Phase 1 and 2 clinical trials of gamma_secretase inhibitor PF_03084014 have shown high response rates in patients with desmoid tumors, which are driven by activating CTNNB1 mutations in the majority of cases (Kummar et al., 2015; ASCO Abstract 10563)(Messersmith et al., 2015; 25231399), suggesting CTNNB1_mutated tumors may be sensitive to gamma_secretase inhibitors. Although WNT pathway inhibitors have been explored preclinically in CTNNB1_mutated cells, clinical data supporting this therapeutic approach are lacking (Zhu et al., 2012; 22964660, Tanwar et al., 2011; 21695255, Kogan et al., 2012; 22356261, Lachenmayer et al., 2012; 22811581).', 'Include': 'true', 'ClinicalTrialNote': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT01582191', 'Include': 'true'}, {'nctId': 'NCT03203525', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'ERBB2', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'ERBB2 (also known as HER2) encodes a receptor tyrosine kinase which is in the same family as EGFR. Amplification or overexpression of ERBB2 can lead to excessive proliferation and tumor formation (Higgins and Baselga, 2011; 21965336). ERBB2 amplification has been reported in a wide range of cancers in the scientific literature (Chmielecki et al., 2015; 25480824) and in the TCGA datasets, with highest prevalence in esophageal carcinoma (15%), breast invasive carcinoma (13_14%)(Cancer Genome Atlas Network., 2012; 23000897, cBio_Ciriello et al., 2015; 26451490), stomach adenocarcinoma (13%)(Cancer Genome Atlas Research Network., 2014; 25079317), pancreatic adenocarcinoma (11%)(cBio_Witkiewicz et al., 2015; 25855536), and uterine carcinosarcoma (11%, 6/56) (cBioPortal, Oct 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). HER2 is predicted to be overexpressed (as assessed by FISH, CNV analysis, or immunohistochemistry) in 12_25% of breast cancers (Chmielecki et al., 2014; 25480824, Stern, 2012; 22461643, Jones and Buzdar, 2009; 19959074). Phosphorylated HER2 was expressed in 62.5% (55/88) of HER2_positive breast cancers (Ramic et al., 2013; 23749902). Reports on the correlation of ERBB2 amplification or HER2 overexpression with prognosis have been mixed for most diseases, including gastric, esophageal, gastroesophageal (Polkowski et al., 1999; 10340889, Haas et al., 2011; 21359545, Maresch et al., 2012; 21783379), bladder urothelial (Tsai et al., 2012; 22991510), colorectal (Martin et al., 2013; 23348520, Seo et al., 2014; 24879338, Sclafani et al., 2013; 24146218). HER2 overexpression in pancreatic carcinoma has been correlated with inferior prognosis (Harder et al., 2012; 22374460, Komoto et al., 2009; 19432892, Safran et al., 2001; 11586103, Tsiambas et al., 2006; 16685109), but ERBB2 amplification was not correlated with prognosis in two studies (Sharif et al., 2008; 18463983, Tsiambas et al., 2006; 16685109). ERBB2 amplification or expression have been associated with higher tumor grade and shorter survival in patients with endometrial adenocarcinoma (Peiró et al., 2004; 14752523, Saffari et al., 1995; 7585656, Kudela et al., 2012; 22611955) and prostate cancer (Zhang et al., 2011; 22340411, Minner et al., 2010; 20179235). On the basis of extensive clinical evidence, ERBB2 amplification or activating mutation may predict sensitivity to therapies targeting HER2, including antibodies such as trastuzumab (Slamon et al., 2001; 11248153, Bang et al., 2010; 20728210, Chumsri et al., 2015; 26358791, Cappuzzo et al., 2006; 16775247, Falchook et al., 2013; 23328556, Mazieres et al., 2013; 23610105), pertuzumab in combination with trastuzumab (Baselga et al., 2012; 22149875, Swain et al., 2015; 25693012, Chumsri et al., 2015; 26358791, Meric_Bernstam et al., 2019; 30857956), and zanidatamab (ZW25) (Meric_Bernstam et al., 2019; ESMO Abstract 453PD), as well as antibody_directed conjugates such as ado_trastuzumab emtansine (T_DM1) (Verma et al., 2012; 23020162) and fam_trastuzumab deruxtecan (T_DXd) (Modi et al., 2020; 31825192, Shitara et al., 2020; 32469182, Li et al., 2022; 34534430, Smit et al., 2021; ESMO Abstract 1361TiP), HER2 kinase inhibitors such as tucatinib (Murthy et al., 2020; 31825569, Borges et al., 2018; 29955792, Murthy et al., 2018; 29804905, Moulder et al., 2017; 28053022), and dual EGFR/HER2 kinase inhibitors such as lapatinib (Fan et al., 2020; 32478891, Cameron et al., 2010; 20736298, Geyer et al., 2006; 17192538, Serra et al., 2013; 23950206, Ali et al., 2014; 24516025, Grellety et al., 2015; 26487584, Vornicova et al., 2014; 25085898, Ronellenfitsch et al., 2020; 32017710, Hou et al., 2020; 32405522), afatinib (Lin et al., 2012; 22418700, Schwab et al., 2014; 25268372, De Greve et al., 2015; 25682316, De Greve et al., 2012; 22325357, Li et al., 2015; 26559459, Mazieres et al., 2013; 23610105, Bedard et al., 2019; AACR Abstract CT139, Dziadziuszko et al., 2019; 30825613, Lai et al., 2019; 30685684, Liu et al., 2018; 30425522, Fang et al., 2019; 31748336, Yuan et al., 2020; 32477948), neratinib (Ben_Baruch et al., 2015; 26358790, Ma et al., 2017; 28679771, Hyman et al., 2018; 29420467, Smyth et al., 2020; 31806627, Li et al., 2020; WCLC Abstract FP14.15), dacomitinib (Kris et al., 2015; 25899785), and pyrotinib (Jiang et al., 2019; ASCO Abstract 1001, Xu et al., 2020; ASCO Abstract 1003). A Phase 1 basket trial of pyrotinib demonstrated an ORR of 17% (4/23) for ERBB2_altered solid tumors, with PRs for 1 patient each with HER2_positive salivary, biliary, ovarian, or endometrial cancers (Li et al., 2020; ASCO Abstract 3510). Patients with ERBB2_mutated non_small cell lung cancer (NSCLC) have also benefited from pyrotinib (30_53% ORR) (Wang et al., 2019; 30596880, Zhou et al. 2020; 32614698).', 'Include': 'true', 'ClinicalTrialNote': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Fam_trastuzumab deruxtecan', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Fam_trastuzumab deruxtecan is an antibody_drug conjugate that targets the protein ERBB2/HER2 on the cell surface and delivers the cytotoxic payload DXd, which inhibits DNA topoisomerase I to induce DNA damage. Fam_trastuzumab deruxtecan is FDA approved to treat patients with HER2_positive breast cancer and gastric or gastroesophageal junction adenocarcinoma who have received prior HER2_targeted therapy. It is also approved for patients with HER2_low advanced breast cancer who have previously been treated with chemotherapy, as well as for patients with advanced ERBB2_mutated non_small cell lung cancer (NSCLC) who have received systemic therapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data in solid cancers, including breast (Modi et al., 2019; 31825192, Tamura et al., 2019; 31047803), gastric (Shitara et al., 2019; 31047804, Shitara et al., 2020; 32469182), non_small cell lung (Tsurutani et al., 2018; IASLC WCLC Abstract OA02.07, Nakagawa et al., 2021; WCLC Abstract OA04.05), and colon (Yoshino et al., 2018; ESMO Abstract 563P) cancers, ERBB2 amplification may predict sensitivity to fam_trastuzumab deruxtecan. </p> <p><b>Supporting Data:</b> Fam_trastuzumab deruxtecan has demonstrated activity in multiple ERBB2_positive cancer types. In the Phase 2 DESTINY trials, clinical benefit was observed for patients treated with fam_trastuzumab deruxtecan monotherapy who had previously treated, HER2_expressing breast (61% ORR, median PFS 16.4 months) (Modi et al., 2019; 31825192), colorectal (45% ORR, median PFS 6.9 months) (Siena et al., 2020; ASCO Abstract 4000), or gastric or gastroesophageal cancer (43% ORR, median PFS 5.6 months) (Shitara et al., 2020; 32469182), as well as HER2_mutated lung cancer (62% ORR, median PFS 14.0 months) (Smit et al., 2020; ASCO Abstract 9504). Benefit was also observed in a Phase 2 trial for ERBB2_expressing biliary tract cancer (30% ORR) (Ohba et al., 2020; ASCO Abstract 4006). In a Phase 1 study evaluating single_agent fam_trastuzumab deruxtecan for the treatment of patients with ERBB2_mutated solid tumors or ERBB2_expressing solid tumors other than breast or gastric cancer, the median PFS was 7.2 months and the ORR was 28% (17/60), with responses reported for patients with non_small cell lung carcinoma (NSCLC), breast cancer, colorectal cancer (CRC), salivary gland carcinoma, cholangiocarcinoma, and endometrial cancer (Tsurutani et al., 2020; 32213540). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Lapatinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Lapatinib is a tyrosine kinase inhibitor that targets EGFR, ERBB2/HER2, and to a lesser degree, ERBB4. It is FDA approved in combination with capecitabine to treat patients with HER2_overexpressing (HER2+) metastatic breast cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Activation or amplification of ERBB2 may predict sensitivity to lapatinib (Cameron et al., 2010; 20736298, Geyer et al., 2006; 17192538, Serra et al., 2013; 23950206, Ali et al., 2014; 24516025, Grellety et al., 2015; 26487584, Fan et al., 2020; 32478891, Vornicova et al., 2014; 25085898, Ronellenfitsch et al., 2020; 32017710, Hou et al., 2020; 32405522). </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of lapatinib have primarily been in the context of breast cancer (Geyer et al., 2006; 17192538, Cameron et al., 2010; 20736298, Bian et al., 2013; 23729232, Baselga et al., 2012; 22257673, Robidoux et al., 2013; 24095300, Alba et al., 2014; 24457911, Gelmon et al., 2015; 25779558, Verma et al., 2012; 23020162). Phase 3 and Phase 2 studies have reported clinical activity of lapatinib plus chemotherapy combinations for HER2+ advanced gastric (Satoh et al., 2014; 24868024), gastroesophageal (Lorenzen et al., 2015; 25694417, Galsky et al., 2012; 20857170), and upper gastrointestinal tract (Hecht et al., 2016; 26628478) cancer. Additionally, Phase 1 studies evaluating lapatinib alone or in combination with chemotherapy agents reported PRs in patients with various solid tumors and 1 CR in a patient with EGFR_overexpressing head and neck squamous cell carcinoma (Burris et al., 2009; 19825948, Chu et al., 2007; 17704424, Chew et al., 2011; 21778300, Siegel_Lakhai et al., 2007; 17671135). In a Phase 1 trial of lapatinib plus pazopanib, one patient with a salivary gland tumor experienced a PR (Tan et al., 2014; 24800949). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Ado_trastuzumab emtansine', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Ado_trastuzumab emtansine (T_DM1) is an antibody_drug conjugate that targets the protein ERBB2/HER2 on the cell surface, which inhibits HER2 signaling; it also releases the cytotoxic therapy DM1 into cells, leading to cell death. T_DM1 is FDA approved to treat patients with HER2_positive (HER2+) metastatic breast cancer and disease progression on prior therapy as well as patients with HER2+ early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab_based treatment. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> ERBB2 amplification or activating mutations may predict sensitivity to T_DM1 (Jhaveri et al., 2019; 31504139, Li et al., 2018; ASCO Abstract 2502, Li et al., 2020; 32213539, Hotta et al., 2018; 29313813, Krop et al., 2014; 24793816, Verma et al., 2012; 23020162, Welslau et al., 2014; 24222194, Krop et al., 2012; 22649126, Burris et al., 2011; 21172893, Jhaveri et al., 2018; ASCO Abstract 100, Baselga et al., 2016; 26920887, Perez et al., 2016; 28056202, Hurvitz et al., 2013; 23382472, von Minckwitz et al., 2019; 30516102, Hurvitz et al., 2019; 31157583, Martin et al., 2016; 27052654, Mondaca et al., 2019; 32923849). </p> <p><b>Supporting Data:</b> The vast majority of data on the therapeutic use of T_DM1 have been collected in the context of breast cancer, although clinical trials investigating T_DM1 are underway in several tumor types, primarily in HER2+ cancers. Phase 2 basket trials for HER2_amplified cancers have reported ORR of 8_28% with T_DM1, including responses in salivary gland, lung, endometrial, biliary tract, and ovarian cancers (Li et al., 2018; ASCO Abstract 2502)(Jhaveri et al., 2018; ASCO Abstract 100). A Phase 3 trial in 602 patients with HER2+ breast cancer reported that those who received T_DM1 showed an improved progression_free survival (PFS) and a lower rate of adverse events than patients who received the physician’s choice of therapy (Krop et al., 2014; 24793816). A second Phase 3 trial in 991 patients with HER2+ breast cancer reported that T_DM1 brought about significantly longer overall survival (OS) and PFS, as compared with lapatinib plus capecitabine, in patients previously treated with trastuzumab plus a taxane (Verma et al., 2012; 23020162, Welslau et al., 2014; 24222194). Two separate Phase 2 trials reported robust activity for single_agent T_DM1 as a treatment for HER2+ metastatic breast cancer in patients previously treated with standard HER2_directed therapies or HER2_directed therapies plus chemotherapy, with objective response rates of 34.5% and 25.9%, respectively, and PFS of 6.9 months and 4.9 months, respectively (Krop et al., 2012; 22649126, Burris et al., 2011; 21172893). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Margetuximab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Margetuximab is an Fc_engineered antibody targeting ERBB2/HER2 that was designed to enhance the anti_tumor immune response. Margetuximab is FDA approved for the treatment of patients with HER2_positive breast cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical studies in multiple tumor types, ERBB2 amplification may predict sensitivity to margetuximab (Rugo et al., 2019; ASCO Abstract 1000, Bang et al., 2017; 28119295, Burris et al., 2013; ASCO Abstract 3004, Catenacci et al., 2019; ESMO Abstract 2812). </p> <p><b>Supporting Data:</b> The Phase 3 SOPHIA trial of margetuximab for HER2+ metastatic breast cancer reported improved median PFS (5.8 vs. 4.9 months, HR=0.76) and ORR (22% vs. 16%) when combining margetuximab with chemotherapy, compared with trastuzumab and chemotherapy, for patients who had progressed on ≥2 prior HER2_directed therapies (Rugo et al., 2019; ASCO Abstract 1000); however, median OS was not statistically different between the 2 treatment arms (21.6 vs. 21.9 months, HR=0.62) (Rugo et al., 2021; SABCS Abstract PD8_01). In a Phase 1 trial for HER2_overexpressing solid tumors, 12% (7/60) of patients, including 4 with breast, 2 with gastroesophageal, and 1 with lacrimal gland cancers, experienced PRs, and a further 52% (31/60) of the cohort experienced SD (Bang et al., 2017; 28119295). In a study of margetuximab for HER2+ cancers, a patient with salivary gland cancer reported a PR (Burris et al., 2013; ASCO Abstract 3004). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Trastuzumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Trastuzumab is a monoclonal antibody that targets the protein ERBB2/HER2. It is FDA approved as monotherapy and in combination with chemotherapy for HER2+ metastatic gastric or gastroesophageal adenocarcinoma. Trastuzumab biosimilars are also FDA approved for these indications. Please see the drug label(s) for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical studies in multiple tumor types, ERBB2 amplification, overexpression, or activating mutations may confer sensitivity to trastuzumab (Gianni et al., 2014; 24657003, Morris et al., 2013; 24037735, Hainsworth et al., 2018; 29320312, Mazières et al., 2013; 23610105, Ali et al., 2014; 24516025, Wang et al., 2016; 27334835, Nishikawa et al., 2017; 27521503, Bang et al., 2010; 20728210, Slamon et al., 2001; 11248153). </p> <p><b>Supporting Data:</b> The majority of data investigating the therapeutic use of trastuzumab has been in the context of breast cancer. Trastuzumab was approved for breast cancer on the basis of a Phase 3 randomized clinical trial comparing treatment with trastuzumab and chemotherapy to treatment with chemotherapy alone. The addition of trastuzumab was associated with significant improvements in time to progression, objective response rate, response duration, and overall survival (Slamon et al., 2001; 11248153). A subsequent Phase 3 study of patients with HER2_positive (HER2+) breast cancer reported 5_year event_free survival in 58% of patients treated with trastuzumab plus neoadjuvant therapy, compared to 43% in patients treated with neoadjuvant therapy alone (Gianni et al., 2014; 24657003). Long_term follow_up Phase 2 analysis reported a 5_year distant disease_free survival rate of 92% in patients with HER2+ breast cancer treated with dose_dense chemotherapy and trastuzumab and 89% in patients treated with lapatinib and dose_sense chemotherapy (Morris et al., 2013; 24037735). A Phase 3 trial of patients with HER2+ breast cancer treated with lapatinib, trastuzumab, or a combination of the two, reported event_free survival rates of 78%, 76%, and 84%, and overall survival of 93%, 90%, and 95%, respectively (de Azambuja et al., 2014; 25130998). In a Phase 2 study of 14 patients with salivary gland carcinoma with overexpressed HER2 protein, trastuzumab had low activity, with a median time to progression of 4.2 months (Haddad et al., 2003; 12907212). A retrospective study of patients with HER2_positive salivary duct carcinoma reported that 62% (5/8) of patients who received adjuvant therapy including chemotherapy with paclitaxel, carboplatin, and trastuzumab (TCH) exhibited no evidence of disease after more than 24 months and 100% (5/5) of patients with metastatic disease exhibited response to TCH (Limaye et al., 2013; 23429737). Trastuzumab was approved in combination with cisplatin and 5_fluorouracil or capecitabine for (HER2+) metastatic gastric or gastroesophageal junction adenocarcinoma in the first line treatment setting based upon improvement in survival observed in the ToGA trial (Bang et al., 2010; 20728210). A Phase 1/2 trial of trastuzumab in patients with HER2+ esophageal adenocarcinoma and co_treated with cisplatin, paclitaxel and radiotherapy reported a median survival of 24 months with a two_year survival rate of 50% (Safran et al., 2007; 17097832). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Trastuzumab + Pertuzumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Trastuzumab is a monoclonal antibody that targets ERBB2/HER2, and pertuzumab is a monoclonal antibody that interferes with the interaction between HER2 and ERBB3. These therapies are FDA approved in combination for the treatment of patients with HER2_positive (HER2+) metastatic breast cancer who have not received prior chemotherapy or HER2_targeted therapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical studies in multiple tumor types, ERBB2 amplification or activating mutations may predict sensitivity to trastuzumab in combination with pertuzumab (Hurvitz et al., 2017; 29175149, von Minckwitz et al., 2017; 28581356, Hainsworth et al., 2018; 29320312, Swain et al., 2015; 25693012, Swain et al., 2018; 29253081, Gianni et al., 2016; 27179402, Shao et al., 2020; 31647503). </p> <p><b>Supporting Data:</b> The Phase 2 MyPathway basket trial for patients with HER2_positive solid tumors treated with trastuzumab plus pertuzumab reported a 23% ORR (60/258), a 45% DCR (115/258), a 7.9 month median duration of response, 2.8 months mPFS, and 10.9 months mOS; clinical responses were observed across multiple tumor types, including CRC, lung, urothelial, biliary, and ovarian (Hainsworth et al., 2018; 2932031, Meric_Bernstam et al., 2019; 30857956, Meric_Bernstam et al., 2021; ASCO Abstract 3004). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Dacomitinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Dacomitinib is a second generation irreversible tyrosine kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4/HER4. It is FDA approved for the first_line treatment of patients with metastatic non_small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Prospective early_phase single_arm clinical trials report anti_tumor activity of dacomitinib in advanced solid tumors with ERBB2 activating mutations (Kris et al., 2015; 25899785, Janne et al., 2011; 21220471), ERBB2 amplification (Kim et al., 2015; 25424851, Reckamp et al., 2014; 24501009), or HER2 overexpression (Oh et al., 2016; 26581547). </p> <p><b>Supporting Data:</b> Investigations into the efficacy of dacomitinib have primarily been in the context of non_small cell lung cancer (NSCLC). Patients with EGFR_mutant NSCLC treated with dacomitinib exhibited significant improvement in OS compared with gefitinib treatment (median OS, 34.1 vs. 26.8 months) (Mok et al., 2018; 2986437, Wu et al., 2017; 28958502). A Phase 2 study of dacomitinib in patients with advanced penile squamous cell carcinoma (SCC) reported an ORR of 32% (1 CR, 8 PR), including a 100% DCR (1 CR, 1 PR, 2 SD) in four patients with EGFR amplification (Necchi et al., 2018; ASCO Abstract 399)(Necchi et al., 2018; 28921872). A Phase 2 study of dacomitinib in patients with recurrent or metastatic head and neck SCC reported clinical benefit (defined as PFS>4 months) in 13/31 (42%) of patients (Kim et al., 2015; 25424851). Studies of dacomitinib in esophageal (Kim et al., 2015; 26462025) and cutaneous (Cavalieri et al., 2018; 29734047) SCC reported RRs of 12.5% (6/48) and 28.6% (12/42), respectively, but high DCRs of 73% and 86%, respectively. In contrast, trials of dacomitinib in heavily pretreated patients with HER2+ gastric cancer (Oh et al., 2016; 26581547) and patients with EGFR_amplified glioblastoma (Sepulveda_Sanchez et al, 2017; 28575464) found RRs of fewer than 10% and DCRs of fewer than 50%: 11/27 (41%) DCR in HER2+ gastric cancer (Oh et al., 2016; 26581547) and 15/49 (31%) in EGFR_amplified glioblastoma (Sepulveda_Sanchez et al, 2017; 28575464). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Neratinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Neratinib is an irreversible tyrosine kinase inhibitor that targets EGFR, ERBB2/HER2, and ERBB4. It is FDA approved for the extended adjuvant treatment of early_stage HER2_positive (HER2+) breast cancer following adjuvant trastuzumab. Neratinib is also approved in combination with capecitabine to treat patients with advanced or metastatic HER2+ breast cancer who have been previously treated with 2 or more anti_HER2 regimens. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of extensive clinical (Li et al., 2020; WCLC Abstract FP14.15, Ma et al., 2017; 28679771, Chan et al., 2016; 26874901, Ben_Baruch et al., 2015; 26358790, Park et al., 2016; 27406346, Hyman et al., 2018; 29420467, Smyth et al., 2020; 31806627) and preclinical (Schwab et al., 2015; 26260909, Menderes et al., 2017; 28397106, Hu et al., 2015; 26375550, Kavuri et al., 2015; 26243863, Bose et al., 2013; 23220880) evidence, ERBB2 amplification or activating mutations may confer sensitivity to neratinib. </p> <p><b>Supporting Data:</b> Neratinib has been largely evaluated in the context of breast cancer and non_small cell lung cancer (NSCLC). For patients with advanced HER2_positive breast cancer, neratinib treatment resulted in PFS of 22.3 weeks for patients with prior trastuzumab treatment and 39.6 weeks for those with no prior trastuzumab treatment (Burstein et al., 2010; 20142587). In patients with HER2_positive breast cancer with brain metastases, neratinib elicited a CNS ORR of 8% (3/40) (Freedman et al., 2016; 26834058). In a Phase 3 study of patients with HER2_positive, early stage breast cancer previously treated with trastuzumab, neratinib significantly improved the 2_year invasive disease_free survival compared to placebo (HR=0.67, p=0.0091)(Chan et al., 2016; 26874901). In Phase 2 trials of single_agent neratinib for patients with ERBB2_mutated, non_amplified metastatic breast cancer, clinical benefit rates of 31_40% and median PFS of 3.5_4 months have been achieved (Ma et al., 2017; 28679771, Hyman et al., 2018; 29420467, Smyth et al., 2019; 31806627). Neratinib in combination with various other agents has also shown significant clinical activity against breast cancer (Hyman et al., 2016; SABCS Abstract PD2_08)(Saura et al., 2014; 25287822, Awada et al., 2012; 22967996, Martin et al., 2013; 23953056, Chow et al., 2013; 23632474, Park et al., 2016; 27406346, Awada et al., 2016; 27078022). In patients with ERBB2_mutated NSCLC, where the majority of cases harbor inhibitor_resistant exon 20 insertions, neratinib monotherapy has resulted in ORRs of 0_4% (Gandhi et al. 2017; WCLC Abstract MA04.02, Gandhi et al., 2014; 24323026, Hyman et al., 2018; 29420467, Li et al., 2020; WCLC Abstract FP14.15). However, clinical outcomes have been improved by combination of neratinib with other targeted agents, such as temsirolimus or trastuzumab (Gandhi et al., 2014; 24323026, Gandhi et al. 2017; WCLC Abstract MA04.02, Li et al., 2020; WCLC Abstract FP14.15). Trials of neratinib have shown high ORRs (up to 44%) in ERBB2_mutated cervical cancer (Hyman et al., 2018; 29420467, D Souza et al., 2019; SGO Abstract 18) but very low ORRs in colorectal and bladder cancer (Hyman et al., 2018; 29420467). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Afatinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Afatinib is an irreversible kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4. It is FDA approved for the first_line treatment of patients with metastatic non_small cell lung cancer (NSCLC) and nonresistant EGFR mutations and for the treatment of patients with metastatic, squamous NSCLC after progression on platinum_based chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Clinical and preclinical data support sensitivity of ERBB2 amplification (Talwar and Cohen, 2012; 24371631, Choudhury et al., 2016; 27044931, Kwak et al., 2013; 23775486, Schwab et al., 2014; 25268372), or HER2 overexpression (Lin et al., 2012; 22418700, Rimawi et al., 2015; 25537159, Gunzer et al., 2016; 26835225, Janjigian et al., 2013; 23578997), to afatinib. </p> <p><b>Supporting Data:</b> Afatinib has been primarily evaluated for the treatment of EGFR_mutant NSCLC, in which treatment with afatinib exhibited significant improvement in progression free survival (PFS) vs. chemotherapy treatments (Sequist et al., 2013; 23816960, Katakami et al., 2013; 23816963). A Phase 2 trial of afatinib in patients with either EGFR or ERBB2 amplification and esophagogastric, biliary tract, urothelial tract, or gynecologic cancer reported a 5% (1/20) objective response rate, with complete response achieved in one patient and stable disease (SD) achieved in 8 patients; the authors concluded that afatinib activity as a single agent was encouraging (Kwak et al., 2013; 23775486). A Phase 1 trial of afatinib in advanced cancer reported SD in 14/31 patients (Marshall et al., 2013; 23414476). A Phase 1 study of afatinib combined with pemetrexed in patients with advanced solid tumors reported confirmed partial response in 3% (1/30) of patients and SD in 33% (10/30) of patients (Chu et al., 2013; ASCO Abstract 2523). Outcomes of partial response and/or stable disease have been reported in various clinical trials involving multiple cancer types, including HER2_positive breast cancer, NSCLC, colorectal cancer, and esophageal cancer (Sequist et al., 2013; 23816960, De Grève et al., 2012; 22325357, Katakami et al., 2013; 23816963, Yap et al., 2010; 20679611, Eskins et al., 2008; 18026190). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04644068', 'Include': 'true'}, {'nctId': 'NCT03239015', 'Include': 'true'}, {'nctId': 'NCT03498521', 'Include': 'true'}, {'nctId': 'NCT04579380', 'Include': 'true'}, {'nctId': 'NCT04162327', 'Include': 'true'}, {'nctId': 'NCT04040699', 'Include': 'true'}, {'nctId': 'NCT05159245', 'Include': 'true'}, {'nctId': 'NCT02693535', 'Include': 'true'}, {'nctId': 'NCT04983238', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'CDKN2A/B', 'Include': 'true', 'Alterations': {'Alteration': [{'Name': 'CDKN2A loss', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'CDKN2A loss'}}, 'Interpretation': 'CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). In the TCGA datasets, concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in several tumor types, with the highest incidences in glioblastoma multiforme (54%), mesothelioma (45%), esophageal adenocarcinoma (39%), bladder urothelial carcinoma (31%), melanoma (31%), and HNSCC (30%) cases (cBioPortal, Mar 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In addition, mutation of CDKN2A has been reported in 45% of cutaneous SCC (Li et al., 2015; 25589618), 21% of HNSCC (HNSCC_Cancer Genome Atlas Network., 2015; 25631445), 17% of lung SCC (Cancer Genome Atlas Research Network., 2012; 22960745), and 3_4.5% of esophageal SCC (cBio_Song et al., 2014; 24670651, cBio_Lin et al., 2014; 24686850) cases. Loss of p16INK4a expression has been reported in 67_80% of pancreatic ductal adenocarcinomas (Oshima et al., 2013; 23470568, Tsiambas et al., 2007; 17600882) and in 59% of NSCLCs (Yanagawa et al., 2013; 23254264). Inactivation of CDKN2A and/or CDKN2B and loss of p16INK4a and/or p15INK4b protein expression have been correlated with poor patient prognosis in several tumor types, including pancreatic ductal adenocarcinoma, gastric cancer, and lung cancer (Chang et al., 2010; 20665497, Oshima et al., 2013; 23470568, Lee et al., 2002; 12060614, Hu et al., 2010; 21302620, Shi et al., 2012; 22206050, Bradly et al., 2012; 23111194, Lou_Qian et al., 2013; 23372805, Tan et al., 2013; 23614702). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}, {'Name': 'CDKN2B loss', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'CDKN2B loss'}}, 'Interpretation': 'CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). In the TCGA datasets, concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in several tumor types, with the highest incidences in glioblastoma multiforme (54%), mesothelioma (45%), esophageal adenocarcinoma (39%), bladder urothelial carcinoma (31%), melanoma (31%), and HNSCC (30%) cases (cBioPortal, Mar 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In addition, mutation of CDKN2A has been reported in 45% of cutaneous SCC (Li et al., 2015; 25589618), 21% of HNSCC (HNSCC_Cancer Genome Atlas Network., 2015; 25631445), 17% of lung SCC (Cancer Genome Atlas Research Network., 2012; 22960745), and 3_4.5% of esophageal SCC (cBio_Song et al., 2014; 24670651, cBio_Lin et al., 2014; 24686850) cases. Loss of p16INK4a expression has been reported in 67_80% of pancreatic ductal adenocarcinomas (Oshima et al., 2013; 23470568, Tsiambas et al., 2007; 17600882) and in 59% of NSCLCs (Yanagawa et al., 2013; 23254264). Inactivation of CDKN2A and/or CDKN2B and loss of p16INK4a and/or p15INK4b protein expression have been correlated with poor patient prognosis in several tumor types, including pancreatic ductal adenocarcinoma, gastric cancer, and lung cancer (Chang et al., 2010; 20665497, Oshima et al., 2013; 23470568, Lee et al., 2002; 12060614, Hu et al., 2010; 21302620, Shi et al., 2012; 22206050, Bradly et al., 2012; 23111194, Lou_Qian et al., 2013; 23372805, Tan et al., 2013; 23614702). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500)(Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126). Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}]}, 'ReferenceLinks': None}, {'Name': 'FANCC', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Q485fs*2', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Q485fs*2'}}, 'Interpretation': 'FANCC encodes a key component of an eight protein (FANCA/B/C/E/F/G/L/M) Fanconi anemia (FA) nuclear E3 ubiquitin ligase complex. This complex is involved in DNA repair and is essential for prevention of chromosome breakage caused by DNA damage (Moldovan and D’Andrea, 2009; 19686080). Upon DNA damage or during the S_phase of the cell cycle, the FA complex is activated and recruited to the sites of DNA damage/DNA repair. The complex then activates FANCD2 and FANCL via monoubiquitination, leading to their co_localization with FANCD1/BRCA2, BRCA1, RAD51, PCNA, and other proteins at the DNA repair foci on chromatin. Germline mutations in FANCC cause Fanconi anemia, a clinically heterogeneous disorder involving various developmental abnormalities as well as predisposition to cancer; underlying these phenotypes are defects in DNA repair (Deakyne and Mazin, 2011; 21568838). Somatic mutations in FANCC are very infrequently observed in human malignancies (COSMIC, Jan 2022)(Tate et al., 2019; 30371878). There are no targeted therapies that directly address loss of FANCC activity. However, limited preclinical evidence (Ghosh et al., 2014; 24200853, Lombardi et al., 2015; 25609062) and clinical evidence in sarcoma (Piha_Paul et al., 2018; AACR_NCI_EORTC Abstract A096) suggest that FANCC alterations may predict sensitivity to PARP inhibitors.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'FH', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'A273T', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'A273T'}}, 'Interpretation': 'FH encodes fumarate hydratase, an enzymatic component of the Krebs cycle. FH has been identified as a possible hypoxia inducible factor activating gene (Morris et al., 2004; 15220362). Loss_of_function germline mutations in FH are associated with hereditary leiomyomatosis and renal cell cancer (HLRCC); tumors arising in FH mutation carriers often demonstrate FH biallelic inactivation (Schmidt et al., 2020; 31085323, Lehtonen et al., 2006; 16155190, Tomlinson et al., 2002; 11865300, Gardie et al., 2011; 21398687). FH mutations have been detected in several tumor types, with the highest incidences reported in tumors of the endometrium (2.6%), skin (2.3%), liver (1.7%), stomach (1.5%), and lung (1.4%)(COSMIC, Jan 2022)(Tate et al., 2019; 30371878). FH_deficient renal cell carcinoma (RCC) arises in about 20% of families affected by hereditary leiomyomatosis and renal cell cancer (HLRCC) and is associated with aggressive disease and poor prognosis (Schmidt et al., 2020; 31085323, Lau et al., 2020; 31524643, Gardie et al., 2011; 21398687). A preclinical study showed that FH_deficient renal cancer cells are dependent on ABL1 activity and sensitive to the multikinase inhibitor vandetanib; treatment with vandetanib inhibited the growth and tumorigenicity of these cells in vitro and in vivo (Sourbier et al., 2014; 25490448). Tumors with FH loss or inactivation may therefore be sensitive to vandetanib, which is approved to treat medullary thyroid cancer and is in clinical trials in solid tumors. A Phase 2 trial of bevacizumab and erlotinib reported overall response rate in 60% (12/20) of patients with hereditary leiomyomatosis and renal cell cancer, and 29% (6/21) of patients with sporadic papillary renal cell carcinoma (Srinivasan et al., 2014; EORTC_NCI_AACR Abstract 5). FH germline inactivating alterations are associated with FH tumor predisposition syndrome, also known as hereditary leiomyomatosis and renal cell cancer (HLRCC), an autosomal_dominant syndrome characterized by cutaneous leiomyomata, uterine fibroids, and aggressive renal cell carcinoma (RCC) (Tomlinson et al., 2002; 11865300). Pheochromocytoma and paraganglioma have also been described at lower frequency (Castro_Vega et al., 2014; 24334767, Muller et al., 2017; 28300276). Whereas cutaneous leiomyomata appear at a mean age of 30 years, increasing in size and number with age, the age at diagnosis of uterine fibroids ranges from 18 to 53 years (Muller et al., 2017; 28300276, Lehtonen, et al., 2011; 21404119). HLRCC has been associated with a 21% lifetime risk of RCC (Forde et al., 2020; 31831373). In the appropriate clinical context, germline testing of FH is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'MAP2K4', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Q327*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Q327*'}}, 'Interpretation': 'MAP2K4 encodes the protein kinase MKK4, a member of a MAPK signaling cascade that leads to apoptosis in response to cellular stress (Curtis et al., 2012; 22522925). MAP2K4 has been proposed to act as a tumor suppressor in several cancer types, including pancreatic cancer, but has also been suggested to act as an oncogene in certain situations (Teng et al., 1997; 9331070, Curtis et al., 2012; 22522925, Ahn et al., 2011; 21896780, Davis et al., 2011; 21575258, Lee et al., 2005; 16115952, Lee et al., 2003; 12714585, Cunningham et al., 2006; 16740690). Alterations such as seen here may disrupt MAP2K4 function or expression (Ahn et al., 2011; 21896780, Kan et al., 2010; 20668451, Teng et al., 1997; 9331070, Takekawa et al., 2005; 15866172, Young_Ho et al., 2011; 21896780). MAP2K4 mutations have been reported at highest frequencies in liver (4.3%), endometrial (3.8%), breast (3.7%), pancreatic (3.5%), biliary tract (3.5%), and gastric (3.3%) carcinomas (COSMIC, Feb 2022)(Tate et al., 2019; 30371878). MAP2K4 homozygous deletion has been observed in multiple tumor types, including stomach adenocarcinoma (3.4%), ovarian serous cystadenocarcinoma (2.6%), breast invasive carcinoma (2.3%), pancreatic adenocarcinoma (2.2%), and colorectal adenocarcinoma (1.9%)(cBioPortal, Feb 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Loss of MKK4 expression has been linked to tumor cell invasion, metastasis, and poor prognosis in some cancer types (Ahn et al., 2011; 21896780, Davis et al., 2011; 21575258, Ishikawa et al., 2010; 21372598, Hickson et al., 2006; 16489030). There are no therapies available to target MAP2K4 loss or inactivation. However, a preclinical study reported that inactivation of MAP2K4 may confer sensitivity to MEK inhibitors (Xue et al., 2018; 29795445).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'MS_Stable', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'MS_Stable'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_high (MSI_H) has been observed at high frequency in endometrial cancers (14_33%)(Santin et al., ASCO 2016; Abstract 414, Zighelboim et al., 2007; 17513808, Hampel et al., 2006; 16885385, Stelloo et al., 2016; 27006490, Kanopiene et al., 2014; 25458958, Black et al., 2006; 16549821, Nout et al., 2012; 22609107, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452), colorectal cancers (CRCs; 10_15%)(Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894), and gastric cancers (12_35%)(Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086) and at lower frequencies in many other tumor types, including esophageal (Hall et al., 2016; ASCO Gastrointestinal Cancer Symposium Abstract 528, Farris et al., 2011; 21422910), small bowel (Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06, Agaramet al., 2010; 20395525, Ruemmele et al., 2009; 19252434, Planck et al., 2003; 12627520, Hibi et al., 1995; 7775257, Muneyuki et al., 2000; 11117578), hepatobiliary (Zhang et al., 2005; 15918185, Chiappini et al., 2004; 14656944, Suto et al., 2001; 11223838, Momoi et al., 2001; 11580146, Liengswangwong et al., 2003; 14506736, Moy et al., 2015; 25680569, Yoshida et al., 2000; 11063221), prostate (Cheng et al., 2016; Genitourinary Cancers Symposium Abstract 251, Pritchard et al., 2014; 25255306, Azzouzi et al., 2007; 17233803, Burger et al., 2006; 16924473), and urinary tract carcinomas (Harper et al., 2015; USCAP Abstract 905, Bai et al., 2013; 23690119, Giedl et al., 2014; 25319978, Yamamoto et al., 2006; 16675567). In one study, MSI_H status was associated with a positive prognostic effect in patients with gastric cancer treated with surgery alone and a negative predictive effect in patients treated with chemotherapy (Smyth et al., 2015; ASCO Gastrointestinal Cancers Symposium Abstract 62). Data regarding the role of MSI_H on prognosis and survival in endometrial cancer are conflicting (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao_Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958, Black et al., 2006; 16549821). However, studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI_H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI_H predicts for poor prognosis in this subset of endometrial tumors. On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TP53', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'G244V', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'G244V'}}, 'Interpretation': 'Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). Pan_cancer analysis of the TCGA datasets across 12 cancer types identified TP53 as the most frequently mutated gene, with 42% of more than 3,000 tumors harboring a TP53 mutation; in this study TP53 mutation occurred most frequently in ovarian serous carcinoma (95%), lung squamous cell carcinoma (SCC) (79%), head and neck SCC (70%), colorectal adenocarcinoma (59%), lung adenocarcinoma (52%), and bladder urothelial carcinoma (50%) (Kandoth et al., 2013; 24132290). TP53 loss of heterozygosity (LOH) is frequently seen in tumors and often occurs when one copy of TP53 harbors a mutation; in some tumors, LOH is correlated with progression (Wongsurawat et al., 2006; 16537709, Brosh and Rotter, 2009; 19693097, Baker et al., 1989; 2649981, Calcagno et al., 2013; 24053468). While the prognostic significance of TP53 alteration or dysregulation varies according to tumor type, studies have shown an association with poor prognosis for patients with breast cancer (Alsner et al., 2008; 18465328, Olivier et al., 2006; 16489069, Végran et al., 2013; 23359294), endometrial cancer (Wild et al., 2012; 22678923, Lee et al., 2010; 20006376), HNSCC (Ganci et al., 2013; 24107801, Lindenbergh_van et al., 2011; 21467160, Peltonen et al., 2011; 21513535), or urothelial cancer (Bringuier et al., 1998; 9761125, Feng et al., 2014; 24500328). In one study of 55 patients with lung adenocarcinoma, TP53 alterations correlated with immunogenic features including PD_L1 expression, tumor mutation burden and neoantigen presentation; likely as a consequence of this association TP53 mutations correlated with improved clinical outcomes to PD_1 inhibitors pembrolizumab and nivolumab in this study (Dong et al., 2016; 28039262). TP53 mutation has not been consistently demonstrated to be a significant independent prognostic marker in the context of CRC (Russo et al., 2005; 16172461, Fong et al., 2022; ASCO GI Abstract 57). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Tumor Mutation Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '01', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '01'}}, 'Interpretation': 'Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Carcinomas that have been reported to harbor the highest frequencies of elevated TMB include colorectal (CRC) (8_25%) (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117), endometrial (7_24%) (Frampton et al., 2016; ASCO Abstract 11558, Santin et al., 2016; ASCO Abstract 414, Cancer Genome Atlas Research Network., 2013; 23636398), intestinal type gastric (20%) (Frampton et al., 2016; ASCO Abstract 11558), and non_small cell lung carcinoma (NSCLC; 8_13%) (Spigel et al., 2016; ASCO Abstract 9017, Jiang et al., 2016; ASCO Abstract e23128). In patients with NSCLC, increased TMB is associated with higher tumor grade and poor prognosis (Xiao et al., 2016; 27009843), as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high_TMB samples each), but not BRAF (10.3%) or KRAS (9.4%) (Spigel et al., 2016; ASCO Abstract 9017). Although some studies have reported a lack of association between smoking and increased TMB in NSCLC (Schwartz et al., 2016; ASCO Abstract 8533, Xiao et al., 2016; 27009843, Shim et al., 2015; 26200269), several other large studies did find a strong link (Govindan et al., 2012; 22980976, Ding et al., 2008; 18948947, Imielinski et al., 2012; 22980975, Kim et al., 2014; 24323028). In CRC, elevated TMB is associated with a higher frequency of BRAF V600E driver mutations (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117) and with microsatellite instability (MSI) (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Stadler et al., 2016; 27022117), which in turn has been reported to correlate with better prognosis (Samowitz et al., 2001; 11535541, Elsaleh and Iacopetta, 2001; 12445368, Brueckl et al., 2003; 12820457, Guidoboni et al., 2001; 11438476, Gryfe et al., 2000; 10631274, Sinicrope et al., 2006; 16952542, Guastadisegni et al., 2010; 20627535, Laghi and Malesci, 2012; 22722556). Although increased TMB is associated with increased tumor grade in endometrioid endometrial carcinoma (Mehnert et al., 2016; 27159395, Cancer Genome Atlas Research Network., 2013; 23636398, Hussein et al., 2015; 25394778, Church et al., 2013; 23528559) and bladder cancer (Cazier et al., 2016; 24777035), it is also linked with improved prognosis in patients with these tumor types (Rosenberg et al., 2016; ASCO Abstract 104, Cancer Genome Atlas Research Network., 2013; 23636398). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB ≥10 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores ≥ 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB ≥ 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB ≥ 16 Muts/Mb than those with TMB ≥ 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'VEGFA', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'true', 'name': 'amplification'}}, 'Interpretation': 'VEGFA (vascular endothelial growth factor A) encodes a ligand that promotes angiogenesis through the receptor tyrosine kinases VEGFR1 and VEGFR2 (Goel and Mercurio., 2013; 24263190). VEGFA promotes tumor growth by activating both autocrine VEGFR signaling in tumor cells and paracrine signaling to fibroblasts and immune cells in the tumor microenvironment (Goel and Mercurio., 2013; 24263190). VEGFA has been reported to be amplified in cancer (Gao et al., 2013; 23550210), and is associated with response to sorafenib (Horwitz et al., 2014; 24687604). In the TCGA datasets, VEGFA amplification was observed in 13% of esophageal carcinoma, 7% of stomach adenocarcinoma, 3% of lung adenocarcinoma, 2% of pancreatic adenocarcinoma, and 1% of colorectal adenocarcinoma (CRC) cases (Cancer Genome Atlas Research Network., 2014; 25079317, Cancer Genome Atlas Research Network., 2014; 25079552, Cancer Genome Atlas Network., 2012; 22810696). Amplification of the 6p12 locus, where VEGFA is located, has been observed in 3% of CRC cases (Vlajnic et al., 2011; 21743435). Increased plasma VEGF_A levels have been associated with decreased overall survival in patients with non_small cell lung cancer (NSCLC) (Mok et al., 2014; 24807156, Hegde et al., 2013; 23169435) and with worse prognosis in patients with cervical cancer (Du et al., 2014; 25374209), and VEGF expression was reported to be correlated with higher stage in hypopharyngeal SCC (Hong et al., 2014; 25158264). There have been conflicting reports regarding the value of serum VEGF_A levels as a prognostic indicator in patients with gastric cancer (Van Cutsem et al., 2012; 22565005, Park do et al., 2014; 24370903), gastroesophageal junction cancer (Park do et al., 2014; 24370903), non_small cell lung cancer (NSCLC) (Mok et al., 2014; 24807156, Hegde et al., 2013; 23169435), pancreatic ductal adenocarcinoma (Chang et al., 2008; 18665074, Georgiadou et al., 2014; 24480377, Rahbari et al., 2011; 21729304); furthermore, it has not been shown that VEGFA amplification or expression in tumor cells results in increased plasma levels of VEGF_A (Mok et al., 2014; 24807156). The approved VEGFA_targeted agents bevacizumab and ziv_aflibercept have demonstrated efficacy in multiple tumor types; however, expression or amplification of VEGFA has not been established as a reliable biomarker of response to these therapies (Van Cutsem et al., 2012; 22565005, Miles et al., 2013; 23422754, Gianni et al., 2013; 23569311, Cameron et al., 2013; 23932548, Hegde et al., 2013; 23169435, Schneider et al., 2012; 23340303, Baumgarten et al., 2016; 26627848, Sathornsumetee et al., 2008; 18182667, Olafson et al., 2019; 31582283, Nishikawa et al., 2013; ASCO Abstract 2023, Wick et al., 2013; WCN Abstract 1207, Duda et al., 2010; 20484123, Stremitzer et al., 2016; 27535973, Weickhardt et al., 2015; 26125443, Kopetz et al., 2009; 20008624, Fountzilas et al., 2011; 21868552, Sánchez_Rovira et al., 2013; 23397155, Mok et al., 2014; 24807156, An et al., 2014; 24577128, Bais et al., 2017; 29059426, Van Cutsem et al., 2011; EMCC Abstract 803, Xu et al., 2009; 19826039, Hasselbalch et al., 2010; 20666740, Marisi et al., 2017; 28465540, Jubb et al., 2005; 16365183, Goede et al., 2010; 20924372, Bruhn et al., 2013; 24374727, Escudier et al., 2007; 18156031, Yang et al., 2003; 12890841, Burstein et al., 2008; 19047116, Jubb et al., 2011; 21224365, Miles et al., 2017; 27817944, Dowlati et al., 2008; 18316562, Horn et al., 2009; 19826110, Blakeley et al., 2016; 26976425). Preclinical hepatocellular carcinoma (HCC) models with VEGFA amplification showed increased sensitivity to sorafenib, and a small retrospective study reported significantly increased OS for 7 patients with VEGFA_amplified HCC treated with sorafenib (Horwitz et al., 2014; 24687604). However, a prospective biomarker study showed that VEGFA amplification detected by circulating cell_free DNA was not significantly associated with DCR, time to progression, or median OS for patients with HCC treated with first_line sorafenib (Oh et al., 2019; 30935424). It is currently not known if VEGFA amplification predicts response to other inhibitors targeting VEGFRs.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'CTNNB1', 'Alteration': 'S45P', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'S45P', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'S45P', 'Title': 'A Phase 1 Trial of Vandetanib (a Multi_kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'mTOR, EGFR, SRC, RET, VEGFRs', 'Locations': 'Texas', 'NCTID': 'NCT01582191', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'CTNNB1', 'Alteration': 'S45P', 'Title': 'Combination Chemotherapy and Bevacizumab With the NovoTTF_100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'VEGFA, mTOR', 'Locations': 'Texas', 'NCTID': 'NCT03203525', 'Note': 'Based on clinical and preclinical evidence, tumors with activating CTNNB1 alterations may be sensitive to mTOR inhibitors.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'amplification', 'Title': 'Study of AZD5305 as Monotherapy and in Combination With Anti_cancer Agents in Patients With Advanced Solid Malignancies', 'StudyPhase': 'PHASE 1/2', 'Target': 'ERBB2, TROP2, PARP', 'Locations': 'Shanghai (China), Seoul (Korea, Republic of), Chongqing (China), Chuo_ku (Japan), Koto_ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Grzepnica (Poland), Budapest (Hungary)', 'NCTID': 'NCT04644068', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'amplification', 'Title': 'Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event', 'StudyPhase': 'PHASE 2', 'Target': 'EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT03239015', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'amplification', 'Title': 'A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum_Based Chemotherapy in Patients With Cancer of Unknown Primary Site', 'StudyPhase': 'PHASE 2', 'Target': 'ALK, RET, SMO, AKTs, PARP, PD_L1, EGFR, VEGFA, MEK, BRAF, ERBB2, TRKB, TRKC, ROS1, TRKA', 'Locations': 'Fukuoka (Japan), Ehime (Japan), Seoul (Korea, Republic of), Aichi (Japan), Tokyo (Japan), Chiba (Japan), Bangkok (Thailand), South Brisbane (Australia), Bedford Park (Australia), Blacktown (Australia)', 'NCTID': 'NCT03498521', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'amplification', 'Title': 'Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations', 'StudyPhase': 'PHASE 2', 'Target': 'ERBB2, ER', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Osakasayama (Japan), Nagoya_shi (Japan), Kawasaki_shi (Japan), Chuo_Ku (Japan), Tokyo (Japan), Kashiwa_shi (Japan), Poznan (Poland), Amsterdam (Netherlands)', 'NCTID': 'NCT04579380', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'amplification', 'Title': 'A Phase Ia/Ib Study of IBI315 in Patients With HER2_expressing Advanced Solid Tumor', 'StudyPhase': 'PHASE 1', 'Target': 'ERBB2, PD_1', 'Locations': 'Beijing (China)', 'NCTID': 'NCT04162327', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'amplification', 'Title': 'KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor', 'StudyPhase': 'PHASE 1', 'Target': 'ERBB2, CTLA_4, PD_L1', 'Locations': 'Beijing (China)', 'NCTID': 'NCT04040699', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'amplification', 'Title': 'The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs', 'StudyPhase': 'PHASE 2', 'Target': 'BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6', 'Locations': 'Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)', 'NCTID': 'NCT05159245', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'amplification', 'Title': 'TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'ALK, ROS1, AXL, TRKA, MET, TRKC, CDK4, CDK6, FLT3, VEGFRs, CSF1R, KIT, RET, mTOR, ERBB2, MEK, BRAF, PARP, PD_1, CTLA_4, EGFR, ERBB4', 'Locations': 'Hawaii, Washington, Oregon, California', 'NCTID': 'NCT02693535', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'amplification', 'Title': 'Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985', 'StudyPhase': 'PHASE 1/2', 'Target': 'ERBB2', 'Locations': 'Antwerp (Belgium), Leuven (Belgium), Lille (France), Paris (France), Bordeaux (France), Barcelona (Spain), L Hospitalet De Llobregat (Spain), Lleida (Spain), Madrid (Spain)', 'NCTID': 'NCT04983238', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.', 'Include': 'true'}, {'Gene': 'ERBB2', 'Alteration': 'amplification', 'Title': 'Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO', 'Locations': 'Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)', 'NCTID': 'NCT03297606', 'Note': 'ERBB2 amplification or activating mutation may confer sensitivity to HER2_targeted and dual EGFR/HER2_directed therapies, and may enhance efficacy of HSP90 inhibitors.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '10679188', 'FullCitation': 'Biochem. Biophys. Res. Commun. (2000) pmid: 10679188', 'Include': 'true'}, {'number': '1', 'ReferenceId': '23258168', 'FullCitation': 'Anastas JN, et al. Nat. Rev. Cancer (2013) pmid: 23258168', 'Include': 'true'}, {'number': '2', 'ReferenceId': '9721853', 'FullCitation': 'Fukuchi T, et al. Cancer Res. (1998) pmid: 9721853', 'Include': 'true'}, {'number': '3', 'ReferenceId': '12824913', 'FullCitation': 'Cancer Sci. (2003) pmid: 12824913', 'Include': 'true'}, {'number': '4', 'ReferenceId': '16523258', 'FullCitation': 'Takahashi Y, et al. Virchows Arch. (2006) pmid: 16523258', 'Include': 'true'}, {'number': '5', 'ReferenceId': '11731417', 'FullCitation': 'Tanaka Y, et al. Cancer Res. (2001) pmid: 11731417', 'Include': 'true'}, {'number': '6', 'ReferenceId': '11943721', 'FullCitation': 'Abraham SC, et al. Am. J. Pathol. (2002) pmid: 11943721', 'Include': 'true'}, {'number': '7', 'ReferenceId': '18282277', 'FullCitation': 'Austinat M, et al. Mol. Cancer (2008) pmid: 18282277', 'Include': 'true'}, {'number': '8', 'ReferenceId': '12820959', 'FullCitation': 'Wu G, et al. Mol. Cell (2003) pmid: 12820959', 'Include': 'true'}, {'number': '9', 'ReferenceId': '15829978', 'FullCitation': 'Provost E, et al. Oncogene (2005) pmid: 15829978', 'Include': 'true'}, {'number': '10', 'ReferenceId': '10072352', 'FullCitation': 'Curr. Opin. Genet. Dev. (1999) pmid: 10072352', 'Include': 'true'}, {'number': '11', 'ReferenceId': '17143297', 'FullCitation': 'Segditsas S, et al. Oncogene (2006) pmid: 17143297', 'Include': 'true'}, {'number': '12', 'ReferenceId': '9024698', 'FullCitation': 'Barth AI, et al. J. Cell Biol. (1997) pmid: 9024698', 'Include': 'true'}, {'number': '13', 'ReferenceId': '10545105', 'FullCitation': 'Harada N, et al. EMBO J. (1999) pmid: 10545105', 'Include': 'true'}, {'number': '14', 'ReferenceId': '9671490', 'FullCitation': 'Hsu SC, et al. Mol. Cell. Biol. (1998) pmid: 9671490', 'Include': 'true'}, {'number': '15', 'ReferenceId': '18491352', 'FullCitation': 'Breuhahn K, et al. J. Pathol. (2008) pmid: 18491352', 'Include': 'true'}, {'number': '16', 'ReferenceId': '18515740', 'FullCitation': 'Soon PS, et al. Oncologist (2008) pmid: 18515740', 'Include': 'true'}, {'number': '17', 'ReferenceId': '21212436', 'FullCitation': 'Tacon LJ, et al. Oncologist (2011) pmid: 21212436', 'Include': 'true'}, {'number': '18', 'ReferenceId': '22266195', 'FullCitation': 'Simon DP, et al. Mol. Cell. Endocrinol. (2012) pmid: 22266195', 'Include': 'true'}, {'number': '19', 'ReferenceId': '26850916', 'FullCitation': 'Hirotsu Y, et al. Hepatol. Res. (2016) pmid: 26850916', 'Include': 'true'}, {'number': '20', 'ReferenceId': '28481359', 'FullCitation': 'Zehir A, et al. Nat. Med. (2017) pmid: 28481359', 'Include': 'true'}, {'number': '21', 'ReferenceId': '16843618', 'FullCitation': 'Nozawa N, et al. Pathol. Res. Pract. (2006) pmid: 16843618', 'Include': 'true'}, {'number': '22', 'ReferenceId': '22402266', 'FullCitation': 'Chiu CG, et al. Am. J. Surg. (2012) pmid: 22402266', 'Include': 'true'}, {'number': '23', 'ReferenceId': '23483484', 'FullCitation': 'Kim H, et al. Korean J Pathol (2013) pmid: 23483484', 'Include': 'true'}, {'number': '24', 'ReferenceId': '19820688', 'FullCitation': 'Rosen DG, et al. Mod. Pathol. (2010) pmid: 19820688', 'Include': 'true'}, {'number': '25', 'ReferenceId': '17504383', 'FullCitation': 'Athanassiadou P, et al. Int. J. Gynecol. Cancer () pmid: 17504383', 'Include': 'true'}, {'number': '26', 'ReferenceId': '30635339', 'FullCitation': 'Luke JJ, et al. Clin Cancer Res (2019) pmid: 30635339', 'Include': 'true'}, {'number': '27', 'ReferenceId': '19403928', 'FullCitation': 'Tanwar PS, et al. Biol. Reprod. (2009) pmid: 19403928', 'Include': 'true'}, {'number': '28', 'ReferenceId': '21695255', 'FullCitation': 'Tanwar PS, et al. PLoS ONE (2011) pmid: 21695255', 'Include': 'true'}, {'number': '29', 'ReferenceId': '18768809', 'FullCitation': 'Fujishita T, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18768809', 'Include': 'true'}, {'number': '30', 'ReferenceId': '20347502', 'FullCitation': 'Bhoori S, et al. J. Hepatol. (2010) pmid: 20347502', 'Include': 'true'}, {'number': '31', 'ReferenceId': '24931142', 'FullCitation': 'Janku F, et al. Oncotarget (2014) pmid: 24931142', 'Include': 'true'}, {'number': '32', 'ReferenceId': '25624430', 'FullCitation': 'Slomovitz BM, et al. J. Clin. Oncol. (2015) pmid: 25624430', 'Include': 'true'}, {'number': '33', 'ReferenceId': '15378020', 'FullCitation': 'Niida A, et al. Oncogene (2004) pmid: 15378020', 'Include': 'true'}, {'number': '34', 'ReferenceId': '15592430', 'FullCitation': 'Chamorro MN, et al. EMBO J. (2005) pmid: 15592430', 'Include': 'true'}, {'number': '35', 'ReferenceId': '28574171', 'FullCitation': 'Kagey MH, et al. Br. J. Pharmacol. (2017) pmid: 28574171', 'Include': 'true'}, {'number': '36', 'ReferenceId': '21841793', 'FullCitation': 'Kwon C, et al. Nat. Cell Biol. (2011) pmid: 21841793', 'Include': 'true'}, {'number': '37', 'ReferenceId': '23868008', 'FullCitation': 'Arcaroli JJ, et al. Br. J. Cancer (2013) pmid: 23868008', 'Include': 'true'}, {'number': '38', 'ReferenceId': '26349011', 'FullCitation': 'Shang H, et al. Cancer (2015) pmid: 26349011', 'Include': 'true'}, {'number': '39', 'ReferenceId': '24429522', 'FullCitation': 'Kode A, et al. Nature (2014) pmid: 24429522', 'Include': 'true'}, {'number': '40', 'ReferenceId': '25231399', 'FullCitation': 'Messersmith WA, et al. Clin. Cancer Res. (2015) pmid: 25231399', 'Include': 'true'}, {'number': '41', 'ReferenceId': '22964660', 'FullCitation': 'Zhu J, et al. Carcinogenesis (2012) pmid: 22964660', 'Include': 'true'}, {'number': '42', 'ReferenceId': '22356261', 'FullCitation': 'Kogan Y, et al. Biochem. J. (2012) pmid: 22356261', 'Include': 'true'}, {'number': '43', 'ReferenceId': '22811581', 'FullCitation': 'Lachenmayer A, et al. Clin. Cancer Res. (2012) pmid: 22811581', 'Include': 'true'}, {'number': '44', 'ReferenceId': '21965336', 'FullCitation': 'Higgins MJ, et al. J. Clin. Invest. (2011) pmid: 21965336', 'Include': 'true'}, {'number': '45', 'ReferenceId': '25480824', 'FullCitation': 'Chmielecki J, et al. Oncologist (2015) pmid: 25480824', 'Include': 'true'}, {'number': '46', 'ReferenceId': '23000897', 'FullCitation': 'Nature (2012) pmid: 23000897', 'Include': 'true'}, {'number': '47', 'ReferenceId': '26451490', 'FullCitation': 'Ciriello G, et al. Cell (2015) pmid: 26451490', 'Include': 'true'}, {'number': '48', 'ReferenceId': '25079317', 'FullCitation': 'Nature (2014) pmid: 25079317', 'Include': 'true'}, {'number': '49', 'ReferenceId': '25855536', 'FullCitation': 'Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536', 'Include': 'true'}, {'number': '50', 'ReferenceId': '22588877', 'FullCitation': 'Cerami E, et al. Cancer Discov (2012) pmid: 22588877', 'Include': 'true'}, {'number': '51', 'ReferenceId': '23550210', 'FullCitation': 'Gao J, et al. Sci Signal (2013) pmid: 23550210', 'Include': 'true'}, {'number': '52', 'ReferenceId': '22461643', 'FullCitation': 'Sci Transl Med (2012) pmid: 22461643', 'Include': 'true'}, {'number': '53', 'ReferenceId': '19959074', 'FullCitation': 'Jones KL, et al. Lancet Oncol. (2009) pmid: 19959074', 'Include': 'true'}, {'number': '54', 'ReferenceId': '23749902', 'FullCitation': 'Ramić S, et al. Anticancer Res. (2013) pmid: 23749902', 'Include': 'true'}, {'number': '55', 'ReferenceId': '10340889', 'FullCitation': 'Polkowski W, et al. Ann. Surg. Oncol. () pmid: 10340889', 'Include': 'true'}, {'number': '56', 'ReferenceId': '21359545', 'FullCitation': 'Haas M, et al. Virchows Arch. (2011) pmid: 21359545', 'Include': 'true'}, {'number': '57', 'ReferenceId': '21783379', 'FullCitation': 'Maresch J, et al. Crit. Rev. Oncol. Hematol. (2012) pmid: 21783379', 'Include': 'true'}, {'number': '58', 'ReferenceId': '22991510', 'FullCitation': 'Tsai YS, et al. Adv Urol (2012) pmid: 22991510', 'Include': 'true'}, {'number': '59', 'ReferenceId': '23348520', 'FullCitation': 'Martin V, et al. Br. J. Cancer (2013) pmid: 23348520', 'Include': 'true'}, {'number': '60', 'ReferenceId': '24879338', 'FullCitation': 'Seo AN, et al. PLoS ONE (2014) pmid: 24879338', 'Include': 'true'}, {'number': '61', 'ReferenceId': '24146218', 'FullCitation': 'Sclafani F, et al. Ann. Oncol. (2013) pmid: 24146218', 'Include': 'true'}, {'number': '62', 'ReferenceId': '22374460', 'FullCitation': 'Harder J, et al. Br. J. Cancer (2012) pmid: 22374460', 'Include': 'true'}, {'number': '63', 'ReferenceId': '19432892', 'FullCitation': 'Komoto M, et al. Cancer Sci. (2009) pmid: 19432892', 'Include': 'true'}, {'number': '64', 'ReferenceId': '11586103', 'FullCitation': 'Safran H, et al. Am. J. Clin. Oncol. (2001) pmid: 11586103', 'Include': 'true'}, {'number': '65', 'ReferenceId': '16685109', 'FullCitation': 'Tsiambas E, et al. JOP (2006) pmid: 16685109', 'Include': 'true'}, {'number': '66', 'ReferenceId': '18463983', 'FullCitation': 'Sharif S, et al. Dig. Dis. Sci. (2008) pmid: 18463983', 'Include': 'true'}, {'number': '67', 'ReferenceId': '14752523', 'FullCitation': 'Peiró G, et al. Mod. Pathol. (2004) pmid: 14752523', 'Include': 'true'}, {'number': '68', 'ReferenceId': '7585656', 'FullCitation': 'Saffari B, et al. Cancer Res. (1995) pmid: 7585656', 'Include': 'true'}, {'number': '69', 'ReferenceId': '22611955', 'FullCitation': 'Kudela M, et al. Eur. J. Gynaecol. Oncol. (2012) pmid: 22611955', 'Include': 'true'}, {'number': '70', 'ReferenceId': '22340411', 'FullCitation': 'Zhang YF, et al. Chin. Med. J. (2011) pmid: 22340411', 'Include': 'true'}, {'number': '71', 'ReferenceId': '20179235', 'FullCitation': 'Minner S, et al. Clin. Cancer Res. (2010) pmid: 20179235', 'Include': 'true'}, {'number': '72', 'ReferenceId': '11248153', 'FullCitation': 'Slamon DJ, et al. N. Engl. J. Med. (2001) pmid: 11248153', 'Include': 'true'}, {'number': '73', 'ReferenceId': '20728210', 'FullCitation': 'Bang YJ, et al. Lancet (2010) pmid: 20728210', 'Include': 'true'}, {'number': '74', 'ReferenceId': '26358791', 'FullCitation': 'Chumsri S, et al. J Natl Compr Canc Netw (2015) pmid: 26358791', 'Include': 'true'}, {'number': '75', 'ReferenceId': '16775247', 'FullCitation': 'Cappuzzo F, et al. N. Engl. J. Med. (2006) pmid: 16775247', 'Include': 'true'}, {'number': '76', 'ReferenceId': '23328556', 'FullCitation': 'Falchook GS, et al. J Thorac Oncol (2013) pmid: 23328556', 'Include': 'true'}, {'number': '77', 'ReferenceId': '23610105', 'FullCitation': 'Mazières J, et al. J. Clin. Oncol. (2013) pmid: 23610105', 'Include': 'true'}, {'number': '78', 'ReferenceId': '22149875', 'FullCitation': 'Baselga J, et al. N. Engl. J. Med. (2012) pmid: 22149875', 'Include': 'true'}, {'number': '79', 'ReferenceId': '25693012', 'FullCitation': 'Swain SM, et al. N. Engl. J. Med. (2015) pmid: 25693012', 'Include': 'true'}, {'number': '80', 'ReferenceId': '30857956', 'FullCitation': 'Meric_Bernstam F, et al. Lancet Oncol. (2019) pmid: 30857956', 'Include': 'true'}, {'number': '81', 'ReferenceId': '23020162', 'FullCitation': 'Verma S, et al. N. Engl. J. Med. (2012) pmid: 23020162', 'Include': 'true'}, {'number': '82', 'ReferenceId': '31825192', 'FullCitation': 'Modi S, et al. N. Engl. J. Med. (2019) pmid: 31825192', 'Include': 'true'}, {'number': '83', 'ReferenceId': '32469182', 'FullCitation': 'Shitara K, et al. N. Engl. J. Med. (2020) pmid: 32469182', 'Include': 'true'}, {'number': '84', 'ReferenceId': '34534430', 'FullCitation': 'Li BT, et al. N Engl J Med (2021) pmid: 34534430', 'Include': 'true'}, {'number': '85', 'ReferenceId': '31825569', 'FullCitation': 'Murthy RK, et al. N. Engl. J. Med. (2020) pmid: 31825569', 'Include': 'true'}, {'number': '86', 'ReferenceId': '29955792', 'FullCitation': 'Borges VF, et al. JAMA Oncol (2018) pmid: 29955792', 'Include': 'true'}, {'number': '87', 'ReferenceId': '29804905', 'FullCitation': 'Murthy R, et al. Lancet Oncol. (2018) pmid: 29804905', 'Include': 'true'}, {'number': '88', 'ReferenceId': '28053022', 'FullCitation': 'Moulder SL, et al. Clin. Cancer Res. (2017) pmid: 28053022', 'Include': 'true'}, {'number': '89', 'ReferenceId': '32478891', 'FullCitation': 'Fan Y, et al. Mol Oncol (2020) pmid: 32478891', 'Include': 'true'}, {'number': '90', 'ReferenceId': '20736298', 'FullCitation': 'Cameron D, et al. Oncologist (2010) pmid: 20736298', 'Include': 'true'}, {'number': '91', 'ReferenceId': '17192538', 'FullCitation': 'Geyer CE, et al. N. Engl. J. Med. (2006) pmid: 17192538', 'Include': 'true'}, {'number': '92', 'ReferenceId': '23950206', 'FullCitation': 'Serra V, et al. Cancer Discov (2013) pmid: 23950206', 'Include': 'true'}, {'number': '93', 'ReferenceId': '24516025', 'FullCitation': 'Ali SM, et al. J. Clin. Oncol. (2014) pmid: 24516025', 'Include': 'true'}, {'number': '94', 'ReferenceId': '26487584', 'FullCitation': 'Grellety T, et al. Ann. Oncol. (2016) pmid: 26487584', 'Include': 'true'}, {'number': '95', 'ReferenceId': '25085898', 'FullCitation': 'Vornicova O, et al. Oncologist (2014) pmid: 25085898', 'Include': 'true'}, {'number': '96', 'ReferenceId': '32017710', 'FullCitation': 'Ronellenfitsch MW, et al. J Clin Invest (2020) pmid: 32017710', 'Include': 'true'}, {'number': '97', 'ReferenceId': '32405522', 'FullCitation': 'Hou JY, et al. Gynecol Oncol Rep (2020) pmid: 32405522', 'Include': 'true'}, {'number': '98', 'ReferenceId': '22418700', 'FullCitation': 'Lin NU, et al. Breast Cancer Res. Treat. (2012) pmid: 22418700', 'Include': 'true'}, {'number': '99', 'ReferenceId': '25268372', 'FullCitation': 'Schwab CL, et al. Br. J. Cancer (2014) pmid: 25268372', 'Include': 'true'}, {'number': '100', 'ReferenceId': '25682316', 'FullCitation': 'De Grève J, et al. Lung Cancer (2015) pmid: 25682316', 'Include': 'true'}, {'number': '101', 'ReferenceId': '22325357', 'FullCitation': 'De Grève J, et al. Lung Cancer (2012) pmid: 22325357', 'Include': 'true'}, {'number': '102', 'ReferenceId': '26559459', 'FullCitation': 'Li BT, et al. Lung Cancer (2015) pmid: 26559459', 'Include': 'true'}, {'number': '103', 'ReferenceId': '30825613', 'FullCitation': 'Dziadziuszko R, et al. J Thorac Oncol (2019) pmid: 30825613', 'Include': 'true'}, {'number': '104', 'ReferenceId': '30685684', 'FullCitation': 'Lai WV, et al. Eur. J. Cancer (2019) pmid: 30685684', 'Include': 'true'}, {'number': '105', 'ReferenceId': '30425522', 'FullCitation': 'Liu Z, et al. Onco Targets Ther (2018) pmid: 30425522', 'Include': 'true'}, {'number': '106', 'ReferenceId': '31748336', 'FullCitation': 'Fang W, et al. Oncologist (2019) pmid: 31748336', 'Include': 'true'}, {'number': '107', 'ReferenceId': '32477948', 'FullCitation': 'Yuan B, et al. Front Oncol (2020) pmid: 32477948', 'Include': 'true'}, {'number': '108', 'ReferenceId': '26358790', 'FullCitation': 'Ben_Baruch NE, et al. J Natl Compr Canc Netw (2015) pmid: 26358790', 'Include': 'true'}, {'number': '109', 'ReferenceId': '28679771', 'FullCitation': 'Ma CX, et al. Clin. Cancer Res. (2017) pmid: 28679771', 'Include': 'true'}, {'number': '110', 'ReferenceId': '29420467', 'FullCitation': 'Hyman DM, et al. Nature (2018) pmid: 29420467', 'Include': 'true'}, {'number': '111', 'ReferenceId': '31806627', 'FullCitation': 'Smyth LM, et al. Cancer Discov (2019) pmid: 31806627', 'Include': 'true'}, {'number': '112', 'ReferenceId': '25899785', 'FullCitation': 'Kris MG, et al. Ann. Oncol. (2015) pmid: 25899785', 'Include': 'true'}, {'number': '113', 'ReferenceId': '30596880', 'FullCitation': 'Wang Y, et al. Ann. Oncol. (2019) pmid: 30596880', 'Include': 'true'}, {'number': '114', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '115', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '116', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '117', 'ReferenceId': '9823339', 'FullCitation': 'Boland CR, et al. Cancer Res. (1998) pmid: 9823339', 'Include': 'true'}, {'number': '118', 'ReferenceId': '15528785', 'FullCitation': 'Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785', 'Include': 'true'}, {'number': '119', 'ReferenceId': '20420947', 'FullCitation': 'Boland CR, et al. Gastroenterology (2010) pmid: 20420947', 'Include': 'true'}, {'number': '120', 'ReferenceId': '17513808', 'FullCitation': 'Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808', 'Include': 'true'}, {'number': '121', 'ReferenceId': '16885385', 'FullCitation': 'Hampel H, et al. Cancer Res. (2006) pmid: 16885385', 'Include': 'true'}, {'number': '122', 'ReferenceId': '27006490', 'FullCitation': 'Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490', 'Include': 'true'}, {'number': '123', 'ReferenceId': '25458958', 'FullCitation': 'Kanopienė D, et al. Medicina (Kaunas) (2014) pmid: 25458958', 'Include': 'true'}, {'number': '124', 'ReferenceId': '16549821', 'FullCitation': 'Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821', 'Include': 'true'}, {'number': '125', 'ReferenceId': '22609107', 'FullCitation': 'Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107', 'Include': 'true'}, {'number': '126', 'ReferenceId': '21547578', 'FullCitation': 'Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578', 'Include': 'true'}, {'number': '127', 'ReferenceId': '20005452', 'FullCitation': 'Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452', 'Include': 'true'}, {'number': '128', 'ReferenceId': '20627535', 'FullCitation': 'Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535', 'Include': 'true'}, {'number': '129', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '130', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '131', 'ReferenceId': '15209621', 'FullCitation': 'Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621', 'Include': 'true'}, {'number': '132', 'ReferenceId': '9537253', 'FullCitation': 'Wu MS, et al. Cancer Res. (1998) pmid: 9537253', 'Include': 'true'}, {'number': '133', 'ReferenceId': '8536886', 'FullCitation': 'dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886', 'Include': 'true'}, {'number': '134', 'ReferenceId': '23555086', 'FullCitation': 'Fang WL, et al. Biomed Res Int (2013) pmid: 23555086', 'Include': 'true'}, {'number': '135', 'ReferenceId': '21422910', 'FullCitation': 'Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910', 'Include': 'true'}, {'number': '136', 'ReferenceId': '20395525', 'FullCitation': 'Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525', 'Include': 'true'}, {'number': '137', 'ReferenceId': '19252434', 'FullCitation': 'Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434', 'Include': 'true'}, {'number': '138', 'ReferenceId': '12627520', 'FullCitation': 'Planck M, et al. Cancer (2003) pmid: 12627520', 'Include': 'true'}, {'number': '139', 'ReferenceId': '7775257', 'FullCitation': 'Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257', 'Include': 'true'}, {'number': '140', 'ReferenceId': '11117578', 'FullCitation': 'Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578', 'Include': 'true'}, {'number': '141', 'ReferenceId': '15918185', 'FullCitation': 'Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185', 'Include': 'true'}, {'number': '142', 'ReferenceId': '14656944', 'FullCitation': 'Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944', 'Include': 'true'}, {'number': '143', 'ReferenceId': '11223838', 'FullCitation': 'Suto T, et al. J Surg Oncol (2001) pmid: 11223838', 'Include': 'true'}, {'number': '144', 'ReferenceId': '11580146', 'FullCitation': 'Momoi H, et al. J. Hepatol. (2001) pmid: 11580146', 'Include': 'true'}, {'number': '145', 'ReferenceId': '14506736', 'FullCitation': 'Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736', 'Include': 'true'}, {'number': '146', 'ReferenceId': '25680569', 'FullCitation': 'Moy AP, et al. Virchows Arch. (2015) pmid: 25680569', 'Include': 'true'}, {'number': '147', 'ReferenceId': '11063221', 'FullCitation': 'Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221', 'Include': 'true'}, {'number': '148', 'ReferenceId': '25255306', 'FullCitation': 'Pritchard CC, et al. Nat Commun (2014) pmid: 25255306', 'Include': 'true'}, {'number': '149', 'ReferenceId': '17233803', 'FullCitation': 'Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803', 'Include': 'true'}, {'number': '150', 'ReferenceId': '16924473', 'FullCitation': 'Burger M, et al. J. Mol. Med. (2006) pmid: 16924473', 'Include': 'true'}, {'number': '151', 'ReferenceId': '23690119', 'FullCitation': 'Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119', 'Include': 'true'}, {'number': '152', 'ReferenceId': '25319978', 'FullCitation': 'Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978', 'Include': 'true'}, {'number': '153', 'ReferenceId': '16675567', 'FullCitation': 'Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567', 'Include': 'true'}, {'number': '154', 'ReferenceId': '25026289', 'FullCitation': 'Bilbao_Sieyro C, et al. Oncotarget (2014) pmid: 25026289', 'Include': 'true'}, {'number': '155', 'ReferenceId': '20304627', 'FullCitation': 'Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627', 'Include': 'true'}, {'number': '156', 'ReferenceId': '19275958', 'FullCitation': 'Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958', 'Include': 'true'}, {'number': '157', 'ReferenceId': '25392179', 'FullCitation': 'Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179', 'Include': 'true'}, {'number': '158', 'ReferenceId': '26140250', 'FullCitation': 'Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250', 'Include': 'true'}, {'number': '159', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '160', 'ReferenceId': '24263190', 'FullCitation': 'Goel HL, et al. Nat. Rev. Cancer (2013) pmid: 24263190', 'Include': 'true'}, {'number': '161', 'ReferenceId': '24687604', 'FullCitation': 'Horwitz E, et al. Cancer Discov (2014) pmid: 24687604', 'Include': 'true'}, {'number': '162', 'ReferenceId': '25079552', 'FullCitation': 'Nature (2014) pmid: 25079552', 'Include': 'true'}, {'number': '163', 'ReferenceId': '21743435', 'FullCitation': 'Vlajnic T, et al. Mod. Pathol. (2011) pmid: 21743435', 'Include': 'true'}, {'number': '164', 'ReferenceId': '24807156', 'FullCitation': 'Mok T, et al. J Thorac Oncol (2014) pmid: 24807156', 'Include': 'true'}, {'number': '165', 'ReferenceId': '23169435', 'FullCitation': 'Hegde PS, et al. Clin. Cancer Res. (2013) pmid: 23169435', 'Include': 'true'}, {'number': '166', 'ReferenceId': '25374209', 'FullCitation': 'Du K, et al. Asian Pac. J. Cancer Prev. (2014) pmid: 25374209', 'Include': 'true'}, {'number': '167', 'ReferenceId': '25158264', 'FullCitation': 'Hong YM, et al. Genet. Mol. Res. (2014) pmid: 25158264', 'Include': 'true'}, {'number': '168', 'ReferenceId': '22565005', 'FullCitation': 'Van Cutsem E, et al. J. Clin. Oncol. (2012) pmid: 22565005', 'Include': 'true'}, {'number': '169', 'ReferenceId': '24370903', 'FullCitation': 'Park DJ, et al. Ann. Surg. Oncol. (2014) pmid: 24370903', 'Include': 'true'}, {'number': '170', 'ReferenceId': '18665074', 'FullCitation': 'Chang YT, et al. Pancreas (2008) pmid: 18665074', 'Include': 'true'}, {'number': '171', 'ReferenceId': '24480377', 'FullCitation': 'Georgiadou D, et al. Eur J Surg Oncol (2014) pmid: 24480377', 'Include': 'true'}, {'number': '172', 'ReferenceId': '21729304', 'FullCitation': 'Rahbari NN, et al. BMC Cancer (2011) pmid: 21729304', 'Include': 'true'}, {'number': '173', 'ReferenceId': '23422754', 'FullCitation': 'Miles DW, et al. Br. J. Cancer (2013) pmid: 23422754', 'Include': 'true'}, {'number': '174', 'ReferenceId': '23569311', 'FullCitation': 'Gianni L, et al. J. Clin. Oncol. (2013) pmid: 23569311', 'Include': 'true'}, {'number': '175', 'ReferenceId': '23932548', 'FullCitation': 'Cameron D, et al. Lancet Oncol. (2013) pmid: 23932548', 'Include': 'true'}, {'number': '176', 'ReferenceId': '23340303', 'FullCitation': 'Schneider BP, et al. Clin. Cancer Res. (2013) pmid: 23340303', 'Include': 'true'}, {'number': '177', 'ReferenceId': '26627848', 'FullCitation': 'Baumgarten P, et al. Neuro_oncology (2016) pmid: 26627848', 'Include': 'true'}, {'number': '178', 'ReferenceId': '18182667', 'FullCitation': 'Sathornsumetee S, et al. J. Clin. Oncol. (2008) pmid: 18182667', 'Include': 'true'}, {'number': '179', 'ReferenceId': '31582283', 'FullCitation': 'Olafson LR, et al. J Clin Neurosci (2019) pmid: 31582283', 'Include': 'true'}, {'number': '180', 'ReferenceId': '20484123', 'FullCitation': 'Duda DG, et al. Oncologist (2010) pmid: 20484123', 'Include': 'true'}, {'number': '181', 'ReferenceId': '27535973', 'FullCitation': 'Stremitzer S, et al. Mol. Cancer Ther. (2016) pmid: 27535973', 'Include': 'true'}, {'number': '182', 'ReferenceId': '26125443', 'FullCitation': 'Weickhardt AJ, et al. Br. J. Cancer (2015) pmid: 26125443', 'Include': 'true'}, {'number': '183', 'ReferenceId': '20008624', 'FullCitation': 'Kopetz S, et al. J. Clin. Oncol. (2010) pmid: 20008624', 'Include': 'true'}, {'number': '184', 'ReferenceId': '21868552', 'FullCitation': 'Fountzilas G, et al. Anticancer Res. (2011) pmid: 21868552', 'Include': 'true'}, {'number': '185', 'ReferenceId': '23397155', 'FullCitation': 'Sánchez_Rovira P, et al. Clin Transl Oncol (2013) pmid: 23397155', 'Include': 'true'}, {'number': '186', 'ReferenceId': '24577128', 'FullCitation': 'An SJ, et al. Cancer Gene Ther. (2014) pmid: 24577128', 'Include': 'true'}, {'number': '187', 'ReferenceId': '29059426', 'FullCitation': 'Bais C, et al. J. Natl. Cancer Inst. (2017) pmid: 29059426', 'Include': 'true'}, {'number': '188', 'ReferenceId': '19826039', 'FullCitation': 'Xu L, et al. Cancer Res. (2009) pmid: 19826039', 'Include': 'true'}, {'number': '189', 'ReferenceId': '20666740', 'FullCitation': 'Hasselbalch B, et al. APMIS (2010) pmid: 20666740', 'Include': 'true'}, {'number': '190', 'ReferenceId': '28465540', 'FullCitation': 'Marisi G, et al. Sci Rep (2017) pmid: 28465540', 'Include': 'true'}, {'number': '191', 'ReferenceId': '16365183', 'FullCitation': 'Jubb AM, et al. J. Clin. Oncol. (2006) pmid: 16365183', 'Include': 'true'}, {'number': '192', 'ReferenceId': '20924372', 'FullCitation': 'Goede V, et al. Br. J. Cancer (2010) pmid: 20924372', 'Include': 'true'}, {'number': '193', 'ReferenceId': '24374727', 'FullCitation': 'Bruhn MA, et al. Int. J. Cancer (2014) pmid: 24374727', 'Include': 'true'}, {'number': '194', 'ReferenceId': '18156031', 'FullCitation': 'Escudier B, et al. Lancet (2007) pmid: 18156031', 'Include': 'true'}, {'number': '195', 'ReferenceId': '12890841', 'FullCitation': 'Yang JC, et al. N. Engl. J. Med. (2003) pmid: 12890841', 'Include': 'true'}, {'number': '196', 'ReferenceId': '19047116', 'FullCitation': 'Burstein HJ, et al. Clin. Cancer Res. (2008) pmid: 19047116', 'Include': 'true'}, {'number': '197', 'ReferenceId': '21224365', 'FullCitation': 'Jubb AM, et al. Clin. Cancer Res. (2011) pmid: 21224365', 'Include': 'true'}, {'number': '198', 'ReferenceId': '27817944', 'FullCitation': 'Miles D, et al. Eur. J. Cancer (2017) pmid: 27817944', 'Include': 'true'}, {'number': '199', 'ReferenceId': '18316562', 'FullCitation': 'Dowlati A, et al. Clin. Cancer Res. (2008) pmid: 18316562', 'Include': 'true'}, {'number': '200', 'ReferenceId': '19826110', 'FullCitation': 'Horn L, et al. J. Clin. Oncol. (2009) pmid: 19826110', 'Include': 'true'}, {'number': '201', 'ReferenceId': '26976425', 'FullCitation': 'Blakeley JO, et al. J. Clin. Oncol. (2016) pmid: 26976425', 'Include': 'true'}, {'number': '202', 'ReferenceId': '30935424', 'FullCitation': 'Oh CR, et al. BMC Cancer (2019) pmid: 30935424', 'Include': 'true'}, {'number': '203', 'ReferenceId': '19686080', 'FullCitation': 'Moldovan GL, et al. Annu. Rev. Genet. (2009) pmid: 19686080', 'Include': 'true'}, {'number': '204', 'ReferenceId': '21568838', 'FullCitation': 'Deakyne JS, et al. Biochemistry Mosc. (2011) pmid: 21568838', 'Include': 'true'}, {'number': '205', 'ReferenceId': '30371878', 'FullCitation': 'Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878', 'Include': 'true'}, {'number': '206', 'ReferenceId': '24200853', 'FullCitation': 'Ghosh S, et al. Am. J. Pathol. (2014) pmid: 24200853', 'Include': 'true'}, {'number': '207', 'ReferenceId': '25609062', 'FullCitation': 'Lombardi AJ, et al. Clin. Cancer Res. (2015) pmid: 25609062', 'Include': 'true'}, {'number': '208', 'ReferenceId': '22522925', 'FullCitation': 'Curtis C, et al. Nature (2012) pmid: 22522925', 'Include': 'true'}, {'number': '209', 'ReferenceId': '9331070', 'FullCitation': 'Teng DH, et al. Cancer Res. (1997) pmid: 9331070', 'Include': 'true'}, {'number': '210', 'ReferenceId': '21896780', 'FullCitation': 'Ahn YH, et al. Mol. Cell. Biol. (2011) pmid: 21896780', 'Include': 'true'}, {'number': '211', 'ReferenceId': '21575258', 'FullCitation': 'Davis SJ, et al. BMC Cancer (2011) pmid: 21575258', 'Include': 'true'}, {'number': '212', 'ReferenceId': '16115952', 'FullCitation': 'Lee HY, et al. Clin. Cancer Res. (2005) pmid: 16115952', 'Include': 'true'}, {'number': '213', 'ReferenceId': '12714585', 'FullCitation': 'Lee HY, et al. J. Biol. Chem. (2003) pmid: 12714585', 'Include': 'true'}, {'number': '214', 'ReferenceId': '16740690', 'FullCitation': 'Cunningham SC, et al. Cancer Res. (2006) pmid: 16740690', 'Include': 'true'}, {'number': '215', 'ReferenceId': '20668451', 'FullCitation': 'Kan Z, et al. Nature (2010) pmid: 20668451', 'Include': 'true'}, {'number': '216', 'ReferenceId': '15866172', 'FullCitation': 'Takekawa M, et al. Mol. Cell (2005) pmid: 15866172', 'Include': 'true'}, {'number': '217', 'ReferenceId': '21372598', 'FullCitation': 'Ishikawa M, et al. Oncology (2010) pmid: 21372598', 'Include': 'true'}, {'number': '218', 'ReferenceId': '16489030', 'FullCitation': 'Hickson JA, et al. Cancer Res. (2006) pmid: 16489030', 'Include': 'true'}, {'number': '219', 'ReferenceId': '29795445', 'FullCitation': 'Xue Z, et al. Cell Res (2018) pmid: 29795445', 'Include': 'true'}, {'number': '220', 'ReferenceId': '19935675', 'FullCitation': 'Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675', 'Include': 'true'}, {'number': '221', 'ReferenceId': '18410249', 'FullCitation': 'Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249', 'Include': 'true'}, {'number': '222', 'ReferenceId': '12826609', 'FullCitation': 'Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609', 'Include': 'true'}, {'number': '223', 'ReferenceId': '20978130', 'FullCitation': 'Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130', 'Include': 'true'}, {'number': '224', 'ReferenceId': '28472496', 'FullCitation': 'Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496', 'Include': 'true'}, {'number': '225', 'ReferenceId': '17690113', 'FullCitation': 'Yamada H, et al. Carcinogenesis (2007) pmid: 17690113', 'Include': 'true'}, {'number': '226', 'ReferenceId': '24132290', 'FullCitation': 'Kandoth C, et al. Nature (2013) pmid: 24132290', 'Include': 'true'}, {'number': '227', 'ReferenceId': '16537709', 'FullCitation': 'Wongsurawat VJ, et al. Cancer Epidemiol. Biomarkers Prev. (2006) pmid: 16537709', 'Include': 'true'}, {'number': '228', 'ReferenceId': '19693097', 'FullCitation': 'Brosh R, et al. Nat. Rev. Cancer (2009) pmid: 19693097', 'Include': 'true'}, {'number': '229', 'ReferenceId': '2649981', 'FullCitation': 'Baker SJ, et al. Science (1989) pmid: 2649981', 'Include': 'true'}, {'number': '230', 'ReferenceId': '24053468', 'FullCitation': 'Calcagno DQ, et al. BMC Gastroenterol (2013) pmid: 24053468', 'Include': 'true'}, {'number': '231', 'ReferenceId': '18465328', 'FullCitation': 'Alsner J, et al. Acta Oncol (2008) pmid: 18465328', 'Include': 'true'}, {'number': '232', 'ReferenceId': '16489069', 'FullCitation': 'Olivier M, et al. Clin. Cancer Res. (2006) pmid: 16489069', 'Include': 'true'}, {'number': '233', 'ReferenceId': '23359294', 'FullCitation': 'Végran F, et al. PLoS ONE (2013) pmid: 23359294', 'Include': 'true'}, {'number': '234', 'ReferenceId': '22678923', 'FullCitation': 'Wild PJ, et al. EMBO Mol Med (2012) pmid: 22678923', 'Include': 'true'}, {'number': '235', 'ReferenceId': '20006376', 'FullCitation': 'Lee EJ, et al. Gynecol. Oncol. (2010) pmid: 20006376', 'Include': 'true'}, {'number': '236', 'ReferenceId': '24107801', 'FullCitation': 'Ganci F, et al. Ann. Oncol. (2013) pmid: 24107801', 'Include': 'true'}, {'number': '237', 'ReferenceId': '21467160', 'FullCitation': 'Lindenbergh_van der Plas M, et al. Clin. Cancer Res. (2011) pmid: 21467160', 'Include': 'true'}, {'number': '238', 'ReferenceId': '21513535', 'FullCitation': 'Peltonen JK, et al. Head Neck Oncol (2011) pmid: 21513535', 'Include': 'true'}, {'number': '239', 'ReferenceId': '9761125', 'FullCitation': 'Bringuier PP, et al. Int. J. Cancer (1998) pmid: 9761125', 'Include': 'true'}, {'number': '240', 'ReferenceId': '24500328', 'FullCitation': 'Feng C, et al. Sci Rep (2014) pmid: 24500328', 'Include': 'true'}, {'number': '241', 'ReferenceId': '28039262', 'FullCitation': 'Dong ZY, et al. Clin. Cancer Res. (2017) pmid: 28039262', 'Include': 'true'}, {'number': '242', 'ReferenceId': '16172461', 'FullCitation': 'Russo A, et al. J. Clin. Oncol. (2005) pmid: 16172461', 'Include': 'true'}, {'number': '243', 'ReferenceId': '20107315', 'FullCitation': 'Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315', 'Include': 'true'}, {'number': '244', 'ReferenceId': '21799033', 'FullCitation': 'Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033', 'Include': 'true'}, {'number': '245', 'ReferenceId': '21389100', 'FullCitation': 'Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100', 'Include': 'true'}, {'number': '246', 'ReferenceId': '25504633', 'FullCitation': 'Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633', 'Include': 'true'}, {'number': '247', 'ReferenceId': '12489850', 'FullCitation': 'Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850', 'Include': 'true'}, {'number': '248', 'ReferenceId': '11713371', 'FullCitation': 'Xu L, et al. Mol. Med. (2001) pmid: 11713371', 'Include': 'true'}, {'number': '249', 'ReferenceId': '23470564', 'FullCitation': 'Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564', 'Include': 'true'}, {'number': '250', 'ReferenceId': '25240597', 'FullCitation': 'Kim SS, et al. Nanomedicine (2015) pmid: 25240597', 'Include': 'true'}, {'number': '251', 'ReferenceId': '27357628', 'FullCitation': 'Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628', 'Include': 'true'}, {'number': '252', 'ReferenceId': '27601554', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554', 'Include': 'true'}, {'number': '253', 'ReferenceId': '27998224', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224', 'Include': 'true'}, {'number': '254', 'ReferenceId': '31315834', 'FullCitation': 'Lee J, et al. Cancer Discov (2019) pmid: 31315834', 'Include': 'true'}, {'number': '255', 'ReferenceId': '29535125', 'FullCitation': 'Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125', 'Include': 'true'}, {'number': '256', 'ReferenceId': '34538072', 'FullCitation': 'Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072', 'Include': 'true'}, {'number': '257', 'ReferenceId': '22965953', 'FullCitation': 'Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953', 'Include': 'true'}, {'number': '258', 'ReferenceId': '26086967', 'FullCitation': 'Mohell N, et al. Cell Death Dis (2015) pmid: 26086967', 'Include': 'true'}, {'number': '259', 'ReferenceId': '27179933', 'FullCitation': 'Fransson Å, et al. J Ovarian Res (2016) pmid: 27179933', 'Include': 'true'}, {'number': '260', 'ReferenceId': '26563132', 'FullCitation': 'Kwok M, et al. Blood (2016) pmid: 26563132', 'Include': 'true'}, {'number': '261', 'ReferenceId': '30975914', 'FullCitation': 'Boudny M, et al. Haematologica (2019) pmid: 30975914', 'Include': 'true'}, {'number': '262', 'ReferenceId': '28062704', 'FullCitation': 'Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704', 'Include': 'true'}, {'number': '263', 'ReferenceId': '30127241', 'FullCitation': 'Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241', 'Include': 'true'}, {'number': '264', 'ReferenceId': '26014290', 'FullCitation': 'Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290', 'Include': 'true'}, {'number': '265', 'ReferenceId': '23355100', 'FullCitation': 'Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100', 'Include': 'true'}, {'number': '266', 'ReferenceId': '11219776', 'FullCitation': 'Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776', 'Include': 'true'}, {'number': '267', 'ReferenceId': '9006316', 'FullCitation': 'Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316', 'Include': 'true'}, {'number': '268', 'ReferenceId': '19204208', 'FullCitation': 'Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208', 'Include': 'true'}, {'number': '269', 'ReferenceId': '12672316', 'FullCitation': 'Lalloo F, et al. Lancet (2003) pmid: 12672316', 'Include': 'true'}, {'number': '270', 'ReferenceId': '31050713', 'FullCitation': 'Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713', 'Include': 'true'}, {'number': '271', 'ReferenceId': '25426837', 'FullCitation': 'Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837', 'Include': 'true'}, {'number': '272', 'ReferenceId': '25426838', 'FullCitation': 'Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838', 'Include': 'true'}, {'number': '273', 'ReferenceId': '25326804', 'FullCitation': 'Xie M, et al. Nat. Med. (2014) pmid: 25326804', 'Include': 'true'}, {'number': '274', 'ReferenceId': '28669404', 'FullCitation': 'Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404', 'Include': 'true'}, {'number': '275', 'ReferenceId': '29678827', 'FullCitation': 'Severson EA, et al. Blood (2018) pmid: 29678827', 'Include': 'true'}, {'number': '276', 'ReferenceId': '29420212', 'FullCitation': 'Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212', 'Include': 'true'}, {'number': '277', 'ReferenceId': '30504320', 'FullCitation': 'Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320', 'Include': 'true'}, {'number': '278', 'ReferenceId': '32269342', 'FullCitation': 'Chabon JJ, et al. Nature (2020) pmid: 32269342', 'Include': 'true'}, {'number': '279', 'ReferenceId': '31768066', 'FullCitation': 'Razavi P, et al. Nat. Med. (2019) pmid: 31768066', 'Include': 'true'}, {'number': '280', 'ReferenceId': '15220362', 'FullCitation': 'Morris MR, et al. J. Clin. Pathol. (2004) pmid: 15220362', 'Include': 'true'}, {'number': '281', 'ReferenceId': '31085323', 'FullCitation': 'Schmidt C, et al. Semin Cell Dev Biol (2020) pmid: 31085323', 'Include': 'true'}, {'number': '282', 'ReferenceId': '16155190', 'FullCitation': 'Lehtonen HJ, et al. J Med Genet (2006) pmid: 16155190', 'Include': 'true'}, {'number': '283', 'ReferenceId': '11865300', 'FullCitation': 'Tomlinson IP, et al. Nat. Genet. (2002) pmid: 11865300', 'Include': 'true'}, {'number': '284', 'ReferenceId': '21398687', 'FullCitation': 'Gardie B, et al. J Med Genet (2011) pmid: 21398687', 'Include': 'true'}, {'number': '285', 'ReferenceId': '31524643', 'FullCitation': 'Lau HD, et al. Am J Surg Pathol (2020) pmid: 31524643', 'Include': 'true'}, {'number': '286', 'ReferenceId': '25490448', 'FullCitation': 'Sourbier C, et al. Cancer Cell (2014) pmid: 25490448', 'Include': 'true'}, {'number': '287', 'ReferenceId': '24334767', 'FullCitation': 'Castro_Vega LJ, et al. Hum Mol Genet (2014) pmid: 24334767', 'Include': 'true'}, {'number': '288', 'ReferenceId': '28300276', 'FullCitation': 'Muller M, et al. Clin Genet (2017) pmid: 28300276', 'Include': 'true'}, {'number': '289', 'ReferenceId': '21404119', 'FullCitation': 'Fam Cancer (2011) pmid: 21404119', 'Include': 'true'}, {'number': '290', 'ReferenceId': '31831373', 'FullCitation': 'Forde C, et al. Eur Urol Oncol (2019) pmid: 31831373', 'Include': 'true'}, {'number': '291', 'ReferenceId': '8521522', 'FullCitation': 'Quelle DE, et al. Cell (1995) pmid: 8521522', 'Include': 'true'}, {'number': '292', 'ReferenceId': '15878778', 'FullCitation': 'Mutat. Res. (2005) pmid: 15878778', 'Include': 'true'}, {'number': '293', 'ReferenceId': '9484839', 'FullCitation': 'Gazzeri S, et al. Oncogene (1998) pmid: 9484839', 'Include': 'true'}, {'number': '294', 'ReferenceId': '10498883', 'FullCitation': 'Oncogene (1999) pmid: 10498883', 'Include': 'true'}, {'number': '295', 'ReferenceId': '16869746', 'FullCitation': 'Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746', 'Include': 'true'}, {'number': '296', 'ReferenceId': '20549699', 'FullCitation': 'Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699', 'Include': 'true'}, {'number': '297', 'ReferenceId': '10498896', 'FullCitation': 'Ruas M, et al. Oncogene (1999) pmid: 10498896', 'Include': 'true'}, {'number': '298', 'ReferenceId': '17909018', 'FullCitation': 'Jones R, et al. Cancer Res. (2007) pmid: 17909018', 'Include': 'true'}, {'number': '299', 'ReferenceId': '18843795', 'FullCitation': 'Haferkamp S, et al. Aging Cell (2008) pmid: 18843795', 'Include': 'true'}, {'number': '300', 'ReferenceId': '12417717', 'FullCitation': 'Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717', 'Include': 'true'}, {'number': '301', 'ReferenceId': '11518711', 'FullCitation': 'Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711', 'Include': 'true'}, {'number': '302', 'ReferenceId': '9324288', 'FullCitation': 'Gombart AF, et al. Leukemia (1997) pmid: 9324288', 'Include': 'true'}, {'number': '303', 'ReferenceId': '7780957', 'FullCitation': 'Yang R, et al. Cancer Res. (1995) pmid: 7780957', 'Include': 'true'}, {'number': '304', 'ReferenceId': '8668202', 'FullCitation': 'Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202', 'Include': 'true'}, {'number': '305', 'ReferenceId': '12606942', 'FullCitation': 'Greenblatt MS, et al. Oncogene (2003) pmid: 12606942', 'Include': 'true'}, {'number': '306', 'ReferenceId': '10491434', 'FullCitation': 'Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434', 'Include': 'true'}, {'number': '307', 'ReferenceId': '11255261', 'FullCitation': 'Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261', 'Include': 'true'}, {'number': '308', 'ReferenceId': '9660926', 'FullCitation': 'Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926', 'Include': 'true'}, {'number': '309', 'ReferenceId': '19260062', 'FullCitation': 'Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062', 'Include': 'true'}, {'number': '310', 'ReferenceId': '10719365', 'FullCitation': 'Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365', 'Include': 'true'}, {'number': '311', 'ReferenceId': '7777061', 'FullCitation': 'Koh J, et al. Nature (1995) pmid: 7777061', 'Include': 'true'}, {'number': '312', 'ReferenceId': '20340136', 'FullCitation': 'McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136', 'Include': 'true'}, {'number': '313', 'ReferenceId': '21462282', 'FullCitation': 'Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282', 'Include': 'true'}, {'number': '314', 'ReferenceId': '905385', 'FullCitation': 'Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385', 'Include': 'true'}, {'number': '315', 'ReferenceId': '24659262', 'FullCitation': 'Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262', 'Include': 'true'}, {'number': '316', 'ReferenceId': '23190892', 'FullCitation': 'Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892', 'Include': 'true'}, {'number': '317', 'ReferenceId': '10389768', 'FullCitation': 'Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768', 'Include': 'true'}, {'number': '318', 'ReferenceId': '12853981', 'FullCitation': 'Rutter JL, et al. Oncogene (2003) pmid: 12853981', 'Include': 'true'}, {'number': '319', 'ReferenceId': '18538737', 'FullCitation': 'Itahana K, et al. Cancer Cell (2008) pmid: 18538737', 'Include': 'true'}, {'number': '320', 'ReferenceId': '10360174', 'FullCitation': 'Zhang Y, et al. Mol. Cell (1999) pmid: 10360174', 'Include': 'true'}, {'number': '321', 'ReferenceId': '9529249', 'FullCitation': 'Zhang Y, et al. Cell (1998) pmid: 9529249', 'Include': 'true'}, {'number': '322', 'ReferenceId': '25873077', 'FullCitation': 'Jafri M, et al. Cancer Discov (2015) pmid: 25873077', 'Include': 'true'}, {'number': '323', 'ReferenceId': '25589618', 'FullCitation': 'Li YY, et al. Clin. Cancer Res. (2015) pmid: 25589618', 'Include': 'true'}, {'number': '324', 'ReferenceId': '25631445', 'FullCitation': 'Nature (2015) pmid: 25631445', 'Include': 'true'}, {'number': '325', 'ReferenceId': '22960745', 'FullCitation': 'Nature (2012) pmid: 22960745', 'Include': 'true'}, {'number': '326', 'ReferenceId': '24670651', 'FullCitation': 'Song Y, et al. Nature (2014) pmid: 24670651', 'Include': 'true'}, {'number': '327', 'ReferenceId': '24686850', 'FullCitation': 'Lin DC, et al. Nat. Genet. (2014) pmid: 24686850', 'Include': 'true'}, {'number': '328', 'ReferenceId': '23470568', 'FullCitation': 'Oshima M, et al. Ann. Surg. (2013) pmid: 23470568', 'Include': 'true'}, {'number': '329', 'ReferenceId': '17600882', 'FullCitation': 'Tsiambas E, et al. J BUON () pmid: 17600882', 'Include': 'true'}, {'number': '330', 'ReferenceId': '23254264', 'FullCitation': 'Yanagawa N, et al. Lung Cancer (2013) pmid: 23254264', 'Include': 'true'}, {'number': '331', 'ReferenceId': '20665497', 'FullCitation': 'Chang DT, et al. Cancer (2010) pmid: 20665497', 'Include': 'true'}, {'number': '332', 'ReferenceId': '12060614', 'FullCitation': 'Lee TL, et al. Clin. Cancer Res. (2002) pmid: 12060614', 'Include': 'true'}, {'number': '333', 'ReferenceId': '21302620', 'FullCitation': 'Hu SL, et al. Tumori () pmid: 21302620', 'Include': 'true'}, {'number': '334', 'ReferenceId': '22206050', 'FullCitation': 'Shi J, et al. Am J Cancer Res (2012) pmid: 22206050', 'Include': 'true'}, {'number': '335', 'ReferenceId': '23111194', 'FullCitation': 'Bradly DP, et al. Diagn. Mol. Pathol. (2012) pmid: 23111194', 'Include': 'true'}, {'number': '336', 'ReferenceId': '23372805', 'FullCitation': 'Lou_Qian Z, et al. PLoS ONE (2013) pmid: 23372805', 'Include': 'true'}, {'number': '337', 'ReferenceId': '23614702', 'FullCitation': 'Tan S, et al. Exp. Lung Res. () pmid: 23614702', 'Include': 'true'}, {'number': '338', 'ReferenceId': '21278246', 'FullCitation': 'Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246', 'Include': 'true'}, {'number': '339', 'ReferenceId': '21871868', 'FullCitation': 'Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868', 'Include': 'true'}, {'number': '340', 'ReferenceId': '22711607', 'FullCitation': 'Cen L, et al. Neuro_oncology (2012) pmid: 22711607', 'Include': 'true'}, {'number': '341', 'ReferenceId': '23898052', 'FullCitation': 'Logan JE, et al. Anticancer Res. (2013) pmid: 23898052', 'Include': 'true'}, {'number': '342', 'ReferenceId': '35157829', 'FullCitation': 'Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829', 'Include': 'true'}, {'number': '343', 'ReferenceId': '28283584', 'FullCitation': 'Elvin JA, et al. Oncologist (2017) pmid: 28283584', 'Include': 'true'}, {'number': '344', 'ReferenceId': '26715889', 'FullCitation': 'Gao J, et al. Curr Oncol (2015) pmid: 26715889', 'Include': 'true'}, {'number': '345', 'ReferenceId': '25501126', 'FullCitation': 'DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126', 'Include': 'true'}, {'number': '346', 'ReferenceId': '25524798', 'FullCitation': 'Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798', 'Include': 'true'}, {'number': '347', 'ReferenceId': '27542767', 'FullCitation': 'Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767', 'Include': 'true'}, {'number': '348', 'ReferenceId': '24797823', 'FullCitation': 'Johnson DB, et al. Oncologist (2014) pmid: 24797823', 'Include': 'true'}, {'number': '349', 'ReferenceId': '21460101', 'FullCitation': 'Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101', 'Include': 'true'}, {'number': '350', 'ReferenceId': '21725357', 'FullCitation': 'Gamble LD, et al. Oncogene (2012) pmid: 21725357', 'Include': 'true'}, {'number': '351', 'ReferenceId': '22090362', 'FullCitation': 'Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362', 'Include': 'true'}, {'number': '352', 'ReferenceId': '23569312', 'FullCitation': 'Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312', 'Include': 'true'}, {'number': '353', 'ReferenceId': '7666917', 'FullCitation': 'Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917', 'Include': 'true'}, {'number': '354', 'ReferenceId': '20687502', 'FullCitation': 'Adv Exp Med Biol (2010) pmid: 20687502', 'Include': 'true'}, {'number': '355', 'ReferenceId': '9479083', 'FullCitation': 'Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083', 'Include': 'true'}, {'number': '356', 'ReferenceId': '29543703', 'FullCitation': 'De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703', 'Include': 'true'}, {'number': '357', 'ReferenceId': '26892650', 'FullCitation': 'Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650', 'Include': 'true'}, {'number': '358', 'ReferenceId': '29405243', 'FullCitation': 'Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243', 'Include': 'true'}, {'number': '359', 'ReferenceId': '8414022', 'FullCitation': 'Kaufman DK, et al. Neurology (1993) pmid: 8414022', 'Include': 'true'}, {'number': '360', 'ReferenceId': '9622062', 'FullCitation': 'Bahuau M, et al. Cancer Res (1998) pmid: 9622062', 'Include': 'true'}, {'number': '361', 'ReferenceId': '28699883', 'FullCitation': 'Chan AK, et al. Clin Neuropathol () pmid: 28699883', 'Include': 'true'}, {'number': '362', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '363', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '364', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '365', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '366', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '367', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '368', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '369', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '370', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '371', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '372', 'ReferenceId': '28835386', 'FullCitation': 'Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386', 'Include': 'true'}, {'number': '373', 'ReferenceId': '32919526', 'FullCitation': 'Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526', 'Include': 'true'}, {'number': '374', 'ReferenceId': '31405947', 'FullCitation': 'Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947', 'Include': 'true'}, {'number': '375', 'ReferenceId': '27022117', 'FullCitation': 'Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117', 'Include': 'true'}, {'number': '376', 'ReferenceId': '27009843', 'FullCitation': 'Xiao D, et al. Oncotarget (2016) pmid: 27009843', 'Include': 'true'}, {'number': '377', 'ReferenceId': '26200269', 'FullCitation': 'Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269', 'Include': 'true'}, {'number': '378', 'ReferenceId': '22980976', 'FullCitation': 'Govindan R, et al. Cell (2012) pmid: 22980976', 'Include': 'true'}, {'number': '379', 'ReferenceId': '18948947', 'FullCitation': 'Ding L, et al. Nature (2008) pmid: 18948947', 'Include': 'true'}, {'number': '380', 'ReferenceId': '22980975', 'FullCitation': 'Imielinski M, et al. Cell (2012) pmid: 22980975', 'Include': 'true'}, {'number': '381', 'ReferenceId': '24323028', 'FullCitation': 'Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028', 'Include': 'true'}, {'number': '382', 'ReferenceId': '11535541', 'FullCitation': 'Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541', 'Include': 'true'}, {'number': '383', 'ReferenceId': '12445368', 'FullCitation': 'Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368', 'Include': 'true'}, {'number': '384', 'ReferenceId': '12820457', 'FullCitation': 'Brueckl WM, et al. Anticancer Res. () pmid: 12820457', 'Include': 'true'}, {'number': '385', 'ReferenceId': '11438476', 'FullCitation': 'Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476', 'Include': 'true'}, {'number': '386', 'ReferenceId': '10631274', 'FullCitation': 'Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274', 'Include': 'true'}, {'number': '387', 'ReferenceId': '16952542', 'FullCitation': 'Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542', 'Include': 'true'}, {'number': '388', 'ReferenceId': '22722556', 'FullCitation': 'Laghi L, et al. Dig Dis (2012) pmid: 22722556', 'Include': 'true'}, {'number': '389', 'ReferenceId': '27159395', 'FullCitation': 'Mehnert JM, et al. J. Clin. Invest. (2016) pmid: 27159395', 'Include': 'true'}, {'number': '390', 'ReferenceId': '25394778', 'FullCitation': 'Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778', 'Include': 'true'}, {'number': '391', 'ReferenceId': '23528559', 'FullCitation': 'Church DN, et al. Hum. Mol. Genet. (2013) pmid: 23528559', 'Include': 'true'}, {'number': '392', 'ReferenceId': '24777035', 'FullCitation': 'Cazier JB, et al. Nat Commun (2014) pmid: 24777035', 'Include': 'true'}, {'number': '393', 'ReferenceId': '30643254', 'FullCitation': 'Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254', 'Include': 'true'}, {'number': '394', 'ReferenceId': '30309915', 'FullCitation': 'Cristescu R, et al. Science (2018) pmid: 30309915', 'Include': 'true'}, {'number': '395', 'ReferenceId': '30785829', 'FullCitation': 'Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829', 'Include': 'true'}, {'number': '396', 'ReferenceId': '29658845', 'FullCitation': 'Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845', 'Include': 'true'}, {'number': '397', 'ReferenceId': '29657128', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128', 'Include': 'true'}, {'number': '398', 'ReferenceId': '29731394', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394', 'Include': 'true'}, {'number': '399', 'ReferenceId': '33558721', 'FullCitation': 'Rozeman EA, et al. Nat Med (2021) pmid: 33558721', 'Include': 'true'}, {'number': '400', 'ReferenceId': '32916128', 'FullCitation': 'Sharma P, et al. Cancer Cell (2020) pmid: 32916128', 'Include': 'true'}, {'number': '401', 'ReferenceId': '30557521', 'FullCitation': 'Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521', 'Include': 'true'}, {'number': '402', 'ReferenceId': '35101941', 'FullCitation': 'Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941', 'Include': 'true'}, {'number': '403', 'ReferenceId': '34876409', 'FullCitation': 'Friedman CF, et al. Cancer Discov (2022) pmid: 34876409', 'Include': 'true'}, {'number': '404', 'ReferenceId': '35274716', 'FullCitation': 'Sturgill EG, et al. Oncologist (2022) pmid: 35274716', 'Include': 'true'}, {'number': '405', 'ReferenceId': '2986437', 'FullCitation': 'Opsomer RJ, et al. Acta Urol Belg (1985) pmid: 2986437', 'Include': 'true'}, {'number': '406', 'ReferenceId': '28958502', 'FullCitation': 'Wu YL, et al. Lancet Oncol. (2017) pmid: 28958502', 'Include': 'true'}, {'number': '407', 'ReferenceId': '28921872', 'FullCitation': 'Necchi A, et al. BJU Int. (2018) pmid: 28921872', 'Include': 'true'}, {'number': '408', 'ReferenceId': '25424851', 'FullCitation': 'Kim HS, et al. Clin. Cancer Res. (2015) pmid: 25424851', 'Include': 'true'}, {'number': '409', 'ReferenceId': '26462025', 'FullCitation': 'Kim HS, et al. Oncotarget (2015) pmid: 26462025', 'Include': 'true'}, {'number': '410', 'ReferenceId': '29734047', 'FullCitation': 'Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047', 'Include': 'true'}, {'number': '411', 'ReferenceId': '26581547', 'FullCitation': 'Oh DY, et al. Gastric Cancer (2016) pmid: 26581547', 'Include': 'true'}, {'number': '412', 'ReferenceId': '28575464', 'FullCitation': 'Sepúlveda_Sánchez JM, et al. Neuro_oncology (2017) pmid: 28575464', 'Include': 'true'}, {'number': '413', 'ReferenceId': '21220471', 'FullCitation': 'Jänne PA, et al. Clin. Cancer Res. (2011) pmid: 21220471', 'Include': 'true'}, {'number': '414', 'ReferenceId': '24501009', 'FullCitation': 'Reckamp KL, et al. Cancer (2014) pmid: 24501009', 'Include': 'true'}, {'number': '415', 'ReferenceId': '28119295', 'FullCitation': 'Bang YJ, et al. Ann. Oncol. (2017) pmid: 28119295', 'Include': 'true'}, {'number': '416', 'ReferenceId': '32213540', 'FullCitation': 'Tsurutani J, et al. Cancer Discov (2020) pmid: 32213540', 'Include': 'true'}, {'number': '417', 'ReferenceId': '31047803', 'FullCitation': 'Tamura K, et al. Lancet Oncol. (2019) pmid: 31047803', 'Include': 'true'}, {'number': '418', 'ReferenceId': '31047804', 'FullCitation': 'Shitara K, et al. Lancet Oncol. (2019) pmid: 31047804', 'Include': 'true'}, {'number': '419', 'ReferenceId': '24793816', 'FullCitation': 'Krop IE, et al. Lancet Oncol. (2014) pmid: 24793816', 'Include': 'true'}, {'number': '420', 'ReferenceId': '24222194', 'FullCitation': 'Welslau M, et al. Cancer (2014) pmid: 24222194', 'Include': 'true'}, {'number': '421', 'ReferenceId': '22649126', 'FullCitation': 'Krop IE, et al. J. Clin. Oncol. (2012) pmid: 22649126', 'Include': 'true'}, {'number': '422', 'ReferenceId': '21172893', 'FullCitation': 'Burris HA, et al. J. Clin. Oncol. (2011) pmid: 21172893', 'Include': 'true'}, {'number': '423', 'ReferenceId': '31504139', 'FullCitation': 'Jhaveri KL, et al. Ann. Oncol. (2019) pmid: 31504139', 'Include': 'true'}, {'number': '424', 'ReferenceId': '32213539', 'FullCitation': 'Li BT, et al. Cancer Discov (2020) pmid: 32213539', 'Include': 'true'}, {'number': '425', 'ReferenceId': '29313813', 'FullCitation': 'Hotta K, et al. J Thorac Oncol (2018) pmid: 29313813', 'Include': 'true'}, {'number': '426', 'ReferenceId': '26920887', 'FullCitation': 'Baselga J, et al. Clin. Cancer Res. (2016) pmid: 26920887', 'Include': 'true'}, {'number': '427', 'ReferenceId': '28056202', 'FullCitation': 'Perez EA, et al. J. Clin. Oncol. (2017) pmid: 28056202', 'Include': 'true'}, {'number': '428', 'ReferenceId': '23382472', 'FullCitation': 'Hurvitz SA, et al. J. Clin. Oncol. (2013) pmid: 23382472', 'Include': 'true'}, {'number': '429', 'ReferenceId': '30516102', 'FullCitation': 'von Minckwitz G, et al. N. Engl. J. Med. (2019) pmid: 30516102', 'Include': 'true'}, {'number': '430', 'ReferenceId': '31157583', 'FullCitation': 'Hurvitz SA, et al. J. Clin. Oncol. (2019) pmid: 31157583', 'Include': 'true'}, {'number': '431', 'ReferenceId': '27052654', 'FullCitation': 'Martin M, et al. Ann. Oncol. (2016) pmid: 27052654', 'Include': 'true'}, {'number': '432', 'ReferenceId': '32923849', 'FullCitation': 'Mondaca S, et al. JCO Precis Oncol (2019) pmid: 32923849', 'Include': 'true'}, {'number': '433', 'ReferenceId': '20142587', 'FullCitation': 'Burstein HJ, et al. J. Clin. Oncol. (2010) pmid: 20142587', 'Include': 'true'}, {'number': '434', 'ReferenceId': '26834058', 'FullCitation': 'Freedman RA, et al. J. Clin. Oncol. (2016) pmid: 26834058', 'Include': 'true'}, {'number': '435', 'ReferenceId': '26874901', 'FullCitation': 'Chan A, et al. Lancet Oncol. (2016) pmid: 26874901', 'Include': 'true'}, {'number': '436', 'ReferenceId': '25287822', 'FullCitation': 'Saura C, et al. J. Clin. Oncol. (2014) pmid: 25287822', 'Include': 'true'}, {'number': '437', 'ReferenceId': '22967996', 'FullCitation': 'Awada A, et al. Ann. Oncol. (2013) pmid: 22967996', 'Include': 'true'}, {'number': '438', 'ReferenceId': '23953056', 'FullCitation': 'Martin M, et al. Eur. J. Cancer (2013) pmid: 23953056', 'Include': 'true'}, {'number': '439', 'ReferenceId': '23632474', 'FullCitation': 'Chow LW, et al. Br. J. Cancer (2013) pmid: 23632474', 'Include': 'true'}, {'number': '440', 'ReferenceId': '27406346', 'FullCitation': 'Park JW, et al. N. Engl. J. Med. (2016) pmid: 27406346', 'Include': 'true'}, {'number': '441', 'ReferenceId': '27078022', 'FullCitation': 'Awada A, et al. JAMA Oncol (2016) pmid: 27078022', 'Include': 'true'}, {'number': '442', 'ReferenceId': '24323026', 'FullCitation': 'Gandhi L, et al. J. Clin. Oncol. (2014) pmid: 24323026', 'Include': 'true'}, {'number': '443', 'ReferenceId': '26260909', 'FullCitation': 'Schwab CL, et al. Gynecol. Oncol. (2015) pmid: 26260909', 'Include': 'true'}, {'number': '444', 'ReferenceId': '28397106', 'FullCitation': 'Menderes G, et al. Med. Oncol. (2017) pmid: 28397106', 'Include': 'true'}, {'number': '445', 'ReferenceId': '26375550', 'FullCitation': 'Hu Z, et al. Oncotarget (2015) pmid: 26375550', 'Include': 'true'}, {'number': '446', 'ReferenceId': '26243863', 'FullCitation': 'Kavuri SM, et al. Cancer Discov (2015) pmid: 26243863', 'Include': 'true'}, {'number': '447', 'ReferenceId': '23220880', 'FullCitation': 'Bose R, et al. Cancer Discov (2013) pmid: 23220880', 'Include': 'true'}, {'number': '448', 'ReferenceId': '2932031', 'FullCitation': 'Hempstead RW, et al. Am J Dermatopathol (1985) pmid: 2932031', 'Include': 'true'}, {'number': '449', 'ReferenceId': '29175149', 'FullCitation': 'Hurvitz SA, et al. Lancet Oncol. (2018) pmid: 29175149', 'Include': 'true'}, {'number': '450', 'ReferenceId': '28581356', 'FullCitation': 'von Minckwitz G, et al. N. Engl. J. Med. (2017) pmid: 28581356', 'Include': 'true'}, {'number': '451', 'ReferenceId': '29320312', 'FullCitation': 'Hainsworth JD, et al. J. Clin. Oncol. (2018) pmid: 29320312', 'Include': 'true'}, {'number': '452', 'ReferenceId': '29253081', 'FullCitation': 'Swain SM, et al. Ann Oncol (2018) pmid: 29253081', 'Include': 'true'}, {'number': '453', 'ReferenceId': '27179402', 'FullCitation': 'Gianni L, et al. Lancet Oncol. (2016) pmid: 27179402', 'Include': 'true'}, {'number': '454', 'ReferenceId': '31647503', 'FullCitation': 'Shao Z, et al. JAMA Oncol (2020) pmid: 31647503', 'Include': 'true'}, {'number': '455', 'ReferenceId': '23816960', 'FullCitation': 'Sequist LV, et al. J. Clin. Oncol. (2013) pmid: 23816960', 'Include': 'true'}, {'number': '456', 'ReferenceId': '23816963', 'FullCitation': 'Katakami N, et al. J. Clin. Oncol. (2013) pmid: 23816963', 'Include': 'true'}, {'number': '457', 'ReferenceId': '20679611', 'FullCitation': 'Yap TA, et al. J. Clin. Oncol. (2010) pmid: 20679611', 'Include': 'true'}, {'number': '458', 'ReferenceId': '18026190', 'FullCitation': 'Eskens FA, et al. Br. J. Cancer (2008) pmid: 18026190', 'Include': 'true'}, {'number': '459', 'ReferenceId': '23775486', 'FullCitation': 'Kwak EL, et al. Cancer (2013) pmid: 23775486', 'Include': 'true'}, {'number': '460', 'ReferenceId': '23414476', 'FullCitation': 'Marshall J, et al. Future Oncol (2013) pmid: 23414476', 'Include': 'true'}, {'number': '461', 'ReferenceId': '24371631', 'FullCitation': 'Talwar S, et al. Gynecol Oncol Case Rep (2012) pmid: 24371631', 'Include': 'true'}, {'number': '462', 'ReferenceId': '27044931', 'FullCitation': 'Choudhury NJ, et al. J. Clin. Oncol. (2016) pmid: 27044931', 'Include': 'true'}, {'number': '463', 'ReferenceId': '25537159', 'FullCitation': 'Rimawi MF, et al. Clin. Breast Cancer (2015) pmid: 25537159', 'Include': 'true'}, {'number': '464', 'ReferenceId': '26835225', 'FullCitation': 'Gunzer K, et al. Springerplus (2016) pmid: 26835225', 'Include': 'true'}, {'number': '465', 'ReferenceId': '23578997', 'FullCitation': 'Janjigian YY, et al. J. Nucl. Med. (2013) pmid: 23578997', 'Include': 'true'}, {'number': '466', 'ReferenceId': '24657003', 'FullCitation': 'Gianni L, et al. Lancet Oncol. (2014) pmid: 24657003', 'Include': 'true'}, {'number': '467', 'ReferenceId': '24037735', 'FullCitation': 'Morris PG, et al. Cancer (2013) pmid: 24037735', 'Include': 'true'}, {'number': '468', 'ReferenceId': '25130998', 'FullCitation': 'de Azambuja E, et al. Lancet Oncol. (2014) pmid: 25130998', 'Include': 'true'}, {'number': '469', 'ReferenceId': '12907212', 'FullCitation': 'Haddad R, et al. Oral Oncol. (2003) pmid: 12907212', 'Include': 'true'}, {'number': '470', 'ReferenceId': '23429737', 'FullCitation': 'Limaye SA, et al. Oncologist (2013) pmid: 23429737', 'Include': 'true'}, {'number': '471', 'ReferenceId': '17097832', 'FullCitation': 'Safran H, et al. Int. J. Radiat. Oncol. Biol. Phys. (2007) pmid: 17097832', 'Include': 'true'}, {'number': '472', 'ReferenceId': '27334835', 'FullCitation': 'Wang K, et al. Clin. Cancer Res. (2016) pmid: 27334835', 'Include': 'true'}, {'number': '473', 'ReferenceId': '27521503', 'FullCitation': 'Nishikawa K, et al. Int. J. Cancer (2017) pmid: 27521503', 'Include': 'true'}, {'number': '474', 'ReferenceId': '23729232', 'FullCitation': 'Bian L, et al. Tumour Biol. (2013) pmid: 23729232', 'Include': 'true'}, {'number': '475', 'ReferenceId': '22257673', 'FullCitation': 'Baselga J, et al. Lancet (2012) pmid: 22257673', 'Include': 'true'}, {'number': '476', 'ReferenceId': '24095300', 'FullCitation': 'Robidoux A, et al. Lancet Oncol. (2013) pmid: 24095300', 'Include': 'true'}, {'number': '477', 'ReferenceId': '24457911', 'FullCitation': 'Alba E, et al. Br. J. Cancer (2014) pmid: 24457911', 'Include': 'true'}, {'number': '478', 'ReferenceId': '25779558', 'FullCitation': 'Gelmon KA, et al. J. Clin. Oncol. (2015) pmid: 25779558', 'Include': 'true'}, {'number': '479', 'ReferenceId': '24868024', 'FullCitation': 'Satoh T, et al. J. Clin. Oncol. (2014) pmid: 24868024', 'Include': 'true'}, {'number': '480', 'ReferenceId': '25694417', 'FullCitation': 'Lorenzen S, et al. Eur. J. Cancer (2015) pmid: 25694417', 'Include': 'true'}, {'number': '481', 'ReferenceId': '20857170', 'FullCitation': 'Galsky MD, et al. Invest New Drugs (2012) pmid: 20857170', 'Include': 'true'}, {'number': '482', 'ReferenceId': '26628478', 'FullCitation': 'Hecht JR, et al. J. Clin. Oncol. (2016) pmid: 26628478', 'Include': 'true'}, {'number': '483', 'ReferenceId': '19825948', 'FullCitation': 'Burris HA, et al. Clin. Cancer Res. (2009) pmid: 19825948', 'Include': 'true'}, {'number': '484', 'ReferenceId': '17704424', 'FullCitation': 'Chu QS, et al. J. Clin. Oncol. (2007) pmid: 17704424', 'Include': 'true'}, {'number': '485', 'ReferenceId': '21778300', 'FullCitation': 'Chew HK, et al. Ann. Oncol. (2012) pmid: 21778300', 'Include': 'true'}, {'number': '486', 'ReferenceId': '17671135', 'FullCitation': 'Siegel_Lakhai WS, et al. Clin. Cancer Res. (2007) pmid: 17671135', 'Include': 'true'}, {'number': '487', 'ReferenceId': '24800949', 'FullCitation': 'Tan AR, et al. Br. J. Cancer (2014) pmid: 24800949', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2022_09_16 00:42:45', 'OpName': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': '796x'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': '1 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': 'Units Not Reported'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease_ontology': 'Unknown primary adenocarcinoma', 'flowcell_analysis': '2000023529', 'gender': 'female', 'pathology_diagnosis': 'Adenocarcinoma, metastatic', 'percent_tumor_nuclei': '40', 'pipeline_version': 'v3.14.0', 'purity_assessment': '50.0', 'specimen': 'ORD_1450681_01*US1390521.01', 'study': 'CLINICAL_F1CDx v2', 'test_request': 'ORD_1450681_01', 'test_type': 'FoundationOneDx', 'tissue_of_origin': 'Brain', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'DX2', 'mean_exon_depth': '949.87', 'name': 'SQ_US1390521.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.4519', 'cds_effect': '125A>G', 'depth': '894', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATM', 'percent_reads': '45.19', 'position': 'chr11:108098555', 'protein_effect': 'H42R', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000051', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'allele_fraction': '0.567', 'cds_effect': '979C>T', 'depth': '448', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'MAP2K4', 'percent_reads': '56.7', 'position': 'chr17:12032543', 'protein_effect': 'Q327*', 'status': 'likely', 'strand': '+', 'transcript': 'NM_003010', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'allele_fraction': '0.4915', 'cds_effect': '961G>A', 'depth': '468', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BAP1', 'percent_reads': '49.15', 'position': 'chr3:52439281', 'protein_effect': 'A321T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004656', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'allele_fraction': '0.5125', 'cds_effect': '731G>T', 'depth': '519', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TP53', 'percent_reads': '51.25', 'position': 'chr17:7577550', 'protein_effect': 'G244V', 'status': 'known', 'strand': '_', 'transcript': 'NM_000546', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'allele_fraction': '0.1302', 'cds_effect': '2278C>T', 'depth': '653', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'STAG2', 'percent_reads': '13.02', 'position': 'chrX:123202426', 'protein_effect': 'R760C', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006603', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'allele_fraction': '0.1845', 'cds_effect': '1453delC', 'depth': '656', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'FANCC', 'percent_reads': '18.45', 'position': 'chr9:97869427', 'protein_effect': 'Q485fs*2', 'status': 'likely', 'strand': '_', 'transcript': 'NM_000136', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'allele_fraction': '0.483', 'cds_effect': '817G>A', 'depth': '824', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FH', 'percent_reads': '48.3', 'position': 'chr1:241669390', 'protein_effect': 'A273T', 'status': 'known', 'strand': '_', 'transcript': 'NM_000143', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'allele_fraction': '0.5274', 'cds_effect': '434G>A', 'depth': '749', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RNF43', 'percent_reads': '52.74', 'position': 'chr17:56440903', 'protein_effect': 'R145Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_017763', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'allele_fraction': '0.8166', 'cds_effect': '239T>C', 'depth': '578', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FANCC', 'percent_reads': '81.66', 'position': 'chr9:98009725', 'protein_effect': 'I80T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000136', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'allele_fraction': '0.2558', 'cds_effect': '133T>C', 'depth': '684', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CTNNB1', 'percent_reads': '25.58', 'position': 'chr3:41266136', 'protein_effect': 'S45P', 'status': 'known', 'strand': '+', 'transcript': 'NM_001904', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'allele_fraction': '0.151', 'cds_effect': '965T>A', 'depth': '596', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '15.1', 'position': 'chr2:212578292', 'protein_effect': 'M322K', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}]}, 'copy_number_alterations': {'copy_number_alteration': [{'copy_number': '0', 'equivocal': 'false', 'gene': 'CDKN2B', 'number_of_exons': '5 of 5', 'position': 'chr9:21998748_22101832', 'ratio': '0.34', 'status': 'known', 'type': 'loss', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'copy_number': '8', 'equivocal': 'true', 'gene': 'VEGFA', 'number_of_exons': '8 of 8', 'position': 'chr6:43738443_43752419', 'ratio': '1.84', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'copy_number': '0', 'equivocal': 'false', 'gene': 'CDKN2A', 'number_of_exons': '5 of 5', 'position': 'chr9:21954944_21998002', 'ratio': '0.34', 'status': 'known', 'type': 'loss', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'copy_number': '204', 'equivocal': 'false', 'gene': 'CDK12', 'number_of_exons': '13 of 14', 'position': 'chr17:37627131_37687569', 'ratio': '38.05', 'status': 'unknown', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}, {'copy_number': '150', 'equivocal': 'false', 'gene': 'ERBB2', 'number_of_exons': '27 of 27', 'position': 'chr17:37807689_37884297', 'ratio': '41.64', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}]}, 'rearrangements': {'rearrangement': {'description': 'LYN(NM_002350) rearrangement intron 2', 'equivocal': 'false', 'in_frame': 'unknown', 'other_gene': 'N/A', 'pos1': 'chr8:56858981_56859213', 'pos2': 'chr1:117285690_117285958', 'status': 'unknown', 'supporting_read_pairs': '99', 'targeted_gene': 'LYN', 'type': 'rearrangement', 'dna_evidence': {'sample': 'SQ_US1390521.01_1'}}}, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '1.21', 'status': 'low', 'unit': 'mutations_per_megabase'}}, 'non_human_content': None}}}}	S111-97892          	PF22102             
11	454	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2022_00023493', 'CSN': None, 'TRF': 'ORD_1461672_01', 'MRN': '21384474', 'PhysicianId': '109266', 'NPI': 'International'}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1201018', 'clinicalId': '1202388', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1461672_01', 'SampleName': 'US1401399.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1461672_01', 'SampleId': 'US1401399.01', 'BlockId': 'CCL 6/20/1961', 'TRFNumber': 'ORD_1461672_01', 'TestType': 'FoundationOneLiquidDx', 'SpecFormat': 'Tube Set', 'ReceivedDate': '2022_09_21', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}]}}, 'PMI': {'ReportId': 'ORD_1461672_01', 'MRN': '21384474', 'FullName': 'Lin, Chin_Chun', 'FirstName': 'Chin_Chun', 'LastName': 'Lin', 'SubmittedDiagnosis': 'Liver cholangiocarcinoma', 'Gender': 'Male', 'DOB': '1961_06_20', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Blood', 'CollDate': '2022_09_15', 'ReceivedDate': '2022_09_21', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': None, 'Summaries': {'alterationCount': '30', 'clinicalTrialCount': '36', 'resistiveCount': '0', 'sensitizingCount': '5'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'ALOX12B', 'isVUS': 'true', 'variantName': 'C341R'}, {'geneName': 'ATR', 'isVUS': 'true', 'variantName': 'I1145T,L196F'}, {'geneName': 'CUL4A', 'isVUS': 'true', 'variantName': 'E277K'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'P98L'}, {'geneName': 'ERRFI1', 'isVUS': 'true', 'variantName': 'V359D'}, {'geneName': 'FGFR4', 'isVUS': 'true', 'variantName': 'L546P'}, {'geneName': 'GRM3', 'isVUS': 'true', 'variantName': 'E55K'}, {'geneName': 'MLL2', 'isVUS': 'true', 'variantName': 'G872R'}, {'geneName': 'MST1R', 'isVUS': 'true', 'variantName': 'D172N'}, {'geneName': 'PTPRO', 'isVUS': 'true', 'variantName': 'E722K'}, {'geneName': 'RARA', 'isVUS': 'true', 'variantName': 'Y2F'}, {'geneName': 'SMAD4', 'isVUS': 'true', 'variantName': 'H92Y,P320L'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'Blood Tumor Mutational Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '18', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '18'}}, 'Interpretation': 'Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a bTMB level that may be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2022). Published data investigating the prognostic implications of bTMB levels in biliary tract cancer are limited (PubMed, Jul 2022). Although cases with hypermutated biliary tract cancer were enriched in a subgroup with poor prognosis in 1 study (Nakamura et al., 2015; 26258846), TMB_high (≥10 mut/Mb) status in biliary adenocarcinoma not treated with immunotherapy was not significantly associated with OS in another study, in which patients with TMB_high tumors experienced numerically longer OS compared with patients with TMB_low tumors (11.5 vs. 8.4 months, adjusted HR=0.65) (Shao et al., 2020; 33119110). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), and anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P). A Phase 2 multi_solid_tumor trial showed that bTMB ≥16 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511).', 'Include': 'true', 'ClinicalTrialNote': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Pembrolizumab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Pembrolizumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved for patients with tumor mutational burden (TMB)_high (≥10 Muts/Mb), microsatellite instability_high (MSI_H), or mismatch repair_deficient (dMMR) solid tumors; as monotherapy for PD_L1_positive non_small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), cervical cancer, or esophageal cancer; and in combination with chemotherapy for PD_L1_positive triple_negative breast cancer (TNBC) or cervical cancer. It is also approved in various treatment settings as monotherapy for patients with melanoma, HNSCC, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma, endometrial carcinoma that is MSI_H or dMMR, classical Hodgkin lymphoma, or primary mediastinal large B_cell lymphoma; and in combination with chemotherapy or targeted therapy for NSCLC, HNSCC, esophageal or gastroesophageal junction cancer, renal cell carcinoma, TNBC, or endometrial carcinoma that is not MSI_H or dMMR. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Schenker et al., 2022; AACR Abstract CT022), blood tumor mutational burden (bTMB) ≥16 Muts/Mb (based on this assay) may predict sensitivity to immune checkpoint inhibitors targeting PD_1. </p> <p><b>Supporting Data:</b> A Phase 2 study of single_agent pembrolizumab reported a 5.8% (6/104) ORR for patients with advanced biliary tract cancer; a Phase 1b study for patients with PD_L1_positive advanced biliary tract cancer reported an ORR of 13% (3/23) (Bang et al., 2019; ASCO Abstract 4079). Clinical benefit has been observed from pembrolizumab in combination with other therapies. The combination of pembrolizumab or nivolumab with the antiangiogenic multikinase inhibitor lenvatinib achieved an ORR of 21.4% (3/14) and median PFS (mPFS) of 5 months for patients with intrahepatic cholangiocarcinoma (Lin et al., 2018; ASCO Abstract 500), as well as an ORR of 10% (3/31) and mPFS of 6.1 months for patients with advanced biliary cancers (Villanueva et al., 2021; ASCO Abstract 321). Combination of pembrolizumab with granulocyte_macrophage colony_stimulating factor (GM_CSF) achieved an ORR of 19% (5/27) for patients with advanced biliary cancer; a longer mPFS was observed for patients with intermediate or high tumor mutational burden (TMB) compared with low TMB (2.1 vs. 12.8 months, p=0.012) (Kelley et al., 2018; ASCO Abstract 4087). Pembrolizumab combined with the VEGFR2_targeting antibody ramucirumab elicited an ORR of 4.2% (1/24) for patients with advanced biliary tract carcinoma; an improved median OS (11.3 vs. 6.1 months), but not mPFS (1.5 vs. 1.6 months), was reported for patients with PD_L1_positive tumors compared with those with PD_L1_negative tumors (combined positive score [CPS] ≥1%) (Arkenau et al., 2018; 29853658). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Cemiplimab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Cemiplimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved to treat patients with NSCLC with high PD_L1 expression (TPS ≥ 50%), cutaneous squamous cell carcinoma (CSCC), or basal cell carcinoma (BCC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Schenker et al., 2022; AACR Abstract CT022), blood tumor mutational burden (bTMB) ≥16 Muts/Mb (based on this assay) may predict sensitivity to immune checkpoint inhibitors targeting PD_1. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of cemiplimab for the treatment of biliary tract carcinoma are limited (PubMed, Jun 2022). Cemiplimab has been studied primarily in advanced cutaneous squamous cell carcinoma (CSCC), where it elicited a combined ORR of 48% (41/85) in Phase 1 and 2 studies (Migden et al., 2018; 29863979). A Phase 2 trial of cemiplimab in patients with basal cell carcinoma (BCC) reported ORRs of 31% (5 CRs and 21 PRs) in patients with locally advanced BCC and 21% (6 PRs) in patients with metastatic BCC (Stratigos et al., 2020; EMSO Abstract LBA47, Lewis et al. 2020; doi: 10.1136/jitc_2020_SITC2020.0428). The Phase 3 EMPOWER_Lung 1 trial for advanced non_small cell lung cancer (NSCLC) with PD_L1 expression ≥50% reported that cemiplimab is associated with improved PFS (8.2 vs. 5.7 months), OS (not reached vs. 14.2 months), and ORR (37% vs. 21%) compared with chemotherapy (Sezer et al., 2020; ESMO Abstract LBA52). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Nivolumab + Ipilimumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response, and ipilimumab is a cytotoxic T_lymphocyte antigen 4 (CTLA_4)_blocking antibody. The combination is FDA approved in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), pleural mesothelioma, and esophageal squamous cell carcinoma (ESCC). Furthermore, nivolumab is approved in combination with ipilimumab to treat patients with mismatch repair_deficient (dMMR) or microsatellite instability_high (MSI_H) colorectal cancer (CRC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Schenker et al., 2022; AACR Abstract CT022), blood tumor mutational burden (bTMB) of ≥16 Muts/Mb (based on this assay) may predict sensitivity to combination nivolumab and ipilimumab treatment. </p> <p><b>Supporting Data:</b> In the Phase 2 CheckMate 848 multi_solid tumor trial, combination treatment with nivolumab and ipilimumab led to improved ORR for patients with blood tumor mutational burden (bTMB) ≥ 16 Muts/Mb (based on this assay) compared with those with bTMB ≥10 Muts/Mb but <16 Muts/Mb (34% [13/38] vs 12% [5/42]) (Schenker et al., 2022; AACR Abstract CT022). A Phase 2 study evaluating nivolumab combined with ipilimumab for patients with biliary cancers, including intrahepatic cholangiocarcinoma and gallbladder carcinoma, reported ORR of 23% (9/39), median PFS of 2.9 months, and median OS of 5.7 months (Klein et al., 2020; 32729929). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Dostarlimab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Dostarlimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer or solid tumors. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Schenker et al., 2022; AACR Abstract CT022), blood tumor mutational burden (bTMB) ≥16 Muts/Mb (based on this assay) may predict sensitivity to immune checkpoint inhibitors targeting PD_1. </p> <p><b>Supporting Data:</b> In the Phase 1 GARNET trial of dostarlimab as a single agent for patients with mismatch repair_deficient tumors, 1 patient with a gallbladder tumor and 1 patient with a biliary neoplasm each exhibited a CR (Andre et al., 2021; ASCO GI Abstract 9). Dostarlimab has been studied primarily in recurrent and advanced mismatch repair_deficient (dMMR) endometrial and non_endometrial cancers (Andre et al., 2021; ASCO GI Abstract 9, Oaknin et al., 2020; 33001143, Berton et al., 2021; ASCO Abstract 2564). In the Phase 1 GARNET trial, single_agent dostarlimab elicited an ORR of 39% (41/106) and an immune_related ORR of 46% (50/110) for patients with non_endometrial dMMR solid tumors (Andre et al., 2021; ASCO GI Abstract 9, Andre et al., 2021; ESMO GI Abstract SO_9). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Nivolumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response. It is FDA approved as a monotherapy in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, colorectal cancer (CRC), classical Hodgkin lymphoma (cHL), gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma or squamous cell carcinoma (ESCC). It is also approved in combination with chemotherapy to treat ESCC, in combination with cabozantinib to treat RCC, and in combination with relatlimab to treat melanoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Schenker et al., 2022; AACR Abstract CT022), blood tumor mutational burden (bTMB) ≥16 Muts/Mb (based on this assay) may predict sensitivity to immune checkpoint inhibitors targeting PD_1. </p> <p><b>Supporting Data:</b> In the Phase 2 CheckMate 848 multi_solid_tumor trial, treatment with the PD_1 inhibitor nivolumab led to improved ORR for patients with a blood tumor mutational burden (bTMB) of 16 Muts/Mb or higher (based on this assay) compared with those with bTMB of 10 Muts/Mb or higher but <16 Muts/MB (22% [5/23] vs. 9.1% [2/22]) (Schenker et al., 2022; AACR Abstract CT022). A Phase 2 study of nivolumab for patients with advanced biliary tract cancers reported an ORR of 10.9% (5/46) and a DCR of 58.7% (27/46) by independent central review; median PFS and OS were 3.7 and 14.2 months, respectively (Kim et al., 2020; 32352498). This study reported a significant association between PD_L1 tumor cell expression >1% and improved median PFS (10.4 vs. 2.3 months, HR=0.23)(Kim et al., 2020; 32352498). A case report described an ongoing, 1+ year response to nivolumab in a patient with intrahepatic cholangiocarcinoma and a high TMB (Gbolahan et al., 2019; 31200359). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04237649', 'Include': 'true'}, {'nctId': 'NCT05007106', 'Include': 'true'}, {'nctId': 'NCT04152018', 'Include': 'true'}, {'nctId': 'NCT03396445', 'Include': 'true'}, {'nctId': 'NCT03530397', 'Include': 'true'}, {'nctId': 'NCT02628067', 'Include': 'true'}, {'nctId': 'NCT03861793', 'Include': 'true'}, {'nctId': 'NCT04047862', 'Include': 'true'}, {'nctId': 'NCT04261439', 'Include': 'true'}, {'nctId': 'NCT04892498', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'CCNE1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'CCNE1 encodes the protein cyclin E1, which plays a role in the regulated transition from the G1 to S phase by binding to and activating cyclin_dependent protein kinase 2 (CDK2). It also has a direct role in initiation of replication and the maintenance of genomic stability (Möröy and Geisen, 2004; 15147722). Amplification of chromosomal region 19q12_q13 has been demonstrated in many types of cancer, and CCNE1 is a well_studied gene within this amplicon (Leung et al., 2006; 16575401, Lin et al., 2000; 11156406). Increased copy number of CCNE1 is highly associated with overexpression of the cyclin E1 protein (Mayr et al., 2006; 16753589, Nakayama et al., 2010; 20336784). Cyclin E1 overexpression can lead to cell transformation as a result of an increase in cyclin E1 activity (Stamatakos et al., 2010; 21176227, Möröy and Geisen, 2004; 15147722). CCNE1 amplification has been reported in 1_2% of samples in published cholangiocarcinoma datasets (cBio_Lowery et al., 2018; 29848569, cBio_Sanchez_Vega et al., 2018; 29625050). Published data investigating the prognostic implications of CCNE1 alterations in biliary tract carcinoma are limited (PubMed, Mar 2022). There are no approved therapies that directly target CCNE1 alterations. Because amplification or overexpression of CCNE1 leads to increased genomic instability though the ATR_CHK1_WEE1 pathway (Lin et al., 2017; 28331049, Chen et al., 2018; 30181387) and cyclin E1 promotes cell cycle progression in a complex with CDK2 (Möröy and Geisen, 2004; 15147722), clinical and preclinical studies have investigated inhibitors of CHK1, ATR, CDK2, and WEE1 as potential therapeutic approaches for tumors with CCNE1 activation. Clinical benefit has been reported for patients with recurrent high_grade serous ovarian carcinoma (HGSOC) with CCNE1 amplification or expression in response to treatment with the CHK1 inhibitor prexasertib (Lee et al., 2018; 29361470). Studies of the WEE1 inhibitor adavosertib observed PRs in patients with CCNE1_amplified HGSOC and ovarian cancer (Lheureux et al., 2021; 33485453, Oza et al., 2020; 32611648). Similarly, in a Phase 2 study of patients with CCNE1_amplified solid tumors, adavosertib elicited an ORR of 26% with PRs reported for patients with ovarian cancer, urothelial carcinoma, or melanoma (Fu et al., 2021; AACR abstract 974). Preclinical studies have demonstrated that cell lines with CCNE1 amplification or overexpression were sensitive to inhibitors of ATR (Toledo et al., 2011; 21552262, Buisson et al., 2015; 26365377), CDK2 (Yang et al., 2015; 26204491), or WEE1 (Kok et al., 2020; 33028815, Chen et al., 2018; 30181387). However, other studies have shown that sensitivity of various cell lines to CDK2 inhibitors, including SNS_032, dinaciclib, and seliciclib, at clinically achievable doses, is largely independent of CCNE1 copy number or expression (Taylor_Harding et al., 2015; 25557169, Etemadmoghadam et al., 2013; 24004674, Scaltriti et al., 2011; 21321214, Nanos_Webb et al., 2012; 21695458). One study has reported a reduction in tumor CCNE1 levels in 4/6 lung and esophageal cancer cases following treatment with the HDAC inhibitor vorinostat (Ma et al., 2013; 23686769).', 'Include': 'true', 'ClinicalTrialNote': 'Strong preclinical and clinical data suggest that CCNE1 amplification may predict sensitivity to WEE1 inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04768868', 'Include': 'true'}, {'nctId': 'NCT05128825', 'Include': 'true'}, {'nctId': 'NCT03968653', 'Include': 'true'}, {'nctId': 'NCT05109975', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'FGFR1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'true', 'name': 'amplification'}}, 'Interpretation': 'FGFR1 encodes the protein fibroblast growth factor receptor 1, which plays key roles in regulation of the cell cycle and angiogenesis and is an upstream regulator of the RAS, MAPK, and AKT signaling pathways (Turner and Grose, 2010; 20094046). Amplification of FGFR1 has been correlated with protein expression (Kohler et al., 2012; 22648708, Kim et al., 2013; 23182986) and may predict pathway activation and sensitivity to therapies targeting this pathway (André et al., 2014; 24508104, Dienstmann et al., 2014; 24265351). Although FGFR1 amplification and mutation have been reported infrequently in biliary tract tumors and cholangiocarcinoma (cBio_Chan_On et al., 2013; 24185513, cBio_Ong et al., 2012; 22561520, cBio_Jiao et al., 2013; 24185509, Ross et al., 2014; 24563076, Nakamura et al., 2015; 26258846, Lee et al., 2015; 26500333), recurrent activating FGFR2 fusions have been reported in 8_50% of intrahepatic cholangiocarcinomas (Javle et al., 2016; 27622582, Ross et al., 2014; 24563076, Borad et al., 2014; 24550739, Arai et al., 2013; 24122810, Sia et al., 2015; 25608663, cBio_Jiao et al., 2013; 24185509, Nakamura et al., 2015; 26258846). Published data investigating the prognostic implications of FGFR1 alterations in biliary tract carcinoma or cholangiocarcinoma are limited (PubMed, Aug 2021). Alterations that activate FGFR1 may predict sensitivity to selective FGFR inhibitors including erdafitinib (Loriot et al., 2019; 31340094, Tabernero et al., 2015; 26324363, Karkera et al., 2017; 28416604, Park et al., 2019; ASCO Abstract 4117), pemigatinib (Necchi et al., 2018; ESMO Abstract 900P), infigratinib (Pal et al., 2018; 29848605, Pal et al., 2020; 32208524), futibatinib (Bahleda et al., 2020; 32622884, Meric_Bernstam et al., 2022; 34551969, Kasbekar et al., 2020; 32649766), rogaratinib (Schuler et al., 2019; 31405822), Debio 1347 (Sait et al., 2021; 34250399, Voss et al., 2019; 30745300), and derazantinib (Papadopoulos et al., 2017; 28972963), or multikinase inhibitors such as pazopanib (Cheng et al., 2017; 29223982, Yuan et al., 2016; SABCS Abstract P6_16_08) and ponatinib (Khodaoust et al., 2015; 26055304, Tanasi et al., 2019; 31434701, Strati et al., 2018; 29119847, Kreil et al., 2015; Abstract 2812). The activity and efficacy of selective FGFR inhibitors for FGFR1_amplified tumors has been modest with limited responses reported in FGFR1_amplified lung squamous cell carcinoma (SCC) treated with infigratinib (Nogova et al., 2017; 27870574) or AZD457 (Aggarwal et al., 2019; 31195180) and no responses reported among patients with FGFR1_amplified breast cancer treated with infigratinib (Nogova et al., 2017; 27870574). Two case studies reported PRs in patients with FGFR1_amplified breast cancer treated with pazopanib (Cheng et al., 2017; 29223982, Yuan et al., 2016; SABCS Abstract P6_16_08).', 'Include': 'true', 'ClinicalTrialNote': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT05024214', 'Include': 'true'}, {'nctId': 'NCT05254847', 'Include': 'true'}, {'nctId': 'NCT05156788', 'Include': 'true'}, {'nctId': 'NCT05010668', 'Include': 'true'}, {'nctId': 'NCT04169672', 'Include': 'true'}, {'nctId': 'NCT05010681', 'Include': 'true'}, {'nctId': 'NCT05098847', 'Include': 'true'}, {'nctId': 'NCT04550624', 'Include': 'true'}, {'nctId': 'NCT05215665', 'Include': 'true'}, {'nctId': 'NCT04976634', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'MDM2', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'MDM2 encodes an E3 ubiquitin protein ligase, which mediates the ubiquitination and subsequent degradation of p53, Rb1, and other proteins (Sdek et al., 2005; 16337594, Brady et al., 2005; 15632057, Li et al., 2004; 15053880). MDM2 acts to prevent the activity of the tumor suppressor p53; therefore, overexpression or amplification of MDM2 may be oncogenic (Brown et al., 2009; 19935675, Cordon_Cardo et al., 1994; 8306343). Overexpression or amplification of MDM2 is frequent in cancer (Beroukhim et al., 2010; 20164920). Although two retrospective clinical studies suggest that MDM2 amplification may predict a short time_to_treatment failure on anti_PD_1/PD_L1 immune checkpoint inhibitors, with 4/5 patients with MDM2 amplification (Kato et al., 2017; 28351930) and 2/3 patients with MDM2 or MDM4 amplification (Singavi et al., 2017; ESMO Abstract 1140PD) experiencing tumor hyperprogression, amplification of MDM2 or MDM4 was not associated with shorter progression_free survival (PFS) in a retrospective analysis of non_small cell lung cancer (NSCLC) outcomes with immune checkpoint inhibitors (hazard ratio of 1.4, p=0.44)(Rizvi et al., 2018; 29337640). The latter study reported PFS of >2 months for 5/8 patients with MDM2/MDM4 amplification (Rizvi et al., 2018; 29337640). MDM2 amplification has been observed in 10.8% of gallbladder carcinoma and 3.2% of cholangiocarcinoma samples (cBio_Narayan et al., 2019; 30427539, cBio_Lowery et al., 2018; 29848569, cBio_Boerner et al., 2021; 33765338). MDM2 overexpression has been reported to be a common event in biliary tract cancers, occurring in 75% of gallbladder adenocarcinoma and in 38_68% of ICC cases, respectively (Momoi et al., 2001; 11580146, Horie et al., 2000; 10963376, Jarnagin et al., 2006; 16505435, Della et al., 2000; 10718212). MDM2 overexpression in pancreatic carcinomas and biliary tract tumors has been associated with advanced tumor stage, metastasis, and poor patient prognosis (Grochola et al., 2011; 21404460, Horie et al., 2000; 10963376, Jarnagin et al., 2006; 16505435). MDM2 antagonists disrupt the MDM2_p53 interaction, thereby stabilizing p53 (Cheok et al., 2011; 20975744). Preclinical studies have suggested that the amplification of MDM2, in the absence of concurrent TP53 mutations, may increase sensitivity to these agents (Ohnstad et al., 2013; 23165797, Gamble et al., 2012; 21725357). Preliminary Phase 1 studies of the MDM2_p53 antagonist alrizomadlin (APG_115) reported a PR in a patient with liposarcoma harboring an MDM2 amplification and wildtype for TP53 and SD in 21%–38% (6/28 and 5/13, respectively) of patients in genomically unselected solid tumors (Zhang et al., 2019; ASCO Abstract 3124, Rasco et al., 2019; ASCO Abstract 3126). A Phase 2 trial of alrizomadlin in combination with pembrolizumab reported a PR in 1 of 3 patients with malignant peripheral nerve sheath tumor that had failed standard therapy, as well as PRs in patients with multiple types of solid tumors that had failed immunotherapy, including 1 out of 14 patients with non_small cell lung cancer; 1 out of 5 patients with urothelial carcinoma; and 2 out of5, 1 out of 5, and 1 out of 11 patients with mucosal, uveal, and cutaneous melanoma, respectively (Tolcher et al., 2021; ASCO Abstract 2506). Phase 1b studies of the MDM2 inhibitor idasanutlin for refractory AML in combination with cytarabine or venetoclax reported anti_leukemic response rates of 33% (25/75) and 37% (11/30), respectively (Martinelli et al., 2016; EHA21 Abstract S504, Daver et al., 2018; ASH Abstract 767); clinical benefit (58% ORR, 7/12) with idasanutlin monotherapy has been reported for patients with polycythemia vera (Mascarenhas et al., 2019; ASH Abstract 134). The dual MDM2/MDM4 inhibitor ALRN_6924 led to an ORR of 27% (4/15) for patients with TP53 wildtype peripheral T_cell lymphoma in a Phase 2 study (Shustov et al., 2018; ASH Abstract 1623); responses have also been observed in TP53 wildtype AML, MDS, Merkel cell carcinoma, colorectal cancer, and liposarcoma (Sallman et al., 2018; ASH Abstract 4066, Meric_Bernstam et al., 2017; ASCO Abstract 2505).', 'Include': 'true', 'ClinicalTrialNote': 'Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04785196', 'Include': 'true'}, {'nctId': 'NCT03611868', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'PTEN', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'splice site 165_1G>C', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'splice site 165_1G>C'}}, 'Interpretation': 'PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K_AKT_mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodríguez_Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andrés_Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454, Shan et al., 2020; 32704382). PTEN mutations have been reported in 1_11% of cholangiocarcinoma samples (Ong et al., 2012; 22561520, Jang et al., 2013; 24186137, Ross et al., 2014; 24563076). PTEN homozygous deletion was reported in fewer than 1% of gallbladder cancer cases (Narayan et al., 2019; 30427539). PTEN was not observed as a significantly altered gene in an analysis of biliary tract cancers (Nakamura et al., 2015; 26258846). In a study of 60 cholangiocarcinoma samples, 60% (36/60) showed a loss of PTEN expression (Kim et al., 2012; 22844568). Loss of PTEN expression has been reported in 51.8% of gallbladder adenocarcinomas (Liu and Yang, 2011; 21719208). Loss of PTEN has been associated with increased invasion, advanced tumor stage, and shorter survival in patients with cholangiocarcinoma (Kim et al., 2012; 22844568, Lee et al., 2012; 21874010, Chung et al., 2009; 19147772), and with poor prognosis in patients with gallbladder adenocarcinoma (Liu and Yang, 2011; 21719208). PTEN loss or mutation leads to activation of the PI3K_AKT_mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). A Phase 2 trial examining treatment with the PI3K inhibitor copanlisib in combination with gemcitabine and cisplatin in biliary tract cancer reported longer response rates for patients with low PTEN expression (PFS of 8.5 months, OS of 18 months) compared with patients with high PTEN expression (PFS of 4.6 months, OS of 7.0 months); however, differences were not statistically significant (p=0.19) (Tan et al., 2021; 33289918). Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes_Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN_altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha_Paul et al., 2018; AACR Abstract A096). One or more of the PTEN variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hamartoma tumor syndrome (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte_Duclos disease (LD), Bannayan_Riley_Ruvalcaba syndrome (BRRS), PTEN_related Proteus syndrome (PS), and Proteus_like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.', 'Include': 'true', 'ClinicalTrialNote': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04644068', 'Include': 'true'}, {'nctId': 'NCT04341259', 'Include': 'true'}, {'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT02264678', 'Include': 'true'}, {'nctId': 'NCT04001569', 'Include': 'true'}, {'nctId': 'NCT04298021', 'Include': 'true'}, {'nctId': 'NCT05035745', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT04497116', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'STK11', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'F157fs*5', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'F157fs*5'}}, 'Interpretation': 'The serine/threonine kinase STK11 (also called LKB1) activates AMPK and negatively regulates the mTOR pathway in response to changes in cellular energy levels (Shaw et al., 2004; 15261145). LKB1 acts as a tumor suppressor in cancer, as loss of function promotes proliferation and tumorigenesis (Carretero et al., 2010; 20541700, Ollila et al., 2011; 21926085). Alterations such as seen here may disrupt STK11 function or expression (Qui et al., 2007; 16407837, Mehenni et al., 1998; 9837816, Karuman et al., 2001; 11430832, Baas et al., 2003; 12805220, Zeng and Berger, 2006; 17108107, Boudeau et al., 2004; 15561763, Scott et al., 2007; 17575127, Xie et al., 2009; 19414597, Boudeau et al., 2003; 12552571, Forcet et al., 2005; 15800014, Zhang et al., 2015; 25960268, Berger et al., 2016; 27478040, Donnelly et al., 2021; 34849607). STK11 mutations have been reported in 3% of biliary tract carcinomas analyzed in the COSMIC database (Mar 2022)(Tate et al., 2019; 30371878). STK11 mutation or loss have also been reported in biliary tract adenocarcinomas in the literature (Olschwang et al., 2001; 11389158, Su et al., 1999; 10362809, Sahin et al., 2003; 12861065). Loss of STK11 protein expression in intrahepatic cholangiocarcinoma has been reported as an independent predictor of shorter OS and time to recurrence (Wang et al., 2015; 26056085). Increased mTOR signaling is present in LKB1_deficient tumors, suggesting therapies targeting mTOR may be relevant for tumors with STK11 alterations (Shaw et al., 2004; 15261145, Ji et al., 2007; 17676035, Contreras et al., 2008; 18245476, Gurumurthy et al., 2008; 18172296, Shackelford et al., 2009; 19541609). Case studies have reported PRs for 2 patients with STK11_mutated pancreatic cancer following treatment with the mTOR inhibitor everolimus (Klümpen et al., 2011; 21189378, Moreira et al., 2015; ASCO Abstract 315), with 1 PR observed in a PJS patient for 9 months until progression (Klümpen et al., 2011; 21189378). However, retrospective analysis of a Phase 2 trial for patients with endometrial carcinoma found LKB1 (STK11) protein levels were not significantly correlated with response to everolimus treatment (Tredan et al., 2013; 23238879). In one preclinical study, STK11 loss was associated with sensitivity to combination treatment including an SRC inhibitor (Carretero et al., 2010; 20541700); however, the clinical relevance of these findings has not been established. STK11 alteration is associated with poorer response to immune checkpoint inhibitors for patients with NSCLC, including those with tumors harboring co_occurring KRAS mutation (Skoulidis et al., 2018; 29773717, Hellmann et al., 2018; 29657128, Scheel et al., 2016; 27467949, Skoulidis et al., 2015; 26069186, Koyama et al., 2016; 26833127, Schabath et al., 2016; 26477306, Dong et al., 2017; 28039262, Kadara et al., 2017; 27687306, Herter_Sprie et al., 2016; 27699275) (Skoulidis et al., 2017; IASLC 17th World Congress on Lung Cancer Abstract MA04.07, Jure_Kunkel et al., 2018; ASCO Abstract 3028, Stephens, 2017; AACR Abstract SY40_02, Skoulidis et al., 2015; ASCO Abstract 11002, Skoulidis et al., 2015; ASCO Abstract 11002). Germline mutations in STK11 underlie Peutz_Jeghers syndrome (PJS), a rare autosomal dominant disorder associated with a predisposition for tumor formation (Amos et al., 2004; 15121768). This disorder has an estimated frequency between 1:29,000 and 1:120,000, although reported rates in the literature vary greatly (Hearle et al., 2006; 16707622, Amos et al., 2004; 15121768, van der Groep et al., 2011; 21336636). Although gastrointestinal tumors are the most common malignancies associated with PJS, patients also exhibit an 18_fold increased risk of developing other epithelial cancers (Hearle et al., 2006; 16707622, Amos et al., 2004; 15121768, van der Groep et al., 2011; 21336636), and individuals with this syndrome have a 30_50% risk of developing breast cancer (Amos et al., 2004; 15121768, van der Groep et al., 2011; 21336636). Given the association with PJS, in the appropriate clinical context testing for the presence of germline mutations in STK11 is recommended.', 'Include': 'true', 'ClinicalTrialNote': 'Increased mTOR signaling is present in LKB1_deficient tumors, suggesting therapies targeting mTOR may be relevant for tumors with STK11 alterations.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': {'nctId': 'NCT04337463', 'Include': 'true'}}}}, 'ReferenceLinks': None}, {'Name': 'ASXL1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'E635fs*15', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'E635fs*15'}}, 'Interpretation': 'ASXL1 regulates epigenetic marks and transcription through interaction with polycomb complex proteins and various transcription activators and repressors (Scheuermann et al., 2010; 20436459, Cho et al., 2006; 16606617, Park et al., 2011; 21047783). Alterations such as seen here may disrupt ASXL1 function or expression (Inoue et al., 2013; 24216483, Abdel_Wahab et al., 2012; 22897849, Katoh et al., 2013; 23736028). ASXL1 alterations occur infrequently across various solid tumor types (cBio_Zehir et al., 2017; 28481359) and are not known to act as drivers in any specific solid cancer type (Bailey et al., 2018; 29625053). Published data investigating the prognostic implications of ASXL1 alterations in solid tumors are limited (PubMed, May 2022). In the context of clonal hematopoiesis, ASXL1 mutations are significantly enriched in current or former smokers (Bolton et al., 2020; 33106634). There are no targeted therapies available to address genomic alterations in ASXL1. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'ESR1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'S341L', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'S341L'}}, 'Interpretation': 'ESR1 encodes estrogen receptor alpha (ER_alpha), one of the major estrogen receptor isoforms in humans. Along with co_activator proteins, the ER complex promotes transcription of genes involved in cell cycle progression and survival (Pearce and Jordan, 2004; 15094156). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. ESR1 mutation has not been reported in multiple cholangiocarcinoma datasets (cBio_Chan et al., 2013; 24185513, cBio_Ong et al., 2012; 22561520, cBio_Jiao et al., 2013; 24185509). Published data investigating the prognostic implications of ESR1 alterations in biliary tract carcinoma are limited (PubMed, Dec 2021). Therapies that directly target ER_alpha, such as selective ER modulators (SERMs) and the selective ER degrader (SERD) fulvestrant, as well as aromatase inhibitors (AIs) that inhibit estrogen production, are approved to treat ER_positive (ER+) and/or hormone receptor_positive (HR+) breast cancer (NCCN Guidelines v4.2022). AI treatment has also been reported to provide clinical benefit in a subset of HR+ gynecologic malignancies (Straubhar et al., 2017; 28560298, Thangavelu et al., 2013; 24076063, Gershenson et al., 2017; 28221866, Eshfani et al., 2014; 24925537, Ramirez et al., 2008; 18457865). Combinations of fulvestrant and CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib, have also demonstrated efficacy for patients with ESR1_mutated breast cancer (Tolaney et al., 2019; Abstract 4458, Neven et al., 2018; SABCS Abstract PD2_05, Turner et al., 2016; ASCO Abstract 512, Turner et al., 2018; 30345905, Martin et al., 2019; SABCS Abstract GS2_07). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'KDM6A', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R1351*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R1351*'}}, 'Interpretation': 'KDM6A encodes a histone H3 lysine 27 demethylase UTX, which functions as a transcriptional regulator (van Haaften et al., 2009; 19330029). A significant number of inactivating KDM6A mutations have been found across multiple tumor types, suggesting a role as a tumor suppressor (van Haaften et al., 2009; 19330029). KDM6A mutations have been reported in 3.9% of samples analyzed, with the highest incidence in tumors of the urinary tract (31%), liver (7.3%), endometrium (6.7%), salivary gland (6.0%), and pancreas (5.1%) (COSMIC, Jan 2022)(Tate et al., 2019; 30371878). KDM6A mutations or copy number alterations have also been identified in medulloblastoma (8.9%)(Robinson et al., 2012; 22722829), adenoid cystic carcinoma (6.7%) (Ho et al., 2013; 23685749), and metastatic prostate cancer (10%) (Grasso et al., 2012; 22722839). KDM6A inactivation has been found as a recurrent tumorigenic event in male T_cell acute lymphoblastic leukemia (T_ALL), and loss of KDM6A increased the sensitivity of T_ALL cells to therapies targeting histone H3 lysine 27 methylation in preclinical assays (Van der Meulen et al., 2014; 25320243). However, KDM6A overexpression has been noted in breast cancer and renal cell carcinoma, and correlated with inferior prognosis in patients with breast cancer (Wang et al., 2013; 23792809, Kim et al., 2014; 24491801, Shen et al., 2012; 23057811). There are no therapies available to address KDM6A alterations in cancer.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Cannot Be Determined', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Cannot Be Determined'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI_H is infrequent in cholangiocarcinoma, reported in 1% of samples (Javle et al., 2019; ASCO Abstract 4087). A non_zero level of MSI has been reported in 18_49% of cholangiocarcinoma cases (Momoi et al., 2001; 11580146, Limpaiboon et al., 2002; 12175538, Liu et al., 2002; 12402306, Liengswangwong et al., 2003; 14506736), although the studies did not specify what fraction of cases were MSI_H. A higher frequency of MSI (63%) was reported in patients with intrahepatic cholangiocarcinoma associated with exposure to Thorotrast (Liu et al., 2002; 12402306). One study reported that MSI is associated with poor prognosis in liver fluke_related cholangiocarcinoma (Limpaiboon et al., 2002; 12175538). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'NSD3 (WHSC1L1)', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'true', 'name': 'amplification'}}, 'Interpretation': 'NSD3, also known as WHSC1L1, encodes an enzyme that mediates histone methylation (Kim et al., 2006; 16682010). NSD3 has been shown to be amplified in various cancers (Kang et al., 2013; 23011637, Chen et al., 2014; 24874471, Morishita et al., 2011; 21664949). In TCGA datasets, NSD3 amplification has been most frequently observed in lung squamous cell carcinoma (17%) (Cancer Genome Atlas Research Network., 2012; 22960745), breast invasive carcinoma (13%) (cBio_Ciriello et al., 2015; 26451490), bladder urothelial carcinoma (9%) (Cancer Genome Atlas Research Network., 2014; 24476821), and head and neck squamous cell carcinoma (9%) (HNSCC_Cancer Genome Atlas Network., 2015; 25631445) samples (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Amplification of at least one member of the NSD3_CHD8_BRD4 pathway has been associated with worse overall survival in ovarian high_grade serous carcinoma and endometrial cancer (Jones et al., 2017; 28781807). In endometrial cancers, amplification of this pathway was more frequent in endometrial serous and endometrioid serious_like carcinomas compared to low_grade endometrioid endometrial adenocarcinomas (Jones et al., 2017; 28781807). There are no targeted therapies available to address genomic alterations in NSD3.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'RAD21', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R450fs*6', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R450fs*6'}}, 'Interpretation': 'RAD21 encodes a protein involved in DNA double_strand break repair and sister chromatid cohesion as a part of the cohesin complex (Xu et al., 2011; 21326324, Hill et al., 2016; 27207471, Solomon et al., 2014; 24856830, Bauerschmidt et al., 2010; 19906707). In preclinical studies, downregulation of RAD21 or other cohesin components leads to loss of expression from amplified genes, as well as amplifications themselves upon cell passaging (Yun et al., 2016; 26420833), but also leads to an increase in deletions, insertions, and other rearrangements (Gelot et al., 2016; 27326661). High RAD21 expression has also been associated with increased genomic instability (Yan et al., 2012; 22537934). Cohesin complex also organizes chromatin domains and regulates gene expression (Sofueva et al., 2013; 24185899, Deng et al., 2012; 23010778). Both overexpression and reduction of expression of RAD21 has been reported to alter gene expression (Yun et al., 2016; 27466323). RAD21 amplification has been correlated with increased expression in breast (Yan et al., 2012; 22537934, Xu et al., 2011; 21255398, Mahmood et al., 2014; 24148822) and endometrial (Supernat et al., 2012; 23205091) cancers. Other RAD21 alterations, including truncating and point mutations, have been reported in the context of cancer, but the majority have not been characterized. RAD21 amplifications have been reported in solid tumors, including breast cancers (7%), melanoma (5.4%), and prostate (2.4%) cancers (cBio_Zehir et al., 2017; 28481359). RAD21 overexpression has been correlated with poor prognosis in endometrial cancer (Supernat et al., 2012; 23205091), breast cancer (Xu et al., 2011; 21255398, Sharaf et al., 2022; 35227290), Ewing sarcoma (Su et al., 2021; 33766983), and colorectal cancer (CRC), especially in KRAS_mutant CRC (Deb et al., 2014; 24548858). There are no therapies to target alterations in this gene.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'RB1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R698S', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R698S'}}, 'Interpretation': 'RB1 encodes the retinoblastoma protein (Rb), a tumor suppressor and negative regulator of the cell cycle (Burkhart and Sage, 2008; 18650841, Knudsen and Knudsen, 2008; 19143056). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. A study of 18 intrahepatic cholangiocarcinoma patients did not detect loss of heterozygosity at the chromosomal region 13q32 (where RB1 is located) in any cases (Kawaki et al., 2000; 11004673). However, studies have demonstrated that 12_41% of analyzed cholangiocarcinomas lack expression of Rb protein (Kang et al., 2002; 12378511, Tannapfel et al., 2002; 12210082). RB1 mutations have been reported across solid tumors including small cell lung cancer (60%), bladder (13%), uterine sarcoma (10%), non_melanoma skin cancer (9.5%), and gastrointestinal neuroendocrine tumors (9.3%) (Nguyen et al., 2022; 35120664). One analysis of 50 cholangiocarcinoma cases did not find a correlation between RB1 gene expression and disease metastasis (Boonjaraspinyo et al., 2012; 21750953). On the basis of limited clinical data (Owonikoko et al., 2016; ESMO Abstract 14230) and strong preclinical data (Hook et al., 2012; 22222631, Gong et al., 2019; 30373917, Oser et al., 2019; 30373918, Yang et al., 2022; 34741392), RB1 inactivation may be associated with sensitivity to inhibitors of Aurora kinase A, particularly in small cell lung cancer (SCLC). A clinical study evaluating the Aurora kinase A inhibitor alisertib for patients with prostate cancer did not find an association between RB1 deletion and clinical benefit (Beltran et al., 2019; 30232224). Other approaches to target RB1 inactivation under investigation in preclinical studies include inhibitors of BCL_2 family members (Allaman_Pillet et al., 2013; 21955141) and activation of the NOTCH pathway (Viatour et al., 2011; 21875955). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. One or more of the RB1 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with retinoblastoma (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Mutations in RB1 underlie the development of retinoblastoma (RB), a rare tumor that arises at a rate of approximately 1:20,000 live births, with nearly 5,000 new cases worldwide per year (Chen et al., 2014; 24282159). Germline mutations in RB1 account for approximately 40% of RB tumors (Yun et al., 2011; 22553621) and are associated with an increased risk of developing secondary malignancies that include soft tissue and bone sarcoma and malignant melanoma (Houston et al., 2011; 21139478, Ng et al., 2010; 19959033). In the appropriate clinical context, germline testing of RB1 is recommended.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TP53', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R280T', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R280T'}}, 'Interpretation': 'Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). Inactivation of p53, through mutation, deletion, or loss of heterozygosity (LOH), has been observed in 25_63% of gallbladder carcinomas and 10_61% of cholangiocarcinomas (Li et al., 2014; 24997986, Ross et al., 2014; 24563076, Jiao et al., 2013; 24185509, Chan_On et al., 2013; 24185513, Borger et al., 2012; 22180306, Suto et al., 2000; 10738270, Ong et al., 2012; 22561520, Javle et al., 2016; 27622582, Nakamura et al., 2015; 26258846, Nault and Zucman_Rossi, 2011; 21538283). TP53 mutations occur more frequently in tumors caused by liver fluke (O. viverrini) infection (40%) than in cholangiocarcinoma cases not related to infection (9%) (Chan_On et al., 2013; 24185513). Aberrant TP53 expression, which is indicative of TP53 dysregulation, has been observed in 20–62% of gallbladder carcinomas and 25% (5/20) of cholangiocarcinomas (Won et al., 2010; 20955617, Chaube et al., 2006; 16686942, Chuang et al., 2004; 15573254). Data regarding the prognostic significance of TP53 mutation in cholangiocarcinoma are conflicting (Ruzzenente et al., 2016; 26717940, Xiaofang et al., 2012; 22230750, Ajiki et al., 1996; 8799388, Saetta, 2006; 16724348, Guo et al., 2014; 24746206, Boerner et al., 2021; 33765338, Conci et al., 2020; 32020551, Simbolo et al., 2018; 29740198, Churi et al., 2014; 25536104). Overexpression of p53 protein has been associated with reduced patient survival in poorly differentiated gallbladder adenocarcinomas and biliary tract cancers (Lee and Pirdas, 1995; 7567135, Ahrendt et al., 2000; 11180865); however, another study did not find such a correlation (Ajiki et al., 1996; 8799388). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29) (Park et al., 2022; 36084396). Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Tumor Fraction', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Elevated Tumor Fraction', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Elevated Tumor Fraction'}}, 'Interpretation': 'Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'ZNF703', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'true', 'name': 'amplification'}}, 'Interpretation': 'ZNF703 encodes a transcriptional repressor that plays roles in stem cell proliferation, cell cycle progression, and other key cellular functions (Bazarov et al., 2011; 21635707, Sircoulomb et al., 2011; 21328542). Amplification of ZNF703 has been correlated with protein expression (Holland et al., 2011; 21337521, Sircoulomb et al., 2011; 21328542). ZNF703 was established as a breast cancer oncoprotein by studies showing that ZNF703 expression resulted in transformation and increased proliferation of cultured cells (Holland et al., 2011; 21337521, Slorach et al., 2011; 21317240, Sircoulomb et al., 2011; 21328542), as well as increased lung metastases in a breast cancer xenograft model (Slorach et al., 2011; 21317240). Amplification and high expression of ZNF703 has been observed in luminal B breast tumors, a subtype associated with aggressive disease progression and poor patient outcomes (Holland et al., 2011; 21337521, Sircoulomb et al., 2011; 21328542, Reynisdottir et al., 2013; 24156016). ZNF703 expression has also been linked with aggressive tumor characteristics in patients with gastric and colorectal cancers (Yang et al., 2014; 24481460, Ma et al., 2014; 25017610). Putative high_level amplification of ZNF703 has been reported with the highest frequency in breast carcinoma, bladder urothelial carcinoma, uterine carcinosarcoma, lung squamous cell carcinoma (SCC), esophageal carcinoma and head and neck SCC (5_13% of samples)(cBioPortal, 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). There are no available targeted therapies to directly address ZNF703 alterations in cancer. One preclinical study suggested that ZNF703 expression in breast cancer cell lines is associated with reduced sensitivity to tamoxifen through AKT_mTOR activation (Zhang et al., 2013; 23991038), although these findings have not been verified in the clinical setting.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '18', 'Title': 'KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'ADORA2A, CD73, PD_1', 'Locations': 'Taipei (Taiwan), Shatin, New Territories (Hong Kong), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Toronto (Canada), Missouri', 'NCTID': 'NCT04237649', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '18', 'Title': 'MK_7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK_7684A_005)', 'StudyPhase': 'PHASE 2', 'Target': 'PD_1, KIT, VEGFRs, FGFRs, PDGFRA, RET, TIGIT', 'Locations': 'Taipei (Taiwan), Taoyuan (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Tokyo (Japan), Kashiwa (Japan), Alaska, Adana (Turkey), Ankara (Turkey), Ramat Gan (Israel)', 'NCTID': 'NCT05007106', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '18', 'Title': 'Study of PF_06940434 in Patients With Advanced or Metastatic Solid Tumors.', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Wollongong (Australia), Washington, Arizona, Missouri, Texas', 'NCTID': 'NCT04152018', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '18', 'Title': 'Safety and Pharmacokinetics Study of MK_5890 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Adults With Advanced Solid Tumors (MK_5890_001)', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, CD27', 'Locations': 'Taipei (Taiwan), Seoul (Korea, Republic of), Be er Sheva (Israel), Amsterdam (Netherlands), Rotterdam (Netherlands), Barcelona (Spain), Madrid (Spain), Pozuelo de Alarcon (Spain), Santiago (Chile)', 'NCTID': 'NCT03396445', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '18', 'Title': 'A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_L1, PD_1, CTLA_4', 'Locations': 'Taipei (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Cheongju_si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Melbourne (Australia), Amsterdam (Netherlands), Ravenna (Italy)', 'NCTID': 'NCT03530397', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '18', 'Title': 'Study of Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_3475_158/KEYNOTE_158)', 'StudyPhase': 'PHASE 2', 'Target': 'PD_1', 'Locations': 'Taipei (Taiwan), Makati (Philippines), Seoul (Korea, Republic of), Beijing (China), North Ryde (Australia), Moscow (Russian Federation), Hod Hasharon (Israel), Drammen (Norway), Glostrup (Denmark), Haar (Germany)', 'NCTID': 'NCT02628067', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '18', 'Title': 'A Dose Escalation and Cohort Expansion Study of Subcutaneously_Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti_PD_1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY_2)', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Suwon (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Edmonton (Canada), Badalona (Spain), Rotterdam (Netherlands), Valencia (Spain), Madrid (Spain)', 'NCTID': 'NCT03861793', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '18', 'Title': 'Study of BGB_A1217 in Combination With Tislelizumab in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, TIGIT', 'Locations': 'Taipei (Taiwan), Taoyuan (Taiwan), Hualien City (Taiwan), Taichung (Taiwan), Fujian (China), Hangzhou (China), Shanghai (China), Guangdong (China), Changsha (China), Wuhan (China)', 'NCTID': 'NCT04047862', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '18', 'Title': 'A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1', 'Locations': 'Taipei (Taiwan), Chuo ku (Japan), Essen (Germany), Napoli (Italy), Leuven (Belgium), Barcelona (Spain), California, Texas', 'NCTID': 'NCT04261439', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Blood Tumor Mutational Burden', 'Alteration': '18', 'Title': 'Hypofractionated Radiotherapy Combined With PD_1 Inhibitor Sequential GM_CSF and IL_2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)', 'StudyPhase': 'PHASE 2', 'Target': 'PD_1', 'Locations': 'Hangzhou (China), Suzhou (China), Wuxi (China), Hefei (China), Xuzhou (China)', 'NCTID': 'NCT04892498', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'CCNE1', 'Alteration': 'amplification', 'Title': 'The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'WEE1', 'Locations': 'Taipei (Taiwan), Taoyuan (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Shanghai (China), Wuhan (China), Beijing (China), Chengdu (China), Kansas, Texas', 'NCTID': 'NCT04768868', 'Note': 'Strong preclinical and clinical data suggest that CCNE1 amplification may predict sensitivity to WEE1 inhibitors.', 'Include': 'true'}, {'Gene': 'CCNE1', 'Alteration': 'amplification', 'Title': 'A Study of ZN_c3 in Subjects With Malignant Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'WEE1', 'Locations': 'Nevada, Colorado, Texas, Ohio, Pennsylvania, Maryland, Virginia', 'NCTID': 'NCT05128825', 'Note': 'Strong preclinical and clinical data suggest that CCNE1 amplification may predict sensitivity to WEE1 inhibitors.', 'Include': 'true'}, {'Gene': 'CCNE1', 'Alteration': 'amplification', 'Title': 'Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'WEE1', 'Locations': 'Groningen (Netherlands), Nijmegen (Netherlands), Leiden (Netherlands), Barcelona (Spain)', 'NCTID': 'NCT03968653', 'Note': 'Strong preclinical and clinical data suggest that CCNE1 amplification may predict sensitivity to WEE1 inhibitors.', 'Include': 'true'}, {'Gene': 'CCNE1', 'Alteration': 'amplification', 'Title': 'A Study to Evaluate Safety and Preliminary Anti_tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'WEE1', 'Locations': 'Bellinzona (Switzerland), Zürich (Switzerland), Michigan, Texas', 'NCTID': 'NCT05109975', 'Note': 'Strong preclinical and clinical data suggest that CCNE1 amplification may predict sensitivity to WEE1 inhibitors.', 'Include': 'true'}, {'Gene': 'FGFR1', 'Alteration': 'amplification', 'Title': 'Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_L1, FGFRs, RET, PDGFRA, VEGFRs, KIT, FLT3, CSF1R', 'Locations': 'Hangzhou (China), Shanghai (China), Dongguan (China), Guangzhou (China), Zhuhai (China), Benbu (China), Zhengzhou (China), Jinan (China), Dalian (China), Tianjin (China)', 'NCTID': 'NCT05024214', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.', 'Include': 'true'}, {'Gene': 'FGFR1', 'Alteration': 'amplification', 'Title': 'Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC', 'StudyPhase': 'PHASE 2', 'Target': 'FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT05254847', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.', 'Include': 'true'}, {'Gene': 'FGFR1', 'Alteration': 'amplification', 'Title': 'Tislelizumab（Anti PD_1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT05156788', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.', 'Include': 'true'}, {'Gene': 'FGFR1', 'Alteration': 'amplification', 'Title': 'Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma', 'StudyPhase': 'PHASE 2', 'Target': 'FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT05010668', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.', 'Include': 'true'}, {'Gene': 'FGFR1', 'Alteration': 'amplification', 'Title': 'Study of Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'FGFR1, CSF1R, VEGFRs, PD_1', 'Locations': 'Shanghai (China), Beijing (China)', 'NCTID': 'NCT04169672', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.', 'Include': 'true'}, {'Gene': 'FGFR1', 'Alteration': 'amplification', 'Title': 'Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'PD_1, FGFRs, RET, PDGFRA, VEGFRs, KIT', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT05010681', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.', 'Include': 'true'}, {'Gene': 'FGFR1', 'Alteration': 'amplification', 'Title': 'Cryoablation Combined With Sintilimab Plus Lenvatinib In Previously Treated Unresectable Liver Metastasis From Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT05098847', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.', 'Include': 'true'}, {'Gene': 'FGFR1', 'Alteration': 'amplification', 'Title': 'Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Cholangiocarcinoma', 'StudyPhase': 'PHASE 2', 'Target': 'PD_1, KIT, VEGFRs, FGFRs, PDGFRA, RET', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT04550624', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.', 'Include': 'true'}, {'Gene': 'FGFR1', 'Alteration': 'amplification', 'Title': 'GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma', 'StudyPhase': 'PHASE null', 'Target': 'FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1', 'Locations': 'Tianjin (China)', 'NCTID': 'NCT05215665', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.', 'Include': 'true'}, {'Gene': 'FGFR1', 'Alteration': 'amplification', 'Title': 'Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK_6482_016)', 'StudyPhase': 'PHASE 2', 'Target': 'HIF2a, PD_1, KIT, VEGFRs, FGFRs, PDGFRA, RET', 'Locations': 'Seoul (Korea, Republic of), Gosford (Australia), Westmead (Australia), Epping (Australia), Malvern (Australia), Haifa (Israel), Jerusalem (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Utrecht (Netherlands)', 'NCTID': 'NCT04976634', 'Note': 'FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.', 'Include': 'true'}, {'Gene': 'MDM2', 'Alteration': 'amplification', 'Title': 'APG_115 in Combination With PD_1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1, MDM2', 'Locations': 'Shanghai (China), Guangzhou (China)', 'NCTID': 'NCT04785196', 'Note': 'Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.', 'Include': 'true'}, {'Gene': 'MDM2', 'Alteration': 'amplification', 'Title': 'A Study of APG_115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'MDM2, PD_1', 'Locations': 'Brisbane (Australia), South Brisbane (Australia), Bedford Park (Australia), Heidelberg (Australia), California, Arizona, Missouri, Arkansas, Ohio, Pennsylvania', 'NCTID': 'NCT03611868', 'Note': 'Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'splice site 165_1G>C', 'Title': 'Study of AZD5305 as Monotherapy and in Combination With Anti_cancer Agents in Patients With Advanced Solid Malignancies', 'StudyPhase': 'PHASE 1/2', 'Target': 'ERBB2, TROP2, PARP', 'Locations': 'Shanghai (China), Seoul (Korea, Republic of), Chongqing (China), Chuo_ku (Japan), Koto_ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Grzepnica (Poland), Budapest (Hungary)', 'NCTID': 'NCT04644068', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'splice site 165_1G>C', 'Title': 'A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.', 'StudyPhase': 'PHASE 1', 'Target': 'AKTs', 'Locations': 'Shanghai City (China)', 'NCTID': 'NCT04341259', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'splice site 165_1G>C', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'splice site 165_1G>C', 'Title': 'Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP, PD_L1', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)', 'NCTID': 'NCT02264678', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'splice site 165_1G>C', 'Title': 'AZD8186 and Paclitaxel in Advanced Gastric Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'PI3K_beta', 'Locations': 'Seongnam_si (Korea, Republic of)', 'NCTID': 'NCT04001569', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'splice site 165_1G>C', 'Title': 'DDR_Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'PD_L1, ATR, PARP', 'Locations': 'Seoul (Korea, Republic of)', 'NCTID': 'NCT04298021', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'splice site 165_1G>C', 'Title': 'Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)', 'StudyPhase': 'PHASE 1/2', 'Target': 'XPO1, PARP', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT05035745', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'splice site 165_1G>C', 'Title': 'Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, AKTs, PD_L1', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT03772561', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'splice site 165_1G>C', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'PTEN', 'Alteration': 'splice site 165_1G>C', 'Title': 'Study of RP_3500 in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP', 'Locations': 'Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Illinois, Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee', 'NCTID': 'NCT04497116', 'Note': 'PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'STK11', 'Alteration': 'F157fs*5', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'Increased mTOR signaling is present in LKB1_deficient tumors, suggesting therapies targeting mTOR may be relevant for tumors with STK11 alterations.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '20094046', 'FullCitation': 'Turner N, et al. Nat. Rev. Cancer (2010) pmid: 20094046', 'Include': 'true'}, {'number': '1', 'ReferenceId': '22648708', 'FullCitation': 'Kohler LH, et al. Virchows Arch. (2012) pmid: 22648708', 'Include': 'true'}, {'number': '2', 'ReferenceId': '23182986', 'FullCitation': 'Kim HR, et al. J. Clin. Oncol. (2013) pmid: 23182986', 'Include': 'true'}, {'number': '3', 'ReferenceId': '24508104', 'FullCitation': 'André F, et al. Lancet Oncol. (2014) pmid: 24508104', 'Include': 'true'}, {'number': '4', 'ReferenceId': '24265351', 'FullCitation': 'Dienstmann R, et al. Ann. Oncol. (2014) pmid: 24265351', 'Include': 'true'}, {'number': '5', 'ReferenceId': '24185513', 'FullCitation': 'Chan_On W, et al. Nat. Genet. (2013) pmid: 24185513', 'Include': 'true'}, {'number': '6', 'ReferenceId': '22561520', 'FullCitation': 'Ong CK, et al. Nat. Genet. (2012) pmid: 22561520', 'Include': 'true'}, {'number': '7', 'ReferenceId': '24185509', 'FullCitation': 'Jiao Y, et al. Nat. Genet. (2013) pmid: 24185509', 'Include': 'true'}, {'number': '8', 'ReferenceId': '24563076', 'FullCitation': 'Ross JS, et al. Oncologist (2014) pmid: 24563076', 'Include': 'true'}, {'number': '9', 'ReferenceId': '26258846', 'FullCitation': 'Nakamura H, et al. Nat. Genet. (2015) pmid: 26258846', 'Include': 'true'}, {'number': '10', 'ReferenceId': '26500333', 'FullCitation': 'Lee H, et al. J. Clin. Pathol. (2016) pmid: 26500333', 'Include': 'true'}, {'number': '11', 'ReferenceId': '27622582', 'FullCitation': 'Javle M, et al. Cancer (2016) pmid: 27622582', 'Include': 'true'}, {'number': '12', 'ReferenceId': '24550739', 'FullCitation': 'Borad MJ, et al. PLoS Genet. (2014) pmid: 24550739', 'Include': 'true'}, {'number': '13', 'ReferenceId': '24122810', 'FullCitation': 'Arai Y, et al. Hepatology (2014) pmid: 24122810', 'Include': 'true'}, {'number': '14', 'ReferenceId': '25608663', 'FullCitation': 'Sia D, et al. Nat Commun (2015) pmid: 25608663', 'Include': 'true'}, {'number': '15', 'ReferenceId': '31340094', 'FullCitation': 'Loriot Y, et al. N. Engl. J. Med. (2019) pmid: 31340094', 'Include': 'true'}, {'number': '16', 'ReferenceId': '26324363', 'FullCitation': 'Tabernero J, et al. J. Clin. Oncol. (2015) pmid: 26324363', 'Include': 'true'}, {'number': '17', 'ReferenceId': '28416604', 'FullCitation': 'Karkera JD, et al. Mol. Cancer Ther. (2017) pmid: 28416604', 'Include': 'true'}, {'number': '18', 'ReferenceId': '29848605', 'FullCitation': 'Pal SK, et al. Cancer Discov (2018) pmid: 29848605', 'Include': 'true'}, {'number': '19', 'ReferenceId': '32208524', 'FullCitation': 'Pal SK, et al. Cancer (2020) pmid: 32208524', 'Include': 'true'}, {'number': '20', 'ReferenceId': '32622884', 'FullCitation': 'Bahleda R, et al. Ann Oncol (2020) pmid: 32622884', 'Include': 'true'}, {'number': '21', 'ReferenceId': '34551969', 'FullCitation': 'Meric_Bernstam F, et al. Cancer Discov (2022) pmid: 34551969', 'Include': 'true'}, {'number': '22', 'ReferenceId': '32649766', 'FullCitation': 'Kasbekar M, et al. Blood Adv (2020) pmid: 32649766', 'Include': 'true'}, {'number': '23', 'ReferenceId': '31405822', 'FullCitation': 'Schuler M, et al. Lancet Oncol. (2019) pmid: 31405822', 'Include': 'true'}, {'number': '24', 'ReferenceId': '34250399', 'FullCitation': 'Farouk Sait S, et al. JCO Precis Oncol (2021) pmid: 34250399', 'Include': 'true'}, {'number': '25', 'ReferenceId': '30745300', 'FullCitation': 'Voss MH, et al. Clin. Cancer Res. (2019) pmid: 30745300', 'Include': 'true'}, {'number': '26', 'ReferenceId': '28972963', 'FullCitation': 'Papadopoulos KP, et al. Br. J. Cancer (2017) pmid: 28972963', 'Include': 'true'}, {'number': '27', 'ReferenceId': '29223982', 'FullCitation': 'Cheng FT, et al. J Natl Compr Canc Netw (2017) pmid: 29223982', 'Include': 'true'}, {'number': '28', 'ReferenceId': '26055304', 'FullCitation': 'Khodadoust MS, et al. Leukemia (2016) pmid: 26055304', 'Include': 'true'}, {'number': '29', 'ReferenceId': '31434701', 'FullCitation': 'Tanasi I, et al. Blood (2019) pmid: 31434701', 'Include': 'true'}, {'number': '30', 'ReferenceId': '29119847', 'FullCitation': 'Strati P, et al. Leuk. Lymphoma (2018) pmid: 29119847', 'Include': 'true'}, {'number': '31', 'ReferenceId': '27870574', 'FullCitation': 'Nogova L, et al. J. Clin. Oncol. (2017) pmid: 27870574', 'Include': 'true'}, {'number': '32', 'ReferenceId': '31195180', 'FullCitation': 'Aggarwal C, et al. J Thorac Oncol (2019) pmid: 31195180', 'Include': 'true'}, {'number': '33', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '34', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '35', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '36', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '37', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '38', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '39', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '40', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '41', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '42', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '43', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '44', 'ReferenceId': '30082870', 'FullCitation': 'Gandara DR, et al. Nat. Med. (2018) pmid: 30082870', 'Include': 'true'}, {'number': '45', 'ReferenceId': '30816954', 'FullCitation': 'Wang Z, et al. JAMA Oncol (2019) pmid: 30816954', 'Include': 'true'}, {'number': '46', 'ReferenceId': '32102950', 'FullCitation': 'Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950', 'Include': 'true'}, {'number': '47', 'ReferenceId': '33119110', 'FullCitation': 'Shao C, et al. JAMA Netw Open (2020) pmid: 33119110', 'Include': 'true'}, {'number': '48', 'ReferenceId': '35274716', 'FullCitation': 'Sturgill EG, et al. Oncologist (2022) pmid: 35274716', 'Include': 'true'}, {'number': '49', 'ReferenceId': '16337594', 'FullCitation': 'Sdek P, et al. Mol. Cell (2005) pmid: 16337594', 'Include': 'true'}, {'number': '50', 'ReferenceId': '15632057', 'FullCitation': 'Brady M, et al. Mol. Cell. Biol. (2005) pmid: 15632057', 'Include': 'true'}, {'number': '51', 'ReferenceId': '15053880', 'FullCitation': 'Li M, et al. Mol. Cell (2004) pmid: 15053880', 'Include': 'true'}, {'number': '52', 'ReferenceId': '19935675', 'FullCitation': 'Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675', 'Include': 'true'}, {'number': '53', 'ReferenceId': '8306343', 'FullCitation': 'Cordon_Cardo C, et al. Cancer Res. (1994) pmid: 8306343', 'Include': 'true'}, {'number': '54', 'ReferenceId': '20164920', 'FullCitation': 'Beroukhim R, et al. Nature (2010) pmid: 20164920', 'Include': 'true'}, {'number': '55', 'ReferenceId': '28351930', 'FullCitation': 'Kato S, et al. Clin. Cancer Res. (2017) pmid: 28351930', 'Include': 'true'}, {'number': '56', 'ReferenceId': '29337640', 'FullCitation': 'Rizvi H, et al. J. Clin. Oncol. (2018) pmid: 29337640', 'Include': 'true'}, {'number': '57', 'ReferenceId': '30427539', 'FullCitation': 'Narayan RR, et al. Cancer (2019) pmid: 30427539', 'Include': 'true'}, {'number': '58', 'ReferenceId': '29848569', 'FullCitation': 'Lowery MA, et al. Clin. Cancer Res. (2018) pmid: 29848569', 'Include': 'true'}, {'number': '59', 'ReferenceId': '33765338', 'FullCitation': 'Boerner T, et al. Hepatology (2021) pmid: 33765338', 'Include': 'true'}, {'number': '60', 'ReferenceId': '11580146', 'FullCitation': 'Momoi H, et al. J. Hepatol. (2001) pmid: 11580146', 'Include': 'true'}, {'number': '61', 'ReferenceId': '10963376', 'FullCitation': 'Horie S, et al. Virchows Arch. (2000) pmid: 10963376', 'Include': 'true'}, {'number': '62', 'ReferenceId': '16505435', 'FullCitation': 'Jarnagin WR, et al. J. Clin. Oncol. (2006) pmid: 16505435', 'Include': 'true'}, {'number': '63', 'ReferenceId': '10718212', 'FullCitation': 'Della Torre G, et al. Diagn. Mol. Pathol. (2000) pmid: 10718212', 'Include': 'true'}, {'number': '64', 'ReferenceId': '21404460', 'FullCitation': 'Grochola LF, et al. Pancreas (2011) pmid: 21404460', 'Include': 'true'}, {'number': '65', 'ReferenceId': '20975744', 'FullCitation': 'Cheok CF, et al. Nat Rev Clin Oncol (2011) pmid: 20975744', 'Include': 'true'}, {'number': '66', 'ReferenceId': '23165797', 'FullCitation': 'Ohnstad HO, et al. Cancer (2013) pmid: 23165797', 'Include': 'true'}, {'number': '67', 'ReferenceId': '21725357', 'FullCitation': 'Gamble LD, et al. Oncogene (2012) pmid: 21725357', 'Include': 'true'}, {'number': '68', 'ReferenceId': '15261145', 'FullCitation': 'Shaw RJ, et al. Cancer Cell (2004) pmid: 15261145', 'Include': 'true'}, {'number': '69', 'ReferenceId': '20541700', 'FullCitation': 'Carretero J, et al. Cancer Cell (2010) pmid: 20541700', 'Include': 'true'}, {'number': '70', 'ReferenceId': '21926085', 'FullCitation': 'Ollila S, et al. J Mol Cell Biol (2011) pmid: 21926085', 'Include': 'true'}, {'number': '71', 'ReferenceId': '16407837', 'FullCitation': 'Qiu W, et al. Oncogene (2006) pmid: 16407837', 'Include': 'true'}, {'number': '72', 'ReferenceId': '9837816', 'FullCitation': 'Mehenni H, et al. Am. J. Hum. Genet. (1998) pmid: 9837816', 'Include': 'true'}, {'number': '73', 'ReferenceId': '11430832', 'FullCitation': 'Karuman P, et al. Mol. Cell (2001) pmid: 11430832', 'Include': 'true'}, {'number': '74', 'ReferenceId': '12805220', 'FullCitation': 'Baas AF, et al. EMBO J. (2003) pmid: 12805220', 'Include': 'true'}, {'number': '75', 'ReferenceId': '17108107', 'FullCitation': 'Zeng PY, et al. Cancer Res. (2006) pmid: 17108107', 'Include': 'true'}, {'number': '76', 'ReferenceId': '15561763', 'FullCitation': 'Boudeau J, et al. J. Cell. Sci. (2004) pmid: 15561763', 'Include': 'true'}, {'number': '77', 'ReferenceId': '17575127', 'FullCitation': 'Scott KD, et al. Cancer Res. (2007) pmid: 17575127', 'Include': 'true'}, {'number': '78', 'ReferenceId': '19414597', 'FullCitation': 'Xie Z, et al. Mol. Cell. Biol. (2009) pmid: 19414597', 'Include': 'true'}, {'number': '79', 'ReferenceId': '12552571', 'FullCitation': 'Boudeau J, et al. Hum. Mutat. (2003) pmid: 12552571', 'Include': 'true'}, {'number': '80', 'ReferenceId': '15800014', 'FullCitation': 'Forcet C, et al. Hum. Mol. Genet. (2005) pmid: 15800014', 'Include': 'true'}, {'number': '81', 'ReferenceId': '25960268', 'FullCitation': 'Zhang L, et al. Sci Rep (2015) pmid: 25960268', 'Include': 'true'}, {'number': '82', 'ReferenceId': '27478040', 'FullCitation': 'Berger AH, et al. Cancer Cell (2016) pmid: 27478040', 'Include': 'true'}, {'number': '83', 'ReferenceId': '34849607', 'FullCitation': 'Donnelly LL, et al. Carcinogenesis (2021) pmid: 34849607', 'Include': 'true'}, {'number': '84', 'ReferenceId': '30371878', 'FullCitation': 'Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878', 'Include': 'true'}, {'number': '85', 'ReferenceId': '11389158', 'FullCitation': 'Olschwang S, et al. J. Med. Genet. (2001) pmid: 11389158', 'Include': 'true'}, {'number': '86', 'ReferenceId': '10362809', 'FullCitation': 'Su GH, et al. Am. J. Pathol. (1999) pmid: 10362809', 'Include': 'true'}, {'number': '87', 'ReferenceId': '12861065', 'FullCitation': 'Sahin F, et al. Mod. Pathol. (2003) pmid: 12861065', 'Include': 'true'}, {'number': '88', 'ReferenceId': '26056085', 'FullCitation': 'Wang J, et al. Oncotarget (2015) pmid: 26056085', 'Include': 'true'}, {'number': '89', 'ReferenceId': '17676035', 'FullCitation': 'Ji H, et al. Nature (2007) pmid: 17676035', 'Include': 'true'}, {'number': '90', 'ReferenceId': '18245476', 'FullCitation': 'Contreras CM, et al. Cancer Res. (2008) pmid: 18245476', 'Include': 'true'}, {'number': '91', 'ReferenceId': '18172296', 'FullCitation': 'Gurumurthy S, et al. Cancer Res. (2008) pmid: 18172296', 'Include': 'true'}, {'number': '92', 'ReferenceId': '19541609', 'FullCitation': 'Shackelford DB, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19541609', 'Include': 'true'}, {'number': '93', 'ReferenceId': '21189378', 'FullCitation': 'Klümpen HJ, et al. J. Clin. Oncol. (2011) pmid: 21189378', 'Include': 'true'}, {'number': '94', 'ReferenceId': '23238879', 'FullCitation': 'Trédan O, et al. Target Oncol (2013) pmid: 23238879', 'Include': 'true'}, {'number': '95', 'ReferenceId': '29773717', 'FullCitation': 'Skoulidis F, et al. Cancer Discov (2018) pmid: 29773717', 'Include': 'true'}, {'number': '96', 'ReferenceId': '29657128', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128', 'Include': 'true'}, {'number': '97', 'ReferenceId': '27467949', 'FullCitation': 'Scheel AH, et al. Oncoimmunology (2016) pmid: 27467949', 'Include': 'true'}, {'number': '98', 'ReferenceId': '26069186', 'FullCitation': 'Skoulidis F, et al. Cancer Discov (2015) pmid: 26069186', 'Include': 'true'}, {'number': '99', 'ReferenceId': '26833127', 'FullCitation': 'Koyama S, et al. Cancer Res. (2016) pmid: 26833127', 'Include': 'true'}, {'number': '100', 'ReferenceId': '26477306', 'FullCitation': 'Schabath MB, et al. Oncogene (2016) pmid: 26477306', 'Include': 'true'}, {'number': '101', 'ReferenceId': '28039262', 'FullCitation': 'Dong ZY, et al. Clin. Cancer Res. (2017) pmid: 28039262', 'Include': 'true'}, {'number': '102', 'ReferenceId': '27687306', 'FullCitation': 'Kadara H, et al. Ann. Oncol. (2017) pmid: 27687306', 'Include': 'true'}, {'number': '103', 'ReferenceId': '27699275', 'FullCitation': 'Herter_Sprie GS, et al. JCI Insight (2016) pmid: 27699275', 'Include': 'true'}, {'number': '104', 'ReferenceId': '15121768', 'FullCitation': 'Amos CI, et al. J. Med. Genet. (2004) pmid: 15121768', 'Include': 'true'}, {'number': '105', 'ReferenceId': '16707622', 'FullCitation': 'Hearle N, et al. Clin. Cancer Res. (2006) pmid: 16707622', 'Include': 'true'}, {'number': '106', 'ReferenceId': '21336636', 'FullCitation': 'van der Groep P, et al. Cell Oncol (Dordr) (2011) pmid: 21336636', 'Include': 'true'}, {'number': '107', 'ReferenceId': '15147722', 'FullCitation': 'Möröy T, et al. Int. J. Biochem. Cell Biol. (2004) pmid: 15147722', 'Include': 'true'}, {'number': '108', 'ReferenceId': '16575401', 'FullCitation': 'Leung SY, et al. Mod. Pathol. (2006) pmid: 16575401', 'Include': 'true'}, {'number': '109', 'ReferenceId': '11156406', 'FullCitation': 'Lin L, et al. Cancer Res. (2000) pmid: 11156406', 'Include': 'true'}, {'number': '110', 'ReferenceId': '16753589', 'FullCitation': 'Mayr D, et al. Am. J. Clin. Pathol. (2006) pmid: 16753589', 'Include': 'true'}, {'number': '111', 'ReferenceId': '20336784', 'FullCitation': 'Nakayama N, et al. Cancer (2010) pmid: 20336784', 'Include': 'true'}, {'number': '112', 'ReferenceId': '21176227', 'FullCitation': 'Stamatakos M, et al. World J Surg Oncol (2010) pmid: 21176227', 'Include': 'true'}, {'number': '113', 'ReferenceId': '29625050', 'FullCitation': 'Sanchez_Vega F, et al. Cell (2018) pmid: 29625050', 'Include': 'true'}, {'number': '114', 'ReferenceId': '28331049', 'FullCitation': 'Lin AB, et al. Clin. Cancer Res. (2017) pmid: 28331049', 'Include': 'true'}, {'number': '115', 'ReferenceId': '30181387', 'FullCitation': 'Chen X, et al. Clin Cancer Res (2018) pmid: 30181387', 'Include': 'true'}, {'number': '116', 'ReferenceId': '29361470', 'FullCitation': 'Lee JM, et al. Lancet Oncol. (2018) pmid: 29361470', 'Include': 'true'}, {'number': '117', 'ReferenceId': '33485453', 'FullCitation': 'Lheureux S, et al. Lancet (2021) pmid: 33485453', 'Include': 'true'}, {'number': '118', 'ReferenceId': '32611648', 'FullCitation': 'Oza AM, et al. Clin Cancer Res (2020) pmid: 32611648', 'Include': 'true'}, {'number': '119', 'ReferenceId': '21552262', 'FullCitation': 'Toledo LI, et al. Nat. Struct. Mol. Biol. (2011) pmid: 21552262', 'Include': 'true'}, {'number': '120', 'ReferenceId': '26365377', 'FullCitation': 'Buisson R, et al. Mol. Cell (2015) pmid: 26365377', 'Include': 'true'}, {'number': '121', 'ReferenceId': '26204491', 'FullCitation': 'Yang L, et al. Oncotarget (2015) pmid: 26204491', 'Include': 'true'}, {'number': '122', 'ReferenceId': '33028815', 'FullCitation': 'Kok YP, et al. Oncogenesis (2020) pmid: 33028815', 'Include': 'true'}, {'number': '123', 'ReferenceId': '25557169', 'FullCitation': 'Taylor_Harding B, et al. Oncotarget (2015) pmid: 25557169', 'Include': 'true'}, {'number': '124', 'ReferenceId': '24004674', 'FullCitation': 'Etemadmoghadam D, et al. Clin. Cancer Res. (2013) pmid: 24004674', 'Include': 'true'}, {'number': '125', 'ReferenceId': '21321214', 'FullCitation': 'Scaltriti M, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 21321214', 'Include': 'true'}, {'number': '126', 'ReferenceId': '21695458', 'FullCitation': 'Nanos_Webb A, et al. Breast Cancer Res. Treat. (2012) pmid: 21695458', 'Include': 'true'}, {'number': '127', 'ReferenceId': '23686769', 'FullCitation': 'Ma T, et al. Mol. Cancer Ther. (2013) pmid: 23686769', 'Include': 'true'}, {'number': '128', 'ReferenceId': '11237521', 'FullCitation': 'Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521', 'Include': 'true'}, {'number': '129', 'ReferenceId': '12857747', 'FullCitation': 'Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747', 'Include': 'true'}, {'number': '130', 'ReferenceId': '21828076', 'FullCitation': 'Rodríguez_Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076', 'Include': 'true'}, {'number': '131', 'ReferenceId': '23475934', 'FullCitation': 'He X, et al. Cancer Res. (2013) pmid: 23475934', 'Include': 'true'}, {'number': '132', 'ReferenceId': '10866302', 'FullCitation': 'Han SY, et al. Cancer Res. (2000) pmid: 10866302', 'Include': 'true'}, {'number': '133', 'ReferenceId': '9811831', 'FullCitation': 'Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831', 'Include': 'true'}, {'number': '134', 'ReferenceId': '24498881', 'FullCitation': 'Pradella LM, et al. BMC Cancer (2014) pmid: 24498881', 'Include': 'true'}, {'number': '135', 'ReferenceId': '21536651', 'FullCitation': 'Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651', 'Include': 'true'}, {'number': '136', 'ReferenceId': '17213812', 'FullCitation': 'Denning G, et al. Oncogene (2007) pmid: 17213812', 'Include': 'true'}, {'number': '137', 'ReferenceId': '16619501', 'FullCitation': 'Hlobilkova A, et al. Anticancer Res. () pmid: 16619501', 'Include': 'true'}, {'number': '138', 'ReferenceId': '20718038', 'FullCitation': 'Redfern RE, et al. Protein Sci. (2010) pmid: 20718038', 'Include': 'true'}, {'number': '139', 'ReferenceId': '22505997', 'FullCitation': 'Shenoy S, et al. PLoS ONE (2012) pmid: 22505997', 'Include': 'true'}, {'number': '140', 'ReferenceId': '19329485', 'FullCitation': 'Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485', 'Include': 'true'}, {'number': '141', 'ReferenceId': '16829519', 'FullCitation': 'Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519', 'Include': 'true'}, {'number': '142', 'ReferenceId': '10555148', 'FullCitation': 'Lee JO, et al. Cell (1999) pmid: 10555148', 'Include': 'true'}, {'number': '143', 'ReferenceId': '9635567', 'FullCitation': 'Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567', 'Include': 'true'}, {'number': '144', 'ReferenceId': '9865913', 'FullCitation': 'Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913', 'Include': 'true'}, {'number': '145', 'ReferenceId': '11051241', 'FullCitation': 'Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241', 'Include': 'true'}, {'number': '146', 'ReferenceId': '22891331', 'FullCitation': 'Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331', 'Include': 'true'}, {'number': '147', 'ReferenceId': '23066114', 'FullCitation': 'Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114', 'Include': 'true'}, {'number': '148', 'ReferenceId': '19457929', 'FullCitation': 'Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929', 'Include': 'true'}, {'number': '149', 'ReferenceId': '23995781', 'FullCitation': 'Liu J, et al. Oncogene (2014) pmid: 23995781', 'Include': 'true'}, {'number': '150', 'ReferenceId': '11395408', 'FullCitation': 'Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408', 'Include': 'true'}, {'number': '151', 'ReferenceId': '10807691', 'FullCitation': 'De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691', 'Include': 'true'}, {'number': '152', 'ReferenceId': '10051603', 'FullCitation': 'Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603', 'Include': 'true'}, {'number': '153', 'ReferenceId': '15988030', 'FullCitation': 'Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030', 'Include': 'true'}, {'number': '154', 'ReferenceId': '15026806', 'FullCitation': 'Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806', 'Include': 'true'}, {'number': '155', 'ReferenceId': '25875300', 'FullCitation': 'Gil A, et al. PLoS ONE (2015) pmid: 25875300', 'Include': 'true'}, {'number': '156', 'ReferenceId': '9823298', 'FullCitation': 'Furnari FB, et al. Cancer Res. (1998) pmid: 9823298', 'Include': 'true'}, {'number': '157', 'ReferenceId': '25527629', 'FullCitation': 'Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629', 'Include': 'true'}, {'number': '158', 'ReferenceId': '29706633', 'FullCitation': 'Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633', 'Include': 'true'}, {'number': '159', 'ReferenceId': '20538496', 'FullCitation': 'Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496', 'Include': 'true'}, {'number': '160', 'ReferenceId': '17942903', 'FullCitation': 'Andrés_Pons A, et al. Cancer Res. (2007) pmid: 17942903', 'Include': 'true'}, {'number': '161', 'ReferenceId': '15805158', 'FullCitation': 'Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158', 'Include': 'true'}, {'number': '162', 'ReferenceId': '10468583', 'FullCitation': 'Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583', 'Include': 'true'}, {'number': '163', 'ReferenceId': '12085208', 'FullCitation': 'Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208', 'Include': 'true'}, {'number': '164', 'ReferenceId': '24292679', 'FullCitation': 'Nguyen HN, et al. Oncogene (2014) pmid: 24292679', 'Include': 'true'}, {'number': '165', 'ReferenceId': '19114656', 'FullCitation': 'Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656', 'Include': 'true'}, {'number': '166', 'ReferenceId': '12808147', 'FullCitation': 'Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147', 'Include': 'true'}, {'number': '167', 'ReferenceId': '18498243', 'FullCitation': 'Wang X, et al. Biochem. J. (2008) pmid: 18498243', 'Include': 'true'}, {'number': '168', 'ReferenceId': '15951562', 'FullCitation': 'Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562', 'Include': 'true'}, {'number': '169', 'ReferenceId': '25263454', 'FullCitation': 'Nguyen HN, et al. Oncogene (2015) pmid: 25263454', 'Include': 'true'}, {'number': '170', 'ReferenceId': '32704382', 'FullCitation': 'Shan L, et al. Cell Discov (2020) pmid: 32704382', 'Include': 'true'}, {'number': '171', 'ReferenceId': '24186137', 'FullCitation': 'Jang S, et al. Mod. Pathol. (2014) pmid: 24186137', 'Include': 'true'}, {'number': '172', 'ReferenceId': '22844568', 'FullCitation': 'Kim JH, et al. Gut Liver (2012) pmid: 22844568', 'Include': 'true'}, {'number': '173', 'ReferenceId': '21719208', 'FullCitation': 'Liu DC, et al. Pathol. Res. Pract. (2011) pmid: 21719208', 'Include': 'true'}, {'number': '174', 'ReferenceId': '21874010', 'FullCitation': 'Lee D, et al. Mod. Pathol. (2012) pmid: 21874010', 'Include': 'true'}, {'number': '175', 'ReferenceId': '19147772', 'FullCitation': 'Chung JY, et al. Clin. Cancer Res. (2009) pmid: 19147772', 'Include': 'true'}, {'number': '176', 'ReferenceId': '20085938', 'FullCitation': 'Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938', 'Include': 'true'}, {'number': '177', 'ReferenceId': '27672108', 'FullCitation': 'Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108', 'Include': 'true'}, {'number': '178', 'ReferenceId': '28220839', 'FullCitation': 'Milella M, et al. Sci Rep (2017) pmid: 28220839', 'Include': 'true'}, {'number': '179', 'ReferenceId': '33289918', 'FullCitation': 'Tan ES, et al. Cancer (2021) pmid: 33289918', 'Include': 'true'}, {'number': '180', 'ReferenceId': '20049735', 'FullCitation': 'Mendes_Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735', 'Include': 'true'}, {'number': '181', 'ReferenceId': '23881923', 'FullCitation': 'Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923', 'Include': 'true'}, {'number': '182', 'ReferenceId': '23565244', 'FullCitation': 'Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244', 'Include': 'true'}, {'number': '183', 'ReferenceId': '26905328', 'FullCitation': 'McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328', 'Include': 'true'}, {'number': '184', 'ReferenceId': '21468130', 'FullCitation': 'Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130', 'Include': 'true'}, {'number': '185', 'ReferenceId': '33242536', 'FullCitation': 'Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536', 'Include': 'true'}, {'number': '186', 'ReferenceId': '33970096', 'FullCitation': 'Pan M, et al. Perm J (2021) pmid: 33970096', 'Include': 'true'}, {'number': '187', 'ReferenceId': '23810788', 'FullCitation': 'Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788', 'Include': 'true'}, {'number': '188', 'ReferenceId': '32988624', 'FullCitation': 'Romero I, et al. Gynecol Oncol (2020) pmid: 32988624', 'Include': 'true'}, {'number': '189', 'ReferenceId': '29165669', 'FullCitation': 'Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669', 'Include': 'true'}, {'number': '190', 'ReferenceId': '18781191', 'FullCitation': 'Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191', 'Include': 'true'}, {'number': '191', 'ReferenceId': '18794875', 'FullCitation': 'Orloff MS, et al. Oncogene (2008) pmid: 18794875', 'Include': 'true'}, {'number': '192', 'ReferenceId': '17167516', 'FullCitation': 'Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516', 'Include': 'true'}, {'number': '193', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '194', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '195', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '196', 'ReferenceId': '12175538', 'FullCitation': 'Limpaiboon T, et al. Cancer Lett. (2002) pmid: 12175538', 'Include': 'true'}, {'number': '197', 'ReferenceId': '12402306', 'FullCitation': 'Liu D, et al. Int. J. Cancer (2002) pmid: 12402306', 'Include': 'true'}, {'number': '198', 'ReferenceId': '14506736', 'FullCitation': 'Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736', 'Include': 'true'}, {'number': '199', 'ReferenceId': '17204026', 'FullCitation': 'Histopathology (2007) pmid: 17204026', 'Include': 'true'}, {'number': '200', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '201', 'ReferenceId': '28734759', 'FullCitation': 'Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759', 'Include': 'true'}, {'number': '202', 'ReferenceId': '29355075', 'FullCitation': 'Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075', 'Include': 'true'}, {'number': '203', 'ReferenceId': '35322232', 'FullCitation': 'Shitara K, et al. Nature (2022) pmid: 35322232', 'Include': 'true'}, {'number': '204', 'ReferenceId': '23169436', 'FullCitation': 'Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436', 'Include': 'true'}, {'number': '205', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '206', 'ReferenceId': '33001143', 'FullCitation': 'Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143', 'Include': 'true'}, {'number': '207', 'ReferenceId': '15094156', 'FullCitation': 'Pearce ST, et al. Crit. Rev. Oncol. Hematol. (2004) pmid: 15094156', 'Include': 'true'}, {'number': '208', 'ReferenceId': '28560298', 'FullCitation': 'Straubhar A, et al. Gynecol Oncol Rep (2017) pmid: 28560298', 'Include': 'true'}, {'number': '209', 'ReferenceId': '24076063', 'FullCitation': 'Thangavelu A, et al. Gynecol. Oncol. (2013) pmid: 24076063', 'Include': 'true'}, {'number': '210', 'ReferenceId': '28221866', 'FullCitation': 'Gershenson DM, et al. J. Clin. Oncol. (2017) pmid: 28221866', 'Include': 'true'}, {'number': '211', 'ReferenceId': '24925537', 'FullCitation': 'Esfahani K, et al. BMJ Case Rep (2014) pmid: 24925537', 'Include': 'true'}, {'number': '212', 'ReferenceId': '18457865', 'FullCitation': 'Ramirez PT, et al. Gynecol. Oncol. (2008) pmid: 18457865', 'Include': 'true'}, {'number': '213', 'ReferenceId': '30345905', 'FullCitation': 'Turner NC, et al. N. Engl. J. Med. (2018) pmid: 30345905', 'Include': 'true'}, {'number': '214', 'ReferenceId': '20436459', 'FullCitation': 'Scheuermann JC, et al. Nature (2010) pmid: 20436459', 'Include': 'true'}, {'number': '215', 'ReferenceId': '16606617', 'FullCitation': 'Cho YS, et al. J. Biol. Chem. (2006) pmid: 16606617', 'Include': 'true'}, {'number': '216', 'ReferenceId': '21047783', 'FullCitation': 'Park UH, et al. J. Biol. Chem. (2011) pmid: 21047783', 'Include': 'true'}, {'number': '217', 'ReferenceId': '24216483', 'FullCitation': 'Inoue D, et al. J. Clin. Invest. (2013) pmid: 24216483', 'Include': 'true'}, {'number': '218', 'ReferenceId': '22897849', 'FullCitation': 'Abdel_Wahab O, et al. Cancer Cell (2012) pmid: 22897849', 'Include': 'true'}, {'number': '219', 'ReferenceId': '23736028', 'FullCitation': 'Br. J. Cancer (2013) pmid: 23736028', 'Include': 'true'}, {'number': '220', 'ReferenceId': '28481359', 'FullCitation': 'Zehir A, et al. Nat. Med. (2017) pmid: 28481359', 'Include': 'true'}, {'number': '221', 'ReferenceId': '29625053', 'FullCitation': 'Bailey MH, et al. Cell (2018) pmid: 29625053', 'Include': 'true'}, {'number': '222', 'ReferenceId': '33106634', 'FullCitation': 'Bolton KL, et al. Nat Genet (2020) pmid: 33106634', 'Include': 'true'}, {'number': '223', 'ReferenceId': '25426837', 'FullCitation': 'Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837', 'Include': 'true'}, {'number': '224', 'ReferenceId': '25426838', 'FullCitation': 'Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838', 'Include': 'true'}, {'number': '225', 'ReferenceId': '25326804', 'FullCitation': 'Xie M, et al. Nat. Med. (2014) pmid: 25326804', 'Include': 'true'}, {'number': '226', 'ReferenceId': '28669404', 'FullCitation': 'Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404', 'Include': 'true'}, {'number': '227', 'ReferenceId': '29678827', 'FullCitation': 'Severson EA, et al. Blood (2018) pmid: 29678827', 'Include': 'true'}, {'number': '228', 'ReferenceId': '29420212', 'FullCitation': 'Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212', 'Include': 'true'}, {'number': '229', 'ReferenceId': '30504320', 'FullCitation': 'Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320', 'Include': 'true'}, {'number': '230', 'ReferenceId': '32269342', 'FullCitation': 'Chabon JJ, et al. Nature (2020) pmid: 32269342', 'Include': 'true'}, {'number': '231', 'ReferenceId': '31768066', 'FullCitation': 'Razavi P, et al. Nat. Med. (2019) pmid: 31768066', 'Include': 'true'}, {'number': '232', 'ReferenceId': '21326324', 'FullCitation': 'Xu H, et al. Nat. Rev. Cancer (2011) pmid: 21326324', 'Include': 'true'}, {'number': '233', 'ReferenceId': '27207471', 'FullCitation': 'Hill VK, et al. Biochim. Biophys. Acta (2016) pmid: 27207471', 'Include': 'true'}, {'number': '234', 'ReferenceId': '24856830', 'FullCitation': 'Solomon DA, et al. BMB Rep (2014) pmid: 24856830', 'Include': 'true'}, {'number': '235', 'ReferenceId': '19906707', 'FullCitation': 'Bauerschmidt C, et al. Nucleic Acids Res. (2010) pmid: 19906707', 'Include': 'true'}, {'number': '236', 'ReferenceId': '26420833', 'FullCitation': 'Yun J, et al. Nucleic Acids Res. (2016) pmid: 26420833', 'Include': 'true'}, {'number': '237', 'ReferenceId': '27326661', 'FullCitation': 'Gelot C, et al. Nucleus (2016) pmid: 27326661', 'Include': 'true'}, {'number': '238', 'ReferenceId': '22537934', 'FullCitation': 'Yan M, et al. Breast Cancer Res. (2012) pmid: 22537934', 'Include': 'true'}, {'number': '239', 'ReferenceId': '24185899', 'FullCitation': 'Sofueva S, et al. EMBO J. (2013) pmid: 24185899', 'Include': 'true'}, {'number': '240', 'ReferenceId': '23010778', 'FullCitation': 'Deng Z, et al. EMBO J. (2012) pmid: 23010778', 'Include': 'true'}, {'number': '241', 'ReferenceId': '27466323', 'FullCitation': 'Yun J, et al. EMBO Rep. (2016) pmid: 27466323', 'Include': 'true'}, {'number': '242', 'ReferenceId': '21255398', 'FullCitation': 'Xu H, et al. Breast Cancer Res. (2011) pmid: 21255398', 'Include': 'true'}, {'number': '243', 'ReferenceId': '24148822', 'FullCitation': 'Mahmood SF, et al. Carcinogenesis (2014) pmid: 24148822', 'Include': 'true'}, {'number': '244', 'ReferenceId': '23205091', 'FullCitation': 'Supernat A, et al. Oncol Lett (2012) pmid: 23205091', 'Include': 'true'}, {'number': '245', 'ReferenceId': '35227290', 'FullCitation': 'Sharaf R, et al. Genome Med (2022) pmid: 35227290', 'Include': 'true'}, {'number': '246', 'ReferenceId': '33766983', 'FullCitation': 'Su XA, et al. Genes Dev (2021) pmid: 33766983', 'Include': 'true'}, {'number': '247', 'ReferenceId': '24548858', 'FullCitation': 'Deb S, et al. Br. J. Cancer (2014) pmid: 24548858', 'Include': 'true'}, {'number': '248', 'ReferenceId': '21635707', 'FullCitation': 'Bazarov AV, et al. Breast Cancer Res. (2011) pmid: 21635707', 'Include': 'true'}, {'number': '249', 'ReferenceId': '21328542', 'FullCitation': 'Sircoulomb F, et al. EMBO Mol Med (2011) pmid: 21328542', 'Include': 'true'}, {'number': '250', 'ReferenceId': '21337521', 'FullCitation': 'Holland DG, et al. EMBO Mol Med (2011) pmid: 21337521', 'Include': 'true'}, {'number': '251', 'ReferenceId': '21317240', 'FullCitation': 'Slorach EM, et al. Genes Dev. (2011) pmid: 21317240', 'Include': 'true'}, {'number': '252', 'ReferenceId': '24156016', 'FullCitation': 'Reynisdottir I, et al. Cancer Med (2013) pmid: 24156016', 'Include': 'true'}, {'number': '253', 'ReferenceId': '24481460', 'FullCitation': 'Yang G, et al. Oncol. Rep. (2014) pmid: 24481460', 'Include': 'true'}, {'number': '254', 'ReferenceId': '25017610', 'FullCitation': 'Ma F, et al. Oncol. Rep. (2014) pmid: 25017610', 'Include': 'true'}, {'number': '255', 'ReferenceId': '22588877', 'FullCitation': 'Cerami E, et al. Cancer Discov (2012) pmid: 22588877', 'Include': 'true'}, {'number': '256', 'ReferenceId': '23550210', 'FullCitation': 'Gao J, et al. Sci Signal (2013) pmid: 23550210', 'Include': 'true'}, {'number': '257', 'ReferenceId': '23991038', 'FullCitation': 'Zhang X, et al. PLoS ONE (2013) pmid: 23991038', 'Include': 'true'}, {'number': '258', 'ReferenceId': '18650841', 'FullCitation': 'Burkhart DL, et al. Nat. Rev. Cancer (2008) pmid: 18650841', 'Include': 'true'}, {'number': '259', 'ReferenceId': '19143056', 'FullCitation': 'Knudsen ES, et al. Nat. Rev. Cancer (2008) pmid: 19143056', 'Include': 'true'}, {'number': '260', 'ReferenceId': '11004673', 'FullCitation': 'Kawaki J, et al. Int. J. Cancer (2000) pmid: 11004673', 'Include': 'true'}, {'number': '261', 'ReferenceId': '12378511', 'FullCitation': 'Kang YK, et al. Hum. Pathol. (2002) pmid: 12378511', 'Include': 'true'}, {'number': '262', 'ReferenceId': '12210082', 'FullCitation': 'Tannapfel A, et al. J. Pathol. (2002) pmid: 12210082', 'Include': 'true'}, {'number': '263', 'ReferenceId': '35120664', 'FullCitation': 'Nguyen B, et al. Cell (2022) pmid: 35120664', 'Include': 'true'}, {'number': '264', 'ReferenceId': '21750953', 'FullCitation': 'Boonjaraspinyo S, et al. Pathol. Oncol. Res. (2012) pmid: 21750953', 'Include': 'true'}, {'number': '265', 'ReferenceId': '22222631', 'FullCitation': 'Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631', 'Include': 'true'}, {'number': '266', 'ReferenceId': '30373917', 'FullCitation': 'Gong X, et al. Cancer Discov (2019) pmid: 30373917', 'Include': 'true'}, {'number': '267', 'ReferenceId': '30373918', 'FullCitation': 'Oser MG, et al. Cancer Discov (2019) pmid: 30373918', 'Include': 'true'}, {'number': '268', 'ReferenceId': '34741392', 'FullCitation': 'Yang W, et al. Kaohsiung J Med Sci (2022) pmid: 34741392', 'Include': 'true'}, {'number': '269', 'ReferenceId': '30232224', 'FullCitation': 'Beltran H, et al. Clin. Cancer Res. (2019) pmid: 30232224', 'Include': 'true'}, {'number': '270', 'ReferenceId': '21955141', 'FullCitation': 'Allaman_Pillet N, et al. Ophthalmic Genet. () pmid: 21955141', 'Include': 'true'}, {'number': '271', 'ReferenceId': '21875955', 'FullCitation': 'Viatour P, et al. J. Exp. Med. (2011) pmid: 21875955', 'Include': 'true'}, {'number': '272', 'ReferenceId': '24282159', 'FullCitation': 'Chen Z, et al. Hum. Mutat. (2014) pmid: 24282159', 'Include': 'true'}, {'number': '273', 'ReferenceId': '22553621', 'FullCitation': 'Yun J, et al. Int J Ophthalmol (2011) pmid: 22553621', 'Include': 'true'}, {'number': '274', 'ReferenceId': '21139478', 'FullCitation': 'Houston SK, et al. Int Ophthalmol Clin (2011) pmid: 21139478', 'Include': 'true'}, {'number': '275', 'ReferenceId': '19959033', 'FullCitation': 'Ng AK, et al. Semin Radiat Oncol (2010) pmid: 19959033', 'Include': 'true'}, {'number': '276', 'ReferenceId': '16682010', 'FullCitation': 'Kim SM, et al. Biochem. Biophys. Res. Commun. (2006) pmid: 16682010', 'Include': 'true'}, {'number': '277', 'ReferenceId': '23011637', 'FullCitation': 'Kang D, et al. Genes Chromosomes Cancer (2013) pmid: 23011637', 'Include': 'true'}, {'number': '278', 'ReferenceId': '24874471', 'FullCitation': 'Chen Y, et al. PLoS ONE (2014) pmid: 24874471', 'Include': 'true'}, {'number': '279', 'ReferenceId': '21664949', 'FullCitation': 'Morishita M, et al. Biochim. Biophys. Acta (2011) pmid: 21664949', 'Include': 'true'}, {'number': '280', 'ReferenceId': '22960745', 'FullCitation': 'Nature (2012) pmid: 22960745', 'Include': 'true'}, {'number': '281', 'ReferenceId': '26451490', 'FullCitation': 'Ciriello G, et al. Cell (2015) pmid: 26451490', 'Include': 'true'}, {'number': '282', 'ReferenceId': '24476821', 'FullCitation': 'Nature (2014) pmid: 24476821', 'Include': 'true'}, {'number': '283', 'ReferenceId': '25631445', 'FullCitation': 'Nature (2015) pmid: 25631445', 'Include': 'true'}, {'number': '284', 'ReferenceId': '28781807', 'FullCitation': 'Jones DH, et al. Mol Clin Oncol (2017) pmid: 28781807', 'Include': 'true'}, {'number': '285', 'ReferenceId': '19330029', 'FullCitation': 'van Haaften G, et al. Nat. Genet. (2009) pmid: 19330029', 'Include': 'true'}, {'number': '286', 'ReferenceId': '22722829', 'FullCitation': 'Robinson G, et al. Nature (2012) pmid: 22722829', 'Include': 'true'}, {'number': '287', 'ReferenceId': '23685749', 'FullCitation': 'Ho AS, et al. Nat. Genet. (2013) pmid: 23685749', 'Include': 'true'}, {'number': '288', 'ReferenceId': '22722839', 'FullCitation': 'Grasso CS, et al. Nature (2012) pmid: 22722839', 'Include': 'true'}, {'number': '289', 'ReferenceId': '25320243', 'FullCitation': 'Van der Meulen J, et al. Blood (2015) pmid: 25320243', 'Include': 'true'}, {'number': '290', 'ReferenceId': '23792809', 'FullCitation': 'Wang L, et al. Nat Commun (2013) pmid: 23792809', 'Include': 'true'}, {'number': '291', 'ReferenceId': '24491801', 'FullCitation': 'Kim JH, et al. Cancer Res. (2014) pmid: 24491801', 'Include': 'true'}, {'number': '292', 'ReferenceId': '23057811', 'FullCitation': 'Shen Y, et al. BMC Cancer (2012) pmid: 23057811', 'Include': 'true'}, {'number': '293', 'ReferenceId': '18410249', 'FullCitation': 'Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249', 'Include': 'true'}, {'number': '294', 'ReferenceId': '12826609', 'FullCitation': 'Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609', 'Include': 'true'}, {'number': '295', 'ReferenceId': '20978130', 'FullCitation': 'Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130', 'Include': 'true'}, {'number': '296', 'ReferenceId': '28472496', 'FullCitation': 'Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496', 'Include': 'true'}, {'number': '297', 'ReferenceId': '17690113', 'FullCitation': 'Yamada H, et al. Carcinogenesis (2007) pmid: 17690113', 'Include': 'true'}, {'number': '298', 'ReferenceId': '24997986', 'FullCitation': 'Li M, et al. Nat. Genet. (2014) pmid: 24997986', 'Include': 'true'}, {'number': '299', 'ReferenceId': '22180306', 'FullCitation': 'Borger DR, et al. Oncologist (2012) pmid: 22180306', 'Include': 'true'}, {'number': '300', 'ReferenceId': '10738270', 'FullCitation': 'Suto T, et al. J Surg Oncol (2000) pmid: 10738270', 'Include': 'true'}, {'number': '301', 'ReferenceId': '21538283', 'FullCitation': 'Nault JC, et al. Semin. Liver Dis. (2011) pmid: 21538283', 'Include': 'true'}, {'number': '302', 'ReferenceId': '20955617', 'FullCitation': 'Won HS, et al. BMC Cancer (2010) pmid: 20955617', 'Include': 'true'}, {'number': '303', 'ReferenceId': '16686942', 'FullCitation': 'Chaube A, et al. BMC Cancer (2006) pmid: 16686942', 'Include': 'true'}, {'number': '304', 'ReferenceId': '15573254', 'FullCitation': 'Chuang SC, et al. World J Surg (2004) pmid: 15573254', 'Include': 'true'}, {'number': '305', 'ReferenceId': '26717940', 'FullCitation': 'Ruzzenente A, et al. Ann. Surg. Oncol. (2016) pmid: 26717940', 'Include': 'true'}, {'number': '306', 'ReferenceId': '22230750', 'FullCitation': 'Xiaofang L, et al. World J Surg Oncol (2012) pmid: 22230750', 'Include': 'true'}, {'number': '307', 'ReferenceId': '8799388', 'FullCitation': 'Ajiki T, et al. Hepatogastroenterology () pmid: 8799388', 'Include': 'true'}, {'number': '308', 'ReferenceId': '16724348', 'FullCitation': 'J Surg Oncol (2006) pmid: 16724348', 'Include': 'true'}, {'number': '309', 'ReferenceId': '24746206', 'FullCitation': 'Guo R, et al. Hum. Pathol. (2014) pmid: 24746206', 'Include': 'true'}, {'number': '310', 'ReferenceId': '32020551', 'FullCitation': 'Conci S, et al. Updates Surg (2020) pmid: 32020551', 'Include': 'true'}, {'number': '311', 'ReferenceId': '29740198', 'FullCitation': 'Simbolo M, et al. Sci Rep (2018) pmid: 29740198', 'Include': 'true'}, {'number': '312', 'ReferenceId': '25536104', 'FullCitation': 'Churi CR, et al. PLoS ONE (2014) pmid: 25536104', 'Include': 'true'}, {'number': '313', 'ReferenceId': '7567135', 'FullCitation': 'Lee CS, et al. Pathology (1995) pmid: 7567135', 'Include': 'true'}, {'number': '314', 'ReferenceId': '11180865', 'FullCitation': 'Ahrendt SA, et al. J Hepatobiliary Pancreat Surg (2000) pmid: 11180865', 'Include': 'true'}, {'number': '315', 'ReferenceId': '20107315', 'FullCitation': 'Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315', 'Include': 'true'}, {'number': '316', 'ReferenceId': '21799033', 'FullCitation': 'Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033', 'Include': 'true'}, {'number': '317', 'ReferenceId': '21389100', 'FullCitation': 'Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100', 'Include': 'true'}, {'number': '318', 'ReferenceId': '25504633', 'FullCitation': 'Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633', 'Include': 'true'}, {'number': '319', 'ReferenceId': '12489850', 'FullCitation': 'Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850', 'Include': 'true'}, {'number': '320', 'ReferenceId': '11713371', 'FullCitation': 'Xu L, et al. Mol. Med. (2001) pmid: 11713371', 'Include': 'true'}, {'number': '321', 'ReferenceId': '23470564', 'FullCitation': 'Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564', 'Include': 'true'}, {'number': '322', 'ReferenceId': '25240597', 'FullCitation': 'Kim SS, et al. Nanomedicine (2015) pmid: 25240597', 'Include': 'true'}, {'number': '323', 'ReferenceId': '27357628', 'FullCitation': 'Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628', 'Include': 'true'}, {'number': '324', 'ReferenceId': '27601554', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554', 'Include': 'true'}, {'number': '325', 'ReferenceId': '27998224', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224', 'Include': 'true'}, {'number': '326', 'ReferenceId': '31315834', 'FullCitation': 'Lee J, et al. Cancer Discov (2019) pmid: 31315834', 'Include': 'true'}, {'number': '327', 'ReferenceId': '29535125', 'FullCitation': 'Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125', 'Include': 'true'}, {'number': '328', 'ReferenceId': '34538072', 'FullCitation': 'Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072', 'Include': 'true'}, {'number': '329', 'ReferenceId': '36084396', 'FullCitation': 'Park H, et al. ESMO Open (2022) pmid: 36084396', 'Include': 'true'}, {'number': '330', 'ReferenceId': '26014290', 'FullCitation': 'Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290', 'Include': 'true'}, {'number': '331', 'ReferenceId': '23355100', 'FullCitation': 'Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100', 'Include': 'true'}, {'number': '332', 'ReferenceId': '11219776', 'FullCitation': 'Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776', 'Include': 'true'}, {'number': '333', 'ReferenceId': '9006316', 'FullCitation': 'Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316', 'Include': 'true'}, {'number': '334', 'ReferenceId': '19204208', 'FullCitation': 'Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208', 'Include': 'true'}, {'number': '335', 'ReferenceId': '12672316', 'FullCitation': 'Lalloo F, et al. Lancet (2003) pmid: 12672316', 'Include': 'true'}, {'number': '336', 'ReferenceId': '31050713', 'FullCitation': 'Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713', 'Include': 'true'}, {'number': '337', 'ReferenceId': '31602320', 'FullCitation': 'Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320', 'Include': 'true'}, {'number': '338', 'ReferenceId': '32757294', 'FullCitation': 'Zhang EW, et al. Cancer (2020) pmid: 32757294', 'Include': 'true'}, {'number': '339', 'ReferenceId': '30833418', 'FullCitation': 'Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418', 'Include': 'true'}, {'number': '340', 'ReferenceId': '24553385', 'FullCitation': 'Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385', 'Include': 'true'}, {'number': '341', 'ReferenceId': '30400802', 'FullCitation': 'Lapin M, et al. J Transl Med (2018) pmid: 30400802', 'Include': 'true'}, {'number': '342', 'ReferenceId': '30131550', 'FullCitation': 'Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550', 'Include': 'true'}, {'number': '343', 'ReferenceId': '30385733', 'FullCitation': 'Choudhury AD, et al. JCI Insight (2018) pmid: 30385733', 'Include': 'true'}, {'number': '344', 'ReferenceId': '29298117', 'FullCitation': 'Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117', 'Include': 'true'}, {'number': '345', 'ReferenceId': '30793095', 'FullCitation': 'Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095', 'Include': 'true'}, {'number': '346', 'ReferenceId': '31059681', 'FullCitation': 'Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681', 'Include': 'true'}, {'number': '347', 'ReferenceId': '28187169', 'FullCitation': 'Fan G, et al. PLoS ONE (2017) pmid: 28187169', 'Include': 'true'}, {'number': '348', 'ReferenceId': '30923679', 'FullCitation': 'Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679', 'Include': 'true'}, {'number': '349', 'ReferenceId': '30093454', 'FullCitation': 'Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454', 'Include': 'true'}, {'number': '350', 'ReferenceId': '30860573', 'FullCitation': 'Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573', 'Include': 'true'}, {'number': '351', 'ReferenceId': '28450425', 'FullCitation': 'Goodall J, et al. Cancer Discov (2017) pmid: 28450425', 'Include': 'true'}, {'number': '352', 'ReferenceId': '29330207', 'FullCitation': 'Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207', 'Include': 'true'}, {'number': '353', 'ReferenceId': '32352498', 'FullCitation': 'Kim RD, et al. JAMA Oncol (2020) pmid: 32352498', 'Include': 'true'}, {'number': '354', 'ReferenceId': '31200359', 'FullCitation': 'Gbolahan O, et al. J Natl Compr Canc Netw (2019) pmid: 31200359', 'Include': 'true'}, {'number': '355', 'ReferenceId': '29863979', 'FullCitation': 'Migden MR, et al. N. Engl. J. Med. (2018) pmid: 29863979', 'Include': 'true'}, {'number': '356', 'ReferenceId': '29853658', 'FullCitation': 'Arkenau HT, et al. Oncologist (2018) pmid: 29853658', 'Include': 'true'}, {'number': '357', 'ReferenceId': '32729929', 'FullCitation': 'Klein O, et al. JAMA Oncol (2020) pmid: 32729929', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2022_10_04 18:28:07', 'OpName': 'Douglas A. Mata, MD, MPH | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Douglas A. Mata, MD, MPH | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': 'N/A'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': '18 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': '24%'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'LIVER', 'disease_ontology': 'Liver cholangiocarcinoma', 'flowcell_analysis': '2000023778', 'gender': 'male', 'pathology_diagnosis': 'Cholangiocarcinoma', 'pipeline_version': 'v3.14.0', 'purity_assessment': '40.9', 'specimen': 'ORD_1461672_01*US1401399.01', 'study': 'CLINICAL_F1LCDx', 'test_request': 'ORD_1461672_01', 'test_type': 'FoundationOneLiquidDx', 'tissue_of_origin': 'Blood', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'AB1', 'name': 'SQ_US1401399.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.174', 'cds_effect': '829G>A', 'depth': '1649', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CUL4A', 'percent_reads': '17.4', 'position': 'chr13:113897375', 'protein_effect': 'E277K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_003589', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.5588', 'cds_effect': '588G>T', 'depth': '5907', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATR', 'percent_reads': '55.88', 'position': 'chr3:142281656', 'protein_effect': 'L196F', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001184', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.4975', 'cds_effect': '514G>A', 'depth': '2207', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MST1R', 'percent_reads': '49.75', 'position': 'chr3:49940529', 'protein_effect': 'D172N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002447', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.1782', 'cds_effect': '165_1G>C', 'depth': '4035', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'PTEN', 'percent_reads': '17.82', 'position': 'chr10:89685269', 'protein_effect': 'splice site 165_1G>C', 'status': 'likely', 'strand': '+', 'transcript': 'NM_000314', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.5421', 'cds_effect': '2614G>C', 'depth': '2612', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MLL2', 'percent_reads': '54.21', 'position': 'chr12:49444852', 'protein_effect': 'G872R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003482', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.1672', 'cds_effect': '1022C>T', 'depth': '5222', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ESR1', 'percent_reads': '16.72', 'position': 'chr6:152265569', 'protein_effect': 'S341L', 'status': 'known', 'strand': '+', 'transcript': 'NM_000125', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.1956', 'cds_effect': '839G>C', 'depth': '5981', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TP53', 'percent_reads': '19.56', 'position': 'chr17:7577099', 'protein_effect': 'R280T', 'status': 'known', 'strand': '_', 'transcript': 'NM_000546', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.1589', 'cds_effect': '2094G>T', 'depth': '3914', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RB1', 'percent_reads': '15.89', 'position': 'chr13:49033957', 'protein_effect': 'R698S', 'status': 'known', 'strand': '+', 'transcript': 'NM_000321', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.0083', 'cds_effect': '3434T>C', 'depth': '4467', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ATR', 'percent_reads': '0.83', 'position': 'chr3:142261523', 'protein_effect': 'I1145T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001184', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.037', 'cds_effect': '293C>T', 'depth': '1188', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '3.7', 'position': 'chr2:212812283', 'protein_effect': 'P98L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.0864', 'cds_effect': '959C>T', 'depth': '822', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SMAD4', 'percent_reads': '8.64', 'position': 'chr18:48591796', 'protein_effect': 'P320L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005359', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.5781', 'cds_effect': '5A>T', 'depth': '1069', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'RARA', 'percent_reads': '57.81', 'position': 'chr17:38498961', 'protein_effect': 'Y2F', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001024809', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.0321', 'cds_effect': '1900_1922del23', 'depth': '2462', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'ASXL1', 'percent_reads': '3.21', 'position': 'chr20:31022414', 'protein_effect': 'E635fs*15', 'status': 'known', 'strand': '+', 'transcript': 'NM_015338', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.0956', 'cds_effect': '1637T>C', 'depth': '2384', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGFR4', 'percent_reads': '9.56', 'position': 'chr5:176522540', 'protein_effect': 'L546P', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_213647', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.0084', 'cds_effect': '2164G>A', 'depth': '948', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PTPRO', 'percent_reads': '0.84', 'position': 'chr12:15679196', 'protein_effect': 'E722K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_030667', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.1835', 'cds_effect': '163G>A', 'depth': '1335', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GRM3', 'percent_reads': '18.35', 'position': 'chr7:86394624', 'protein_effect': 'E55K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000840', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.2135', 'cds_effect': '471_472delCT', 'depth': '4702', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'STK11', 'percent_reads': '21.35', 'position': 'chr19:1220377', 'protein_effect': 'F157fs*5', 'status': 'likely', 'strand': '+', 'transcript': 'NM_000455', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.3072', 'cds_effect': '4051C>T', 'depth': '319', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'KDM6A', 'percent_reads': '30.72', 'position': 'chrX:44969369', 'protein_effect': 'R1351*', 'status': 'likely', 'strand': '+', 'transcript': 'NM_021140', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.0031', 'cds_effect': '1348delC', 'depth': '1604', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'RAD21', 'percent_reads': '0.31', 'position': 'chr8:117864308', 'protein_effect': 'R450fs*6', 'status': 'likely', 'strand': '_', 'transcript': 'NM_006265', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.1897', 'cds_effect': '274C>T', 'depth': '601', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SMAD4', 'percent_reads': '18.97', 'position': 'chr18:48575080', 'protein_effect': 'H92Y', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005359', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.0049', 'cds_effect': '1076T>A', 'depth': '6552', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERRFI1', 'percent_reads': '0.49', 'position': 'chr1:8073583', 'protein_effect': 'V359D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_018948', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'allele_fraction': '0.0422', 'cds_effect': '1021T>C', 'depth': '1304', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ALOX12B', 'percent_reads': '4.22', 'position': 'chr17:7982764', 'protein_effect': 'C341R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001139', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}]}, 'copy_number_alterations': {'copy_number_alteration': [{'copy_number': '7', 'equivocal': 'true', 'gene': 'WHSC1L1', 'number_of_exons': '23 of 23', 'position': 'chr8:38133159_38205689', 'ratio': '1.39', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'copy_number': '13', 'equivocal': 'false', 'gene': 'MDM2', 'number_of_exons': '9 of 11', 'position': 'chr12:69207306_69277205', 'ratio': '2.17', 'status': 'known', 'type': 'amplification'}, {'copy_number': '28', 'equivocal': 'false', 'gene': 'CCNE1', 'number_of_exons': '10 of 10', 'position': 'chr19:30253918_30360638', 'ratio': '4.23', 'status': 'known', 'type': 'amplification'}, {'copy_number': '7', 'equivocal': 'true', 'gene': 'ZNF703', 'number_of_exons': '2 of 2', 'position': 'chr8:37553497_37556192', 'ratio': '1.35', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'copy_number': '7', 'equivocal': 'true', 'gene': 'FGFR1', 'number_of_exons': '18 of 18', 'position': 'chr8:38226104_38363070', 'ratio': '1.42', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}]}, 'rearrangements': None, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '17.7', 'status': 'intermediate', 'unit': 'mutations_per_megabase'}}, 'non_human_content': {'non_human': [{'organism': 'HPV_16', 'reads_per_million': '47', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'organism': 'HHV_4', 'reads_per_million': '60', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}, {'organism': 'HHV_8', 'reads_per_million': '26', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1401399.01_1'}}]}}}}}	S111-97924          	PF22108             
12	466	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2022_00024318', 'CSN': None, 'TRF': 'ORD_1485630_01', 'MRN': '44954598', 'PhysicianId': '109266', 'NPI': 'International'}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1214406', 'clinicalId': '1215776', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1485630_01', 'SampleName': 'US1422354.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1485630_01', 'SampleId': 'US1422354.01', 'BlockId': 'YWL 3/30/1993', 'TRFNumber': 'ORD_1485630_01', 'TestType': 'FoundationOneLiquidDx', 'SpecFormat': 'Tube Set', 'ReceivedDate': '2022_10_24', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}]}}, 'PMI': {'ReportId': 'ORD_1485630_01', 'MRN': '44954598', 'FullName': 'Lin, Yen_Wei', 'FirstName': 'Yen_Wei', 'LastName': 'Lin', 'SubmittedDiagnosis': 'Testis germ cell tumor (seminoma)', 'Gender': 'Male', 'DOB': '1993_03_30', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Blood', 'CollDate': '2022_10_20', 'ReceivedDate': '2022_10_24', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': None, 'Summaries': {'alterationCount': '12', 'clinicalTrialCount': '10', 'resistiveCount': '0', 'sensitizingCount': '0'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'BARD1', 'isVUS': 'true', 'variantName': 'G82V'}, {'geneName': 'C11orf30 (EMSY)', 'isVUS': 'true', 'variantName': 'S1076G'}, {'geneName': 'CEBPA', 'isVUS': 'true', 'variantName': 'A358G'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'E133K'}, {'geneName': 'FLT1', 'isVUS': 'true', 'variantName': 'P470H'}, {'geneName': 'KDR', 'isVUS': 'true', 'variantName': 'splice site 1092_1G>T'}, {'geneName': 'MST1R', 'isVUS': 'true', 'variantName': 'V670G'}, {'geneName': 'PIK3C2B', 'isVUS': 'true', 'variantName': 'H1145L'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'RAD54L', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'C391fs*1', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'C391fs*1'}}, 'Interpretation': 'RAD54L encodes a member of the SNF2/SWI2 superfamily and forms part of the RAD52 complex involved in recombination and DNA repair in response to ionizing radiation (Kanaar et al., 1996; 8805304, Sigurdsson et al., 2002; 12205100, Swagemakers et al., 1998; 9774452, van Veelen et al., 2005; 15914205). Alterations leading to disruption of critical domains with RAD54L are predicted to enhance genomic instability (Smirnova et al., 2004; 15056673). Alterations such as seen here may disrupt RAD54L function or expression (Smirnova et al., 2004; 15056673, Matsuda et al., 1999; 10362365, Golub et al., 1997; 9321665, Spies et al., 2016; 27264870, Goyal et al., 2018; 29295984, Burgess et al. 2013; 24376557, Lengert et al., 2019; 30961891). RAD54L alterations are rare in cancer (cBio_Zehir et al., 2017; 28481359). Loss of heterozygosity (LOH) at chromosomal region 1p32_34, in which RAD54L resides, has been reported as a frequent event in breast cancer (Rasio et al., 1997; 9192813), oligodendroglioma (Bello et al., 2000; 10640146), nontypical meningioma (Kim et al., 2009; 19347254, Leuraud et al., 2000; 11263500, Lopez_Gines et al., 2004; 14734222, Mendiola et al., 1999; 10326867), and parathyroid adenoma (Carling et al., 1999; 10449612), but it is not clear whether RAD54L loss of function is pathogenic in these cases. Increased RAD54L expression was reported in NSCLC samples in response to increased mutation rate (Välk et al., 2010; 21412013) and also in castration_resistant prostate cancer (CRPC) cells (Li et al., 2017; 28536297). RAD54L polymorphisms have been associated with increased risk of developing meningioma (Leone et al., 2003; 12614485), glioma (Zhang et al., 2016; 26514363), and decreased overall survival (P<0.004) in patients with potentially resectable pancreatic adenocarcinoma (Li et al., 2006; 16520463). Germline mutations of RAD54L has been associated with increased risk of gastric cancer (Li et al., 2013; 23504502) but not lymphoid malignancies (Shinozuka et al., 2015; 26743341). There are no therapies available that directly target RAD54L. Limited clinical evidence in ovarian cancer (O Malley et al., 2017; AACR Abstract LB_A12, Swisher et al., 2017; 27908594) and prostate cancer (de Bono et al., 2020; 32343890) indicates that RAD54L inactivation may confer sensitivity to PARP inhibitors.', 'Include': 'true', 'ClinicalTrialNote': 'RAD54L inactivation may predict sensitivity to PARP inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04644068', 'Include': 'true'}, {'nctId': 'NCT04123366', 'Include': 'true'}, {'nctId': 'NCT03742895', 'Include': 'true'}, {'nctId': 'NCT02264678', 'Include': 'true'}, {'nctId': 'NCT05035745', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT04497116', 'Include': 'true'}, {'nctId': 'NCT04991480', 'Include': 'true'}, {'nctId': 'NCT04901702', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'Blood Tumor Mutational Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '00', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '00'}}, 'Interpretation': 'Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2022). Compared to other tumor types, germ cell tumors (GCTs) have been reported to have a low TMB (mean 0.51 mutations per megabase [muts/Mb] as measured in tissue), with a similar mutation rate reported for seminoma (0.50 muts/Mb) and non_seminoma (0.49 muts/Mb) tumors (Litchfield et al., 2015; 25609015). Published data investigating the prognostic implications of TMB in germ cell tumors are limited (PubMed, Sep 2022). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti_PD_L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi_solid_tumor trial showed that bTMB ≥16 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB ≥28 Muts/Mb (approximate equivalency ≥14 Muts/Mb as measured by this assay) was associated with improved OS from a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Cannot Be Determined', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Cannot Be Determined'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI positivity at any level has been reported in 0_31% (n = 17_188) of testicular germ cell tumors (GCTs) (Lothe et al., 1993; 8261392, Murty et al., 1994; 8033127, Huddart et al., 1995; 7669575, Faulkner and Friedlander, 2000; 11006028, Devouassoux_Shisheboran et al., 2001; 11719586, Velasco et al., 2004; 15492498, Olasz et al., 2005; 16309235, Vladušić et al., 2014; 25075023, Cárcano et al., 2016; 27153176) and in 33% (12/36) of ovarian GCTs (Faulkner and Friedlander, 2000; 11006028). Within testicular GCTs, 12_31% of cases (n = 17_51) have been classified as having low_level MSI (MSI_L) and 69_100% (n = 17_133) have been classified as MSS (Devouassoux_Shisheboran et al., 2001; 11719586, Olasz et al., 2005; 16309235, Cárcano et al., 2016; 27153176), with MSI_high (MSI_H) rarely reported; one study identified MSI_L in 6% (6/100) and MSI_H in 0% (0/100) of unselected testicular GCTs, and MSI_L in 6% (2/35) and MSI_H in 26% (9/35) of chemotherapy_resistant cases (Mayer et al., 2002; 12019150, Honecker et al., 2009; 19289622). The significance of MSI in the context of GCTs is not well established (PubMed, Nov 2021). One study reported MSI_H to be significantly more frequent in chemotherapy_resistant than unselected testicular GCT cases (Mayer et al., 2002; 12019150, Honecker et al., 2009; 19289622), and some studies have associated MSI positivity with reduced PFS and/or increased risk of recurrence (Mayer et al., 2002; 12019150, Honecker et al., 2009; 19289622, Velasco et al., 2004; 15492498, Velasco et al., 2008; 18076065); however, another study found no correlation between MSI status and clinicopathologic features, including chemotherapy sensitivity and outcome (Olasz et al., 2005; 16309235). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Tumor Fraction', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Elevated Tumor Fraction Not Detected', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Elevated Tumor Fraction Not Detected'}}, 'Interpretation': 'Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'RAD54L', 'Alteration': 'C391fs*1', 'Title': 'Study of AZD5305 as Monotherapy and in Combination With Anti_cancer Agents in Patients With Advanced Solid Malignancies', 'StudyPhase': 'PHASE 1/2', 'Target': 'ERBB2, TROP2, PARP', 'Locations': 'Shanghai (China), Seoul (Korea, Republic of), Chongqing (China), Chuo_ku (Japan), Koto_ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Grzepnica (Poland), Budapest (Hungary)', 'NCTID': 'NCT04644068', 'Note': 'RAD54L inactivation may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'RAD54L', 'Alteration': 'C391fs*1', 'Title': 'Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP, PD_1', 'Locations': 'Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)', 'NCTID': 'NCT04123366', 'Note': 'RAD54L inactivation may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'RAD54L', 'Alteration': 'C391fs*1', 'Title': 'Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Nedlands (Australia), Darlinghurst (Australia), Adana (Turkey), Jerusalem (Israel), Konya (Turkey), Ramat Gan (Israel), Tel Aviv (Israel), Beer_Sheva (Israel)', 'NCTID': 'NCT03742895', 'Note': 'RAD54L inactivation may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'RAD54L', 'Alteration': 'C391fs*1', 'Title': 'Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP, PD_L1', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)', 'NCTID': 'NCT02264678', 'Note': 'RAD54L inactivation may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'RAD54L', 'Alteration': 'C391fs*1', 'Title': 'Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)', 'StudyPhase': 'PHASE 1/2', 'Target': 'XPO1, PARP', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT05035745', 'Note': 'RAD54L inactivation may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'RAD54L', 'Alteration': 'C391fs*1', 'Title': 'Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, AKTs, PD_L1', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT03772561', 'Note': 'RAD54L inactivation may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'RAD54L', 'Alteration': 'C391fs*1', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'RAD54L inactivation may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'RAD54L', 'Alteration': 'C391fs*1', 'Title': 'Study of RP_3500 in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP', 'Locations': 'Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Illinois, Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee', 'NCTID': 'NCT04497116', 'Note': 'RAD54L inactivation may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'RAD54L', 'Alteration': 'C391fs*1', 'Title': 'A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'PARP, Pol theta', 'Locations': 'London (United Kingdom), Oklahoma, Connecticut, New York, Pennsylvania, Tennessee, Texas, Florida', 'NCTID': 'NCT04991480', 'Note': 'RAD54L inactivation may predict sensitivity to PARP inhibitors.', 'Include': 'true'}, {'Gene': 'RAD54L', 'Alteration': 'C391fs*1', 'Title': 'Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma', 'StudyPhase': 'PHASE 1/2', 'Target': 'TOP1, PARP', 'Locations': 'Tennessee', 'NCTID': 'NCT04901702', 'Note': 'RAD54L inactivation may predict sensitivity to PARP inhibitors.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '8805304', 'FullCitation': 'Kanaar R, et al. Curr. Biol. (1996) pmid: 8805304', 'Include': 'true'}, {'number': '1', 'ReferenceId': '12205100', 'FullCitation': 'Sigurdsson S, et al. J. Biol. Chem. (2002) pmid: 12205100', 'Include': 'true'}, {'number': '2', 'ReferenceId': '9774452', 'FullCitation': 'Swagemakers SM, et al. J. Biol. Chem. (1998) pmid: 9774452', 'Include': 'true'}, {'number': '3', 'ReferenceId': '15914205', 'FullCitation': 'van Veelen LR, et al. Mutat. Res. (2005) pmid: 15914205', 'Include': 'true'}, {'number': '4', 'ReferenceId': '15056673', 'FullCitation': 'Smirnova M, et al. J. Biol. Chem. (2004) pmid: 15056673', 'Include': 'true'}, {'number': '5', 'ReferenceId': '10362365', 'FullCitation': 'Matsuda M, et al. Oncogene (1999) pmid: 10362365', 'Include': 'true'}, {'number': '6', 'ReferenceId': '9321665', 'FullCitation': 'Golub EI, et al. Nucleic Acids Res. (1997) pmid: 9321665', 'Include': 'true'}, {'number': '7', 'ReferenceId': '27264870', 'FullCitation': 'Spies J, et al. Mol. Cell (2016) pmid: 27264870', 'Include': 'true'}, {'number': '8', 'ReferenceId': '29295984', 'FullCitation': 'Goyal N, et al. Nat Commun (2018) pmid: 29295984', 'Include': 'true'}, {'number': '9', 'ReferenceId': '30961891', 'FullCitation': 'Lengert N, et al. Biophys. J. (2019) pmid: 30961891', 'Include': 'true'}, {'number': '10', 'ReferenceId': '28481359', 'FullCitation': 'Zehir A, et al. Nat. Med. (2017) pmid: 28481359', 'Include': 'true'}, {'number': '11', 'ReferenceId': '9192813', 'FullCitation': 'Rasio D, et al. Cancer Res. (1997) pmid: 9192813', 'Include': 'true'}, {'number': '12', 'ReferenceId': '10640146', 'FullCitation': 'Bello MJ, et al. Cancer Genet. Cytogenet. (2000) pmid: 10640146', 'Include': 'true'}, {'number': '13', 'ReferenceId': '19347254', 'FullCitation': 'Kim NR, et al. J. Neurooncol. (2009) pmid: 19347254', 'Include': 'true'}, {'number': '14', 'ReferenceId': '11263500', 'FullCitation': 'Leuraud P, et al. J. Neurooncol. (2000) pmid: 11263500', 'Include': 'true'}, {'number': '15', 'ReferenceId': '14734222', 'FullCitation': 'Lopez_Gines C, et al. Cancer Genet. Cytogenet. (2004) pmid: 14734222', 'Include': 'true'}, {'number': '16', 'ReferenceId': '10326867', 'FullCitation': 'Mendiola M, et al. Mol. Carcinog. (1999) pmid: 10326867', 'Include': 'true'}, {'number': '17', 'ReferenceId': '10449612', 'FullCitation': 'Carling T, et al. Int. J. Cancer (1999) pmid: 10449612', 'Include': 'true'}, {'number': '18', 'ReferenceId': '21412013', 'FullCitation': 'Välk K, et al. Oncology (2010) pmid: 21412013', 'Include': 'true'}, {'number': '19', 'ReferenceId': '28536297', 'FullCitation': 'Li L, et al. Sci Signal (2017) pmid: 28536297', 'Include': 'true'}, {'number': '20', 'ReferenceId': '12614485', 'FullCitation': 'Leone PE, et al. BMC Cancer (2003) pmid: 12614485', 'Include': 'true'}, {'number': '21', 'ReferenceId': '26514363', 'FullCitation': 'Zhang H, et al. J. Neurooncol. (2016) pmid: 26514363', 'Include': 'true'}, {'number': '22', 'ReferenceId': '16520463', 'FullCitation': 'Li D, et al. J. Clin. Oncol. (2006) pmid: 16520463', 'Include': 'true'}, {'number': '23', 'ReferenceId': '23504502', 'FullCitation': 'Li WQ, et al. Carcinogenesis (2013) pmid: 23504502', 'Include': 'true'}, {'number': '24', 'ReferenceId': '26743341', 'FullCitation': 'Shinozuka K, et al. Biol. Blood Marrow Transplant. (2016) pmid: 26743341', 'Include': 'true'}, {'number': '25', 'ReferenceId': '27908594', 'FullCitation': 'Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594', 'Include': 'true'}, {'number': '26', 'ReferenceId': '32343890', 'FullCitation': 'de Bono J, et al. N. Engl. J. Med. (2020) pmid: 32343890', 'Include': 'true'}, {'number': '27', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '28', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '29', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '30', 'ReferenceId': '8261392', 'FullCitation': 'Lothe RA, et al. Cancer Res. (1993) pmid: 8261392', 'Include': 'true'}, {'number': '31', 'ReferenceId': '8033127', 'FullCitation': 'Murty VV, et al. Cancer Res. (1994) pmid: 8033127', 'Include': 'true'}, {'number': '32', 'ReferenceId': '7669575', 'FullCitation': 'Huddart RA, et al. Br. J. Cancer (1995) pmid: 7669575', 'Include': 'true'}, {'number': '33', 'ReferenceId': '11006028', 'FullCitation': 'Faulkner SW, et al. Gynecol. Oncol. (2000) pmid: 11006028', 'Include': 'true'}, {'number': '34', 'ReferenceId': '11719586', 'FullCitation': 'Devouassoux_Shisheboran M, et al. Mol. Hum. Reprod. (2001) pmid: 11719586', 'Include': 'true'}, {'number': '35', 'ReferenceId': '15492498', 'FullCitation': 'Velasco A, et al. Cancer Biol. Ther. (2004) pmid: 15492498', 'Include': 'true'}, {'number': '36', 'ReferenceId': '16309235', 'FullCitation': 'Olasz J, et al. Anticancer Res. () pmid: 16309235', 'Include': 'true'}, {'number': '37', 'ReferenceId': '25075023', 'FullCitation': 'Vladušić T, et al. Anticancer Res. (2014) pmid: 25075023', 'Include': 'true'}, {'number': '38', 'ReferenceId': '27153176', 'FullCitation': 'Cárcano FM, et al. Andrology (2016) pmid: 27153176', 'Include': 'true'}, {'number': '39', 'ReferenceId': '12019150', 'FullCitation': 'Mayer F, et al. Cancer Res. (2002) pmid: 12019150', 'Include': 'true'}, {'number': '40', 'ReferenceId': '19289622', 'FullCitation': 'Honecker F, et al. J. Clin. Oncol. (2009) pmid: 19289622', 'Include': 'true'}, {'number': '41', 'ReferenceId': '18076065', 'FullCitation': 'Velasco A, et al. Int. J. Cancer (2008) pmid: 18076065', 'Include': 'true'}, {'number': '42', 'ReferenceId': '17204026', 'FullCitation': 'Histopathology (2007) pmid: 17204026', 'Include': 'true'}, {'number': '43', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '44', 'ReferenceId': '28734759', 'FullCitation': 'Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759', 'Include': 'true'}, {'number': '45', 'ReferenceId': '29355075', 'FullCitation': 'Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075', 'Include': 'true'}, {'number': '46', 'ReferenceId': '35322232', 'FullCitation': 'Shitara K, et al. Nature (2022) pmid: 35322232', 'Include': 'true'}, {'number': '47', 'ReferenceId': '23169436', 'FullCitation': 'Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436', 'Include': 'true'}, {'number': '48', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '49', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '50', 'ReferenceId': '33001143', 'FullCitation': 'Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143', 'Include': 'true'}, {'number': '51', 'ReferenceId': '31602320', 'FullCitation': 'Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320', 'Include': 'true'}, {'number': '52', 'ReferenceId': '32757294', 'FullCitation': 'Zhang EW, et al. Cancer (2020) pmid: 32757294', 'Include': 'true'}, {'number': '53', 'ReferenceId': '30833418', 'FullCitation': 'Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418', 'Include': 'true'}, {'number': '54', 'ReferenceId': '24553385', 'FullCitation': 'Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385', 'Include': 'true'}, {'number': '55', 'ReferenceId': '30400802', 'FullCitation': 'Lapin M, et al. J Transl Med (2018) pmid: 30400802', 'Include': 'true'}, {'number': '56', 'ReferenceId': '30131550', 'FullCitation': 'Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550', 'Include': 'true'}, {'number': '57', 'ReferenceId': '30385733', 'FullCitation': 'Choudhury AD, et al. JCI Insight (2018) pmid: 30385733', 'Include': 'true'}, {'number': '58', 'ReferenceId': '29298117', 'FullCitation': 'Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117', 'Include': 'true'}, {'number': '59', 'ReferenceId': '30793095', 'FullCitation': 'Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095', 'Include': 'true'}, {'number': '60', 'ReferenceId': '31059681', 'FullCitation': 'Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681', 'Include': 'true'}, {'number': '61', 'ReferenceId': '28187169', 'FullCitation': 'Fan G, et al. PLoS ONE (2017) pmid: 28187169', 'Include': 'true'}, {'number': '62', 'ReferenceId': '30923679', 'FullCitation': 'Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679', 'Include': 'true'}, {'number': '63', 'ReferenceId': '30093454', 'FullCitation': 'Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454', 'Include': 'true'}, {'number': '64', 'ReferenceId': '30860573', 'FullCitation': 'Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573', 'Include': 'true'}, {'number': '65', 'ReferenceId': '28450425', 'FullCitation': 'Goodall J, et al. Cancer Discov (2017) pmid: 28450425', 'Include': 'true'}, {'number': '66', 'ReferenceId': '29330207', 'FullCitation': 'Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207', 'Include': 'true'}, {'number': '67', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '68', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '69', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '70', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '71', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '72', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '73', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '74', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '75', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '76', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '77', 'ReferenceId': '30082870', 'FullCitation': 'Gandara DR, et al. Nat. Med. (2018) pmid: 30082870', 'Include': 'true'}, {'number': '78', 'ReferenceId': '30816954', 'FullCitation': 'Wang Z, et al. JAMA Oncol (2019) pmid: 30816954', 'Include': 'true'}, {'number': '79', 'ReferenceId': '32102950', 'FullCitation': 'Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950', 'Include': 'true'}, {'number': '80', 'ReferenceId': '25609015', 'FullCitation': 'Litchfield K, et al. Nat Commun (2015) pmid: 25609015', 'Include': 'true'}, {'number': '81', 'ReferenceId': '35274716', 'FullCitation': 'Sturgill EG, et al. Oncologist (2022) pmid: 35274716', 'Include': 'true'}, {'number': '82', 'ReferenceId': '32379280', 'FullCitation': 'Chen EX, et al. JAMA Oncol (2020) pmid: 32379280', 'Include': 'true'}, {'number': '83', 'ReferenceId': '32271377', 'FullCitation': 'Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377', 'Include': 'true'}, {'number': '84', 'ReferenceId': '33355200', 'FullCitation': 'Si H, et al. Clin Cancer Res (2021) pmid: 33355200', 'Include': 'true'}, {'number': '85', 'ReferenceId': '34800700', 'FullCitation': 'Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2022_11_01 16:03:24', 'OpName': 'J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'J. Keith Killian, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': 'N/A'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': '0 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': '0%'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'TESTIS', 'disease_ontology': 'Testis germ cell tumor (seminoma)', 'flowcell_analysis': '2000024250', 'gender': 'male', 'pathology_diagnosis': 'Seminoma', 'pipeline_version': 'v3.15.0', 'purity_assessment': '14.0', 'specimen': 'ORD_1485630_01*US1422354.01', 'study': 'CLINICAL_F1LCDx', 'test_request': 'ORD_1485630_01', 'test_type': 'FoundationOneLiquidDx', 'tissue_of_origin': 'Blood', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'AB1', 'name': 'SQ_US1422354.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.0017', 'cds_effect': '1092_1G>T', 'depth': '2858', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'KDR', 'percent_reads': '0.17', 'position': 'chr4:55976734', 'protein_effect': 'splice site 1092_1G>T', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002253', 'dna_evidence': {'sample': 'SQ_US1422354.01_1'}}, {'allele_fraction': '0.3211', 'cds_effect': '1092_1093insCGAGACGCTGCTGCTAGTGAGGCAGACAGGCAGCTAGGAGAGGAGCGGCTGCGGGAGCTCACCAGCATTGTGAATAGGTAATGACCTTAAGC', 'depth': '1694', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'RAD54L', 'percent_reads': '32.11', 'position': 'chr1:46736380', 'protein_effect': 'C391fs*1', 'status': 'likely', 'strand': '+', 'transcript': 'NM_003579', 'dna_evidence': {'sample': 'SQ_US1422354.01_1'}}, {'allele_fraction': '0.4935', 'cds_effect': '3434A>T', 'depth': '841', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PIK3C2B', 'percent_reads': '49.35', 'position': 'chr1:204408145', 'protein_effect': 'H1145L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002646', 'dna_evidence': {'sample': 'SQ_US1422354.01_1'}}, {'allele_fraction': '0.467', 'cds_effect': '245G>T', 'depth': '713', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BARD1', 'percent_reads': '46.7', 'position': 'chr2:215657140', 'protein_effect': 'G82V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000465', 'dna_evidence': {'sample': 'SQ_US1422354.01_1'}}, {'allele_fraction': '0.5367', 'cds_effect': '1073C>G', 'depth': '1267', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CEBPA', 'percent_reads': '53.67', 'position': 'chr19:33792248', 'protein_effect': 'A358G', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004364', 'dna_evidence': {'sample': 'SQ_US1422354.01_1'}}, {'allele_fraction': '0.5036', 'cds_effect': '1409C>A', 'depth': '965', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FLT1', 'percent_reads': '50.36', 'position': 'chr13:29001323', 'protein_effect': 'P470H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002019', 'dna_evidence': {'sample': 'SQ_US1422354.01_1'}}, {'allele_fraction': '0.4667', 'cds_effect': '397G>A', 'depth': '962', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '46.67', 'position': 'chr2:212812179', 'protein_effect': 'E133K', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1422354.01_1'}}, {'allele_fraction': '0.5298', 'cds_effect': '2009T>G', 'depth': '1744', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MST1R', 'percent_reads': '52.98', 'position': 'chr3:49934990', 'protein_effect': 'V670G', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002447', 'dna_evidence': {'sample': 'SQ_US1422354.01_1'}}, {'allele_fraction': '0.5067', 'cds_effect': '3226A>G', 'depth': '1202', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EMSY', 'percent_reads': '50.67', 'position': 'chr11:76255819', 'protein_effect': 'S1076G', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_020193', 'dna_evidence': {'sample': 'SQ_US1422354.01_1'}}]}, 'copy_number_alterations': None, 'rearrangements': None, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '0.0', 'status': 'low', 'unit': 'mutations_per_megabase'}}, 'non_human_content': {'non_human': [{'organism': 'HPV_16', 'reads_per_million': '43', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1422354.01_1'}}, {'organism': 'HHV_8', 'reads_per_million': '23', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1422354.01_1'}}, {'organism': 'HHV_4', 'reads_per_million': '54', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1422354.01_1'}}]}}}}}	S111-97975          	PF22070             
13	480	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2021_00018167', 'CSN': None, 'TRF': 'ORD_1269426_01', 'MRN': '44954598', 'PhysicianId': '109266', 'NPI': 'International'}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1010063', 'clinicalId': '1011447', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1269426_01', 'SampleName': 'US1223968.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1269426_01', 'SampleId': 'US1223968.01', 'BlockId': 'S107_36281 E (PF21077)', 'TRFNumber': 'ORD_1269426_01', 'TestType': 'FoundationOne CDX', 'SpecFormat': 'Slide Deck', 'ReceivedDate': '2021_12_28', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}]}}, 'PMI': {'ReportId': 'ORD_1269426_01', 'MRN': '44954598', 'FullName': 'Lin, Yen_Wei', 'FirstName': 'Yen_Wei', 'LastName': 'Lin', 'SubmittedDiagnosis': 'Testis germ cell tumor (seminoma)', 'Gender': 'Male', 'DOB': '1993_03_30', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Testis', 'CollDate': '2018_09_20', 'ReceivedDate': '2021_12_28', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': None, 'Summaries': {'alterationCount': '21', 'clinicalTrialCount': '26', 'resistiveCount': '0', 'sensitizingCount': '4'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'BARD1', 'isVUS': 'true', 'variantName': 'G82V'}, {'geneName': 'C11orf30 (EMSY)', 'isVUS': 'true', 'variantName': 'S1076G'}, {'geneName': 'CDKN1B', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'CEBPA', 'isVUS': 'true', 'variantName': 'A358G'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'E133K'}, {'geneName': 'FLT1', 'isVUS': 'true', 'variantName': 'P470H'}, {'geneName': 'MST1R', 'isVUS': 'true', 'variantName': 'V670G'}, {'geneName': 'PDGFRA', 'isVUS': 'true', 'variantName': 'rearrangement'}, {'geneName': 'PIK3C2B', 'isVUS': 'true', 'variantName': 'H1145L'}, {'geneName': 'PIK3C2G', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'PTPRO', 'isVUS': 'true', 'variantName': 'amplification'}, {'geneName': 'RAD52', 'isVUS': 'true', 'variantName': 'amplification'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'CCND2', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'CCND2 encodes the protein cyclin D2, which binds and regulates the cyclin_dependent kinases that control cell cycle progression, and is a downstream target of cancer signaling pathways including hedgehog and PI3K (Katoh and Katoh, 2009; 19860666, White et al., 2006; 16301994). CCND2 has been reported to be amplified in cancer (Gao et al., 2013; 23550210), and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). CCND2 in germ cell neoplasms has been most extensively studied in the context of testicular germ cell tumors. The amplification of the chromosomal region that includes CCND2 has been reported in at least 10% of testicular germ cell tumors (Rodriguez et al., 2003; 12660824, Korkola et al., 2006; 16424014, Skotheim et al., 2006; 17167184). Overexpression of CCND2, at an average of 8_fold, has been reported in 69% (31/45) to 83% (25/30) of testicular germ cell tumors, and CCND2 was reported to be one of the six most highly overexpressed genes in this tumor type (Schmidt et al., 2001; 11358847, Skotheim et al., 2006; 17167184, Kukoski et al., 2003; 12777997). Published data investigating the prognostic implications of CCND2 in germ cell tumors are limited (PubMed, Mar 2021). Although preclinical studies suggest that cyclin D2 activates CDK4/6 (Busk et al., 2005; 15707582, Busk, 2003; 12695654), it is unknown whether CCND2 amplification or activating mutation predicts response to CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib. Clinical studies of CDK4/6 inhibitors have shown the most promise for estrogen receptor_positive breast cancer (Finn et al., 2014; 25524798, DeMichele et al., 2014; 25501126).', 'Include': 'true', 'ClinicalTrialNote': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04594005', 'Include': 'true'}, {'nctId': 'NCT03099174', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT03994796', 'Include': 'true'}, {'nctId': 'NCT02896335', 'Include': 'true'}, {'nctId': 'NCT03310879', 'Include': 'true'}, {'nctId': 'NCT03065062', 'Include': 'true'}, {'nctId': 'NCT03454035', 'Include': 'true'}, {'nctId': 'NCT02897375', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'KIT', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'KIT (also called c_KIT) encodes a cell surface tyrosine kinase receptor that, upon ligand binding and dimerization, activates the PI3K_AKT and RAS_MAPK signaling pathways (Linnekin, 1999; 10582339). KIT aberrations, including point mutations, translocations, amplification, and overexpression, have been associated with various malignancies, and KIT is considered an oncoprotein (Fletcher, 2004; 15175998). KIT has been reported to be amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). KIT amplification was reported in 21% of seminoma and 9% of nonseminoma germ cell tumors (McIntyre et al., 2005; 16166280). In seminoma, KIT amplification was reported to be associated with increased gene expression (McIntyre et al., 2005; 16166280). KIT gene expression was reported to be increased in seminoma compared with non_seminoma (McIntyre et al., 2005; 16166280). In the Testicular Germ Cell TCGA and the Germ Cell Tumors MSKCC datasets, KIT amplification has been observed in 2.0% (3/149) and 2.2% (4/180) of cases, respectively (cBioPortal, Apr 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). The prognostic significance of KIT alterations in germ cell neoplasms has not been established (PubMed, Apr 2021). On the basis of clinical evidence, primarily in GIST, AML, and systemic mastocytosis, KIT activating alterations are associated with sensitivity to KIT tyrosine kinase inhibitors including imatinib, sunitinib, sorafenib, dasatinib, nilotinib, pazopanib, regorafenib, ponatinib, midostaurin, avapritinib, and ripretinib (Heinrich et al., 2014; ASCO Abstract 10506, Heinrich et al., 2017; ASCO Abstract 11011, DeAngelo et al., 2017; ASH Abstract 2, Evans et al., 2017; 29093181, Abbaspour Babaei et al., 2016; 27536065, Ramaswamy et al., 2016; 27563456, Demetri et al., 2013; 23177515, Gotlib et al., 2016; 27355533, Jawhar et al., 2017; 28424161, Xu et al., 2014; 25031773, Gotlib et al., 2005; 15972446, George et al., 2018; ASCO Abstract 11511). The use of mTOR inhibitors as an alternative therapeutic strategy has demonstrated limited success in KIT_mutated, imatinib_resistant melanoma, with 1 PR and 3 SD observed for 4 patients treated with everolimus (Si et al., 2012; ASCO Abstract 8562, Si et al., 2012; 22162580). However, no responses were observed for 10 patients with mastocytosis following everolimus monotherapy, with 8/10 patients harboring the KIT D816V mutation (Parikh et al., 2010; 20038218). The role of KIT amplification as a biomarker for response to mTOR inhibitors has not been investigated (PubMed, Mar 2021). Clinical benefit has been observed for patients with KIT amplified or overexpressing tumors following treatment with imatinib (Wei et al., 2019; 30075827, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685, Guo et al., 2011; 21690468, Debiec_Rychter et al., 2005; 15685537, DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Hotte et al., 2005; 15659505, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Reardon et al., 2009; 19904263), nilotinib (Lee et al., 2015; 26424760), sorafenib (Llovet et al., 2012; 22374331, Zhang et al., 2013; 23058498, Seino et al., 2014; 25450081, Li et al., 2009; 18846437), and sunitinib (Minor et al., 2012; 22261812, Mahipal et al., 2012; 23114504), suggesting that KIT amplification may be sensitive to these inhibitors. However, evidence demonstrating clinical benefit for regorafenib, dasatinib, pazopanib, or ponatinib in the context of KIT amplified or overexpressing tumors is limited.', 'Include': 'true', 'ClinicalTrialNote': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Nilotinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Nilotinib targets tyrosine kinases such as ABL (including BCR_ABL), PDGFRs, KIT, CSF1R, DDR1, and DDR2. It is FDA approved to treat newly diagnosed pediatric or adult patients with Philadelphia chromosome_positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, adults with Ph+ CML in chronic or accelerated phase with resistance or intolerance to prior therapy including imatinib, and pediatric patients with Ph+ CML in chronic phase with resistance or intolerance to prior tyrosine_kinase inhibitor therapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Lee et al., 2015; 26424760, Carvajal et al., 2015; 25695690, Hochhaus et al., 2015; 26002753, Blay et al., 2015; 25882987, Kaijimoto et al., 2015; 26722383), KIT_amplified (Lee et al., 2015; 26424760), or KIT_expressing tumors (Sako et al., 2014; 25221952), KIT activating alterations may confer sensitivity to nilotinib. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of nilotinib for the treatment of germ cell tumors are limited (PubMed, Nov 2021). Nilotinib has been primarily investigated as a therapeutic option for the treatment of CML or gastrointestinal stromal tumors (GIST). In the context of CML, a Phase 3 clinical trial of Ph+ patients treated with imatinib or nilotinib (300 mg or 400 mg) reported progression_free survival (PFS) rates of 93% and 97_98% and overall survival (OS) rates of 93% and 94_97%, respectively, at 4 years (Hughes et al., 2014; 24335106). For imatinib_resistant Japanese patients with CML, a Phase 2 trial reported a 47.8% major medical response rate to treatment with nilotinib at 12 months (Takahashi et al., 2014; 24650752). A Phase 3 clinical trial of single_agent nilotinib in 240 patients with advanced GIST who failed prior treatment with imatinib or sunitinib reported no significant difference in progression_free survival between nilotinib and the best supportive care, but did report increased overall survival for nilotinib_treated patients (Reichardt et al., 2012; 22357255). A Phase 2 trial has shown that nilotinib was well tolerated and suggested it may be particularly useful for treating patients with GIST harboring mutations in KIT exon 17 (Cauchi et al., 2012; 22119758). Preclinical, cell_based assays have reported efficacy for nilotinib alone and in combination with additional therapies in the context of leiomyosarcoma and synovial sarcoma (Villar et al., 2012; 22662203). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Sunitinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Sunitinib is a small_molecule tyrosine kinase inhibitor that targets PDGFRs, VEGFRs, KIT, FLT3, CSF_1R, and RET. It is FDA approved for the treatment of advanced or metastatic pancreatic neuroendocrine tumors, gastrointestinal stromal tumors (GISTs) in patients who have progressed on or are intolerant to imatinib, and advanced renal cell carcinoma (RCC) as well as for the adjuvant treatment of patients at high risk of recurrent RCC after nephrectomy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Minor et al., 2012; 22261812, Heinrich et al., 2008; 18955458, Buchbinder et al., 2015; 26264378, Reichardt et al., 2016; 26772734, Hirai et al., 2016; 27073655, Goemans et al., 2010; 20435347) or KIT_expressing tumors (Mahipal et al., 2012; 23114504, Minor et al., 2012; 22261812), KIT activating alterations may predict sensitivity to sunitinib. </p> <p><b>Supporting Data:</b> One study of sunitinib in cisplatin_refractory or multiply relapsed germ cell tumors reported a total response rate of 13% in 33 patients, including three confirmed partial responses (PR) and one unconfirmed PR (Oechsle et al., 2011; 21415240). However, a Phase 2 trial of sunitinib in patients with relapsed or refractory germ cell tumors found no objective responses in ten patients, with five cases of stable disease and five exhibiting progressive disease (Feldman et al., 2010; 19547919). A case study has reported an exceptional response to sunitinib in a patient with RET_amplified germ cell tumor (Subbiah et al., 2014; 25085632). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Sorafenib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Sorafenib is a kinase inhibitor that targets the RAF kinases, KIT, FLT3, RET, VEGFRs, and PDGFRs. It is FDA approved for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and recurrent or metastatic differentiated thyroid carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Quintás_Cardama et al., 2008; 18936790, Bisagni et al., 2009; 19461405, Handolias et al., 2010; 20372153, Disel et al., 2011; 20970876, Park et al., 2012; 22270258, Catania et al., 2014; 24855380, Guo et al., 2007; 17699867, Hu et al., 2008; 18483300) or KIT_expressing tumors (Llovet et al., 2012; 22374331, Zhang et al., 2013; 23058498, Seino et al., 2014; 25450081, Li et al., 2009; 18846437), KIT activating alterations may predict sensitivity to sorafenib. </p> <p><b>Supporting Data:</b> In a Phase 2 study for patients with relapsed or refractory testicular germ cell tumors, none of the 18 patients experienced a PR or CR, but 3 experienced SD lasting >11 months (Skoneczna et al., 2014; ASCO Abstract 367). One patient with a KRAS_amplified testicular germ cell tumor who was refractory to chemotherapy and immunotherapy experienced CRs and PRs in metastatic lesions in the lung and brain upon treatment with the combination of carboplatin, paclitaxel, and sorafenib (Lian et al., 2019; 31492770). Phase 2 studies in non_small cell lung cancer (NSCLC) report that single_agent sorafenib improved disease control rates and that the addition of sorafenib to erlotinib increased survival in EGFR wild_type patients (Wakelee et al., 2012; 22982658, Spigel et al., 2011; 21576636). A Phase 1 trial of everolimus combined with sorafenib reported 11% partial responses and 77% stable disease (You et al., 2016; ASCO Abstract 2532). In the context of small cell lung carcinoma, sorafenib combined with cisplatin plus etoposide was highly toxic and ineffective (Sharma et al., 2014; 24420556). In HER2_negative breast cancer, Phase 2b trials found improved progression_free survival for sorafenib added to capecitabine, but not when added to paclitaxel (Baselga et al., 2012; 22412143, Gradishar et al., 2012; 22954665). Phase 2 studies of sorafenib in biliary tract cancer reported disease control rates of 33_39% (Bengala et al., 2010; 19935794). Three patients with cholangiocarcinoma derived clinical benefit from sorafenib (Qun and Tao, 2010; 20698202, LaRocca et al., 2007; 19089671). However, the addition of sorafenib to gemcitabine did not improve outcome in patients with biliary tract tumors compared with gemcitabine alone (Moehler et al., 2014; 25446376). A Phase 2 study of sorafenib and bicalutamide in castration_resistant prostate cancer (CRPC) observed a PSA response or stable disease (>6 months) in 47% (18/39) of patients (Beardsley et al., 2012; 21785998). Single_agent sorafenib was moderately active as second_line treatment for CRPC (3.7 months PFS and 18.0 months OS) (Aragon_Ching et al., 2009; 19154507). For the treatment of glioblastoma or high_grade gliomas, sorafenib alone or combined with temozolomide/radiotherapy or erlotinib did not show efficacy (Reardon et al., 2011; 20443129, Lee et al., 2012; 23099651, Peereboom et al., 2013; 23328813, Hottinger et al., 2014; 24786603). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Imatinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Imatinib targets the BCR_ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT_positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Carvajal et al., 2011; 21642685, Debiec_Rychter et al., 2006; 16624552, Heinrich et al., 2003; 14645423, Hodi et al., 2013; 23775962), KIT_amplified (Wei et al., 2019; 30075827, Guo et al., 2011; 21690468, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685), or KIT_expressing tumors (DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Hotte et al., 2005; 15659505, Reardon et al., 2009; 19904263, Kamenz et al., 2006; 16570351, Wang et al., 2005; 15650049), KIT activating alterations may confer sensitivity to imatinib. PDGFRA amplification may predict sensitivity to tyrosine kinase inhibitors such as imatinib; a patient with Merkel cell carcinoma expressing PDGFRA achieved a complete response to imatinib (Frenard et al., 2016; 27051816). </p> <p><b>Supporting Data:</b> Although a Phase 2 trial of imatinib in chemotherapy_refractory germ cell tumors expressing KIT reported no significant clinical benefit (Einhorn et al., 2006; 16462496), two case studies have reported responses of KIT_expressing testicular seminomas to imatinib, including one complete response for 28 months (Pedersini et al., 2007; 17976614, Okamura et al., 2010; 20080832). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04337463', 'Include': 'true'}, {'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT02461849', 'Include': 'true'}, {'nctId': 'NCT03564691', 'Include': 'true'}, {'nctId': 'NCT04008797', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}, {'nctId': 'NCT04729348', 'Include': 'true'}, {'nctId': 'NCT03711058', 'Include': 'true'}, {'nctId': 'NCT04449549', 'Include': 'true'}, {'nctId': 'NCT03065062', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'KRAS', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244, Kahn et al., 1987; 3310850). In numerous cancer type_specific studies as well as a large_scale pan_cancer analysis, KRAS amplification was shown to correlate with increased expression (McIntyre et al., 2005; 16354586, Mita et al., 2009; 19545448, Birkeland et al., 2012; 23099803, Chen et al., 2014; 24874471). Additionally, KRAS amplification correlated with sensitivity of cancer cell lines to KRAS knockdown, suggesting that amplified KRAS is an oncogenic driver (Chen et al., 2014; 24874471). KRAS in germ cell neoplasms has been most extensively studied in the context of testicular germ cell tumors. KRAS amplification and mutation have been observed in 8.1_20.0% and 0.0_40.0% of testicular germ cell tumors, respectively (cBioPortal, Feb 2021)(cBio_Bagrodia et al., 2016; 27646943, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Goddard et al., 2007; 17573850, McIntyre et al., 2005; 16354586, Moul et al., 1992; 1381946). KRAS mutations have been infrequently reported in ovarian germ cell tumors, but have been identified in malignant tumors arising from teratomas (Li et al., 2014; 25297496, Hershkovitz et al., 2013; 24422958, Stanojevic et al., 2012; 22682753). KRAS amplification and mutation have been linked to invasive growth of testicular germ cell tumors but were found not to provide predictive information regarding response to therapy and patient survival (Mayer et al., 2011; 20955261, Honecker et al., 2009; 19289622, Roelofs et al., 2000; 11021820). Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib (Nakano et al., 1984; 6320174, Pylayeva_Gupta et al., 2011; 21993244, Yamaguchi et al., 2011; 21523318, Watanabe et al., 2013; 23438367, Gilmartin et al., 2011; 21245089, Yeh et al., 2009; 19372556). Clinical evidence that KRAS amplification in the absence of a concurrent KRAS activating mutation is sensitive to MEK inhibitors is limited. A Phase 2 study of selumetinib plus docetaxel in patients with gastric cancer reported 1/2 patients with KRAS amplification experienced a PR (Lee et al., 2018; ASCO Abstract 4061). A patient with cervical cancer harboring both KRAS and PIK3CA amplification treated with the combination of trametinib and the AKT inhibitor GSK2141795 achieved a SD (Lui et al., 2019; 31118140).', 'Include': 'true', 'ClinicalTrialNote': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04803318', 'Include': 'true'}, {'nctId': 'NCT03989115', 'Include': 'true'}, {'nctId': 'NCT03284502', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT03905148', 'Include': 'true'}, {'nctId': 'NCT02407509', 'Include': 'true'}, {'nctId': 'NCT04800822', 'Include': 'true'}, {'nctId': 'NCT02070549', 'Include': 'true'}, {'nctId': 'NCT03162627', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'PDGFRA', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'PDGFRA encodes platelet_derived growth factor receptor alpha (PDGFR_alpha), a tyrosine kinase receptor that, upon binding of cognate ligands (PDGFA or PDGFB), activates several signaling pathways, including PI3K and MAPK (Andrae et al., 2008; 18483217). PDGFR aberrations, including point mutations, translocations, amplification, and/or overexpression, have been associated with various malignancies (Fletcher, 2004; 15175998). Amplification of PDGFRA, frequently occurring with amplification of the genes KDR and KIT, has been associated with increased PDGFRA expression (Burford et al., 2013; 23990986, Flavahan et al., 2016; 26700815, Roszik et al., 2016; 26787600, Verhaak et al., 2010; 20129251) and poor prognosis (Burford et al., 2013; 23990986, Koschmann et al., 2016; 27582545, Phillips et al., 2013; 23438035, Puget et al., 2012; 22389665) in some subtypes of glioma. PDGFRA amplification has been reported in 1.7% of testicular germ cell tumors (cBio_Bagrodia et al., 2016; 27646943, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In a study of 49 central nervous system germinomas, amplification of 4q12, the region where PDGFRA is located, was reported in 1 pineal gland germinoma (Schulte et al., 2016;27391150). One study reported that PDGFRA gene expression was not associated with PDGFRA amplification in germ cell tumors (McIntyre et al., 2005; 16166280). Amplification of PDGFRA or 4q12 was not reported in a study of 87 ovarian germ cell tumors (Nieuwenhuysen et al., 2018;30170975). The frequency of PDGFRA amplification in mediastinal germinomas and retroperitoneal germ cell tumors has not been evaluated (cBioPortal, PubMed, Nov 2021) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of PDGFRA alterations in germ cell tumors are limited (PubMed, Nov 2018). Published data investigating the prognostic implications of PDGFRA alterations in germ cell tumors are limited (PubMed, Jul 2021). On the basis of extensive clinical evidence in solid tumors and hematologic cancers, PDGFRA activating alterations are associated with sensitivity to imatinib (Arefi et al., 2012; 22806436, Baccarani et al., 2007; 17666373, Cassier et al., 2012; 22718859, Chalmers et al., 2015; 25658984, Cools et al., 2003; 12660384, Curtis et al., 2007; 17555450, Debiec_Rychter et al., 2016; 15010069, Dileo et al., 2011; 20473908, Fanta et al., 2015; 24638008, Florian et al., 2006; 16406018, Frenard et al., 2016; 27051816, Griffin et al., 2003; 12808148, Heinrich et al., 2003; 14645423, Helbig et al., 2009; 19120352, Helbig et al., 2014; 24009127, Hus et al., 2011; 21093052, Ikezoe et al., 2010; 20303172, Intermesoli et al., 2009; 19735261, Jain et al., 2009; 19013640, Jovanovic et al., 2007; 17299092, Kang et al., 2012; 22150077, Klion et al., 2004; 14504092, Kobayashi et al., 2009; 19192229, Kocáková et al., 2014; 24635438, Metzgeroth et al., 2008; 18950453, Murayama et al., 2012; 22645636, Ogbogu et al., 2009; 19910029, Ohnishi et al., 2006; 16856885, Pardanani et al., 2003; 12842979, Pardanani et al., 2004; 15284118, Qu et al., 2016; 27120808, Score et al., 2006; 16498388, Shah et al., 2011; 24669761, Sugimoto et al., 2015; 26319757, Volz et al., 2011; 20609486, von Bubnoff et al., 2005; 15618966, Walz et al., 2006; 16845659, Yoo et al., 2016; 26130666). Sorafenib has shown clinical and preclinical activity against the FIP1L1_PDGFRA fusion in chronic eosinophilic leukemia (CEL) and mutations associated with clinical resistance to imatinib and sunitinib in both CEL and gastrointestinal stromal tumor (GIST)(Fumagalli et al., 2012; ESMO Abstract 1491P, Al_Riyami et al., 2013; 23157309, Lierman et al., 2006; 16645167, Lierman et al., 2009; 19212337, Metzgeroth et al., 2012; 21818111, Roubaud et al., 2012; 22294526, Von Bubnoff et al., 2011; 20972453). Complete responses to nilotinib have been reported in patients with CEL or hypereosinophilic syndrome with FIP1L1_PDGFRA or activating mutations (Hochhaus et al., 2013; 24057647, Ikezoe et al., 2010; 20303172, Tabouret et al., 2011; 20832858); preclinical evidence has reported efficacy of nilotinib in the context of PDGFRA mutations associated with GIST (Dewaele et al., 2008; 18794084, Weisberg et al., 2006; 17087936). Patients with GIST harboring PDGFRA activating mutations have been reported to derive clinical benefit from treatment with sunitinib (Heinrich et al., 2006; ASCO Abstract 9502, Brohl et al., 2015; 26396737) or regorafenib (Grellety et al., 2015; 28031906, Kollar et al., 2014; 25905001). Preclinical studies have reported sensitivity of activating PDGFRA mutations and FIP1L1_PDGFRA fusion to dasatinib (Dewaele et al., 2008; 18794084, Lierman et al., 2009; 19212337). PDGFRA D842 mutations were reported to be sensitive to avapritinib in clinical (Heinrich et al., 2017; ASCO Abstract 11011, Evans et al., 2017; 29093181) and preclinical (Evans et al., 2017; 29093181) studies of GIST, and demonstrated sensitivity to ripretinib for 1 patient (Jaku et al., 2017; ASCO Abstract 2515).', 'Include': 'true', 'ClinicalTrialNote': 'PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies.', 'Therapies': {'Therapy': {'Name': None, 'GenericName': 'Imatinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Imatinib targets the BCR_ABL fusion protein, PDGFR, and KIT. It is FDA approved for the treatment of KIT_positive gastrointestinal stromal tumors (GIST), Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative syndrome (MDS/MPS), aggressive systemic mastocytosis without a D816V KIT mutation, hypereosinophilic syndrome and/or chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical and preclinical data in KIT_mutated (Carvajal et al., 2011; 21642685, Debiec_Rychter et al., 2006; 16624552, Heinrich et al., 2003; 14645423, Hodi et al., 2013; 23775962), KIT_amplified (Wei et al., 2019; 30075827, Guo et al., 2011; 21690468, Hodi et al., 2013; 23775962, Carvajal et al., 2011; 21642685), or KIT_expressing tumors (DeMatteo et al., 2009; 19303137, Faivre et al., 2005; 16135502, Alcedo et al., 2004; 15350030, Brandwein et al., 2011; 21403650, Hotte et al., 2005; 15659505, Reardon et al., 2009; 19904263, Kamenz et al., 2006; 16570351, Wang et al., 2005; 15650049), KIT activating alterations may confer sensitivity to imatinib. PDGFRA amplification may predict sensitivity to tyrosine kinase inhibitors such as imatinib; a patient with Merkel cell carcinoma expressing PDGFRA achieved a complete response to imatinib (Frenard et al., 2016; 27051816). </p> <p><b>Supporting Data:</b> Although a Phase 2 trial of imatinib in chemotherapy_refractory germ cell tumors expressing KIT reported no significant clinical benefit (Einhorn et al., 2006; 16462496), two case studies have reported responses of KIT_expressing testicular seminomas to imatinib, including one complete response for 28 months (Pedersini et al., 2007; 17976614, Okamura et al., 2010; 20080832). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': {'nctId': 'NCT01738139', 'Include': 'true'}}}}, 'ReferenceLinks': None}, {'Name': 'FGF23', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'FGF23 encodes a member of the fibroblast growth factor protein family that plays a central role in phosphate homeostasis (Jonsson et al., 2003; 12711740). Overexpression of FGF23 by tumor cells can cause hypophosphatemia through excessive renal phosphate clearance (Shimada et al., 2001; 11344269), while germline gain_of_function (protein stabilizing) mutations in FGF23 cause autosomal dominant hypophosphatemic rickets (Xu and White, 2005; 15863037). FGF23 alterations have been reported with highest incidence in uterine carcinosarcoma (7.0%), ovarian carcinoma (6.5%), testicular germ cell cancer (5.4%), cutaneous melanoma (5.0%), low_grade glioma (4.9%), lung squamous cell carcinoma (4.5%), sarcoma (4.3%), colorectal adenocarcinoma (4.2%), lung adenocarcinoma (3.7%), and head and neck squamous cell carcinoma (3.4%) (cBioPortal, 2022) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). There are no targeted therapies that directly address genomic alterations in FGF23. Inhibitors of FGF receptors, however, are undergoing clinical trials in a number of different cancers. Limited data suggest that pan_FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan_FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR (Dumbrava et al., 2018; doi/full/10.1200/PO.18.00100).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'FGF6', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'FGF6 (also known as HST_2) encodes a member of the fibroblast growth factor protein family and is hypothesized to play a role in muscle tissue regeneration (Neuhaus et al., 2003; 12917328) by signaling through FGFR4, and to a lesser extent FGFR1 and FGFR2 (Ornitz et al., 1996; 8663044). FGF6 expression has been observed in several cancers (Iida et al., 1992; 1549352, Ropiquet et al., 2000; 10945637, Niini et al., 2002; 12399964) and was shown to be oncogenic in preclinical models (Marics et al., 1989; 2649847, Iida et al., 1992; 1549352). FGF6 has been reported as amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). Somatic alterations affecting FGF6 are infrequently documented, with the highest rates reported in penile cancer (4%), cutaneous melanoma (1_3%), stomach carcinoma (1_3%) and colorectal cancer (1%) (cBioPortal, COSMIC, Jan 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Amplification of FGF6 has been frequently observed in testicular germ cell cancer (5%) and ovarian serous cystadenocarcinoma (5%), and in 2_6% of lower_grade gliomas, glioblastomas, sarcomas, breast invasive carcinomas, uterine carcinosarcomas, lung squamous cell carcinomas (SCC), head and neck SCC, pancreatic adenocarcinomas, and esophageal carcinomas (cBioPortal, Jan 2022) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). FGF6 is co_localized with FGF23 and CCND2 at chromosomal locus 12p13 and has been reported to be co_amplified with these genes in 1.3% of patients with breast cancer (Parish et al., 2015; 25950492). FGF6 expression has been reported in 54% (14/26) of prostate cancer samples, which also frequently express FGFR4 (Ropiquet et al., 2000; 10945637). FGF6 expression has also been observed in 71% (12/17) of patients with childhood acute lymphoblastic leukemia (Niini et al., 2002; 12399964). There are no targeted therapies that directly address genomic alterations in FGF6. Inhibitors of FGF receptors, however, are undergoing clinical trials in a number of different cancers. Limited data suggest that pan_FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan_FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR (Dumbrava et al., 2018; doi/full/10.1200/PO.18.00100).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'KDR', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'KDR encodes vascular endothelial growth factor receptor 2 (VEGFR2), a member of the vascular endothelial growth factor receptor (VEGFR) family. It is a receptor tyrosine kinase that transmits signals from VEGFA and is involved in both tumor angiogenesis and vasculogenesis during development (Takahashi, 2011; 22130231). KDR amplification has been reported in many tumor types and may be oncogenic (Takahashi, 2011; 22130231). KDR amplification has been reported in 2.2% of testicular germ cell tumors (cBio_Bagrodia et al., 2016; 27646943, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In a study of 49 central nervous system germinomas, amplification of 4q12, the region where KDR is located, was reported in 1 pineal gland germinoma (Schulte et al., 2016;27391150). Amplification of KDR or 4q12 was not reported in a study of 87 ovarian germ cell tumors (Nieuwenhuysen et al., 2018;30170975). The frequency of KDR amplification in mediastinal germinomas and retroperitoneal germ cell tumors has not been evaluated (cBioPortal, PubMed, Nov 2021) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of KDR alterations in germ cell tumors are limited (PubMed, Nov 2021). On the basis of clinical benefit for patients with ccRCC (Beuselinck et al., 2018; 29095068, Song et al., 2015; 26228213, Dornbusch et al., 2013; 24086736, Terakawa et al., 2013; 21478036, You et al., 2015; 24710685) and a patient with breast angiosarcoma (Silva et al., 2015; 25639617), high VEGFR_2 expression has been associated with sensitivity to sunitinib. However, because data supporting concordance between VEGFR_2 expression and KDR genomic biomarkers are limited, it is unclear whether these therapeutic strategies would be beneficial in this case. On the basis of extensive clinical evidence across multiple tumor types, expression of plasma or tumor VEGFR_1 or VEGFR_2 has not been established as a reliable biomarker to predict response to the VEGFA_targeted agent bevacizumab (Baumgarten et al., 2016; 26627848, Sathornsumetee et al., 2008; 18182667, Olafson et al., 2019; 31582283, Nishikawa et al., 2013; ASCO Abstract 2023, Wick et al., 2013; WCN Abstract 1207, Duda et al., 2010; 20484123, Stremitzer et al., 2016; 27535973, Weickhardt et al., 2015; 26125443, Kopetz et al., 2009; 20008624, Miles et al., 2013; 23422754, Fountzilas et al., 2011; 21868552, Gianni et al., 2013; 23569311, Sánchez_Rovira et al., 2013; 23397155, Cameron et al., 2013; 23932548, Mok et al., 2014; 24807156, An et al., 2014; 24577128, Bais et al., 2017; 29059426, Cohen et al., 2009; 19201650, Van Cutsem et al., 2011; EMCC Abstract 803, Van Cutsem et al., 2012; 22565005, Lee et al., 2018; 29941486, Xu et al., 2009; 19826039, Heist et al., 2014; 25605928).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'MS_Stable', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'MS_Stable'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI positivity at any level has been reported in 0_31% (n = 17_188) of testicular germ cell tumors (GCTs) (Lothe et al., 1993; 8261392, Murty et al., 1994; 8033127, Huddart et al., 1995; 7669575, Faulkner and Friedlander, 2000; 11006028, Devouassoux_Shisheboran et al., 2001; 11719586, Velasco et al., 2004; 15492498, Olasz et al., 2005; 16309235, Vladušić et al., 2014; 25075023, Cárcano et al., 2016; 27153176) and in 33% (12/36) of ovarian GCTs (Faulkner and Friedlander, 2000; 11006028). Within testicular GCTs, 12_31% of cases (n = 17_51) have been classified as having low_level MSI (MSI_L) and 69_100% (n = 17_133) have been classified as MSS (Devouassoux_Shisheboran et al., 2001; 11719586, Olasz et al., 2005; 16309235, Cárcano et al., 2016; 27153176), with MSI_high (MSI_H) rarely reported; one study identified MSI_L in 6% (6/100) and MSI_H in 0% (0/100) of unselected testicular GCTs, and MSI_L in 6% (2/35) and MSI_H in 26% (9/35) of chemotherapy_resistant cases (Mayer et al., 2002; 12019150, Honecker et al., 2009; 19289622). The significance of MSI in the context of GCTs is not well established (PubMed, Nov 2021). One study reported MSI_H to be significantly more frequent in chemotherapy_resistant than unselected testicular GCT cases (Mayer et al., 2002; 12019150, Honecker et al., 2009; 19289622), and some studies have associated MSI positivity with reduced PFS and/or increased risk of recurrence (Mayer et al., 2002; 12019150, Honecker et al., 2009; 19289622, Velasco et al., 2004; 15492498, Velasco et al., 2008; 18076065); however, another study found no correlation between MSI status and clinicopathologic features, including chemotherapy sensitivity and outcome (Olasz et al., 2005; 16309235). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Tumor Mutation Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '00', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '00'}}, 'Interpretation': 'Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Compared to other tumor types, germ cell tumors (GCTs) have been reported to have a low TMB (mean 0.51 mutations per megabase [muts/Mb] as measured in tissue), with a similar mutation rate reported for seminoma (0.50 muts/Mb) and non_seminoma (0.49 muts/Mb) tumors (Litchfield et al., 2015; 25609015). Published data investigating the prognostic implications of TMB in germ cell tumors are limited (PubMed, Sep 2021). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB ≥10 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB ≥10 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'CDK4/6 Tumor, Abemaciclib, Paclitaxel', 'StudyPhase': 'PHASE 1/2', 'Target': 'CDK4, CDK6', 'Locations': 'Seoul (Korea, Republic of)', 'NCTID': 'NCT04594005', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.', 'StudyPhase': 'PHASE 1', 'Target': 'CDK4, CDK6, IGF_1, IGF_2, Aromatase, ER', 'Locations': 'Seoul (Korea, Republic of), Goyang (Korea, Republic of), Aichi, Nagoya (Japan), Kanagawa, Isehara (Japan), Tokyo, Chuo_ku (Japan), Tokyo, Koto_ku (Japan), Chiba, Kashiwa (Japan), Helsinki (Finland), Tampere (Finland), Turku (Finland)', 'NCTID': 'NCT03099174', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'Genetic Testing in Guiding Treatment for Patients With Brain Metastases', 'StudyPhase': 'PHASE 2', 'Target': 'TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR', 'Locations': 'Alaska, Washington', 'NCTID': 'NCT03994796', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'Palbociclib In Progressive Brain Metastases', 'StudyPhase': 'PHASE 2', 'Target': 'CDK4, CDK6', 'Locations': 'Massachusetts', 'NCTID': 'NCT02896335', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D_type Cyclins or Amplification of CDK4 or CDK6', 'StudyPhase': 'PHASE 2', 'Target': 'CDK4, CDK6', 'Locations': 'Massachusetts', 'NCTID': 'NCT03310879', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6', 'Locations': 'Massachusetts', 'NCTID': 'NCT03065062', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'MAPK3, MAPK1, CDK4, CDK6', 'Locations': 'North Carolina', 'NCTID': 'NCT03454035', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'CCND2', 'Alteration': 'amplification', 'Title': 'Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'CDK4, CDK6', 'Locations': 'Georgia', 'NCTID': 'NCT02897375', 'Note': 'CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy', 'StudyPhase': 'PHASE 2', 'Target': 'KIT, ABL', 'Locations': 'Seoul (Korea, Republic of)', 'NCTID': 'NCT02461849', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Study of MK_4830 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_4830_001)', 'StudyPhase': 'PHASE 1', 'Target': 'ITL4, FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1', 'Locations': 'Seoul (Korea, Republic of), Tokyo (Japan), Haifa (Israel), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Warszawa (Poland), Gdansk (Poland), Heraklion (Greece), Washington', 'NCTID': 'NCT03564691', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor', 'StudyPhase': 'PHASE 1', 'Target': 'CBP, Beta_catenin, FGFRs, RET, PDGFRA, VEGFRs, KIT', 'Locations': 'Osakasayama (Japan), Chuo_Ku (Japan), Kashiwa (Japan)', 'NCTID': 'NCT04008797', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, ERBB3, MEK, BRAF, SMO', 'Locations': 'Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)', 'NCTID': 'NCT03297606', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Pembrolizumab And Lenvatinib In Leptomeningeal Metastases', 'StudyPhase': 'PHASE 2', 'Target': 'PD_1, KIT, VEGFRs, FGFRs, PDGFRA, RET', 'Locations': 'Massachusetts', 'NCTID': 'NCT04729348', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Study of PI3Kinase Inhibition (Copanlisib) and Anti_PD_1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch_repair Proficient (MSS) Colorectal Cancer', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1, PI3K', 'Locations': 'Maryland', 'NCTID': 'NCT03711058', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Rapid Analysis and Response Evaluation of Combination Anti_Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel', 'StudyPhase': 'PHASE 2', 'Target': 'ABL, KIT', 'Locations': 'Maryland', 'NCTID': 'NCT04449549', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KIT', 'Alteration': 'amplification', 'Title': 'Study of the CDK4/6 Inhibitor Palbociclib (PD_0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF_05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PI3K_alpha, PI3K_gamma, mTORC1, mTORC2, CDK4, CDK6', 'Locations': 'Massachusetts', 'NCTID': 'NCT03065062', 'Note': 'KIT amplification or activating mutations may predict sensitivity to small molecule tyrosine kinase inhibitors. Also, because KIT activation leads to activation of the PI3K_AKT_mTOR pathway, PI3K and mTOR pathway inhibitors may be relevant in a tumor with KIT activation.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'amplification', 'Title': 'Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors', 'StudyPhase': 'PHASE 2', 'Target': 'mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK', 'Locations': 'Guangzhou (China)', 'NCTID': 'NCT04803318', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'amplification', 'Title': 'Dose_Escalation and Dose_Expansion of RMC_4630 and Cobimetinib in Relapsed/Refractory Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'SHP2, MEK', 'Locations': 'Seoul (Korea, Republic of), Oregon, California, Colorado, Arizona, Wisconsin, Illinois', 'NCTID': 'NCT03989115', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'amplification', 'Title': 'Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'MEK, RAFs', 'Locations': 'Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of)', 'NCTID': 'NCT03284502', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'amplification', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'amplification', 'Title': 'Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors', 'StudyPhase': 'PHASE 1/2', 'Target': 'RAFs, EGFR, MEK', 'Locations': 'Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), Texas', 'NCTID': 'NCT03905148', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'amplification', 'Title': 'Phase I Trial of RO5126766', 'StudyPhase': 'PHASE 1', 'Target': 'RAFs, MEK, mTOR', 'Locations': 'London (United Kingdom), Sutton (United Kingdom)', 'NCTID': 'NCT02407509', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'amplification', 'Title': 'PF_07284892 in Participants With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'SHP2, ROS1, ALK, MEK, BRAF, EGFR', 'Locations': 'California, Michigan, New York, Tennessee, Texas', 'NCTID': 'NCT04800822', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'amplification', 'Title': 'Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction', 'StudyPhase': 'PHASE 1', 'Target': 'MEK', 'Locations': 'Toronto (Canada)', 'NCTID': 'NCT02070549', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.', 'Include': 'true'}, {'Gene': 'KRAS', 'Alteration': 'amplification', 'Title': 'Selumetinib and Olaparib in Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'MEK, PARP', 'Locations': 'Texas', 'NCTID': 'NCT03162627', 'Note': 'KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors.', 'Include': 'true'}, {'Gene': 'PDGFRA', 'Alteration': 'amplification', 'Title': 'Ipilimumab and Imatinib Mesylate in Advanced Cancer', 'StudyPhase': 'PHASE 1', 'Target': 'KIT, ABL, CTLA_4', 'Locations': 'Texas', 'NCTID': 'NCT01738139', 'Note': 'PDGFRA amplification may predict sensitivity to imatinib and to anti_PDGFRA antibodies.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '18483217', 'FullCitation': 'Andrae J, et al. Genes Dev. (2008) pmid: 18483217', 'Include': 'true'}, {'number': '1', 'ReferenceId': '15175998', 'FullCitation': 'Semin. Oncol. (2004) pmid: 15175998', 'Include': 'true'}, {'number': '2', 'ReferenceId': '23990986', 'FullCitation': 'Burford A, et al. PLoS ONE (2013) pmid: 23990986', 'Include': 'true'}, {'number': '3', 'ReferenceId': '26700815', 'FullCitation': 'Flavahan WA, et al. Nature (2016) pmid: 26700815', 'Include': 'true'}, {'number': '4', 'ReferenceId': '26787600', 'FullCitation': 'Roszik J, et al. Sci Rep (2016) pmid: 26787600', 'Include': 'true'}, {'number': '5', 'ReferenceId': '20129251', 'FullCitation': 'Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251', 'Include': 'true'}, {'number': '6', 'ReferenceId': '27582545', 'FullCitation': 'Koschmann C, et al. Oncotarget (2016) pmid: 27582545', 'Include': 'true'}, {'number': '7', 'ReferenceId': '23438035', 'FullCitation': 'Phillips JJ, et al. Brain Pathol. (2013) pmid: 23438035', 'Include': 'true'}, {'number': '8', 'ReferenceId': '22389665', 'FullCitation': 'Puget S, et al. PLoS ONE (2012) pmid: 22389665', 'Include': 'true'}, {'number': '9', 'ReferenceId': '27646943', 'FullCitation': 'Bagrodia A, et al. J. Clin. Oncol. (2016) pmid: 27646943', 'Include': 'true'}, {'number': '10', 'ReferenceId': '22588877', 'FullCitation': 'Cerami E, et al. Cancer Discov (2012) pmid: 22588877', 'Include': 'true'}, {'number': '11', 'ReferenceId': '23550210', 'FullCitation': 'Gao J, et al. Sci Signal (2013) pmid: 23550210', 'Include': 'true'}, {'number': '12', 'ReferenceId': '27391150', 'FullCitation': 'Schulte SL, et al. Oncotarget (2016) pmid: 27391150', 'Include': 'true'}, {'number': '13', 'ReferenceId': '16166280', 'FullCitation': 'McIntyre A, et al. Cancer Res. (2005) pmid: 16166280', 'Include': 'true'}, {'number': '14', 'ReferenceId': '30170975', 'FullCitation': 'Van Nieuwenhuysen E, et al. Gynecol. Oncol. (2018) pmid: 30170975', 'Include': 'true'}, {'number': '15', 'ReferenceId': '22806436', 'FullCitation': 'Arefi M, et al. Int. J. Hematol. (2012) pmid: 22806436', 'Include': 'true'}, {'number': '16', 'ReferenceId': '17666373', 'FullCitation': 'Baccarani M, et al. Haematologica (2007) pmid: 17666373', 'Include': 'true'}, {'number': '17', 'ReferenceId': '22718859', 'FullCitation': 'Cassier PA, et al. Clin. Cancer Res. (2012) pmid: 22718859', 'Include': 'true'}, {'number': '18', 'ReferenceId': '25658984', 'FullCitation': 'Chalmers ZR, et al. Blood Cancer J (2015) pmid: 25658984', 'Include': 'true'}, {'number': '19', 'ReferenceId': '12660384', 'FullCitation': 'Cools J, et al. N. Engl. J. Med. (2003) pmid: 12660384', 'Include': 'true'}, {'number': '20', 'ReferenceId': '17555450', 'FullCitation': 'Curtis CE, et al. Br. J. Haematol. (2007) pmid: 17555450', 'Include': 'true'}, {'number': '21', 'ReferenceId': '15010069', 'FullCitation': 'Debiec_Rychter M, et al. Eur. J. Cancer (2004) pmid: 15010069', 'Include': 'true'}, {'number': '22', 'ReferenceId': '20473908', 'FullCitation': 'Dileo P, et al. Int. J. Cancer (2011) pmid: 20473908', 'Include': 'true'}, {'number': '23', 'ReferenceId': '24638008', 'FullCitation': 'Fanta PT, et al. J. Clin. Oncol. (2015) pmid: 24638008', 'Include': 'true'}, {'number': '24', 'ReferenceId': '16406018', 'FullCitation': 'Florian S, et al. Leuk. Res. (2006) pmid: 16406018', 'Include': 'true'}, {'number': '25', 'ReferenceId': '27051816', 'FullCitation': 'Frenard C, et al. JAAD Case Rep (2016) pmid: 27051816', 'Include': 'true'}, {'number': '26', 'ReferenceId': '12808148', 'FullCitation': 'Griffin JH, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808148', 'Include': 'true'}, {'number': '27', 'ReferenceId': '14645423', 'FullCitation': 'Heinrich MC, et al. J. Clin. Oncol. (2003) pmid: 14645423', 'Include': 'true'}, {'number': '28', 'ReferenceId': '19120352', 'FullCitation': 'Helbig G, et al. Br. J. Haematol. (2009) pmid: 19120352', 'Include': 'true'}, {'number': '29', 'ReferenceId': '24009127', 'FullCitation': 'Helbig G, et al. Am. J. Hematol. (2014) pmid: 24009127', 'Include': 'true'}, {'number': '30', 'ReferenceId': '21093052', 'FullCitation': 'Hus M, et al. Leuk. Res. (2011) pmid: 21093052', 'Include': 'true'}, {'number': '31', 'ReferenceId': '20303172', 'FullCitation': 'Ikezoe T, et al. Leuk. Res. (2010) pmid: 20303172', 'Include': 'true'}, {'number': '32', 'ReferenceId': '19735261', 'FullCitation': 'Intermesoli T, et al. Br. J. Haematol. (2009) pmid: 19735261', 'Include': 'true'}, {'number': '33', 'ReferenceId': '19013640', 'FullCitation': 'Jain N, et al. Leuk. Res. (2009) pmid: 19013640', 'Include': 'true'}, {'number': '34', 'ReferenceId': '17299092', 'FullCitation': 'Jovanovic JV, et al. Blood (2007) pmid: 17299092', 'Include': 'true'}, {'number': '35', 'ReferenceId': '22150077', 'FullCitation': 'Kang HJ, et al. Acta Oncol (2012) pmid: 22150077', 'Include': 'true'}, {'number': '36', 'ReferenceId': '14504092', 'FullCitation': 'Klion AD, et al. Blood (2004) pmid: 14504092', 'Include': 'true'}, {'number': '37', 'ReferenceId': '19192229', 'FullCitation': 'Kobayashi M, et al. Respirology (2009) pmid: 19192229', 'Include': 'true'}, {'number': '38', 'ReferenceId': '24635438', 'FullCitation': 'Kocáková I, et al. Klin Onkol (2014) pmid: 24635438', 'Include': 'true'}, {'number': '39', 'ReferenceId': '18950453', 'FullCitation': 'Metzgeroth G, et al. Br. J. Haematol. (2008) pmid: 18950453', 'Include': 'true'}, {'number': '40', 'ReferenceId': '22645636', 'FullCitation': 'Murayama Y, et al. World J Gastrointest Oncol (2012) pmid: 22645636', 'Include': 'true'}, {'number': '41', 'ReferenceId': '19910029', 'FullCitation': 'Ogbogu PU, et al. J. Allergy Clin. Immunol. (2009) pmid: 19910029', 'Include': 'true'}, {'number': '42', 'ReferenceId': '16856885', 'FullCitation': 'Ohnishi H, et al. Br. J. Haematol. (2006) pmid: 16856885', 'Include': 'true'}, {'number': '43', 'ReferenceId': '12842979', 'FullCitation': 'Pardanani A, et al. Blood (2003) pmid: 12842979', 'Include': 'true'}, {'number': '44', 'ReferenceId': '15284118', 'FullCitation': 'Pardanani A, et al. Blood (2004) pmid: 15284118', 'Include': 'true'}, {'number': '45', 'ReferenceId': '27120808', 'FullCitation': 'Qu SQ, et al. Oncotarget (2016) pmid: 27120808', 'Include': 'true'}, {'number': '46', 'ReferenceId': '16498388', 'FullCitation': 'Score J, et al. Leukemia (2006) pmid: 16498388', 'Include': 'true'}, {'number': '47', 'ReferenceId': '24669761', 'FullCitation': 'Shah S, et al. J Hematol Oncol (2014) pmid: 24669761', 'Include': 'true'}, {'number': '48', 'ReferenceId': '26319757', 'FullCitation': 'Sugimoto Y, et al. Cancer Genet (2015) pmid: 26319757', 'Include': 'true'}, {'number': '49', 'ReferenceId': '20609486', 'FullCitation': 'Volz HC, et al. Int. J. Cardiol. (2011) pmid: 20609486', 'Include': 'true'}, {'number': '50', 'ReferenceId': '15618966', 'FullCitation': 'von Bubnoff N, et al. Leukemia (2005) pmid: 15618966', 'Include': 'true'}, {'number': '51', 'ReferenceId': '16845659', 'FullCitation': 'Walz C, et al. Genes Chromosomes Cancer (2006) pmid: 16845659', 'Include': 'true'}, {'number': '52', 'ReferenceId': '26130666', 'FullCitation': 'Yoo C, et al. Cancer Res Treat (2016) pmid: 26130666', 'Include': 'true'}, {'number': '53', 'ReferenceId': '23157309', 'FullCitation': 'Al_Riyami AZ, et al. Leuk. Lymphoma (2013) pmid: 23157309', 'Include': 'true'}, {'number': '54', 'ReferenceId': '16645167', 'FullCitation': 'Lierman E, et al. Blood (2006) pmid: 16645167', 'Include': 'true'}, {'number': '55', 'ReferenceId': '19212337', 'FullCitation': 'Lierman E, et al. Leukemia (2009) pmid: 19212337', 'Include': 'true'}, {'number': '56', 'ReferenceId': '21818111', 'FullCitation': 'Metzgeroth G, et al. Leukemia (2012) pmid: 21818111', 'Include': 'true'}, {'number': '57', 'ReferenceId': '22294526', 'FullCitation': 'Roubaud G, et al. Ann. Oncol. (2012) pmid: 22294526', 'Include': 'true'}, {'number': '58', 'ReferenceId': '20972453', 'FullCitation': 'von Bubnoff N, et al. Oncogene (2011) pmid: 20972453', 'Include': 'true'}, {'number': '59', 'ReferenceId': '24057647', 'FullCitation': 'Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2013) pmid: 24057647', 'Include': 'true'}, {'number': '60', 'ReferenceId': '20832858', 'FullCitation': 'Tabouret E, et al. Leuk. Res. (2011) pmid: 20832858', 'Include': 'true'}, {'number': '61', 'ReferenceId': '18794084', 'FullCitation': 'Dewaele B, et al. Clin. Cancer Res. (2008) pmid: 18794084', 'Include': 'true'}, {'number': '62', 'ReferenceId': '17087936', 'FullCitation': 'Weisberg E, et al. Gastroenterology (2006) pmid: 17087936', 'Include': 'true'}, {'number': '63', 'ReferenceId': '26396737', 'FullCitation': 'Brohl AS, et al. Clin Sarcoma Res (2015) pmid: 26396737', 'Include': 'true'}, {'number': '64', 'ReferenceId': '28031906', 'FullCitation': 'Grellety T, et al. Future Sci OA (2015) pmid: 28031906', 'Include': 'true'}, {'number': '65', 'ReferenceId': '25905001', 'FullCitation': 'Kollàr A, et al. Clin Sarcoma Res (2014) pmid: 25905001', 'Include': 'true'}, {'number': '66', 'ReferenceId': '29093181', 'FullCitation': 'Evans EK, et al. Sci Transl Med (2017) pmid: 29093181', 'Include': 'true'}, {'number': '67', 'ReferenceId': '10582339', 'FullCitation': 'Int. J. Biochem. Cell Biol. (1999) pmid: 10582339', 'Include': 'true'}, {'number': '68', 'ReferenceId': '24071852', 'FullCitation': 'Zack TI, et al. Nat. Genet. (2013) pmid: 24071852', 'Include': 'true'}, {'number': '69', 'ReferenceId': '20164920', 'FullCitation': 'Beroukhim R, et al. Nature (2010) pmid: 20164920', 'Include': 'true'}, {'number': '70', 'ReferenceId': '27536065', 'FullCitation': 'Abbaspour Babaei M, et al. Drug Des Devel Ther (2016) pmid: 27536065', 'Include': 'true'}, {'number': '71', 'ReferenceId': '27563456', 'FullCitation': 'Ramaswamy A, et al. J Gastrointest Oncol (2016) pmid: 27563456', 'Include': 'true'}, {'number': '72', 'ReferenceId': '23177515', 'FullCitation': 'Demetri GD, et al. Lancet (2013) pmid: 23177515', 'Include': 'true'}, {'number': '73', 'ReferenceId': '27355533', 'FullCitation': 'Gotlib J, et al. N. Engl. J. Med. (2016) pmid: 27355533', 'Include': 'true'}, {'number': '74', 'ReferenceId': '28424161', 'FullCitation': 'Jawhar M, et al. Blood (2017) pmid: 28424161', 'Include': 'true'}, {'number': '75', 'ReferenceId': '25031773', 'FullCitation': 'Xu X, et al. Int J Clin Exp Pathol (2014) pmid: 25031773', 'Include': 'true'}, {'number': '76', 'ReferenceId': '15972446', 'FullCitation': 'Gotlib J, et al. Blood (2005) pmid: 15972446', 'Include': 'true'}, {'number': '77', 'ReferenceId': '22162580', 'FullCitation': 'Si L, et al. J. Clin. Oncol. (2012) pmid: 22162580', 'Include': 'true'}, {'number': '78', 'ReferenceId': '20038218', 'FullCitation': 'Parikh SA, et al. Leuk Lymphoma (2010) pmid: 20038218', 'Include': 'true'}, {'number': '79', 'ReferenceId': '30075827', 'FullCitation': 'Wei X, et al. Oncol. Res. (2019) pmid: 30075827', 'Include': 'true'}, {'number': '80', 'ReferenceId': '23775962', 'FullCitation': 'Hodi FS, et al. J. Clin. Oncol. (2013) pmid: 23775962', 'Include': 'true'}, {'number': '81', 'ReferenceId': '21642685', 'FullCitation': 'Carvajal RD, et al. JAMA (2011) pmid: 21642685', 'Include': 'true'}, {'number': '82', 'ReferenceId': '21690468', 'FullCitation': 'Guo J, et al. J. Clin. Oncol. (2011) pmid: 21690468', 'Include': 'true'}, {'number': '83', 'ReferenceId': '15685537', 'FullCitation': 'Debiec_Rychter M, et al. Gastroenterology (2005) pmid: 15685537', 'Include': 'true'}, {'number': '84', 'ReferenceId': '19303137', 'FullCitation': 'Dematteo RP, et al. Lancet (2009) pmid: 19303137', 'Include': 'true'}, {'number': '85', 'ReferenceId': '16135502', 'FullCitation': 'Faivre S, et al. J. Clin. Oncol. (2005) pmid: 16135502', 'Include': 'true'}, {'number': '86', 'ReferenceId': '15659505', 'FullCitation': 'Hotte SJ, et al. J. Clin. Oncol. (2005) pmid: 15659505', 'Include': 'true'}, {'number': '87', 'ReferenceId': '15350030', 'FullCitation': 'Alcedo JC, et al. Head Neck (2004) pmid: 15350030', 'Include': 'true'}, {'number': '88', 'ReferenceId': '21403650', 'FullCitation': 'Brandwein JM, et al. Leukemia (2011) pmid: 21403650', 'Include': 'true'}, {'number': '89', 'ReferenceId': '19904263', 'FullCitation': 'Reardon DA, et al. Br. J. Cancer (2009) pmid: 19904263', 'Include': 'true'}, {'number': '90', 'ReferenceId': '26424760', 'FullCitation': 'Lee SJ, et al. Oncologist (2015) pmid: 26424760', 'Include': 'true'}, {'number': '91', 'ReferenceId': '22374331', 'FullCitation': 'Llovet JM, et al. Clin. Cancer Res. (2012) pmid: 22374331', 'Include': 'true'}, {'number': '92', 'ReferenceId': '23058498', 'FullCitation': 'Zhang HL, et al. Clin Genitourin Cancer (2013) pmid: 23058498', 'Include': 'true'}, {'number': '93', 'ReferenceId': '25450081', 'FullCitation': 'Seino S, et al. Gastroenterology (2014) pmid: 25450081', 'Include': 'true'}, {'number': '94', 'ReferenceId': '18846437', 'FullCitation': 'Li XF, et al. Med. Oncol. (2009) pmid: 18846437', 'Include': 'true'}, {'number': '95', 'ReferenceId': '22261812', 'FullCitation': 'Minor DR, et al. Clin. Cancer Res. (2012) pmid: 22261812', 'Include': 'true'}, {'number': '96', 'ReferenceId': '23114504', 'FullCitation': 'Mahipal A, et al. Melanoma Res. (2012) pmid: 23114504', 'Include': 'true'}, {'number': '97', 'ReferenceId': '19860666', 'FullCitation': 'Katoh Y, et al. Curr. Mol. Med. (2009) pmid: 19860666', 'Include': 'true'}, {'number': '98', 'ReferenceId': '16301994', 'FullCitation': 'White PC, et al. Oncogene (2006) pmid: 16301994', 'Include': 'true'}, {'number': '99', 'ReferenceId': '12660824', 'FullCitation': 'Rodriguez S, et al. Oncogene (2003) pmid: 12660824', 'Include': 'true'}, {'number': '100', 'ReferenceId': '16424014', 'FullCitation': 'Korkola JE, et al. Cancer Res. (2006) pmid: 16424014', 'Include': 'true'}, {'number': '101', 'ReferenceId': '17167184', 'FullCitation': 'Skotheim RI, et al. Cell. Oncol. (2006) pmid: 17167184', 'Include': 'true'}, {'number': '102', 'ReferenceId': '11358847', 'FullCitation': 'Schmidt BA, et al. Cancer Res. (2001) pmid: 11358847', 'Include': 'true'}, {'number': '103', 'ReferenceId': '12777997', 'FullCitation': 'Kukoski R, et al. Appl. Immunohistochem. Mol. Morphol. (2003) pmid: 12777997', 'Include': 'true'}, {'number': '104', 'ReferenceId': '15707582', 'FullCitation': 'Busk PK, et al. Exp. Cell Res. (2005) pmid: 15707582', 'Include': 'true'}, {'number': '105', 'ReferenceId': '12695654', 'FullCitation': 'Busk PK, et al. Cell Cycle () pmid: 12695654', 'Include': 'true'}, {'number': '106', 'ReferenceId': '25524798', 'FullCitation': 'Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798', 'Include': 'true'}, {'number': '107', 'ReferenceId': '25501126', 'FullCitation': 'DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126', 'Include': 'true'}, {'number': '108', 'ReferenceId': '21993244', 'FullCitation': 'Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244', 'Include': 'true'}, {'number': '109', 'ReferenceId': '3310850', 'FullCitation': 'Kahn S, et al. Anticancer Res. () pmid: 3310850', 'Include': 'true'}, {'number': '110', 'ReferenceId': '16354586', 'FullCitation': 'McIntyre A, et al. Neoplasia (2005) pmid: 16354586', 'Include': 'true'}, {'number': '111', 'ReferenceId': '19545448', 'FullCitation': 'Mita H, et al. BMC Cancer (2009) pmid: 19545448', 'Include': 'true'}, {'number': '112', 'ReferenceId': '23099803', 'FullCitation': 'Birkeland E, et al. Br. J. Cancer (2012) pmid: 23099803', 'Include': 'true'}, {'number': '113', 'ReferenceId': '24874471', 'FullCitation': 'Chen Y, et al. PLoS ONE (2014) pmid: 24874471', 'Include': 'true'}, {'number': '114', 'ReferenceId': '17573850', 'FullCitation': 'Goddard NC, et al. Int. J. Androl. (2007) pmid: 17573850', 'Include': 'true'}, {'number': '115', 'ReferenceId': '1381946', 'FullCitation': 'Moul JW, et al. Genes Chromosomes Cancer (1992) pmid: 1381946', 'Include': 'true'}, {'number': '116', 'ReferenceId': '25297496', 'FullCitation': 'Li Y, et al. J Ovarian Res (2014) pmid: 25297496', 'Include': 'true'}, {'number': '117', 'ReferenceId': '24422958', 'FullCitation': 'Hershkovitz D, et al. Pathol. Int. (2013) pmid: 24422958', 'Include': 'true'}, {'number': '118', 'ReferenceId': '22682753', 'FullCitation': 'Stanojevic B, et al. BMC Cancer (2012) pmid: 22682753', 'Include': 'true'}, {'number': '119', 'ReferenceId': '20955261', 'FullCitation': 'Mayer F, et al. BJU Int. (2011) pmid: 20955261', 'Include': 'true'}, {'number': '120', 'ReferenceId': '19289622', 'FullCitation': 'Honecker F, et al. J. Clin. Oncol. (2009) pmid: 19289622', 'Include': 'true'}, {'number': '121', 'ReferenceId': '11021820', 'FullCitation': 'Roelofs H, et al. Am. J. Pathol. (2000) pmid: 11021820', 'Include': 'true'}, {'number': '122', 'ReferenceId': '6320174', 'FullCitation': 'Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174', 'Include': 'true'}, {'number': '123', 'ReferenceId': '21523318', 'FullCitation': 'Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318', 'Include': 'true'}, {'number': '124', 'ReferenceId': '23438367', 'FullCitation': 'Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367', 'Include': 'true'}, {'number': '125', 'ReferenceId': '21245089', 'FullCitation': 'Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089', 'Include': 'true'}, {'number': '126', 'ReferenceId': '19372556', 'FullCitation': 'Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556', 'Include': 'true'}, {'number': '127', 'ReferenceId': '31118140', 'FullCitation': 'Liu JF, et al. Gynecol. Oncol. (2019) pmid: 31118140', 'Include': 'true'}, {'number': '128', 'ReferenceId': '22130231', 'FullCitation': 'Biol. Pharm. Bull. (2011) pmid: 22130231', 'Include': 'true'}, {'number': '129', 'ReferenceId': '29095068', 'FullCitation': 'Beuselinck B, et al. Acta Oncol (2018) pmid: 29095068', 'Include': 'true'}, {'number': '130', 'ReferenceId': '26228213', 'FullCitation': 'Song Y, et al. Chin. Med. J. (2015) pmid: 26228213', 'Include': 'true'}, {'number': '131', 'ReferenceId': '24086736', 'FullCitation': 'Dornbusch J, et al. PLoS ONE (2013) pmid: 24086736', 'Include': 'true'}, {'number': '132', 'ReferenceId': '21478036', 'FullCitation': 'Terakawa T, et al. Urol. Oncol. (2013) pmid: 21478036', 'Include': 'true'}, {'number': '133', 'ReferenceId': '24710685', 'FullCitation': 'You D, et al. World J Urol (2015) pmid: 24710685', 'Include': 'true'}, {'number': '134', 'ReferenceId': '25639617', 'FullCitation': 'Silva E, et al. Breast J () pmid: 25639617', 'Include': 'true'}, {'number': '135', 'ReferenceId': '26627848', 'FullCitation': 'Baumgarten P, et al. Neuro_oncology (2016) pmid: 26627848', 'Include': 'true'}, {'number': '136', 'ReferenceId': '18182667', 'FullCitation': 'Sathornsumetee S, et al. J. Clin. Oncol. (2008) pmid: 18182667', 'Include': 'true'}, {'number': '137', 'ReferenceId': '31582283', 'FullCitation': 'Olafson LR, et al. J Clin Neurosci (2019) pmid: 31582283', 'Include': 'true'}, {'number': '138', 'ReferenceId': '20484123', 'FullCitation': 'Duda DG, et al. Oncologist (2010) pmid: 20484123', 'Include': 'true'}, {'number': '139', 'ReferenceId': '27535973', 'FullCitation': 'Stremitzer S, et al. Mol. Cancer Ther. (2016) pmid: 27535973', 'Include': 'true'}, {'number': '140', 'ReferenceId': '26125443', 'FullCitation': 'Weickhardt AJ, et al. Br. J. Cancer (2015) pmid: 26125443', 'Include': 'true'}, {'number': '141', 'ReferenceId': '20008624', 'FullCitation': 'Kopetz S, et al. J. Clin. Oncol. (2010) pmid: 20008624', 'Include': 'true'}, {'number': '142', 'ReferenceId': '23422754', 'FullCitation': 'Miles DW, et al. Br. J. Cancer (2013) pmid: 23422754', 'Include': 'true'}, {'number': '143', 'ReferenceId': '21868552', 'FullCitation': 'Fountzilas G, et al. Anticancer Res. (2011) pmid: 21868552', 'Include': 'true'}, {'number': '144', 'ReferenceId': '23569311', 'FullCitation': 'Gianni L, et al. J. Clin. Oncol. (2013) pmid: 23569311', 'Include': 'true'}, {'number': '145', 'ReferenceId': '23397155', 'FullCitation': 'Sánchez_Rovira P, et al. Clin Transl Oncol (2013) pmid: 23397155', 'Include': 'true'}, {'number': '146', 'ReferenceId': '23932548', 'FullCitation': 'Cameron D, et al. Lancet Oncol. (2013) pmid: 23932548', 'Include': 'true'}, {'number': '147', 'ReferenceId': '24807156', 'FullCitation': 'Mok T, et al. J Thorac Oncol (2014) pmid: 24807156', 'Include': 'true'}, {'number': '148', 'ReferenceId': '24577128', 'FullCitation': 'An SJ, et al. Cancer Gene Ther. (2014) pmid: 24577128', 'Include': 'true'}, {'number': '149', 'ReferenceId': '29059426', 'FullCitation': 'Bais C, et al. J. Natl. Cancer Inst. (2017) pmid: 29059426', 'Include': 'true'}, {'number': '150', 'ReferenceId': '19201650', 'FullCitation': 'Cohen EE, et al. Lancet Oncol. (2009) pmid: 19201650', 'Include': 'true'}, {'number': '151', 'ReferenceId': '22565005', 'FullCitation': 'Van Cutsem E, et al. J. Clin. Oncol. (2012) pmid: 22565005', 'Include': 'true'}, {'number': '152', 'ReferenceId': '29941486', 'FullCitation': 'Lee EQ, et al. Clin. Cancer Res. (2018) pmid: 29941486', 'Include': 'true'}, {'number': '153', 'ReferenceId': '19826039', 'FullCitation': 'Xu L, et al. Cancer Res. (2009) pmid: 19826039', 'Include': 'true'}, {'number': '154', 'ReferenceId': '25605928', 'FullCitation': 'Heist RS, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25605928', 'Include': 'true'}, {'number': '155', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '156', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '157', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '158', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '159', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '160', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '161', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '162', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '163', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '164', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '165', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '166', 'ReferenceId': '28835386', 'FullCitation': 'Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386', 'Include': 'true'}, {'number': '167', 'ReferenceId': '32919526', 'FullCitation': 'Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526', 'Include': 'true'}, {'number': '168', 'ReferenceId': '31405947', 'FullCitation': 'Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947', 'Include': 'true'}, {'number': '169', 'ReferenceId': '25609015', 'FullCitation': 'Litchfield K, et al. Nat Commun (2015) pmid: 25609015', 'Include': 'true'}, {'number': '170', 'ReferenceId': '30643254', 'FullCitation': 'Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254', 'Include': 'true'}, {'number': '171', 'ReferenceId': '30309915', 'FullCitation': 'Cristescu R, et al. Science (2018) pmid: 30309915', 'Include': 'true'}, {'number': '172', 'ReferenceId': '30785829', 'FullCitation': 'Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829', 'Include': 'true'}, {'number': '173', 'ReferenceId': '29658845', 'FullCitation': 'Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845', 'Include': 'true'}, {'number': '174', 'ReferenceId': '29657128', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128', 'Include': 'true'}, {'number': '175', 'ReferenceId': '29731394', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394', 'Include': 'true'}, {'number': '176', 'ReferenceId': '33558721', 'FullCitation': 'Rozeman EA, et al. Nat Med (2021) pmid: 33558721', 'Include': 'true'}, {'number': '177', 'ReferenceId': '32916128', 'FullCitation': 'Sharma P, et al. Cancer Cell (2020) pmid: 32916128', 'Include': 'true'}, {'number': '178', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '179', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '180', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '181', 'ReferenceId': '9823339', 'FullCitation': 'Boland CR, et al. Cancer Res. (1998) pmid: 9823339', 'Include': 'true'}, {'number': '182', 'ReferenceId': '15528785', 'FullCitation': 'Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785', 'Include': 'true'}, {'number': '183', 'ReferenceId': '20420947', 'FullCitation': 'Boland CR, et al. Gastroenterology (2010) pmid: 20420947', 'Include': 'true'}, {'number': '184', 'ReferenceId': '8261392', 'FullCitation': 'Lothe RA, et al. Cancer Res. (1993) pmid: 8261392', 'Include': 'true'}, {'number': '185', 'ReferenceId': '8033127', 'FullCitation': 'Murty VV, et al. Cancer Res. (1994) pmid: 8033127', 'Include': 'true'}, {'number': '186', 'ReferenceId': '7669575', 'FullCitation': 'Huddart RA, et al. Br. J. Cancer (1995) pmid: 7669575', 'Include': 'true'}, {'number': '187', 'ReferenceId': '11006028', 'FullCitation': 'Faulkner SW, et al. Gynecol. Oncol. (2000) pmid: 11006028', 'Include': 'true'}, {'number': '188', 'ReferenceId': '11719586', 'FullCitation': 'Devouassoux_Shisheboran M, et al. Mol. Hum. Reprod. (2001) pmid: 11719586', 'Include': 'true'}, {'number': '189', 'ReferenceId': '15492498', 'FullCitation': 'Velasco A, et al. Cancer Biol. Ther. (2004) pmid: 15492498', 'Include': 'true'}, {'number': '190', 'ReferenceId': '16309235', 'FullCitation': 'Olasz J, et al. Anticancer Res. () pmid: 16309235', 'Include': 'true'}, {'number': '191', 'ReferenceId': '25075023', 'FullCitation': 'Vladušić T, et al. Anticancer Res. (2014) pmid: 25075023', 'Include': 'true'}, {'number': '192', 'ReferenceId': '27153176', 'FullCitation': 'Cárcano FM, et al. Andrology (2016) pmid: 27153176', 'Include': 'true'}, {'number': '193', 'ReferenceId': '12019150', 'FullCitation': 'Mayer F, et al. Cancer Res. (2002) pmid: 12019150', 'Include': 'true'}, {'number': '194', 'ReferenceId': '18076065', 'FullCitation': 'Velasco A, et al. Int. J. Cancer (2008) pmid: 18076065', 'Include': 'true'}, {'number': '195', 'ReferenceId': '25392179', 'FullCitation': 'Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179', 'Include': 'true'}, {'number': '196', 'ReferenceId': '26140250', 'FullCitation': 'Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250', 'Include': 'true'}, {'number': '197', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '198', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '199', 'ReferenceId': '12917328', 'FullCitation': 'Neuhaus P, et al. Mol. Cell. Biol. (2003) pmid: 12917328', 'Include': 'true'}, {'number': '200', 'ReferenceId': '8663044', 'FullCitation': 'Ornitz DM, et al. J. Biol. Chem. (1996) pmid: 8663044', 'Include': 'true'}, {'number': '201', 'ReferenceId': '1549352', 'FullCitation': 'Iida S, et al. Oncogene (1992) pmid: 1549352', 'Include': 'true'}, {'number': '202', 'ReferenceId': '10945637', 'FullCitation': 'Ropiquet F, et al. Cancer Res. (2000) pmid: 10945637', 'Include': 'true'}, {'number': '203', 'ReferenceId': '12399964', 'FullCitation': 'Niini T, et al. Leukemia (2002) pmid: 12399964', 'Include': 'true'}, {'number': '204', 'ReferenceId': '2649847', 'FullCitation': 'Marics I, et al. Oncogene (1989) pmid: 2649847', 'Include': 'true'}, {'number': '205', 'ReferenceId': '30371878', 'FullCitation': 'Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878', 'Include': 'true'}, {'number': '206', 'ReferenceId': '25950492', 'FullCitation': 'Parish A, et al. Cell Cycle (2015) pmid: 25950492', 'Include': 'true'}, {'number': '207', 'ReferenceId': '12711740', 'FullCitation': 'Jonsson KB, et al. N. Engl. J. Med. (2003) pmid: 12711740', 'Include': 'true'}, {'number': '208', 'ReferenceId': '11344269', 'FullCitation': 'Shimada T, et al. Proc. Natl. Acad. Sci. U.S.A. (2001) pmid: 11344269', 'Include': 'true'}, {'number': '209', 'ReferenceId': '15863037', 'FullCitation': 'Yu X, et al. Cytokine Growth Factor Rev. (2005) pmid: 15863037', 'Include': 'true'}, {'number': '210', 'ReferenceId': '24335106', 'FullCitation': 'Hughes TP, et al. Blood (2014) pmid: 24335106', 'Include': 'true'}, {'number': '211', 'ReferenceId': '24650752', 'FullCitation': 'Takahashi N, et al. Biomark Res (2014) pmid: 24650752', 'Include': 'true'}, {'number': '212', 'ReferenceId': '22357255', 'FullCitation': 'Reichardt P, et al. Ann. Oncol. (2012) pmid: 22357255', 'Include': 'true'}, {'number': '213', 'ReferenceId': '22119758', 'FullCitation': 'Cauchi C, et al. Cancer Chemother. Pharmacol. (2012) pmid: 22119758', 'Include': 'true'}, {'number': '214', 'ReferenceId': '22662203', 'FullCitation': 'Villar VH, et al. PLoS ONE (2012) pmid: 22662203', 'Include': 'true'}, {'number': '215', 'ReferenceId': '25695690', 'FullCitation': 'Carvajal RD, et al. Clin. Cancer Res. (2015) pmid: 25695690', 'Include': 'true'}, {'number': '216', 'ReferenceId': '26002753', 'FullCitation': 'Hochhaus A, et al. J. Cancer Res. Clin. Oncol. (2015) pmid: 26002753', 'Include': 'true'}, {'number': '217', 'ReferenceId': '25882987', 'FullCitation': 'Blay JY, et al. Lancet Oncol. (2015) pmid: 25882987', 'Include': 'true'}, {'number': '218', 'ReferenceId': '26722383', 'FullCitation': 'Kajimoto N, et al. Int J Clin Exp Pathol (2015) pmid: 26722383', 'Include': 'true'}, {'number': '219', 'ReferenceId': '25221952', 'FullCitation': 'Sako H, et al. PLoS ONE (2014) pmid: 25221952', 'Include': 'true'}, {'number': '220', 'ReferenceId': '16462496', 'FullCitation': 'Einhorn LH, et al. Am. J. Clin. Oncol. (2006) pmid: 16462496', 'Include': 'true'}, {'number': '221', 'ReferenceId': '17976614', 'FullCitation': 'Pedersini R, et al. Lancet Oncol. (2007) pmid: 17976614', 'Include': 'true'}, {'number': '222', 'ReferenceId': '20080832', 'FullCitation': 'Okamura A, et al. Ann. Oncol. (2010) pmid: 20080832', 'Include': 'true'}, {'number': '223', 'ReferenceId': '16624552', 'FullCitation': 'Debiec_Rychter M, et al. Eur. J. Cancer (2006) pmid: 16624552', 'Include': 'true'}, {'number': '224', 'ReferenceId': '16570351', 'FullCitation': 'Kamenz T, et al. World J. Gastroenterol. (2006) pmid: 16570351', 'Include': 'true'}, {'number': '225', 'ReferenceId': '15650049', 'FullCitation': 'Wang YY, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15650049', 'Include': 'true'}, {'number': '226', 'ReferenceId': '21415240', 'FullCitation': 'Oechsle K, et al. Ann. Oncol. (2011) pmid: 21415240', 'Include': 'true'}, {'number': '227', 'ReferenceId': '19547919', 'FullCitation': 'Feldman DR, et al. Invest New Drugs (2010) pmid: 19547919', 'Include': 'true'}, {'number': '228', 'ReferenceId': '25085632', 'FullCitation': 'Subbiah V, et al. J Hematol Oncol (2014) pmid: 25085632', 'Include': 'true'}, {'number': '229', 'ReferenceId': '18955458', 'FullCitation': 'Heinrich MC, et al. J. Clin. Oncol. (2008) pmid: 18955458', 'Include': 'true'}, {'number': '230', 'ReferenceId': '26264378', 'FullCitation': 'Buchbinder EI, et al. Cancer (2015) pmid: 26264378', 'Include': 'true'}, {'number': '231', 'ReferenceId': '26772734', 'FullCitation': 'Reichardt P, et al. BMC Cancer (2016) pmid: 26772734', 'Include': 'true'}, {'number': '232', 'ReferenceId': '27073655', 'FullCitation': 'Hirai F, et al. Mol Clin Oncol (2016) pmid: 27073655', 'Include': 'true'}, {'number': '233', 'ReferenceId': '20435347', 'FullCitation': 'Goemans BF, et al. Leuk. Res. (2010) pmid: 20435347', 'Include': 'true'}, {'number': '234', 'ReferenceId': '22982658', 'FullCitation': 'Wakelee HA, et al. J Thorac Oncol (2012) pmid: 22982658', 'Include': 'true'}, {'number': '235', 'ReferenceId': '21576636', 'FullCitation': 'Spigel DR, et al. J. Clin. Oncol. (2011) pmid: 21576636', 'Include': 'true'}, {'number': '236', 'ReferenceId': '24420556', 'FullCitation': 'Sharma N, et al. Invest New Drugs (2014) pmid: 24420556', 'Include': 'true'}, {'number': '237', 'ReferenceId': '22412143', 'FullCitation': 'Baselga J, et al. J. Clin. Oncol. (2012) pmid: 22412143', 'Include': 'true'}, {'number': '238', 'ReferenceId': '22954665', 'FullCitation': 'Gradishar WJ, et al. Eur. J. Cancer (2013) pmid: 22954665', 'Include': 'true'}, {'number': '239', 'ReferenceId': '19935794', 'FullCitation': 'Bengala C, et al. Br. J. Cancer (2010) pmid: 19935794', 'Include': 'true'}, {'number': '240', 'ReferenceId': '20698202', 'FullCitation': 'Qun W, et al. Hepatogastroenterology () pmid: 20698202', 'Include': 'true'}, {'number': '241', 'ReferenceId': '19089671', 'FullCitation': 'LaRocca RV, et al. J Gastrointest Cancer (2007) pmid: 19089671', 'Include': 'true'}, {'number': '242', 'ReferenceId': '25446376', 'FullCitation': 'Moehler M, et al. Eur. J. Cancer (2014) pmid: 25446376', 'Include': 'true'}, {'number': '243', 'ReferenceId': '21785998', 'FullCitation': 'Beardsley EK, et al. Invest New Drugs (2012) pmid: 21785998', 'Include': 'true'}, {'number': '244', 'ReferenceId': '19154507', 'FullCitation': 'Aragon_Ching JB, et al. BJU Int. (2009) pmid: 19154507', 'Include': 'true'}, {'number': '245', 'ReferenceId': '20443129', 'FullCitation': 'Reardon DA, et al. J. Neurooncol. (2011) pmid: 20443129', 'Include': 'true'}, {'number': '246', 'ReferenceId': '23099651', 'FullCitation': 'Lee EQ, et al. Neuro_oncology (2012) pmid: 23099651', 'Include': 'true'}, {'number': '247', 'ReferenceId': '23328813', 'FullCitation': 'Peereboom DM, et al. Neuro_oncology (2013) pmid: 23328813', 'Include': 'true'}, {'number': '248', 'ReferenceId': '24786603', 'FullCitation': 'Hottinger AF, et al. Br. J. Cancer (2014) pmid: 24786603', 'Include': 'true'}, {'number': '249', 'ReferenceId': '31492770', 'FullCitation': 'Lian B, et al. Oncologist (2019) pmid: 31492770', 'Include': 'true'}, {'number': '250', 'ReferenceId': '18936790', 'FullCitation': 'Quintás_Cardama A, et al. Nat Clin Pract Oncol (2008) pmid: 18936790', 'Include': 'true'}, {'number': '251', 'ReferenceId': '19461405', 'FullCitation': 'Bisagni G, et al. J Thorac Oncol (2009) pmid: 19461405', 'Include': 'true'}, {'number': '252', 'ReferenceId': '20372153', 'FullCitation': 'Handolias D, et al. Br. J. Cancer (2010) pmid: 20372153', 'Include': 'true'}, {'number': '253', 'ReferenceId': '20970876', 'FullCitation': 'Dişel U, et al. Lung Cancer (2011) pmid: 20970876', 'Include': 'true'}, {'number': '254', 'ReferenceId': '22270258', 'FullCitation': 'Park SH, et al. Invest New Drugs (2012) pmid: 22270258', 'Include': 'true'}, {'number': '255', 'ReferenceId': '24855380', 'FullCitation': 'Catania C, et al. Onco Targets Ther (2014) pmid: 24855380', 'Include': 'true'}, {'number': '256', 'ReferenceId': '17699867', 'FullCitation': 'Guo T, et al. Clin. Cancer Res. (2007) pmid: 17699867', 'Include': 'true'}, {'number': '257', 'ReferenceId': '18483300', 'FullCitation': 'Hu S, et al. Mol. Cancer Ther. (2008) pmid: 18483300', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2022_01_12 20:43:44', 'OpName': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': '755x'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': '0 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': 'Units Not Reported'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'TESTIS', 'disease_ontology': 'Testis germ cell tumor (seminoma)', 'flowcell_analysis': '2000019573', 'gender': 'male', 'pathology_diagnosis': 'Seminoma', 'percent_tumor_nuclei': '60', 'pipeline_version': 'v3.9.0', 'purity_assessment': '67.3', 'specimen': 'ORD_1269426_01*US1223968.01', 'study': 'CLINICAL_F1CDx', 'test_request': 'ORD_1269426_01', 'test_type': 'FoundationOneDx', 'tissue_of_origin': 'Testis', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'DX1', 'mean_exon_depth': '789.82', 'name': 'SQ_US1223968.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.6746', 'cds_effect': '1073C>G', 'depth': '421', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CEBPA', 'percent_reads': '67.46', 'position': 'chr19:33792248', 'protein_effect': 'A358G', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004364', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'allele_fraction': '0.5171', 'cds_effect': '245G>T', 'depth': '876', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BARD1', 'percent_reads': '51.71', 'position': 'chr2:215657140', 'protein_effect': 'G82V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000465', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'allele_fraction': '0.4927', 'cds_effect': '3226A>G', 'depth': '546', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EMSY', 'percent_reads': '49.27', 'position': 'chr11:76255819', 'protein_effect': 'S1076G', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_020193', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'allele_fraction': '0.5186', 'cds_effect': '3434A>T', 'depth': '752', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PIK3C2B', 'percent_reads': '51.86', 'position': 'chr1:204408145', 'protein_effect': 'H1145L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002646', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'allele_fraction': '0.4741', 'cds_effect': '1409C>A', 'depth': '521', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FLT1', 'percent_reads': '47.41', 'position': 'chr13:29001323', 'protein_effect': 'P470H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002019', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'allele_fraction': '0.4902', 'cds_effect': '397G>A', 'depth': '1073', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '49.02', 'position': 'chr2:212812179', 'protein_effect': 'E133K', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'allele_fraction': '0.3716', 'cds_effect': '2009T>G', 'depth': '557', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MST1R', 'percent_reads': '37.16', 'position': 'chr3:49934990', 'protein_effect': 'V670G', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002447', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}]}, 'copy_number_alterations': {'copy_number_alteration': [{'copy_number': '10', 'equivocal': 'false', 'gene': 'CDKN1B', 'number_of_exons': '3 of 3', 'position': 'chr12:12870773_12874150', 'ratio': '2.97', 'status': 'unknown', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'copy_number': '8', 'equivocal': 'false', 'gene': 'RAD52', 'number_of_exons': '11 of 11', 'position': 'chr12:1022522_1042247', 'ratio': '2.77', 'status': 'unknown', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'copy_number': '9', 'equivocal': 'false', 'gene': 'PDGFRA', 'number_of_exons': '22 of 22', 'position': 'chr4:55079414_55202195', 'ratio': '2.46', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'copy_number': '8', 'equivocal': 'false', 'gene': 'CCND2', 'number_of_exons': '5 of 5', 'position': 'chr12:4335813_4445571', 'ratio': '2.64', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'copy_number': '9', 'equivocal': 'false', 'gene': 'KIT', 'number_of_exons': '21 of 21', 'position': 'chr4:55475828_55651041', 'ratio': '2.77', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'copy_number': '11', 'equivocal': 'false', 'gene': 'PTPRO', 'number_of_exons': '27 of 27', 'position': 'chr12:15475633_15747987', 'ratio': '3.27', 'status': 'unknown', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'copy_number': '8', 'equivocal': 'false', 'gene': 'FGF23', 'number_of_exons': '3 of 3', 'position': 'chr12:4462589_4488748', 'ratio': '2.25', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'copy_number': '9', 'equivocal': 'false', 'gene': 'KDR', 'number_of_exons': '30 of 30', 'position': 'chr4:55896637_56038755', 'ratio': '2.69', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'copy_number': '8', 'equivocal': 'false', 'gene': 'FGF6', 'number_of_exons': '3 of 3', 'position': 'chr12:4494593_4598143', 'ratio': '2.25', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'copy_number': '11', 'equivocal': 'false', 'gene': 'PIK3C2G', 'number_of_exons': '31 of 31', 'position': 'chr12:18435015_18800962', 'ratio': '3.34', 'status': 'unknown', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}, {'copy_number': '10', 'equivocal': 'false', 'gene': 'KRAS', 'number_of_exons': '5 of 5', 'position': 'chr12:25344730_25448217', 'ratio': '3.23', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}]}, 'rearrangements': {'rearrangement': {'description': 'PDGFRA(NM_006206) rearrangement exon 7', 'equivocal': 'false', 'in_frame': 'unknown', 'other_gene': 'N/A', 'pos1': 'chr4:55133747_55134015', 'pos2': 'chr4:61518351_61518628', 'status': 'unknown', 'supporting_read_pairs': '134', 'targeted_gene': 'PDGFRA', 'type': 'rearrangement', 'dna_evidence': {'sample': 'SQ_US1223968.01_1'}}}, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '0.0', 'status': 'low', 'unit': 'mutations_per_megabase'}}, 'non_human_content': None}}}}	S111-98146          	PF21077             
14	525	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2022_00019878', 'CSN': None, 'TRF': 'ORD_1336448_02', 'MRN': '43982770', 'PhysicianId': '109266', 'NPI': 'International'}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1097561', 'clinicalId': '1098932', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1336448_02', 'SampleName': 'US1284630.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1336448_02', 'SampleId': 'US1284630.01', 'BlockId': 'S111_07951 A (PF22046)', 'TRFNumber': 'ORD_1336448_02', 'TestType': 'FoundationOne Heme', 'SpecFormat': 'Slide Deck', 'ReceivedDate': '2022_04_04', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}, {'address': '7010 Kit Creek Road, Morrisville, NC 27560', 'cliaNumber': '34D2044309', 'locationID': '2', 'locationName': 'RTP', 'processID': '2', 'processName': 'Extracted DNA'}]}}, 'PMI': {'ReportId': 'ORD_1336448_02', 'MRN': '43982770', 'FullName': 'Lin, Mei_Chen', 'FirstName': 'Mei_Chen', 'LastName': 'Lin', 'SubmittedDiagnosis': 'Unknown primary malignant neoplasm', 'Gender': 'Female', 'DOB': '1981_01_30', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Mouth', 'CollDate': '2022_02_23', 'ReceivedDate': '2022_04_04', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': None, 'Summaries': {'alterationCount': '73', 'clinicalTrialCount': '17', 'resistiveCount': '0', 'sensitizingCount': '12'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'ABL1', 'isVUS': 'true', 'variantName': 'S1007*'}, {'geneName': 'ALK', 'isVUS': 'true', 'variantName': 'E201Q'}, {'geneName': 'ARID2', 'isVUS': 'true', 'variantName': 'H48Y'}, {'geneName': 'ASXL1', 'isVUS': 'true', 'variantName': 'I980N'}, {'geneName': 'BCORL1', 'isVUS': 'true', 'variantName': 'D77N,T1111M'}, {'geneName': 'BRCA1', 'isVUS': 'true', 'variantName': 'G1232L'}, {'geneName': 'BRD4', 'isVUS': 'true', 'variantName': 'E657Q'}, {'geneName': 'BRIP1', 'isVUS': 'true', 'variantName': 'R814C'}, {'geneName': 'CD22', 'isVUS': 'true', 'variantName': 'S105N'}, {'geneName': 'CIC', 'isVUS': 'true', 'variantName': 'A531T'}, {'geneName': 'CIITA', 'isVUS': 'true', 'variantName': 'A462S,A648E'}, {'geneName': 'EPHA5', 'isVUS': 'true', 'variantName': 'E881D,T176A'}, {'geneName': 'EPHB1', 'isVUS': 'true', 'variantName': 'I236M'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'A345V,D1131Y,P1132H'}, {'geneName': 'FAM123B', 'isVUS': 'true', 'variantName': 'G327C'}, {'geneName': 'FBXO11', 'isVUS': 'true', 'variantName': 'S34N'}, {'geneName': 'FBXO31', 'isVUS': 'true', 'variantName': 'R19P'}, {'geneName': 'FLT4', 'isVUS': 'true', 'variantName': 'A634D,Y435C'}, {'geneName': 'FRS2', 'isVUS': 'true', 'variantName': 'P240S'}, {'geneName': 'GPR124', 'isVUS': 'true', 'variantName': 'R369Q'}, {'geneName': 'HGF', 'isVUS': 'true', 'variantName': 'G31*'}, {'geneName': 'HIST1H1C', 'isVUS': 'true', 'variantName': 'E3K'}, {'geneName': 'HIST1H3B', 'isVUS': 'true', 'variantName': 'A92P'}, {'geneName': 'IL7R', 'isVUS': 'true', 'variantName': 'K104N,L123V'}, {'geneName': 'JUN', 'isVUS': 'true', 'variantName': 'R221Q'}, {'geneName': 'LRP1B', 'isVUS': 'true', 'variantName': 'S1198Y,S913R'}, {'geneName': 'MAPK1', 'isVUS': 'true', 'variantName': 'D210H'}, {'geneName': 'MKI67', 'isVUS': 'true', 'variantName': 'I2578V'}, {'geneName': 'MYST3', 'isVUS': 'true', 'variantName': 'A1442S,P1766L'}, {'geneName': 'NOTCH1', 'isVUS': 'true', 'variantName': 'P1884Q'}, {'geneName': 'NSD1', 'isVUS': 'true', 'variantName': 'R1074L'}, {'geneName': 'NTRK2', 'isVUS': 'true', 'variantName': 'A187E'}, {'geneName': 'P2RY8', 'isVUS': 'true', 'variantName': 'P341H'}, {'geneName': 'PCLO', 'isVUS': 'true', 'variantName': 'E3034D,P995A'}, {'geneName': 'PDGFRA', 'isVUS': 'true', 'variantName': 'A7P'}, {'geneName': 'PLCG2', 'isVUS': 'true', 'variantName': 'E1208K'}, {'geneName': 'POT1', 'isVUS': 'true', 'variantName': 'T425A'}, {'geneName': 'PPP2R1A', 'isVUS': 'true', 'variantName': 'V259F'}, {'geneName': 'PRKDC', 'isVUS': 'true', 'variantName': 'D3411H'}, {'geneName': 'SMARCA4', 'isVUS': 'true', 'variantName': 'D1183Y'}, {'geneName': 'SMC3', 'isVUS': 'true', 'variantName': 'E998*'}, {'geneName': 'SMO', 'isVUS': 'true', 'variantName': 'R703P'}, {'geneName': 'SOCS1', 'isVUS': 'true', 'variantName': 'L150Q'}, {'geneName': 'SOX2', 'isVUS': 'true', 'variantName': 'A30S'}, {'geneName': 'SPEN', 'isVUS': 'true', 'variantName': 'S2185F'}, {'geneName': 'SUZ12', 'isVUS': 'true', 'variantName': 'S53L'}, {'geneName': 'TAF1', 'isVUS': 'true', 'variantName': 'R123T'}, {'geneName': 'TNFAIP3', 'isVUS': 'true', 'variantName': 'E451Q'}, {'geneName': 'TSHR', 'isVUS': 'true', 'variantName': 'G235R'}, {'geneName': 'WDR90', 'isVUS': 'true', 'variantName': 'R690Q'}, {'geneName': 'ZNF217', 'isVUS': 'true', 'variantName': 'P823L'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'ERBB3', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'V104L', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'V104L'}}, 'Interpretation': 'ERBB3 (also known as HER3) encodes a member of the epidermal growth factor receptor (EGFR) family (Sheng et al., 2011; 21364581). ERBB3 mutations such as observed here have been shown to be activating (Jaiswal et al., 2013; 23680147, Li et al., 2014; 24997986, Collier et al., 2013; 23843458, Mishra et al., 2018; 29963236). ERBB3 mutations have been reported with highest incidence in cancers of the meninges (31%), urinary tract (11%), stomach (7.5%), skin (7.2%), endometrium (6.8%), prostate (5.3%), large intestine (5.2%), biliary tract (4.7%), and cervix (4%) and at lower frequencies in other tumor types (COSMIC, Apr 2022)(Tate et al., 2019; 30371878). High expression of ERBB3 mRNA or ERBB3 protein has been found in a number of tumor types, including those of the breast, lung, ovary, stomach, colon, and bladder (Gunes et al., 2013; 23333248, Bellezza et al., 2013; 24013863, Skrzypski et al., 2013; 23870818, Müller_Tidow et al., 2005; 15753374, Yoon et al., 2013; 24151090, Peng et al., 2008; 18000824, Wei et al., 2007; 17671674, Paterson et al., 2013; 22733579, Leng et al., 1997; 11324501, Tanner et al., 2006; 16896008, Lédel et al., 2014; 24300455). Elevated ERBB3 expression has been associated with increased disease severity or negative prognostic indicators in glioblastoma (Song et al., 2018; 29888103), gastric cancer (Begnami et al., 2011; 21709195, Hayashi et al., 2008; 19047113), non_small cell lung cancer (Müller_Tidow et al., 2005; 15753374), and colorectal cancer (Baiocchi et al., 2009; 19390858). ERBB3 amplification in breast cancer has been correlated with reduced disease_free survival, although some studies have found no association with prognosis (Sassen et al., 2008; 18182100, Witton et al., 2003; 12845624, Koutras et al., 2008; 18985033, Pawlowski et al., 2000; 11106235, Travis et al., 1996; 8688326, Quinn et al., 1994; 7821892, Gasparini et al., 1994; 7908213, Lemoine et al., 1992; 1333787). The data associating ERBB3 expression and invasion and metastasis in urothelial carcinoma were similarly conflicting (Rajkumar et al., 1996; 8869284, Junttila et al., 2003; 14614020, Rotterud et al., 2005; 15892828, Tsai et al., 2005; 16360440, Chow et al., 1997; 9230911, Chow et al., 2001; 11448910). ERBB3 cooperates with other ERBB family members, in particular ERBB2, for efficient signaling (Black et al., 2019; 31351986, Baselga and Swain, 2009; 19536107, Jaiswal et al., 2013; 23680147, Jura et al., 2009; 20007378). Therefore, ERBB3 amplification or activating mutation may predict sensitivity to therapies targeting ERBB2, including antibodies such as trastuzumab, pertuzumab, and ado_trastuzumab emtansine (T_DM1), and dual EGFR/HER2 TKIs such as lapatinib and afatinib. Preclinical studies support the sensitivity of cells with ERBB3 activating mutations to various anti_ERBB2 agents (Jaiswal et al., 2013; 23680147, Umelo et al., 2016; 26689995, Mishra et al., 2018; 29963236). In a Phase 2 study of afatinib in platinum_refractory urothelial cancer, 2 patients with activating ERBB3 mutations but no EGFR or HER2 activating alterations experienced clinical benefit and PFS > 6 months (Choudhury et al., 2016; 27044931). Other studies in solid tumors have reported mixed efficacy for afatinib for patients with uncharacterized ERBB3 mutations (Verlingue et al., 2018; 29413684, Goss et al., 2018; 29902295). Case studies report clinical benefit from lapatinib combined with either capecitabine (Verlingue et al., 2018; 29413684) or trastuzumab (Bidard et al., 2015; 25953157, Verlingue et al., 2018; 29413684) for patients with breast cancer harboring activating ERBB3 mutations. However, Phase 2 trials have suggested limited efficacy of other ERBB2_targeting TKIs against ERBB3 mutations, with no objective response to neratinib in any of 16 patients with ERBB3_mutated solid tumors (Hyman et al., 2018; 29420467) or dacomitinib in either of 2 patients with ERBB3_mutated cutaneous squamous cell carcinoma (Cavalieri et al., 2018; 29734047).', 'Include': 'true', 'ClinicalTrialNote': 'Clinical and preclinical data support sensitivity of ERBB3 activating mutations to HER2_targeting TKIs, including afatinib and lapatinib. ERBB3 amplification or activating mutations may confer sensitivity to therapies targeting ERBB3.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': {'nctId': 'NCT03810872', 'Include': 'true'}}}}, 'ReferenceLinks': None}, {'Name': 'MET', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'amplification', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'amplification'}}, 'Interpretation': 'MET encodes a receptor tyrosine kinase, also known as c_MET or hepatocyte growth factor receptor (HGFR), that is activated by the ligand HGF; MET activation results in signaling mediated partly by the RAS_RAF_MAPK and PI3K pathways to promote proliferation (Appleman, 2011; 22042966, Jung et al., 2012; 22553051). MET has been reported to be amplified in cancer (Gao et al., 2013; 23550210), with amplification positively correlating with protein expression in some cancer types (Ang et al., 2013; 23898085, Abou_Bakr and Elbasmi, 2013; 23996864, Ho et al., 2013; 24258573, Dziadziuszko et al., 2012; 22237262, Madoz_Gúrpide et al., 2015; 26319934) and associating with therapeutic response to MET inhibitors in a variety of cancer types (Kwak et al., 2015; ASCO GI Abstract 01, Ou et al., 2011; 21623265, Schwab et al., 2014; 24192513, Lennerz et al., 2011; 22042947, Chi et al., 2012; 22162573, Palma et al., 2014; 25232318, Le et al., 2015; 25922291, Ali et al., 2015; 25882375, Kwak et al., 2015; 26432108). In the TCGA datasets, amplification of MET has been found in several tumor types, with the highest incidences in ovarian serous cystadenocarcinoma (5.5%), esophageal carcinoma (3.4%), stomach adenocarcinoma (3.7%), and lung adenocarinoma (3.0%) datasets; lower incidences were observed in various other tumor types (cBioPortal, Sep 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Overexpression of MET mRNA and protein has been observed in a number of cancers (Ang et al., 2013; 23898085, Abou_Bakr and Elbasmi, 2013; 23996864, Ho et al., 2013; 24258573). MET amplification has been associated with poor prognosis in gastroesophageal adenocarcinoma, gastric and esophageal cancer (Miller et al., 2006; 16186806, Tuynman et al., 2008; 18349821, Anderson et al., 2006; 17062664, Lennerz et al., 2011; 22042947, Graziano et al., 2011; 22042954, Lee et al., 2011; 21424128, Lee et al., 2012; 22644302). Increased MET expression has been associated with poor prognosis in cutaneous malignant melanoma (Cruz et al., 2003; 12837985), gallbladder adenocarcinoma (Yang et al., 2012; 22172411), lung large cell neuroendocrine carcinoma (Rossi et al., 2005; 16314638), and breast cancer (Camp et al., 1999; 10590366, Lengyel et al., 2005; 15455388, Ghoussoub et al., 1998; 9554529). The prognostic value of MET amplification or expression in non_small cell lung cancer (NSCLC) (Yang et al., 2013; 23079155, Dziadziuszko et al., 2012; 22237262, Cappuzzo et al., 2009; 19255323, Park et al., 2012; 22207554, Chen et al., 2011; 22052229, Kanteti et al., 2009; 19817696, To et al., 2002; 11795945, Tsuta et al., 2012; 22198430), endometrial carcinoma (Felix et al., 2012; 22617129, Wagatsuma et al., 1998; 9452270, Bishop et al., 2011; 21168200, Felix et al., 2010; 20527227) or colon cancer (Garouniatis et al., 2013; 22733437, Liu et al., 2012; 22495710, Resnick et al., 2004; 15131045) have yielded conflicting results, although concurrent MET amplification and EGFR mutation have been correlated with reduced disease_free survival in NSCLC (Tanaka et al., 2012; 21733594). On the basis of extensive clinical evidence, MET amplification or activating mutations may predict sensitivity to MET_targeting therapies such as kinase inhibitors crizotinib, capmatinib, tepotinib, and cabozantinib. Crizotinib has benefited patients with MET_amplified non_small cell lung cancer (NSCLC) of varied histologies (Vassal et al., 2015; ASCO Abstract 2595, Li et al., 2015; ASCO Abstract 8090, Ou et al., 2011; 21623265, Schwab et al., 2014; 24192513, Le et al., 2015; 25922291, Schrock et al., 2017; 28315738), gastroesophageal cancer (Lennerz et al., 2011; 22042947), glioblastoma (Chi et al., 2012; 22162573), and carcinoma of unknown primary (Palma et al., 2014; 25232318). Capmatinib has demonstrated clinical efficacy for patients with MET_amplified NSCLC both as a monotherapy (Schuler et al., 2016; ASCO Abstract 9067, Wu et al., 2018; WCLC Abstract P1.01_97) and in combination with an EGFR_TKI for patients with concurrent activating EGFR mutations (Wu et al., 2018; 30156984, Gainor et al., 2020; 31864558, Gautschi et al., 2020; 31864554). Tepotinib has demonstrated efficacy for patients with MET_amplified hepatocellular carcinoma (Faivre et al., 2021; ASCO GI Abstract 329) and NSCLC (Le et al., 2021; ASCO Abstract 9021) as a monotherapy, as well as in combination with gefitinib for patients with MET_amplified and EGFR_mutated NSCLC (Yang et al., 2019; AACR Abstract CT193, Park et al., 2019; ESMO Abstract 477O, Wu et al., 2019; IASLC Abstract MA09.09). Savolitinib elicited responses in patients with MET_amplified papillary renal cell carcinoma (Gan et al., 2019; 30952639) and gastric cancer either alone or in combination with docetaxel (Lee et al., 2019; 31315834, Kim et al., 2019; 30695737). AMG 337 elicited an ORR of 50% (5/10), including 1 CR, for patients with MET_amplified gastric, esophageal, or gastroesophageal junction cancer (Kwak et al., 2015; ASCO GI Abstract 01). Patients with MET_amplified NSCLC (Spigel et al., 2013; 24101053) or MET_amplified gastric cancer (Catenacci et al., 2011; 22389872) treated with the MET_targeting antibody onartuzumab (MetMAb) achieved clinical responses. In addition, high MET expression has been suggested to predict patient response to therapies such as the monoclonal HGF_targeting antibody rilotumumab, as well as the combination of ramucirumab and the monoclonal MET_targeting antibody emibetuzumab (Oliner et al., 2012; ASCO Abstract 4005, Harding et al., 2019; 31142504). A first_in_human Phase 1 trial of telisotuzumab vedotin (teliso_V), a MET antibody_drug conjugate, reported activity in a subset of patients with MET_positive NSCLC, with an ORR of 19% (3/16) and a DCR of 56% (9/16); no responses were observed in any other patients (Strickler et al., 2019; 30285518). A subsequent Phase 2 trial of teliso_V in patients with MET_positive NSCLC reported a 35% (13/37) ORR in patients with non_squamous, EGFR_wildtype tumors, which met the prespecified criteria for transition to the next stage; lower ORRs were observed in patients with squamous (14%; 3/21) or non_squamous EGFR_mutated (13%; 4/30) tumors (Camidge et al., 2021; AACR Abstract CT179).', 'Include': 'true', 'ClinicalTrialNote': 'Activating MET alterations may confer sensitivity to MET inhibitors.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Capmatinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Capmatinib is a selective MET tyrosine kinase inhibitor that is FDA approved to treat patients with non_small cell lung cancer harboring MET exon 14 skipping_associated alterations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data in non_small cell lung cancer (Schuler et al., 2016; ASCO Abstract 9067, Wu et al., 2018; WLCL Abstract P1.01_97, Yang et al., 2019; AACR Abstract CT193, Park et al., 2019; ESMO Abstract 477O, Wu et al., 2019; IASLC Abstract MA09.09, Le et al., 2021; ASCO Abstract 9021), hepatocellular carcinoma (Faivre et al., 2021; ASCO GI Abstract 329), renal cell carcinoma (Gan et al., 2019; 30952639), and gastric cancer (Lee et al., 2019; 31315834), MET amplification may predict sensitivity to selective MET inhibitors. </p> <p><b>Supporting Data:</b> Capmatinib has been investigated primarily for the treatment of NSCLC, demonstrating efficacy as monotherapy for patients with MET amplification (Wolf et al., 2020; ASCO Abstract 9509, Schuler et al., 2020; 32240796, Wu et al., 2018; WCLC Abstract P1.01_97) or MET exon 14 skipping alterations (Wolf et al., 2020; 32877583, Schuler et al., 2020; 32240796) as well as in combination with EGFR inhibitors for patients with MET amplification (Wu et al. 2018; 30156984, Gainor et al., 2020; 31864558, Gautschi et al., 2020; 31864554). Multiple Phase 1 and 2 clinical studies have reported limited efficacy for capmatinib monotherapy in non_NSCLC indications, with no responses observed for patients with MET_amplified glioblastoma (n=10)(Van den Bent et al., 2020; 31776899), MET_overexpressing gastric cancer (n=9)(Bang et al., 2020; 31778267), or other advanced solid tumors with MET amplification or overexpression (n=11)(Bang et al., 2020; 31778267, Esaki et al., 2019; 30724423). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Crizotinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Crizotinib is an inhibitor of the kinases MET, ALK, ROS1, and RON. It is FDA approved to treat patients with ALK rearrangement_ or ROS1 rearrangement_positive non_small cell lung cancer (NSCLC), and to treat pediatric and young adult patients with ALK rearrangement_positive anaplastic large cell lymphoma (ALCL). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Sensitivity of MET alterations to crizotinib is suggested by extensive clinical data in patients with MET_amplified cancers, including non_small cell lung cancer (NSCLC) (Vassal et al., 2015; ASCO Abstract 2595, Li et al., 2015; ASCO Abstract 8090)(Ou et al., 2011; 21623265, Schwab et al., 2014; 24192513, Le et al., 2015; 25922291), gastric cancer (Ali et al., 2015; 25882375), gastroesophageal cancer (Lennerz et al., 2011; 22042947), glioblastoma (Chi et al., 2012; 22162573), and carcinoma of unknown primary (Palma et al., 2014; 25232318), as well as in patients with MET_mutated cancers, including NSCLC (Frampton et al., 2015; 25971938, Paik et al., 2015; 25971939, Benderra et al., 2016; 26845121, Waqar et al., 2015; 25898962, Mendenhall and Goldman, 2015; 25898965, Jenkins et al., 2015; 25769807), renal cell carcinoma (RCC) (Stein et al., 2015; 25457019), and histiocytic sarcoma (Frampton et al., 2015; 25971938). Crizotinib has also benefited patients with NSCLC or histiocytic sarcoma tumors harboring various alterations associated with MET exon 14 skipping (Awad et al., 2017; ASCO Abstract 8511, Frampton et al., 2015; 25971938, Paik et al., 2015; 25971939, Waqar et al., 2015; 25898962, Mendenhall and Goldman, 2015; 25898965, Jenkins et al., 2015; 25769807). </p> <p><b>Supporting Data:</b> Crizotinib has demonstrated efficacy in patients with NSCLC and ALK rearrangements (Shaw et al., 2016; ASCO Abstract 9066, Lu et al., 2016; ASCO Abstract 9058, Yoshida et al., 2016; 27354483, Solomon et al., 2014; 25470694, Shaw et al., 2013; 23724913), ROS1 rearrangements (Moro_Sibilot et al., 2015; ASCO Abstract 8065, Goto et al., 2016; ASCO Abstract 9022, Shaw et al., 2014; 25264305, Mazieres et al., 2015; 25667280, Scheffler et al., 2015; 25868855), an NTRK1 fusion (Vaishnavi et al., 2013; 24162815), or MET activation (Drilon et al., 2016; ASCO Abstract 108, Vassal et al., 2015; ASCO Abstract 2595, Camidge et al., 2014; ASCO Abstract 8001, Li et al., 2015; ASCO Abstract 8090, Schrock et al., 2016; 27343443, Jorge et al., 2015; 26791794, Paik et al., 2015; 25971939, Mahjoubi et al., 2016; 26892698, Benderra et al., 2016; 26845121, Waqar et al., 2015; 25898962, Mendenhall and Goldman, 2015; 25898965, Jenkins et al., 2015; 25769807, Awad et al., 2016; 26729443, Jorge et al., 2015; 26791794, Schwab et al., 2014; 24192513, Zhang et al., 2016; 26724472, Ou et al., 2011; 21623265, Le et al., 2015; 25922291). Crizotinib has also benefited patients with MET_mutated renal cell carcinoma (Diamond et al., 2013; 23610116) and patients with MET_amplified gastroesophageal cancer, glioblastoma, and carcinoma of unknown primary (Lennerz et al., 2011; 22042947, Shi et al., 2012; 22162573, Palma et al., 2014; 25232318). While a Phase 1b study evaluating crizotinib for the treatment of patients with ALK_positive malignancies, reported ORR of 52.9% (9/17) and 66.7% (6/9) in patients with lymphoma and inflammatory myofibroblastic tumors (IMT), respectively, an ORR of 11.8% (2/17) was reported for patients with other types of tumors (Gambacorti_Passerini et al., 2017; ASH Abstract 4128). Whereas median PFS and median OS were not reached for patients with lymphoma or IMT, median PFS was 1.3 months and median OS was 8.3 months for patients with other tumor types, and the median duration of treatment was ~1 month relative to 1_3 years for patients with lymphoma or IMT (Gambacorti_Passerini et al., 2017; ASH Abstract 4128). A Phase 1 clinical trial of crizotinib in pediatric solid tumors reported objective responses in 14/79 patients, including nine CRs and five PRs; response was enriched in patients with activating alterations in ALK (Mossé et al., 2013; 23598171). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Cabozantinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Cabozantinib inhibits multiple tyrosine kinases, including MET, RET, VEGFRs, and ROS1. It is FDA approved as monotherapy to treat patients with renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), medullary thyroid cancer (MTC), and differentiated thyroid cancer (DTC). It is also approved in combination with nivolumab to treat RCC. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Sensitivity of MET alterations to cabozantinib is suggested by clinical responses in patients with non_small cell lung cancer (NSCLC) harboring MET mutations associated with MET exon 14 skipping, with or without concurrent MET amplification (Paik et al., 2015; 25971939, Klempner et al., 2016; 27693535), as well as by extensive preclinical data (Yakes et al., 2011; 21926191, Weber et al., 2014; 25260782, Navis et al., 2013; 23484006, Yeh et al., 2015; 26013381, Lee et al., 2014; 25534569, Torres et al., 2011; 21540237, Sameni et al., 2015; 26432786). </p> <p><b>Supporting Data:</b> A randomized Phase 2 discontinuation study of cabozantinib in 9 solid tumor types reported ORRs of 0% to 22% and response durations of 3.3 to 11.2 months across cohorts with ORRs of 10% or greater observed for patients with ovarian cancer (22% [15/69, 1 CR]), metastatic breast cancer (14% [6/44]), and non_small cell lung cancer (NSCLC) (10% [6/60]) (Schöffski et al., 2017; 29059635, Hellerstedt et al., 2019; 30528315). A Phase 1 study of cabozantinib for advanced solid tumors reported a 17% (4/23) ORR in the dose escalation cohort and an ORR of 20% (4/20) and a DCR of 100% (20/20) in the expansion cohort for Japanese patients with NSCLC (Nokihara et al., 2019; 30718102). In the context of studies for specific solid tumors, the randomized Phase 3 EXAM study for patients with advanced medullary thyroid cancer reported an association of cabozantinib with improved PFS compared with placebo (11.2 vs. 4.0 months, HR=0.28) and a higher ORR (28% vs. 0%), with PFS improvement observed regardless of RET mutation status (Elisei et al., 2013; 24002501). The randomized Phase 3 CELESTIAL study for patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib reported significantly longer OS (10.2 vs. 8.0 months, HR=0.76) and PFS (5.2 vs. 1.9 months, HR=0.44) as well as an increased ORR (3.8% vs. 0.4%) with cabozantinib when compared to placebo (Abou_Alfa et al., 2018; 29972759). The Phase 2 CABOSUN trial of first line cabozantinib versus sunitinib for patients with intermediate_ or poor_risk advanced clear cell renal cell carcinoma demonstrated significantly improved median PFS (8.2 vs. 5.6 months, HR=0.66), prolonged median OS (30.3 vs. 21.8 months), and higher ORR (33% [26/79] vs. 12% [9/78]) with cabozantinib compared with sunitinib (Choueiri et al., 2017; 28199818). The Phase 2 CABONE study of cabozantinib reported ORRs of 26% (10/39) for patients with advanced Ewing sarcoma and 12% (5/42) for patients with advanced osteosarcoma (Italiano et al., 2020; 32078813). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Tepotinib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Tepotinib is a selective MET tyrosine kinase inhibitor that is FDA approved to treat patients with non_small cell lung cancer harboring MET exon 14 skipping alterations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data in non_small cell lung cancer (Schuler et al., 2016; ASCO Abstract 9067, Wu et al., 2018; WLCL Abstract P1.01_97, Yang et al., 2019; AACR Abstract CT193, Park et al., 2019; ESMO Abstract 477O, Wu et al., 2019; IASLC Abstract MA09.09, Le et al., 2021; ASCO Abstract 9021), hepatocellular carcinoma (Faivre et al., 2021; ASCO GI Abstract 329), renal cell carcinoma (Gan et al., 2019; 30952639), and gastric cancer (Lee et al., 2019; 31315834), MET amplification may predict sensitivity to selective MET inhibitors. </p> <p><b>Supporting Data:</b> Tepotinib has primarily been investigated in non_small cell lung cancer and has demonstrated efficacy as a single agent for patients with MET amplification (Le et al., 2021; ASCO Abstract 9021) and MET exon 14_skipping alterations (Paik et al., 2020; 32469185, Mazieres et al., 2020; ESMO Abstract 1283P). Tepotinib has also been shown to be efficacious in combination with gefitinib for patients with concurrent EGFR mutation and MET amplification or MET overexpression in Phase 2 studies (Wu et al., 2019; IASLC Abstract MA09.09, Park et al., 2019; ESMO Abstract 477O). In advanced hepatocellular carcinoma, Phase 2 studies of tepotinib reported improved ORR and PFS for both treatment_naive and previously treated patients with MET protein overexpression (Ryoo et al., 2018; ESMO Abstract 186P, Ryoo et al., 2018; ESMO Abstract 621PD, Decaens et al., 2019; ESMO Abstract 698P, Faivre et al., 2021; ASCO GI Abstract 329). In a Phase 1 study of advanced solid tumors, tepotinib monotherapy yielded an ORR of 1.3% and a DCR of 24%, with 2 confirmed PRs observed for patients with esophageal or lung cancer and 2 unconfirmed PRs for patients with colorectal or nasopharyngeal cancer (Falchook et al., 2020; 31822497). In another Phase 1 study of solid tumors, tepotinib yielded a DCR of 17% (2/12), with 2 SD of ≥12 weeks observed in a patient with gastric cancer and another with urachal cancer (Shitara et al., 2020; 32328660). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT03175224', 'Include': 'true'}, {'nctId': 'NCT04647838', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}, {'nctId': 'NCT04116541', 'Include': 'true'}, {'nctId': 'NCT04887194', 'Include': 'true'}, {'nctId': 'NCT04693468', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'Tumor Mutation Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '63', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '63'}}, 'Interpretation': 'Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level that may be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors in multiple solid tumor types (Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915). High or elevated TMB has been most frequently reported in melanoma (17_42%) (Johnson et al., 2016; 27671167, Snyder et al., 2014; 25409260, Van Allen et al., 2015; 26359337), colorectal cancer (CRC; 8_25%) (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103)(Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117), endometrial carcinoma (7_24%) (Frampton et al., 2016; ASCO Abstract 11558, Santin et al., 2016; ASCO Abstract 414)(Cancer Genome Atlas Research Network., 2013; 23636398), intestinal_type stomach adenocarcinoma (20%) (Frampton et al., 2016; ASCO Abstract 11558), and non_small cell lung carcinoma (NSCLC; 8_13%) (Spigel et al., 2016; ASCO Abstract 9017, Jiang et al., 2016; ASCO Abstract e23128). In patients with NSCLC, increased TMB is associated with higher tumor grade and poor prognosis (Xiao et al., 2016; 27009843), as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high_TMB samples each), but not BRAF (10.3%) or KRAS (9.4%) (Spigel et al., 2016; ASCO Abstract 9017). Although some studies have reported a lack of association between smoking and increased TMB in NSCLC (Schwartz et al., 2016; ASCO Abstract 8533, Xiao et al., 2016; 27009843, Shim et al., 2015; 26200269), several other large studies did find a strong link (Govindan et al., 2012; 22980976, Ding et al., 2008; 18948947, Imielinski et al., 2012; 22980975, Kim et al., 2014; 24323028). In CRC, elevated TMB is associated with a higher frequency of BRAF V600E driver mutations (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117) and with microsatellite instability (MSI) (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Stadler et al., 2016; 27022117), which in turn has been reported to correlate with better prognosis (Samowitz et al., 2001; 11535541, Elsaleh and Iacopetta, 2001; 12445368, Brueckl et al., 2003; 12820457, Guidoboni et al., 2001; 11438476, Gryfe et al., 2000; 10631274, Sinicrope et al., 2006; 16952542, Guastadisegni et al., 2010; 20627535, Laghi and Malesci, 2012; 22722556). Although increased TMB is associated with increased tumor grade in endometrioid endometrial carcinoma (Mehnert et al., 2016; 27159395, Cancer Genome Atlas Research Network., 2013; 23636398, Hussein et al., 2015; 25394778, Church et al., 2013; 23528559) and bladder cancer (Cazier et al., 2016; 24777035), it is also linked with improved prognosis in patients with these tumor types (Rosenberg et al., 2016; ASCO Abstract 104, Cancer Genome Atlas Research Network., 2013; 23636398). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB ≥10 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB ≥10 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors.', 'Include': 'true', 'ClinicalTrialNote': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Cemiplimab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Cemiplimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved to treat patients with NSCLC with high PD_L1 expression (TPS ≥ 50%), cutaneous squamous cell carcinoma (CSCC), or basal cell carcinoma (BCC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Cemiplimab has been studied primarily in advanced cutaneous squamous cell carcinoma (CSCC), where it elicited a combined ORR of 48% (41/85) in Phase 1 and 2 studies (Migden et al., 2018; 29863979). A Phase 2 trial of cemiplimab in patients with basal cell carcinoma (BCC) reported ORRs of 31% (5 CRs and 21 PRs) in patients with locally advanced BCC and 21% (6 PRs) in patients with metastatic BCC (Stratigos et al., 2020; EMSO Abstract LBA47, Lewis et al. 2020; doi: 10.1136/jitc_2020_SITC2020.0428). The Phase 3 EMPOWER_Lung 1 trial for advanced non_small cell lung cancer (NSCLC) with PD_L1 expression ≥50% reported that cemiplimab is associated with improved PFS (8.2 vs. 5.7 months), OS (not reached vs. 14.2 months), and ORR (37% vs. 21%) compared with chemotherapy (Sezer et al., 2020; ESMO Abstract LBA52). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Dostarlimab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Dostarlimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer or solid tumors. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Dostarlimab has been studied primarily in recurrent and advanced mismatch repair_deficient (dMMR) endometrial and non_endometrial cancers (Andre et al., 2021; ASCO GI Abstract 9, Oaknin et al., 2020; 33001143, Berton et al., 2021; ASCO Abstract 2564). In the Phase 1 GARNET trial, single_agent dostarlimab elicited an ORR of 39% (41/106) and an immune_related ORR of 46% (50/110) for patients with non_endometrial dMMR solid tumors (Andre et al., 2021; ASCO GI Abstract 9, Andre et al., 2021; ESMO GI Abstract SO_9). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Nivolumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response. It is FDA approved as a monotherapy in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, colorectal cancer (CRC), classical Hodgkin lymphoma (cHL), gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma or squamous cell carcinoma (ESCC). It is also approved in combination with cabozantinib to treat RCC, and in combination with relatlimab to treat melanoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Nivolumab monotherapy has been reported to elicit clinical benefit for patients with multiple types of solid tumors, including melanoma (27_31% ORR) (Postow et al., 2015; 25891304, Larkin et al., 2015; 26027431, Robert et al., 2014; 25399552, Topalian et al., 2014; 24590637, Weber et al., 2015; 25795410), non_small cell lung cancer (NSCLC; 17_20% ORR and 9_10 months median OS [mOS] for unselected patients) (Brahmer et al., 2014; ASCO Abstract 8112, Gettinger et al., 2014; ASCO Abstract 8024, Antonia et al., 2014; ASCO Abstract 8023, Rizvi et al., 2014; ASCO Abstract 8022, Antonia et al., 2014; ASCO Abstract 8113, Brahmer et al., 2015; 26028407, Borghaei et al., 2015; 26412456), urothelial carcinoma (20_26% ORR for unselected patients) (Sharma et al., 2019; 31100038, Sharma et al., 2017; 28131785), renal cell carcinoma (RCC; 26% ORR) (Amin et al., 2014; ASCO Abstract 5010, McDermott et al., 2016, ASCO Abstract 4507) (Motzer et al., 2014; 25452452, Topalian et al., 2012; 22658127, Brahmer et al., 2010; 20516446, Motzer et al., 2015; 26406148), microsatellite instability_high (MSI_High) colorectal cancer (CRC; 58% ORR) (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO GI Abstract 481), head and neck squamous cell carcinoma (11_17% ORR) (Gillison et al., 2016; AACR Abstract CT099, Ferris et al., 2016; ASCO Abstract 6009, Ferris et al. 2019; 31239321), ovarian cancer (6_15% ORR) (Brahmer et al., 2012; 22658128, Hamanishi et al., 2015; 26351349, Normann et al., 2019; 31074244), small cell lung cancer (SCLC; 10_12% ORR) (Calvo et al., 2015; ECC Abstract 3098, Hellmann et al., 2017; ASCO Abstract 8503, Antonia et al., 2016; 27269741), gastroesophageal carcinoma (12_18% ORR) (Le et al., 2016; ASCO GI Cancers Abstract 06, Kojima et al., 2016; ASCO GI Cancers Abstract TPS175, Janjigian et al., 2018; 30110194), and cancer of unknown primary (CUP; 22% ORR for unselected, previously treated patients) (Tanizaki et al., 2021; 34843940), as well as with Hodgkin lymphoma (66_87% ORR) (Ansell et al., 2015; ASH Abstract 583, Ansell et al., 2015; 25482239, Younes et al., 2016; 27451390). Combination treatment with nivolumab plus the CTLA_4 inhibitor ipilimumab has achieved further efficacy in melanoma (up to 61% ORR; mOS >60 months for the combination vs. 37 months for nivolumab monotherapy) (Hodi et al., 2018; 30361170, Postow et al., 2015; 25891304, Hodi et al., 2016; 27622997, Larkin et al., 2019; 31562797), NSCLC (mOS of 17 months) (Hellmann et al., 2019; 31562796), MSI_High CRC (64% ORR) (Lenz et al., 2020; ASCO GI Abstract 11), RCC (42% ORR) (Motzer et al., 2019; 31427204, Motzer et al., 2018; 29562145), SCLC (19_25% ORR) (Hellmann et al., 2017; ASCO Abstract 8503, Antonia et al., 2016; 27269741), urothelial carcinoma (38% ORR for unselected patients; 58% ORR for patients with ≥1% tumor PD_L1 expression) (Sharma et al., 2019; 31100038), and other solid tumors. Combinations of nivolumab with various targeted therapies, such as pazopanib (1 PR for a patient with epithelioid sarcoma) (Paoluzzi et al., 2016; ASCO Abstract 11047), sunitinib (9% ORR for unselected patients with sarcoma) (Broto et al., 2019; ESMO Abstract 1669O), cabozantinib (29% ORR for patients with immunotherapy_refractory urothelial carcinoma) (Nadal et al., 2018; ASCO Abstract 4528), or vemurafenib (1 durable PR for a patient with BRAF_V600E_mutated and PD_L1_positive anaplastic thyroid cancer) (Kollipara et al., 2017; 28778959), have also shown evidence of efficacy and continue to undergo clinical investigation. </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Atezolizumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Atezolizumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC) and urothelial carcinoma, depending on treatment setting. Atezolizumab is also approved in combination with other therapies to treat patients with non_squamous NSCLC lacking EGFR or ALK alterations, small cell lung cancer, hepatocellular carcinoma, and BRAF V600_positive melanoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In the prospective Phase 2a MyPathway basket study evaluating atezolizumab for patients with TMB_High solid tumors, patients with TMB ≥16 Muts/Mb achieved improved ORR (38% [16/42] vs. 2.1% [1/48]), DCR (62% [26/42] vs. 23% [11/48]), mPFS (5.7 vs. 1.8 months, HR 0.34), and mOS (19.8 vs. 11.4, HR 0.53) as compared to those with TMB ≥10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). In a retrospective analysis of patients with 17 solid tumor types (comprised of 47% NSCLC, 40% urothelial carcinoma, and 13% encompassing 15 other solid tumors), TMB of 16 Muts/Mb or greater was reported to be associated with an improved ORR to atezolizumab compared to chemotherapy (30% vs. 14%)(Legrand et al., 2018; ASCO Abstract 12000). Atezolizumab has been studied primarily for the treatment of non_small cell lung cancer (NSCLC) (Smith et al., 2016; ASCO Abstract 9028, Mazieres et al., 2016; ASCO Abstract 9032, Besse et al., 2015; ECC Abstract 16LBA, Spigel et al., 2015; ASCO Abstract 8028, Fehrenbacher et al., 2016; 26970723, Herbst et al., 2014; 25428504) and urothelial carcinoma (Balar et al., 2016; ASCO Abstract LBA4500, Dreicer et al., 2016; ASCO Abstract 4515)(Rosenberg et al., 2016; 26952546, Powles et al., 2014; 25428503). A study of atezolizumab as monotherapy for patients with advanced solid tumors reported a median PFS of 18 weeks and an ORR of 21%, including confirmed responses in 25.6% (11/43) of melanomas, 12.5% (7/56) of renal cell carcinomas (RCC) and 16.7% (1/6) of colorectal cancers (CRCs)(Herbst et al., 2014; 25428504). As single_agent therapy in genomically unselected young patients (<30 years old) with relapsed or refractory cancers, atezolizumab elicited an ORR of 1.5% (1/67) for patients with solid tumors, with similar safety and pharmacokinetics as seen in adults (Geoerger et al., 2020; 31780255). A Phase 1a study of atezolizumab reported an ORR of 14.5% (9/62), a median PFS of 5.6 months, and a median OS of 28.9 months for patients with clear cell RCC (McDermott et al., 2016; 26755520). A Phase 1b study evaluated atezolizumab combined with nab_paclitaxel for patients with previously treated metastatic triple_negative breast cancer (mTNBC) and reported confirmed objective responses for 41.7% (10/24) of patients; no dose_limiting toxicities were observed (Adams et al., 2016; ASCO Abstract 1009). A Phase 1b study that evaluated atezolizumab in combination with the MEK inhibitor cobimetinib for advanced solid tumors reported an ORR of 8.3% (7/84) in patients with CRC, 40.9% (9/22) in patients with melanoma, 17.9% (5/28) in patients with NSCLC, and 18.8% (3/16) in patients with other tumors (ovarian cancer, clear_cell sarcoma, and RCC); there was no association between BRAF or KRAS mutation status and response rate in any disease setting, and no dose_limiting toxicities were encountered (Hellmann et al., 2019; 30918950, Bendell et al., 2016; ASCO Abstract 3502). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Avelumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Avelumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 in order to enhance antitumor immune responses. It is FDA approved to treat patients 12 years and older with Merkel cell carcinoma, or for urothelial carcinoma in various treatment settings. The combination of avelumab and axitinib is FDA approved for patients with renal cell carcinoma (RCC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> The JAVELIN Phase 1b study has demonstrated clinical benefit from single_agent avelumab in a variety of solid tumor types, including non_small cell lung carcinoma (NSCLC)(Verschraegen et al., 2016; ASCO Abstract 9036), gastric carcinoma and gastroesophageal junction (GEJ) adenocarcinoma (Chung et al., 2016; ASCO Abstract 4009), urothelial carcinoma (Patel et al., 2016; ESMO Abstract 777PD), mesothelioma (Hassan et al., 2016; ASCO Abstract 8503), ovarian carcinoma (Disis et al., 2016; ASCO Abstract 5533), and breast cancer (Dirix et al., 2016; SABCS Abstract S1_04), and from avelumab combined with axitinib in renal cell carcinoma (Larkin et al., 2016; ESMO Abstract 775PD). Emerging clinical data show a positive trend toward the association of tumor cell PD_L1 expression and improved ORR, PFS, or OS in NSCLC in the first_line setting and in ovarian and breast cancer (Disis et al., 2016; ASCO Abstract 5533, Dirix et al., 2016; SABCS Abstract S1_04, Verschraegen et al., 2016; ASCO Abstract 9036). Limited clinical data indicate activity of avelumab in adrenocortical carcinoma, metastatic castration_resistant prostate cancer, and thymic cancer (Le Tourneau et al., 2016; ASCO Abstract 4516, Fakhrejahani et al., 2017; ASCO GU Abstract 159, Rajan et al., 2016; ASCO Abstract e20106). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Nivolumab + Ipilimumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response, and ipilimumab is a cytotoxic T_lymphocyte antigen 4 (CTLA_4)_blocking antibody. The combination is FDA approved in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and pleural mesothelioma. Furthermore, nivolumab is approved in combination with ipilimumab to treat patients with mismatch repair_deficient (dMMR) or microsatellite instability_high (MSI_H) colorectal cancer (CRC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hodi et al., 2019; AACR abstract CT037), a TMB score of ≥10 Muts/Mb (as measured by this assay) may predict sensitivity to combination nivolumab and ipilimumab treatment. </p> <p><b>Supporting Data:</b> Combination treatment with nivolumab plus the CTLA_4 inhibitor ipilimumab has achieved efficacy in melanoma (up to 61% ORR; mOS >60 months for the combination vs. 37 months for nivolumab monotherapy) (Hodi et al., 2018; 30361170, Postow et al., 2015; 25891304, Hodi et al., 2016; 27622997, Larkin et al., 2019; 31562797), NSCLC (17 months mOS) (Hellmann et al., 2019; 31562796), MSI_High CRC (64% ORR) (Lenz et al., 2020; ASCO GI Abstract 11), RCC (42% ORR) (Motzer et al., 2019; 31427204, Motzer et al., 2018; 29562145), SCLC (19–25% ORR) (Hellmann et al., 2017; ASCO Abstract 8503, Antonia et al., 2016; 27269741), urothelial carcinoma (38% ORR in unselected patients; 58% ORR in patients with ≥1% tumor PD_L1 expression) (Sharma et al., 2019; 31100038), and other solid tumors. </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Pembrolizumab', 'FDAApproved': 'true', 'Rationale': '<p><b>Approved Indications:</b> Pembrolizumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved for patients with tumor mutational burden (TMB)_high (≥10 Muts/Mb), microsatellite instability_high (MSI_H), or mismatch repair_deficient (dMMR) solid tumors; as monotherapy for PD_L1_positive non_small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), cervical cancer, or esophageal cancer; and in combination with chemotherapy for PD_L1_positive triple_negative breast cancer (TNBC) or cervical cancer. It is also approved in various treatment settings as monotherapy for patients with melanoma, HNSCC, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma, endometrial carcinoma that is MSI_H or dMMR, classical Hodgkin lymphoma, or primary mediastinal large B_cell lymphoma; and in combination with chemotherapy or targeted therapy for NSCLC, HNSCC, esophageal or gastroesophageal junction cancer, renal cell carcinoma, TNBC, or endometrial carcinoma that is not MSI_H or dMMR. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In the Phase 2 KEYNOTE 158 multi_solid tumor trial, treatment with the PD_1 inhibitor pembrolizumab led to improved ORR for patients with TMB of 10 Muts/Mb or higher compared those with TMB <10 Muts/Mb (28.3% [34/120] vs. 6.5% [41/635])(Marabelle et al., 2020; 32919526). In the KEYNOTE 028/012 pan_solid tumor trials, a similar improvement in ORR was reported for patients with >103 non_synonymous mutations/exome (~ equivalency >8 Muts/Mb as measured by this assay) compared to those with <103 non_synonymous mutations/exome (30.6% [11/36] vs. 6.5% [5/77])(Cristescu et al., 2018; 30309915). Pembrolizumab has achieved significant clinical benefit for patients with PD_L1_expressing solid tumors including gastric carcinoma (ORR=22.0%)(Muro et al., 2016; 27157491), esophageal carcinoma (ORR=22.0%)(Doi et al., 2015; ASCO Abstract 4010), endometrial carcinoma (ORR=13.0%)(Ott et al., 2016; ASCO Abstract 5581, Mehnert et al., 2016; 27159395), lung carcinoma (median OS=14.9 months)(Herbst et al., 2015; 26712084), urothelial tract carcinoma (ORR=24.0%)(Pilmack et al., 2014; ESMO Abstract LBA23), head and neck carcinoma (ORR=12.0–26.0%)(Chow et al., 2014; ESMO Abstract LBA31, Hsu et al., 2015; ESMO Abstract 2801, Cohen et al., 2016; ASCO Abstract 6017, Seiwert et al., 2016; 27247226), breast carcinoma (ORR=16.0_25.0%)(Nanda et al., 2014; SABCS Abstract S1_09, Nanda et al., 2016; 27138582), cervical squamous cell carcinoma (ORR=12.5%)(Frenel et al., 2016; ASCO Abstract 5515), thyroid carcinoma (ORR=9.0%)(Mehnert et al., 2016; ASCO Abstract 6091), and pleural mesothelioma (ORR=24.0%)(Alley et al., 2015; AACR Abstract CT103). In the KEYNOTE_051 Phase 1/2 study of pembrolizumab for the treatment of pediatric patients with advanced cancer, PRs were reported in 8 patients including 2 adrenocortical carcinomas, 2 mesotheliomas, 1 malignant ganglioglioma, 1 epithelioid sarcoma, 1 lymphoepithelial carcinoma, and 1 malignant rhabdoid (Geoerger et al., 2020; 31812554). Clinical studies have reported responses to pembrolizumab in combination with other immunotherapies such as ipilimumab in recurrent advanced non_small cell lung carcinoma (NSCLC)(ORR=24.0%) (Patnaik et al., 2015; ASCO Abstract 8011, Gubens et al., 2016; ASCO Abstract 9027), and nivolumab in glioma (2/12 PRs, 4/12 SDs)(Schaff et al., 2015; SNO Abstract IMCT_18). Clinical benefit has also been achieved with pembrolizumab in combination with chemotherapy for advanced non_squamous NSCLC (Papadimitrakopoulou et al., 2015; ASCO Abstract 8031), IDO_1 inhibitor epacadostat for solid tumors (Gangadhar et al., 2015; SITC Abstract 511), HDAC inhibitor entinostat for breast and endometrial cancer (Tolcher et al., 2018; AACR Abstract CT179), bevacizumab for glioblastoma (Reardon et al., 2016; ASCO Abstract 2010), and lenvatinib for patients with advanced endometrial carcinoma that is not MSI_H or dMMR (Makker et al., 2019; 30922731). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Durvalumab', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> Durvalumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of ≥10 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Single_agent durvalumab has demonstrated efficacy in non_small cell lung cancer (Bais et al., 2017; AACR Abstract 3720/5, Garassino et al., 2016; IASLC Abstract PLO4a.03), and head and neck squamous cell carcinoma (Segal et al., 2016; ESMO Abstract 949O, Segal et al., 2015; ASCO Abstract 3011). In patients with advanced solid tumors, durvalumab monotherapy has elicited disease control rates (DCRs) of 36.8–46.2% (7/19 to 12/26) in Phase 1/2 studies (Lutzky et al., 2014; ASCO Abstract 3001, Iguchi et al., 2015; ASCO Abstract 3039). Durvalumab is also under investigation in combination with other agents in Phase 1/2 trials. In advanced melanoma, durvalumab in combination with trametinib and dabrafenib elicited ORRs and DCRs of 76.2% (16/21) and 100% (21/21) in patients with BRAF_mutant tumors, and durvalumab with trametinib elicited ORRs and DCRs of 21.4% (3/14) and 64.3% (9/14) in patients whose tumors were BRAF wild_type (Ribas et al., 2015; ASCO Abstract 3003). Durvalumab in combination with the PARP inhibitor olaparib has shown activity in patients with metastatic castration_resistant prostate cancer and progression on enzalutamide and/or abiraterone (Karzai et al., 2017; ASCO Genitourinary Abstract 162) and in patients with BRCA_wild_type breast or gynecological cancer (Lee et al., 2016; ASCO Abstract 3015). Durvalumab in combination with the anti_CTLA4 antibody tremelimumab, but not durvalumab as a single_agent, has shown activity in patients with previously treated advanced germ cell tumors (Necchi et al., 2019; 30243800). Responses have also been reported for patients with solid tumors treated with durvalumab in combination with the anti_PD_1 antibody MEDI0680 (Hamid et al., 2016; ESMO Abstract 1050PD), the CXCR2 antagonist AZD5069 (Hong et al., 2016; ESMO 2016 Abstract 1049PD), or the ATR inhibitor AZD6738 (Yap et al., 2016; EORTC_NCI_AACR Abstract 1LBA). In patients with treatment_refractory solid tumors, concurrent durvalumab and radiotherapy achieved an ORR of 60% (6/10) for in_field evaluable lesions, including 2 CRs and 4 PRs (Levy et al., 2016; 27764686). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04237649', 'Include': 'true'}, {'nctId': 'NCT04589845', 'Include': 'true'}, {'nctId': 'NCT04521621', 'Include': 'true'}, {'nctId': 'NCT04261439', 'Include': 'true'}, {'nctId': 'NCT03799003', 'Include': 'true'}, {'nctId': 'NCT03861793', 'Include': 'true'}, {'nctId': 'NCT04047862', 'Include': 'true'}, {'nctId': 'NCT03530397', 'Include': 'true'}, {'nctId': 'NCT03396445', 'Include': 'true'}, {'nctId': 'NCT04892498', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'ETV6', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'inversion intron 5, rearrangement intron 5', 'AlterationProperties': {'AlterationProperty': [{'isEquivocal': 'false', 'name': 'inversion intron 5'}, {'isEquivocal': 'false', 'name': 'rearrangement intron 5'}]}, 'Interpretation': 'ETV6 encodes an ETS family transcription factor required for hematopoiesis. The portion of chromosome 12 that encodes ETV6 is frequently involved in translocation events, and at least 30 fusion partners have been identified to date (Kralik et al., 2011; 21401966, De Braekeleer et al., 2012; 22578774). ETV6 rearrangements have been implicated in various hematopoietic malignancies (Wlodarska et al., 1996; 9031109) and have been reported to be pathogenic by a number of different mechanisms including activation of a partner oncogene, ETV6 inactivation, or aberrant transcription factor activity (De Braekeleer et al., 2012; 22578774). Alterations such as seen here may disrupt ETV6 function or expression (Montpetit and Sinnett, 2001; 11423994, Donaldson et al., 1996; 8598195, Green et al., 2010; 20400516, Tognon et al., 2004; 15143160, Kim et al., 2001; 11483520). ETV6 mutation has been observed in up to 7% of cutaneous squamous cell carcinomas (cBio_Li et al., 2015; 25589618), 6% of colorectal adenocarcinomas (cBio_Seshagiri et al., 2012; 22895193), 5.5% of bladder cancers (cBio_Kim et al., 2015; 25092538), 4% each of melanomas and endometrial carcinomas, and in lower frequencies in other tumor types cBioPortal, Apr 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). High ETV6 expression associated with poor prognosis in one study (Ke et al., 2017; 28831010), and low ETV6 expression associated with improved OS and disease_free survival in patients with NSCLC (Liang et al., 2015; 26045802). There are no approved therapies that address ETV6 mutation or inactivation.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'FLT4', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'V160L', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'V160L'}}, 'Interpretation': 'FLT4 encodes the protein fms_related tyrosine kinase 4, also known as VEGFR_3 (vascular endothelial growth factor receptor 3). Targeting of VEGF receptors has been a major therapeutic strategy in cancer as growth of new blood and lymph vessels is a critical determinant of tumor growth and metastasis (Koch et al., 2011; 21711246, Werynska et al., 2009; 20164015). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. In the TCGA datasets, FLT4 mutation has been reported in 11.6% of cutaneous melanomas, 7.5% of endometrial carcinomas, 5.6% of colorectal adenocarcinomas, 5.5% of stomach adenocarcinomas, and at lower incidence across a range of other tumor types (cBioPortal, Apr 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of FLT4 alterations in solid tumors are generally limited (PubMed, Apr 2022). Based on clinical studies, FLT4 amplification may be associated with sensitivity to kinase inhibitors with activity against VEGFR3 such as axitinib and sorafenib; responses to axitinib have been observed in patients with FLT4_amplified differentiated thyroid carcinoma (Schechter et al., 2015; 25641339), and responses to sorafenib have been reported in patients with FLT4_amplified angiosarcoma (Guo et al., 2011; 20949568, D Angelo et al., 2012; ASCO Abstract 10019). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'HIST1H1D', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Q182*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Q182*'}}, 'Interpretation': 'HIST1H1D encodes histone H1.3 (H1D), a linker histone that interacts with DNA between nucleosomes and functions in the regulation of gene expression and compaction of chromatin into higher order structures (Sancho et al., 2008; 18927631, Soshnev et al., 2021; 34580064). Missense mutations in linker histones affecting the globular and C_terminal domains have been identified in cancer and often correlate with loss of function (Soshnev et al., 2021; 34580064), whereas other alterations are mostly uncharacterized. Recurrent missense mutations in the genes that encode H1 isoforms B–E, have been reported at high frequencies in B cell lymphomas, including 30–40% of diffuse large B cell lymphomas (DLBCLs), 30% of follicular lymphomas and 50% of Hodgkin lymphomas, and lower frequencies across other tumor types (Yusufova et al., 2020; 33299181, Krysiak et al., 2017; 28064239, Okosun et al., 2014; 24362818, Li et al., 2014; 24435047, Lohr et al., 2012; 22343534). Published data investigating the prognostic implications of HIST1H1D alterations in cancer are limited (PubMed, Apr 2022). There are currently no therapies available to directly address genomic alterations in HISTH1D.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'KEAP1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'E41*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'E41*'}}, 'Interpretation': 'KEAP1 encodes a substrate adaptor protein that regulates the cellular response to oxidative stress by providing substrate specificity for a CUL3_dependent ubiquitin ligase (Lo and Hannink, 2006; 17046835). KEAP1 exerts anti_tumor effects through negative regulation of NRF2, a transcription factor encoded by NFE2L2 (Wakabayashi et al., 2003; 14517554, Kansanen et al., 2013; 24024136, Hast et al., 2013; 23382044); KEAP1 inactivation promotes cancer progression through NRF2_mediated chemoresistance and cell growth (Kansanen et al., 2013; 24024136, Hast et al., 2013; 23382044). Somatic mutation of KEAP1 occurs in a range of solid tumors, including gastric, hepatocellular, colorectal, and lung cancers (Yoo et al., 2012; 22348534). KEAP1 mutations are rare in hematological malignancies, occurring in fewer than 1% of samples analyzed (COSMIC, 2022)(Tate et al., 2019; 30371878). In a retrospective analysis of the pan_solid MSKCC dataset, KEAP1 mutation correlated with reduced OS (13.28 vs. 26.53 months) (Xu et al., 2020; 32272498). A study of patients with localized non_small cell lung cancer (NSCLC) identified pathogenic KEAP1 and NFE2L2 mutations as predictors of local recurrence following radiotherapy but not surgery; limited preclinical data also showed that treatment with a glutaminase inhibitor sensitized KEAP1_mutated NSCLC cells to radiation (Binkley et al., 2020; 33071215). In other preclinical studies, treatment with AKT inhibitors sensitized lung cancer cells harboring KEAP1 or NFE2L2 mutations to both chemotherapy and radiation therapy (Chowdhry et al., 2013; 22964642, Abazeed et al., 2013; 23980093). Mixed clinical data have been reported for the association between KEAP1 mutations and the response to immunotherapy. A pan_cancer study of immunotherapy showed that patients with KEAP1 mutations had shorter OS (10 vs. 20 months) than those without (Chen et al., 2020; 32175433). However, another study across solid tumors showed that KEAP1 mutations were associated with higher tumor mutational burden (TMB) and PD_L1 expression, as well as improved survival outcomes with immunotherapy compared with other treatments (20.0 vs. 11.5 months) (Xu et al., 2020; 32272498). For patients with non_small cell lung cancer (NSCLC), a study of PD_L1 inhibitors showed that patients with concurrent mutations of STK11 and KEAP1 (n=39) experienced significantly shorter PFS (1.6 vs. 2.5 months, HR=1.5) and OS (4 vs. 11 months, HR=1.9) compared with patients with STK11_ and KEAP1_wildtype tumors (n=210) despite significantly higher TMB in the group harboring STK11 and KEAP1 mutations (median 9.4 vs. 6.1 Muts/Mb) (Arbour et al., 2018; IASLC WCLC Abstract MA19.09). Retrospective analyses of patients with NSCLC who received immunotherapy reported reduced OS (p=0.040) for patients harboring KEAP1_ or NFE2L2_mutated tumors (Zhang et al., 2020; 32471565) or STK11_ or KEAP1_mutated tumors (p <0.001) (Shang et al., 2020; WCLC Abstract P75.02) compared with those without. Studies of immune checkpoint inhibitors for patients with lung adenocarcinoma showed that coexisting mutations between KEAP1, PBRM1, SMARCA4, STK11, and KRAS were associated with worse OS (Marinelli et al., 2020; 32866624, Ricciuti et al., 2020; WCLC Abstract P14.26). An exploratory analysis of a subset of patients with PD_L1_positive NSCLC treated in the first_line setting with pembrolizumab showed similar ORR, PFS, and OS when comparing patients with STK11 or KEAP1 mutations and those without (Cho et al., 2020; AACR Abstract CT084). In addition, preclinical data suggest that KEAP1 inactivation increases tumor demand for glutamine and increases tumor sensitivity to glutaminase inhibitors like telaglenastat (Gwinn et al., 2018; 29316436, Sayin et al., 2017; 28967864, Romero et al., 2017; 28967920). Limited clinical data suggest that KEAP1 mutations may predict improved clinical benefit from combinations of glutaminase inhibitors and anti_PD_1 inhibitors (Skoulidis et al., 2021; ASCO Abstract TPS9627); a Phase 1/2 study of the glutaminase inhibitor telaglenastat (CB_839) plus nivolumab to treat advanced NSCLC reported better clinical benefit rates and median PFS for patients with KEAP1 mutations (75% [3/4] vs. 15% [2/13], 6.4 vs. 3.7 months), KRAS mutations (38% [3/8] vs. 20% [2/10], 4.5 vs. 3.7 months), or KEAP1 and KRAS concurrent mutations (100% [2/2] vs. 13% [1/8], 7.2 vs. 3.7 months) compared with patients without these mutations (Skoulidis et al., 2021; ASCO Abstract TPS9627). The KEAP1 mutation has also been identified as a potential biomarker for sensitivity to combined AKT and TXNRD1 inhibition in lung cancer (Dai et al., 2013; 23824739).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'MS_Stable', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'MS_Stable'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_high (MSI_H) has been observed at high frequency in endometrial cancers (14_33%)(Santin et al., ASCO 2016; Abstract 414, Zighelboim et al., 2007; 17513808, Hampel et al., 2006; 16885385, Stelloo et al., 2016; 27006490, Kanopiene et al., 2014; 25458958, Black et al., 2006; 16549821, Nout et al., 2012; 22609107, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452), colorectal cancers (CRCs; 10_15%)(Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894), and gastric cancers (12_35%)(Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086) and at lower frequencies in many other tumor types, including esophageal (Hall et al., 2016; ASCO Gastrointestinal Cancer Symposium Abstract 528, Farris et al., 2011; 21422910), small bowel (Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06, Agaramet al., 2010; 20395525, Ruemmele et al., 2009; 19252434, Planck et al., 2003; 12627520, Hibi et al., 1995; 7775257, Muneyuki et al., 2000; 11117578), hepatobiliary (Zhang et al., 2005; 15918185, Chiappini et al., 2004; 14656944, Suto et al., 2001; 11223838, Momoi et al., 2001; 11580146, Liengswangwong et al., 2003; 14506736, Moy et al., 2015; 25680569, Yoshida et al., 2000; 11063221), prostate (Cheng et al., 2016; Genitourinary Cancers Symposium Abstract 251, Pritchard et al., 2014; 25255306, Azzouzi et al., 2007; 17233803, Burger et al., 2006; 16924473), and urinary tract carcinomas (Harper et al., 2015; USCAP Abstract 905, Bai et al., 2013; 23690119, Giedl et al., 2014; 25319978, Yamamoto et al., 2006; 16675567). In one study, MSI_H status was associated with a positive prognostic effect in patients with gastric cancer treated with surgery alone and a negative predictive effect in patients treated with chemotherapy (Smyth et al., 2015; ASCO Gastrointestinal Cancers Symposium Abstract 62). Data regarding the role of MSI_H on prognosis and survival in endometrial cancer are conflicting (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao_Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958, Black et al., 2006; 16549821). However, studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI_H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI_H predicts for poor prognosis in this subset of endometrial tumors. On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TET2', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'V1417F', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'V1417F'}}, 'Interpretation': 'TET2 encodes a tumor suppressor involved in reversing DNA methylation marks, a process critical for proper gene regulation (Ito et al., 2010; 20639862, Guo et al., 2011; 21496894). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. TET2 alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Jan 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of TET2 alterations in solid tumors are limited (PubMed, Jan 2022). There are no targeted therapies available to address genomic alterations in TET2 in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TP53', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'splice site 375G>T', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'splice site 375G>T'}}, 'Interpretation': 'Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). Pan_cancer analysis of the TCGA datasets across 12 cancer types identified TP53 as the most frequently mutated gene, with 42% of more than 3,000 tumors harboring a TP53 mutation; in this study TP53 mutation occurred most frequently in ovarian serous carcinoma (95%), lung squamous cell carcinoma (SCC) (79%), head and neck SCC (70%), colorectal adenocarcinoma (59%), lung adenocarcinoma (52%), and bladder urothelial carcinoma (50%) (Kandoth et al., 2013; 24132290). In one study of 55 patients with lung adenocarcinoma, TP53 alterations correlated with immunogenic features including PD_L1 expression, tumor mutation burden and neoantigen presentation; likely as a consequence of this association TP53 mutations correlated with improved clinical outcomes to PD_1 inhibitors pembrolizumab and nivolumab in this study (Dong et al., 2016; 28039262). TP53 mutation has not been consistently demonstrated to be a significant independent prognostic marker in the context of CRC (Russo et al., 2005; 16172461). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'TRAF3', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Q492*', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Q492*'}}, 'Interpretation': 'TRAF3, a member of the TRAF family of adaptor proteins, has E3 ubiquitin ligase activity and is a critical determinant of B_cell survival (Xie et al., 2008; 18499506, Kayagaki et al., 2007; 17991829). TRAF3 loss leads to the activation of the NF_kB pathway and is thought to function as a tumor suppressor in a variety of B_cell lineage neoplasms (Keats et al., 2007; 17692805, Liao et al., 2004; 15084608, Annunziata et al., 2007; 17692804, Nagel et al., 2009; 19693093, Gardam et al., 2011; 21300983). Alterations such as seen here may disrupt TRAF3 function or expression. TRAF3 mutations have been reported with the highest incidences in the uterine corpus endometrial carcinoma (3.4%), skin cutaneous melanoma (2.7%), cervical squamous cell carcinoma (2.4%), stomach adenocarcinoma (2.3%), and colorectal adenocarcinoma (2.0%) TCGA datasets (cBioPortal, Mar 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of TRAF3 alterations in solid tumors are limited (PubMed, Mar 2022). There are no approved therapies that directly target TRAF3 inactivation or the activation of the NF_kB pathway, although these are under development. The Bruton’s tyrosine kinase inhibitor ibrutinib has been reported to inhibit NF_kB pathway activation in chronic lymphocytic leukemia samples and myeloma cells (Herman et al., 2014; 24659631, Herman et al., 2011; 21422473; Rushworth et al., 2013; 22975686). However, preclinical data in mantle cell lymphoma cells suggest that inactivation of TRAF3 or the related TRAF2 may correlate with insensitivity to ibrutinib and to the PKC inhibitor sotrastaurin (Rahal et al., 2014; 24362935). This insensitivity was attributed to activation of alternative NF_kB signaling, which could be inhibited by targeting the kinase NIK (MAP3K14) in preclinical assays (Rahal et al., 2014; 24362935).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'ERBB3', 'Alteration': 'V104L', 'Title': 'An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation', 'StudyPhase': 'PHASE 2', 'Target': 'EGFR, ERBB4, ERBB2', 'Locations': 'Liège (Belgium), Brussels (Belgium), Gent (Belgium)', 'NCTID': 'NCT03810872', 'Note': 'Clinical and preclinical data support sensitivity of ERBB3 activating mutations to HER2_targeting TKIs, including afatinib and lapatinib. ERBB3 amplification or activating mutations may confer sensitivity to therapies targeting ERBB3.', 'Include': 'true'}, {'Gene': 'MET', 'Alteration': 'amplification', 'Title': 'CBT_101 Study for Advanced Solid Tumors and c_Met Dysregulation', 'StudyPhase': 'PHASE 1/2', 'Target': 'MET', 'Locations': 'Taipei City (Taiwan), Taipei (Taiwan), New Taipei City (Taiwan), Taoyuan City (Taiwan), Tainan (Taiwan), Singapore (Singapore), Nedlands (Australia), Saransk (Russian Federation), North Adelaide (Australia), Bedford Park (Australia)', 'NCTID': 'NCT03175224', 'Note': 'Activating MET alterations may confer sensitivity to MET inhibitors.', 'Include': 'true'}, {'Gene': 'MET', 'Alteration': 'amplification', 'Title': 'Tepotinib in Solid Tumors Harboring MET Alterations', 'StudyPhase': 'PHASE 2', 'Target': 'MET', 'Locations': 'Cheonan (Korea, Republic of), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of)', 'NCTID': 'NCT04647838', 'Note': 'Activating MET alterations may confer sensitivity to MET inhibitors.', 'Include': 'true'}, {'Gene': 'MET', 'Alteration': 'amplification', 'Title': 'Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO', 'Locations': 'Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)', 'NCTID': 'NCT03297606', 'Note': 'Activating MET alterations may confer sensitivity to MET inhibitors.', 'Include': 'true'}, {'Gene': 'MET', 'Alteration': 'amplification', 'Title': 'A Study Evaluating the Activity of Anti_cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.', 'StudyPhase': 'PHASE 2', 'Target': 'CDK6, CDK4, MDM2, MET, ROS1, RET, VEGFRs', 'Locations': 'Nice (France), Lyon (France), Marseille (France), Toulouse (France), Bordeaux (France)', 'NCTID': 'NCT04116541', 'Note': 'Activating MET alterations may confer sensitivity to MET inhibitors.', 'Include': 'true'}, {'Gene': 'MET', 'Alteration': 'amplification', 'Title': 'PK Study to Assess Drug_drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates', 'StudyPhase': 'PHASE 1', 'Target': 'AXL, KIT, DDR2, VEGFRs, PDGFRA, TRKA, MET, FLT3, RET, TRKB, PD_1', 'Locations': 'Texas, Virginia', 'NCTID': 'NCT04887194', 'Note': 'Activating MET alterations may confer sensitivity to MET inhibitors.', 'Include': 'true'}, {'Gene': 'MET', 'Alteration': 'amplification', 'Title': 'Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, CDK4, CDK6, VEGFRs, ALK, ROS1, AXL, TRKA, MET, TRKC', 'Locations': 'Texas', 'NCTID': 'NCT04693468', 'Note': 'Activating MET alterations may confer sensitivity to MET inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '63', 'Title': 'KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'ADORA2A, CD73, PD_1', 'Locations': 'Taipei (Taiwan), Shatin, New Territories (Hong Kong), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Toronto (Canada), Missouri', 'NCTID': 'NCT04237649', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '63', 'Title': 'Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study', 'StudyPhase': 'PHASE 2', 'Target': 'TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha', 'Locations': 'Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi an (China), Tianjin (China), Beijing (China), Chengdu City (China), Changchun (China)', 'NCTID': 'NCT04589845', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '63', 'Title': 'A Study of V937 in Combination With Pembrolizumab (MK_3475) in Participants With Advanced/Metastatic Solid Tumors (V937_013)', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1', 'Locations': 'Taipei (Taiwan), Taoyuan (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Kashiwa (Japan), Afula (Israel), Jerusalem (Israel), Tel Aviv (Israel), Warszawa (Poland), Oslo (Norway)', 'NCTID': 'NCT04521621', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '63', 'Title': 'A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1', 'Locations': 'Taipei (Taiwan), Chuo ku (Japan), Essen (Germany), Napoli (Italy), Leuven (Belgium), Barcelona (Spain), California, Texas', 'NCTID': 'NCT04261439', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '63', 'Title': 'A Study of ASP1951 in Subjects With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, TNFRSF18', 'Locations': 'Taipei (Taiwan), Taichung (Taiwan), Daegu (Korea, Republic of), Chungcheongbukdo (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Washington, California, Utah', 'NCTID': 'NCT03799003', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '63', 'Title': 'A Dose Escalation and Cohort Expansion Study of Subcutaneously_Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti_PD_1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY_2)', 'StudyPhase': 'PHASE 1/2', 'Target': 'PD_1', 'Locations': 'Taipei (Taiwan), Tainan (Taiwan), Suwon (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Edmonton (Canada), Badalona (Spain), Rotterdam (Netherlands), Valencia (Spain), Madrid (Spain)', 'NCTID': 'NCT03861793', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '63', 'Title': 'Study of BGB_A1217 in Combination With Tislelizumab in Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, TIGIT', 'Locations': 'Taipei (Taiwan), Hualien City (Taiwan), Taichung (Taiwan), Fujian (China), Hangzhou (China), Shanghai (China), Guangdong (China), Changsha (China), Wuhan (China), Jinju_si (Korea, Republic of)', 'NCTID': 'NCT04047862', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '63', 'Title': 'A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors', 'StudyPhase': 'PHASE 1', 'Target': 'PD_L1, PD_1, CTLA_4', 'Locations': 'Taipei (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Cheongju_si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Amsterdam (Netherlands), Ravenna (Italy), Meldola (Italy)', 'NCTID': 'NCT03530397', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '63', 'Title': 'Safety and Pharmacokinetics Study of MK_5890 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Adults With Advanced Solid Tumors (MK_5890_001)', 'StudyPhase': 'PHASE 1', 'Target': 'PD_1, CD27', 'Locations': 'Taipei (Taiwan), Seoul (Korea, Republic of), Jerusalem (Israel), Ramat Gan (Israel), Be er Sheva (Israel), Amsterdam (Netherlands), Rotterdam (Netherlands), Barcelona (Spain), Madrid (Spain), Pozuelo de Alarcon (Spain)', 'NCTID': 'NCT03396445', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}, {'Gene': 'Tumor Mutation Burden', 'Alteration': '63', 'Title': 'Hypofractionated Radiotherapy Combined With PD_1 Inhibitor Sequential GM_CSF and IL_2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)', 'StudyPhase': 'PHASE 2', 'Target': 'PD_1', 'Locations': 'Hangzhou (China), Suzhou (China), Wuxi (China), Hefei (China), Xuzhou (China)', 'NCTID': 'NCT04892498', 'Note': 'Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '21401966', 'FullCitation': 'Kralik JM, et al. Diagn Pathol (2011) pmid: 21401966', 'Include': 'true'}, {'number': '1', 'ReferenceId': '22578774', 'FullCitation': 'De Braekeleer E, et al. Leuk. Res. (2012) pmid: 22578774', 'Include': 'true'}, {'number': '2', 'ReferenceId': '9031109', 'FullCitation': 'Wlodarska I, et al. Leuk. Lymphoma (1996) pmid: 9031109', 'Include': 'true'}, {'number': '3', 'ReferenceId': '11423994', 'FullCitation': 'Montpetit A, et al. Oncogene (2001) pmid: 11423994', 'Include': 'true'}, {'number': '4', 'ReferenceId': '8598195', 'FullCitation': 'Donaldson LW, et al. EMBO J. (1996) pmid: 8598195', 'Include': 'true'}, {'number': '5', 'ReferenceId': '20400516', 'FullCitation': 'Green SM, et al. J. Biol. Chem. (2010) pmid: 20400516', 'Include': 'true'}, {'number': '6', 'ReferenceId': '15143160', 'FullCitation': 'Tognon CE, et al. Mol. Cell. Biol. (2004) pmid: 15143160', 'Include': 'true'}, {'number': '7', 'ReferenceId': '11483520', 'FullCitation': 'Kim CA, et al. EMBO J. (2001) pmid: 11483520', 'Include': 'true'}, {'number': '8', 'ReferenceId': '25589618', 'FullCitation': 'Li YY, et al. Clin. Cancer Res. (2015) pmid: 25589618', 'Include': 'true'}, {'number': '9', 'ReferenceId': '22895193', 'FullCitation': 'Seshagiri S, et al. Nature (2012) pmid: 22895193', 'Include': 'true'}, {'number': '10', 'ReferenceId': '25092538', 'FullCitation': 'Kim PH, et al. Eur. Urol. (2015) pmid: 25092538', 'Include': 'true'}, {'number': '11', 'ReferenceId': '22588877', 'FullCitation': 'Cerami E, et al. Cancer Discov (2012) pmid: 22588877', 'Include': 'true'}, {'number': '12', 'ReferenceId': '23550210', 'FullCitation': 'Gao J, et al. Sci Signal (2013) pmid: 23550210', 'Include': 'true'}, {'number': '13', 'ReferenceId': '28831010', 'FullCitation': 'Ke L, et al. Proc. Natl. Acad. Sci. U.S.A. (2017) pmid: 28831010', 'Include': 'true'}, {'number': '14', 'ReferenceId': '26045802', 'FullCitation': 'Liang JZ, et al. Int J Clin Exp Pathol (2015) pmid: 26045802', 'Include': 'true'}, {'number': '15', 'ReferenceId': '21364581', 'FullCitation': 'Sheng Q, et al. Br. J. Cancer (2011) pmid: 21364581', 'Include': 'true'}, {'number': '16', 'ReferenceId': '23680147', 'FullCitation': 'Jaiswal BS, et al. Cancer Cell (2013) pmid: 23680147', 'Include': 'true'}, {'number': '17', 'ReferenceId': '24997986', 'FullCitation': 'Li M, et al. Nat. Genet. (2014) pmid: 24997986', 'Include': 'true'}, {'number': '18', 'ReferenceId': '23843458', 'FullCitation': 'Collier TS, et al. J. Biol. Chem. (2013) pmid: 23843458', 'Include': 'true'}, {'number': '19', 'ReferenceId': '29963236', 'FullCitation': 'Mishra R, et al. Oncotarget (2018) pmid: 29963236', 'Include': 'true'}, {'number': '20', 'ReferenceId': '30371878', 'FullCitation': 'Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878', 'Include': 'true'}, {'number': '21', 'ReferenceId': '23333248', 'FullCitation': 'Gunes S, et al. Pathol. Res. Pract. (2013) pmid: 23333248', 'Include': 'true'}, {'number': '22', 'ReferenceId': '24013863', 'FullCitation': 'Bellezza G, et al. Virchows Arch. (2013) pmid: 24013863', 'Include': 'true'}, {'number': '23', 'ReferenceId': '23870818', 'FullCitation': 'Skrzypski M, et al. Clin Lung Cancer (2013) pmid: 23870818', 'Include': 'true'}, {'number': '24', 'ReferenceId': '15753374', 'FullCitation': 'Müller_Tidow C, et al. Cancer Res. (2005) pmid: 15753374', 'Include': 'true'}, {'number': '25', 'ReferenceId': '24151090', 'FullCitation': 'Yoon HH, et al. Cancer (2014) pmid: 24151090', 'Include': 'true'}, {'number': '26', 'ReferenceId': '18000824', 'FullCitation': 'Peng D, et al. Int. J. Cancer (2008) pmid: 18000824', 'Include': 'true'}, {'number': '27', 'ReferenceId': '17671674', 'FullCitation': 'Wei Q, et al. Int. J. Oncol. (2007) pmid: 17671674', 'Include': 'true'}, {'number': '28', 'ReferenceId': '22733579', 'FullCitation': 'Paterson AL, et al. J. Pathol. (2013) pmid: 22733579', 'Include': 'true'}, {'number': '29', 'ReferenceId': '11324501', 'FullCitation': 'Leng J, et al. Chin. Med. Sci. J. (1997) pmid: 11324501', 'Include': 'true'}, {'number': '30', 'ReferenceId': '16896008', 'FullCitation': 'Tanner B, et al. J. Clin. Oncol. (2006) pmid: 16896008', 'Include': 'true'}, {'number': '31', 'ReferenceId': '24300455', 'FullCitation': 'Lédel F, et al. Eur. J. Cancer (2014) pmid: 24300455', 'Include': 'true'}, {'number': '32', 'ReferenceId': '29888103', 'FullCitation': 'Song K, et al. Am J Cancer Res (2018) pmid: 29888103', 'Include': 'true'}, {'number': '33', 'ReferenceId': '21709195', 'FullCitation': 'Begnami MD, et al. J. Clin. Oncol. (2011) pmid: 21709195', 'Include': 'true'}, {'number': '34', 'ReferenceId': '19047113', 'FullCitation': 'Hayashi M, et al. Clin. Cancer Res. (2008) pmid: 19047113', 'Include': 'true'}, {'number': '35', 'ReferenceId': '19390858', 'FullCitation': 'Baiocchi G, et al. Int J Colorectal Dis (2009) pmid: 19390858', 'Include': 'true'}, {'number': '36', 'ReferenceId': '18182100', 'FullCitation': 'Sassen A, et al. Breast Cancer Res. (2008) pmid: 18182100', 'Include': 'true'}, {'number': '37', 'ReferenceId': '12845624', 'FullCitation': 'Witton CJ, et al. J. Pathol. (2003) pmid: 12845624', 'Include': 'true'}, {'number': '38', 'ReferenceId': '18985033', 'FullCitation': 'Koutras AK, et al. Br. J. Cancer (2008) pmid: 18985033', 'Include': 'true'}, {'number': '39', 'ReferenceId': '11106235', 'FullCitation': 'Pawlowski V, et al. Clin. Cancer Res. (2000) pmid: 11106235', 'Include': 'true'}, {'number': '40', 'ReferenceId': '8688326', 'FullCitation': 'Travis A, et al. Br. J. Cancer (1996) pmid: 8688326', 'Include': 'true'}, {'number': '41', 'ReferenceId': '7821892', 'FullCitation': 'Quinn CM, et al. Histopathology (1994) pmid: 7821892', 'Include': 'true'}, {'number': '42', 'ReferenceId': '7908213', 'FullCitation': 'Gasparini G, et al. Eur. J. Cancer (1994) pmid: 7908213', 'Include': 'true'}, {'number': '43', 'ReferenceId': '1333787', 'FullCitation': 'Lemoine NR, et al. Br. J. Cancer (1992) pmid: 1333787', 'Include': 'true'}, {'number': '44', 'ReferenceId': '8869284', 'FullCitation': 'Rajkumar T, et al. J. Pathol. (1996) pmid: 8869284', 'Include': 'true'}, {'number': '45', 'ReferenceId': '14614020', 'FullCitation': 'Junttila TT, et al. Clin. Cancer Res. (2003) pmid: 14614020', 'Include': 'true'}, {'number': '46', 'ReferenceId': '15892828', 'FullCitation': 'Røtterud R, et al. BJU Int. (2005) pmid: 15892828', 'Include': 'true'}, {'number': '47', 'ReferenceId': '16360440', 'FullCitation': 'Tsai YS, et al. Urology (2005) pmid: 16360440', 'Include': 'true'}, {'number': '48', 'ReferenceId': '9230911', 'FullCitation': 'Chow NH, et al. Virchows Arch. (1997) pmid: 9230911', 'Include': 'true'}, {'number': '49', 'ReferenceId': '11448910', 'FullCitation': 'Chow NH, et al. Clin. Cancer Res. (2001) pmid: 11448910', 'Include': 'true'}, {'number': '50', 'ReferenceId': '31351986', 'FullCitation': 'Black LE, et al. Am. J. Pathol. (2019) pmid: 31351986', 'Include': 'true'}, {'number': '51', 'ReferenceId': '19536107', 'FullCitation': 'Baselga J, et al. Nat. Rev. Cancer (2009) pmid: 19536107', 'Include': 'true'}, {'number': '52', 'ReferenceId': '20007378', 'FullCitation': 'Jura N, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 20007378', 'Include': 'true'}, {'number': '53', 'ReferenceId': '26689995', 'FullCitation': 'Umelo I, et al. Oncotarget (2016) pmid: 26689995', 'Include': 'true'}, {'number': '54', 'ReferenceId': '27044931', 'FullCitation': 'Choudhury NJ, et al. J. Clin. Oncol. (2016) pmid: 27044931', 'Include': 'true'}, {'number': '55', 'ReferenceId': '29413684', 'FullCitation': 'Verlingue L, et al. Eur. J. Cancer (2018) pmid: 29413684', 'Include': 'true'}, {'number': '56', 'ReferenceId': '29902295', 'FullCitation': 'Goss GD, et al. JAMA Oncol (2018) pmid: 29902295', 'Include': 'true'}, {'number': '57', 'ReferenceId': '25953157', 'FullCitation': 'Bidard FC, et al. Ann. Oncol. (2015) pmid: 25953157', 'Include': 'true'}, {'number': '58', 'ReferenceId': '29420467', 'FullCitation': 'Hyman DM, et al. Nature (2018) pmid: 29420467', 'Include': 'true'}, {'number': '59', 'ReferenceId': '29734047', 'FullCitation': 'Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047', 'Include': 'true'}, {'number': '60', 'ReferenceId': '22042966', 'FullCitation': 'J. Clin. Oncol. (2011) pmid: 22042966', 'Include': 'true'}, {'number': '61', 'ReferenceId': '22553051', 'FullCitation': 'Jung KH, et al. Arch. Pharm. Res. (2012) pmid: 22553051', 'Include': 'true'}, {'number': '62', 'ReferenceId': '23898085', 'FullCitation': 'Ang CS, et al. Anticancer Res. (2013) pmid: 23898085', 'Include': 'true'}, {'number': '63', 'ReferenceId': '23996864', 'FullCitation': 'Abou_Bakr AA, et al. Gulf J Oncolog (2013) pmid: 23996864', 'Include': 'true'}, {'number': '64', 'ReferenceId': '24258573', 'FullCitation': 'Ho JC, et al. Semin Respir Crit Care Med (2013) pmid: 24258573', 'Include': 'true'}, {'number': '65', 'ReferenceId': '22237262', 'FullCitation': 'Dziadziuszko R, et al. J Thorac Oncol (2012) pmid: 22237262', 'Include': 'true'}, {'number': '66', 'ReferenceId': '26319934', 'FullCitation': 'Madoz_Gúrpide J, et al. J Transl Med (2015) pmid: 26319934', 'Include': 'true'}, {'number': '67', 'ReferenceId': '21623265', 'FullCitation': 'Ou SH, et al. J Thorac Oncol (2011) pmid: 21623265', 'Include': 'true'}, {'number': '68', 'ReferenceId': '24192513', 'FullCitation': 'Schwab R, et al. Lung Cancer (2014) pmid: 24192513', 'Include': 'true'}, {'number': '69', 'ReferenceId': '22042947', 'FullCitation': 'Lennerz JK, et al. J. Clin. Oncol. (2011) pmid: 22042947', 'Include': 'true'}, {'number': '70', 'ReferenceId': '22162573', 'FullCitation': 'Chi AS, et al. J. Clin. Oncol. (2012) pmid: 22162573', 'Include': 'true'}, {'number': '71', 'ReferenceId': '25232318', 'FullCitation': 'Palma NA, et al. Case Rep Oncol (2014) pmid: 25232318', 'Include': 'true'}, {'number': '72', 'ReferenceId': '25922291', 'FullCitation': 'Le X, et al. Clin Lung Cancer (2015) pmid: 25922291', 'Include': 'true'}, {'number': '73', 'ReferenceId': '25882375', 'FullCitation': 'Ali SM, et al. Oncologist (2015) pmid: 25882375', 'Include': 'true'}, {'number': '74', 'ReferenceId': '26432108', 'FullCitation': 'Kwak EL, et al. Cancer Discov (2015) pmid: 26432108', 'Include': 'true'}, {'number': '75', 'ReferenceId': '16186806', 'FullCitation': 'Miller CT, et al. Oncogene (2006) pmid: 16186806', 'Include': 'true'}, {'number': '76', 'ReferenceId': '18349821', 'FullCitation': 'Tuynman JB, et al. Br. J. Cancer (2008) pmid: 18349821', 'Include': 'true'}, {'number': '77', 'ReferenceId': '17062664', 'FullCitation': 'Anderson MR, et al. Clin. Cancer Res. (2006) pmid: 17062664', 'Include': 'true'}, {'number': '78', 'ReferenceId': '22042954', 'FullCitation': 'Graziano F, et al. J. Clin. Oncol. (2011) pmid: 22042954', 'Include': 'true'}, {'number': '79', 'ReferenceId': '21424128', 'FullCitation': 'Lee J, et al. Oncol. Rep. (2011) pmid: 21424128', 'Include': 'true'}, {'number': '80', 'ReferenceId': '22644302', 'FullCitation': 'Lee HE, et al. Br. J. Cancer (2012) pmid: 22644302', 'Include': 'true'}, {'number': '81', 'ReferenceId': '12837985', 'FullCitation': 'Cruz J, et al. Oncology (2003) pmid: 12837985', 'Include': 'true'}, {'number': '82', 'ReferenceId': '22172411', 'FullCitation': 'Yang L, et al. Hepatogastroenterology (2012) pmid: 22172411', 'Include': 'true'}, {'number': '83', 'ReferenceId': '16314638', 'FullCitation': 'Rossi G, et al. J. Clin. Oncol. (2005) pmid: 16314638', 'Include': 'true'}, {'number': '84', 'ReferenceId': '10590366', 'FullCitation': 'Camp RL, et al. Cancer (1999) pmid: 10590366', 'Include': 'true'}, {'number': '85', 'ReferenceId': '15455388', 'FullCitation': 'Lengyel E, et al. Int. J. Cancer (2005) pmid: 15455388', 'Include': 'true'}, {'number': '86', 'ReferenceId': '9554529', 'FullCitation': 'Ghoussoub RA, et al. Cancer (1998) pmid: 9554529', 'Include': 'true'}, {'number': '87', 'ReferenceId': '23079155', 'FullCitation': 'Yang JJ, et al. Lung Cancer (2013) pmid: 23079155', 'Include': 'true'}, {'number': '88', 'ReferenceId': '19255323', 'FullCitation': 'Cappuzzo F, et al. J. Clin. Oncol. (2009) pmid: 19255323', 'Include': 'true'}, {'number': '89', 'ReferenceId': '22207554', 'FullCitation': 'Park S, et al. Histol. Histopathol. (2012) pmid: 22207554', 'Include': 'true'}, {'number': '90', 'ReferenceId': '22052229', 'FullCitation': 'Chen YT, et al. J Thorac Oncol (2011) pmid: 22052229', 'Include': 'true'}, {'number': '91', 'ReferenceId': '19817696', 'FullCitation': 'Kanteti R, et al. J. Environ. Pathol. Toxicol. Oncol. (2009) pmid: 19817696', 'Include': 'true'}, {'number': '92', 'ReferenceId': '11795945', 'FullCitation': 'To C, et al. Exp. Cell Res. (2002) pmid: 11795945', 'Include': 'true'}, {'number': '93', 'ReferenceId': '22198430', 'FullCitation': 'Tsuta K, et al. J Thorac Oncol (2012) pmid: 22198430', 'Include': 'true'}, {'number': '94', 'ReferenceId': '22617129', 'FullCitation': 'Felix AS, et al. Br. J. Cancer (2012) pmid: 22617129', 'Include': 'true'}, {'number': '95', 'ReferenceId': '9452270', 'FullCitation': 'Wagatsuma S, et al. Cancer (1998) pmid: 9452270', 'Include': 'true'}, {'number': '96', 'ReferenceId': '21168200', 'FullCitation': 'Bishop EA, et al. Gynecol. Oncol. (2011) pmid: 21168200', 'Include': 'true'}, {'number': '97', 'ReferenceId': '20527227', 'FullCitation': 'Felix AS, et al. Eur. J. Gynaecol. Oncol. (2010) pmid: 20527227', 'Include': 'true'}, {'number': '98', 'ReferenceId': '22733437', 'FullCitation': 'Garouniatis A, et al. Int J Colorectal Dis (2013) pmid: 22733437', 'Include': 'true'}, {'number': '99', 'ReferenceId': '22495710', 'FullCitation': 'Liu Y, et al. Tumori () pmid: 22495710', 'Include': 'true'}, {'number': '100', 'ReferenceId': '15131045', 'FullCitation': 'Resnick MB, et al. Clin. Cancer Res. (2004) pmid: 15131045', 'Include': 'true'}, {'number': '101', 'ReferenceId': '21733594', 'FullCitation': 'Tanaka A, et al. Lung Cancer (2012) pmid: 21733594', 'Include': 'true'}, {'number': '102', 'ReferenceId': '28315738', 'FullCitation': 'Schrock AB, et al. J Thorac Oncol (2017) pmid: 28315738', 'Include': 'true'}, {'number': '103', 'ReferenceId': '30156984', 'FullCitation': 'Wu YL, et al. J. Clin. Oncol. (2018) pmid: 30156984', 'Include': 'true'}, {'number': '104', 'ReferenceId': '31864558', 'FullCitation': 'Gainor JF, et al. J Thorac Oncol (2020) pmid: 31864558', 'Include': 'true'}, {'number': '105', 'ReferenceId': '31864554', 'FullCitation': 'Gautschi O, et al. J Thorac Oncol (2020) pmid: 31864554', 'Include': 'true'}, {'number': '106', 'ReferenceId': '30952639', 'FullCitation': 'Gan HK, et al. Clin. Cancer Res. (2019) pmid: 30952639', 'Include': 'true'}, {'number': '107', 'ReferenceId': '31315834', 'FullCitation': 'Lee J, et al. Cancer Discov (2019) pmid: 31315834', 'Include': 'true'}, {'number': '108', 'ReferenceId': '30695737', 'FullCitation': 'Kim ST, et al. Transl Oncol (2019) pmid: 30695737', 'Include': 'true'}, {'number': '109', 'ReferenceId': '24101053', 'FullCitation': 'Spigel DR, et al. J. Clin. Oncol. (2013) pmid: 24101053', 'Include': 'true'}, {'number': '110', 'ReferenceId': '22389872', 'FullCitation': 'Catenacci DV, et al. Cancer Discov (2011) pmid: 22389872', 'Include': 'true'}, {'number': '111', 'ReferenceId': '31142504', 'FullCitation': 'Harding JJ, et al. Clin. Cancer Res. (2019) pmid: 31142504', 'Include': 'true'}, {'number': '112', 'ReferenceId': '30285518', 'FullCitation': 'Strickler JH, et al. J. Clin. Oncol. (2018) pmid: 30285518', 'Include': 'true'}, {'number': '113', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '114', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '115', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '116', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '117', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '118', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '119', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '120', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '121', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '122', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '123', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '124', 'ReferenceId': '32919526', 'FullCitation': 'Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526', 'Include': 'true'}, {'number': '125', 'ReferenceId': '31405947', 'FullCitation': 'Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947', 'Include': 'true'}, {'number': '126', 'ReferenceId': '28835386', 'FullCitation': 'Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386', 'Include': 'true'}, {'number': '127', 'ReferenceId': '30309915', 'FullCitation': 'Cristescu R, et al. Science (2018) pmid: 30309915', 'Include': 'true'}, {'number': '128', 'ReferenceId': '27671167', 'FullCitation': 'Johnson DB, et al. Cancer Immunol Res (2016) pmid: 27671167', 'Include': 'true'}, {'number': '129', 'ReferenceId': '25409260', 'FullCitation': 'Snyder A, et al. N. Engl. J. Med. (2014) pmid: 25409260', 'Include': 'true'}, {'number': '130', 'ReferenceId': '26359337', 'FullCitation': 'Van Allen EM, et al. Science (2015) pmid: 26359337', 'Include': 'true'}, {'number': '131', 'ReferenceId': '27022117', 'FullCitation': 'Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117', 'Include': 'true'}, {'number': '132', 'ReferenceId': '27009843', 'FullCitation': 'Xiao D, et al. Oncotarget (2016) pmid: 27009843', 'Include': 'true'}, {'number': '133', 'ReferenceId': '26200269', 'FullCitation': 'Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269', 'Include': 'true'}, {'number': '134', 'ReferenceId': '22980976', 'FullCitation': 'Govindan R, et al. Cell (2012) pmid: 22980976', 'Include': 'true'}, {'number': '135', 'ReferenceId': '18948947', 'FullCitation': 'Ding L, et al. Nature (2008) pmid: 18948947', 'Include': 'true'}, {'number': '136', 'ReferenceId': '22980975', 'FullCitation': 'Imielinski M, et al. Cell (2012) pmid: 22980975', 'Include': 'true'}, {'number': '137', 'ReferenceId': '24323028', 'FullCitation': 'Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028', 'Include': 'true'}, {'number': '138', 'ReferenceId': '11535541', 'FullCitation': 'Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541', 'Include': 'true'}, {'number': '139', 'ReferenceId': '12445368', 'FullCitation': 'Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368', 'Include': 'true'}, {'number': '140', 'ReferenceId': '12820457', 'FullCitation': 'Brueckl WM, et al. Anticancer Res. () pmid: 12820457', 'Include': 'true'}, {'number': '141', 'ReferenceId': '11438476', 'FullCitation': 'Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476', 'Include': 'true'}, {'number': '142', 'ReferenceId': '10631274', 'FullCitation': 'Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274', 'Include': 'true'}, {'number': '143', 'ReferenceId': '16952542', 'FullCitation': 'Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542', 'Include': 'true'}, {'number': '144', 'ReferenceId': '20627535', 'FullCitation': 'Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535', 'Include': 'true'}, {'number': '145', 'ReferenceId': '22722556', 'FullCitation': 'Laghi L, et al. Dig Dis (2012) pmid: 22722556', 'Include': 'true'}, {'number': '146', 'ReferenceId': '27159395', 'FullCitation': 'Mehnert JM, et al. J. Clin. Invest. (2016) pmid: 27159395', 'Include': 'true'}, {'number': '147', 'ReferenceId': '25394778', 'FullCitation': 'Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778', 'Include': 'true'}, {'number': '148', 'ReferenceId': '23528559', 'FullCitation': 'Church DN, et al. Hum. Mol. Genet. (2013) pmid: 23528559', 'Include': 'true'}, {'number': '149', 'ReferenceId': '24777035', 'FullCitation': 'Cazier JB, et al. Nat Commun (2014) pmid: 24777035', 'Include': 'true'}, {'number': '150', 'ReferenceId': '30643254', 'FullCitation': 'Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254', 'Include': 'true'}, {'number': '151', 'ReferenceId': '30785829', 'FullCitation': 'Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829', 'Include': 'true'}, {'number': '152', 'ReferenceId': '29658845', 'FullCitation': 'Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845', 'Include': 'true'}, {'number': '153', 'ReferenceId': '29657128', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128', 'Include': 'true'}, {'number': '154', 'ReferenceId': '29731394', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394', 'Include': 'true'}, {'number': '155', 'ReferenceId': '33558721', 'FullCitation': 'Rozeman EA, et al. Nat Med (2021) pmid: 33558721', 'Include': 'true'}, {'number': '156', 'ReferenceId': '32916128', 'FullCitation': 'Sharma P, et al. Cancer Cell (2020) pmid: 32916128', 'Include': 'true'}, {'number': '157', 'ReferenceId': '17046835', 'FullCitation': 'Lo SC, et al. J. Biol. Chem. (2006) pmid: 17046835', 'Include': 'true'}, {'number': '158', 'ReferenceId': '14517554', 'FullCitation': 'Wakabayashi N, et al. Nat. Genet. (2003) pmid: 14517554', 'Include': 'true'}, {'number': '159', 'ReferenceId': '24024136', 'FullCitation': 'Kansanen E, et al. Redox Biol (2013) pmid: 24024136', 'Include': 'true'}, {'number': '160', 'ReferenceId': '23382044', 'FullCitation': 'Hast BE, et al. Cancer Res. (2013) pmid: 23382044', 'Include': 'true'}, {'number': '161', 'ReferenceId': '22348534', 'FullCitation': 'Yoo NJ, et al. Histopathology (2012) pmid: 22348534', 'Include': 'true'}, {'number': '162', 'ReferenceId': '32272498', 'FullCitation': 'Xu X, et al. Oncologist (2020) pmid: 32272498', 'Include': 'true'}, {'number': '163', 'ReferenceId': '33071215', 'FullCitation': 'Binkley MS, et al. Cancer Discov (2020) pmid: 33071215', 'Include': 'true'}, {'number': '164', 'ReferenceId': '22964642', 'FullCitation': 'Chowdhry S, et al. Oncogene (2013) pmid: 22964642', 'Include': 'true'}, {'number': '165', 'ReferenceId': '23980093', 'FullCitation': 'Abazeed ME, et al. Cancer Res. (2013) pmid: 23980093', 'Include': 'true'}, {'number': '166', 'ReferenceId': '32175433', 'FullCitation': 'Chen X, et al. Ann Transl Med (2020) pmid: 32175433', 'Include': 'true'}, {'number': '167', 'ReferenceId': '32471565', 'FullCitation': 'Zhang C, et al. J Thorac Oncol (2020) pmid: 32471565', 'Include': 'true'}, {'number': '168', 'ReferenceId': '32866624', 'FullCitation': 'Marinelli D, et al. Ann Oncol (2020) pmid: 32866624', 'Include': 'true'}, {'number': '169', 'ReferenceId': '29316436', 'FullCitation': 'Gwinn DM, et al. Cancer Cell (2018) pmid: 29316436', 'Include': 'true'}, {'number': '170', 'ReferenceId': '28967864', 'FullCitation': 'Sayin VI, et al. Elife (2017) pmid: 28967864', 'Include': 'true'}, {'number': '171', 'ReferenceId': '28967920', 'FullCitation': 'Romero R, et al. Nat. Med. (2017) pmid: 28967920', 'Include': 'true'}, {'number': '172', 'ReferenceId': '23824739', 'FullCitation': 'Dai B, et al. Cancer Res. (2013) pmid: 23824739', 'Include': 'true'}, {'number': '173', 'ReferenceId': '18927631', 'FullCitation': 'Sancho M, et al. PLoS Genet. (2008) pmid: 18927631', 'Include': 'true'}, {'number': '174', 'ReferenceId': '34580064', 'FullCitation': 'Soshnev AA, et al. Cancer Res (2021) pmid: 34580064', 'Include': 'true'}, {'number': '175', 'ReferenceId': '33299181', 'FullCitation': 'Yusufova N, et al. Nature (2021) pmid: 33299181', 'Include': 'true'}, {'number': '176', 'ReferenceId': '28064239', 'FullCitation': 'Krysiak K, et al. Blood (2017) pmid: 28064239', 'Include': 'true'}, {'number': '177', 'ReferenceId': '24362818', 'FullCitation': 'Okosun J, et al. Nat. Genet. (2014) pmid: 24362818', 'Include': 'true'}, {'number': '178', 'ReferenceId': '24435047', 'FullCitation': 'Li H, et al. Blood (2014) pmid: 24435047', 'Include': 'true'}, {'number': '179', 'ReferenceId': '22343534', 'FullCitation': 'Lohr JG, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22343534', 'Include': 'true'}, {'number': '180', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '181', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '182', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '183', 'ReferenceId': '9823339', 'FullCitation': 'Boland CR, et al. Cancer Res. (1998) pmid: 9823339', 'Include': 'true'}, {'number': '184', 'ReferenceId': '15528785', 'FullCitation': 'Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785', 'Include': 'true'}, {'number': '185', 'ReferenceId': '20420947', 'FullCitation': 'Boland CR, et al. Gastroenterology (2010) pmid: 20420947', 'Include': 'true'}, {'number': '186', 'ReferenceId': '17513808', 'FullCitation': 'Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808', 'Include': 'true'}, {'number': '187', 'ReferenceId': '16885385', 'FullCitation': 'Hampel H, et al. Cancer Res. (2006) pmid: 16885385', 'Include': 'true'}, {'number': '188', 'ReferenceId': '27006490', 'FullCitation': 'Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490', 'Include': 'true'}, {'number': '189', 'ReferenceId': '25458958', 'FullCitation': 'Kanopienė D, et al. Medicina (Kaunas) (2014) pmid: 25458958', 'Include': 'true'}, {'number': '190', 'ReferenceId': '16549821', 'FullCitation': 'Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821', 'Include': 'true'}, {'number': '191', 'ReferenceId': '22609107', 'FullCitation': 'Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107', 'Include': 'true'}, {'number': '192', 'ReferenceId': '21547578', 'FullCitation': 'Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578', 'Include': 'true'}, {'number': '193', 'ReferenceId': '20005452', 'FullCitation': 'Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452', 'Include': 'true'}, {'number': '194', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '195', 'ReferenceId': '15209621', 'FullCitation': 'Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621', 'Include': 'true'}, {'number': '196', 'ReferenceId': '9537253', 'FullCitation': 'Wu MS, et al. Cancer Res. (1998) pmid: 9537253', 'Include': 'true'}, {'number': '197', 'ReferenceId': '8536886', 'FullCitation': 'dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886', 'Include': 'true'}, {'number': '198', 'ReferenceId': '23555086', 'FullCitation': 'Fang WL, et al. Biomed Res Int (2013) pmid: 23555086', 'Include': 'true'}, {'number': '199', 'ReferenceId': '21422910', 'FullCitation': 'Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910', 'Include': 'true'}, {'number': '200', 'ReferenceId': '20395525', 'FullCitation': 'Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525', 'Include': 'true'}, {'number': '201', 'ReferenceId': '19252434', 'FullCitation': 'Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434', 'Include': 'true'}, {'number': '202', 'ReferenceId': '12627520', 'FullCitation': 'Planck M, et al. Cancer (2003) pmid: 12627520', 'Include': 'true'}, {'number': '203', 'ReferenceId': '7775257', 'FullCitation': 'Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257', 'Include': 'true'}, {'number': '204', 'ReferenceId': '11117578', 'FullCitation': 'Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578', 'Include': 'true'}, {'number': '205', 'ReferenceId': '15918185', 'FullCitation': 'Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185', 'Include': 'true'}, {'number': '206', 'ReferenceId': '14656944', 'FullCitation': 'Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944', 'Include': 'true'}, {'number': '207', 'ReferenceId': '11223838', 'FullCitation': 'Suto T, et al. J Surg Oncol (2001) pmid: 11223838', 'Include': 'true'}, {'number': '208', 'ReferenceId': '11580146', 'FullCitation': 'Momoi H, et al. J. Hepatol. (2001) pmid: 11580146', 'Include': 'true'}, {'number': '209', 'ReferenceId': '14506736', 'FullCitation': 'Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736', 'Include': 'true'}, {'number': '210', 'ReferenceId': '25680569', 'FullCitation': 'Moy AP, et al. Virchows Arch. (2015) pmid: 25680569', 'Include': 'true'}, {'number': '211', 'ReferenceId': '11063221', 'FullCitation': 'Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221', 'Include': 'true'}, {'number': '212', 'ReferenceId': '25255306', 'FullCitation': 'Pritchard CC, et al. Nat Commun (2014) pmid: 25255306', 'Include': 'true'}, {'number': '213', 'ReferenceId': '17233803', 'FullCitation': 'Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803', 'Include': 'true'}, {'number': '214', 'ReferenceId': '16924473', 'FullCitation': 'Burger M, et al. J. Mol. Med. (2006) pmid: 16924473', 'Include': 'true'}, {'number': '215', 'ReferenceId': '23690119', 'FullCitation': 'Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119', 'Include': 'true'}, {'number': '216', 'ReferenceId': '25319978', 'FullCitation': 'Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978', 'Include': 'true'}, {'number': '217', 'ReferenceId': '16675567', 'FullCitation': 'Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567', 'Include': 'true'}, {'number': '218', 'ReferenceId': '25026289', 'FullCitation': 'Bilbao_Sieyro C, et al. Oncotarget (2014) pmid: 25026289', 'Include': 'true'}, {'number': '219', 'ReferenceId': '20304627', 'FullCitation': 'Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627', 'Include': 'true'}, {'number': '220', 'ReferenceId': '19275958', 'FullCitation': 'Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958', 'Include': 'true'}, {'number': '221', 'ReferenceId': '25392179', 'FullCitation': 'Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179', 'Include': 'true'}, {'number': '222', 'ReferenceId': '26140250', 'FullCitation': 'Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250', 'Include': 'true'}, {'number': '223', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '224', 'ReferenceId': '21711246', 'FullCitation': 'Koch S, et al. Biochem. J. (2011) pmid: 21711246', 'Include': 'true'}, {'number': '225', 'ReferenceId': '20164015', 'FullCitation': 'Weryńska B, et al. Folia Histochem. Cytobiol. (2009) pmid: 20164015', 'Include': 'true'}, {'number': '226', 'ReferenceId': '25641339', 'FullCitation': 'Schechter RB, et al. Cancer Lett. (2015) pmid: 25641339', 'Include': 'true'}, {'number': '227', 'ReferenceId': '20949568', 'FullCitation': 'Guo T, et al. Genes Chromosomes Cancer (2011) pmid: 20949568', 'Include': 'true'}, {'number': '228', 'ReferenceId': '18499506', 'FullCitation': 'Xie P, et al. Cytokine Growth Factor Rev. () pmid: 18499506', 'Include': 'true'}, {'number': '229', 'ReferenceId': '17991829', 'FullCitation': 'Kayagaki N, et al. Science (2007) pmid: 17991829', 'Include': 'true'}, {'number': '230', 'ReferenceId': '17692805', 'FullCitation': 'Keats JJ, et al. Cancer Cell (2007) pmid: 17692805', 'Include': 'true'}, {'number': '231', 'ReferenceId': '15084608', 'FullCitation': 'Liao G, et al. J. Biol. Chem. (2004) pmid: 15084608', 'Include': 'true'}, {'number': '232', 'ReferenceId': '17692804', 'FullCitation': 'Annunziata CM, et al. Cancer Cell (2007) pmid: 17692804', 'Include': 'true'}, {'number': '233', 'ReferenceId': '19693093', 'FullCitation': 'Nagel I, et al. Leukemia (2009) pmid: 19693093', 'Include': 'true'}, {'number': '234', 'ReferenceId': '21300983', 'FullCitation': 'Gardam S, et al. Blood (2011) pmid: 21300983', 'Include': 'true'}, {'number': '235', 'ReferenceId': '24659631', 'FullCitation': 'Herman SE, et al. Blood (2014) pmid: 24659631', 'Include': 'true'}, {'number': '236', 'ReferenceId': '21422473', 'FullCitation': 'Herman SE, et al. Blood (2011) pmid: 21422473', 'Include': 'true'}, {'number': '237', 'ReferenceId': '22975686', 'FullCitation': 'Rushworth SA, et al. Cell. Signal. (2013) pmid: 22975686', 'Include': 'true'}, {'number': '238', 'ReferenceId': '24362935', 'FullCitation': 'Rahal R, et al. Nat. Med. (2014) pmid: 24362935', 'Include': 'true'}, {'number': '239', 'ReferenceId': '19935675', 'FullCitation': 'Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675', 'Include': 'true'}, {'number': '240', 'ReferenceId': '18410249', 'FullCitation': 'Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249', 'Include': 'true'}, {'number': '241', 'ReferenceId': '12826609', 'FullCitation': 'Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609', 'Include': 'true'}, {'number': '242', 'ReferenceId': '20978130', 'FullCitation': 'Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130', 'Include': 'true'}, {'number': '243', 'ReferenceId': '28472496', 'FullCitation': 'Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496', 'Include': 'true'}, {'number': '244', 'ReferenceId': '17690113', 'FullCitation': 'Yamada H, et al. Carcinogenesis (2007) pmid: 17690113', 'Include': 'true'}, {'number': '245', 'ReferenceId': '24132290', 'FullCitation': 'Kandoth C, et al. Nature (2013) pmid: 24132290', 'Include': 'true'}, {'number': '246', 'ReferenceId': '28039262', 'FullCitation': 'Dong ZY, et al. Clin. Cancer Res. (2017) pmid: 28039262', 'Include': 'true'}, {'number': '247', 'ReferenceId': '16172461', 'FullCitation': 'Russo A, et al. J. Clin. Oncol. (2005) pmid: 16172461', 'Include': 'true'}, {'number': '248', 'ReferenceId': '20107315', 'FullCitation': 'Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315', 'Include': 'true'}, {'number': '249', 'ReferenceId': '21799033', 'FullCitation': 'Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033', 'Include': 'true'}, {'number': '250', 'ReferenceId': '21389100', 'FullCitation': 'Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100', 'Include': 'true'}, {'number': '251', 'ReferenceId': '25504633', 'FullCitation': 'Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633', 'Include': 'true'}, {'number': '252', 'ReferenceId': '12489850', 'FullCitation': 'Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850', 'Include': 'true'}, {'number': '253', 'ReferenceId': '11713371', 'FullCitation': 'Xu L, et al. Mol. Med. (2001) pmid: 11713371', 'Include': 'true'}, {'number': '254', 'ReferenceId': '23470564', 'FullCitation': 'Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564', 'Include': 'true'}, {'number': '255', 'ReferenceId': '25240597', 'FullCitation': 'Kim SS, et al. Nanomedicine (2015) pmid: 25240597', 'Include': 'true'}, {'number': '256', 'ReferenceId': '27357628', 'FullCitation': 'Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628', 'Include': 'true'}, {'number': '257', 'ReferenceId': '27601554', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554', 'Include': 'true'}, {'number': '258', 'ReferenceId': '27998224', 'FullCitation': 'Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224', 'Include': 'true'}, {'number': '259', 'ReferenceId': '29535125', 'FullCitation': 'Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125', 'Include': 'true'}, {'number': '260', 'ReferenceId': '34538072', 'FullCitation': 'Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072', 'Include': 'true'}, {'number': '261', 'ReferenceId': '26563132', 'FullCitation': 'Kwok M, et al. Blood (2016) pmid: 26563132', 'Include': 'true'}, {'number': '262', 'ReferenceId': '30975914', 'FullCitation': 'Boudny M, et al. Haematologica (2019) pmid: 30975914', 'Include': 'true'}, {'number': '263', 'ReferenceId': '28062704', 'FullCitation': 'Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704', 'Include': 'true'}, {'number': '264', 'ReferenceId': '30127241', 'FullCitation': 'Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241', 'Include': 'true'}, {'number': '265', 'ReferenceId': '26014290', 'FullCitation': 'Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290', 'Include': 'true'}, {'number': '266', 'ReferenceId': '23355100', 'FullCitation': 'Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100', 'Include': 'true'}, {'number': '267', 'ReferenceId': '11219776', 'FullCitation': 'Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776', 'Include': 'true'}, {'number': '268', 'ReferenceId': '9006316', 'FullCitation': 'Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316', 'Include': 'true'}, {'number': '269', 'ReferenceId': '19204208', 'FullCitation': 'Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208', 'Include': 'true'}, {'number': '270', 'ReferenceId': '12672316', 'FullCitation': 'Lalloo F, et al. Lancet (2003) pmid: 12672316', 'Include': 'true'}, {'number': '271', 'ReferenceId': '31050713', 'FullCitation': 'Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713', 'Include': 'true'}, {'number': '272', 'ReferenceId': '25426837', 'FullCitation': 'Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837', 'Include': 'true'}, {'number': '273', 'ReferenceId': '25426838', 'FullCitation': 'Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838', 'Include': 'true'}, {'number': '274', 'ReferenceId': '25326804', 'FullCitation': 'Xie M, et al. Nat. Med. (2014) pmid: 25326804', 'Include': 'true'}, {'number': '275', 'ReferenceId': '28669404', 'FullCitation': 'Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404', 'Include': 'true'}, {'number': '276', 'ReferenceId': '29678827', 'FullCitation': 'Severson EA, et al. Blood (2018) pmid: 29678827', 'Include': 'true'}, {'number': '277', 'ReferenceId': '29420212', 'FullCitation': 'Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212', 'Include': 'true'}, {'number': '278', 'ReferenceId': '30504320', 'FullCitation': 'Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320', 'Include': 'true'}, {'number': '279', 'ReferenceId': '32269342', 'FullCitation': 'Chabon JJ, et al. Nature (2020) pmid: 32269342', 'Include': 'true'}, {'number': '280', 'ReferenceId': '31768066', 'FullCitation': 'Razavi P, et al. Nat. Med. (2019) pmid: 31768066', 'Include': 'true'}, {'number': '281', 'ReferenceId': '20639862', 'FullCitation': 'Ito S, et al. Nature (2010) pmid: 20639862', 'Include': 'true'}, {'number': '282', 'ReferenceId': '21496894', 'FullCitation': 'Guo JU, et al. Cell (2011) pmid: 21496894', 'Include': 'true'}, {'number': '283', 'ReferenceId': '32469185', 'FullCitation': 'Paik PK, et al. N. Engl. J. Med. (2020) pmid: 32469185', 'Include': 'true'}, {'number': '284', 'ReferenceId': '31822497', 'FullCitation': 'Falchook GS, et al. Clin. Cancer Res. (2020) pmid: 31822497', 'Include': 'true'}, {'number': '285', 'ReferenceId': '32328660', 'FullCitation': 'Shitara K, et al. Jpn. J. Clin. Oncol. (2020) pmid: 32328660', 'Include': 'true'}, {'number': '286', 'ReferenceId': '30243800', 'FullCitation': 'Necchi A, et al. Eur. Urol. (2019) pmid: 30243800', 'Include': 'true'}, {'number': '287', 'ReferenceId': '27764686', 'FullCitation': 'Levy A, et al. Eur. J. Cancer (2016) pmid: 27764686', 'Include': 'true'}, {'number': '288', 'ReferenceId': '27354483', 'FullCitation': 'Yoshida T, et al. J. Clin. Oncol. (2016) pmid: 27354483', 'Include': 'true'}, {'number': '289', 'ReferenceId': '25470694', 'FullCitation': 'Solomon BJ, et al. N. Engl. J. Med. (2014) pmid: 25470694', 'Include': 'true'}, {'number': '290', 'ReferenceId': '23724913', 'FullCitation': 'Shaw AT, et al. N. Engl. J. Med. (2013) pmid: 23724913', 'Include': 'true'}, {'number': '291', 'ReferenceId': '25264305', 'FullCitation': 'Shaw AT, et al. N. Engl. J. Med. (2014) pmid: 25264305', 'Include': 'true'}, {'number': '292', 'ReferenceId': '25667280', 'FullCitation': 'Mazières J, et al. J. Clin. Oncol. (2015) pmid: 25667280', 'Include': 'true'}, {'number': '293', 'ReferenceId': '25868855', 'FullCitation': 'Scheffler M, et al. Oncotarget (2015) pmid: 25868855', 'Include': 'true'}, {'number': '294', 'ReferenceId': '24162815', 'FullCitation': 'Vaishnavi A, et al. Nat. Med. (2013) pmid: 24162815', 'Include': 'true'}, {'number': '295', 'ReferenceId': '27343443', 'FullCitation': 'Schrock AB, et al. J Thorac Oncol (2016) pmid: 27343443', 'Include': 'true'}, {'number': '296', 'ReferenceId': '26791794', 'FullCitation': 'Jorge SE, et al. Lung Cancer (2015) pmid: 26791794', 'Include': 'true'}, {'number': '297', 'ReferenceId': '25971939', 'FullCitation': 'Paik PK, et al. Cancer Discov (2015) pmid: 25971939', 'Include': 'true'}, {'number': '298', 'ReferenceId': '26892698', 'FullCitation': 'Mahjoubi L, et al. Invest New Drugs (2016) pmid: 26892698', 'Include': 'true'}, {'number': '299', 'ReferenceId': '26845121', 'FullCitation': 'Benderra MA, et al. J Thorac Oncol (2016) pmid: 26845121', 'Include': 'true'}, {'number': '300', 'ReferenceId': '25898962', 'FullCitation': 'Waqar SN, et al. J Thorac Oncol (2015) pmid: 25898962', 'Include': 'true'}, {'number': '301', 'ReferenceId': '25898965', 'FullCitation': 'Mendenhall MA, et al. J Thorac Oncol (2015) pmid: 25898965', 'Include': 'true'}, {'number': '302', 'ReferenceId': '25769807', 'FullCitation': 'Jenkins RW, et al. Clin Lung Cancer (2015) pmid: 25769807', 'Include': 'true'}, {'number': '303', 'ReferenceId': '26729443', 'FullCitation': 'Awad MM, et al. J. Clin. Oncol. (2016) pmid: 26729443', 'Include': 'true'}, {'number': '304', 'ReferenceId': '26724472', 'FullCitation': 'Zhang Y, et al. J Thorac Oncol (2016) pmid: 26724472', 'Include': 'true'}, {'number': '305', 'ReferenceId': '23610116', 'FullCitation': 'Diamond JR, et al. J. Clin. Oncol. (2013) pmid: 23610116', 'Include': 'true'}, {'number': '306', 'ReferenceId': '23598171', 'FullCitation': 'Mossé YP, et al. Lancet Oncol. (2013) pmid: 23598171', 'Include': 'true'}, {'number': '307', 'ReferenceId': '25971938', 'FullCitation': 'Frampton GM, et al. Cancer Discov (2015) pmid: 25971938', 'Include': 'true'}, {'number': '308', 'ReferenceId': '25457019', 'FullCitation': 'Stein MN, et al. Eur. Urol. (2015) pmid: 25457019', 'Include': 'true'}, {'number': '309', 'ReferenceId': '29863979', 'FullCitation': 'Migden MR, et al. N. Engl. J. Med. (2018) pmid: 29863979', 'Include': 'true'}, {'number': '310', 'ReferenceId': '25891304', 'FullCitation': 'Postow MA, et al. N. Engl. J. Med. (2015) pmid: 25891304', 'Include': 'true'}, {'number': '311', 'ReferenceId': '26027431', 'FullCitation': 'Larkin J, et al. N. Engl. J. Med. (2015) pmid: 26027431', 'Include': 'true'}, {'number': '312', 'ReferenceId': '25399552', 'FullCitation': 'Robert C, et al. N. Engl. J. Med. (2015) pmid: 25399552', 'Include': 'true'}, {'number': '313', 'ReferenceId': '24590637', 'FullCitation': 'Topalian SL, et al. J. Clin. Oncol. (2014) pmid: 24590637', 'Include': 'true'}, {'number': '314', 'ReferenceId': '25795410', 'FullCitation': 'Weber JS, et al. Lancet Oncol. (2015) pmid: 25795410', 'Include': 'true'}, {'number': '315', 'ReferenceId': '26028407', 'FullCitation': 'Brahmer J, et al. N. Engl. J. Med. (2015) pmid: 26028407', 'Include': 'true'}, {'number': '316', 'ReferenceId': '26412456', 'FullCitation': 'Borghaei H, et al. N. Engl. J. Med. (2015) pmid: 26412456', 'Include': 'true'}, {'number': '317', 'ReferenceId': '31100038', 'FullCitation': 'Sharma P, et al. J. Clin. Oncol. (2019) pmid: 31100038', 'Include': 'true'}, {'number': '318', 'ReferenceId': '28131785', 'FullCitation': 'Sharma P, et al. Lancet Oncol. (2017) pmid: 28131785', 'Include': 'true'}, {'number': '319', 'ReferenceId': '25452452', 'FullCitation': 'Motzer RJ, et al. J. Clin. Oncol. (2015) pmid: 25452452', 'Include': 'true'}, {'number': '320', 'ReferenceId': '22658127', 'FullCitation': 'Topalian SL, et al. N. Engl. J. Med. (2012) pmid: 22658127', 'Include': 'true'}, {'number': '321', 'ReferenceId': '20516446', 'FullCitation': 'Brahmer JR, et al. J. Clin. Oncol. (2010) pmid: 20516446', 'Include': 'true'}, {'number': '322', 'ReferenceId': '26406148', 'FullCitation': 'Motzer RJ, et al. N. Engl. J. Med. (2015) pmid: 26406148', 'Include': 'true'}, {'number': '323', 'ReferenceId': '28734759', 'FullCitation': 'Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759', 'Include': 'true'}, {'number': '324', 'ReferenceId': '29355075', 'FullCitation': 'Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075', 'Include': 'true'}, {'number': '325', 'ReferenceId': '22658128', 'FullCitation': 'Brahmer JR, et al. N. Engl. J. Med. (2012) pmid: 22658128', 'Include': 'true'}, {'number': '326', 'ReferenceId': '26351349', 'FullCitation': 'Hamanishi J, et al. J. Clin. Oncol. (2015) pmid: 26351349', 'Include': 'true'}, {'number': '327', 'ReferenceId': '31074244', 'FullCitation': 'Normann MC, et al. J Gynecol Oncol (2019) pmid: 31074244', 'Include': 'true'}, {'number': '328', 'ReferenceId': '27269741', 'FullCitation': 'Antonia SJ, et al. Lancet Oncol. (2016) pmid: 27269741', 'Include': 'true'}, {'number': '329', 'ReferenceId': '30110194', 'FullCitation': 'Janjigian YY, et al. J. Clin. Oncol. (2018) pmid: 30110194', 'Include': 'true'}, {'number': '330', 'ReferenceId': '34843940', 'FullCitation': 'Tanizaki J, et al. Ann Oncol (2021) pmid: 34843940', 'Include': 'true'}, {'number': '331', 'ReferenceId': '25482239', 'FullCitation': 'Ansell SM, et al. N. Engl. J. Med. (2015) pmid: 25482239', 'Include': 'true'}, {'number': '332', 'ReferenceId': '27451390', 'FullCitation': 'Younes A, et al. Lancet Oncol. (2016) pmid: 27451390', 'Include': 'true'}, {'number': '333', 'ReferenceId': '30361170', 'FullCitation': 'Hodi FS, et al. Lancet Oncol. (2018) pmid: 30361170', 'Include': 'true'}, {'number': '334', 'ReferenceId': '27622997', 'FullCitation': 'Hodi FS, et al. Lancet Oncol. (2016) pmid: 27622997', 'Include': 'true'}, {'number': '335', 'ReferenceId': '31562797', 'FullCitation': 'Larkin J, et al. N. Engl. J. Med. (2019) pmid: 31562797', 'Include': 'true'}, {'number': '336', 'ReferenceId': '31562796', 'FullCitation': 'Hellmann MD, et al. N. Engl. J. Med. (2019) pmid: 31562796', 'Include': 'true'}, {'number': '337', 'ReferenceId': '31427204', 'FullCitation': 'Motzer RJ, et al. Lancet Oncol. (2019) pmid: 31427204', 'Include': 'true'}, {'number': '338', 'ReferenceId': '29562145', 'FullCitation': 'Motzer RJ, et al. N. Engl. J. Med. (2018) pmid: 29562145', 'Include': 'true'}, {'number': '339', 'ReferenceId': '28778959', 'FullCitation': 'Kollipara R, et al. Oncologist (2017) pmid: 28778959', 'Include': 'true'}, {'number': '340', 'ReferenceId': '33001143', 'FullCitation': 'Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143', 'Include': 'true'}, {'number': '341', 'ReferenceId': '26970723', 'FullCitation': 'Fehrenbacher L, et al. Lancet (2016) pmid: 26970723', 'Include': 'true'}, {'number': '342', 'ReferenceId': '25428504', 'FullCitation': 'Herbst RS, et al. Nature (2014) pmid: 25428504', 'Include': 'true'}, {'number': '343', 'ReferenceId': '26952546', 'FullCitation': 'Rosenberg JE, et al. Lancet (2016) pmid: 26952546', 'Include': 'true'}, {'number': '344', 'ReferenceId': '25428503', 'FullCitation': 'Powles T, et al. Nature (2014) pmid: 25428503', 'Include': 'true'}, {'number': '345', 'ReferenceId': '31780255', 'FullCitation': 'Geoerger B, et al. Lancet Oncol. (2020) pmid: 31780255', 'Include': 'true'}, {'number': '346', 'ReferenceId': '26755520', 'FullCitation': 'McDermott DF, et al. J. Clin. Oncol. (2016) pmid: 26755520', 'Include': 'true'}, {'number': '347', 'ReferenceId': '30918950', 'FullCitation': 'Hellmann MD, et al. Ann. Oncol. (2019) pmid: 30918950', 'Include': 'true'}, {'number': '348', 'ReferenceId': '34876409', 'FullCitation': 'Friedman CF, et al. Cancer Discov (2022) pmid: 34876409', 'Include': 'true'}, {'number': '349', 'ReferenceId': '32240796', 'FullCitation': 'Schuler M, et al. Ann. Oncol. (2020) pmid: 32240796', 'Include': 'true'}, {'number': '350', 'ReferenceId': '32877583', 'FullCitation': 'Wolf J, et al. N Engl J Med (2020) pmid: 32877583', 'Include': 'true'}, {'number': '351', 'ReferenceId': '31776899', 'FullCitation': 'van den Bent M, et al. J. Neurooncol. (2020) pmid: 31776899', 'Include': 'true'}, {'number': '352', 'ReferenceId': '31778267', 'FullCitation': 'Bang YJ, et al. Cancer Sci. (2020) pmid: 31778267', 'Include': 'true'}, {'number': '353', 'ReferenceId': '30724423', 'FullCitation': 'Esaki T, et al. Cancer Sci. (2019) pmid: 30724423', 'Include': 'true'}, {'number': '354', 'ReferenceId': '27157491', 'FullCitation': 'Muro K, et al. Lancet Oncol. (2016) pmid: 27157491', 'Include': 'true'}, {'number': '355', 'ReferenceId': '26712084', 'FullCitation': 'Herbst RS, et al. Lancet (2016) pmid: 26712084', 'Include': 'true'}, {'number': '356', 'ReferenceId': '27247226', 'FullCitation': 'Seiwert TY, et al. Lancet Oncol. (2016) pmid: 27247226', 'Include': 'true'}, {'number': '357', 'ReferenceId': '27138582', 'FullCitation': 'Nanda R, et al. J. Clin. Oncol. (2016) pmid: 27138582', 'Include': 'true'}, {'number': '358', 'ReferenceId': '31812554', 'FullCitation': 'Geoerger B, et al. Lancet Oncol. (2020) pmid: 31812554', 'Include': 'true'}, {'number': '359', 'ReferenceId': '30922731', 'FullCitation': 'Makker V, et al. Lancet Oncol. (2019) pmid: 30922731', 'Include': 'true'}, {'number': '360', 'ReferenceId': '29059635', 'FullCitation': 'Schöffski P, et al. Eur. J. Cancer (2017) pmid: 29059635', 'Include': 'true'}, {'number': '361', 'ReferenceId': '30528315', 'FullCitation': 'Hellerstedt BA, et al. Clin Lung Cancer (2019) pmid: 30528315', 'Include': 'true'}, {'number': '362', 'ReferenceId': '30718102', 'FullCitation': 'Nokihara H, et al. Clin Lung Cancer (2019) pmid: 30718102', 'Include': 'true'}, {'number': '363', 'ReferenceId': '24002501', 'FullCitation': 'Elisei R, et al. J. Clin. Oncol. (2013) pmid: 24002501', 'Include': 'true'}, {'number': '364', 'ReferenceId': '29972759', 'FullCitation': 'Abou_Alfa GK, et al. N. Engl. J. Med. (2018) pmid: 29972759', 'Include': 'true'}, {'number': '365', 'ReferenceId': '28199818', 'FullCitation': 'Choueiri TK, et al. J. Clin. Oncol. (2017) pmid: 28199818', 'Include': 'true'}, {'number': '366', 'ReferenceId': '32078813', 'FullCitation': 'Italiano A, et al. Lancet Oncol. (2020) pmid: 32078813', 'Include': 'true'}, {'number': '367', 'ReferenceId': '27693535', 'FullCitation': 'Klempner SJ, et al. J Thorac Oncol (2017) pmid: 27693535', 'Include': 'true'}, {'number': '368', 'ReferenceId': '21926191', 'FullCitation': 'Yakes FM, et al. Mol. Cancer Ther. (2011) pmid: 21926191', 'Include': 'true'}, {'number': '369', 'ReferenceId': '25260782', 'FullCitation': 'Weber H, et al. J Biomol Screen (2014) pmid: 25260782', 'Include': 'true'}, {'number': '370', 'ReferenceId': '23484006', 'FullCitation': 'Navis AC, et al. PLoS ONE (2013) pmid: 23484006', 'Include': 'true'}, {'number': '371', 'ReferenceId': '26013381', 'FullCitation': 'Yeh I, et al. Nat Commun (2015) pmid: 26013381', 'Include': 'true'}, {'number': '372', 'ReferenceId': '25534569', 'FullCitation': 'Lee YH, et al. Cancers (Basel) (2014) pmid: 25534569', 'Include': 'true'}, {'number': '373', 'ReferenceId': '21540237', 'FullCitation': 'Torres KE, et al. Clin. Cancer Res. (2011) pmid: 21540237', 'Include': 'true'}, {'number': '374', 'ReferenceId': '26432786', 'FullCitation': 'Sameni M, et al. Clin. Cancer Res. (2016) pmid: 26432786', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2022_04_19 14:18:36', 'OpName': 'Leah Commander, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Leah Commander, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': '761x'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': '63 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': 'Units Not Reported'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease_ontology': 'Unknown primary malignant neoplasm', 'flowcell_analysis': '2000021269', 'gender': 'female', 'pathology_diagnosis': 'Malignant tumor', 'percent_tumor_nuclei': '40', 'pipeline_version': 'v3.10.2', 'purity_assessment': '47.8', 'specimen': 'ORD_1336448_02*US1284630.01', 'study': 'CLINICAL_HEME_COMPLETE', 'test_request': 'ORD_1336448_02', 'test_type': 'HemeComplete', 'tissue_of_origin': 'Mouth', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': [{'bait_set': 'D2', 'mean_exon_depth': '788.57', 'name': 'SQ_US1284630.01_1', 'nucleic_acid_type': 'DNA'}, {'bait_set': 'R2', 'mean_exon_depth': '509.65', 'name': 'SQ_US1284630.01_2', 'nucleic_acid_type': 'RNA'}]}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.1765', 'cds_effect': '6554C>T', 'depth': '742', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SPEN', 'percent_reads': '17.65', 'position': 'chr1:16259289', 'protein_effect': 'S2185F', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_015001', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0922', 'cds_effect': '1384G>T', 'depth': '998', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CIITA', 'percent_reads': '9.22', 'position': 'chr16:11000733', 'protein_effect': 'A462S', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000246', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1418', 'cds_effect': '10231G>C', 'depth': '656', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PRKDC', 'percent_reads': '14.18', 'position': 'chr8:48711837', 'protein_effect': 'D3411H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006904', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.3245', 'cds_effect': '2108G>C', 'depth': '789', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SMO', 'percent_reads': '32.45', 'position': 'chr7:128852036', 'protein_effect': 'R703P', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005631', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0866', 'cds_effect': '367C>G', 'depth': '566', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IL7R', 'percent_reads': '8.66', 'position': 'chr5:35867553', 'protein_effect': 'L123V', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002185', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1003', 'cds_effect': '3391G>T', 'depth': '778', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '10.03', 'position': 'chr2:212251668', 'protein_effect': 'D1131Y', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0781', 'cds_effect': '56G>C', 'depth': '64', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FBXO31', 'percent_reads': '7.81', 'position': 'chr16:87417295', 'protein_effect': 'R19P', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_024735', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0577', 'cds_effect': '1304A>G', 'depth': '555', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FLT4', 'percent_reads': '5.77', 'position': 'chr5:180052986', 'protein_effect': 'Y435C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002020', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1051', 'cds_effect': '703G>A', 'depth': '609', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TSHR', 'percent_reads': '10.51', 'position': 'chr14:81574966', 'protein_effect': 'G235R', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001018036', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0938', 'cds_effect': '1943C>A', 'depth': '821', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CIITA', 'percent_reads': '9.38', 'position': 'chr16:11001292', 'protein_effect': 'A648E', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000246', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1941', 'cds_effect': '5297C>T', 'depth': '1216', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MYST3', 'percent_reads': '19.41', 'position': 'chr8:41790441', 'protein_effect': 'P1766L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006766', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1006', 'cds_effect': '2992G>T', 'depth': '666', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'SMC3', 'percent_reads': '10.06', 'position': 'chr10:112361823', 'protein_effect': 'E998*', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005445', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.137', 'cds_effect': '449T>A', 'depth': '511', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SOCS1', 'percent_reads': '13.7', 'position': 'chr16:11348887', 'protein_effect': 'L150Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003745', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.053', 'cds_effect': '19G>C', 'depth': '887', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PDGFRA', 'percent_reads': '5.3', 'position': 'chr4:55124954', 'protein_effect': 'A7P', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006206', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0494', 'cds_effect': '544C>T', 'depth': '871', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'HIST1H1D', 'percent_reads': '4.94', 'position': 'chr6:26234618', 'protein_effect': 'Q182*', 'status': 'known', 'strand': '_', 'transcript': 'NM_005320', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0522', 'cds_effect': '3221G>T', 'depth': '862', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NSD1', 'percent_reads': '5.22', 'position': 'chr5:176638621', 'protein_effect': 'R1074L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_022455', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0947', 'cds_effect': '628G>C', 'depth': '665', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MAPK1', 'percent_reads': '9.47', 'position': 'chr22:22143079', 'protein_effect': 'D210H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002745', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.103', 'cds_effect': '3694_3695GG>CT', 'depth': '1010', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRCA1', 'percent_reads': '10.3', 'position': 'chr17:41243853', 'protein_effect': 'G1232L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_007294', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1315', 'cds_effect': '3547G>T', 'depth': '502', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SMARCA4', 'percent_reads': '13.15', 'position': 'chr19:11143966', 'protein_effect': 'D1183Y', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_003072', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.5496', 'cds_effect': '101G>A', 'depth': '544', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FBXO11', 'percent_reads': '54.96', 'position': 'chr2:48066788', 'protein_effect': 'S34N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_025133', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0458', 'cds_effect': '478G>T', 'depth': '633', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FLT4', 'percent_reads': '4.58', 'position': 'chr5:180057260', 'protein_effect': 'V160L', 'status': 'known', 'strand': '_', 'subclonal': 'false', 'transcript': 'NM_002020', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1096', 'cds_effect': '1901C>A', 'depth': '520', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FLT4', 'percent_reads': '10.96', 'position': 'chr5:180048661', 'protein_effect': 'A634D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002020', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1043', 'cds_effect': '2643G>C', 'depth': '585', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EPHA5', 'percent_reads': '10.43', 'position': 'chr4:66213787', 'protein_effect': 'E881D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004439', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0967', 'cds_effect': '1474C>T', 'depth': '848', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'TRAF3', 'percent_reads': '9.67', 'position': 'chr14:103371888', 'protein_effect': 'Q492*', 'status': 'likely', 'strand': '+', 'transcript': 'NM_003300', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1399', 'cds_effect': '1022C>A', 'depth': '636', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'P2RY8', 'percent_reads': '13.99', 'position': 'chrX:1584430', 'protein_effect': 'P341H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_178129', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.4444', 'cds_effect': '2440C>T', 'depth': '450', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRIP1', 'percent_reads': '44.44', 'position': 'chr17:59793364', 'protein_effect': 'R814C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_032043', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.122', 'cds_effect': '314G>A', 'depth': '967', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CD22', 'percent_reads': '12.2', 'position': 'chr19:35823729', 'protein_effect': 'S105N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001771', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0983', 'cds_effect': '708C>G', 'depth': '946', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EPHB1', 'percent_reads': '9.83', 'position': 'chr3:134670797', 'protein_effect': 'I236M', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_004441', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.2703', 'cds_effect': '1106G>A', 'depth': '518', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GPR124', 'percent_reads': '27.03', 'position': 'chr8:37690536', 'protein_effect': 'R369Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_032777', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0968', 'cds_effect': '601G>C', 'depth': '775', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ALK', 'percent_reads': '9.68', 'position': 'chr2:30142925', 'protein_effect': 'E201Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004304', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1108', 'cds_effect': '274G>C', 'depth': '686', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'HIST1H3B', 'percent_reads': '11.08', 'position': 'chr6:26032015', 'protein_effect': 'A92P', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_003537', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.3619', 'cds_effect': '718C>T', 'depth': '970', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FRS2', 'percent_reads': '36.19', 'position': 'chr12:69967926', 'protein_effect': 'P240S', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006654', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1738', 'cds_effect': '1969G>C', 'depth': '650', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BRD4', 'percent_reads': '17.38', 'position': 'chr19:15366186', 'protein_effect': 'E657Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_014299', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0987', 'cds_effect': '2739C>A', 'depth': '689', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'LRP1B', 'percent_reads': '9.87', 'position': 'chr2:141747132', 'protein_effect': 'S913R', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_018557', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1113', 'cds_effect': '3622G>A', 'depth': '665', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PLCG2', 'percent_reads': '11.13', 'position': 'chr16:81990351', 'protein_effect': 'E1208K', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002661', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1092', 'cds_effect': '7G>A', 'depth': '760', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'HIST1H1C', 'percent_reads': '10.92', 'position': 'chr6:26056650', 'protein_effect': 'E3K', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005319', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1181', 'cds_effect': '3020C>G', 'depth': '686', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'ABL1', 'percent_reads': '11.81', 'position': 'chr9:133760697', 'protein_effect': 'S1007*', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_005157', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.5307', 'cds_effect': '2069G>A', 'depth': '456', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'WDR90', 'percent_reads': '53.07', 'position': 'chr16:706404', 'protein_effect': 'R690Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_145294', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0665', 'cds_effect': '526A>G', 'depth': '887', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'EPHA5', 'percent_reads': '6.65', 'position': 'chr4:66467743', 'protein_effect': 'T176A', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004439', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0911', 'cds_effect': '158C>T', 'depth': '593', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SUZ12', 'percent_reads': '9.11', 'position': 'chr17:30264423', 'protein_effect': 'S53L', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_015355', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.2111', 'cds_effect': '375G>T', 'depth': '559', 'equivocal': 'false', 'functional_effect': 'splice', 'gene': 'TP53', 'percent_reads': '21.11', 'position': 'chr17:7579312', 'protein_effect': 'splice site 375G>T', 'status': 'known', 'strand': '_', 'transcript': 'NM_000546', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1053', 'cds_effect': '121G>T', 'depth': '750', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'KEAP1', 'percent_reads': '10.53', 'position': 'chr19:10610589', 'protein_effect': 'E41*', 'status': 'likely', 'strand': '_', 'transcript': 'NM_012289', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.227', 'cds_effect': '662G>A', 'depth': '771', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'JUN', 'percent_reads': '22.7', 'position': 'chr1:59248081', 'protein_effect': 'R221Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002228', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.3824', 'cds_effect': '3332C>T', 'depth': '782', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BCORL1', 'percent_reads': '38.24', 'position': 'chrX:129150080', 'protein_effect': 'T1111M', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_021946', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.5088', 'cds_effect': '1591G>A', 'depth': '627', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CIC', 'percent_reads': '50.88', 'position': 'chr19:42794511', 'protein_effect': 'A531T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_015125', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1285', 'cds_effect': '4324G>T', 'depth': '1136', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MYST3', 'percent_reads': '12.85', 'position': 'chr8:41791414', 'protein_effect': 'A1442S', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006766', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0582', 'cds_effect': '7732A>G', 'depth': '911', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'MKI67', 'percent_reads': '5.82', 'position': 'chr10:129902372', 'protein_effect': 'I2578V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_002417', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.3022', 'cds_effect': '9102G>T', 'depth': '675', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PCLO', 'percent_reads': '30.22', 'position': 'chr7:82580802', 'protein_effect': 'E3034D', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_014510', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1464', 'cds_effect': '368G>C', 'depth': '717', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TAF1', 'percent_reads': '14.64', 'position': 'chrX:70587976', 'protein_effect': 'R123T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_138923', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1367', 'cds_effect': '229G>A', 'depth': '717', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'BCORL1', 'percent_reads': '13.67', 'position': 'chrX:129146977', 'protein_effect': 'D77N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_021946', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1029', 'cds_effect': '560C>A', 'depth': '544', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NTRK2', 'percent_reads': '10.29', 'position': 'chr9:87325683', 'protein_effect': 'A187E', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006180', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.3601', 'cds_effect': '2983C>G', 'depth': '983', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PCLO', 'percent_reads': '36.01', 'position': 'chr7:82763883', 'protein_effect': 'P995A', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_014510', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.5842', 'cds_effect': '2468C>T', 'depth': '1027', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ZNF217', 'percent_reads': '58.42', 'position': 'chr20:52192835', 'protein_effect': 'P823L', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_006526', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0995', 'cds_effect': '3593C>A', 'depth': '774', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'LRP1B', 'percent_reads': '9.95', 'position': 'chr2:141660662', 'protein_effect': 'S1198Y', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_018557', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1028', 'cds_effect': '310G>T', 'depth': '749', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB3', 'percent_reads': '10.28', 'position': 'chr12:56478854', 'protein_effect': 'V104L', 'status': 'known', 'strand': '+', 'transcript': 'NM_001982', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1062', 'cds_effect': '88G>T', 'depth': '471', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'SOX2', 'percent_reads': '10.62', 'position': 'chr3:181430236', 'protein_effect': 'A30S', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_003106', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0534', 'cds_effect': '5651C>A', 'depth': '281', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'NOTCH1', 'percent_reads': '5.34', 'position': 'chr9:139395287', 'protein_effect': 'P1884Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_017617', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0887', 'cds_effect': '312G>C', 'depth': '620', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IL7R', 'percent_reads': '8.87', 'position': 'chr5:35867498', 'protein_effect': 'K104N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_002185', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0948', 'cds_effect': '4249G>T', 'depth': '865', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TET2', 'percent_reads': '9.48', 'position': 'chr4:106193787', 'protein_effect': 'V1417F', 'status': 'known', 'strand': '+', 'transcript': 'NM_001127208', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0617', 'cds_effect': '775G>T', 'depth': '567', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'PPP2R1A', 'percent_reads': '6.17', 'position': 'chr19:52716331', 'protein_effect': 'V259F', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_014225', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.2936', 'cds_effect': '1273A>G', 'depth': '654', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'POT1', 'percent_reads': '29.36', 'position': 'chr7:124481123', 'protein_effect': 'T425A', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_015450', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.5371', 'cds_effect': '2939T>A', 'depth': '916', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ASXL1', 'percent_reads': '53.71', 'position': 'chr20:31023454', 'protein_effect': 'I980N', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_015338', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.0889', 'cds_effect': '1034C>T', 'depth': '461', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '8.89', 'position': 'chr2:212576865', 'protein_effect': 'A345V', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1111', 'cds_effect': '1351G>C', 'depth': '936', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TNFAIP3', 'percent_reads': '11.11', 'position': 'chr6:138199933', 'protein_effect': 'E451Q', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_006290', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.085', 'cds_effect': '91G>T', 'depth': '353', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'HGF', 'percent_reads': '8.5', 'position': 'chr7:81392186', 'protein_effect': 'G31*', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000601', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.13', 'cds_effect': '3395C>A', 'depth': '777', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '13.0', 'position': 'chr2:212251664', 'protein_effect': 'P1132H', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1669', 'cds_effect': '142C>T', 'depth': '677', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ARID2', 'percent_reads': '16.69', 'position': 'chr12:46123876', 'protein_effect': 'H48Y', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_152641', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'allele_fraction': '0.1033', 'cds_effect': '979G>T', 'depth': '949', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FAM123B', 'percent_reads': '10.33', 'position': 'chrX:63412188', 'protein_effect': 'G327C', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_152424', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}]}, 'copy_number_alterations': {'copy_number_alteration': {'copy_number': '10', 'equivocal': 'false', 'gene': 'MET', 'number_of_exons': '20 of 20', 'position': 'chr7:116297505_116484285', 'ratio': '2.2', 'status': 'known', 'type': 'amplification', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}}, 'rearrangements': {'rearrangement': [{'description': 'ETV6(NM_001987) rearrangement intron 5', 'equivocal': 'false', 'in_frame': 'unknown', 'other_gene': 'AUTS2', 'pos1': 'chr12:12023286_12023586', 'pos2': 'chr7:69790453_69790649', 'status': 'likely', 'supporting_read_pairs': '41', 'targeted_gene': 'ETV6', 'type': 'truncation', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}, {'description': 'ETV6(NM_001987) inversion intron 5 _ intron 5', 'equivocal': 'false', 'in_frame': 'unknown', 'other_gene': 'ETV6', 'pos1': 'chr12:12030985_12031188', 'pos2': 'chr12:12033621_12033982', 'status': 'likely', 'supporting_read_pairs': '16', 'targeted_gene': 'ETV6', 'type': 'truncation', 'dna_evidence': {'sample': 'SQ_US1284630.01_1'}}]}, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '62.72', 'status': 'high', 'unit': 'mutations_per_megabase'}}, 'non_human_content': None}}}}	S111-99076          	PF22046             
15	556	{'ResultsReport': {'xmlns': 'http://integration.foundationmedicine.com/reporting', 'xmlnsxsi': 'http://www.w3.org/2001/XMLSchema_instance', 'xsischemaLocation': 'http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd', 'CustomerInformation': {'ReferenceID': '01_2022_00021634', 'CSN': None, 'TRF': 'ORD_1404958_01', 'MRN': '26184758', 'PhysicianId': '109266', 'NPI': 'International'}, 'ResultsPayload': {'FinalReport': {'xmlnsxsd': 'http://www.w3.org/2001/XMLSchema', 'StagingId': '1150817', 'clinicalId': '1152187', 'xsinoNamespaceSchemaLocation': 'http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd', 'Application': {'ApplicationSettings': {'ApplicationSetting': {'Name': 'Statement', 'Value': None}}}, 'DemographicCorrectionDate': None, 'ReportId': 'ORD_1404958_01', 'SampleName': 'US1347344.01', 'Version': '0', 'Sample': {'FM_Id': 'ORD_1404958_01', 'SampleId': 'US1347344.01', 'BlockId': 'L.C.H. 11/14/1956', 'TRFNumber': 'ORD_1404958_01', 'TestType': 'FoundationOneLiquidDx', 'SpecFormat': 'Tube Set', 'ReceivedDate': '2022_07_05', 'processSites': {'processSite': [{'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'LC'}, {'address': '150 Second St., 1st Floor, Cambridge, MA 02141', 'cliaNumber': '22D2027531', 'locationID': '1', 'locationName': 'Cambridge', 'processID': '1', 'processName': 'Extracted DNA'}]}}, 'PMI': {'ReportId': 'ORD_1404958_01', 'MRN': '26184758', 'FullName': 'Hsiao, Li_Chuan', 'FirstName': 'Li_Chuan', 'LastName': 'Hsiao', 'SubmittedDiagnosis': 'Liver cholangiocarcinoma', 'Gender': 'Female', 'DOB': '1956_11_14', 'OrderingMD': 'Yeh, Yi_Chen', 'OrderingMDId': '109266', 'Pathologist': 'Not Provided', 'CopiedPhysician1': None, 'MedFacilName': 'Taipei Veterans General Hospital', 'MedFacilID': '205872', 'SpecSite': 'Blood', 'CollDate': '2022_06_30', 'ReceivedDate': '2022_07_05', 'CountryOfOrigin': 'TW'}, 'PertinentNegatives': None, 'Summaries': {'alterationCount': '17', 'clinicalTrialCount': '13', 'resistiveCount': '0', 'sensitizingCount': '4'}, 'VariantProperties': {'VariantProperty': [{'geneName': 'CARD11', 'isVUS': 'true', 'variantName': 'A534N'}, {'geneName': 'CCND3', 'isVUS': 'true', 'variantName': 'R95P'}, {'geneName': 'DNMT3A', 'isVUS': 'true', 'variantName': 'C710S'}, {'geneName': 'ERBB3', 'isVUS': 'true', 'variantName': 'G804W'}, {'geneName': 'ERBB4', 'isVUS': 'true', 'variantName': 'R979Q'}, {'geneName': 'FGF14', 'isVUS': 'true', 'variantName': 'S49P'}, {'geneName': 'GRM3', 'isVUS': 'true', 'variantName': 'R235S'}, {'geneName': 'IKBKE', 'isVUS': 'true', 'variantName': 'A421T'}, {'geneName': 'KIT', 'isVUS': 'true', 'variantName': 'R634W'}, {'geneName': 'P2RY8', 'isVUS': 'true', 'variantName': 'T153A'}, {'geneName': 'TSC1', 'isVUS': 'true', 'variantName': 'Q654E'}]}, 'priorTests': None, 'Genes': {'Gene': [{'Name': 'BRCA1', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'E1222fs*13', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'E1222fs*13'}}, 'Interpretation': 'The protein encoded by BRCA1 is involved in the maintenance of genomic stability, including DNA repair, cell cycle checkpoint, and chromosome segregation (O Donovan and Livingston, 2010; 20400477). Alterations such as seen here may disrupt BRCA1 function or expression (Nelson et al., 2010; 20681793, Silver and Livingston, 2012; 22843421, Ludwig et al., 2001; 11358863). BRCA1 mutations have been reported in 0_2% (1/51) of cholangiocarcinoma cases in several small sequencing studies, while BRCA1 genomic loss was not detected (cBio_Chan_On et al., 2013; 24185513, cBio_Ong et al., 2012; 22561520, cBio_Jiao et al., 2013; 24185509). BRCA1 mutation has also been reported in one of 28 intrahepatic cholangiocarcinomas in one study (Ross et al., 2014; 24563076). BRCA1 mutations have been reported in 2.0% of biliary tract carcinomas analyzed in COSMIC, including in 2.8% of gallbladder adenocarcinoma cases (Jan 2022)(Tate et al., 2019; 30371878). In a study of pancreatobiliary cancers in Irish families with pathogenic BRCA variants, biliary tract cancer was reported in 1.7% of BRCA1_positive pedigrees (Power et al., 2021; 32918181). A case study reported 1 patient with gallbladder carcinoma harboring a confirmed BRCA1 germline mutation (Xie et al., 2016; 28028375). Published data investigating the prognostic implications of BRCA1 mutations in biliary tract carcinomas are limited (PubMed, Nov 2021). Alterations that inactivate BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors (Kaufman et al., 2015; 25366685, Mateo et al., 2015; 26510020, Tutt et al., 2010; 20609467, Robson et al., 2017; 28578601, Mirza et al., 2016; 27717299, Sandhu et al., 2013; 23810788, Swisher et al., 2016; 27908594, Drew et al., 2016; 27002934, Pujade_Lauraine et al., 2017; 28754483, Ledermann et al., 2016; 27617661, Fong et al., 2009; 19553641, Audeh et al., 2010; 20609468, Fong et al., 2010; 20406929, Gelmon et al., 2011; 21862407, Kaye et al., 2012; 22203755, Domchek et al., 2016; 26723501, Moore et al., 2018; 30345884, Golan et al., 2019; 31157963) or ATR inhibitors (Yap et al., 2020; 32988960, Thomas et al., 2018; 29252124, O Carrigan et al., 2016; ASCO Abstract 2504, Yap et al., 2016; AACR_NCI_EORTC Abstract 1LBA, Saito et al., 2018; 31299005). Clinical responses to PARP inhibitors have been reported for patients with either germline or somatic BRCA1/2 mutations (Mateo et al., 2015; 26510020, Swisher et al., 2016; 27908594, Ledermann et al., 2016; 27617661, Moore et al., 2018; 30345884, Golan et al., 2019; 31157963) and for patients with platinum_resistant or _refractory disease (Fong et al., 2010; 20406929, Kaufman et al., 2015; 25366685, Sandhu et al., 2013; 23810788, Domchek et al., 2016; 26723501). In a Phase 1 trial of monotherapy treatment with the ATR inhibitor BAY1895344, 2 patients with deleterious BRCA1 alterations and platinum_refractory ovarian carcinoma experienced a PR or prolonged SD (Yap et al., 2020; 32988960). In other Phase 1 trials of combination approaches, a patient with BRCA1_mutated ovarian carcinoma experienced prolonged SD from the ATR inhibitor berzosertib combined with topotecan (Thomas et al., 2018; 29252124); another patient with platinum_ and PARP_inhibitory refractory ovarian cancer and an inactivating germline BRCA1 mutation experienced a PR from berzosertib plus carboplatin (O Carrigan et al., 2016; ASCO Abstract 2504); and a third patient with BRCA1_mutated triple_negative breast cancer (TNBC) experienced a PR to the ATR inhibitor ceralasertib combined with olaparib (Yap et al., 2016; AACR_NCI_EORTC Abstract 1LBA). Preclinical studies of BRCA1/2 inactivation in T_cell acute lymphoblastic leukemia (T_ALL) (Pouliot et al., 2019; 31721781), ovarian carcinoma (Kim et al., 2017; 27993965), and TNBC (Jin et al., 2018; 29605721) showing reduced cell viability and increased DNA damage during ATR treatment further support the sensitivity of BRCA1_deficient cells to ATR inhibitors. The WEE1 inhibitor adavosertib has been evaluated as a monotherapy and in combination with PARP_inhibitor, olaparib. In a Phase 2 study for patients with PARP_resistant ovarian cancer, the combination of olaparib and adavosertib elicited improved clinical benefit (ORR: 29%; DCR: 89%) compared to adavosertib alone (ORR: 23%; DCR: 63%); however, in the BRCA_mutated cohort, no significant difference in clinical benefit was observed between the combination (ORR: 19%) and monotherapy (ORR: 20%) treatments (Westin et al., 2021; ASCO Abstract 5505). In a Phase 1 monotherapy trial of adavosertib that included 9 patients with BRCA1/2_mutated solid tumors, 2 patients with BRCA1_mutated cancers (1 with ovarian serous carcinoma and 1 with oral squamous cell carcinoma) achieved PRs, and a third patient with ovarian serous carcinoma harboring mutations in BRCA1 and TP53 experienced 14% tumor shrinkage prior to disease progression (Do et al., 2015; 25964244). Inactivation of BRCA1 may also predict sensitivity to the DNA_damaging agents trabectedin and lurbinectedin (Cruz et al., 2018; 30240327, Awada et al., 2018; ASCO Abstract 1072, Poveda et al., 2017; 28368437, Garcia et al., 2013; 23364677, Schöffski et al., 2011; 21376569, Aracil et al., 2014; Abstract 35, Italiano et al., 2011; 21287534, Laroche_Clary et al., 2015; 25602962, Ghouadni et al., 2017; 28467918, Tedesco et al., 2011; ASCO Abstract 1125, Monk et al., 2015; 25722380, Monk et al., 2020; 31924332, Yasui et al., 2016; 27077926). One or more of the BRCA1 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hereditary breast and ovarian cancer syndrome (ClinVar, Mar 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Inactivating germline mutations in BRCA1 or BRCA2 are associated with autosomal dominant hereditary breast and ovarian cancer (Miki et al., 1994; 7545954, Wooster et al., 1995; 8524414), and the lifetime risk of breast and ovarian cancer in BRCA1/2 mutation carriers has been estimated to be as high as 87% and 44%, respectively (Ford et al., 1994; 7907678). Elevated risk for other cancer types, including gastric, pancreatic, prostate, and colorectal, has also been identified, with an increase in risk ranging from 20 to 60% (Friedenson, 2005; 16369438). The estimated prevalence of deleterious germline BRCA1/2 mutations in the general population is between 1:400 and 1:800, with an approximately 10_fold higher prevalence in the Ashkenazi Jewish population (Ford et al., 1994; 7907678, Whittemore et al., 1997; 9042908, Claus et al., 1996; 8635102, Struewing et al., 1997; 9145676, Oddoux et al., 1996; 8841192, King et al., 2003; 14576434, Hall et al., 2009; 19241424). In the appropriate clinical context, germline testing of BRCA1 is recommended.', 'Include': 'true', 'ClinicalTrialNote': 'BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.', 'Therapies': {'Therapy': [{'Name': None, 'GenericName': 'Rucaparib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> The PARP inhibitor rucaparib is FDA approved to treat patients with metastatic castration_resistant prostate cancer (mCRPC) or epithelial ovarian, Fallopian tube, or primary peritoneal cancer and deleterious somatic or germline BRCA mutations. Rucaparib is also approved as a maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence in ovarian cancer (Shapira_Frommer et al., 2015; ASCO Abstract 5513)(Swisher et al., 2016; 27908594, Drew et al., 2016; 27002934), as well as clinical data in other cancer types (Kristeleit et al., 2014; ASCO Abstract 2573, Domcheck et al., 2016; ASCO Abstract 4110)(Drew et al., 2016; 27002934), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to rucaparib. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of rucaparib for the treatment of biliary tract cancers are limited (PubMed, Jun 2022). Rucaparib has primarily been evaluated in the context of ovarian carcinoma, breast carcinoma, pancreatic carcinoma, and melanoma. In a Phase 2 study of rucaparib for recurrent, platinum_sensitive ovarian, peritoneal, or fallopian tube carcinoma, median PFS was significantly longer in patients with BRCA1/2 mutations (12.8 months) or high loss of heterozygosity (LOH; 5.7 months) compared to patients with low LOH (5.2 months). Objective responses were observed for 80% (32/40) of patients with BRCA1/2 mutations, for 29% (24/82) with high LOH, and for 10% (7/10) with low LOH (Swisher et al., 2016; 27908594). In heavily pretreated patients with a germline BRCA1/2 mutation who had received 2_4 prior chemotherapy treatments and had a progression free interval of greater than 6 months, 65% (17/26) of patients achieved an objective response with rucaparib treatment (Shapira_Frommer et al., 2015; ASCO Abstract 5513). In a Phase 2 study evaluating rucaparib for patients with advanced breast or ovarian cancer and germline BRCA1/2 mutations, disease control was observed in 92% (12/13) of patients with ovarian cancer treated with oral rucaparib dosed continuously, but no objective responses were reported in breast cancer patients (n=23). However, 39% (9/23) of evaluable patients with breast cancer achieved SD lasting 12 weeks or more (Drew et al., 2016; 27002934). In a Phase 1 study of rucaparib treatment in patients with solid tumors, 3/4 patients with ovarian cancer and 1/1 patient with breast cancer given the recommended Phase 2 dose reported objective responses; all responders harbored BRCA1/2 mutations (Kristeleit et al., 2014; ASCO Abstract 2573). A Phase 2 study of rucaparib treatment for patients with relapsed pancreatic cancer reported 1/19 CR, 2/19 PR (one unconfirmed) and 4/19 SD. Of the 19 patients treated in the study, 15 (79%) had a BRCA2 mutation (Domcheck et al., 2016; ASCO Abstract 4110). In a Phase 2 study of intravenous rucaparib in combination with temozolomide for patients with metastatic melanoma, 8/46 patients achieved a PR and 8/46 had SD (Plummer et al., 2013; 23423489); a Phase 1 study reported 1 CR, 1 PR, and 4 SD lasting six months or longer in patients with metastatic melanoma (Plummer et al., 2008; 19047122). A Phase 1 study of intravenous and oral rucaparib in combination with chemotherapy for the treatment of advanced solid tumors reported a disease control rate of 68.8% (53/77), including 1 CR and 9 PRs (Wilson et al., 2017; 28222073). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Olaparib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> The PARP inhibitor olaparib is FDA approved to treat patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer, patients with deleterious or suspected deleterious gBRCA_mutated pancreatic adenocarcinoma or HER2_negative breast cancer, and patients with prostate cancer and mutations in homologous recombination repair genes. Olaparib is also approved in combination with bevacizumab to treat patients with ovarian, Fallopian tube, or primary peritoneal cancer with deleterious or suspected deleterious somatic or gBRCA mutation and/or genomic instability. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of extensive clinical evidence in ovarian cancer (Fong et al., 2009; 19553641, Audeh et al., 2010; 20609468, Fong et al., 2010; 20406929, Gelmon et al., 2011; 21862407, Kaye et al., 2012; 22203755) as well as strong clinical evidence in multiple other cancer types (Fong et al., 2009; 19553641, Tutt et al., 2010; 20609467, Gelmon et al., 2011; 21862407, Del Conte et al., 2014; 25025963, Kaufman et al., 2015; 25366685, Mateo et al., 2015; 26510020, Golan et al., 2019; 31157963), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to olaparib. </p> <p><b>Supporting Data:</b> In a Phase 2 study of olaparib plus pembrolizumab for advanced solid tumors, patients with BRCA1 or BRCA2 mutations achieved an ORR of 29% (6/21), whereas patients with mutations in other homologous recombination repair genes achieved an ORR of 6.3% (2/32) (Maio et al., 2021; AACR Abstract CT178). A disease control rate of 71% (5/7), including 3 PRs, was reported for patients with BRCA2_mutant intrahepatic cholangiocarcinoma (ICC) treated with olaparib following progression on prior chemotherapeutic regimens; the PRs were reported in patients with germline mutations (Lin et al., 2019; 31068370). In another study, a heavily pretreated patient with BRCA2_mutant ICC experienced an ongoing PR from olaparib monotherapy (Cheng et al., 2018; 30271179). A PR was also reported in a patient with gallbladder carcinoma harboring a confirmed BRCA1 germline alteration treated with olaparib (Xie et al., 2016; 28028375). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Talazoparib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> The PARP inhibitor talazoparib is FDA approved to treat HER2_negative locally advanced or metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical data in breast cancer (Turner et al., 2017; ASCO Abstract 1007)(Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753) and additional clinical evidence in ovarian, pancreatic, and prostate cancer (Meehan et al., 2017; AACR Abstract 4687)(de Bono et al., 2017; 28242752, Lu et al., 2018; 30099369, De Bono et al., 2020; ASCO Abstract 5566), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to talazoparib. </p> <p><b>Supporting Data:</b> In a basket trial of talazoparib for patients with alterations in homologous repair genes, 1 patient with ATM_mutated cholangiocarcinoma experienced a PR (Piha_Paul et al., 2017; EORTC_NCI_AACR Abstract A096). Talazoparib has been studied primarily in the context of BRCA_mutated, HER2_negative breast cancer, where patients achieved significantly longer median PFS (8.6 vs. 5.6 months, HR=0.54), a higher ORR (62.6% vs. 27.2%), and improved quality of life on talazoparib compared with standard chemotherapy in a Phase 3 study (Litton et al., 2018; 30110579, Ettl et al., 2018; 30124753). In a Phase 2 study of talazoparib for BRCA1/2_wildtype patients with homologous recombination pathway alterations, the best outcome in non_breast tumors was SD ≥ 6 months for 2/7 patients who had colon cancer with germline ATM alteration or testicular cancer with germline CHEK2 and somatic ATM alteration (Gruber et al., 2019; ASCO Abstract 3006). Clinical activity of single_agent talazoparib has been observed in numerous other solid tumors, including responses in BRCA_mutated ovarian, pancreatic, prostate, and ampulla of Vater cancers; PALB2_mutated pancreatic and bladder cancers; ATM_mutated cholangiocarcinoma; and small cell lung cancer (deBono et al., 2017; 28242752, Lu et al., 2018; 30099369)(Piha_Paul et al., 2017; EORTC_NCI_AACR Abstract A096, Meehan et al., 2017; AACR Abstract 4687). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}, {'Name': None, 'GenericName': 'Niraparib', 'FDAApproved': 'false', 'Rationale': '<p><b>Approved Indications:</b> The PARP inhibitor niraparib is FDA approved to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, with or without homologous recombination deficiency (HRD)_positive status. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in ovarian and breast cancers (Konstantinopolous et al., 2018; ASCO Abstract 106, Mirza et al., 2016; 27717299, Sandhu et al., 2013; 23810788), loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors such as niraparib. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of niraparib for the treatment of biliary tract carcinoma are limited (PubMed, Apr 2022). Niraparib has been primarily evaluated in the context of ovarian cancer. In a Phase 3 study of patients with platinum_sensitive, recurrent ovarian cancer, niraparib significantly increased median PFS, as compared to placebo, in patients with germline BRCA mutations (21 vs. 5.5 months) and in patients without germline BRCA mutations (9.3 vs. 3.9 months) as well as in a subgroup of the patients without germline BRCA mutations with homologous recombination_deficient tumors (12.9 vs. 3.8 months)(Mirza et al., 2016; 27717299). In a Phase 1 study of niraparib treatment for patients with solid tumors, 40% (8/20) of patients with ovarian cancer and BRCA mutations and 50% (2/4) of patients with breast cancer and BRCA mutations experienced a PR, and 43% (9/21) of patients with castration_resistant prostate cancer and 100% (2/2) of patients with non_small cell lung cancer achieved SD (Sandhu et al., 2013; 23810788). A Phase 1 study of the combination of niraparib and bevacizumab in patients with platinum_sensitive, high_grade ovarian cancer reported a DCR of 91% (10/11), with a response rate of 45% (5/11)(Mirza et al., 2016; ASCO Abstract 5555). </p>', 'ApprovedUses': None, 'Effect': 'Sensitizing', 'Include': 'true', 'IncludeInSummary': 'true', 'ReferenceLinks': None}]}, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04644068', 'Include': 'true'}, {'nctId': 'NCT03239015', 'Include': 'true'}, {'nctId': 'NCT04123366', 'Include': 'true'}, {'nctId': 'NCT03742895', 'Include': 'true'}, {'nctId': 'NCT02264678', 'Include': 'true'}, {'nctId': 'NCT04298008', 'Include': 'true'}, {'nctId': 'NCT04298021', 'Include': 'true'}, {'nctId': 'NCT05035745', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'CHEK2', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'M1L', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'M1L'}}, 'Interpretation': 'CHEK2 encodes the protein checkpoint kinase 2, a serine/threonine kinase that plays an important role in the DNA_damage response; it is a putative tumor suppressor (Tomlinson et al., 2012; 22294770, Xu et al., 1990; 2205842, van der Groep et al., 2011; 21336636, Schutte et al., 2003; 12610780). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. Somatic CHEK2 mutations have been reported in 0_3% of various solid tumors, with the highest incidence reported in endometrial, urothelial, and skin tumors (COSMIC, Jan 2022)(Tate et al., 2019; 30371878). In breast cancer, certain CHEK2 mutations are associated with higher grade and larger tumors as well as bilateral disease (Kilpivaara et al., 2005; 15472904). A study reported that a polymorphism in CHEK2 was associated with worse survival of patients with GBM, but this association lost significance after adjusting for other prognostic factors (Simon et al., 2006; 17016233, Dong et al., 2014; 24532427). Another study in prostate cancer reported that CHEK2 expression is decreased in higher grade tumors and that CHEK2 is a tumor suppressor that decreases the growth of prostate cancer cells and regulates androgen receptor signaling (Ta et al., 2015; 26573794). Limited clinical data indicate that CHEK2 inactivation may predict sensitivity to PARP inhibitors. Patients with CHEK2_altered prostate cancer have experienced clinical responses to PARP inhibitors (Abida et al., 2020; 32086346, Mateo et al., 2020; 31806540, Mateo et al., 2015; 26510020). Clinical benefit has been observed for patients with ovarian (Swisher et al., 2017; 27908594, O Malley et al., 2017; AACR Abstract LB_A12) and testicular (Gruber et al., 2019; ASCO Abstract 3006) cancers treated with PARP inhibitors. In a study of patients with metastatic breast cancer, 8 patients with CHEK2 mutation did not respond to olaparib treatment (Tung et al., 2020; 33119476). One study of patients with breast cancer reported that carriers of the CHEK2 H371Y mutation have a higher likelihood of response to neoadjuvant chemotherapy (Liu et al., 2015; 25884806), whereas another study found that those who carry CHEK2 mutations have a lower frequency of objective clinical responses to neoadjuvant therapy (Pfeifer et al., 2014; 25414026). A third study reported that the CHEK2 1100delC mutation is not associated with differential efficacy of chemotherapy and endocrine therapy in patients with metastatic breast cancer (Kriege et al., 2015; 25958056). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. Germline CHEK2 mutation has been associated with cancer susceptibility of low to moderate penetrance, especially in hereditary breast cancer (Mahdavi et al., 2019; 30552672). CHEK2 germline mutation has been identified in approximately 2.5% of familial or high_risk breast cancer cases (Kleiblová et al., 2019; 31409080, Hauke et al., 2018; 29522266). Although heterozygous germline CHEK2 mutation increases breast cancer risk two_ to three_fold, it is not associated with younger age at diagnosis (Hauke et al., 2018; 29522266, Lu et al., 2019; 30128536). In the appropriate clinical context, germline testing of CHEK2 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). Comprehensive genomic profiling of solid tumors may detect nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.', 'Include': 'true', 'ClinicalTrialNote': 'On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': [{'nctId': 'NCT04644068', 'Include': 'true'}, {'nctId': 'NCT04123366', 'Include': 'true'}, {'nctId': 'NCT03742895', 'Include': 'true'}, {'nctId': 'NCT02264678', 'Include': 'true'}, {'nctId': 'NCT04298021', 'Include': 'true'}, {'nctId': 'NCT05035745', 'Include': 'true'}, {'nctId': 'NCT03772561', 'Include': 'true'}, {'nctId': 'NCT04801966', 'Include': 'true'}, {'nctId': 'NCT03297606', 'Include': 'true'}, {'nctId': 'NCT02484404', 'Include': 'true'}]}}}, 'ReferenceLinks': None}, {'Name': 'STK11', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'R297K', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'R297K'}}, 'Interpretation': 'The serine/threonine kinase STK11 (also called LKB1) activates AMPK and negatively regulates the mTOR pathway in response to changes in cellular energy levels (Shaw et al., 2004; 15261145). LKB1 acts as a tumor suppressor in cancer, as loss of function promotes proliferation and tumorigenesis (Carretero et al., 2010; 20541700, Ollila et al., 2011; 21926085). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. STK11 mutations have been reported in 3% of biliary tract carcinomas analyzed in the COSMIC database (Mar 2022)(Tate et al., 2019; 30371878). STK11 mutation or loss have also been reported in biliary tract adenocarcinomas in the literature (Olschwang et al., 2001; 11389158, Su et al., 1999; 10362809, Sahin et al., 2003; 12861065). Loss of STK11 protein expression in intrahepatic cholangiocarcinoma has been reported as an independent predictor of shorter OS and time to recurrence (Wang et al., 2015; 26056085). Increased mTOR signaling is present in LKB1_deficient tumors, suggesting therapies targeting mTOR may be relevant for tumors with STK11 alterations (Shaw et al., 2004; 15261145, Ji et al., 2007; 17676035, Contreras et al., 2008; 18245476, Gurumurthy et al., 2008; 18172296, Shackelford et al., 2009; 19541609). Case studies have reported PRs for 2 patients with STK11_mutated pancreatic cancer following treatment with the mTOR inhibitor everolimus (Klümpen et al., 2011; 21189378, Moreira et al., 2015; ASCO Abstract 315), with 1 PR observed in a PJS patient for 9 months until progression (Klümpen et al., 2011; 21189378). However, retrospective analysis of a Phase 2 trial for patients with endometrial carcinoma found LKB1 (STK11) protein levels were not significantly correlated with response to everolimus treatment (Tredan et al., 2013; 23238879). In one preclinical study, STK11 loss was associated with sensitivity to combination treatment including an SRC inhibitor (Carretero et al., 2010; 20541700); however, the clinical relevance of these findings has not been established. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. STK11 alteration is associated with poorer response to immune checkpoint inhibitors for patients with NSCLC, including those with tumors harboring co_occurring KRAS mutation (Skoulidis et al., 2018; 29773717, Hellmann et al., 2018; 29657128, Scheel et al., 2016; 27467949, Skoulidis et al., 2015; 26069186, Koyama et al., 2016; 26833127, Schabath et al., 2016; 26477306, Dong et al., 2017; 28039262, Kadara et al., 2017; 27687306, Herter_Sprie et al., 2016; 27699275) (Skoulidis et al., 2017; IASLC 17th World Congress on Lung Cancer Abstract MA04.07, Jure_Kunkel et al., 2018; ASCO Abstract 3028, Stephens, 2017; AACR Abstract SY40_02, Skoulidis et al., 2015; ASCO Abstract 11002, Skoulidis et al., 2015; ASCO Abstract 11002). One or more of the STK11 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Peutz_Jeghers syndrome (ClinVar, Mar 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in STK11 underlie Peutz_Jeghers syndrome (PJS), a rare autosomal dominant disorder associated with a predisposition for tumor formation (Amos et al., 2004; 15121768). This disorder has an estimated frequency between 1:29,000 and 1:120,000, although reported rates in the literature vary greatly (Hearle et al., 2006; 16707622, Amos et al., 2004; 15121768, van der Groep et al., 2011; 21336636). Although gastrointestinal tumors are the most common malignancies associated with PJS, patients also exhibit an 18_fold increased risk of developing other epithelial cancers (Hearle et al., 2006; 16707622, Amos et al., 2004; 15121768, van der Groep et al., 2011; 21336636), and individuals with this syndrome have a 30_50% risk of developing breast cancer (Amos et al., 2004; 15121768, van der Groep et al., 2011; 21336636). Given the association with PJS, in the appropriate clinical context testing for the presence of germline mutations in STK11 is recommended.', 'Include': 'true', 'ClinicalTrialNote': 'Increased mTOR signaling is present in LKB1_deficient tumors, suggesting therapies targeting mTOR may be relevant for tumors with STK11 alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': {'ClinicalTrialLink': {'nctId': 'NCT04337463', 'Include': 'true'}}}}, 'ReferenceLinks': None}, {'Name': 'Blood Tumor Mutational Burden', 'Include': 'true', 'Alterations': {'Alteration': {'Name': '04', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': '04'}}, 'Interpretation': 'Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Published data investigating the prognostic implications of bTMB levels in biliary tract cancer are limited (PubMed, Jul 2022). Although cases with hypermutated biliary tract cancer were enriched in a subgroup with poor prognosis in 1 study (Nakamura et al., 2015; 26258846), TMB_high (≥10 mut/Mb) status in biliary adenocarcinoma not treated with immunotherapy was not significantly associated with OS in another study, in which patients with TMB_high tumors experienced numerically longer OS compared with patients with TMB_low tumors (11.5 vs. 8.4 months, adjusted HR=0.65) (Shao et al., 2020; 33119110). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), and anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P). A Phase 2 multi_solid_tumor trial showed that bTMB ≥16 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Microsatellite status', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Cannot Be Determined', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Cannot Be Determined'}}, 'Interpretation': 'Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI_H is infrequent in cholangiocarcinoma, reported in 1% of samples (Javle et al., 2019; ASCO Abstract 4087). A non_zero level of MSI has been reported in 18_49% of cholangiocarcinoma cases (Momoi et al., 2001; 11580146, Limpaiboon et al., 2002; 12175538, Liu et al., 2002; 12402306, Liengswangwong et al., 2003; 14506736), although the studies did not specify what fraction of cases were MSI_H. A higher frequency of MSI (63%) was reported in patients with intrahepatic cholangiocarcinoma associated with exposure to Thorotrast (Liu et al., 2002; 12402306). One study reported that MSI is associated with poor prognosis in liver fluke_related cholangiocarcinoma (Limpaiboon et al., 2002; 12175538). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143) and PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}, {'Name': 'Tumor Fraction', 'Include': 'true', 'Alterations': {'Alteration': {'Name': 'Elevated Tumor Fraction Not Detected', 'AlterationProperties': {'AlterationProperty': {'isEquivocal': 'false', 'name': 'Elevated Tumor Fraction Not Detected'}}, 'Interpretation': 'Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).', 'Include': 'true', 'ClinicalTrialNote': None, 'Therapies': None, 'ReferenceLinks': None, 'ClinicalTrialLinks': None}}, 'ReferenceLinks': None}]}, 'Trials': {'Trial': [{'Gene': 'BRCA1', 'Alteration': 'E1222fs*13', 'Title': 'Study of AZD5305 as Monotherapy and in Combination With Anti_cancer Agents in Patients With Advanced Solid Malignancies', 'StudyPhase': 'PHASE 1/2', 'Target': 'ERBB2, TROP2, PARP', 'Locations': 'Shanghai (China), Seoul (Korea, Republic of), Chuo_ku (Japan), Koto_ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Grzepnica (Poland), Budapest (Hungary), Brno (Czechia)', 'NCTID': 'NCT04644068', 'Note': 'BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.', 'Include': 'true'}, {'Gene': 'BRCA1', 'Alteration': 'E1222fs*13', 'Title': 'Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event', 'StudyPhase': 'PHASE 2', 'Target': 'EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6', 'Locations': 'Shanghai (China)', 'NCTID': 'NCT03239015', 'Note': 'BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.', 'Include': 'true'}, {'Gene': 'BRCA1', 'Alteration': 'E1222fs*13', 'Title': 'Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP, PD_1', 'Locations': 'Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)', 'NCTID': 'NCT04123366', 'Note': 'BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.', 'Include': 'true'}, {'Gene': 'BRCA1', 'Alteration': 'E1222fs*13', 'Title': 'Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Nedlands (Australia), Port Macquarie (Australia), Darlinghurst (Australia), Adana (Turkey), Ankara (Turkey), Jerusalem (Israel), Konya (Turkey), Ramat Gan (Israel)', 'NCTID': 'NCT03742895', 'Note': 'BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.', 'Include': 'true'}, {'Gene': 'BRCA1', 'Alteration': 'E1222fs*13', 'Title': 'Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP, PD_L1', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Villejuif (France)', 'NCTID': 'NCT02264678', 'Note': 'BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.', 'Include': 'true'}, {'Gene': 'BRCA1', 'Alteration': 'E1222fs*13', 'Title': 'AZD6738 Plus Durvalumab in Biliary Tract Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'ATR, PD_L1', 'Locations': 'Seoul (Korea, Republic of)', 'NCTID': 'NCT04298008', 'Note': 'BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.', 'Include': 'true'}, {'Gene': 'BRCA1', 'Alteration': 'E1222fs*13', 'Title': 'DDR_Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'PD_L1, ATR, PARP', 'Locations': 'Seoul (Korea, Republic of)', 'NCTID': 'NCT04298021', 'Note': 'BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.', 'Include': 'true'}, {'Gene': 'BRCA1', 'Alteration': 'E1222fs*13', 'Title': 'Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)', 'StudyPhase': 'PHASE 1/2', 'Target': 'XPO1, PARP', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT05035745', 'Note': 'BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.', 'Include': 'true'}, {'Gene': 'BRCA1', 'Alteration': 'E1222fs*13', 'Title': 'Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, AKTs, PD_L1', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT03772561', 'Note': 'BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.', 'Include': 'true'}, {'Gene': 'BRCA1', 'Alteration': 'E1222fs*13', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.', 'Include': 'true'}, {'Gene': 'CHEK2', 'Alteration': 'M1L', 'Title': 'Study of AZD5305 as Monotherapy and in Combination With Anti_cancer Agents in Patients With Advanced Solid Malignancies', 'StudyPhase': 'PHASE 1/2', 'Target': 'ERBB2, TROP2, PARP', 'Locations': 'Shanghai (China), Seoul (Korea, Republic of), Chuo_ku (Japan), Koto_ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Grzepnica (Poland), Budapest (Hungary), Brno (Czechia)', 'NCTID': 'NCT04644068', 'Note': 'On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CHEK2', 'Alteration': 'M1L', 'Title': 'Study of Olaparib (MK_7339) in Combination With Pembrolizumab (MK_3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)_Positive Advanced Cancer (MK_7339_007/KEYLYNK_007)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP, PD_1', 'Locations': 'Fukuoka (Japan), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)', 'NCTID': 'NCT04123366', 'Note': 'On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CHEK2', 'Alteration': 'M1L', 'Title': 'Efficacy and Safety of Olaparib (MK_7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK_7339_002 / LYNK_002)', 'StudyPhase': 'PHASE 2', 'Target': 'PARP', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Nedlands (Australia), Port Macquarie (Australia), Darlinghurst (Australia), Adana (Turkey), Ankara (Turkey), Jerusalem (Israel), Konya (Turkey), Ramat Gan (Israel)', 'NCTID': 'NCT03742895', 'Note': 'On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CHEK2', 'Alteration': 'M1L', 'Title': 'Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents', 'StudyPhase': 'PHASE 1/2', 'Target': 'ATR, PARP, PD_L1', 'Locations': 'Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Villejuif (France)', 'NCTID': 'NCT02264678', 'Note': 'On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CHEK2', 'Alteration': 'M1L', 'Title': 'DDR_Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer', 'StudyPhase': 'PHASE 2', 'Target': 'PD_L1, ATR, PARP', 'Locations': 'Seoul (Korea, Republic of)', 'NCTID': 'NCT04298021', 'Note': 'On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CHEK2', 'Alteration': 'M1L', 'Title': 'Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)', 'StudyPhase': 'PHASE 1/2', 'Target': 'XPO1, PARP', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT05035745', 'Note': 'On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CHEK2', 'Alteration': 'M1L', 'Title': 'Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies', 'StudyPhase': 'PHASE 1', 'Target': 'PARP, AKTs, PD_L1', 'Locations': 'Singapore (Singapore)', 'NCTID': 'NCT03772561', 'Note': 'On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CHEK2', 'Alteration': 'M1L', 'Title': 'Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study', 'StudyPhase': 'PHASE null', 'Target': 'CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF', 'Locations': 'Melbourne (Australia)', 'NCTID': 'NCT04801966', 'Note': 'On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CHEK2', 'Alteration': 'M1L', 'Title': 'Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)', 'StudyPhase': 'PHASE 2', 'Target': 'VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO', 'Locations': 'Vancouver (Canada), Kelowna (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)', 'NCTID': 'NCT03297606', 'Note': 'On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'CHEK2', 'Alteration': 'M1L', 'Title': 'Phase I/II Study of the Anti_Programmed Death Ligand_1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers', 'StudyPhase': 'PHASE 1/2', 'Target': 'PARP, VEGFRs, PDGFRA, PDGFRB, KIT, PD_L1', 'Locations': 'Maryland', 'NCTID': 'NCT02484404', 'Note': 'On the basis of clinical evidence in prostate and other solid cancers, CHEK2 loss or inactivation may confer sensitivity to PARP inhibitors. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}, {'Gene': 'STK11', 'Alteration': 'R297K', 'Title': 'ATG_008 Combined With Toripalimab in Advanced Solid Tumors', 'StudyPhase': 'PHASE null', 'Target': 'mTORC1, mTORC2, PD_1', 'Locations': 'Chongqing (China), Chengdu (China)', 'NCTID': 'NCT04337463', 'Note': 'Increased mTOR signaling is present in LKB1_deficient tumors, suggesting therapies targeting mTOR may be relevant for tumors with STK11 alterations. It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.', 'Include': 'true'}]}, 'References': {'Reference': [{'number': '0', 'ReferenceId': '22294770', 'FullCitation': 'Tomlinson IP, et al. Mutagenesis (2012) pmid: 22294770', 'Include': 'true'}, {'number': '1', 'ReferenceId': '2205842', 'FullCitation': 'Xu HP, et al. Nucleic Acids Res. (1990) pmid: 2205842', 'Include': 'true'}, {'number': '2', 'ReferenceId': '21336636', 'FullCitation': 'van der Groep P, et al. Cell Oncol (Dordr) (2011) pmid: 21336636', 'Include': 'true'}, {'number': '3', 'ReferenceId': '12610780', 'FullCitation': 'Schutte M, et al. Am. J. Hum. Genet. (2003) pmid: 12610780', 'Include': 'true'}, {'number': '4', 'ReferenceId': '30371878', 'FullCitation': 'Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878', 'Include': 'true'}, {'number': '5', 'ReferenceId': '15472904', 'FullCitation': 'Kilpivaara O, et al. Int. J. Cancer (2005) pmid: 15472904', 'Include': 'true'}, {'number': '6', 'ReferenceId': '17016233', 'FullCitation': 'Simon M, et al. Neurosurgery (2006) pmid: 17016233', 'Include': 'true'}, {'number': '7', 'ReferenceId': '24532427', 'FullCitation': 'Dong YS, et al. Tumour Biol. (2014) pmid: 24532427', 'Include': 'true'}, {'number': '8', 'ReferenceId': '26573794', 'FullCitation': 'Ta HQ, et al. Cancer Res. (2015) pmid: 26573794', 'Include': 'true'}, {'number': '9', 'ReferenceId': '32086346', 'FullCitation': 'Abida W, et al. Clin. Cancer Res. (2020) pmid: 32086346', 'Include': 'true'}, {'number': '10', 'ReferenceId': '31806540', 'FullCitation': 'Mateo J, et al. Lancet Oncol. (2019) pmid: 31806540', 'Include': 'true'}, {'number': '11', 'ReferenceId': '26510020', 'FullCitation': 'Mateo J, et al. N. Engl. J. Med. (2015) pmid: 26510020', 'Include': 'true'}, {'number': '12', 'ReferenceId': '27908594', 'FullCitation': 'Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594', 'Include': 'true'}, {'number': '13', 'ReferenceId': '33119476', 'FullCitation': 'Tung NM, et al. J Clin Oncol (2020) pmid: 33119476', 'Include': 'true'}, {'number': '14', 'ReferenceId': '25884806', 'FullCitation': 'Liu Y, et al. BMC Cancer (2015) pmid: 25884806', 'Include': 'true'}, {'number': '15', 'ReferenceId': '25414026', 'FullCitation': 'Pfeifer W, et al. Breast Cancer Res. Treat. (2014) pmid: 25414026', 'Include': 'true'}, {'number': '16', 'ReferenceId': '25958056', 'FullCitation': 'Kriege M, et al. J. Cancer Res. Clin. Oncol. (2015) pmid: 25958056', 'Include': 'true'}, {'number': '17', 'ReferenceId': '30552672', 'FullCitation': 'Mahdavi M, et al. J Cell Physiol (2019) pmid: 30552672', 'Include': 'true'}, {'number': '18', 'ReferenceId': '31409080', 'FullCitation': 'Kleiblová P, et al. Klin Onkol (2019) pmid: 31409080', 'Include': 'true'}, {'number': '19', 'ReferenceId': '29522266', 'FullCitation': 'Hauke J, et al. Cancer Med (2018) pmid: 29522266', 'Include': 'true'}, {'number': '20', 'ReferenceId': '30128536', 'FullCitation': 'Lu HM, et al. JAMA Oncol (2019) pmid: 30128536', 'Include': 'true'}, {'number': '21', 'ReferenceId': '25426837', 'FullCitation': 'Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837', 'Include': 'true'}, {'number': '22', 'ReferenceId': '25426838', 'FullCitation': 'Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838', 'Include': 'true'}, {'number': '23', 'ReferenceId': '25326804', 'FullCitation': 'Xie M, et al. Nat. Med. (2014) pmid: 25326804', 'Include': 'true'}, {'number': '24', 'ReferenceId': '28669404', 'FullCitation': 'Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404', 'Include': 'true'}, {'number': '25', 'ReferenceId': '29678827', 'FullCitation': 'Severson EA, et al. Blood (2018) pmid: 29678827', 'Include': 'true'}, {'number': '26', 'ReferenceId': '29420212', 'FullCitation': 'Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212', 'Include': 'true'}, {'number': '27', 'ReferenceId': '32269342', 'FullCitation': 'Chabon JJ, et al. Nature (2020) pmid: 32269342', 'Include': 'true'}, {'number': '28', 'ReferenceId': '31768066', 'FullCitation': 'Razavi P, et al. Nat. Med. (2019) pmid: 31768066', 'Include': 'true'}, {'number': '29', 'ReferenceId': '20400477', 'FullCitation': 'O Donovan PJ, et al. Carcinogenesis (2010) pmid: 20400477', 'Include': 'true'}, {'number': '30', 'ReferenceId': '20681793', 'FullCitation': 'Nelson AC, et al. Radiat. Res. (2010) pmid: 20681793', 'Include': 'true'}, {'number': '31', 'ReferenceId': '22843421', 'FullCitation': 'Silver DP, et al. Cancer Discov (2012) pmid: 22843421', 'Include': 'true'}, {'number': '32', 'ReferenceId': '11358863', 'FullCitation': 'Ludwig T, et al. Genes Dev. (2001) pmid: 11358863', 'Include': 'true'}, {'number': '33', 'ReferenceId': '24185513', 'FullCitation': 'Chan_On W, et al. Nat. Genet. (2013) pmid: 24185513', 'Include': 'true'}, {'number': '34', 'ReferenceId': '22561520', 'FullCitation': 'Ong CK, et al. Nat. Genet. (2012) pmid: 22561520', 'Include': 'true'}, {'number': '35', 'ReferenceId': '24185509', 'FullCitation': 'Jiao Y, et al. Nat. Genet. (2013) pmid: 24185509', 'Include': 'true'}, {'number': '36', 'ReferenceId': '24563076', 'FullCitation': 'Ross JS, et al. Oncologist (2014) pmid: 24563076', 'Include': 'true'}, {'number': '37', 'ReferenceId': '32918181', 'FullCitation': 'Power R, et al. Fam Cancer (2021) pmid: 32918181', 'Include': 'true'}, {'number': '38', 'ReferenceId': '28028375', 'FullCitation': 'Xie Y, et al. World J. Gastroenterol. (2016) pmid: 28028375', 'Include': 'true'}, {'number': '39', 'ReferenceId': '25366685', 'FullCitation': 'Kaufman B, et al. J. Clin. Oncol. (2015) pmid: 25366685', 'Include': 'true'}, {'number': '40', 'ReferenceId': '20609467', 'FullCitation': 'Tutt A, et al. Lancet (2010) pmid: 20609467', 'Include': 'true'}, {'number': '41', 'ReferenceId': '28578601', 'FullCitation': 'Robson M, et al. N. Engl. J. Med. (2017) pmid: 28578601', 'Include': 'true'}, {'number': '42', 'ReferenceId': '27717299', 'FullCitation': 'Mirza MR, et al. N. Engl. J. Med. (2016) pmid: 27717299', 'Include': 'true'}, {'number': '43', 'ReferenceId': '23810788', 'FullCitation': 'Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788', 'Include': 'true'}, {'number': '44', 'ReferenceId': '27002934', 'FullCitation': 'Drew Y, et al. Br. J. Cancer (2016) pmid: 27002934', 'Include': 'true'}, {'number': '45', 'ReferenceId': '28754483', 'FullCitation': 'Pujade_Lauraine E, et al. Lancet Oncol. (2017) pmid: 28754483', 'Include': 'true'}, {'number': '46', 'ReferenceId': '27617661', 'FullCitation': 'Ledermann JA, et al. Lancet Oncol. (2016) pmid: 27617661', 'Include': 'true'}, {'number': '47', 'ReferenceId': '19553641', 'FullCitation': 'Fong PC, et al. N. Engl. J. Med. (2009) pmid: 19553641', 'Include': 'true'}, {'number': '48', 'ReferenceId': '20609468', 'FullCitation': 'Audeh MW, et al. Lancet (2010) pmid: 20609468', 'Include': 'true'}, {'number': '49', 'ReferenceId': '20406929', 'FullCitation': 'Fong PC, et al. J. Clin. Oncol. (2010) pmid: 20406929', 'Include': 'true'}, {'number': '50', 'ReferenceId': '21862407', 'FullCitation': 'Gelmon KA, et al. Lancet Oncol. (2011) pmid: 21862407', 'Include': 'true'}, {'number': '51', 'ReferenceId': '22203755', 'FullCitation': 'Kaye SB, et al. J. Clin. Oncol. (2012) pmid: 22203755', 'Include': 'true'}, {'number': '52', 'ReferenceId': '26723501', 'FullCitation': 'Domchek SM, et al. Gynecol. Oncol. (2016) pmid: 26723501', 'Include': 'true'}, {'number': '53', 'ReferenceId': '30345884', 'FullCitation': 'Moore K, et al. N. Engl. J. Med. (2018) pmid: 30345884', 'Include': 'true'}, {'number': '54', 'ReferenceId': '31157963', 'FullCitation': 'Golan T, et al. N. Engl. J. Med. (2019) pmid: 31157963', 'Include': 'true'}, {'number': '55', 'ReferenceId': '32988960', 'FullCitation': 'Yap TA, et al. Cancer Discov (2021) pmid: 32988960', 'Include': 'true'}, {'number': '56', 'ReferenceId': '29252124', 'FullCitation': 'Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124', 'Include': 'true'}, {'number': '57', 'ReferenceId': '31299005', 'FullCitation': 'Saito YD, et al. Cancer Treat Res Commun (2018) pmid: 31299005', 'Include': 'true'}, {'number': '58', 'ReferenceId': '31721781', 'FullCitation': 'Pouliot GP, et al. PLoS ONE (2019) pmid: 31721781', 'Include': 'true'}, {'number': '59', 'ReferenceId': '27993965', 'FullCitation': 'Kim H, et al. Clin. Cancer Res. (2017) pmid: 27993965', 'Include': 'true'}, {'number': '60', 'ReferenceId': '29605721', 'FullCitation': 'Jin J, et al. Neoplasia (2018) pmid: 29605721', 'Include': 'true'}, {'number': '61', 'ReferenceId': '25964244', 'FullCitation': 'Do K, et al. J. Clin. Oncol. (2015) pmid: 25964244', 'Include': 'true'}, {'number': '62', 'ReferenceId': '30240327', 'FullCitation': 'Cruz C, et al. J. Clin. Oncol. (2018) pmid: 30240327', 'Include': 'true'}, {'number': '63', 'ReferenceId': '28368437', 'FullCitation': 'Poveda A, et al. Ann. Oncol. (2017) pmid: 28368437', 'Include': 'true'}, {'number': '64', 'ReferenceId': '23364677', 'FullCitation': 'García MJ, et al. Mol. Cancer Ther. (2013) pmid: 23364677', 'Include': 'true'}, {'number': '65', 'ReferenceId': '21376569', 'FullCitation': 'Schöffski P, et al. Eur. J. Cancer (2011) pmid: 21376569', 'Include': 'true'}, {'number': '66', 'ReferenceId': '21287534', 'FullCitation': 'Italiano A, et al. Cancer (2011) pmid: 21287534', 'Include': 'true'}, {'number': '67', 'ReferenceId': '25602962', 'FullCitation': 'Laroche_Clary A, et al. Br. J. Cancer (2015) pmid: 25602962', 'Include': 'true'}, {'number': '68', 'ReferenceId': '28467918', 'FullCitation': 'Ghouadni A, et al. Breast (2017) pmid: 28467918', 'Include': 'true'}, {'number': '69', 'ReferenceId': '25722380', 'FullCitation': 'Monk BJ, et al. Ann. Oncol. (2015) pmid: 25722380', 'Include': 'true'}, {'number': '70', 'ReferenceId': '31924332', 'FullCitation': 'Monk BJ, et al. Gynecol. Oncol. (2020) pmid: 31924332', 'Include': 'true'}, {'number': '71', 'ReferenceId': '27077926', 'FullCitation': 'Yasui H, et al. J Chemother (2016) pmid: 27077926', 'Include': 'true'}, {'number': '72', 'ReferenceId': '29165669', 'FullCitation': 'Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669', 'Include': 'true'}, {'number': '73', 'ReferenceId': '7545954', 'FullCitation': 'Miki Y, et al. Science (1994) pmid: 7545954', 'Include': 'true'}, {'number': '74', 'ReferenceId': '8524414', 'FullCitation': 'Wooster R, et al. Nature () pmid: 8524414', 'Include': 'true'}, {'number': '75', 'ReferenceId': '7907678', 'FullCitation': 'Ford D, et al. Lancet (1994) pmid: 7907678', 'Include': 'true'}, {'number': '76', 'ReferenceId': '16369438', 'FullCitation': 'MedGenMed (2005) pmid: 16369438', 'Include': 'true'}, {'number': '77', 'ReferenceId': '9042908', 'FullCitation': 'Whittemore AS, et al. Am. J. Hum. Genet. (1997) pmid: 9042908', 'Include': 'true'}, {'number': '78', 'ReferenceId': '8635102', 'FullCitation': 'Claus EB, et al. Cancer (1996) pmid: 8635102', 'Include': 'true'}, {'number': '79', 'ReferenceId': '9145676', 'FullCitation': 'Struewing JP, et al. N. Engl. J. Med. (1997) pmid: 9145676', 'Include': 'true'}, {'number': '80', 'ReferenceId': '8841192', 'FullCitation': 'Oddoux C, et al. Nat. Genet. (1996) pmid: 8841192', 'Include': 'true'}, {'number': '81', 'ReferenceId': '14576434', 'FullCitation': 'King MC, et al. Science (2003) pmid: 14576434', 'Include': 'true'}, {'number': '82', 'ReferenceId': '19241424', 'FullCitation': 'Hall MJ, et al. Cancer (2009) pmid: 19241424', 'Include': 'true'}, {'number': '83', 'ReferenceId': '15261145', 'FullCitation': 'Shaw RJ, et al. Cancer Cell (2004) pmid: 15261145', 'Include': 'true'}, {'number': '84', 'ReferenceId': '20541700', 'FullCitation': 'Carretero J, et al. Cancer Cell (2010) pmid: 20541700', 'Include': 'true'}, {'number': '85', 'ReferenceId': '21926085', 'FullCitation': 'Ollila S, et al. J Mol Cell Biol (2011) pmid: 21926085', 'Include': 'true'}, {'number': '86', 'ReferenceId': '11389158', 'FullCitation': 'Olschwang S, et al. J. Med. Genet. (2001) pmid: 11389158', 'Include': 'true'}, {'number': '87', 'ReferenceId': '10362809', 'FullCitation': 'Su GH, et al. Am. J. Pathol. (1999) pmid: 10362809', 'Include': 'true'}, {'number': '88', 'ReferenceId': '12861065', 'FullCitation': 'Sahin F, et al. Mod. Pathol. (2003) pmid: 12861065', 'Include': 'true'}, {'number': '89', 'ReferenceId': '26056085', 'FullCitation': 'Wang J, et al. Oncotarget (2015) pmid: 26056085', 'Include': 'true'}, {'number': '90', 'ReferenceId': '17676035', 'FullCitation': 'Ji H, et al. Nature (2007) pmid: 17676035', 'Include': 'true'}, {'number': '91', 'ReferenceId': '18245476', 'FullCitation': 'Contreras CM, et al. Cancer Res. (2008) pmid: 18245476', 'Include': 'true'}, {'number': '92', 'ReferenceId': '18172296', 'FullCitation': 'Gurumurthy S, et al. Cancer Res. (2008) pmid: 18172296', 'Include': 'true'}, {'number': '93', 'ReferenceId': '19541609', 'FullCitation': 'Shackelford DB, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19541609', 'Include': 'true'}, {'number': '94', 'ReferenceId': '21189378', 'FullCitation': 'Klümpen HJ, et al. J. Clin. Oncol. (2011) pmid: 21189378', 'Include': 'true'}, {'number': '95', 'ReferenceId': '23238879', 'FullCitation': 'Trédan O, et al. Target Oncol (2013) pmid: 23238879', 'Include': 'true'}, {'number': '96', 'ReferenceId': '29773717', 'FullCitation': 'Skoulidis F, et al. Cancer Discov (2018) pmid: 29773717', 'Include': 'true'}, {'number': '97', 'ReferenceId': '29657128', 'FullCitation': 'Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128', 'Include': 'true'}, {'number': '98', 'ReferenceId': '27467949', 'FullCitation': 'Scheel AH, et al. Oncoimmunology (2016) pmid: 27467949', 'Include': 'true'}, {'number': '99', 'ReferenceId': '26069186', 'FullCitation': 'Skoulidis F, et al. Cancer Discov (2015) pmid: 26069186', 'Include': 'true'}, {'number': '100', 'ReferenceId': '26833127', 'FullCitation': 'Koyama S, et al. Cancer Res. (2016) pmid: 26833127', 'Include': 'true'}, {'number': '101', 'ReferenceId': '26477306', 'FullCitation': 'Schabath MB, et al. Oncogene (2016) pmid: 26477306', 'Include': 'true'}, {'number': '102', 'ReferenceId': '28039262', 'FullCitation': 'Dong ZY, et al. Clin. Cancer Res. (2017) pmid: 28039262', 'Include': 'true'}, {'number': '103', 'ReferenceId': '27687306', 'FullCitation': 'Kadara H, et al. Ann. Oncol. (2017) pmid: 27687306', 'Include': 'true'}, {'number': '104', 'ReferenceId': '27699275', 'FullCitation': 'Herter_Sprie GS, et al. JCI Insight (2016) pmid: 27699275', 'Include': 'true'}, {'number': '105', 'ReferenceId': '15121768', 'FullCitation': 'Amos CI, et al. J. Med. Genet. (2004) pmid: 15121768', 'Include': 'true'}, {'number': '106', 'ReferenceId': '16707622', 'FullCitation': 'Hearle N, et al. Clin. Cancer Res. (2006) pmid: 16707622', 'Include': 'true'}, {'number': '107', 'ReferenceId': '26337942', 'FullCitation': 'Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942', 'Include': 'true'}, {'number': '108', 'ReferenceId': '21081928', 'FullCitation': 'You JF, et al. Br. J. Cancer (2010) pmid: 21081928', 'Include': 'true'}, {'number': '109', 'ReferenceId': '24623249', 'FullCitation': 'Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249', 'Include': 'true'}, {'number': '110', 'ReferenceId': '11580146', 'FullCitation': 'Momoi H, et al. J. Hepatol. (2001) pmid: 11580146', 'Include': 'true'}, {'number': '111', 'ReferenceId': '12175538', 'FullCitation': 'Limpaiboon T, et al. Cancer Lett. (2002) pmid: 12175538', 'Include': 'true'}, {'number': '112', 'ReferenceId': '12402306', 'FullCitation': 'Liu D, et al. Int. J. Cancer (2002) pmid: 12402306', 'Include': 'true'}, {'number': '113', 'ReferenceId': '14506736', 'FullCitation': 'Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736', 'Include': 'true'}, {'number': '114', 'ReferenceId': '17204026', 'FullCitation': 'Histopathology (2007) pmid: 17204026', 'Include': 'true'}, {'number': '115', 'ReferenceId': '25949894', 'FullCitation': 'Lal N, et al. Oncoimmunology (2015) pmid: 25949894', 'Include': 'true'}, {'number': '116', 'ReferenceId': '28734759', 'FullCitation': 'Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759', 'Include': 'true'}, {'number': '117', 'ReferenceId': '29355075', 'FullCitation': 'Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075', 'Include': 'true'}, {'number': '118', 'ReferenceId': '23169436', 'FullCitation': 'Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436', 'Include': 'true'}, {'number': '119', 'ReferenceId': '26028255', 'FullCitation': 'Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255', 'Include': 'true'}, {'number': '120', 'ReferenceId': '25765070', 'FullCitation': 'Rizvi NA, et al. Science (2015) pmid: 25765070', 'Include': 'true'}, {'number': '121', 'ReferenceId': '33001143', 'FullCitation': 'Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143', 'Include': 'true'}, {'number': '122', 'ReferenceId': '31602320', 'FullCitation': 'Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320', 'Include': 'true'}, {'number': '123', 'ReferenceId': '32757294', 'FullCitation': 'Zhang EW, et al. Cancer (2020) pmid: 32757294', 'Include': 'true'}, {'number': '124', 'ReferenceId': '30833418', 'FullCitation': 'Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418', 'Include': 'true'}, {'number': '125', 'ReferenceId': '24553385', 'FullCitation': 'Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385', 'Include': 'true'}, {'number': '126', 'ReferenceId': '30400802', 'FullCitation': 'Lapin M, et al. J Transl Med (2018) pmid: 30400802', 'Include': 'true'}, {'number': '127', 'ReferenceId': '30131550', 'FullCitation': 'Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550', 'Include': 'true'}, {'number': '128', 'ReferenceId': '30385733', 'FullCitation': 'Choudhury AD, et al. JCI Insight (2018) pmid: 30385733', 'Include': 'true'}, {'number': '129', 'ReferenceId': '29298117', 'FullCitation': 'Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117', 'Include': 'true'}, {'number': '130', 'ReferenceId': '30793095', 'FullCitation': 'Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095', 'Include': 'true'}, {'number': '131', 'ReferenceId': '31059681', 'FullCitation': 'Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681', 'Include': 'true'}, {'number': '132', 'ReferenceId': '28187169', 'FullCitation': 'Fan G, et al. PLoS ONE (2017) pmid: 28187169', 'Include': 'true'}, {'number': '133', 'ReferenceId': '30923679', 'FullCitation': 'Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679', 'Include': 'true'}, {'number': '134', 'ReferenceId': '30093454', 'FullCitation': 'Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454', 'Include': 'true'}, {'number': '135', 'ReferenceId': '30860573', 'FullCitation': 'Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573', 'Include': 'true'}, {'number': '136', 'ReferenceId': '28450425', 'FullCitation': 'Goodall J, et al. Cancer Discov (2017) pmid: 28450425', 'Include': 'true'}, {'number': '137', 'ReferenceId': '29330207', 'FullCitation': 'Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207', 'Include': 'true'}, {'number': '138', 'ReferenceId': '15748635', 'FullCitation': 'Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635', 'Include': 'true'}, {'number': '139', 'ReferenceId': '23875803', 'FullCitation': 'Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803', 'Include': 'true'}, {'number': '140', 'ReferenceId': '12379884', 'FullCitation': 'Pfeifer GP, et al. Oncogene (2002) pmid: 12379884', 'Include': 'true'}, {'number': '141', 'ReferenceId': '24336570', 'FullCitation': 'Johnson BE, et al. Science (2014) pmid: 24336570', 'Include': 'true'}, {'number': '142', 'ReferenceId': '29452419', 'FullCitation': 'Choi S, et al. Neuro_oncology (2018) pmid: 29452419', 'Include': 'true'}, {'number': '143', 'ReferenceId': '23636398', 'FullCitation': 'Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398', 'Include': 'true'}, {'number': '144', 'ReferenceId': '23447401', 'FullCitation': 'Briggs S, et al. J. Pathol. (2013) pmid: 23447401', 'Include': 'true'}, {'number': '145', 'ReferenceId': '24583393', 'FullCitation': 'Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393', 'Include': 'true'}, {'number': '146', 'ReferenceId': '22810696', 'FullCitation': 'Nature (2012) pmid: 22810696', 'Include': 'true'}, {'number': '147', 'ReferenceId': '25568919', 'FullCitation': 'Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919', 'Include': 'true'}, {'number': '148', 'ReferenceId': '30082870', 'FullCitation': 'Gandara DR, et al. Nat. Med. (2018) pmid: 30082870', 'Include': 'true'}, {'number': '149', 'ReferenceId': '30816954', 'FullCitation': 'Wang Z, et al. JAMA Oncol (2019) pmid: 30816954', 'Include': 'true'}, {'number': '150', 'ReferenceId': '32102950', 'FullCitation': 'Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950', 'Include': 'true'}, {'number': '151', 'ReferenceId': '22588877', 'FullCitation': 'Cerami E, et al. Cancer Discov (2012) pmid: 22588877', 'Include': 'true'}, {'number': '152', 'ReferenceId': '23550210', 'FullCitation': 'Gao J, et al. Sci Signal (2013) pmid: 23550210', 'Include': 'true'}, {'number': '153', 'ReferenceId': '26258846', 'FullCitation': 'Nakamura H, et al. Nat. Genet. (2015) pmid: 26258846', 'Include': 'true'}, {'number': '154', 'ReferenceId': '33119110', 'FullCitation': 'Shao C, et al. JAMA Netw Open (2020) pmid: 33119110', 'Include': 'true'}, {'number': '155', 'ReferenceId': '35274716', 'FullCitation': 'Sturgill EG, et al. Oncologist (2022) pmid: 35274716', 'Include': 'true'}, {'number': '156', 'ReferenceId': '23423489', 'FullCitation': 'Plummer R, et al. Cancer Chemother. Pharmacol. (2013) pmid: 23423489', 'Include': 'true'}, {'number': '157', 'ReferenceId': '19047122', 'FullCitation': 'Plummer R, et al. Clin. Cancer Res. (2008) pmid: 19047122', 'Include': 'true'}, {'number': '158', 'ReferenceId': '28222073', 'FullCitation': 'Wilson RH, et al. Br. J. Cancer (2017) pmid: 28222073', 'Include': 'true'}, {'number': '159', 'ReferenceId': '31068370', 'FullCitation': 'Lin J, et al. Clin. Cancer Res. (2019) pmid: 31068370', 'Include': 'true'}, {'number': '160', 'ReferenceId': '30271179', 'FullCitation': 'Cheng Y, et al. Onco Targets Ther (2018) pmid: 30271179', 'Include': 'true'}, {'number': '161', 'ReferenceId': '25025963', 'FullCitation': 'Del Conte G, et al. Br. J. Cancer (2014) pmid: 25025963', 'Include': 'true'}, {'number': '162', 'ReferenceId': '30110579', 'FullCitation': 'Litton JK, et al. N. Engl. J. Med. (2018) pmid: 30110579', 'Include': 'true'}, {'number': '163', 'ReferenceId': '30124753', 'FullCitation': 'Ettl J, et al. Ann. Oncol. (2018) pmid: 30124753', 'Include': 'true'}, {'number': '164', 'ReferenceId': '28242752', 'FullCitation': 'de Bono J, et al. Cancer Discov (2017) pmid: 28242752', 'Include': 'true'}, {'number': '165', 'ReferenceId': '30099369', 'FullCitation': 'Lu E, et al. J Natl Compr Canc Netw (2018) pmid: 30099369', 'Include': 'true'}]}, 'Signatures': {'Signature': {'ServerTime': '2022_07_12 23:39:01', 'OpName': 'Naomi Lynn Ferguson, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director', 'Text': 'Naomi Lynn Ferguson, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director'}}, 'reportProperties': {'reportProperty': [{'identifier': 'QualityControlMetrics', 'key': 'MedianCoverageValue', 'value': 'N/A'}, {'identifier': 'AdditionalFindings', 'key': 'TumorMutationBurdenScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'MicrosatelliteStatusScore', 'value': '0 fraction_unstable_loci'}, {'identifier': 'AdditionalFindings', 'key': 'LossOfHeterozygosityScore', 'value': 'Units Not Reported'}, {'identifier': 'AdditionalFindings', 'key': 'BloodTumorMutationalBurdenScore', 'value': '4 Muts/Mb'}, {'identifier': 'AdditionalFindings', 'key': 'TumorFractionScore', 'value': '0%'}]}, 'comments': None, 'AAC': {'Amendmends': None}}, 'variant_report': {'xmlns': 'http://foundationmedicine.com/compbio/variant_report_external', 'disease': 'LIVER', 'disease_ontology': 'Liver cholangiocarcinoma', 'flowcell_analysis': '2000022383', 'gender': 'female', 'pathology_diagnosis': 'Cholangiocarcinoma', 'pipeline_version': 'v3.11.0', 'purity_assessment': '37.8', 'specimen': 'ORD_1404958_01*US1347344.01', 'study': 'CLINICAL_F1LCDx', 'test_request': 'ORD_1404958_01', 'test_type': 'FoundationOneLiquidDx', 'tissue_of_origin': 'Blood', 'xsischemaLocation': 'http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd', 'samples': {'sample': {'bait_set': 'AB1', 'name': 'SQ_US1347344.01_1', 'nucleic_acid_type': 'DNA'}}, 'quality_control': {'status': 'Pass'}, 'short_variants': {'short_variant': [{'allele_fraction': '0.503', 'cds_effect': '284G>C', 'depth': '3155', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CCND3', 'percent_reads': '50.3', 'position': 'chr6:41908238', 'protein_effect': 'R95P', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_001760', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'allele_fraction': '0.4743', 'cds_effect': '457A>G', 'depth': '2020', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'P2RY8', 'percent_reads': '47.43', 'position': 'chrX:1584995', 'protein_effect': 'T153A', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_178129', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'allele_fraction': '0.0019', 'cds_effect': '1A>T', 'depth': '4182', 'equivocal': 'false', 'functional_effect': 'nonsense', 'gene': 'CHEK2', 'percent_reads': '0.19', 'position': 'chr22:29130709', 'protein_effect': 'M1L', 'status': 'likely', 'strand': '_', 'transcript': 'NM_007194', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'allele_fraction': '0.0013', 'cds_effect': '2410G>T', 'depth': '8606', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB3', 'percent_reads': '0.13', 'position': 'chr12:56490964', 'protein_effect': 'G804W', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_001982', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'allele_fraction': '0.5152', 'cds_effect': '2936G>A', 'depth': '953', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'ERBB4', 'percent_reads': '51.52', 'position': 'chr2:212286760', 'protein_effect': 'R979Q', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_005235', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'allele_fraction': '0.5062', 'cds_effect': '1600_1601GC>AA', 'depth': '1863', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'CARD11', 'percent_reads': '50.62', 'position': 'chr7:2969678', 'protein_effect': 'A534N', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_032415', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'allele_fraction': '0.0456', 'cds_effect': '703C>A', 'depth': '2653', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'GRM3', 'percent_reads': '4.56', 'position': 'chr7:86415811', 'protein_effect': 'R235S', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000840', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'allele_fraction': '0.4805', 'cds_effect': '1261G>A', 'depth': '1049', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'IKBKE', 'percent_reads': '48.05', 'position': 'chr1:206653377', 'protein_effect': 'A421T', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_014002', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'allele_fraction': '0.0035', 'cds_effect': '1900C>T', 'depth': '4529', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'KIT', 'percent_reads': '0.35', 'position': 'chr4:55594197', 'protein_effect': 'R634W', 'status': 'unknown', 'strand': '+', 'transcript': 'NM_000222', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'allele_fraction': '0.003', 'cds_effect': '3665delA', 'depth': '8601', 'equivocal': 'false', 'functional_effect': 'frameshift', 'gene': 'BRCA1', 'percent_reads': '0.3', 'position': 'chr17:41243882', 'protein_effect': 'E1222fs*13', 'status': 'likely', 'strand': '_', 'transcript': 'NM_007294', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'allele_fraction': '0.4978', 'cds_effect': '1960C>G', 'depth': '1563', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'TSC1', 'percent_reads': '49.78', 'position': 'chr9:135781005', 'protein_effect': 'Q654E', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_000368', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'allele_fraction': '0.0049', 'cds_effect': '145T>C', 'depth': '1425', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'FGF14', 'percent_reads': '0.49', 'position': 'chr13:102568851', 'protein_effect': 'S49P', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_004115', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'allele_fraction': '0.0058', 'cds_effect': '2128T>A', 'depth': '2422', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'DNMT3A', 'percent_reads': '0.58', 'position': 'chr2:25463554', 'protein_effect': 'C710S', 'status': 'unknown', 'strand': '_', 'transcript': 'NM_022552', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'allele_fraction': '0.003', 'cds_effect': '890G>A', 'depth': '5724', 'equivocal': 'false', 'functional_effect': 'missense', 'gene': 'STK11', 'percent_reads': '0.3', 'position': 'chr19:1221975', 'protein_effect': 'R297K', 'status': 'known', 'strand': '+', 'transcript': 'NM_000455', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}]}, 'copy_number_alterations': None, 'rearrangements': None, 'biomarkers': {'microsatellite_instability': {'status': 'MSS'}, 'tumor_mutation_burden': {'score': '3.79', 'status': 'low', 'unit': 'mutations_per_megabase'}}, 'non_human_content': {'non_human': [{'organism': 'HPV_16', 'reads_per_million': '29', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'organism': 'HHV_8', 'reads_per_million': '14', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}, {'organism': 'HHV_4', 'reads_per_million': '53', 'status': 'unknown', 'dna_evidence': {'sample': 'SQ_US1347344.01_1'}}]}}}}}	S111-99792          	PF22079             
